<SEC-DOCUMENT>0001641172-25-001246.txt : 20250328
<SEC-HEADER>0001641172-25-001246.hdr.sgml : 20250328
<ACCEPTANCE-DATETIME>20250328165433
ACCESSION NUMBER:		0001641172-25-001246
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250328
DATE AS OF CHANGE:		20250328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CONDUIT PHARMACEUTICALS INC.
		CENTRAL INDEX KEY:			0001896212
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				873272543
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41245
		FILM NUMBER:		25787301

	BUSINESS ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL NORTH
		STREET 2:		SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103
		BUSINESS PHONE:		(646) 491 9132

	MAIL ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL NORTH
		STREET 2:		SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Murphy Canyon Acquisition Corp.
		DATE OF NAME CHANGE:	20211130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:CDT="http://conduitpharma.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_034_CDT_conduitpharma.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0001896212 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_065_sqft_8_utr%2D%2Dsqft -->
<!-- Field: Set; Name: xdx; ID: xdx_06C_GBPShares_0_iso4217%2D%2DGBP_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_061_GBP_0_iso4217%2D%2DGBP -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000006" name="dei:EntityCentralIndexKey">0001896212</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="xdx2ixbrl0085" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl0088" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0109" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNotesPayable" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl0115" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNotesPayable" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0118" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNotesPayable" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0121" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0127" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0130" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0136" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0141" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0147" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0148" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0172" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0173" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="xdx2ixbrl0183" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="xdx2ixbrl0185" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="xdx2ixbrl0187" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="xdx2ixbrl0189" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:ChangeInFairValueAndIncomeImpactOfOptionLiabilities" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValuePurchaseOfRevenue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValuePurchaseOfRevenue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValuePurchaseOfRevenue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValuePurchasesOfRevenue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValuePurchasesOfRevenue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValuePurchasesOfRevenue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuedForServicesOne" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuedForServicesOne" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuedForServicesOne" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuedForServicesOne" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuedForServicesOne" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:GainLossOnChangeInFairValueOfCizzleOption" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0528" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:GainOnChangeInFairValueOfVelaOption" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:LossOnIssuanceOfVelaOption" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:ChangesInForeignCurrencyTransactionUnrealized" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0541" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:LossOnRelatedPartyLoanForgiveness" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0543" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:RealizedGainOnShorttermInvestments" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0547" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:LossOnIssuanceOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:NoncashLeaseExpense" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:IssuanceOfCommonStockForLicensingRight" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0577" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:AmortizationExpense" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0583" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:AmortizationOfDebtDiscount" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0586" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0589" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0604" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0606" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0612" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0616" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0619" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0622" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:ProceedsFromIssuanceOfOption" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0624" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:ProceedsFromLoanRepaymentRelatedParty" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0627" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0636" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0640" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0643" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:ProceedsFromIssuanceOfCapitalContributionRelatedParty" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0645" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:ProceedsFromExerciseOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0652" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0655" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0658" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0660" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="xdx2ixbrl0676" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0685" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0688" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0691" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:IssuanceOfCommonStockInExchangeForDebtExtension" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0694" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0697" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0699" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0702" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesReduction" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0705" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:DeferredUnderwritingCosts" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0708" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0711" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0714" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0717" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:NoncashAssetsAssumedInMergerFinancing" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0720" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:NoncashLiabilitiesAssumedInMergerFinancing" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0723" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember" id="xdx2ixbrl0886" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember" id="xdx2ixbrl0888" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0894" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0896" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ConvertibleNotesPayableMember" id="xdx2ixbrl0900" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ConvertibleNotesPayableMember" id="xdx2ixbrl0902" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="xdx2ixbrl0908" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0916" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0918" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="xdx2ixbrl0924" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="xdx2ixbrl0928" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0932" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0936" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember" id="xdx2ixbrl0942" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="xdx2ixbrl0943" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="xdx2ixbrl0949" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl1051" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl1054" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31" id="xdx2ixbrl1518" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl1520" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreePlanMember" id="xdx2ixbrl1560" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember" id="xdx2ixbrl1570" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember" id="xdx2ixbrl1572" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember" id="xdx2ixbrl1580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember" id="xdx2ixbrl1588" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember" id="xdx2ixbrl1596" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1620" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1621" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1623" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1624" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1626" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1627" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1630" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1647" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1648" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember" id="xdx2ixbrl1657" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1662" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1666" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:IncomeTaxReconciliationConvertibleDebtAdjustment" contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1670" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:IncomeTaxReconciliationStateReRate" contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1674" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember" id="xdx2ixbrl1685" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1686" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1687" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1694" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember" id="xdx2ixbrl1697" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1706" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:IncomeTaxReconciliationConvertibleDebtAdjustment" contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember" id="xdx2ixbrl1709" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:IncomeTaxReconciliationPurchaseAccountingAdjustments" contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1714" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember" id="xdx2ixbrl1721" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1722" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1723" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:DeferredTaxAssetsStockOptions" contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1728" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsHedgingTransactions" contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1732" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1736" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1740" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember" id="xdx2ixbrl1755" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1756" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1757" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:DeferredTaxAssetsStockOptions" contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1760" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="xdx2ixbrl1779" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember" id="xdx2ixbrl1780" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1781" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember" id="xdx2ixbrl1789" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="xdx2ixbrl1815" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="xdx2ixbrl1817" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="xdx2ixbrl1819" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="xdx2ixbrl1821" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:ChangeInFairValueAndIncomeImpactOfOptionLiabilities" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1836" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:OptionLiabilityConversionShares" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1845" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_PIPEMember" id="xdx2ixbrl1862" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember20778968" id="xdx2ixbrl1874" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_AugustTwentyTwentyFourNirlandNoteMember" id="xdx2ixbrl1878" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_AGPConvertibleNoteMember" id="xdx2ixbrl1881" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_MarchTwentyTwentyFourWarrantsMember" id="xdx2ixbrl1884" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_AprilTwentyTwentyFourWarrantsMember" id="xdx2ixbrl1887" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_AGPTwentyTwentyFourWarrantsMember" id="xdx2ixbrl1890" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:RecognitionOfDeferredRevenueUponOptionExercise" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1929" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:RecognitionOfDeferredRevenueUponOptionExerciseOne" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1932" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:ChangeInFairValueOfOption" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1935" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:ChangeInFairValueOfOptions" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1938" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:ChangeInFairValueOfConvertibleNotePayment" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1945" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:GainOnDebtExtinguishment" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1948" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:IncomeTaxRefund" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1954" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:LossOnIssuanceOfOptionOne" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1965" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:OtherIncomeUnrealizedForeignCurrencyTransactionLoss" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1968" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1975" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:LossOnIssuanceOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1978" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:LossOnDebtExtinguishment" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1981" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CDT:OtherExpense" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1987" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_NewLicensesMember" id="xdx2ixbrl2099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cdt-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CDT:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CDT:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-242025-01-24_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-24</xbrli:startDate>
        <xbrli:endDate>2025-01-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_OldConduitPharmaceuticalsLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:OldConduitPharmaceuticalsLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_ConduitConvertibleNoteHoldersMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:ConduitConvertibleNoteHoldersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_ConduitShareHoldersandConvertibleNoteHoldersMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:ConduitShareHoldersandConvertibleNoteHoldersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_srt_DirectorMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SponsorMember_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SubscriptionAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SubscriptionAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember_us-gaap_CommonStockSubjectToMandatoryRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_srt_DirectorMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SponsorMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CDT:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SubscriptionAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AGPConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ConvertibleNotesPayableMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-112024-12-11_custom_PIPEWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CDT:PIPEWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-11</xbrli:startDate>
        <xbrli:endDate>2024-12-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PIPEWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CDT:PIPEWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-22_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-312024-10-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-31</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-222024-11-22_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-22</xbrli:startDate>
        <xbrli:endDate>2024-11-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_CorporateBondYieldEstimatedTimingOfConversionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:CorporateBondYieldEstimatedTimingOfConversionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-22_custom_CorporateBondYieldEstimatedTimingOfConversionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:CorporateBondYieldEstimatedTimingOfConversionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CorporateBondYieldEstimatedTimingOfConversionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:CorporateBondYieldEstimatedTimingOfConversionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_us-gaap_MeasurementInputCreditSpreadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-22_us-gaap_MeasurementInputCreditSpreadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputCreditSpreadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_MeasurementInputProbabilityOfDefaultMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputProbabilityOfDefaultMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-22_custom_MeasurementInputProbabilityOfDefaultMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputProbabilityOfDefaultMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MeasurementInputProbabilityOfDefaultMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputProbabilityOfDefaultMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_MeasurementInputRecoveryUponDefaultMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputRecoveryUponDefaultMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-22_custom_MeasurementInputRecoveryUponDefaultMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputRecoveryUponDefaultMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MeasurementInputRecoveryUponDefaultMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputRecoveryUponDefaultMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_us-gaap_MeasurementInputDiscountRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-22_us-gaap_MeasurementInputDiscountRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_us-gaap_MeasurementInputSharePriceMember_custom_AGPConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_AGPConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-252024-11-25_us-gaap_MeasurementInputExpectedTermMember_custom_AGPConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-25</xbrli:startDate>
        <xbrli:endDate>2024-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_AGPConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_CorporateBondYieldEstimatedTimingOfConversionMember_custom_AGPConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:CorporateBondYieldEstimatedTimingOfConversionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CorporateBondYieldEstimatedTimingOfConversionMember_custom_AGPConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:CorporateBondYieldEstimatedTimingOfConversionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_us-gaap_MeasurementInputCreditSpreadMember_custom_AGPConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputCreditSpreadMember_custom_AGPConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_MeasurementInputProbabilityOfDefaultMember_custom_AGPConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputProbabilityOfDefaultMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MeasurementInputProbabilityOfDefaultMember_custom_AGPConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputProbabilityOfDefaultMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_MeasurementInputRecoveryUponDefaultMember_custom_AGPConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputRecoveryUponDefaultMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MeasurementInputRecoveryUponDefaultMember_custom_AGPConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputRecoveryUponDefaultMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-29_us-gaap_MeasurementInputSharePriceMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-29_us-gaap_MeasurementInputExercisePriceMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExercisePriceMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-29_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-29_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-292024-10-29_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-29</xbrli:startDate>
        <xbrli:endDate>2024-10-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-202020-10-20_custom_VelaAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:VelaAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-20</xbrli:startDate>
        <xbrli:endDate>2020-10-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_VelaAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:VelaAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_VelaAgreementMember_custom_VelaTechnologiesPLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:VelaAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">CDT:VelaTechnologiesPLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-04-30_custom_VelaOptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:VelaOptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_custom_VelaOptionAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:VelaOptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_custom_VelaOptionAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:VelaOptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_custom_VelaOptionAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:VelaOptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-302023-11-30_custom_VelaOptionLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:VelaOptionLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-30</xbrli:startDate>
        <xbrli:endDate>2023-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-30_custom_VelaOptionLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:VelaOptionLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_VelaOptionLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:VelaOptionLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-112022-02-11_custom_CizzlePlcAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:CizzlePlcAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-11</xbrli:startDate>
        <xbrli:endDate>2022-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-11_custom_CizzlePlcAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:CizzlePlcAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CizzlePlcAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:CizzlePlcAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-15_custom_CizzlePlcAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:CizzlePlcAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-262023-09-26_custom_CizzlePlcAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:CizzlePlcAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-26</xbrli:startDate>
        <xbrli:endDate>2023-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CizzlePlcAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:CizzlePlcAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CizzlePlcAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:CizzlePlcAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ConvertiblePromissoryNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-012023-03-31_custom_ConvertiblePromissoryNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-092024-10-09_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-09</xbrli:startDate>
        <xbrli:endDate>2024-10-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-112024-10-11_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-11</xbrli:startDate>
        <xbrli:endDate>2024-10-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-092024-10-09_custom_ConvertiblePromissoryNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-09</xbrli:startDate>
        <xbrli:endDate>2024-10-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-09_custom_ConvertiblePromissoryNotePayableMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNotePayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-092024-10-09_custom_ConvertiblePromissoryNotePayableMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNotePayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-09</xbrli:startDate>
        <xbrli:endDate>2024-10-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-112024-10-11_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-11</xbrli:startDate>
        <xbrli:endDate>2024-10-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-102024-10-10_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-10</xbrli:startDate>
        <xbrli:endDate>2024-10-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-10_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ConvertiblePromissoryNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-062025-03-06_custom_TwentyTwentyThreeConvertibleNoteMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:TwentyTwentyThreeConvertibleNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-06</xbrli:startDate>
        <xbrli:endDate>2025-03-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-132025-03-13_custom_TwentyTwentyThreeConvertibleNoteMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:TwentyTwentyThreeConvertibleNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-13</xbrli:startDate>
        <xbrli:endDate>2025-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:SeniorSecuredPromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:NirlandLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-062024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:SeniorSecuredPromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:NirlandLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-06</xbrli:startDate>
        <xbrli:endDate>2024-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-062024-08-06_custom_SeniorSecuredPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:SeniorSecuredPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-06</xbrli:startDate>
        <xbrli:endDate>2024-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:SeniorSecuredPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:SeniorSecuredPromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-06_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_FirstAmendmentNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:FirstAmendmentNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_NirlandLimitedMember_custom_FirstAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:NirlandLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:FirstAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-312024-10-31_custom_NirlandLimitedMember_custom_FirstAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:NirlandLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:FirstAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-31</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-222024-11-22_custom_SecondAmendmentNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:SecondAmendmentNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-22</xbrli:startDate>
        <xbrli:endDate>2024-11-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-22_custom_SecondAmendmentNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:SecondAmendmentNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-22_custom_FirstAmendmentNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:FirstAmendmentNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-22_custom_SecondAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:SecondAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-22_custom_FirstAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:FirstAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-092024-12-09_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-09</xbrli:startDate>
        <xbrli:endDate>2024-12-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:NirlandLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember_custom_FirstAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:NirlandLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:FirstAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember_custom_SecondAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:NirlandLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SecondAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AllianceGobalPartnersConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-252025-01-25_custom_AllianceGobalPartnersConvertibleNoteMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AllianceGobalPartnersConvertibleNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-25</xbrli:startDate>
        <xbrli:endDate>2025-01-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-252024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AllianceGobalPartnersConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-25</xbrli:startDate>
        <xbrli:endDate>2024-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AllianceGobalPartnersConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AllianceGobalPartnersConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-01_custom_LoanAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:LoanAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-05-01_custom_LoanAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:LoanAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-01_custom_TrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CDT:TrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-01_custom_TrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CDT:TrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-01_custom_TrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CDT:TrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-092024-10-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-09</xbrli:startDate>
        <xbrli:endDate>2024-10-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-112024-10-11_custom_LoanHoldersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">CDT:LoanHoldersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-11</xbrli:startDate>
        <xbrli:endDate>2024-10-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-112024-10-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-11</xbrli:startDate>
        <xbrli:endDate>2024-10-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-012025-02-28_custom_LoansAmendmentMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:LoansAmendmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-01</xbrli:startDate>
        <xbrli:endDate>2025-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:OctoberTwoThousandTwentyFourNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:OctoberTwoThousandTwentyFourNirlandNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:OctoberTwoThousandTwentyFourNirlandNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-282024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:OctoberTwoThousandTwentyFourNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-28</xbrli:startDate>
        <xbrli:endDate>2024-10-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_OctoberTwoThousandTwentyFourNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:OctoberTwoThousandTwentyFourNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-292024-10-29_custom_BridgeLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:BridgeLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-29</xbrli:startDate>
        <xbrli:endDate>2024-10-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-29_custom_BridgeLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:BridgeLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-06_custom_BridgeLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:BridgeLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BridgeLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:BridgeLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_AllianceGlobalPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_AllianceGlobalPartnersMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-22_custom_AllianceGlobalPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-22_custom_AllianceGlobalPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AllianceGlobalPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_AllianceGlobalPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AstraZenecaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AstraZenecaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SARBORGServiceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SARBORGServiceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SARBORGServiceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SARBORGServiceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SARBORGServiceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SARBORGServiceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_SARBORGServiceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SARBORGServiceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-22_custom_TwentyTwentyThreeStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CDT:TwentyTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-06_custom_TwentyTwentyThreeStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CDT:TwentyTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-01_custom_TwentyTwentyThreeStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CDT:TwentyTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_TwentyTwentyThreeStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CDT:TwentyTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwentyTwentyThreeStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CDT:TwentyTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-242024-06-24_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-24</xbrli:startDate>
        <xbrli:endDate>2024-06-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-24_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-242024-06-24_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-24</xbrli:startDate>
        <xbrli:endDate>2024-06-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-182024-11-18_custom_NonEmployeeDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:NonEmployeeDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-18</xbrli:startDate>
        <xbrli:endDate>2024-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-18_custom_NonEmployeeDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:NonEmployeeDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-182024-11-18_srt_BoardOfDirectorsChairmanMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-18</xbrli:startDate>
        <xbrli:endDate>2024-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-18_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-182024-11-18_custom_MrHeilbronMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:MrHeilbronMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-18</xbrli:startDate>
        <xbrli:endDate>2024-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-18_custom_ConsultingAgreementMember_custom_MrHeilbronMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:MrHeilbronMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-012023-12-01_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-01</xbrli:startDate>
        <xbrli:endDate>2023-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-012023-12-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-01</xbrli:startDate>
        <xbrli:endDate>2023-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-072024-06-07_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-07</xbrli:startDate>
        <xbrli:endDate>2024-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandTwentyThreePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CDT:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TwoThousandTwentyThreePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CDT:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CDT:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CDT:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-232024-10-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-23</xbrli:startDate>
        <xbrli:endDate>2024-10-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PIPEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:PIPEMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PIPEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:PIPEMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AGPWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AGPWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AGPWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AGPWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember20778937">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ConvertiblePromissoryNotesPayableMember20778953">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember20778968">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember20778968">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AugustTwentyTwentyFourNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AugustTwentyTwentyFourNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AGPConvertibleNoteMember20778984">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AGPConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MarchTwentyTwentyFourWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:MarchTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MarchTwentyTwentyFourWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:MarchTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AprilTwentyTwentyFourWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AprilTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AprilTwentyTwentyFourWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AprilTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AGPTwentyTwentyFourWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AGPTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AGPTwentyTwentyFourWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AGPTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-312023-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-31</xbrli:startDate>
        <xbrli:endDate>2023-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-312023-08-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-31</xbrli:startDate>
        <xbrli:endDate>2023-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-22_custom_CorvusCapitalLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CDT:CorvusCapitalLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CorvusCapitalLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CDT:CorvusCapitalLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-28_custom_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:TwentyTwentyTwoConvertibleLoanNoteInstrumentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012023-02-28_custom_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:TwentyTwentyTwoConvertibleLoanNoteInstrumentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2023-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CorvusCapitalLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CDT:CorvusCapitalLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-22_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SARBORGLtdMember_custom_SARBORGServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CDT:SARBORGLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SARBORGServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-222024-04-22_custom_OfficersAndDirectorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CDT:OfficersAndDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-22</xbrli:startDate>
        <xbrli:endDate>2024-04-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-22_custom_OfficersAndDirectorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CDT:OfficersAndDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-20_custom_MarchLockUpAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:MarchLockUpAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MarchLockUpAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:MarchLockUpAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-20_custom_AprilLockUpAgreementMember_custom_AprilTwentyTwentyFourWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:AprilLockUpAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CDT:AprilTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-202024-04-20_us-gaap_WarrantMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-20</xbrli:startDate>
        <xbrli:endDate>2024-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-12-31_us-gaap_WarrantMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-12-31_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-29_custom_AllianceGlobalPartnersMember_custom_AGPTwentyTwentyFourWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CDT:AGPTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-22_us-gaap_IPOMember_custom_PublicWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CDT:PublicWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_IPOMember_custom_PublicWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CDT:PublicWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-22_us-gaap_IPOMember_custom_PrivatePlacementWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CDT:PrivatePlacementWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-31_custom_MarchLockUpAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:MarchLockUpAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_us-gaap_WarrantMember_custom_AprilLockUpAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:AprilLockUpAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-04-30_custom_AprilLockUpAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:AprilLockUpAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-21</xbrli:startDate>
        <xbrli:endDate>2023-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-292024-10-29_custom_AGPTwentyTwentyFourWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CDT:AGPTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-29</xbrli:startDate>
        <xbrli:endDate>2024-10-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-11_custom_PIPEWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CDT:PIPEWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-112024-12-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-11</xbrli:startDate>
        <xbrli:endDate>2024-12-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-202024-03-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-20</xbrli:startDate>
        <xbrli:endDate>2024-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-202024-04-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-20</xbrli:startDate>
        <xbrli:endDate>2024-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_NewLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:NewLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_NewLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:NewLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_ClinicalAssetDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:ClinicalAssetDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_ClinicalAssetDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:ClinicalAssetDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_LegalAndProfessionalFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:LegalAndProfessionalFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_LegalAndProfessionalFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:LegalAndProfessionalFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_AccountingAndAuditFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:AccountingAndAuditFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_AccountingAndAuditFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:AccountingAndAuditFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_SalariesPayrollAndStockBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:SalariesPayrollAndStockBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_SalariesPayrollAndStockBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:SalariesPayrollAndStockBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-242024-01-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-24</xbrli:startDate>
        <xbrli:endDate>2024-01-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-07_us-gaap_SubsequentEventMember_custom_OctoberTwentyTwentyFourNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:OctoberTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-072025-02-07_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-07</xbrli:startDate>
        <xbrli:endDate>2025-02-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-07_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-122024-12-12_custom_AugustTwentyTwentyFourNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-12</xbrli:startDate>
        <xbrli:endDate>2024-12-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-132025-01-13_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-13</xbrli:startDate>
        <xbrli:endDate>2025-01-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-102025-02-10_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-10</xbrli:startDate>
        <xbrli:endDate>2025-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-13_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_TwentyTwentyThreeConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:TwentyTwentyThreeConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-13_custom_TwentyTwentyThreeConvertibleNoteMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:TwentyTwentyThreeConvertibleNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-152025-01-15_us-gaap_SubsequentEventMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-15</xbrli:startDate>
        <xbrli:endDate>2025-01-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-062025-02-06_us-gaap_SubsequentEventMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-06</xbrli:startDate>
        <xbrli:endDate>2025-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-102025-02-10_us-gaap_SubsequentEventMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-10</xbrli:startDate>
        <xbrli:endDate>2025-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-192025-02-19_us-gaap_SubsequentEventMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-19</xbrli:startDate>
        <xbrli:endDate>2025-02-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-102025-03-10_us-gaap_SubsequentEventMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-10</xbrli:startDate>
        <xbrli:endDate>2025-03-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-222025-01-22_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-22</xbrli:startDate>
        <xbrli:endDate>2025-01-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-22_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-282025-03-28_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-28</xbrli:startDate>
        <xbrli:endDate>2025-03-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="GBPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:GBP</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="GBP">
      <xbrli:measure>iso4217:GBP</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000288" toRefs="Footnote000387"/>
  <ix:relationship fromRefs="xdx2ixbrl0289" toRefs="Footnote000387"/>
  <ix:relationship fromRefs="Fact000290" toRefs="Footnote000387"/>
  <ix:relationship fromRefs="Fact000291" toRefs="Footnote000387"/>
  <ix:relationship fromRefs="Fact000292" toRefs="Footnote000387"/>
  <ix:relationship fromRefs="Fact000294" toRefs="Footnote000387"/>
  <ix:relationship fromRefs="xdx2ixbrl0282" toRefs="Footnote000388"/>
  <ix:relationship fromRefs="Fact000283" toRefs="Footnote000388"/>
  <ix:relationship fromRefs="Fact000284" toRefs="Footnote000388"/>
  <ix:relationship fromRefs="xdx2ixbrl0285" toRefs="Footnote000388"/>
  <ix:relationship fromRefs="xdx2ixbrl0286" toRefs="Footnote000388"/>
  <ix:relationship fromRefs="xdx2ixbrl0296" toRefs="Footnote000389"/>
  <ix:relationship fromRefs="Fact000297" toRefs="Footnote000389"/>
  <ix:relationship fromRefs="Fact000298" toRefs="Footnote000389"/>
  <ix:relationship fromRefs="xdx2ixbrl0299" toRefs="Footnote000389"/>
  <ix:relationship fromRefs="xdx2ixbrl0300" toRefs="Footnote000389"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90C_edei--DocumentType_c20240101__20241231_zhYzJSEkJMO6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000015" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--DocumentAnnualReport_c20240101__20241231_zHZnkb844dvb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000016" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <span id="xdx_904_edei--DocumentPeriodEndDate_c20240101__20241231_zcSXiPKXVbsc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000017" name="dei:DocumentPeriodEndDate"><span id="xdx_901_edei--CurrentFiscalYearEndDate_c20240101__20241231_zEibU84QRVD4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayen" id="Fact000018" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90B_edei--DocumentFiscalYearFocus_c20240101__20241231_zZDqiKMo8rij"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000019" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--DocumentTransitionReport_c20240101__20241231_zqlv65K9XnZf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000020" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File No. <span id="xdx_909_edei--EntityFileNumber_c20240101__20241231_z7SCgYuSyPni"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000021" name="dei:EntityFileNumber">001-41245</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_901_edei--EntityRegistrantName_c20240101__20241231_zYjUPMFWsKdb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000022" name="dei:EntityRegistrantName">CONDUIT
PHARMACEUTICALS INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20240101__20241231_zvNUcwgLjzJl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000023" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20240101__20241231_zdO0xTZlU6uh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000024" name="dei:EntityTaxIdentificationNumber">87-3272543</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
                                            or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation or organization)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
                                            Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    Number)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20240101__20241231_zjLtAKIJpCLe"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000025" name="dei:EntityAddressAddressLine1">4581
                                            Tamiami Trail North</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressAddressLine2_c20240101__20241231_zo420BVCGcXi"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000026" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20240101__20241231_zBVxj8J4zVpb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000027" name="dei:EntityAddressCityOrTown">Naples</ix:nonNumeric></span>,
    <span id="xdx_905_edei--EntityAddressStateOrProvince_c20240101__20241231_zk2HYo3Rv9t3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000028" name="dei:EntityAddressStateOrProvince">Florida</ix:nonNumeric></span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressPostalZipCode_c20240101__20241231_zeoRWgibmiA1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000029" name="dei:EntityAddressPostalZipCode">34103</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
    of principal executive offices)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip
    Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90E_edei--CityAreaCode_c20240101__20241231_z5WKuuaGLg9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000030" name="dei:CityAreaCode">(646)</ix:nonNumeric></span>-<span id="xdx_908_edei--LocalPhoneNumber_c20240101__20241231_zWfVPCBrjLPa"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000031" name="dei:LocalPhoneNumber">491-9132</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--Security12bTitle_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zvdBDoMHgG4e"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember" id="Fact000032" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--TradingSymbol_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zkON5Hx1dgzh"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember" id="Fact000033" name="dei:TradingSymbol">CDT</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_90C_edei--SecurityExchangeName_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zGQLXzeDstg7"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000034" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_z1E7SW8JWCug"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" id="Fact000035" name="dei:Security12bTitle">Redeemable
    Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $1,150</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--TradingSymbol_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_z3R7keAhwFAl"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" id="Fact000036" name="dei:TradingSymbol">CDTTW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_901_edei--SecurityExchangeName_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_zpdDRRPeNAVd"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" format="ixt-sec:exchnameen" id="Fact000037" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_905_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_z1xmKaLIxfNd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000038" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes &#9744;
<span id="xdx_900_edei--EntityVoluntaryFilers_c20240101__20241231_zniE4DTE4Lxg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000039" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_906_edei--EntityCurrentReportingStatus_c20240101__20241231_zdwQOMMghmhi"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000040" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_90B_edei--EntityInteractiveDataCurrent_c20240101__20241231_zDVf5MT8mezf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000041" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntityFilerCategory_c20240101__20241231_zdKdfcHA202"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000042" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_909_edei--EntitySmallBusiness_c20240101__20241231_zEBwwYrx5kc5"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000043" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_904_edei--EntityEmergingGrowthCompany_c20240101__20241231_zJPQl9MxDaOj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000044" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_904_edei--EntityExTransitionPeriod_c20240101__20241231_z2ARRCaK6jt7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000045" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_904_edei--IcfrAuditorAttestationFlag_c20240101__20241231_zM7CCbRfKA8c"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000046" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_909_edei--DocumentFinStmtErrorCorrectionFlag_dbF_c20240101__20241231_zPIBPumnz6Cl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000047" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <span id="xdx_903_edei--EntityShellCompany_dbF_c20240101__20241231_zAYAePhP7xZd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000048" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 28, 2025, there were <span id="xdx_90D_edei--EntityCommonStockSharesOutstanding_iI_c20250328_zhyPfy2DCZU9"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-03-28" id="Fact000049" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,662,755</ix:nonFraction></span> shares of common stock, $<span id="xdx_90F_edei--EntityListingParValuePerShare_c20240101__20241231_zzQlKsDyZGof"><ix:nonFraction name="dei:EntityListingParValuePerShare" contextRef="From2024-01-01to2024-12-31" id="Fact000050" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value, of the Registrant issued and outstanding. The aggregate
market value of the common stock held by non-affiliates of the registrant as of June 28, 2024, the last business day of the registrant&#8217;s
most recently completed second fiscal quarter, was $<span id="xdx_90D_edei--EntityPublicFloat_iI_c20240628_zJOCvpSJ0Sk1"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-06-28" id="Fact000051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,401,162</ix:nonFraction></span> based upon the closing price reported for such date on The Nasdaq Global
Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2025, the Registrant effected a 1-for-100 reverse stock split of its authorized shares of common stock, accompanied by a
corresponding decrease in its issued and outstanding shares of common stock. All references to numbers of shares of common stock and
per-share information in this Annual Report on Form 10-K have been adjusted retroactively, as appropriate, to reflect the reverse stock
split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A. </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    IC.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Cybersecurity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Market For Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Reserved</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Financial Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B. </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_019">PART III</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">Executive Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sj_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sj_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART IV</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sj_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits and Financial Statement Schedules</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sj_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K Summary.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sj_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K (this &#8220;Annual Report&#8221;) and the information incorporated herein by reference contain forward-looking
statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only
on the Company&#8217;s current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies,
projections, anticipated events and trends, the economy, and other future conditions. This includes, without limitation, statements regarding
the financial position and the plans and objectives of management for our future operations. Such statements can be identified by the
fact that they do not relate strictly to historical or current facts. When used in this Annual Report, words such as &#8220;anticipate,&#8221;
&#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221;
&#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221;
&#8220;should,&#8221; &#8220;strive,&#8221; &#8220;would&#8221;&#160; and similar expressions may identify forward-looking statements,
but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this Annual Report
and in any document incorporated by reference in this Annual Report may include, for example, statements about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to maintain the listing of our securities on The Nasdaq Global Market and The Nasdaq Capital Market of The Nasdaq Stock Market
    LLC (&#8220;Nasdaq&#8221;), and the potential liquidity and trading of our securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk of disruption to our current plans and operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to recognize the anticipated benefits of our business and the business combination completed in September 2023 (the &#8220;Business
    Combination&#8221;), which may be affected by, among other things, competition and the ability to grow, manage growth profitably,
    and retain key employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to our business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable laws or regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to meet future capital requirements to fund our operations, which may involve debt and/or equity financing, and to obtain
    such debt and/or equity financing on favorable terms, and our sources and uses of cash;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to execute our plans to develop and commercialize our current clinical assets, as well as any future clinical assets that
    we license, and the timing of any such commercialization;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain existing license agreements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
estimates regarding expenses, future revenue, capital requirements, and needs for additional financing;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to use artificial intelligence to enhance our decision-making processes and maximize the value of our pharmaceutical asset
    portfolio;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    occurrence of any event, change or other circumstances, including the outcome of any legal proceedings that may be instituted against
    us; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    factors disclosed under the section entitled &#8220;Risk Factors&#8221; in this Annual Report.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements are based on information available as of the date of this Annual Report and current expectations, forecasts,
and assumptions, and involve a number of judgments, risks, and uncertainties. Accordingly, forward-looking statements should not be relied
upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements
to reflect events or circumstances after the date they were made, whether as a result of new information, future events, or otherwise,
except as may be required under applicable securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRADEMARKS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade
names referred to in this Annual Report may appear without the &#174; or &#8482; symbols, but such references are not intended to indicate,
in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks
and trade names. We do not intend our use or display of other companies&#8217; trade names, trademarks, or service marks to imply a relationship
with, or endorsement or sponsorship of it by, any other companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
OF RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the principal risks that could adversely affect our business, financial condition, operating results, cash
flows and/or stock price. Discussion of the risks listed below, and other risks that we face, are discussed in the section titled &#8220;Risk
Factors&#8221; in Part I, Item 1A of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Business and Industry</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
    business is dependent on the successful development, regulatory approval, and commercialization of our clinical assets, in particular
    a glucokinase activator which we believe is active in a range of autoimmune disorders, which we refer to as AZD1656, and a potent,
    irreversible inhibitor of human Myeloperoxidase that has the potential to treat idiopathic male infertility, which we refer to as
    AZD5904.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preclinical
    drug development for our clinical assets is expensive, time-consuming, and uncertain. Our preclinical trials may fail to adequately
    demonstrate pharmacologic activity in therapeutic areas of interest; cause unintended short- or long-term effects in other bodily
    systems; or produce unexpected toxicity that may alter or risk benefit assessment.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>It
    is difficult to accurately predict the time and cost of development and of subsequently obtaining regulatory approval for AZD1656
    as it employs newly developed technology.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
    may not be successful in our efforts to use and expand our research and development platform to build a pipeline of clinical assets.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
    drug development for our clinical assets is very expensive, time-consuming, difficult to design and implement, and uncertain. Our
    clinical trials may fail to adequately demonstrate the safety and efficacy of our clinical assets, which could prevent or delay regulatory
    approval and commercialization.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
    may be unable to obtain regulatory approval for our early-stage clinical assets under applicable regulatory requirements. The U.S. Food and Drug Administration (the &#8220;FDA&#8221;)
    and foreign regulatory bodies have substantial discretion in the approval process, including the ability to delay, limit, or deny
    approval of clinical assets. The delay, limitation, or denial of any regulatory approval would adversely impact commercialization,
    our potential to generate revenue, our business, and our operating results.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
    may face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance
    coverage for those claims is inadequate.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
    currently rely on, and expect to continue to rely on, third-party contract research organizations (&#8220;CROs&#8221;) and other third parties to conduct and oversee our clinical
    trials and other aspects of product development. If these third parties do not meet our requirements or otherwise conduct the trials
    as required, we may not be able to satisfy our contractual obligations or obtain regulatory approval for, or commercialize, our clinical
    assets when expected or at all.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
    currently rely on agreements with a related party and third parties for the purpose of licensing our clinical assets. In the near-term,
    we intend to rely on third parties for the licensing of clinical assets and those which may arise through future partnerships.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Manufacturing
    and supply of the active pharmaceutical ingredients (&#8220;APIs&#8221;) and other substances and materials used in our clinical assets is a complex and technically challenging undertaking,
    and there is potential for failure at many points in the manufacturing, testing, quality assurance, and distribution supply chain,
    as well as the potential for latent defects after products have been manufactured and distributed.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Intellectual Property</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Failure
    to adequately protect our intellectual property could adversely affect our business, financial condition, and operating results.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
    may not be able to protect our intellectual property rights throughout the world.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
    intellectual property rights throughout the world may be challenged by third parties, on prospectively a correct or incorrect basis
    </i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Securities Markets and Investment in Our Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#9679;</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Claims
    for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against
    us and may reduce the amount of money available to us.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Finances and Capital Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#9679;</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>There
    is substantial doubt regarding our ability to continue as a going concern. We will need to raise additional funding, which may not
    be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or
    terminate our commercial programs, product development efforts or other operations, all of which could have a material adverse effect
    on the Company and its financial results.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#9679;</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
    may issue additional shares of common stock or preferred stock, including under an employee incentive plan, which would dilute the
    interest of our stockholders.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_002"></span><b>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="a_001"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1. Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2023, a merger transaction (the &#8220;Business Combination&#8221;) between Conduit Pharmaceuticals Limited (&#8220;Old
Conduit&#8221;), Murphy Canyon Acquisition Corp (&#8220;MURF&#8221;) and Conduit Merger Sub, Inc., a Cayman Islands exempted company
and a wholly owned subsidiary of MURF (&#8220;Merger Sub&#8221;), was completed pursuant to the Agreement and Plan of Merger, dated November
8, 2022, as amended, (the &#8220;Merger Agreement&#8221;). Pursuant to the terms of the Merger Agreement, at the closing, (i) Merger
Sub merged with and into Old Conduit, with Old Conduit surviving the Business Combination as a wholly-owned subsidiary of MURF, and (ii)
MURF changed its name from Murphy Canyon Acquisition Corp. to Conduit Pharmaceuticals Inc. (&#8220;Conduit&#8221; or the &#8220;Company&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit
has developed a unique business model that allows it to act as a conduit to bring clinical assets from pharmaceutical companies and
develop new treatments for patients. Our novel approach addresses unmet medical needs and lengthens the intellectual property for
our existing assets through cutting-edge solid-form technology and then commercializing these products with life science companies.
We continue to evaluate novel artificial intelligence (&#8220;AI&#8221;) and cybernetics approaches to drug re-purposing,
intellectual property and asset selection to give Conduit a competitive advantage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are led by highly experienced pharmaceutical executives: Dr. Freda Lewis-Hall, former Chief Medical Officer of Pfizer Inc., the Chair
of our Board of Directors, and Dr. David Tapolczay, former Chief Executive Officer of the United Kingdom-based medical research charity
LifeArc, our Chief Executive Officer. Our management team includes active senior scientists who have an extensive understanding of the
pharmaceuticals market, which supports our strategy of developing clinical assets in a cost-efficient manner while focusing on therapeutic
efficacy and patient safety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously,
Conduit leverages the capabilities of our Cambridge laboratory facility and highly experienced team of solid-form experts to extend or
develop proprietary solid-form intellectual property for our existing and future clinical assets. Our own intellectual property portfolio
comprises pending patent applications in several international jurisdictions describing a solid-form compound, including the AZD1656
Cocrystal (a HK-4 Glucokinase Activator), targeting a wide range of autoimmune disorders. Our pipeline research includes a number of
compounds that serve as promising alternatives to existing clinical assets currently marketed and sold by large pharmaceutical companies,
which we have identified as having an opportunity to develop further intellectual property positions through solid-form technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the funding and development of clinical assets, we evaluate and select the specific molecules to be developed and collaborate
with external CROs and Key Opinion Leaders (&#8220;KOLs&#8221;) to run clinical trials
that are managed, funded, and overseen by us. We intend to leverage our comprehensive clinical and scientific expertise in order to facilitate
development of clinical assets through Phase II trials in an efficient manner by using CROs and third-party service providers. We will
also collaborate closely with disease specific KOLs to collectively assess and determine the most appropriate indications for all our
current and forthcoming assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that successful Phase II trials of the clinical assets in our pipeline will increase the value of our assets. There is no assurance
that any clinical trials on the assets owned or licensed by us will be successful, however, following a successful Phase II clinical
trial, we would look to licensing opportunities with large biotech or pharmaceutical companies, typically for up-front milestone payments
and royalty income streams for the life of the asset patent. We anticipate using any future royalty income stream to develop our asset
portfolio in combination with other potential sources of financing, including debt or equity financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
of our proprietary owned patented clinical assets, AstraZeneca agreed to grant a license to the Company under certain intellectual property
rights controlled by AstraZeneca related to HK-4 Glucokinase activators AZD1656 and AZD5658 in all indications and myeloperoxidase inhibitor
AZD5904 for the treatment, prevention, and prophylaxis of idiopathic male infertility. The Company will be responsible for the development
and commercialization of the relevant products licensed under the related License Agreement (the &#8220;Licensed Products&#8221;). The
Company is required to use commercially reasonable efforts to develop and commercialize the Licensed Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AstraZeneca
has conducted initial pre-clinical and, in some instances, clinical trials on these assets, but has decided to license them for further
development. As the clinical assets have undergone initial pre-clinical and clinical testing conducted by AstraZeneca, we are able to
use the safety data generated in these clinical trials to assess which clinical assets to further develop and for which indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
this relationship, there are considerable APIs that were manufactured by AstraZeneca
(prior to conducting its clinical trials) available to Conduit. As a result, Conduit may not have to develop the APIs, which is often
a time consuming and expensive process, and the APIs already produced were subject to rigorous quality control measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
collaboration with SARBORG Limited (&#8220;Sarborg&#8221;), Conduit intends to leverage an advanced
artificial intelligence (AI) and cybernetics platform to evaluate key deliverables across multiple areas of the Company&#8217;s
operations, including drug repurposing, drug discovery, solid-form identification, and clinical trial monitoring.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarborg Agreement (defined and described below) is designed to address longstanding challenges in the pharmaceutical sector, in
particular by reducing human error in critical decision-making processes in both clinical development and asset identification. By
integrating Sarborg&#8217;s algorithmic AI/cybernetics technology, Conduit aims to enhance efficiency, lower costs, and accelerate
timelines by minimizing human intervention, ultimately optimizing the drug development cycle and giving Conduit a competitive
advantage in the sector.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
this relationship, Conduit will gain access to cutting-edge predictive models and dashboards, enabling the Company to evaluate drug candidates,
streamline clinical trials, and optimize asset management with real-time data. These tools will drive faster, more accurate decisions,
improving efficiency and reducing costs. By leveraging these insights, Conduit to differentiate itself in a competitive sector and gain
unique data-driven insights that position the Company for success across both its current and future asset portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Conduit will retain a perpetual, non-exclusive, royalty-free, and assignable right to use any platform or technology developed
by Sarborg in association with the deliverables. Ongoing support from Sarborg will ensure these systems evolve with Conduit&#8217;s needs,
driving long-term innovation in areas like IP creation, regulatory strategy, and clinical trial monitoring. This partnership reinforces
Conduit&#8217;s commitment to leveraging AI-driven solutions to accelerate growth, deliver value to stockholders, and maintain a competitive
edge in the pharmaceutical sector.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Sarborg is considered to
be a related party of conduit, as Dr. Andrew Regan, a stockholder of Conduit and member of Conduit&#8217;s board of directors,
also sits on the board of directors of Sarborg. Refer to Note 16 to our financial statements included elsewhere in this Annual Report
for additional details on the relationship between Conduit and Sarborg.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
strategic move reaffirms Conduit&#8217;s commitment to adopting forward-thinking solutions to stay at the forefront of innovation in
the pharmaceutical industry. By reducing reliance on traditional, labor-intensive methods and harnessing the power of AI-driven technology,
Conduit is well-positioned to lead in areas such as drug repurposing, clinical trial monitoring, and IP creation, ensuring the Company&#8217;s
long-term growth and market leadership.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
Conduit believes that it is well positioned to pursue, and intends to pursue, additional relationships and/or partnerships with
third parties for the licensing of further assets which are currently deprioritized. We plan to focus our efforts on developing
clinical assets to address disorders that impact a large population where there is no present treatment or the present treatment,
carries significant unwanted side effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Initial Pipeline: HK-4 Glucokinase Activator Cocrystal, AZD1656, and its metabolite AZD5658 and AZD5904</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
wholly own the intellectual property and the rights to further develop the solid-form Cocrystals of AZD1656 (AZD1656 Cocrystal&#8211;
pending international patent applications, which, if granted should expire no earlier than 2042) that we intend to target a wide range
of autoimmune disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we currently have the exclusive rights to develop clinical assets, AZD1656 and AZD5658 in all human indications and AZD5904
in idiopathic male infertility which are licensed to us by AstraZeneca.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
of our proprietary owned patented clinical assets, AstraZeneca granted a license to the Company of certain intellectual property rights
controlled by AstraZeneca related to HK-4 Glucokinase activators AZD1656 and AZD5658 in all indications and myeloperoxidase inhibitor
AZD5904 for the treatment, prevention, and prophylaxis of idiopathic male infertility. The Company will be responsible for the development
and commercialization of the Licensed Products. The Company is required to use commercially reasonable efforts to develop and commercialize
the Licensed Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to our relationship with AstraZeneca, we intend to leverage the data generated from these historical trials in order to investigate the
efficacy and safety to AZD1656 to potentially treat Lupus and ANCA Vasculitis patients, and the efficacy and safety of AZD5904 to treat
IMI. AZD1656 has undergone testing in a total of 20 Phase I clinical trials and five Phase II clinical trials conducted by AstraZeneca
since 2008 and 19 of which were conducted in the U.S. Additional information about those clinical trials is available at the U.S. National
Library of Medicine&#8217;s website at www.clinicaltrials.gov (however, the information contained on or otherwise accessible through
such website is not part of this annual report). AZD5904 has undergone testing in five Phase I clinical trials conducted by AstraZeneca,
one of which was conducted in the U.S. While a significant amount of clinical trial data has already been generated for both AZD1656
and AZD5904, some of this data was generated outside of the U.S. and accordingly may not be accepted by the FDA. In the event that such
data is not accepted by the FDA, additional clinical trials may be required to commercialize these assets in the United States, which
would result in additional costs and time to develop these clinical assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD1656
underwent Phase I and Phase II clinical trials consisting of 23 studies in 526 subjects, 446 of whom were dosed with AZD1656. Other
than for the intended effect of lowering glucose, there were no difference identified between the AZD1656-treated and
placebo-treated subjects relating to adverse events. All of the cases where low glucose levels were identified were managed by the
patients and resolved. Based on these clinical trials, no safety signals were identified regarding vital signs, safety laboratory
values or electrocardiogram data. No deaths occurred in any studies with healthy volunteers or patients. AZD1656 was also subject to
Phase II clinical trials consisting of two studies where AZD1656 was given to patients with Type 2 Diabetes Mellitus for four months
or longer. In total, there were 754 randomized patients, 516 of whom were exposed to AZD1656 (316 men and 200 women). There were no
clinically important differences in the adverse effects profile between the AZD1656 treatment group and the AZD1656 placebo group
and there were no deaths in either of the Phase II studies. The efficacy of AZD1656 as a potential treatment for diabetes was also
assessed during the Phase II clinical trials, including whether the efficacy was statistically significant. Clinically relevant and
statistically significant reductions in HbA1c were seen after four months; however, the initial improvement in glucose control
deteriorated over time and the change in HbA1c levels after four months were not statistically different than the placebo. This
decreasing efficacy over time was seen in both Phase II studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD5658
was subject to a randomized, single-blind, placebo-controlled, single-center, Phase I study to assess the safety, tolerability, pharmacokinetics,
pharmacodynamics and the effect of fasting after single ascending oral doses of AZD5658 in Type 2 Diabetes Mellitus patients. There were
six dose levels with eight patients in each cohort, six receiving AZD5658 and two receiving placebo. The effect of fasting on the pharmacokinetics
of AZD5658 was also studied for two dose levels. Each patient treated with metformin received a maximum of two single oral suspension
doses (one on a low dose of AZD5658/placebo and one on a high dose of AZD5658/placebo under fed conditions), except for patients participating
in the evaluation of the effect of fasting, who received a maximum of three single oral suspension doses. For each patient the study
included a pre-entry visit (Visit 1), two or three clinic-based treatment visits (Visit 2, 3, and 4) and a follow-up visit (Visit 5).
Hence, the total duration of the study for each patient was approximately two and one-half months, assuming three weeks between dose
levels. There were no deaths, serious adverse events, discontinuations due to adverse events, or adverse events of severe intensity during
the study. Overall, there were 13 (61.9%) AZD5658-treated patients with adverse events compared to 2 (28.6%) patients who received placebo.
There were no trends noted with increasing dose in the number of adverse events overall or within any preferred term. The most frequently
occurring adverse events were hypoglycemia and diarrhea, each occurring in three AZD5658-treated patients. One adverse event of ear
pain (30 mg AZD5658 fed) was assessed by the study investigator as moderate in intensity; all other adverse events were of mild intensity.
Five adverse events in AZD5658- treated patients were assessed by the investigator as causally related to investigational product, including
hypoglycemia in three patients (100 mg, 200 mg fasted, and 400 mg AZD5658), diarrhea in one patient (200 mg AZD5658 fasted), and headache
in one patient (30 mg AZD5658). No adverse events in placebo-treated patients were assessed as causally related to investigational product.
The three patients who experienced hypoglycemia adverse events were treated with intake of food or orange juice and the episodes resolved
in less than one hour.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD5904
was subject to five Phase I clinical studies, with a total of 1,181 subjects being exposed to AZD5904. Single doses of up to 1200 mg
and multiple doses of up to 325 mg for up to three times per day for 21 days have been administered as an oral solution in the completed
clinical studies. In addition, single doses of up to 1,400 mg and multiple doses of up to 600 mg for 10 days have been administered as
an &#8220;extended release&#8221; formulation. The data from these studies did not identify any expected adverse drug reactions for AZD5904
and no adverse effects were reported as related to AZD5904. In addition, the data revealed no clinically significant changes in blood
pressure or pulse rate related to AZD5904 and electrocardiogram data was within the physiological range for the population studied. The
effect of AZD5904 on human myeloperoxidase, which we refer to as MPO, activity was evaluated by determination in an ex vivo assay of
MPO activity in plasma. The correlation between MPO activity and plasma concentrations was assessed for single and multiple doses of
AZD5904. A relationship between plasma concentrations of AZD5904 and MPO activity was demonstrated, which indicates that AZD5904 may
be an effective inhibitor of MPO activity in humans. However, Phase I trials do not assess statistical significance so additional Phase
II trials are necessary to determine if the inhibition of MPO activity as a result of AZD5904 is statistically significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Asset
Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
initial development plan is to conduct a Phase II clinical trial on AZD1656 in Lupus (including Lupus Nephritis) and ANCA Vasculitis
(AAV). Should we choose to develop AZD1656, AZD5658, or AZD5904, that development would be subject to the terms of the License Agreement,
described in more detail below. We anticipate developing our Initial Pipeline (which has already undergone pre-clinical and clinical
trials) through the Phase II stage and then monetizing such clinical assets through a license, royalty, or other transaction at this
stage. At this time, we do not expect that we will commercialize any clinical assets or seek marketing approval from the FDA (or similar
organizations) as we intend to enter into agreements with third parties following Phase II clinical trials for each such clinical asset
that would provide that such third party would pursue the further development, commercialization, and marketing of such assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
enable us to monetize our clinical assets, we, in partnership with CROs and KOLs, intend to conduct additional clinical trials on our
clinical assets in order to generate clinical data to support the further development of our clinical assets beyond the Phase II stage.
In the event successful clinical trial data is generated for a clinical asset with a particular indication, at that point, we will seek
to enter into a license, royalty, or other transaction with a third party whereby the third party would continue to pursue the development
of the clinical asset in Phase III clinical trials. There is no assurance that any clinical trials on the assets owned or licensed by
us will be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the income received from licensing clinical assets in our pipeline to fund the development of additional clinical assets,
which will allow us to use the existing income stream from clinical assets that have been licensed to fund our on-going operations, including
the development and commercialization of additional clinical assets, without having to rely solely on debt and/or equity financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Development Strategy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy is to generate value through the development of new medicines, or clinical assets, for patients where our research
indicates that there are not effective pharmaceutical treatments available or such existing pharmaceutical treatments are not
adequate due to, among other things, cost of such pharmaceuticals and side effects. We are working to develop new medicines in
disorders where competitive treatments carry a high incidence of unacceptable side effects resulting in tolerability and compliance
issues. We aim to extend and develop solid-form intellectual property on assets which are licensed from pharmaceutical companies or
generated within our facility in Cambridge, United Kingdom (the&#8220;UK&#8221;). We believe that our Cambridge facility positions us at the nexus of scientific
advancement, providing an environment to drive cutting-edge research and development initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is evidence that promising solid-form candidates can supersede original pharmaceutical products. We are currently in the process of developing
new solid-form intellectual property on clinical assets which we believe will serve as promising alternatives for existing products on
the market. We believe that our expertise and utilization of solid-form technology can potentially enhance the efficacy, bioavailability,
solubility and delivery of existing products on the market. Once a candidate has been identified and patented, we will fund and conduct
clinical trials through CROs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously indicated, our strategy also involves establishing strategic collaborations with globally recognized KOLs. We will collaborate
closely with disease specific KOLs to collectively assess and determine the most appropriate indications for all our current and forthcoming
assets. This approach ensures that the selection of indications aligns with the KOLs&#8217; insights, in addition to our internal expertise,
optimizing the development and success of Conduit&#8217;s diverse portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
unique relationships allow us to bypass certain traditional hurdles for the development of clinical assets. Through our relationship
with AstraZeneca, our Initial Pipeline has already undergone initial pre-clinical, and, in some instances, clinical testing conducted
by AstraZeneca, which enables us to use the safety data generated in the prior trials in order to assess which assets to continue to
develop. We regularly assess our asset portfolio to identify potential risks and take steps to mitigate those risks, such as the repurposing
of assets, which reduces development costs and timelines, as the clinical asset has already undergone safety and toxicity testing in
humans, as well as extending the remaining patent life by up to 20 years on all assets which are licensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prior preclinical and clinical studies conducted by AstraZeneca allow us to reduce the costs, expenses, and time in the development of
these assets by allowing us to continue the Phase Ib or Phase II stage, rather than the preclinical or Phase I stage, even if we are
investigating the assets for a new indication. For example, if a clinical asset was subject to a Phase I trial, such clinical asset may
be advanced to a Phase II trial even if the clinical asset is being investigated for a different indication. In addition, we have access
to API manufactured by AstraZeneca and as a result, should we use their formulation, we do not have to develop a route of manufacture
for the API, which is time consuming and expensive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Strategic Partnerships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>License
Agreement &#8211; Conduit and AstraZeneca</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 7, 2024, the Company and AstraZeneca entered into the License Agreement. Pursuant to such License Agreement, AstraZeneca agreed
to grant a license to the Company under certain intellectual property rights controlled by AstraZeneca related to HK-4 Glucokinase activators
AZD1656 and AZD5658 in all indications and myeloperoxidase inhibitor AZD5904 for the treatment, prevention, and prophylaxis of idiopathic
male infertility. The Company will be responsible for the development and commercialization of the Licensed Products under the
related License Agreement. The Company is required to use commercially reasonable efforts to develop
and commercialize the Licensed Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for the grant of the license, the Company (i) granted AstraZeneca common stock pursuant to the Issuance Agreement (as further
set out below), (ii) paid AstraZeneca an up-front payment of $1.5 million, and (iii) is obligated to pay AstraZeneca a percentage (on
a tiered basis) of any amounts it may receive in connection with a grant of a sublicense (subject to various customary exceptions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AstraZeneca
has been granted a right of first negotiation to develop, manufacture, and commercialize a Licensed Product if the Company receives an
offer for, or solicits, a transaction where a third party would obtain the right to develop, manufacture, or commercialize a Licensed
Product. If AstraZeneca exercises such right, the parties would negotiate in good faith for an agreed period of time on an exclusive
basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
party may terminate the License Agreement for material breach (subject to a cure period) or insolvency of the other party. The Company
may terminate the License Agreement for convenience (in its entirety or on a Licensed Product-by-Licensed Product basis). In addition,
AstraZeneca may terminate the License Agreement in certain circumstances, including (but not limited to) the Company ceasing development
of all Licensed Products (subject to certain exceptions for normal pauses or gaps between clinical studies).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in connection with the execution of the License Agreement, the Company and AstraZeneca entered into the Issuance Agreement,
whereby the Company issued AstraZeneca 95,044 shares of the Company&#8217;s Common Stock. The Issuance Agreement provides
AstraZeneca with resale registration rights for such shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Services
Agreement &#8211; Conduit and Sarborg Limited</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2024, the Company entered into a Services Agreement (the &#8220;Sarborg Agreement&#8221;) with Sarborg, a Cayman
Islands company and related party of the Company. Under the terms of the Sarborg Agreement, Sarborg will provide algorithmic and cybernetic technology services to
Conduit, including the development of decision-support tools and advanced cybernetic systems tailored to enhance Conduit&#8217;s
decision-making processes and maximize the value of its pharmaceutical asset portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarborg
will perform the services to Conduit comprised of three phases: the Initial Phase (0-24 weeks) focuses on establishing a foundation for
collaboration and aligning Sarborg&#8217;s services with Conduit&#8217;s strategic goals; the Development Phase (24-36 weeks) involves
building technological infrastructure, including dashboards and predictive models; and the Ongoing Services Phase (36-52 weeks) ensures
the sustained functionality and relevance of Sarborg&#8217;s deliverables while supporting Conduit&#8217;s growth through iterative improvements
and updates. Sarborg will create specific deliverables, including reports, computer programs, software applications, APIs, mobile applications,
source code, written technical specifications and designs, operating and maintenance manuals, and other recorded data and information
arising from or relating to the services. Sarborg will provide all necessary resources to perform the services and deliver the deliverables
in accordance with the Sarborg Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, Conduit has successfully completed the Initial Phase of its collaboration with Sarborg, establishing a strong foundation for integrating
AI-driven solutions into our operations. This phase focused on identifying key inputs for the algorithmic approach and ensuring alignment
between Sarborg&#8217;s services and Conduit&#8217;s strategic goals. As part of this effort, Sarborg has successfully delivered three
key milestones. First, they conducted detailed teach-in sessions with Conduit&#8217;s management team to gain a deeper understanding
of our objectives, challenges, and operational workflows, resulting in documented meeting agendas, minutes, and action plans. Second,
they finalized and validated a set of proprietary inputs essential for their cybernetic models, tailored specifically to Conduit&#8217;s
portfolio and R&amp;D pipeline. Finally, they completed an in-depth market analysis of potential cocrystal candidates, assessing the
patent landscape, competitive positioning, and market size. The insights from this Annual Report are now informing Conduit&#8217;s ongoing
strategic decision-making. With these key milestones delivered, we are now progressing to the next phase of development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarborg
has now commenced Phase II: The Development Phase, which focuses on building the technological infrastructure necessary to integrate
AI into Conduit&#8217;s operations. As part of this, Sarborg has successfully completed the first milestone, Dashboard Creation and Refinement,
delivering personalized dashboards that provide Conduit&#8217;s key personnel with real-time access to critical data related to deliverables,
clinical trials, and drug discovery. These initial dashboards, along with user interface mock-ups and a dashboard user guide, will serve
as the foundation for further refinements. Moving forward, the platform will continue to be optimized to maximize efficiency and ensure
seamless integration into Conduit&#8217;s workflows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Master
Service Agreement &#8211; Conduit and Charles River Laboratories </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 7, 2025, Conduit and Charles River Laboratories (&#8220;Charles River&#8221;) entered into a Master Services Agreement (the
&#8220;Charles River MSA&#8221;). Under the Charles River MSA, Charles River agreed to provide preclinical testing and research
services to Conduit, including the evaluation of compounds in animal models and other related services. The services are defined in
individual Statements of Work (&#8220;SOWs&#8221;) or Protocols, which outline the specific scope, design, and timelines for each
study. To date, one SOW, dated February 11, 2025, has been entered into. Charles River will conduct the studies in compliance with
applicable laws and industry standards, and Conduit will provide necessary test articles and materials. The Charles River MSA
includes provisions for confidentiality, intellectual property ownership, indemnification, and dispute resolution. The Charles River
MSA has a term of five years and can be terminated by either party under specified conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Global
Biotechnology Industry</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global biotechnology industry comprises a large range of companies engaged in diverse activities, such as biopharmaceutical development.
The industry companies also span across a wide spectrum of operational models. Some small, dedicated biotechnology companies are research
and development (&#8220;R&amp;D&#8221;) intensive and operate primarily with venture capital, grants, initial public offerings and collaborative
agreements. Conversely, large, diversified companies hold significant in-house R&amp;D resources and well-established production, commercialization,
and distribution processes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
believes that the global biotechnology market was valued at $1.68 trillion in 2024 and is projected to grow at a compound annual growth
rate (&#8220;CAGR&#8221;) of 9.18% from 2024 to 2033.<sup>1</sup> The market is driven by strong government support through initiatives
aimed at the modernization of regulatory framework, improvements in approval processes and reimbursement policies, as well as standardization
of clinical studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
investor confidence has fallen during the period, which served to somewhat subdue revenue growth. However, global investment in R&amp;D
has grown strongly and consistently in recent years, with much of this funding funneled into medical biotechnology development, aimed
at providing better care for the aging global population, thus bolstering industry revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Global
Pharmaceutical Industry</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the previous five years, pharmaceutical companies have benefited from an aging population in developed economies and a growing middle
class in emerging economies. Many companies have also tapped into regional demand for pharmaceuticals that may differ from developed
markets and have expanded their global presence to tap into regional market needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
cliffs have continued to hamper industry revenue during the current period. When drugs lose patent exclusivity, the market is inundated
with low-cost generic drugs. As manufacturers contend with more price-based competition from generics, many operators respond by lowering
their R&amp;D expenditures, which limits the industry&#8217;s drug pipelines. Additionally, many governments and health insurance organizations
have reduced their drug reimbursements to control healthcare costs, such as implementing incentives for patients to use generic drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moving
forward, revenue is forecast to grow an annualized 3.2% to $1.3 trillion over the next five years amid an anticipated persistence of
global demand for industry products.<sup>2</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Initial Pipeline: AZD1656, AZD5658 and AZD5904</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
wholly own the intellectual property and the rights to further develop the solid-form Cocrystals of AZD1656 (AZD1656 Cocrystal&#8211;
pending international patent applications if granted should expire no earlier than 2042) which we intend to target a wide range of autoimmune
disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we currently have the exclusive rights to develop clinical assets, AZD1656 and AZD5658 in all human indications and AZD5904
in idiopathic male infertility which are licensed to us by AstraZeneca.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
of our proprietary owned patented clinical assets, AstraZeneca granted a license to the Company of certain intellectual property rights
controlled by AstraZeneca related to HK-4 Glucokinase activators AZD1656 and AZD5658 in all indications and myeloperoxidase inhibitor
AZD5904 for the treatment, prevention, and prophylaxis of idiopathic male infertility. The Company will be responsible for the development
and commercialization of the Licensed Products. The Company is required to use commercially reasonable efforts to develop and commercialize
the Licensed Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to our relationship with AstraZeneca, we intend to leverage the data generated from these historical trials in order to investigate the
efficacy and safety to AZD1656 to potentially treat Lupus and ANCA Vasculitis patients, and the efficacy and safety of AZD5904 to treat
IMI. AZD1656 has undergone testing in a total of 20 Phase I clinical trials and five Phase II clinical trials conducted by AstraZeneca
since 2008 and 19 of which were conducted in the U.S. Additional information about those clinical trials is available at the U.S. National
Library of Medicine&#8217;s website at www.clinicaltrials.gov (however, the information contained on or otherwise accessible through
such website is not part of this annual report). AZD5904 has undergone testing in five Phase I clinical trials conducted by AstraZeneca,
one of which was conducted in the U.S. While a significant amount of clinical trial data has already been generated for both AZD1656
and AZD5904, some of this data was generated outside of the U.S. and accordingly may not be accepted by the FDA. In the event that such
data is not accepted by the FDA, additional clinical trials may be required, which would result in additional costs and time to develop
these clinical assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup></span>(2025,
January 8). <i>Biotechnology Market Size to Worth Around USD 3.54 Trillion by 2033</i>. BioSpace.com. https://www.biospace.com/press-releases/biotechnology-market-size-to-worth-around-usd-3-54-trillion-by-2033</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2</sup></span>
<i>IBISWorld Industry Report L6724-GL &#8211; Global Biotechnology, May 2021</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the pre-clinical or clinical trials that have been conducted by or at the direction of AstraZeneca to date on
the particular clinical asset. All of these pre-clinical or clinical trials were conducted by AstraZeneca prior to Conduit entering into
the License Agreement with AstraZeneca. None of the pre-clinical or clinical trials that have taken place to date were conducted by or
at the direction of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asset</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutic
    Area</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stage
    of Development</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Location
    of Trials</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD1656</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    2 Diabetes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary,
    Phase I and Phase II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    Kingdom; United States</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD1656</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renal
    Transplant Patients with Type II Diabetes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary,
    Phase I and Phase II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    Kingdom</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD1656</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covid-19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary,
    Phase I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    Kingdom</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD5904</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Idiopathic
    Male Infertility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary,
    Phase I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Union; United States</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD5658</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    2 Diabetes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary,
    Phase I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the current asset development stage for each of AZD1656 and AZD5904 for the indications noted below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asset</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutic
    Area</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
    at Their Present Stage of Readiness<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Next
    Stage of Development to be Conducted by Conduit</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated
    Exit Stage for Monetization<sup>(3)</sup></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 19%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD1656</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lupus
    &amp; ANCA Vasculitis</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#9746;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
    completion of Phase II</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD5904</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Idiopathic
    Male Infertility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#9746;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
    completion of Phase II</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD5658</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
    Autoimmune Disorders</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#9746;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
    completion of Phase II</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD1656</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covid-19,
    Long Covid</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#9746;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A<sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A<sup>(2)</sup></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    that the asset is considered ready for this Phase. For example, if an asset is listed under Phase II, this means that the asset has
    already completed Phase I trials and is therefore considered Phase II ready.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not intend to provide additional funding to develop AZD1656 for Covid-19, which is principally owned by third parties. However,
    we are entitled to a portion of the revenues in the event that AZD1656 is further developed by a third party and is monetized, whether
    through a sale, license agreement, or otherwise.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    the stage at which we currently anticipate that we will seek to monetize such assets through a license, royalty, or other transaction
    with a third party, who would then seek to continue the development of such clinical asset until its potential commercialization
    after Phase III clinical trials were completed. There is no assurance that we will be able to monetize such assets by entering into
    a license, royalty, or other transaction with a third party. In addition, there is no assurance that any of the clinical assets licensed
    or owned by us will successfully complete Phase II or Phase III clinical trials or obtain regulatory approvals, or that such assets
    will be monetized or commercialized.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD1656
was subject to Phase I and Phase II clinical trials consisting of 23 studies in 526 subjects, 446 of whom were dosed with AZD1656.
Other than for the intended effect of lowering glucose, there were no difference identified between the AZD1656-treated and
placebo-treated subjects relating to adverse events. All of the cases where low glucose levels were identified were managed by the
patients and resolved. Based on these clinical trials, no safety signals were identified regarding vital signs, safety laboratory
values or electrocardiogram data. No deaths occurred in any studies with healthy volunteers or patients. AZD1656 was also subject to
Phase II clinical trials consisting of two studies where AZD1656 was given to patients with Type 2 Diabetes Mellitus for four months
or longer. In total, there were 754 randomized patients, 516 of whom were exposed to AZD1656 (316 men and 200 women). There were no
clinically important differences in the adverse effects profile between the AZD1656 treatment group and the AZD1656 placebo group
and there were no deaths in either of the Phase II studies. The efficacy of AZD1656 as a potential treatment for diabetes was also
assessed during the Phase II clinical trials, including whether the efficacy was statistically significant. Clinically relevant and
statistically significant reductions in HbA1c were seen after four months; however, the initial improvement in glucose control
deteriorated over time and the change in HbA1c levels after four months were not statistically different than the placebo. This
decreasing efficacy over time was seen in both Phase II studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD5658
was subject to a randomized, single-blind, placebo-controlled, single-center, Phase I study to assess the safety, tolerability, pharmacokinetics,
pharmacodynamics and the effect of fasting after single ascending oral doses of AZD5658 in Type 2 Diabetes Mellitus patients. There were
six dose levels with eight patients in each cohort, six receiving AZD5658 and two receiving placebo. The effect of fasting on the pharmacokinetics
of AZD5658 was also studied for two dose levels. Each patient treated with metformin received a maximum of two single oral suspension
doses (one on a low dose of AZD5658/placebo and one on a high dose of AZD5658/placebo under fed conditions), except for patients participating
in the evaluation of the effect of fasting, who received a maximum of three single oral suspension doses. For each patient the study
included a pre-entry visit (Visit 1), two or three clinic-based treatment visits (Visit 2, 3, and 4) and a follow-up visit (Visit 5).
Hence, the total duration of the study for each patient was approximately two and one-half months, assuming three weeks between dose
levels. There were no deaths, serious adverse events, discontinuations due to adverse events, or adverse events of severe intensity during
the study. Overall, there were 13 (61.9%) AZD5658-treated patients with adverse events compared to 2 (28.6%) patients who received placebo.
There were no trends noted with increasing dose in the number of adverse events overall or within any preferred term. The most frequently
occurring adverse events were hypoglycemia and diarrhea, each occurring in three AZD5658-treated patients. One adverse event of ear pain
(30 mg AZD5658 fed) was assessed by the study investigator as moderate in intensity; all other adverse events were of mild intensity.
Five adverse events in AZD5658- treated patients were assessed by the investigator as causally related to investigational product, including
hypoglycemia in three patients (100 mg, 200 mg fasted, and 400 mg AZD5658), diarrhea in one patient (200 mg AZD5658 fasted), and headache
in one patient (30 mg AZD5658). No adverse events in placebo-treated patients were assessed as causally related to investigational product.
The three patients who experienced hypoglycemia adverse events were treated with intake of food or orange juice and the episodes resolved
in less than one hour.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD5904
was subject to five Phase I clinical studies, with a total of 1,181 subjects being exposed to AZD5904. Single doses of up to 1,200 mg and
multiple doses of up to 325 mg for up to three times per day for 21 days have been administered as an oral solution in the completed
clinical studies. In addition, single doses of up to 1,400 mg and multiple doses of up to 600 mg for 10 days have been administered as
an &#8220;extended release&#8221; formulation. The data from these studies did not identify any expected adverse drug reactions for AZD5904
and no adverse effects were reported as related to AZD5904. In addition, the data revealed no clinically significant changes in blood
pressure or pulse rate related to AZD5904 and electrocardiogram data was within the physiological range for the population studied. The
effect of AZD5904 on human myeloperoxidase, which we refer to as MPO, activity was evaluated by determination in an ex vivo assay of
MPO activity in plasma. The correlation between MPO activity and plasma concentrations was assessed for single and multiple doses of
AZD5904. A relationship between plasma concentrations of AZD5904 and MPO activity was demonstrated, which indicates that AZD5904 may
be an effective inhibitor of MPO activity in humans. However, Phase I trials do not assess statistical significance so additional Phase
II trials are necessary to determine if the inhibition of MPO activity as a result of AZD5904 is statistically significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AZ1656
in Autoimmune Disorders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Autoimmune
disorders refers to a broad group of disorders and conditions that arise from an abnormal immune response to a functioning body part.
For example, autoimmune disorders may arise from an abnormal immune response of major organs (i.e., the heart, kidneys, bladder, liver,
lungs, and skin), glands (i.e., the adrenal gland, pancreas, thyroid, or reproductive organs), digestive system, and tissue (i.e., blood,
connective tissue, muscle, eyes, ears, or vascular system). Management believes that there are over 80 types of autoimmune disorders
that have been identified, including lupus, celiac disease, multiple sclerosis, rheumatoid arthritis, psoriasis, and inflammatory bowel
disease. Autoimmune disorders are often difficult to diagnose and often the cause of the disorders is not known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is estimated by the American Autoimmune Related Diseases Association (&#8220;AARDA&#8221;) that as many as 50 million Americans are living
with an autoimmune disease &#8211; at a cost of $86 billion a year and there is presently no totally effective treatment known to management.
The currently available treatments for autoimmune disorders include non-steroidal anti-inflammatory drugs (&#8220;NSAIDS&#8221;) or immune
suppressants. These treatments often improve the symptoms but ultimately do not cure the disease and often involve side effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD1656
is a highly specific glucokinase activator; originally developed by AstraZeneca for use in diabetes mellitus. It has now been tested
in over 1,000 patients with both type I and II diabetes and no significant safety concerns have been raised. It was most recently tested
in the ARCADIA Phase II trial in diabetic patients hospitalized with Covid-19 on the basis of new research into immunometabolic modulation.
We believe that AZD1656 may be used to activate a patient&#8217;s own immune system in order to limit harmful inflation. We have identified
several autoimmune disorders, which reflects good market potential, with a high level of need that may be treatable using AZD1656. We
believe that our clinical assets have the potential to treat numerous autoimmune disorders. We intend to initially focus on the indications
below in order to maximize the commercial potential of our clinical assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lupus
Nephritis</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lupus
Nephritis (&#8220;LN&#8221;) is a severe progression of Systemic Lupus Erythematosus (&#8220;SLE&#8221;) where the immune system attacks
the kidneys, often resulting in renal failure. There is currently no cure or long-term remission treatment available. LN is clinically
evident in 50-60% of patients with SLE, and is histologically evident in most SLE patients, even those without clinical manifestations
of kidney disease. LN is the main cause of SLE related mortality. Current therapy is based on long-term corticosteroid or immunosuppressive
therapy, with clinical efficacy of biological drugs not yet proven in LN. Side effect issues of all current therapies demonstrate an
unmet need for a safer, patient compliant therapy in LN.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes that LN presents a lucrative opportunity given the potential oversight of two conditions, as a Phase IIa trial can be
designed to allow readouts on the wider characteristics of SLE as well as the nephritis aspects, allowing assessment of the potential
of AZD1656 in the field of SLE as a whole. Additionally, LN is an orphan disease that the Company believes has around 80,000 to 100,000
patients in the U.S., and one million patients worldwide, thereby offering additional incentives for investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes the global LN market was valued at $3.3 billion in 2022 and is projected to grow from $3.6 billion in 2023 to $6.78
billion by 2032, exhibiting a CAGR of 10.3% during the forecast period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SLE
is characterized by dysregulation and a hyperactivity of immune response. In LN, Teff subtype (TH17) has shown significant hyperactivation
leading to skewed T cell differentiation resulting in continued proinflammatory environment, leading to prolonged inflammation and subsequent
tissue damage and organ function loss. TH17/Treg dysregulation has been characterized in lupus patients compared to healthy individuals.<sup>1</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
a study in mice, findings showed that the IL2/CD25 fusion protein that selectively targets IL-2 on Treg cells induced immune suppression
in a preclinical LN model demonstrating inhibition of LN based on levels of proteinuria, autoantibody titers and kidney histology scores.<sup>2</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ANCA
Vasculitis</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANCA
Vasculitis (&#8220;AAV&#8221;) is an orphan status autoimmune disease affecting small blood vessels which can lead to multiple organ
injury, especially the kidneys, lungs and peripheral nerves. Undiagnosed AAV has a 90% mortality rate within two years.<sup>3</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
maintenance therapies rely on combination of corticosteroid and rituximab, both known for long term use side effects. Recently approved
drugs target specific subpopulations of AAV and have tolerability and side effect issues which demonstrate an unmet need for safer long-term
therapies applicable to all AAV sufferers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
imbalance of Th17/activated Treg cells has been shown in AAV and this has been correlated with renal involvement (with a positive correlation
in creatinine and BUN levels). <sup>4</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low
dose IL2 therapy in AAV patients, the Company believes, resulted in rebalance of Th17/Treg ration. The levels of Erythrocyte Sedimentation
Rate (ESR) and C-Reactive Protein (CSR) were also significantly decreased, which the Company believes indicates an improvement in disease
activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes the seven major AAV markets reached a value of $339.0 million in 2023 and is expected to reach $534.3 million by 2034,
exhibiting a CAGR of 4.22% during 2024 to 2034.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1
</sup>Paquissi FC et al. Front Med (Lausanne). 2021 Sep; 8: 654912 (<span style="text-decoration: underline">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446428/</span>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2
</sup>Wang et al. Mol Immunol. 2020; 118: 19-29 (https://pubmed.ncbi.nlm.nih.gov/34108258/)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>3
</sup>Hunter et al. BMJ. 2020;369 (https://www.bmj.com/content/369/bmj.m1070)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>4
</sup>Wang et al. Mol Immunol. 2020; 118: 19-29 (https://pubmed.ncbi.nlm.nih.gov/34108258/)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD1656
was previously subject to preclinical and clinical trials, including Phase I and Phase II trials, conducted by AstraZeneca relating to
its potential to treat type 2 diabetes. As of the date hereof, no preclinical or clinical trials have been conducted on the use of AZD1656
to treat autoimmune disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to conduct further trials on AZD1656 relating to autoimmune disorders. We plan to conduct further research on AZD1656 to investigate
if AZD1656 is a treatment option, including investigating any negative side effects in the use of AZD1656 as compared to the currently
available treatment options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AZD5904
in Idiopathic Male Infertility</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Idiopathic
Male Infertility (&#8220;IMI&#8221;) is defined as failure of a couple to conceive after one year of regular sexual intercourse where
the physical examination and endocrine laboratory testing of the male are normal, but semen analysis reveals sperm abnormalities. Approximately
15% of couples globally, or 48.5 million couples globally, are infertile and that 30% of infertility cases can be attributed solely to
the female, 30% can be attributed solely to the male, 30% can be attributed to a combination of both partners, and 10% of cases have
an unknown cause.<sup>5</sup> According to the National Library of Medicine, male infertility accounts for 30% of infertility cases
and its prevalence in the general population approximately ranges between 9 to 15%.<sup>6</sup> Our management believes that male
sperm counts have declined in Western men and will continue to decline due, in part, to increasing rates of disorders such as obesity
and diabetes that can reduce fertility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMI
affects families worldwide and is inherent in problems of reproduction. Currently, there are no specific treatments for male infertility,
and we are not aware of any other company that is developing a treatment for male infertility. There are no approved pharmacotherapies
for idiopathic male infertility. Lifestyle medicine and unproven supplements are often used. Intracytoplasmic sperm injection, a form
of in vitro fertilization, is the only treatment currently available for male infertility. This process is not a treatment of male infertility
but rather is an alternative means of fertilizing the egg. In vitro fertilization places a significant burden on the woman as it requires
the induction of egg production and harvesting of eggs. In vitro fertilization is costly and time consuming and has modest success rates.
Management believes that the male infertility market size is expected to grow from $3.72 billion in 2023 to $4.42 billion by 2028, at
a CAGR of 3.54% during the period 2023-2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Damaged
sperm are unable to successfully fertilize eggs due to factors including impaired motility, impaired ability to penetrate and/or DNA
damaged sperm that is unable to form a viable fetus. Our development pipeline for AZD5904 includes a potent, irreversible inhibitor of
human myeloperoxidase, which we refer to as MPO, that has the potential to treat idiopathic male infertility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD5904
was investigated by AstraZeneca for the treatment of idiopathic male infertility in Phase I trials, which confirmed the suitability to
progress to Phase II trials. While AZD5904 is Phase II ready, our management intends to conduct a Phase Ib &#8220;proof of mechanism&#8221;
trial to verify AZD5904 has the intended biological effect in semen (as well as in blood) prior to commencing a Phase II trial for the
use of AZD5904 to treat idiopathic male infertility. Specifically, our management intends to conduct the Phase Ib study in order to see
if the trial will provide evidence that AZD5904 has its intended effect of inhibiting myeloperoxidase and reduce oxidative stress in
semen. We believe that AZD5904 has the potential to be used to create a tablet that could treat IMI and would be the first drug developed
to directly treat IMI. We, in connection with a CRO, have prepared clinical trial protocols relating to the use of AZD5904 to treat IMI
in a Phase Ib clinical trial: a Phase Ib, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety,
tolerability and preliminary efficacy of AZD5904 in adult men with IMI with an anticipated enrollment of 60 patients, and a Phase II
clinical trial: a Phase II, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of AZD5904
in the treatment of IMI with an anticipated enrollment of 200 patients. There can be no assurances that the clinical trials that we intend
to conduct on AZD5904 to treat idiopathic male infertility will be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Future
Clinical Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of our strategic planning process, we intend to explore the efficacy of using AZD1656 and AZD5658 to treat other disorders.
Specifically, we intend to conduct research on whether AZD1656 and AZD5658 may be effective treating other autoimmune disorders,
include rheumatoid arthritis, multiple sclerosis, motor neuron disease, and amyotrophic lateral sclerosis. As part of our strategic
planning process, we intend to explore the efficacy of using AZD1656 to treat other disorders. We also plan to further develop the
co-crystals that we own from our prior development work on AZD1656, including to research the ability of the co-crystals developed
from AZD1656 to treat psoriasis, Crohn&#8217;s disease, lupus, sarcoidosis, diabetic wound healing, idiopathic pulmonary fibrosis,
and non-alcoholic steatohepatitis. In addition, we currently intend to explore the use of AZD5904 for the treatment of glioma. We
expect to seek to develop other clinical assets and determine based on pre-clinical and clinical data which clinical assets in order
to determine which assets in our pipeline to continue to develop. Accordingly, we believe that our management team will be able to
effectively allocate resources to the development of clinical assets that we believe show the most promise. However, there can be no
guarantee that the clinical trials conducted by us of our clinical assets will be successful. If we are unable to commercialize our
clinical assets or experience significant delays in doing so, our business will be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently own or operate any facilities to formulate, manufacture, test, store, package, or distribute any of the clinical assets
that we are developing or may seek to develop and do not currently have the capabilities to conduct such activities. We currently rely
on third parties to manufacture, store, and test the clinical assets that we seek to develop, including material manufactured originally
by AstraZeneca. We will depend on third-party suppliers and manufacturing organizations for all our required raw materials and drug substance
and to formulate, manufacture, test, store, package, and distribute clinical trial quantities of clinical assets that we may seek to
develop. We plan to continue to use third-party suppliers and manufacturing organizations and we anticipate expanding our network of
third-party suppliers and manufacturing organizations as our operations expand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>5
</sup>&#8220;A unique view on male infertility around the globe,&#8221; by Ashok Agarwal, Aditi Mulgund, Alaa Hamada, and Michelle Renee
Chyatte (Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424520/).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>6
</sup>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057583/#B1-jcm-12-02366</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have internal personnel and utilize consultants with extensive technical, manufacturing, analytical, and quality experience to oversee
our contract manufacturing and testing activities. Manufacturing is subject to extensive regulations that impose procedural and documentation
requirements, including, but not limited to, record-keeping, manufacturing processes and controls, personnel, quality control, and quality
assurance. Our systems, procedures, and contractors are required to be in compliance with these regulations and are assessed through
regular monitoring and formal audits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development activities have included developing co-crystals of AZD1656 to increase patent life. Most of this work is conducted
in our laboratories based in Cambridge, UK, but parts of this work is completed by third-party CROs but all intellectual property is
retained by us. The successful completion of clinical trials increases the value of clinical assets and may lead to the commercialization
and/or licensing of such assets to other pharmaceutical companies. There is no assurance that any clinical trials on the assets owned
or licensed by us will be successful or any assurance our co-crystal development will be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not intend to further fund the research and development of the use of AZD1656 in Covid; however, we retain an economic interest in
the AZD1656 in the indication of Covid and if AZD1656 is further developed in Covid through funding provided by other third parties,
then we may be entitled to receive compensation from those development activities conducted by third parties due to its economic interest
in AZD1656 in Covid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
and Marketing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have marketing, sales, or distribution capabilities. In order to commercialize any clinical asset that is approved for
commercial sale, we must either develop our own sales, marketing, and distribution infrastructure or collaborate with third parties that
have such commercial infrastructure and relevant marketing and sales experience. We anticipate relying on licensing, co-sale, co-promotion,
and distribution agreements with strategic partners for the commercialization of our products. We do not currently anticipate that we
would develop our own internal sales force organization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in the highly competitive pharmaceutical and biotechnology industry. Our competitors may include public and private companies,
universities, governmental agencies, and other research organizations actively engaged in the research and development of clinical assets
and biopharmaceutical products. Our competitors may have greater financial, technical, and human resources than we currently have and/or
may be better equipped to develop, manufacture, and market their products. Our competitors may be developing clinical assets for products
for similar indications. However, we believe that we have an unprecedented advantage in novelty. As discussed above, AZD1656 is an activator
(not an inhibitor) of a metabolic process. We anticipate that the number of companies seeking to develop clinical assets, biopharmaceutical
products, and therapies will continue to increase. As a result, the competition we face may also increase. However, both in the treatment
of autoimmune disease and idiopathic male infertility the competition is currently expected to come in years, even if biopharmaceutical
products that we develop and/or commercialize were not to compete with products of our competitors based on the product efficacy, safety,
ease of use, price, demonstrated cost-effectiveness, marketing effectiveness, service, reputation, and access to technical information.
However, we believe that our ability to focus on clinical assets that have been deprioritized by larger pharmaceutical companies is a
competitive advantage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold exclusive rights to develop AZD1656, AZD5658, and AZD5904 through our License Agreement with AstraZeneca and we also own the intellectual
property and the rights to further develop co-crystals resulting from our prior research and development work on AZD1656.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On December 18, 2024, Conduit UK Management Limited (&#8220;Conduit&#8221;) received a notification from the UK Intellectual
Property Office (&#8220;UK IPO&#8221;) notifying the company that St George Street Capital had initiated patent entitlement proceedings
with respect to patent application PCT/IB2022/00775 (&#8220;Patent Application&#8221;). Conduit refutes the claims made by St George Street
Capital and filed a counterstatement on February 26, 2025 with the UK IPO. In addition, each of the three inventors named in the Patent
Application filed simultaneous counterstatements fully supporting Conduit&#8217;s position, and assertions that the claims are without
merit. Further updates will be made following notification by the UK IPO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have eight pending patent applications in several international jurisdictions. Even though we have filed patent applications,
there is no guarantee that the validity of the patents will be upheld if challenged by a third party, that patents will be granted on
the applications filed in the respective jurisdictions, or that once granted, the patents will contain claims that encompass our commercial
products. There can be no assurance that any of our intellectual property rights will afford us any protection from competition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following patent applications are relevant to the operation of our business:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
    Clinical Asset</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mechanism
    of Action</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
    Information and Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 28%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership/Licensing</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status;
    Patent Status</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jurisdictions
    Protected</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD1656</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glucokinase
    Activator</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition
    of Matter Patent; 101901 (family number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed
    to Conduit from AstraZeneca for use in all human indications. Granted and in force.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil,
    Canada, Switzerland, China, Germany, European Procedure, Spain, France, United Kingdom, Hong Kong, India, Japan, South Korea, Mexico,
    Netherlands, Russian Federation, Sweden, Turkey, United States. Granted in Australia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expires
                                            July 3, 2026.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD1656</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glucokinase
    Activator</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymorph
    Patent; 103631 (family number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed
    to Conduit from AstraZeneca for use in human applications. Granted and in force.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China
    and United States</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expires
    February 2030.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD1656</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glucokinase
    Activator</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-crystal
    PCT/IB2022/00075</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned
                                            by Conduit Pharmaceuticals.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    September 2, 2022.</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing
    date September 2, 2022. If granted, will expire September 2, 2042. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD1656</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glucokinase
    Activator</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-crystal
    JP2022-176753</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned
                                            by Conduit Pharmaceuticals.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    November 2, 2022.</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted:
    Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expires
    November 2, 2042.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD5904</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPO
    Inhibitor</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Idiopathic
                                            Male Infertility; AZD5904 use patent; 200644 (family number)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[WO/2019/016074]</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed
    to Conduit from AstraZeneca.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
    Description</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expires
                                            July 12, 2038.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD5658</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glucokinase
    Activator</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition
    of Matter Patent; 101901 (family number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed
    to Conduit from AstraZeneca for use in all human indications. Granted and in force.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia,
    Brazil, Canada, Switzerland, China, Germany, European Procedure, Spain, France, United Kingdom, Hong Kong, India, Japan, South Korea,
    Mexico, Netherlands, Russian Federation, Sweden, Turkey, United States</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expires
    July 3, 2026</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not filed any applications for trademark protection of any names or logos for products or technologies in development. We plan to
seek trademark protection inside and outside of the United States where and when appropriate and if available. We intend to use these
registered marks in connection with our pharmaceutical research and development, including proprietary technologies, as well as our clinical
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to protect our products and technologies through a combination of patents, regulatory exclusivity, and potentially confidential
and proprietary know-how. We intend to actively seek to obtain, where appropriate, the broadest commercially reasonable intellectual
property protection possible for our clinical assets and technologies, including any future clinical assets and technologies under development,
our proprietary information, and our proprietary technology through a combination of contractual arrangements and patents, in the United
States and abroad. However, we cannot guarantee that patent protection will provide complete protection against competitors who seek
to circumvent our patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation and Product Approval</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
authorities in the United States, at the federal, state, and local level, and in other countries, extensively regulate, among other things,
the research, development, clinical trials, testing, manufacture, including any manufacturing changes, authorization, pharmacovigilance,
adverse event reporting, recalls, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import
and export of pharmaceutical products and clinical assets, including clinical assets such as those we are developing. The processes for
obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes
and regulations have no guaranteed outcomes and require the expenditure of substantial time and financial resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
development plan for each of AZD1656, AZD5658 and AZD5904 is to conduct clinical trials and if those trials are successful, we will then
seek to enter into a transaction with a third party with respect to AZD1656, AZD5658 orAZD5904, as applicable, for the particular indication.
We do not intend to continue development of such clinical assets beyond Phase II clinical trials. Accordingly, we anticipate developing
clinical assets, which we own or license from third parties, that have undergone pre-clinical and clinical trials through the Phase II
stage and then monetizing such clinical assets through a license, royalty, or other transaction. We do not expect that we will commercialize
any clinical assets or seek marketing approval from the FDA (or similar organizations) as we intend to enter into agreements with third
parties following Phase II clinical trials for each such clinical asset that would provide that such third party would pursue the further
development, commercialization, and marketing of such assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description of the process relating to obtaining regulatory approvals in the United States and in foreign countries is intended
for informational purposes only as we do not expect to continue the development of any of the clinical assets beyond the Phase II stage.
There is no assurance that any clinical trials on the assets owned or licensed by us will be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>United
States Government Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic
Act (&#8220;FDCA&#8221;) and implementing regulations. Failure to comply with the applicable United States requirements at any time during
the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial
sanctions, such as the FDA&#8217;s refusal to approve pending New Drug Applications (&#8220;NDAs&#8221;), withdrawal of an approval,
imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production
or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil and/or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the United States generally involves the following steps, each of which
requires the expenditure of substantial time and financial resources:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of preclinical laboratory tests, animal studies and formulation studies in compliance with good laboratory practices (&#8220;GLPs&#8221;)
    and other applicable regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an Investigational New Drug Application (&#8220;IND&#8221;), which must become effective before human clinical trials
    may begin;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an independent institutional review board (&#8220;IRB&#8221;) at each clinical site before each trial may be initiated;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of well-controlled human clinical trials in accordance with good clinical practices (&#8220;GCPs&#8221;), which may include placebo
    controls, to establish the safety and efficacy of the proposed drug product for each indication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an NDA and payment of fees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA advisory committee review, if applicable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the product is produced to assess
    compliance with current good manufacturing practices (&#8220;cGMPs&#8221;) and to assure that the facilities, methods and controls
    are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of audits of clinical trial sites conducted by FDA to assure compliance with GCPs and the integrity of clinical data;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the NDA.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preclinical
Studies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
studies include laboratory evaluation of product chemistry, toxicity, and formulation, as well as animal studies to assess potential
safety and efficacy. Preclinical tests intended for submission to the FDA to support the safety of a clinical asset must be conducted
in compliance with GLP regulations and the U.S. Department of Agriculture&#8217;s Animal Welfare Act. A drug sponsor must submit the
results of the preclinical tests, together with manufacturing information, analytical data and any available ex-U.S. clinical data or
relevant literature, among other things, to the FDA as part of an IND. Some nonclinical testing may continue even after the IND is submitted.
An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions
related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and
the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in
the FDA allowing clinical trials to commence. A clinical hold may occur at any time during the life of an IND and may affect one or more
specific studies or all studies conducted under the IND.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research
subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or
terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s
requirements or if the drug candidate has been associated with unexpected serious harm to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trials</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators
in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing
for their participation in any clinical trial along with the requirement to ensure that the data and results reported from the clinical
trials are credible and accurate. Clinical trials are conducted under protocols detailing, among other things, the objectives of the
trial, the criteria for determining subject eligibility, the dosing plan, the parameters to be used in monitoring safety, the procedure
for timely reporting of adverse events, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent
protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical
trial must review and approve the plan for any clinical trial before it commences at that institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
about certain clinical trials and clinical trial results must be submitted within specific timeframes to the National Institutes of Health
for public dissemination on the Clinicaltrials.gov registry. Failure to timely register a covered clinical study or to submit study results
as provided for in the law can give rise to civil monetary penalties and prevent the non-compliant party from receiving future grant
funds from the federal government. The government has begun enforcing these registration and results reporting requirements
against non-compliant clinical trial sponsors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in at least three sequential phases and occasionally four or more, which may require repetition,
or overlap or be combined:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase
I</i></b>: The drug candidate is initially introduced into healthy human subjects or patients with the target disease or condition and
tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of
its effectiveness. During Phase I clinical trials, sufficient information about the investigational drug&#8217;s pharmacokinetics and
pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase II clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase
II</i></b>: The drug candidate is administered to a larger, but still limited patient population to identify possible adverse effects
and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted indications and to determine dosage tolerance
and optimal dosage. Phase II clinical trials are typically well-controlled and closely monitored.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase
III</i></b>: The drug candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial
sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for
approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.
Phase III clinical trials usually involve a larger number of participants than a Phase II clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no guarantee that a clinical asset will successfully complete any such clinical trials. There is no assurance that any clinical trials
on the assets owned or licensed by Conduit will be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interactions
with FDA During the Clinical Development Program</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the clearance of an IND and the commencement of clinical trials, the sponsor of such trial will continue to have interactions with the
FDA. Progress reports detailing the results of clinical trials must be submitted at least annually to the FDA and more frequently if
serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected
suspected adverse reactions; findings from other studies or animal or in vitro testing that suggest a significant risk in humans exposed
to the product; and any clinically important increase in the occurrence of a serious suspected adverse reaction over that listed in the
protocol or investigator brochure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, sponsors are given opportunities to meet with the FDA at certain points in the clinical development program. Specifically,
sponsors may meet with the FDA prior to the submission of an IND (&#8220;pre-IND meeting&#8221;), at the end of Phase II clinical trial
(&#8220;EOP2&#8221; meeting) and before an NDA is submitted (&#8220;pre-NDA meeting&#8221;). Meetings at other times may also be requested.
These meetings provide an opportunity for the sponsor to share information about the data gathered to date with the FDA and for the FDA
to provide advice on the next phase of development. For example, at an EOP2, a sponsor may discuss its Phase II clinical results and
present its plans for the pivotal Phase III clinical trial(s) that it believes will support the approval of the new product. Such meetings
may be conducted in person, via teleconference/videoconference or written response only with minutes reflecting the questions that the
sponsor posed to the FDA and the agency&#8217;s responses. The FDA has indicated that its responses, as conveyed in meeting minutes and
advice letters, only constitute recommendations and/or advice made to a sponsor and, as such, sponsors are not bound by such recommendations
and/or advice. Nonetheless, from a practical perspective, a sponsor&#8217;s failure to follow the FDA&#8217;s recommendations for design
of a clinical program may put the program at significant risk of failure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Acceptance
of NDAs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, along with information
relating to the product&#8217;s chemistry, manufacturing, controls, safety updates, patent information, abuse information and proposed
labeling, are submitted to the FDA as part of an application requesting approval to market the clinical asset for one or more indications.
Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number
of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient
in quality and quantity to establish the safety and efficacy of a drug product. The fee required for the submission and review of an
application under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) is substantial, and the sponsor of an approved application
is also subject to an annual program fee assessed based on eligible prescription drug products. These fees are typically adjusted annually,
and exemptions and waivers may be available under certain circumstances, such as where a waiver is necessary to protect the public health,
where the fee would present a significant barrier to innovation, or where the applicant is a small business submitting its first human
therapeutic application for review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA conducts a preliminary review of all applications within 60 days of receipt and must inform the sponsor at that time or before whether
an application is sufficiently complete to permit substantive review. In pertinent part, the FDA&#8217;s regulations provide that the
agency may refuse to file an application if the application does not include all pertinent information and data necessary for review
by the FDA. In the event that the FDA determines that an application does not satisfy this standard, it will issue a Refuse to File (&#8220;RTF&#8221;)
determination to the applicant. Typically, an RTF will be based on administrative incompleteness, such as clear omission of information
or sections of required information; scientific incompleteness, such as omission of critical data, information or analyses needed to
evaluate safety and efficacy or provide adequate directions for use; or inadequate content, presentation, or organization of information
such that substantive and meaningful review is precluded. The FDA may request additional information rather than accept an application
for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject
to review before the FDA accepts it for filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Review
of NDAs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the submission is accepted for filing, the FDA begins an in-depth substantive review of the application. The FDA reviews the application
to determine, among other things, whether the proposed product is safe and effective for its intended use, whether it has an acceptable
purity profile and whether the product is being manufactured in accordance with cGMP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months from the filing date in which to complete its initial
review of a standard application that is a new molecular entity, and six months from the filing date for an application with &#8220;priority
review.&#8221; The review process may be extended by the FDA for three additional months to consider new information or in the case of
a clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.
Despite these review goals, the NDA review process can be very lengthy, and it is not uncommon for FDA review of an application to extend
beyond the PDUFA target action date. Most innovative drug products (other than biological products) obtain FDA marketing approval pursuant
to an NDA submitted under Section 505(b)(1) of the FDCA, commonly referred to as a traditional or &#8220;full NDA.&#8221; In 1984, with
passage of the Drug Price Competition and Patent Term Restoration Act, informally known as the Hatch-Waxman Act, that established an
abbreviated regulatory scheme authorizing the FDA to approve generic drugs based on an innovator or &#8220;reference&#8221; product,
Congress also enacted Section 505(b)(2) of the FDCA, which provides a hybrid pathway combining features of a traditional NDA and a generic
drug application. Section 505(b)(2) enables the applicant to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy
data for an existing product, or published literature, in support of its application. Section 505(b)(2) NDAs may provide an alternate
path to FDA approval for new or improved formulations or new uses of previously approved products that would require new clinical data
to demonstrate safety or effectiveness. Section 505(b)(2) permits the filing of an NDA in which the applicant relies, at least in part,
on information from studies made to show whether a drug is safe or effective that were not conducted by or for the applicant and for
which the applicant has not obtained a right of reference or use. A Section 505(b)(2) applicant may eliminate or reduce the need to conduct
certain preclinical or clinical studies, if it can establish that reliance on studies conducted for a previously approved product is
scientifically appropriate. The FDA may also require companies to perform additional studies or measurements, including nonclinical and
clinical studies, to support the change from the approved product. The FDA may then approve the new clinical asset for all or some of
the labeled indications for which the referenced product has been approved, as well as for any new indication for which the Section 505(b)(2)
NDA applicant has submitted data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with its review of an application, the FDA will typically submit information requests to the applicant and set deadlines for
responses thereto. The FDA will also conduct a pre-approval inspection of the manufacturing facilities for the new product to determine
whether the manufacturing processes and facilities comply with cGMPs. The FDA will not approve the product unless it determines that
the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production
of the product within required specifications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with IND and GCP requirements and the integrity
of the clinical data submitted to the FDA. To ensure cGMP and GCP compliance by its employees and third-party contractors, an applicant
may incur significant expenditure of time, money and effort in the areas of training, record keeping, production and quality control.
The FDA generally accepts data from foreign clinical trials in support of an NDA if the trials were conducted under an IND. If a foreign
clinical trial is not conducted under an IND, the FDA nevertheless may accept the data in support of an NDA if the study was conducted
in accordance with GCPs and the FDA is able to validate the data through an on-site inspection, if deemed necessary. Although the FDA
generally requests that marketing applications be supported by some data from domestic clinical trials, the FDA may accept foreign data
as the sole basis for marketing approval if (1) the foreign data are applicable to the United States population and United States medical
practice, (2) the studies were performed by clinical investigators with recognized competence, and (3) the data may be considered valid
without the need for an on-site inspection or, if the FDA considers the inspection to be necessary, the FDA is able to validate the data
through an on-site inspection or other appropriate means.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also refer an application, including applications for novel clinical asset which present difficult questions of safety or efficacy,
to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions.
Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews,
evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound
by the recommendation of an advisory committee, but it considers such recommendations when making final decisions on approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
from clinical trials are not always conclusive, and the FDA or its advisory committee may interpret data differently than the sponsor
interprets the same data. The FDA may also re-analyze the clinical trial data, which could result in extensive discussions between the
FDA and the applicant during the review process or delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely
basis or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also may require submission of a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) if it determines that a REMS is necessary
to ensure that the benefits of the drug product outweigh its risks and to assure the safe use of the product. The REMS could include
medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution
methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific
REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed
REMS and the FDA will not approve the application without a REMS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Decisions
on NDAs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews an application to determine, among other things, whether the product is safe and whether it is effective for its intended
use(s), with the latter determination being made on the basis of substantial evidence. The term &#8220;substantial evidence&#8221; is
defined under the FDCA as &#8220;evidence consisting of adequate and well-controlled investigations, including clinical investigations,
by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which
it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have
under the conditions of use prescribed, recommended, or suggested in the labeling or proposed labeling thereof.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has interpreted this evidentiary standard to require at least two adequate and well-controlled clinical investigations to establish
effectiveness of a new product. Under certain circumstances, however, the FDA has indicated that a single trial with certain characteristics
and additional information may satisfy this standard. This approach was subsequently endorsed by Congress in 1998 with legislation providing,
in pertinent part, that &#8220;If [the FDA] determines, based on relevant science, that data from one adequate and well-controlled clinical
investigation and confirmatory evidence (obtained prior to or after such investigation) are sufficient to establish effectiveness, the
FDA may consider such data and evidence to constitute substantial evidence.&#8221; This modification to the law recognized the potential
for the FDA to find that one adequate and well controlled clinical investigation with confirmatory evidence, including supportive data
outside of a controlled trial, is sufficient to establish effectiveness. In December 2019, the FDA issued draft guidance further explaining
the studies that are needed to establish substantial evidence of effectiveness, and in September 2023 it issued a draft guidance that
complements the 2019 draft guidance. The FDA has not yet finalized either guidance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
evaluating the application and all related information, including the advisory committee recommendations, if any, and inspection reports
of manufacturing facilities and clinical trial sites, the FDA will issue either a Complete Response Letter (&#8220;CRL&#8221;) or an
approval letter. To approve the application, the FDA must determine that the drug is effective and that its expected benefits outweigh
its potential risks to patients. This &#8220;benefit-risk&#8221; assessment is informed by the extensive body of evidence about the product&#8217;s
safety and efficacy in the NDA. This assessment is also informed by other factors, including: the severity of the underlying condition
and how well patients&#8217; medical needs are addressed by currently available therapies; uncertainty about how the premarket clinical
trial evidence will extrapolate to real-world use of the product in the post-market setting; and whether risk management tools are necessary
to manage specific risks. In connection with this assessment, the FDA review team will assemble all individual reviews and other documents
into an &#8220;action package,&#8221; which becomes the record for FDA review. The review team then issues a recommendation, and a senior
FDA official makes a decision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL
generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the
FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase III clinical trial(s)
and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is
issued, the applicant will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application
withdrawn or, in its discretion, grant the applicant an additional six-month extension to respond. The FDA has committed to reviewing
resubmissions in response to an issued CRL in either two or six months depending on the type of information included. Even with the submission
of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria
for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific
indications. That is, the approval will be limited to the conditions of use (<i>e.g.</i>, patient population, indication) described in
the FDA-approved labeling. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings
or precautions be included in the product labeling, require that post-approval trials, including Phase 4 clinical trials, be conducted
to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization
or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS which can materially
affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the
results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding
new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and
approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Special
FDA Expedited Review Programs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA is authorized to designate certain products for expedited development or review if they are intended to address an unmet medical
need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough
therapy designation, and priority review designation. The purpose of these programs is to provide important new drugs to patients earlier
than under standard FDA review procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be eligible for a fast-track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat
a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine
that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially
superior to existing therapy based on efficacy or safety factors. Fast track designation provides additional opportunities for interaction
with the FDA&#8217;s review team and may allow for a rolling review of NDA components before the completed application is submitted,
if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines
that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. In addition,
fast track designation may be withdrawn by the sponsor or rescinded by the FDA if the designation is no longer supported by data emerging
in the clinical trial process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, with the enactment of the FDA Safety and Innovation Act (&#8220;FDASIA&#8221;) in 2012, Congress created a new regulatory program
for therapeutic candidates designated by FDA as &#8220;breakthrough therapies&#8221; upon a request made by the IND sponsors. A breakthrough
therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening
disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing
therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
The FDA must take certain actions with respect to breakthrough therapies, such as holding timely meetings with and providing advice to
the product sponsor, intended to expedite the development and review of an application for approval of a breakthrough therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finally,
the FDA may designate a product for priority review if it is a drug that treats a serious condition and, if approved, would provide a
significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a
case-by-case basis, whether the proposed drug represents a significant improvement in treatment, prevention or diagnosis of disease when
compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment
of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance
that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation
is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for
taking action on a marketing application from ten months to six months for an NDA for a new molecular entity from the date of filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for
qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, breakthrough
therapy designation and priority review do not change the standards for approval and may not ultimately expedite the development or approval
process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accelerated
Approval Pathway</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a product studied for its safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful
therapeutic benefit over existing treatments may receive accelerated approval, meaning that it may be approved on (i) the basis of adequate
and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely
to predict clinical benefit, or (ii) on an intermediate clinical endpoint that can be measured earlier than irreversible morbidity or
mortality (&#8220;IMM&#8221;) and that is reasonably likely to predict an effect on IMM or other clinical benefits, taking into account
the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval,
the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted
effect on IMM or other clinical endpoints, and the drug may be subject to expedited withdrawal procedures. Drugs granted accelerated
approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional
post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. As a result, a therapeutic candidate
approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or
post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or
to confirm the predicted clinical benefit of the product during post-marketing studies, would allow the FDA to withdraw approval of
the drug. All promotional materials for drug products being considered and approved under the accelerated approval program are
subject to prior review by the FDA. Lawmakers, FDA officials, and other stakeholders continually evaluate the accelerated approval
program which may lead to legislative and/or administrative changes in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-Approval
Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion
and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications
or other labeling claims, are subject to prior FDA review and approval. Certain modifications to the product, including changes in indications
or manufacturing processes or facilities, may require the applicant to develop additional data or conduct additional preclinical studies
and clinical trials to support the submission to FDA. As previously noted, there also are continuing, annual user fee requirements for
any marketed products, as well as new application fees for supplemental applications with clinical data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing
testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness
after commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP
regulations include requirements relating to the organization of personnel, buildings and facilities, equipment, control of components
and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution,
laboratory controls, records and reports and returned or salvaged products. Drug manufacturers and other entities involved in the manufacture
and distribution of approved drugs are required to register their establishments with the FDA and some state agencies and are subject
to periodic unannounced inspections by the FDA for compliance with cGMP requirements and other laws. Changes to the manufacturing process
are strictly regulated and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA
regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements
upon the sponsor and any third-party manufacturers. Accordingly, manufacturers must continue to expend time, money, and effort in production
and quality control to maintain compliance with cGMP and other aspects of quality control and quality assurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA strictly regulates the marketing, labeling, advertising and promotion of drug products that are placed on the market. A product cannot
be commercially promoted before it is approved, and approved drugs may generally be promoted only for their approved indications and
for use in patient populations described in the product&#8217;s approved labeling. Promotional claims must also be consistent with the
product&#8217;s FDA-approved label, including claims related to safety and effectiveness. The government closely scrutinizes the promotion
of prescription drugs in specific contexts such as direct-to-consumer advertising, industry-sponsored scientific and educational activities,
and promotional activities involving the Internet and social media. Although physicians may prescribe legally available products for
off-label uses, manufacturers may not market or promote such uses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Later
discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing
processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety
information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other
restrictions under a REMS program. Other potential consequences of regulatory non-compliance include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on, or suspensions of, the marketing or manufacturing of the product, complete withdrawal of the product from the market or product
    recalls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    of production processes, including the shutdown of manufacturing facilities or production lines or the imposition of new manufacturing
    requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning letters or other enforcement letters or clinical holds on post-approval clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandated
    modification of promotional materials and labeling and the issuance of corrective information;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal to permit the import or export of products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consent
    decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;)
which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation
of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples
and impose requirements to ensure accountability in distribution. The Drug Supply Chain Security Act (the &#8220;DSCSA&#8221;),
was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United
States. The DSCSA mandated phased-in and resource-intensive obligations for pharmaceutical
manufacturers, wholesale distributors and dispensers by November 2023, but, so as not to disrupt supply chains, the FDA has granted certain
exemptions from enhanced drug distribution security requirements for eligible trading partners for particular periods of time. From time to time, new legislation and regulations
may be implemented that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products
regulated by the FDA. For example, the FDA released proposed regulations in February 2022 to amend the national standards for licensing
of wholesale drug distributors by the states; establish new minimum standards for state licensing third-party logistics providers; and
create a federal system for licensure for use in the absence of a state program, each of which is mandated by the DSCSA. It is impossible
to predict whether further legislative or regulatory changes will be enacted, or FDA regulations, guidance or interpretations will be
changed or what the impact of such potential changes, if any, may be.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulatory
Exclusivity and Approval of Follow-on Products</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Hatch-Waxman
Exclusivity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to enacting Section 505(b)(2) of the FDCA as part of the Hatch-Waxman Amendments to the FDCA, Congress also established an abbreviated
regulatory scheme authorizing the FDA to approve generic drugs that are shown to contain the same active ingredients as, and to be bioequivalent
to, drugs previously approved by the FDA pursuant to NDAs. To obtain approval of a generic drug, an applicant must submit an abbreviated
new drug application (&#8220;ANDA&#8221;) to the agency. An ANDA is a comprehensive submission that contains, among other things, data
and information pertaining to the active pharmaceutical ingredient, bioequivalence, drug product formulation, specifications and stability
of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are &#8220;abbreviated&#8221;
because they cannot include preclinical and clinical data to demonstrate safety and effectiveness. Instead, in support of such applications,
a generic manufacturer must rely on the preclinical and clinical testing previously conducted for a drug product previously approved
under an NDA, known as the reference listed drug (&#8220;RLD&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients,
the route of administration, the dosage form, the strength of the drug and the conditions of use of the drug. At the same time, the FDA
must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is
bioequivalent to an RLD if &#8220;the rate and extent of absorption of the drug do not show a significant difference from the rate and
extent of absorption of the listed drug.&#8221; Unlike the 505(b)(2) NDA pathway that permits a follow-on applicant to conduct and submit
data from additional clinical trials or nonclinical studies in order to support the proposed change(s) to the reference product, the
ANDA regulatory pathway does not allow applicants to submit new clinical data other than bioavailability or bioequivalence data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
approval of an ANDA, the FDA indicates whether the generic product is &#8220;therapeutically equivalent&#8221; to the RLD in its publication
&#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians
and pharmacists consider a therapeutic equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of certain
state laws and numerous health insurance programs, the FDA&#8217;s designation of therapeutic equivalence often results in substitution
of the generic drug without the knowledge or consent of either the prescribing physician or patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the NDA review and approval process, applicants are required to list with the FDA each patent that has claims that cover the
applicant&#8217;s product or method of therapeutic use. Upon approval of a new drug, each of the patents listed in the application for
the drug is then published in the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential follow-on competitors
in support of approval of an ANDA or 505(b)(2) NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
an ANDA applicant submits its application to the FDA, it is required to certify to the FDA concerning any patents listed for the reference
product in the FDA&#8217;s Orange Book. Specifically, the applicant must certify that: (i) the required patent information has not been
filed; (ii) the listed patent has expired; (iii) the listed patent has not expired but will expire on a particular date and approval
is sought after patent expiration; or (iv) the listed patent is invalid or will not be infringed by the new product. Moreover, to the
extent that the Section 505(b)(2) NDA applicant is relying on studies conducted for an already approved product, the applicant also is
required to certify to the FDA concerning any patents listed for the NDA-approved product in the Orange Book to the same extent that
an ANDA applicant would.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the follow-on applicant does not challenge the innovator&#8217;s listed patents, the FDA will not approve the ANDA or 505(b)(2) application
until all the listed patents claiming the referenced product have expired. A certification that the new product will not infringe the
already approved product&#8217;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the follow-on
applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification
to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent
infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within
45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA or 505(b)(2) NDA until
the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable
to the ANDA or 505(b)(2) applicant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivities listed in the Orange Book for the
referenced product have expired. The Hatch-Waxman Amendments to the FDCA provided a five-year period of non-patent data exclusivity within
the United States to the first applicant to gain approval of an NDA for a new chemical entity (&#8220;NCE&#8221;). For the purposes of
this provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active
moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such
NCE exclusivity has been granted, an ANDA or 505(b)(2) NDA may not be filed with the FDA until the expiration of five years unless the
submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its application four years following
the original product approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDCA also provides for a period of three years of data exclusivity if an NDA or NDA supplement includes reports of one or more new clinical
investigations, other than bioavailability or bioequivalence studies, that were conducted or sponsored by the applicant are deemed by
the FDA to be essential to the approval of the application. This three-year exclusivity period often protects changes to a previously
approved drug product, such as new indications, dosage forms, route of administration or combination of ingredients. Three-year exclusivity
would be available for a drug product that contains a previously approved active moiety, provided the statutory requirement for a new
clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from
accepting ANDAs or 505(b)(2) NDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product;
rather, this three-year exclusivity covers only the conditions of use associated with the new clinical investigations and, as a general
matter, does not prohibit the FDA from approving follow-on applications for drugs containing the original active ingredient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five-year
and three-year exclusivity also will not delay the submission or approval of a traditional NDA filed under Section 505(b)(1) of the FDCA;
however, an applicant submitting a traditional NDA would be required to conduct or obtain a right of reference to all of the preclinical
studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Orphan
Drug Designation and Exclusivity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally
a disease or condition that affects either (i) fewer than 200,000 individuals in the United States, or (ii) more than 200,000 individuals
in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United
States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Legislative proposals
are currently being considered that would revise or revoke the second option available for a drug candidate to receive an orphan designation,
the so-called &#8220;cost recovery&#8221; pathway. Orphan drug designation must be requested before submitting an NDA. After the FDA
grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use will be disclosed publicly by the
FDA; the posting will also indicate whether a drug is no longer designated as an orphan drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
than one clinical asset may receive an orphan drug designation for the same indication, and the same clinical asset can be designated
for more than one qualified orphan indication. The benefits of orphan drug designation include research and development tax credits and
exemption from FDA prescription drug user fees. Orphan drug designation does not convey any advantage in or shorten the duration of the
regulatory review and approval process if or when an NDA for the drug candidate is filed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product that has orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation,
the product is entitled to orphan product exclusivity, which means that for seven years, the FDA may not approve any other marketing
applications for the same drug for the same indication, except under limited circumstances described further below. Orphan exclusivity
does not block the approval of a different drug for the same rare disease or condition, nor does it block the approval of the same drug
for different conditions. As a result, the FDA can still approve different drugs for use in treating the same indication or disease.
Additionally, if a drug designated as an orphan product receives marketing approval for an indication broader than what was designated,
it may not be entitled to orphan drug exclusivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
exclusivity will not bar approval of another product with the same drug for the same condition under certain circumstances, including
if a subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis
of greater efficacy or safety or a major contribution to patient care, or if the company with orphan drug exclusivity cannot assure the
availability of sufficient quantities of the drug to meet the needs of persons with the disease or condition for which the drug was designated.
The FDA is now required to publish a summary of the clinical superiority findings when a drug is eligible for orphan product exclusivity
on the basis of a demonstration of clinical superiority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Patent
Term Extension</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
patent claiming a prescription drug for which FDA approval is granted may be eligible for a limited patent term extension under the FDCA,
which permits a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review
provided that certain statutory and regulatory requirements are met. The length of the patent term extension is related to the length
of time the drug is under regulatory review while the patent is in force. The restoration period granted on a patent covering a new FDA-regulated
medical product is typically one-half the time between the date a clinical investigation on human beings is begun and the submission
date of an application for premarket approval of the product, plus the time between the submission date of an application for approval
of the product and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a
total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the
extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers
multiple products for which approval is sought can only be extended in connection with one of the marketing approvals. The USPTO reviews
and approves the application for any patent term extension or restoration in consultation with the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
U.S. Healthcare Laws and Regulations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing,
sales, promotion, and other activities following product approval may also be subject to regulation by other regulatory authorities in
the United States in addition to the FDA. Depending on the nature of the product, those authorities may include the Centers for Medicare
and Medicaid Services (&#8220;CMS&#8221;), other divisions of the Department of Health and Human Services (&#8220;HHS&#8221;), the Department
of Justice, the Drug Enforcement Administration, the Federal Trade Commission, the Occupational Safety and Health Administration, and
state and local governments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, in the United States, sales and marketing for prescription biopharmaceutical products must comply with state and federal fraud
and abuse laws. These laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription
drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that
is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which
payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by up to
ten years in prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs.
In addition, the Patient Protection and Affordable Care Act, or ACA, among other things, amended the intent requirement of the federal
Anti-Kickback Statute and two of the five criminal healthcare fraud statutes created by the Health Insurance Portability and Accountability
Act of 1996, or HIPAA. A person or entity no longer needs to have actual knowledge of these two provisions in the statute or specific
intent to violate them; specifically with respect to the prohibition on executing or attempting to execute a scheme or artifice to defraud
or to fraudulently obtain money or property of any healthcare benefit program and the prohibition on disposing of assets to enable a
person to become eligible for Medicaid. Moreover, the government may now assert that a claim including items or services resulting from
a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more
recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services
Administration, additional laws and requirements apply. There also are federal transparency requirements under the Physician Payments
Sunshine Act that require manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid
to report, on an annual basis, to CMS information related to payments and other transfers of value to physicians, teaching hospitals,
and certain advanced non-physician healthcare practitioners and physician ownership and investment interests. Prescription drug products
also must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing,
sales, promotion, and other activities also are potentially subject to federal and state consumer protection and unfair competition laws.
Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines,
or the relevant compliance guidance promulgated by the federal government, in addition to requiring drug manufacturers to report information
related to payments to physicians and other healthcare providers or marketing expenditures to the extent that those laws impose requirements
that are more stringent than the Physician Payments Sunshine Act. State and foreign laws also govern the privacy and security of health
information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus
complicating compliance efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending
on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties,
injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals
or refusal to allow a firm to enter into supply contracts, including government contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Government
Regulation Outside the U.S.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the United States, we will be subject to a variety of foreign regulations that govern, among other things,
clinical trials and any commercial sales and distribution of our products, if approved, either directly or through distribution partners.
Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in
foreign countries or economic areas, such as the European Union and the United Kingdom, among other foreign countries, before we may
commence clinical trials or market products in those countries or areas. The foreign regulatory approval process includes all of the
risks associated with the FDA approval described above, and the time required to obtain approval in other countries and jurisdictions
might differ from and be longer than that required to obtain FDA approval. Some foreign jurisdictions have a drug product approval process
similar to that in the U.S., which requires the submission of a clinical trial application much like the IND prior to the commencement
of clinical studies. In Europe, for example, a clinical trial application, or CTA, must be submitted to each country&#8217;s national
health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance
with a country&#8217;s requirements, clinical trial development may proceed. To obtain regulatory approval of a medicinal product candidate
under European Union regulatory systems, we would be required to submit a Marketing Authorisation Application, or MAA, which is similar
to the NDA, except that, among other things, there are country-specific document requirements. For countries outside of the European
Union, such as countries in Eastern Europe, Latin America or Asia, and recently the United Kingdom, the requirements governing the conduct
of clinical trials, product approval, pricing and reimbursement vary from country to country. Regulatory approval in one country or jurisdiction
does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction
may negatively impact the regulatory process in others. Moreover, some nations may not accept clinical studies performed for U.S. approval
to support approval in their countries or require that additional studies be performed on natives of their countries. In addition, in
certain foreign markets, the pricing of drug products is subject to government control and reimbursement may in some cases be unavailable
or insufficient. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines,
suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 31, 2020, the United Kingdom is no longer a member state of the European Union, and therefore a separate marketing authorization
application and approval will be required to market a medicinal product in the U.K. The Medicines and Healthcare products Regulatory
Agency, or the MHRA, is the U.K.&#8217;s standalone pharmaceutical regulator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trials and Regulation of Medicinal Products in Europe</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
in the United States, medicinal products can be marketed in the European Union only if a marketing authorization from the competent regulatory
agencies has been obtained. Similar to the United States, the various phases of preclinical and clinical research in the European Union
are subject to significant regulatory controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the European Clinical Trials Directive, a system for the approval of clinical trials in the European Union has been implemented through
national legislation of the member states. Under this system, an applicant must obtain approval from the competent national authority
of a European Union member state in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical
trial after a competent ethics committee has issued a favorable opinion. Clinical trial applications must be accompanied by an investigational
medicinal product dossier with supporting information prescribed by the European Clinical Trials Directive and corresponding national
laws of the member states and further detailed in applicable guidance documents. In April 2014, the new Clinical Trials Regulation, (EU)
No 536/2014 (Clinical Trials Regulation) was adopted and became effective on January 31, 2022. The Clinical Trials Regulation is directly
applicable in all the European Union Member States, repealing the prior Clinical Trials Directive 2001/20/EC. The extent to which ongoing
clinical trials will be governed by the Clinical Trials Regulation will depend on the duration of the individual clinical trial; if a
clinical trial continues for more than three years from the day on which the Clinical Trials Regulation becomes applicable the Clinical
Trials Regulation will at that time begin to apply to the clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics
of the regulation include: a streamlined application procedure via a single entry point; a single set of documents to be prepared and
submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for
the assessment of applications for clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain marketing approval of a drug in the European Union, an applicant must submit a MAA either under a centralized or decentralized
procedure. The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid
for all European Union member states, Iceland, Lichtenstein and Norway. The centralized procedure is compulsory for specific products,
including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy
products (such as gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products with a new active substance indicated
for the treatment of certain disorders. For products with a new active substance indicated for the treatment of certain disorders and
products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may
be optional. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the European Medicines Agency (&#8220;EMA&#8221;)
is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions
asked by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;). Accelerated assessment might be granted by the CHMP
in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view
of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is of 150 days, excluding
stop-clocks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
decentralized procedure is available to applicants who wish to market a product in specific European Union member states where such product
has not received marketing approval in any European Union member states before. The decentralized procedure provides for an applicant
to apply to one-member state to assess the application (the reference member state) and specifically list other member states in which
it wishes to obtain approval (concerned member states).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, only products for which marketing authorizations have been granted may be promoted. A marketing authorization is
valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a re-evaluation of
the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization
holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy,
including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization
ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the
competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any
authorization which is not followed by the actual placing of the drug on the European Union market (in case of centralized procedure)
or on the market of the authorizing member state within three years after authorization ceases to be valid (the so-called sunset clause).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
even if authorized to be marketed in the European Union, prescription medicines may only be promoted to healthcare professionals, not
the general public. All promotion should be in accordance with the particulars listed in the summary of product characteristics. Promotional
materials must also comply with various laws, and codes of conduct developed by pharmaceutical industry bodies in the European Union
which govern (among other things) the training of sales staff, promotional claims and their justification, comparative advertising, misleading
advertising, endorsements, and (where permitted) advertising to the general public. Failure to comply with these requirements could lead
to the imposition of penalties by the competent authorities of the European Union member states. The penalties could include warnings,
orders to discontinue the promotion of the drug product, seizure of promotional materials, fines and possible imprisonment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulation
of New Drugs in the United Kingdom</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United Kingdom left the European Union on January 31, 2020 (commonly referred to as &#8220;Brexit&#8221;), with a transitional period
that expired on December 31, 2020. The United Kingdom and the European Union entered into a trade agreement known as the Trade and Cooperation
Agreement, which went into effect on January 1, 2021. We are currently evaluating the potential
impacts on our business of the Trade and Cooperation Agreement and guidance issued to date by the United Kingdom&#8217;s MHRA regarding
the requirements for licensing and marketing medicinal products in the United Kingdom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the regulatory framework for pharmaceutical products in the United Kingdom covering the quality, safety and efficacy of pharmaceutical
products, clinical trials, marketing authorization, commercial sales and distribution of medicinal products has only recently changed,
it is difficult to draw comparisons about the impact of the new regulatory regime and impact on the approval of product candidates in
the United Kingdom. In addition, even if a drug is licensed in the UK by the MHRA, it must further be approved by the National Institute
for Health &amp; Care Excellence to ensure use within the UK&#8217;s National Health Service (NHS).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pharmaceutical
Coverage, Pricing and Reimbursement, and Healthcare Reform</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our products, if approved for marketing, will depend, in part, on the availability and extent of coverage and reimbursement by third-party
payors, such as government health programs, including Medicare and Medicaid, commercial insurance and managed healthcare organizations.
These third-party payors are increasingly challenging the price and limiting the coverage and reimbursement amounts for medical products
and services. There may be significant delays in obtaining coverage and reimbursement for approved products, and coverage may be more
limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. It is time-consuming
and expensive to seek reimbursement from third-party payors. Moreover, eligibility for reimbursement does not imply that any product
will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution.
Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment
rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for
lower-cost products that are already reimbursed and may be incorporated into existing payments for other services. Net prices for products
may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict
imports of products from countries where they may be sold at lower prices than in the United States. In the United States, third-party
payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but they also have
their own methods and approval process apart from Medicare coverage and reimbursement determinations. Accordingly, one third-party payor&#8217;s
determination to provide coverage for a product does not assure that other payors will also provide coverage for the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the containment of healthcare costs has become a priority for federal and state governments, and the prices of drugs have been
a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing
cost-containment programs, including price controls, restrictions on coverage and reimbursement, and requirements for substitution of
generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions
with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our
clinical assets or a decision by a third-party payor to not cover our clinical assets could reduce physician usage of the clinical asset
and have a material adverse effect on our sales, results of operations and financial condition. Moreover, there has been heightened governmental
scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries
and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review
the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug
products. Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control
pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing. In December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states&#8217; ability
to regulate pharmaceutical benefit managers (&#8220;PBMs&#8221;) and other members of the healthcare and pharmaceutical supply chain,
an important decision that has led to further and more aggressive efforts by states in this area.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On August 16, 2022, President
Biden signed into the law the Inflation Reduction Act of 2022, or the IRA. Among other things, the IRA has multiple provisions that can
impact the prices of drug products that are both sold into the Medicare program and throughout the United States. Beginning in 2023, a
manufacturer of drugs covered by Medicare Parts B or D must pay a rebate to the federal government if their drug product&#8217;s price
increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of the rebate
owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally,
starting for payment year 2026, CMS will negotiate drug prices annually for a select number of single source Part D drugs without generic
or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If
a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements
governing drug pricing vary widely from country to country. For example, in the European Union, the sole legal instrument at the European
Union level governing the pricing and reimbursement of medicinal products is Council Directive 89/105/EEC (the &#8220;Price Transparency
Directive&#8221;). The aim of the Price Transparency Directive is to ensure that pricing and reimbursement mechanisms established in
the European Union Member States are transparent and objective, do not hinder the free movement of and trade in medicinal products in
the European Union, and do not hinder, prevent or distort competition on the market. The Price Transparency Directive does not provide
any guidance concerning the specific criteria on the basis of which pricing and reimbursement decisions are to be made in the individual
European Union Member States, nor does it have any direct consequence for pricing or reimbursement levels in the individual European
Union Member States. The European Union Member States are free to restrict the range of medicinal products for which their national health
insurance systems provide reimbursement, and to control the prices and/or reimbursement levels of medicinal products for human use. A
European Union Member State may approve a specific price or level of reimbursement for the medicinal product, or alternatively adopt
a system of direct or indirect controls on the profitability of the company responsible for placing the medicinal product on the market,
including volume-based arrangements, caps and reference pricing mechanisms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
Technology Assessment (&#8220;HTA&#8221;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement
procedures in some European Union Member States, including France, Germany, Ireland, Italy and Sweden. The HTA process in the European
Union Member States is governed by the national laws of these countries. HTA is the procedure according to which the assessment of the
public health impact, therapeutic impact, and the economic and societal impact of the use of a given medicinal product in the national
healthcare systems of the individual country is conducted. HTA generally focuses on the clinical efficacy and effectiveness, safety,
cost, and cost-effectiveness of individual medicinal products as well as their potential implications for the healthcare system. Those
elements of medicinal products are compared with other treatment options available on the market. The outcome of HTA regarding specific
medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities
of individual European Union Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the
specific medicinal product vary between the European Union Member States. For example, European Union Member States that have not yet
developed HTA mechanisms could rely to some extent on the HTA performed in countries with a developed HTA framework when adopting decisions
concerning the pricing and reimbursement of a specific medicinal product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separately
from cost containment efforts, in the United States and some foreign jurisdictions, there also have been, and continue to be, several
legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval
of product candidates or restrict or regulate post-approval activities. The FDA&#8217;s and other regulatory authorities&#8217; policies
may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our current
or future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Data
Privacy and the Protection of Personal Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to laws and regulations governing data privacy and the protection of personal information including health information. The
legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy
and data protection issues which will continue to affect our business. In the United States, we may be subject to state security breach
notification laws, state laws protecting the privacy of health and personal information and federal and state consumer protections laws
that regulate the collection, use, disclosure and transmission of personal information. These laws overlap and often conflict and each
of these laws is subject to varying interpretations by courts and government agencies, creating complex compliance issues. If we fail
to comply with applicable laws and regulations we could be subject to penalties or sanctions, including criminal penalties. Our customers
and research partners must comply with laws governing the privacy and security of health information, including HIPAA and state health
information privacy laws. If we knowingly obtain health information that is protected under HIPAA, called &#8220;protected health information,&#8221;
our customers or research collaborators may be subject to enforcement, and we may have direct liability for the unlawful receipt of protected
health information or for aiding and abetting a HIPAA violation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
laws protecting health and personal information are becoming increasingly stringent. For example, California has implemented the California
Confidentiality of Medical Information Act that imposes restrictive requirements regulating the use and disclosure of health information
and other personally identifiable information, and California has recently adopted the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;).
The CCPA mirrors a number of the key provisions of the EU General Data Protection Regulation (&#8220;GDPR&#8221;) described below. The
CCPA establishes a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing
new data privacy rights for consumers in the State of California, imposing special rules on the collection of consumer data from minors,
and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement
reasonable security procedures and practices to prevent data breaches. Since passage of the CCPA, several other states (Connecticut,
Colorado, Virginia, and Utah) have also enacted comprehensive consumer privacy laws that include key differences from California&#8217;s
law, further complicating compliance by industry and other stakeholders. Other states in the U.S. are considering privacy laws similar
to the CCPA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Europe, the GDPR went into effect in May 2018, implementing a broad data protection framework that expanded the scope of European Union
data protection law, including to non- European Union entities that process, or control the processing of, personal data relating to
individuals located in the European Union, including clinical trial data. The GDPR sets out a number of requirements that must be complied
with when handling the personal data of European Union-based data subjects including: providing expanded disclosures about how their
personal data will be used; higher standards for organizations to demonstrate that they have obtained valid consent or have another legal
basis in place to justify their data processing activities; the obligation to appoint data protection officers in certain circumstances;
new rights for individuals to be &#8220;forgotten&#8221; and rights to data portability, as well as enhanced current rights (e.g. access
requests); the principal of accountability and demonstrating compliance through policies, procedures, training and audit; and a new mandatory
data breach regime. In particular, medical or health data, genetic data and biometric data where the latter is used to uniquely identify
an individual are all classified as &#8220;special category&#8221; data under the GDPR and afforded greater protection and require additional
compliance obligations. Further, European Union member states have a broad right to impose additional conditions &#8211; including restrictions
&#8211; on these data categories. This is because the GDPR allows European Union member states to derogate from the requirements of the
GDPR mainly in regard to specific processing situations (including special category data and processing for scientific or statistical
purposes). As the European Union states continue to reframe their national legislation to harmonize with the GDPR, we will need to monitor
compliance with all relevant European Union member states&#8217; laws and regulations, including where permitted derogations from the
GDPR are introduced. We will also be subject to evolving European Union laws on data export, if we transfer data outside the European
Union to ourselves or third parties outside of the European Union.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The EU GDPR is an EU Regulation
and it no longer applies to the UK. If you operate inside the UK, you need to comply with the Data Protection Act 2018 (DPA 2018). The
provisions of the EU GDPR have been incorporated directly into UK law as the UK GDPR. On 28 June 2021, the EU approved adequacy decisions
for the EU GDPR and the Law Enforcement Directive (LED). This means data can continue to flow freely from the EU to the UK, in the majority
of cases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Cayman Islands Government enacted the Data Protection Act on May 18, 2017 (as amended, the &#8220;DPA&#8221;). The DPA regulates the
processing of personal data in the Cayman Islands. Under the DPA, the Company is a &#8220;data controller&#8221; and the Company&#8217;s
affiliates and/or its delegates may be &#8220;data processors&#8221; (or, in some circumstances, data controllers in their own right),
in respect of such personal data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Foreign Corrupt Practices Act and Anti-bribery Regulations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, the Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, prohibits offering to pay, paying, promising to pay, or
authorizing the payment of money or anything of value to a foreign official in order to influence any act or decision of the foreign
official in his or her official capacity or to secure any other improper advantage in order to obtain or retain business for or with,
or in order to direct business to, any person. The prohibitions apply not only to payments made to &#8220;any foreign official,&#8221;
but also to those made to &#8220;any foreign political party or official thereof,&#8221; to &#8220;any candidate for foreign political
office&#8221; or to any person, while knowing that all or a portion of the payment will be offered, given, or promised to anyone in any
of the foregoing categories. &#8220;Foreign officials&#8221; under the FCPA include officers or employees of a department, agency, or
instrumentality of a foreign government. The term &#8220;instrumentality&#8221; is broad and can include state-owned or state-controlled
entities. Importantly, United States authorities deem most healthcare professionals and other employees of foreign hospitals, clinics,
research facilities and medical schools in countries with public healthcare and/or public education systems to be &#8220;foreign officials&#8221;
under the FCPA. When we interact with foreign healthcare professionals and researchers in testing and marketing our products abroad,
should any of our product candidates receive foreign regulatory approval in the future, we must have policies and procedures in place
sufficient to prevent us and agents acting on our behalf from providing any bribe, gift or gratuity, including excessive or lavish meals,
travel or entertainment in connection with marketing our products and services or securing required permits and approvals. The FCPA also
obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books
and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise
and maintain an adequate system of internal accounting controls for international operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to U.K. Bribery Act of 2010, which prohibits both domestic and international bribery, as well as bribery across both
private and public sectors. In addition, an organization that &#8220;fails to prevent bribery&#8221; committed by anyone associated with
the organization can be charged under the U.K. Bribery Act unless the organization can establish the defense of having implemented &#8220;adequate
procedures&#8221; to prevent bribery. As we expand our operations, we are likely to be subject to additional laws and restrictions relating
to anti-bribery.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Environmental,
Health, and Safety Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous federal, state, and local environmental, health, and safety (&#8220;EHS&#8221;) laws and regulations relating
to, among other matters, safe working conditions, product stewardship, environmental protection, and handling or disposition of products,
including those governing the generation, storage, handling, use, transportation, release, and disposal of hazardous or potentially hazardous
materials, medical waste, and infectious materials that may be handled by our partner research laboratories. Some of these laws and regulations
also require us to obtain licenses or permits to conduct our operations. If we fail to comply with such laws or obtain and comply with
the applicable permits, we could face substantial fines or possible revocation of our permits or limitations on our ability to conduct
our operations. Certain of our development and manufacturing activities may involve, from time to time, use of hazardous materials, and
we believe we are in compliance with the applicable environmental laws, regulations, permits, and licenses. However, we cannot ensure
that EHS liabilities will not develop in the future. EHS laws and regulations are complex, change frequently and have tended to become
more stringent over time. Although the costs to comply with applicable laws and regulations, have not been material, we cannot predict
the impact on our business of new or amended laws or regulations or any changes in the way existing and future laws and regulations are
interpreted or enforced, nor can we ensure we will be able to obtain or maintain any required licenses or permits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we had a total of six full-time employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely on several consultants who provide services to our Company. None of our employees are represented by a labor union or
covered by collective bargaining agreements. We consider our relationship with our employees to be good. We anticipate that the number
of employees will increase as we continue to develop the assets in our pipeline and other clinical assets that we seek to develop. Additionally,
we utilize and expect to continue to utilize clinical research organizations and third parties to perform our pre-clinical studies, clinical
studies, and manufacturing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated under the name &#8220;Murphy Canyon Acquisition Corp.&#8221; in October 2021 under the laws of the State of Delaware
for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business
combination with one or more businesses. We changed our name to &#8220;Conduit Pharmaceuticals Inc.&#8221; in connection with the completion
of the Business Combination in September 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 4581 Tamiami Trail North, Suite 200 Naples, Florida. Our telephone number is +1 (646)-491-9132,
and our website can be found at https://www.conduitpharma.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in our securities involves a high degree of risk. Investors should carefully consider the risks described below before making
an investment decision. Our business, prospects, financial condition, or operating results could be harmed by any of these risks, as
well as other risks not currently known to us or that we currently consider immaterial. The trading price of our securities could decline
due to any of these risks, and, as a result, stockholders may lose all or part of their investment. Certain statements in &#8220;Risk
Factors&#8221; are forward-looking statements. See &#8220;Cautionary Statement Regarding Forward-Looking Statements.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business and Industry</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred significant net losses since our inception and we anticipate future losses and negative cash flow. It is uncertain if or
when we will become profitable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred net losses since our inception. Our net losses were $17.8 million for the year ended December 31, 2024 and $0.5 million
for the year ended December 31, 2023. As of December 31, 2024, we had an accumulated deficit of $29.1 million. We do not expect to generate
any significant revenues, if any, until we successfully complete adequate development of our first clinical asset. As of December 31,
2024, our clinical assets are still in development and have not been approved by the FDA or any other regulatory body.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet demonstrated our ability to generate revenue, and we may never be able to produce revenues or operate on a profitable basis.
We expect to experience operating losses and negative cash flow for the foreseeable future. Even if we are able to commercialize our
technology, which may include licensing, we may never recover our research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is dependent on the successful development, regulatory approval, and commercialization of our clinical assets, in particular
a glucokinase activator which we believe is active in a range of autoimmune disorders, which we refer to as AZD1656, and a potent, irreversible
inhibitor of human Myeloperoxidase that has the potential to treat idiopathic male infertility, which we refer to as AZD5904.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of our business, including our ability to finance our operations and generate any revenue in the future, will primarily depend
on the successful development, regulatory approval, and commercialization or partnering of our clinical assets. In the future, we may
also become dependent on just one of our clinical assets or any future clinical assets that we may in-license, acquire, or develop. The
preclinical, clinical and commercial success of our clinical assets will depend on a number of factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to raise additional capital to fund our current pre-clinical and clinical plans on acceptable terms, or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timely completion of our clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend
    substantially upon the performance of third-party contractors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we are required by the FDA or similar foreign regulatory agencies to conduct additional preclinical or clinical trials beyond those
    planned to support the approval and commercialization of our clinical assets or any future clinical assets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our clinical assets
    by the FDA or similar foreign regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to demonstrate the safety and efficacy of our clinical assets or any future clinical assets to the satisfaction of the FDA
    and similar foreign regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence, duration, and severity of potential side effects experienced in connection with our clinical assets or future approved
    products, if any;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual
    obligations and with all regulatory requirements applicable to our clinical assets or any future clinical assets or approved products,
    if any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of third parties with whom we contract to manufacture clinical trial and commercial supplies of our clinical assets or any
    future clinical assets, remain in good standing with regulatory agencies, and develop, validate, and maintain commercially viable
    manufacturing processes that are compliant with cGMP;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    continued acceptable safety profile during preclinical and clinical development and following approval of our clinical assets or
    any future clinical assets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully commercialize our clinical assets or any future clinical assets in the U.S. and internationally, if approved
    for marketing, sale, and distribution in such countries and territories, whether alone or in collaboration with others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    acceptance by physicians, patients, and payors of the benefits, safety, and efficacy of our clinical assets or any future clinical
    assets, if approved, including relative to alternative and competing treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to comply with numerous post-approval regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    and our partners&#8217; ability to establish and enforce intellectual property rights in and to our clinical assets or any future
    clinical assets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    and our partners&#8217; ability to avoid third-party patent interference or intellectual property infringement claims; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to in-license or acquire additional clinical assets or commercial-stage products that we believe that we can successfully
    develop and commercialize.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to achieve one or more of the above factors, many of which are beyond our control, in a timely manner or at all, we could
experience significant delays and increased costs or an inability to obtain regulatory approvals or commercialize our clinical assets.
Even if regulatory approvals are obtained, we may never be able to successfully commercialize any of our clinical assets. Accordingly,
we cannot assure investors that we will be able to generate sufficient revenue through the sale of our clinical assets or any future
clinical assets to continue operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>There is substantial
doubt regarding our ability to continue as a going concern. We will need to raise additional funding, which may not be available on acceptable
terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our commercial programs,
product development efforts or other operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The report of our independent registered public accounting
firm on the Company&#8217;s financial statements as of and for the year ended December 31, 2024, includes an explanatory paragraph indicating
that there is substantial doubt about our ability to continue as a going concern for at least one year from the date of filing. Through
the date of the Business Combination, Old Conduit financed its working capital requirements by raising capital through private placements
of its ordinary shares and issuing of short-term and convertible notes. The Company has financed its working capital requirements since
the Business Combination primarily through the PIPE Financing (the &#8220;PIPE Financing&#8221;) completed in September 2023, and through
issuing of short-term and convertible notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will need to raise additional funding, which may
not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or
terminate our commercial programs, product development efforts or other operations. We do not expect to generate meaningful product revenues
in the foreseeable future. Based on our current business plan as of the date of our consolidated financial statements appearing elsewhere
in this Annual Report on Form 10-K, there is substantial doubt regarding our ability to continue as a going concern. We will need to raise
additional funding in order to execute on our current business plans and strategy, including prior to becoming profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our efforts to raise additional funding may divert
our management from their day-to-day activities, which may adversely affect our ability to develop our products. In addition, we cannot
guarantee that financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing
may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt,
by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible
securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations, and
we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our
ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise
at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product
candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results
and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, as a result of recent volatile market conditions,
the cost and availability of capital has been and may continue to be adversely affected. Concern about the stability of the banking sector
has generally led many lenders and institutional investors to reduce, and in some cases, cease to provide credit to businesses and consumers.
Continued turbulence in the U.S. market and economy may adversely affect our liquidity and financial condition, including our ability
to access the capital markets to meet liquidity needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we are unable to obtain funding on a timely basis,
or if revenues from collaboration arrangements are less than we have projected, we may be required to further revise our business plan
and strategy, which may result in us significantly curtailing, delaying or discontinuing one or more of our research or development programs
or may result in our being unable to expand our operations or otherwise capitalize on our business opportunities. As a result, our business,
financial condition and results of operations could be materially affected.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
a result of our limited operating history, we may not be able to correctly estimate, operating expenses, need for investment capital,
or stability of operations, which could lead to cash shortfalls.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a limited operating history from which to evaluate our business. As a result, our historical financial data is of limited value
in estimating future operating expenses. We have not obtained regulatory approvals for any of our clinical assets. Therefore, our budgeted
operating expense levels are based in part on our expectations concerning the FDA approval process and expenses related to development
of other clinical assets. Failing to reach our short-term developmental milestones within anticipated timelines due to serious adverse or unacceptable side effects caused by our clinical assets, or other events, many of which
may be beyond our control, may cause our financial condition and operating results to continue to fluctuate significantly from quarter
to quarter and year to year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preclinical
drug development for our clinical assets (AZD1656 and AZD5904) is expensive, time-consuming, and uncertain. Our preclinical trials may
fail to adequately demonstrate pharmacologic activity in therapeutic areas of interest; cause unintended short- or long-term effects
in other bodily systems; or produce unexpected toxicity that may alter or risk benefit assessment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
scientific discoveries that form the basis for our efforts to generate and develop our clinical assets are relatively recent. AZD1656
is a glucokinase activator that is in a number of Phase II ready autoimmune disorders including uveitis, Hashimoto&#8217;s thyroiditis,
preterm labor, and renal transplant, and the successful development of AZD1656 may require additional studies and efforts to optimize
its therapeutic potential. In addition, our development pipeline includes what we believe to be a potent irreversible inhibitor of human
Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility, which we refer to as AZD5904. AZD5904 may not demonstrate
in patients the therapeutic properties ascribed to it in the laboratory or preclinical studies, and may interact with human biological
systems in unforeseen, ineffective, or even harmful ways. If we are not able to successfully develop and commercialize our clinical assets,
including AZD1656 and AZD5904, we may never become profitable and the value of our capital stock may decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
is difficult to predict the time and cost of development and of subsequently obtaining regulatory approval for AZD1656 as it employs
newly developed technology.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AZD1656
uses a novel mechanism to reduce inflammation in many of the immune pathways. We have concentrated our research and development efforts
of AZD1656 on a limited number of initial targeted disease indications for AZD1656. There can be no assurance that we will not experience
problems or delays in developing our current or future indications for AZD1656 and that such problems or delays will not cause unanticipated
costs, or that any such development problems can be solved. Moreover, AZD1656 would also represent a novel approach for the treatment
of uveitis as steroids are currently the most common treatment for uveitis even though there are numerous side effects associated with
the use of steroids. The clinical development of these novel technologies will require review and allowance by the FDA under an Investigational
New Drug Application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in our efforts to use and expand our development platform to build a pipeline of clinical assets.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key element of our strategy is to use our experienced management and scientific team to build a pipeline of clinical assets that address
a broad range of human diseases in order to treat unmet medical needs. Our current clinical assets and pipeline address the areas of
autoimmune disease and idiopathic male infertility. Although our research and development efforts to date have resulted in potential
clinical assets, we may not be able to continue to identify and develop additional clinical assets. Even if we are successful in continuing
to build our pipeline, the potential clinical assets that we identify may not be suitable for clinical development. For example, these
potential clinical assets may be shown to have harmful side effects or other characteristics that indicate that they are unlikely to
receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize clinical assets based upon
our approach, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial
position. There is no assurance that we will be successful in our preclinical and clinical development of our current or future clinical
assets, and the process of obtaining regulatory approvals will, in any event, require the expenditure of substantial time and financial
resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
drug development for our clinical assets is very expensive, time-consuming, difficult to design and implement, and uncertain. Our clinical
trials may fail to adequately demonstrate the safety and efficacy of our clinical assets, which could prevent or delay regulatory approval
and commercialization.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
drug development for our clinical assets is very expensive, time-consuming, difficult to design and implement, and its outcome is inherently
uncertain. Before obtaining regulatory approval for the commercial sale of a clinical asset, we must demonstrate through clinical trials
that a clinical asset is both safe and effective for use in the target indication, which is impossible to predict. Most clinical assets
that commence clinical trials are never approved by regulatory authorities for commercialization. Our clinical assets are in various
stages of development and a failure of one more clinical trial can occur at any stage of testing or at any time during the trial process.
We expect that clinical trials for these clinical assets will continue for several years but may take significantly longer than expected
to complete. Not all of our clinical assets have been tested in humans and the first use in humans may reveal unexpected effects. We
have not completed all clinical trials for the approval of any of our clinical assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience delays in ongoing and future clinical trials for our clinical assets and we do not know if future clinical trials, if
any, will begin on time, need to be redesigned, enroll adequate number of patients on time or be completed on schedule, if at all. In
addition, the Company, any partner with which we currently or may in the future collaborate, the FDA, an IRB or other regulatory authorities, including state and local agencies and counterpart agencies in foreign countries, may suspend,
delay, require modifications to, or terminate our clinical trials at any time, for various reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discovery
    of safety or tolerability concerns, such as serious or unexpected toxicities or side effects or exposure to otherwise unacceptable
    health risks, experienced by study participants or other safety issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of effectiveness of any clinical asset during clinical trials or the failure of our clinical assets to meet specified endpoints;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower
    than expected rates of subject recruitment and enrollment rates or inability to enroll a sufficient number of patients in clinical
    trials resulting from numerous factors, including the prevalence of other companies&#8217; clinical trials for their clinical assets
    for the same indication, or clinical trials for indications for which patients do not as commonly seek treatment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in retaining subjects who have initiated a clinical trial but may withdraw at any time due to adverse side effects from the therapy,
    insufficient efficacy, fatigue with the clinical trial process, or for any other reason;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in obtaining IRB approval for studies to be conducted at each clinical trial site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in manufacturing or obtaining, or inability to manufacture or obtain, sufficient quantities of materials for use in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequacy
    of or changes in our manufacturing process or the product formulation or method of delivery;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable laws, regulations, and regulatory policies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols with prospective CROs, clinical trial sites, and other third-party contractors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to add a sufficient number of clinical trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainty
    regarding proper formulation and dosing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by us, our employees, our CROs or their employees, or other third-party contractors to comply with contractual and applicable regulatory
    requirements or to perform their services in a timely or acceptable manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by us, our employees, our CROs or their employees, or any partner with which we may collaborate or their employees to comply with
    applicable FDA or other regulatory requirements relating to the conduct of clinical trials or the handling, storage, security, and
    recordkeeping for drug and biologic products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">scheduling
    conflicts with participating clinicians and clinical institutions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to design appropriate clinical trial protocols;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
    data to support regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    or unwillingness of medical investigators to follow our clinical trial protocols; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in maintaining contact with subjects during or after treatment, which may result in incomplete data.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
or any partner with which we may collaborate may suffer significant setbacks in their clinical trials similar to the experience of a
number of other companies in the pharmaceutical and biotechnology industries, even after receiving promising results in earlier trials.
In the event that we or our potential partners abandon or are delayed in the clinical development efforts related to our clinical assets,
we may not be able to execute on our business plan effectively and our business, financial condition, operating results, and prospects
would be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to obtain regulatory approval for our early-stage clinical assets under applicable regulatory requirements. The FDA and
foreign regulatory bodies have substantial discretion in the approval process, including the ability to delay, limit, or deny approval
of clinical assets. The delay, limitation, or denial of any regulatory approval would adversely impact commercialization, our potential
to generate revenue, our business, and our operating results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have no products approved for sale, and we may never obtain regulatory approval to commercialize any of our current or future
clinical assets. The research, testing, manufacturing, safety surveillance, efficacy, quality control, recordkeeping, labeling, packaging,
storage, approval, sale, marketing, distribution, import, export, and reporting of safety and other post-market information related to
our drug products are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and in foreign countries,
and such regulations differ from country to country. We are not permitted to market any of our current clinical assets in the U.S. until
we receive approval of an NDA, Biologics License Application (a &#8220;BLA&#8221;), or other applicable regulatory filing from the FDA.
We are also not permitted to market any of our current clinical assets in any foreign countries until we or our partners receive the
requisite approval from the applicable regulatory authorities of such countries. To gain approval to market a new drug such as AZD1656
and AZD5904, the FDA and/or foreign regulatory authorities must receive, among other things, preclinical and clinical data that adequately
demonstrate the safety, purity, potency, efficacy, and compliant manufacturing of the drug product for the intended indication applied
for in a NDA, BLA, or other applicable regulatory filing. The development and approval of new drug products involves a long, expensive,
and uncertain process, and delay or failure can occur at any stage. A number of companies in the pharmaceutical and biopharmaceutical
industry have suffered significant setbacks in nonclinical development, clinical trials, including in Phase III clinical development,
even after promising results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things,
findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported
adverse events. Success in clinical trials does not ensure that later clinical trials will be successful, or that nonclinical studies
will be successful. The results of clinical trials by other parties may not be indicative of the results in trials that we or our partners
may conduct.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and foreign regulatory bodies have substantial discretion in the drug development and approval process, including the ability to
delay, limit drug development, or limit or deny approval of clinical assets for many reasons. The FDA or the applicable foreign regulatory
body may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagree
    with the design or implementation of one or more clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    deem a clinical asset safe and effective for its proposed indication, or may deem a clinical asset&#8217;s safety or other perceived
    risks to outweigh its clinical or other benefits;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    find the data from preclinical studies and clinical trials sufficient to support approval, or the results of clinical trials may
    not meet the level of statistical or clinical significance required by the FDA or the applicable foreign regulatory body for approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagree
    with our interpretation of data from preclinical studies or clinical trials performed by us or third parties, or with the interpretation
    of any partner with which we may collaborate;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the data collected from preclinical or clinical trials may not be sufficient to support the submission of an Investigational New
    Drug Application (&#8220;IND&#8221;) or NDA, or other applicable regulatory filing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    additional preclinical studies or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    deficiencies in the formulation, quality control, labeling, or specifications of our current or future clinical assets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    clinical trials in pediatric patients in order to establish pharmacokinetics or safety for this more drug-sensitive population;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">grant
    approval contingent on the performance of costly additional post-approval clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approve
    our current or any future clinical assets for a more limited indication or a narrower patient population than we originally requested
    or with strong warnings that may affect marketability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    approve the labeling that we believe is necessary or desirable for the successful commercialization of our clinical assets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    approve of the manufacturing processes, controls, or facilities of third-party manufacturers or testing labs with which we contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consider
    our products a device instead of a drug requiring a different approval process and manufacturing needs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consider
    one of our products a combination product instead of a singular drug requiring additional clinical trials or increased number of
    patients per study; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">change
    its approval policies or adopt new regulations in a manner rendering our clinical data or regulatory filings insufficient for approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay, limitation, or denial in any applicable regulatory approval for any of our clinical assets would delay or adversely impact commercialization
of our clinical assets and would harm our business, financial condition, operating results, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have identified material weaknesses in our internal control over financial reporting. If we fail to remedy these weaknesses or maintain
an effective system of internal controls, then our ability to produce timely and accurate financial statements or comply with applicable
regulations could be adversely affected. We may identify additional material weaknesses in our internal controls over financing reporting
which we may not be able to remedy in a timely manner.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the preparation and audit of the financial statements as of and for the fiscal years ended December 31, 2024 and 2023,
material weaknesses were identified in our internal control over financial reporting. A material weakness is a deficiency, or a combination
of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement
of annual or interim financial statements will not be prevented or detected on a timely basis. These material weaknesses primarily relate
to the following matters that are relevant to the preparation of our financial statements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have limited segregation of duties. For the periods under audit, the Company did not have any internal personnel in the financial
    accounting and reporting department, instead relied upon third party consultants to perform these activities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    lack a formal process for review and approval of financial statements. For the periods under audit, especially prior to the business
    combination, numerous, recurring errors in account balances and disclosures were detected in the financial statements that resulted
    in a reasonable possibility that a material misstatement would not have been detected on a timely basis.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    did not design adequate and appropriate internal controls, including monitoring controls, to review and evaluate the accounting implications
    of all material transactions that occurred in the audit period.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
these material weaknesses are not remediated, it could result in a misstatement of account balances or disclosures that would result
in a material misstatement to the annual or interim financial statements that would not be prevented or detected. We are reviewing measures
designed to improve our internal control over financial reporting to remediate these material weaknesses, although they have not been
fully remediated as of the date of this filing. As a part of these measures, we also expect to engage an external advisor to assist with
evaluating and documenting the design and operating effectiveness of internal controls and assisting with the remediation of deficiencies
when funding and additional liquidity becomes available, as necessary. The primary costs associated with such measures are corresponding
recruiting and additional salary and consulting costs, which are difficult to estimate but which may be significant. These additional
resources and procedures are intended to enable us to broaden the scope and quality of our internal review of underlying information
related to financial reporting and to formalize and enhance our internal control procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material weaknesses will not be considered remediated until a remediation plan has been fully implemented, the applicable controls
operate for a sufficient period of time, and we have concluded, through testing, that the newly implemented and enhanced controls are
operating effectively. A failure to implement and maintain effective internal control over financial reporting could result
in errors in our financial statements that could result in a restatement of our financial statements and could cause us to fail to meet
our reporting obligations, any of which could diminish investor confidence in us and cause a decline in the price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control over
financial reporting until after we are no longer an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. At such time,
our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level
at which our internal control over financial reporting is documented, designed, or operating.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is a risk that we will fail to maintain an effective system of internal controls and our ability to produce timely and accurate financial
statements or comply with applicable regulations could be adversely affected. We may identify material weaknesses in our internal controls
over financing reporting which we may not be able to remedy in a timely manner.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley
Act, the regulations of Nasdaq, the rules and regulations of the SEC, expanded disclosure requirements, accelerated reporting requirements,
and more complex accounting rules. Responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate
internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to
produce reliable financial reports and are important to help prevent financial fraud.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may discover additional weaknesses in our system of internal financial and accounting controls and procedures that could result in a
material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors
and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that
the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls
can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud
will be detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain
proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If we cannot provide
reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence
in our reported financial information, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory
authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not develop and implement all required accounting practices and policies, we may be unable to provide the financial information
required of a U.S. publicly traded company in a timely and reliable manner.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to develop and maintain effective internal controls and procedures and disclosure procedures and controls, we may be unable to
provide financial information and required SEC reports that a U.S. publicly traded company is required to provide in a timely and reliable
fashion. Any such delays or deficiencies could penalize us, including by limiting our ability to obtain financing, either in the public
capital markets or from private sources and hurt our reputation and could thereby impede our ability to implement our growth strategy.
In addition, any such delays or deficiencies could result in our failure to meet the requirements for continued listing of our shares
of common stock on a national securities exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance
coverage for those claims is inadequate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face an inherent risk of product liability as a result of the clinical testing of our clinical assets and will face an even greater risk
if we commercialize any products. This risk exists even if a product is approved for commercial sale by the FDA and manufactured in facilities
licensed and regulated by the FDA or an applicable foreign regulatory authority. Our products and clinical assets are designed to affect
important bodily functions and processes. Any side effects, manufacturing defects, misuse, or abuse associated with our clinical assets
could result in injury to a patient or even death. We cannot offer any assurance that we will not face product liability suits in the
future, nor can we assure investors that our insurance coverage will be sufficient to cover our liability under any such cases. In addition,
a liability claim may be brought against us even if our clinical assets merely appear to have caused an injury. Product liability claims
may be brought against us by consumers, health care providers, pharmaceutical companies, or others selling or otherwise coming into contact
with our clinical assets, among others. If we cannot successfully defend ourselves against product liability claims, we will incur substantial
liabilities and reputational harm.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently rely on, and expect to continue to rely on, third-party CROs and other third parties to conduct and oversee our clinical trials
and other aspects of product development. If these third parties do not meet our requirements or otherwise conduct the trials as required,
we may not be able to satisfy our contractual obligations or obtain regulatory approval for, or commercialize, our clinical assets when
expected or at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have in the past relied and expect to continue to rely on third-party CROs to conduct and oversee our clinical trials and other aspects
of product development. We also rely upon various medical institutions, clinical investigators, and contract laboratories to conduct
our trials in accordance with our clinical trial protocols and all applicable regulatory requirements, including the FDA&#8217;s regulations
and GCPs, which are an international standard meant to protect the rights and health of patients and to define the roles of clinical
trial sponsors, administrators and monitors, and state regulations governing the handling, storage, security, and recordkeeping for drug
and biologic products. These CROs and other third parties play a significant role in the conduct of these trials and the subsequent collection
and analysis of data from the clinical trials. We rely heavily on these parties for the execution of our clinical trials and preclinical
studies, and control only certain aspects of their activities. We, our CROs, and other third-party contractors are required to comply
with GCP, GLP, and GACP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities
for products in clinical development. Regulatory authorities enforce these GCP, GLP, and GACP requirements through periodic inspections
of trial sponsors, principal investigators, and trial sites. If we or any of these third parties fail to comply with applicable GCP,
GLP, or GACP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or other regulatory
authority may require us to perform additional clinical trials before approving our or our partners&#8217; marketing applications. We
cannot assure investors that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our
clinical or preclinical trials complies with applicable GCP and GLP requirements. In addition, our clinical trials must generally be
conducted with product produced under cGMP regulations. Our failure to comply with these regulations and policies may require us to repeat
clinical trials, which would delay the regulatory approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CROs are not our employees, and we do not control whether or not they devote sufficient time and resources to our clinical trials. Our
CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical
trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure
or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow potential competitors
to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations,
fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to
adhere to our clinical trial protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed,
or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any clinical asset that we develop.
As a result, our financial results and the commercial prospects for any clinical asset that we develop would be harmed, our costs could
increase, and our ability to generate revenue could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our CROs or clinical trial sites terminate their involvement in one of our clinical trials for any reason, we may not be able
to enter into arrangements with alternative CROs or clinical trial sites or do so on commercially reasonable terms. In addition, if our
relationship with clinical trial sites is terminated, we may experience the loss of follow-up information on patients enrolled in our
ongoing clinical trials unless we are able to transfer the care of those patients to another qualified clinical trial site. In addition,
principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and could receive
cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived
or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site may be questioned by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely completely on third-party contractors to supply, manufacture, and distribute clinical drug supplies for our clinical assets, including
certain sole-source suppliers and manufacturers. We intend to rely on third parties for commercial supply, manufacturing, and distribution
if any of our clinical assets receive regulatory approval and we expect to rely on third parties for supply, manufacturing, and distribution
of preclinical, clinical, and commercial supplies of any future clinical assets.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have, nor do we plan to acquire, the infrastructure or capability to supply, manufacture, or distribute preclinical,
clinical, or commercial quantities of drug substances or products. Our ability to develop our clinical assets depends and our ability
to commercially supply our products will depend, in part, on our ability to successfully obtain the raw materials and APIs and other
substances and materials used in our clinical assets from third parties and to have finished products manufactured by third parties in
accordance with regulatory requirements and in sufficient quantities for preclinical and clinical testing and commercialization. If we
fail to develop and maintain supply relationships with these third parties, we may be unable to continue to develop or commercialize
our clinical assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely and will continue to rely on certain third parties as the sole source of the materials they supply or the finished products they
manufacture. Any of our existing suppliers or manufacturers may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fail
    to supply us with product on a timely basis or in the requested amount due to unexpected damage to or destruction of facilities or
    equipment or otherwise;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fail
    to increase manufacturing capacity and produce drug product and components in larger quantities and at higher yields in a timely
    or cost-effective manner, or at all, to sufficiently meet our commercial needs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    unable to meet our production demands due to issues related to their reliance on sole-source suppliers and manufacturers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">supply
    us with product that fails to meet regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">become
    unavailable through business interruption or financial insolvency;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lose
    regulatory status as an approved source;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    unable or unwilling to renew current supply agreements when such agreements expire on a timely basis, on acceptable terms or at all;
    or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discontinue
    production or manufacturing of necessary drug substances or products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any of the foregoing, if we do not have an alternative supplier or manufacturer in place, we would be required to expend
substantial management time and expense to identify, qualify, and transfer processes to alternative suppliers or manufacturers. Transferring
technology to other sites may require additional processes, technologies, and validation studies, which are costly, may take considerable
amounts of time, may not be successful and, in most cases, require review and approval by the FDA. Any need to find and qualify new suppliers
or manufacturers could significantly delay production of our clinical assets, adversely impact our ability to market our clinical assets,
and adversely affect our business. Replacements may not be available to us on a timely basis, on acceptable terms, or at all. Additionally,
we and our manufacturers do not currently maintain significant inventory of drug substances and other materials. Any interruption in
the supply of a drug substance or other material or in the manufacture of our clinical assets could have a material adverse effect on
our business, financial condition, operating results, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have direct control over the ability of our contract suppliers and manufacturers to maintain adequate capacity and capabilities
to serve our needs, including quality control, quality assurance, and qualified personnel. Although we are ultimately responsible for
ensuring compliance with regulatory requirements such as cGMPs and GACP, we are dependent on our contract suppliers and manufacturers
for day-to-day compliance with cGMPs or GACP for production of raw materials, APIs, and finished products. Facilities used by our contract
suppliers and manufacturers to produce the APIs and other substances and materials or finished products for commercial sale must pass
inspection and be approved by the FDA and other relevant regulatory authorities. Our contract suppliers and manufacturers must comply
with cGMP and GACP requirements enforced by the FDA through its facilities inspection program and review of submitted technical information.
If the safety of any product or clinical asset or component is compromised due to a failure to adhere to applicable laws or for other
reasons, we may not be able to successfully commercialize or obtain regulatory approval for the affected product or clinical asset, and
we may be held liable for injuries sustained as a result. Any of these factors could cause a delay or termination of preclinical studies,
clinical trials, or regulatory submissions or approvals of our clinical assets, and could entail higher costs or result in us being unable
to effectively commercialize our approved products on a timely basis, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, these contract manufacturers are engaged with other companies to supply and manufacture materials or products for such companies,
which also exposes our suppliers and manufacturers to regulatory risks for the production of such materials and products. As a result,
failure to meet the regulatory requirements for the production of those materials and products may also affect the regulatory clearance
of a contract supplier&#8217;s or manufacturer&#8217;s facility. If the FDA or a comparable foreign regulatory agency does not approve
these facilities for the supply or manufacture of our clinical assets, or if it withdraws its approval in the future, we may need to
find alternative supply or manufacturing facilities, which would negatively impact our ability to develop, obtain regulatory approval
of, or market our clinical assets, if approved.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our third-party contractors terminate their involvement in the supply, manufacture, or distribution of clinical drug supplies
for us for any reason, we may not be able to enter into arrangements with alternative third party-contractors, or do so on commercially
reasonable terms. In addition, if our relationship with such third-party contractors is terminated, we may experience a negative impact
to the respective licenses on which we rely and, therefore, on our ability to obtain regulatory approval for, or commercialize, our clinical
assets when expected or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reliance on contract manufacturers and suppliers further exposes us to the possibility that they, or third parties with access to their
facilities, will have access to and may misappropriate our trade secrets or other proprietary information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the manufacturing facilities of certain of our suppliers are located outside of the U.S. This may give rise to difficulties
in importing our products or clinical assets or their components into the U.S. or other countries as a result of, among other things,
regulatory agency approval requirements or import inspections, incomplete or inaccurate import documentation, or defective packaging.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently rely on agreements with third parties for the purpose of licensing our clinical assets. In the near-term, we intend to rely
on third parties for the licensing of clinical assets and those which may arise through future partnerships.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely on agreements with third parties for the purpose of licensing clinical assets from large pharmaceutical companies. For
example, we have agreements with AstraZeneca pursuant to which we license clinical assets from AstraZeneca. If we are in breach of the
agreements, the termination of such agreement(s) could materially adversely affect our business, financial condition, operating results,
and prospects. Our business strategy heavily depends on our ability to commercialize our clinical assets and our ability to enter into
license agreements relating to such clinical assets is critical to the success of our operations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may choose not to continue developing or commercializing any of our clinical assets at any time during development or after approval,
which would reduce or eliminate our potential return on investment for those clinical assets.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may decide to discontinue the development of any of our clinical assets or not to continue commercializing one or more of our approved
clinical assets for a variety of reasons, including the appearance of new technologies that make a product obsolete, competition from
a competing product, or changes in or failure to comply with applicable regulatory requirements at any time. If we terminate a program
in which we have invested significant resources, we will not receive any return on our investment and we will have missed the opportunity
to have allocated those resources to potentially more productive uses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop or commercialize
our clinical assets or otherwise implement our business plan.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to compete in the highly competitive pharmaceuticals industry depends upon our ability to attract and retain highly qualified
managerial, scientific, medical, sales, marketing, and other personnel. We are highly dependent on our management, including our Chief
Executive Officer, David Tapolczay. The loss of the services of any of these individuals could impede, delay, or prevent the successful
development of our product pipeline, completion of our planned clinical trials, commercialization of our clinical assets, or in-licensing
or acquisition of new assets and could negatively impact our ability to successfully implement our business plan. If we lose the services
of any of these individuals, we might not be able to find suitable replacements on a timely basis or at all, and our business could be
harmed as a result. We do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any
of our other employees. In order to retain valuable employees, in addition to salary and cash incentives, we provide stock options that
vest over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for
qualified personnel among biotechnology, pharmaceutical, and other businesses. We could have difficulty attracting experienced personnel
to the Company and may be required to expend significant financial resources in our employee recruitment and retention efforts. Many
of the other pharmaceutical companies with whom we compete for qualified personnel have greater financial and other resources, different
risk profiles, and longer histories in the industry than we do. They also may provide more diverse opportunities and better chances for
career advancement. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience
constraints that will harm our ability to implement our business strategy and achieve our business objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have scientific and clinical advisors who assist us in formulating our development and clinical strategies. These advisors
are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability
to us. In addition, our advisors may have arrangements with other companies to assist those companies in developing products or technologies
that may compete with those of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently have limited marketing capabilities and no sales organization. If we do not establish sales and marketing capabilities on our
own or through third parties, we will be limited in our commercialization to license deals with third parties following successful Phase
II trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have limited marketing capabilities and no sales organization. If we do not establish sales and marketing capabilities on our
own or through third parties, we will be limited in our commercialization to license deals with third parties following successful Phase
II trials. To commercialize our clinical assets, if approved, in the U.S., Canada, the European Union, and other jurisdictions that we
seek to enter, we must build our marketing, sales, distribution, managerial, and other non-technical capabilities or make arrangements
with third parties to perform these services, and we may not be successful in doing so. Although our management team has experience in
the marketing, sale, and distribution of pharmaceutical products from prior employment at other companies, we as a company have no prior
experience in the marketing, sale, and distribution of pharmaceutical products and there are significant risks involved in building and
managing a sales organization, including our ability to hire, retain, and incentivize qualified individuals, generate sufficient sales
leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing
team. Any failure or delay in the development of our internal sales, marketing, and distribution capabilities would adversely impact
the commercialization of these products. We may choose to collaborate with additional third parties that have direct sales forces and
established distribution systems, either to augment our own sales force and distribution systems or in lieu of its own sales force and
distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully
commercialize our clinical assets. If we are unable to successfully commercialize our clinical assets, either on our own or through collaborations
with one or more third parties, our business, financial condition, operating results, and prospects would suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to successfully in-license, acquire, develop, and market additional clinical assets or approved products would impair our ability
to grow our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to in-license, acquire, develop, and market additional products and clinical assets and we may in-license or acquire commercial-stage
products or engage in other strategic transactions. Because our internal research and development capabilities are limited, we may be
dependent upon pharmaceutical companies, academic scientists, and other researchers to sell or license products or technology to us.
The success of this strategy depends partly upon our ability to identify and select promising pharmaceutical clinical assets and products,
negotiate licensing or acquisition agreements with their current owners, and finance these arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of proposing, negotiating, and implementing a license or acquisition of a clinical asset or approved product is lengthy and complex.
Other companies, including some with substantially greater financial, marketing, sales, and other resources, may compete with us for
the license or acquisition of clinical assets and approved products. We have limited resources to identify and execute the acquisition
or in-licensing of third-party products, businesses, and technologies and integrate them into our current infrastructure. Moreover, we
may devote resources to potential acquisitions or licensing opportunities that are never completed, or we may fail to realize the anticipated
benefits of such efforts. We may not be able to acquire the rights to additional clinical assets on terms that we find acceptable, or
at all.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
any clinical asset that we acquire may require additional development efforts prior to commercial sale, including preclinical or clinical
testing and approval by the FDA and applicable foreign regulatory authorities. All clinical assets are prone to risks of failure typical
of pharmaceutical product development, including the possibility that a clinical asset will not be shown to be sufficiently safe and
effective for approval by regulatory authorities. In addition, we cannot provide assurance that any approved products that we acquire
will be manufactured or sold profitably or achieve market acceptance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
potential transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships,
joint ventures, restructurings, divestitures, business combinations, and investments. Any such transaction may require us to incur non-recurring
or other charges, may increase our near- and long-term expenditures, and may pose significant integration challenges or disrupt our management
or business, which could adversely affect our operations and financial results. For example, these transactions entail numerous potential
operational and financial risks, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure
    to unknown liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption
    of our business and diversion of our management&#8217;s time and attention in order to develop acquired products, clinical assets,
    or technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incurrence
    of substantial debt or dilutive issuances of equity securities to pay for acquisitions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    acquisition and integration costs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">write-downs
    of assets or impairment charges;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    amortization expenses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment
    of relationships with key suppliers, partners, or customers of any acquired businesses due to changes in management and ownership;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to retain our key employees or those of any acquired businesses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, and any transaction
that we do complete could harm our business, financial condition, operating results, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Manufacturing
and supply of the APIs and other substances and materials used in our clinical assets is a complex and technically challenging undertaking,
and there is potential for failure at many points in the manufacturing, testing, quality assurance, and distribution supply chain, as
well as the potential for latent defects after products have been manufactured and distributed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing
and supply of APIs, other substances, and materials and finished drug products is technically challenging. Changes beyond our direct
control can impact the quality, volume, price, and successful delivery of our clinical assets and can impede, delay, limit, or prevent
the successful development and commercialization of our clinical assets. Mistakes and mishandling are not uncommon and can affect successful
production and supply. Some of these risks include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our manufacturers to follow cGMP or GACP requirements or mishandling of product while in production or in preparation for transit;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    of our contract suppliers and manufacturers to efficiently and cost-effectively increase and maintain high yields and batch quality,
    consistency, and stability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to develop an FDA-approved bioassay for release of any future product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in establishing optimal drug delivery substances and techniques, production, and storage methods and packaging and shipment processes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transportation
    and import/export risk, particularly given the global nature of our supply chain;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in analytical results or failure of analytical techniques that we depend on for quality control and release of any future product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural
    disasters, pandemics, labor disputes, financial distress, lack of raw material supply, issues with facilities and equipment, or other
    forms of disruption to business operations of our contract manufacturers and suppliers; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">latent
    defects that may become apparent after the product has been released and which may result in recall and destruction of product.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors could result in delays or higher costs in connection with our clinical trials, regulatory submissions, required approvals,
or commercialization of our clinical assets, which could harm our business, financial condition, operating results, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating
results to fall below expectations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
operations of the Company since the Business Combination and of Old Conduit prior to the Business Combination have been primarily limited
to researching and developing our clinical assets and undertaking preclinical studies and clinical trials of our clinical assets. We
have not yet obtained regulatory approvals for any of our clinical assets. Consequently, any predictions investors make about our future
success or viability may not be as accurate as they could be if we had a longer operating history or approved products on the market.
Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may
be difficult to predict, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in the commencement, enrollment, and the timing of clinical testing for our clinical assets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and success or failure of clinical trials for our clinical assets or competing clinical assets, or any other change in the
    competitive landscape of our industry, including consolidation among our competitors or partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delays in regulatory review and approval of clinical assets in clinical development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and cost of, and level of investment in, research and development activities relating to our clinical assets, which may change
    from time to time;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of manufacturing our clinical assets, which may vary depending on FDA guidelines and requirements, and the quantity of production;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain additional funding to develop our clinical assets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenditures
    that we will or may incur to acquire or develop additional clinical assets and technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    level of demand for our clinical assets, should they receive approval, which may vary significantly;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    side effects of our clinical assets that could delay or prevent commercialization or cause an approved drug to be taken off the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for our clinical assets, if approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    dependency on third-party manufacturers to supply or manufacture our clinical assets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish an effective sales, marketing, and distribution infrastructure in a timely manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    acceptance of our clinical assets, if approved, and our ability to forecast demand for those clinical assets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to receive approval and commercialize our clinical assets outside of the U.S.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain collaborations, licensing, or other arrangements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability and third parties&#8217; abilities to protect intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to and outcomes of potential litigation or other disputes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to adequately support future growth;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain key personnel to manage our business effectively;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    liabilities associated with hazardous materials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain adequate insurance policies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    accounting pronouncements or changes in our accounting policies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fluctuations
in foreign currency could have an effect on our reported results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
exposure to fluctuations in foreign currency rates results primarily from the translation exposure associated with the preparation of
our consolidated financial statements, as well as from transaction exposure associated with transactions in currencies other than our
functional currency. While our consolidated financial statements are reported in U.S. dollars, our financial statements of foreign subsidiaries
are prepared using the British pound sterling as the functional currency and then translated into U.S. dollars. We cannot accurately
predict the nature or extent of future exchange rate variability of the British pound sterling or the exchange rate relative to the U.S.
dollar. Foreign exchange rates are sensitive to factors beyond our control. In addition, Brexit has caused, and may continue to cause,
significant volatility in currency exchange rates, especially between the U.S. dollar and the British pound sterling. These fluctuations
in foreign currency exchange rates could negatively affect our results of operations and impact reported financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operating results and liquidity needs could be negatively affected by market fluctuations and economic downturn.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating results and liquidity could be negatively affected by economic conditions generally, both in the U.S. and elsewhere around
the world. The market for discretionary medical products and procedures may be particularly vulnerable to unfavorable economic conditions.
Some patients may consider certain of our clinical assets to be discretionary, and if full reimbursement for such products is not available,
demand for these products may be tied to the discretionary spending levels of our targeted patient populations. Domestic and international
equity and debt markets have experienced and may continue to experience heightened volatility and turmoil based on domestic and international
economic conditions and concerns. In the event these economic conditions and concerns continue or worsen and the markets continue to
remain volatile, our operating results and liquidity could be adversely affected by those factors in many ways, including weakening demand
for certain of our products and making it more difficult for us to raise funds if necessary. Additionally, although we plan to market
our products primarily in the U.S., we could in the future have partners with extensive global operations, indirectly exposing us to
risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain our cash and cash equivalents with high quality, accredited financial institutions. However, some of these accounts exceed the
government-insured limits, and, while we believe that we are not exposed to significant credit risk due to the financial strength of
these depository institutions or investments, the failure or collapse of one or more of these depository institutions or default on these
investments could materially adversely affect our ability to recover these assets and/or materially harm our financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are increasingly dependent on information technology, and our systems and infrastructure face certain risks, including cybersecurity
and data leakage risks.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
disruptions to our information technology systems or breaches of information security could adversely affect our business. In the ordinary
course of business, we collect, store, and transmit large amounts of confidential information, and it is critical that we do so in a
secure manner to maintain the confidentiality and integrity of such confidential information. The size and complexity of our information
technology systems, and those of our third-party vendors with whom we contract, make such systems potentially vulnerable to service interruptions
and security breaches from inadvertent or intentional actions by our employees, partners, or vendors, from attacks by malicious third
parties, or from intentional or accidental physical damage to our systems infrastructure maintained by us or by third parties. Maintaining
the secrecy of this confidential, proprietary, or trade secret information is important to our competitive business position. While we
have taken steps to protect such information and invested in information technology, there can be no assurance that our efforts will
prevent service interruptions or security breaches in our systems or the unauthorized or inadvertent wrongful use or disclosure of confidential
information that could adversely affect our business operations or result in the loss, dissemination, or misuse of critical or sensitive
information. A breach of our security measures or the accidental loss, inadvertent disclosure, unapproved dissemination, misappropriation
or misuse of trade secrets, proprietary information, or other confidential information, whether as a result of theft, hacking, fraud,
trickery, or other forms of deception, or for any other reason, could enable others to produce competing products, use our proprietary
technology or information, or adversely affect our business or financial condition. Further, any such interruption, security breach,
loss, or disclosure of confidential information could result in financial, legal, business, and reputational harm to us and could have
a material adverse effect on our business, financial position, results of operations, or cash flow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and operations would suffer in the event of failures in our internal computer systems.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures, our computer systems and those of our current and any future partners, contractors, and consultants
are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical
failures. While we have not experienced any such material system failure, accident, or security breach to date, if such an event were
to occur and cause interruptions in our operations, it could result in a material disruption of our manufacturing activities, development
programs, and business operations. For example, the loss of manufacturing records or clinical trial data from completed or future clinical
trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.
If we experienced a security breach, our online sources were hacked, or we experienced a data leak, it could result in confidential clinical
trial data being leaked to competitors and the market. To the extent that any disruption or security breach were to result in a loss
of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability
and the further commercialization and development of our products and clinical assets could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to adequately protect our intellectual property could adversely affect our business, financial condition, and operating results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business depends on our intellectual property and proprietary technology, the protection of which is crucial to the success of our business.
We rely on a combination of trademark, copyright, and trade secret laws, license agreements, intellectual property assignment agreements,
and confidentiality procedures to protect our intellectual property. Additionally, we rely on proprietary information (such as trade
secrets, know-how, and confidential information) to protect intellectual property that may not be patentable, or that we believe is best
protected by means that do not require public disclosure. We generally attempt to protect our intellectual property, technology, and
confidential information by requiring our employees and consultants who develop intellectual property on our behalf to enter into confidentiality
and invention assignment agreements and third parties that we share information with to enter into nondisclosure agreements. These agreements
may not effectively prevent unauthorized use or disclosure of our confidential information, intellectual property, or technology and
may not provide an adequate remedy in the event of unauthorized use or disclosure of our confidential information or technology, or infringement
of our intellectual property. For example, we may fail to enter into the necessary agreements, and even if entered into, these agreements
may be willfully breached or may otherwise fail to prevent disclosure, third-party infringement, or misappropriation of our proprietary
information, may be limited as to their term, and may not provide an adequate remedy in the event of unauthorized disclosure or use of
proprietary information. In addition, our proprietary information may otherwise become known or be independently developed by our competitors
or other third parties. To the extent that our employees, consultants, contractors, and other third parties use intellectual property
owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. Costly and
time-consuming litigation could be necessary to enforce and determine the scope of our intellectual property rights and other proprietary
rights, and failure to obtain or maintain protection for our proprietary information could adversely affect our competitive business
position.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
our efforts to protect our proprietary rights, other parties may unintentionally or willfully disclose, obtain, or use our technologies
or systems, which may allow unauthorized parties to copy aspects of our platform or other software, technology, and functionality or
obtain and use information that we consider proprietary. In addition, unauthorized parties may also attempt, or successfully endeavor,
to obtain our intellectual property, confidential information, and trade secrets through various methods, including through scraping
of public data or other content from our website or mobile applications, cybersecurity attacks, and legal or other methods of protecting
this data may be inadequate. Monitoring unauthorized use and disclosures of our intellectual property, proprietary technology, or confidential
information can be difficult and expensive and we cannot be sure that the steps we have taken will prevent misappropriation or infringement
of our intellectual property or proprietary rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have registered the domain name for the website that we use in our business, which is www.conduitpharma.com. The inclusion of the website
address in this Annual Report does not include or incorporate by reference the information on the Company&#8217;s website into this document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
have and may continue to adopt service names similar to ours, thereby harming our ability to build brand identity and possibly leading
to user confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks
that are similar to our trademarks. Further, litigation or proceedings before the U.S. Patent and Trademark Office or other governmental
authorities and administrative bodies in the U.S. and abroad may be necessary in the future to enforce our intellectual property rights
and to determine the validity and scope of the proprietary rights of others. Any litigation initiated by us concerning the violation
by third parties of our intellectual property rights is likely to be expensive and time-consuming and could lead to the invalidation
of, or render unenforceable, our intellectual property, or could otherwise have negative consequences for us. Even when we sue other
parties for such infringement, that suit may have adverse consequences for our business. In addition, we may not timely or successfully
apply for a patent or register our trademarks or otherwise secure our intellectual property, which could result in negative effects to
our market share, financial condition, and results of operations. Our efforts to protect, maintain, or enforce our proprietary rights
may not be respected in the future or may be invalidated, circumvented, or challenged, and could result in substantial costs and diversion
of resources, which could adversely affect our business, financial condition, and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to continue to use the domain name that we use in our business or prevent third parties from acquiring and using domain
names that infringe on, are similar to, or otherwise decrease the value of our brand, trademarks, or service marks.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have registered the domain name that we use in our business. If we lose the ability to use that domain name, whether due to trademark
claims, failure to renew the applicable registration, or any other cause, we may be forced to market our business under a new domain
name, which could cause us substantial harm, or to incur significant expense in order to purchase rights to the domain name in question.
We may not be able to obtain preferred domain names outside the U.S. due to a variety of reasons, including because they are already
held by others. In addition, our competitors and others could attempt to capitalize on our brand recognition by using domain names similar
to our domain name. We may be unable to prevent third parties from acquiring and using domain names that infringe on, are similar to,
or otherwise decrease the value of our brand or our trademarks or service marks. Protecting, maintaining, and enforcing our rights in
our domain names may require litigation, which could result in substantial costs and diversion of resources, which could in turn adversely
affect our business, financial condition, and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property rights throughout the world.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting, and defending patents on our clinical assets in all countries throughout the world would be prohibitively expensive. The
requirements for patentability may differ in certain countries, particularly developing countries. In addition, the laws of some foreign
countries do not protect intellectual property rights to the same extent as laws in the U.S. Consequently, we may not be able to prevent
third parties from practicing our inventions in all countries outside the U.S. Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to
territories where we have patent protection, but enforcement on infringing activities is inadequate. These products may compete with
our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual
property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of
our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights
in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could
put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke
third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded,
if any, may not be commercially meaningful. In addition, certain countries in Europe and certain developing countries have compulsory
licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited
remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which could materially
diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual
property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we
own or license. Our ability to protect and enforce our intellectual property rights may also be adversely affected by unforeseen changes
in foreign intellectual property laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance and annuity fees on any issued patent are due to be paid to the United States Patent and Trademark Office (&#8220;USPTO&#8221;)
and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies
require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application
process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable
rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or
lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of
fees, and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications
covering our clinical assets, our competitors might be able to enter the market, which would have an adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with our obligations under our intellectual property license agreements, we could lose license rights that are important
to our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a party to certain license agreements that impose various diligence, milestone, royalty, insurance, and other obligations on us.
If we fail to comply with these obligations, the respective licensors may have the right to terminate the license, in which event we
may not be able to develop or market the affected clinical asset. Our business strategy depends on our ability to commercialize our
clinical assets and our ability to enter into license agreements relating to such clinical assets is critical to the success of our
operations. The loss of such rights could materially adversely affect our business, financial condition, operating results, and
prospects. For more information about these license arrangements, see &#8220;Business &#8212; Principal Strategic Partnerships.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome
in that litigation could have a material adverse effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon its ability to develop, manufacture, market, and sell our clinical assets and use our proprietary technologies
without infringing the proprietary rights of third parties. We cannot guarantee that marketing and selling such candidates and using
such technologies will not infringe existing or future patents. Numerous U.S. and foreign issued patents and pending patent applications
owned by third parties exist in the fields relating to our clinical assets. As the biotechnology and pharmaceutical industries expand
and more patents are issued, the risk increases that others may assert that our clinical assets, technologies, or methods of delivery
or use infringe their patent rights. Moreover, it is not always clear to industry participants, including us, which patents cover various
drugs, biologics, drug delivery systems, or their methods of use, and which of these patents may be valid and enforceable. Thus, because
of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege
they have patent rights encompassing our clinical assets, technologies, or methods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there may be issued patents of third parties that are infringed or are alleged to be infringed by our clinical assets or proprietary
technologies. We cannot be certain that others have not filed patent applications for technology covered by our own and in-licensed issued
patents or our pending applications because some patent applications in the U.S. may be maintained in secrecy until the patents are issued,
patent applications in the U.S. and many foreign jurisdictions are typically not published until eighteen months after filing, and publications
in the scientific literature often lag behind actual discoveries. Our competitors may have filed, and may in the future file, patent
applications covering our clinical assets or technology similar to ours. Any such patent application may have priority over our own and
in-licensed patent applications or patents, which could further require us to obtain rights to issued patents covering such technologies.
If another party has filed a U.S. patent application on inventions similar to those owned or in-licensed to us, we or, in the case of
in-licensed technology, the licensor may have to participate, in the U.S., in an interference proceeding to determine priority of invention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging
that our clinical assets or proprietary technologies infringe such third parties&#8217; intellectual property rights, including litigation.
These lawsuits could claim that there are existing patent rights for such drug and this type of litigation can be costly and could adversely
affect our operating results and divert the attention of managerial and technical personnel, even if we do not infringe such patents
or the patents asserted against us are ultimately established as invalid. There is a risk that a court would decide that we are infringing
the third party&#8217;s patents and would order us to stop the activities covered by the patents. In addition, there is a risk that a
court will order us to pay the other party damages for having violated the other party&#8217;s patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of patent infringement claims, or to avoid potential claims, we may choose or be required to seek licenses from third parties.
These licenses may not be available on commercially acceptable terms, or at all. Even if we are able to obtain a license, the license
would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result
in our competitors gaining access to the same intellectual property, or such rights might be restrictive and limit our present and future
activities. Ultimately, we or a licensee could be prevented from commercializing a product or be forced to cease some aspect of our business
operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to possible infringement claims against us, we may become a party to other patent litigation and other proceedings, including
interference, derivation, re-examination, or other post-grant proceedings declared or granted by the USPTO, and similar proceedings in
foreign countries, regarding intellectual property rights with respect to our current or future products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical
industries generally. To date, no litigation asserting infringement claims has ever been brought against us. If a third-party claims
that we infringe its intellectual property rights, we may face a number of issues, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">infringement
    and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert
    our management&#8217;s attention from our core business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    damages for infringement, which we may have to pay if a court decides that the product or technology at issue infringes or violates
    the third party&#8217;s rights, and if the court finds that the infringement was willful, we could be ordered to pay treble damages
    and the patent owner&#8217;s attorneys&#8217; fees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    court prohibiting us from selling or licensing the product or using the technology unless the third party licenses its intellectual
    property rights to us, which it is not required to do;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    a license is available from a third party, we may have to pay substantial royalties or upfront fees or grant cross-licenses to intellectual
    property rights for our products or technologies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">redesigning
    our products or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and
    time.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially
greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could harm our ability
to raise additional funds or otherwise adversely affect our business, financial condition, operating results, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we rely on certain third-party licensors and partners, and will continue to do so in the future, if one of our licensors or partners
is sued for infringing a third party&#8217;s intellectual property rights, our business, financial condition, operating results, and
prospects could suffer in the same manner as if we were sued directly. In addition to facing litigation risks, we have agreed to indemnify
certain third-party licensors and partners against claims of infringement caused by our proprietary technologies, and we have entered
or may enter into cost-sharing agreements with some our licensors and partners that could require us to pay some of the costs of patent
litigation brought against those third parties whether or not the alleged infringement is caused by our proprietary technologies. In
certain instances, these cost-sharing agreements could also require us to assume greater responsibility for infringement damages than
would be assumed just on the basis of our technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any of the foregoing could adversely affect our business, financial condition, or operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, or
other claims may be made against us, which could be expensive and time-consuming.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our intellectual property, including our patents or the patents of our licensors. As a result, we may be required to file
infringement claims to stop third-party infringement or unauthorized use. This can be expensive and time-consuming, particularly for
a company of our size. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable
or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology
or that the factors necessary to grant an injunction against an infringer are not satisfied. An adverse determination of any litigation
or other proceedings could put one or more of our patents at risk of being invalidated, interpreted narrowly, or amended such that they
do not cover our clinical assets. Moreover, such adverse determinations could put our patent applications at risk of not issuing or issuing
with limited and potentially inadequate scope to cover our clinical assets or to prevent others from marketing similar products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interference,
derivation, or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with
respect to our patent applications or those of our licensors or potential partners. Litigation or USPTO proceedings brought by us may
fail or may be invoked against us by third parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent
office proceedings may result in substantial costs and distraction to our management. We may not be able, alone or with our licensors
or potential partners, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect
such rights as fully as in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there
is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.
In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings,
motions, or other interim proceedings or developments or public access to related documents.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in August 2023, prior to the Business Combination, our now wholly-owned subsidiary, Conduit Pharmaceuticals Limited, received
a letter from Strand Hanson Limited (&#8220;Strand&#8221;) claiming it was owed advisory fees pursuant to a previously executed letter.
Conduit rejected and disputed the substance of the letter in full. Following such rejection, on September 7, 2023, Strand filed a claim
in the Business and Property Courts of England and Wales claiming it is entitled to be paid the sum of $2 million and, as a result of
the event the Business Combination is completed, to be issued 65 thousand shares of common stock. We intend to vigorously defend against
these claims. Regardless of its outcome, the litigation may impact our business due to, among other things, defense legal cost and the
diversion of the attention of our management.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated
or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets
and protect other proprietary information.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider proprietary trade secrets or confidential know-how and unpatented know-how to be important to our business. We may rely on trade
secrets or confidential know-how to protect our technology, especially where we believe that patent protection is of limited value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants,
collaborators, contractors, and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting
agreements, or other similar agreements with us prior to beginning research or disclosing proprietary information. These agreements typically
limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current
or former employees, consultants, collaborators, contractors, and advisors may unintentionally or willfully disclose our confidential
information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure
of confidential information. The need to share trade secrets and other confidential information increases the risk that such trade secrets
become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation
of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery
of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on
our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential
know-how is expensive, time consuming, and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction
to jurisdiction.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, these agreements typically restrict the ability of our employees, consultants, collaborators, contractors, and advisors to
publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite
our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with
third parties, independent development, or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery
of our trade secrets would impair our competitive position and have an adverse impact on our business.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed to us alleged
trade secrets of their former employers or their former or current customers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is common in the biotechnology and pharmaceutical industries, certain of our employees were formerly employed by other biotechnology
or pharmaceutical companies, including our competitors or potential competitors. Moreover, we engage the services of consultants to assist
it in the development of our products and clinical assets, many of whom were previously employed at or may have previously been or are
currently providing consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors.
We may be subject to claims that these employees and consultants or we have inadvertently or otherwise used or disclosed trade secrets
or other proprietary information of their former employers or their former or current customers. Although we have no knowledge of any
such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such claims. Even
if we are successful in defending against any such claims, any such litigation could be protracted, expensive, a distraction to our management
team, not viewed favorably by investors and other third parties, and may potentially result in an unfavorable outcome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing
on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition
among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar
to those of ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could
be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate
variations of our unregistered trademarks or trade names. Over the long term, if we are unable to successfully register its trademarks
and trade names and establish name recognition based on its trademarks and trade names, then we may not be able to compete effectively,
and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets,
domain names, copyrights, or other intellectual property may be ineffective and could result in substantial costs and diversion of resources
and could adversely impact our financial condition or results of operations.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
proprietary information may be lost, or we may suffer security breaches.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, proprietary
business information, personal data, and personally identifiable information of our clinical trial subjects and employees, in our data
centers and on our networks. The secure processing, maintenance, and transmission of this information is critical to our operations.
Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due
to employee error, malfeasance, or other disruptions. Although, to our knowledge, we have not experienced any such material security
breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed,
lost, or stolen. Any such access, disclosure, or other loss of information could result in legal claims or proceedings, liability under
laws that protect the privacy of personal information, significant regulatory penalties, disrupt our operations, damage our reputation,
and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay
our clinical development of our clinical assets.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
use artificial intelligence technology in our business, specifically, in relation to our service agreement with Sarborg and
challenges with properly managing such technology could result in reputational harm, competitive harm and legal liability, and
adversely affect our business, financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2024, we entered into the Sarborg Agreement with Sarborg. Under the terms of the Sarborg Agreement, Sarborg will provide
algorithmic and cybernetic technology services to Conduit, including the development of decision-support tools and advanced cybernetic
systems tailored to enhance Conduit&#8217;s decision-making processes and maximize the value of its pharmaceutical asset portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarborg
will perform the services to Conduit comprised of three phases: the Initial Phase (0-24 weeks) focuses on establishing a foundation for
collaboration and aligning Sarborg&#8217;s services with Conduit&#8217;s strategic goals; the Development Phase (24-36 weeks) involves
building technological infrastructure, including dashboards and predictive models; and the Ongoing Services Phase (36-52 weeks) ensures
the sustained functionality and relevance of Sarborg&#8217;s deliverables while supporting Conduit&#8217;s growth through iterative improvements
and updates. Sarborg will create specific deliverables, including reports, computer programs, software applications, APIs, mobile applications,
source code, written technical specifications and designs, operating and maintenance manuals, and other recorded data and information
arising from or relating to the services. Sarborg will provide all necessary resources to perform the services and deliver the deliverables
in accordance with the Sarborg Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, Conduit has successfully completed the Initial Phase of its collaboration with Sarborg, establishing a strong foundation for
integrating AI-driven solutions into our operations. This phase focused on identifying key inputs for the algorithmic approach and
ensuring alignment between Sarborg&#8217;s services and Conduit&#8217;s strategic goals. As part of this effort, Sarborg has
successfully delivered three key milestones. First, they conducted detailed teach-in sessions with Conduit&#8217;s management team
to gain a deeper understanding of our objectives, challenges, and operational workflows, resulting in documented meeting agendas,
minutes, and action plans. Second, they finalized and validated a set of proprietary inputs essential for their cybernetic models,
tailored specifically to Conduit&#8217;s portfolio and R&amp;D pipeline. Finally, they completed an in-depth market analysis of
potential cocrystal candidates, assessing the patent landscape, competitive positioning, and market size. The insights from this
market analysis are now informing Conduit&#8217;s ongoing strategic decision-making. With these key milestones delivered, we are now
progressing to the next phase of development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarborg
has now commenced Phase II: The Development Phase, which focuses on building the technological infrastructure necessary to integrate
AI into Conduit&#8217;s operations. As part of this, Sarborg has successfully completed the first milestone, Dashboard Creation and Refinement,
delivering personalized dashboards that provide Conduit&#8217;s key personnel with real-time access to critical data related to deliverables,
clinical trials, and drug discovery. These initial dashboards, along with user interface mock-ups and a dashboard user guide, will serve
as the foundation for further refinements. Moving forward, the platform will continue to be optimized to maximize efficiency and ensure
seamless integration into Conduit&#8217;s workflows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
with many developing technologies, AI presents risks and challenges that could affect its further development, adoption, and use, and
therefore our business. AI algorithms may be flawed or biased. Datasets used to train or develop AI systems may be insufficient, of inferior
quality, or contain biased information. Additionally, the laws and regulations concerning the use of AI continue to evolve. If the use
or integration of AI systems, or the outputs generated by such systems, were determined to be non-compliant (e.g., in relation to intellectual
property or data privacy rights), this may result in liability, including legal liability, or adversely affect our business, reputation,
brand, financial condition and results of operations. It is possible that emerging regulations may limit or block the use of AI in our
business and solutions or otherwise impose other restrictions that may affect or impair the usability or efficiency of our business or
services for an extended period of time or indefinitely. Our competitors or other third parties may incorporate AI into their product
development, technology and infrastructure more quickly or more successfully than us, which could impair our ability to compete effectively
and adversely affect our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Securities Markets and Investment in Our Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>If we do not maintain
our trading market&#8217;s listing requirements, Nasdaq may delist our securities from trading on its exchange.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In August 2024, the Company
received deficiency letters from Nasdaq&#160;notifying the Company that it was not in compliance with Listing Rule 5450(a)(1) (the &#8220;Bid
Price Rule&#8221;), Listing Rule 5450(b)(2)(C) (the &#8220;MVPHS Rule&#8221;) and Listing Rule 5450(b)(2)(A) (the &#8220;MVLS Rule&#8221;,
together with the Bid Price Rule and the MVPHS Rule, the &#8220;Rules&#8221;). The Company had until February 10, 2025, and February
11, 2025, to regain compliance with the Rules. On December 17, 2024, Nasdaq issued a letter to the Company that as of December 17, 2024,
it determined that the Company&#8217;s securities had a closing bid price of $0.10 or less for ten consecutive trading days. As a result,
Nasdaq had determined to delist the Company&#8217;s common stock and redeemable warrants from The Nasdaq Global Market, on December 27,
2024. The Company subsequently requested and received a hearing (the &#8220;Nasdaq Hearing&#8221;) from the Nasdaq Hearings Panel (the
&#8220;Panel&#8221;). The Company submitted a written plan of compliance to cure its Rule deficiencies to Nasdaq on January 22, 2025,
and attended the Nasdaq Hearing for the Company on February 11, 2025. On March 5, 2025, the Company received a written notification (the
&#8220;Notice&#8221;) from the Panel confirming it has granted the Company such an extension for the Company to regain compliance with
the MVPHS and MVLS rules, provided that the Company, (i) on or before March 12, 2025, files an application to transfer to the Nasdaq
Capital Market, which application was submitted on March 7, 2025, and (ii) on or before March 31, 2025, demonstrates compliance with all Nasdaq listing rules,
which it intends to do, and believes it will satisfy. Additionally, the Company was also notified in the Notice that as of February
26, 2025, it had regained compliance with the Bid Price Rule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the transfer to the Nasdaq Capital Market, the Company&#8217;s current MVPHS will be compliant with the MVPHS continued listing
standard of greater than $1.0 million and the Company believes it will be able to demonstrate its compliance with the Equity
Standard of Stockholder&#8217;s Equity greater than $2.5 million prior to the March 31, 2025, deadline to the satisfaction of
Nasdaq, although no such assurance can be given. The inability to comply with Nasdaq&#8217;s continued requirements or standards
could result in the delisting of our common stock, which could have a material adverse effect on our financial condition and could
cause the value of the common stock to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our common stock were to be delisted from trading on The Nasdaq Global Market and the trading price of our common stock were below $5.00
per share on the date the common stock is delisted, trading in our common stock would also be subject to the requirements of certain
rules promulgated under the Exchange Act. These rules require additional disclosure by broker-dealers in connection with any trades involving
a stock defined as a &#8220;penny stock&#8221; and impose various sales practice requirements on broker-dealers who sell penny stocks
to persons other than established customers and accredited investors, generally institutions. These additional requirements may discourage
broker-dealers from effecting transactions in securities that are classified as penny stocks, which could severely limit the market price
and liquidity of such securities and the ability of purchasers to sell such securities in the secondary market. A penny stock is defined
generally as any non-exchange listed equity security that has a market price of less than $5.00 per share, subject to certain exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not anticipate paying any dividends in the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current expectation is that we will retain our future earnings to fund the development and growth of our business. As a result, capital
appreciation, if any, of the shares of our common stock will stockholders&#8217; sole source of gain, if any, for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Second Amended and Restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;) provides, subject to limited
exceptions, that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain stockholder litigation
matters, which could limit our stockholders&#8217; ability to obtain a chosen judicial forum for disputes with us or our directors, officers,
employees, or stockholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation requires to the fullest extent permitted by law, that derivative actions brought in our name, actions against
directors, officers and employees for breach of fiduciary duty and other similar actions may be brought in the Court of Chancery in the
State of Delaware or, if that court lacks subject matter jurisdiction, another federal or state court situated in the State of Delaware.
Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of
and consented to the forum provisions in our Certificate of Incorporation. In addition, our Certificate of Incorporation and Bylaws provide
that the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause
of action under the Securities Act and the Exchange Act. Neither the exclusive forum provisions nor the federal securities laws (and
the rules and regulations thereunder) may be waived by a stockholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the Delaware Supreme Court issued a decision in <i>Salzburg et al. v. Sciabacucchi</i>, which found that an exclusive forum
provision providing for claims under the Securities Act to be brought in federal court is facially valid under Delaware law. We intend
to enforce this provision, but we do not know whether courts in other jurisdictions will agree with this decision or enforce it.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum of its choosing for disputes with
us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims and,
if a stockholder were to bring such a claim, the choice of forum provision may result in the stockholder incurring increased costs in
connection with bring such a claim as such stockholder will be required to bring the claim in the state or federal courts located in
the State of Delaware. Alternatively, if a court were to find the choice of forum provision contained in our Certificate of Incorporation
to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions,
which could harm its business, operating results, and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
charter documents and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce the market price
of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws contain provisions that could delay or prevent a change in control of the Company. These provisions
could also make it more difficult for stockholders to elect directors and take other corporate actions. These provisions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorizing
    our board of directors to issue preferred stock with voting or other rights or preferences that could discourage a takeover attempt
    or delay changes in control;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prohibiting
    cumulative voting in the election of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing
    that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prohibiting
    stockholder action by written consent;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
    the persons who may call special meetings of stockholders; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
    advance notification of stockholder nominations and proposals.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult
for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. These
and other provisions in our Certificate of Incorporation and Bylaws and under Delaware law could discourage potential takeover attempts,
reduce the price investors might be willing to pay in the future for shares of common stock and result in the market price of common
stock being lower than it would be without these provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish or cease publishing research or reports about us, our business, or our market, or if they
adversely change their recommendations or publish negative reports regarding our business or our common stock, our share price and trading
volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will depend on the research and reports that securities or industry analysts publish about us, our
business, or our market. Currently, we do not have any analyst coverage and may not obtain analyst coverage in the future. In the event
we obtain analyst coverage, we will not have any control over such analysts. If one or more of the analysts who cover us downgrade the
common stock or change their opinion of such shares, the share price of the common stock would likely decline. If one or more of these
analysts cease coverage of the Company or fail to regularly publish reports on the Company, we could lose visibility in the financial
markets, which could cause the share price or trading volume of the common stock to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an &#8220;emerging growth company&#8221; and we cannot be certain if the reduced disclosure requirements applicable to emerging growth
companies will make our securities less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. Emerging growth companies can delay adopting new or revised
accounting standards until such time as those standards apply to private companies. As an emerging growth company, we are not required
to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, we have reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements, and we are exempt from the requirements of holding a nonbinding
advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We cannot
predict if investors will find our stock less attractive because we may rely on these provisions. If some investors find our stock less
attractive as a result, there may be a less active trading market for our shares and our stock price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an emerging growth company until the earliest of (i) the end of the fiscal year in which the market value of our common stock
that is held by non-affiliates exceeds $700 million as of the end of the second fiscal quarter, (ii) the end of the fiscal year in which
we have total annual gross revenues of $1.235 billion or more during such fiscal year, (iii) the date on which we issue more than $1
billion in non-convertible debt in a three-year period, or (iv) the end of the fiscal year following the fifth anniversary of the date
of the first sale of our common stock pursuant to an effective registration statement filed under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Claims
for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us
and may reduce the amount of money available to us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws provides that we will indemnify our directors and officers, in each case to the fullest extent
permitted by Delaware law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as permitted by Section 145 of the DGCL, our Bylaws and our indemnity agreements that we entered into with our directors and
officers provide that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request,
    to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person
    acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant
    and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will be required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except
    that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled
    to indemnification;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will not be obligated pursuant to our Bylaws to indemnify a person with respect to proceedings initiated by that person against us
    or our other indemnitees, except with respect to proceedings authorized by our board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rights conferred in our Bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors,
    officers, employees and agents and to obtain insurance to indemnify such persons; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not retroactively amend our Bylaw provisions to reduce our indemnification obligations to directors, officers, employees and
    agents.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Finances and Capital Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will require substantial additional funding in the future, which may not be available to us on acceptable terms, or at all, and, if not
so available, may require us to delay, limit, reduce, or cease our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations have consumed substantial amounts of cash since our inception. As of December 31, 2024, we had an accumulated deficit of $29.1
million and our net loss was $17.8 million for the fiscal year ended December 31, 2024. We expect to continue to incur significant expenses
and increasing operating losses for the foreseeable future. Our business will require substantial additional capital for implementation
of our long-term business plan and development of clinical assets. Our ability to raise additional funds may be adversely impacted by
potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in
the U.S. As we require additional funds, we may seek to fund our operations through the sale of additional equity securities, debt financing,
and/or strategic collaboration agreements. We cannot be sure that additional financing from any of these sources will be available when
needed or that, if available, the additional financing will be obtained on favorable terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future funding requirements will depend on many factors, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress, timing, scope, and costs of our clinical trials, including the ability to timely enroll patients in our potential future
    clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    outcome, timing, and cost of regulatory approvals by the FDA and comparable regulatory authorities, including the potential that
    the FDA or comparable regulatory authorities may require that we perform more studies than those that we currently expect;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of revenues, if any, from our current clinical assets or any future clinical assets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and timing of any potential future collaborations, licensing, or other arrangements that we may establish;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cash
    requirements of any future acquisitions and/or the development of other clinical assets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of operating as a public company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    time and cost necessary to respond to technological and market developments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    disputes which may occur between us, employees, collaborators, or other prospective business partners; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise additional funds by selling shares of our common stock or other equity-linked securities, the ownership interest of our current
stockholders will be diluted. We may seek to access the public or private capital markets whenever conditions are favorable, even if
we do not have an immediate need for additional capital at that time. If we raise additional funds through collaborations, strategic
alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our
technologies, future revenue streams, or clinical assets or to grant licenses on terms that may not be acceptable to us. If we raise
additional funds through debt financing, we may have to grant a security interest on our assets to the future lenders, our debt service
costs may be substantial, and the lenders may have a preferential position in connection with any future bankruptcy or liquidation involving
the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2025, the last quoted sale price for our common stock as reported on Nasdaq was $0.77 per share. Currently, the exercise
prices of the Company&#8217;s warrants are significantly greater than the current market price of our common stock. Accordingly,
such warrants are unlikely to be exercised and therefore the Company does not expect to receive any proceeds from such exercise of
the warrants in the near term. Whether any holders of Warrants determine to exercise such warrants, which would result in cash
proceeds to the Company, will likely depend upon the market price of our common stock at the time of any such holder&#8217;s
determination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to raise additional capital when needed, we may be required to curtail the development of our technology or materially
curtail or reduce our operations. We could be forced to sell or dispose of our rights or assets. Any inability to raise adequate funds
on commercially reasonable terms could have a material adverse effect on our business, results of operations, and financial condition,
including the possibility that a lack of funds could cause our business to fail and our Company to dissolve and liquidate with little
or no return to investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will continue to incur significant increased costs as a result of operating as a public company, and our management will be required
to devote substantial time to new compliance initiatives.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a publicly traded company, we will incur significant legal, accounting, and other expenses under the Exchange Act, the Sarbanes-Oxley
Act, and other applicable securities rules and regulations. In addition, new and changing laws, regulations, and standards relating to
corporate governance and public disclosure, including the Dodd Frank Wall Street Reform and Consumer Protection Act and the rules and
regulations promulgated and to be promulgated thereunder, as well as under the Sarbanes-Oxley Act, the JOBS Act, and the rules and regulations
of the SEC and national securities exchanges have created uncertainty for public companies and increased the costs and the time that
our board of directors and management must devote to complying with these rules and regulations. We expect these rules and regulations
to increase our legal and financial compliance costs and will divert management time and attention from revenue generating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the need to establish the corporate infrastructure demanded of a public company may divert management&#8217;s attention from implementing
our growth strategy, which could prevent us from improving our business, results of operations, and financial condition. We have made,
and will continue to make, changes to our internal controls and procedures for financial reporting and accounting systems to meet our
reporting obligations as a publicly traded company. However, the measures we take may not be sufficient to satisfy our obligations as
a publicly traded company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
as long as we remain an &#8220;emerging growth company&#8221; as defined in the JOBS Act, we may take advantage of certain exemptions
from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies.&#8221;
We may remain an &#8220;emerging growth company&#8221; until the earliest of (i) the last day of our fiscal year following February 7,
2027 (the fifth anniversary of the consummation of the SPAC IPO), (ii) the last day of the fiscal year in which the market value of our
shares of common stock that are held by non-affiliates exceeds $700 million as of June 30 of that fiscal year, (iii) the last day of
the fiscal year in which we have total annual gross revenue of $1.235 billion or more during such fiscal year (as indexed for inflation)
or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt in the prior three-year period. Further, there
is no guarantee that the exemptions available to us under the JOBS Act will result in significant savings. To the extent we choose not
to use exemptions from various reporting requirements under the JOBS Act, we will incur additional compliance costs, which may impact
earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may issue additional shares of common stock or preferred stock under an employee incentive plan or under our existing at the market offering program, which would dilute the interest of
our stockholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue a substantial number of additional shares of common or preferred stock under an employee incentive plan or under our ongoing at the market offering program. The issuance of
additional shares of common or preferred stock:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
    significantly dilute the equity interest of investors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
    subordinate the rights of holders of common stock if preferred stock is issued with rights senior to those afforded our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">could
    cause a change of control if a substantial number of shares of our common stock are issued, which may affect, among other things,
    our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers
    and directors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
    adversely affect prevailing market prices for the common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_004"></span><b>Item
1B. Unresolved Staff Comments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_005"></span><b>Item
1C. Cybersecurity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_983_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240101__20241231_gBFCRMPFAIAMT-NIOQFU_zeRpfm6xCeae" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000055-01" escape="true" id="Fact000055" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in the biotechnology sector, which is subject to various cybersecurity risks that could adversely affect our business,
financial condition, and results of operations, including intellectual property theft; fraud; extortion; harm to employees or
customers; violation of privacy laws and other litigation and legal risk; and reputational risk. We have implemented a risk-based
approach to identify and assess the cybersecurity threats that could affect our business and information systems. <span id="xdx_909_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zPoYDOIWgNB8" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000056" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">We
have implemented a risk-based approach to identify and assess cybersecurity threats that could impact our business and information
systems. As part of this strategy, the Company has engaged a third-party service provider to implement comprehensive IT and
cybersecurity policies, including Guardz, Cyber Essentials, and others. These initiatives are supported by detailed policies, staff
training programs, and the use of advanced tools such as firewalls and VPNs to prevent cybersecurity incidents. Additionally,
consultation with third-party experts has further strengthened the Company&#8217;s IT framework and improved overall compliance. We
require third-party service providers with access to personal, confidential or proprietary information</ix:nonNumeric></span> to implement and
maintain comprehensive cybersecurity practices consistent with applicable legal standards and industry best practices.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0D_gBFCRMPFAIAMT-NIOQFU_zib5dsKFpaZ6"><ix:continuation continuedAt="ConU000055-02" id="ConU000055-01">&#160;</ix:continuation></span></span></p>

<div id="xdx_C0F_gBFCRMPFAIAMT-NIOQFU_zw0kRvqngFUe"><ix:continuation continuedAt="ConU000055-03" id="ConU000055-02"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has engaged a third-party service provider
to implement comprehensive IT and cybersecurity policies, including Guardz, Cyber Essentials, and others. These initiatives are supported
by detailed policies and staff training programs, which have strengthened the Company&#8217;s IT framework and improved compliance.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
light of the pervasive and increasing threat from cyberattacks, the Company&#8217;s <span id="xdx_90D_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zCmPOEA4fMO7" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000057" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">Board
of Directors and the Audit Committee, with input from management, assess the Company&#8217;s cybersecurity threats</ix:nonNumeric> </span>and the
measures implemented by the Company to mitigate and prevent cyberattacks. The <span id="xdx_90A_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_dbT_c20240101__20241231_zhFBMgui0wy3" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000058" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">Audit
Committee consults with management regarding ongoing cybersecurity initiatives, and requests management to report </ix:nonNumeric></span>to the
Audit Committee or the full Board regularly on their assessment of the Company&#8217;s cybersecurity program and risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, the Company is not aware of any risks from cybersecurity threats that have <span id="xdx_906_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240101__20241231_zxFc8G9jBSJc" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000059" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">materially affected or
are reasonably likely to materially affect the Company, including its business strategy, results of operations, or financial condition.</ix:nonNumeric></span></span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C05_gBFCRMPFAIAMT-NIOQFU_zKrQjyhcJ1W2"><ix:continuation id="ConU000055-03">&#160;</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>Item
2. Properties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently operate as a virtual company, but also lease property in the United Kingdom. On March 7, 2024, we entered into a lease for
laboratory space at Cambridge Science Park. Rent is &#163;92,925 per annum, the equivalent of approximately $10,000 per month. The lease
runs until January of 2027, and the laboratory space is intended to provide us with the ability to extend or develop proprietary solid-form
intellectual property for existing and future clinical assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>Item
3. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as set forth below, we are not currently party to or aware of being subject to any material legal proceedings. However, we may from
time to time become a party to various legal proceedings arising in the ordinary course of our business, which could have a material
adverse effect on our business, financial condition, or results of operations. Regardless of outcome, litigation could impact our business
due to defense and settlement costs, diversion of management resources and other factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2023, prior to the Business Combination, our now wholly-owned subsidiary, Conduit Pharmaceuticals Limited, received a letter from
Strand Hanson Limited (&#8220;Strand&#8221;) claiming it was owed advisory fees pursuant to a previously executed letter. Conduit rejected
and disputes the substance of the letter in full. Following such rejection, on September 7, 2023, Strand filed a claim in the Business
and Property Courts of England and Wales claiming it is entitled to be paid the sum of $2 million and, as a result of the completion
of the Business Combination, to be issued 6.5 million shares of common stock. As of December 31, 2024, the potential contingency is considered
probable and reasonably estimable and as such, the Company accrued an estimated liability of $0.4 million in the accompanying financial
statements. We intend to vigorously defend against these claims. Regardless of its outcome, the litigation may impact our business due
to, among other things, defense legal cost and the diversion of the attention of our management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 18, 2024, Conduit UK Management Limited
(&#8220;Conduit&#8221;) received a notification from the UK Intellectual Property Office (&#8220;UK IPO&#8221;) notifying the company
that St George Street Capital had initiated patent entitlement proceedings with respect to patent application PCT/IB2022/00775 (&#8220;Patent
Application&#8221;). Conduit refutes the claims made by St George Street Capital and filed a counterstatement on February 26, 2025 with
the UK IPO. In addition, each of the three inventors named in the Patent Application filed simultaneous counterstatements fully supporting
Conduit&#8217;s position, and assertions that the claims are without merit. Further updates will be made following notification by the
UK IPO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="a_008"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
4. Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_009"></span><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
Market Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock and warrants are traded on The Nasdaq Global Market and The Nasdaq Capital Market, respectively, under the symbols &#8220;CDT&#8221;
and &#8220;CDTTW&#8221;, respectively. Prior to the completion of the Business Combination, the securities of MURF were listed on The
Nasdaq Global Market under the symbols &#8220;MURFU,&#8221; &#8220;MURF,&#8221; and &#8220;MURFW&#8221;, all of which are no longer listed
on The Nasdaq Global Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2025, the last quoted sale price for our common stock as reported on Nasdaq was $0.77 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 28, 2025, there were approximately 400 holders of record of our common stock. Such numbers do not include beneficial owners
holding our securities through nominee names.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)
Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our capital stock, and we do not currently intend to pay any cash dividends for the
foreseeable future. We expect to retain future earnings, if any, to fund the development and growth of our business. Any future determination
to pay dividends on our common stock will be at the discretion of our board of directors and will depend upon, among other factors, our
financial condition, operating results, current and anticipated cash needs, plans for expansion, and other factors that our board of
directors may deem relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)
Securities Authorized for Issuance Under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
is made to the information contained in the Equity Compensation Plan table contained in Item 11 of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(e)
Recent Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no unregistered sales of equity securities which have not been
previously disclosed in a quarterly report on Form 10-Q or a current report on Form 8-K since January 1, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(f)
Use of Proceeds from Registered Offerings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(g)
Purchases of Equity Securities by the Issuer and Affiliated Purchasers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="a_011"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
6. [Reserved].</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>Item
7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion and analysis of our financial condition and results of operations should be read together with the other sections
of this Annual Report on Form 10-K, including our audited financial statements for the year ended December 31, 2024, together with related
notes thereto, included elsewhere in this Annual Report. The following discussion contains forward-looking statements based upon current
expectations that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these
forward-looking statements as a result of various factors, including those set forth under the section titled &#8220;Risk Factors&#8221;
or in other parts of this Annual Report and our other filings with the SEC. Our historical results are not necessarily indicative of
the results that may be expected for any period in the future. Conduit Pharmaceuticals Limited entered into an Agreement and Plan of
Merger (the &#8220;Merger Agreement&#8221;) with Murphy Canyon Acquisition Corp. (&#8220;MURF&#8221;) on November 8, 2022. The transaction
contemplated by the terms of the Merger Agreement was completed on September 22, 2023, in conjunction with which MURF changed its name
to Conduit Pharmaceuticals Inc. (hereafter referred to, collectively with is subsidiaries as &#8220;Conduit&#8221;, the &#8220;Company&#8221;,
&#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;, unless the context otherwise requires. All dollar amounts are expressed in thousands
of United States dollars (&#8220;$&#8221;), unless otherwise indicated.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2023, a merger transaction (the &#8220;Business Combination&#8221;) between Conduit Pharmaceuticals Limited (&#8220;Old
Conduit&#8221;), Murphy Canyon Acquisition Corp (&#8220;MURF&#8221;) and Conduit Merger Sub, Inc., a Cayman Islands exempted company
and a wholly owned subsidiary of MURF (&#8220;Merger Sub&#8221;), was completed pursuant to the Agreement and Plan of Merger, dated November
8, 2022, as amended, (the &#8220;Merger Agreement&#8221;). Pursuant to the terms of the Merger Agreement, at the closing, (i) Merger
Sub merged with and into Old Conduit, with Old Conduit surviving the Business Combination as a wholly-owned subsidiary of MURF, and (ii)
MURF changed its name from Murphy Canyon Acquisition Corp. to Conduit Pharmaceuticals Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit
has developed a unique business model that allows it to act as a conduit to bring clinical assets from pharmaceutical companies and develop
new treatments for patients. Our novel approach addresses unmet medical needs and lengthens the intellectual property for our existing
assets through cutting-edge solid-form technology and then commercializing these products with life science companies. We continue to
evaluate novel artificial intelligence and cybernetics approaches to drug re-purposing, intellectual property and asset selection to
give Conduit a competitive advantage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are led by highly experienced pharmaceutical executives: Dr. Freda Lewis-Hall, former Chief Medical Officer of Pfizer Inc., the Chair
of our Board of Directors, and Dr. David Tapolczay, former Chief Executive Officer of the United Kingdom-based medical research charity
LifeArc, our Chief Executive Officer. Our management team includes active senior scientists who have an extensive understanding of the
pharmaceuticals market, which supports our strategy of developing clinical assets in a cost-efficient manner while focusing on therapeutic
efficacy and patient safety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously,
Conduit leverages the capabilities of our Cambridge laboratory facility and highly experienced team of solid-form experts to extend or
develop proprietary solid-form intellectual property for our existing and future clinical assets. Our own intellectual property portfolio
comprises pending patent applications in several international jurisdictions describing a solid-form compound, including the AZD1656
Cocrystal (a HK-4 Glucokinase Activator), targeting a wide range of autoimmune disorders. Our pipeline research includes a number of
compounds that serve as promising alternatives to existing clinical assets currently marketed and sold by large pharmaceutical companies,
which we have identified as having an opportunity to develop further intellectual property positions through solid-form technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the funding and development of clinical assets, we expect to evaluate and select the specific molecules to be
developed and collaborate with external CROs and Key Opinion Leaders
(&#8220;KOLs&#8221;) to run clinical trials that are managed, funded, and overseen by us. We intend to leverage our comprehensive
clinical and scientific expertise in order to facilitate development of clinical assets through Phase II trials in an efficient
manner by using CROs and third-party service providers. We will also collaborate closely with disease specific KOLs to collectively
assess and determine the most appropriate indications for all our current and forthcoming assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that successful Phase II trials of the clinical assets in our pipeline will increase the value of our assets. There is no assurance
that any clinical trials on the assets owned or licensed by us will be successful, however, following a successful Phase II clinical
trial, we would look to licensing opportunities with large biotech or pharmaceutical companies, typically for up-front milestone payments
and royalty income streams for the life of the asset patent. We anticipate using any future royalty income stream to develop our asset
portfolio in combination with other potential sources of financing, including debt or equity financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
of our proprietary owned patented clinical assets, AstraZeneca agreed to grant a license to the Company under certain intellectual property
rights controlled by AstraZeneca related to HK-4 Glucokinase activators AZD1656 and AZD5658 in all indications and myeloperoxidase inhibitor
AZD5904 for the treatment, prevention, and prophylaxis of idiopathic male infertility. The Company will be responsible for the development
and commercialization of the Licensed Products under the related License Agreement. The
Company is required to use commercially reasonable efforts to develop and commercialize the Licensed Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AstraZeneca
has conducted initial pre-clinical and, in some instances, clinical trials on these assets, but has decided to license them for further
development. As the clinical assets have undergone initial pre-clinical and clinical testing conducted by AstraZeneca, we are able to
use the safety data generated in these clinical trials to assess which clinical assets to further develop and for which indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
this relationship, there are considerable APIs that were manufactured by AstraZeneca
(prior to conducting its clinical trials) available to Conduit. As a result, Conduit may not have to develop the APIs, which is often
a time consuming and expensive process, and the APIs already produced were subject to rigorous quality control measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
collaboration with SARBORG Limited (&#8220;Sarborg&#8221;), a related party, Conduit intends to leverage an advanced AI and cybernetics platform to evaluate key deliverables across multiple areas of the Company&#8217;s operations,
including drug repurposing, drug discovery, solid-form identification, and clinical trial monitoring.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarborg Agreement is designed to address longstanding challenges in the pharmaceutical sector, in particular by reducing human error
in critical decision-making processes in both clinical development and asset identification. By integrating Sarborg&#8217;s
algorithmic AI/cybernetics technology, Conduit aims to enhance efficiency, lower costs, and accelerate timelines by minimizing human
intervention, ultimately optimizing the drug development cycle and giving Conduit a competitive advantage in the sector.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
this relationship, Conduit will gain access to cutting-edge predictive models and dashboards, enabling the Company to evaluate drug candidates,
streamline clinical trials, and optimize asset management with real-time data. These tools will drive faster, more accurate decisions,
improving efficiency and reducing costs. By leveraging these insights, Conduit can differentiate itself in a competitive sector and gain
unique data-driven insights that position the Company for success across both its current and future asset portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Conduit will retain a perpetual, non-exclusive, royalty-free, and assignable right to use any platform or technology developed
by Sarborg in association with the deliverables. Ongoing support from Sarborg will ensure these systems evolve with Conduit&#8217;s needs,
driving long-term innovation in areas like IP creation, regulatory strategy, and clinical trial monitoring. This partnership reinforces
Conduit&#8217;s commitment to leveraging AI-driven solutions to accelerate growth, deliver value to shareholders, and maintain a competitive
edge in the pharmaceutical sector.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
strategic move reaffirms Conduit&#8217;s commitment to adopting forward-thinking solutions to stay at the forefront of innovation in
the pharmaceutical industry. By reducing reliance on traditional, labor-intensive methods and harnessing the power of AI-driven technology,
Conduit is well-positioned to lead in areas such as drug repurposing, clinical trial monitoring, and IP creation, ensuring the Company&#8217;s
long-term growth and market leadership.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
Conduit is well positioned to pursue, and intends to pursue, additional relationships and/or partnerships with third parties for the
licensing of further assets which are currently deprioritized. We plan to focus our efforts on developing clinical assets to address
disorders that impact a large population where there is no present treatment or the present treatment, carries significant unwanted side
effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2025, we filed a certificate of amendment to the Company&#8217;s Second Amended and Restated Certificate of Incorporation
(the &#8220;Amendment&#8221;) with the Secretary of State of the State of Delaware to effectuate a 1-for-100 reverse stock split (the
&#8220;Reverse Stock Split&#8221;) of the outstanding shares of our common stock. Our stockholders previously approved the Reverse Stock
Split and granted the board of directors the authority to determine the exact split ratio and when to proceed with the Reverse Stock
Split at our annual meeting of stockholders held on December 18, 2024. The Reverse Stock Split became effective on January 24, 2025,
and the common stock begin trading on The Nasdaq Global Market on a Reverse Stock Split-adjusted basis on January 27, 2025. The par value
and other terms of the common stock were not affected by the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the reverse stock split, every 100 shares of our common stock issued or outstanding were automatically reclassified into
and became one new share of common stock, and the number of our issued and outstanding shares of common stock was reduced to 1,384,801
and 738,295 as of December 31, 2024 and December 31, 2023, respectively. All references to numbers of shares of common stock and per-share
information in this Annual Report on Form 10-K have been adjusted retroactively, as appropriate, to reflect the reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Nasdaq Stock Market Correspondence and Subsequent
Nasdaq Capital Market Listing</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">We are compliant with the&#160;MVPHS
continued listing standard of Nasdaq Capital Market being greater than $1.0 million. The current MVPHS is&#160;$5,166,785&#160;based on
the closing price of the common stock on March 27, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">On a pro-forma basis at March 31, 2025,&#160;we expect to satisfy&#160;compliance
with the Nasdaq Capital Market Equity Standard of Stockholder&#8217;s Equity greater than $2.5 million,&#160;after anticipating all Q1
2025 expected losses. Through the date of the consolidated financial statements, Stockholder&#8217;s Equity has increased significantly,
through (i) fundraising of an additional $8.332 million from the Sales Agreement with AGP, (ii) conversion of $1.785 million from the
Nirland Notes into 924,200 shares of common stock,&#160;and (iii) capitalization of certain invoices and fees.&#160;We expect to maintain
continued compliance with the Equity Standard&#160;through additional issuance under its Sales Agreement, additional conversions of outstanding
debt and capitalization of fees and a tight control of expenditure,&#160;although no such assurance can be given.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Component of Result of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 21.6pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred in connection with the research and development of our candidates and programs.
We expense research and development costs and intangible assets acquired that have no alternative future use as incurred. These expenses
include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">personnel-related
    expenses, including salaries, bonuses, benefits and stock-based compensation for employees engaged in research and development functions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred in connection with the clinical development and regulatory approval of our clinical assets, including under agreements with
    third parties, such as consultants, contractors and CROs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">license
    fees with no alternative use; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    expenses related to research and development.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expense research and development costs as incurred. Advance payments that we make for goods or services to be received in the future
for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the benefits are
consumed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our research and development
activities have been wholly focused on developing co-crystals of AZD1656 to increase patent life. Some of this work was completed by
third-party CROs but all intellectual property is retained by us. We currently have one pending international patent application and
two pending national patent applications. The successful completion of clinical trials increases the value of clinical assets and may
lead to the commercialization and/or licensing of such assets to other pharmaceutical companies. There is no assurance that any clinical
trials on the assets owned or licensed by us will be successful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 21.6pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist of salaries and other related costs, legal fees relating to intellectual property and corporate matters,
professional fees for accounting, auditing, tax and consulting services, insurance costs, travel, and other operating costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our general and administrative expenses will increase substantially for the foreseeable future as we increase our administrative
headcount to operate as a public company and as we advance clinical assets through clinical development. We also will incur additional
expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the
SEC and the Nasdaq listing rules, additional insurance expenses, investor relations activities and other administrative and professional
services. In addition, if regulatory approval is obtained for clinical assets, we expect to incur expenses associated with building a
sales and marketing team.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Income (Expenses)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
income (expenses), net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income (expense), net consists of change in the fair value of options, change in fair value of convertible notes, and expense incurred
upon the issuance of warrants during the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
expense, net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense, net consists primarily of interest expense on convertible loan notes and promissory notes and interest expense on deferred commissions
payable to an advisor for fees related to the merger, as well as a small amount of interest income on cash and cash equivalents held
by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table set forth our results of operations for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 21.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">(Dollar amounts in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,378</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,288</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">3,653</td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 21.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses increased by approximately $3.3 million, or 3,653%, to approximately $3.4 million for the year ended December
31, 2024, as compared to approximately $90 thousand for the year ended December 31, 2023. The increase was primarily driven by a $3.1
million upfront payment to AstraZeneca in connection with the license agreement, comprised of $1.5 million cash and $1.6 million of our
common shares issued to AstraZeneca with no comparable activity in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and administrative expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">(Dollar amounts in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">General and administrative expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">12,041</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,173</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">6,868</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">133</td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 21.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses increased by $6.9 million, or 133%, to approximately $12.0 million for the year ended December 31, 2024,
as compared to approximately $5.2 million for the year ended December 31, 2023. The increase was primarily driven by a $3.4 million increase
in salaries, stock-based compensation and payroll, a $1.3 million increase in other G&amp;A expenses, a $1.1 million increase in D&amp;O
insurance, a $0.5 million increase in professional fees including: legal fees, accounting and tax expense, listing fees and consulting
fees and a $0.5 million increase in travel expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
income (expense), net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 21.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">(Dollar amounts in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Other income (expense), net</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(890</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">4,923</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(5,813</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(118</td><td style="width: 1%; text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income (expense), net changed by $5.8 million, or 118%, to other expense of approximately $0.9 million for the year ended December
31, 2024, as compared to other income of $4.9 million for the year ended December 31, 2023. In 2024, other expense was driven by a
$2.7 million loss on the issuance of warrants, and a $0.7 million expense related to a net loss on extinguishments, offset by a $2.0
million gain on the change in fair value of convertible notes payable, a $0.3 million increase from an income tax refund and a $0.2
million increase in the gain on change in fair value of warrants. In 2023, other income was driven by a $1.5 million gain on the
derecognition of the Cizzle option in 2023, a $1.3 million gain on the change in fair value of the Cizzle option, a $2.8 million
gain on the derecognition of the deferred revenue for the Vela option prior to the exercise of the Vela option, and a $1.0 million
gain on the change in fair value of the Vela option. This was offset by a $1.0 million loss on issuance related to the Vela option,
$0.4 million change in the fair value of convertible notes payable and $0.3 million realized foreign currency transaction
loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further details refer to Note 17 in the consolidated financial statements as of December 31, 2024 and 2023 included elsewhere in this
Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
expense, net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">(Dollar amounts in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Interest expense, net</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(1,506</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(211</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(1,295</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">614</td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense, net changed by $1.3 million or 614%, to $1.5 million for the year ended December 31, 2024, from $0.2 million for the year
ended December 31, 2023. The change was driven by a $0.9 million increase in the amortization of debt issuance costs and debt
discounts and a $0.4 million increase in interest expense incurred on interest-bearing convertible promissory notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assesses liquidity in terms of our ability to generate cash to fund operating, investing and financing activities. Since our inception,
and in line with our growth strategy, we have prepared our financial statements assuming we will continue as a going concern. Since our
inception, we have incurred net losses and experienced negative cash flows from operations. To date, our primary sources of capital have
been through private placements of equity securities and convertible debt and the Sales Agreement with A.G.P. During the years ended December
31, 2024 and 2023, we incurred operating losses of $15.4 million and $5.3 million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary uses of cash are to fund our operations as we continue to grow our business. We will require a significant amount of cash
for expenditures as we invest in ongoing research and development and business operations. Until such time we can generate
significant revenue from the successful approval and commercialization of a product candidate, we expect to finance our cash needs for
ongoing research and development and business operations through public or private equity or debt financings or other capital
sources, including strategic partnerships. However, we may be unable to raise additional funds or enter into such other
arrangements, when needed, on favorable terms or at all. To the extent that we raise additional capital through the sale of equity
or convertible debt securities, the ownership interest of our stockholders will be, or could be, diluted, and the terms of these
securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing
and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take
specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise
additional funds through equity or debt financings when needed, we may be required to delay, limit, or substantially reduce research
and development efforts all of which could have a material adverse effect on the Company and its financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company believes in the viability of its ability to raise additional funds, there can be no assurances to that effect. We have based
our estimates on assumptions of operating costs that may prove to be wrong. As a result, we could deplete our capital resources sooner
than we currently expect. If, for any reason, our expenses differ materially from our assumptions or we utilize our cash more quickly
than anticipated, or if we are unable to obtain funding on a timely basis we may be required to revise our business plan and strategy,
which may result in significantly curtailing, delaying or discontinuing one or more of our research or development programs or the commercialization
of any product candidates or may result in our being unable to expand our operations or otherwise capitalize on our business opportunities.
As a result, our business, financial condition, and results of operations could be materially affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has concluded that there is substantial doubt regarding our ability to continue as a going concern for a period of at least 12 months
from the date of the filing of this Annual Report. This is based on our analysis under applicable accounting principles. These financial
statements have been prepared assuming the Company will continue as a going concern and do not include adjustments to reflect the possible
effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the
outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 21.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
material cash requirements include the following contractual and other obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loans
Payable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2022, we entered into two loan agreements (the &#8220;Loans&#8221;), with an aggregate principal amount of $0.2 million, with
two lenders. The Loans were to mature and become payable in full two years from the date of the loan agreement and they bear no
interest. On October 9, 2024, the Company executed agreements to extend the loan maturity date for each loan to December 19, 2024.
As of December 31, 2024, the Loans are still outstanding and considered to be in default. The Company repaid the lenders in full during February 2025. Refer to Note 8 to our financial statements included elsewhere in this
Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 21.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 21.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 21.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Promissory
Convertible Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, we issued an aggregate principal amount of $0.8 million convertible promissory note (the &#8220;March 2023 Convertible Note&#8221;)
payable to an investor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
March 2023 Convertible Note originally was to mature and become payable in full, 18 months from the date of the March 2023 Convertible
Note. The March 2023 Convertible Note carries 20% interest per annum and interest is payable every six months from the date of the March
2023 Convertible Note until the maturity date. The March 2023 Convertible Note became convertible into Common Stock following the consummation
of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 9, 2024, the Company and the loan holder signed an extension for the March 2023 Convertible Note to extend the maturity date
from September 20, 2024 to October 20, 2024 with the option for the Company to further extend the maturity date two times, each by
an additional 30-day period. The Company exercised both options to extend the maturity date to December 19, 2024. As of December 31,
2024, the March 2023 Convertible Note is still outstanding and considered to be in default. On March 6, 2025, the Company reached an agreement with the loan holder
to pay $0.7 million in order to settle the March 2023 Convertible Note in full. The Company repaid the loan holder the settlement amount
$0.7 million on March 13, 2025. Refer to Note 7 to our financial statements included elsewhere in this
Annual Report. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>A.G.P
Convertible Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 25, 2024, the Company issued to A.G.P. a convertible promissory note (the &#8220;A.G.P. Convertible Note&#8221;) in the principal
amount of $5.7 million to evidence the A.G.P.&#8217;s currently owed deferred commission payable. Unless earlier converted as specified
in the Convertible Note, the principal amount plus all accrued but unpaid interest is due on November 25, 2025 (the &#8220;Maturity Date&#8221;).
The A.G.P. Convertible Note accrues interest at 5.5% per annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any time prior to the full payment of the A.G.P. Convertible Note, provided that the A.G.P. has given at least three business days
written notice to the Company, A.G.P., in its sole discretion, may elect to have all or any portion of the outstanding principal amount
and all interest accrued converted into shares of the Company&#8217;s common stock, at the lower of the Reverse Split price and the market
price per share at the time of the conversion date, but in no event less than $1.00, subject to adjustment as provided therein and to
take into account any future share splits or reverse splits. However, the conversion of the A.G.P. Convertible Note may not occur
prior to the Company having sufficiently authorized shares of common stock to permit the entire conversion of the convertible promissory
note. Refer to Note 8 to our financial statements included elsewhere in this Annual Report. Per the terms outlined in the agreement, we are required to undertake capital raises to paydown the A.G.P. Convertible
Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>August
2024 Nirland Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 6, 2024, the Company entered into a Senior Secured Promissory Note (the &#8220;August 2024 Nirland Note&#8221;) with Nirland,
a related party of the Company, pursuant to which the Company issued and sold to Nirland the August 2024 Note in the original principal
amount of $2,650,000, inclusive of a $500,000&#160;original issuance discount. Refer to Note 8 to our financial statements included elsewhere
in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 31, 2024, the Company and Nirland amended the August 2024 Nirland Note, whereby the August 2024 Nirland Note was amended to (i)
provide for the conversion of the August 2024 Nirland Note into shares of Common Stock, at Nirland&#8217;s discretion, in a multiple
of any unpaid amounts, if not otherwise previously paid, pursuant to the conversion rate contained therein, (ii) remove Nirland&#8217;s
Mandatory Prepayment Right, and (iii) remove Nirland&#8217;s right of first refusal to participate in any future equity or debt offerings
of the Company. The number of shares of Common Stock issuable upon conversion of any Conversion Amount pursuant to&#160;shall be determined
by dividing (x) such conversion amount by (y) the conversion price. Conversion amount means two and one quarter times the sum of (x)
portion of the principal to be converted, redeemed or otherwise with respect to which this determination is being made and (y) all accrued
and unpaid interest with respect to such portion of the principal amount, if any. Conversion price means, as of any conversion date or
other date of determination, $10, subject to adjustment as provided within the amended agreement. Note 7 to our financial statements
included elsewhere in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt">On
November 22, 2024, the Company and Nirland entered into a Second Amendment to the August 2024 Nirland Note (the &#8220;Second
Amendment&#8221;). Pursuant to the Second Amendment, the Nirland Note may not be converted (other than partial conversions that may
be permitted pursuant to the rules and regulations of NASDAQ (or any successor entity)) prior to receipt of stockholder approval to
provide for such conversion of the Nirland Note, and subsequent issuance of the Company&#8217;s Common Stock, pursuant to the
stockholder approval rules under the rules and regulations of The Nasdaq Stock Market. If the Company has not held a special meeting
of the stockholders to approve the full conversion of the August 2024 Nirland Note on or before January 9, 2025, then the Company
shall be obligated to pay Nirland a penalty of $100,000 per day until the special meeting is held. The special meeting was held on
January 9, 2025, in which stockholder approval was obtained. In addition, the existing conversion rate was amended to be two and one
half times the sum of (x) the portion of the principal to be converted, redeemed or otherwise with respect to which this
determination is being made and (y) all accrued and unpaid interest (including default interest) with respect to such portion of the
principal amount, if any divided by $0.10, pre-split in January 2025 (or following any reverse splits that may occur in a ratio greater than 10 to 1, the lower
of such reverse split price and the market price per share at the time of the conversion date, but in no event less than $1.00),
subject to adjustment as provided therein and to take into account any future share splits or reverse splits. On January 24, 2025, the Reverse Stock Split became effective, resulting in every 100 shares of our common stock
issued or outstanding becoming one new share of our common stock, resulting in the conversion price increasing to $6.86 as of December
31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 9, 2024, Nirland
exercised their conversion option and converted $0.1 million of principal for 23,000 shares of common stock pursuant to the rules and
regulations of the NASDAQ. As of December 31, 2024, $2.6 million of principal and accrued interest remains outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>October
2024 Nirland Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 36pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 28, 2024, the Company issued a promissory note (the &#8220;October 2024 Nirland Note&#8221;) to Nirland in the original
principal amount of $0.6 million in exchange for funds in such amount. The October 2024 Nirland Note bears interest at a rate of 12%
per annum, is due and payable semi-annually in arrears, and matures on October 31, 2025. If an event of default under and as defined
in the Nirland Note occurs, the interest rate will be increased to 18% per annum or to the maximum rate permitted by law. In
connection with the Nirland Note, the Company has agreed to pay Nirland a 1% arrangement fee, which will be included with the
principal and interest owed under the Nirland Note. The Company paid down $0.2 million of the October 2024 Nirland Note on December
11, 2024 and as of the date of filing this Annual Report, such note has been repaid in full. Refer to Note 8 and Note 20 to our
financial statements included elsewhere in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Working
Capital</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently anticipate that cash required for working capital for the next 12 months is approximately $22.9 million, which includes forecasted
research and development costs of $6.0 million, forecasted operating expenses of $6.2 million, accrued expenses and other current liabilities
of $3.4 million, a convertible promissory note payable, if not converted prior to maturity of $6.0 million, a convertible promissory
note, if not converted prior to maturity, of $0.8 million and loans payable due within the next 12 months of $0.5 million. We do anticipate
being able to fund required working capital for the next 12 months with cash and cash equivalents on hand and current borrowings. Management
believes that we will be able to fund cash required for the next 12 months through borrowings and equity raises. We have historically
been able to access funds through the issuance of debt, and more recently the at the market offering program agreement, and believe we
can continue to obtain funding through such debt financing agreements and Sales  agreement as needed to meet cash requirements
for the next 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we have raised $3.3 million (net of fees) out of the $23.9 million available to us
through the Sales agreement and expect to raise the additional $20.4 million over the next 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt">Through the date of the issuance of the consolidated financial statements,
we have raised an additional $8.1 million, net of fees due to A.G.P., through the Sales Agreement. After considering the issuances subsequent
to December 31, 2024, we have $12.0 million available to us through the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table set forth our cash flows for the period indicated (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash (used in) provided by:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Operating Activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(9,682</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(7,725</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Investing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">725</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,067</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,929</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Effect of exchange rate changes on cash and cash equivalents</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(16</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">299</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net (decrease) increase in cash and cash equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,674</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,228</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Flows Used in Operating Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities for the year ended December 31, 2024 was $9.7 million, resulting primarily from a net loss of $17.8
million, a gain on the change in fair value of convertible notes payable of $2.0 million, a gain on change in fair value of warrant liabilities
of $0.2 million and a $0.1 million cash outflow from operating assets and liabilities. This was partially offset by a $2.7 million loss
on the issuance of warrants, $1.7 million of amortization of directors and officers insurance, a $1.6 million outflow attributable to
the purchase of licensing rights, $1.6 million of stock-based compensation, $0.9 million of debt discount amortization, a $0.7 million
loss on debt extinguishment, $0.5 million of non-cash interest expense, $0.4 million of amortization expense, a $0.2 million share issuance
for services and a $0.1 million of non-cash lease expense. The $0.1 million cash outflow from operating assets and liabilities is primarily
due to a $2.3 million cash outflow from prepaid expenses and other current assets and a $0.1 million cash outflow from lease liabilities,
partially offset by a cash inflow of $1.2 million from accounts payable and a cash inflow of $1.2 million from accrued expenses and other
current liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities for the year ended December 31, 2023 was $7.7 million, resulting primarily from a net loss of $0.5
million, adjusted for non-cash items including a $4.3 million reduction of deferred income upon exercise of the Cizzle and Vela option,
a $2.5 million change in operating assets and liabilities, a $2.3 million gain on the change in fair value of the Vela and Cizzle options,
a $0.2 million change in the reserve for uncollectible loans and a $0.1 million gain on warrant remeasurement, partially offset by a
$1.0 million loss upon the issuance of the Vela option, a $0.5 million change in amortization on directors &amp; officers insurance,
a $0.4 million loss on change in fair value of convertible notes and a $0.2 million increase in stock based compensation expense. The
$2.5 million cash outflow from operating assets and liabilities is primarily due to a $1.0 million cash outflow from prepaid expenses
and a $1.7 million cash outflow from accrued expenses and other current liabilities partially offset by a $0.2 million cash inflow from
accounts payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Flows (Used) Provided by Investing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities for the year ended December 31, 2024 was $43 thousand, resulting from purchases
of short-term investments of $0.5 million and purchases of property, plant and equipment of $0.1 million, partially offset by sales of
short-term investments of $0.5 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by investing activities for the year ended December 31, 2023 was $0.7 million, resulting from $0.5 million in proceeds from
an option fee received from Vela and $0.6 million proceeds from the repayment of a loan from a related party, partially
offset by an issuance of a loan to a related party of $0.4 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Flows Provided by Financing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities for the year ended December 31, 2024 was $6.1 million, resulting from proceeds from the Sales Agreement
of $3.3 million, proceeds from the issuance of notes payable of $3.2 million, proceeds from the exercise of warrants of $0.2 million
and proceeds from the exercise of warrants of $0.1 million, partially offset by repayments of notes payable of $0.8 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities during the year ended December 31, 2023 was $11.0 million. resulting from the proceeds from the
Merger and related PIPE financing, net of transaction costs of $8.5 million, $2.3 million from issuance of convertible notes payable,
and $0.2 million capital contribution from a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
Obligations and Other Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Laboratory Lease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, </span>we are the lessee under one laboratory space lease for a term of two years. The annual rent payments
are $0.1 million for the years ending December 31, 2025 and December 31, 2026. The laboratory space lease has a remaining lease term
of approximately 1.2 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires us to make estimates, judgments and assumptions that affect
the amounts reported in the Consolidated Financial Statements. These estimates, judgments and assumptions are evaluated on an ongoing
basis. We base our estimates on historical experience and on various other assumptions that we believe are reasonable at that time, the
results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. Actual results may differ materially from those estimates. The accounting policies that reflect our more significant
estimates, judgments and assumptions and which we believe are the most critical to aid in fully understanding and evaluating our reported
financial results include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Convertible Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected the fair value measurement option for convertible debt with embedded derivatives that would otherwise require bifurcation,
and has recorded the entire hybrid financial instrument at fair value under the guidance in&#160;ASC 825,&#160;Financial Instruments.
To value the convertible debt, the Company utilizes Binomial Lattice Pricing Models. The Binomial Lattice Pricing Models involve the
construction of various intermediate lattices: stock price tree, conversion value tree, conversion probability tree, and discount rate
tree. In doing so, we assume the holders act rationally to maximize return and minimize cost at each decision point. We computed the
notes payoff at maturity and at intermediate decision nodes based upon the better of (i) conversion or (ii) repayment of principal and
interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant inputs and assumptions used to estimate the fair value include: (i) the Company&#8217;s stock price, (ii) the term of the
convertible debt, (iii) the sum of the notes&#8217; principal and unpaid accrued interest, (iv) expected volatility, (v) risk-free interest
rate, (vi) the corporate bond yield, (vii) the credit spread, (viii) probability of default, and (ix) the estimated recovery upon default.
Any change to the unobservable inputs to estimate fair value could produce significantly higher or lower fair value measurements and
result in a material change within the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
convertible debt will subsequently be remeasured at fair value each reporting date until settled or converted. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued warrants to investors in our debt and equity offerings. The Company has also issued warrants to service providers
in relation to our financing offerings. We evaluate all warrants issued to determine the appropriate classification under&#160;ASC 480&#160;and&#160;ASC
815. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
warrants that are determined to be equity-classified, we estimate the fair value at issuance and record the amounts to additional paid
in capital. For warrants that are determined to be liability-classified, we estimate the fair value at issuance and each subsequent reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Company&#8217;s liability classified warrants, we estimate fair value using the Black-Scholes model. The significant inputs and assumptions
used to estimate the fair value include: (i) the Company&#8217;s stock price, (ii) the risk-free rate, (iii) the expected volatility,
and (iv) the dividend yield. The use of these valuation models requires the input of highly subjective assumptions. Any change to these
inputs could produce significantly higher or lower fair value measurements and result in a material change within the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"></p>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contingencies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 18pt">In
the ordinary course of business, we are involved in various legal proceedings that are complex in nature and have outcomes that are difficult
to predict. We describe our legal proceedings and other matters that are significant or that we believe could become significant in Note
15 to the consolidated financial statements. We record accruals for loss contingencies to the extent that we conclude it is probable
that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis,
developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has
been accrued previously or modifications to contingency disclosures that are considered material.</p>

<p style="margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 18pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 18pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 18pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
record stock compensation expense related to our 2023 Plan in accordance with&#160;ASC 718,&#160;<i>Compensation</i>-<i>Stock Compensation
</i>which requires our stock-based awards, including restricted stock units (&#8220;RSUs&#8221;) and stock options to be measured at
fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 18pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 18pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model. The calculation of stock-based
compensation expense requires that we make assumptions and judgments about the variables used in the Black- Scholes option-valuation
model, including the fair value of our common stock, expected term, expected volatility of the underlying common stock, and risk-free
interest rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 18pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 18pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumption inputs subject to significant estimation include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 18pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 18pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Term.&#160;</i>The expected term represents the period that the Company&#8217;s stock options are expected to be outstanding. Due to
limitations on the sale or transfer of the Company&#8217;s common stock under the lock-up agreements and market standoff components of
the stock option agreements, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience
after restricted periods expire. The Company uses the simplified method to calculate the expected term, which is the average of the contractual
term and vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 18pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 18pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Volatility.</i>&#160;We
determine the price volatility based on the historical volatilities of industry peers as we have limited trading history for our common
stock price. We intend to continue to consistently apply this process using the same or a similar peer group of public companies, until
a sufficient amount of historical information regarding the volatility of our own common stock price becomes available, or unless circumstances
change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock
prices are publicly available would be utilized in the calculation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
discussion of recent accounting pronouncements is included in Note 1 <i>- Nature of the Business and Basis of Presentation and Summary
of Significant Accounting Policies</i> to our financial statements included elsewhere in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Emerging
Growth Company Status and Smaller Reporting Company Status</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under
the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of
the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period
for complying with new or revised accounting standards that have different effective dates for public and private companies until the
earlier of the date that: (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended
transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with
the new or revised accounting pronouncements as of public company effective dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
closing of the Merger, the surviving company remained an emerging growth company, as defined by the Jumpstart Our Business Startups act
of 2012, until the earliest of (i) the last day of the combined entity&#8217;s first fiscal year following the fifth anniversary of the
completion of MURF&#8217;s initial public offering, (ii) the last day of the fiscal year in which the combined entity has total annual
gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the combined entity is deemed to be a large
accelerated filer, which means the market value of the combined entity&#8217;s common stock that is held by non-affiliates exceeds $700.0
million as of the prior December 31st or (iv) the date on which the combined entity has issued more than $1.0 billion in non-convertible
debt securities during the prior three year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Conduit is a smaller reporting company as defined in the Exchange Act. The Company may continue to be a smaller reporting company
even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller
reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) Conduit&#8217;s voting and non-voting
common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii)
Conduit&#8217;s annual revenue is less than $100.0 million during the most recently completed fiscal year and its voting and non-voting
common stock held by non-affiliates is less than $700.0 million measured on the last business day of its second fiscal quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="a_013"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7A. Quantitative and Qualitative Disclosures about Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a smaller reporting company, we are not required to provide the information required by this item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_014"></span><b>Item
8. Financial Statements and Supplementary Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
information appears following Item 15 of this Annual Report and is included herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_015"></span><b>Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="a_016"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9A. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Controls
and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed
under the Exchange Act, such as this Annual Report, is recorded, processed, summarized, and reported within the time period specified
in the SEC&#8217;s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated
and communicated to our management, including the chief executive officer and chief financial officer, as appropriate to allow timely
decisions regarding required disclosure. Our management evaluated, with the participation of our current chief executive officer and
chief financial officer (our &#8220;Certifying Officers&#8221;), the effectiveness of our disclosure controls and procedures as of December
31, 2024, pursuant to Rule 13a-15(b) under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and
procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the
disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there
are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure
controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all
our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated
goals under all potential future conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Report on Internal Controls Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined
in Exchange Act Rules 13a-15(f). Under the supervision and with the participation of our Management, including our Chief Executive Officer
and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting. In connection
with the preparation and audit of the financial statements as of and for the fiscal years ended December 31, 2024 and 2023, material
weaknesses were identified in our internal control over financial reporting. A material weakness is a deficiency, or a combination of
deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of
annual or interim financial statements will not be prevented or detected on a timely basis. These material weaknesses primarily relate
to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The segregation of duties is limited and heavily reliant on interim personnel and third-party consultants to perform these activities.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company lacks a formal process for review and approval of significant transactions and accounts on a contemporaneous basis and there have been numerous, recurring errors in account balances and disclosures.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company has not designed adequate and appropriate internal controls
    under an appropriate internal control over financial reporting framework.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company did not appropriately review and evaluate the accounting implications of all material transactions that occurred in the audit period which resulted in a restatement of previous periods.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#9679;</td>
    <td style="text-align: justify">The review controls around certain related party transactions did no operate
consistently and the review of such transactions was not always contemporaneously documented.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
these material weaknesses are not remediated, it could result in a misstatement of account balances or disclosures that would result
in a material misstatement to the annual or interim financial statements that would not be prevented or detected. We are reviewing
measures designed to improve our internal control over financial reporting to remediate these material weaknesses, although they
have not been fully remediated as of the date of this filing. We anticipate hiring additional qualified accounting personnel with
experience with complex GAAP and SEC rules while, meanwhile, continuing to engage consultants to assist with our financial statement
close process, segregating duties among accounting personnel to enable adequate review controls, further developing and documenting
our accounting policies, and designing, implementing, and/or expanding IT systems and application controls in our systems relevant
to the preparation of the consolidated financial statements. We also expect to engage an external advisor to assist with evaluating
and documenting the design and operating effectiveness of internal controls and assisting with the remediation of deficiencies, as
necessary if sufficient capital resources become available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The ability to perform these remediation plans are dependent on
our ability to enhance funding and liquidity.<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> The primary
costs associated with such measures are corresponding recruiting and additional salary and consulting costs, which are difficult to
estimate but which may be significant. These additional resources and procedures are intended to enable us to broaden the scope and
quality of our internal review of underlying information related to financial reporting and to formalize and enhance our internal
control procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material weaknesses will not be considered remediated until a remediation plan has been fully implemented, the applicable controls
operate for a sufficient period of time, and we have concluded, through testing, that the newly implemented and enhanced controls, provided we are able to obtain sufficient capital resources to cover
the cost of our remediation plan, are
operating effectively. A failure to implement and maintain effective internal control over financial reporting could result
in errors in our financial statements that could result in a restatement of our financial statements and could cause us to fail to meet
our reporting obligations, any of which could diminish investor confidence in us and cause a decline in the price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control over
financial reporting until after we are no longer an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. At such time,
our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level
at which our internal control over financial reporting is documented, designed, or operating.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been a number of changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f)
of the Exchange Act) during the most recent fiscal year that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting. These changes include the implementation of enterprise resource planning accounting systems,
and increased accounting and financial reporting consulting resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_017"></span>Item
9B. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fiscal quarter ended December 31, 2024, none of the Company&#8217;s directors or officers (as defined in Rule 16a-1(f) of the Exchange Act)
<span id="xdx_908_eecd--Rule10b51ArrAdoptedFlag_dbF_c20241001__20241231_zpnhnvMP98G6" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_902_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20241001__20241231_z3IHbooUWtqh" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000060" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000061" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span> or <span id="xdx_90C_eecd--Rule10b51ArrTrmntdFlag_dbF_c20241001__20241231_zzGxDrvDdBP3" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90C_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20241001__20241231_zdjWAwHouQAi" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000062" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000063" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy
the affirmative defense conditions of Rule 10b5-1(c) or any &#8220;non-Rule 10b5-1 trading arrangement&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_018"></span>Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_019"></span><b>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="a_020"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
10. Directors, Executive Officers and Corporate Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Officers and Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information concerning our executive officers and directors as of March 28, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Tapolczay</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Bligh</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Chief Financial Officer and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Freda
    Lewis-Hall</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairperson
    of the Board of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Faith
    L. Charles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chele
    Chiavacci Farley</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simon
    Fry</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Regan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>David
Tapolczay</i></b>. Dr. Tapolczay has more than 20 years of experience in research and development management. He has served as our Chief
Executive Officer and a member of the board of directors since September 2023. He was a co-founder and served as the Chief Executive
Officer a member of the board of directors of Old Conduit from 2019 until the Business Combination in September 2023. He served as Chief
Executive Officer of St George Street Capital, a United Kingdom-based medical research charity that is a business partner to Conduit,
from July 2018 to September 2023. He also serves as Chief Executive Officer of Medeor Pharma Ltd, a pharmaceutical consultancy company,
a position which he has held since 2006.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
February 2008 to December 2018, he served as Chief Executive Officer at LifeArc (formerly the Medical Research Counsel Technology Group
(MRCT)), a United-Kingdom based charity advancing lab-based scientific discoveries to a point at which they can be developed into the
next generation of diagnostics, treatments and cures. He previously served as joint worldwide head of chemistry for Zeneca Agrochemicals,
a research and development unit of AstraZeneca, and as senior manager of chemical development for GlaxoSmithKlein plc, a pharmaceutical
and biotechnology company. Dr. Tapolczay served as Executive Vice President at Cambridge Discovery Chemistry, where he was responsible
for the rapid growth of Cambridge Discovery Chemistry and was a key figure in two successful sales of that company, the first to Oxford
Molecular and the second to Millennium Pharmaceuticals. After this last acquisition, Dr. Tapolczay was Senior Vice President of Pharmaceutical
Sciences at Millennium Pharmaceuticals, with responsibility for over 230 scientists. On leaving Millennium, Dr. Tapolczay was a founder
and Chairman of Pharmorphix Ltd., which was acquired by Sigma Aldrich Fine Chemicals in August 2006. He has also been involved with the
start-up of five companies, all of which are still trading and one of which has been AIM listed. He was VP of Technology Development
for GSK Pharmaceuticals from December 2005 to April 2007. He was awarded visiting Professorial Chair in Chemistry at Sussex University
from August 1999 to May 2007 and has previously held the position of visiting lecturer at Nottingham, Reading and Durham Universities
and a member of both the Technical Opportunities Panel and the User Panel of the EPSRC. He holds a BSc Hons and PhD in Chemistry from
the University of Southampton. Dr. Tapolczay also completed his Post-Doctoral Experience in Organic Chemistry from the University of
Oxford. Dr. Tapolczay was selected to serve on our board of directors following the Business Combination based on his deep knowledge
of Conduit, his extensive experience in research and development of clinical assets, and his in-depth knowledge of the pharmaceutical
industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>James
(&#8220;Jamie&#8221;) Bligh. </i></b>Mr. Bligh has served as a member of our board of directors since September 2023, and also currently
serves as our Interim Chief Financial Officer. He was a co-founder of Conduit Pharmaceuticals Limited in 2019 and has served as a member
of its board of directors since its inception. From 2008 to 2019, Mr. Bligh worked closely with investment vehicle Corvus Capital Limited,
including as a Partner, where he led a number of reverse takeover transactions, stock market listings, initial public offerings, secondary
fundraisings, and merger transactions. Mr. Bligh&#8217;s prior transaction experience includes advising several special purpose acquisition
vehicles in listing on the London Stock Exchange, including the listing of Bermele Plc, a special purpose acquisition vehicle, and the
subsequent acquisition of Bermele by East Imperial Pte. Ltd., a global purveyor of ultra-premium beverages, in June 2019; the listing
of Leverett Plc, which subsequently acquired Nuformix Plc, a pharmaceutical development company targeting unmet medical needs in fibrosis
and oncology via drug repurposing; and Cizzle Biotechnology Holdings PLC, a UK-based diagnostics developer. Jamie previously served as
a director of Bermele Plc from June 2021 through February 2022; Mertz Plc from January 2021 through March 2022; and East Imperial Pte.
Ltd. from September 2017 through April 2018. Jamie graduated from the University of Bristol with a BSc in Economics &amp; Finance. Mr.
Bligh was selected to serve on our board of directors following the Business Combination based on his past experience with business development,
capital raising, financings, public offerings and other strategic transactions, including mergers and acquisitions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Freda
Lewis-Hall, M.D., DFAPA</i></b>. Dr. Lewis-Hall has served as a member of our Board since September 2023. She served as Senior Medical
Advisor to the CEO of Pfizer Inc., or Pfizer, from December 2019 until her retirement in March 2020. Before assuming that responsibility,
beginning January 2019, Dr. Lewis-Hall served as Chief Patient Officer and Executive Vice President of Pfizer. Dr. Lewis-Hall served
as Pfizer&#8217;s Chief Medical Officer from 2009 to January 2019. Prior to joining Pfizer in 2009, Dr. Lewis-Hall held various senior
leadership positions including Chief Medical Officer and Executive Vice President, Medicines Development at Vertex Pharmaceuticals Incorporated
from June 2008 to May 2009; Senior Vice President, U.S. Pharmaceuticals, Medical Affairs for Bristol-Myers Squibb Company from 2003 until
May 2008; Vice President Research and Development at Pharmacia Corporation from 2002-2003; Product Team Leader at Pharmacia and Eli Lilly
and Company from 1998 to 2002; Director of Lilly Center for Women&#8217;s Health from 1996-1999; and Clinical Research Physician at Eli
Lilly from 1994 through 1996. In October 2021, Dr. Lewis-Hall became a member of the board of directors for Pyxis Oncology (Nasdaq: PYXS),
(where she serves as a member of the Nominating and Corporate Governance Committee); she serves as a member of the board of directors
for Milliken &amp; Company since July 2019, as a member of the Audit and HR and Compensation Committees; and as a member of the board
of directors of SpringWorks Therapeutics, Inc. (Nasdaq GS: SWTX) since 2017, where she serves as the chair of the Nominating and Governance
Committee and as a member of the audit committee. Dr. Lewis-Hall served as a member of the board of directors for Exact Sciences Corporation
(Nasdaq: EXAS) from April 2020 to June 2024 where she served as a member of the Human Capital and Innovation, Technology and Pipeline
Committees; a member of 1LifeHealthCare, Inc. (Nasdaq: ONEM) board from November 2019 to 2023, serving as a member of the Nominating
and Corporate Governance Committee; she also served as a member of the board of directors for Tenet Healthcare Corporation (NYSE: THC)
from 2014 to 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Lewis-Hall holds an M.D. from Howard University College of Medicine and a B.A. in natural sciences from the Johns Hopkins University.
The Company believes Dr. Lewis-Hall is qualified to serve on the Board based on her expertise and experience in the biopharmaceutical
industry and her leadership experience as a senior executive at various biopharmaceutical companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Faith
L. Charles</i></b>. Ms. Charles has served as a member of our board of directors since September 2023. She has been a corporate
transactions and securities partner at the law firm of Thompson Hine LLP since 2010. She leads Thompson Hine&#8217;s Life Sciences practice
and co-heads the securities practice, advising public and emerging biotech and pharmaceutical companies in the U.S. and internationally.
Ms. Charles negotiates complex private and public financing transactions, mergers and acquisitions, licensing transactions and strategic
collaborations. She serves as outside counsel to a myriad of life sciences companies and is known in the industry as an astute business
advisor, providing valuable insights into capital markets, corporate governance and strategic development. Ms. Charles has been a member
of the board of directors of: CNS Pharmaceuticals, Inc. (Nasdaq: CNSP), a biotechnology company developing novel treatments for cancers
of the brain and central nervous system, since December 2022; Avenue Therapeutics, Inc. (Nasdaq: ATXI), a specialty pharmaceutical company
specializing in developing and commercializing therapies for the treatment of the central nervous system, since May 2022; and Abeona
Therapeutics, Inc. (Nasdaq: ABEO), a fully integrated gene and cell therapy company, since March 2021. Ms. Charles serves as Chair of
CNS Pharmaceuticals, on the Audit Committee of Avenue Therapeutics and on the Audit Committee and as the Chair of the Nominating and
Governance Committee of Abeona Therapeutics. From 2018 until October 2021, Ms. Charles served on the Board of Directors and as a member
of the Audit Committee and Chair of the Compensation Committee of Entera Bio Ltd., a publicly-traded biotechnology company. Ms. Charles
founded the Women in Bio Metro New York chapter and chaired the chapter for five years. She also served on the national board of Women
in Bio. Ms. Charles is also a member of the board of Red Door Community (formerly Gilda&#8217;s Club New York City.) She has been recognized
as a Life Sciences Star by Euromoney&#8217;s LMG Life Sciences, has been named a BTI Client Service All-Star, and was named by Crain&#8217;s
New York Business to the list of 2020 Notable Women in the Law. Ms. Charles holds a J.D degree from The George Washington University
Law School and a B.A. in Psychology from Barnard College, Columbia University. Ms. Charles is a graduate of Women in Bio&#8217;s Boardroom
Ready Program, an Executive Education Program taught by The George Washington University School of Business. Ms. Charles&#8217; qualifications
to serve on our Board include her leadership skills and her vast legal experience representing companies in the biotech and pharmaceutical
field.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Chele
Chiavacci Farley</i></b>. Ms. Chiavacci Farley has served on our board of directors since the closing of our initial public offering.
She currently serves as a partner and managing director of Mistral Capital International (&#8220;Mistral&#8221;), a private equity firm,
that she has been a part of since 1995. In her role as Partner and Managing Director of Mistral, Ms. Farley originates, evaluates and
executes equity investment opportunities, creates and implements deal and financial structures, negotiates with banks for credit facilities,
and oversees management. Ms. Farley is the President and a member of the Board of Directors and Management Committee of Palmilla San
Jose Inmobiliaria, the Master Developer of the luxury Palmilla resort development in Cabo San Lucas, Mexico. Prior to Mistral, Ms. Farley
was Vice President of Tricap International from 1994 to 1995. From 1992 to 1994, Ms. Farley was an Associate at UBS Capital Corporation,
and analyzed and evaluated principal investment and financing opportunities for the firm&#8217;s internal $1 billion fund. Ms. Farley
began her career as a Financial Analyst in the Global Finance department - Energy and Telecom Group of Goldman, Sachs &amp; Co. Ms. Farley
has also had an active political career. In 2020, Ms. Farley ran for election to the U.S. House of Representatives to represent New York&#8217;s
18th Congressional district. In 2018, Ms. Farley ran for election to the U.S. Senate to represent New York. Ms. Farley graduated from
Stanford University with a B.S. and M.S. in Industrial Engineering. She is a member of YPO - Young Presidents&#8217; Organization. Ms.
Farley was selected to serve on our board of directors following the Business Combination based on her past experience with business
development, capital raising, financings, and banking.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Simon
Fry. </i></b>Mr. Fry has served as a member of our board of directors since November 2024. Mr. Fry has over 30 years&#8217; experience
in investment banking having held senior executive positions at various top-tier institutions, such as Nomura and Credit Suisse First
Boston. In 2003, Mr. Fry was appointed as Chief Executive Officer at Crosby Asset Management. He previously worked at Nomura, where he
was Managing Director and European Board member, as well as a member of the risk committee and credit committee. During his time at Nomura,
Mr. Fry initiated and built the Company&#8217;s Asset Investment Group, whose focus was to create specific product and strategy groups
within it to invest in mis-priced and undervalued credit and equity exposures. During this period, Mr. Fry was also responsible for building
Nomura&#8217;s highly regarded International Markets Division, which was responsible for all the European capital market activity in
equity, fixed income and derivatives including primary origination. Prior to this, Mr. Fry spent 14 years at Credit Suisse First Boston
(CSFB) trading a variety of securities including both fixed income and equities. From 1990, Mr. Fry developed CSFB&#8217;s Asset Trading
Group, and as Managing Director built a team that generated significant returns over a number of years for CSFB. Mr. Fry is based in
Los Angeles. His expertise in capital markets and strategic asset management is expected to contribute to Conduit&#8217;s growth goals
as the company pursues development-ready assets and aims to enhance shareholder value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Andrew
Regan</i></b>. Dr. Regan is a British born polar explorer and entrepreneur. He has served as a member of our board of directors since
September 2023. He was a co-founder of Conduit Pharmaceuticals Limited and has served as a board member of Old Conduit since 2019. Dr.
Regan also founded Corvus Capital Limited and has been its Chief Executive Officer since 2008. Corvus Capital is an investment vehicle
that was previously listed on the London Stock Exchange prior to being taken private in 2008. Corvus Capital continues to invest in a
number of industries and sectors. Dr. Regan also has experience as an investor in a number of public and private companies, including
ASOS.com Ltd, a global online fashion and beauty retailer, Virtual Internet, an IT services company that specializes in hosting infrastructure
such as VMWare cloud hosting and Managed and Dedicated Servers, and Imperial Energy Corporation plc, an upstream oil and gas exploration
and production company. Prior to that, Dr. Regan was the Chief Executive Officer of Hobson Plc, which was listed on the London Stock
Exchange, until its sale in 1996 through a cash takeover. Dr. Regan has a strong interest in the use of bio-inspired science to create
solutions for present day problems. In 2014, he was awarded a PhD from Oxford Brookes University for his research in writing and developing
a bio-inspired algorithm for forecasting the financial markets. He is passionate about the polar regions and is an accomplished polar
explorer having led a number of expeditions to both the Arctic and Antarctica. Dr. Regan was selected to serve on our board of directors
following the Business Combination based on his knowledge of Old Conduit and his extensive experience in investing, financing, overseeing
and developing companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Composition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and affairs are organized under the direction of our board of directors. The board of directors will meet on a regular basis
and additionally as required. In accordance with the terms of the amended and restated certificate of incorporation, the board of directors
may establish the authorized number of directors from time to time by resolution. Our board of directors currently consists of seven
directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Nasdaq listing standards, a majority of the members of our board of directors must qualify as &#8220;independent,&#8221; as affirmatively
determined by the board of directors. The Company&#8217;s board of directors affirmatively determined that all of the Company&#8217;s
directors, except for Messrs. Bligh, Tapolczay, and Regan are independent directors within the meaning of the applicable Nasdaq listing
standards. A majority of the members of the board of directors and all members of the Audit Committee, Compensation Committee, and Nominating
and Corporate Governance Committee are independent directors under the applicable Nasdaq listing standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Leadership Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors is responsible for the control and direction of the Company. We separate the positions of Chairperson of the board
of directors and Chief Executive Officer of the Company. Dr. Lewis-Hall serves as the Chairperson of the board of directors and Dr. Tapolczay
serves as the Chief Executive Officer of the Company and as a member of the board of directors. The board of directors believe that this
structure serves us well by maintaining a link between management, through Dr. Tapolczay&#8217;s membership on the board of directors,
and the non-executive directors led by Dr. Lewis-Hall in her role as a non-executive Chairperson.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Oversight of Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the key functions of our board of directors is to conduct informed oversight of our risk management process. The board of directors
does not anticipate having a standing risk management committee, but rather administers this oversight function directly through the
board of directors as a whole, as well as through various standing committees of the board of directors that address risks inherent in
their respective areas of oversight. In particular, the board of directors will be responsible for monitoring and assessing strategic
risk exposure and the Audit Committee will have the responsibility to consider and discuss the Company&#8217;s major financial risk exposures
and the steps our management will take to monitor and control such exposures, including guidelines and policies to govern the process
by which risk assessment and management is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements.
The Compensation Committee assesses and monitors whether our compensation plans, policies, and programs comply with applicable legal
and regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of the Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors has formed the committees described below. Each of the committees operates pursuant to a written charter adopted by
the committee or our board of directors. Each charter sets forth the committee&#8217;s specific functions and responsibilities. The board
of directors of may from time to time establish other committees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee assists the board of directors with its oversight of the integrity of the financial statements; the compliance with legal
and regulatory requirements; the qualifications, independence and performance of the independent registered public accounting firm; the
design and implementation of the financial risk assessment and risk management. Among other things, the Audit Committee is responsible
for reviewing and discussing with management the adequacy and effectiveness of disclosure controls and procedures. The Audit Committee
also discusses with management and independent registered public accounting firm the annual audit plan and scope of audit activities,
scope, and timing of the annual audit of the financial statements, and the results of the audit, quarterly reviews of the financial statements
and, as appropriate, initiates inquiries into certain aspects of the financial affairs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee is responsible for establishing and overseeing procedures for the receipt, retention, and treatment of any complaints
regarding accounting, internal accounting controls or auditing matters, as well as for the confidential and anonymous submissions by
employees of concerns regarding questionable accounting or auditing matters. In addition, the Audit Committee has direct responsibility
for the appointment, compensation, retention, and oversight of the work of the independent registered public accounting firm. The Audit
Committee has sole authority to approve the hiring and discharging of the independent registered public accounting firm, all audit engagement
terms and fees and all permissible non-audit engagements with the independent auditor. The Audit Committee reviews and oversees all related
party transactions in accordance with policies and procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee is comprised of three members: Ms. Farley (Chairperson), Dr. Lewis-Hall and Mr. Fry. Each member of the Audit Committee
meets the requirements for independence under the current Nasdaq and SEC rules and regulations and each member is financially literate.
In addition, the board of directors has determined that each of Ms. Farley and Mr. Fry is an &#8220;audit committee financial expert&#8221;
as defined in Item 407(d)(5)(ii) of Regulation S-K promulgated under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee assists the board of directors with its oversight of the forms and amount of compensation for executive officers
(including officers reporting under Section 16 of the Exchange Act), the administration of equity and non-equity incentive plans for
employees and other service providers and certain other matters related to compensation programs. The Compensation Committee, among other
responsibilities, evaluates the performance of our Chief Executive Officer and, in consultation with the Chief Executive Officer, evaluates
the performance of other executive officers (including officers reporting under Section 16 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee is comprised of three members: Ms. Charles (Chairperson), Ms. Farley, and Mr. Fry. The composition of the Compensation
Committee meets the requirements for independence under the current Nasdaq and SEC rules and regulations. Each member of the Compensation
Committee is a &#8220;non-employee&#8221; director within the meaning of Rule 16b-3 promulgated under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
and Governance Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating and Corporate Governance Committee assists the board of directors with its oversight of and identification of individuals
qualified to become members of the board of directors, consistent with criteria approved by the board of directors, and selects, or recommends
that the board of directors selects, director nominees; develops and recommends to the board of directors a set of corporate governance
guidelines; oversees the evaluation of the board of directors; and reviews the environmental, safety, sustainability, and corporate social
responsibility policies, objectives, and practices on a periodic basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating and Corporate Governance Committee is comprised of two members: Dr. Lewis-Hall (Chairperson) and Ms. Charles. The composition
of the Nominating and Corporate Governance Committee meets the requirements for independence under the current Nasdaq and SEC rules and
regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Committee Interlocks and Insider Participation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
member of our Compensation Committee was at any time during fiscal year 2024, or at any other time, one of our officers or employees.
None of our executive officers have served as a director or member of a compensation committee (or other committee serving an equivalent
function) of any entity, one of whose executive officers served as a director of our board of directors or member of our Compensation
Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among our directors and executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Conduct</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
adopted a written Code of Conduct applicable to all of our directors, officers, and employees, which is available on the Company&#8217;s
website at http://www.conduitpharma.com. Our Internet website address is provided as an inactive textual reference only. The Code of
Conduct covers fundamental ethical and compliance-related principles and practices such as accurate accounting records and financial
reporting, avoiding conflicts of interest, the protection and use of property and information, and compliance with legal and regulatory
requirements. The Code of Conduct is a &#8220;code of ethics,&#8221; as defined in Item 406(b) of Regulation S-K. The Company will make
any legally required disclosures regarding amendments to, or waivers of, provisions of its Code of Conduct on its corporate website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
and Officer Liability and Indemnification</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have purchased directors&#8217; and officers&#8217; liability insurance and have entered into indemnification agreements with each of
directors and executive officers. The indemnification agreements and our amended and restated certificate of incorporation and amended
and restated bylaws require us to indemnify our directors and officers to the fullest extent permitted by Delaware law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of material non-public information in securities transactions or the communication of such information to others who use it in securities
trading (&#8220;Tipping&#8221;) violates the federal securities laws. Such violations are likely to result in harsh consequences for
the individuals involved including exposure to investigations by the SEC, criminal and civil prosecution, disgorgement of any profits
realized or losses avoided through use of the non-public information and penalties equal to three times such profits or losses. Further,
insider trading violations expose the Company, its management, and other personnel acting in supervisory capacities to potential civil
liabilities and penalties for the actions of employees under their control who engage in Insider Trading violations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Insider Trading Policy (the &#8220;Insider Trading Policy&#8221;) prohibits our executive officers, the non-employee members of our board
of directors and certain other employees from engaging in the following transactions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selling
    any of our securities that they do not own at the time of the sale (referred to as a &#8220;short sale&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">passing
    material nonpublic information on to others or recommending that another engage in transactions in any securities that they have
    information on;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">buying
    or selling puts, calls, other derivative securities of the Company or any derivative securities that provide the economic equivalent
    of ownership of any of our securities or an opportunity, direct or indirect, to profit from any change in the value of our securities
    or engaging in any other hedging transaction with respect to our securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">using
    our securities as collateral in a margin account; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pledging
    our securities as collateral for a loan (or modifying an existing pledge).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company has not adopted a formal policy governing transactions by the Company in its securities, the Company will not engage in transactions
in Company securities, or adopt any securities repurchase plans, while in possession of material non-public information relating to the
Company or its securities other than in compliance with applicable law, subject to the policies and procedures adopted by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
or around August 14, 2024, the Company was first made aware that one of its directors, through a wholly owned subsidiary, had
previously entered into certain collateral pledge agreements that resulted in the disposition of a substantial amount of shares in
the Company pursuant to those agreements without the Company&#8217;s knowledge. In addition, the Company also became aware that
approximately 300,000 thousand shares (or 31% of our then outstanding common stock as of August 14, 2024) were subject to a
further third-party pledge arrangement with a then significant stockholder of the Company. Upon learning of these transactions, the
board of directors has appointed an independent committee of the board of directors (the &#8220;Special Committee&#8221;) and
delegated to the Special Committee the authority to review these matters and determine action(s), if any, to be taken by the Company
in response thereto. Additionally, the Company formed another committee of the board of directors (the &#8220;Trading Review
Committee&#8221;) and delegated to the Trading Review Committee the authority to investigate and review the trading patterns of
certain of the Company&#8217;s stockholders and determine action(s), if any, to be taken by the Company in response thereto. The
Company values its stockholders and wants to have all available data at its disposal to act in its fiduciary capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section
16(a) Beneficial Ownership Reporting Compliance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Exchange Act requires that our directors and executive officers, and persons who own more than ten percent of a registered
class of our equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock
and other equity securities of the Company. Officers, directors and greater than ten percent stockholders are required by SEC regulation
to furnish us with copies of all Section 16(a) forms they file.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, based solely on a review of the copies of such reports furnished to us and written representations that no other
reports were required, during the year ended December 31, 2024, all Section 16(a) filing requirements applicable to our officers,
directors and greater than ten percent beneficial owners were complied with, except for the Form 4 filed Andrew Regan on September
19, 2024 reporting a pledging of shares on June 14, 2024 and the sale of shares from July 2, 2024 to July 17, 2024. The delinquent
filing was inadvertent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_021"></span>Item
11. Executive Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fiscal
2024 Summary Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the compensation earned by or paid to our principal executive officer and our principal financial officer,
who constitute all of our executive officers, for fiscal 2024 and fiscal 2023. We have no defined benefit or actuarial pension plan,
and no deferred compensation plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NAME AND PRINCIPAL POSITION</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">FISCAL YEAR</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">SALARY<br/>
 (1) ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">STOCK AWARDS<br/>
 (2) ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">OPTION AWARDS<br/>
 (3) ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NONEQUITY INCENTIVE PLAN COMPENSATIONS<br/>
 ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ALL OTHER COMPENSATION<br/>
 (4)  </td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">TOTAL<br/>
 ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">David Tapolczay</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: center">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">558,578</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">58,800</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">617,378</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Chief Executive Officer and Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">139,933</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,203,239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,343,172</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">James Bligh, Interim Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">438,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">105,852</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">132,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,732</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">692,944</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Adam Sragovicz <sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">143,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">103,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">246,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">116,667</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">410,743</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">-</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><p style="margin: 0">$</p></td><td style="text-align: right"><p style="margin: 0">-</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">-</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">527,410</p></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salaries
    converted from British Pounds to US Dollars based on the following exchange rate in effect as of December 31, 2024: 1.2549.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    the grant date fair value of the 372 fully vested shares issued to Mr. Bligh in June 2024 to reflect his increased responsibilities
    as interim Chief Executive Officer, based on a stock price of $284 on the date of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    the grant date fair value of stock option awards for the applicable year computed in accordance with FASB ASC Topic 718. See Note
    11 to the consolidated financial statements included in this Annual Report for a discussion of the relevant assumptions used in calculating
    the grant date fair value pursuant to FASB ASC Topic 718. As required by SEC rules, the amounts shown exclude the impact of estimated
    forfeitures related to service-based vesting conditions. Our named executive officers will only realize compensation to the extent
    the trading price of our common stock is greater than the exercise price of such stock options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><sup>(4)</sup></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The amounts shown for 2024 represent 401(k) matching contributions
of $16,732 and $3,300 for Mr. Bligh and Mr. Sragovicz, respectively.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    Mr. Sragovicz, includes severance benefits of continued payment of his base salary, and subsidized health insurance premiums, for
    a period of four months after the effective date of his resignation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: left; text-indent: -18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Adjustments for 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Annual
Base Salaries</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
provide a base salary to retain and attract key executive talent and to align our compensation with market practices. Base salaries are
reviewed and established by the Compensation Committee and the board of directors on a competitive basis each year to align with market
levels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2024, the board of directors (i) increased Dr. Tapolczay&#8217;s base salary by 3%, and (ii) increased Mr. Bligh&#8217;s base salary
by &#163;60,000 to compensate for his additional duties as Chief Financial Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
Awards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee believes that a competitive long-term incentive program is an important component of the compensation of our named
executive officers because it: (i) enhances the retentive value of our compensation; (ii) rewards executives for increasing our stock
price and developing long-term value; and (iii) provides executives with an opportunity for stock ownership to align their interests
with those of our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the board of directors, with the help of Aon, its independent compensation consultant, conducted a review of the long-term
incentive opportunities for our named executive officers. Based on a review of each executive&#8217;s individual performance, Mr. Bligh&#8217;s
additional duties as interim Chief Financial Officer, and the applicable market data, the board of directors approved the following stock
option grants: (i) Dr. Tapolczay received a stock option to purchase 8,400 shares, and (ii) Mr. Bligh received a stock option to purchase
18,900 shares. Each stock option vests 50% of the grant date and 50% in three equal annual installments thereafter. Also, Mr. Bligh received
a one-time grant of 372.72 full vested shares in June 2024, in recognition of his increased responsibilities as interim Chief Executive
Officer. These grant levels have been adjusted to reflect the 1-for-100 reverse stock split on January 24, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an employment agreement with our chief executive officer on September 22, 2023, which was the closing date of
the Business Combination. Mr. James Bligh is serving as the Company&#8217;s interim chief
financial officer. These agreements are summarized below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Tapolczay</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2023, we entered into an employment agreement (the &#8220;Tapolczay Employment Agreement&#8221;) with Dr. Tapolczay, pursuant
to which he serves as our Chief Executive Officer of and a member of our board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Tapolczay Employment Agreement, Dr. Tapolczay is entitled to (i) an annual base salary of $550,000 increased to $566,500 effective November 1, 2024, and (ii) a target annual
bonus opportunity equal to 50% of his base salary, payable based on the achievement of performance objectives as determined by our
board of directors. In addition, the Tapolczay Employment Agreement provides that Dr. Tapolczay is entitled to receive a sign-on
stock option award to purchase 0.40% of the shares of our Common Stock pursuant to the terms of the 2023 Stock Incentive Plan, which
shall vest in equal annual installments on the first four anniversaries of the Business Combination. The Tapolczay Employment
Agreement provides that if we terminate Dr. Tapolczay&#8217;s employment other than for cause or disability, or if he terminates his
employment for good reason, in either case other than the change in control protection period (described below), he would be
entitled to receive (i) continued payment of his annual base salary for 12 months following the date of termination, (ii) a lump sum
payment of his annual cash performance bonus that had been earned by him for a completed fiscal year or other measuring period but
that had not yet been paid to him as of the date of termination, (iii) a lump sum payment equal to his then target annual bonus
opportunity, pro-rated based on the total number of days elapsed in the calendar year through the date of termination, (iv) payment
or reimbursement of the COBRA premiums for him and his eligible dependents, or if COBRA is not available under our group health
plan, a cash amount equal to such payments or reimbursements (in either case, less the premiums he was paying for such coverage
while employed), until the earliest of (x) the last day of the applicable salary continuation period specified above, or (y) the
date he becomes eligible for comparable health insurance coverage under a subsequent employer&#8217;s group health plan; and (v)
accelerated vesting of such number of his unvested equity awards as would have vested had he remained employed during the 12-month
period following his date of termination (provided, however, that, any equity awards that vest in whole or in part based on the
attainment of performance-vesting conditions shall be governed by the terms of the applicable award agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tapolczay Employment Agreement provides that if we terminate Dr. Tapolczay&#8217;s employment other than for cause or disability, or
if he terminates his employment for good reason, in either case within three months prior to or 12 months after a change in control (such
period, the change in control period), he would be entitled to receive (i) continued payment of his annual base salary for 18 months
following the date of termination, (ii) a lump sum payment of his annual cash performance bonus that had been earned by him for a completed
fiscal year or other measuring period but that had not yet been paid to him as of the date of termination, (iii) a lump sum payment equal
to 150% of his then target annual bonus opportunity (without pro-ration), (iv) payment or reimbursement of the COBRA premiums for him
and his eligible dependents, or if COBRA is not available under our group health plan, a cash amount equal to such payments or reimbursements
(in either case, less the premiums he was paying for such coverage while employed), until the earliest of (x) the last day of the applicable
salary continuation period specified above, or (y) the date he becomes eligible for comparable health insurance coverage under a subsequent
employer&#8217;s group health plan; and (v) accelerated vesting of 100% of his unvested equity awards (provided, however, that, any equity
awards that vest in whole or in part based on the attainment of performance-vesting conditions shall be governed by the terms of the
applicable award agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
to the extent that any payment or benefit received in connection with a change in control would be subject to an excise tax under Section
4999 of the Code, such payments and/or benefits will be subject to a &#8220;best pay cap&#8221; reduction if such reduction would result
in a greater net after-tax benefit to the executive than receiving the full amount of such payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
exchange for the severance benefits described above, Dr. Tapolczay must (i) sign and not revoke a release of claims in favor of the Company,
(ii) comply with his proprietary information and inventions assignment agreement, (iii) refrain from soliciting employees of the Company
for a period of one year after his termination of employment, and (iv) comply with the other provisions of the Tapolczay Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white"><b><i>James Bligh</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On November 15, 2024,&#160;Conduit
Pharmaceuticals Limited and&#160;Conduit UK Management LTD., wholly-owned subsidiaries of the Company, entered into an amended and restated
employment agreement (the &#8220;Bligh Employment Agreement&#8221;) with James&#160;Bligh, pursuant to which Mr.&#160;Bligh&#160;will
continue to be employed by Conduit UK Management LTD. and continue to serve as the&#160;Interim Chief Financial Officer&#160;and Senior
Vice President - Strategy of the Company. Under the Bligh Employment Agreement, Mr.&#160;Bligh&#160;will receive an annual base salary
of &#163;400,000 and will be entitled to a discretionary cash bonus of up to 40% of his base salary, subject to the achievement of certain
milestones that may be established by the Board of Directors or a committee thereof, from time to time. Mr. Bligh is also entitled to
reimbursement for reasonable out-of-pocket expenses incurred by him in the performance of his duties, subject to the terms of any expenses
policy the Company may have.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Bligh Employment Agreement requires at least six months&#8217; advanced
written notice for Mr.&#160;Bligh&#160;or Conduit UK Management LTD.&#160;to terminate Mr. Bligh&#8217;s employment, except in the case
of a summary dismissal (as described in the Bligh Employment Agreement). However, Conduit UK Management LTD.&#160;may, at its sole discretion
and by written notice, terminate Mr. Bligh&#8217;s employment immediately and provide compensation to Mr.&#160;Bligh&#160;for the unexpired
portion of such notice period. The Bligh Employment Agreement replaces and supersedes the prior employment agreement between Conduit Pharmaceuticals
Limited and Mr.&#160;Bligh.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mr.
Sragovicz</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 10, 2024, Adam Sragovicz informed the Board of Directors of his intention to resign as Chief Financial Officer of the Company. In
connection with his resignation, Mr. Sragovicz agreed to continue in his current role, with the same responsibilities and obligations
as he previously had, through the day after the filing of this Quarterly Report on Form 10-Q, so that his resignation will become effective
on May 15, 2024. Mr. Sragovicz&#8217;s resignation was not due to any disagreement with management or the Company&#8217;s operations,
policies or practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a separation agreement with Mr. Sragovicz on May 12, 2024, which provides for continued payment of his base salary,
and subsidized health insurance premiums, for a period of four months after the effective date of his resignation. In exchange for these
benefits, Mr. Sragovicz has signed a mutual release of claims, agreed to a mutual non-disparagement covenant, and re-affirmed certain
confidentiality, non-solicitation and post-departure cooperation covenants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at 2024 Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes all of the outstanding equity-based awards held by our named executive officers as of December 31, 2024, the
end of our fiscal year. The option shares reported below have been adjusted to reflect the 1-for-100
reverse stock split on January 24, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">OPTION AWARDS</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NAME</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">OPTION OR STOCK AWARD GRANT DATE</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NUMBER OF SECURITIES UNDERLYING UNEXERCISED OPTIONS (#) EXERCISABLE</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NUMBER OF SECURITIES UNDERLYING UNEXERCISED OPTIONS
(#) UNEXERCISABLE
</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">OPTION EXERCISE PRICE <br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">OPTION EXPIRATION DATE</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: left">David Tapolczay</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: right">11/18/2024</td><td style="width: 2%"><p style="margin: 0">(2)</p></td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">4,200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">4,200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">9.20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 13%; text-align: right">11/17/2034</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/1/2023</td><td>(1)</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">551</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/30/2033</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">James Bligh</td><td>&#160;</td>
    <td style="text-align: right">11/18/2024</td><td>(2)</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,450</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,450</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/17/2034</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/18/2024</td><td>(1)</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,677</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">551</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/30/2033</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    stock option vests as to 1/4 of the underlying shares on each of the first four anniversaries of the vesting commencement date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">(2)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The stock options vests 50% of the grant date and 50% in three equal annual installments thereafter</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Stock Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2023, MURF stockholders approved the Conduit Pharmaceuticals Inc. 2023 Stock Incentive Plan (the &#8220;2023 Plan&#8221;).
The 2023 Plan permits our board of directors or compensation committee to grant may grant or issue stock options, stock appreciation
rights, restricted stock, restricted stock units, performance stock units, other stock- or cash-based awards and dividend equivalents,
or any combination thereof, to officers, employees, directors or consultants of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to adjustment for stock splits or similar events, the 2023 Plan initially reserved 114,976 shares of Common Stock for issuance
pursuant to awards, plus an annual increase on the first day of each calendar year beginning in 2024 and ending in 2033 equal to the
lesser of (i) 5% of the shares of Common Stock outstanding on the last day of the immediately preceding calendar year and (ii) such
smaller number of shares of Common Stock as determined by our board of directors. </span>The 2023 Plan was increased
by 36,914 shares of common stock effective January 1, 2024, and by 69,240&#160;shares of common stock effective January 1,
2025. On February 6, 2025, the Company filed a registration statement on Form S-8 that increased the number of shares of Common
Stock available for issuance under the 2023 Plan by 69,240 shares.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the securities authorized for issuance under our equity compensation plans as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Plan category</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities to be issued upon exercise of outstanding options, warrants and rights</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average exercise price of outstanding options,<br/> warrants and rights</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities<br/> remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(a)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(b)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(c)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity compensation plans approved by security holders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 46%">2023 Plan</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">65,509</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">81.52</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">84,885 </td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Equity compensation plans not approved by security holders</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">65,509</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">81.52</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">84,885 </td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the compensation we paid to our non-employee directors during fiscal 2024:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fees earned or<br/> paid in cash<br/>
 ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock <br/> awards<br/> ($) (1)(2)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option<br/>
 awards<br/> ($) (3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other<br/>
 Compensation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">TOTAL <br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 35%">Faith L. Charles</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 9%">24,500</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 9%">31,400</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 9%">21,000</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 9%">-</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 9%">76,900</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Chele Chiavacci Farley</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">27,500 </td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">133,352</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">181,852</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Freda Lewis-Hall</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">40,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">40,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">101,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Simon Fry</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jennifer I. McNealey<sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11,875</p>

</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11,875</p>

</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Andrew Regan<sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
                                            Lewis-Hall elected to receive $40,250 of her cash fees in the form of fully vested shares,
                                            Ms. Chiavacci Farley elected to receive $27,500 of her cash fees in the form of fully vested
                                            shares, and Ms. Charles elected to receive $24,500 of her cash fees in the form of fully
                                            vested shares.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    the grant date fair value of (i) the 372 fully vested shares issued to Ms. Chiavacci Farley in June 2024, based on a stock price
    of $284 on the date of grant, and (ii) the 750 fully vested shares issued to Ms. Charles in November 2024, based on a stock price
    of $9.20 on the date of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    in this column represents the aggregate grant date fair value, determined in accordance with FASB ASC Topic 718, of option awards
    granted to participating non-employee directors in 2024. For a description of the assumptions we used to calculate these amounts,
    see Note 11 to the consolidated financial statements included in this Annual Report. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(4)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On May 12, 2024, Ms. McNealey announced her resignation, due to personal
reasons, as a member of the Board of Directors of the Company and from all committees on which she served, effective as of May 13, 2024.
Ms. McNealey&#8217;s resignation was not due to any disagreement with management or the Company&#8217;s operations, policies or practices.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Regan waived his right to receive any compensation for services as
a non-employee director of the Company, effective as of the closing of the Business Combination.&#160;As a result, Dr. Regan has not been
paid any cash retainers or received any equity retainers since the closing date.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">As of December 31, 2024, our non-employee directors held the following
stock options:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">OPTION AWARDS</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NAME</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">OPTION OR<br/>
 STOCK AWARD<br/>
 GRANT DATE</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NUMBER OF<br/>
 SECURITIES<br/>
 UNDERLYING<br/>
 UNEXERCISED<br/>
 OPTIONS<br/>
 (#)<br/>
 EXERCISABLE</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NUMBER OF<br/>
 SECURITIES<br/>
 UNDERLYING<br/>
 UNEXERCISED<br/>
 OPTIONS<br/> (#)<br/>
 UNEXERCISABLE</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">OPTION<br/>
 EXERCISE PRICE<br/>
 ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">OPTION<br/>
 EXPIRATION <br/>DATE</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left">Faith L. Charles</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: right">12/18/2024</td><td style="width: 2%">(2)</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">4,200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">7.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: right">12/17/2034</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/1/2023</td><td>(1)</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">551</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/30/2033</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Chele Chiavacci Farley</td><td>&#160;</td>
    <td style="text-align: right">12/18/2024</td><td>(2)</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/17/2034</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/1/2023</td><td>(1)</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">551</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/30/2033</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Freda Lewis-Hall</td><td>&#160;</td>
    <td style="text-align: right">12/18/2024</td><td>(2)</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/17/2034</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/1/2023</td><td>(1)</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">551</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/30/2033</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Simon Fry</td><td>&#160;</td>
    <td style="text-align: right">12/18/2024</td><td>(2)</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/17/2034</td></tr>
  </table>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The stock option vests as to 1/3 of the underlying shares on each of the first three anniversaries of the vesting commencement date</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The stock options vests 100% of the underlying shares on the first anniversary of the vesting commencement date</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Program for the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
adopted a compensation program for our board of directors, which became effective upon completion of the Business Combination, and was
amended on November 15, 2024. Under the compensation program, the non-employee directors will receive the following annual cash
retainers for their service on the board of directors and its committees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$35,000
    for each non-employee director;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$30,000
    for the Chairperson of the board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$15,000
    for the chair of the Audit Committee and $7,500 for each of the other members of that committee;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10,000
    for the chair of the Compensation Committee and $5,000 for each of the other members of that committee; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$8,000
    for the chair of the Nominating and Corporate Governance Committee and $4,000 for each of the other members of that committee.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, each non-employee director who is
initially elected or appointed to the board of directors will automatically be granted on the day of such first election or appointment
a stock option to purchase 4,200 shares of our Common Stock (the &#8220;Initial Award&#8221;). Each Initial Award will vest and become
exercisable in substantially equal installments on each of the first three anniversaries of the date of grant, subject to the non-employee
director continuing in service on the board of directors through each such vesting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A non-employee director who is serving on the
board of directors as of the date of any annual meeting after the effective date of the new program, and who will continue to serve as
a non-employee director immediately following such meeting, will automatically be granted on the date of such annual meeting a stock option
to purchase 4,200 shares of our Common Stock, which amount is pro-rated for new directors to reflect their service since the last annual
meeting (the &#8220;Annual Award&#8221;). Each Annual Award will vest and become exercisable on the earlier of (i) the first anniversary
of the date of grant, or (ii) the date immediately prior to the next annual meeting of the Company&#8217;s stockholders following the
date of grant, subject to the non-employee director continuing in service on the board of directors through such vesting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon a change in control, all outstanding equity
awards that are held by a non-employee director shall become fully vested and exercisable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In 2024, the board of directors appointed Dr. Hall and Ms. Charles
to serve on the Special Committee and approved an additional cash retainer of $7,500 for each of them to reflect her service on the Special
Committee. In June 2024, the board of directors authorized the grant of a one-time additional equity retainer to Ms. Chiavacci Farley
in the form of 372 fully vested shares to recognize the significant time she has devoted to the Company since September 2023, in her capacity
as a member of the board, assisting and advising the Company on certain strategic transactions, financings and accounting matters. In
November 2024, the board of directors authorized the grant of a one-time additional equity retainer to Ms. Charles in the form of 750
fully vested shares to recognize the significant time she has devoted to the Company since September 2023, in her capacity as a member
of the board, assisting and advising the Company on certain strategic transactions and financings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Board members who are also
employees of the Company, such as Dr. Tapolczay and Mr. Bligh, are not eligible to participate in the non-employee director compensation
program described above and did not receive any compensation for service on the board of directors. Moreover, Dr. Regan waived his right
to receive any compensation under the program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Plan provides that the sum of the grant date fair value of all equity-based awards and the maximum amount of cash that may become
payable to any individual for services as a non-employee director during any calendar year may not exceed $750,000, increased to $1,000,000
in the calendar year of a non-employee director&#8217;s initial service as a non-employee director. The plan administrator may make exceptions
to this limit for individual non-employee directors in extraordinary circumstances, as the plan administrator may determine in its discretion,
provided that the non-employee director receiving such additional compensation may not participate in the decision to award such compensation
or in other contemporaneous compensation decisions involving non-employee directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_022"></span><b>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth beneficial ownership of the Company&#8217;s Common Stock as of March 28, 2025 by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person known to be the beneficial owner of more than 5% of the outstanding Common Stock of the Company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of the Company&#8217;s executive officers and directors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of the Company&#8217;s current executive officers and directors as a group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security
if he, she or it possesses sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes
securities that the individual or entity has the right to acquire, such as through the exercise of warrants or stock options or the vesting
of restricted stock units, within 60 days of March 28, 2025. Shares subject to warrants or options that are currently exercisable or
exercisable within 60 days of March 28, 2025 or subject to restricted stock units that vest within 60 days of March 28, 2025 are considered
outstanding and beneficially owned by the person holding such warrants, options, or restricted stock units for the purpose of computing
the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any
other person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as noted by footnote, and subject to community property laws where applicable, based on the information provided to the Company, the
persons and entities named in the table below have sole voting and investment power with respect to all shares shown as beneficially
owned by them. Unless otherwise indicated, the business address of each beneficial owner listed in the table below is c/o Conduit Pharmaceuticals
Inc., 4581 Tamiami Trail North, Suite 200 Naples, Florida 34103.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
beneficial ownership of our Common Stock is based on 6,662,755 shares of Common Stock issued and outstanding as of March 28, 2025, which
number excludes the shares of Common Stock issuable upon exercise of the warrants. Unless otherwise indicated, we believe that all persons
named in the table have sole voting and investment power with respect to all of the shares shown to be beneficially owned by them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name and Address of Beneficial Owner<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>% of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock*</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Directors and executive officers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">James Bligh</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">10,381</td><td style="width: 1%; text-align: left"><sup>(2)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Faith L. Charles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,631</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Chele Chiavacci Farley</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,914</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Freda Lewis-Hall</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,836</td><td style="text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left"/>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Andrew Regan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">302,926</td><td style="text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.55</td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">David Tapolczay</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,987</td><td style="text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left"/>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Simon Fry</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000</td><td style="text-align: left"><sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">All directors and executive officers as a group (6 individuals)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">390,675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.81</td><td style="text-align: left">%</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    beneficial ownership of less than 1%.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    table does not include Adam Sragovicz, the Company&#8217;s former Chief Financial Officer, who resigned effective May 15, 2024, and
    following such resignation, to the Company&#8217;s knowledge, did not beneficially own any securities of the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 372 shares of Common Stock and (ii) options to purchase 10,009 shares Common Stock that are currently exercisable. Excludes
    11,127 unvested options to purchase shares of Common Stock that are not exercisable within 60 days.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 3,415 shares of Common Stock and (ii) options to purchase 216 shares of Common Stock that are currently exercisable. Excludes
    4,633 unvested options to purchase shares of Common Stock that are not exercisable within 60 days.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 3,515 shares of Common Stock, (ii) warrants to purchase 2,183 shares of Common Stock and (iii) options to purchase 216 shares
    of Common Stock that are currently exercisable. Excludes 4,633 unvested options to purchase shares of Common Stock that are not
    exercisable within 60 days.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                                                              234,836 shares of Common Stock, of which (i) 4,379 are held directly by Dr. Lewis-Hall, (ii) 20,033 were issued to Intelmed LLC, of which
                                                                              Dr. Lewis-Hall is the Managing Director, (iii) 5,169 shares of Common Stock were received by Mr. Emerson Hall, Jr., Dr.
                                                                              Lewis-Hall&#8217;s spouse, and (iv) 216 are underlying options that are currently exercisable and are held directly by Dr.
                                                                              Lewis-Hall, (v) warrants to purchase 1,033 shares of Common Stock held directly by Dr. Lewis-Hall and (vi) warrants to purchase
4,006 shares of Common Stock held by Intelmed LLC. By virtue of this relationship with both Intelmed LLC and her spouse, Dr. Lewis-Hall may be deemed to share beneficial
                                                                              ownership of the securities held of record by Intelmed LLC and Mr. Emerson Hall, Jr. Dr. Lewis-Hall disclaims any such beneficial
                                                                              ownership except to the extent of her pecuniary interest therein. Excludes 4,633 unvested options to purchase shares of Common Stock
                                                                              that are not exercisable within 60 days. The business address of
                                                                              Intelmed LLC is 11421 Golden Eagle Court Naples, Florida 34120.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 666 shares of Common Stock held directly by Dr. Regan, (ii) 300,484 shares of Common Stock held by Corvus Capital Limited, and
    (iii) 1,776 shares of Common Stock held by Algo Holdings, Inc. Dr. Regan is the Chief Executive Officer of Corvus Capital Limited and
    Algo Holdings, Inc. is a wholly owned subsidiary of Corvus Capital Limited. By virtue of this relationship, Dr. Regan may be deemed
    to share beneficial ownership of the securities held of record by Corvus Capital Limited and Algo Holdings, Inc. Dr. Regan disclaims
    any such beneficial ownership except to the extent of his pecuniary interest therein. Pursuant to a participation and inducement
    agreement with Nirland Limited, the 30,048 shares of Common Stock held by Corvus Capital Limited may, in certain circumstances, be
    subject to transfer to Nirland Limited and all such shares of Common Stock are subject to a pledge agreement with respect to such
    arrangement. The business address of Corvus Capital Limited is Floor 2, Willow House, Cricket Square PO Box 709 Grand Cayman KY1-1107,
    Cayman Islands.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 20,033 shares received pursuant to the Agreement and Plan of Merger, dated as of November 8, 2022 and as amended on January
    27, 2023 and May 11, 2023, by and among the Company, Conduit and the Merger Sub and (ii) options to purchase 4,945 shares of Common
    Stock that are currently exercisable and, (iii) warrants to purchase 6,009 shares of Common Stock. Excludes 6,436 options to purchase shares of Common Stock that are not exercisable within 60 days.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">(8)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Consist of 2,000 shares of common stock and excludes 4,200 options
to purchase shares of Common Stock that are not exercisable within 60 days.
</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_023"></span>Item
13. Certain Relationships and Related Transactions, and Director Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the compensation arrangements with directors and executive officers described under the sections titled &#8220;Executive
Compensation&#8221; and &#8220;Management,&#8221; the following is a description of each transaction since January 1, 2023 and each currently
proposed transaction, in which:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    have been or are to be a participant;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount involved exceeds or will exceed $120,000; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    of our directors, executive officers, or beneficial holders of more than 5% of our capital stock, or any immediate family member
    of, or person sharing the household with, any of these individuals (other than tenants or employees), had or will have a direct or
    indirect material interest.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policies
and Procedures for Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors adopted a policy, at the closing of the Business Combination, with respect to the review, approval, and ratification
of related party transactions. Under the policy, the audit committee of the board of directors is responsible for reviewing and approving
related party transactions. In the course of its review and approval of related party transactions, the audit committee will consider
the relevant facts and circumstances to decide whether to approve such transactions. In particular, the policy requires the audit committee
to consider, among other factors it deems appropriate:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the transaction was undertaken in the ordinary course of business of the Company;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the related party transaction was initiated by the Company, a subsidiary, or the related party;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the transaction with the related party is proposed to be, or was, entered into on terms no less favorable to the Company than terms
    that could have been reached with an unrelated third party;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    purpose of, and the potential benefits to the Company of, the related party transaction;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the approximate dollar value of the amount involved in the related party transaction, particularly as it relates to the related party;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    related party&#8217;s interest in the related party transaction;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the related party transaction would impair the independence of an otherwise independent director; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other information regarding the related party transaction or the related party that would be material to investors in light of the
    circumstances of the particular transaction</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee may approve the related party transaction only if the audit committee determines in good faith that, under all of the
circumstances, the transaction is in the best interests of the Company and its stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Founder
Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 16, 2021, the Sponsor, Murphy Canyon Acquisition Sponsor LLC, previously an affiliate of MURF, purchased an aggregate of 43,125
shares of Common Stock for the aggregate price of $25,000 (the &#8220;Founder Shares&#8221;). The Founder Shares included an aggregate
of up to 7,500 shares subject to forfeiture by the Sponsor to the extent that the underwriters&#8217; over-allotment was not exercised
in full or in part, or 10,062 shares if the underwriters&#8217; over-allotment was exercised in full, so that the Sponsor would collectively
own 20% of the Company&#8217;s issued and outstanding shares after the IPO (assuming that, in the IPO, the Sponsor only purchased Class
A common stock consisting of (i) the Founder Shares and (ii) the 7,540 shares of Class A common stock included in the units purchased
by the Sponsor in connection with the IPO (together, the &#8220;Private Shares&#8221;). As a result of the underwriters&#8217; election
to exercise their over-allotment option, on January 26, 2022, the Sponsor surrendered and forfeited 10,062 Founder Shares. Following
such forfeiture, the Sponsor held 33,062 Founder Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sponsor agreed, subject to certain limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to
occur of: (A) six months after the completion of our initial business combination, and (B) subsequent to the initial business combination
if we complete a liquidation, merger, stock exchange or other similar transaction that results in all of our public stockholders having
the right to exchange their public shares for cash, securities or other property. Notwithstanding the foregoing, the Sponsor shall have
the right to transfer its ownership in the Founder Shares at any time to the extent that it determines, in good faith, that such transfer
is necessary to ensure that it and/or any of its parents, subsidiaries or affiliates are in compliance with the Investment Company Act
of 1940.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Private
Units</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contemporaneously
with the closing of the IPO and the exercise of the overallotment option, the Sponsor purchased an aggregate of 754,000 private units
of MURF in a private placement at a price of $10.00 per private unit. Each private unit consists of one Private Share and one Private
Warrant (the &#8220;Private Warrant&#8221;). The private units are identical to the units sold in the IPO except that the (a) the placement
units and their component securities will not be transferable, assignable or saleable until October 22, 2023 except to permitted transferees
and (b) the warrants and rights included as a component of the placement units, so long as they are held by the Sponsor or its permitted
transferees, will be entitled to registration rights, respectively. Additionally, the warrants underlying the placement units contain
a cashless exercise provision and shall be non-redeemable while held by the initial purchasers thereof or their permitted assignees.
The Sponsor had agreed not to transfer, assign or sell any of the private units and underlying securities (except in connection with
the same limited exceptions that the Private Shares may be transferred as described above) until after the Business Combination. In connection
with completion of the Business Combination, the Sponsor transferred 45,000 placement units (15,000 each) to each of Mrs. Knuettell and
Feinberg, former Directors of MURF, and Ms. Chiavacci Farley, former Director of MURF and current Director of Conduit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sponsor
Support Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with the execution of the Merger Agreement, the Company entered into a support agreement with the Sponsor pursuant to which the Sponsor
agreed to, among other things, vote all of the shares of MURF common stock legally and beneficially owned by it in favor of the Business
Combination. On September 20, 2023, the Sponsor voted all of the shares of MURF common stock then legally and beneficially owned by it
in favor of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PIPE
Subscription Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2023, concurrently with the completion of the Business Combination, pursuant to the PIPE Subscription Agreement (the &#8220;PIPE
Subscription Agreement &#8220;) for an aggregate purchase price of $20.0 million, the Company issued an aggregate of 20,000 shares
of the Company&#8217;s Common Stock and PIPE Warrants (the &#8220;PIPE Warrants&#8221;) to purchase 20,000 shares of Company Common
Stock. In conjunction with the execution of the PIPE Subscription Agreement, Corvus Capital and its affiliates entered into a participation
and inducement agreement with the Private Placement Investor whereby Corvus agreed to provide certain payments and economic benefits
to such investor in the event Corvus Capital sold or pledged in a debt transaction any of the shares it was receiving in the Business
Combination. In certain circumstances, such investor may have a right to cause Corvus Capital to transfer certain of its shares to such
investor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PIPE Subscription Agreement contains registration rights, pursuant to which within 15 business days after the closing of the PIPE Financing,
the Company was required to use reasonable best efforts to file with the SEC a registration statement registering the resale of shares
of the Company&#8217;s common stock. On October 17, 2023, the Company filed a registration statement on Form S-1 (SEC File No. 333-275056)
to satisfy that contractual requirement, which registration statement was declared effective by the SEC on December 15, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PIPE Warrants are exercisable until September 22, 2028 (five years after the completion of the Business Combination) and have an exercise
price of $11.50 per share, subject to adjustment as set forth in the PIPE Warrants for stock splits, stock dividends, recapitalizations
and similar customary adjustments. The Private Placement Investor may exercise each PIPE Warrant on a cashless basis if the shares underlying
the PIPE Warrants are not then registered for resale pursuant to an effective registration statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company common stock and PIPE Warrants to purchase Company common stock issued pursuant to the PIPE Subscription Agreement were not registered
under the Securities Act and were issued in reliance upon the exemption provided under Section 4(a)(2) of the Securities Act and/or Regulation
D promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 11, 2024, the warrants were modified to reduce the exercise price to $0.0883 and the warrants were exercised on December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consulting
Agreement with Jack K. Heilbron</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jack
K. Heilbron, who served as the MURF&#8217;s Chief Executive Officer, President, and Chairman of the board of directors until September
22, 2023, has entered into a Consulting Agreement (the &#8220;Consulting Agreement&#8221;) with the Company, which became effective upon
the closing of the Business Combination. The Consulting Agreement provides that Mr. Heilbron will provide advisory and consulting services
from time to time to the Company until September 22, 2024. Pursuant to the terms of the Consulting Agreement, Mr. Heilbron is entitled
to rights as an observer to the Company&#8217;s board of directors. Mr. Heilbron is entitled to be paid $25,000 per calendar quarter
for his consulting services and is also entitled to a stock option to purchase the number of shares of Common Stock determined by dividing
(i) $300,000, by (ii) the per share Black-Scholes valuation as of the grant date, utilizing the same assumptions used in preparation
of the financial statements, with the resulting quotient rounded down to the nearest whole share. Mr. Heilbron was award stock options to purchase 30,000 shares of Common
Stock on December 1, 2023. As of December 31, 2024, and subsequent
agreement between the parties, the Company has paid Mr. Heilbron approximately $25,000 and granted Mr. Heilbron 6,900 shares of the Company&#8217;s
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholder
Support Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with the execution of the Merger Agreement, MURF, Old Conduit, and certain shareholders of Old Conduit (the &#8220;Old Conduit Shareholders&#8221;)
entered into a certain shareholder support agreement dated November 8, 2022, pursuant to which the Old Conduit Shareholders agreed to
vote all Old Conduit shares beneficially owned by them, including any additional shares of Old Conduit they acquire ownership of or the
power to vote, in favor of the Business Combination and related transactions. Under the support agreements, each Old Conduit Shareholder
also agreed that, prior to the termination of the applicable support agreement, such Old Conduit Shareholder would not transfer or otherwise
enter into any agreement or understanding with respect to a transfer relating to any shares of Old Conduit owned by such shareholder.
The support agreements automatically terminated on September 22, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Old
Conduit Shareholder Lockup Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Merger Agreement, as a condition to receiving Common Stock of the Company after the closing of the Business Combination in respect
of their Old Conduit shares, certain shareholders of Old Conduit executed lockup agreements pursuant to which such shareholders agreed
not to sell, transfer or take certain other actions with respect to such shares of our Common Stock for a period of 180 days after the
closing of the Business Combination, subject to certain customary exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transactions
with Corvus Capital Limited</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corvus
Capital Limited (&#8220;Corvus Capital&#8221;) received 311,484 shares of our common stock, pursuant to the terms of the Merger
Agreement, following the completion of the Business Combination. As of December 31, 2024, Corvus Capital owned 300,484 shares of our
Common Stock directly and 1,776 shares of our Common Stock through its wholly-owned subsidiary Algo Holdings, Inc., or in the
aggregate approximately 21.8% of the then outstanding shares of our Common Stock. Dr. Andrew Regan, the Chief Executive Officer of
Corvus Capital and 100% ultimate beneficial owner, is also a member of our board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>August
2024 Nirland Note</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 6, 2024, the Company entered into a Senior Secured Promissory Note (the &#8220;August 2024 Nirland Note&#8221;) with Nirland,
a related party of the Company, pursuant to which the Company issued and sold to Nirland the August 2024 Note in the original principal
amount of $2,650,000, inclusive of a $500,000 original issuance discount. Refer to Note 7 for additional details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 31, 2024, the Company and Nirland amended the August 2024 Nirland Note, whereby the August 2024 Nirland Note was amended to (i)
provide for the conversion of the August 2024 Nirland Note into shares of Common Stock, at Nirland&#8217;s discretion, in a multiple
of any unpaid amounts, if not otherwise previously paid, pursuant to the conversion rate contained therein, (ii) remove Nirland&#8217;s
Mandatory Prepayment Right, and (iii) remove Nirland&#8217;s right of first refusal to participate in any future equity or debt offerings
of the Company. The number of shares of Common Stock issuable upon conversion of any Conversion Amount pursuant to shall be determined
by dividing (x) such conversion amount by (y) the conversion price. Conversion amount means two and one quarter times the sum of (x)
portion of the principal to be converted, redeemed or otherwise with respect to which this determination is being made and (y) all accrued
and unpaid interest with respect to such portion of the principal amount, if any. Conversion price means, as of any conversion date or
other date of determination, $10, subject to adjustment as provided within the amended agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>October 2024 Nirland Note</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On October 28, 2024, the Company issued a promissory note (the &#8220;October
2024 Nirland Note&#8221;) to Nirland, a related party, in the original principal amount of $600,000 in exchange for funds in such amount.
In connection with the October 2024 Nirland Note, the Company paid Nirland a 1% arrangement fee. The October 2024 Nirland Note bears interest
at a rate of 12% per annum, is due and payable semi-annually in arrears, and matures on October 31, 2025. Refer to Note 8 for additional
details.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Sarborg Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On December 12, 2024, the Company
entered into the Sarborg Agreement with Sarborg. Under the terms of the Sarborg Agreement,&#160;Sarborg&#160;will provide algorithmic
and cybernetic technology services to Conduit, including the development of decision-support tools and advanced cybernetic systems tailored
to enhance Conduit&#8217;s decision-making processes and maximize the value of its pharmaceutical asset portfolio.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Sarborg&#160;will perform the
services to Conduit comprised of three phases: the Initial Phase (0-24 weeks) focuses on establishing a foundation for collaboration and
aligning Sarborg&#8217;s services with Conduit&#8217;s strategic goals; the Development Phase (24-36 weeks) involves building technological
infrastructure, including dashboards and predictive models; and the Ongoing Services Phase (36-52 weeks) ensures the sustained functionality
and relevance of Sarborg&#8217;s deliverables while supporting Conduit&#8217;s growth through iterative improvements and updates.&#160;Sarborg&#160;will
create specific deliverables, including reports, computer programs, software applications, APIs, mobile applications, source code, written
technical specifications and designs, operating and maintenance manuals, and other recorded data and information arising from or relating
to the services.&#160;Sarborg&#160;will provide all necessary resources to perform the services and deliver the deliverables in accordance
with the Sarborg Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Sarborg Agreement has an
initial term of twelve months, commencing on the effective date, and may be renewed or extended upon mutual written agreement of the parties.
Either party may terminate the Sarborg Agreement for any reason upon ninety days&#8217; written notice or immediately upon written notice
if the other party breaches any material term of the Sarborg Agreement and fails to cure such breach within thirty days or becomes insolvent,
files for bankruptcy, or is placed under the control of a receiver, trustee, or similar authority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In consideration of the services,
Conduit has agreed to pay&#160;Sarborg&#160;an initial cash payment of $200,000 and $200,000 payable&#160;through the issuance of 22,727
shares of&#160;common stock, determined by the closing price on the day preceding the execution of the Sarborg Agreement. Further milestone
payments payable in conjunction with the achievement of certain milestones over the term of the Sarborg Agreement, totaling up to $1,800,000,
are payable in cash or shares, at the discretion of Conduit.&#160;Sarborg&#160;will be reimbursed for pre-approved, necessary, and reasonable
out-of-pocket expenses directly incurred in connection with the performance of the services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Sarborg Agreement includes
provisions for the ownership and use of intellectual property.&#160;Sarborg&#160;will own its pre-existing intellectual property rights,
including proprietary tools and methodologies used in the performance of the services. Conduit will own all deliverables resulting from
the services performed by&#160;Sarborg&#160;under the Sarborg Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Sarborg Agreement provides&#160;Sarborg&#160;with
registration rights for any common stock of Conduit that&#160;Sarborg&#160;receives as consideration under the Sarborg Agreement. Conduit
must use commercially reasonable efforts to prepare and file a registration statement covering the resale of the common stock within sixty
days after the issuance of the shares to Sarborg. The Company must cause the registration statement covering such shares to become effective
withing ninety days of the filing of the registration statement. The Sarborg Agreement also includes confidentiality obligations, representations
and warranties, indemnification, limitation of liability, and insurance requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Dr. Andrew Regan, a member of Conduit&#8217;s board of directors, also
sits on the board of directors of&#160;Sarborg.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
and Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of the individuals that serve as members of our board of directors since completion of the Business Combination have relationships with
MURF, Old Conduit, and/or one of their respective stockholders. Dr. Freda Lewis-Hall, the Chairperson of our board of directors, was
an indirect shareholder of Conduit and indirectly received 2,003 shares of our Common Stock upon completion of the Business Combination.
Dr. David Tapolczay, our Chief Executive Officer and a member of our board of directors, was a shareholder of Old Conduit and received
2,003 shares of our Common Stock upon completion of the Business Combination. Dr. Tapolczay is also a director of Old Conduit. Dr. Andrew
Regan, a member of our board of directors, is a director of Old Conduit and received 67 shares of our Common Stock upon completion of
the Business Combination. James Bligh, a member of our board of directors and interim chief financial officer, was an employee of Old
Conduit and currently serves as a member of its board of directors. Faith L. Charles, a member of our board of directors, is a partner
at Thompson Hine LLP, a law firm that provides legal services to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On April 22, 2024, the Company issued in a private placement common stock
purchase warrants (the &#8220;April Warrants&#8221;) to third parties, including certain directors, to purchase up to an aggregate of
9,077 shares of the Company&#8217;s common stock, in exchange for entering into a lock-up with respect to the shares of common stock held
by such holder and for such directors, $12.50 per warrant. The April Warrants are not exercisable until one year after their date of issuance.
Each April Warrant is exercisable into one share of the Company&#8217;s common stock at a price per share of $312 (as adjusted from time
to time in accordance with the terms thereof) for a two-year period after the date of exercisability. There is no established public trading
market for the April Warrants. The issuance of the April Warrants were made in reliance on the exemption from registration provided by
Section 4(a)(3) of the Securities Act, and/or Regulation D promulgated thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sj_007"></span><b>Item
14. Principal Accountant Fees and Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of fees paid or to be paid to Marcum LLP, or Marcum, for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Fees</i>. Audit fees consist of fees billed for professional services rendered for the audit of our year-end financial statements and
services that are normally provided by Marcum in connection with regulatory filings. The aggregate fees billed by Marcum for professional
services rendered for the audit of our annual financial statements for the year ended December 31, 2024 totaled approximately $341,200,
and for the year ended December 31, 2023 totaled approximately $440,200.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Audit-Related Fees</i>. Audit-related
services consist of fees billed for assurance and related services that are reasonably related to performance of the audit or review of
our financial statements and are not reported under &#8220;Audit Fees.&#8221; Audit related fees primarily include review of regulatory
documents filed with the SEC. For the year ended December 31, 2024, we paid Marcum audit-related fees totaling approximately $120,170.
For the year ended December 31, 2023, we paid Marcum audit-related fees totaling approximately $118,525.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Tax Fees</i>. Tax fees consists
of fees billed for tax compliance, tax planning and tax advice. We paid Marcum tax fees for the year ended December 31, 2024 totaling
approximately $83,405. We did not pay Marcum tax fees for the year ended December 31, 2023.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>All
Other Fees</i>. We did not pay Marcum for other services for the years ended December 31, 2024 or December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Approval
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee was formed upon the consummation of our initial public offering. As a result, the audit committee did not pre-approve
all of the foregoing services, although any services rendered prior to the formation of our audit committee were approved by our board
of directors. Since the formation of our audit committee, and on a going-forward basis, the audit committee has and will pre-approve
all auditing services and permitted non-audit services to be performed for us by our auditors, including the fees and terms thereof (subject
to the <i>de minimis </i>exceptions for non-audit services described in the Exchange Act which are approved by the audit committee prior
to the completion of the audit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_008"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sj_009"></span><b>Item
15. Exhibits, Financial Statement Schedules</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following documents are filed as part of this annual report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements: (see &#8220;Financial Statements and Supplementary Data&#8221; at Item 8 and incorporated herein by reference).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statement Schedule: (Schedules to the Financial Statements have been omitted because the information required to be set forth therein
    is not applicable or is shown in the accompanying Financial Statements or notes thereto).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits:
    The exhibits listed in the accompanying &#8220;Exhibit Index&#8221; are filed or incorporated by reference as part of this Annual
    Report on Form 10-K.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223027856/form424b3.htm#annex_001" style="-sec-extract: exhibit">Agreement
    and Plan of Merger Agreement dated as of November 8, 2022, by and among Murphy Canyon Acquisition Corp., Conduit Merger Sub, Inc.
    and Conduit Pharmaceuticals Limited (filed as Annex A-1 to the Registrant&#8217;s Proxy Statement/Prospectus filed on August 11,
    2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223027856/form424b3.htm#annex_002" style="-sec-extract: exhibit">Amendment
    to Agreement and Plan of Merger dated as of January 27, 2023, by and among Murphy Canyon Acquisition Corp., Conduit Merger Sub, Inc.
    and Conduit Pharmaceuticals Limited (filed as Annex A-2 to the Registrant&#8217;s Proxy Statement/Prospectus filed on August 11,
    2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223027856/form424b3.htm#A3_001" style="-sec-extract: exhibit">Second
    Amendment to Agreement and Plan of Merger dated as of May 11, 2023, by and among Murphy Canyon Acquisition Corp., Conduit Merger
    Sub, Inc. and Conduit Pharmaceuticals Limited (filed as Annex A-3 to the Registrant&#8217;s Proxy Statement/Prospectus filed on August
    11, 2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/ex3-1.htm" style="-sec-extract: exhibit">Second
    Amended and Restated Certificate of Incorporation of the Registrant (filed as Exhibit 3.1 to the Registrant&#8217;s Current Report
    on Form 8-K filed on September 29, 2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/ex3-2.htm" style="-sec-extract: exhibit">Amended
    and Restated Bylaws of the Registrant (filed as Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K filed on September
    29, 2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">3.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315224046849/ex3-1.htm" style="-sec-extract: exhibit">Amendment No.1 to the Amended and Restated Bylaws (filed as Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed on November 19, 2024, and incorporated herein by reference)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">3.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315225003316/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment filed with the Delaware Secretary of State on January 22, 2025 (filed as Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed on January 23, 2025, and incorporated herein by reference).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><a href="ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">Description of Registered Securities</span></span></a></p></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315224030568/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Senior Secured Promissory Note (filed as Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed on August 7, 2024, and incorporated herein by reference).</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315224043330/ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant (Filed as Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed on November 1, 2024, and incorporated herein by reference).</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315224043330/ex4-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nirland Note (Filed as Exhibit 4.3 to the Registrant&#8217;s Current Report on Form 8-K filed on November 1, 2024, and incorporated herein by reference).</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315224043330/ex4-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to the Senior Secured Promissory Note and Security Agreement, dated October 31, 2024, between Nirland Limited and Conduit Pharmaceuticals Inc. (filed as Exhibit 4.4 to the Registrant&#8217;s Current Report on Form 8-K filed on November 1, 2024, and incorporated herein by reference).</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315224047631/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Promissory Note, dated November 25, 2024, between Conduit Pharmaceuticals Inc. and A.G.P./Alliance Global Partners (filed as Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed on November 25, 2024, and incorporated herein by reference).</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315224047631/ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment to the Senior Secured Promissory Note, dated November 22, 2024, between Conduit Pharmaceuticals Inc. and Nirland Limited (filed as Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed on November 25, 2024, and incorporated herein by reference).</span></a></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315222003484/ex10-1.htm" style="-sec-extract: exhibit">Letter
    Agreement, dated February 2, 2022, among Murphy Canyon Acquisition Corp., Murphy Canyon Acquisition Sponsor, LLC, and each of the
    executive officers and directors of Murphy Canyon Acquisition Corp. (filed as Exhibit 10.1 to the Registrant&#8217;s Current Report
    on Form 8-K filed on February 8, 2022, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315222003484/ex1-1.htm" style="-sec-extract: exhibit">Underwriting
    Agreement (filed as Exhibit 1.1 to the Registrant&#8217;s Current Report on Form 8-K filed February 8, 2022, and incorporated herein
    by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315222000566/ex10-2.htm" style="-sec-extract: exhibit">Promissory
    Note, dated November 4, 2021, issued to Murphy Canyon Acquisition Sponsor, LLC, by Murphy Canyon Acquisition Corp. (filed as Exhibit
    10.2 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-262036) filed on January 6, 2022, and incorporated
    herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315222003484/ex10-2.htm" style="-sec-extract: exhibit">Investment
    Management Trust Agreement, dated February 2, 2022, between Murphy Canyon Acquisition Corp. and Wilmington Trust Company (filed as
    Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed on February 2, 2022, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315222003484/ex10-3.htm" style="-sec-extract: exhibit">Registration
    Rights Agreement, dated February 2, 2022, among Murphy Canyon Acquisition Corp. and certain securityholders (filed as Exhibit 10.3
    to the Registrant&#8217;s Current Report on Form 8-K filed on February 2, 2022, and incorporated herein by reference)</a></span></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315222000566/ex10-5.htm" style="-sec-extract: exhibit">Securities
    Subscription Agreement, dated November 4, 2021, between Murphy Canyon Acquisition Corp. and Murphy Canyon Acquisition Sponsor, LLC
    (filed as Exhibit 10.5 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-262036) filed on January 6, 2022,
    and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315222003484/ex10-4.htm" style="-sec-extract: exhibit">Placement
    Unit Purchase Agreement, dated February 2, 2022, between Murphy Canyon Acquisition Corp. and Murphy Canyon Acquisition Sponsor, LLC
    (filed as Exhibit 10.4 to the Registrant&#8217;s Current Report on Form 8-K filed on February 8, 2022, and incorporated herein by
    reference).</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/ex10-9.htm" style="-sec-extract: exhibit">Form
    of Conduit Pharmaceuticals Inc. Indemnity Agreement (filed as Exhibit 10.9 to the Registrant&#8217;s Current Report on Form 8-K filed
    on September 29, 2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315222003484/ex10-6.htm" style="-sec-extract: exhibit">Administrative
    Support Agreement, dated February 2, 2022, by and between Murphy Canyon Acquisition Corp. and Murphy Canyon Management Group, Inc.
    (filed as Exhibit 10.6 to the Registrant&#8217;s Current Report on Form 8-K filed on February 8, 2022, and incorporated herein by
    reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315222032104/ex10-2.htm" style="-sec-extract: exhibit">Form
    of Lock-Up Agreement (filed as Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed on November 14, 2022, and
    incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315222032104/ex10-3.htm" style="-sec-extract: exhibit">Sponsor
    Support Agreement, dated as of November 8, 2022, by and among Murphy Canyon Acquisition Corp. and each of the Persons set forth on
    Schedule I attached thereto (filed as Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K filed on November 14, 2022,
    and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315222032104/ex10-4.htm" style="-sec-extract: exhibit">Shareholder
    Support Agreement dated as of November 8, 2022, by and among Murphy Canyon Acquisition Corp., Conduit Pharmaceuticals Limited and
    each of the Persons set forth on Schedule I attached thereto (filed as Exhibit 10.4 to the Registrant&#8217;s Current Report on Form
    8-K filed November 14, 2022, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223002970/ex4-1.htm" style="-sec-extract: exhibit">Form
    of Amended and Restated Warrant (filed as Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed on January 30, 2023,
    and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223006939/ex10-1.htm" style="-sec-extract: exhibit">Form
    of Note, issued March 7, 2023, by and between Murphy Canyon Acquisition Corp. and Murphy Canyon Acquisition Sponsor, LLC (filed as
    Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed March 7, 2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223032446/ex10-1.htm" style="-sec-extract: exhibit">Form
    of Subscription Agreement between Murphy Canyon Acquisition Corp. and the investor named therein (filed as Exhibit 10.1 to the Registrant&#8217;s
    Current Report on Form 8-K filed on September 13, 2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223032446/ex4-1.htm" style="-sec-extract: exhibit">Form
    of PIPE Warrant (filed as Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed on September 13, 2023, and incorporated
    herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223027856/form424b3.htm#annex_004" style="-sec-extract: exhibit">Conduit
    Pharmaceuticals Inc. 2023 Stock Incentive Plan (filed as Annex C to the Registrant&#8217;s Proxy Statement/Prospectus filed on August
    11, 2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223016741/ex10-17.htm" style="-sec-extract: exhibit">Form
    of Stock Option Agreement under Conduit Pharmaceuticals Inc. 2023 Stock Incentive Plan (filed as Exhibit 10.17 to the Registrant&#8217;s
    Registration Statement on Form S-4 (File No. 333-271903) filed on May 12, 2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223025880/ex10-17.htm" style="-sec-extract: exhibit">Form
    of Employment Agreement with David Tapolczay (filed as Exhibit 10.17 to the Registrant&#8217;s Amendment No. 2 to Registration Statement
    on Form S-4 (File No. 333-271903) filed on July 28, 2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223016741/ex10-21.htm" style="-sec-extract: exhibit">AZD1656
    Project Funding Agreement For Use In Renal Transplant between St George Street Capital Limited and Conduit Pharmaceuticals Limited,
    dated November 2, 2022 (filed as Exhibit 10.21 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-271903)
    filed on May 12, 2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223016741/ex10-22.htm" style="-sec-extract: exhibit">AZD1656
    Project Funding Agreement For Use In Preterm Labor between St George Street Capital Limited and Conduit Pharmaceuticals Limited,
    dated November 2, 2022 (filed as Exhibit 10.22 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-271903)
    filed on May 12, 2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223016741/ex10-23.htm" style="-sec-extract: exhibit">AZD1656
    Project Funding Agreement For Use In Hashimoto&#8217;s Thyroiditis between St George Street Capital Limited and Conduit Pharmaceuticals
    Limited, dated November 2, 2022 (filed as Exhibit 10.23 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-271903)
    filed on May 12, 2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223016741/ex10-24.htm" style="-sec-extract: exhibit">AZD1656
    Project Funding Agreement For Use In Uveitis between St George Street Capital Limited and Conduit Pharmaceuticals Limited, dated
    November 2, 2022 (filed as Exhibit 10.24 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-271903) filed
    on May 12, 2023, and incorporated herein by reference).</a></span></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223016741/ex10-25.htm" style="-sec-extract: exhibit">AZD5904
    Project Funding Agreement between St George Street Capital Limited and Conduit Pharmaceuticals Limited, dated November 2, 2022 (filed
    as Exhibit 10.25 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-271903) filed on May 12, 2023, and incorporated
    herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223024231/ex10-24.htm" style="-sec-extract: exhibit">Consulting
    Agreement between with Jack Heilbron and Murphy Canyon Acquisition Corp. (filed as Exhibit 10.24 to the Registrant&#8217;s Amendment
    No. 1 to Registration Statement on Form S-4 (File No. 333-271903) filed on July 11, 2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223025880/ex10-26.htm" style="-sec-extract: exhibit">Form
    of Non-Employee Director Compensation Program (filed as Exhibit 10.26 to the Registrant&#8217;s Amendment No. 2 to Registration Statement
    on Form S-4 (File No. 333-271903) filed on July 28, 2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0">10.29</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315224019230/ex10-1.htm" style="-sec-extract: exhibit">Separation Agreement, dated May 12, 2024, between Mr. Sragovicz and Conduit Pharmaceuticals Inc. (filed as Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 14, 2024, and incorporated herein by reference).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10.30</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315224030568/ex10-1.htm" style="-sec-extract: exhibit">Security Agreement, dated August 6, 2024, between Nirland Limited and Conduit Pharmaceuticals Inc. (filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on August 7, 2024, and incorporated herein by reference).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10.31</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315224041154/ex10-1.htm" style="-sec-extract: exhibit">Convertible Promissory Note between Conduit Pharmaceuticals Limited and Vrezh and Sharon Lee Isayan, dated March 20, 2023 (filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on October 15, 2024, and incorporated herein by reference).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10.32</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315224043330/ex10-1.htm" style="-sec-extract: exhibit">Bridge Loan Agreement, dated October 29, 2024, between A.G.P./Alliance Global Partners and Conduit Pharmaceuticals (filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on November 1, 2024, and incorporated herein by reference).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10.33#</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315224046849/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement, dated November 15, 2024, between James Bligh, Conduit Pharmaceuticals Limited and Conduit UK Management LTD. (filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on November 19, 2024, and incorporated herein by reference).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10.34</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315224050443/ex10-1.htm" style="-sec-extract: exhibit">Services Agreement dated December 12, 2024, between Conduit Pharmaceuticals Inc. and SARBORG Limited. (filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on December 17, 2024, and incorporated herein by reference).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">19.1*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex19-1.htm">Conduit Pharmaceuticals, Inc. Insider Trading Policy</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315223025880/ex21-1.htm" style="-sec-extract: exhibit">Subsidiaries
    of Conduit Pharmaceuticals Limited (filed as Exhibit 21.1 to the Registrant&#8217;s Amendment No. 2 to Registration Statement on
    Form S-4 (File No. 333-271903) filed on July 28, 2023, and incorporated herein by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex23-1.htm"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">Consent of Marcum LLP, independent public accounting firm of Conduit Pharmaceuticals Inc.</span></span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#poa_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (reference is made to the signature page hereto).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">Certification of Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1&#167;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2&#167;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"/>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1896212/000149315224014889/ex97-1.htm" style="-sec-extract: exhibit">Conduit Pharmaceuticals, Inc. Compensation Recovery Policy (filed as Exhibit 97.1 to the Registrant&#8217;s Annual Report filed on April 16, 2024, and incorporated herein by reference).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Labels Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#
Management contract or compensatory plan or arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+
Certain portions of this Exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K. The Registrant agrees to furnish
supplementally an unredacted copy of this Exhibit to the SEC upon its request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#167;
In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release Nos. 33-8238 and 34-47986, Final Rule: Management&#8217;s Reports
on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished
in Exhibits 32.1 and 32.2 hereto is deemed to accompany this Annual Report on Form 10-K and will not be deemed &#8220;filed&#8221; for
purposes of Section 18 of the Exchange Act. Such certification will not be deemed to be incorporated by reference into any filing under
the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_010"></span>Item
16. Form 10&#8211;K Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_011"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDUIT
    PHARMACEUTICALS INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 28, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    David Tapolczay</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Tapolczay</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="poa_001"></span>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Tapolczay and James Bligh,
and each of them, as his or her attorneys-in-fact, with the power of substitution, for him or her in any and all capacities, to sign
any amendments to this report, and to file the same, with exhibits thereto and other documents in connection therewith with the Securities
and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact, and each of them, or his or her substitute
or substitutes may lawfully do or cause to be done by virtue hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    David Tapolczay</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    28, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Tapolczay</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    James Bligh</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Chief Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    28, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jamie
    Bligh</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer and Principal Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Freda Lewis-Hall</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    and Chairperson of the Board of Directors</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    28, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Freda
    Lewis-Hall</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    James Bligh</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    28, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Bligh</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Faith L. Charles</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    28, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Faith
    L. Charles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Chele Chiavacci Farley</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    28, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chele
    Chiavacci Farley</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Simon Fry</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    28, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simon
    Fry</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Andrew Regan</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    28, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Regan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDUIT
PHARMACEUTICALS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audited
    Financial Statements of Conduit Pharmaceuticals Inc.:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sj_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB No. <span id="xdx_900_edei--AuditorFirmId_c20240101__20241231_z6Aqb8FR1Mni"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000064" name="dei:AuditorFirmId">688</ix:nonNumeric></span>)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sj_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of December 31, 2024 and 2023</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sj_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended December 31, 2024 and 2023</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sj_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Stockholders&#8217; Deficit for the years ended December 31, 2024 and 2023</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sj_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sj_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Financial Statements</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="sj_001"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders and Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit
Pharmaceuticals Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--AuditorOpinionTextBlock_c20240101__20241231_z4IdLX6Vzb0g"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000065" name="dei:AuditorOpinionTextBlock">We
have audited the accompanying consolidated balance sheets of Conduit Pharmaceuticals Inc. (the &#8220;Company&#8221;) as of December
31, 2024 and 2023, the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; deficit and
cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial
statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the
Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period
ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Explanatory
Paragraph &#8211; Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more
fully described in Note 1, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise
additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company&#8217;s
ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated
financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_907_edei--AuditorName_c20240101__20241231_zWxcqKRvp5X5"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000066" name="dei:AuditorName">Marcum LLP</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
LLP</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--AuditorLocation_c20240101__20241231_zrdIJf29CVSl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000067" name="dei:AuditorLocation">Morristown, NJ</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">March 28, 2025</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sj_002"></span>CONDUIT
PHARMACEUTICALS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except share amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_111_pn3n3_zYlEfTbfKcAa" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20241231_zlUZ3Utn0iRi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/>
2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_ziEUorJNfeg8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/>
2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsAbstract_iB_zHyGYX5pQ96j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_zjobbr8wCnS" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACz9w4_zU75NR08WUXk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">554</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000076" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,228</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACz9w4_zsdut4rVA9U7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,161</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,505</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrent_i02TI_mtACz9w4_maAz9x9_zUQirztYv34f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,715</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,733</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAz9x9_zJRBqPRHna4l" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating lease right-of-use assets. net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">263</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0085">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAz9x9_zYYjP2oW4Gs5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Property, plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0088">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsNoncurrent_i01I_maAz9x9_z6Nbr0hv3Mr1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other long-term assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,175</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,491</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Assets_i01TI_mtAz9x9_zmB5ebkYxSk2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,193</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,224</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_i01B_zEIuvBCYelej" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccountsPayableCurrent_i02I_maLCzaLh_zRVn72eLE6s2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,428</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherAccruedLiabilitiesCurrent_i02I_maLCzaLh_zrDmvEW9sCL2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,963</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">601</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzaLh_zz7NwFZ4ubB6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating lease liability, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">119</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0109">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ConvertibleNotesPayable_i02I_maLCzaLh_z1LXeBDekLlc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Convertible promissory note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2024-12-31" id="Fact000111" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2023-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherNotesPayable_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maLCzaLh_zde3nc8RCk11" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible promissory notes payable at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNotesPayable" contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember" id="Fact000114" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,985</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0115">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherNotesPayable_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzaLh_z8M0YO27LEg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Convertible promissory notes payable at fair value &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:OtherNotesPayable" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000117" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,871</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0118">-</span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNotesPayable_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzaLh_z7bLMHYWNo1c" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Convertible promissory notes payable at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:OtherNotesPayable" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000120" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,871</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0121">-</span></p></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maLCzaLh_z7RICuGdScCj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember" id="Fact000123" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" id="Fact000124" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">185</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzaLh_z4TWFnduVu7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Notes payable &#8211; related parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000126" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">425</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0127">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzaLh_ztuERPz6Kdi9" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Notes payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000129" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">425</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0130">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzaLh_maLz0or_zsc1h8s6ZYia" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000132" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,741</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,801</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLz0or_zCGQgbLqEGJj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease liability, non-current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">107</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0136">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeLiabilitiesNoncurrent_i01I_maLz0or_zf95Ag8gAsVf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Derivative warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact000138" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">142</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredCompensationLiabilityClassifiedNoncurrent_i01I_maLz0or_zadKn4BjE997" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Deferred commission payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0141">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" contextRef="AsOf2023-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,738</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Liabilities_i01TI_mtLz0or_maLASEz7pI_zzxUB2NFMivi" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000144" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,986</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,681</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CommitmentsAndContingencies_i01I_maLASEz7pI_zQFpDZKwgoCi" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Commitments and contingencies (see note 15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0147">-</span></span></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0148">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CommonStockValue_i02I_maSEzyTZ_zl64ZloLWjbe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zgKfdSn21095" title="Common stock, par value"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zw1plRmxc304" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000156" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>;
<span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zZYs0oelyVii" title="Common stock, shares authorized"><span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_z0dEr9uxHUE1" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000162" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized at December
31, 2024 and December 31, 2023, respectively, <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_z0UubuAaZeag" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zT7mb4gA54ma" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,384,801</ix:nonFraction></ix:nonFraction></span>
</span>shares and <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zCueGWlarsl" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zdWe697bxowe" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">738,295</ix:nonFraction></ix:nonFraction></span></span> shares issued
and outstanding at December 31, 2024 and December 31, 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PreferredStockValue_i02I_maSEzyTZ_zEAxNwpEc4G6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred stock, par value $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_zWq89J7ejsXh" title="Preferred stock, par value"><span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_zDwwZnmsKRD1" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000175" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000177" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>; <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_z5VnVfiRqu4" title="Preferred stock, shares authorized"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_z1ZcIop22Yhi" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000181" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized at December 31, 2024 and December 31, 2023, respectively; <span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_pid_dxL_c20241231_zniHaOm3tPRi" title="Preferred stock, shares issued::XDX::-"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dxL_c20241231_z89Qer4buQB6" title="Preferred stock, shares outstanding::XDX::-"><span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_dxL_c20231231_ztpnEUFL5kgf" title="Preferred stock, shares issued::XDX::-"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dxL_c20231231_ze7G00Ssq4fa" title="Preferred stock, shares outstanding::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0183"><span style="-sec-ix-hidden: xdx2ixbrl0185"><span style="-sec-ix-hidden: xdx2ixbrl0187"><span style="-sec-ix-hidden: xdx2ixbrl0189">nil</span></span></span></span></span></span></span></span> shares issued and outstanding at December 31, 2024 and December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0172">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0173">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdditionalPaidInCapital_i02I_maSEzyTZ_zYM288K1FyE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,424</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzyTZ_zQ5Z17BHlAXe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,101</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,299</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maSEzyTZ_ziytdOkqetV6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">414</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">411</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockholdersEquity_i02TI_maLASEz7pI_mtSEzyTZ_z49z6eNB4rsf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total stockholders&#8217; deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,793</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">457</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEz7pI_zYq00EKhFqA5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,193</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,224</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sj_003"></span><b>CONDUIT
PHARMACEUTICALS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS</b>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except share amounts and per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_113_pn3n3_zo8NwHrAtXIa" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_zjbKIRnophNe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zuExKCTdav05" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingExpensesAbstract_iB_zaBPAEJ3ekFl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEzrcA_zJvTOh9FPAPf" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Research and development expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,378</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_i01_pn3n3_maOEzrcA_zp53TuzHJZ91" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">General and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,041</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000213" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,172</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpenses_i01T_pn3n3_mtOEzrcA_msOILzLXC_z1EWp8LFl7Fe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total operating costs and expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,419</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,262</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_iT_pn3n3_mtOILzLXC_maNILzYD4_zoClem9Ib2Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">15,419</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000219" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,262</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zYd6MrmKJtD1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other income (expenses):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherNonoperatingIncomeExpense_i01_pn3n3_maNIEz0ad_zkkRHG6vRPff" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">890</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000225" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,923</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InvestmentIncomeNet_i01_pn3n3_maNIEz0ad_z7C66ZfP0db" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="From2024-01-01to2024-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="From2023-01-012023-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InterestIncomeExpenseNonoperatingNet_i01_pn3n3_maNIEz0ad_zidM51SQAVp1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Interest expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2024-01-01to2024-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,506</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2023-01-012023-12-31" id="Fact000231" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">211</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpense_i01T_pn3n3_mtNIEz0ad_maNILzYD4_zUDJpEsAEw04" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total other (expense) income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,383</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,727</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILzYD4_maCINOTzSyU_maNILATzTXQ_zC2Eze3rPav4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,802</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000237" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">535</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--ChangeInFairValueAndIncomeImpactOfOptionLiabilities_iN_pn3n3_di_msNILATzTXQ_zU7UNA9jeTLb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Less: Change in fair value and income impact of option liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0239">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CDT:ChangeInFairValueAndIncomeImpactOfOptionLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,521</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_iT_pn3n3_mtNILATzTXQ_zBMrtMZJuExh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net income (loss) - diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000242" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,802</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2023-01-012023-12-31" id="Fact000243" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,056</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_zGvJNOBMvXO5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Basic earnings/(net loss) per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000245" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">20.53</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000246" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.79</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareDiluted_pid_zkDTFEkebiwe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Diluted earnings/(net loss) per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000248" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">20.53</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000249" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">8.92</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zIT0xXKhBPR2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic weighted-average common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">867,096</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000252" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">669,739</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_ztDBbSRxzuD" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Diluted weighted-average common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000254" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">867,096</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000255" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">678,939</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_iB_zqPYSZjWGMdl" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Comprehensive income (loss):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_i01_pn3n3_maCINOTzSyU_zTtFS8RvRZ2h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-01to2024-12-31" id="Fact000260" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000261" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">264</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ComprehensiveIncomeNetOfTax_i01T_pn3n3_mtCINOTzSyU_zpOog3aih4Zj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-01to2024-12-31" id="Fact000263" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,799</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000264" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">799</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sj_004"></span><b>CONDUIT
PHARMACEUTICALS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; DEFICIT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except share amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_114_pn3n3_zEpP2Uv2zhXa" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Deficit" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-style: italic">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zR6R9Qud1e1g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zOhqcrA9OuIe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zInxXROdYP9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_z1Ez22a0182e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">income</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_zvHuUvGyLxx4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>paid-in</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>comprehensive</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>stockholders&#8217;</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">income</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_439_c20230101__20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_eus-gaap--StockholdersEquity_iS_zrmDIXft6MFl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z4e66QhsQcZa" title="Balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember" id="Fact000272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember" id="Fact000268" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,764</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000269" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">675</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact000270" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,089</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_435_c20230101__20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_eus-gaap--StockholdersEquity_iS_zgOQwtgMpsYl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Retroactive application of Merger</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zgdVCWFGGcE5" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_CommonStockMember" id="Fact000280" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">646,244</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_CommonStockMember" id="Fact000274" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember" id="Fact000275" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0276">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20230101__20231231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_eus-gaap--StockholdersEquity_iS_zWXa6M14jL5i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Reclassification of additional paid-in-capital<span id="xdx_F4F_z1S24Lixe2l6">**</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember" id="Fact000283" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember" id="Fact000284" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20230101__20231231_eus-gaap--StockholdersEquity_iS_ztM7UZprQ334" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Adjusted Balances, beginning of period<span id="xdx_F43_zFpbWEcYkmd2">*</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKg_____zoV5UZADOz5f" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000294" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">646,264</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000288" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000290" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,770</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000291" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">675</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000292" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,089</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_43E_c20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_eus-gaap--StockholdersEquity_iS_z0FZQVLk6Po8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Reclassification of additional paid-in-capital <span id="xdx_F48_zY1FG1MdVow8">***</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember" id="Fact000297" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember" id="Fact000298" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zCzHOIorALUd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date (Note 2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuzpqD9j2fG8" title="Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000308" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,735</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember" id="Fact000303" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,685</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact000306" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,685</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_iN_di_zATm1iXLRYYd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock upon conversion of MURF Class A &amp; Class B common stock in connection with merger (Note 2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwmx2Fn060Cf" title="Issuance of common stock upon conversion of MURF Class A &amp; Class B common stock in connection with merger, shares" style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000316" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,183</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember" id="Fact000310" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember" id="Fact000311" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,219</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact000314" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,218</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing_zVlDpQsragBh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing (Note 2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBDLfMF5OQue" title="Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing, shares" style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000324" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember" id="Fact000319" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact000322" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,779</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodValuePurchaseOfRevenue_zBtJ6zZUBO04" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--StockIssuedDuringPeriodSharesPurchaseOfRevenue_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8jQMh8Xohni" title="Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC, shares" style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodSharesPurchaseOfRevenue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000332" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,955</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValuePurchaseOfRevenue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember" id="Fact000327" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValuePurchaseOfRevenue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact000330" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValuePurchasesOfRevenue_zpF8pKK7vo2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of Conduit Pharmaceuticals Inc. common stock to Vela Technologies PLC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesPurchasesOfRevenue_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLAryY4q6Vg6" title="Issuance of Conduit Pharmaceuticals Inc. common stock to Vela Technologies PLC, shares" style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodSharesPurchasesOfRevenue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000340" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValuePurchasesOfRevenue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember" id="Fact000335" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">544</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValuePurchasesOfRevenue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact000338" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">544</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueIssuedForServicesOne_zI1rRJR0pYu9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger (Note 2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--StockIssuedDuringPeriodSharesIssuedForServicesOne_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmT3n7DzVSV5" title="Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger, shares" style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodSharesIssuedForServicesOne" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000348" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger_zs2g0jhBNZ27" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reduction of excise tax liability associated with the Merger (Note2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember" id="Fact000351" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,141</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact000354" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,141</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty_zeBLWR3jRybg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capital contribution - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember" id="Fact000357" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact000360" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ze9Y3ZJTOsIg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember" id="Fact000363" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">199</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact000366" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">199</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_zsXkq398edCe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000371" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">264</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact000372" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">264</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_zkPugvRAABi1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember" id="Fact000376" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">535</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact000378" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">535</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_430_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zqmy1KASOrxe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5uDMYn8jdB7" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000386" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">738,295</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000380" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000381" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,424</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000382" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,299</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000383" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">411</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000384" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">457</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F06_z4LqjtKpEVw8" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zHSqSVoCxW27" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000387" xml:lang="en-US">Shares
    of legacy common stock have been retroactively restated to give effect to the Merger.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_F09_zs1LhRUqGFdi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zFy23BggLco" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000388" xml:lang="en-US">Reclassification
    is made as additional paid-in capital cannot be presented as a negative for either its beginning or ending balance.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_F08_zCC6PcF4Asrb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_ziF8JcvghiE8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000389" xml:lang="en-US">Reclassification
    is made as the impact of the retroactive application of the Merger can be shown as a reduction to additional paid-in capital during
    the period as presenting the reduction does not result in additional paid-in capital being presented as a negative for its ending
    balance.</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>paid-in</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>comprehensive</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>stockholders&#8217;</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">income</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_435_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zZOiR8MSqO75" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXE8OsjzCvMj" title="Balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000397" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">738,295</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000391" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000392" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,424</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000393" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,299</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000394" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">411</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000395" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">457</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_435_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zPnfnwOailOb" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zL95kdpPAJu3" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000405" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">738,295</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000399" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000400" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,424</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000401" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,299</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000402" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">411</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000403" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">457</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_409_ecustom--AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense_zZsuZr0XYKW5" style="vertical-align: bottom; background-color: White">
    <td style="font-style: normal; font-weight: normal">Correction of immaterial error related to franchise tax expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000408" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">144</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000411" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">144</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_z1VXhtU0MiL3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Common Stock for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdVlBQcgkpF2" title="Issuance of Common Stock for services, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000419" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000414" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">242</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-01to2024-12-31" id="Fact000417" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">242</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueOther_z3bK8tqNwbOl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of Common Stock upon vesting of restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHmmdAMRtHL3" title="Issuance of Common Stock upon vesting of restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000427" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable_zijswH5lXFsi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Common Stock for note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEZZbsbypFxh" title="Issuance of Common Stock for note payable, shares" style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000435" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,045</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000429" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000430" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">995</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable" contextRef="From2024-01-01to2024-12-31" id="Fact000433" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">997</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zHO4dWZ2GhD1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of Common Stock for licensing right</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjZXl3js1Cmk" title="Issuance of Common Stock for licensing right, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000443" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000437" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000438" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,567</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-12-31" id="Fact000441" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,568</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStock_zds2gtXVl6og" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Common Stock under the ATM Program</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStock_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsaU695Zw0gc" title="Issuance of Common Stock under the ATM Program, shares" style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000451" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">323,273</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000445" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000446" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,218</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStock" contextRef="From2024-01-01to2024-12-31" id="Fact000449" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,221</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification_zJdnB0whQXxb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of Common Stock in Exchange for Debt Modification</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcVgp7PNnYdk" title="Issuance of Common Stock in Exchange for Debt Modification, shares" style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000459" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,193</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000453" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000454" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">488</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification" contextRef="From2024-01-01to2024-12-31" id="Fact000457" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">489</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption_zImb0K83vAFb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Common Stock upon Exercise of Conversion Option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAi6TAMrIiF7" title="Issuance of Common Stock upon Exercise of Conversion Option, shares" style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000467" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000462" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" contextRef="From2024-01-01to2024-12-31" id="Fact000465" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">92</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zcZmpz4yDIO5" style="vertical-align: bottom; background-color: White">
    <td>Issuance of Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000470" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,890</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-01to2024-12-31" id="Fact000473" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,890</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants_zdsACKguLqQ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Common Stock Upon Exercise of Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqp8zda5W2La" title="Issuance of Common Stock Upon Exercise of Warrants, shares" style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000481" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0475">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000476" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">188</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0477">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0478">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000479" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">188</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zc4yj1RGn1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIWYasqkHTgf" title="Issuance of Common Stock Upon Exercise of Warrants, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000489" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000484" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000487" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,632</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_zgGvVMWT0I8d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000494" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-01-01to2024-12-31" id="Fact000495" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_zfdKPKYYLZ7l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0498">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000499" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,802</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0500">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000501" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,802</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43A_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zEjD5s9QrVg5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvUAboZX3Fm1" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000509" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,384,801</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000503" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000504" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000505" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,101</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000506" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">414</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000507" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,793</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_432_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zO7BRhqkZmOk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG03CWgsGqx6" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000517" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,384,801</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000511" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000512" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000513" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,101</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000514" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">414</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000515" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,793</ix:nonFraction></td><td style="text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sj_005"></span><b>CONDUIT
PHARMACEUTICALS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_112_pn3n3_zeLasgCLBcRh" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zmSaLIL9rn6b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_z94V2crPO817" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zxzNux5fvFj5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_i01_maNCPBUzDHt_zDdSJpVY1Rsh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000522" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,802</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000523" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">535</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zdkMk9NsxDz8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--GainLossOnChangeInFairValueOfCizzleOption_i02N_di_msNCPBUzDHt_zLD4bfg9EpZe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Gain on change in fair value of Cizzle option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0528">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CDT:GainLossOnChangeInFairValueOfCizzleOption" contextRef="From2023-01-012023-12-31" id="Fact000529" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,280</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--GainOnChangeInFairValueOfVelaOption_i02N_di_msNCPBUzDHt_zLUQZ1m9g917" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on change in fair value of Vela option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0531">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CDT:GainOnChangeInFairValueOfVelaOption" contextRef="From2023-01-012023-12-31" id="Fact000532" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">970</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--LossOnIssuanceOfVelaOption_i02_maNCPBUzDHt_zwlxAgjF1ue6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on issuance of Vela option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:LossOnIssuanceOfVelaOption" contextRef="From2023-01-012023-12-31" id="Fact000535" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">987</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ChangesInForeignCurrencyTransactionUnrealized_i02N_di_msNCPBUzDHt_zxlSUaKbctw4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in reserve for related party uncollectible loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CDT:ChangesInForeignCurrencyTransactionUnrealized" contextRef="From2023-01-012023-12-31" id="Fact000538" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">240</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msNCPBUzDHt_zpYb66Wl0o89" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on debt extinguishment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-01to2024-12-31" id="Fact000540" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">707</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LossOnRelatedPartyLoanForgiveness_i02_maNCPBUzDHt_zsFgyIVVVYZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss on related party loan forgiveness</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0543">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:LossOnRelatedPartyLoanForgiveness" contextRef="From2023-01-012023-12-31" id="Fact000544" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--RealizedGainOnShorttermInvestments_i02N_di_msNCPBUzDHt_zQkGmLxyAyt8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Realized gain on short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CDT:RealizedGainOnShorttermInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000546" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0547">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ForeignCurrencyTransactionGainLossUnrealizedAfterTax_i02N_di_msNCPBUzDHt_zeOY0lr9tbMj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Unrealized foreign exchange gain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax" contextRef="From2024-01-01to2024-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax" contextRef="From2023-01-012023-12-31" id="Fact000550" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--LossOnChangeInFairValueOfConvertibleNotesPayable_i02_maNCPBUzDHt_zzma7o51bYcl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss (gain) on change in fair value of convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CDT:LossOnChangeInFairValueOfConvertibleNotesPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000552" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,018</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:LossOnChangeInFairValueOfConvertibleNotesPayable" contextRef="From2023-01-012023-12-31" id="Fact000553" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">426</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueAdjustmentOfWarrants_i02_maNCPBUzDHt_zCkOHw3lIro2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on change in FV of the warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000555" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">221</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="Fact000556" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">81</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability_i02N_di_msNCPBUzDHt_z4s20x2Lp9Qa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Non-cash reduction of deferred income upon exercise of option liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CDT:NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability" contextRef="From2023-01-012023-12-31" id="Fact000559" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,254</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--LossOnIssuanceOfWarrants_i02_maNCPBUzDHt_zRFZyDrNKYa1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss on issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:LossOnIssuanceOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000561" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,710</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0562">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--NoncashLeaseExpense_i02I_maNCPBUzDHt_z1ujHfXOwDeb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Non-cash lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:NoncashLeaseExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000564" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">89</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensation_i02_maNCPBUzDHt_z8U9siZUvDb2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000567" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000568" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">199</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--IssuanceOfCommonStockForLicensingRight_i02_maNCPBUzDHt_zX1a0gY6dVi5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of Common Stock for licensing right</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:IssuanceOfCommonStockForLicensingRight" contextRef="From2024-01-01to2024-12-31" id="Fact000570" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--NoncashInterestExpense_i02_maNCPBUzDHt_z2iwkccdDcp" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Non-cash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:NoncashInterestExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000573" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">536</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:NoncashInterestExpense" contextRef="From2023-01-012023-12-31" id="Fact000574" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Depreciation_i02_maNCPBUzDHt_zqxv96qlpfsd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact000576" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentForAmortization_i02_maNCPBUzDHt_zn0wZaDZhkBg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Amortization of financed Directors and Officers insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact000579" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,666</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2023-01-012023-12-31" id="Fact000580" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">479</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AmortizationExpense_i02_maNCPBUzDHt_z6Ky6wo0QPH8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:AmortizationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000582" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">447</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0583">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AmortizationOfDebtDiscount_i02_maNCPBUzDHt_zd7idrkWdCR5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:AmortizationOfDebtDiscount" contextRef="From2024-01-01to2024-12-31" id="Fact000585" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">929</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_maNCPBUzDHt_zlee17GyAsr3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-01to2024-12-31" id="Fact000588" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">202</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0589">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zo3nIu4kL3X7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzDHt_zxjLGfuPc28f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000594" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,273</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000595" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">990</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzDHt_zsvwfk7C5E7i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000597" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,225</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-12-31" id="Fact000598" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_i03N_di_msNCPBUzDHt_zuKUHfSiMMF4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000600" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,030</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CDT:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000601" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,746</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzDHt_zpUySyzSHvFi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000603" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">124</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0604">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInIntangibleAssetsCurrent_i03N_di_msNCPBUzDHt_zp8QYvZSGd74" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Intangible assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0606">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent" contextRef="From2023-01-012023-12-31" id="Fact000607" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzDHt_maCCERCzgwg_z1PoZZUtc7Oa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash flows from operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000609" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,682</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000610" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,725</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PaymentsToFundLongtermLoansToRelatedParties_i01N_di_msNCPBUzfPO_zYD64ZGTGUFh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of loan - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0612">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" contextRef="From2023-01-012023-12-31" id="Fact000613" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">357</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzfPO_z8hRgXIIiWV6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-12-31" id="Fact000615" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0616">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PaymentsToAcquireShortTermInvestments_i01N_di_msNCPBUzfPO_zGjpAZZ4Qv6b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Purchases of short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000618" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">490</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0619">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromSaleOfShortTermInvestments_i01_maNCPBUzfPO_zxn0165zayX7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from the sale of short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000621" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">498</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0622">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ProceedsFromIssuanceOfOption_i01_maNCPBUzfPO_zrTKIhSbcr3f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0624">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:ProceedsFromIssuanceOfOption" contextRef="From2023-01-012023-12-31" id="Fact000625" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">497</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ProceedsFromLoanRepaymentRelatedParty_i01_maNCPBUzfPO_z8Oaa3hvZoih" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Proceeds from loan repayment - related party</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0627">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="CDT:ProceedsFromLoanRepaymentRelatedParty" contextRef="From2023-01-012023-12-31" id="Fact000628" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">585</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzfPO_maCCERCzgwg_znqFRA3xh7ci" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash flows from investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000630" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000631" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">725</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zE9Skkdkuewh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts_i01_maNCPBUz80K_ztunTGba2IIh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from Merger and related PIPE Financing, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0636">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts" contextRef="From2023-01-012023-12-31" id="Fact000637" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,493</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromNotesPayable_i01_maNCPBUz80K_zXCPeB0NzRPg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from the issuance of notes payable &#8211; related parties
</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000639" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,626</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromRelatedPartyDebt_i01_maNCPBUz80K_zR4Jso6ozoPa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from the issuance of notes payable &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-01-01to2024-12-31" id="Fact000642" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">600</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0643">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ProceedsFromIssuanceOfCapitalContributionRelatedParty_i01_maNCPBUz80K_zg4Tiw2Oq5fd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Capital contribution - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:ProceedsFromIssuanceOfCapitalContributionRelatedParty" contextRef="From2023-01-012023-12-31" id="Fact000646" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUz80K_zqLNw8P7jAB3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common shares related to ATM program</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-01to2024-12-31" id="Fact000648" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ProceedsFromExerciseOfWarrants_i01_maNCPBUz80K_zeXWE411jA7c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:ProceedsFromExerciseOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000651" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">176</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0652">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RepaymentsOfNotesPayable_i01N_di_msNCPBUz80K_zn9iIXCCRU53" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Repayment of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000654" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">776</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfWarrants_i01_maNCPBUz80K_zUw0kPkuW9e2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000657" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">113</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromConvertibleDebt_i01_maNCPBUz80K_zufBJklxVJbc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Proceeds from issuance of convertible promissory note payable, carried at cost</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0660">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-012023-12-31" id="Fact000661" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,286</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUz80K_maCCERCzgwg_ze99lcOYFmt1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash flows from financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000663" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,067</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000664" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,929</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_i01T_mtCCERCzgwg_maCCERCzjkR_zQwRrVQAYF6j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net change in cash and cash equivalents before effect of exchange rate changes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000666" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,658</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000667" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,929</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_maCCERCzjkR_zE0ob3da19ic" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Effect of exchange rate changes on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2024-01-01to2024-12-31" id="Fact000669" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2023-01-012023-12-31" id="Fact000670" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">299</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzjkR_zrkQ6ki8QQlg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net change in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000672" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,674</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000673" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,228</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zbFGAOUz78U8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000675" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,228</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_z0OAEyb0oA2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000678" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">554</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000679" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,228</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zxGovnhNnWzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash investing and financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_i01_z3vs9xGxHfe3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Right of Use Asset obtained in exchange for Operating Lease Liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000684" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">352</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense_i01_z3xhU8NVS4u7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Correction of immaterial error related to franchise tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CDT:CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000687" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">144</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0688">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption_i01_zXVhgnvhrgs" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Issuance of Common Stock upon exercise of conversion option</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" contextRef="From2024-01-01to2024-12-31" id="Fact000690" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">92</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0691">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--IssuanceOfCommonStockInExchangeForDebtExtension_i01_zIvyGWJMU436" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Issuance of Common Stock in exchange for debt extension</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CDT:IssuanceOfCommonStockInExchangeForDebtExtension" contextRef="From2024-01-01to2024-12-31" id="Fact000693" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">489</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote_i01_z2ZXNzmL8Lb7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Conversion of deferred commission payable to convertible promissory note</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CDT:ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote" contextRef="From2024-01-01to2024-12-31" id="Fact000696" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,378</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0697">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc_i01_z8xMnCxqQnq7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC upon exercise of option</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0699">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CDT:IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc" contextRef="From2023-01-012023-12-31" id="Fact000700" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssued1_i01_zgaIeVAc0ub1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Issuance of Conduit Pharmaceuticals Inc. common stock to Vela Technologies PLC upon exercise of option</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0702">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2023-01-012023-12-31" id="Fact000703" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">544</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NotesReduction_i01_z50j5wP1zTyj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Exchange of Conduit Pharmaceuticals Limited convertible notes for shares of Conduit Pharmaceuticals Inc. common stock in connection with the Merger</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NotesReduction" contextRef="From2023-01-012023-12-31" id="Fact000706" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,685</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredUnderwritingCosts_i01_zcEQAi7A6eR8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Deferred Underwriting Costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0708">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CDT:DeferredUnderwritingCosts" contextRef="From2023-01-012023-12-31" id="Fact000709" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,738</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger_i01_z3AvPUHIEr7d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Prepaid expense of directors and officers insurance paid out of PIPE financings proceeds in connection with the Merger</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CDT:PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger" contextRef="From2023-01-012023-12-31" id="Fact000712" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,253</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination_i01_z2WEDXmR8iFl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Accumulated deficit assumed to APIC as a result of the business combination</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0714">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CDT:AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination" contextRef="From2023-01-012023-12-31" id="Fact000715" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,124</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing_i01_zLQ9ufE0aRpd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Initial value of warrant liabilities issued in connection with PIPE Financing</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0717">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CDT:InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing" contextRef="From2023-01-012023-12-31" id="Fact000718" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">223</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--NoncashAssetsAssumedInMergerFinancing_i01_zuYVLIcQyKEa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Non-Cash Assets Assumed in the Merger Financing</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0720">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CDT:NoncashAssetsAssumedInMergerFinancing" contextRef="From2023-01-012023-12-31" id="Fact000721" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--NoncashLiabilitiesAssumedInMergerFinancing_i01_zCSXvRZ6CLi2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Non-Cash Liabilities Assumed in the Merger Financing</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0723">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CDT:NoncashLiabilitiesAssumedInMergerFinancing" contextRef="From2023-01-012023-12-31" id="Fact000724" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">124</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--SupplementalCashFlowElementsAbstract_iB_zFoDUnYBalUe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Supplemental Cash Disclosures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestPaidNet_i01_zjoje8SNlQFh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-12-31" id="Fact000729" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="Fact000730" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">124</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="sj_006"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDUIT
PHARMACEUTICALS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000732" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_80F_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zdVkDUL0Skpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82B_z21UO3OlmiQb">Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit
Pharmaceuticals Inc., a Delaware corporation (&#8220;Conduit&#8221; or the &#8220;Company&#8221;), is a clinical-stage specialty
biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets. The Company has
developed a unique business model that allows it to act as a conduit to bring clinical assets from pharmaceutical companies and
develop new treatments for patients. Our novel approach addresses unmet medical needs and lengthens the intellectual property for
our existing assets through cutting-edge solid-form technology with the expectation of commercializing these products with life
science companies. </span>Our initial development plan is to conduct a Phase II clinical trial on AZD1656 in Lupus (including Lupus
Nephritis) and ANCA Vasculitis (AAV). We anticipate developing our Initial Pipeline (which has already undergone pre-clinical and
clinical trials) through the Phase II stage and then monetizing such clinical assets through a license, royalty, or other
transaction at this stage. At this time, we do not expect that we will commercialize any clinical assets or seek marketing approval
from the FDA (or similar organizations) as we intend to enter into agreements with third parties following Phase II clinical trials
for each such clinical asset that would provide that such third party would pursue the further development, commercialization, and
marketing of such assets.</p>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Merger
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2023 (the &#8220;Closing Date&#8221;), a merger transaction between Conduit Pharmaceuticals Limited (&#8220;Old Conduit&#8221;),
Murphy Canyon Acquisition Corp (&#8220;MURF&#8221;) and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly owned
subsidiary of MURF (&#8220;Merger Sub&#8221;), was completed (the &#8220;Merger&#8221;, see Note 2) pursuant to the initial merger agreement
dated November 8, 2022 and subsequent amendments to the merger agreement dated January 27, 2023 and May 11, 2023 (together, the &#8220;Merger
Agreement&#8221;). Pursuant to the terms of the Merger Agreement, on the Closing Date, (i) Merger Sub merged with and into Old Conduit,
with Old Conduit surviving the merger as a wholly-owned subsidiary of MURF, and (ii) MURF changed its name from Murphy Canyon Acquisition
Corp. to Conduit Pharmaceuticals Inc. The common stock of the Company (the &#8220;Common Stock&#8221;) commenced trading on The Nasdaq
Global Market under the symbol &#8220;CDT&#8221; on September 25, 2023, and the Company&#8217;s warrants commenced trading on The Nasdaq
Capital Market under the symbol &#8220;CDTTW&#8221; on September 25, 2023. On March 7, 2025, the Company filed an application to list our Common Stock on The Nasdaq Capital Market as part
of our plan to regain compliance with all NASDAQ rules. See Note 20 for additional details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Merger was accounted for as a reverse recapitalization in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;). Under the reverse recapitalization method, MURF was treated as the acquired company for financial
reporting purposes, and the accounting acquirer was assumed to have issued shares of stock for the net assets of MURF, with no goodwill
or other intangible assets recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared by the Company in accordance with U.S. GAAP as set forth by the Financial
Accounting Standards Board (&#8220;FASB&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange
Commission (&#8220;SEC&#8221;). References to U.S. GAAP issued by the FASB in these notes to the accompanying consolidated financial
statements are to the FASB Accounting Standards Codifications (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASUs&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Principles
of Consolidation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the accounts of Conduit Pharmaceuticals, Inc. and its wholly owned subsidiaries
Conduit UK Management Ltd. (United Kingdom) and Conduit Pharmaceuticals, Ltd. (Cayman Islands). As used herein, references to the &#8220;Company&#8221;
include references to Conduit Pharmaceuticals, Inc, and its subsidiaries. All intercompany balances and transactions have been eliminated
in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
and Going Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate,
that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial
statements are issued. Since its inception, the Company has generated significant losses and as of December 31, 2024, the Company had
an accumulated deficit of $<span id="xdx_901_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zj4o87HU4pTh" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000734" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">29.1</ix:nonFraction></span> million. As of December 31, 2024 and December 31, 2023, the Company had cash and cash equivalents and
short-term investments of $<span id="xdx_903_eus-gaap--Cash_iI_pn5n6_c20241231_zn0jMmbhI3x7" title="Cash and cash equivalents"><span id="xdx_903_eus-gaap--Cash_iI_pn5n6_c20231231_zw7Y2hvtVDs3" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000736" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000738" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></ix:nonFraction></span></span> million and $<span id="xdx_90D_eus-gaap--ShortTermInvestments_iI_pn5n6_c20241231_zRUEM8rneAkg" title="Short term investments"><span id="xdx_90E_eus-gaap--ShortTermInvestments_iI_pn5n6_c20231231_zvDMqDwwSH11" title="Short term investments"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2024-12-31" id="Fact000740" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2023-12-31" id="Fact000742" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.2</ix:nonFraction></ix:nonFraction></span></span> million, respectively. For the year ended December 31, 2024 and 2023, the Company had
net operating losses of $<span id="xdx_901_eus-gaap--OperatingIncomeLoss_iN_pn5n6_di_c20240101__20241231_zHLAYgQY1vva" title="Net loss"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000744" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">15.4</ix:nonFraction></span> million and $<span id="xdx_907_eus-gaap--OperatingIncomeLoss_iN_pn5n6_di_c20230101__20231231_zioLWMcGsLy9" title="Net loss"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000746" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">5.3</ix:nonFraction></span> million, respectively, and cash used in operating activities of $<span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zcXo0VEgDcmf" title="Operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000748" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">9.7</ix:nonFraction></span> million and $<span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20231231_z5au0uVxXQ9f" title="Operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000750" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">7.7</ix:nonFraction></span>
million, respectively. Management has determined that it does not have sufficient cash and other sources of liquidity to fund its current
business plan. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern for at least
the next 12 months from the financial statement filing date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s expectation is to generate operating losses and negative operating cash flows in the future and will need additional
funding to support its current business plan in addition to the remaining at the market offering program (the &#8220;Sales
Agreement&#8221;) of $<span id="xdx_90A_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20241231_zifFDEbaRNuc" title="Offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2024-12-31" id="Fact000752" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.0</ix:nonFraction></span> million (See Note 20), as of the financial statement release date. Management&#8217;s plans to alleviate the
conditions that raise substantial doubt through the pursuit of additional cash resources through public or private equity or debt
financings. However, there is no assurance that such funding will be available when needed or on acceptable terms. If additional
funding is not available when required, the Company would need to delay or curtail its operations and its research and development
activities until such funding is received, all of which could have a material adverse effect on the Company and its financial
condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements have been prepared assuming the Company will continue as a going concern and do not include adjustments to reflect
the possible effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result
from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2025, the Company amended its Second Amended and Restated Certificate of Incorporation with the Secretary of State of the
State of Delaware in order to effect a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20250124__20250124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9DL8phwKiq" title="Reverse stock split"><ix:nonNumeric contextRef="From2025-01-242025-01-24_us-gaap_SubsequentEventMember" id="Fact000754" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-100</ix:nonNumeric></span> reverse stock split of its outstanding shares of common stock (the &#8220;Reverse Stock
Split&#8221;). As a result of the reverse stock split, every 100 shares of the Company&#8217;s common stock issued or outstanding were
automatically reclassified into one new share of common stock, subject to the treatment of fractional shares as described below, without
any action on the part of the holders. All historical share and per-share amounts reflected throughout the accompanying consolidated
financial statements and other financial information in this Annual Report on Form 10-K have been retroactively adjusted to reflect the
2025 Reverse Stock Split as if the split occurred as of the earliest period presented. The Reverse Stock Split did not affect the number
of authorized shares of common stock or the par value of the common stock. No fractional shares were issued in connection with the Reverse
Stock Split. Stockholders who would otherwise have been entitled to receive fractional shares as a result of the Reverse Stock Split
were entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled
multiplied by the closing price per share of the common stock (as adjusted to give effect to the Reverse Stock Split) on The Nasdaq Global
Market on January 24, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Risks and Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to companies in the development stage and pharmaceutical industry including, but not limited to, uncertainties
related to pre-clinical and clinical outcomes competitor products, regulatory approvals, dependence on key products, dependence on key
suppliers and protection of intellectual property rights (see note 15 for details on a claim against our AZD 1656 co-crystal patent).
Clinical assets currently under development will require significant additional research and development efforts, including extensive
preclinical and clinical testing and regulatory approval prior to commercialization. These efforts will require significant amounts of
additional capital, adequate personnel, infrastructure, and extensive compliance and reporting capabilities. Even if the Company&#8217;s
efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from royalties or product sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company licenses clinical assets from AstraZeneca. See Note 10. If there is a breach or other termination of such agreements, there could
be a material adverse effect on the Company&#8217;s business, financial condition, operating results, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is also subject
to risks associated with the Nasdaq Stock Market Correspondence and Subsequent Nasdaq Capital Market Listing. See note 20 for further
details.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Significant Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000756" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9N5EBnEnmaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zIe5vxmUeFeg">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents are primarily maintained with major financial institutions in the United States, United Kingdom, and Switzerland.
The Company considers cash equivalents to be short-term, highly liquid investments that (a) are readily convertible into known amounts
of cash, (b) are traded and held for cash management purposes, and (c) have original maturities of three months or less at the time of
purchase. The Switzerland bank accounts holding cash balances are uninsured, and the UK bank account, with a year-end balance of approximately
&#163;<span id="xdx_905_eus-gaap--CashUninsuredAmount_iI_uGBP_c20241231_zQI4bUKQnUY6" title="Cash, uninsured amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2024-12-31" id="Fact000758" format="ixt:numdotdecimal" decimals="0" unitRef="GBP">100,000</ix:nonFraction></span> (or approximately $<span id="xdx_904_eus-gaap--CashUninsuredAmount_iI_c20241231_zaGRR62Uw4Z9"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2024-12-31" id="Fact000759" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span>) exceeds the country&#8217;s deposit limit of &#163;<span id="xdx_90F_eus-gaap--DepositAssets_iI_uGBP_c20241231_z3ShePxF9WH1" title="Deposit assets"><ix:nonFraction name="us-gaap:DepositAssets" contextRef="AsOf2024-12-31" id="Fact000761" format="ixt:numdotdecimal" decimals="0" unitRef="GBP">85,000</ix:nonFraction></span> (approximately $<span id="xdx_90C_eus-gaap--DepositAssets_iI_c20241231_z0WdGHQohBQ4" title="Deposit assets"><ix:nonFraction name="us-gaap:DepositAssets" contextRef="AsOf2024-12-31" id="Fact000763" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,000</ix:nonFraction></span>). The Company&#8217;s
US depository bank participates in the Demand Deposit Marketplace program, insuring deposits up to $<span id="xdx_900_eus-gaap--DemandDepositAccounts_iI_pn5n6_c20241231_zfZWgquLidRl" title="Demand deposit accounts"><ix:nonFraction name="us-gaap:DemandDepositAccounts" contextRef="AsOf2024-12-31" id="Fact000765" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10</ix:nonFraction></span> million by sweeping amounts in
excess of the $<span id="xdx_903_ecustom--DepositInsuranceLimit_iI_c20241231_ziy0DytOkTc4" title="Deposit insurance limit"><ix:nonFraction name="CDT:DepositInsuranceLimit" contextRef="AsOf2024-12-31" id="Fact000767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> deposit insurance limit among participating banks. The Company has not experienced any losses on any accounts
through the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_z2fXvuCTKKHd"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000768" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
and $<span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_z8CmV6dzZ03l"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000769" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.2</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
in cash and cash equivalents on hand as of December 31, 2024 and December 31, 2023, respectively. As of December 31, 2024, $<span id="xdx_908_ecustom--CashAndCashEquivalentsNetBankOverdrafts_iI_pn5n6_c20241231_zOWaCmXXcOL1" title="Cash and cash equivalents net bank overdrafts"><ix:nonFraction name="CDT:CashAndCashEquivalentsNetBankOverdrafts" contextRef="AsOf2024-12-31" id="Fact000771" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of the Company&#8217;s $<span id="xdx_904_ecustom--CashAndCashEquivalentsNetBankOverdrafts_iI_pn5n6_c20231231_zbpgW4zK93r1" title="Cash and cash equivalents net bank overdrafts"><ix:nonFraction name="CDT:CashAndCashEquivalentsNetBankOverdrafts" contextRef="AsOf2023-12-31" id="Fact000773" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million cash and cash equivalents balance was
invested in money market funds. The money market funds do not have significant liquidity restrictions that would require the exclusion
from cash and cash equivalents.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000775" name="us-gaap:MarketableSecuritiesPolicy"><p id="xdx_84D_eus-gaap--MarketableSecuritiesPolicy_z11uILEwtqR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000777" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zr2oaR3Pft5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zGvFhdFehme6">Property,
Plant and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment are initially recorded at cost. Depreciation and amortization are computed using the straight-line method over the
estimated useful lives of the assets or, for leasehold improvements, the life of the lease, if shorter. When assets are retired or otherwise
disposed of, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected
in other income or expense for the period. As of December 31, 2024, property, plant and equipment primarily consisted of leasehold improvements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000779" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zFWyZzHoR1O1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zYTsYzI9vQQ1">Leases</span>
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 842, Leases (ASC 842), the Company records a right-of-use (ROU) asset and a lease liability on the balance sheet
for all leases with terms longer than 12 months and classifies them as either operating or finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and
circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset,
whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has
the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets,
lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases
with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components,
the Company has elected not to allocate the contract consideration, and to account for the lease and non-lease components as a single
lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term.
The implicit rate within our operating leases is generally not determinable and, therefore, the Company uses the incremental borrowing
rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#8217;s incremental
borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing
rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The
operating lease ROU asset also includes any lease prepayments, offset by lease incentives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain
we will exercise that option. An option to terminate is considered unless it is reasonably certain we will not exercise the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000781" name="us-gaap:UseOfEstimates"><p id="xdx_843_eus-gaap--UseOfEstimates_zY7dhmJYGLo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zuZg498GV7R2">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial
statements as well as the reported amounts of revenues and expenses during the reporting period. Estimates are based on several factors
including the facts and circumstances available at the time the estimates are made, historical experience, risk of loss, general economic
conditions and trends, and the assessment of the probable future outcome. Actual results could differ materially from such estimates.
Estimates and assumptions are reviewed periodically by management and changes in estimates are made as management becomes aware of changes
in circumstances surrounding the estimates. The effects of changes are reflected in the financial statements in the period that they
are determined.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000783" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z0hboc6fhfs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zw3w6L0i2dUl">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 820, <i>Fair Value Measurements and Disclosures</i>, defines fair value, establishes a framework for measuring fair value, and
expands disclosures about fair value measurements. Fair value is to be determined based on the exchange price that would be received
for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants. In determining fair value, the Company used various valuation approaches. A fair
value hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes
the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that
market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
inputs reflect the Company&#8217;s assumption about the inputs that market participants would use in pricing the asset or liability developed
based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the
inputs, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1&#8212;Valuations based on quoted prices for identical instruments in active markets. Since valuations are based on quoted prices
    that are readily and regularly available in an active market, valuation of these instruments does not entail a significant degree
    of judgment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2&#8212; Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for either similar
    instruments in active markets, identical or similar instruments in markets that are not active, or model-derived valuations whose
    inputs or significant value drivers are observable or can be corroborated by observable market data.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3&#8212;Valuations based on inputs that are unobservable. These valuations require significant judgment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Level 1 assets consist of cash and cash equivalents, including money market funds, in the accompanying balance sheets
and the value of accrued expenses and other current liabilities approximate fair value due to the short-term nature of these assets and
liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company has two financial liabilities, warrant liabilities for which the fair value is determined based on
Level 2 and Level 3 inputs, and convertible debt carried at fair value for which the fair value is
determined based on Level 3 input. The Level 2 inputs are valued based on observable inputs other than quoted
prices included in Level 1, such as quoted prices for similar instruments in active markets. The level 3 inputs as such inputs are based
on unobservable inputs and require significant judgement. As of December 31 2023, the Company has one financial liability, a warrant liability for which the fair value is determined
based on Level 2 inputs as such inputs are valued based on observable inputs other than quoted prices included in Level 1, such as
quoted prices for similar instruments in active markets.  See Note 3 for further information on the Company&#8217;s
financial liabilities carried at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000785" name="us-gaap:FairValueTransferPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--FairValueTransferPolicyPolicyTextBlock_zmMVpIcF9dy7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zJ210n5wYSd8">Fair
Value Option</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected the fair value measurement option for convertible debt with embedded derivatives that would otherwise require bifurcation
and has recorded the entire hybrid financial instrument at fair value under the guidance in ASC 825, Financial Instruments. As a result,
the August 2024 Nirland Note was recorded at fair value subsequent to the Second Amendment and the A.G.P. Convertible Note was recorded
at fair value upon issuance. The notes will subsequently be remeasured at fair value each reporting date until settled or converted.
The Company reports interest expense, including accrued interest, related to the convertible debt under the fair value option, separately
from within the change in fair value of the convertible debt in the accompanying consolidated statement of operations and comprehensive
income (loss). Any changes in fair value caused by instrument-specific credit risk are presented separately in other comprehensive income.
During the year ended December 31, 2024, the Company did not record any changes in fair value related to instrument-specific credit risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000787" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zmqny0wbGnq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zWcwKdDcWrMc">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred in connection with the research and development of our clinical assets
and programs, see Note 10 for further discussion of research and development expense. Conduit holds all licenses to conduct clinical
research through a third-party pharmaceutical company. The Company expenses research and development costs and intangible assets
acquired that have no alternative future use as incurred. These expenses include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred under agreements with organizations that support the Company&#8217;s drug discovery and development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred in connection with the preclinical and clinical development of the Company&#8217;s clinical assets and programs, including
    under agreements with contract research organizations, or CROs&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to contract manufacturing organizations, or CMOs, that are primarily engaged to provide drug substance and product for our
    clinical trials, research and development programs, as well as investigative sites and consultants that conduct the Company&#8217;s
    clinical trials, nonclinical studies and other scientific development services&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing registration and validation
    batches&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related
    expenses, including salaries, related benefits and equity-based compensation expense, for employees engaged in research and development
    functions&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">acquisition costs related to the purchase of licensed intellectual property;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to compliance with quality and regulatory requirements&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments
    made under third-party licensing agreements&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">direct
    and allocated costs related to facilities, information technology, personnel and other overhead.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance
payments that we make for goods or services to be received in the future for use in research and development activities are recorded
as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or consumed or the related services are performed,
or until it is no longer expected that the goods will be delivered, or the services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000789" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p id="xdx_84B_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_znRfGS37jvN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zZOsh9rAdqGa">General
and Administrative Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries and related costs for personnel in executive management, finance, corporate
and business development, and administrative functions. General and administrative expenses also include legal fees relating to patent
and corporate matters&#894; professional fees for accounting, auditing, tax, and administrative consulting services&#894; insurance costs&#894;
administrative travel expenses and other operating costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000791" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zpAczA2q79t5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z0NlpMWvYCrg">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 740, <i>Income Taxes</i>, sets forth standards for financial presentation and disclosure of income tax liabilities and expense.
Interest and penalties recognized have been classified in the consolidated statements of operations and comprehensive income (loss) as
income taxes. Deferred tax assets and liabilities are recognized for future tax consequences attributable to temporary differences between
the financial statement carrying amount of existing assets and liabilities and their respective tax bases and operating losses carried
forward. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change
in tax rates is recognized in the consolidated statements of operations and comprehensive income (loss) in the period that includes the
enactment date. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits of which
future realization is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000793" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zJkBnbjryKMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zWQwRNE8GDh2">Earnings/(Net
Loss) per Share</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates basic and diluted earnings/(net loss) per share under ASC Topic 260, <i>Earnings Per Share</i>. Basic earnings/(net
loss) per share is computed by dividing the net income/(loss) by the number of weighted-average common shares outstanding for the period.
Diluted earnings/(net loss) is computed by adjusting net income/(loss) based on the impact of any dilutive instruments. Diluted earnings/(net
loss) per share is computed by dividing the diluted net income/(loss) by the number of weighted-average common shares outstanding for
the period including the effect, if dilutive, of any instruments that can be settled in common shares. When computing diluted net income/(loss)
per share, the numerator is adjusted to eliminate the effects that have been recorded in net income/(loss) (net of tax, if any) attributable
to any liability-classified dilutive instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000795" name="CDT:WarrantInstrumentsPolicyTextBlock"><p id="xdx_84B_ecustom--WarrantInstrumentsPolicyTextBlock_zb3ifZGf9Nf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_86C_zZCtQMd1f6Ne" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the accounting classification of Warrants as either liability or equity by first assessing whether the Warrants meet
liability classification in accordance with ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;). Under ASC 480, a
financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies
a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares must be classified as
a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly
on any one of the following: (a) a fixed monetary amount known at inception; (b) variations in something other than the fair value of
the issuer&#8217;s equity shares; or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
financial instruments, such as the Warrants, are not required to be classified as liabilities under ASC 480, the Company assesses whether
such instruments are indexed to the Company&#8217;s own stock under ASC 815-40. In order for an instrument to be considered indexed to
an entity&#8217;s own stock, its settlement amount must always equal the difference between the following: (a) the fair value of a fixed
number of the Company&#8217;s equity shares, and (b) a fixed monetary amount or a fixed amount of a debt instrument issued by the Company.
The Company determined that the settlement amount of the Equity Classified Warrants would equal the difference between the fair value
of a fixed number of shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified as equity, while
the settlement amount of the Liability Classified Warrants would not equal the difference between the fair value of a fixed number of
shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified as a liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Equity Classified Warrants are recorded in stockholders&#8217; deficit and the Liability Classified Warrants are recorded as liabilities
in the Consolidated Balance Sheet. The Liability Classified Warrants are remeasured each period with changes in fair value recorded in
the Consolidated Statements of Operations and Comprehensive Income (Loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000797" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zfXSfxa44aaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zTvJEe4YQyb5">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company translated the assets and liabilities of foreign subsidiaries from their respective functional currency, the British pound, to
United States dollars at the appropriate spot rates as of the balance sheet date. Income and expenses of operations are translated to
United States dollars using weighted average exchange rates during the year. The foreign subsidiaries use the local currency as their
functional currency. The effects of foreign currency translation adjustments are included as a component of accumulated other comprehensive
income in the accompanying consolidated statements of changes in stockholders&#8217; deficit. Non-monetary items in the subsidiaries&#8217;
functional currency are re-measured into the reporting currency at the historical exchange rate (i.e., the rate of exchange at the date
of the transaction).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000799" name="CDT:EmergingGrowthCompanyStatusPolicyTextBlock"><p id="xdx_84E_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zviwSQVWkuNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zT0gOeUHmSN7">Emerging
Growth Company Status</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under
the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of
the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period
for complying with new or revised accounting standards that have different effective dates for public and private companies until the
earlier of the date that: (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended
transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with
the new or revised accounting pronouncements as of public company effective dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Merger, the Company will remain an emerging growth company, as defined by the Jumpstart Our Business Startups act of 2012, until
the earliest of <span id="xdx_906_ecustom--DescriptionForEmergingGrowthCompany_c20240101__20241231_zjcsk4iASiNa" title="Emerging growth description"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000801" name="CDT:DescriptionForEmergingGrowthCompany">(i) the last day of the combined entity&#8217;s first fiscal year following the fifth anniversary of the completion of
MURF&#8217;s initial public offering (the &#8220;MURF IPO&#8221;), (ii) the last day of the fiscal year in which the combined entity
has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the combined entity is deemed
to be a large accelerated filer, which means the market value of the combined entity&#8217;s common stock that is held by non-affiliates
exceeds $700.0 million as of the prior December 31st or (iv) the date on which the combined entity has issued more than $1.0 billion
in non-convertible debt securities during the prior three year period.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000803" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1ZDVaMonHk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zZTzVojdLiYe">Recently
Adopted Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) (&#8220;ASU 2023-07&#8221;), which enhances the segment disclosure
requirements for public entities on an annual and interim basis. Under this proposal, public entities are required to disclose significant
segment expenses that are regularly provided to the chief operating decision maker (the &#8220;CODM&#8221;) and included within each
reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#8217;s profit or loss
and assets will be required on an interim basis. Entities are also required to disclose information about the CODM&#8217;s title and
position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment
of segment performance and deciding whether how to allocate resources. Finally, ASU 2023-07 requires all segment disclosures for public
entities, even those with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023,
and interim periods within fiscal years beginning after December 15, 2024, and should be applied on a retrospective basis to all periods
presented. As of December 31, 2024, the Company only has one reportable segment. The Company adopted this accounting standard as of January
1, 2024. See Note 19 for the Company&#8217;s segments disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>


<ix:exclude><!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000805" name="CDT:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"><p id="xdx_845_ecustom--NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_zn0GSboqcEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zzGJPSdxsV7b">Recently
Issued Accounting Standards Not Yet Adopted</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;).
ASU 2023-09 modifies the reporting requirements for income tax disclosures related to effective tax rates and cash income taxes paid.
Pursuant to ASU 2023-09, public business entities are required to disclose certain categories in the income tax rate reconciliation,
as well as additional information for reconciling items that meet a specific quantitative threshold. Additionally, ASU 2023-09 requires
annual disclosures of income taxes paid for all entities, including the amount of income taxes paid, net of refunds received, disaggregated
by federal, state, and foreign jurisdictions. The standard is effective for fiscal years beginning after December 15, 2024, with early
adoption permitted. The Company is currently evaluating the impact of ASU 2023-09 on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, which is intended to provide more detailed information about specified categories
of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented
on the consolidated statements of operations and comprehensive income (loss). The guidance in this ASU is effective for fiscal years
beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted.
The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU
or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the
impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</span></p>

</ix:nonNumeric><p id="xdx_850_zuQfE7pbO0X1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000807" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p id="xdx_80F_eus-gaap--BusinessCombinationDisclosureTextBlock_zOt19ohlSSL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_82C_zrSPVGUYkYpe">Merger and Financing</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 1 &#8211; <i>Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies</i>, on September
22, 2023, the Company and MURF completed the Merger. Upon the closing of the Merger, the following occurred:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    share of Old Conduit common stock issued and outstanding immediately prior to the closing of the Merger, which totaled <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--OldConduitPharmaceuticalsLimitedMember_zRQc7HVorekl" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--OldConduitPharmaceuticalsLimitedMember_zecslu5V7UJk" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_OldConduitPharmaceuticalsLimitedMember" id="Fact000809" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_OldConduitPharmaceuticalsLimitedMember" id="Fact000811" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000</ix:nonFraction></ix:nonFraction></span></span> shares,
    was exchanged for the right to receive <span id="xdx_905_eus-gaap--NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRjBoli97ZZf" title="Business acquisition right to receive number of shares"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember" id="Fact000813" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">323</ix:nonFraction></span> shares of the Company&#8217;s Common Stock (&#8220;Common Stock&#8221;) resulting
    in the issuance of <span id="xdx_90E_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrp2eqWJhe59" title="Number of shares issued"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">646,264</ix:nonFraction></span> shares of Conduit Pharmaceuticals, Inc. Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition to the shares issued to legacy Conduit shareholders noted above, an additional <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__custom--ConduitConvertibleNoteHoldersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk5FXvbXgJOi" title="Shares issued after merger"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_ConduitConvertibleNoteHoldersMember_us-gaap_CommonStockMember" id="Fact000817" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,735</ix:nonFraction></span> shares of Common Stock was issued
    to Conduit convertible note holders, resulting in a total of <span id="xdx_901_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__custom--ConduitShareHoldersandConvertibleNoteHoldersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znGJEvbid2U1" title="Number of shares issued"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_ConduitShareHoldersandConvertibleNoteHoldersMember_us-gaap_CommonStockMember" id="Fact000819" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">650,000</ix:nonFraction></span> shares of Common Stock being issued to Conduit shareholders
    and holders of Conduit convertible notes payable.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    connection with the Merger, <span id="xdx_90E_ecustom--BusinessAcquisitionNumberOfSharesTransferred_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zLdIrzuOdHYa" title="Number of shares transferred"><ix:nonFraction name="CDT:BusinessAcquisitionNumberOfSharesTransferred" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_srt_DirectorMember_us-gaap_CommonClassAMember" id="Fact000821" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">450</ix:nonFraction></span> shares of MURF Class A common stock held by the MURF Sponsor was transferred to MURF Directors. Each
    share was exchanged on a <span id="xdx_906_eus-gaap--CommonStockConversionBasis_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zXUotxubHbF5" title="Common stock conversion basis"><ix:nonNumeric contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_srt_DirectorMember_us-gaap_CommonClassAMember" id="Fact000823" name="us-gaap:CommonStockConversionBasis">one-for-one basis</ix:nonNumeric></span> for shares of Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    share of MURF Class A common stock held by the MURF Sponsor prior to the closing of the Merger, which totaled <span id="xdx_901_ecustom--BusinessAcquisitionNumberOfSharesTransferred_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2ZrROw2Xi8k" title="Number of shares transferred"><ix:nonFraction name="CDT:BusinessAcquisitionNumberOfSharesTransferred" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonClassAMember" id="Fact000825" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,090</ix:nonFraction></span> shares, was exchanged
    for, on a one-for-one basis for shares of Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    share of MURF common stock subject to possible redemption that was not redeemed prior to the closing of the Merger, which totaled
    <span id="xdx_90C_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxZoPEBM1ppk" title="Number of shares held prior to business combination"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember" id="Fact000827" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">580</ix:nonFraction></span> shares, was exchanged for, on a one-for-one basis for shares of Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    connection with the Merger, <span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zfqLcnhQ43gb" title="Number of shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SponsorMember_us-gaap_CommonClassBMember" id="Fact000829" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,062</ix:nonFraction></span> shares of MURF Class B common stock held by the Sponsor was automatically converted into shares
    of MURF Class A common stock and then subsequently converted into shares of Common Stock on a one-for-one basis.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    connection with the Merger, A.G.P./Alliance Global Partners (&#8220;A.G.P.&#8221;), whom acted as a financial advisor to both MURF
    and Conduit, was due to receive (i) a cash fee of $<span id="xdx_90C_eus-gaap--ProfessionalFees_pn5n6_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zBVaLTSO4OWe" title="Cash fee"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember" id="Fact000831" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.5</ix:nonFraction></span> million, <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zlPFvmw6ogT7" title="Shares issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember" id="Fact000833" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,000</ix:nonFraction></span> shares of Common Stock and warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pp0p0_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zD9AOimPgLB6" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember" id="Fact000835" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">540</ix:nonFraction></span> shares
    of Common Stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zFuk1ZCZna11" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember" id="Fact000837" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,100</ix:nonFraction></span> per share pursuant to its engagement agreement with Conduit entered into on August
    2, 2022 and (ii) $<span id="xdx_90D_ecustom--DeferredUnderwritingFee_pn5n6_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zwnSjHyICE71" title="Deferred underwriting fee"><ix:nonFraction name="CDT:DeferredUnderwritingFee" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember" id="Fact000839" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.6</ix:nonFraction></span> million of deferred underwriting fees as a result of its engagement for MURF&#8217;s initial public offering.
    Upon closing of the Merger, A.G.P. received a cash payment of $<span id="xdx_909_ecustom--PaymentForAdvisoryServices_pn5n6_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zoIjICMLxc6l" title="Financial advisory fee"><ix:nonFraction name="CDT:PaymentForAdvisoryServices" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember" id="Fact000841" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.6</ix:nonFraction></span> million, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zE0SCy0Cjo39" title="Shares issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember" id="Fact000843" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,000</ix:nonFraction></span> shares of Common Stock, and <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zXoL0YwQYmwj"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember" id="Fact000844" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">540</ix:nonFraction> </span>warrants to purchase
    <span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesStockWarrantsExercised_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zRFVq2FtqWSi" title="Warrants to purchase common stock"><ix:nonFraction name="CDT:StockIssuedDuringPeriodSharesStockWarrantsExercised" contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember" id="Fact000846" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">540</ix:nonFraction></span> shares of Common Stock. The remaining $<span id="xdx_905_ecustom--DeferredCashPaymentsAmount_iI_pn5n6_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zKI5msY6RDX7" title="Cash payments due"><ix:nonFraction name="CDT:DeferredCashPaymentsAmount" contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember" id="Fact000848" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.7</ix:nonFraction></span> million of cash payments due to A.G.P upon closing of the Merger was deferred and
    to be paid on or before March 21, 2025, with annual interest of <span id="xdx_907_ecustom--AnnualInterestRate_iI_pid_dp_uPure_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zrmPDhU5WAkh" title="Interest rate"><ix:nonFraction name="CDT:AnnualInterestRate" contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember" id="Fact000850" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.5</ix:nonFraction></span>%. The remaining cash payments due, which were directly attributable
    to the Merger, were accounted for as a liability with an offset to additional paid-in capital in accordance with SAB Topic 5.A on
    the Company&#8217;s consolidated balance sheet. See Note 7 for discussion of amendment of the note that took place during the year ended December 31, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    connection with the Merger, MURF entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with certain accredited
    investors (the &#8220;PIPE Investors&#8221;) for an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zPU344Rnltmd" title="Shares issued during the period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember" id="Fact000852" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span> units, with each unit consisting of one share of Company
    common stock (the &#8220;PIPE Shares&#8221;), together with one warrant exercisable into one share of Company common stock (the &#8220;PIPE
    Warrants&#8221;), at a purchase price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zaaaJ8VZeLuh" title="Shares issued, purchase price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember" id="Fact000854" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></span> per unit, for an aggregate purchase price of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z1M3Ea2YVfw4" title="Shares issued during the period, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember" id="Fact000856" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></span> (the &#8220;PIPE Financing&#8221;).
    Upon the closing of the PIPE Financing (which closed in connection with the closing of the Merger), the Company received $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zgPeYyITNGce" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember" id="Fact000858" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.0</ix:nonFraction></span> million
    in cash from the PIPE Financing, which was used to settle related party promissory notes issued by MURF to the MURF Sponsor and an
    affiliate of the MURF Sponsor as well as transaction costs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    proceeds received by the Company from the Merger and PIPE Financing, net of transaction costs, and other payments for existing liabilities
    and prepayments, totaled $8.5 million.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, MURF was treated
    as the acquired company for financial reporting purposes (see Note 1 for further details). Accordingly, for accounting purposes,
    the Merger was treated as the equivalent of the Company issuing shares for the net assets of MURF, accompanied by a recapitalization.
    The net assets of MURF were stated at historical cost with no goodwill or other intangible assets recorded.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000860" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zMHzmmRuPXxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the total Common Stock outstanding immediately after the closing of the Merger:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zmRwfzhSC5Zh" style="display: none">Schedule
of Common Stock Outstanding</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Exchange of MURF common stock subject to possible redemption for Conduit Pharmaceuticals Inc. common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pip0_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis__us-gaap--CommonStockSubjectToMandatoryRedemptionMember_z1RCLOhnbOLe" title="Exchange of MURF common stock subject to possible redemption for Conduit Pharmaceuticals Inc. common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember_us-gaap_CommonStockSubjectToMandatoryRedemptionMember" id="Fact000862" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">580</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exchange of MURF Class A common stock held by MURF Directors for Conduit Pharmaceuticals Inc. common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxC6b0h09OHk" title="Exchange of MURF Class A common stock held by MURF Directors for Conduit Pharmaceuticals Inc. common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_srt_DirectorMember_us-gaap_CommonStockMember" id="Fact000864" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">450</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Exchange of MURF Class A common stock held by MURF Sponsor for Conduit Pharmaceuticals Inc. common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxfpbvUTjoS8" title="Exchange of MURF Class A common stock held by MURF Sponsor for Conduit Pharmaceuticals Inc. common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SponsorMember_us-gaap_CommonStockMember" id="Fact000866" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,152</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Subtotal - Merger, net of redemptions</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zozAQ9XrK4gi" title="Business Combination, net of redemptions, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember" id="Fact000868" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,182</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3CppKDwcUa5" title="Issuance of Conduit Pharmaceuticals, Inc. common stock in connection with PIPE Financing, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember_us-gaap_CommonStockMember" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Exchange of Conduit Pharmaceuticals Limited ordinary shares for Conduit Pharmaceuticals Inc. common stock on the Closing Date</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWY0VDeUjWld" title="Exchange of Conduit Pharmaceuticals Limited ordinary shares for Conduit Pharmaceuticals Inc. common stock on the Closing Date, shares"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember" id="Fact000872" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">646,264</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXQi6JjWROI5" title="Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date,shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember" id="Fact000874" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,735</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxuWF0bLXB76" title="Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the transaction, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember" id="Fact000876" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total - Conduit Pharmaceuticals Inc. common stock outstanding as a result of the Merger, PIPE Financing, exchange of Conduit Pharmaceuticals Limited shares for shares of Conduit Pharmaceuticals Inc., issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes, and advisors.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zAbAtWqta8i2" title="Total - Conduit Pharmaceuticals Inc. common stock outstanding as a result of Business Combination, PIPE Financing, exchange of Conduit Pharmaceuticals Limited shares for shares of Conduit Pharmaceuticals Inc., issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes, and transaction services agreements, shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember" id="Fact000878" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">724,181</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zgh2j1YuwUUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000880" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zhBmad4CwYhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_82F_zRCO19RmjpZd">Fair Value</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000882" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock"><p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zCtFMn43Fv61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period ended December 31, 2024, there were no transfers between Level 1 and Level 2, nor into or out of Level 3. The following
table presents as of December 31, 2024 the Company&#8217;s assets and liabilities subject to measurement at fair value on a
recurring basis (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_z3goVReCnn35" style="display: none">Schedule
of  Assets Subject to Measurement at Fair Value on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Cash equivalents</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_zW0HAnUpsvPi" title="Cash equivalents" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember" id="Fact000884" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">192</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_z33wWa7lwO0j" title="Cash equivalents" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0886">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_z9IX5fTZ4kj7" title="Cash equivalents" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0888">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_zb5yiPIDU7l3" title="Cash equivalents" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember" id="Fact000890" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">192</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdQMgbeQS6v1" title="Total Assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000892" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">192</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2kiDDR5Tmkl" title="Total Assets" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0894">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzUmQ2pkcK2k" title="Total Assets" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUo15aFKnWJ9" title="Total Assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000898" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">192</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible notes payable at fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_zyb4WrTSaAhj" title="Option liability" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0900">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_zUl5DKjzekr9" title="Option liability" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_zcXTKq4up5m3" title="Option liability" style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ConvertibleNotesPayableMember" id="Fact000904" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,856</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoUOgP3F4u9g" title="Option liability" style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_ConvertibleNotesPayableMember_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000906" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,856</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Liability Classified Warrants</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zSQzp4WpuF8h" title="Warrant Liability - PIPE Warrants" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0908">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zqRtJD0od3tg" title="Warrant Liability - PIPE Warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="Fact000910" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_z29P0jaeyOLi" title="Warrant Liability - PIPE Warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="Fact000912" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zU3ETZrXfeIh" title="Warrant Liability - PIPE Warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="Fact000914" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgT4eaYNsP06" title="Total Liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8JNrw2ygA12" title="Total Liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0918">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUMv3HreeBu1" title="Total Liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000920" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,994</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zknkSqE01W5k" title="Total Liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000922" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,994</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents as of December 31, 2023 the Company&#8217;s liabilities subject to measurement at fair value on a recurring
basis (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Liability Classified Warrants</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zXOzm6huL3sf" title="Warrant Liability - PIPE Warrants" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zENvKENrXooi" title="Warrant Liability - PIPE Warrants" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="Fact000926" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">142</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zl9wcldzfSQe" title="Warrant Liability - PIPE Warrants" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0928">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zmNKSSwrtGql" title="Warrant Liability - PIPE Warrants" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="Fact000930" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">142</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6q6LJ2Ls69a" title="Total Liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0932">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5bDizCJVXh" title="Total Liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000934" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">142</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLXYPUPearZ7" title="Total Liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0936">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFBw8ee5C1L3" title="Total Liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000938" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">142</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zOwa1FKpVIff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents consist of highly liquid money market funds with maturities of three months or less and are reflected in the Consolidated
Balance Sheets at carrying value, which approximates fair value due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000940" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_892_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zyye7A4TPG83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents additional information about the Convertible Notes Payable subject to measurement at fair value on a recurring
basis and warrant liabilities, for which the Company used significant unobservable inputs (Level 3) (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zqxT7pULAy3b" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_z6393p8CaGjj" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible Notes</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payable</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_z1GM2RkDB3le" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Liability Classified Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ConvertibleDebtFairValueDisclosures_iS_pn3n3_zee7e5WmrIkc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0942">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsOfDebtIssuanceCosts_pn3n3_zs2UpKq7Jqof" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Fair value at Issuance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember" id="Fact000945" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,899</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000946" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">229</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_iN_pn3n3_di_zR8QJkt8jZr1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of convertible note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember" id="Fact000948" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">92</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0949">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ChangeInFairValueOfConvertibleNotesPayable_pn3n3_z4jevABFubjj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="CDT:ChangeInFairValueOfConvertibleNotesPayable" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember" id="Fact000951" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,951</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="CDT:ChangeInFairValueOfConvertibleNotesPayable" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000952" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">91</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--ConvertibleDebtFairValueDisclosures_iE_pn3n3_zDGdPFy27977" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember" id="Fact000954" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,856</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000955" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zq8srlYULYDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Notes Payable</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 7, during on October 31, 2024, the Company and Nirland agreed to amend the August 2024 Nirland Note, whereby the
August 2024 Nirland Note was amended to provide for the conversion of the August 2024 Nirland Note into shares of common stock, at
Nirland&#8217;s discretion, in a multiple of any unpaid amounts, if not otherwise previously paid, pursuant to the conversion rate
contained therein. The August 2024 Nirland Note was then amended for a second time on November
22, 2024.Additionally, as discussed in Note 7, during November 2024, the Company issued to A.G.P. a convertible promissory
note (the &#8220;A.G.P. Convertible Note&#8221;) in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241130_zbl3vtjqhtnk" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-11-30" id="Fact000957" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.7</ix:nonFraction></span>
million to evidence the A.G.P.&#8217;s currently owed deferred commission payable. The Company elected to account for the August
2024 Nirland Note and A.G.P. Convertible Note (collectively the &#8220;Convertible Notes Payable&#8221;) at fair value. The fair
value of the Convertible Notes Payable is estimated each period using a binomial lattice model. Significant estimates in the
binomial lattice model include the Company&#8217;s stock price, volatility, risk-free rate, corporate bond yield, credit
spread, probability of default, and recovery upon default.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the August 2024 Nirland Note and A.G.P. Convertible Note as of December 31, 2024 were estimated using a binomial
lattice model. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following
table outlines the range of significant unobservable inputs used in calculating the fair value of the August 2024 Nirland Note as of
the dates noted below:</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000959" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock"><p id="xdx_895_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_zbfLS4JMsCAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zz0NnNr931ll" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Fair Value  of Assumptions</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>October 31,</b></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>2024</b></p>

</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>November 22,</b></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>2024</b></p>

</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">2024</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Stock Price</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 14%"><span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zXP1MgYtPeec" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-10-31_us-gaap_MeasurementInputSharePriceMember" id="Fact000961" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">9.10</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 14%"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zqD7KjVRhKm1" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-22_us-gaap_MeasurementInputSharePriceMember" id="Fact000963" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">10.40</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zJwzZ7tNojW9" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember" id="Fact000965" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">6.90</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term (years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20241031__20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z8hbVV8uD26e" title="Measurement input"><ix:nonNumeric contextRef="From2024-10-312024-10-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact000967" name="us-gaap:DebtInstrumentTerm">0.8</ix:nonNumeric></span></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20241122__20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zNmDiM14K2X4" title="Measurement input"><ix:nonNumeric contextRef="From2024-11-222024-11-22_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact000969" name="us-gaap:DebtInstrumentTerm">0.7</ix:nonNumeric></span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zaP1nUSbEZOe" title="Measurement input"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact000971" name="us-gaap:DebtInstrumentTerm">0.6</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Corporate bond yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember_zZuiHbbsiz9h"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-10-31_custom_CorporateBondYieldEstimatedTimingOfConversionMember" id="Fact000972" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">9.1</ix:nonFraction></span></td>
    <td>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember_zbRAZVJcZYje"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-22_custom_CorporateBondYieldEstimatedTimingOfConversionMember" id="Fact000973" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">8.7</ix:nonFraction></span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember_zu7d2zNDqHU3"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_custom_CorporateBondYieldEstimatedTimingOfConversionMember" id="Fact000974" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">11.4</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit Spread</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zAIYKzu1Az6i"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-10-31_us-gaap_MeasurementInputCreditSpreadMember" id="Fact000975" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">15.9</ix:nonFraction></span></td>
    <td>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zZ859OayB6ne"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-22_us-gaap_MeasurementInputCreditSpreadMember" id="Fact000976" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">15.9</ix:nonFraction></span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zpRIg4xqVtc1"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputCreditSpreadMember" id="Fact000977" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">15.9</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Probability of default</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember_zfTGPxLaGWI1"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-10-31_custom_MeasurementInputProbabilityOfDefaultMember" id="Fact000978" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">40</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember_z5C3X9drZTHd"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-22_custom_MeasurementInputProbabilityOfDefaultMember" id="Fact000979" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">40</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember_zuGVIZAp9sHk"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_custom_MeasurementInputProbabilityOfDefaultMember" id="Fact000980" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">40</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Recovery upon default</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember_zeZSEtaKzvrb"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-10-31_custom_MeasurementInputRecoveryUponDefaultMember" id="Fact000981" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">20</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember_zFAalIqNOa5d"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-22_custom_MeasurementInputRecoveryUponDefaultMember" id="Fact000982" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">20</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember_znbq2A2VwvZa"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_custom_MeasurementInputRecoveryUponDefaultMember" id="Fact000983" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">20</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>

  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zsQCAwt4dx23"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-10-31_us-gaap_MeasurementInputDiscountRateMember" id="Fact000984" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">103.2</ix:nonFraction></span></td>
    <td>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zOLVsGF4n2gk"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-22_us-gaap_MeasurementInputDiscountRateMember" id="Fact000985" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">96.5</ix:nonFraction></span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zYRcTsjYsIkl"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember" id="Fact000986" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">123.7</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zfP14TqACEL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_AGPConvertibleNoteMember" escape="true" id="Fact000988" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock"><p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_hus-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zaf84Dforup9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table outlines the range of significant unobservable inputs used in calculating the fair value of the A.G.P. Convertible
Note as of the dates noted below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zkqDuKLIvqSc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Fair Value  of Assumptions</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>November 25,</b></p>
                                               <p style="margin-top: 0; margin-bottom: 0"><b>2024</b></p></td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2024</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Stock Price</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 16%"><span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zBul29jM6eL2" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-25_us-gaap_MeasurementInputSharePriceMember_custom_AGPConvertibleNoteMember" id="Fact000990" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">9.10</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zu6TcECljG2f" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_AGPConvertibleNoteMember" id="Fact000992" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">6.90</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term (years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentTerm_dtY_c20241125__20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zUa4mcOSVE1l" title="Measurement input"><ix:nonNumeric contextRef="From2024-11-252024-11-25_us-gaap_MeasurementInputExpectedTermMember_custom_AGPConvertibleNoteMember" format="ixt-sec:duryear" id="Fact000994" name="us-gaap:DebtInstrumentTerm">1</ix:nonNumeric></span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zdsyCXtNdts9" title="Measurement input"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_AGPConvertibleNoteMember" format="ixt-sec:duryear" id="Fact000996" name="us-gaap:DebtInstrumentTerm">0.9</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Corporate bond yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_z9MXSGtaez2h"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-25_custom_CorporateBondYieldEstimatedTimingOfConversionMember_custom_AGPConvertibleNoteMember" id="Fact000997" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">8.8</ix:nonFraction></span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zoNZAFPL0UM3"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_custom_CorporateBondYieldEstimatedTimingOfConversionMember_custom_AGPConvertibleNoteMember" id="Fact000998" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">9.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit Spread</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zRg8nu2t6hgg"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-25_us-gaap_MeasurementInputCreditSpreadMember_custom_AGPConvertibleNoteMember" id="Fact000999" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">26.2</ix:nonFraction></span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zUwDQlb64STf"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputCreditSpreadMember_custom_AGPConvertibleNoteMember" id="Fact001000" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">26.2</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Probability of Default</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zeMJhHg9bEjl"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-25_custom_MeasurementInputProbabilityOfDefaultMember_custom_AGPConvertibleNoteMember" id="Fact001001" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">40</ix:nonFraction></span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zI8Mtigw1iX4"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_custom_MeasurementInputProbabilityOfDefaultMember_custom_AGPConvertibleNoteMember" id="Fact001002" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">40</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Recovery upon default</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zPIXvbm8OyOc" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-25_custom_MeasurementInputRecoveryUponDefaultMember_custom_AGPConvertibleNoteMember" id="Fact001004" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zfYuVgGDKdq6" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_custom_MeasurementInputRecoveryUponDefaultMember_custom_AGPConvertibleNoteMember" id="Fact001006" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zz2qzFr4YgDj" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-25_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001008" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">108.7</ix:nonFraction></span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zD7lCIloP8Fd" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001010" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">101.6</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zZTljc42Ld47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liability
Classified Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PIPE Warrants, A.G.P. Warrants, and A.G.P. 2024 Warrants, as defined in Note 18, are accounted for as liabilities in accordance with ASC 815-40 and are presented
within Warrant liabilities in the consolidated balance sheets. Warrant liabilities are measured at fair value at inception and on a recurring
basis, with changes in fair value presented within other income (expense), net in the consolidated statements of operations and comprehensive
income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
measurement of the PIPE Warrants and the measurement of the A.G.P warrants are classified as Level 2 fair value measurements due to the
use of an observable market quote for the Company&#8217;s publicly traded warrants, which are considered to be a similar asset in an
active market. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PIPE Warrant and A.G.P. Warrant liabilities are calculated by multiplying the quoted market price of the Company&#8217;s publicly traded
warrants by the number of liability classified warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 11, 2024, the Company amended the exercise price of the PIPE Warrants to be $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241211_zKEFHmScQN98" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-11" id="Fact001012" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.83</ix:nonFraction></span>,
at which time all PIPE Warrants were exercised. As the exercise price was amended on the same date that the PIPE Warrants were
exercised, the Company remeasured the warrant liability immediately before exercise based on the difference between the closing
stock price of the Company&#8217;s common stock on December 11, 2024, and the amendment exercise price of the PIPE Warrants,
resulting in a gain on the change in fair value of warrant liability of approximately $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20241211__20241211__us-gaap--StatementEquityComponentsAxis__custom--PIPEWarrantsMember_zJh8PVgG1982" title="Change in fair value of warrant liability"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-12-112024-12-11_custom_PIPEWarrantsMember" id="Fact001014" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></span>
thousand. Refer to Note 18 for additional information. Upon exercise of the PIPE Warrants, less than $<span id="xdx_904_ecustom--WarrantsExcercise_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PIPEWarrantsMember_z1zplZmyXaae" title="Warrants excercise"><ix:nonFraction name="CDT:WarrantsExcercise" contextRef="AsOf2024-12-31_custom_PIPEWarrantsMember" id="Fact001016" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span>
thousand of Level 2 liability classified warrants remain on the consolidated balance sheet as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member" escape="true" id="Fact001018" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock"><p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zrlqaJL1wSv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
measurement of the A.G.P. 2024 Warrants is classified as Level 3 due to the use of an option-pricing model that utilizes unobservable inputs and requires significant judgement. The Company estimated
the fair value of the warrants issued as the issuance date, October 29, 2024, and as of December 31, 2024, using a Black-Scholes
option-pricing model utilizing the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_z29Sb08l0Ne8" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Fair Value  of Assumptions</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>October 29, 2024</b></td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Closing stock price</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 16%"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zL0MGY7X4re1" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-10-29_us-gaap_MeasurementInputSharePriceMember_us-gaap_FairValueInputsLevel3Member" id="Fact001020" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">10.48</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIu51AZP2dIe" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_FairValueInputsLevel3Member" id="Fact001022" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">6.90</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Contractual exercise price</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCikayCpEta7" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-10-29_us-gaap_MeasurementInputExercisePriceMember_us-gaap_FairValueInputsLevel3Member" id="Fact001024" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">10</ix:nonFraction></span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYgt4d7PslL" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExercisePriceMember_us-gaap_FairValueInputsLevel3Member" id="Fact001026" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">10.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zK4NQDMEYmGc" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-10-29_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member" id="Fact001028" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.11</ix:nonFraction></span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zER6wFIDSePb" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member" id="Fact001030" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.38</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Estimated volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaNjNJ2d2Opk" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-10-29_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member" id="Fact001032" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">98.4</ix:nonFraction></span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7GMCDnDHHd9" title="Measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member" id="Fact001034" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">98.6</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Time period to expiration (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentTerm_dtY_c20241029__20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFkT9SINyWc" title="Measurement input"><ix:nonNumeric contextRef="From2024-10-292024-10-29_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member" format="ixt-sec:duryear" id="Fact001036" name="us-gaap:DebtInstrumentTerm">5.2</ix:nonNumeric></span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjfcPSu19W48" title="Measurement input" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member" format="ixt-sec:duryear" id="Fact001038" name="us-gaap:DebtInstrumentTerm">5.0</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zTjVzXNlD7Tb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001040" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock"><p id="xdx_80D_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_zYsJbxvyAxR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82C_zEKMPzE0lnz6">Balance Sheet Details &#8211; Current Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001042" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock"><p id="xdx_894_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_z8g51x79iSz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
assets consisted of the following as of December 31, 2024 and December 31, 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_z49AnDy71Qgh" style="display: none">Schedule
of Balance Sheet Details</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zzu6ecM4gGE" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_z6Ucz8rrw931" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzWXV_zvJ2rACh1pFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid directors&#8217; and officers&#8217; insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2024-12-31" id="Fact001044" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,187</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2023-12-31" id="Fact001045" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,365</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maPEAOAzWXV_zVKTyQP1yqFj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember" id="Fact001047" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" id="Fact001048" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">140</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maPEAOAzWXV_zHxa6sYCZ0l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact001050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1051">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherReceivablesNetCurrent_iI_pn3n3_maPEAOAzWXV_zmYxqf7s0nb6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-12-31" id="Fact001053" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">489</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzWXV_ziXxF2umDgdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact001056" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,161</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact001057" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,505</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zh2SMobu80wc" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001059" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_zbjJT32UVxM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_829_zyVSz3lelv5l">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, we entered into an operating lease for laboratory space. The remaining lease terms for our operating
lease is approximately two years and does not provide a renewal option. We apply the short-term lease policy election, which allows us
to exclude from recognition leases with an original term of 12 months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
commencement of the laboratory lease on March 7, 2024, the Company recorded a right-of-use asset of $<span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn5n6_c20240307_z7y5MuTyDiD9" title="Right of use asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-03-07" id="Fact001061" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million, short-term lease liability
of $<span id="xdx_900_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn5n6_c20240307_zZfG7804jXD1" title="Short term lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-03-07" id="Fact001063" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million, and long-term lease liability of $<span id="xdx_90C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn5n6_c20240307_zjsPBCgW0Rbk" title="Short term lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-03-07" id="Fact001065" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
costs associated the Company&#8217;s operating and short-term leases are recorded within general and administrative expense in the consolidated
statement of operations and comprehensive income (loss). The following table sets forth information about our lease costs for the year
ended December 31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001067" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_ztFEfP5fALic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8B0_zH483udmyJXh" style="display: none">Schedule
of Lease Cost</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Lease Cost</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zLwTLQhOvST4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/>
2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_pn3n3_maLCzbUU_zbnjE8urBSP3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact001069" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">116</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzbUU_zjRy0JmvT1mf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short-term lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact001071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">128</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--VariableLeaseCost_pn3n3_maLCzbUU_zcVbGeQ6OUOh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Variable lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact001073" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LeaseCost_iT_pn3n3_mtLCzbUU_z9QQSkoMn9wc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact001075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">259</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_z1oDpuusiI63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001077" name="CDT:LesseeOperatingLeaseLiabilityTableTextBlock"><p id="xdx_898_ecustom--LesseeOperatingLeaseLiabilityTableTextBlock_zrEGc5eOYk62" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information about our operating lease for the year ended December 31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8BE_zMSqtLCKem1g" style="display: none">Schedule
of Operating Lease Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Supplemental cash flow and other information</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231_z9kLoVIN0577" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/>
2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeasePayments_pn3n3_zXsxgxfBRaC" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; text-align: left">Operating cash flows from operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-01to2024-12-31" id="Fact001079" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">143</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zcppdSH0PxU" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">ROU assets obtained in the exchange for lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2024-01-01to2024-12-31" id="Fact001081" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">352</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average remaining lease term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zv6l9UDkzsb2" title="Weighted-average remaining lease term (in years)"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:duryear" id="Fact001083" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.0</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zs39Vo5dcmu2" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact001085" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.2</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zy45fqanh866" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001087" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zZKj1736oPGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s future minimum lease payments for our operating lease as of the year ended December 31, 2024, are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8BC_zfNkFLRq0Y0i" style="display: none">Schedule
of Future Minimum Lease Payments For Operating Lease</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_zLfU9sYmzFl6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/>
2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold">Year ending December 31,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz2P5_zUZJ8YG7x6ck" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact001089" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">140</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz2P5_zjA7uzVRRFwb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="Fact001091" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">113</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz2P5_zaEqk5RbT9gj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact001093" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">253</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z70CJ5JAsMSf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-12-31" id="Fact001095" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zgV8WrDqUxJ5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001097" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">226</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zDfohRnlO9ek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001099" name="CDT:LiabilityRelatedToTheSaleOfFutureRevenueTextBlock"><p id="xdx_80B_ecustom--LiabilityRelatedToTheSaleOfFutureRevenueTextBlock_zSo4gYSMpXzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_82B_zvBa60A7Tgic">Liability Related to the Sale of Future Revenue</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Vela
Technologies PLC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an Agreement with SGSC to approve an Indirect Investment from Vela Technologies PLC (&#8220;Vela&#8221;) on October
20, 2020, whereby Vela agreed to provide funding to the Company for an indirect investment in AZD 1656 for use in the field in exchange
for <span id="xdx_90E_ecustom--PercentageOfFutureRevenueEarned_dp_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_z4Mg115RLVF8" title="Percentage of future revenue earned"><ix:nonFraction name="CDT:PercentageOfFutureRevenueEarned" contextRef="From2020-10-202020-10-20_custom_VelaAgreementMember" id="Fact001101" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% of future revenue earned if AZD 1656 is commercialized (the &#8220;Vela Agreement&#8221;). Total consideration under the Vela
Agreement was $<span id="xdx_906_eus-gaap--AssetAcquisitionConsiderationTransferred_pn5n6_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zPIu4nuj8hR4"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="From2020-10-202020-10-20_custom_VelaAgreementMember" id="Fact001102" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.9</ix:nonFraction></span> million (&#163;<span id="xdx_903_eus-gaap--AssetAcquisitionConsiderationTransferred_pn4n6_uGBP_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zkMX9NWBC1Ik"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="From2020-10-202020-10-20_custom_VelaAgreementMember" id="Fact001103" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="GBP">2.35</ix:nonFraction></span> million), consisting of $<span id="xdx_903_eus-gaap--PaymentsToAcquireProductiveAssets_pn5n6_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_ztV5k1WsjBuf"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2020-10-202020-10-20_custom_VelaAgreementMember" id="Fact001104" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span> million (&#163;<span id="xdx_906_eus-gaap--PaymentsToAcquireProductiveAssets_pn4n6_uGBP_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zte4CvUUmz41"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2020-10-202020-10-20_custom_VelaAgreementMember" id="Fact001105" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="GBP">1.25</ix:nonFraction></span> million) cash and the issuance of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn8n9_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zjdu2zS7lsqd" title="Number of shares, issuance"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-10-202020-10-20_custom_VelaAgreementMember" id="Fact001107" format="ixt:numdotdecimal" decimals="-8" scale="9" unitRef="Shares">1.1</ix:nonFraction></span> billion
common shares in Vela, which based on the Vela&#8217;s fair value per share and was $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_ztSPx52mHzl4" title="Number of shares issuance, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-202020-10-20_custom_VelaAgreementMember" id="Fact001109" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million. During the year ended December 31,
2021, the Company sold all <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn8n9_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zkny5zvtDFHb" title="Number of shares, issuance"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_VelaAgreementMember" id="Fact001111" format="ixt:numdotdecimal" decimals="-8" scale="9" unitRef="Shares">1.1</ix:nonFraction></span> billion of its Vela shares for $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zCLuHH80Xsa4" title="Number of shares issuance, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_custom_VelaAgreementMember" id="Fact001113" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million and recorded a loss of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zX5dF9mWOy2c" title="Loss"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-12-31_custom_VelaAgreementMember" id="Fact001115" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million on the sale. The Company
received the $<span id="xdx_902_eus-gaap--PaymentsToAcquireProductiveAssets_pn5n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember__us-gaap--AssetAcquisitionAxis__custom--VelaTechnologiesPLCMember_zpDydQmJy4fi"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2020-01-012020-12-31_custom_VelaAgreementMember_custom_VelaTechnologiesPLCMember" id="Fact001116" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span> million (&#163;<span id="xdx_90A_eus-gaap--PaymentsToAcquireProductiveAssets_pn4n6_uGBP_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember__us-gaap--AssetAcquisitionAxis__custom--VelaTechnologiesPLCMember_zTvkeF5odv23"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2020-01-012020-12-31_custom_VelaAgreementMember_custom_VelaTechnologiesPLCMember" id="Fact001117" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="GBP">1.25</ix:nonFraction></span>) million cash consideration during the year ended December 31, 2020. This consideration was recorded
as a liability related to the future sale of revenue on the balance sheet in accordance with ASC 470-10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, the Company entered into an agreement with Vela which granted Vela the right, but not the obligation, to sell its <span id="xdx_901_ecustom--RoyaltyPercentage_dp_c20230401__20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember_zboLKPS4VNth" title="Royalty percentage"><ix:nonFraction name="CDT:RoyaltyPercentage" contextRef="From2023-04-012023-04-30_custom_VelaOptionAgreementMember" id="Fact001119" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% royalty
interest in AZD 1656 back to Conduit. Vela paid a one-time, non-refundable option fee to Conduit of $<span id="xdx_902_ecustom--NonRefundableOptionFee_pn5n6_c20230401__20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember_zNsdqpEqSgs7" title="Non refundable option fee"><ix:nonFraction name="CDT:NonRefundableOptionFee" contextRef="From2023-04-012023-04-30_custom_VelaOptionAgreementMember" id="Fact001121" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million (&#163;<span id="xdx_90D_ecustom--NonRefundableOptionFee_pn5n6_uGBP_c20230401__20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember_zoorhKrkBxZe"><ix:nonFraction name="CDT:NonRefundableOptionFee" contextRef="From2023-04-012023-04-30_custom_VelaOptionAgreementMember" id="Fact001122" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="GBP">0.4</ix:nonFraction></span> million).
Total consideration payable to Vela upon exercise of the option was &#163;<span id="xdx_908_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn5n6_uGBP_c20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWUyWOyjgOm1" title="Total consideration payable"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-04-30_custom_VelaOptionAgreementMember_us-gaap_CommonStockMember" id="Fact001124" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="GBP">4.0</ix:nonFraction></span> million ($<span id="xdx_905_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn4n6_c20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpKKT40JdmVj" title="Total consideration payable"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-04-30_custom_VelaOptionAgreementMember_us-gaap_CommonStockMember" id="Fact001126" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">5.08</ix:nonFraction></span> million on the exercise date) worth of
new common shares in the combined entity after the Merger between Conduit Pharmaceuticals Limited and MURF, following the consummation
of the Merger, at a price per share equal to the volume-weighted average price per share over the ten (10) business days prior to the
date of the notice of exercise. The option contained a provision stating that in no event would the price per share for the consideration
shares be lower than $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember__srt--RangeAxis__srt--MinimumMember_z0QP0MvNRqGa"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-04-30_custom_VelaOptionAgreementMember_srt_MinimumMember" id="Fact001127" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5</ix:nonFraction></span> or higher than $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember__srt--RangeAxis__srt--MaximumMember_z92GQi5UHpa6"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-04-30_custom_VelaOptionAgreementMember_srt_MaximumMember" id="Fact001128" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15</ix:nonFraction></span>. <span id="xdx_905_ecustom--OptionAgreementDescription_c20230401__20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember_zRVFHFN3ZwG8" title="Option agreement description"><ix:nonNumeric contextRef="From2023-04-012023-04-30_custom_VelaOptionAgreementMember" id="Fact001130" name="CDT:OptionAgreementDescription">The option was exercisable in whole at any time from the close of the Merger (the &#8220;Effective
Time&#8221;) until the earlier of (i) the date that was six (6) months from the Effective Time, and (ii) February 7, 2024, the expiration
date of the term.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 30, 2023, Vela exercised its option to sell back its indirect investment in AZD 1656 in exchange for <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20231130__20231130__us-gaap--MeasurementInputTypeAxis__custom--VelaOptionLiabilityMember_zPvwWOkdQ0Fl"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-11-302023-11-30_custom_VelaOptionLiabilityMember" id="Fact001131" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,157</ix:nonFraction></span> shares of the Common
Stock. The Company recognized the $<span id="xdx_90C_eus-gaap--DeferredRevenue_iI_pn5n6_c20231130__us-gaap--MeasurementInputTypeAxis__custom--VelaOptionLiabilityMember_zg0xzKJuwtde" title="Deferred revenue"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2023-11-30_custom_VelaOptionLiabilityMember" id="Fact001133" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span> million of deferred revenue and recorded $<span id="xdx_90F_eus-gaap--OtherNonoperatingIncomeExpense_pn5n6_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__custom--VelaOptionLiabilityMember_z76vsjCrZy57" title="Other income (expense), net"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31_custom_VelaOptionLiabilityMember" id="Fact001135" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span> million to other income (expense), net, on the consolidated
statement of operations and comprehensive income (loss) for the year ended December 31, 2023. As of December 31, 2023, there was no liability
for the sale of future revenue related to Vela.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cizzle
Biotechnology Holdings PLC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2022, the Company entered into an agreement with Cizzle PLC (&#8220;Cizzle&#8221;) whereby Cizzle agreed to purchase a percentage
of future revenue earned in AZD 1656, should it reach the commercialization stage. Total consideration under the agreement is specified
as $<span id="xdx_90F_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20220211__20220211__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_ztTHJoNwsxZe"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2022-02-112022-02-11_custom_CizzlePlcAgreementMember" id="Fact001136" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span> million (&#163;<span id="xdx_90B_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_uGBP_c20220211__20220211__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zZTUeZakprLi"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2022-02-112022-02-11_custom_CizzlePlcAgreementMember" id="Fact001137" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="GBP">1.2</ix:nonFraction></span> million), consisting of the issuance of the fair value of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220211__20220211__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zb6PYZDCRkB3"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-02-112022-02-11_custom_CizzlePlcAgreementMember" id="Fact001138" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25.0</ix:nonFraction></span> million new common shares in Cizzle on the
date of the agreement and the fair value of <span id="xdx_904_eus-gaap--SharesIssued_iI_pn5n6_c20220211__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zTG1CHNu5dw1"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2022-02-11_custom_CizzlePlcAgreementMember" id="Fact001139" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">22.0</ix:nonFraction></span> million shares to be issued at the earlier of Cizzle&#8217;s shareholder approval or
one year from the date of the agreement. The <span id="xdx_90C_eus-gaap--SharesIssued_iI_pn5n6_c20221231__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zaPuj0oNCgF5"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2022-12-31_custom_CizzlePlcAgreementMember" id="Fact001140" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">22.0</ix:nonFraction></span> million shares were received by the Company in the fourth quarter of 2022 and were
subsequently sold within the fourth quarter of 2022. The Company recorded a liability related to deferred revenue of $<span id="xdx_90F_eus-gaap--DeferredRevenue_iI_pn5n6_c20221231__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zHlMqOmSzKC3"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2022-12-31_custom_CizzlePlcAgreementMember" id="Fact001141" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million for
the consideration received from Cizzle as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
payments received for the sale of future revenue were classified as a liability related to the future sale of revenue. Under ASC 470-10-25,
a seller of future revenue should evaluate whether the proceeds received should be accounted for as debt or deferred income. In assessing
the factors that created a rebuttable presumption of debt within the guidance, the Company determined that there were factors present
to overcome the debt presumption and deferred income classification to be appropriate. The main factors the Company considered were that
the transactions in form were sales, and not debt transactions. Each agreement does not guarantee a return to each purchaser, the return
is based solely on future performance of AZD 1656 should it reach commercialization, with neither purchaser having an involvement in
generating future cash flows from AZD 1656.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 15, 2022, the Company entered into an agreement with Cizzle whereby the Company granted Cizzle the option, but not the obligation,
to sell its economic interest in AZD 1656 back to the Company. The agreement contained an option period of nine months from the date
of the agreement for Cizzle to notify the Company of its intent to exercise the option to sell its economic interest in AZD 1656. Upon
closing of the agreement, Cizzle agreed to pay the Company an option fee of $<span id="xdx_90A_ecustom--OptionFee_iI_pn5n6_c20221215__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zDoaiIwdCBO" title="Option fee"><ix:nonFraction name="CDT:OptionFee" contextRef="AsOf2022-12-15_custom_CizzlePlcAgreementMember" id="Fact001143" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million (&#163;<span id="xdx_90C_ecustom--OptionFee_iI_pn5n6_uGBP_c20221215__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_za2yRUuswu7c"><ix:nonFraction name="CDT:OptionFee" contextRef="AsOf2022-12-15_custom_CizzlePlcAgreementMember" id="Fact001144" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="GBP">0.1</ix:nonFraction></span> million).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, Cizzle exercised its option to sell back its indirect investment in AZD 1656 in exchange for <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pid_c20230926__20230926__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztpradnkmBO1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2023-09-262023-09-26_custom_CizzlePlcAgreementMember_us-gaap_CommonStockMember" id="Fact001145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,954</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Common Stock. The Company recognized
the $<span id="xdx_903_eus-gaap--DeferredRevenue_iI_pn5n6_c20231231__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zXVkhfhbOH9f"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2023-12-31_custom_CizzlePlcAgreementMember" id="Fact001146" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of deferred revenue and recorded $<span id="xdx_90F_eus-gaap--OtherOperatingIncomeExpenseNet_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zFziWPv6Re9g"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="From2023-01-012023-12-31_custom_CizzlePlcAgreementMember" id="Fact001147" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to other income (expense), net, on the
consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2023. As of December 31, 2023,
there was no liability for the sale of future revenue related to Cizzle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001149" name="CDT:ConvertibleNotesPayableTextBlock"><p id="xdx_809_ecustom--ConvertibleNotesPayableTextBlock_zlot8IxaK9O8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_82C_zMkPmw4V5gz8">Convertible Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Promissory Notes Payable</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
March 2023, the Company issued a convertible promissory note payable (the &#8220;Convertible Promissory Notes Payable&#8221;) with an
aggregate principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zSt33ZPaLgC6"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-03-31_custom_ConvertiblePromissoryNotesPayableMember" id="Fact001150" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to a non-related third party. <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDateDescription_c20230301__20230331__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zteyJ4NdrUT2"><ix:nonNumeric contextRef="From2023-03-012023-03-31_custom_ConvertiblePromissoryNotesPayableMember" id="Fact001151" name="us-gaap:DebtInstrumentMaturityDateDescription">The
Convertible Promissory Note Payable had a maturity date of 18 months from the date of issuance.</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
note carries interest at a rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_z4bB1vxqxWS1"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-03-31_custom_ConvertiblePromissoryNotesPayableMember" id="Fact001152" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
annually, which is payable every six (6) months from the date of the note until the maturity date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 9, 2024, the Company and the loan holder signed an extension to extend the maturity date from September 20, 2024 to October
20, 2024 with the option for the Company to further extend the maturity date two times, each by an additional 30-day period. The
Company exercised both options to extend the maturity date to December 19, 2024 which included interest previously payable as well as the principal. As consideration for extending the maturity date,
the Company amended the form of repayment of the remaining interest due on the loan. As payment for the interest, the Company issued
the loan holder, (i) $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241009__20241009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJLbnt57xAil" title="Issuance of shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-10-092024-10-09_us-gaap_CommonStockMember" id="Fact001154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,000</ix:nonFraction></span>&#160;worth
of Common Stock to be issued at the closing market price on the date prior to issuance and (ii)&#160;<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241009__20241009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z95rpcx4AkH3" title="Iissuance of loan shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-10-092024-10-09_us-gaap_CommonStockMember" id="Fact001156" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span>&#160;shares
of Common Stock. On October 11, 2024, the Company issued the loan holder&#160;<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241011__20241011__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT3s4zQhlqb9" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-10-112024-10-11_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember" id="Fact001158" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,812</ix:nonFraction></span>&#160;shares
of Common Stock in satisfaction of the obligations in (i) and (ii) in the preceding sentence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extension met the criteria for as a debt extinguishment under ASC 470-50. As of October 9, 2024, the Company recorded a gain on debt extinguishment
of $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20241009__20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember_zIbN1jvX9LD5" title="Gain on debt extinguishment"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-10-092024-10-09_custom_ConvertiblePromissoryNotePayableMember" id="Fact001160" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million, calculated as the difference between (i) the $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmFpPpxrJ4Wc" title="Convertible promissory notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2024-10-09_custom_ConvertiblePromissoryNotePayableMember_us-gaap_CommonStockMember" id="Fact001162" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction> </span>million
carrying value of the Convertible Promissory Note Payable immediately prior to the amendment (ii) the $<span id="xdx_909_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zofRopCmLZXi" title=" Fair value convertible promissory notes payable"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="AsOf2024-10-09_custom_ConvertiblePromissoryNotePayableMember_us-gaap_CommonStockMember" id="Fact001164" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span>
million fair value of the Convertible Promissory Note Payable immediately after the amendment and (iii) the $<span id="xdx_90D_eus-gaap--StockIssued1_pn5n6_c20241009__20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFn0zJY3JUHa" title="Stock issued"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2024-10-092024-10-09_custom_ConvertiblePromissoryNotePayableMember_us-gaap_CommonStockMember" id="Fact001166" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span>
million fair value of the shares issued to the holder as consideration for extending the maturity date. The difference between the
$<span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqxlqRj8N0F4" title="Carrying value"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-10-09_custom_ConvertiblePromissoryNotePayableMember_us-gaap_CommonStockMember" id="Fact001168" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction> </span>million
carrying value immediately prior to the amendment and the $<span id="xdx_908_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7D6uvshsWY9" title="Stock issued"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="AsOf2024-10-09_custom_ConvertiblePromissoryNotePayableMember_us-gaap_CommonStockMember" id="Fact001170" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span>
million fair value immediately after the amendment was recorded as a debt discount and amortized over the amended maturity date of
the Convertible Promissory Note using the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the extension of the loan, the Company entered into a consulting agreement with an unrelated third party to negotiate
the extension of the of the convertible note with the loan holder on behalf of the Company. The Company issued the third-party&#160;<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241011__20241011__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zHOOv6aVMCIc" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-10-112024-10-11_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember_custom_ConsultingAgreementMember" id="Fact001172" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,500</ix:nonFraction></span>&#160;shares
on October 11, 2024, in exchange for services provided. The fair value of the shares were $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20241010__20241010__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zZfyFIvPavT6" title="Fair value of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-10-102024-10-10_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember_custom_ConsultingAgreementMember" id="Fact001174" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million, as determined
by multiplying the closing share price on October 10, 2024 (day prior to issuance) of $<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20241010__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_znTcvRKg1Io1" title="Issuance of shares"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-10-10_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember_custom_ConsultingAgreementMember" id="Fact001176" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.24</ix:nonFraction></span> by the total number of shares issued, <span id="xdx_900_eus-gaap--SharesIssued_iI_pid_c20241010__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z9uR7IPV2N22" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-10-10_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember_custom_ConsultingAgreementMember" id="Fact001178" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,500</ix:nonFraction></span>.
This amount was capitalized as a debt issuance cost and accreted over the amended term of the Convertible Promissory Notes Payable
using the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, and December 31, 2023, the Company incurred interest expense on the Convertible Promissory Note
Payable of $<span id="xdx_902_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zywh8nK8E95" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember" id="Fact001180" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span>
million and $<span id="xdx_909_eus-gaap--InterestExpenseDebt_pn5n6_c20230101__20231231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zTNr3EzMtwA9" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-01-012023-12-31_custom_ConvertiblePromissoryNotesPayableMember" id="Fact001182" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million, respectively. The promissory note payable remained outstanding as of December 31, 2024, therefore the Company was
considered to be in default. On March 6, 2025, the Company reached an agreement with the loan holder to pay $<span id="xdx_906_eus-gaap--RepaymentsOfConvertibleDebt_pn5n6_c20250306__20250306__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztEPp1HVmk71" title="Settlement of debt"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2025-03-062025-03-06_custom_TwentyTwentyThreeConvertibleNoteMember_us-gaap_SubsequentEventMember" id="Fact001184" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span>
million in order to settle the March 2023 Convertible Note in full. The Company repaid the loan holder the settlement amount $<span id="xdx_908_eus-gaap--RepaymentsOfConvertibleDebt_pn5n6_c20250313__20250313__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXIbN89pBUW6" title="Settlement of debt"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2025-03-132025-03-13_custom_TwentyTwentyThreeConvertibleNoteMember_us-gaap_SubsequentEventMember" id="Fact001186" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span>
million on March 13, 2025. See Note 20 for additional details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>August
2024 Nirland Note</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 6, 2024, the Company entered into a Senior Secured Promissory Note (the &#8220;August 2024 Nirland Note&#8221;) with Nirland,
a related party of the Company, pursuant to which the Company issued and sold to Nirland the August 2024 Note in the original principal
amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_z4aywVAoRh0c" title="Original principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember" id="Fact001188" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span> million, inclusive of a $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zn5ojNRRbKbg" title="Original issue discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember" id="Fact001190" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million&#160;original issuance discount. See Note 16 for further reference to the relationship
between the Company and Nirland. Of the total amount of the August 2024 Nirland Note, $<span id="xdx_90F_ecustom--DebtIssuedUponExecution_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zcfdqWwJPU1c" title="Debt issued upon execution"><ix:nonFraction name="CDT:DebtIssuedUponExecution" contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember" id="Fact001192" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million&#160;was issued upon execution of
the August 2024 Nirland Note. In connection with the August 2024 Nirland Note, the Company issued to Nirland&#160;<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240806__20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_ze2WEpY7UvU6" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-08-062024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember" id="Fact001194" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000</ix:nonFraction></span>&#160;shares
of the Company&#8217;s Common Stock on August 6, 2024. The balance of $<span id="xdx_906_ecustom--PaymentOfCommonStock_pn5n6_c20240806__20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zRTY4impwJIc" title="Payment to common stock"><ix:nonFraction name="CDT:PaymentOfCommonStock" contextRef="From2024-08-062024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember" id="Fact001196" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million&#160;became payable to the Company when the shares
were registered for resale in September 2024. In the event the Company completes any public or private equity or debt financing, the
Company shall be required to mandatorily prepay (&#8220;Mandatory Prepayment Right&#8221;), any amounts that may be then outstanding
under the August 2024 Nirland Note, within two business days following the closing of such financing, in an amount of no less than&#160;<span id="xdx_901_ecustom--NetProceedsReceivedPercentage_iI_pid_dp_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zYZi96ueMzx9" title="Net proceeds received, percentage"><ix:nonFraction name="CDT:NetProceedsReceivedPercentage" contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember" id="Fact001198" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">75</ix:nonFraction></span>%
of the net proceeds received. Per the terms of the August 2024 Nirland Note, the Company is prohibited from entering into a variable
rate transaction without prior written consent from Nirland. The August 2024 Nirland Note bears interest at a rate of&#160;<span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zYMZ9grX2c6l" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember" id="Fact001200" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum,
accruing daily on a 365-day basis, payable monthly in arrears as cash, or accrued at Nirland&#8217;s discretion.&#160;<span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateDescription_c20240806__20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zVloMYCgi4b8" title="Debt instrument maturity description"><ix:nonNumeric contextRef="From2024-08-062024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember" id="Fact001202" name="us-gaap:DebtInstrumentMaturityDateDescription">The August 2024
Nirland Note matures 12 months from August 6, 2024.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the Company issued to Nirland&#160;<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240806__20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_zpWUbnDVvPdc"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-08-062024-08-06_custom_SeniorSecuredPromissoryNoteMember" id="Fact001203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000</ix:nonFraction></span>&#160;shares
of the Company&#8217;s Common Stock on August 6, 2024. The Company determined that loan agreement and share issuance should were part
of a basket transaction and allocated the net proceeds on a relative fair value basis. Of the total $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_zchcntSfVCla" title="Net proceeds"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember" id="Fact001205" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.2</ix:nonFraction></span>&#160;net proceeds, $<span id="xdx_90E_eus-gaap--DebtInstrumentFeeAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_z2mTZbn4AQpj" title="Debt instrument allocated"><ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember" id="Fact001207" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span>&#160;million
was allocated to the August 2024 Nirland Note including $<span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_z5UguVrOwkY1" title="Gross proceeds"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember" id="Fact001209" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span>&#160;million gross proceeds, less $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_zwNy0swKsBs9" title="Original issue discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember" id="Fact001211" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span>&#160;million Original Issue Discount
(&#8220;OID&#8221;). The remaining $<span id="xdx_90F_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLVaNSqTG902" title="Remaining allocated to common stock"><ix:nonFraction name="us-gaap:DebtDefaultLongtermDebtAmount" contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_us-gaap_CommonStockMember" id="Fact001213" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span>&#160;million was allocated to the common stock, including $<span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFtYXaezSCsg" title="Gross proceeds"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_us-gaap_CommonStockMember" id="Fact001215" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span>&#160;million gross proceeds less
$<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5XBaVbuWEp1" title="Debt instrument, orginal issue discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_us-gaap_CommonStockMember" id="Fact001217" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>&#160;OID. The $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9Vd3RGXSuRl"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2024-08-06_us-gaap_CommonStockMember" id="Fact001218" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span>&#160;million allocated to the common stock was considered to be a discount on the August 2024 Nirland Note making
the balance of the note to be $<span id="xdx_90E_eus-gaap--NotesPayable_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_zkjH9shq4TCb" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember" id="Fact001220" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span>&#160;million note payable, less a total debt discount of $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806_zB96tVDytGSf" title="Total debt discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2024-08-06" id="Fact001222" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span>&#160;million. The debt discount will
be amortized to interest expense using the effective interest method over the life of the note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 31, 2024, the Company and Nirland amended the August 2024 Nirland Note (the &#8220;First Amendment&#8221;), whereby the August
2024 Nirland Note was amended to (i) provides for the conversion of the August 2024 Nirland Note into shares of Common Stock, at Nirland&#8217;s
discretion, in a multiple of any unpaid amounts, if not otherwise previously paid, pursuant to the conversion rate contained therein,
(ii) removes Nirland&#8217;s Mandatory Prepayment Right, and (iii) removes Nirland&#8217;s right of first refusal to participate in any
future equity or debt offerings of the Company. The number of shares of Common Stock issuable upon conversion of any Conversion Amount
pursuant to&#160;shall be determined by dividing (x) such conversion amount by (y) the conversion price. Conversion amount means two
and one quarter times the sum of (x) portion of the principal to be converted, redeemed or otherwise with respect to which this determination
is being made and (y) all accrued and unpaid interest with respect to such portion of the principal amount, if any. Conversion price
means, as of any conversion date or other date of determination, $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241031__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentNirlandNoteMember_zDeCD5m9M4U6" title="Conversion price per share"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-10-31_custom_FirstAmendmentNirlandNoteMember" id="Fact001224" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span>, subject to adjustment as provided within the amended agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluated the conversion feature of this note offering for embedded derivatives in accordance with&#160;ASC 815,&#160;<i>Derivatives
and Hedging</i>, and the&#160;substantial premium model&#160;in accordance with&#160;ASC 470,&#160;<i>Debt</i>. Based on our assessment,
separate accounting for the conversion feature of this note offering is not required and will be accounted for under the substantial
premium model. Under the substantial premium model, the excess above the fair value of the August 2024 Nirland Note will be recorded
in additional paid-in-capital. The August 2024 Nirland Note will be carried at amortized cost using the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the fair value of the August 2024 Nirland Note to be $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn5n6_c20241031__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zrZWpx4kR3Qe" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2024-10-31_custom_NirlandLimitedMember_custom_FirstAmendmentMember" id="Fact001226" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.6</ix:nonFraction></span> million as of October 31, 2024 through the use of a binomial
lattice model. See Note 3 for additional information regarding the fair value measurement of the August 2024 Nirland Note. The Company
accounted for the First Amendment as a debt extinguishment, as the First Amendment added a substantive conversion option. As of October
31, 2024, a loss on debt extinguishment of $<span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20241031__20241031__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zeHigcpOxwx3" title="Gain on debt extinguishment"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-10-312024-10-31_custom_NirlandLimitedMember_custom_FirstAmendmentMember" id="Fact001228" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.2</ix:nonFraction></span> million was recorded consisting of (i) the derecognition of the $<span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241031__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zBu6SkXPjVui" title="Carrying value"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-10-31_custom_NirlandLimitedMember_custom_FirstAmendmentMember" id="Fact001230" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million carrying
value immediately prior to the First Amendment (ii) recognition of the $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleLiquidationPreferenceValue_iI_pn5n6_c20241031__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zmigBlPDP8xg" title="Par value"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleLiquidationPreferenceValue" contextRef="AsOf2024-10-31_custom_NirlandLimitedMember_custom_FirstAmendmentMember" id="Fact001232" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span> million par value and (iii) recognition of the $<span id="xdx_905_eus-gaap--ConvertibleDebt_iI_pn5n6_c20241031__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zyi6IJegKsL1" title="Convertible debt"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2024-10-31_custom_NirlandLimitedMember_custom_FirstAmendmentMember" id="Fact001234" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million
substantial premium.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 22, 2024, the Company and Nirland entered into a Second Amendment to the August 2024 Nirland Note (the &#8220;Second
Amendment&#8221;). Pursuant to the Second Amendment, the Nirland Note may not be converted (other than partial conversions that may
be permitted pursuant to the rules and regulations of NASDAQ (or any successor entity)) prior to receipt of stockholder approval to
provide for such conversion of the Nirland Note, and subsequent issuance of the Company&#8217;s Common Stock, pursuant to the
stockholder approval rules under the rules and regulations of The Nasdaq Stock Market. If the Company has not held a special meeting
of the stockholders to approve the full conversion of the August 2024 Nirland Note on or before January 9, 2025, then the Company
shall be obligated to pay Nirland a penalty of $<span id="xdx_90C_ecustom--PenaltyPayment_pn5n6_c20241122__20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_zdhMSGQdaJdb" title="Penalty payment"><ix:nonFraction name="CDT:PenaltyPayment" contextRef="From2024-11-222024-11-22_custom_SecondAmendmentNirlandNoteMember" id="Fact001236" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million per day until the special meeting is held. In addition, the existing conversion rate was amended to be two and one half
times the sum of (x) the portion of the principal to be converted, redeemed or otherwise with respect to which this determination is
being made and (y) all accrued and unpaid interest (including default interest) with respect to such portion of the principal
amount, if any divided by $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_zgB7uEnKa4J4" title="Conversion price per share"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-11-22_custom_SecondAmendmentNirlandNoteMember" id="Fact001238" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></span>, prior to the Reverse Stock Split, (or following any reverse splits that may occur in a ratio greater than 10 to 1, the lower of
such reverse split price and the market price per share at the time of the Conversion Date, but in no event less than $1.00),
subject to adjustment as provided therein and to take into account any future share splits or reverse splits to maintain the
economic equivalence of the conversion rights as at the amendment effective date. The Company notes that the reverse split provision
in the preceding sentence was tripped, effective January 25, 2025, following the <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20241122__20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_ziFQJkwQFaxd" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-11-222024-11-22_custom_SecondAmendmentNirlandNoteMember" id="Fact001240" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-100</ix:nonNumeric></span>
reverse stock split that occurred on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the Second Amendment, the Company elected to account for the August 2024 Nirland Note at fair value under ASC 825. The Company determined that the amendment to the conversion features present in the Second Amendment fall under the
guidance within ASC 825 that notes that if a significant modification of debt occurs an entity is able to make an accounting election
on that date to account for that debt under the fair value option. At the end of each
reporting period, the Company calculates the fair value of the August 2024 Nirland Note, and any changes in fair value are reported in
the current period&#8217;s consolidated statements of operations and comprehensive income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company remeasured the fair value of the August 2024 Nirland Note as of the Second Amendment date and calculated a fair value of $<span id="xdx_904_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pn5n6_c20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_zhjAG02gNknd" title="Fair value"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="AsOf2024-11-22_custom_SecondAmendmentNirlandNoteMember" id="Fact001242" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span>
million using a binomial lattice model. See Note 3 for additional information regarding the fair value measurement of the August 2024
Nirland Note. The Company accounted for the Second Amendment as a debt extinguishment, as the terms of the August 2024 Nirland Note were
deemed to be substantially different after the Second Amendment. As of November 22, 2024, a loss on debt extinguishment of $<span id="xdx_906_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20241122__20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_zNCj0bxYUXA8" title="Loss on debt extinguishment"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-11-222024-11-22_custom_SecondAmendmentNirlandNoteMember" id="Fact001244" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span> million
was recorded consisting of (i) the derecognition of the <span id="xdx_907_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241122__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentNirlandNoteMember_zbCuY3YFpPYg" title="Carrying value"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-11-22_custom_FirstAmendmentNirlandNoteMember" id="Fact001246" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span> million carrying value immediately prior to the First Amendment (ii) derecognition
of $<span id="xdx_903_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20241122__20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_zWAnbk72OOYi" title="Accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2024-11-222024-11-22_custom_SecondAmendmentNirlandNoteMember" id="Fact001248" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million in accrued interest (iii) derecognition of the $<span id="xdx_90A_eus-gaap--ConvertibleDebt_iI_pn5n6_c20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentMember_zpNls8sqTQsd" title="Convertible debt"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2024-11-22_custom_SecondAmendmentMember" id="Fact001250" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million substantial premium and (iv) recognition of the $<span id="xdx_907_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241122__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zt5Bc81OACHf" title="Debt instrument fair value"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="AsOf2024-11-22_custom_FirstAmendmentMember" id="Fact001252" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.4</ix:nonFraction></span> million
fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 9, 2024, and prior to obtaining shareholder approval, Nirland exercised their conversion option and converted $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20241209__20241209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6Ae9LQD4f87" title="Conversion option"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2024-12-092024-12-09_us-gaap_CommonStockMember" id="Fact001254" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million of
principal for<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20241209__20241209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaS6x1SGLbr5" title="Conversion shares"> <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2024-12-092024-12-09_us-gaap_CommonStockMember" id="Fact001256" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,000</ix:nonFraction></span> shares of common stock pursuant to the rules and regulations of the NASDAQ. As of December 31, 2024, $<span id="xdx_90A_eus-gaap--InterestPayableCurrent_iI_pn5n6_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFyyYlEIxbej" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact001258" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.6</ix:nonFraction></span> million
of principal and accrued interest remains outstanding. As of December 31, 2024, the August 2024 Nirland Note had a fair value of approximately $<span id="xdx_903_eus-gaap--NotesPayableFairValueDisclosure_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zcGh1zoWf7V8" title="Payable at fair value"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember" id="Fact001260" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span> million and is included
within <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible promissory notes payable at fair value &#8211;
related parties on the consolidated balance sheets. </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, the Company recorded a $<span id="xdx_905_eus-gaap--DebtSecuritiesTradingGainLoss_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zWdchzUgyU72" title="Fair value of convertible promissory notes"><ix:nonFraction name="us-gaap:DebtSecuritiesTradingGainLoss" contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember" id="Fact001262" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span>&#160;million
gain from the change in fair value of convertible promissory note and interest expense of approximately $<span id="xdx_901_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zygE3Z8TCqve" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember" id="Fact001264" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span>
million. The interest expense of $<span id="xdx_901_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zO3CSBKmcCkd" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember" id="Fact001266" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million is comprised of (i) accrued interest of $<span id="xdx_902_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zH3SjwvshHuc" title="Accured interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember" id="Fact001268" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million and (ii) $<span id="xdx_90D_eus-gaap--AdjustmentForAmortization_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zlheVdlpiZal" title="Amortization expenses"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember" id="Fact001270" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million in
amortization expense related to the initial debt discount of $<span id="xdx_902_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zzS38OQIM9J3" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember" id="Fact001272" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million. The $<span id="xdx_90E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--TypeOfArrangementAxis__custom--FirstAmendmentMember_zXAvcfi2szHe" title="Loss on debt extinguishment"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember_custom_FirstAmendmentMember" id="Fact001274" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.2</ix:nonFraction></span>
million loss on debt extinguishment from the Frist Amendment, $<span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentMember_zMynDIssUDC" title="Loss on debt extinguishment"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember_custom_SecondAmendmentMember" id="Fact001276" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span>
million loss on debt extinguishment from the Second Amendment, and the $<span id="xdx_90A_ecustom--GainOnChangeInFairValue_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zSKb0HdeoUhg" title="Gain on change in fair value"><ix:nonFraction name="CDT:GainOnChangeInFairValue" contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember" id="Fact001278" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span>
million gain on the change in fair value are presented within other income (expense), net, while the $<span id="xdx_90D_eus-gaap--InterestIncomeExpenseNonoperatingNet_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zoJD0F3dyi17" title="Interest expense net"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember" id="Fact001280" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span>
million of interest expense is presented within Interest expense, net, in the consolidated statement of operations and comprehensive
income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A.G.P.
Convertible Note</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 25, 2024, the Company issued to A.G.P. a convertible promissory note (the &#8220;A.G.P. Convertible Note&#8221;) in the principal
amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zSuHMwrKtMC9" title="Debt instrument face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember" id="Fact001282" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.7</ix:nonFraction></span> million to evidence the A.G.P.&#8217;s currently owed deferred commission payable. Refer to the Note 9 for additional
information. Unless earlier converted as specified in the Convertible Note, the principal amount, plus all accrued but unpaid interest,
is due on November 25, 2025 (the &#8220;Maturity Date&#8221;). The convertible promissory note accrues interest at <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_z5JFikkkOLD3" title="Convertible notes interest per annum"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember" id="Fact001284" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.5</ix:nonFraction></span>% per annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any time prior to the full payment of the convertible promissory note, provided that the A.G.P. has given at least three business
days written notice to the Company, A.G.P., in its sole discretion, may elect to have all or any portion of the outstanding
principal amount and all interest accrued converted into shares of the Company&#8217;s common stock, at a fixed price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_ziG7WomMJ154" title="Fixed price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember" id="Fact001286" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span>
(or following any reverse splits that may occur in a ratio greater than 10 to 1, the lower of such reverse split price and the
market price per share at the time of the conversion date, but in no event less than $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zDy9G8AqD5j7" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember" id="Fact001288" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span>),
subject to adjustment as provided therein and to take into account any future share splits or reverse splits. <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_pid_c20250125__20250125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zO6Iz6UrLM12" title="Reverse stock split, description"><ix:nonNumeric contextRef="From2025-01-252025-01-25_custom_AllianceGobalPartnersConvertibleNoteMember_us-gaap_SubsequentEventMember" id="Fact001290" name="us-gaap:StockholdersEquityReverseStockSplit">The
Company notes that the reverse split provision in the preceding sentence was tripped, effective January 25, 2025, following the 1-for-100 reverse stock split
that occurred on that date</ix:nonNumeric></span>. However, the conversion of the convertible promissory note may not occur prior to the
Company having sufficiently authorized shares of common stock to permit the entire conversion of the convertible promissory note. In
addition, the conversion of the convertible promissory note may also not occur prior to receipt of stockholder approval to provide
for such conversion of the convertible promissory note, and subsequent issuance of the Company&#8217;s common stock, pursuant to the
stockholder approval rules under the rules and regulations of The Nasdaq Stock Market. Further, following the A.G.P.&#8217;s ability
to convert the convertible promissory note, if at all, A.G.P. will not be entitled to receive the Company&#8217;s common stock upon
conversion, if such conversion would result in A.G.P. owning greater than <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zmTWFk59Tfbl" title="Conversion percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember" id="Fact001292" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>%
of the Company&#8217;s then currently outstanding common stock. A.G.P. is also entitled to resale registration rights as identified
in the convertible promissory note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may prepay the convertible promissory note in whole or in part. In the event of certain Events of Default (as defined in the
convertible promissory note), all outstanding principal and accrued interest under the Convertible Note will become, or may become at
A.G.P.&#8217;s election, immediately due and payable to the A.G.P.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company elected to account for the A.G.P. Convertible Note at fair value under ASC 825. The Company determined that the substantive
conversion option within the A.G.P. Convertible Note falls under the guidance within ASC 825 that notes that if a significant
modification of debt occurs an entity is able to make an accounting election on that date to account for that debt under the fair
value option. At the end of each reporting period, the Company calculates the fair value of the A.G.P. Convertible Note, and any
changes in fair value are reported in the current period&#8217;s consolidated statements of operations and comprehensive income
(loss). The change in fair value attributable to instrument-specific credit risk, if any, will be recognize within other
comprehensive income each reporting period. As an accounting policy, the Company elected to present interest expense separately from
other changes in the A.G.P. Convertible Note&#8217;s fair value. Interest expense will be presented within Interest expense, net,
while the other changes in the fair value with be presented within other income (expense), net in the consolidated statements of
operations and comprehensive income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the fair value of the A.G.P. Convertible Note to be $<span id="xdx_909_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pn5n6_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zjYQeviNrtcl" title="Fair value of convertible note"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember" id="Fact001294" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.4</ix:nonFraction></span> million as of November 25, 2024 through the use of a binomial
lattice model. See Note 3 for additional information regarding the fair value measurement of the A.G.P Convertible Promissory Note. The
Company accounted for the issuance on the A.G.P. Convertible Promissory Note as a debt extinguishment, as it was issued to evidence the
A.G.P.&#8217;s currently owed deferred commission payable discussed in Note 9. A gain on debt extinguishment of $<span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20241125__20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zA3dsNlKqew3" title="Gain on debt extinguishment"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-11-252024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember" id="Fact001296" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million was recorded
as of November 25, 2024, consisting of (i) the derecognition of the $<span id="xdx_90C_ecustom--DeferredCommissionPayable_iI_pn5n6_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zoIY0oGukjih" title="Deferred commission payable"><ix:nonFraction name="CDT:DeferredCommissionPayable" contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember" id="Fact001298" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.7</ix:nonFraction></span> million deferred commission payable and (ii) recognition of
the $<span id="xdx_907_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zKomL3d4W2Tj" title="Fair value of convertible note"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember" id="Fact001300" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.4</ix:nonFraction></span> million fair value of the A.G.P. Convertible Note. For the year ended December 31, 2024, the Company recorded a $<span id="xdx_90E_ecustom--GainOnChangeInFairValue_pn5n6_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zfqidlawkTsd" title="Gain on change in fair value"><ix:nonFraction name="CDT:GainOnChangeInFairValue" contextRef="From2024-01-012024-12-31_custom_AllianceGobalPartnersConvertibleNoteMember" id="Fact001302" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span>&#160;million
gain in the change in fair value of the A.G.P. Convertible Note and interest expense of approximately $<span id="xdx_900_eus-gaap--InterestExpenseDebt_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zBS52vGGfOvj" title="Interest expense debt"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2024-01-012024-12-31_custom_AllianceGobalPartnersConvertibleNoteMember" id="Fact001304" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction></span> thousand. The $<span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zHlRnK0oina7" title="Gain on debt extinguishment"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-012024-12-31_custom_AllianceGobalPartnersConvertibleNoteMember" id="Fact001306" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million
gain on extinguishment and $<span id="xdx_90F_ecustom--GainOnChangeInFairValueOfConvertibleNote_pn5n6_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_z5asJdUCpdaj" title="Gain on change in fair value of convertible note"><ix:nonFraction name="CDT:GainOnChangeInFairValueOfConvertibleNote" contextRef="From2024-01-012024-12-31_custom_AllianceGobalPartnersConvertibleNoteMember" id="Fact001308" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million gain on the change in fair value are presented within other income (expense), net, while the
$<span id="xdx_90D_eus-gaap--InterestIncomeExpenseNonoperatingNet_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zHi93s1To5Rh" title="Interest expense"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2024-01-012024-12-31_custom_AllianceGobalPartnersConvertibleNoteMember" id="Fact001310" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction> </span>thousand of interest expense is presented within Interest expense, net, in the consolidated statement of operations and comprehensive
income (loss).</span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001312" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_zqaxLvbOUin1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_820_zGCsXPJkl3c7">Loans Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loans</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2022, the Company entered into Loan Agreements (the &#8220;Loans&#8221;) with two lenders, totaling $<span id="xdx_906_eus-gaap--LoansPayable_iI_pn5n6_c20220501__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_zZYgh4PKbNoj"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-05-01_custom_LoanAgreementsMember" id="Fact001313" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million. <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateDescription_c20220501__20220501__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_z9QoObv7fxcl"><ix:nonNumeric contextRef="From2022-05-012022-05-01_custom_LoanAgreementsMember" id="Fact001314" name="us-gaap:DebtInstrumentMaturityDateDescription">The Loans
mature two years from the date of the agreement and bear no interest.</ix:nonNumeric></span> Each loan was made available to the Company by the lenders in
three tranches of (i) $<span id="xdx_90F_eus-gaap--LoansPayable_iI_pn3n3_c20220501__us-gaap--AwardTypeAxis__custom--TrancheOneMember_zz1Alc6UY8J7"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-05-01_custom_TrancheOneMember" id="Fact001315" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></span> thousand (&#163;<span id="xdx_904_eus-gaap--LoansPayable_iI_pn3n3_uGBP_c20220501__us-gaap--AwardTypeAxis__custom--TrancheOneMember_zLhFVV7tbOYd"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-05-01_custom_TrancheOneMember" id="Fact001316" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="GBP">30</ix:nonFraction></span> thousand); (ii) $<span id="xdx_908_eus-gaap--LoansPayable_iI_pn3n3_c20220501__us-gaap--AwardTypeAxis__custom--TrancheTwoMember_zxUgMOgIz6Lj"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-05-01_custom_TrancheTwoMember" id="Fact001317" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></span> thousand (&#163;<span id="xdx_906_eus-gaap--LoansPayable_iI_pn3n3_uGBP_c20220501__us-gaap--AwardTypeAxis__custom--TrancheTwoMember_zrRZvIUlzBC9"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-05-01_custom_TrancheTwoMember" id="Fact001318" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="GBP">30</ix:nonFraction></span> thousand) and (iii) $<span id="xdx_902_eus-gaap--LoansPayable_iI_pn3n3_c20220501__us-gaap--AwardTypeAxis__custom--TrancheThreeMember_zuacbFWSNf4"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-05-01_custom_TrancheThreeMember" id="Fact001319" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></span> thousand (&#163;<span id="xdx_907_eus-gaap--LoansPayable_iI_pn3n3_uGBP_c20220501__us-gaap--AwardTypeAxis__custom--TrancheThreeMember_zdlk1x920wa8"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-05-01_custom_TrancheThreeMember" id="Fact001320" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="GBP">25</ix:nonFraction></span>
thousand), totaling $<span id="xdx_903_eus-gaap--LoansPayable_iI_pn5n6_c20220501_z3Pf4rrrpxr4"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-05-01" id="Fact001321" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million. The Loans provided for events of default, including, among others, failure to make payment,
bankruptcy and non-compliance with the terms of the Loans. As of December 31, 2024, the Company utilized all three tranches of the
first loan and two out of three tranches of the second loan, with loans payable totaling $<span id="xdx_906_eus-gaap--LoansPayable_iI_pn5n6_c20241231_zsmPi7mTDGOi"><span id="xdx_907_eus-gaap--LoansPayable_iI_pn5n6_c20231231_zF5y5rjDoy97"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2024-12-31" id="Fact001322" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2023-12-31" id="Fact001323" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></ix:nonFraction></span></span> million at December 31, 2023 and
December 31, 2024 respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 9, 2024, the Company and the Loans holders amended the loan agreements (the &#8220;Loans Amendment&#8221;) to extend the maturity
date for the Loans to&#160;<span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20241009__20241009_zpDK1htzGvt5" title="Maturity date"><ix:nonNumeric contextRef="From2024-10-092024-10-09" format="ixt:datemonthdayyearen" id="Fact001325" name="us-gaap:DebtInstrumentMaturityDate">December 19, 2024</ix:nonNumeric></span>. The Loans Amendment also modified the payment terms for the Loans from a cash payment of
&#163;<span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_uGBP_c20241009__20241009_z97DrB6edE26" title="Payment terms for loan payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2024-10-092024-10-09" id="Fact001327" format="ixt:numdotdecimal" decimals="0" unitRef="GBP">85,000</ix:nonFraction></span>&#160;per loan to (1) a cash payment of &#163;<span id="xdx_903_eus-gaap--RepaymentsOfNotesPayable_uGBP_c20241009__20241009_zJplNaQtoFv2" title="Cash payment"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2024-10-092024-10-09" id="Fact001329" format="ixt:numdotdecimal" decimals="0" unitRef="GBP">60,000</ix:nonFraction></span>, (2) &#163;<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_uGBP_c20241009__20241009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ6untE11eI4" title="Common stock converted"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2024-10-092024-10-09_us-gaap_CommonStockMember" id="Fact001331" format="ixt:numdotdecimal" decimals="0" unitRef="GBP">25,000</ix:nonFraction></span>&#160;worth of shares of Common Stock converted
into USD at the prevailing exchange rate, to be issued at the closing market price on the date prior to issuance, and in consideration
for the extension, and (3)&#160;<span id="xdx_90D_ecustom--StockIssuedDuringPeriodAdditionalSharesIssued_c20241009__20241009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1t3h5UI57Ua" title="Additional shares issued"><ix:nonFraction name="CDT:StockIssuedDuringPeriodAdditionalSharesIssued" contextRef="From2024-10-092024-10-09_us-gaap_CommonStockMember" id="Fact001333" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500</ix:nonFraction></span>&#160;additional shares of Common stock. On October 11, 2024, the Company issued each of the Loan
holders&#160;<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241011__20241011__us-gaap--InvestmentTypeAxis__custom--LoanHoldersMember_zGx3lEWyZn46" title="Shares issued during period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-10-112024-10-11_custom_LoanHoldersMember" id="Fact001335" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,690</ix:nonFraction></span>&#160;shares (<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241011__20241011_zuo4h6s4ZTTc" title="Shares issued during period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-10-112024-10-11" id="Fact001337" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,380</ix:nonFraction></span>&#160;in total). The Loans remain outstanding as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extension was accounted for as a debt extinguishment. On October 9, 2024, the Company recorded a loss on debt extinguishment of approximately
$<span id="xdx_900_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_c20241009__20241009_zUe9pjTbVFBc" title="Loss on debt extinguishment"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-10-092024-10-09" id="Fact001339" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></span> thousand calculated as the difference between (i) the $<span id="xdx_905_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241009_zDyB6BLrTHZd" title="Debt instrument carrying value"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-10-09" id="Fact001341" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million carrying value of the Loans immediately prior to the Loans Amendment
(ii) the $<span id="xdx_908_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241009_zPdAe5Nw9nwi" title="Debt instrument fair value"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="AsOf2024-10-09" id="Fact001343" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million fair value of the Loans immediately after the Loans Amendment and (iii) the $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20241009__20241009_ztnQnbqnspdl" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-10-092024-10-09" id="Fact001345" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million fair value of the shares
issued to the holder as consideration for extending the maturity date. The difference between the $<span id="xdx_905_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241009_zpZYIVIRLHD8" title="Debt instrument carrying value"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-10-09" id="Fact001347" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million carrying value immediately
prior to the Loans Amendment and the $<span id="xdx_908_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241009_zUbmXtLUymHl" title="Debt instrument fair value"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="AsOf2024-10-09" id="Fact001349" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million fair value immediately after the Loans Amendment was recorded as a debt discount and
amortized over the term date of the Loans using the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company incurred interest expense on the Loans of approximately $<span id="xdx_905_eus-gaap--InterestExpenseDebt_pn3n3_c20240101__20241231_zFFAkuIzHpfi"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2024-01-01to2024-12-31" id="Fact001350" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand related to the amortization of the debt
discount recorded as a result of the Loans Amendment. <span id="xdx_907_eus-gaap--InterestExpenseDebt_pn3n3_do_c20230101__20231231_zq7DGNEPhnle"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-01-012023-12-31" id="Fact001351" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD">No
</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interest expense was recorded for the year ended
December 31, 2023. The Loans remained outstanding as of December 31, 2024, therefore the Company was considered to be in default. The
Company repaid the lenders the outstanding principal balance of $<span id="xdx_909_eus-gaap--RepaymentsOfDebt_pn5n6_c20250201__20250228__us-gaap--TypeOfArrangementAxis__custom--LoansAmendmentMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAk9o8ZGLPE4"><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2025-02-012025-02-28_custom_LoansAmendmentMember_us-gaap_SubsequentEventMember" id="Fact001352" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in February 2025. See Note 20 for additional
details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>October
2024 Nirland Note</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 28, 2024, the Company issued a promissory note (the &#8220;October 2024 Nirland Note&#8221;) to Nirland, a related party, in
the original principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241028__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_z2VPzvuBUCe" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember" id="Fact001354" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span>
million in exchange for funds in such amount. See Note 16 for further reference to the relationship between the Company and Nirland.
The Nirland Note bears interest at a rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241028__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember__srt--RangeAxis__srt--MinimumMember_zSmrvO0flhCg" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember_srt_MinimumMember" id="Fact001356" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>%
per annum, is due and payable semi-annually in arrears, and matures on October 31, 2025. If an event of default under and as defined
in the Nirland Note occurs, the interest rate will be increased to <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241028__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember__srt--RangeAxis__srt--MaximumMember_zFAYLqcitnyb" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember_srt_MaximumMember" id="Fact001358" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span>%
per annum or to the maximum rate permitted by law. In connection with the Nirland Note, the Company has agreed to pay Nirland a <span id="xdx_903_ecustom--ArrangementFeePercentage_pid_dp_c20241028__20241028__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zlCIe1omRMua" title="Arrangement fee percentage"><ix:nonFraction name="CDT:ArrangementFeePercentage" contextRef="From2024-10-282024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember" id="Fact001360" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>%
arrangement fee, which will be included with the principal and interest owed under the Nirland Note. The <span id="xdx_903_ecustom--ArrangementFeePercentage_pid_dp_c20241028__20241028__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zoPS1WcAXMQ" title="Arrangement fee percentage"><ix:nonFraction name="CDT:ArrangementFeePercentage" contextRef="From2024-10-282024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember" id="Fact001362" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>%
arrangement fee is accounted for as a debt discount and will be amortized to interest expense, net in the consolidated statement of
operations and comprehensive income (loss) using the effective interest method over the life of the October 2024 Nirland
Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company recorded approximately $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zU05k46ODRQ9" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2024-01-012024-12-31_custom_OctoberTwoThousandTwentyFourNirlandNoteMember" id="Fact001364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of interest expense. The interest expense of $<span id="xdx_905_eus-gaap--InterestExpense_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zNe4PWTonRw" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-012024-12-31_custom_OctoberTwoThousandTwentyFourNirlandNoteMember" id="Fact001366" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,000</ix:nonFraction></span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">is comprised of (i) accrued interest of $<span id="xdx_905_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zbGWkAjldhsc" title="Accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2024-01-012024-12-31_custom_OctoberTwoThousandTwentyFourNirlandNoteMember" id="Fact001368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">based on the coupon rate of the debt and (ii) amortization of the debt discount of $<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zzZxlEXxlp9j" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-012024-12-31_custom_OctoberTwoThousandTwentyFourNirlandNoteMember" id="Fact001370" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand,
with both components recorded within interest expense, net in the consolidated statement of operations and comprehensive income
(loss). Accrued interest of $<span id="xdx_90D_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zgg8SnxuywMh" title="Accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2024-01-012024-12-31_custom_OctoberTwoThousandTwentyFourNirlandNoteMember" id="Fact001372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was recorded as a liability on the Company&#8217;s consolidated balance sheet within accrued expenses and other current liabilities.
The $<span id="xdx_901_eus-gaap--AmortizationOfDebtDiscountPremium_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zuLhTAkhP266" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-012024-12-31_custom_OctoberTwoThousandTwentyFourNirlandNoteMember" id="Fact001374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amortization of the debt discount decreased the debt discount contra-liability included within the Loans payable, current portion on
the consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A.G.P.
Bridge Note</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 29, 2024, the Company entered into a Bridge Loan Agreement (the &#8220;Bridge Agreement&#8221;), with A.G.P., pursuant to which
AGP. made an advance (the &#8220;Advance&#8221;) to the Company in an amount not to exceed $<span id="xdx_901_ecustom--CommitmentFees_pn5n6_c20241029__20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_z6y0OuIQip53"><ix:nonFraction name="CDT:CommitmentFees" contextRef="From2024-10-292024-10-29_custom_BridgeLoanAgreementMember" id="Fact001375" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million (the &#8220;Commitment&#8221;).
As partial consideration for the Advance, the Company entered into a Common Stock Purchase Warrant Agreement (the &#8220;Warrant Agreement&#8221;)
and issued AGP warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zrcVNxYnLyH" title="Shares issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-10-29_custom_BridgeLoanAgreementMember" id="Fact001377" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,625</ix:nonFraction></span> shares of the Company&#8217;s common stock, $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zsDornk4mrii" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-10-29_custom_BridgeLoanAgreementMember" id="Fact001379" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value per share, which is equal
to <span id="xdx_904_ecustom--CommonStockClosingPricePercentage_iI_pid_dp_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_z0RECplG9Ln9"><ix:nonFraction name="CDT:CommonStockClosingPricePercentage" contextRef="AsOf2024-10-29_custom_BridgeLoanAgreementMember" id="Fact001380" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of the sum of the Commitment divided by the closing price of the Company&#8217;s Common Stock on October 29, 2024, at an exercise
price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zi0sXjQo6jYg"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-10-29_custom_BridgeLoanAgreementMember" id="Fact001381" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.48</ix:nonFraction></span> per share. Refer to Note 18 for additional information on the warrants issued to A.G.P.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Advance, the Company issued a promissory note (the &#8220;A.G.P. Bridge Note&#8221;) to A.G.P. in the original principal
amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zOKbYeEJkwRc"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-10-29_custom_BridgeLoanAgreementMember" id="Fact001382" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million. The Bridge Note bears interest at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zutQZLuQwIpc"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-10-29_custom_BridgeLoanAgreementMember" id="Fact001383" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.21</ix:nonFraction></span>% per annum and is due and payable on December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted above, the Company issued to A.G.P. warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zv26Nn7i2C56"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-10-29_custom_BridgeLoanAgreementMember" id="Fact001384" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,625</ix:nonFraction></span>
shares of the Company&#8217;s common stock. The Company determined that the Bridge Note and Warrant Agreement issuance were part of
a basket transaction and allocated the net proceeds using the residual value method. The warrants issued under the Warrant Agreement
were initially recorded at their fair value of $<span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20241029__20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zoUZQKyS0hUf" title="Fair value adjustment of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-10-292024-10-29_custom_BridgeLoanAgreementMember" id="Fact001386" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million. The warrants were classified as derivative liabilities because they do not meet the criteria in ASC 815-40 to be considered
indexed to the entity&#8217;s own stock. Refer to Note 18 for additional information and discussion of liability classification. The $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20240806__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zQp4o5bPAUe8" title="Warrants"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2024-08-06_custom_BridgeLoanAgreementMember" id="Fact001388" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>&#160;million
recorded for the warrants was considered to be a discount on the A.G.P. Bridge Note making the balance of the note to be $<span id="xdx_900_eus-gaap--NotesPayable_iI_pn5n6_c20240806__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zFDWwXGpjXfh" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-08-06_custom_BridgeLoanAgreementMember" id="Fact001390" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span>&#160;million
note payable, less a total debt discount of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zMTZ3SlZazye" title="Total debt discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2024-08-06_custom_BridgeLoanAgreementMember" id="Fact001392" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>&#160;million.
The debt discount will be amortized to interest expense using the effective interest method over the life of the note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company recorded and paid approximately $<span id="xdx_90A_eus-gaap--InterestExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zqaBCFM3xzhk" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-012024-12-31_custom_BridgeLoanAgreementMember" id="Fact001394" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span> thousand of interest expense related to the A.G.P. Additionally,
the entire debt discount of $<span id="xdx_900_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zdaPLz5wotdb" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-012024-12-31_custom_BridgeLoanAgreementMember" id="Fact001396" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million was amortized and recorded as interest expense during the year. The interest expense of $<span id="xdx_90C_eus-gaap--InterestExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zCTzKZMBDQyf" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-012024-12-31_custom_BridgeLoanAgreementMember" id="Fact001398" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span> thousand
and amortization of the debt discount of $<span id="xdx_900_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_z0fqAjA52Haa" title="Amortization of debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-012024-12-31_custom_BridgeLoanAgreementMember" id="Fact001400" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million were recorded within Interest expense, net in the consolidated statement of operations
and comprehensive income (loss). As of December 31, 2024, the A.G.P. Bridge note was fully repaid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001402" name="CDT:DeferredCommissionPayableTextBlock"><p id="xdx_80B_ecustom--DeferredCommissionPayableTextBlock_ze7F4iIFqe5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_828_zJpDUtE6Q0L2">Deferred Commission Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 2, A.G.P was a financial advisor to both MURF and Old Conduit in connection with the Merger transaction. Upon the completion
of the Merger, A.G.P.: (i) received a cash fee of $<span id="xdx_900_eus-gaap--ProceedsFromFeesReceived_pn5n6_c20230921__20230922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zyLbAGLrJa71" title="Cash fee received"><ix:nonFraction name="us-gaap:ProceedsFromFeesReceived" contextRef="From2023-09-212023-09-22_custom_AllianceGlobalPartnersMember" id="Fact001404" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.5</ix:nonFraction></span> million, <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230921__20230922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgUEGmx3ucl8" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-09-212023-09-22_custom_AllianceGlobalPartnersMember_us-gaap_CommonStockMember" id="Fact001406" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,000</ix:nonFraction></span> shares of Common Stock, and warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zALiIPeBOtr5" title="Warrants to purchase share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-09-22_custom_AllianceGlobalPartnersMember" id="Fact001408" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">540</ix:nonFraction></span> shares of
Common Stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_z6csMjfMg0F6" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-22_custom_AllianceGlobalPartnersMember" id="Fact001410" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,100</ix:nonFraction></span> per share pursuant to its engagement agreement with Old Conduit entered into on August 2,
2022, and (ii) agreed to defer payment, to be paid in the future under certain circumstances by a date no later than March 21, 2025,
of $<span id="xdx_90E_eus-gaap--PaymentsForFees_pn5n6_c20230921__20230922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zHOGL4kqbFxf" title="Deferred payment fees"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2023-09-212023-09-22_custom_AllianceGlobalPartnersMember" id="Fact001412" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.7</ix:nonFraction></span> million of fees plus annual interest of <span id="xdx_90E_ecustom--DeferredCommissionPayableAnnualInterestRate_iI_pid_dp_c20230922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zCjs9VMyFa57" title="Annual interest rate"><ix:nonFraction name="CDT:DeferredCommissionPayableAnnualInterestRate" contextRef="AsOf2023-09-22_custom_AllianceGlobalPartnersMember" id="Fact001414" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.5</ix:nonFraction></span>% as a result of its engagement for MURF&#8217;s IPO. The $<span id="xdx_90A_ecustom--DeferredCommissionPayableNonCurrent_iI_pn5n6_c20231231__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zU3sT1cp4Dph" title="Deferred commissions payable, non-current liability"><ix:nonFraction name="CDT:DeferredCommissionPayableNonCurrent" contextRef="AsOf2023-12-31_custom_AllianceGlobalPartnersMember" id="Fact001416" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.7</ix:nonFraction></span> million deferred commissions
payable was recorded as a non-current liability on the Company&#8217;s consolidated balance sheet as of December 31, 2023. Accrued interest
was recorded as a liability on the Company&#8217;s consolidated balance sheet under accrued expenses and other current liabilities and
totaled $<span id="xdx_90F_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20241231_zHs1if2qFWY8" title="Accrued expenses and other current liabilities"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact001418" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million and $<span id="xdx_901_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20231231_zm7js835ONB1" title="Accrued expenses and other current liabilities"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact001420" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million as of December 31, 2024, and December 31, 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 25, 2024, the Company issued the A.G.P. Convertible Note in the principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241125__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_z21NUAKr6Ixl" title="Convertible principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-11-25_custom_AllianceGlobalPartnersMember" id="Fact001422" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.7</ix:nonFraction></span> million to evidence the currently owed
deferred commission payable, at which time the deferred commission payable balance was removed. Refer to the Note 7 for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001424" name="CDT:DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock"><p id="xdx_809_ecustom--DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock_zubJDKQDiaY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_829_zjS5XWJP8Onj">Research and Development Expense</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>August
2024 License Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 7, 2024, the Company and AstraZeneca AB (PUBL) (&#8220;AstraZeneca&#8221;) entered into a License Agreement, dated August 7,
2024 (the &#8220;August 2024 License Agreement&#8221;). Pursuant to the August 2024 License Agreement, AstraZeneca agreed to grant a
license to the Company under certain intellectual property rights controlled by AstraZeneca related to HK-4 Glucokinase activators AZD1656
and AZD5658 in all indications and myeloperoxidase inhibitor AZD5904 for the treatment, prevention, and prophylaxis of idiopathic male
infertility. The Company will be responsible for the development and commercialization of the Licensed Products under the August
2024 License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for the grant of the license, the Company (i) granted AstraZeneca Common Stock pursuant to a stock issuance agreement
(the &#8220;Issuance Agreement&#8221;), (ii) paid AstraZeneca an up-front payment of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--AstraZenecaMember_z3zwzbohA6gb"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31_custom_AstraZenecaMember" id="Fact001425" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million,
and (iii) is obligated to pay AstraZeneca a percentage (on a tiered basis) of any amounts it may receive in connection with a grant
of a sublicense (subject to various customary exceptions). The Issuance Agreement called for the Company to issue AstraZeneca <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__dei--LegalEntityAxis__custom--AstraZenecaMember_z0A67zeqVOD6"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_custom_AstraZenecaMember" id="Fact001426" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,044</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
shares of the Company&#8217;s Common Stock. The Issuance Agreement provides AstraZeneca with resale registration rights for such
shares. As of December 31, 2024, the Company recorded $<span id="xdx_901_eus-gaap--GeneralAndAdministrativeExpense_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--AstraZenecaMember_zxoqncFMLZu4"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_AstraZenecaMember" id="Fact001427" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--AstraZenecaMember_zCOxGRIShsJl"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_AstraZenecaMember" id="Fact001428" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
in research and development expenses related to the share issuance and upfront payment to AstraZeneca, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AstraZeneca
has been granted a right of first negotiation to develop, manufacture, and commercialize a Licensed Product if the Company receives an
offer for, or solicits, a transaction where a third party would obtain the right to develop, manufacture, or commercialize a Licensed
Product. If AstraZeneca exercises such right, the parties will negotiate in good faith for an agreed period of time on an exclusive basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
party may terminate the August 2024 License Agreement for material breach (subject to a cure period) or insolvency of the other party.
The Company may terminate the August 2024 License Agreement for convenience (in its entirety or on a Licensed Product-by-Licensed Product
basis). In addition, AstraZeneca may terminate the August 2024 License Agreement in certain circumstances, including (but not limited
to) the Company ceasing development of all Licensed Products (subject to certain exceptions for normal pauses or gaps between clinical
studies).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the above, the Company will no longer fund the development of AZD1656 or AZD5904 under the terms of the Exclusive Funding
Agreement, dated March 26, 2021 with St George Street Capital (the &#8220;Funding Agreement&#8221;). In this regard, the Company previously
entered into a deed of amendment amending such Funding Agreement. The parties agreed that the project funding provisions of such Funding
Agreement whereby the Company had the right to fund a project or refer other parties to St George Street Capital, were amended to provide
that St George Street Capital must still include the Company in any project funding opportunities and requests but may now seek other
third-parties to fund projects in addition to the Company. In November and December 2024, the Company received a letter from St George Street Capital and formal complaints
filed with the Intellectual Property Office claiming the Company was not the sole owner of the AZD 1656 co-crystal patent. See note 15
for additional details on the claim.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>SARBORG
Service Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2024, the Company entered into a Services Agreement (the &#8220;Sarborg Service Agreement&#8221;) with SARBORG Limited
(&#8220;Sarborg&#8221;), a Cayman Islands company and related party of the Company. See Note 16 for further reference to the
relationship between the Company and Sarborg. Under the terms of the Sarborg Service Agreement, Sarborg will provide algorithmic and
cybernetic technology services to Conduit, including the development of decision-support tools and advanced cybernetic systems
tailored to enhance Conduit&#8217;s decision-making processes and maximize the value of its pharmaceutical asset
portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarborg
will perform the services to Conduit comprised of three phases: the Initial Phase (0-24 weeks) focuses on establishing a foundation for
collaboration and aligning Sarborg&#8217;s services with Conduit&#8217;s strategic goals; the Development Phase (24-36 weeks) involves
building technological infrastructure, including dashboards and predictive models; and the Ongoing Services Phase (36-52 weeks) ensures
the sustained functionality and relevance of Sarborg&#8217;s deliverables while supporting Conduit&#8217;s growth through iterative improvements
and updates. Sarborg will create specific deliverables, including reports, computer programs, software applications, APIs, mobile applications,
source code, written technical specifications and designs, operating and maintenance manuals, and other recorded data and information
arising from or relating to the services. Sarborg will provide all necessary resources to perform the services and deliver the deliverables
in accordance with the Sarborg Service Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarborg Service Agreement has an initial term of 12 months, which commenced on the effective date, and may be renewed or extended
upon mutual written agreement of the parties. Either party may terminate the Sarborg Service Agreement for any reason upon 90
days&#8217; written notice or immediately upon written notice if the other party breaches any material term of the Sarborg Service
Agreement and fails to cure such breach within thirty days or becomes insolvent, files for bankruptcy, or is placed under the
control of a receiver, trustee, or similar authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarborg Service Agreement includes provisions for the ownership and use of intellectual property. Sarborg will own its pre-existing
intellectual property rights, including proprietary tools and methodologies used in the performance of the services. Conduit will
own all deliverables resulting from the services performed by Sarborg under the Sarborg Service Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sarborg Service Agreement provides Sarborg with registration rights
for any Common Stock of Conduit that Sarborg receives as consideration under the Sarborg Service Agreement. In such event, Conduit will
use commercially reasonable efforts to (i) file a registration statement covering the resale of the Common Stock within 60 days after
the issuance; and (ii) ensure that such registration statement becomes effective within 90 days after filing. This Agreement also includes
confidentiality obligations, representations and warranties, indemnification, limitation of liability, and insurance requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the services, Conduit agreed to pay Sarborg an initial cash payment of $<span id="xdx_901_ecustom--PaymentToResearchAndDevolpmentAmount_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zGSBEwjlUzy8" title="Cash payment"><ix:nonFraction name="CDT:PaymentToResearchAndDevolpmentAmount" contextRef="From2024-01-012024-12-31_custom_SARBORGServiceAgreementMember" id="Fact001430" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million and $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zaGPaxjLMJth" title="Shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SARBORGServiceAgreementMember" id="Fact001432" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million payable&#160;through the issuance of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zitFwoh9tVkd" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SARBORGServiceAgreementMember" id="Fact001434" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,727</ix:nonFraction></span>
shares of&#160;common stock, determined by the closing price on the day preceding the execution of the Sarborg Service Agreement.
Further milestone payments payable in conjunction with the achievement of certain milestones over the term of the Sarborg Service
Agreement, totaling up to $<span id="xdx_904_ecustom--CashPayment_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_z3X3vxg9KAKl" title="Payable in cash"><ix:nonFraction name="CDT:CashPayment" contextRef="AsOf2024-12-31_custom_SARBORGServiceAgreementMember" id="Fact001436" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.8</ix:nonFraction></span>
million, are payable in cash or shares, at the discretion of Conduit. Sarborg will be reimbursed for pre-approved, necessary, and
reasonable out-of-pocket expenses directly incurred in connection with the performance of the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
determined that the cost incurred under the Sarborg Service Agreement should be recorded to research and development expense in the
statement of operations and comprehensive income (loss), as the Sarborg Service Agreement is designed to provide the
Company with software/dashboard to aid in research and development activities. The initial cash payment of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zdTjjtUF9ay8" title="Shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SARBORGServiceAgreementMember" id="Fact001438" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million and issuance of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zhb8ih1P5wu7" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SARBORGServiceAgreementMember" id="Fact001440" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,727</ix:nonFraction></span>
shares of Common Stock were recorded to prepaid expense and will be amortized over the initial term of the Sarborg Service Agreement to research and
development expense. As of December 31, 2024, the <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zJqrM2d0msJ8" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SARBORGServiceAgreementMember" id="Fact001442" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,727</ix:nonFraction></span>
shares of common stock were yet to be issued and are recorded within accrued expense and other current liabilities in the
consolidated balance sheets. As of December 31, 2024, the Company has recognized $<span id="xdx_901_eus-gaap--AdjustmentForAmortization_pn5n6_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zirSUlvBMhF4" title="Amortization"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_SARBORGServiceAgreementMember" id="Fact001444" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million of amortization within research and development expense in the consolidated statement of operations and comprehensive income
(loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001446" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_80C_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zHY0JLIDfVDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_825_z1goBzzbw7ok">Share Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2023, in connection with the Merger, the Company adopted the Conduit Pharmaceuticals Inc. 2023 Stock Incentive Plan
(the &#8220;2023 Plan&#8221;). The 2023 Plan became effective upon the closing of the Merger. The 2023 Plan initially provided for
the issuance of up to&#160;<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20230922__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeStockIncentivePlanMember_zeoQ0ABJNyhf" title="Issuance of common stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2023-09-22_custom_TwentyTwentyThreeStockIncentivePlanMember" id="Fact001448" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">114,976</ix:nonFraction></span>&#160;shares
of Common Stock. Pursuant to the 2023 Plan&#8217;s &#8220;evergreen&#8221; provision, on February 6, 2025, the Company increased the
number of shares of Common Stock available for issuance under the 2023 Plan by <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20250206__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeStockIncentivePlanMember_zpg7tFAi2QH9" title="Issuance of common stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2025-02-06_custom_TwentyTwentyThreeStockIncentivePlanMember" id="Fact001450" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">69,240</ix:nonFraction></span>
shares. Total shares available for issuance is <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20250101__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeStockIncentivePlanMember_zFtXfXWHh6R" title="Issuance of common stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2025-01-01_custom_TwentyTwentyThreeStockIncentivePlanMember" id="Fact001452" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">154,125</ix:nonFraction></span> effective January
1, 2025. The number of authorized shares will automatically increase on January 1, 2026 and
continuing annually on each anniversary thereof through (and including) January 1, 2033, equal to the lesser of (i)&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_c20230921__20230922__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeStockIncentivePlanMember_zZSEblBFdode" title="Shares issued percentage"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="From2023-09-212023-09-22_custom_TwentyTwentyThreeStockIncentivePlanMember" id="Fact001454" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
of the shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of
shares of common stock as determined by the Board or the applicable committee of the Board. The 2023 Plan allows for awards to be
issued to employees and non-employee directors in the form of options, stock appreciation rights, restricted stock, restricted stock
units (&#8220;RSUs&#8221;), performance stock units, dividend equivalents, other stock-based, or other cash-based awards. As of
December 31, 2024, there were&#160;<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20241231__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeStockIncentivePlanMember_zjlc6qhr0Psc" title="Shares available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-12-31_custom_TwentyTwentyThreeStockIncentivePlanMember" id="Fact001456" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">84,885</ix:nonFraction></span>&#160;shares
of Common Stock available for issuance under the 2023 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2024, the Company issued a total of
<span id="xdx_903_eus-gaap--SharesIssued_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxPOfTBCt3T8" title="Stock options to employees shares"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001458" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,700</ix:nonFraction></span> stock options to employees and non-employee directors with an aggregate grant date fair value of $<span id="xdx_90E_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUDZ8cmoLMec" title="Stock options to employees shares granted"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001460" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million. For
the year ended December 31, 2024 and December 31, 2023, there was a total of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zaPfzGjpnvy9" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001462" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span>&#160;million and $<span id="xdx_906_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zXlDHavOxlt5" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001464" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million, respectively in stock-based
compensation expense recognized within General and Administrative expenses on the consolidated statements of operations and Comprehensive
Loss, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2024, in connection with a services agreement with an unrelated third party to provide marketing services, the Company
issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240624__20240624__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAr2UgbhSLS1" title="Shares new issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-06-242024-06-24_us-gaap_CommonStockMember" id="Fact001466" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">961</ix:nonFraction></span> shares of its Common Stock (the &#8220;Service Shares&#8221;). The Company valued the Service Shares at $<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20240624__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxpG1u3uTKA3" title="Shares issued for services, per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-24_us-gaap_CommonStockMember" id="Fact001468" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">156</ix:nonFraction></span>&#160;per
share, the closing price of the Company&#8217;s Common Stock on June 21, 2024, adjusted for the Reverse Stock Split. The total
compensation for these shares is $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pn5n6_c20240624__20240624__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWSkChCcPySk" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-06-242024-06-24_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001470" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>&#160;million
which will be recognized within general and administrative expense over the service period of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2024, certain non-employee directors elected to receive a portion of their unpaid cash retainers due under the Director
Compensation Program in the form of shares. In total, $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20241118__20241118__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorsMember_z2Kj9i6M5lze"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-11-182024-11-18_custom_NonEmployeeDirectorsMember" id="Fact001471" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
of unpaid retainers was settled through the issuance <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241118__20241118__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorsMember_zeqCSzXEyFn8"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-11-182024-11-18_custom_NonEmployeeDirectorsMember" id="Fact001472" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,027</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Common Stock (the &#8220;Retainer Shares&#8221;). The Company valued the Retainer Shares at $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20241118__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorsMember_zGp5kyicjAk"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-11-18_custom_NonEmployeeDirectorsMember" id="Fact001473" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.0</ix:nonFraction></span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share, the closing price of the Company&#8217;s Common Stock on November 18, 2024, adjusted for the Reverse Stock Split. The Company
previously accrued in the unpaid retainers in Accrued expenses and other current liabilities in the Company&#8217;s consolidated
balance sheets. Upon issuance of the shares of Common Stock, the accrual was reduced based on the value of the shares
issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2024, the Board of Directors approved a one-time equity retainer in the form of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20241118__20241118__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBmLefyjKCZ5"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-11-182024-11-18_srt_BoardOfDirectorsChairmanMember_us-gaap_CommonStockMember" id="Fact001474" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fully
vested shares of Common Stock (the &#8220;Board Shares&#8221;) to a member of the Board of Directors for prior services. The Company
valued the Board Shares at $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241118__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zEpLlroMDCz3" title="Share price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-11-18_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember" id="Fact001476" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.20</ix:nonFraction></span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share, the closing price of the Company&#8217;s Common Stock on November 18, 2024, adjusted for the Reverse Stock Split. The total
compensation for these shares is $<span id="xdx_902_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20241118__20241118__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zaL7tRiVxE93" title="Total compensation"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-11-182024-11-18_srt_BoardOfDirectorsChairmanMember_us-gaap_CommonStockMember" id="Fact001478" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand
which was immediately recognized within General and administrative expense in the consolidated statement of operations and
comprehensive income (loss). The shares of common stock were issued under the 2023 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
18, 2024, Mr. Heilbron elected to have the $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn5n6_c20241118__20241118__srt--TitleOfIndividualAxis__custom--MrHeilbronMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zIbELbZxenJa" title="Stock issued during period value issued for services, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-11-182024-11-18_custom_MrHeilbronMember_custom_ConsultingAgreementMember" id="Fact001480" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million owed to him under the Consulting Agreement paid in share of the Company&#8217;s
Common Stock. In total <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20241118__20241118__srt--TitleOfIndividualAxis__custom--MrHeilbronMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zlSBJelfm9i" title="Stock issued during period value issued for services, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-11-182024-11-18_custom_MrHeilbronMember_custom_ConsultingAgreementMember" id="Fact001482" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,161</ix:nonFraction></span> shares are to be issued to Mr. Heilbron based on the closing price of the Company&#8217;s Common Stock on
November 18, 2024, $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20241118__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--MrHeilbronMember_z6fHwIaUs8Mh" title="Shares issued for services, per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-11-18_custom_ConsultingAgreementMember_custom_MrHeilbronMember" id="Fact001484" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.20</ix:nonFraction></span> per share, adjusted for the Reverse Stock Split. As of December 31, 2024, the shares had not been issued to Mr.
Heilbron. The value of the shares are recorded as an accrued expense and other current liability on the consolidated balance sheets as
of December 31, 2024.</span></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Merger, as discussed in Notes 1 and 2, and by Unanimous Written Consent of the Board of Directors, the then
Chief Financial Officer of the Company was granted&#160;<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20231201__20231201__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zZOOk3nwlFSe" title="Shares granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-12-012023-12-01_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember" id="Fact001486" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">745</ix:nonFraction></span>&#160;RSUs
on December 1, 2023 at a weighted average grant date fair value of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20231201__20231201_zJuFPpPskTs8" title="Weighted average grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-12-012023-12-01" id="Fact001488" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">551</ix:nonFraction></span> per unit.
The RSUs were to vest in equal annual instalments on the first three anniversaries of the closing of the Merger. Upon the then Chief
Financial Officer&#8217;s resignation, effective May 15, 2024, all such RSUs were forfeited. On June 7, 2024, by Unanimous Written
Consent of the Board of Directors, the Interim Chief Financial Officer of the Company and a Board member were each
granted&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240607__20240607__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zRrDa2KFs7Hj" title="Shares granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-06-072024-06-07_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember" id="Fact001490" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">372</ix:nonFraction></span>&#160;shares
of immediately vested restricted stock at a weighted average grant date fair value of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240607__20240607__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zYQEGP8lBcve" title="Weighted average grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-06-072024-06-07_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember" id="Fact001492" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">284</ix:nonFraction></span>.
The shares of restricted stock were fully vested as of the grant date.&#160;<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_do_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zv8wBqFaW3hi" title="Shares granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001494" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">No</ix:nonFraction></span>&#160;additional
RSU&#8217;s or shares of restricted common stock were granted during the year ended December 31, 2024. There were&#160;<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znwVjeILgbZj" title="Shares vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001496" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">745</ix:nonFraction></span>&#160;shares
of restricted common stock vested as of December 31, 2024 and&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zujcwuSwv8E2" title="Shares vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001498" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span>&#160;RSUs
vested as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001500" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zrKDiWEdwHB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes restricted stock activity for the 2023 Plan:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span id="xdx_8BE_z3DO0Eys0G8j" style="display: none">Schedule
of Restricted Stock Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards</b></span></p></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value Per Unit</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231_zvAzJuP4BzY4" title="Number of Awards, Outstanding" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31" id="Fact001502" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">745</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231_z7dcBqJqSAoc" title="Weighted Average Grant Date Fair Value, Outstanding" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31" id="Fact001504" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">551</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231_zy4r9o6O4czh" title="Number of Awards, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-01to2024-12-31" id="Fact001506" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zY3ZhFI8v3G8" title="Weighted Average Grant Date Fair Value, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-01to2024-12-31" id="Fact001508" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">284</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231_zkG3qLdNmqL4" title="Number of Awards, Cancelled/Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-01to2024-12-31" id="Fact001510" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">745</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_iN_pid_di_c20240101__20241231_zCtdIEGtRuhj" title="Weighted Average Grant Date Fair Value, Cancelled/Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-01-01to2024-12-31" id="Fact001512" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">551</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231_zMeNMKBTdbV7" title="Number of Awards, Vested" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-01to2024-12-31" id="Fact001514" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">745</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_iN_pid_di_c20240101__20241231_zB9bUhufF7Y2" title="Weighted Average Grant Date Fair Value, Vested" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-01to2024-12-31" id="Fact001516" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">284</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231_zjQYtVpsvdH5" title="Number of Awards, Outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1518">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231_zTLLMpuwAGJj" title="Weighted Average Grant Date Fair Value, Outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1520">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zYSMwp7EYgte" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of each option award on the date of grant using the Black-Scholes option-pricing model. The Company
then recognizes the grant date fair value of each option as compensation expense ratably using the straight-line attribution method over
the service period (generally the vesting period). The Black-Scholes model incorporates the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility &#8211; the Company estimates the volatility of the share price of their peer companies at the date of grant using a &#8220;look-back&#8221;
    period which coincides with the expected term, defined below. The Company believes using a &#8220;look-back&#8221; period which coincides
    with the expected term is the most appropriate measure for determining expected volatility.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term &#8211; the Company estimates the expected term using the &#8220;simplified&#8221; method outlined in SEC Staff Accounting Bulletin
    No. 107, &#8220;Share-Based Payment.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate &#8211; the Company estimates the risk- free interest rate using the U.S. Treasury Yield curve for periods equal to
    the expected term of the options in effect at the time of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
    &#8211; the Company uses an expected dividend yield of zero because the Company has not declared nor paid a cash dividend, nor are
    there any plans to declare a dividend.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001522" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zBaIaJl265s5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimated the fair value of stock options granted in the periods presented using a Black-Scholes option-pricing model utilizing
the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B2_zGRBcoYo0Cq7" style="display: none">Schedule of Fair Value
of Stock Option Granted</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zTe9FxoLtNFh" title="Expected Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_srt_MinimumMember" id="Fact001524" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">83.2</ix:nonFraction></span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zcl1d02WjwT" title="Expected Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_srt_MaximumMember" id="Fact001526" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85.4</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z9UGhjz6BM4l" title="Expected Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31_srt_MinimumMember" id="Fact001528" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">79.0</ix:nonFraction></span>% - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zjt4AnyIiAg2" title="Expected Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31_srt_MaximumMember" id="Fact001530" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80.0</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z3JgiqKT57df" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001532" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.5</ix:nonNumeric></span> - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zxXQXcvmcwEh" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001534" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.6</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zyBX57jSy0a4" title="Expected term (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001536" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.5</ix:nonNumeric></span> - <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_ztaWcF6568Ki" title="Expected term (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001538" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.5</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zZMa1v43seSj" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_srt_MinimumMember" id="Fact001540" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.28</ix:nonFraction></span>% - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z9WtdAI2SJK8" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_srt_MaximumMember" id="Fact001542" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.40</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zjbMLbwsQhuh" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_srt_MinimumMember" id="Fact001544" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.16</ix:nonFraction></span>% - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zrjfVl4qTcCl" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_srt_MaximumMember" id="Fact001546" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.35</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Expected dividend yield (%)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20241231_zeDDkprb70g9" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-01to2024-12-31" id="Fact001548" format="ixt:numdotdecimal" decimals="-3" scale="1" unitRef="Pure">0</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230101__20231231_zuz1k08Guxf8" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31" id="Fact001550" format="ixt:numdotdecimal" decimals="-3" scale="1" unitRef="Pure">0</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zOGwosEQdR16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for forfeitures as they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures
arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001552" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zlD4LccAaC7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes stock option activity for the 2023 Plan:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BE_zEM2SYKmrjH9" style="display: none">Schedule
of Stock Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Intrinsic Value (in thousands)</p></td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_z89lSJcEixcg" title="Number of Options, Outstanding" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreePlanMember" id="Fact001554" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,717</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zaXw5uDHyNC6" title="Weighted Average Exercise Price, Outstanding" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreePlanMember" id="Fact001556" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">551</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zqmlZa8fWW5k" title="Weighted Average Remaining Contractual Term Years"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreePlanMember" format="ixt-sec:duryear" id="Fact001558" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.85</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zSNWNOOx17Nf" title="Aggregate Intrinsic Value" style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1560">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zaPG7aLhLJcg" title="Number of Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember" id="Fact001562" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">56,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zmQ4YTeY53k" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember" id="Fact001564" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zfdVIuu2lu45" title="Number of Options, Cancelled/forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember" id="Fact001566" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,908</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zb2MSpYym9Kl" title="Weighted Average Exercise Price, Cancelled/Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember" id="Fact001568" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">551</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zYYZSYL4Qqdg" title="Number of Options, Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1570">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zP19SrsdlKD2" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1572">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_z1jc3SEVYEi7" title="Number of Options, Outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember" id="Fact001574" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,509</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zk9sxTdDKnf9" title="Weighted Average Exercise Price, Outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember" id="Fact001576" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">81.52</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zn3Gqjnt0d2i" title="Weighted Average Remaining Contractual Term Years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember" format="ixt-sec:duryear" id="Fact001578" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.72</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zu9y0C3WCqk7" title="Aggregate Intrinsic Value" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1580">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zfPXv2RcdScj" title="Number of Options, Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember" id="Fact001582" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">23,154</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zfYT7HapQtik" title="Weighted Average Exercise Price, Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember" id="Fact001584" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">84.18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zTeBGUka45G1" title="Weighted Average Remaining Contractual Term Years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember" format="ixt-sec:duryear" id="Fact001586" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">9.66</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zsoDPz366TDk" title="Aggregate Intrinsic Value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1588">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_ziJRyvS6oSo9" title="Number of Options, Unvested" style="text-align: right"><ix:nonFraction name="CDT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember" id="Fact001590" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">42,355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zHZP7SGlZN15" title="Weighted Average Exercise Price, Unvested" style="text-align: right"><ix:nonFraction name="CDT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember" id="Fact001592" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">80.07</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zXZUWGtMgEJ3" title="Weighted Average Remaining Contractual Term Years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember" format="ixt-sec:duryear" id="Fact001594" name="CDT:ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1">9.76</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zjP7aVdxXTB2" title="Aggregate Intrinsic Value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1596">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zW7FXtZw68J" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair
value of the Company&#8217;s common stock for those options that had exercise prices lower than the fair value of the Company&#8217;s
common stock. As of December 31, 2024, the total compensation cost related to non-vested option awards not yet recognized was $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20241231_zOlHt25vwM4h" title="Cost related to non-vested option"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2024-12-31" id="Fact001598" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million
with a weighted average remaining vesting period of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zboIsSjBkl64" title="Weighted average remaining vesting"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001600" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.07</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001602" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zMffBXayQx58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span id="xdx_822_zjXscbwacXga">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001604" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zUcA0awPmLg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Loss from operations before income
taxes for the years ended December 31, 2024 and 2023 is summarized below (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zMVxAIiHVcYl" style="display: none">Schedule of Income before Income Tax, Domestic and Foreign</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231_zj8aoHNv8tki" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_z1IT1RIWy1fb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_iB_zbAoRlECz5Wd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations before income taxes:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i01_maILFCOzobr_zQsoEnZ56P78" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; padding-left: 0.5in">US</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2024-01-01to2024-12-31" id="Fact001609" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,855</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2023-01-012023-12-31" id="Fact001610" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,990</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i01_maILFCOzobr_zRwjiNfo36Yj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.5in">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2024-01-01to2024-12-31" id="Fact001612" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,947</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2023-01-012023-12-31" id="Fact001613" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,454</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_mtILFCOzobr_zikm4NYzBAs1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-01to2024-12-31" id="Fact001615" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,802</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact001616" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">536</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zBoGoEzeKrd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001618" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z0DMoB3vjxg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provision (benefit) for income taxes for the years ended December 31, 2024 and December 31, 2023 is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B2_zxhmnoyBXHKj" style="display: none">Schedule of Provision for Income Tax</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_zkf2jmA5U8yg" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zfVRTsnxp1yk" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For The Years Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2024</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_zcD79FYKzuv1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1620">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1621">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_zTlVy8Beh0dh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1623">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1624">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_zlanbZ1RLPkk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Foreign</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1626">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1627">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_zf2uGegnBRG2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Current income tax</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1629">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1630">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_z3MeELTHQa1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%">Federal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001632" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,429</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001633" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">843</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_zPYSZliV9Hie" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001635" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001636" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">355</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_pn3n3_znCwMjmrOSYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Foreign</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001638" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">931</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001639" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">251</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3n3_zzva8tygFM3h" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income tax</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001641" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,005</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001642" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,449</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_ztZLWMAGlhI5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in Valuation Allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" contextRef="From2024-01-01to2024-12-31" id="Fact001644" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,005</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" contextRef="From2023-01-012023-12-31" id="Fact001645" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,449</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zzMTb2QetDP9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Income Tax Expense</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1647">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1648">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zYm6iPW3AKyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001650" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zeq9Kfy0ZFJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax provision differed from the amount computed by applying the U.S. federal income tax rate of <span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_zY0243RDodYl"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001651" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>% to income (loss) before taxes, as
follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zlaiIzT87Rj4" style="display: none">Schedule
of Federal Income Tax Rate</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zREUvd2H3s3c" style="border-bottom: Black 1pt solid; text-align: center">US</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zioxz5mvuNth" style="border-bottom: Black 1pt solid; text-align: center">Foreign</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zEIGnpM0vrU8" style="border-bottom: Black 1pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>For The Year Ended</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>US</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Foreign</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Consolidated</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzbix_zsMbfVAp9cNg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Taxes at federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember" id="Fact001653" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,705</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember" id="Fact001654" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,039</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001655" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,744</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maITEBzbix_zuUmSswPUKU5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign Rate Differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1657">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember" id="Fact001658" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91</ix:nonFraction> </td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2024-01-01to2024-12-31" id="Fact001659" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maITEBzbix_zIvbgV5iFirc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Meals &amp; Entertainment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember" id="Fact001661" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1662">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" contextRef="From2024-01-01to2024-12-31" id="Fact001663" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_pn3n3_maITEBzbix_zaqsfP2LujIh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Eq Comp Perm</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember" id="Fact001665" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1666">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" contextRef="From2024-01-01to2024-12-31" id="Fact001667" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IncomeTaxReconciliationConvertibleDebtAdjustment_pn3n3_maITEBzbix_zT2Npgc5Wbh9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible Debt Adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:IncomeTaxReconciliationConvertibleDebtAdjustment" contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember" id="Fact001669" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">268</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1670">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:IncomeTaxReconciliationConvertibleDebtAdjustment" contextRef="From2024-01-01to2024-12-31" id="Fact001671" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">268</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--IncomeTaxReconciliationStateReRate_pn3n3_maITEBzbix_zokB8Ld15Oxc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State Re-Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:IncomeTaxReconciliationStateReRate" contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember" id="Fact001673" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1674">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:IncomeTaxReconciliationStateReRate" contextRef="From2024-01-01to2024-12-31" id="Fact001675" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">355</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maITEBzbix_zuEidSykYiu5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember" id="Fact001677" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">76</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember" id="Fact001678" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2024-01-01to2024-12-31" id="Fact001679" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">59</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzbix_zy1n58puvGEg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change In Valuation Allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember" id="Fact001681" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,074</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember" id="Fact001682" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">931</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact001683" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,005</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzbix_zlhSe7jytOLk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total provision (benefit) for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1685">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1686">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1687">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmASuhfEOQo6" style="border-bottom: Black 1pt solid; text-align: center">US</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zXpfATiNFTCh" style="border-bottom: Black 1pt solid; text-align: center">Foreign</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zBFlZWCWregl" style="border-bottom: Black 1pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>For The Year Ended</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>US</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Foreign</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Consolidated</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzbix_zHfGaUT0Pye8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Taxes at federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember" id="Fact001689" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">417</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember" id="Fact001690" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">305</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001691" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">112</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzbix_zmZ9OVyOM44a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State Taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember" id="Fact001693" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">175</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1694">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact001695" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">175</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maITEBzbix_z8DbuhbmDJic" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign Rate Differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1697">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember" id="Fact001698" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">490</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-01-012023-12-31" id="Fact001699" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">490</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maITEBzbix_zJbdDWvcgoH" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Meals &amp; Entertainment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember" id="Fact001701" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember" id="Fact001702" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" contextRef="From2023-01-012023-12-31" id="Fact001703" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_pn3n3_maITEBzbix_zv0Pr4kfU13j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Eq Comp Perm</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember" id="Fact001705" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1706">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" contextRef="From2023-01-012023-12-31" id="Fact001707" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncomeTaxReconciliationConvertibleDebtAdjustment_pn3n3_maITEBzbix_z6tILXxHK4j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Debt Adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1709">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CDT:IncomeTaxReconciliationConvertibleDebtAdjustment" contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember" id="Fact001710" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,048</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CDT:IncomeTaxReconciliationConvertibleDebtAdjustment" contextRef="From2023-01-012023-12-31" id="Fact001711" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,048</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--IncomeTaxReconciliationPurchaseAccountingAdjustments_pn3n3_maITEBzbix_zxmD3op3Czzh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Purchase Accounting Adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CDT:IncomeTaxReconciliationPurchaseAccountingAdjustments" contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember" id="Fact001713" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">609</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1714">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CDT:IncomeTaxReconciliationPurchaseAccountingAdjustments" contextRef="From2023-01-012023-12-31" id="Fact001715" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">609</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzbix_zKInzUrrpnhd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change In Valuation Allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember" id="Fact001717" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,198</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember" id="Fact001718" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">251</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001719" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,449</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzbix_zi9aJ1MvZug6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total provision (benefit) for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1721">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1722">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1723">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A1_z2QPcpWsJELg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001725" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zSMZBNIYmoDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effects of temporary differences which give rise to significant portions of deferred tax assets are as follows as of December 31
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zXEONsTeVo4" style="display: none">Schedule
of Deferred Tax Assets and Liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zbiDH8OVEin7" style="border-bottom: Black 1pt solid; text-align: center">US</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zfu5jwUxRBfl" style="border-bottom: Black 1pt solid; text-align: center">Foreign</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20241231_zkzR5g3PH9S9" style="border-bottom: Black 1pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>For The Year Ended</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>US</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Foreign</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Consolidated</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Deferred Tax Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DeferredTaxAssetsStockOptions_iI_pn3n3_maDTAGzJ4A_zpGtcoAV3Fmh" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="CDT:DeferredTaxAssetsStockOptions" contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember" id="Fact001727" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">280</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1728">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="CDT:DeferredTaxAssetsStockOptions" contextRef="AsOf2024-12-31" id="Fact001729" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">280</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsHedgingTransactions_iI_pn3n3_maDTAGzJ4A_zP3jcOXwpTyk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Transaction Costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsHedgingTransactions" contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember" id="Fact001731" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">393</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1732">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsHedgingTransactions" contextRef="AsOf2024-12-31" id="Fact001733" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">393</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzJ4A_z47NOXKKQNrj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research &amp; Development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember" id="Fact001735" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">671</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1736">-</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact001737" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">671</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_pn3n3_maDTAGzJ4A_zZ4ACcBvPOH8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember" id="Fact001739" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">141</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1740">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2024-12-31" id="Fact001741" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">141</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzJ4A_z0lrxbxmVF0h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net operating loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember" id="Fact001743" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,788</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember" id="Fact001744" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,182</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001745" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,970</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzJ4A_maNDTAzpU6_zzOChQgdkKJ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember" id="Fact001747" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,273</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember" id="Fact001748" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,182</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001749" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,455</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzjwi_zTg0HciqIuB7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember" id="Fact001751" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,273</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember" id="Fact001752" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,182</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001753" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,455</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTALNzjwi_zIniBtnKe5Ve" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets (liability)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1755">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1756">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1757">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_znmEnIClDEKe" style="border-bottom: Black 1pt solid; text-align: center">US</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zt7U4vfjY3hh" style="border-bottom: Black 1pt solid; text-align: center">Foreign</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zNNh3iKZH5ri" style="border-bottom: Black 1pt solid; text-align: center">Consolidated</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>For The Year Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>US</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Foreign</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Consolidated</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Deferred Tax Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxAssetsStockOptions_iI_pn3n3_maDTAGzJ4A_zCUi9CCfy8Sg" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="CDT:DeferredTaxAssetsStockOptions" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact001759" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1760">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="CDT:DeferredTaxAssetsStockOptions" contextRef="AsOf2023-12-31" id="Fact001761" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsHedgingTransactions_iI_pn3n3_maDTAGzJ4A_zvxOLF2rEw11" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Transaction Costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsHedgingTransactions" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact001763" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">599</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsHedgingTransactions" contextRef="AsOf2023-12-31" id="Fact001765" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">599</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzJ4A_zJt5jqeQdw03" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net operating loss</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact001767" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">562</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember" id="Fact001768" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">251</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001769" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">813</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzJ4A_maNDTAzpU6_zrbfj4BlPjxa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact001771" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,198</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember" id="Fact001772" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">251</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact001773" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,449</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzjwi_zNC0hv4gSJ0f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Valuation allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact001775" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,198</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember" id="Fact001776" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">251</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001777" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,449</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTALNzjwi_z1HzbCuagGjk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net deferred tax assets (liability)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1779">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1780">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1781">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zYvYVgkdfzIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and December 31, 2023, the Company had net operating loss (&#8220;NOL&#8221;) carryforwards for U.S.
federal&#8221; purposes of approximately $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zONcUIuFwhQl" title="Net operating loss"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember" id="Fact001783" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.5</ix:nonFraction></span>
million and $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zrQZtTEafhz3" title="Net operating loss"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact001785" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span>
million, respectively, which carryforward indefinitely and can offset <span id="xdx_90A_ecustom--EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate_pid_dp_uPure_c20230101__20231231_zxP8Q80J9Ikc" title="Effective income tax rate reconciliation future income years tax rate"><ix:nonFraction name="CDT:EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001787" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>%
of taxable income in future years. As of December 31, 2024 and December 31, 2023, the Company had state NOL carryforwards of <span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_dxL_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z54Ipa0mrWZa" title="Net operating loss::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1789">nil</span></span> and $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zsBp23lxSEL6" title="Net operating loss"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001791" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span>
million, respectively. As of December 31, 2024 and December 31, 2023, the Company had net
operating loss (&#8220;NOL&#8221;) carryforwards for foreign purposes of approximately $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z6sBzjl8N1Vd" title="Net operating loss"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember" id="Fact001793" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.7</ix:nonFraction></span>
million and $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z2mqYdV4CR6a" title="Net operating loss"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember" id="Fact001795" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span>
million, respectively, which carryforward indefinitely. Net operating loss (NOL) carryforwards are subject to limitations in
the event of a change in control under Section 382 of the Internal Revenue Code. This section limits the amount of taxable income
that can be offset by NOLs after an ownership change. The limitation is calculated as the value of the old loss corporation
multiplied by the long-term tax-exempt rate. If the new loss corporation does not continue the business enterprise of the old loss
corporation for a specified period, the NOL carryforwards may be disallowed. The Company has not yet conducted a Section 382 study
to determine whether any ownership changes have occurred that would impose annual limitations on its ability to utilize its NOL
carryforwards. Until such a study is completed, there is substantial uncertainty regarding the amount of NOL carryforwards that
could be utilized annually to offset future taxable income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company establishes a valuation allowance when it is more likely than not that the Company&#8217;s recorded net deferred tax asset
will not be realized. In determining whether a valuation allowance is required, the Company must take into account all positive and
negative evidence with regard to the utilization of a deferred tax asset. As of December 31, 2024 and December 31, 2023, the
valuation allowance for deferred tax assets totaled approximately $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20241231_z0hvDipLYfYk" title="Deferred tax assets valuation allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001797" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span>
million and $<span id="xdx_901_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20231231_zFAUjGhdS6mj" title="Deferred tax assets valuation allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001799" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span>
million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001801" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zs1qrt9ByTA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_82C_zrrD6CPabe2j">Common Stock and Preferred Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, and December 31, 2023, the Company has authorized the issuance of up to <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zFNloFgi4DNa"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact001802" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of common stock, respectively, at a par value $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zbCsuUxa08vj"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact001803" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, and December 31, 2023 there were <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_znJXFoBn2Xsk" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_z7ll3rjrklYj" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact001805" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact001807" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,384,801</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zun38lDOR0R5" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zD0jJX6loLli" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact001809" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact001811" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">738,295</ix:nonFraction></ix:nonFraction></span></span> shares of Common Stock issued and outstanding, respectively.
<span id="xdx_905_eus-gaap--DividendsCash_do_c20240101__20241231_zJ9MCI6mzbG1"><ix:nonFraction name="us-gaap:DividendsCash" contextRef="From2024-01-01to2024-12-31" id="Fact001812" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></span> cash dividends have been declared or paid as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of the Common Stock are entitled to one vote per share, and to receive dividends, on and if declared by the board of directors and, upon
liquidation or dissolution, are entitled to receive all assets available for distribution, subordinate to the rights, preferences, and
privileges of any outstanding preferred shares (if any) with respect to dividends and in connection with liquidation, winding up and
dissolution of the Company. The holders have no preemptive or other subscription rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company has authorized the issuance of up to <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zFo4yNFaO5W5"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact001813" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of Conduit Pharmaceuticals, Inc. preferred stock
(the &#8220;Preferred Stock&#8221;). As of December 31, 2024, and December 31, 2023, <span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_dxL_c20241231_zJ2bW9FgKsrj" title="Preferred stock, shares issued::XDX::-"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_dxL_c20241231_z9eeZtHsLyji" title="Preferred stock, shares outstanding::XDX::-"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pid_dxL_c20231231_zSdI97jxcfb3" title="Preferred stock, shares issued::XDX::-"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dxL_c20231231_zmPztFppNXG3" title="Preferred stock, shares outstanding::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1815"><span style="-sec-ix-hidden: xdx2ixbrl1817"><span style="-sec-ix-hidden: xdx2ixbrl1819"><span style="-sec-ix-hidden: xdx2ixbrl1821">no</span></span></span></span></span></span></span></span> preferred shares were issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>At-the-Market
Offering</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 23, 2024, the Company entered into the Sales Agreement with A.G.P. relating to shares of the Company&#8217;s Common Stock. In
accordance with the terms of the Sales Agreement, the Company may offer and sell shares of our Common Stock having an aggregate offering
price of up to $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20241023__20241023_zTMVvXX7FPg1"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-10-232024-10-23" id="Fact001822" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.6</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million&#160;from time to time through A.G.P.,
acting as our sales agent or principal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation to A.G.P. for sales of common stock sold pursuant to the Sales Agreement will be equal to <span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zuldWhtwn2Sd" title="Sale of stock, percentage"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SalesAgreementMember" id="Fact001824" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% of the gross proceeds of
any shares of common stock sold under the sales agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company sold <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z3m1KsPNxmoj"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SalesAgreementMember" id="Fact001825" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">323,273</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock under the Sales Agreement
and generated $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zV5EmLbdFHw6"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SalesAgreementMember" id="Fact001826" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million&#160;in net proceeds after paying fees
to A.G.P. and other issuance costs of $<span id="xdx_908_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zo9K1JKZTQVi"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SalesAgreementMember" id="Fact001827" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. See Note 20 for information on the issuances
and increases to the aggregate offering price subsequent to December 31, 2024.</span></p>
<!-- Field: Split-Segment; Name: 002 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001829" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_800_eus-gaap--EarningsPerShareTextBlock_zvYudql1tvnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
<span id="xdx_823_zjtxFW3Iawnc">Earnings/(Net Loss) Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001831" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zIgahDeMW377" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the calculation of basic and diluted earnings/(net loss) per share (in thousands, except share amounts and per
share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zplVRWoff8he" style="display: none">Schedule
of Basic and Diluted Net Loss Per Share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zfn0S5lN5Lqe" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zOHpaNx3a6r2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
                                            the years ended</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span><b>December 31,</b></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_maNILATzJEp_z8UQOiBwl1ae" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net income (loss) - basic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-12-31" id="Fact001833" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,802</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31" id="Fact001834" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">535</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--ChangeInFairValueAndIncomeImpactOfOptionLiabilities_iN_pn3n3_di_msNILATzJEp_z1Ky9hZe9hdj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Less: Change in fair value and income impact of option liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1836">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="CDT:ChangeInFairValueAndIncomeImpactOfOptionLiabilities" contextRef="From2023-01-012023-12-31" id="Fact001837" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,521</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_iT_pn3n3_mtNILATzJEp_z7YWM3wqGVS3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Net income (loss) - diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact001839" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,802</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2023-01-012023-12-31" id="Fact001840" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,056</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zZtAdU2VVZ7g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Weighted average common stock outstanding, basic</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact001842" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">867,096</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact001843" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">669,739</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--OptionLiabilityConversionShares_pid_zhR4WG7c9cLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Add: Option liability conversion shares</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1845">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="CDT:OptionLiabilityConversionShares" contextRef="From2023-01-012023-12-31" id="Fact001846" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_zcgCt1xPrTUc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Weighted average shares used in computing net loss per share - diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact001848" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">867,096</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact001849" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">678,939</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EarningsPerShareBasic_pid_zrRj4i04auhc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income (loss) per share, basic</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact001851" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">20.53</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact001852" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.79</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_pid_zHYVozj43l1b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net income (loss) per share, diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact001854" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">20.53</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact001855" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">8.92</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zedPTUQnSKR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company notes that the adjustment to the numerator in 2023 for the change in fair value and income impact of Vela and Cizzle
accounts for changes in fair value of each option, gains (losses) at the time of issuance of each option and the statement of
operations impact of the derecognition of deferred revenue that originated upon the initial sale of royalties to both Vela and
Cizzle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001857" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ziQtr3IBQtLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities (upon conversion) that were not included in the diluted per share calculations because they would have been anti-dilutive
were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zm7r1qoMmG5i" style="display: none">Schedule
of Potentially Dilutive Securities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20241231_z8lF6z0IaIk2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zF2M9MghyTs7" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PublicWarrantsMember_zl5JWAfU4uH3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Public warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_PublicWarrantsMember" id="Fact001859" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">139,790</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember" id="Fact001860" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">139,790</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PIPEMember_zmQQ5phS9h55" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">PIPE Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1862">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_PIPEMember" id="Fact001863" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AGPWarrantsMember_z0CMGaPf10k6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">A.G.P. Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_AGPWarrantsMember" id="Fact001865" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">540</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_AGPWarrantsMember" id="Fact001866" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">540</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePromissoryNotesPayableMember_zGpdAfvxPI6j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Promissory Notes Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember20778937" id="Fact001868" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_ConvertiblePromissoryNotesPayableMember20778953" id="Fact001869" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">805</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zC9p8TYuoeCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember" id="Fact001871" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,509</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember" id="Fact001872" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,717</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zct5Ft3E26O2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1874">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember20778968" id="Fact001875" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,470</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zpWC5guhU2B2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>August 2024 Nirland Note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_AugustTwentyTwentyFourNirlandNoteMember" id="Fact001877" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">672,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1878">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AGPConvertibleNoteMember_zXTJrNfL7Lje" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">A.G.P. Convertible Note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_AGPConvertibleNoteMember20778984" id="Fact001880" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">576,949</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1881">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--MarchTwentyTwentyFourWarrantsMember_zuf4MDpqNsm7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>March 2024 Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_MarchTwentyTwentyFourWarrantsMember" id="Fact001883" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1884">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AprilTwentyTwentyFourWarrantsMember_zn1dkvEjbyyi" style="vertical-align: bottom; background-color: White">
    <td>April 2024 Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_AprilTwentyTwentyFourWarrantsMember" id="Fact001886" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,477</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1887">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AGPTwentyTwentyFourWarrantsMember_zD0sqjeOpkNk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">A.G.P. 2024 Warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_AGPTwentyTwentyFourWarrantsMember" id="Fact001889" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,626</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1890">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zifmr5T3zFlb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Antidilutive Securities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-12-31" id="Fact001892" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,501,298</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact001893" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">173,322</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zkv2dY1HCjqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001895" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zfCF6Ud2Tnt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.
<span id="xdx_828_zXUxlwsY9dm5">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to certain claims and contingent liabilities that arise in the normal course of business. While we do not expect that
the ultimate resolution of any of these pending actions will have a material effect on our consolidated results of operations, financial
position or cash flows, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action,
does not become material in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2023, prior to the Business Combination, our now wholly-owned subsidiary, Conduit Pharmaceuticals Limited, received a letter
from Strand Hanson Limited (&#8220;Strand&#8221;) claiming it was owed advisory fees pursuant to a previously executed letter.
Conduit rejected the claim from Strand and disputed the substance of the letter in full. Following such rejection, on September 7,
2023, Strand filed a claim in the Business and Property Courts of England and Wales claiming it is entitled to be paid the sum of
$<span id="xdx_901_eus-gaap--LitigationSettlementExpense_pn6n6_c20230831__20230831_zyYXKWKhT8Wd" title="Settelment expense"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2023-08-312023-08-31" id="Fact001897" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span>
million and, as a result of the completion of the Business Combination, to be issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20230831__20230831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwg6AAIH1l6d" title="Shares issued in business combination"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-08-312023-08-31_us-gaap_CommonStockMember" id="Fact001899" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">65</ix:nonFraction></span>
thousand shares of common stock. As of December 31, 2024, the potential contingency is considered probable and reasonably estimable
and as such, the Company accrued an estimated liability of $<span id="xdx_904_eus-gaap--LossContingencyAccrualProvision_pn5n6_c20240101__20241231_zs0e9gnc3TCa" title="Accrued estimated liability"><ix:nonFraction name="us-gaap:LossContingencyAccrualProvision" contextRef="From2024-01-01to2024-12-31" id="Fact001901" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span>&#160;million
in the accompanying financial statements. The trial in this matter remains scheduled for October 20, 2025. We intend to vigorously
defend against these claims. Regardless of its outcome, the litigation may impact our business due to, among other things, legal
costs and the diversion of the attention of our management.<b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In November and
December 2024, the Company received a letter from St George Street Capital and formal complaints filed with the Intellectual
Property Office claiming the Company was assigned the US Application, and was not the sole owner, of the AZD 1656 co-crystal patent.
In January 2025, Conduit issued a counter statement to the Intellectual Property Office disputing the claim filed by St George
Street Capital. As of December 31, 2024, the damages sought by St George Street Capital are unknown and the potential contingency is
not considered probable. As such, the Company has not accrued a loss contingency in the accompanying
financial statements. We intend to vigorously defend against these claims. Regardless of its outcome, the litigation may impact our
business due to, among other things, legal costs and the diversion of the attention of our management.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<ix:exclude><!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001903" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zPbsDD63tZc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.
<span id="xdx_829_z0s2GRX0ebrk">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Corvus
Capital Limited</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corvus
Capital Limited (&#8220;Corvus&#8221;) is a significant investor in the Company through subscribing to <span id="xdx_90F_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_pid_c20230922__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CorvusCapitalLimitedMember_zXt6Agvtmmfb"><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="AsOf2023-09-22_custom_CorvusCapitalLimitedMember" id="Fact001904" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common
shares prior to the closing of the Merger on September 22, 2023. As discussed in Note 2, the shares held by Corvus on the closing
date of the Merger were exchanged for shares of Conduit Pharmaceuticals Inc. common stock. The Chief Executive Officer and principal
owner of Corvus is a member of Conduit&#8217;s board of directors. Occasionally, Corvus provides advisory services to the Company
and is paid a fee for the services. As of December 31, 2024, and December 31, 2023, no advisory fees were due to Corvus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024 and 2023, the Company incurred director travel expenses payable to the board of directors member
of approximately $<span id="xdx_906_eus-gaap--TravelAndEntertainmentExpense_pn5n6_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zNOJyYXzbef1"><ix:nonFraction name="us-gaap:TravelAndEntertainmentExpense" contextRef="From2024-01-012024-12-31_custom_BoardOfDirectorsMember" id="Fact001905" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
and $<span id="xdx_901_eus-gaap--TravelAndEntertainmentExpense_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zoeFBQS99jO9"><ix:nonFraction name="us-gaap:TravelAndEntertainmentExpense" contextRef="From2023-01-012023-12-31_custom_BoardOfDirectorsMember" id="Fact001906" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million,
respectively. As of December 31, 2024, and December 31, 2023, the Company did not owe the CEO of Corvus any director&#8217;s fees as
the CEO of Corvus and the Company agreed to cease director&#8217;s fees to the CEO of Corvus effective at the closing of the Merger.
Amounts owed to this director are included in accrued expenses and other current liabilities in the
balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, Corvus provided a $<span id="xdx_909_eus-gaap--ProceedsFromContributedCapital_pn5n6_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CorvusCapitalLimitedMember_zK1iCl3gbjle"><ix:nonFraction name="us-gaap:ProceedsFromContributedCapital" contextRef="From2023-01-012023-12-31_custom_CorvusCapitalLimitedMember" id="Fact001907" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million cash contribution to the Company to maintain liquidity through the closing
of the Merger. There was no intention of repayment by both Corvus and the Company, and as such, the Company recorded the contribution
to the consolidated statement of changes in stockholders&#8217; deficit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
January and February 2023, the Company issued convertible notes payable with an aggregate principal amount of $<span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20230228__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleLoanNoteInstrumentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z1egGwZvyZXh"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2023-02-28_custom_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_srt_ChiefExecutiveOfficerMember" id="Fact001908" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million (&#163;<span id="xdx_902_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_uGBP_c20230228__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleLoanNoteInstrumentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zPENOSvRqrlf"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2023-02-28_custom_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_srt_ChiefExecutiveOfficerMember" id="Fact001909" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="GBP">0.3</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million) to this related party. The convertible
notes payable mature three years after issuance and bear <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230201__20230228__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleLoanNoteInstrumentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zQkHrPCvjwI2"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-02-012023-02-28_custom_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_srt_ChiefExecutiveOfficerMember" id="Fact001910" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
interest, only to be paid in the event of a material breach by the Company. In the event of a Change of Control, the convertible notes
payable automatically convert into common shares of the Company at a conversion price equal to a <span id="xdx_901_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_c20230201__20230228__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleLoanNoteInstrumentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zAl1IT2x6OEj"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="From2023-02-012023-02-28_custom_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_srt_ChiefExecutiveOfficerMember" id="Fact001911" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
discount to the price per share paid for the most senior class of shares in respect of such Change of Control. All of the convertible
notes payable converted into Common Stock upon the closing of the Merger at a <span id="xdx_908_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_c20230201__20230228__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleLoanNoteInstrumentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zuk8ESXKDXT2"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="From2023-02-012023-02-28_custom_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_srt_ChiefExecutiveOfficerMember" id="Fact001912" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
discount as specified. Refer to Note 2 above for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">At the time of the execution of the PIPE Subscription Agreement, Corvus
and its affiliates entered into a participation and inducement agreement with Nirland whereby Corvus agreed to provide certain payments
and economic benefits to Nirland. In certain circumstances, Nirland may have a right to cause Corvus to transfer <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CorvusCapitalLimitedMember_zNNFGcqS1kLg" title="New stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_custom_CorvusCapitalLimitedMember" id="Fact001914" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">300,484</ix:nonFraction></span> shares held to Nirland.</p>

<p style="margin: 0pt 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Related
Party Loan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loans made to a related party were stated at a total principal amount of $<span id="xdx_90F_eus-gaap--LoansAndLeasesReceivableRelatedParties_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zGfUyUKNGUr9"><ix:nonFraction name="us-gaap:LoansAndLeasesReceivableRelatedParties" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact001915" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million, with <span id="xdx_909_eus-gaap--OtherReceivables_iI_do_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z322FP3izxS6"><span id="xdx_901_eus-gaap--OtherReceivables_iI_do_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zDDkj9EVDRYh"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact001916" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact001917" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> balance outstanding at December 31, 2024
and December 31, 2023, respectively. The loan carried no interest, and as such, no interest receivable was recorded. The Company recorded
a full reserve against the loan as the related party did not have the ability to repay the loans as of December 31, 2022. On September
22, 2023, the related party paid back a significant portion of its outstanding loan and the Company forgave the remaining portion of
the loan and the Company recorded the $<span id="xdx_903_eus-gaap--LoansPayable_iI_pn5n6_c20230922__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSt0lBbusar"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2023-09-22_us-gaap_RelatedPartyMember" id="Fact001918" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million payoff as a gain within general and administrative expense on the consolidated statement
of operations and comprehensive income (loss), as it had previously been fully reserved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nirland</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 6, 2024, the Company entered into the August 2024 Nirland Note with Nirland, a related party of the Company. The Company
determined that Nirland was a related party due to Nirland&#8217;s ownership interest in the Company concurrently with the execution
of the August 2024 Nirland Note. Additionally, on October 28, 2024, the Company issued the October 2024 Nirland Note to Nirland, and
on October 31, 2024, the Company and Nirland amended the August 2024 Nirland Note, and on November 22, 2024, the Company and Nirland
amended the August 2024 Nirland Note for a second time. Refer to Note 7, Note 8 and Note 20 above for additional
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>SARBORG</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2024, the Company entered into the Sarborg Service Agreement with Sarborg. Dr. Andrew Regan, a member of
Conduit&#8217;s board of directors, also sits on the board of directors of Sarborg but does not have an equity interest in Sarborg.
During the year ended December 31, 2024, the Company recorded $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SARBORGLtdMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServicesAgreementMember_zMYTNcXSubQh" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_SARBORGLtdMember_custom_SARBORGServicesAgreementMember" id="Fact001920" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million as research and development expense related to the Sarborg Service Agreement. Refer to Note 10 above for additional
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Officers and
Directors</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">On April 22, 2024,
the Company issued in a private placement common stock purchase warrants (the &#8220;April Warrants&#8221;) to third parties which also
included certain directors, to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240422__20240422__us-gaap--RelatedPartyTransactionAxis__custom--OfficersAndDirectorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy39m5Mfj2Te"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-04-222024-04-22_custom_OfficersAndDirectorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember" id="Fact001921" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,077</ix:nonFraction>
</span>shares of the Company&#8217;s common stock, in exchange for entering into a lock-up with respect to the shares of common stock
held by such holder and for such directors, $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240422__us-gaap--RelatedPartyTransactionAxis__custom--OfficersAndDirectorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZgzjVw0jI53"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-04-22_custom_OfficersAndDirectorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember" id="Fact001922" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.50</ix:nonFraction>
</span>per warrant. The April Warrants are not exercisable until one year after their date of issuance. Each April Warrant is exercisable
into one share of the Company&#8217;s common stock at a price per share of $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pid_c20240422__20240422__us-gaap--RelatedPartyTransactionAxis__custom--OfficersAndDirectorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8JLgtznRP9h"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2024-04-222024-04-22_custom_OfficersAndDirectorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember" id="Fact001923" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">312</ix:nonFraction>
</span>(as adjusted from time to time in accordance with the terms thereof) for a two-year period after the date of exercisability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001925" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock"><p id="xdx_80C_eus-gaap--OtherNonoperatingIncomeAndExpenseTextBlock_zYfWDs9LQpEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span id="xdx_82B_zKFbqUt3TWxb">Other Income (expense), net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001927" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_zRaz7PHeDELc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents other income (expense), net, for the years ended December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zLEROoD1vXac" style="display: none">Schedule
of Other Expense, Net</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zCHJTZcrMjA8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zA6X4xw5wDef" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the years ended<br/> December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--RecognitionOfDeferredRevenueUponOptionExercise_pn3n3_maONIzvdl_zdwIaMrG2xX2" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Recognition of Cizzle deferred revenue upon option exercise</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1929">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="CDT:RecognitionOfDeferredRevenueUponOptionExercise" contextRef="From2023-01-012023-12-31" id="Fact001930" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,480</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--RecognitionOfDeferredRevenueUponOptionExerciseOne_pn3n3_maONIzvdl_zhHvM7NbHSm3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Recognition of Vela deferred revenue upon option exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1932">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:RecognitionOfDeferredRevenueUponOptionExerciseOne" contextRef="From2023-01-012023-12-31" id="Fact001933" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,774</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfOption_pn3n3_maONIzvdl_zJAEl2Djxle1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of Cizzle option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1935">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:ChangeInFairValueOfOption" contextRef="From2023-01-012023-12-31" id="Fact001936" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,280</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfOptions_pn3n3_maONIzvdl_zB06sDcImqhh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of Vela option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1938">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:ChangeInFairValueOfOptions" contextRef="From2023-01-012023-12-31" id="Fact001939" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">970</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfWarrantLiability_pn3n3_maONIzvdl_zUuqeccjAtm" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:ChangeInFairValueOfWarrantLiability" contextRef="From2024-01-01to2024-12-31" id="Fact001941" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">221</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:ChangeInFairValueOfWarrantLiability" contextRef="From2023-01-012023-12-31" id="Fact001942" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">81</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ChangeInFairValueOfConvertibleNotePayment_pn3n3_maONIzvdl_zuGyz8pDIRIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of convertible note payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:ChangeInFairValueOfConvertibleNotePayment" contextRef="From2024-01-01to2024-12-31" id="Fact001944" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,018</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1945">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--GainOnDebtExtinguishment_pn3n3_maONIzvdl_ze3kMRRDTqkd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gain on debt extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:GainOnDebtExtinguishment" contextRef="From2024-01-01to2024-12-31" id="Fact001947" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,473</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1948">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InterestIncomeOther_pn3n3_maONIzvdl_z1ZODWLtxLkh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2024-01-01to2024-12-31" id="Fact001950" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2023-01-012023-12-31" id="Fact001951" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxRefund_pn3n3_maONIzvdl_zPHoTmqFWzz2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income Tax Refund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:IncomeTaxRefund" contextRef="From2024-01-01to2024-12-31" id="Fact001953" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">314</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1954">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ForeignCurrencyTransactionGainLossUnrealized_pn3n3_maONIzvdl_zX3cx1jkESmk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unrealized foreign currency transaction gain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" contextRef="From2024-01-01to2024-12-31" id="Fact001956" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" contextRef="From2023-01-012023-12-31" id="Fact001957" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherIncome_pn3n3_maONIzvdl_zNTeZ8sHMXb3" style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2024-01-01to2024-12-31" id="Fact001959" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2023-01-012023-12-31" id="Fact001960" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">115</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherNonoperatingIncome_iT_pn3n3_mtONIzvdl_maNIEzWCX_zCofSRuvuno" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total other income:</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2024-01-01to2024-12-31" id="Fact001962" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2023-01-012023-12-31" id="Fact001963" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,754</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other expense:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--LossOnIssuanceOfOptionOne_maONEzInN_zC40JIPLbHN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Loss on issuance of Vela option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1965">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:LossOnIssuanceOfOptionOne" contextRef="From2023-01-012023-12-31" id="Fact001966" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">987</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--OtherIncomeUnrealizedForeignCurrencyTransactionLoss_pn3n3_maONEzInN_zUTM7r7N79U1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Change in fair value of convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1968">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:OtherIncomeUnrealizedForeignCurrencyTransactionLoss" contextRef="From2023-01-012023-12-31" id="Fact001969" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">426</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpenseOther_pn3n3_maONEzInN_zf9T4tlX67cf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2024-01-01to2024-12-31" id="Fact001971" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">577</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2023-01-012023-12-31" id="Fact001972" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">211</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_pn3n3_maONEzInN_zIZKBsRBHjT3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Amortization of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2024-01-01to2024-12-31" id="Fact001974" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">929</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1975">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LossOnIssuanceOfWarrants_pn3n3_maONEzInN_zVp9UX2yQaPc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Loss on issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:LossOnIssuanceOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact001977" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,710</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1978">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LossOnDebtExtinguishment_pn3n3_maONEzInN_zdOWng6ia3o" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Loss on Debt Extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:LossOnDebtExtinguishment" contextRef="From2024-01-01to2024-12-31" id="Fact001980" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,179</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1981">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OtherExpenseChangeInFairValueOfConvertibleNotesPayable_pn3n3_maONEzInN_zeToQGOj2d85" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Realized foreign currency transaction loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:OtherExpenseChangeInFairValueOfConvertibleNotesPayable" contextRef="From2024-01-01to2024-12-31" id="Fact001983" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CDT:OtherExpenseChangeInFairValueOfConvertibleNotesPayable" contextRef="From2023-01-012023-12-31" id="Fact001984" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">403</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--OtherExpense_pn3n3_maONEzInN_zlIUEjUUOWtd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Other expense</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="CDT:OtherExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001986" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1987">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNonoperatingExpense_iT_pn3n3_msNIEzWCX_mtONEzInN_zI8XW3D9aGRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total other expense</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001989" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,431</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2023-01-012023-12-31" id="Fact001990" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,027</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NonoperatingIncomeExpense_iT_pn3n3_mtNIEzWCX_zcQ5VcY0Bxv9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total other (expense) income, net</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001992" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,383</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact001993" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,727</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zmtiTluQTbXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001995" name="CDT:WarrantLiabilityDisclosureTextBlock"><p id="xdx_806_ecustom--WarrantLiabilityDisclosureTextBlock_zWqswt08YScb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.
<span id="xdx_822_z0z1vQFCL2he">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of the Merger, the Company assumed (i) the warrants initially included in the MURF units issued in MURF&#8217;s initial public
offering (the &#8220;Publicly Traded Warrants&#8221;), and (ii) the warrants that were included in the private placement units issued
to the Sponsor simultaneously with the closing of MURF&#8217;s initial public offering (the &#8220;Private Placement Warrants&#8221;).
In connection with the Merger, the Company also issued warrants to the PIPE Investors (the &#8220;PIPE Warrants&#8221;) pursuant to the
Subscription Agreements and to an advisor (the &#8220;A.G.P. Warrants,&#8221; and together with the PIPE Warrants, the &#8220;Liability
Classified Warrants&#8221;) pursuant to the Company&#8217;s engagement agreement with the advisor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that the settlement amount of the Publicly Traded Warrants and the Private Placement Warrants would equal the difference
between the fair value of a fixed number of shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified
as equity, while the settlement amount of the Liability Classified Warrants would not equal the difference between the fair value of
a fixed number of shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified as a liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 20, 2024, the Company issued in a private placement equity classified common stock purchase warrants (the &#8220;March 2024
Warrants&#8221;) to an investor to purchase up to an aggregate <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240320__us-gaap--TypeOfArrangementAxis__custom--MarchLockUpAgreementMember_z5drcXnXkUb5" title="Common stock purchase of waarants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-03-20_custom_MarchLockUpAgreementMember" id="Fact001997" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,600</ix:nonFraction></span>
shares of the Company&#8217;s Common Stock, in exchange for entering into a lock-up with respect to the shares of common stock held
by such holder (the &#8220;March Lock-Up Agreement&#8221;). The Company recognized at $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--MarchLockUpAgreementMember_z2P8hk5KQ8f" title="Issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-12-31_custom_MarchLockUpAgreementMember" id="Fact001999" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span>
million loss on the issuance of the warrants during the year ended December 31, 2024. The Company determined that the March 2024 Warrants
should be classified within equity and estimated the fair value of the warrants issued as of March 20, 2024, using a Black-Scholes
option-pricing model utilizing the following assumptions:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU002003-01" escape="true" id="Fact002003" name="CDT:ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock"><p id="xdx_89C_ecustom--ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock_gL3SOSBPASPWV-MQTQ_zhfw2PgPJCyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zO1HuPsadJOc" style="display: none">Schedule
of Black-Scholes Option Pricing Model</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 20, 2024</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Closing stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20240320_zDYyrtH6M8fk" title="Closing stock price" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-20" id="Fact002005" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">347</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Contractual exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20240320_z4TqI1iGO2C5" title="Contractual exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-03-20" id="Fact002007" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">318</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240320__20240320_zRP4KJdUxw1b" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-03-202024-03-20" id="Fact002009" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.41</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Estimated volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240320__20240320_zASslSdPQ4sj" title="Estimated volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-03-202024-03-20" id="Fact002011" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">78.5</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Time period to expiration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240320__20240320_z4w1CDTsOCG" title="Time period to expiration"><ix:nonNumeric contextRef="From2024-03-202024-03-20" format="ixt-sec:duryear" id="Fact002013" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3</ix:nonNumeric></span> Years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zGx42WK9gYXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<ix:exclude><!-- Field: Page; Sequence: 130; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 20, 2024, the Company issued in a private placement equity classified common stock purchase warrants (the &#8220;April 2024 Warrants&#8221;)
to shareholders&#8217; of the Company to purchase up to an aggregate <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240420__us-gaap--TypeOfArrangementAxis__custom--AprilLockUpAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AprilTwentyTwentyFourWarrantsMember_zqV3OarfyFZj" title="Class of warrant or right outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-04-20_custom_AprilLockUpAgreementMember_custom_AprilTwentyTwentyFourWarrantsMember" id="Fact002015" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,477</ix:nonFraction></span> shares of the Company&#8217;s Common Stock, in exchange for
(1) $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240420__us-gaap--TypeOfArrangementAxis__custom--AprilLockUpAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AprilTwentyTwentyFourWarrantsMember_zwlt4ZsNVnB7" title="Common stock purchase of warants price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-04-20_custom_AprilLockUpAgreementMember_custom_AprilTwentyTwentyFourWarrantsMember" id="Fact002017" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.50</ix:nonFraction></span> per warrant and (2) entering into a lock-up with respect to the shares of common stock held by such holders (the &#8220;April
Lock-Up Agreement&#8221;). <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240420__20240420__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z7koa7c4FtDj" title="Issuance of stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-04-202024-04-20_us-gaap_WarrantMember_srt_DirectorMember" id="Fact002019" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,077</ix:nonFraction></span> of the total April 2024 Warrants issued were issued to directors, related parties and management of
the Company. The Company received cash of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240401__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zlHKlDrNCFcj" title="Proceeds from warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-04-012024-12-31_us-gaap_WarrantMember_srt_DirectorMember" id="Fact002021" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million and recognized a $<span id="xdx_903_eus-gaap--GainLossOnInvestments_pn5n6_c20240401__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember_zyloiAWgsLcd" title="Loss from issuance of warrants"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2024-04-012024-12-31_srt_DirectorMember" id="Fact002023" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.2</ix:nonFraction></span> million loss on the issuance of the warrants during the year ended December 31, 2024. The Company determined that the April 2024 Warrants should be classified within equity and estimated the
fair value of the warrants issued as of April 20, 2024, using a Black-Scholes option-pricing model utilizing the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_C07_gL3SOSBPASPWV-MQTQ_z88lnxcVcsJi"><ix:continuation continuedAt="ConU002003-02" id="ConU002003-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<div id="xdx_C0C_gL3SOSBPASPWV-MQTQ_zEWk4k4PUQGk"><ix:continuation id="ConU002003-02"><div><table cellpadding="0" cellspacing="0" id="xdx_305_134_zZIyFq14jANh" summary="xdx: Disclosure - Schedule of Black-Scholes Option Pricing Model (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 20, 2024</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Closing stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20240420_z5bNvZoBeXf1" title="Closing stock price" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-04-20" id="Fact002025" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">308</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Contractual exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20240420_zyZrkxWLBv9a" title="Contractual exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-04-20" id="Fact002027" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">312</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240420__20240420_zFJ5eTblTUG" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-04-202024-04-20" id="Fact002029" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.81</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Estimated volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240420__20240420_zWZLvLeZaVM5" title="Estimated volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-04-202024-04-20" id="Fact002031" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">78.3</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Time period to expiration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240420__20240420_zCpkfb2n14Ti" title="Time period to expiration"><ix:nonNumeric contextRef="From2024-04-202024-04-20" format="ixt-sec:duryear" id="Fact002033" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3</ix:nonNumeric></span> Years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</div></ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
partial consideration for the Advance issued to the Company by A.G.P. on October 29, 2024, the Company issued A.G.P. Warrants (the &#8220;A.G.P.
2024 Warrants&#8221;) to purchase up to&#160;<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241029__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AGPTwentyTwentyFourWarrantsMember_zo38UquRmUP3" title="Exercise price of warrants per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-10-29_custom_AllianceGlobalPartnersMember_custom_AGPTwentyTwentyFourWarrantsMember" id="Fact002035" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,625</ix:nonFraction></span>&#160;shares of the Company&#8217;s Common Stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241029__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AGPTwentyTwentyFourWarrantsMember_z46gnHTDbvub" title="Exercise price of warrants per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-10-29_custom_AllianceGlobalPartnersMember_custom_AGPTwentyTwentyFourWarrantsMember" id="Fact002037" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.1048</ix:nonFraction></span>&#160;per
share. The Company determined that the A.G.P. 2024 Warrants should be classified as a liability and estimated the fair value of the warrants
as of October 29, 2024, and December 31, 2024, using a Black-Scholes option-pricing model. Refer to Note 3 above for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Classified Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to MURF&#8217;s initial public offering, the Company sold <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230922__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zE22S92K5r5c" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-09-22_us-gaap_IPOMember_custom_PublicWarrantMember" id="Fact002039" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">132,250</ix:nonFraction></span> units at a price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230922__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zk8ZmclFULT7" title="Warrants price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-09-22_us-gaap_IPOMember_custom_PublicWarrantMember" id="Fact002041" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per unit. Each unit consisted of one share
of MURF Class A common stock and one redeemable Publicly Traded Warrant. Each whole Publicly Traded Warrant entitled the holder to purchase
one share of Class A common stock at a price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_z3MvsRpB5Qae" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_us-gaap_IPOMember_custom_PublicWarrantMember" id="Fact002043" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></span> per share, subject to adjustment. The warrants are publicly traded on The Nasdaq
Capital Market under the trading symbol CDTTW.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the closing of its initial public offering, MURF consummated the private sale to the Sponsor of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230922__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantMember_zd5SlDkbHi2h" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-09-22_us-gaap_IPOMember_custom_PrivatePlacementWarrantMember" id="Fact002045" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,540</ix:nonFraction></span> private placement units at
a price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230922__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantMember_zCu0bw6tzfIj" title="Warrants price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-09-22_us-gaap_IPOMember_custom_PrivatePlacementWarrantMember" id="Fact002047" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per private placement unit. Each private placement unit was comprised of one share of MURF Class A common stock and
one Private Placement Warrant. Each Private Placement Warrant was exercisable to purchase one share of MURF Class A common stock at a
price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230922__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantMember_zeiq3nGePO4h" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-09-22_us-gaap_IPOMember_custom_PrivatePlacementWarrantMember" id="Fact002049" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></span> per share, subject to adjustment. The private placement units (including the Class A common stock issuable upon exercise
of the warrants included in the private placement units) were not transferable, assignable, or saleable until 30 days after the completion
of a Merger, subject to certain exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the closing of the Merger on September 22, 2023, the Equity Classified Warrants were amended to entitle each holder to
purchase one share of the Company&#8217;s Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Equity Classified Warrants became exercisable 30 days after the Closing Date of the Merger. The Equity Classified Warrants will expire
five years after the Closing Date of the Merger or earlier upon redemption or liquidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will not be obligated to deliver any shares of Common Stock pursuant to the exercise of an Equity Classified Warrant and will
have no obligation to settle such exercise unless a registration statement under the Securities Act with respect to the shares of Common
Stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations
described below with respect to registration. No Equity Classified Warrant will be exercisable and we will not be obligated to issue
shares of Common Stock upon exercise unless the Common Stock issuable upon such exercise has been registered, qualified or deemed to
be exempt under the securities laws of the state of residence of the registered holder of the Equity Classified Warrant. In the event
that the conditions in the two immediately preceding sentences are not satisfied with respect to an Equity Classified Warrant, the holder
of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will
we be required to net cash settle any Equity Classified Warrant. In the event that a registration statement is not effective for the
exercised Equity Classified Warrant, the purchaser of a unit containing such Equity Classified Warrant will have paid the full purchase
price for the unit solely for the share of Common Stock underlying such unit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 131; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit
may call the Publicly Traded Warrants in whole and not in part, at a price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231_zfNABH78lE72" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31" id="Fact002051" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per warrant,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    not less than 30 days&#8217; prior written notice of redemption to each Publicly Traded Warrant holder; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
and only if, the reported last sale price of the Common Stock equals or exceeds $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr2umUGNi4x2" title="Share price per shares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact002053" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,800.00</ix:nonFraction></span> per share (as adjusted for stock splits, stock
dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing once the
Publicly Traded Warrants become exercisable and ending three business days before we send the notice of redemption to the warrant holders.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
and when the Publicly Traded Warrants become redeemable by Conduit, Conduit may not exercise its redemption right if the issuance of
shares of Common Stock upon exercise of the Publicly Traded Warrants is not exempt from registration or qualification under applicable
state blue sky laws or Conduit are unable to effect such registration or qualification. Conduit will use its best efforts to register
or qualify such shares of Common Stock under the blue sky laws of the state of residence in those states in which the Publicly Traded
Warrants were offered by Conduit in the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Conduit calls the Publicly Traded Warrants for redemption as described above, Conduit&#8217;s management will have the option to require
any holder that wishes to exercise its Publicly Traded Warrant to do so on a &#8220;cashless basis.&#8221; In determining whether to
require all holders to exercise their Publicly Traded Warrants on a &#8220;cashless basis,&#8221; Conduit&#8217;s management will consider,
among other factors, Conduit&#8217;s cash position, the number of Publicly Traded Warrants that are outstanding and the dilutive effect
on Conduit stockholders of issuing the maximum number of shares of Common Stock issuable upon the exercise of our Publicly Traded Warrants.
If Conduit&#8217;s management takes advantage of this option, all holders of Publicly Traded Warrants would pay the exercise price by
surrendering their Publicly Traded Warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x)
the product of the number of shares of Common Stock underlying the Publicly Traded Warrants, multiplied by the difference between the
exercise price of the Publicly Traded Warrants and the &#8220;fair market value&#8221; (defined below) by (y) the fair market value.
The &#8220;fair market value&#8221; for this purpose shall mean the average reported last sale price of the Common Stock for the 10 trading
days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of Publicly Traded Warrants.
If Conduit&#8217;s management takes advantage of this option, the notice of redemption will contain the information necessary to calculate
the number of shares of Common Stock to be received upon exercise of the Publicly Traded Warrants, including the &#8220;fair market value&#8221;
in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive
effect of a Publicly Traded Warrant redemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Private Placement Warrants are identical to the Publicly Traded Warrants, except that such warrants will be exercisable for cash or on
a cashless basis, at the holder&#8217;s option, and will not be redeemable by Conduit, in each case so long as they are still held by
the Sponsor or its permitted transferees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
summarized above, the Company has the option to redeem all of the Publicly Traded Warrants at a cash price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z94CLhTSFEBk" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact002055" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per warrant during
the exercisability period if the Company&#8217;s common stock has closed at a trading price above $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPAYK1sEjI97" title="Share price per shares"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact002057" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.00</ix:nonFraction></span> for 20 days during a 30-day
trading window. Management notes that this option is within the Company&#8217;s control, therefore it does not represent an &#8220;obligation&#8221;
and does not create a liability under ASC 480. Management considered the guidance within ASC 815-40-15-7A, noting that an exercise contingency
would not preclude permanent equity classification if all of the other equity criteria are met. As all other criteria to be classified
as permanent equity are met, the Publicly Traded Warrants are classified as permanent equity on the Consolidated Balance Sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 132; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assessed the Private Placement Warrants and determined that the warrants are considered to be indexed to the entity&#8217;s own stock
and met all the criteria for permanent equity classification. As such, the Publicly Traded Warrants are classified as permanent equity
on the Consolidated Balance Sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The March 2024 Warrants are not exercisable until one year after their date of issuance. Each March
2024 Warrant is exercisable into one share of the Company&#8217;s Common Stock at a price per share of $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20240331_z2FaSSK2pOo4" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-31" id="Fact002059" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.18</ix:nonFraction></span> (as adjusted from time to
time in accordance with the terms thereof) for a two-year period after the date of exercisability. <span id="xdx_90A_eus-gaap--SubsequentEventDescription_c20240301__20240331__us-gaap--TypeOfArrangementAxis__custom--MarchLockUpAgreementMember_zmooEv2PWghh" title="Subsequent event, description"><ix:nonNumeric contextRef="From2024-03-012024-03-31_custom_MarchLockUpAgreementMember" id="Fact002061" name="us-gaap:SubsequentEventDescription">There is no established public trading
market for the March 2024 Warrants. Notwithstanding the foregoing, the March 2024 Warrants shall vest, and not be subject to forfeiture,
with respect to 25% of such March 2024 Warrants commencing on the 90th day after the date of the March Lock-Up Agreement and 25% on each
subsequent 90-day anniversary, in each case vesting only if the holder agrees to continue to have its shares of common stock remain locked
up pursuant to the March Lock-Up Agreement on such date.</ix:nonNumeric></span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
April 2024 Warrants are not exercisable until one year after their date of issuance. Each April 2024 Warrant is exercisable into one
share of the Company&#8217;s Common Stock at a price per share of $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20240430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--AprilLockUpAgreementMember_z5ihtOA0EO2a" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-04-30_us-gaap_WarrantMember_custom_AprilLockUpAgreementMember" id="Fact002063" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">312</ix:nonFraction></span> (as adjusted from time to time in accordance with the terms thereof)
for a two-year period after the date of exercisability. <span id="xdx_900_eus-gaap--SubsequentEventDescription_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--AprilLockUpAgreementMember_zk90ILUsewu1" title="Subsequent event, description"><ix:nonNumeric contextRef="From2024-04-012024-04-30_custom_AprilLockUpAgreementMember" id="Fact002065" name="us-gaap:SubsequentEventDescription">There is no established public trading market for the April 2024 Warrants. Notwithstanding
the foregoing, the April 2024 Warrants shall vest, and not be subject to forfeiture, with respect to 25% of such March 2024 Warrants
commencing on the 90th day after the date of the April Lock-Up Agreement and 25% on each subsequent 90-day anniversary, in each case
vesting only if the holder agrees to continue to have its shares of common stock remain locked up pursuant to the April Lock-Up Agreement
on such date.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liability
Classified Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 2, <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z6huybZNwY3d" title="Shares issued during the period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember" id="Fact002067" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span> PIPE Warrants were issued to the PIPE Investors as of the closing of the Merger pursuant to subscription
agreements. The warrants provide the PIPE Investors the right to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zO64Ex1Mltbg" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember" id="Fact002069" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span> shares of Common Stock at an exercise price of
$<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zrBmXn4aL4Xl" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember" id="Fact002071" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,150</ix:nonFraction></span>. Additionally, on the Closing Date of the Merger, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zH4J9NVIsBV3" title="Shares issued during the period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember" id="Fact002073" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">540</ix:nonFraction></span> A.G.P. Warrants to an advisor for services provided directly
related to the Merger. The warrants provide the advisor the right to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pip0_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zoD2uTnQmg45" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember" id="Fact002075" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">540</ix:nonFraction></span> shares of Common Stock at an exercise price of
$<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zSRXlfaBGYka" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember" id="Fact002077" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,100</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants issued to the PIPE Investors and the advisor contain materially the same terms and are exercisable for a period of five years,
beginning on October 22, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PIPE Warrants are exercisable for cash or on a cashless basis, at the holder&#8217;s option. The PIPE Warrants are not redeemable by
the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
A.G.P. Warrants are exercisable for cash or on a cashless basis, at the holder&#8217;s option. The Company may call the A.G.P. Warrants
for redemption, in whole and not in part, at any time after the A.G.P. Warrants become exercisable and prior to their expiration, at
a price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230922_zLItLLVxv1Wc" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-09-22" id="Fact002079" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per A.G.P. Warrant,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    not less than 30 days&#8217; prior written notice of redemption to each warrant holder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, the reported last sale price of the Common Stock equals or exceeds $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230922_zEe1CqE7pCG2" title="Common stock per share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-22" id="Fact002081" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,800</ix:nonFraction></span> per share (as adjusted for stock splits, stock
    dividends, recapitalizations and other similar events) for any 20 trading days within a 30-trading day period commencing once the
    A.G.P. Warrants become exercisable and ending three business days before we send the notice of redemption to the warrant holders;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
    there is a current registration statement in effect with respect to the shares of Common Stock underlying the A.G.P. Warrants for
    each day in the 30-trading day period and continuing each thereafter until the redemption date.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company calls the A.G.P. Warrants for redemption as described above, our management will have the option to require any holder that
wishes to exercise its A.G.P. Warrant to do so on a &#8220;cashless basis.&#8221; If our management takes advantage of this option, holders
of A.G.P. Warrants would pay the exercise price by surrendering their A.G.P. Warrants for that number of shares of Common Stock as calculated
pursuant to the A.G.P. Warrant. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby
lessen the dilutive effect of an A.G.P. Warrant redemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise of the A.G.P. 2024 Warrants and the issuance of the shares of Common Stock underlying the Warrants is subject to stockholder
approval under applicable rules and regulations of Nasdaq. The warrants are exercisable for a period of five years, beginning on the
stockholder approval date. The A.G.P 2024 Warrants are exercisable for cash, or on a cashless basis if at the time of exercise there
is no effective registration statement registering the resale of the warrant shares. The A.G.P. 2024 Warrants are not redeemable by the
Company. On October 29, 2024, the Company recorded a warrant liability of $<span id="xdx_907_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20241029__20241029__us-gaap--ClassOfWarrantOrRightAxis__custom--AGPTwentyTwentyFourWarrantsMember_zQ5AwxhQmKld" title="Warrant liability"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-10-292024-10-29_custom_AGPTwentyTwentyFourWarrantsMember" id="Fact002083" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million. As part of the special meeting of stockholders
taking place on January 9, 2025, the stockholders approved the issuance of up to an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20241029__20241029__us-gaap--ClassOfWarrantOrRightAxis__custom--AGPTwentyTwentyFourWarrantsMember_z2yaXQ7m2PBf" title="Common stock upon exercise, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-10-292024-10-29_custom_AGPTwentyTwentyFourWarrantsMember" id="Fact002085" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,625</ix:nonFraction></span> shares of the Company&#8217;s
common stock upon exercise of the A.G.P. 2024 Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PIPE Warrants, A.G.P. Warrants, and the A.G.P 2024 Warrants (collectively the &#8220;Liability Classified Warrants&#8221;) are classified
as derivative liabilities because they do not meet the criteria in ASC 815-40 to be considered indexed to the entity&#8217;s own stock
as the warrants could be settled for an amount that is not equal to the difference between the fair value of a fixed number of the entity&#8217;s
shares and a fixed monetary amount. The Liability Classified Warrants are initially measured at fair value and are remeasured at fair
value at subsequent financial reporting period end dates and upon exercise (see Note 7 for additional information regarding fair value).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 11, 2024, the Company reduced the exercise price of the PIPE Warrants to be $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241211__us-gaap--ClassOfWarrantOrRightAxis__custom--PIPEWarrantsMember_zki1xQWESpWk"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-11_custom_PIPEWarrantsMember" id="Fact002086" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.83</ix:nonFraction></span>, at which time all PIPE Warrants were exercised.
The Company received approximately $<span id="xdx_907_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20241211__20241211_zEN3F8LmrRba" title="Proceeds from the exercise warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-12-112024-12-11" id="Fact002088" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million of proceeds from the exercise of the Warrants, all of which was used to pay down the
October 2024 Nirland Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024, and December 31, 2023, the Company remeasured the fair value of the Liability Classified Warrants
and recorded a gain on the change in the fair value of $<span id="xdx_900_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_pn5n6_c20240101__20241231_zsQPe7Qc4rBl"><ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="From2024-01-01to2024-12-31" id="Fact002089" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_905_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_pn5n6_c20230101__20231231_zU5ijkra8ir3"><ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="From2023-01-012023-12-31" id="Fact002090" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respective. The gains were recorded
to other income (expense), net, on the consolidated statements of operations and comprehensive income (loss). As of December 31, 2024
and December 31, 2024, the balance sheets contained warrant liabilities of $<span id="xdx_907_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn5n6_c20241231_zU1kz0Spsjrc"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact002091" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_903_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn4n6_c20231231_zLavmWgmrIj6"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact002092" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.01</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 133; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002094" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_zd8CxAnBPR76" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.
<span id="xdx_826_z6ds53LXNvu9">Segments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has one operating segment focused on the research and development of clinical assets. The accounting policies of the single operating
segment are identical to those described in Note 1. The CODM, which the Company has identified as David Tapolczay, Chief Executive
Officer, manages the Company&#8217;s operations on a consolidated basis, assesses performance for the operating segment and decides how
to allocate resources based on consolidated net loss, which is reported on the consolidated statements of operations and comprehensive
income (loss). Depreciation expense, amortization expense, stock-based compensation expense, and non-cash lease expense are significant
noncash items included in consolidated net loss reviewed by the CODM and are reported on the consolidated statements of cash flows. The
measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. Expenditures for additions to
long-lived assets, which include purchases of property and equipment, are included in total consolidated assets reviewed by the chief
operating decision maker and are reported on the consolidated statements of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CODM uses consolidated net loss and budget-to-actual variances to assess the performance of the operating segment and determine if the
Company is progressing towards its goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002096" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zeq29aukxZVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents certain financial data for the Company&#8217;s reportable segment (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zwnjdjWmq04k">Schedule
of Financial Data for the Company&#8217;s Reportable Segment</span><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; font-weight: bold; text-align: center">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zQuzlzBZCsi" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zSHo6cOoit5b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NewLicensesMember_zwzjhtJnjcZk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Research &amp; development expense &#8211; new licenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_NewLicensesMember" id="Fact002098" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,114</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2099">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalAssetDevelopmentMember_zQjXPw4bUVJ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Research &amp; development expense &#8211; clinical asset development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_ClinicalAssetDevelopmentMember" id="Fact002101" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">264</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_ClinicalAssetDevelopmentMember" id="Fact002102" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--LegalAndProfessionalFeesMember_zrUmRuEc6tai" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">General and administrative expenses &#8211; legal &amp; professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_LegalAndProfessionalFeesMember" id="Fact002104" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,258</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_LegalAndProfessionalFeesMember" id="Fact002105" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">314</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--AccountingAndAuditFeesMember_z50BW13V11fa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">General and administrative expenses &#8211; accounting &amp; audit fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_AccountingAndAuditFeesMember" id="Fact002107" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,625</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_AccountingAndAuditFeesMember" id="Fact002108" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,064</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--SalariesPayrollAndStockBasedCompensationMember_z540kLE8Dve4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">General and administrative expenses &#8211; salaries, payroll and stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_SalariesPayrollAndStockBasedCompensationMember" id="Fact002110" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,098</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_SalariesPayrollAndStockBasedCompensationMember" id="Fact002111" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">721</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_zNfIlJ5g4HA5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">General and administrative expenses &#8211; other</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact002113" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,060</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact002114" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,073</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_pn3n3_maNILzclF_zgW3TKhaO0Be" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from segment operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact002116" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact002117" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,262</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zcaBlpAaiUn1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
segment items consist of the items within Note 17 to the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002119" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zcHl3ZWg25T3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20.
<span id="xdx_82E_zTYsuP6cGUT6">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2025, the Company effected the Reverse Stock Split, pursuant to which every <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20240124__20240124_zvoh26VIF3v5" title="Number shares reverse stock split during the period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2024-01-242024-01-24" id="Fact002121" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></span> shares of the Company&#8217;s common stock
issued or outstanding were automatically reclassified into one new share of common stock, subject to the treatment of fractional shares
as previously described, without any action on the part of the holders. For a description of the Reverse Stock Split, refer to Note 1
above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Nirland Notes
Repayment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">On February 7, 2025,
the Company fully repaid its outstanding October 2024 Nirland Note to Nirland Limited in the principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20250207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--OctoberTwentyTwentyFourNirlandNoteMember_zqfUOxVMdj6e"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-02-07_us-gaap_SubsequentEventMember_custom_OctoberTwentyTwentyFourNirlandNoteMember" id="Fact002122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span>.
This payment settled all obligations under the October 2024 Nirland Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the August 2024 Nirland Note, the Lender converted approximately $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20250207__20250207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_z6G0PLoH5LMi" title="Debt conversion amount"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2025-02-072025-02-07_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember" id="Fact002124" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
of the original principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20250207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zBarsZKCOfcd" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-02-07_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember" id="Fact002126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,650,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
into shares of common stock of the Company. Of the $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20250207__20250207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zgwpgBkRpGZb" title="Debt conversion amount"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2025-02-072025-02-07_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember" id="Fact002128" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million of original principal that was converted into shares of common stock
of the Company, $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20241212__20241212__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zq9aYdW75lJa" title="Debt conversion amount"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2024-12-122024-12-12_custom_AugustTwentyTwentyFourNirlandNoteMember" id="Fact002130" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million was converted on December 12, 2024, while the remaining $<span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20250113__20250113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_z0AcZVIpZSof" title="Debt conversion amount"><span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20250210__20250210__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zXrqZQsRh4Ud" title="Debt conversion amount"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2025-01-132025-01-13_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember" id="Fact002132" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2025-02-102025-02-10_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember" id="Fact002134" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></ix:nonFraction></span></span> million was converted between January 13,
2025 and February 10, 2025. On February 13, 2025,&#160;the&#160;Company paid the remaining outstanding portion of the August 2024
Nirland Note, approximately $<span id="xdx_906_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20250213__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zwhr68DAEyA2" title="Remaining outstanding"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2025-02-13_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember" id="Fact002136" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span>
million, and, accordingly, satisfied all of its obligations in all respects to Nirland. As a result of satisfying its obligations under the
August 2024 Nirland Note, all of the Company&#8217;s assets are once again free and clear of any liens, security interests or
encumbrances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>March 2023 Convertible Note
Repayment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">On March 13, 2025,
the Company fully repaid its outstanding March 2023 Convertible Note. The Company notes that the note holder agreed on March 6, 2025
to reduce the principal from $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeConvertibleNoteMember_zvmOgLfGnGJh"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-03-31_custom_TwentyTwentyThreeConvertibleNoteMember" id="Fact002137" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span>
million to $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250313__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4cg8aG1SYM5"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-03-13_custom_TwentyTwentyThreeConvertibleNoteMember_us-gaap_SubsequentEventMember" id="Fact002138" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span>
million. This payment settled all obligations under the March 2023 Convertible Note. The March 2023 Convertible Note Repayment was considered
to be in default until payment on March 13, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Nasdaq Stock
Market Correspondence and Subsequent Nasdaq Capital Market Listing</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2025, the Company presented its plan of compliance to The Nasdaq Stock Market LLC Hearing Panel (the &#8220;Panel&#8221;)
and requested an extension of time to achieve compliance with Nasdaq Listing Rules, the Minimum Bid Price (&#8220;Bid Price&#8221;),
Market Value of Publicly Held Shares (&#8220;MVPHS&#8221;) and Market Value of Listed Securities (&#8220;MVLS&#8221;) rules, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 5, 2025, the Company received a written notification from the Panel confirming it has granted the Company such an extension for
the Company to regain compliance with the MVPHS and MVLS rules, provided that the Company, (i) on or before March 12, 2025, files an
application to transfer to the Nasdaq Capital Market, which application was submitted on March 7, 2025, and (ii) on or before March 31,
2025, demonstrates compliance with all Nasdaq listing rules, which it intends to do. Additionally, the Company was also notified in the
Notice that as of February 26, 2025, it had regained compliance with the Bid Price rule. The Company notes that there is no assurance
that the Company can maintain ongoing compliance with the Bid Price Rule. The Company expects to submit its compliance document with
respect to the MVPHS and MVLS rules which will be subject to review by the Panel. The Panel, may, in its discretion, request additional
information before determining that the Company has complied with the terms of the exception. There can be no assurances that the Panel&#8217;s
decision will agree with the Company&#8217;s compliance document. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><b><i>Common Stock
Issuances in Relation to the Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The Company
increased the aggregate offering price under the Sales Agreement to up to $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250115__20250115__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zotNnjf67GW2" title="Issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-152025-01-15_us-gaap_SubsequentEventMember_custom_SalesAgreementMember" id="Fact002140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,835,433</ix:nonFraction></span>,
$<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250206__20250206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zh6sOaEMpl4e" title="Issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-02-062025-02-06_us-gaap_SubsequentEventMember_custom_SalesAgreementMember" id="Fact002142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,183,156</ix:nonFraction></span>,
$<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250210__20250210__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zPHHFLhnpl9h" title="Issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-02-102025-02-10_us-gaap_SubsequentEventMember_custom_SalesAgreementMember" id="Fact002144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,450,017</ix:nonFraction></span>,
$<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250219__20250219__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zor3mp1JLC75" title="Issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-02-192025-02-19_us-gaap_SubsequentEventMember_custom_SalesAgreementMember" id="Fact002146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,816,270</ix:nonFraction></span>,
and $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250310__20250310__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zUzluFCmZkcb" title="Issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-03-102025-03-10_us-gaap_SubsequentEventMember_custom_SalesAgreementMember" id="Fact002148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,922,782</ix:nonFraction></span> on January 15, 2025, February 6, 2025, February 10, 2025, February 19, 2025, and March 10, respectively. From
January 22, 2025 through the issuance of the Company&#8217;s consolidated financial statements, the Company sold <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250122__20250122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMOwQp4j8m8e" title="Commons tock shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2025-01-222025-01-22_us-gaap_SubsequentEventMember" id="Fact002150" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,345,913</ix:nonFraction></span>
shares of the Company&#8217;s Common Stock through the Sales Agreement. The Company received proceeds of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20250122__20250122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znTxp22uLSp8" title="Commons tock shares sold, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-222025-01-22_us-gaap_SubsequentEventMember" id="Fact002152" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.1</ix:nonFraction></span>
million, net of commissions payable to A.G.P. of $<span id="xdx_903_ecustom--CommissionsPayable_iI_pn5n6_c20250122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zm8Jlj4rgSnb" title="Commissions payable"><ix:nonFraction name="CDT:CommissionsPayable" contextRef="AsOf2025-01-22_us-gaap_SubsequentEventMember" id="Fact002154" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million. As of the financial statement filing date, the Company has $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250328__20250328__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zGyvmDnDsHIe" title="Available common stock issuances"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-03-282025-03-28_custom_SalesAgreementMember" id="Fact002156" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.0</ix:nonFraction></span> million
available under the Sales Agreement.</p>

</ix:nonNumeric><p id="xdx_819_zAcj9EO006L9" style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"></p>

<!-- Field: Page; Sequence: 134; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kk1uwjAQhU/AHUZRlwicVHSRHUWAqkKJAEG3JkyKReKJxubvSL1lbUcpLNrIUhzPe/nejBxF3WhKE1Uiw+frcgZrrOpSWoQlFsioc3SK0dt7Cu69xC9lLEttw2drHJHzoPMMeslg5wpBelYG9ymIpJ+89JOB26TxM2TzqOPrI9KF2qO2SpYg9R4yppoVWsm35g9reSVN1S2gNshGkU4h7omm/A2JiBP4oLO8EB8NzGajqNMNTyeaMp1qpxpfLWrvhHGJlcOZxn1fIU1+MpaqdIl7xEruStxK9m2ascwP2wP9HoyvyLkyXjIhXmhcHSTjonAjqEivLOXHYSvCjFXuanHcG4g5Vjtkh4pFksRiKNoxtURokV1AB4WLp8KlOQS8c6EgBtIIxqOBCmjgEOggrRtnq0eofQYvegox/mj6IXomeSPLE4qeECLOkEN3/0R/pHahlgxn74Wnxg21uxkhYsv8AelJwX4= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF OUR SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of our securities of as set forth in certain provisions of our Second Amended and Restated Certificate of
Incorporation (the &ldquo;Charter&rdquo;), our Amended and Restated Bylaws (the &ldquo;Bylaws&rdquo;), and the applicable provisions
of the Delaware General Corporation Law. This information is qualified entirely by reference to the applicable provisions of our Charter,
Bylaws and the Delaware General Corporation Law. We encourage you to read our Charter, Bylaws, applicable forms of warrant, and the applicable
portions of the DGCL carefully.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authorized
Capitalization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total amount of authorized capital stock of the Company consists of 250,000,000 shares of Common Stock, par value $0.0001 per share,
and 1,000,000 shares of preferred stock, par value $0.0001 per share (&ldquo;Preferred Stock&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of the Common Stock are entitled to one vote for each share held of record on all matters to be voted on by stockholders. There
is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the voting power
represented by shares of Common Stock voted for the election of directors can elect all of the directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividend
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable law and the rights, if any, of the holders of any outstanding series of the Preferred Stock, the holders of shares of Common
Stock are entitled to receive such dividends and other distributions (payable in cash, property or capital stock of the Company) when,
as and if declared thereon by the board of directors from time to time out of any assets or funds of the Company legally available therefor
and shall share equally on a per share basis in such dividends and distributions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Common Stock do not have any conversion, pre-emptive or other subscription rights and there is no sinking fund or redemption provisions
applicable to the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Charter authorizes the issuance of 1,000,000 shares of Preferred Stock by the board of directors, in one or more series, and the board
of directors may establish the number of shares to be included in each such series and may fix the voting rights, if any, designations,
powers, preferences and relative, participating, optional, special and other rights, if any, of each such series and any qualifications,
limitations, and restrictions thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights of Preferred Stock could adversely affect the voting power or other rights of the holders of Common Stock. In addition, the Preferred
Stock could be utilized as a method of discouraging, delaying, or preventing a change in control of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2024, we have warrants outstanding
to purchase an aggregate of 140,330 shares of Common Stock, which amount consists of the A.G.P. Warrants, the Private Warrants, and the
Public Warrants.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the number of outstanding shares of Common Stock is increased by a stock dividend payable in shares of common stock, or by a split-up
of shares of Common Stock or other similar event, then, on the effective date of such stock dividend, split-up or similar event, the
number of shares of Common Stock issuable on exercise of each whole Warrant will be increased in proportion to such increase in the outstanding
shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant holders, solely by virtue of holding Warrants, do not have the rights or privileges of holders of Common Stock or any voting
rights until they exercise their Warrants and receive shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A.G.P.
Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
outstanding whole A.G.P. Warrant represents the right to purchase one share of Common Stock at a price of $11.00 per share, subject to
adjustment as described in this annual report, at any time on or after October 22, 2023 and ending on or prior to the earlier of (i)
5:00 p.m. (New York City time) on October 22, 2028, or (ii) the date fixed for redemption of the shares underlying the A.G.P. Warrants
as provided in the A.G.P. Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
A.G.P. Warrants are exercisable for cash or on a cashless basis, at the holder&rsquo;s option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may call the A.G.P. Warrants for redemption, in whole and not in part, at any time after the A.G.P. Warrants become exercisable and prior
to their expiration, at a price of $0.01 per A.G.P. Warrant,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    not less than 30 days&rsquo; prior written notice of redemption to each warrant holder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, the reported last sale price of the Common Stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock
    dividends, recapitalizations and other similar events) for any 20 trading days within a 30-trading day period commencing once the
    A.G.P. Warrants become exercisable and ending three business days before we send the notice of redemption to the warrant holders;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
    there is a current registration statement in effect with respect to the shares of Common Stock underlying the A.G.P. Warrants for
    each day in the 30-trading day period and continuing each thereafter until the redemption date.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we call the A.G.P. Warrants for redemption as described above, our management will have the option to require any holder that wishes
to exercise its A.G.P. Warrant to do so on a &ldquo;cashless basis.&rdquo; If our management takes advantage of this option, holders
of A.G.P. Warrants would pay the exercise price by surrendering their A.G.P. Warrants for that number of shares of Common Stock as calculated
pursuant to the A.G.P. Warrant. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby
lessen the dilutive effect of an A.G.P. Warrant redemption. We believe this feature is an attractive option to us if we do not need the
cash from the exercise of the A.G.P. Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of the A.G.P. Warrants may be decreased and/or the number of shares of Common Stock issuable upon exercise of the A.G.P.
Warrants may be adjusted upon the occurrence of certain events such as, in certain circumstances, if we pay a stock dividend or make
a distribution on shares of Common Stock, if we subdivide the outstanding shares of Common Stock into a larger number of shares, or upon
certain other types of stock dividends or splits. The A.G.P. Warrants also give the holder, in certain circumstances, the right to acquire
securities if we conduct a future offering of Common Stock or certain other securities. Subject to stock market rules, we may, subject
to the prior written consent of the holder, reduce the then current exercise price of the A.G.P. Warrants to any amount for any period
of time deemed appropriate by the board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Private
Warrants and Public Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
outstanding whole Private Warrant and Public Warrant represents the right to purchase one share of Common Stock at a price of $11.50
per share, subject to adjustment as discussed in this annual report, at any time commencing 30 days after the Business Combination and
ending five years after the Business Combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Private Warrants, as well as any warrants underlying additional units issued to the Sponsor or our officers, directors or their affiliates
in payment of working capital loans, are identical to the Public Warrants except that the Private Warrants (i) will be exercisable for
cash or on a cashless basis, at the holder&rsquo;s option, and (ii) will not be redeemable by us, in each case so long as they are still
held by the Sponsor or its permitted transferees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may call the Public Warrants for redemption (excluding any warrants underlying additional units issued to the Sponsor, our officers,
directors or their affiliates in payment of working capital loans made to us), in whole and not in part, at a price of $0.01 per Public
Warrant,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    not less than 30 days&rsquo; prior written notice of redemption to each warrant holder; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, the reported last sale price of the Common Stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock
    dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing once
    the applicable warrants become exercisable and ending three business days before we send the notice of redemption to the warrant
    holders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
and when the Public Warrants become redeemable by us, we may not exercise our redemption right if the issuance of shares of Common Stock
upon exercise of the Public Warrants is not exempt from registration or qualification under applicable state blue sky laws or we are
unable to effect such registration or qualification. We will use our best efforts to register or qualify such shares of Common Stock
under the blue sky laws of the state of residence in those states in which such Public Warrants were offered by us in the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we call the Public Warrants for redemption as described above, our management will have the option to require any holder that wishes
to exercise its Public Warrant to do so on a &ldquo;cashless basis.&rdquo; If our management takes advantage of this option, all holders
of Public Warrants would pay the exercise price by surrendering their Public Warrants for that number of shares of Common Stock equal
to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Public Warrants, multiplied
by the difference between the exercise price of the Public Warrants and the &ldquo;fair market value&rdquo; (defined below) by (y) the
fair market value. The &ldquo;fair market value&rdquo; for this purpose means the average reported last sale price of the Common Stock
for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of
Public Warrants. If our management takes advantage of this option, the notice of redemption will contain the information necessary to
calculate the number of shares of Common Stock to be received upon exercise of the Public Warrants, including the &ldquo;fair market
value&rdquo; in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen
the dilutive effect of a Public Warrant redemption. We believe this feature is an attractive option to us if we do not need the cash
from the exercise of the Public Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if we, at any time while the Public Warrants or Private Warrants are outstanding and unexpired, pay a dividend or make a distribution
in cash, securities or other assets to the holders of Common Stock on account of such shares of Common Stock (or other shares of our
capital stock into which the Public Warrants or Private Warrants are convertible), other than (a) as described above, (b) certain ordinary
cash dividends, (c) to satisfy the redemption rights of the holders of Common Stock in connection with a proposed initial business combination,
(d) to satisfy the redemption rights of the holders of Common Stock in connection with a stockholder vote to amend our amended and restated
certificate of incorporation (i) to modify the substance or timing of our obligation to allow redemption in connection with our initial
business combination or certain amendments to our charter prior thereto or to redeem 100% of our Common Stock if we do not complete our
initial business combination within 12 months from the closing of this offering (or up to 18 months from the closing of the offering
at the election of the Company subject to satisfaction of certain conditions or as extended by the Company&rsquo;s stockholders in accordance
with our amended and restated certificate of incorporation) or (ii) with respect to any other provision relating to stockholders&rsquo;
rights or pre-initial business combination activity, or (e) in connection with the redemption of our public shares upon our failure to
complete our initial business combination, then the Public Warrants and Private Warrants exercise price will be decreased, effective
immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets
paid on each share of Common Stock in respect of such event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the number of outstanding shares of Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification
of shares of Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split,
reclassification or similar event, the number of shares of Common Stock issuable on exercise of each Public Warrant and Private Warrant
will be decreased in proportion to such decrease in outstanding shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case of any reclassification or reorganization of the outstanding shares of Common Stock (other than those described above or that solely
affects the par value of such shares of Common Stock), or in the case of any merger or consolidation of us with or into another corporation
(other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or
reorganization of our outstanding shares of Common Stock), or in the case of any sale or conveyance to another corporation or entity
of the assets or other property of ours as an entirety or substantially as an entirety in connection with which we are dissolved, the
holders of the Public Warrants and Private Warrants will thereafter have the right to purchase and receive, upon the basis and upon the
terms and conditions specified in the Public Warrants and Private Warrants and in lieu of the shares of Common Stock immediately theretofore
purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities
or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following
any such sale or transfer, that the holder of the Public Warrants or Private Warrants (as applicable) would have received if such holder
had exercised their Public Warrants or Private Warrant (as applicable) immediately prior to such event. However, if less than 70% of
the consideration receivable by the holders of common stock in such a transaction is payable in the form of common stock in the successor
entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter market, or is to
be so listed for trading or quoted immediately following such event, and if the registered holder of the Public Warrant or Private Warrant
(as applicable) properly exercises such warrant within 30 days following public disclosure of such transaction, the warrant exercise
price will be reduced as specified in the warrant agreement based on the Black-Scholes value (as defined in the warrant agreement) of
the warrant. The purpose of such exercise price reduction is to provide additional value to holders of the Public Warrants and Private
Warrants when an extraordinary transaction occurs during the exercise period of such warrants pursuant to which the holders of such warrants
otherwise do not receive the full potential value of such warrants in order to determine and realize the option value component of the
applicable warrant. This formula is to compensate the Public Warrant or Private Warrant holder for the loss of the option value portion
of the warrant due to the requirement that the warrant holder exercise the warrant within 30 days of the event. The Black-Scholes model
is an accepted pricing model for estimating fair market value where no quoted market price for an instrument is available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Public Warrants and Private Warrants are issued in registered form under a warrant agreement between Vstock Transfer, LLC, as warrant
agent, and the Company. The warrant agreement provides that the terms of the Public Warrants and Private Warrants may be amended without
the consent of any holder to cure any ambiguity or correct any mistake, or defective provision, but requires the approval by the holders
of at least a majority of the then outstanding Public Warrants to make any change that adversely affects the interests of the registered
holders of Public Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of the Charter, the Bylaws, and Delaware Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have certain anti-takeover provisions in place as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Special
Meeting of Stockholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Bylaws provide that, subject to the rights of the holders of any outstanding series of our Preferred Stock and to the requirements of
applicable law, special meetings of stockholders, for any purpose or purposes, may be called only by (i) the chairperson of the board
of directors, (ii) the chief executive officer, or (iii) a majority vote of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
Notice Requirements for Stockholder Proposals and Director Nominations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Bylaws provide that, in addition to any other applicable requirements, for a nomination to be made by a stockholder, such stockholder
must have given timely notice thereof in proper written form to the Secretary. To be timely, a stockholder&rsquo;s notice to the Secretary
must be received by the Secretary at our principal executive offices (i) in the case of an annual meeting, not later than the close of
business on the 90th day nor earlier than the close of business on the 120th day before the anniversary date of the immediately preceding
annual meeting of stockholders; provided, however, that in the event that the annual meeting is more than 30 days before or more than
60 days after such anniversary date, notice by the stockholder to be timely must be so received no earlier than the close of business
on the 120th day before the meeting and not later than the later of (x) the close of business on the 90th day before the meeting, or
(y) the close of business on the 10th day following the day on which public announcement of the date of the annual meeting was first
made by the Company; and (ii) in the case of a special meeting of stockholders called for the purpose of electing directors, not later
than the close of business on the 10th day following the day on which public announcement of the date of the special meeting is first
made by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Authorized
but Unissued Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized but unissued Common Stock and Preferred Stock will be available for future issuances without stockholder approval and could
be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions, and employee benefit
plans. The existence of authorized but unissued and unreserved Common Stock and Preferred Stock could render more difficult or discourage
an attempt to obtain control of the Company by means of a proxy contest, tender offer, merger, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exclusive
Forum Selection</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Charter requires that, to the fullest extent permitted by the applicable law, the Court of Chancery of the State of Delaware shall be
the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i) any derivative action or proceeding brought
on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee
of the Company to the Company or the Company&rsquo;s stockholders, (iii) any action asserting a claim against the Company, its directors,
officers or employees arising pursuant to any provision of the DGCL or the second amended and restated certificate of incorporation or
the bylaws, or (iv) any action asserting a claim against the Company, its directors, officers or employees governed by the internal affairs
doctrine and, if brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process
on such stockholder&rsquo;s counsel except any action (A) as to which the Court of Chancery in the State of Delaware determines that
there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent
to the personal jurisdiction of the Court of Chancery within ten days following such determination), (B) which is vested in the exclusive
jurisdiction of a court or forum other than the Court of Chancery, or (C) for which the Court of Chancery does not have subject matter
jurisdiction. Notwithstanding the foregoing, (i) the foregoing will not apply to suits brought to enforce any liability or duty created
by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction and (ii) to the fullest extent permitted
by the applicable law, the federal district courts of the United States of America for the District of Delaware and the Court of Chancery
of the State of Delaware shall have concurrent jurisdiction for the resolution of any complaint asserting a cause of action arising under
the Securities Act or the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
choice of forum provision may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for disputes
with the Company or any of the Company&rsquo;s directors, officers, other employees or stockholders, which may discourage lawsuits with
respect to such claims. The Company cannot be certain that a court will decide that this provision is either applicable or enforceable,
and if a court were to find the choice of forum provision contained in the Charter to be inapplicable or unenforceable in an action,
the Company may incur additional costs associated with resolving such action in other jurisdictions, which could harm the Company&rsquo;s
business, operating results, and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Limitation
on Liability and Indemnification of Directors and Officers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Charter provides that directors and officers will be indemnified by the Company to the fullest extent authorized by Delaware law as it
now exists or may in the future be amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Bylaws also permit us to secure insurance on behalf of any officer, director or employee for any liability arising out of his or her
actions, regardless of whether Delaware law would permit indemnification. We have purchased a policy of directors&rsquo; and officers&rsquo;
liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment in some
circumstances and insures the Company against its obligations to indemnify the directors and officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions may discourage stockholders from bringing a lawsuit against the Company&rsquo;s directors for breach of their fiduciary duty.
These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though
such an action, if successful, might otherwise benefit the Company and the Company&rsquo;s stockholders. Furthermore, a stockholder&rsquo;s
investment may be adversely affected to the extent the Company pays the costs of settlement and damage awards against directors and officers
pursuant to these indemnification provisions. We believe that these provisions, the insurance and the indemnity agreements are necessary
to attract and retain talented and experienced directors and officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to the Company&rsquo;s directors, officers and controlling
persons pursuant to the foregoing provisions, or otherwise, the Company has been advised that, in the opinion of the SEC, such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for the Common Stock and the warrant agent for the Warrants is Vstock Transfer, LLC, with an address of
18 Lafayette Place, Woodmere, NY 11598.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>






















































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>ex19-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
19.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit
Pharmaceuticals Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSIDER
TRADING AND SECURITIES LAW COMPLIANCE POLICY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1. Background</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors of Conduit Pharmaceuticals Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;) has adopted this Insider Trading and Securities
Law Compliance Policy relating to transactions in Company securities as well as the securities of publicly-traded companies with whom
the Company engages in transactions or has a business relationship. The terms the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo;
and &ldquo;our&rdquo; mean Conduit Pharmaceuticals Inc. and any and all of its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
and state securities laws prohibit the purchase or sale of a company&rsquo;s securities by persons who are aware of material information
about that company that is not generally known or available to the public. These laws also prohibit persons who are aware of such material
nonpublic information from disclosing this information to others who may trade. Companies and their controlling persons are also subject
to liability if they fail to take reasonable steps to prevent insider trading by company personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is important that you understand the breadth of activities that constitute illegal insider trading and the resulting consequences, which
can be severe. This policy is applicable to all transactions in our securities. Both the U.S. Securities and Exchange Commission (the
&ldquo;<B><I>SEC</I></B>&rdquo;) and the Nasdaq investigate and are very effective at detecting insider trading. The SEC and U.S. Attorneys
pursue insider trading violations vigorously. Cases have been successfully prosecuted against trading by employees through foreign accounts,
trading by family members and friends, and trading involving only a small number of shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
policy is designed to prevent insider trading or allegations of insider trading and protect our reputation for integrity and ethical
conduct. It is your obligation to understand and comply with this policy. Should you have any questions regarding this policy, please
contact our principal executive officer, principal accounting officer, principal financial officer, corporate secretary, or such other
individual(s) designated by the Chair of the Company&rsquo;s board of directors (each, a &ldquo;<B><I>Compliance Officer</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2. Basic
Policy / Additional Restrictions on Restricted Persons</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
director, officer, employee, consultant, or agent (or their family members and members of their household) of the Company and its subsidiaries
and affiliates may engage in transactions in securities on the basis of material nonpublic information or engage in any other action
to take advantage of, or pass on to others, that information. To avoid even the appearance of impropriety, additional restrictions on
engaging in transactions in our securities apply to our directors, executive officers and certain other persons identified by us from
time to time and who have been notified that they have been so identified (collectively with our directors and executive officers, &ldquo;<B><I>Restricted
Persons</I></B>&rdquo;). For the purposes of this policy, the term &ldquo;<B><I>Restricted Persons</I></B>&rdquo; shall also include
any person, regardless of title or job description, who works in any of the following departments or is a member on any of the following
committees:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Executive Officer;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Financial Officer;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
                                            Accounting Officer;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Scientific Officer;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior
                                            Vice President of Clinical Development and Project Management;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior
                                            Vice President of Commercial Operations;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
                                            Department;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
                                            Committee;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
                                            Relations Department; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
                                            Development Department.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transactions
in our securities by Restricted Persons are subject to pre-clearance. See &ldquo;Regular Blackout Periods,&rdquo; &ldquo;Special Blackout
Periods,&rdquo; and &ldquo;Pre-Clearance Provisions.&rdquo;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3. Scope
of Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Persons</U>.
This policy applies to directors, officers, employees, consultants, contractors, advisors, and agents of the Company and its subsidiaries
and affiliates. The same restrictions that apply to you apply to your family members who reside with you, anyone else who lives in your
household and any family members who do not live in your household but whose transactions in our securities are directed by you or are
subject to your influence or control (such as parents or children who consult with you before they engage in transactions in securities),
including any entities over which you have control (such as a business entity or a trust). You are responsible for making sure that the
purchase or sale of, or other transaction in, any security covered by this policy by any such person complies with this policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Companies</U>.
The prohibition on insider trading in this policy is not limited to transactions in our securities. It includes transactions in the securities
of other firms, such as our customers or suppliers and those with which we may be negotiating major transactions, such as an acquisition,
investment, or sale. Information that is not material to the Company may nevertheless be material to one of those other firms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transactions</U>.
The transactions covered by this policy includes purchases and sales of our common stock (including initial elections, changes in elections,
or reallocation of funds relating to 401(k) plan accounts), derivative securities relating to our common stock (such as options for our
common stock, put and call options, and convertible debentures), preferred stock, warrants, and debt securities (including debentures,
bonds, and notes). Loans, pledges, gifts, charitable donations, and other contributions of our securities are also subject to this policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4. Definition
of Material Nonpublic Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Material
Information</U>. Information is material if there is a substantial likelihood that a reasonable investor would consider it important
in deciding whether to buy, hold or sell a security. Any information that could reasonably be expected to affect the price of the security
is material. Common examples of material information are:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            results, projections of future earnings or losses, or other earnings guidance;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
                                            that are inconsistent with the consensus expectations of the investment community or any
                                            earnings guidance released by the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Communications
                                            with government agencies about pending regulatory actions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determinations
                                            to continue or to end the discovery or development of product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
                                            write-downs in assets or increases in reserves;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
                                            changes in the Company&#8217;s prospects;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposals,
                                            plans, or agreements, even if preliminary in nature, involving mergers, acquisitions, divestitures,
                                            recapitalizations, strategic alliances, licensing arrangements, potential tender offers or
                                            proxy fights, contract awards or cancellations, or purchases or sales of substantial assets;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partner
                                            or collaborator relationships;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
                                            in management or the board of directors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extraordinary
                                            borrowings;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major
                                            changes in accounting methods or policies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major
                                            events regarding our securities, including the declaration of a stock split or the offering
                                            of additional securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
                                            clinical trial or regulatory updates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developments
                                            regarding significant litigation or government agency investigations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            liquidity problems;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity
                                            or data privacy incidents, including vulnerabilities and breaches, or any other significant
                                            disruptions in the Company&#8217;s operations, or unauthorized access of the Company&#8217;s
                                            property or assets;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            effects of any natural disaster, terrorist event, or other catastrophic event on the Company&#8217;s
                                            business, including any epidemic or pandemic;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actual
                                            or threatened major litigation, or a significant development with respect to such litigation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
                                            major contracts, material agreements, licenses, orders, suppliers, customers, or finance
                                            sources, or the loss or termination thereof; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            imposition of a special blackout on transactions in the Company&#8217;s securities or the
                                            securities of another company or the extension or termination of such restriction.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
list is not exhaustive; other types of information may also be material. Both positive and negative information can be material. Because
a transaction in securities that receives scrutiny will be evaluated after the fact with the benefit of hindsight, questions concerning
the materiality of particular information should be resolved in favor of materiality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
information is not limited to historical facts but may also include projections and forecasts. With respect to a future event, such as
a merger, acquisition, or introduction of a new product, the point at which negotiations or product development are determined to be
material is determined by balancing the probability that the event will occur against the magnitude of the effect the event would have
on a company&rsquo;s operations or stock price should it occur. Thus, information concerning an event that would have a large effect
on stock price, such as a merger, clinical trial, or regulatory update, may be material even if the possibility that the event will occur
is relatively small. When in doubt about whether particular nonpublic information is material, you should presume it is material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If
you are unsure whether information is material, you should either consult a Compliance Officer before making any decision to disclose
such information (other than to persons who need to know it) or to engage in transactions in or recommend securities to which that information
relates or assume that the information is material.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Nonpublic
Information</U>. Insider trading prohibitions come into play only when you possess information that is material and &ldquo;nonpublic.&rdquo;
Nonpublic information is information that is not generally known or available to the public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fact that information has been disclosed to a few members of the public does not make it public for insider trading purposes. In addition,
a common misconception is that material information loses its &ldquo;nonpublic&rdquo; status as soon as a press release is issued disclosing
the information. In fact, information is considered to be available to the public only when it has been released broadly to the marketplace
(such as by a press release or an SEC filing) and the investing public has had time to absorb the information fully. As a general rule,
after nonpublic information is publicly disseminated, 1 full trading day must elapse before such information loses its status as nonpublic
information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonpublic
information may include:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
                                            available to a select group of analysts or brokers or institutional investors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">undisclosed
                                            facts that are the subject of rumors, even if the rumors are widely circulated; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
                                            that has been entrusted to the Company on a confidential basis until a public announcement
                                            of the information has been made and enough time has elapsed for the market to respond to
                                            a public announcement of the information (normally 1 trading day).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
with questions of materiality, if you are not sure whether information is considered public, you should either consult with a Compliance
Officer or assume that the information is nonpublic and treat it as confidential.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5. Restrictions
On Purchases, Sales, and Tipping</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Trading
on Inside Information</U>. You may not engage in transactions in our securities, directly or indirectly (through family members or other
persons or entities), if you are aware of material nonpublic information relating to the Company. Similarly, you may not engage in transactions
in the securities of any other company, directly or indirectly, if you are aware of material nonpublic information about that company
which you obtained in the course of your relationship with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Tipping</U>.
You may not pass material nonpublic information on to others or recommend that anyone engage in transactions in any securities when you
are aware of such information. This practice, known as &ldquo;tipping,&rdquo; also violates the securities laws and can result in the
same civil and criminal penalties that apply to insider trading, even though you did not trade and did not gain any benefit from another&rsquo;s
trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Short
Sales</U>. You may not engage in any short sales of our securities (sales of securities that are not then owned), including a &ldquo;sale
against the box&rdquo; (a sale with delayed delivery).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Hedging
Transactions</U>. Certain forms of hedging or monetization transactions relating to our securities (such as zero-cost collars and forward
sale contracts) could involve the establishment of a short position in our securities and limit or eliminate your ability to profit from
an increase in the value of our securities. Therefore, you are prohibited from engaging in any hedging or monetization transactions involving
our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Publicly-Traded
Options</U>. You may not engage in transactions in publicly-traded or other third-party options relating to our securities, such as puts,
calls, and other derivative securities, on an exchange, in any other organized market, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Limit
Orders</U>. You are prohibited from placing limit orders for our securities that remain effective after the day on which they are placed
(such as &ldquo;good until cancelled&rdquo; orders).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Margin
Accounts</U>. Securities held in a margin account as collateral for a margin loan may be sold by the broker without the customer&rsquo;s
consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be
sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor
is aware of material nonpublic information or otherwise is not permitted to engage in transactions in our securities, directors, officers,
and other employees of the Company and its subsidiaries are prohibited from holding our securities in a margin account or otherwise pledging
our securities as collateral for a loan. (Pledges of our securities arising from certain types of hedging transactions are governed by
the paragraph above captioned &ldquo;Hedging Transactions.&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Blackout
Periods</U>.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Regular
                                            Blackout Periods Applicable to Restricted Persons</I>. In addition to the general policy
                                            prohibiting engaging in transactions in securities while in possession of material nonpublic
                                            information, all Restricted Persons, and all family members of such persons and members of
                                            their household, are also prohibited from engaging in transactions in our securities during
                                            the period beginning at the close of the market on 2 weeks before the end of each fiscal
                                            quarter and ending after the passage of 2 full trading days after earnings have been publicly
                                            released with respect to such quarter or fiscal year (each, a &#8220;<B><I>regular blackout
                                            period</I></B>&#8221;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Special
                                            Blackout Periods</I>. From time to time, the Company may also prohibit our Restricted Persons
                                            and potentially a larger group of employees, consultants and agents from engaging in transactions
                                            our securities because of material developments known to the Company and not yet disclosed
                                            to the public (each, a &#8220;<B><I>special blackout period</I></B>&#8221;). The existence
                                            of a special blackout period will not be announced, other than to those who are aware of
                                            the event giving rise to the special blackout. If, however, a person subject to a special
                                            blackout period requests permission to engage in transactions in our securities during such
                                            period, a Compliance Officer will inform the requesting person of the existence of a special
                                            blackout period, without disclosing the reason for the special blackout. Any person made
                                            aware of the existence of a special blackout period shall not disclose the existence of the
                                            blackout to any other person.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Open
                                            Orders</I>. If you have any open orders during any regular or special blackout period, it
                                            is your responsibility to cancel these orders with your broker. If you have an open order
                                            and it executes after the commencement of any regular or special blackout period, it is a
                                            violation of our insider trading policy and may also be a violation of the insider trading
                                            laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
                                            Safe Harbor</I>. <B>For those persons who are subject to blackout periods, the existence
                                            of such blackouts shall <U>not</U> be considered a safe harbor for engaging in transactions
                                            in securities during other periods, and all of our officers, directors, other employees and
                                            agents should use good judgment at all times. </B>For example, occasions may arise when individuals
                                            covered by this policy become aware prior to the blackout period that earnings for that quarter
                                            are likely to exceed, or fall below, market expectations to an extent that is material. In
                                            such a case, the general policy against trading on inside information would still prohibit
                                            engaging in transactions in securities even though the time period is not within the blackout
                                            period or even if you are not a Restricted Person subject to the blackout periods. If you
                                            have any questions about whether you are permitted to engage in transactions in our securities
                                            at any particular time, you should contact a Compliance Officer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6. Pre-Clearance
Provisions Applicable to Restricted Persons</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
help prevent inadvertent violations of the federal securities laws and avoid even the appearance of trading on the basis of inside information,
the following pre-clearance provisions are applicable to our Restricted Persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Restricted Persons, together with their family members and other members of their household (including any entities over which such person
has control), shall not engage in any transaction involving our securities (including a stock plan transaction such as an option exercise,
or a gift, loan, pledge, contribution to a trust, 401(k) transfer or any other transfer) without first obtaining pre-clearance of the
transaction from a Compliance Officer in accordance with the following procedures:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            Restricted Person may, directly or indirectly, purchase or sell (or otherwise make any transfer,
                                            gift, pledge, or loan of) any Company security at any time without first obtaining prior
                                            approval from a Compliance Officer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requests
                                            for pre-clearance should be submitted to a Compliance Officer at least 2 business days in
                                            advance of the proposed transaction.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Compliance Officer shall record the date each request is received and the date and time each
                                            request is approved or disapproved.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            Compliance Officer is under any obligation to approve a transaction submitted for pre-clearance
                                            and may determine not to permit the transaction.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            revoked, a grant of permission will normally remain valid until the close of trading 5 business
                                            days following the date on which it was granted, but regardless may not be exercised if material
                                            nonpublic information is obtained during that time. If the transaction does not occur during
                                            such period, pre-clearance of the transaction must be re-requested.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            Compliance Officer may engage in transactions in our securities unless our Chief Executive
                                            Officer has approved the transaction in accordance with the procedures set forth herein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
requesting pre-clearance, please provide the following information to the Compliance Officer:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
                                            you believe may be aware of any material non-public information about the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
                                            you have effected any non-exempt &#8220;opposite-way&#8221; transactions within the past
                                            six months;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
                                            you intend to purchase, sell, or otherwise gift or transfer, and whether such transaction
                                            will be conducted through in the open market or otherwise;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximate
                                            timing and number of shares that you intend to purchase, sell, or otherwise gift or transfer;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
                                            you will notify the Compliance Officer promptly upon the completion of the pre-cleared transaction.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
procedures also apply to transactions by such person&rsquo;s spouse, other persons living in such person&rsquo;s household and minor
children and to transactions by entities over which such person exercises control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clearance
is not required for purchases and sales of securities under an Approved 10b5-1 Plan (as defined below) once the applicable cooling-off
period has expired. No trades may be made under an Approved 10b5-1 Plan until expiration of the applicable cooling-off period. With respect
to any purchase or sale under an Approved 10b5-1 Plan, the third-party effecting transactions on behalf of the Restricted Person should
be instructed to send duplicate confirmations of all such transactions to a Compliance Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7. Exceptions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Approved
Rule 10b5-1 Plans</U>. Trades in our securities that are executed pursuant to an Approved 10b5-1 Plan (as defined below) are not subject
to the prohibition on trading on the basis of material nonpublic information contained in this policy or the restrictions relating to
pre-clearance procedures and blackout periods. Rule 10b5-1 provides an affirmative defense from insider trading liability under the federal
securities laws for trading plans that meet certain requirements. In general, a 10b5-1 plan must be entered into before you are aware
of material nonpublic information. You may not adopt a 10b5-1 plan during any regular or special blackout period. Note that once the
Approved 10b5-1 Plan is adopted, you must not exercise any influence over the amount of securities to be traded, the price at which they
are to be traded, or the date of the trade. The plan must either specify (including by formula) the amount, pricing, and timing of transactions
in advance or delegate discretion on those matters to an independent third party. All persons entering into a 10b5-1 plan must act in
good faith with respect to that plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Policy, an &ldquo;<B><I>Approved 10b5-1 Plan</I></B>&rdquo; means a pre-existing written plan, contract, instruction,
or arrangement under Rule 10b5-1 under the Securities Exchange Act of 1934 that:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">has
                                            been reviewed and approved in writing at least 1 month in advance of being entered into by
                                            a Compliance Officer (or, if revised or amended, such revisions or amendments have been reviewed
                                            and approved by a Compliance Officer at least 1 month in advance of being entered into);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            entered into in good faith by the Restricted Person, and not as part of a plan or scheme
                                            to evade the prohibitions of Rule 10b5-1, at a time when the Restricted Person is not in
                                            possession of material nonpublic information about the Company; and, if the Restricted Person
                                            is a director or officer, the 10b5-1 plan must include representations by the Restricted
                                            Person certifying to that effect;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">gives
                                            a third party the discretionary authority to execute such purchases and sales, outside the
                                            control of the Restricted Person, so long as such third party does not possess any material
                                            nonpublic information about the Company; or explicitly specifies the security or securities
                                            to be purchased or sold, the number of shares, the prices and/or dates of transactions, or
                                            other formula(s) describing such transactions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provides
                                            that no trades may occur thereunder until expiration of the applicable cooling-off period
                                            specified in Rule 10b5-1(c)(ii)(B), and no trades occur until after that time. The appropriate
                                            cooling-off period will vary based on the status of the Restricted Person. For directors
                                            and officers, the cooling-off period ends on the later of (A) 90 days after adoption or certain
                                            modifications of the 10b5-1 plan; or (B) 2 business days following disclosure of the Company&rsquo;s
                                            financial results in a Form 10-Q or Form 10-K for the quarter in which the 10b5-1 plan was
                                            adopted (in any case, subject to a 120-day maximum). For all other Restricted Persons, the
                                            cooling-off period ends 30 days after adoption or modification of the 10b5-1 plan. This required
                                            cooling-off period will apply to the entry into a new 10b5-1 plan and any revision or modification
                                            of a 10b5-1 plan; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            the only outstanding Approved 10b5-1 Plan entered into by the Restricted Person (subject
                                            to the exceptions set out in Rule 10b5-1(c)(ii)(D)).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may only enter into 1 single-trade Rule 10b5-1 plans during any 12-month period, subject to limited exceptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Option
Exercises</U>. You may exercise stock options where cash is paid for the exercise price and tax withholding obligation, and in turn receive
shares. However, <B><I>you may not sell any securities so acquired </I></B>(either outright or in connection with a &ldquo;cashless&rdquo;
exercise transaction through a broker) or otherwise settle the option during a regular or special blackout period or any time that you
are aware of material nonpublic information. If you choose to exercise and hold the shares, you will be responsible at that time for
any taxes due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
Employee Plans</U>. This policy does not apply to:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquisitions
                                            or dispositions of the Company&#8217;s common stock under the Company&#8217;s 401(k) or other
                                            individual account plan that are made pursuant to standing instructions not entered into
                                            or modified while you were aware of material nonpublic information or were subject to a regular
                                            or special blackout period (<I>provided</I>, <I>however</I>, that (A) this policy does apply
                                            to sales of the Company&#8217;s securities purchased received pursuant to such plan, and
                                            (B) any changes in your investment election regarding the Company&#8217;s stock are subject
                                            to trading restrictions under this policy); or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                            purchases of securities from the Company (including purchases under any employee stock purchase
                                            plan) or sales of securities to the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Special
Circumstances</U>. Notwithstanding anything to the contrary contained herein, you may request that any regular blackout period or special
blackout period be waived by the Company&rsquo;s principal executive officer, principal financial officer, or principal accounting officer
(each, a &ldquo;<B><I>Clearing Officer</I></B>&rdquo;), provided that you affirm in writing that you do not have any material non-public
information. Any such waivers shall be in the sole discretion of the Clearing Officer, shall be limited in scope and duration, and may
be revoked at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Underwritten
Public Offerings</U>. Nothing in this policy is intended to limit the ability of any person to sell the Company&rsquo;s securities as
a selling stockholder in an underwritten public offering pursuant to an effective registration statement in accordance with applicable
securities law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>For
clarity, please be reminded that the following are subject to this policy, including any regular and special blackout periods: (a) any
&ldquo;cashless&rdquo; exercise of stock options or other equity awards; (b) any market sale of the Company&rsquo;s securities for the
purpose of generating the cash needed to pay the exercise price of any stock option or equity award or other derivative security; (c)
the sale of any shares issued on the exercise of stock options or other equity award elections made under 401(k) plans to (i) increase
or decrease the percentage of periodic contributions that will be allocated to the Company&rsquo;s securities, (ii) make an intra-plan
transfer of an existing account balance into or out of the Company&rsquo;s securities, (iii) borrow money against a 401(k) plan account
if the loan will result in a liquidation of all or some of the Company&rsquo;s securities in the account, and (iv) pre-pay any loan if
the pre-payment will result in an allocation of loan proceeds to the Company&rsquo;s securities; (d) elections to participate in or increase
participation in an employee stock purchase plan and to a participant&rsquo;s sale of the Company&rsquo;s securities purchased pursuant
to such plan; (e) elections to participate in or increase participation in any dividend reinvestment plan, voluntary purchases of the
Company&rsquo;s securities that result from additional contributions a participant chooses to make under such plan, and a participant&rsquo;s
sale of the Company&rsquo;s securities purchased pursuant to such plan; and (f) gifts.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8. Post-Termination
Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are aware of material nonpublic information when you terminate employment or services, you may not engage in transactions in our
securities until that information has become public or is no longer material. In addition, if you are subject to a blackout period at
the time of your termination of employment or services, the restrictions on engaging in transactions in our securities will not cease
to apply until the expiration of such blackout period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9. Unauthorized
Disclosure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintaining
the confidentiality of our information is essential for competitive, security and other business reasons, as well as to comply with securities
laws. You should treat all information you learn about the Company or its business plans in connection with your employment as confidential
and proprietary to us. Inadvertent disclosure of confidential or inside information may expose us and you to significant risk of investigation
and litigation. Nothing in this policy prevents reporting of violations to regulatory agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timing and nature of our disclosure of material information to outsiders is subject to legal rules, including the SEC&rsquo;s Regulation
FD, the breach of which could result in substantial liability to you, us and our management. Accordingly, it is important that responses
to inquiries about us by the press, financial analysts, investors or others in the financial community be made on our behalf only through
authorized individuals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10. Personal
Responsibility</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should remember that <B><U>the ultimate responsibility for adhering to this policy and avoiding improper trading rests with you</U>.
</B>If you violate this policy, the Company may take disciplinary action, including dismissal for cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11. Additional
Information for Directors and Section 16 Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officers
and directors have additional obligations under the federal securities laws, most notably the obligations to report their share ownership
and transactions, and to forfeit the profits on any purchases and sales of Company stock within a 6-month period under Section 16(b)
of the Securities Exchange Act of 1934. Short sales by such persons are also prohibited under Section 16(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
becoming an officer or director, a person must report the person&rsquo;s holdings of equity securities of the Company on a Form 3, and
any transaction in such securities (including purchases, sales, gifts, award or exercise of stock options) must be reported to the SEC
within 2 business days on a Form 4. Late filing of these reports must be reported by the Company in its periodic reports filed with the
SEC. Consequently, it is critical that such transactions be reported to the Company&rsquo;s Compliance Officers immediately so that proper
reports can be timely prepared and filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company may assist you in the assessing your obligations under Section 16 and coordinate the filing of your Section 16 reports, <B><U>such
legal responsibilities and obligations are ultimately yours</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officers,
directors and other affiliates should also be prepared to file Forms 144, if necessary, at the time of any sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should also understand that compliance with the obligations described above does not excuse violation of the laws against trading on
material inside information which apply to any single transaction regardless of whether or not it is reported on Form 4 or subject to
the recapture of profits under Section 16(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12. Penalties
for Noncompliance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalties
for trading on or communicating material nonpublic information can be severe, both for individuals involved in such unlawful conduct
and their employers and supervisors, and may include jail terms, criminal fines, civil penalties, and civil enforcement injunctions.
Given the severity of the potential penalties, compliance with this policy is absolutely mandatory. If you believe that you may have
violated this policy or any federal or state laws governing insider trading or tipping, or you know of the possibility of any such violation
by any person, you must report such matter immediately to a Compliance Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Civil
and Criminal Penalties</U>. A person who violates insider trading laws by engaging in transactions in a company&rsquo;s securities when
the person has material nonpublic information can be sentenced to a substantial jail term and required to pay a criminal penalty of several
times the amount of profits gained or losses avoided.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a person who tips others may also be liable for transactions by the tippees to whom the person has disclosed material nonpublic
information. Tippers can be subject to the same penalties and sanctions as the tippees, and the SEC has imposed large penalties even
when the tipper did not profit from the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC can also seek substantial civil penalties from any person who, at the time of an insider trading violation, &ldquo;directly or indirectly
controlled the person who committed such violation,&rdquo; which would apply to the Company and/or management and supervisory personnel.
These control persons may be held liable for up to the greater of $1 million or three times the amount of the profits gained or losses
avoided. Even for violations that result in a small or no profit, the SEC can seek penalties from a company and/or its management and
supervisory personnel as control persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Controlling
Person Liability</U>. If we fail to take appropriate steps to prevent illegal insider trading, we may have &ldquo;controlling person&rdquo;
liability for a trading violation and be subject to civil penalties of up to the greater of $1 million and three times the profit gained
or loss avoided as well as a criminal penalty of up to $25 million. The civil penalties can extend personal liability to our directors,
officers, and other supervisory personnel if they fail to take appropriate steps to prevent insider trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Company-Imposed
Penalties</U>. Failure to comply with this policy may also subject you to sanctions imposed by the Company, including dismissal for cause,
whether or not your failure to comply with this policy results in a violation of law. Any exceptions to this policy, if permitted, may
only be granted by a Compliance Officer and must be provided before any activity contrary to the above requirements takes place.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13. Assistance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
compliance with this policy is of the utmost importance both for you and the Company. If you have any questions about this policy or
its application to any proposed transaction, you may obtain additional guidance from any Compliance Officer. Do not try to resolve uncertainties
on your own, as the rules relating to insider trading are often complex, not always intuitive and carry severe consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>As
adopted by the Board of Directors of Conduit Pharmaceuticals Inc. on September 21, 2023.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Independent Registered
Public Accounting Firm&rsquo;s Consent</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statements on Form S-8 (File No. 333-284741, 333-276461, and 333-275860)
and Form S-3 (File No. 333-284714, 333-286449, and 333-282802) of our report dated March 28, 2025, relating to the financial statements
of Conduit Pharmaceuticals Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morristown,
NJ</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
28, 2025</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
David Tapolczay, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of Conduit Pharmaceuticals Inc.:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an Annual Report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 28, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David Tapolczay</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>David
                                            Tapolczay</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
and Chief Executive Officer</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Principal
    Executive Officer)</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
James Bligh, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of Conduit Pharmaceuticals Inc.:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an Annual Report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 28, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    James Bligh</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>James
                                            Bligh</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interim
Chief Financial Officer</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Principal
Financial and Accounting Officer)</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &sect; 1350), David Tapolczay, Director and Chief
Executive Officer of Conduit Pharmaceuticals Inc. (the &ldquo;Company&rdquo;), and James Bligh, Interim Chief Financial Officer of
the company, each hereby certifies that, to his knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&rsquo;s Annual Report on Form 10-K for the period ended December 31, 2024, to which this Certification is attached as Exhibit
    32.1 (the &ldquo;Report&rdquo;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition of the Company at the end
    of the period covered by the Report and results of operations of the Company for the period covered by the Report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 28, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David Tapolczay</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>David
Tapolczay</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
and Chief Executive Officer</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Principal
    Executive Officer)</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 28, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    James Bligh</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
Bligh</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interim
Chief Financial Officer</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Principal
    Financial and Accounting Officer)</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section 906 of 18 U.S.C. &sect; 1350 has been provided to Conduit Pharmaceuticals
Inc. and will be retained by Conduit Pharmaceuticals Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not
to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether
made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, in his capacity as Interim CFO of Conduit Pharmaceuticals Inc.
(the &ldquo;Company&rdquo;) that, to the best of his knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Annual Report for the year ended December 31, 2024 of the Company on Form 10-K (the &ldquo;Report&rdquo;) fully complies with the
    requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    information contained in the Report fairly presents, in all material respects, the financial condition and the results of operations
    of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 28, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    James Bligh</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Bligh</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Financial and Accounting Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting
the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided
to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>cdt-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaaO2bP9z5Z8OekhvWB2bdlqTykipdS+LCHU5yJGMc0I -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:CDT="http://conduitpharma.com/20241231" elementFormDefault="qualified" targetNamespace="http://conduitpharma.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://conduitpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" id="StatementsOfOperationsAndComprehensiveIncomeLoss">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit" id="StatementsOfChangesInStockholdersDeficit">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
          <link:definition>999014 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/MergerAndFinancing" id="MergerAndFinancing">
          <link:definition>999015 - Disclosure - Merger and Financing</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/FairValue" id="FairValue">
          <link:definition>999016 - Disclosure - Fair Value</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssets" id="BalanceSheetDetailsCurrentAssets">
          <link:definition>999017 - Disclosure - Balance Sheet Details &#8211; Current Assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/Leases" id="Leases">
          <link:definition>999018 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenue" id="LiabilityRelatedToSaleOfFutureRevenue">
          <link:definition>999019 - Disclosure - Liability Related to the Sale of Future Revenue</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ConvertibleNotesPayable" id="ConvertibleNotesPayable">
          <link:definition>999020 - Disclosure - Convertible Notes Payable</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/LoansPayable" id="LoansPayable">
          <link:definition>999021 - Disclosure - Loans Payable</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/DeferredCommissionPayable" id="DeferredCommissionPayable">
          <link:definition>999022 - Disclosure - Deferred Commission Payable</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ResearchAndDevelopmentExpense" id="ResearchAndDevelopmentExpense">
          <link:definition>999023 - Disclosure - Research and Development Expense</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ShareBasedCompensation" id="ShareBasedCompensation">
          <link:definition>999024 - Disclosure - Share Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999025 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/CommonStockAndPreferredStock" id="CommonStockAndPreferredStock">
          <link:definition>999026 - Disclosure - Common Stock and Preferred Stock</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/EarningsnetLossPerShare" id="EarningsnetLossPerShare">
          <link:definition>999027 - Disclosure - Earnings/(Net Loss) Per Share</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999028 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999029 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/OtherIncomeExpenseNet" id="OtherIncomeExpenseNet">
          <link:definition>999030 - Disclosure - Other Income (expense), net</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/Warrants" id="Warrants">
          <link:definition>999031 - Disclosure - Warrants</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/Segments" id="Segments">
          <link:definition>999032 - Disclosure - Segments</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999033 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999034 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/MergerAndFinancingTables" id="MergerAndFinancingTables">
          <link:definition>999035 - Disclosure - Merger and Financing (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/FairValueTables" id="FairValueTables">
          <link:definition>999036 - Disclosure - Fair Value (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssetsTables" id="BalanceSheetDetailsCurrentAssetsTables">
          <link:definition>999037 - Disclosure - Balance Sheet Details &#8211; Current Assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999038 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ShareBasedCompensationTables" id="ShareBasedCompensationTables">
          <link:definition>999039 - Disclosure - Share Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999040 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/EarningsnetLossPerShareTables" id="EarningsnetLossPerShareTables">
          <link:definition>999041 - Disclosure - Earnings/(Net Loss) Per Share (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/OtherIncomeExpenseNetTables" id="OtherIncomeExpenseNetTables">
          <link:definition>999042 - Disclosure - Other Income (expense), net (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/WarrantsTables" id="WarrantsTables">
          <link:definition>999043 - Disclosure - Warrants (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/SegmentsTables" id="SegmentsTables">
          <link:definition>999044 - Disclosure - Segments (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999045 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails" id="ScheduleOfCommonStockOutstandingDetails">
          <link:definition>999046 - Disclosure - Schedule of Common Stock Outstanding (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative" id="MergerAndFinancingDetailsNarrative">
          <link:definition>999047 - Disclosure - Merger and Financing (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails" id="ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails">
          <link:definition>999048 - Disclosure - Schedule of Assets Subject to Measurement at Fair Value on Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails" id="ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails">
          <link:definition>999049 - Disclosure - Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails" id="ScheduleOfFairValueOfAssumptionsDetails">
          <link:definition>999050 - Disclosure - Schedule of Fair Value of Assumptions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/FairValueDetailsNarrative" id="FairValueDetailsNarrative">
          <link:definition>999051 - Disclosure - Fair Value (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails" id="ScheduleOfBalanceSheetDetailsDetails">
          <link:definition>999052 - Disclosure - Schedule of Balance Sheet Details (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfLeaseCostDetails" id="ScheduleOfLeaseCostDetails">
          <link:definition>999053 - Disclosure - Schedule of Lease Cost (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" id="ScheduleOfOperatingLeaseLiabilitiesDetails">
          <link:definition>999054 - Disclosure - Schedule of Operating Lease Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" id="ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails">
          <link:definition>999055 - Disclosure - Schedule of Future Minimum Lease Payments For Operating Lease (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999056 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative" id="LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative">
          <link:definition>999057 - Disclosure - Liability Related to the Sale of Future Revenue (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative" id="ConvertibleNotesPayableDetailsNarrative">
          <link:definition>999058 - Disclosure - Convertible Notes Payable (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/LoansPayableDetailsNarrative" id="LoansPayableDetailsNarrative">
          <link:definition>999059 - Disclosure - Loans Payable (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative" id="DeferredCommissionPayableDetailsNarrative">
          <link:definition>999060 - Disclosure - Deferred Commission Payable (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative" id="ResearchAndDevelopmentExpenseDetailsNarrative">
          <link:definition>999061 - Disclosure - Research and Development Expense (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails" id="ScheduleOfRestrictedStockActivityDetails">
          <link:definition>999062 - Disclosure - Schedule of Restricted Stock Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails" id="ScheduleOfFairValueOfStockOptionGrantedDetails">
          <link:definition>999063 - Disclosure - Schedule of Fair Value of Stock Option Granted (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>999064 - Disclosure - Schedule of Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative" id="ShareBasedCompensationDetailsNarrative">
          <link:definition>999065 - Disclosure - Share Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" id="ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails">
          <link:definition>999066 - Disclosure - Schedule of Income before Income Tax, Domestic and Foreign (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails" id="ScheduleOfProvisionForIncomeTaxDetails">
          <link:definition>999067 - Disclosure - Schedule of Provision for Income Tax (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails" id="ScheduleOfFederalIncomeTaxRateDetails">
          <link:definition>999068 - Disclosure - Schedule of Federal Income Tax Rate (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>999069 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999070 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative" id="CommonStockAndPreferredStockDetailsNarrative">
          <link:definition>999071 - Disclosure - Common Stock and Preferred Stock (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" id="ScheduleOfBasicAndDilutedNetLossPerShareDetails">
          <link:definition>999072 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" id="ScheduleOfPotentiallyDilutiveSecuritiesDetails">
          <link:definition>999073 - Disclosure - Schedule of Potentially Dilutive Securities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999074 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999075 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails" id="ScheduleOfOtherExpenseNetDetails">
          <link:definition>999076 - Disclosure - Schedule of Other Expense, Net (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails" id="ScheduleOfBlack-scholesOptionPricingModelDetails">
          <link:definition>999077 - Disclosure - Schedule of Black-Scholes Option Pricing Model (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/WarrantsDetailsNarrative" id="WarrantsDetailsNarrative">
          <link:definition>999078 - Disclosure - Warrants (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails" id="ScheduleOfFinancialDataForCompanysReportableSegmentDetails">
          <link:definition>999079 - Disclosure - Schedule of Financial Data for the Company&#8217;s Reportable Segment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://conduitpharma.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999080 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cdt-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cdt-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cdt-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cdt-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <element id="CDT_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" name="RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_MurphyCanyonAcquisitionCorpMember" name="MurphyCanyonAcquisitionCorpMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_OldConduitPharmaceuticalsLimitedMember" name="OldConduitPharmaceuticalsLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ConduitConvertibleNoteHoldersMember" name="ConduitConvertibleNoteHoldersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ConduitShareHoldersandConvertibleNoteHoldersMember" name="ConduitShareHoldersandConvertibleNoteHoldersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_SponsorMember" name="SponsorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AllianceGlobalPartnersMember" name="AllianceGlobalPartnersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_SubscriptionAgreementsMember" name="SubscriptionAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AGPConvertibleNoteMember" name="AGPConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_PIPEWarrantsMember" name="PIPEWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_CorporateBondYieldEstimatedTimingOfConversionMember" name="CorporateBondYieldEstimatedTimingOfConversionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_MeasurementInputProbabilityOfDefaultMember" name="MeasurementInputProbabilityOfDefaultMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_MeasurementInputRecoveryUponDefaultMember" name="MeasurementInputRecoveryUponDefaultMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_VelaAgreementMember" name="VelaAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_VelaTechnologiesPLCMember" name="VelaTechnologiesPLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_VelaOptionAgreementMember" name="VelaOptionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_VelaOptionLiabilityMember" name="VelaOptionLiabilityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_CizzlePlcAgreementMember" name="CizzlePlcAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ConvertiblePromissoryNotesPayableMember" name="ConvertiblePromissoryNotesPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ConvertiblePromissoryNoteMember" name="ConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ConvertiblePromissoryNotePayableMember" name="ConvertiblePromissoryNotePayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_TwentyTwentyThreeConvertibleNoteMember" name="TwentyTwentyThreeConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_SeniorSecuredPromissoryNoteMember" name="SeniorSecuredPromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_NirlandLimitedMember" name="NirlandLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_FirstAmendmentNirlandNoteMember" name="FirstAmendmentNirlandNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_FirstAmendmentMember" name="FirstAmendmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_SecondAmendmentNirlandNoteMember" name="SecondAmendmentNirlandNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_SecondAmendmentMember" name="SecondAmendmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ConvertiblePromissoryNotesMember" name="ConvertiblePromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AllianceGobalPartnersConvertibleNoteMember" name="AllianceGobalPartnersConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_LoanAgreementsMember" name="LoanAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_TrancheOneMember" name="TrancheOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_TrancheTwoMember" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_TrancheThreeMember" name="TrancheThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_LoanHoldersMember" name="LoanHoldersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_LoansAmendmentMember" name="LoansAmendmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_OctoberTwoThousandTwentyFourNirlandNoteMember" name="OctoberTwoThousandTwentyFourNirlandNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_BridgeLoanAgreementMember" name="BridgeLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AstraZenecaMember" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_SARBORGServiceAgreementMember" name="SARBORGServiceAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_TwentyTwentyThreeStockIncentivePlanMember" name="TwentyTwentyThreeStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_MrHeilbronMember" name="MrHeilbronMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_TwoThousandTwentyThreePlanMember" name="TwoThousandTwentyThreePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_SalesAgreementMember" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_PublicWarrantsMember" name="PublicWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_PIPEMember" name="PIPEMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AGPWarrantsMember" name="AGPWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AugustTwentyTwentyFourNirlandNoteMember" name="AugustTwentyTwentyFourNirlandNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_MarchTwentyTwentyFourWarrantsMember" name="MarchTwentyTwentyFourWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AprilTwentyTwentyFourWarrantsMember" name="AprilTwentyTwentyFourWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AGPTwentyTwentyFourWarrantsMember" name="AGPTwentyTwentyFourWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_CorvusCapitalLimitedMember" name="CorvusCapitalLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_BoardOfDirectorsMember" name="BoardOfDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember" name="TwentyTwentyTwoConvertibleLoanNoteInstrumentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_SARBORGLtdMember" name="SARBORGLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_SARBORGServicesAgreementMember" name="SARBORGServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_OfficersAndDirectorsMember" name="OfficersAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_MarchLockUpAgreementMember" name="MarchLockUpAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AprilLockUpAgreementMember" name="AprilLockUpAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_PublicWarrantMember" name="PublicWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_PrivatePlacementWarrantMember" name="PrivatePlacementWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_NewLicensesMember" name="NewLicensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ClinicalAssetDevelopmentMember" name="ClinicalAssetDevelopmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_LegalAndProfessionalFeesMember" name="LegalAndProfessionalFeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AccountingAndAuditFeesMember" name="AccountingAndAuditFeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_SalariesPayrollAndStockBasedCompensationMember" name="SalariesPayrollAndStockBasedCompensationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_OctoberTwentyTwentyFourNirlandNoteMember" name="OctoberTwentyTwentyFourNirlandNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities" name="ChangeInFairValueAndIncomeImpactOfOptionLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing" name="StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing" name="StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodValuePurchaseOfRevenue" name="StockIssuedDuringPeriodValuePurchaseOfRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodSharesPurchaseOfRevenue" name="StockIssuedDuringPeriodSharesPurchaseOfRevenue" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodValuePurchasesOfRevenue" name="StockIssuedDuringPeriodValuePurchasesOfRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodSharesPurchasesOfRevenue" name="StockIssuedDuringPeriodSharesPurchasesOfRevenue" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodValueIssuedForServicesOne" name="StockIssuedDuringPeriodValueIssuedForServicesOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodSharesIssuedForServicesOne" name="StockIssuedDuringPeriodSharesIssuedForServicesOne" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger" name="AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty" name="AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" name="AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStock" name="StockIssuedDuringPeriodValueIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStock" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_GainLossOnChangeInFairValueOfCizzleOption" name="GainLossOnChangeInFairValueOfCizzleOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_GainOnChangeInFairValueOfVelaOption" name="GainOnChangeInFairValueOfVelaOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_LossOnIssuanceOfVelaOption" name="LossOnIssuanceOfVelaOption" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ChangesInForeignCurrencyTransactionUnrealized" name="ChangesInForeignCurrencyTransactionUnrealized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_LossOnRelatedPartyLoanForgiveness" name="LossOnRelatedPartyLoanForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_RealizedGainOnShorttermInvestments" name="RealizedGainOnShorttermInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_LossOnChangeInFairValueOfConvertibleNotesPayable" name="LossOnChangeInFairValueOfConvertibleNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability" name="NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_LossOnIssuanceOfWarrants" name="LossOnIssuanceOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_NoncashLeaseExpense" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_IssuanceOfCommonStockForLicensingRight" name="IssuanceOfCommonStockForLicensingRight" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_NoncashInterestExpense" name="NoncashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AmortizationExpense" name="AmortizationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AmortizationOfDebtDiscount" name="AmortizationOfDebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" name="IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ProceedsFromIssuanceOfOption" name="ProceedsFromIssuanceOfOption" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ProceedsFromLoanRepaymentRelatedParty" name="ProceedsFromLoanRepaymentRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts" name="ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty" name="ProceedsFromIssuanceOfCapitalContributionRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ProceedsFromExerciseOfWarrants" name="ProceedsFromExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" name="CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_IssuanceOfCommonStockInExchangeForDebtExtension" name="IssuanceOfCommonStockInExchangeForDebtExtension" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote" name="ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc" name="IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DeferredUnderwritingCosts" name="DeferredUnderwritingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger" name="PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination" name="AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing" name="InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_NoncashAssetsAssumedInMergerFinancing" name="NoncashAssetsAssumedInMergerFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_NoncashLiabilitiesAssumedInMergerFinancing" name="NoncashLiabilitiesAssumedInMergerFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract" name="DisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_LiabilityRelatedToTheSaleOfFutureRevenueTextBlock" name="LiabilityRelatedToTheSaleOfFutureRevenueTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DisclosureConvertibleNotesPayableAbstract" name="DisclosureConvertibleNotesPayableAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ConvertibleNotesPayableTextBlock" name="ConvertibleNotesPayableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DisclosureDeferredCommissionPayableAbstract" name="DisclosureDeferredCommissionPayableAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DeferredCommissionPayableTextBlock" name="DeferredCommissionPayableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DisclosureResearchAndDevelopmentExpenseAbstract" name="DisclosureResearchAndDevelopmentExpenseAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock" name="DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DisclosureWarrantsAbstract" name="DisclosureWarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_WarrantLiabilityDisclosureTextBlock" name="WarrantLiabilityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_WarrantInstrumentsPolicyTextBlock" name="WarrantInstrumentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" name="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_LesseeOperatingLeaseLiabilityTableTextBlock" name="LesseeOperatingLeaseLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DepositInsuranceLimit" name="DepositInsuranceLimit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_CashAndCashEquivalentsNetBankOverdrafts" name="CashAndCashEquivalentsNetBankOverdrafts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DescriptionForEmergingGrowthCompany" name="DescriptionForEmergingGrowthCompany" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_BusinessAcquisitionNumberOfSharesTransferred" name="BusinessAcquisitionNumberOfSharesTransferred" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DeferredUnderwritingFee" name="DeferredUnderwritingFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_PaymentForAdvisoryServices" name="PaymentForAdvisoryServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised" name="StockIssuedDuringPeriodSharesStockWarrantsExercised" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DeferredCashPaymentsAmount" name="DeferredCashPaymentsAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AnnualInterestRate" name="AnnualInterestRate" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ChangeInFairValueOfConvertibleNotesPayable" name="ChangeInFairValueOfConvertibleNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_WarrantsExcercise" name="WarrantsExcercise" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_PercentageOfFutureRevenueEarned" name="PercentageOfFutureRevenueEarned" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_RoyaltyPercentage" name="RoyaltyPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_NonRefundableOptionFee" name="NonRefundableOptionFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_OptionAgreementDescription" name="OptionAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_OptionFee" name="OptionFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DebtIssuedUponExecution" name="DebtIssuedUponExecution" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_PaymentOfCommonStock" name="PaymentOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_NetProceedsReceivedPercentage" name="NetProceedsReceivedPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_PenaltyPayment" name="PenaltyPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_GainOnChangeInFairValue" name="GainOnChangeInFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DeferredCommissionPayable" name="DeferredCommissionPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_GainOnChangeInFairValueOfConvertibleNote" name="GainOnChangeInFairValueOfConvertibleNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_StockIssuedDuringPeriodAdditionalSharesIssued" name="StockIssuedDuringPeriodAdditionalSharesIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ArrangementFeePercentage" name="ArrangementFeePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_CommitmentFees" name="CommitmentFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_CommonStockClosingPricePercentage" name="CommonStockClosingPricePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DeferredCommissionPayableAnnualInterestRate" name="DeferredCommissionPayableAnnualInterestRate" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DeferredCommissionPayableNonCurrent" name="DeferredCommissionPayableNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_PaymentToResearchAndDevolpmentAmount" name="PaymentToResearchAndDevolpmentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_CashPayment" name="CashPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1" name="ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_IncomeTaxReconciliationConvertibleDebtAdjustment" name="IncomeTaxReconciliationConvertibleDebtAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_IncomeTaxReconciliationStateReRate" name="IncomeTaxReconciliationStateReRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments" name="IncomeTaxReconciliationPurchaseAccountingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_DeferredTaxAssetsStockOptions" name="DeferredTaxAssetsStockOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate" name="EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_OptionLiabilityConversionShares" name="OptionLiabilityConversionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_RecognitionOfDeferredRevenueUponOptionExercise" name="RecognitionOfDeferredRevenueUponOptionExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_RecognitionOfDeferredRevenueUponOptionExerciseOne" name="RecognitionOfDeferredRevenueUponOptionExerciseOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ChangeInFairValueOfOption" name="ChangeInFairValueOfOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ChangeInFairValueOfOptions" name="ChangeInFairValueOfOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ChangeInFairValueOfWarrantLiability" name="ChangeInFairValueOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ChangeInFairValueOfConvertibleNotePayment" name="ChangeInFairValueOfConvertibleNotePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_GainOnDebtExtinguishment" name="GainOnDebtExtinguishment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_IncomeTaxRefund" name="IncomeTaxRefund" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_LossOnIssuanceOfOptionOne" name="LossOnIssuanceOfOptionOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_OtherIncomeUnrealizedForeignCurrencyTransactionLoss" name="OtherIncomeUnrealizedForeignCurrencyTransactionLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_LossOnDebtExtinguishment" name="LossOnDebtExtinguishment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_OtherExpenseChangeInFairValueOfConvertibleNotesPayable" name="OtherExpenseChangeInFairValueOfConvertibleNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_OtherExpense" name="OtherExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_CommissionsPayable" name="CommissionsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AprilTwoThousandTwentyFourMember" name="AprilTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AdjustmentsToAdditionalPaidInCapital" name="AdjustmentsToAdditionalPaidInCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_PriorPeriodAdjustment" name="PriorPeriodAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ExchangeOfConduitPharmaceuticalsLimitedConvertibleNotesForSharesOfConduitPharmaceuticalsInc.CommonStockInConnectionWithMerger" name="ExchangeOfConduitPharmaceuticalsLimitedConvertibleNotesForSharesOfConduitPharmaceuticalsInc.CommonStockInConnectionWithMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToVelaTechnologiesPlcUponExerciseOfOption" name="IssuanceOfConduitPharmaceuticalsInc.CommonStockToVelaTechnologiesPlcUponExerciseOfOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ScheduleOfLiabilityForTheSaleOfFutureRevenueTableTextBlock" name="ScheduleOfLiabilityForTheSaleOfFutureRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_SaleOfFutureRoyalties" name="SaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_ReversalOfFutureRoyaltiesUponOptionExercise" name="ReversalOfFutureRoyaltiesUponOptionExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_SaleOfFutureRoyaltiesOfForeignCurrencyExchangeImpact" name="SaleOfFutureRoyaltiesOfForeignCurrencyExchangeImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_CommonStockConversionPrice" name="CommonStockConversionPrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_NoncashResearchAndDevelopmentExpense" name="NoncashResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_BridgeAgreementMember" name="BridgeAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_WarrantAgreementMember" name="WarrantAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AugustTwoThousandTwentyFourNirlandNoteMember" name="AugustTwoThousandTwentyFourNirlandNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_LiabilityClassifiedWarrantsMember" name="LiabilityClassifiedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_SecurityAgreementMember" name="SecurityAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_NasdaqCapitalMarketDescription" name="NasdaqCapitalMarketDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_GuaranteedReturnAmount" name="GuaranteedReturnAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_AmountTransferToCapitalMarket" name="AmountTransferToCapitalMarket" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_CurrentMarketValueOfPubliclyHeldShares" name="CurrentMarketValueOfPubliclyHeldShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_BidPricePerShare" name="BidPricePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>cdt-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://conduitpharma.com/role/Cover" xlink:href="cdt-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/BalanceSheets" xlink:href="cdt-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/BalanceSheetsParenthetical" xlink:href="cdt-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="cdt-20241231.xsd#StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="cdt-20241231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/StatementsOfCashFlows" xlink:href="cdt-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cdt-20241231.xsd#NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/MergerAndFinancing" xlink:href="cdt-20241231.xsd#MergerAndFinancing" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/FairValue" xlink:href="cdt-20241231.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssets" xlink:href="cdt-20241231.xsd#BalanceSheetDetailsCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/Leases" xlink:href="cdt-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenue" xlink:href="cdt-20241231.xsd#LiabilityRelatedToSaleOfFutureRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ConvertibleNotesPayable" xlink:href="cdt-20241231.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LoansPayable" xlink:href="cdt-20241231.xsd#LoansPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/DeferredCommissionPayable" xlink:href="cdt-20241231.xsd#DeferredCommissionPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ResearchAndDevelopmentExpense" xlink:href="cdt-20241231.xsd#ResearchAndDevelopmentExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ShareBasedCompensation" xlink:href="cdt-20241231.xsd#ShareBasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/IncomeTaxes" xlink:href="cdt-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/CommonStockAndPreferredStock" xlink:href="cdt-20241231.xsd#CommonStockAndPreferredStock" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/EarningsnetLossPerShare" xlink:href="cdt-20241231.xsd#EarningsnetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/CommitmentsAndContingencies" xlink:href="cdt-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/RelatedPartyTransactions" xlink:href="cdt-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/OtherIncomeExpenseNet" xlink:href="cdt-20241231.xsd#OtherIncomeExpenseNet" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/Warrants" xlink:href="cdt-20241231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/Segments" xlink:href="cdt-20241231.xsd#Segments" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/SubsequentEvents" xlink:href="cdt-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cdt-20241231.xsd#NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/MergerAndFinancingTables" xlink:href="cdt-20241231.xsd#MergerAndFinancingTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/FairValueTables" xlink:href="cdt-20241231.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssetsTables" xlink:href="cdt-20241231.xsd#BalanceSheetDetailsCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LeasesTables" xlink:href="cdt-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ShareBasedCompensationTables" xlink:href="cdt-20241231.xsd#ShareBasedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/IncomeTaxesTables" xlink:href="cdt-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/EarningsnetLossPerShareTables" xlink:href="cdt-20241231.xsd#EarningsnetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/OtherIncomeExpenseNetTables" xlink:href="cdt-20241231.xsd#OtherIncomeExpenseNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/WarrantsTables" xlink:href="cdt-20241231.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/SegmentsTables" xlink:href="cdt-20241231.xsd#SegmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cdt-20241231.xsd#NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails" xlink:href="cdt-20241231.xsd#ScheduleOfCommonStockOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative" xlink:href="cdt-20241231.xsd#MergerAndFinancingDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails" xlink:href="cdt-20241231.xsd#ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails" xlink:href="cdt-20241231.xsd#ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails" xlink:href="cdt-20241231.xsd#ScheduleOfFairValueOfAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/FairValueDetailsNarrative" xlink:href="cdt-20241231.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails" xlink:href="cdt-20241231.xsd#ScheduleOfBalanceSheetDetailsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfLeaseCostDetails" xlink:href="cdt-20241231.xsd#ScheduleOfLeaseCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:href="cdt-20241231.xsd#ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:href="cdt-20241231.xsd#ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LeasesDetailsNarrative" xlink:href="cdt-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative" xlink:href="cdt-20241231.xsd#LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="cdt-20241231.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LoansPayableDetailsNarrative" xlink:href="cdt-20241231.xsd#LoansPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative" xlink:href="cdt-20241231.xsd#DeferredCommissionPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative" xlink:href="cdt-20241231.xsd#ResearchAndDevelopmentExpenseDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails" xlink:href="cdt-20241231.xsd#ScheduleOfRestrictedStockActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails" xlink:href="cdt-20241231.xsd#ScheduleOfFairValueOfStockOptionGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="cdt-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative" xlink:href="cdt-20241231.xsd#ShareBasedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:href="cdt-20241231.xsd#ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails" xlink:href="cdt-20241231.xsd#ScheduleOfProvisionForIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails" xlink:href="cdt-20241231.xsd#ScheduleOfFederalIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="cdt-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="cdt-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative" xlink:href="cdt-20241231.xsd#CommonStockAndPreferredStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="cdt-20241231.xsd#ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="cdt-20241231.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cdt-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cdt-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails" xlink:href="cdt-20241231.xsd#ScheduleOfOtherExpenseNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails" xlink:href="cdt-20241231.xsd#ScheduleOfBlack-scholesOptionPricingModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/WarrantsDetailsNarrative" xlink:href="cdt-20241231.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails" xlink:href="cdt-20241231.xsd#ScheduleOfFinancialDataForCompanysReportableSegmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="cdt-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable" xlink:label="loc_us-gaapOtherNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityClassifiedNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredCompensationLiabilityClassifiedNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities" xlink:label="loc_CDTChangeInFairValueAndIncomeImpactOfOptionLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="loc_CDTChangeInFairValueAndIncomeImpactOfOptionLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GainLossOnChangeInFairValueOfCizzleOption" xlink:label="loc_CDTGainLossOnChangeInFairValueOfCizzleOption" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CDTGainLossOnChangeInFairValueOfCizzleOption" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GainOnChangeInFairValueOfVelaOption" xlink:label="loc_CDTGainOnChangeInFairValueOfVelaOption" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CDTGainOnChangeInFairValueOfVelaOption" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnIssuanceOfVelaOption" xlink:label="loc_CDTLossOnIssuanceOfVelaOption" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CDTLossOnIssuanceOfVelaOption" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangesInForeignCurrencyTransactionUnrealized" xlink:label="loc_CDTChangesInForeignCurrencyTransactionUnrealized" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CDTChangesInForeignCurrencyTransactionUnrealized" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnRelatedPartyLoanForgiveness" xlink:label="loc_CDTLossOnRelatedPartyLoanForgiveness" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CDTLossOnRelatedPartyLoanForgiveness" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_RealizedGainOnShorttermInvestments" xlink:label="loc_CDTRealizedGainOnShorttermInvestments" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CDTRealizedGainOnShorttermInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossUnrealizedAfterTax" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnChangeInFairValueOfConvertibleNotesPayable" xlink:label="loc_CDTLossOnChangeInFairValueOfConvertibleNotesPayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CDTLossOnChangeInFairValueOfConvertibleNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability" xlink:label="loc_CDTNoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CDTNoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnIssuanceOfWarrants" xlink:label="loc_CDTLossOnIssuanceOfWarrants" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CDTLossOnIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NoncashLeaseExpense" xlink:label="loc_CDTNoncashLeaseExpense" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CDTNoncashLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IssuanceOfCommonStockForLicensingRight" xlink:label="loc_CDTIssuanceOfCommonStockForLicensingRight" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CDTIssuanceOfCommonStockForLicensingRight" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NoncashInterestExpense" xlink:label="loc_CDTNoncashInterestExpense" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CDTNoncashInterestExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AmortizationExpense" xlink:label="loc_CDTAmortizationExpense" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CDTAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AmortizationOfDebtDiscount" xlink:label="loc_CDTAmortizationOfDebtDiscount" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CDTAmortizationOfDebtDiscount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_CDTIncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" />
      <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CDTIncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInIntangibleAssetsCurrent" />
      <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIntangibleAssetsCurrent" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="loc_us-gaapPaymentsToFundLongtermLoansToRelatedParties" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToFundLongtermLoansToRelatedParties" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaapPaymentsToAcquireShortTermInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireShortTermInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaapProceedsFromSaleOfShortTermInvestments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ProceedsFromIssuanceOfOption" xlink:label="loc_CDTProceedsFromIssuanceOfOption" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_CDTProceedsFromIssuanceOfOption" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ProceedsFromLoanRepaymentRelatedParty" xlink:label="loc_CDTProceedsFromLoanRepaymentRelatedParty" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_CDTProceedsFromLoanRepaymentRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts" xlink:label="loc_CDTProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CDTProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty" xlink:label="loc_CDTProceedsFromIssuanceOfCapitalContributionRelatedParty" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CDTProceedsFromIssuanceOfCapitalContributionRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ProceedsFromExerciseOfWarrants" xlink:label="loc_CDTProceedsFromExerciseOfWarrants" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CDTProceedsFromExerciseOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/MergerAndFinancing" xlink:title="999015 - Disclosure - Merger and Financing" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/FairValue" xlink:title="999016 - Disclosure - Fair Value" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssets" xlink:title="999017 - Disclosure - Balance Sheet Details &#8211; Current Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Leases" xlink:title="999018 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenue" xlink:title="999019 - Disclosure - Liability Related to the Sale of Future Revenue" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ConvertibleNotesPayable" xlink:title="999020 - Disclosure - Convertible Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LoansPayable" xlink:title="999021 - Disclosure - Loans Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/DeferredCommissionPayable" xlink:title="999022 - Disclosure - Deferred Commission Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ResearchAndDevelopmentExpense" xlink:title="999023 - Disclosure - Research and Development Expense" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ShareBasedCompensation" xlink:title="999024 - Disclosure - Share Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/IncomeTaxes" xlink:title="999025 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/CommonStockAndPreferredStock" xlink:title="999026 - Disclosure - Common Stock and Preferred Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/EarningsnetLossPerShare" xlink:title="999027 - Disclosure - Earnings/(Net Loss) Per Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/CommitmentsAndContingencies" xlink:title="999028 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/RelatedPartyTransactions" xlink:title="999029 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/OtherIncomeExpenseNet" xlink:title="999030 - Disclosure - Other Income (expense), net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Warrants" xlink:title="999031 - Disclosure - Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Segments" xlink:title="999032 - Disclosure - Segments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/SubsequentEvents" xlink:title="999033 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999034 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/MergerAndFinancingTables" xlink:title="999035 - Disclosure - Merger and Financing (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/FairValueTables" xlink:title="999036 - Disclosure - Fair Value (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssetsTables" xlink:title="999037 - Disclosure - Balance Sheet Details &#8211; Current Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LeasesTables" xlink:title="999038 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ShareBasedCompensationTables" xlink:title="999039 - Disclosure - Share Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/EarningsnetLossPerShareTables" xlink:title="999041 - Disclosure - Earnings/(Net Loss) Per Share (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/OtherIncomeExpenseNetTables" xlink:title="999042 - Disclosure - Other Income (expense), net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/WarrantsTables" xlink:title="999043 - Disclosure - Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/SegmentsTables" xlink:title="999044 - Disclosure - Segments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999045 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails" xlink:title="999046 - Disclosure - Schedule of Common Stock Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative" xlink:title="999047 - Disclosure - Merger and Financing (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails" xlink:title="999048 - Disclosure - Schedule of Assets Subject to Measurement at Fair Value on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails" xlink:title="999049 - Disclosure - Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails" xlink:title="999050 - Disclosure - Schedule of Fair Value of Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/FairValueDetailsNarrative" xlink:title="999051 - Disclosure - Fair Value (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails" xlink:title="999052 - Disclosure - Schedule of Balance Sheet Details (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfLeaseCostDetails" xlink:title="999053 - Disclosure - Schedule of Lease Cost (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:title="999054 - Disclosure - Schedule of Operating Lease Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:title="999055 - Disclosure - Schedule of Future Minimum Lease Payments For Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LeasesDetailsNarrative" xlink:title="999056 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative" xlink:title="999057 - Disclosure - Liability Related to the Sale of Future Revenue (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="999058 - Disclosure - Convertible Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LoansPayableDetailsNarrative" xlink:title="999059 - Disclosure - Loans Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative" xlink:title="999060 - Disclosure - Deferred Commission Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative" xlink:title="999061 - Disclosure - Research and Development Expense (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails" xlink:title="999062 - Disclosure - Schedule of Restricted Stock Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails" xlink:title="999063 - Disclosure - Schedule of Fair Value of Stock Option Granted (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999064 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative" xlink:title="999065 - Disclosure - Share Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:title="999066 - Disclosure - Schedule of Income before Income Tax, Domestic and Foreign (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails" xlink:title="999067 - Disclosure - Schedule of Provision for Income Tax (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails" xlink:title="999068 - Disclosure - Schedule of Federal Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncomeTaxReconciliationConvertibleDebtAdjustment" xlink:label="loc_CDTIncomeTaxReconciliationConvertibleDebtAdjustment" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_CDTIncomeTaxReconciliationConvertibleDebtAdjustment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncomeTaxReconciliationStateReRate" xlink:label="loc_CDTIncomeTaxReconciliationStateReRate" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_CDTIncomeTaxReconciliationStateReRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments" xlink:label="loc_CDTIncomeTaxReconciliationPurchaseAccountingAdjustments" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_CDTIncomeTaxReconciliationPurchaseAccountingAdjustments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999069 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredTaxAssetsStockOptions" xlink:label="loc_CDTDeferredTaxAssetsStockOptions" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CDTDeferredTaxAssetsStockOptions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsHedgingTransactions" xlink:label="loc_us-gaapDeferredTaxAssetsHedgingTransactions" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsHedgingTransactions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999070 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative" xlink:title="999071 - Disclosure - Common Stock and Preferred Stock (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="999072 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities" xlink:label="loc_CDTChangeInFairValueAndIncomeImpactOfOptionLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="loc_CDTChangeInFairValueAndIncomeImpactOfOptionLiabilities" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="999073 - Disclosure - Schedule of Potentially Dilutive Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999074 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999075 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails" xlink:title="999076 - Disclosure - Schedule of Other Expense, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_RecognitionOfDeferredRevenueUponOptionExercise" xlink:label="loc_CDTRecognitionOfDeferredRevenueUponOptionExercise" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncome" xlink:to="loc_CDTRecognitionOfDeferredRevenueUponOptionExercise" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_RecognitionOfDeferredRevenueUponOptionExerciseOne" xlink:label="loc_CDTRecognitionOfDeferredRevenueUponOptionExerciseOne" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncome" xlink:to="loc_CDTRecognitionOfDeferredRevenueUponOptionExerciseOne" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueOfOption" xlink:label="loc_CDTChangeInFairValueOfOption" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncome" xlink:to="loc_CDTChangeInFairValueOfOption" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueOfOptions" xlink:label="loc_CDTChangeInFairValueOfOptions" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncome" xlink:to="loc_CDTChangeInFairValueOfOptions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueOfWarrantLiability" xlink:label="loc_CDTChangeInFairValueOfWarrantLiability" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncome" xlink:to="loc_CDTChangeInFairValueOfWarrantLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueOfConvertibleNotePayment" xlink:label="loc_CDTChangeInFairValueOfConvertibleNotePayment" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncome" xlink:to="loc_CDTChangeInFairValueOfConvertibleNotePayment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GainOnDebtExtinguishment" xlink:label="loc_CDTGainOnDebtExtinguishment" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncome" xlink:to="loc_CDTGainOnDebtExtinguishment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncome" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncomeTaxRefund" xlink:label="loc_CDTIncomeTaxRefund" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncome" xlink:to="loc_CDTIncomeTaxRefund" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossUnrealized" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncome" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncome" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnIssuanceOfOptionOne" xlink:label="loc_CDTLossOnIssuanceOfOptionOne" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingExpense" xlink:to="loc_CDTLossOnIssuanceOfOptionOne" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OtherIncomeUnrealizedForeignCurrencyTransactionLoss" xlink:label="loc_CDTOtherIncomeUnrealizedForeignCurrencyTransactionLoss" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingExpense" xlink:to="loc_CDTOtherIncomeUnrealizedForeignCurrencyTransactionLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingExpense" xlink:to="loc_us-gaapInterestExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingExpense" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnIssuanceOfWarrants" xlink:label="loc_CDTLossOnIssuanceOfWarrants" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingExpense" xlink:to="loc_CDTLossOnIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnDebtExtinguishment" xlink:label="loc_CDTLossOnDebtExtinguishment" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingExpense" xlink:to="loc_CDTLossOnDebtExtinguishment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OtherExpenseChangeInFairValueOfConvertibleNotesPayable" xlink:label="loc_CDTOtherExpenseChangeInFairValueOfConvertibleNotesPayable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingExpense" xlink:to="loc_CDTOtherExpenseChangeInFairValueOfConvertibleNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OtherExpense" xlink:label="loc_CDTOtherExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingExpense" xlink:to="loc_CDTOtherExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails" xlink:title="999077 - Disclosure - Schedule of Black-Scholes Option Pricing Model (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/WarrantsDetailsNarrative" xlink:title="999078 - Disclosure - Warrants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails" xlink:title="999079 - Disclosure - Schedule of Financial Data for the Company&#8217;s Reportable Segment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999080 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>cdt-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://conduitpharma.com/role/Cover" xlink:href="cdt-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/BalanceSheets" xlink:href="cdt-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/BalanceSheetsParenthetical" xlink:href="cdt-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="cdt-20241231.xsd#StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="cdt-20241231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/StatementsOfCashFlows" xlink:href="cdt-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cdt-20241231.xsd#NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/MergerAndFinancing" xlink:href="cdt-20241231.xsd#MergerAndFinancing" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/FairValue" xlink:href="cdt-20241231.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssets" xlink:href="cdt-20241231.xsd#BalanceSheetDetailsCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/Leases" xlink:href="cdt-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenue" xlink:href="cdt-20241231.xsd#LiabilityRelatedToSaleOfFutureRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ConvertibleNotesPayable" xlink:href="cdt-20241231.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LoansPayable" xlink:href="cdt-20241231.xsd#LoansPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/DeferredCommissionPayable" xlink:href="cdt-20241231.xsd#DeferredCommissionPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ResearchAndDevelopmentExpense" xlink:href="cdt-20241231.xsd#ResearchAndDevelopmentExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ShareBasedCompensation" xlink:href="cdt-20241231.xsd#ShareBasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/IncomeTaxes" xlink:href="cdt-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/CommonStockAndPreferredStock" xlink:href="cdt-20241231.xsd#CommonStockAndPreferredStock" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/EarningsnetLossPerShare" xlink:href="cdt-20241231.xsd#EarningsnetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/CommitmentsAndContingencies" xlink:href="cdt-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/RelatedPartyTransactions" xlink:href="cdt-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/OtherIncomeExpenseNet" xlink:href="cdt-20241231.xsd#OtherIncomeExpenseNet" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/Warrants" xlink:href="cdt-20241231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/Segments" xlink:href="cdt-20241231.xsd#Segments" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/SubsequentEvents" xlink:href="cdt-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cdt-20241231.xsd#NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/MergerAndFinancingTables" xlink:href="cdt-20241231.xsd#MergerAndFinancingTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/FairValueTables" xlink:href="cdt-20241231.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssetsTables" xlink:href="cdt-20241231.xsd#BalanceSheetDetailsCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LeasesTables" xlink:href="cdt-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ShareBasedCompensationTables" xlink:href="cdt-20241231.xsd#ShareBasedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/IncomeTaxesTables" xlink:href="cdt-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/EarningsnetLossPerShareTables" xlink:href="cdt-20241231.xsd#EarningsnetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/OtherIncomeExpenseNetTables" xlink:href="cdt-20241231.xsd#OtherIncomeExpenseNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/WarrantsTables" xlink:href="cdt-20241231.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/SegmentsTables" xlink:href="cdt-20241231.xsd#SegmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cdt-20241231.xsd#NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails" xlink:href="cdt-20241231.xsd#ScheduleOfCommonStockOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative" xlink:href="cdt-20241231.xsd#MergerAndFinancingDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails" xlink:href="cdt-20241231.xsd#ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails" xlink:href="cdt-20241231.xsd#ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails" xlink:href="cdt-20241231.xsd#ScheduleOfFairValueOfAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/FairValueDetailsNarrative" xlink:href="cdt-20241231.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails" xlink:href="cdt-20241231.xsd#ScheduleOfBalanceSheetDetailsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfLeaseCostDetails" xlink:href="cdt-20241231.xsd#ScheduleOfLeaseCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:href="cdt-20241231.xsd#ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:href="cdt-20241231.xsd#ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LeasesDetailsNarrative" xlink:href="cdt-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative" xlink:href="cdt-20241231.xsd#LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="cdt-20241231.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LoansPayableDetailsNarrative" xlink:href="cdt-20241231.xsd#LoansPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative" xlink:href="cdt-20241231.xsd#DeferredCommissionPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative" xlink:href="cdt-20241231.xsd#ResearchAndDevelopmentExpenseDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails" xlink:href="cdt-20241231.xsd#ScheduleOfRestrictedStockActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails" xlink:href="cdt-20241231.xsd#ScheduleOfFairValueOfStockOptionGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="cdt-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative" xlink:href="cdt-20241231.xsd#ShareBasedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:href="cdt-20241231.xsd#ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails" xlink:href="cdt-20241231.xsd#ScheduleOfProvisionForIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails" xlink:href="cdt-20241231.xsd#ScheduleOfFederalIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="cdt-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="cdt-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative" xlink:href="cdt-20241231.xsd#CommonStockAndPreferredStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="cdt-20241231.xsd#ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="cdt-20241231.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cdt-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cdt-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails" xlink:href="cdt-20241231.xsd#ScheduleOfOtherExpenseNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails" xlink:href="cdt-20241231.xsd#ScheduleOfBlack-scholesOptionPricingModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/WarrantsDetailsNarrative" xlink:href="cdt-20241231.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails" xlink:href="cdt-20241231.xsd#ScheduleOfFinancialDataForCompanysReportableSegmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="cdt-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CommonStockParValue0.0001PerShareMember" xlink:label="loc_CDTCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CDTCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:label="loc_CDTRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CDTRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_60" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_60" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_60" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_60" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_60" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_60" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_60" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_60" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_60" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_60" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_60" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_60" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_60" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_60" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_60" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_60" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_60" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_60" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_60" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_60" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_60" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_60" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_60" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_60" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_60" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_60" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_60" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_60" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_60" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_60" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag_60" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag_60" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_deiEntityListingParValuePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityListingParValuePerShare_60" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorOpinionTextBlock_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation_60" xlink:type="arc" order="64" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsNoncurrent_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableCurrent_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapConvertibleNotesPayable_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable" xlink:label="loc_us-gaapOtherNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOtherNotesPayable_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapNotesPayableCurrent_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityClassifiedNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapDeferredCompensationLiabilityClassifiedNoncurrent_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommitmentsAndContingencies_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockValue_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" xlink:label="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" xlink:label="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing" xlink:label="loc_CDTStockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing_210" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing" xlink:label="loc_CDTStockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing_210" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValuePurchaseOfRevenue" xlink:label="loc_CDTStockIssuedDuringPeriodValuePurchaseOfRevenue_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValuePurchaseOfRevenue_210" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesPurchaseOfRevenue" xlink:label="loc_CDTStockIssuedDuringPeriodSharesPurchaseOfRevenue_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesPurchaseOfRevenue_210" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValuePurchasesOfRevenue" xlink:label="loc_CDTStockIssuedDuringPeriodValuePurchasesOfRevenue_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValuePurchasesOfRevenue_210" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesPurchasesOfRevenue" xlink:label="loc_CDTStockIssuedDuringPeriodSharesPurchasesOfRevenue_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesPurchasesOfRevenue_210" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuedForServicesOne" xlink:label="loc_CDTStockIssuedDuringPeriodValueIssuedForServicesOne_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueIssuedForServicesOne_210" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuedForServicesOne" xlink:label="loc_CDTStockIssuedDuringPeriodSharesIssuedForServicesOne_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesIssuedForServicesOne_210" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger" xlink:label="loc_CDTAdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTAdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger_210" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty" xlink:label="loc_CDTAdjustmentsToAdditionalPaidInCapitalContributionRelatedParty_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTAdjustmentsToAdditionalPaidInCapitalContributionRelatedParty_210" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_210" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_210" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_210" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" xlink:label="loc_CDTAdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTAdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense_210" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_210" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_210" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_210" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_210" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable" xlink:label="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable_210" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable" xlink:label="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable_210" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_210" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStock" xlink:label="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStock_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStock_210" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStock" xlink:label="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStock_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStock_210" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification" xlink:label="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification_210" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification" xlink:label="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification_210" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" xlink:label="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption_210" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption" xlink:label="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption_210" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_210" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants_210" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants_210" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_210" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_210" xlink:type="arc" order="39" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/MergerAndFinancing" xlink:title="999015 - Disclosure - Merger and Financing" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/FairValue" xlink:title="999016 - Disclosure - Fair Value" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssets" xlink:title="999017 - Disclosure - Balance Sheet Details &#8211; Current Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Leases" xlink:title="999018 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenue" xlink:title="999019 - Disclosure - Liability Related to the Sale of Future Revenue" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ConvertibleNotesPayable" xlink:title="999020 - Disclosure - Convertible Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LoansPayable" xlink:title="999021 - Disclosure - Loans Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/DeferredCommissionPayable" xlink:title="999022 - Disclosure - Deferred Commission Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ResearchAndDevelopmentExpense" xlink:title="999023 - Disclosure - Research and Development Expense" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ShareBasedCompensation" xlink:title="999024 - Disclosure - Share Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/IncomeTaxes" xlink:title="999025 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/CommonStockAndPreferredStock" xlink:title="999026 - Disclosure - Common Stock and Preferred Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/EarningsnetLossPerShare" xlink:title="999027 - Disclosure - Earnings/(Net Loss) Per Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/CommitmentsAndContingencies" xlink:title="999028 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/RelatedPartyTransactions" xlink:title="999029 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/OtherIncomeExpenseNet" xlink:title="999030 - Disclosure - Other Income (expense), net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Warrants" xlink:title="999031 - Disclosure - Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Segments" xlink:title="999032 - Disclosure - Segments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/SubsequentEvents" xlink:title="999033 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999034 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/MergerAndFinancingTables" xlink:title="999035 - Disclosure - Merger and Financing (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/FairValueTables" xlink:title="999036 - Disclosure - Fair Value (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AGPConvertibleNoteMember" xlink:label="loc_CDTAGPConvertibleNoteMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTAGPConvertibleNoteMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssetsTables" xlink:title="999037 - Disclosure - Balance Sheet Details &#8211; Current Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LeasesTables" xlink:title="999038 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ShareBasedCompensationTables" xlink:title="999039 - Disclosure - Share Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/EarningsnetLossPerShareTables" xlink:title="999041 - Disclosure - Earnings/(Net Loss) Per Share (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/OtherIncomeExpenseNetTables" xlink:title="999042 - Disclosure - Other Income (expense), net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/WarrantsTables" xlink:title="999043 - Disclosure - Warrants (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/SegmentsTables" xlink:title="999044 - Disclosure - Segments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999045 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCash_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShortTermInvestments_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCashUninsuredAmount_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDepositAssets_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DemandDepositAccounts" xlink:label="loc_us-gaapDemandDepositAccounts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDemandDepositAccounts_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DepositInsuranceLimit" xlink:label="loc_CDTDepositInsuranceLimit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_CDTDepositInsuranceLimit_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CashAndCashEquivalentsNetBankOverdrafts" xlink:label="loc_CDTCashAndCashEquivalentsNetBankOverdrafts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_CDTCashAndCashEquivalentsNetBankOverdrafts_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DescriptionForEmergingGrowthCompany" xlink:label="loc_CDTDescriptionForEmergingGrowthCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_CDTDescriptionForEmergingGrowthCompany_60" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails" xlink:title="999046 - Disclosure - Schedule of Common Stock Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MurphyCanyonAcquisitionCorpMember" xlink:label="loc_CDTMurphyCanyonAcquisitionCorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_CDTMurphyCanyonAcquisitionCorpMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:label="loc_us-gaapScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="loc_us-gaapSharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:to="loc_us-gaapSharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="loc_us-gaapSharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:to="loc_us-gaapSharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="loc_us-gaapCommonStockSubjectToMandatoryRedemptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:to="loc_us-gaapCommonStockSubjectToMandatoryRedemptionMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SponsorMember" xlink:label="loc_CDTSponsorMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CDTSponsorMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SubscriptionAgreementsMember" xlink:label="loc_CDTSubscriptionAgreementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSubscriptionAgreementsMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative" xlink:title="999047 - Disclosure - Merger and Financing (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MurphyCanyonAcquisitionCorpMember" xlink:label="loc_CDTMurphyCanyonAcquisitionCorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_CDTMurphyCanyonAcquisitionCorpMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OldConduitPharmaceuticalsLimitedMember" xlink:label="loc_CDTOldConduitPharmaceuticalsLimitedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CDTOldConduitPharmaceuticalsLimitedMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AllianceGlobalPartnersMember" xlink:label="loc_CDTAllianceGlobalPartnersMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CDTAllianceGlobalPartnersMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConduitConvertibleNoteHoldersMember" xlink:label="loc_CDTConduitConvertibleNoteHoldersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CDTConduitConvertibleNoteHoldersMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConduitShareHoldersandConvertibleNoteHoldersMember" xlink:label="loc_CDTConduitShareHoldersandConvertibleNoteHoldersMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CDTConduitShareHoldersandConvertibleNoteHoldersMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SponsorMember" xlink:label="loc_CDTSponsorMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CDTSponsorMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SubscriptionAgreementsMember" xlink:label="loc_CDTSubscriptionAgreementsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSubscriptionAgreementsMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_BusinessAcquisitionNumberOfSharesTransferred" xlink:label="loc_CDTBusinessAcquisitionNumberOfSharesTransferred_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_CDTBusinessAcquisitionNumberOfSharesTransferred_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaapCommonStockConversionBasis_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCommonStockConversionBasis_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapProfessionalFees_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredUnderwritingFee" xlink:label="loc_CDTDeferredUnderwritingFee_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_CDTDeferredUnderwritingFee_140" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PaymentForAdvisoryServices" xlink:label="loc_CDTPaymentForAdvisoryServices_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_CDTPaymentForAdvisoryServices_140" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_CDTStockIssuedDuringPeriodSharesStockWarrantsExercised_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesStockWarrantsExercised_140" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredCashPaymentsAmount" xlink:label="loc_CDTDeferredCashPaymentsAmount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_CDTDeferredCashPaymentsAmount_140" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AnnualInterestRate" xlink:label="loc_CDTAnnualInterestRate_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_CDTAnnualInterestRate_140" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_140" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_140" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_140" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails" xlink:title="999048 - Disclosure - Schedule of Assets Subject to Measurement at Fair Value on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaapCashAndCashEquivalentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapCashAndCashEquivalentsMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_250" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails" xlink:title="999049 - Disclosure - Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaapConvertibleDebtFairValueDisclosures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapConvertibleDebtFairValueDisclosures_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueOfConvertibleNotesPayable" xlink:label="loc_CDTChangeInFairValueOfConvertibleNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_CDTChangeInFairValueOfConvertibleNotesPayable_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails" xlink:title="999050 - Disclosure - Schedule of Fair Value of Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CorporateBondYieldEstimatedTimingOfConversionMember" xlink:label="loc_CDTCorporateBondYieldEstimatedTimingOfConversionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_CDTCorporateBondYieldEstimatedTimingOfConversionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputCreditSpreadMember" xlink:label="loc_us-gaapMeasurementInputCreditSpreadMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputCreditSpreadMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MeasurementInputProbabilityOfDefaultMember" xlink:label="loc_CDTMeasurementInputProbabilityOfDefaultMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_CDTMeasurementInputProbabilityOfDefaultMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MeasurementInputRecoveryUponDefaultMember" xlink:label="loc_CDTMeasurementInputRecoveryUponDefaultMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_CDTMeasurementInputRecoveryUponDefaultMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaapMeasurementInputDiscountRateMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDiscountRateMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_390" xlink:type="arc" order="391" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AGPConvertibleNoteMember" xlink:label="loc_CDTAGPConvertibleNoteMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTAGPConvertibleNoteMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_350" xlink:type="arc" order="352" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput_460" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_460" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/FairValueDetailsNarrative" xlink:title="999051 - Disclosure - Fair Value (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PIPEWarrantsMember" xlink:label="loc_CDTPIPEWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CDTPIPEWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_WarrantsExcercise" xlink:label="loc_CDTWarrantsExcercise_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTWarrantsExcercise_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails" xlink:title="999052 - Disclosure - Schedule of Balance Sheet Details (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPrepaidInsurance_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrent_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfLeaseCostDetails" xlink:title="999053 - Disclosure - Schedule of Lease Cost (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:title="999054 - Disclosure - Schedule of Operating Lease Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:title="999055 - Disclosure - Schedule of Future Minimum Lease Payments For Operating Lease (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LeasesDetailsNarrative" xlink:title="999056 - Disclosure - Leases (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative" xlink:title="999057 - Disclosure - Liability Related to the Sale of Future Revenue (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_VelaAgreementMember" xlink:label="loc_CDTVelaAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTVelaAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_VelaOptionAgreementMember" xlink:label="loc_CDTVelaOptionAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTVelaOptionAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CizzlePlcAgreementMember" xlink:label="loc_CDTCizzlePlcAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTCizzlePlcAgreementMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_VelaTechnologiesPLCMember" xlink:label="loc_CDTVelaTechnologiesPLCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_CDTVelaTechnologiesPLCMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_VelaOptionLiabilityMember" xlink:label="loc_CDTVelaOptionLiabilityMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_CDTVelaOptionLiabilityMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PercentageOfFutureRevenueEarned" xlink:label="loc_CDTPercentageOfFutureRevenueEarned_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTPercentageOfFutureRevenueEarned_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferred_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferred_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_RoyaltyPercentage" xlink:label="loc_CDTRoyaltyPercentage_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTRoyaltyPercentage_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NonRefundableOptionFee" xlink:label="loc_CDTNonRefundableOptionFee_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTNonRefundableOptionFee_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OptionAgreementDescription" xlink:label="loc_CDTOptionAgreementDescription_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTOptionAgreementDescription_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRevenue_180" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_180" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_180" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued_180" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OptionFee" xlink:label="loc_CDTOptionFee_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTOptionFee_180" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_180" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet_180" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="999058 - Disclosure - Convertible Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertiblePromissoryNotesPayableMember" xlink:label="loc_CDTConvertiblePromissoryNotesPayableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CDTConvertiblePromissoryNotesPayableMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SeniorSecuredPromissoryNoteMember" xlink:label="loc_CDTSeniorSecuredPromissoryNoteMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CDTSeniorSecuredPromissoryNoteMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertiblePromissoryNoteMember" xlink:label="loc_CDTConvertiblePromissoryNoteMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTConvertiblePromissoryNoteMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertiblePromissoryNotePayableMember" xlink:label="loc_CDTConvertiblePromissoryNotePayableMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTConvertiblePromissoryNotePayableMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TwentyTwentyThreeConvertibleNoteMember" xlink:label="loc_CDTTwentyTwentyThreeConvertibleNoteMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTTwentyTwentyThreeConvertibleNoteMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_FirstAmendmentNirlandNoteMember" xlink:label="loc_CDTFirstAmendmentNirlandNoteMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTFirstAmendmentNirlandNoteMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_FirstAmendmentMember" xlink:label="loc_CDTFirstAmendmentMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTFirstAmendmentMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SecondAmendmentNirlandNoteMember" xlink:label="loc_CDTSecondAmendmentNirlandNoteMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTSecondAmendmentNirlandNoteMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SecondAmendmentMember" xlink:label="loc_CDTSecondAmendmentMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTSecondAmendmentMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertiblePromissoryNotesMember" xlink:label="loc_CDTConvertiblePromissoryNotesMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTConvertiblePromissoryNotesMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AllianceGobalPartnersConvertibleNoteMember" xlink:label="loc_CDTAllianceGobalPartnersConvertibleNoteMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTAllianceGobalPartnersConvertibleNoteMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConsultingAgreementMember" xlink:label="loc_CDTConsultingAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTConsultingAgreementMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_FirstAmendmentMember" xlink:label="loc_CDTFirstAmendmentMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTFirstAmendmentMember_330" xlink:type="arc" order="333" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SecondAmendmentMember" xlink:label="loc_CDTSecondAmendmentMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSecondAmendmentMember_340" xlink:type="arc" order="343" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NirlandLimitedMember" xlink:label="loc_CDTNirlandLimitedMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CDTNirlandLimitedMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_400" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription_400" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_400" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_400" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_400" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_400" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_400" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue_400" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssued1_400" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_400" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharePrice_400" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharesIssued_400" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_400" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt_400" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_400" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DebtIssuedUponExecution" xlink:label="loc_CDTDebtIssuedUponExecution_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTDebtIssuedUponExecution_400" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PaymentOfCommonStock" xlink:label="loc_CDTPaymentOfCommonStock_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTPaymentOfCommonStock_400" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NetProceedsReceivedPercentage" xlink:label="loc_CDTNetProceedsReceivedPercentage_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTNetProceedsReceivedPercentage_400" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount_400" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="loc_us-gaapDebtDefaultLongtermDebtAmount_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtDefaultLongtermDebtAmount_400" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable_400" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_400" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_400" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleLiquidationPreferenceValue" xlink:label="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferenceValue_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferenceValue_400" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebt_400" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PenaltyPayment" xlink:label="loc_CDTPenaltyPayment_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTPenaltyPayment_400" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_400" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaapConvertibleDebtFairValueDisclosures_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebtFairValueDisclosures_400" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_400" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_400" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_400" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrent_400" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaapNotesPayableFairValueDisclosure_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayableFairValueDisclosure_400" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingGainLoss" xlink:label="loc_us-gaapDebtSecuritiesTradingGainLoss_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtSecuritiesTradingGainLoss_400" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization_400" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_400" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GainOnChangeInFairValue" xlink:label="loc_CDTGainOnChangeInFairValue_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTGainOnChangeInFairValue_400" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet_400" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_400" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_400" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredCommissionPayable" xlink:label="loc_CDTDeferredCommissionPayable_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTDeferredCommissionPayable_400" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GainOnChangeInFairValueOfConvertibleNote" xlink:label="loc_CDTGainOnChangeInFairValueOfConvertibleNote_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTGainOnChangeInFairValueOfConvertibleNote_400" xlink:type="arc" order="41" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LoansPayableDetailsNarrative" xlink:title="999059 - Disclosure - Loans Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LoanAgreementsMember" xlink:label="loc_CDTLoanAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTLoanAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LoansAmendmentMember" xlink:label="loc_CDTLoansAmendmentMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTLoansAmendmentMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_BridgeLoanAgreementMember" xlink:label="loc_CDTBridgeLoanAgreementMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTBridgeLoanAgreementMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TrancheOneMember" xlink:label="loc_CDTTrancheOneMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CDTTrancheOneMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TrancheTwoMember" xlink:label="loc_CDTTrancheTwoMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CDTTrancheTwoMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TrancheThreeMember" xlink:label="loc_CDTTrancheThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CDTTrancheThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LoanHoldersMember" xlink:label="loc_CDTLoanHoldersMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_CDTLoanHoldersMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OctoberTwoThousandTwentyFourNirlandNoteMember" xlink:label="loc_CDTOctoberTwoThousandTwentyFourNirlandNoteMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTOctoberTwoThousandTwentyFourNirlandNoteMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLoansPayable_260" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription_260" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_260" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_260" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_260" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_260" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodAdditionalSharesIssued" xlink:label="loc_CDTStockIssuedDuringPeriodAdditionalSharesIssued_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodAdditionalSharesIssued_260" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_260" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_260" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_260" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue_260" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_260" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_260" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt_260" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_260" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_260" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ArrangementFeePercentage" xlink:label="loc_CDTArrangementFeePercentage_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTArrangementFeePercentage_260" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpense_260" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_260" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_260" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CommitmentFees" xlink:label="loc_CDTCommitmentFees_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTCommitmentFees_260" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_260" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_260" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CommonStockClosingPricePercentage" xlink:label="loc_CDTCommonStockClosingPricePercentage_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTCommonStockClosingPricePercentage_260" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_260" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_260" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_260" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable_260" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_260" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative" xlink:title="999060 - Disclosure - Deferred Commission Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AllianceGlobalPartnersMember" xlink:label="loc_CDTAllianceGlobalPartnersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CDTAllianceGlobalPartnersMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="loc_us-gaapProceedsFromFeesReceived_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromFeesReceived_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForFees_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredCommissionPayableAnnualInterestRate" xlink:label="loc_CDTDeferredCommissionPayableAnnualInterestRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTDeferredCommissionPayableAnnualInterestRate_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredCommissionPayableNonCurrent" xlink:label="loc_CDTDeferredCommissionPayableNonCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTDeferredCommissionPayableNonCurrent_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_90" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative" xlink:title="999061 - Disclosure - Research and Development Expense (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AstraZenecaMember" xlink:label="loc_CDTAstraZenecaMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CDTAstraZenecaMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SARBORGServiceAgreementMember" xlink:label="loc_CDTSARBORGServiceAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSARBORGServiceAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PaymentToResearchAndDevolpmentAmount" xlink:label="loc_CDTPaymentToResearchAndDevolpmentAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTPaymentToResearchAndDevolpmentAmount_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CashPayment" xlink:label="loc_CDTCashPayment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTCashPayment_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails" xlink:title="999062 - Disclosure - Schedule of Restricted Stock Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails" xlink:title="999063 - Disclosure - Schedule of Fair Value of Stock Option Granted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999064 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TwoThousandTwentyThreePlanMember" xlink:label="loc_CDTTwoThousandTwentyThreePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CDTTwoThousandTwentyThreePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber" xlink:label="loc_CDTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CDTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice" xlink:label="loc_CDTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CDTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1" xlink:label="loc_CDTShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CDTShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" xlink:label="loc_CDTSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CDTSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_50" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative" xlink:title="999065 - Disclosure - Share Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TwentyTwentyThreeStockIncentivePlanMember" xlink:label="loc_CDTTwentyTwentyThreeStockIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CDTTwentyTwentyThreeStockIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NonEmployeeDirectorsMember" xlink:label="loc_CDTNonEmployeeDirectorsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CDTNonEmployeeDirectorsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MrHeilbronMember" xlink:label="loc_CDTMrHeilbronMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CDTMrHeilbronMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConsultingAgreementMember" xlink:label="loc_CDTConsultingAgreementMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTConsultingAgreementMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_260" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_260" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_260" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssued_260" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross_260" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_260" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_260" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_260" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_260" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_260" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_260" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_260" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_260" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_260" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_260" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_260" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_260" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:title="999066 - Disclosure - Schedule of Income before Income Tax, Domestic and Foreign (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails" xlink:title="999067 - Disclosure - Schedule of Provision for Income Tax (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails" xlink:title="999068 - Disclosure - Schedule of Federal Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncomeTaxReconciliationConvertibleDebtAdjustment" xlink:label="loc_CDTIncomeTaxReconciliationConvertibleDebtAdjustment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CDTIncomeTaxReconciliationConvertibleDebtAdjustment_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncomeTaxReconciliationStateReRate" xlink:label="loc_CDTIncomeTaxReconciliationStateReRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CDTIncomeTaxReconciliationStateReRate_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments" xlink:label="loc_CDTIncomeTaxReconciliationPurchaseAccountingAdjustments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CDTIncomeTaxReconciliationPurchaseAccountingAdjustments_70" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999069 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredTaxAssetsStockOptions" xlink:label="loc_CDTDeferredTaxAssetsStockOptions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CDTDeferredTaxAssetsStockOptions_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsHedgingTransactions" xlink:label="loc_us-gaapDeferredTaxAssetsHedgingTransactions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsHedgingTransactions_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsNet_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999070 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate" xlink:label="loc_CDTEffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CDTEffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_100" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative" xlink:title="999071 - Disclosure - Common Stock and Preferred Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SalesAgreementMember" xlink:label="loc_CDTSalesAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSalesAgreementMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCash" xlink:label="loc_us-gaapDividendsCash_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDividendsCash_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipBeforeTransaction_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipBeforeTransaction_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_60" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="999072 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="999073 - Disclosure - Schedule of Potentially Dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PublicWarrantsMember" xlink:label="loc_CDTPublicWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTPublicWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PIPEMember" xlink:label="loc_CDTPIPEMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTPIPEMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AGPWarrantsMember" xlink:label="loc_CDTAGPWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTAGPWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertiblePromissoryNotesPayableMember" xlink:label="loc_CDTConvertiblePromissoryNotesPayableMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTConvertiblePromissoryNotesPayableMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AugustTwentyTwentyFourNirlandNoteMember" xlink:label="loc_CDTAugustTwentyTwentyFourNirlandNoteMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTAugustTwentyTwentyFourNirlandNoteMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AGPConvertibleNoteMember" xlink:label="loc_CDTAGPConvertibleNoteMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTAGPConvertibleNoteMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MarchTwentyTwentyFourWarrantsMember" xlink:label="loc_CDTMarchTwentyTwentyFourWarrantsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTMarchTwentyTwentyFourWarrantsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AprilTwentyTwentyFourWarrantsMember" xlink:label="loc_CDTAprilTwentyTwentyFourWarrantsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTAprilTwentyTwentyFourWarrantsMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AGPTwentyTwentyFourWarrantsMember" xlink:label="loc_CDTAGPTwentyTwentyFourWarrantsMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTAGPTwentyTwentyFourWarrantsMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_250" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999074 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLitigationSettlementExpense_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaapLossContingencyAccrualProvision_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLossContingencyAccrualProvision_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999075 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CorvusCapitalLimitedMember" xlink:label="loc_CDTCorvusCapitalLimitedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CDTCorvusCapitalLimitedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SARBORGLtdMember" xlink:label="loc_CDTSARBORGLtdMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CDTSARBORGLtdMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_BoardOfDirectorsMember" xlink:label="loc_CDTBoardOfDirectorsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CDTBoardOfDirectorsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember" xlink:label="loc_CDTTwentyTwentyTwoConvertibleLoanNoteInstrumentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTTwentyTwentyTwoConvertibleLoanNoteInstrumentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SARBORGServicesAgreementMember" xlink:label="loc_CDTSARBORGServicesAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSARBORGServicesAgreementMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OfficersAndDirectorsMember" xlink:label="loc_CDTOfficersAndDirectorsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CDTOfficersAndDirectorsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaapCommonStockSharesSubscribedButUnissued_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCommonStockSharesSubscribedButUnissued_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapTravelAndEntertainmentExpense_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="loc_us-gaapProceedsFromContributedCapital_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromContributedCapital_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:label="loc_us-gaapLoansAndLeasesReceivableRelatedParties_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLoansAndLeasesReceivableRelatedParties_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivables_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLoansPayable_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_140" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_140" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails" xlink:title="999076 - Disclosure - Schedule of Other Expense, Net (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails" xlink:title="999077 - Disclosure - Schedule of Black-Scholes Option Pricing Model (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/WarrantsDetailsNarrative" xlink:title="999078 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MarchLockUpAgreementMember" xlink:label="loc_CDTMarchLockUpAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTMarchLockUpAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AprilLockUpAgreementMember" xlink:label="loc_CDTAprilLockUpAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTAprilLockUpAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SubscriptionAgreementsMember" xlink:label="loc_CDTSubscriptionAgreementsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSubscriptionAgreementsMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AprilTwentyTwentyFourWarrantsMember" xlink:label="loc_CDTAprilTwentyTwentyFourWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CDTAprilTwentyTwentyFourWarrantsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AGPTwentyTwentyFourWarrantsMember" xlink:label="loc_CDTAGPTwentyTwentyFourWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CDTAGPTwentyTwentyFourWarrantsMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PIPEWarrantsMember" xlink:label="loc_CDTPIPEWarrantsMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CDTPIPEWarrantsMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PublicWarrantMember" xlink:label="loc_CDTPublicWarrantMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CDTPublicWarrantMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PrivatePlacementWarrantMember" xlink:label="loc_CDTPrivatePlacementWarrantMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CDTPrivatePlacementWarrantMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AllianceGlobalPartnersMember" xlink:label="loc_CDTAllianceGlobalPartnersMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CDTAllianceGlobalPartnersMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MurphyCanyonAcquisitionCorpMember" xlink:label="loc_CDTMurphyCanyonAcquisitionCorpMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_CDTMurphyCanyonAcquisitionCorpMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_290" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_290" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_290" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_290" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainLossOnInvestments_290" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_290" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_290" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_290" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaapSubsequentEventDescription_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSubsequentEventDescription_290" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_290" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_290" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_290" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaapFairValueOptionChangesInFairValueGainLoss1_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueOptionChangesInFairValueGainLoss1_290" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_290" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails" xlink:title="999079 - Disclosure - Schedule of Financial Data for the Company&#8217;s Reportable Segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srtConsolidationItemsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtConsolidationItemsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaapOperatingSegmentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_us-gaapOperatingSegmentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NewLicensesMember" xlink:label="loc_CDTNewLicensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CDTNewLicensesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ClinicalAssetDevelopmentMember" xlink:label="loc_CDTClinicalAssetDevelopmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CDTClinicalAssetDevelopmentMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LegalAndProfessionalFeesMember" xlink:label="loc_CDTLegalAndProfessionalFeesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CDTLegalAndProfessionalFeesMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AccountingAndAuditFeesMember" xlink:label="loc_CDTAccountingAndAuditFeesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CDTAccountingAndAuditFeesMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SalariesPayrollAndStockBasedCompensationMember" xlink:label="loc_CDTSalariesPayrollAndStockBasedCompensationMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CDTSalariesPayrollAndStockBasedCompensationMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_130" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999080 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OctoberTwentyTwentyFourNirlandNoteMember" xlink:label="loc_CDTOctoberTwentyTwentyFourNirlandNoteMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTOctoberTwentyTwentyFourNirlandNoteMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AugustTwentyTwentyFourNirlandNoteMember" xlink:label="loc_CDTAugustTwentyTwentyFourNirlandNoteMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTAugustTwentyTwentyFourNirlandNoteMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TwentyTwentyThreeConvertibleNoteMember" xlink:label="loc_CDTTwentyTwentyThreeConvertibleNoteMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTTwentyTwentyThreeConvertibleNoteMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SalesAgreementMember" xlink:label="loc_CDTSalesAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSalesAgreementMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CommissionsPayable" xlink:label="loc_CDTCommissionsPayable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_CDTCommissionsPayable_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_190" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TrancheOneMember" xlink:label="loc_CDTTrancheOneMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CDTTrancheOneMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TrancheTwoMember" xlink:label="loc_CDTTrancheTwoMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CDTTrancheTwoMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TrancheThreeMember" xlink:label="loc_CDTTrancheThreeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CDTTrancheThreeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TwoThousandTwentyThreePlanMember" xlink:label="loc_CDTTwoThousandTwentyThreePlanMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CDTTwoThousandTwentyThreePlanMember" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>cdt-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CommonStockParValue0.0001PerShareMember" xlink:label="CDT_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CommonStockParValue0.0001PerShareMember" xlink:to="CDT_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:label="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:to="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_lbl" xml:lang="en-US">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_lbl" xml:lang="en-US">Revision of Prior Period, Error Correction, Adjustment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_lbl" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MurphyCanyonAcquisitionCorpMember" xlink:label="CDT_MurphyCanyonAcquisitionCorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_MurphyCanyonAcquisitionCorpMember" xlink:to="CDT_MurphyCanyonAcquisitionCorpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_MurphyCanyonAcquisitionCorpMember_lbl" xml:lang="en-US">Murphy Canyon Acquisition Corp [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OldConduitPharmaceuticalsLimitedMember" xlink:label="CDT_OldConduitPharmaceuticalsLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OldConduitPharmaceuticalsLimitedMember" xlink:to="CDT_OldConduitPharmaceuticalsLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_OldConduitPharmaceuticalsLimitedMember_lbl" xml:lang="en-US">Old Conduit Pharmaceuticals Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConduitConvertibleNoteHoldersMember" xlink:label="CDT_ConduitConvertibleNoteHoldersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConduitConvertibleNoteHoldersMember" xlink:to="CDT_ConduitConvertibleNoteHoldersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ConduitConvertibleNoteHoldersMember_lbl" xml:lang="en-US">Conduit Convertible Note Holders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConduitShareHoldersandConvertibleNoteHoldersMember" xlink:label="CDT_ConduitShareHoldersandConvertibleNoteHoldersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConduitShareHoldersandConvertibleNoteHoldersMember" xlink:to="CDT_ConduitShareHoldersandConvertibleNoteHoldersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ConduitShareHoldersandConvertibleNoteHoldersMember_lbl" xml:lang="en-US">Conduit Share Holders and Convertible Note Holders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US">Common Class A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SponsorMember" xlink:label="CDT_SponsorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SponsorMember" xlink:to="CDT_SponsorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_SponsorMember_lbl" xml:lang="en-US">Sponsor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Common Class B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AllianceGlobalPartnersMember" xlink:label="CDT_AllianceGlobalPartnersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AllianceGlobalPartnersMember" xlink:to="CDT_AllianceGlobalPartnersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AllianceGlobalPartnersMember_lbl" xml:lang="en-US">Alliance Global Partners [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SubscriptionAgreementsMember" xlink:label="CDT_SubscriptionAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SubscriptionAgreementsMember" xlink:to="CDT_SubscriptionAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_SubscriptionAgreementsMember_lbl" xml:lang="en-US">Subscription Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:label="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:to="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_lbl" xml:lang="en-US">Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_CommonStockSubjectToMandatoryRedemptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:to="us-gaap_CommonStockSubjectToMandatoryRedemptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSubjectToMandatoryRedemptionMember_lbl" xml:lang="en-US">Common Stock Subject to Mandatory Redemption [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AGPConvertibleNoteMember" xlink:label="CDT_AGPConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AGPConvertibleNoteMember" xlink:to="CDT_AGPConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AGPConvertibleNoteMember_lbl" xml:lang="en-US">AGP Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PIPEWarrantsMember" xlink:label="CDT_PIPEWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PIPEWarrantsMember" xlink:to="CDT_PIPEWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_PIPEWarrantsMember_lbl" xml:lang="en-US">PIPE Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CorporateBondYieldEstimatedTimingOfConversionMember" xlink:label="CDT_CorporateBondYieldEstimatedTimingOfConversionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CorporateBondYieldEstimatedTimingOfConversionMember" xlink:to="CDT_CorporateBondYieldEstimatedTimingOfConversionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_CorporateBondYieldEstimatedTimingOfConversionMember_lbl" xml:lang="en-US">Corporate Bond Yield Estimated Timing Of Conversion [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputCreditSpreadMember" xlink:label="us-gaap_MeasurementInputCreditSpreadMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputCreditSpreadMember" xlink:to="us-gaap_MeasurementInputCreditSpreadMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputCreditSpreadMember_lbl" xml:lang="en-US">Measurement Input, Credit Spread [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MeasurementInputProbabilityOfDefaultMember" xlink:label="CDT_MeasurementInputProbabilityOfDefaultMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_MeasurementInputProbabilityOfDefaultMember" xlink:to="CDT_MeasurementInputProbabilityOfDefaultMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_MeasurementInputProbabilityOfDefaultMember_lbl" xml:lang="en-US">Measurement Input Probability Of Default [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MeasurementInputRecoveryUponDefaultMember" xlink:label="CDT_MeasurementInputRecoveryUponDefaultMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_MeasurementInputRecoveryUponDefaultMember" xlink:to="CDT_MeasurementInputRecoveryUponDefaultMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_MeasurementInputRecoveryUponDefaultMember_lbl" xml:lang="en-US">Measurement Input Recovery Upon Default [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_VelaAgreementMember" xlink:label="CDT_VelaAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_VelaAgreementMember" xlink:to="CDT_VelaAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_VelaAgreementMember_lbl" xml:lang="en-US">Vela Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_VelaTechnologiesPLCMember" xlink:label="CDT_VelaTechnologiesPLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_VelaTechnologiesPLCMember" xlink:to="CDT_VelaTechnologiesPLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_VelaTechnologiesPLCMember_lbl" xml:lang="en-US">Vela Technologies PLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_VelaOptionAgreementMember" xlink:label="CDT_VelaOptionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_VelaOptionAgreementMember" xlink:to="CDT_VelaOptionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_VelaOptionAgreementMember_lbl" xml:lang="en-US">Vela Option Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_VelaOptionLiabilityMember" xlink:label="CDT_VelaOptionLiabilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_VelaOptionLiabilityMember" xlink:to="CDT_VelaOptionLiabilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_VelaOptionLiabilityMember_lbl" xml:lang="en-US">Vela Option Liability [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CizzlePlcAgreementMember" xlink:label="CDT_CizzlePlcAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CizzlePlcAgreementMember" xlink:to="CDT_CizzlePlcAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_CizzlePlcAgreementMember_lbl" xml:lang="en-US">Cizzle Plc Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertiblePromissoryNotesPayableMember" xlink:label="CDT_ConvertiblePromissoryNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConvertiblePromissoryNotesPayableMember" xlink:to="CDT_ConvertiblePromissoryNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ConvertiblePromissoryNotesPayableMember_lbl" xml:lang="en-US">Convertible Promissory Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertiblePromissoryNoteMember" xlink:label="CDT_ConvertiblePromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConvertiblePromissoryNoteMember" xlink:to="CDT_ConvertiblePromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ConvertiblePromissoryNoteMember_lbl" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertiblePromissoryNotePayableMember" xlink:label="CDT_ConvertiblePromissoryNotePayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConvertiblePromissoryNotePayableMember" xlink:to="CDT_ConvertiblePromissoryNotePayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ConvertiblePromissoryNotePayableMember_lbl" xml:lang="en-US">Convertible Promissory Note Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConsultingAgreementMember" xlink:label="CDT_ConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConsultingAgreementMember" xlink:to="CDT_ConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TwentyTwentyThreeConvertibleNoteMember" xlink:label="CDT_TwentyTwentyThreeConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_TwentyTwentyThreeConvertibleNoteMember" xlink:to="CDT_TwentyTwentyThreeConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_TwentyTwentyThreeConvertibleNoteMember_lbl" xml:lang="en-US">2023 Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SeniorSecuredPromissoryNoteMember" xlink:label="CDT_SeniorSecuredPromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SeniorSecuredPromissoryNoteMember" xlink:to="CDT_SeniorSecuredPromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_SeniorSecuredPromissoryNoteMember_lbl" xml:lang="en-US">Senior Secured Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NirlandLimitedMember" xlink:label="CDT_NirlandLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NirlandLimitedMember" xlink:to="CDT_NirlandLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_NirlandLimitedMember_lbl" xml:lang="en-US">Nirland Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_FirstAmendmentNirlandNoteMember" xlink:label="CDT_FirstAmendmentNirlandNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_FirstAmendmentNirlandNoteMember" xlink:to="CDT_FirstAmendmentNirlandNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_FirstAmendmentNirlandNoteMember_lbl" xml:lang="en-US">First Amendment Nirland Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_FirstAmendmentMember" xlink:label="CDT_FirstAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_FirstAmendmentMember" xlink:to="CDT_FirstAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_FirstAmendmentMember_lbl" xml:lang="en-US">First Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SecondAmendmentNirlandNoteMember" xlink:label="CDT_SecondAmendmentNirlandNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SecondAmendmentNirlandNoteMember" xlink:to="CDT_SecondAmendmentNirlandNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_SecondAmendmentNirlandNoteMember_lbl" xml:lang="en-US">Second Amendment Nirland Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SecondAmendmentMember" xlink:label="CDT_SecondAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SecondAmendmentMember" xlink:to="CDT_SecondAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_SecondAmendmentMember_lbl" xml:lang="en-US">Second Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertiblePromissoryNotesMember" xlink:label="CDT_ConvertiblePromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConvertiblePromissoryNotesMember" xlink:to="CDT_ConvertiblePromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ConvertiblePromissoryNotesMember_lbl" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AllianceGobalPartnersConvertibleNoteMember" xlink:label="CDT_AllianceGobalPartnersConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AllianceGobalPartnersConvertibleNoteMember" xlink:to="CDT_AllianceGobalPartnersConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AllianceGobalPartnersConvertibleNoteMember_lbl" xml:lang="en-US">Alliance Gobal Partners Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LoanAgreementsMember" xlink:label="CDT_LoanAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LoanAgreementsMember" xlink:to="CDT_LoanAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_LoanAgreementsMember_lbl" xml:lang="en-US">Loan Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TrancheOneMember" xlink:label="CDT_TrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_TrancheOneMember" xlink:to="CDT_TrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_TrancheOneMember_lbl" xml:lang="en-US">Tranche One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TrancheTwoMember" xlink:label="CDT_TrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_TrancheTwoMember" xlink:to="CDT_TrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_TrancheTwoMember_lbl" xml:lang="en-US">Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TrancheThreeMember" xlink:label="CDT_TrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_TrancheThreeMember" xlink:to="CDT_TrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_TrancheThreeMember_lbl" xml:lang="en-US">Tranche Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LoanHoldersMember" xlink:label="CDT_LoanHoldersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LoanHoldersMember" xlink:to="CDT_LoanHoldersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_LoanHoldersMember_lbl" xml:lang="en-US">Loan Holders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LoansAmendmentMember" xlink:label="CDT_LoansAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LoansAmendmentMember" xlink:to="CDT_LoansAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_LoansAmendmentMember_lbl" xml:lang="en-US">Loans Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OctoberTwoThousandTwentyFourNirlandNoteMember" xlink:label="CDT_OctoberTwoThousandTwentyFourNirlandNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OctoberTwoThousandTwentyFourNirlandNoteMember" xlink:to="CDT_OctoberTwoThousandTwentyFourNirlandNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_OctoberTwoThousandTwentyFourNirlandNoteMember_lbl" xml:lang="en-US">October Two Thousand Twenty Four Nirland Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_BridgeLoanAgreementMember" xlink:label="CDT_BridgeLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_BridgeLoanAgreementMember" xlink:to="CDT_BridgeLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_BridgeLoanAgreementMember_lbl" xml:lang="en-US">Bridge Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AstraZenecaMember" xlink:label="CDT_AstraZenecaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AstraZenecaMember" xlink:to="CDT_AstraZenecaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AstraZenecaMember_lbl" xml:lang="en-US">Astra Zeneca [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SARBORGServiceAgreementMember" xlink:label="CDT_SARBORGServiceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SARBORGServiceAgreementMember" xlink:to="CDT_SARBORGServiceAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_SARBORGServiceAgreementMember_lbl" xml:lang="en-US">SARBORG Service Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TwentyTwentyThreeStockIncentivePlanMember" xlink:label="CDT_TwentyTwentyThreeStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_TwentyTwentyThreeStockIncentivePlanMember" xlink:to="CDT_TwentyTwentyThreeStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_TwentyTwentyThreeStockIncentivePlanMember_lbl" xml:lang="en-US">2023 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NonEmployeeDirectorsMember" xlink:label="CDT_NonEmployeeDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NonEmployeeDirectorsMember" xlink:to="CDT_NonEmployeeDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_NonEmployeeDirectorsMember_lbl" xml:lang="en-US">Non-employee Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MrHeilbronMember" xlink:label="CDT_MrHeilbronMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_MrHeilbronMember" xlink:to="CDT_MrHeilbronMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_MrHeilbronMember_lbl" xml:lang="en-US">Mr. Heilbron [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TwoThousandTwentyThreePlanMember" xlink:label="CDT_TwoThousandTwentyThreePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_TwoThousandTwentyThreePlanMember" xlink:to="CDT_TwoThousandTwentyThreePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_TwoThousandTwentyThreePlanMember_lbl" xml:lang="en-US">2023 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SalesAgreementMember" xlink:label="CDT_SalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SalesAgreementMember" xlink:to="CDT_SalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PublicWarrantsMember" xlink:label="CDT_PublicWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PublicWarrantsMember" xlink:to="CDT_PublicWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_PublicWarrantsMember_lbl" xml:lang="en-US">Public Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PIPEMember" xlink:label="CDT_PIPEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PIPEMember" xlink:to="CDT_PIPEMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_PIPEMember_lbl" xml:lang="en-US">PIPE [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AGPWarrantsMember" xlink:label="CDT_AGPWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AGPWarrantsMember" xlink:to="CDT_AGPWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AGPWarrantsMember_lbl" xml:lang="en-US">AGP Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AugustTwentyTwentyFourNirlandNoteMember" xlink:label="CDT_AugustTwentyTwentyFourNirlandNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AugustTwentyTwentyFourNirlandNoteMember" xlink:to="CDT_AugustTwentyTwentyFourNirlandNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AugustTwentyTwentyFourNirlandNoteMember_lbl" xml:lang="en-US">August 2024 Nirland Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MarchTwentyTwentyFourWarrantsMember" xlink:label="CDT_MarchTwentyTwentyFourWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_MarchTwentyTwentyFourWarrantsMember" xlink:to="CDT_MarchTwentyTwentyFourWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_MarchTwentyTwentyFourWarrantsMember_lbl" xml:lang="en-US">March 2024 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AprilTwentyTwentyFourWarrantsMember" xlink:label="CDT_AprilTwentyTwentyFourWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AprilTwentyTwentyFourWarrantsMember" xlink:to="CDT_AprilTwentyTwentyFourWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AprilTwentyTwentyFourWarrantsMember_lbl" xml:lang="en-US">April 2024 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AGPTwentyTwentyFourWarrantsMember" xlink:label="CDT_AGPTwentyTwentyFourWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AGPTwentyTwentyFourWarrantsMember" xlink:to="CDT_AGPTwentyTwentyFourWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AGPTwentyTwentyFourWarrantsMember_lbl" xml:lang="en-US">AGP 2024 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CorvusCapitalLimitedMember" xlink:label="CDT_CorvusCapitalLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CorvusCapitalLimitedMember" xlink:to="CDT_CorvusCapitalLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_CorvusCapitalLimitedMember_lbl" xml:lang="en-US">Corvus Capital Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_BoardOfDirectorsMember" xlink:label="CDT_BoardOfDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_BoardOfDirectorsMember" xlink:to="CDT_BoardOfDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_BoardOfDirectorsMember_lbl" xml:lang="en-US">Board of Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember" xlink:label="CDT_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember" xlink:to="CDT_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_lbl" xml:lang="en-US">2022 Convertible Loan Note Instrument [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SARBORGLtdMember" xlink:label="CDT_SARBORGLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SARBORGLtdMember" xlink:to="CDT_SARBORGLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_SARBORGLtdMember_lbl" xml:lang="en-US">SARBORG Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SARBORGServicesAgreementMember" xlink:label="CDT_SARBORGServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SARBORGServicesAgreementMember" xlink:to="CDT_SARBORGServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_SARBORGServicesAgreementMember_lbl" xml:lang="en-US">SARBORG Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OfficersAndDirectorsMember" xlink:label="CDT_OfficersAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OfficersAndDirectorsMember" xlink:to="CDT_OfficersAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_OfficersAndDirectorsMember_lbl" xml:lang="en-US">Officers and Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MarchLockUpAgreementMember" xlink:label="CDT_MarchLockUpAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_MarchLockUpAgreementMember" xlink:to="CDT_MarchLockUpAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_MarchLockUpAgreementMember_lbl" xml:lang="en-US">March Lock Up Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AprilLockUpAgreementMember" xlink:label="CDT_AprilLockUpAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AprilLockUpAgreementMember" xlink:to="CDT_AprilLockUpAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AprilLockUpAgreementMember_lbl" xml:lang="en-US">April Lock Up Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PublicWarrantMember" xlink:label="CDT_PublicWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PublicWarrantMember" xlink:to="CDT_PublicWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_PublicWarrantMember_lbl" xml:lang="en-US">Public Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PrivatePlacementWarrantMember" xlink:label="CDT_PrivatePlacementWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PrivatePlacementWarrantMember" xlink:to="CDT_PrivatePlacementWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_PrivatePlacementWarrantMember_lbl" xml:lang="en-US">Private Placement Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsAxis_lbl" xml:lang="en-US">Consolidation Items [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US">Operating Segments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NewLicensesMember" xlink:label="CDT_NewLicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NewLicensesMember" xlink:to="CDT_NewLicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_NewLicensesMember_lbl" xml:lang="en-US">New Licenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ClinicalAssetDevelopmentMember" xlink:label="CDT_ClinicalAssetDevelopmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ClinicalAssetDevelopmentMember" xlink:to="CDT_ClinicalAssetDevelopmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ClinicalAssetDevelopmentMember_lbl" xml:lang="en-US">Clinical Asset Development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LegalAndProfessionalFeesMember" xlink:label="CDT_LegalAndProfessionalFeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LegalAndProfessionalFeesMember" xlink:to="CDT_LegalAndProfessionalFeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_LegalAndProfessionalFeesMember_lbl" xml:lang="en-US">Legal And Professional Fees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AccountingAndAuditFeesMember" xlink:label="CDT_AccountingAndAuditFeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AccountingAndAuditFeesMember" xlink:to="CDT_AccountingAndAuditFeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AccountingAndAuditFeesMember_lbl" xml:lang="en-US">Accounting And Audit Fees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SalariesPayrollAndStockBasedCompensationMember" xlink:label="CDT_SalariesPayrollAndStockBasedCompensationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SalariesPayrollAndStockBasedCompensationMember" xlink:to="CDT_SalariesPayrollAndStockBasedCompensationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_SalariesPayrollAndStockBasedCompensationMember_lbl" xml:lang="en-US">Salaries Payroll And Stock Based Compensation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OctoberTwentyTwentyFourNirlandNoteMember" xlink:label="CDT_OctoberTwentyTwentyFourNirlandNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OctoberTwentyTwentyFourNirlandNoteMember" xlink:to="CDT_OctoberTwentyTwentyFourNirlandNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_OctoberTwentyTwentyFourNirlandNoteMember_lbl" xml:lang="en-US">October 2024 Nirland Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingParValuePerShare" xlink:label="dei_EntityListingParValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingParValuePerShare" xlink:to="dei_EntityListingParValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingParValuePerShare_lbl" xml:lang="en-US">Entity Listing, Par Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorOpinionTextBlock_lbl" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets. net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl" xml:lang="en-US">Prepaid expenses and other long-term assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible promissory note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable" xlink:label="us-gaap_OtherNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayable_lbl" xml:lang="en-US">Convertible promissory notes payable at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, non-current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Derivative warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_lbl" xml:lang="en-US">Deferred commission payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (see note 15)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.0001; 250,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively, 1,384,801 shares and 738,295 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, par value $0.0001; 1,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively; nil shares issued and outstanding at December 31, 2024 and December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating costs and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other (expense) income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities" xlink:label="CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities" xlink:to="CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities_lbl" xml:lang="en-US">Less: Change in fair value and income impact of option liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net income (loss) - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic earnings/(net loss) per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted earnings/(net loss) per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic weighted-average common shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted weighted-average common shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Comprehensive income (loss):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Total comprehensive income (loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date (Note 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" xlink:to="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_lbl" xml:lang="en-US">Issuance of common stock upon conversion of MURF Class A &amp; Class B common stock in connection with merger (Note 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" xlink:to="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_lbl" xml:lang="en-US">Issuance of common stock upon conversion of MURF Class A &amp; Class B common stock in connection with merger, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing" xlink:label="CDT_StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing" xlink:to="CDT_StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing_lbl" xml:lang="en-US">Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing (Note 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing" xlink:label="CDT_StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing" xlink:to="CDT_StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing_lbl" xml:lang="en-US">Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValuePurchaseOfRevenue" xlink:label="CDT_StockIssuedDuringPeriodValuePurchaseOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValuePurchaseOfRevenue" xlink:to="CDT_StockIssuedDuringPeriodValuePurchaseOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodValuePurchaseOfRevenue_lbl" xml:lang="en-US">Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesPurchaseOfRevenue" xlink:label="CDT_StockIssuedDuringPeriodSharesPurchaseOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesPurchaseOfRevenue" xlink:to="CDT_StockIssuedDuringPeriodSharesPurchaseOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodSharesPurchaseOfRevenue_lbl" xml:lang="en-US">Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValuePurchasesOfRevenue" xlink:label="CDT_StockIssuedDuringPeriodValuePurchasesOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValuePurchasesOfRevenue" xlink:to="CDT_StockIssuedDuringPeriodValuePurchasesOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodValuePurchasesOfRevenue_lbl" xml:lang="en-US">Issuance of Conduit Pharmaceuticals Inc. common stock to Vela Technologies PLC</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesPurchasesOfRevenue" xlink:label="CDT_StockIssuedDuringPeriodSharesPurchasesOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesPurchasesOfRevenue" xlink:to="CDT_StockIssuedDuringPeriodSharesPurchasesOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodSharesPurchasesOfRevenue_lbl" xml:lang="en-US">Issuance of Conduit Pharmaceuticals Inc. common stock to Vela Technologies PLC, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuedForServicesOne" xlink:label="CDT_StockIssuedDuringPeriodValueIssuedForServicesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuedForServicesOne" xlink:to="CDT_StockIssuedDuringPeriodValueIssuedForServicesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodValueIssuedForServicesOne_lbl" xml:lang="en-US">Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger (Note 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuedForServicesOne" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuedForServicesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesIssuedForServicesOne" xlink:to="CDT_StockIssuedDuringPeriodSharesIssuedForServicesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuedForServicesOne_lbl" xml:lang="en-US">Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger" xlink:label="CDT_AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger" xlink:to="CDT_AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger_lbl" xml:lang="en-US">Reduction of excise tax liability associated with the Merger (Note2)</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty" xlink:label="CDT_AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty" xlink:to="CDT_AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty_lbl" xml:lang="en-US">Capital contribution - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" xlink:label="CDT_AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" xlink:to="CDT_AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense_lbl" xml:lang="en-US">Correction of immaterial error related to franchise tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of Common Stock for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of Common Stock for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of Common Stock upon vesting of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of Common Stock upon vesting of restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable" xlink:to="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable_lbl" xml:lang="en-US">Issuance of Common Stock for note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable" xlink:to="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable_lbl" xml:lang="en-US">Issuance of Common Stock for note payable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Common Stock for licensing right</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Common Stock for licensing right, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStock" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStock" xlink:to="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of Common Stock under the ATM Program</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStock" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStock" xlink:to="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of Common Stock under the ATM Program, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification" xlink:to="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification_lbl" xml:lang="en-US">Issuance of Common Stock in Exchange for Debt Modification</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification" xlink:to="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification_lbl" xml:lang="en-US">Issuance of Common Stock in Exchange for Debt Modification, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" xlink:to="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption_lbl" xml:lang="en-US">Issuance of Common Stock upon Exercise of Conversion Option</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption" xlink:to="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption_lbl" xml:lang="en-US">Issuance of Common Stock upon Exercise of Conversion Option, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants" xlink:to="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants_lbl" xml:lang="en-US">Issuance of Common Stock Upon Exercise of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants" xlink:to="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants_lbl" xml:lang="en-US">Issuance of Common Stock Upon Exercise of Warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Issuance of Common Stock Upon Exercise of Warrants, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GainLossOnChangeInFairValueOfCizzleOption" xlink:label="CDT_GainLossOnChangeInFairValueOfCizzleOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_GainLossOnChangeInFairValueOfCizzleOption" xlink:to="CDT_GainLossOnChangeInFairValueOfCizzleOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CDT_GainLossOnChangeInFairValueOfCizzleOption_lbl" xml:lang="en-US">Gain on change in fair value of Cizzle option</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GainOnChangeInFairValueOfVelaOption" xlink:label="CDT_GainOnChangeInFairValueOfVelaOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_GainOnChangeInFairValueOfVelaOption" xlink:to="CDT_GainOnChangeInFairValueOfVelaOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CDT_GainOnChangeInFairValueOfVelaOption_lbl" xml:lang="en-US">Gain on change in fair value of Vela option</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnIssuanceOfVelaOption" xlink:label="CDT_LossOnIssuanceOfVelaOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LossOnIssuanceOfVelaOption" xlink:to="CDT_LossOnIssuanceOfVelaOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_LossOnIssuanceOfVelaOption_lbl" xml:lang="en-US">Loss on issuance of Vela option</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangesInForeignCurrencyTransactionUnrealized" xlink:label="CDT_ChangesInForeignCurrencyTransactionUnrealized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangesInForeignCurrencyTransactionUnrealized" xlink:to="CDT_ChangesInForeignCurrencyTransactionUnrealized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CDT_ChangesInForeignCurrencyTransactionUnrealized_lbl" xml:lang="en-US">Change in reserve for related party uncollectible loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on debt extinguishment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnRelatedPartyLoanForgiveness" xlink:label="CDT_LossOnRelatedPartyLoanForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LossOnRelatedPartyLoanForgiveness" xlink:to="CDT_LossOnRelatedPartyLoanForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_LossOnRelatedPartyLoanForgiveness_lbl" xml:lang="en-US">Loss on related party loan forgiveness</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_RealizedGainOnShorttermInvestments" xlink:label="CDT_RealizedGainOnShorttermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_RealizedGainOnShorttermInvestments" xlink:to="CDT_RealizedGainOnShorttermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CDT_RealizedGainOnShorttermInvestments_lbl" xml:lang="en-US">Realized gain on short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax_lbl" xml:lang="en-US">Unrealized foreign exchange gain</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnChangeInFairValueOfConvertibleNotesPayable" xlink:label="CDT_LossOnChangeInFairValueOfConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LossOnChangeInFairValueOfConvertibleNotesPayable" xlink:to="CDT_LossOnChangeInFairValueOfConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_LossOnChangeInFairValueOfConvertibleNotesPayable_lbl" xml:lang="en-US">Loss (gain) on change in fair value of convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Gain on change in FV of the warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability" xlink:label="CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability" xlink:to="CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability_lbl" xml:lang="en-US">Non-cash reduction of deferred income upon exercise of option liability</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnIssuanceOfWarrants" xlink:label="CDT_LossOnIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LossOnIssuanceOfWarrants" xlink:to="CDT_LossOnIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_LossOnIssuanceOfWarrants_lbl" xml:lang="en-US">Loss on issuance of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NoncashLeaseExpense" xlink:label="CDT_NoncashLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NoncashLeaseExpense" xlink:to="CDT_NoncashLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_NoncashLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IssuanceOfCommonStockForLicensingRight" xlink:label="CDT_IssuanceOfCommonStockForLicensingRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IssuanceOfCommonStockForLicensingRight" xlink:to="CDT_IssuanceOfCommonStockForLicensingRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CDT_IssuanceOfCommonStockForLicensingRight_lbl" xml:lang="en-US">Issuance of Common Stock for licensing right</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NoncashInterestExpense" xlink:label="CDT_NoncashInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NoncashInterestExpense" xlink:to="CDT_NoncashInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_NoncashInterestExpense_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US">Amortization of financed Directors and Officers insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AmortizationExpense" xlink:label="CDT_AmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AmortizationExpense" xlink:to="CDT_AmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AmortizationExpense_lbl" xml:lang="en-US">Amortization Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AmortizationOfDebtDiscount" xlink:label="CDT_AmortizationOfDebtDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AmortizationOfDebtDiscount" xlink:to="CDT_AmortizationOfDebtDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AmortizationOfDebtDiscount_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of common stock for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:label="us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:to="us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash flows from operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl" xml:lang="en-US">Issuance of loan - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Purchases of short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US">Proceeds from the sale of short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ProceedsFromIssuanceOfOption" xlink:label="CDT_ProceedsFromIssuanceOfOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ProceedsFromIssuanceOfOption" xlink:to="CDT_ProceedsFromIssuanceOfOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ProceedsFromIssuanceOfOption_lbl" xml:lang="en-US">Proceeds from issuance of option</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ProceedsFromLoanRepaymentRelatedParty" xlink:label="CDT_ProceedsFromLoanRepaymentRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ProceedsFromLoanRepaymentRelatedParty" xlink:to="CDT_ProceedsFromLoanRepaymentRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ProceedsFromLoanRepaymentRelatedParty_lbl" xml:lang="en-US">Proceeds from loan repayment - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash flows from investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts" xlink:label="CDT_ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts" xlink:to="CDT_ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts_lbl" xml:lang="en-US">Proceeds from Merger and related PIPE Financing, net of transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from the issuance of notes payable &#8211; related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from the issuance of notes payable &#8211; related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty" xlink:label="CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty" xlink:to="CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty_lbl" xml:lang="en-US">Capital contribution - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common shares related to ATM program</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ProceedsFromExerciseOfWarrants" xlink:label="CDT_ProceedsFromExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ProceedsFromExerciseOfWarrants" xlink:to="CDT_ProceedsFromExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible promissory note payable, carried at cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash flows from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and cash equivalents before effect of exchange rate changes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of Use Asset obtained in exchange for Operating Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" xlink:label="CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" xlink:to="CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense_lbl" xml:lang="en-US">Correction of immaterial error related to franchise tax expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" xlink:to="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption_2_lbl" xml:lang="en-US">Issuance of Common Stock upon exercise of conversion option</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IssuanceOfCommonStockInExchangeForDebtExtension" xlink:label="CDT_IssuanceOfCommonStockInExchangeForDebtExtension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IssuanceOfCommonStockInExchangeForDebtExtension" xlink:to="CDT_IssuanceOfCommonStockInExchangeForDebtExtension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_IssuanceOfCommonStockInExchangeForDebtExtension_lbl" xml:lang="en-US">Issuance of Common Stock in exchange for debt extension</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote" xlink:label="CDT_ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote" xlink:to="CDT_ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote_lbl" xml:lang="en-US">Conversion of deferred commission payable to convertible promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc" xlink:label="CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc" xlink:to="CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc_lbl" xml:lang="en-US">Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC upon exercise of option</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Issuance of Conduit Pharmaceuticals Inc. common stock to Vela Technologies PLC upon exercise of option</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesReduction" xlink:label="us-gaap_NotesReduction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReduction" xlink:to="us-gaap_NotesReduction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReduction_lbl" xml:lang="en-US">Exchange of Conduit Pharmaceuticals Limited convertible notes for shares of Conduit Pharmaceuticals Inc. common stock in connection with the Merger</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredUnderwritingCosts" xlink:label="CDT_DeferredUnderwritingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredUnderwritingCosts" xlink:to="CDT_DeferredUnderwritingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DeferredUnderwritingCosts_lbl" xml:lang="en-US">Deferred Underwriting Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger" xlink:label="CDT_PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger" xlink:to="CDT_PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger_lbl" xml:lang="en-US">Prepaid expense of directors and officers insurance paid out of PIPE financings proceeds in connection with the Merger</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination" xlink:label="CDT_AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination" xlink:to="CDT_AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination_lbl" xml:lang="en-US">Accumulated deficit assumed to APIC as a result of the business combination</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing" xlink:label="CDT_InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing" xlink:to="CDT_InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing_lbl" xml:lang="en-US">Initial value of warrant liabilities issued in connection with PIPE Financing</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NoncashAssetsAssumedInMergerFinancing" xlink:label="CDT_NoncashAssetsAssumedInMergerFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NoncashAssetsAssumedInMergerFinancing" xlink:to="CDT_NoncashAssetsAssumedInMergerFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_NoncashAssetsAssumedInMergerFinancing_lbl" xml:lang="en-US">Non-Cash Assets Assumed in the Merger Financing</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NoncashLiabilitiesAssumedInMergerFinancing" xlink:label="CDT_NoncashLiabilitiesAssumedInMergerFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NoncashLiabilitiesAssumedInMergerFinancing" xlink:to="CDT_NoncashLiabilitiesAssumedInMergerFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_NoncashLiabilitiesAssumedInMergerFinancing_lbl" xml:lang="en-US">Non-Cash Liabilities Assumed in the Merger Financing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US">Supplemental Cash Disclosures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Merger and Financing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">Balance Sheet Details &#8211; Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureLeasesAbstract" xlink:label="CDT_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DisclosureLeasesAbstract" xlink:to="CDT_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract" xlink:label="CDT_DisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract" xlink:to="CDT_DisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract_lbl" xml:lang="en-US">Liability Related To Sale Of Future Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LiabilityRelatedToTheSaleOfFutureRevenueTextBlock" xlink:label="CDT_LiabilityRelatedToTheSaleOfFutureRevenueTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LiabilityRelatedToTheSaleOfFutureRevenueTextBlock" xlink:to="CDT_LiabilityRelatedToTheSaleOfFutureRevenueTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_LiabilityRelatedToTheSaleOfFutureRevenueTextBlock_lbl" xml:lang="en-US">Liability Related to the Sale of Future Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureConvertibleNotesPayableAbstract" xlink:label="CDT_DisclosureConvertibleNotesPayableAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DisclosureConvertibleNotesPayableAbstract" xlink:to="CDT_DisclosureConvertibleNotesPayableAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DisclosureConvertibleNotesPayableAbstract_lbl" xml:lang="en-US">Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertibleNotesPayableTextBlock" xlink:label="CDT_ConvertibleNotesPayableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConvertibleNotesPayableTextBlock" xlink:to="CDT_ConvertibleNotesPayableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CDT_ConvertibleNotesPayableTextBlock_lbl" xml:lang="en-US">Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Loans Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureDeferredCommissionPayableAbstract" xlink:label="CDT_DisclosureDeferredCommissionPayableAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DisclosureDeferredCommissionPayableAbstract" xlink:to="CDT_DisclosureDeferredCommissionPayableAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DisclosureDeferredCommissionPayableAbstract_lbl" xml:lang="en-US">Deferred Commission Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredCommissionPayableTextBlock" xlink:label="CDT_DeferredCommissionPayableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredCommissionPayableTextBlock" xlink:to="CDT_DeferredCommissionPayableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CDT_DeferredCommissionPayableTextBlock_lbl" xml:lang="en-US">Deferred Commission Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureResearchAndDevelopmentExpenseAbstract" xlink:label="CDT_DisclosureResearchAndDevelopmentExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DisclosureResearchAndDevelopmentExpenseAbstract" xlink:to="CDT_DisclosureResearchAndDevelopmentExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DisclosureResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US">Research And Development Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock" xlink:label="CDT_DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock" xlink:to="CDT_DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock_lbl" xml:lang="en-US">Research and Development Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock and Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings/(Net Loss) Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xml:lang="en-US">Other Income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureWarrantsAbstract" xlink:label="CDT_DisclosureWarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DisclosureWarrantsAbstract" xlink:to="CDT_DisclosureWarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DisclosureWarrantsAbstract_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_WarrantLiabilityDisclosureTextBlock" xlink:label="CDT_WarrantLiabilityDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_WarrantLiabilityDisclosureTextBlock" xlink:to="CDT_WarrantLiabilityDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CDT_WarrantLiabilityDisclosureTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueTransferPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueTransferPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueTransferPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueTransferPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueTransferPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Option</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings/(Net Loss) per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_WarrantInstrumentsPolicyTextBlock" xlink:label="CDT_WarrantInstrumentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_WarrantInstrumentsPolicyTextBlock" xlink:to="CDT_WarrantInstrumentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CDT_WarrantInstrumentsPolicyTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="CDT_EmergingGrowthCompanyStatusPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="CDT_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xml:lang="en-US">Emerging Growth Company Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="CDT_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="CDT_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Standards Not Yet Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Common Stock Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of Assets Subject to Measurement at Fair Value on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of Balance Sheet Details</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LesseeOperatingLeaseLiabilityTableTextBlock" xlink:label="CDT_LesseeOperatingLeaseLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LesseeOperatingLeaseLiabilityTableTextBlock" xlink:to="CDT_LesseeOperatingLeaseLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_LesseeOperatingLeaseLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Lease Payments For Operating Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Stock Option Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Provision for Income Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Federal Income Tax Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Potentially Dilutive Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Expense, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock" xlink:label="CDT_ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock" xlink:to="CDT_ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Black-Scholes Option Pricing Model</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Financial Data for the Company&#8217;s Reportable Segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short term investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, uninsured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositAssets_lbl" xml:lang="en-US">Deposit assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DemandDepositAccounts" xlink:label="us-gaap_DemandDepositAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DemandDepositAccounts" xlink:to="us-gaap_DemandDepositAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DemandDepositAccounts_lbl" xml:lang="en-US">Demand deposit accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DepositInsuranceLimit" xlink:label="CDT_DepositInsuranceLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DepositInsuranceLimit" xlink:to="CDT_DepositInsuranceLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DepositInsuranceLimit_lbl" xml:lang="en-US">Deposit insurance limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CashAndCashEquivalentsNetBankOverdrafts" xlink:label="CDT_CashAndCashEquivalentsNetBankOverdrafts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CashAndCashEquivalentsNetBankOverdrafts" xlink:to="CDT_CashAndCashEquivalentsNetBankOverdrafts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_CashAndCashEquivalentsNetBankOverdrafts_lbl" xml:lang="en-US">Cash and cash equivalents net bank overdrafts</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DescriptionForEmergingGrowthCompany" xlink:label="CDT_DescriptionForEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DescriptionForEmergingGrowthCompany" xlink:to="CDT_DescriptionForEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DescriptionForEmergingGrowthCompany_lbl" xml:lang="en-US">Emerging growth description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Business Combination, net of redemptions, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date,shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US">Exchange of Conduit Pharmaceuticals Limited ordinary shares for Conduit Pharmaceuticals Inc. common stock on the Closing Date, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the transaction, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Total - Conduit Pharmaceuticals Inc. common stock outstanding as a result of Business Combination, PIPE Financing, exchange of Conduit Pharmaceuticals Limited shares for shares of Conduit Pharmaceuticals Inc., issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes, and transaction services agreements, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_lbl" xml:lang="en-US">Business acquisition right to receive number of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Shares issued during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_BusinessAcquisitionNumberOfSharesTransferred" xlink:label="CDT_BusinessAcquisitionNumberOfSharesTransferred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_BusinessAcquisitionNumberOfSharesTransferred" xlink:to="CDT_BusinessAcquisitionNumberOfSharesTransferred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_BusinessAcquisitionNumberOfSharesTransferred_lbl" xml:lang="en-US">Number of shares transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionBasis" xlink:to="us-gaap_CommonStockConversionBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xml:lang="en-US">Common stock conversion basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Number of shares held prior to business combination</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Number of shares converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Cash fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_3_lbl" xml:lang="en-US">Shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredUnderwritingFee" xlink:label="CDT_DeferredUnderwritingFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredUnderwritingFee" xlink:to="CDT_DeferredUnderwritingFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DeferredUnderwritingFee_lbl" xml:lang="en-US">Deferred underwriting fee</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PaymentForAdvisoryServices" xlink:label="CDT_PaymentForAdvisoryServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PaymentForAdvisoryServices" xlink:to="CDT_PaymentForAdvisoryServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_PaymentForAdvisoryServices_lbl" xml:lang="en-US">Financial advisory fee</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xml:lang="en-US">Warrants to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredCashPaymentsAmount" xlink:label="CDT_DeferredCashPaymentsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredCashPaymentsAmount" xlink:to="CDT_DeferredCashPaymentsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DeferredCashPaymentsAmount_lbl" xml:lang="en-US">Cash payments due</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AnnualInterestRate" xlink:label="CDT_AnnualInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AnnualInterestRate" xlink:to="CDT_AnnualInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_AnnualInterestRate_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued, purchase price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Shares issued during the period, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Balance as of December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Fair value at Issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Conversion of convertible note</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueOfConvertibleNotesPayable" xlink:label="CDT_ChangeInFairValueOfConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangeInFairValueOfConvertibleNotesPayable" xlink:to="CDT_ChangeInFairValueOfConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ChangeInFairValueOfConvertibleNotesPayable_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_2_lbl" xml:lang="en-US">Balance as of December 31, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_WarrantsExcercise" xlink:label="CDT_WarrantsExcercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_WarrantsExcercise" xlink:to="CDT_WarrantsExcercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_WarrantsExcercise_lbl" xml:lang="en-US">Warrants excercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid directors&#8217; and officers&#8217; insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses &#8211; related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DisclosureLeasesAbstract" xlink:to="CDT_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CDT_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Lease Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DisclosureLeasesAbstract" xlink:to="CDT_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="CDT_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Operating Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_lbl" xml:lang="en-US">ROU assets obtained in the exchange for lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Short term lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Short term lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PercentageOfFutureRevenueEarned" xlink:label="CDT_PercentageOfFutureRevenueEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PercentageOfFutureRevenueEarned" xlink:to="CDT_PercentageOfFutureRevenueEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_PercentageOfFutureRevenueEarned_lbl" xml:lang="en-US">Percentage of future revenue earned</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xml:lang="en-US">Number of shares issuance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_RoyaltyPercentage" xlink:label="CDT_RoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_RoyaltyPercentage" xlink:to="CDT_RoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NonRefundableOptionFee" xlink:label="CDT_NonRefundableOptionFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NonRefundableOptionFee" xlink:to="CDT_NonRefundableOptionFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_NonRefundableOptionFee_lbl" xml:lang="en-US">Non refundable option fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Total consideration payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OptionAgreementDescription" xlink:label="CDT_OptionAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OptionAgreementDescription" xlink:to="CDT_OptionAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_OptionAgreementDescription_lbl" xml:lang="en-US">Option agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OptionFee" xlink:label="CDT_OptionFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OptionFee" xlink:to="CDT_OptionFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_OptionFee_lbl" xml:lang="en-US">Option fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Debt instrument face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Debt instrument maturity description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Conversion percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Gain on debt extinguishment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_2_lbl" xml:lang="en-US">Convertible promissory notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US">Fair value of convertible note</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssued1_2_lbl" xml:lang="en-US">Stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Carrying value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_2_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Total debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DebtIssuedUponExecution" xlink:label="CDT_DebtIssuedUponExecution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DebtIssuedUponExecution" xlink:to="CDT_DebtIssuedUponExecution_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DebtIssuedUponExecution_lbl" xml:lang="en-US">Debt issued upon execution</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PaymentOfCommonStock" xlink:label="CDT_PaymentOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PaymentOfCommonStock" xlink:to="CDT_PaymentOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_PaymentOfCommonStock_lbl" xml:lang="en-US">Payment to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NetProceedsReceivedPercentage" xlink:label="CDT_NetProceedsReceivedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NetProceedsReceivedPercentage" xlink:to="CDT_NetProceedsReceivedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_NetProceedsReceivedPercentage_lbl" xml:lang="en-US">Net proceeds received, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Debt instrument allocated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDefaultLongtermDebtAmount" xlink:to="us-gaap_DebtDefaultLongtermDebtAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount_lbl" xml:lang="en-US">Remaining allocated to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleLiquidationPreferenceValue" xlink:label="us-gaap_DebtInstrumentConvertibleLiquidationPreferenceValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleLiquidationPreferenceValue" xlink:to="us-gaap_DebtInstrumentConvertibleLiquidationPreferenceValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleLiquidationPreferenceValue_lbl" xml:lang="en-US">Par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PenaltyPayment" xlink:label="CDT_PenaltyPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PenaltyPayment" xlink:to="CDT_PenaltyPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_PenaltyPayment_lbl" xml:lang="en-US">Penalty payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_2_lbl" xml:lang="en-US">Reverse stock split, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_3_lbl" xml:lang="en-US">Fair value of convertible note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Accured interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Conversion option</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Conversion shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xml:lang="en-US">Payable at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingGainLoss" xlink:label="us-gaap_DebtSecuritiesTradingGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesTradingGainLoss" xlink:to="us-gaap_DebtSecuritiesTradingGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesTradingGainLoss_lbl" xml:lang="en-US">Fair value of convertible promissory notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentForAmortization_2_lbl" xml:lang="en-US">Amortization expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GainOnChangeInFairValue" xlink:label="CDT_GainOnChangeInFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_GainOnChangeInFairValue" xlink:to="CDT_GainOnChangeInFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_GainOnChangeInFairValue_lbl" xml:lang="en-US">Gain on change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_2_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Convertible notes interest per annum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_2_lbl" xml:lang="en-US">Fixed price</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredCommissionPayable" xlink:label="CDT_DeferredCommissionPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredCommissionPayable" xlink:to="CDT_DeferredCommissionPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CDT_DeferredCommissionPayable_lbl" xml:lang="en-US">Deferred commission payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GainOnChangeInFairValueOfConvertibleNote" xlink:label="CDT_GainOnChangeInFairValueOfConvertibleNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_GainOnChangeInFairValueOfConvertibleNote" xlink:to="CDT_GainOnChangeInFairValueOfConvertibleNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_GainOnChangeInFairValueOfConvertibleNote_lbl" xml:lang="en-US">Gain on change in fair value of convertible note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Loans Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_2_lbl" xml:lang="en-US">Debt Instrument, Maturity Date, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Payment terms for loan payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Cash payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Common stock converted</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodAdditionalSharesIssued" xlink:label="CDT_StockIssuedDuringPeriodAdditionalSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodAdditionalSharesIssued" xlink:to="CDT_StockIssuedDuringPeriodAdditionalSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodAdditionalSharesIssued_lbl" xml:lang="en-US">Additional shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xml:lang="en-US">Debt instrument carrying value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFairValue_2_lbl" xml:lang="en-US">Debt instrument fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpenseDebt_2_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments of Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ArrangementFeePercentage" xlink:label="CDT_ArrangementFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ArrangementFeePercentage" xlink:to="CDT_ArrangementFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ArrangementFeePercentage_lbl" xml:lang="en-US">Arrangement fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_2_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CommitmentFees" xlink:label="CDT_CommitmentFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CommitmentFees" xlink:to="CDT_CommitmentFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_CommitmentFees_lbl" xml:lang="en-US">Commitment fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CommonStockClosingPricePercentage" xlink:label="CDT_CommonStockClosingPricePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CommonStockClosingPricePercentage" xlink:to="CDT_CommonStockClosingPricePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_CommonStockClosingPricePercentage_lbl" xml:lang="en-US">Common stock closing price percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair value adjustment of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl" xml:lang="en-US">Cash fee received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Deferred payment fees</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredCommissionPayableAnnualInterestRate" xlink:label="CDT_DeferredCommissionPayableAnnualInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredCommissionPayableAnnualInterestRate" xlink:to="CDT_DeferredCommissionPayableAnnualInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DeferredCommissionPayableAnnualInterestRate_lbl" xml:lang="en-US">Annual interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredCommissionPayableNonCurrent" xlink:label="CDT_DeferredCommissionPayableNonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredCommissionPayableNonCurrent" xlink:to="CDT_DeferredCommissionPayableNonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DeferredCommissionPayableNonCurrent_lbl" xml:lang="en-US">Deferred commissions payable, non-current liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_3_lbl" xml:lang="en-US">Convertible principal amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and Development Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PaymentToResearchAndDevolpmentAmount" xlink:label="CDT_PaymentToResearchAndDevolpmentAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PaymentToResearchAndDevolpmentAmount" xlink:to="CDT_PaymentToResearchAndDevolpmentAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CDT_PaymentToResearchAndDevolpmentAmount_lbl" xml:lang="en-US">Cash payment</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CashPayment" xlink:label="CDT_CashPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CashPayment" xlink:to="CDT_CashPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_CashPayment_lbl" xml:lang="en-US">Payable in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentForAmortization_3_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Awards, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Awards, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Awards, Cancelled/Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Cancelled/Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of Awards, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of Awards, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term Years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options, Cancelled/forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled/Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of Options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term Years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber" xlink:label="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber" xlink:to="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice" xlink:label="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice" xlink:to="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1" xlink:label="CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1" xlink:to="CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term Years</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" xlink:label="CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" xlink:to="CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US">Shares issued percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_3_lbl" xml:lang="en-US">Stock options to employees shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_lbl" xml:lang="en-US">Stock options to employees shares granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Shares issued for services, per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_3_lbl" xml:lang="en-US">Total compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Stock issued during period value issued for services, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Shares granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average grant date fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Shares vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Cost related to non-vested option</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted average remaining vesting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Loss from operations before income taxes:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">US</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss from operations before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_lbl" xml:lang="en-US">Change in Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Net Income Tax Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Taxes at federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign Rate Differential</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_lbl" xml:lang="en-US">Meals &amp; Entertainment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_lbl" xml:lang="en-US">Eq Comp Perm</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncomeTaxReconciliationConvertibleDebtAdjustment" xlink:label="CDT_IncomeTaxReconciliationConvertibleDebtAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IncomeTaxReconciliationConvertibleDebtAdjustment" xlink:to="CDT_IncomeTaxReconciliationConvertibleDebtAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_IncomeTaxReconciliationConvertibleDebtAdjustment_lbl" xml:lang="en-US">Convertible Debt Adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncomeTaxReconciliationStateReRate" xlink:label="CDT_IncomeTaxReconciliationStateReRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IncomeTaxReconciliationStateReRate" xlink:to="CDT_IncomeTaxReconciliationStateReRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_IncomeTaxReconciliationStateReRate_lbl" xml:lang="en-US">State Re-Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change In Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Total provision (benefit) for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments" xlink:label="CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments" xlink:to="CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments_lbl" xml:lang="en-US">Purchase Accounting Adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredTaxAssetsStockOptions" xlink:label="CDT_DeferredTaxAssetsStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredTaxAssetsStockOptions" xlink:to="CDT_DeferredTaxAssetsStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DeferredTaxAssetsStockOptions_lbl" xml:lang="en-US">Stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsHedgingTransactions" xlink:label="us-gaap_DeferredTaxAssetsHedgingTransactions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsHedgingTransactions" xlink:to="us-gaap_DeferredTaxAssetsHedgingTransactions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsHedgingTransactions_lbl" xml:lang="en-US">Transaction Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research &amp; Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets (liability)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate" xlink:label="CDT_EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate" xlink:to="CDT_EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate_lbl" xml:lang="en-US">Effective income tax rate reconciliation future income years tax rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred tax assets valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCash" xlink:label="us-gaap_DividendsCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCash" xlink:to="us-gaap_DividendsCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCash_lbl" xml:lang="en-US">Dividends, Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_lbl" xml:lang="en-US">Sale of stock, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net income (loss) - basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average common stock outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OptionLiabilityConversionShares" xlink:label="CDT_OptionLiabilityConversionShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OptionLiabilityConversionShares" xlink:to="CDT_OptionLiabilityConversionShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_OptionLiabilityConversionShares_lbl" xml:lang="en-US">Add: Option liability conversion shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted average shares used in computing net loss per share - diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Net income (loss) per share, basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Net income (loss) per share, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US">Settelment expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="us-gaap_LossContingencyAccrualProvision" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualProvision" xlink:to="us-gaap_LossContingencyAccrualProvision_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualProvision_lbl" xml:lang="en-US">Accrued estimated liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xml:lang="en-US">Common Stock, Shares Subscribed but Unissued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="us-gaap_TravelAndEntertainmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TravelAndEntertainmentExpense_lbl" xml:lang="en-US">Travel and Entertainment Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US">Proceeds from Contributed Capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_3_lbl" xml:lang="en-US">Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl" xml:lang="en-US">Loans and Leases Receivable, Related Parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_RecognitionOfDeferredRevenueUponOptionExercise" xlink:label="CDT_RecognitionOfDeferredRevenueUponOptionExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_RecognitionOfDeferredRevenueUponOptionExercise" xlink:to="CDT_RecognitionOfDeferredRevenueUponOptionExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_RecognitionOfDeferredRevenueUponOptionExercise_lbl" xml:lang="en-US">Recognition of Cizzle deferred revenue upon option exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_RecognitionOfDeferredRevenueUponOptionExerciseOne" xlink:label="CDT_RecognitionOfDeferredRevenueUponOptionExerciseOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_RecognitionOfDeferredRevenueUponOptionExerciseOne" xlink:to="CDT_RecognitionOfDeferredRevenueUponOptionExerciseOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_RecognitionOfDeferredRevenueUponOptionExerciseOne_lbl" xml:lang="en-US">Recognition of Vela deferred revenue upon option exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueOfOption" xlink:label="CDT_ChangeInFairValueOfOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangeInFairValueOfOption" xlink:to="CDT_ChangeInFairValueOfOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ChangeInFairValueOfOption_lbl" xml:lang="en-US">Change in fair value of Cizzle option</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueOfOptions" xlink:label="CDT_ChangeInFairValueOfOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangeInFairValueOfOptions" xlink:to="CDT_ChangeInFairValueOfOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ChangeInFairValueOfOptions_lbl" xml:lang="en-US">Change in fair value of Vela option</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueOfWarrantLiability" xlink:label="CDT_ChangeInFairValueOfWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangeInFairValueOfWarrantLiability" xlink:to="CDT_ChangeInFairValueOfWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ChangeInFairValueOfWarrantLiability_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueOfConvertibleNotePayment" xlink:label="CDT_ChangeInFairValueOfConvertibleNotePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangeInFairValueOfConvertibleNotePayment" xlink:to="CDT_ChangeInFairValueOfConvertibleNotePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ChangeInFairValueOfConvertibleNotePayment_lbl" xml:lang="en-US">Change in fair value of convertible note payment</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GainOnDebtExtinguishment" xlink:label="CDT_GainOnDebtExtinguishment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_GainOnDebtExtinguishment" xlink:to="CDT_GainOnDebtExtinguishment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CDT_GainOnDebtExtinguishment_lbl" xml:lang="en-US">Gain on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest Income</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncomeTaxRefund" xlink:label="CDT_IncomeTaxRefund" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IncomeTaxRefund" xlink:to="CDT_IncomeTaxRefund_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_IncomeTaxRefund_lbl" xml:lang="en-US">Income Tax Refund</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Unrealized foreign currency transaction gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Total other income:</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnIssuanceOfOptionOne" xlink:label="CDT_LossOnIssuanceOfOptionOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LossOnIssuanceOfOptionOne" xlink:to="CDT_LossOnIssuanceOfOptionOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CDT_LossOnIssuanceOfOptionOne_lbl" xml:lang="en-US">Loss on issuance of Vela option</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OtherIncomeUnrealizedForeignCurrencyTransactionLoss" xlink:label="CDT_OtherIncomeUnrealizedForeignCurrencyTransactionLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OtherIncomeUnrealizedForeignCurrencyTransactionLoss" xlink:to="CDT_OtherIncomeUnrealizedForeignCurrencyTransactionLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_OtherIncomeUnrealizedForeignCurrencyTransactionLoss_lbl" xml:lang="en-US">Change in fair value of convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="us-gaap_InterestExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnDebtExtinguishment" xlink:label="CDT_LossOnDebtExtinguishment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LossOnDebtExtinguishment" xlink:to="CDT_LossOnDebtExtinguishment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_LossOnDebtExtinguishment_lbl" xml:lang="en-US">Loss on Debt Extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OtherExpenseChangeInFairValueOfConvertibleNotesPayable" xlink:label="CDT_OtherExpenseChangeInFairValueOfConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OtherExpenseChangeInFairValueOfConvertibleNotesPayable" xlink:to="CDT_OtherExpenseChangeInFairValueOfConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_OtherExpenseChangeInFairValueOfConvertibleNotesPayable_lbl" xml:lang="en-US">Realized foreign currency transaction loss</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OtherExpense" xlink:label="CDT_OtherExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OtherExpense" xlink:to="CDT_OtherExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_OtherExpense_lbl" xml:lang="en-US">Other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Total other expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_3_lbl" xml:lang="en-US">Closing stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Contractual exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk-free rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Estimated volatility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Time period to expiration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_3_lbl" xml:lang="en-US">Share price per shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Class of warrant or right outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xml:lang="en-US">Proceeds from warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Loss from issuance of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants to purchase common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_2_lbl" xml:lang="en-US">Warrants price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventDescription" xlink:label="us-gaap_SubsequentEventDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Subsequent event, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from the exercise warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Common stock upon exercise, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative Liability, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses &#8211; other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_3_lbl" xml:lang="en-US">Loss from segment operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Number shares reverse stock split during the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_2_lbl" xml:lang="en-US">Debt conversion amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_3_lbl" xml:lang="en-US">Remaining outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Commons tock shares sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xml:lang="en-US">Commons tock shares sold, value</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CommissionsPayable" xlink:label="CDT_CommissionsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CommissionsPayable" xlink:to="CDT_CommissionsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_CommissionsPayable_lbl" xml:lang="en-US">Commissions payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:to="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_doc" xml:lang="en-US">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CommonStockParValue0.0001PerShareMember" xlink:to="CDT_CommonStockParValue0.0001PerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_CommonStockParValue0.0001PerShareMember_doc" xml:lang="en-US">Common Stock, par value $0.0001 per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CashAndCashEquivalentsNetBankOverdrafts" xlink:to="CDT_CashAndCashEquivalentsNetBankOverdrafts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_CashAndCashEquivalentsNetBankOverdrafts_doc" xml:lang="en-US">Cash and cash equivalents net bank overdrafts.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DepositInsuranceLimit" xlink:to="CDT_DepositInsuranceLimit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_DepositInsuranceLimit_doc" xml:lang="en-US">Deposit insurance limit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities" xlink:to="CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities_doc" xml:lang="en-US">Change in fair value and income impact of option liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_WarrantInstrumentsPolicyTextBlock" xlink:to="CDT_WarrantInstrumentsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_WarrantInstrumentsPolicyTextBlock_doc" xml:lang="en-US">Warrant Instruments [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" xlink:to="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_doc" xml:lang="en-US">Stock issued during period value issuance of common stock upon conversion of common stock in connection with merge.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValuePurchaseOfRevenue" xlink:to="CDT_StockIssuedDuringPeriodValuePurchaseOfRevenue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodValuePurchaseOfRevenue_doc" xml:lang="en-US">Stock issued during period value purchase of revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValuePurchasesOfRevenue" xlink:to="CDT_StockIssuedDuringPeriodValuePurchasesOfRevenue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodValuePurchasesOfRevenue_doc" xml:lang="en-US">Stock issued during period value purchases of revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty" xlink:to="CDT_AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty_doc" xml:lang="en-US">Capital contribution - related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger" xlink:to="CDT_AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger_doc" xml:lang="en-US">Adjustments to additional paid in capital reduction of excise tax liability associated with merger</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesPurchasesOfRevenue" xlink:to="CDT_StockIssuedDuringPeriodSharesPurchasesOfRevenue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodSharesPurchasesOfRevenue_doc" xml:lang="en-US">Stock issued during period shares purchases of revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesPurchaseOfRevenue" xlink:to="CDT_StockIssuedDuringPeriodSharesPurchaseOfRevenue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodSharesPurchaseOfRevenue_doc" xml:lang="en-US">Stock issued during period shares purchase of revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" xlink:to="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_doc" xml:lang="en-US">Stock issued during period shares issuance of common stock upon conversion of common stock in connection with merge.</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AprilTwoThousandTwentyFourMember" xlink:label="CDT_AprilTwoThousandTwentyFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AprilTwoThousandTwentyFourMember" xlink:to="CDT_AprilTwoThousandTwentyFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AprilTwoThousandTwentyFourMember_doc" xml:lang="en-US">April 2024 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable" xlink:to="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable_doc" xml:lang="en-US">Issuance of common stock for note payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable" xlink:to="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable_doc" xml:lang="en-US">Issuance of common stock for note payable, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="CDT_EmergingGrowthCompanyStatusPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_EmergingGrowthCompanyStatusPolicyTextBlock_doc" xml:lang="en-US">Emerging Growth Company Status [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DescriptionForEmergingGrowthCompany" xlink:to="CDT_DescriptionForEmergingGrowthCompany_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_DescriptionForEmergingGrowthCompany_doc" xml:lang="en-US">Description for emerging growth company</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="CDT_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_doc" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted [Policy Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_MurphyCanyonAcquisitionCorpMember" xlink:to="CDT_MurphyCanyonAcquisitionCorpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_MurphyCanyonAcquisitionCorpMember_doc" xml:lang="en-US">Murphy Canyon Acquisition Corp [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OldConduitPharmaceuticalsLimitedMember" xlink:to="CDT_OldConduitPharmaceuticalsLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_OldConduitPharmaceuticalsLimitedMember_doc" xml:lang="en-US">Old Conduit Pharmaceuticals Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStock" xlink:to="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStock_doc" xml:lang="en-US">Stock issued during period value issuance of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStock" xlink:to="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStock_doc" xml:lang="en-US">StockIssuedDuringPeriodSharesIssuanceOfCommonStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConduitConvertibleNoteHoldersMember" xlink:to="CDT_ConduitConvertibleNoteHoldersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ConduitConvertibleNoteHoldersMember_doc" xml:lang="en-US">Conduit Convertible Note Holders [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConduitShareHoldersandConvertibleNoteHoldersMember" xlink:to="CDT_ConduitShareHoldersandConvertibleNoteHoldersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ConduitShareHoldersandConvertibleNoteHoldersMember_doc" xml:lang="en-US">Conduit Share Holders and Convertible Note Holders [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification" xlink:to="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification_doc" xml:lang="en-US">Stock issued during period value issuance of common stock in exchange for debt modification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification" xlink:to="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification_doc" xml:lang="en-US">Stock issued during period shares issuance of common stock in exchange for debt modification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_BusinessAcquisitionNumberOfSharesTransferred" xlink:to="CDT_BusinessAcquisitionNumberOfSharesTransferred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_BusinessAcquisitionNumberOfSharesTransferred_doc" xml:lang="en-US">Business acquisition number of shares transferred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SponsorMember" xlink:to="CDT_SponsorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_SponsorMember_doc" xml:lang="en-US">Sponsor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AllianceGlobalPartnersMember" xlink:to="CDT_AllianceGlobalPartnersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AllianceGlobalPartnersMember_doc" xml:lang="en-US">Alliance Global Partners [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredUnderwritingFee" xlink:to="CDT_DeferredUnderwritingFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_DeferredUnderwritingFee_doc" xml:lang="en-US">Deferred underwriting fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption" xlink:to="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption_doc" xml:lang="en-US">Stock issued during period shares issuance of common stock upon exercise of conversion option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PaymentForAdvisoryServices" xlink:to="CDT_PaymentForAdvisoryServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_PaymentForAdvisoryServices_doc" xml:lang="en-US">Payment for advisory services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredCashPaymentsAmount" xlink:to="CDT_DeferredCashPaymentsAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_DeferredCashPaymentsAmount_doc" xml:lang="en-US">Deferred cash payments amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AnnualInterestRate" xlink:to="CDT_AnnualInterestRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AnnualInterestRate_doc" xml:lang="en-US">Annual interest rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SubscriptionAgreementsMember" xlink:to="CDT_SubscriptionAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_SubscriptionAgreementsMember_doc" xml:lang="en-US">Subscription Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants" xlink:to="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants_doc" xml:lang="en-US">Stock issued during period value issuance of common stock upon exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants" xlink:to="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants_doc" xml:lang="en-US">Stock issued during period shares issuance of common stock upon exercise of warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AdjustmentsToAdditionalPaidInCapital" xlink:label="CDT_AdjustmentsToAdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AdjustmentsToAdditionalPaidInCapital" xlink:to="CDT_AdjustmentsToAdditionalPaidInCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AdjustmentsToAdditionalPaidInCapital_doc" xml:lang="en-US">Adjustments to additional paid in capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_GainLossOnChangeInFairValueOfCizzleOption" xlink:to="CDT_GainLossOnChangeInFairValueOfCizzleOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_GainLossOnChangeInFairValueOfCizzleOption_doc" xml:lang="en-US">Gain loss on change in fair value of Cizzle option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_GainOnChangeInFairValueOfVelaOption" xlink:to="CDT_GainOnChangeInFairValueOfVelaOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_GainOnChangeInFairValueOfVelaOption_doc" xml:lang="en-US">Gain on change in fair value of Vela option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LossOnIssuanceOfVelaOption" xlink:to="CDT_LossOnIssuanceOfVelaOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_LossOnIssuanceOfVelaOption_doc" xml:lang="en-US">Loss on issuance of Vela option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_doc" xml:lang="en-US">Increase decrease in accrued expenses and other current liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LossOnRelatedPartyLoanForgiveness" xlink:to="CDT_LossOnRelatedPartyLoanForgiveness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_LossOnRelatedPartyLoanForgiveness_doc" xml:lang="en-US">Loss on related party loan forgiveness.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LossOnChangeInFairValueOfConvertibleNotesPayable" xlink:to="CDT_LossOnChangeInFairValueOfConvertibleNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_LossOnChangeInFairValueOfConvertibleNotesPayable_doc" xml:lang="en-US">Loss on change in fair value of convertible notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_RealizedGainOnShorttermInvestments" xlink:to="CDT_RealizedGainOnShorttermInvestments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_RealizedGainOnShorttermInvestments_doc" xml:lang="en-US">Realized gain on shortterm investments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability" xlink:to="CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability_doc" xml:lang="en-US">Non-cash reduction of deferred income upon exercise of option liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LossOnIssuanceOfWarrants" xlink:to="CDT_LossOnIssuanceOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_LossOnIssuanceOfWarrants_doc" xml:lang="en-US">Loss on issuance of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NoncashLeaseExpense" xlink:to="CDT_NoncashLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_NoncashLeaseExpense_doc" xml:lang="en-US">Noncash lease expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NoncashInterestExpense" xlink:to="CDT_NoncashInterestExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_NoncashInterestExpense_doc" xml:lang="en-US">Non-cash interest expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IssuanceOfCommonStockForLicensingRight" xlink:to="CDT_IssuanceOfCommonStockForLicensingRight_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_IssuanceOfCommonStockForLicensingRight_doc" xml:lang="en-US">Issuance of common stock for licensing right.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ProceedsFromIssuanceOfOption" xlink:to="CDT_ProceedsFromIssuanceOfOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ProceedsFromIssuanceOfOption_doc" xml:lang="en-US">Proceeds from issuance of option</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ProceedsFromLoanRepaymentRelatedParty" xlink:to="CDT_ProceedsFromLoanRepaymentRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ProceedsFromLoanRepaymentRelatedParty_doc" xml:lang="en-US">Proceeds from loan repayment - related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts" xlink:to="CDT_ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts_doc" xml:lang="en-US">Proceeds from Merger and related PIPE Financing, net of transaction costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangeInFairValueOfConvertibleNotesPayable" xlink:to="CDT_ChangeInFairValueOfConvertibleNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ChangeInFairValueOfConvertibleNotesPayable_doc" xml:lang="en-US">Change in fair value of convertible notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty" xlink:to="CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty_doc" xml:lang="en-US">Proceeds from issuance of capital contribution related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ProceedsFromExerciseOfWarrants" xlink:to="CDT_ProceedsFromExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ProceedsFromExerciseOfWarrants_doc" xml:lang="en-US">Proceeds from exercise of warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PriorPeriodAdjustment" xlink:label="CDT_PriorPeriodAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PriorPeriodAdjustment" xlink:to="CDT_PriorPeriodAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_PriorPeriodAdjustment_doc" xml:lang="en-US">Prior period adjustment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NoncashAssetsAssumedInMergerFinancing" xlink:to="CDT_NoncashAssetsAssumedInMergerFinancing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_NoncashAssetsAssumedInMergerFinancing_doc" xml:lang="en-US">Noncash assets assumed in merger financing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NoncashLiabilitiesAssumedInMergerFinancing" xlink:to="CDT_NoncashLiabilitiesAssumedInMergerFinancing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_NoncashLiabilitiesAssumedInMergerFinancing_doc" xml:lang="en-US">Noncash liabilities assumed in merger financing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing" xlink:to="CDT_InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing_doc" xml:lang="en-US">Initial value of warrant liabilities issued in connection with pipe financing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination" xlink:to="CDT_AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination_doc" xml:lang="en-US">Accumulated deficit assumed to Apic as result of business combination.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger" xlink:to="CDT_PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger_doc" xml:lang="en-US">Prepaid expense of directors and officers insurance paid included in Apic in connection with merger.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredUnderwritingCosts" xlink:to="CDT_DeferredUnderwritingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_DeferredUnderwritingCosts_doc" xml:lang="en-US">Deferred underwriting costs.</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ExchangeOfConduitPharmaceuticalsLimitedConvertibleNotesForSharesOfConduitPharmaceuticalsInc.CommonStockInConnectionWithMerger" xlink:label="CDT_ExchangeOfConduitPharmaceuticalsLimitedConvertibleNotesForSharesOfConduitPharmaceuticalsInc.CommonStockInConnectionWithMerger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ExchangeOfConduitPharmaceuticalsLimitedConvertibleNotesForSharesOfConduitPharmaceuticalsInc.CommonStockInConnectionWithMerger" xlink:to="CDT_ExchangeOfConduitPharmaceuticalsLimitedConvertibleNotesForSharesOfConduitPharmaceuticalsInc.CommonStockInConnectionWithMerger_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ExchangeOfConduitPharmaceuticalsLimitedConvertibleNotesForSharesOfConduitPharmaceuticalsInc.CommonStockInConnectionWithMerger_doc" xml:lang="en-US">Exchange of Conduit Pharmaceuticals Limited convertible notes for shares of Conduit Pharmaceuticals Inc. common stock in connection with the Merger.</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToVelaTechnologiesPlcUponExerciseOfOption" xlink:label="CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToVelaTechnologiesPlcUponExerciseOfOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToVelaTechnologiesPlcUponExerciseOfOption" xlink:to="CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToVelaTechnologiesPlcUponExerciseOfOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToVelaTechnologiesPlcUponExerciseOfOption_doc" xml:lang="en-US">Issuance of conduit pharmaceuticals inc common stock to vela technologies plc upon exercise of option</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc" xlink:to="CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc_doc" xml:lang="en-US">Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IssuanceOfCommonStockInExchangeForDebtExtension" xlink:to="CDT_IssuanceOfCommonStockInExchangeForDebtExtension_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_IssuanceOfCommonStockInExchangeForDebtExtension_doc" xml:lang="en-US">Issuance of common stock in exchange for debt extension.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CorporateBondYieldEstimatedTimingOfConversionMember" xlink:to="CDT_CorporateBondYieldEstimatedTimingOfConversionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_CorporateBondYieldEstimatedTimingOfConversionMember_doc" xml:lang="en-US">Corporate Bond Yield Estimated Timing Of Conversion [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AGPConvertibleNoteMember" xlink:to="CDT_AGPConvertibleNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AGPConvertibleNoteMember_doc" xml:lang="en-US">AGP Convertible Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AmortizationExpense" xlink:to="CDT_AmortizationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AmortizationExpense_doc" xml:lang="en-US">Amortization Expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AmortizationOfDebtDiscount" xlink:to="CDT_AmortizationOfDebtDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AmortizationOfDebtDiscount_doc" xml:lang="en-US">Amortization of debt discount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LiabilityRelatedToTheSaleOfFutureRevenueTextBlock" xlink:to="CDT_LiabilityRelatedToTheSaleOfFutureRevenueTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_LiabilityRelatedToTheSaleOfFutureRevenueTextBlock_doc" xml:lang="en-US">Liability Related To The Sale Of Future Revenue [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PercentageOfFutureRevenueEarned" xlink:to="CDT_PercentageOfFutureRevenueEarned_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_PercentageOfFutureRevenueEarned_doc" xml:lang="en-US">Percentage of future revenue earned.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_VelaAgreementMember" xlink:to="CDT_VelaAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_VelaAgreementMember_doc" xml:lang="en-US">Vela Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_VelaTechnologiesPLCMember" xlink:to="CDT_VelaTechnologiesPLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_VelaTechnologiesPLCMember_doc" xml:lang="en-US">Vela Technologies PLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_RoyaltyPercentage" xlink:to="CDT_RoyaltyPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_RoyaltyPercentage_doc" xml:lang="en-US">Royalty percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_VelaOptionAgreementMember" xlink:to="CDT_VelaOptionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_VelaOptionAgreementMember_doc" xml:lang="en-US">Vela Option Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NonRefundableOptionFee" xlink:to="CDT_NonRefundableOptionFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_NonRefundableOptionFee_doc" xml:lang="en-US">Non refundable option fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OptionAgreementDescription" xlink:to="CDT_OptionAgreementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_OptionAgreementDescription_doc" xml:lang="en-US">Option agreement description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_VelaOptionLiabilityMember" xlink:to="CDT_VelaOptionLiabilityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_VelaOptionLiabilityMember_doc" xml:lang="en-US">Vela Option Liability [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CizzlePlcAgreementMember" xlink:to="CDT_CizzlePlcAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_CizzlePlcAgreementMember_doc" xml:lang="en-US">Cizzle Plc Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OptionFee" xlink:to="CDT_OptionFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_OptionFee_doc" xml:lang="en-US">Option fee.</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ScheduleOfLiabilityForTheSaleOfFutureRevenueTableTextBlock" xlink:label="CDT_ScheduleOfLiabilityForTheSaleOfFutureRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ScheduleOfLiabilityForTheSaleOfFutureRevenueTableTextBlock" xlink:to="CDT_ScheduleOfLiabilityForTheSaleOfFutureRevenueTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ScheduleOfLiabilityForTheSaleOfFutureRevenueTableTextBlock_doc" xml:lang="en-US">Schedule Of Liability For The Sale Of Future Revenue [TableTextBlock]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SaleOfFutureRoyalties" xlink:label="CDT_SaleOfFutureRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SaleOfFutureRoyalties" xlink:to="CDT_SaleOfFutureRoyalties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_SaleOfFutureRoyalties_doc" xml:lang="en-US">Sale of future royalties.</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ReversalOfFutureRoyaltiesUponOptionExercise" xlink:label="CDT_ReversalOfFutureRoyaltiesUponOptionExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ReversalOfFutureRoyaltiesUponOptionExercise" xlink:to="CDT_ReversalOfFutureRoyaltiesUponOptionExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ReversalOfFutureRoyaltiesUponOptionExercise_doc" xml:lang="en-US">Reversal of future royalties upon option exercise.</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SaleOfFutureRoyaltiesOfForeignCurrencyExchangeImpact" xlink:label="CDT_SaleOfFutureRoyaltiesOfForeignCurrencyExchangeImpact" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SaleOfFutureRoyaltiesOfForeignCurrencyExchangeImpact" xlink:to="CDT_SaleOfFutureRoyaltiesOfForeignCurrencyExchangeImpact_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_SaleOfFutureRoyaltiesOfForeignCurrencyExchangeImpact_doc" xml:lang="en-US">Sale of future royalties of foreign currency exchange impact.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConvertibleNotesPayableTextBlock" xlink:to="CDT_ConvertibleNotesPayableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ConvertibleNotesPayableTextBlock_doc" xml:lang="en-US">Convertible Notes Payable [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember" xlink:to="CDT_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_doc" xml:lang="en-US">2022 Convertible Loan Note Instrument [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConvertiblePromissoryNotesPayableMember" xlink:to="CDT_ConvertiblePromissoryNotesPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ConvertiblePromissoryNotesPayableMember_doc" xml:lang="en-US">Convertible Promissory Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CommonStockConversionPrice" xlink:label="CDT_CommonStockConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CommonStockConversionPrice" xlink:to="CDT_CommonStockConversionPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_CommonStockConversionPrice_doc" xml:lang="en-US">Common stock conversion price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConvertiblePromissoryNoteMember" xlink:to="CDT_ConvertiblePromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ConvertiblePromissoryNoteMember_doc" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SeniorSecuredPromissoryNoteMember" xlink:to="CDT_SeniorSecuredPromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_SeniorSecuredPromissoryNoteMember_doc" xml:lang="en-US">Senior Secured Promissory Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NirlandLimitedMember" xlink:to="CDT_NirlandLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_NirlandLimitedMember_doc" xml:lang="en-US">Nirland Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OctoberTwoThousandTwentyFourNirlandNoteMember" xlink:to="CDT_OctoberTwoThousandTwentyFourNirlandNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_OctoberTwoThousandTwentyFourNirlandNoteMember_doc" xml:lang="en-US">October Two Thousand Twenty Four Nirland Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LoanAgreementsMember" xlink:to="CDT_LoanAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_LoanAgreementsMember_doc" xml:lang="en-US">Loan Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_TrancheOneMember" xlink:to="CDT_TrancheOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_TrancheOneMember_doc" xml:lang="en-US">Tranche One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_TrancheTwoMember" xlink:to="CDT_TrancheTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_TrancheTwoMember_doc" xml:lang="en-US">Tranche Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_TrancheThreeMember" xlink:to="CDT_TrancheThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_TrancheThreeMember_doc" xml:lang="en-US">Tranche Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodAdditionalSharesIssued" xlink:to="CDT_StockIssuedDuringPeriodAdditionalSharesIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodAdditionalSharesIssued_doc" xml:lang="en-US">Stock issued during period additional shares issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LoanHoldersMember" xlink:to="CDT_LoanHoldersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_LoanHoldersMember_doc" xml:lang="en-US">Loan Holders [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DebtIssuedUponExecution" xlink:to="CDT_DebtIssuedUponExecution_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_DebtIssuedUponExecution_doc" xml:lang="en-US">Debt issuance upon execution.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PaymentOfCommonStock" xlink:to="CDT_PaymentOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_PaymentOfCommonStock_doc" xml:lang="en-US">Payment of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NetProceedsReceivedPercentage" xlink:to="CDT_NetProceedsReceivedPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_NetProceedsReceivedPercentage_doc" xml:lang="en-US">Net proceeds received percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ArrangementFeePercentage" xlink:to="CDT_ArrangementFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ArrangementFeePercentage_doc" xml:lang="en-US">Arrangement fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CommitmentFees" xlink:to="CDT_CommitmentFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_CommitmentFees_doc" xml:lang="en-US">Commitment fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_BridgeLoanAgreementMember" xlink:to="CDT_BridgeLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_BridgeLoanAgreementMember_doc" xml:lang="en-US">Bridge Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CommonStockClosingPricePercentage" xlink:to="CDT_CommonStockClosingPricePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_CommonStockClosingPricePercentage_doc" xml:lang="en-US">Common stock closing price percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredCommissionPayableTextBlock" xlink:to="CDT_DeferredCommissionPayableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_DeferredCommissionPayableTextBlock_doc" xml:lang="en-US">Deferred Commission Payable [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OptionLiabilityConversionShares" xlink:to="CDT_OptionLiabilityConversionShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_OptionLiabilityConversionShares_doc" xml:lang="en-US">Option liability conversion shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredCommissionPayableAnnualInterestRate" xlink:to="CDT_DeferredCommissionPayableAnnualInterestRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_DeferredCommissionPayableAnnualInterestRate_doc" xml:lang="en-US">Deferred commission payable annual interest rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredCommissionPayableNonCurrent" xlink:to="CDT_DeferredCommissionPayableNonCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_DeferredCommissionPayableNonCurrent_doc" xml:lang="en-US">Deferred commission payable non current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock" xlink:to="CDT_DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock_doc" xml:lang="en-US">Disclosure Of Research And Development License Agreement [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AstraZenecaMember" xlink:to="CDT_AstraZenecaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AstraZenecaMember_doc" xml:lang="en-US">Astra Zeneca [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PublicWarrantsMember" xlink:to="CDT_PublicWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_PublicWarrantsMember_doc" xml:lang="en-US">Public Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PIPEMember" xlink:to="CDT_PIPEMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_PIPEMember_doc" xml:lang="en-US">PIPE [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AugustTwentyTwentyFourNirlandNoteMember" xlink:to="CDT_AugustTwentyTwentyFourNirlandNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AugustTwentyTwentyFourNirlandNoteMember_doc" xml:lang="en-US">August 2024 Nirland Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_MarchTwentyTwentyFourWarrantsMember" xlink:to="CDT_MarchTwentyTwentyFourWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_MarchTwentyTwentyFourWarrantsMember_doc" xml:lang="en-US">March 2024 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AprilTwentyTwentyFourWarrantsMember" xlink:to="CDT_AprilTwentyTwentyFourWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AprilTwentyTwentyFourWarrantsMember_doc" xml:lang="en-US">April 2024 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AGPTwentyTwentyFourWarrantsMember" xlink:to="CDT_AGPTwentyTwentyFourWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AGPTwentyTwentyFourWarrantsMember_doc" xml:lang="en-US">AGP 2024 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CorvusCapitalLimitedMember" xlink:to="CDT_CorvusCapitalLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_CorvusCapitalLimitedMember_doc" xml:lang="en-US">Corvus Capital Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_TwentyTwentyThreeStockIncentivePlanMember" xlink:to="CDT_TwentyTwentyThreeStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_TwentyTwentyThreeStockIncentivePlanMember_doc" xml:lang="en-US">2023 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_RecognitionOfDeferredRevenueUponOptionExercise" xlink:to="CDT_RecognitionOfDeferredRevenueUponOptionExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_RecognitionOfDeferredRevenueUponOptionExercise_doc" xml:lang="en-US">Recognition of deferred revenue upon option exercise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_RecognitionOfDeferredRevenueUponOptionExerciseOne" xlink:to="CDT_RecognitionOfDeferredRevenueUponOptionExerciseOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_RecognitionOfDeferredRevenueUponOptionExerciseOne_doc" xml:lang="en-US">Recognition of deferred revenue upon option exercise one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangeInFairValueOfOption" xlink:to="CDT_ChangeInFairValueOfOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ChangeInFairValueOfOption_doc" xml:lang="en-US">Change in fair value of option</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangeInFairValueOfOptions" xlink:to="CDT_ChangeInFairValueOfOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ChangeInFairValueOfOptions_doc" xml:lang="en-US">Change in fair value of options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LossOnIssuanceOfOptionOne" xlink:to="CDT_LossOnIssuanceOfOptionOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_LossOnIssuanceOfOptionOne_doc" xml:lang="en-US">Loss on issuance of option one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OtherIncomeUnrealizedForeignCurrencyTransactionLoss" xlink:to="CDT_OtherIncomeUnrealizedForeignCurrencyTransactionLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_OtherIncomeUnrealizedForeignCurrencyTransactionLoss_doc" xml:lang="en-US">Other income unrealized foreign currency transaction loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OtherExpenseChangeInFairValueOfConvertibleNotesPayable" xlink:to="CDT_OtherExpenseChangeInFairValueOfConvertibleNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_OtherExpenseChangeInFairValueOfConvertibleNotesPayable_doc" xml:lang="en-US">Other expense change in fair value of convertible notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OtherExpense" xlink:to="CDT_OtherExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_OtherExpense_doc" xml:lang="en-US">Other expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_TwoThousandTwentyThreePlanMember" xlink:to="CDT_TwoThousandTwentyThreePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_TwoThousandTwentyThreePlanMember_doc" xml:lang="en-US">Two Thousand Twenty Three Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_WarrantLiabilityDisclosureTextBlock" xlink:to="CDT_WarrantLiabilityDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_WarrantLiabilityDisclosureTextBlock_doc" xml:lang="en-US">Warrant Liability Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_MarchLockUpAgreementMember" xlink:to="CDT_MarchLockUpAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_MarchLockUpAgreementMember_doc" xml:lang="en-US">March Lock Up Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber" xlink:to="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options unvested outstanding number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice" xlink:to="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by dhare based payment award options vested and expected to unvested outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1" xlink:to="CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment unvested award vesting period 1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" xlink:to="CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment Award options unvested intrinsic value 1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock" xlink:to="CDT_ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock_doc" xml:lang="en-US">Schedule Of Share Based Payment Award Stock Purchase Warrants Valuation Assumptions [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AprilLockUpAgreementMember" xlink:to="CDT_AprilLockUpAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AprilLockUpAgreementMember_doc" xml:lang="en-US">April Lock Up Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" xlink:to="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption_doc" xml:lang="en-US">Stocki ssued during period value issuance of common stock upon exercise of conversion option</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangesInForeignCurrencyTransactionUnrealized" xlink:to="CDT_ChangesInForeignCurrencyTransactionUnrealized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ChangesInForeignCurrencyTransactionUnrealized_doc" xml:lang="en-US">Changes in foreign currency transaction unrealized</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NoncashResearchAndDevelopmentExpense" xlink:label="CDT_NoncashResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NoncashResearchAndDevelopmentExpense" xlink:to="CDT_NoncashResearchAndDevelopmentExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_NoncashResearchAndDevelopmentExpense_doc" xml:lang="en-US">Noncash research and development expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LesseeOperatingLeaseLiabilityTableTextBlock" xlink:to="CDT_LesseeOperatingLeaseLiabilityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_LesseeOperatingLeaseLiabilityTableTextBlock_doc" xml:lang="en-US">Lessee Operating Lease Liability [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConsultingAgreementMember" xlink:to="CDT_ConsultingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ConsultingAgreementMember_doc" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_FirstAmendmentNirlandNoteMember" xlink:to="CDT_FirstAmendmentNirlandNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_FirstAmendmentNirlandNoteMember_doc" xml:lang="en-US">First Amendment Nirland Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SecondAmendmentNirlandNoteMember" xlink:to="CDT_SecondAmendmentNirlandNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_SecondAmendmentNirlandNoteMember_doc" xml:lang="en-US">Second Amendment Nirland Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_FirstAmendmentMember" xlink:to="CDT_FirstAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_FirstAmendmentMember_doc" xml:lang="en-US">First Amendment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SecondAmendmentMember" xlink:to="CDT_SecondAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_SecondAmendmentMember_doc" xml:lang="en-US">Second Amendment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_GainOnChangeInFairValue" xlink:to="CDT_GainOnChangeInFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_GainOnChangeInFairValue_doc" xml:lang="en-US">Gain on change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_BridgeAgreementMember" xlink:label="CDT_BridgeAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_BridgeAgreementMember" xlink:to="CDT_BridgeAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_BridgeAgreementMember_doc" xml:lang="en-US">Bridge Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AllianceGobalPartnersConvertibleNoteMember" xlink:to="CDT_AllianceGobalPartnersConvertibleNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AllianceGobalPartnersConvertibleNoteMember_doc" xml:lang="en-US">Alliance Gobal Partners Convertible Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SARBORGLtdMember" xlink:to="CDT_SARBORGLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_SARBORGLtdMember_doc" xml:lang="en-US">SARBORG Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SARBORGServicesAgreementMember" xlink:to="CDT_SARBORGServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_SARBORGServicesAgreementMember_doc" xml:lang="en-US">SARBORG Services Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredCommissionPayable" xlink:to="CDT_DeferredCommissionPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_DeferredCommissionPayable_doc" xml:lang="en-US">Deferred commission payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_GainOnChangeInFairValueOfConvertibleNote" xlink:to="CDT_GainOnChangeInFairValueOfConvertibleNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_GainOnChangeInFairValueOfConvertibleNote_doc" xml:lang="en-US">Gain on change in fair value of convertible note</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PublicWarrantMember" xlink:to="CDT_PublicWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_PublicWarrantMember_doc" xml:lang="en-US">Public Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IncomeTaxReconciliationConvertibleDebtAdjustment" xlink:to="CDT_IncomeTaxReconciliationConvertibleDebtAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_IncomeTaxReconciliationConvertibleDebtAdjustment_doc" xml:lang="en-US">Income tax reconciliation convertible debt adjustment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments" xlink:to="CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments_doc" xml:lang="en-US">Income tax reconciliation purchase accounting adjustments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredTaxAssetsStockOptions" xlink:to="CDT_DeferredTaxAssetsStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_DeferredTaxAssetsStockOptions_doc" xml:lang="en-US">Deferred tax assets stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate" xlink:to="CDT_EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate_doc" xml:lang="en-US">Effective income tax rate reconciliation future income years tax rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PrivatePlacementWarrantMember" xlink:to="CDT_PrivatePlacementWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_PrivatePlacementWarrantMember_doc" xml:lang="en-US">Private Placement Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NonEmployeeDirectorsMember" xlink:to="CDT_NonEmployeeDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_NonEmployeeDirectorsMember_doc" xml:lang="en-US">Non Employee Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConvertiblePromissoryNotePayableMember" xlink:to="CDT_ConvertiblePromissoryNotePayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ConvertiblePromissoryNotePayableMember_doc" xml:lang="en-US">Convertible Promissory Note Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_WarrantAgreementMember" xlink:label="CDT_WarrantAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_WarrantAgreementMember" xlink:to="CDT_WarrantAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_WarrantAgreementMember_doc" xml:lang="en-US">Warrant Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AugustTwoThousandTwentyFourNirlandNoteMember" xlink:label="CDT_AugustTwoThousandTwentyFourNirlandNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AugustTwoThousandTwentyFourNirlandNoteMember" xlink:to="CDT_AugustTwoThousandTwentyFourNirlandNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AugustTwoThousandTwentyFourNirlandNoteMember_doc" xml:lang="en-US">August 2024 Nirland Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NewLicensesMember" xlink:to="CDT_NewLicensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_NewLicensesMember_doc" xml:lang="en-US">New Licenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ClinicalAssetDevelopmentMember" xlink:to="CDT_ClinicalAssetDevelopmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ClinicalAssetDevelopmentMember_doc" xml:lang="en-US">Clinical Asset Development [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LegalAndProfessionalFeesMember" xlink:to="CDT_LegalAndProfessionalFeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_LegalAndProfessionalFeesMember_doc" xml:lang="en-US">Legal And Professional Fees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AccountingAndAuditFeesMember" xlink:to="CDT_AccountingAndAuditFeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AccountingAndAuditFeesMember_doc" xml:lang="en-US">Accounting And Audit Fees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SalariesPayrollAndStockBasedCompensationMember" xlink:to="CDT_SalariesPayrollAndStockBasedCompensationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_SalariesPayrollAndStockBasedCompensationMember_doc" xml:lang="en-US">Salaries Payroll And Stock Based Compensation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PaymentToResearchAndDevolpmentAmount" xlink:to="CDT_PaymentToResearchAndDevolpmentAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_PaymentToResearchAndDevolpmentAmount_doc" xml:lang="en-US">Payment to research and devolpment amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_GainOnDebtExtinguishment" xlink:to="CDT_GainOnDebtExtinguishment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_GainOnDebtExtinguishment_doc" xml:lang="en-US">Gain on debt extinguishment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LossOnDebtExtinguishment" xlink:to="CDT_LossOnDebtExtinguishment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_LossOnDebtExtinguishment_doc" xml:lang="en-US">Loss on debt extinguishment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangeInFairValueOfConvertibleNotePayment" xlink:to="CDT_ChangeInFairValueOfConvertibleNotePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ChangeInFairValueOfConvertibleNotePayment_doc" xml:lang="en-US">Change in fair value of convertible note payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_MrHeilbronMember" xlink:to="CDT_MrHeilbronMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_MrHeilbronMember_doc" xml:lang="en-US">Mr Heilbron [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SalesAgreementMember" xlink:to="CDT_SalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_SalesAgreementMember_doc" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CashPayment" xlink:to="CDT_CashPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_CashPayment_doc" xml:lang="en-US">Cash payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SARBORGServiceAgreementMember" xlink:to="CDT_SARBORGServiceAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_SARBORGServiceAgreementMember_doc" xml:lang="en-US">Sarborg Service Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangeInFairValueOfWarrantLiability" xlink:to="CDT_ChangeInFairValueOfWarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ChangeInFairValueOfWarrantLiability_doc" xml:lang="en-US">Change in fair value of warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IncomeTaxRefund" xlink:to="CDT_IncomeTaxRefund_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_IncomeTaxRefund_doc" xml:lang="en-US">Income tax refund.</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LiabilityClassifiedWarrantsMember" xlink:label="CDT_LiabilityClassifiedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LiabilityClassifiedWarrantsMember" xlink:to="CDT_LiabilityClassifiedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_LiabilityClassifiedWarrantsMember_doc" xml:lang="en-US">Liability Classified Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PenaltyPayment" xlink:to="CDT_PenaltyPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_PenaltyPayment_doc" xml:lang="en-US">Penalty payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PIPEWarrantsMember" xlink:to="CDT_PIPEWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_PIPEWarrantsMember_doc" xml:lang="en-US">PIPE Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuedForServicesOne" xlink:to="CDT_StockIssuedDuringPeriodValueIssuedForServicesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodValueIssuedForServicesOne_doc" xml:lang="en-US">Stock issed during period value issued for services one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesIssuedForServicesOne" xlink:to="CDT_StockIssuedDuringPeriodSharesIssuedForServicesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodSharesIssuedForServicesOne_doc" xml:lang="en-US">Stock issed during period shares issued for services one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing" xlink:to="CDT_StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing_doc" xml:lang="en-US">Stock issed during period value issues in connection with pipe financing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing" xlink:to="CDT_StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing_doc" xml:lang="en-US">Stock issed during period share issues in connection with pipe financing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised_doc" xml:lang="en-US">Stock issed during period shares stock warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_MeasurementInputProbabilityOfDefaultMember" xlink:to="CDT_MeasurementInputProbabilityOfDefaultMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_MeasurementInputProbabilityOfDefaultMember_doc" xml:lang="en-US">Measurement Input Probability Of Default [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_MeasurementInputRecoveryUponDefaultMember" xlink:to="CDT_MeasurementInputRecoveryUponDefaultMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_MeasurementInputRecoveryUponDefaultMember_doc" xml:lang="en-US">Measurement Input Recovery Upon Default [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AGPWarrantsMember" xlink:to="CDT_AGPWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AGPWarrantsMember_doc" xml:lang="en-US">AGP Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OctoberTwentyTwentyFourNirlandNoteMember" xlink:to="CDT_OctoberTwentyTwentyFourNirlandNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_OctoberTwentyTwentyFourNirlandNoteMember_doc" xml:lang="en-US">October 2024 Nirland Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SecurityAgreementMember" xlink:label="CDT_SecurityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SecurityAgreementMember" xlink:to="CDT_SecurityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_SecurityAgreementMember_doc" xml:lang="en-US">Security Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NasdaqCapitalMarketDescription" xlink:label="CDT_NasdaqCapitalMarketDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NasdaqCapitalMarketDescription" xlink:to="CDT_NasdaqCapitalMarketDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_NasdaqCapitalMarketDescription_doc" xml:lang="en-US">Nasdaq capital market description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_TwentyTwentyThreeConvertibleNoteMember" xlink:to="CDT_TwentyTwentyThreeConvertibleNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_TwentyTwentyThreeConvertibleNoteMember_doc" xml:lang="en-US">2023 Convertible Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_OfficersAndDirectorsMember" xlink:to="CDT_OfficersAndDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_OfficersAndDirectorsMember_doc" xml:lang="en-US">Officers and Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" xlink:to="CDT_AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense_doc" xml:lang="en-US">Adjustments to additional paid in capital correction of immaterial error related to franchise tax expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" xlink:to="CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense_doc" xml:lang="en-US">Correction of immaterial error related to franchise tax expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_BoardOfDirectorsMember" xlink:to="CDT_BoardOfDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_BoardOfDirectorsMember_doc" xml:lang="en-US">Board of Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GuaranteedReturnAmount" xlink:label="CDT_GuaranteedReturnAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_GuaranteedReturnAmount" xlink:to="CDT_GuaranteedReturnAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_GuaranteedReturnAmount_doc" xml:lang="en-US">Guaranteed return amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CommissionsPayable" xlink:to="CDT_CommissionsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_CommissionsPayable_doc" xml:lang="en-US">Commissions payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_WarrantsExcercise" xlink:to="CDT_WarrantsExcercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_WarrantsExcercise_doc" xml:lang="en-US">Warrants excercise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConvertiblePromissoryNotesMember" xlink:to="CDT_ConvertiblePromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ConvertiblePromissoryNotesMember_doc" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IncomeTaxReconciliationStateReRate" xlink:to="CDT_IncomeTaxReconciliationStateReRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_IncomeTaxReconciliationStateReRate_doc" xml:lang="en-US">Income tax reconciliation state re rate.</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AmountTransferToCapitalMarket" xlink:label="CDT_AmountTransferToCapitalMarket" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_AmountTransferToCapitalMarket" xlink:to="CDT_AmountTransferToCapitalMarket_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_AmountTransferToCapitalMarket_doc" xml:lang="en-US">Amount transfer to capital market.</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CurrentMarketValueOfPubliclyHeldShares" xlink:label="CDT_CurrentMarketValueOfPubliclyHeldShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CurrentMarketValueOfPubliclyHeldShares" xlink:to="CDT_CurrentMarketValueOfPubliclyHeldShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_CurrentMarketValueOfPubliclyHeldShares_doc" xml:lang="en-US">Current market value of publicly held shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote" xlink:to="CDT_ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote_doc" xml:lang="en-US">Conversion of deferred commission payable to convertible promissory note.</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_BidPricePerShare" xlink:label="CDT_BidPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_BidPricePerShare" xlink:to="CDT_BidPricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CDT_BidPricePerShare_doc" xml:lang="en-US">Bid price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities" xlink:to="CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities_3_lbl" xml:lang="en-US">ChangeInFairValueAndIncomeImpactOfOptionLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" xlink:to="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2_lbl" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2_lbl" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_GainLossOnChangeInFairValueOfCizzleOption" xlink:to="CDT_GainLossOnChangeInFairValueOfCizzleOption_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_GainLossOnChangeInFairValueOfCizzleOption_3_lbl" xml:lang="en-US">GainLossOnChangeInFairValueOfCizzleOption</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_GainOnChangeInFairValueOfVelaOption" xlink:to="CDT_GainOnChangeInFairValueOfVelaOption_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_GainOnChangeInFairValueOfVelaOption_3_lbl" xml:lang="en-US">GainOnChangeInFairValueOfVelaOption</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ChangesInForeignCurrencyTransactionUnrealized" xlink:to="CDT_ChangesInForeignCurrencyTransactionUnrealized_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ChangesInForeignCurrencyTransactionUnrealized_3_lbl" xml:lang="en-US">ChangesInForeignCurrencyTransactionUnrealized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_RealizedGainOnShorttermInvestments" xlink:to="CDT_RealizedGainOnShorttermInvestments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_RealizedGainOnShorttermInvestments_3_lbl" xml:lang="en-US">RealizedGainOnShorttermInvestments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax_2_lbl" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, after Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability" xlink:to="CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability_3_lbl" xml:lang="en-US">NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IssuanceOfCommonStockForLicensingRight" xlink:to="CDT_IssuanceOfCommonStockForLicensingRight_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_IssuanceOfCommonStockForLicensingRight_3_lbl" xml:lang="en-US">IssuanceOfCommonStockForLicensingRight</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_3_lbl" xml:lang="en-US">IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:to="us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_2_lbl" xml:lang="en-US">Increase (Decrease) in Intangible Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_2_lbl" xml:lang="en-US">Payments to Fund Long-Term Loans to Related Parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xml:lang="en-US">Proceeds from Related Party Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty" xlink:to="CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty_3_lbl" xml:lang="en-US">ProceedsFromIssuanceOfCapitalContributionRelatedParty</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" xlink:to="CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense_3_lbl" xml:lang="en-US">CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ConvertibleNotesPayableTextBlock" xlink:to="CDT_ConvertibleNotesPayableTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ConvertibleNotesPayableTextBlock_3_lbl" xml:lang="en-US">Convertible Notes Payable [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredCommissionPayableTextBlock" xlink:to="CDT_DeferredCommissionPayableTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DeferredCommissionPayableTextBlock_3_lbl" xml:lang="en-US">Deferred Commission Payable [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_WarrantLiabilityDisclosureTextBlock" xlink:to="CDT_WarrantLiabilityDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_WarrantLiabilityDisclosureTextBlock_3_lbl" xml:lang="en-US">Warrant Liability Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_WarrantInstrumentsPolicyTextBlock" xlink:to="CDT_WarrantInstrumentsPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_WarrantInstrumentsPolicyTextBlock_3_lbl" xml:lang="en-US">Warrant Instruments [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodSharesStockWarrantsExercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_4_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_2_lbl" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_2_lbl" xml:lang="en-US">Debt Instrument, Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_2_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_DeferredCommissionPayable" xlink:to="CDT_DeferredCommissionPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_DeferredCommissionPayable_3_lbl" xml:lang="en-US">DeferredCommissionPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_2_lbl" xml:lang="en-US">Loans Payable [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_PaymentToResearchAndDevolpmentAmount" xlink:to="CDT_PaymentToResearchAndDevolpmentAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_PaymentToResearchAndDevolpmentAmount_3_lbl" xml:lang="en-US">PaymentToResearchAndDevolpmentAmount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber" xlink:to="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice" xlink:to="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1" xlink:to="CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" xlink:to="CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_2_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_GainOnDebtExtinguishment" xlink:to="CDT_GainOnDebtExtinguishment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_GainOnDebtExtinguishment_3_lbl" xml:lang="en-US">GainOnDebtExtinguishment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_2_lbl" xml:lang="en-US">Other Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_2_lbl" xml:lang="en-US">Other Nonoperating Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_LossOnIssuanceOfOptionOne" xlink:to="CDT_LossOnIssuanceOfOptionOne_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_LossOnIssuanceOfOptionOne_3_lbl" xml:lang="en-US">LossOnIssuanceOfOptionOne</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_2_lbl" xml:lang="en-US">Interest Expense, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_2_lbl" xml:lang="en-US">Other Nonoperating Expense</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>cdt-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://conduitpharma.com/role/Cover" xlink:href="cdt-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/BalanceSheets" xlink:href="cdt-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/BalanceSheetsParenthetical" xlink:href="cdt-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="cdt-20241231.xsd#StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="cdt-20241231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/StatementsOfCashFlows" xlink:href="cdt-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cdt-20241231.xsd#NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/MergerAndFinancing" xlink:href="cdt-20241231.xsd#MergerAndFinancing" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/FairValue" xlink:href="cdt-20241231.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssets" xlink:href="cdt-20241231.xsd#BalanceSheetDetailsCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/Leases" xlink:href="cdt-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenue" xlink:href="cdt-20241231.xsd#LiabilityRelatedToSaleOfFutureRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ConvertibleNotesPayable" xlink:href="cdt-20241231.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LoansPayable" xlink:href="cdt-20241231.xsd#LoansPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/DeferredCommissionPayable" xlink:href="cdt-20241231.xsd#DeferredCommissionPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ResearchAndDevelopmentExpense" xlink:href="cdt-20241231.xsd#ResearchAndDevelopmentExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ShareBasedCompensation" xlink:href="cdt-20241231.xsd#ShareBasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/IncomeTaxes" xlink:href="cdt-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/CommonStockAndPreferredStock" xlink:href="cdt-20241231.xsd#CommonStockAndPreferredStock" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/EarningsnetLossPerShare" xlink:href="cdt-20241231.xsd#EarningsnetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/CommitmentsAndContingencies" xlink:href="cdt-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/RelatedPartyTransactions" xlink:href="cdt-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/OtherIncomeExpenseNet" xlink:href="cdt-20241231.xsd#OtherIncomeExpenseNet" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/Warrants" xlink:href="cdt-20241231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/Segments" xlink:href="cdt-20241231.xsd#Segments" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/SubsequentEvents" xlink:href="cdt-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cdt-20241231.xsd#NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/MergerAndFinancingTables" xlink:href="cdt-20241231.xsd#MergerAndFinancingTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/FairValueTables" xlink:href="cdt-20241231.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssetsTables" xlink:href="cdt-20241231.xsd#BalanceSheetDetailsCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LeasesTables" xlink:href="cdt-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ShareBasedCompensationTables" xlink:href="cdt-20241231.xsd#ShareBasedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/IncomeTaxesTables" xlink:href="cdt-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/EarningsnetLossPerShareTables" xlink:href="cdt-20241231.xsd#EarningsnetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/OtherIncomeExpenseNetTables" xlink:href="cdt-20241231.xsd#OtherIncomeExpenseNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/WarrantsTables" xlink:href="cdt-20241231.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/SegmentsTables" xlink:href="cdt-20241231.xsd#SegmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cdt-20241231.xsd#NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails" xlink:href="cdt-20241231.xsd#ScheduleOfCommonStockOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative" xlink:href="cdt-20241231.xsd#MergerAndFinancingDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails" xlink:href="cdt-20241231.xsd#ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails" xlink:href="cdt-20241231.xsd#ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails" xlink:href="cdt-20241231.xsd#ScheduleOfFairValueOfAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/FairValueDetailsNarrative" xlink:href="cdt-20241231.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails" xlink:href="cdt-20241231.xsd#ScheduleOfBalanceSheetDetailsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfLeaseCostDetails" xlink:href="cdt-20241231.xsd#ScheduleOfLeaseCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:href="cdt-20241231.xsd#ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:href="cdt-20241231.xsd#ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LeasesDetailsNarrative" xlink:href="cdt-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative" xlink:href="cdt-20241231.xsd#LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="cdt-20241231.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/LoansPayableDetailsNarrative" xlink:href="cdt-20241231.xsd#LoansPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative" xlink:href="cdt-20241231.xsd#DeferredCommissionPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative" xlink:href="cdt-20241231.xsd#ResearchAndDevelopmentExpenseDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails" xlink:href="cdt-20241231.xsd#ScheduleOfRestrictedStockActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails" xlink:href="cdt-20241231.xsd#ScheduleOfFairValueOfStockOptionGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="cdt-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative" xlink:href="cdt-20241231.xsd#ShareBasedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:href="cdt-20241231.xsd#ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails" xlink:href="cdt-20241231.xsd#ScheduleOfProvisionForIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails" xlink:href="cdt-20241231.xsd#ScheduleOfFederalIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="cdt-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="cdt-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative" xlink:href="cdt-20241231.xsd#CommonStockAndPreferredStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="cdt-20241231.xsd#ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="cdt-20241231.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cdt-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cdt-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails" xlink:href="cdt-20241231.xsd#ScheduleOfOtherExpenseNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails" xlink:href="cdt-20241231.xsd#ScheduleOfBlack-scholesOptionPricingModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/WarrantsDetailsNarrative" xlink:href="cdt-20241231.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails" xlink:href="cdt-20241231.xsd#ScheduleOfFinancialDataForCompanysReportableSegmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://conduitpharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="cdt-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CommonStockParValue0.0001PerShareMember" xlink:label="loc_CDTCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CDTCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:label="loc_CDTRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CDTRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_deiEntityListingParValuePerShare" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityListingParValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorOpinionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable" xlink:label="loc_us-gaapOtherNotesPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityClassifiedNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDeferredCompensationLiabilityClassifiedNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities" xlink:label="loc_CDTChangeInFairValueAndIncomeImpactOfOptionLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_CDTChangeInFairValueAndIncomeImpactOfOptionLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" xlink:label="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" xlink:label="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing" xlink:label="loc_CDTStockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing" xlink:label="loc_CDTStockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValuePurchaseOfRevenue" xlink:label="loc_CDTStockIssuedDuringPeriodValuePurchaseOfRevenue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValuePurchaseOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesPurchaseOfRevenue" xlink:label="loc_CDTStockIssuedDuringPeriodSharesPurchaseOfRevenue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesPurchaseOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValuePurchasesOfRevenue" xlink:label="loc_CDTStockIssuedDuringPeriodValuePurchasesOfRevenue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValuePurchasesOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesPurchasesOfRevenue" xlink:label="loc_CDTStockIssuedDuringPeriodSharesPurchasesOfRevenue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesPurchasesOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuedForServicesOne" xlink:label="loc_CDTStockIssuedDuringPeriodValueIssuedForServicesOne" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueIssuedForServicesOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuedForServicesOne" xlink:label="loc_CDTStockIssuedDuringPeriodSharesIssuedForServicesOne" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesIssuedForServicesOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger" xlink:label="loc_CDTAdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTAdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty" xlink:label="loc_CDTAdjustmentsToAdditionalPaidInCapitalContributionRelatedParty" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTAdjustmentsToAdditionalPaidInCapitalContributionRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" xlink:label="loc_CDTAdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTAdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable" xlink:label="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable" xlink:label="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStock" xlink:label="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStock" xlink:label="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStock" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification" xlink:label="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification" xlink:label="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" xlink:label="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption" xlink:label="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GainLossOnChangeInFairValueOfCizzleOption" xlink:label="loc_CDTGainLossOnChangeInFairValueOfCizzleOption" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTGainLossOnChangeInFairValueOfCizzleOption" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GainOnChangeInFairValueOfVelaOption" xlink:label="loc_CDTGainOnChangeInFairValueOfVelaOption" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTGainOnChangeInFairValueOfVelaOption" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnIssuanceOfVelaOption" xlink:label="loc_CDTLossOnIssuanceOfVelaOption" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTLossOnIssuanceOfVelaOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangesInForeignCurrencyTransactionUnrealized" xlink:label="loc_CDTChangesInForeignCurrencyTransactionUnrealized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTChangesInForeignCurrencyTransactionUnrealized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnRelatedPartyLoanForgiveness" xlink:label="loc_CDTLossOnRelatedPartyLoanForgiveness" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTLossOnRelatedPartyLoanForgiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_RealizedGainOnShorttermInvestments" xlink:label="loc_CDTRealizedGainOnShorttermInvestments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTRealizedGainOnShorttermInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossUnrealizedAfterTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnChangeInFairValueOfConvertibleNotesPayable" xlink:label="loc_CDTLossOnChangeInFairValueOfConvertibleNotesPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTLossOnChangeInFairValueOfConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability" xlink:label="loc_CDTNoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTNoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnIssuanceOfWarrants" xlink:label="loc_CDTLossOnIssuanceOfWarrants" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTLossOnIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NoncashLeaseExpense" xlink:label="loc_CDTNoncashLeaseExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTNoncashLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IssuanceOfCommonStockForLicensingRight" xlink:label="loc_CDTIssuanceOfCommonStockForLicensingRight" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTIssuanceOfCommonStockForLicensingRight" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NoncashInterestExpense" xlink:label="loc_CDTNoncashInterestExpense" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTNoncashInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AmortizationExpense" xlink:label="loc_CDTAmortizationExpense" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AmortizationOfDebtDiscount" xlink:label="loc_CDTAmortizationOfDebtDiscount" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTAmortizationOfDebtDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="loc_CDTIncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_CDTIncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInIntangibleAssetsCurrent" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIntangibleAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="loc_us-gaapPaymentsToFundLongtermLoansToRelatedParties" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToFundLongtermLoansToRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaapPaymentsToAcquireShortTermInvestments" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireShortTermInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaapProceedsFromSaleOfShortTermInvestments" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ProceedsFromIssuanceOfOption" xlink:label="loc_CDTProceedsFromIssuanceOfOption" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTProceedsFromIssuanceOfOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ProceedsFromLoanRepaymentRelatedParty" xlink:label="loc_CDTProceedsFromLoanRepaymentRelatedParty" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CDTProceedsFromLoanRepaymentRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts" xlink:label="loc_CDTProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CDTProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty" xlink:label="loc_CDTProceedsFromIssuanceOfCapitalContributionRelatedParty" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CDTProceedsFromIssuanceOfCapitalContributionRelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ProceedsFromExerciseOfWarrants" xlink:label="loc_CDTProceedsFromExerciseOfWarrants" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CDTProceedsFromExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" xlink:label="loc_CDTCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CDTCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" xlink:label="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CDTStockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IssuanceOfCommonStockInExchangeForDebtExtension" xlink:label="loc_CDTIssuanceOfCommonStockInExchangeForDebtExtension" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CDTIssuanceOfCommonStockInExchangeForDebtExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote" xlink:label="loc_CDTConversionOfDeferredCommissionPayableToConvertiblePromissoryNote" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CDTConversionOfDeferredCommissionPayableToConvertiblePromissoryNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc" xlink:label="loc_CDTIssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CDTIssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesReduction" xlink:label="loc_us-gaapNotesReduction" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapNotesReduction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredUnderwritingCosts" xlink:label="loc_CDTDeferredUnderwritingCosts" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CDTDeferredUnderwritingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger" xlink:label="loc_CDTPrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CDTPrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination" xlink:label="loc_CDTAccumulatedDeficitAssumedToApicAsResultOfBusinessCombination" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CDTAccumulatedDeficitAssumedToApicAsResultOfBusinessCombination" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing" xlink:label="loc_CDTInitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CDTInitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NoncashAssetsAssumedInMergerFinancing" xlink:label="loc_CDTNoncashAssetsAssumedInMergerFinancing" />
      <link:presentationArc order="670" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CDTNoncashAssetsAssumedInMergerFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NoncashLiabilitiesAssumedInMergerFinancing" xlink:label="loc_CDTNoncashLiabilitiesAssumedInMergerFinancing" />
      <link:presentationArc order="680" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CDTNoncashLiabilitiesAssumedInMergerFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaapSupplementalCashFlowElementsAbstract" />
      <link:presentationArc order="690" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowElementsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowElementsAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/MergerAndFinancing" xlink:title="999015 - Disclosure - Merger and Financing">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/FairValue" xlink:title="999016 - Disclosure - Fair Value">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssets" xlink:title="999017 - Disclosure - Balance Sheet Details &#8211; Current Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaapSupplementalBalanceSheetDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Leases" xlink:title="999018 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureLeasesAbstract" xlink:label="loc_CDTDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenue" xlink:title="999019 - Disclosure - Liability Related to the Sale of Future Revenue">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract" xlink:label="loc_CDTDisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LiabilityRelatedToTheSaleOfFutureRevenueTextBlock" xlink:label="loc_CDTLiabilityRelatedToTheSaleOfFutureRevenueTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract" xlink:to="loc_CDTLiabilityRelatedToTheSaleOfFutureRevenueTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ConvertibleNotesPayable" xlink:title="999020 - Disclosure - Convertible Notes Payable">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureConvertibleNotesPayableAbstract" xlink:label="loc_CDTDisclosureConvertibleNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertibleNotesPayableTextBlock" xlink:label="loc_CDTConvertibleNotesPayableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureConvertibleNotesPayableAbstract" xlink:to="loc_CDTConvertibleNotesPayableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LoansPayable" xlink:title="999021 - Disclosure - Loans Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/DeferredCommissionPayable" xlink:title="999022 - Disclosure - Deferred Commission Payable">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureDeferredCommissionPayableAbstract" xlink:label="loc_CDTDisclosureDeferredCommissionPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredCommissionPayableTextBlock" xlink:label="loc_CDTDeferredCommissionPayableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureDeferredCommissionPayableAbstract" xlink:to="loc_CDTDeferredCommissionPayableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ResearchAndDevelopmentExpense" xlink:title="999023 - Disclosure - Research and Development Expense">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureResearchAndDevelopmentExpenseAbstract" xlink:label="loc_CDTDisclosureResearchAndDevelopmentExpenseAbstract" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock" xlink:label="loc_CDTDisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureResearchAndDevelopmentExpenseAbstract" xlink:to="loc_CDTDisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ShareBasedCompensation" xlink:title="999024 - Disclosure - Share Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/IncomeTaxes" xlink:title="999025 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/CommonStockAndPreferredStock" xlink:title="999026 - Disclosure - Common Stock and Preferred Stock">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/EarningsnetLossPerShare" xlink:title="999027 - Disclosure - Earnings/(Net Loss) Per Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/CommitmentsAndContingencies" xlink:title="999028 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/RelatedPartyTransactions" xlink:title="999029 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/OtherIncomeExpenseNet" xlink:title="999030 - Disclosure - Other Income (expense), net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:label="loc_us-gaapOtherNonoperatingIncomeAndExpenseTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeAndExpenseTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Warrants" xlink:title="999031 - Disclosure - Warrants">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureWarrantsAbstract" xlink:label="loc_CDTDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_WarrantLiabilityDisclosureTextBlock" xlink:label="loc_CDTWarrantLiabilityDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureWarrantsAbstract" xlink:to="loc_CDTWarrantLiabilityDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Segments" xlink:title="999032 - Disclosure - Segments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/SubsequentEvents" xlink:title="999033 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999034 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaapMarketableSecuritiesPolicy" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueTransferPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueTransferPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueTransferPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_WarrantInstrumentsPolicyTextBlock" xlink:label="loc_CDTWarrantInstrumentsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CDTWarrantInstrumentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="loc_CDTEmergingGrowthCompanyStatusPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CDTEmergingGrowthCompanyStatusPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="loc_CDTNewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CDTNewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/MergerAndFinancingTables" xlink:title="999035 - Disclosure - Merger and Financing (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/FairValueTables" xlink:title="999036 - Disclosure - Fair Value (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AGPConvertibleNoteMember" xlink:label="loc_CDTAGPConvertibleNoteMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTAGPConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssetsTables" xlink:title="999037 - Disclosure - Balance Sheet Details &#8211; Current Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="loc_srtScheduleOfCondensedBalanceSheetTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_srtScheduleOfCondensedBalanceSheetTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LeasesTables" xlink:title="999038 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureLeasesAbstract" xlink:label="loc_CDTDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LesseeOperatingLeaseLiabilityTableTextBlock" xlink:label="loc_CDTLesseeOperatingLeaseLiabilityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_CDTLesseeOperatingLeaseLiabilityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ShareBasedCompensationTables" xlink:title="999039 - Disclosure - Share Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/EarningsnetLossPerShareTables" xlink:title="999041 - Disclosure - Earnings/(Net Loss) Per Share (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/OtherIncomeExpenseNetTables" xlink:title="999042 - Disclosure - Other Income (expense), net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/WarrantsTables" xlink:title="999043 - Disclosure - Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureWarrantsAbstract" xlink:label="loc_CDTDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock" xlink:label="loc_CDTScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureWarrantsAbstract" xlink:to="loc_CDTScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/SegmentsTables" xlink:title="999044 - Disclosure - Segments (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999045 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDepositAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DemandDepositAccounts" xlink:label="loc_us-gaapDemandDepositAccounts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDemandDepositAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DepositInsuranceLimit" xlink:label="loc_CDTDepositInsuranceLimit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_CDTDepositInsuranceLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CashAndCashEquivalentsNetBankOverdrafts" xlink:label="loc_CDTCashAndCashEquivalentsNetBankOverdrafts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_CDTCashAndCashEquivalentsNetBankOverdrafts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DescriptionForEmergingGrowthCompany" xlink:label="loc_CDTDescriptionForEmergingGrowthCompany" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_CDTDescriptionForEmergingGrowthCompany" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails" xlink:title="999046 - Disclosure - Schedule of Common Stock Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MurphyCanyonAcquisitionCorpMember" xlink:label="loc_CDTMurphyCanyonAcquisitionCorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_CDTMurphyCanyonAcquisitionCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:label="loc_us-gaapScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="loc_us-gaapSharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:to="loc_us-gaapSharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="loc_us-gaapCommonStockSubjectToMandatoryRedemptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:to="loc_us-gaapCommonStockSubjectToMandatoryRedemptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SponsorMember" xlink:label="loc_CDTSponsorMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CDTSponsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SubscriptionAgreementsMember" xlink:label="loc_CDTSubscriptionAgreementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSubscriptionAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative" xlink:title="999047 - Disclosure - Merger and Financing (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MurphyCanyonAcquisitionCorpMember" xlink:label="loc_CDTMurphyCanyonAcquisitionCorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_CDTMurphyCanyonAcquisitionCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OldConduitPharmaceuticalsLimitedMember" xlink:label="loc_CDTOldConduitPharmaceuticalsLimitedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CDTOldConduitPharmaceuticalsLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AllianceGlobalPartnersMember" xlink:label="loc_CDTAllianceGlobalPartnersMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CDTAllianceGlobalPartnersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConduitConvertibleNoteHoldersMember" xlink:label="loc_CDTConduitConvertibleNoteHoldersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CDTConduitConvertibleNoteHoldersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConduitShareHoldersandConvertibleNoteHoldersMember" xlink:label="loc_CDTConduitShareHoldersandConvertibleNoteHoldersMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CDTConduitShareHoldersandConvertibleNoteHoldersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SponsorMember" xlink:label="loc_CDTSponsorMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CDTSponsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SubscriptionAgreementsMember" xlink:label="loc_CDTSubscriptionAgreementsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSubscriptionAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_BusinessAcquisitionNumberOfSharesTransferred" xlink:label="loc_CDTBusinessAcquisitionNumberOfSharesTransferred" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_CDTBusinessAcquisitionNumberOfSharesTransferred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaapCommonStockConversionBasis" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCommonStockConversionBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredUnderwritingFee" xlink:label="loc_CDTDeferredUnderwritingFee" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_CDTDeferredUnderwritingFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PaymentForAdvisoryServices" xlink:label="loc_CDTPaymentForAdvisoryServices" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_CDTPaymentForAdvisoryServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_CDTStockIssuedDuringPeriodSharesStockWarrantsExercised" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredCashPaymentsAmount" xlink:label="loc_CDTDeferredCashPaymentsAmount" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_CDTDeferredCashPaymentsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AnnualInterestRate" xlink:label="loc_CDTAnnualInterestRate" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_CDTAnnualInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails" xlink:title="999048 - Disclosure - Schedule of Assets Subject to Measurement at Fair Value on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaapCashAndCashEquivalentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapCashAndCashEquivalentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails" xlink:title="999049 - Disclosure - Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaapConvertibleDebtFairValueDisclosures" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapConvertibleDebtFairValueDisclosures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueOfConvertibleNotesPayable" xlink:label="loc_CDTChangeInFairValueOfConvertibleNotesPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_CDTChangeInFairValueOfConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaapConvertibleDebtFairValueDisclosures_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapConvertibleDebtFairValueDisclosures_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails" xlink:title="999050 - Disclosure - Schedule of Fair Value of Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CorporateBondYieldEstimatedTimingOfConversionMember" xlink:label="loc_CDTCorporateBondYieldEstimatedTimingOfConversionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_CDTCorporateBondYieldEstimatedTimingOfConversionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputCreditSpreadMember" xlink:label="loc_us-gaapMeasurementInputCreditSpreadMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputCreditSpreadMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MeasurementInputProbabilityOfDefaultMember" xlink:label="loc_CDTMeasurementInputProbabilityOfDefaultMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_CDTMeasurementInputProbabilityOfDefaultMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MeasurementInputRecoveryUponDefaultMember" xlink:label="loc_CDTMeasurementInputRecoveryUponDefaultMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_CDTMeasurementInputRecoveryUponDefaultMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaapMeasurementInputDiscountRateMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDiscountRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AGPConvertibleNoteMember" xlink:label="loc_CDTAGPConvertibleNoteMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTAGPConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/FairValueDetailsNarrative" xlink:title="999051 - Disclosure - Fair Value (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PIPEWarrantsMember" xlink:label="loc_CDTPIPEWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CDTPIPEWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_WarrantsExcercise" xlink:label="loc_CDTWarrantsExcercise" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTWarrantsExcercise" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails" xlink:title="999052 - Disclosure - Schedule of Balance Sheet Details (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfLeaseCostDetails" xlink:title="999053 - Disclosure - Schedule of Lease Cost (Details)">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureLeasesAbstract" xlink:label="loc_CDTDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:title="999054 - Disclosure - Schedule of Operating Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureLeasesAbstract" xlink:label="loc_CDTDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:title="999055 - Disclosure - Schedule of Future Minimum Lease Payments For Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureLeasesAbstract" xlink:label="loc_CDTDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LeasesDetailsNarrative" xlink:title="999056 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureLeasesAbstract" xlink:label="loc_CDTDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative" xlink:title="999057 - Disclosure - Liability Related to the Sale of Future Revenue (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract" xlink:label="loc_CDTDisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_VelaAgreementMember" xlink:label="loc_CDTVelaAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTVelaAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_VelaOptionAgreementMember" xlink:label="loc_CDTVelaOptionAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTVelaOptionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CizzlePlcAgreementMember" xlink:label="loc_CDTCizzlePlcAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTCizzlePlcAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_VelaTechnologiesPLCMember" xlink:label="loc_CDTVelaTechnologiesPLCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_CDTVelaTechnologiesPLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_VelaOptionLiabilityMember" xlink:label="loc_CDTVelaOptionLiabilityMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_CDTVelaOptionLiabilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PercentageOfFutureRevenueEarned" xlink:label="loc_CDTPercentageOfFutureRevenueEarned" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTPercentageOfFutureRevenueEarned" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferred" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_RoyaltyPercentage" xlink:label="loc_CDTRoyaltyPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NonRefundableOptionFee" xlink:label="loc_CDTNonRefundableOptionFee" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTNonRefundableOptionFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OptionAgreementDescription" xlink:label="loc_CDTOptionAgreementDescription" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTOptionAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OptionFee" xlink:label="loc_CDTOptionFee" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTOptionFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="999058 - Disclosure - Convertible Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureConvertibleNotesPayableAbstract" xlink:label="loc_CDTDisclosureConvertibleNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureConvertibleNotesPayableAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertiblePromissoryNotesPayableMember" xlink:label="loc_CDTConvertiblePromissoryNotesPayableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CDTConvertiblePromissoryNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SeniorSecuredPromissoryNoteMember" xlink:label="loc_CDTSeniorSecuredPromissoryNoteMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CDTSeniorSecuredPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertiblePromissoryNoteMember" xlink:label="loc_CDTConvertiblePromissoryNoteMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTConvertiblePromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertiblePromissoryNotePayableMember" xlink:label="loc_CDTConvertiblePromissoryNotePayableMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTConvertiblePromissoryNotePayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TwentyTwentyThreeConvertibleNoteMember" xlink:label="loc_CDTTwentyTwentyThreeConvertibleNoteMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTTwentyTwentyThreeConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_FirstAmendmentNirlandNoteMember" xlink:label="loc_CDTFirstAmendmentNirlandNoteMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTFirstAmendmentNirlandNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_FirstAmendmentMember" xlink:label="loc_CDTFirstAmendmentMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTFirstAmendmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SecondAmendmentNirlandNoteMember" xlink:label="loc_CDTSecondAmendmentNirlandNoteMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTSecondAmendmentNirlandNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SecondAmendmentMember" xlink:label="loc_CDTSecondAmendmentMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTSecondAmendmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertiblePromissoryNotesMember" xlink:label="loc_CDTConvertiblePromissoryNotesMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTConvertiblePromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AllianceGobalPartnersConvertibleNoteMember" xlink:label="loc_CDTAllianceGobalPartnersConvertibleNoteMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTAllianceGobalPartnersConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConsultingAgreementMember" xlink:label="loc_CDTConsultingAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_FirstAmendmentMember" xlink:label="loc_CDTFirstAmendmentMember_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTFirstAmendmentMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SecondAmendmentMember" xlink:label="loc_CDTSecondAmendmentMember_2" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSecondAmendmentMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NirlandLimitedMember" xlink:label="loc_CDTNirlandLimitedMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CDTNirlandLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DebtIssuedUponExecution" xlink:label="loc_CDTDebtIssuedUponExecution" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTDebtIssuedUponExecution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PaymentOfCommonStock" xlink:label="loc_CDTPaymentOfCommonStock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTPaymentOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NetProceedsReceivedPercentage" xlink:label="loc_CDTNetProceedsReceivedPercentage" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTNetProceedsReceivedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="loc_us-gaapDebtDefaultLongtermDebtAmount" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtDefaultLongtermDebtAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleLiquidationPreferenceValue" xlink:label="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferenceValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferenceValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PenaltyPayment" xlink:label="loc_CDTPenaltyPayment" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTPenaltyPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaapConvertibleDebtFairValueDisclosures" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebtFairValueDisclosures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaapNotesPayableFairValueDisclosure" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayableFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingGainLoss" xlink:label="loc_us-gaapDebtSecuritiesTradingGainLoss" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtSecuritiesTradingGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GainOnChangeInFairValue" xlink:label="loc_CDTGainOnChangeInFairValue" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTGainOnChangeInFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredCommissionPayable" xlink:label="loc_CDTDeferredCommissionPayable" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTDeferredCommissionPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GainOnChangeInFairValueOfConvertibleNote" xlink:label="loc_CDTGainOnChangeInFairValueOfConvertibleNote" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTGainOnChangeInFairValueOfConvertibleNote" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/LoansPayableDetailsNarrative" xlink:title="999059 - Disclosure - Loans Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LoanAgreementsMember" xlink:label="loc_CDTLoanAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTLoanAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LoansAmendmentMember" xlink:label="loc_CDTLoansAmendmentMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTLoansAmendmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_BridgeLoanAgreementMember" xlink:label="loc_CDTBridgeLoanAgreementMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTBridgeLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TrancheOneMember" xlink:label="loc_CDTTrancheOneMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CDTTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TrancheTwoMember" xlink:label="loc_CDTTrancheTwoMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CDTTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TrancheThreeMember" xlink:label="loc_CDTTrancheThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CDTTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LoanHoldersMember" xlink:label="loc_CDTLoanHoldersMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_CDTLoanHoldersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OctoberTwoThousandTwentyFourNirlandNoteMember" xlink:label="loc_CDTOctoberTwoThousandTwentyFourNirlandNoteMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTOctoberTwoThousandTwentyFourNirlandNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtRangeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_StockIssuedDuringPeriodAdditionalSharesIssued" xlink:label="loc_CDTStockIssuedDuringPeriodAdditionalSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTStockIssuedDuringPeriodAdditionalSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ArrangementFeePercentage" xlink:label="loc_CDTArrangementFeePercentage" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTArrangementFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CommitmentFees" xlink:label="loc_CDTCommitmentFees" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTCommitmentFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CommonStockClosingPricePercentage" xlink:label="loc_CDTCommonStockClosingPricePercentage" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CDTCommonStockClosingPricePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative" xlink:title="999060 - Disclosure - Deferred Commission Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureDeferredCommissionPayableAbstract" xlink:label="loc_CDTDisclosureDeferredCommissionPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureDeferredCommissionPayableAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AllianceGlobalPartnersMember" xlink:label="loc_CDTAllianceGlobalPartnersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CDTAllianceGlobalPartnersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="loc_us-gaapProceedsFromFeesReceived" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromFeesReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredCommissionPayableAnnualInterestRate" xlink:label="loc_CDTDeferredCommissionPayableAnnualInterestRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTDeferredCommissionPayableAnnualInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredCommissionPayableNonCurrent" xlink:label="loc_CDTDeferredCommissionPayableNonCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTDeferredCommissionPayableNonCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative" xlink:title="999061 - Disclosure - Research and Development Expense (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureResearchAndDevelopmentExpenseAbstract" xlink:label="loc_CDTDisclosureResearchAndDevelopmentExpenseAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureResearchAndDevelopmentExpenseAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AstraZenecaMember" xlink:label="loc_CDTAstraZenecaMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CDTAstraZenecaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SARBORGServiceAgreementMember" xlink:label="loc_CDTSARBORGServiceAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSARBORGServiceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PaymentToResearchAndDevolpmentAmount" xlink:label="loc_CDTPaymentToResearchAndDevolpmentAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTPaymentToResearchAndDevolpmentAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CashPayment" xlink:label="loc_CDTCashPayment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CDTCashPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails" xlink:title="999062 - Disclosure - Schedule of Restricted Stock Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails" xlink:title="999063 - Disclosure - Schedule of Fair Value of Stock Option Granted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999064 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TwoThousandTwentyThreePlanMember" xlink:label="loc_CDTTwoThousandTwentyThreePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CDTTwoThousandTwentyThreePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber" xlink:label="loc_CDTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CDTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice" xlink:label="loc_CDTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CDTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1" xlink:label="loc_CDTShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CDTShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" xlink:label="loc_CDTSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CDTSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative" xlink:title="999065 - Disclosure - Share Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TwentyTwentyThreeStockIncentivePlanMember" xlink:label="loc_CDTTwentyTwentyThreeStockIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CDTTwentyTwentyThreeStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NonEmployeeDirectorsMember" xlink:label="loc_CDTNonEmployeeDirectorsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CDTNonEmployeeDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MrHeilbronMember" xlink:label="loc_CDTMrHeilbronMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CDTMrHeilbronMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConsultingAgreementMember" xlink:label="loc_CDTConsultingAgreementMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" xlink:title="999066 - Disclosure - Schedule of Income before Income Tax, Domestic and Foreign (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails" xlink:title="999067 - Disclosure - Schedule of Provision for Income Tax (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaapIncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails" xlink:title="999068 - Disclosure - Schedule of Federal Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncomeTaxReconciliationConvertibleDebtAdjustment" xlink:label="loc_CDTIncomeTaxReconciliationConvertibleDebtAdjustment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CDTIncomeTaxReconciliationConvertibleDebtAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncomeTaxReconciliationStateReRate" xlink:label="loc_CDTIncomeTaxReconciliationStateReRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CDTIncomeTaxReconciliationStateReRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments" xlink:label="loc_CDTIncomeTaxReconciliationPurchaseAccountingAdjustments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CDTIncomeTaxReconciliationPurchaseAccountingAdjustments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999069 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DeferredTaxAssetsStockOptions" xlink:label="loc_CDTDeferredTaxAssetsStockOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CDTDeferredTaxAssetsStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsHedgingTransactions" xlink:label="loc_us-gaapDeferredTaxAssetsHedgingTransactions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsHedgingTransactions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999070 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate" xlink:label="loc_CDTEffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CDTEffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative" xlink:title="999071 - Disclosure - Common Stock and Preferred Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SalesAgreementMember" xlink:label="loc_CDTSalesAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCash" xlink:label="loc_us-gaapDividendsCash" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDividendsCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipBeforeTransaction" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="999072 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities" xlink:label="loc_CDTChangeInFairValueAndIncomeImpactOfOptionLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_CDTChangeInFairValueAndIncomeImpactOfOptionLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OptionLiabilityConversionShares" xlink:label="loc_CDTOptionLiabilityConversionShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_CDTOptionLiabilityConversionShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="999073 - Disclosure - Schedule of Potentially Dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PublicWarrantsMember" xlink:label="loc_CDTPublicWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTPublicWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PIPEMember" xlink:label="loc_CDTPIPEMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTPIPEMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AGPWarrantsMember" xlink:label="loc_CDTAGPWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTAGPWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ConvertiblePromissoryNotesPayableMember" xlink:label="loc_CDTConvertiblePromissoryNotesPayableMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTConvertiblePromissoryNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AugustTwentyTwentyFourNirlandNoteMember" xlink:label="loc_CDTAugustTwentyTwentyFourNirlandNoteMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTAugustTwentyTwentyFourNirlandNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AGPConvertibleNoteMember" xlink:label="loc_CDTAGPConvertibleNoteMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTAGPConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MarchTwentyTwentyFourWarrantsMember" xlink:label="loc_CDTMarchTwentyTwentyFourWarrantsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTMarchTwentyTwentyFourWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AprilTwentyTwentyFourWarrantsMember" xlink:label="loc_CDTAprilTwentyTwentyFourWarrantsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTAprilTwentyTwentyFourWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AGPTwentyTwentyFourWarrantsMember" xlink:label="loc_CDTAGPTwentyTwentyFourWarrantsMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CDTAGPTwentyTwentyFourWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999074 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLitigationSettlementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaapLossContingencyAccrualProvision" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLossContingencyAccrualProvision" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999075 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CorvusCapitalLimitedMember" xlink:label="loc_CDTCorvusCapitalLimitedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CDTCorvusCapitalLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SARBORGLtdMember" xlink:label="loc_CDTSARBORGLtdMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CDTSARBORGLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_BoardOfDirectorsMember" xlink:label="loc_CDTBoardOfDirectorsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CDTBoardOfDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember" xlink:label="loc_CDTTwentyTwentyTwoConvertibleLoanNoteInstrumentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTTwentyTwentyTwoConvertibleLoanNoteInstrumentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SARBORGServicesAgreementMember" xlink:label="loc_CDTSARBORGServicesAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSARBORGServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OfficersAndDirectorsMember" xlink:label="loc_CDTOfficersAndDirectorsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CDTOfficersAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaapCommonStockSharesSubscribedButUnissued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCommonStockSharesSubscribedButUnissued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapTravelAndEntertainmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="loc_us-gaapProceedsFromContributedCapital" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromContributedCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:label="loc_us-gaapLoansAndLeasesReceivableRelatedParties" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLoansAndLeasesReceivableRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails" xlink:title="999076 - Disclosure - Schedule of Other Expense, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_RecognitionOfDeferredRevenueUponOptionExercise" xlink:label="loc_CDTRecognitionOfDeferredRevenueUponOptionExercise" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CDTRecognitionOfDeferredRevenueUponOptionExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_RecognitionOfDeferredRevenueUponOptionExerciseOne" xlink:label="loc_CDTRecognitionOfDeferredRevenueUponOptionExerciseOne" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CDTRecognitionOfDeferredRevenueUponOptionExerciseOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueOfOption" xlink:label="loc_CDTChangeInFairValueOfOption" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CDTChangeInFairValueOfOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueOfOptions" xlink:label="loc_CDTChangeInFairValueOfOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CDTChangeInFairValueOfOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueOfWarrantLiability" xlink:label="loc_CDTChangeInFairValueOfWarrantLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CDTChangeInFairValueOfWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ChangeInFairValueOfConvertibleNotePayment" xlink:label="loc_CDTChangeInFairValueOfConvertibleNotePayment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CDTChangeInFairValueOfConvertibleNotePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_GainOnDebtExtinguishment" xlink:label="loc_CDTGainOnDebtExtinguishment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CDTGainOnDebtExtinguishment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_IncomeTaxRefund" xlink:label="loc_CDTIncomeTaxRefund" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CDTIncomeTaxRefund" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossUnrealized" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnIssuanceOfOptionOne" xlink:label="loc_CDTLossOnIssuanceOfOptionOne" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CDTLossOnIssuanceOfOptionOne" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OtherIncomeUnrealizedForeignCurrencyTransactionLoss" xlink:label="loc_CDTOtherIncomeUnrealizedForeignCurrencyTransactionLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CDTOtherIncomeUnrealizedForeignCurrencyTransactionLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInterestExpenseOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnIssuanceOfWarrants" xlink:label="loc_CDTLossOnIssuanceOfWarrants" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CDTLossOnIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LossOnDebtExtinguishment" xlink:label="loc_CDTLossOnDebtExtinguishment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CDTLossOnDebtExtinguishment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OtherExpenseChangeInFairValueOfConvertibleNotesPayable" xlink:label="loc_CDTOtherExpenseChangeInFairValueOfConvertibleNotesPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CDTOtherExpenseChangeInFairValueOfConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OtherExpense" xlink:label="loc_CDTOtherExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CDTOtherExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails" xlink:title="999077 - Disclosure - Schedule of Black-Scholes Option Pricing Model (Details)">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureWarrantsAbstract" xlink:label="loc_CDTDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureWarrantsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/WarrantsDetailsNarrative" xlink:title="999078 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_DisclosureWarrantsAbstract" xlink:label="loc_CDTDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CDTDisclosureWarrantsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MarchLockUpAgreementMember" xlink:label="loc_CDTMarchLockUpAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTMarchLockUpAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AprilLockUpAgreementMember" xlink:label="loc_CDTAprilLockUpAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTAprilLockUpAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SubscriptionAgreementsMember" xlink:label="loc_CDTSubscriptionAgreementsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSubscriptionAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AprilTwentyTwentyFourWarrantsMember" xlink:label="loc_CDTAprilTwentyTwentyFourWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CDTAprilTwentyTwentyFourWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AGPTwentyTwentyFourWarrantsMember" xlink:label="loc_CDTAGPTwentyTwentyFourWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CDTAGPTwentyTwentyFourWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PIPEWarrantsMember" xlink:label="loc_CDTPIPEWarrantsMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CDTPIPEWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PublicWarrantMember" xlink:label="loc_CDTPublicWarrantMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CDTPublicWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_PrivatePlacementWarrantMember" xlink:label="loc_CDTPrivatePlacementWarrantMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CDTPrivatePlacementWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AllianceGlobalPartnersMember" xlink:label="loc_CDTAllianceGlobalPartnersMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CDTAllianceGlobalPartnersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_MurphyCanyonAcquisitionCorpMember" xlink:label="loc_CDTMurphyCanyonAcquisitionCorpMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_CDTMurphyCanyonAcquisitionCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaapSubsequentEventDescription" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSubsequentEventDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaapFairValueOptionChangesInFairValueGainLoss1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueOptionChangesInFairValueGainLoss1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails" xlink:title="999079 - Disclosure - Schedule of Financial Data for the Company&#8217;s Reportable Segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srtConsolidationItemsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtConsolidationItemsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaapOperatingSegmentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_us-gaapOperatingSegmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_NewLicensesMember" xlink:label="loc_CDTNewLicensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CDTNewLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_ClinicalAssetDevelopmentMember" xlink:label="loc_CDTClinicalAssetDevelopmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CDTClinicalAssetDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_LegalAndProfessionalFeesMember" xlink:label="loc_CDTLegalAndProfessionalFeesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CDTLegalAndProfessionalFeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AccountingAndAuditFeesMember" xlink:label="loc_CDTAccountingAndAuditFeesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CDTAccountingAndAuditFeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SalariesPayrollAndStockBasedCompensationMember" xlink:label="loc_CDTSalariesPayrollAndStockBasedCompensationMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CDTSalariesPayrollAndStockBasedCompensationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999080 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_OctoberTwentyTwentyFourNirlandNoteMember" xlink:label="loc_CDTOctoberTwentyTwentyFourNirlandNoteMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTOctoberTwentyTwentyFourNirlandNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_AugustTwentyTwentyFourNirlandNoteMember" xlink:label="loc_CDTAugustTwentyTwentyFourNirlandNoteMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTAugustTwentyTwentyFourNirlandNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_TwentyTwentyThreeConvertibleNoteMember" xlink:label="loc_CDTTwentyTwentyThreeConvertibleNoteMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CDTTwentyTwentyThreeConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_SalesAgreementMember" xlink:label="loc_CDTSalesAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CDTSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241231.xsd#CDT_CommissionsPayable" xlink:label="loc_CDTCommissionsPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_CDTCommissionsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 28, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CONDUIT
PHARMACEUTICALS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001896212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-3272543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4581
                                            Tamiami Trail North<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Naples<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">491-9132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,401,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,662,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingParValuePerShare', window );">Entity Listing, Par Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text">We
have audited the accompanying consolidated balance sheets of Conduit Pharmaceuticals Inc. (the &#8220;Company&#8221;) as of December
31, 2024 and 2023, the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; deficit and
cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial
statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the
Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period
ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Morristown, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CDT_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CDT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member', window );">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable
    Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CDTTW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CDT_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CDT_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 554<span></span>
</td>
<td class="nump">$ 4,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,715<span></span>
</td>
<td class="nump">5,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets. net</a></td>
<td class="nump">263<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">40<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other long-term assets</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,193<span></span>
</td>
<td class="nump">7,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,963<span></span>
</td>
<td class="nump">601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current portion</a></td>
<td class="nump">119<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible promissory note payable</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,741<span></span>
</td>
<td class="nump">1,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current portion</a></td>
<td class="nump">107<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liability</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred commission payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,738<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,986<span></span>
</td>
<td class="nump">7,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see note 15)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001; 250,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively, 1,384,801 shares and 738,295 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.0001; 1,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively; nil shares issued and outstanding at December 31, 2024 and December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">21,880<span></span>
</td>
<td class="nump">10,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(29,101)<span></span>
</td>
<td class="num">(11,299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(6,793)<span></span>
</td>
<td class="num">(457)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">4,193<span></span>
</td>
<td class="nump">7,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Convertible promissory notes payable at fair value</a></td>
<td class="nump">2,985<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Convertible promissory notes payable at fair value</a></td>
<td class="nump">2,871<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="nump">$ 425<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1,384,801<span></span>
</td>
<td class="nump">738,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">1,384,801<span></span>
</td>
<td class="nump">738,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 3,378<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">12,041<span></span>
</td>
<td class="nump">5,172<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">15,419<span></span>
</td>
<td class="nump">5,262<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(15,419)<span></span>
</td>
<td class="num">(5,262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(890)<span></span>
</td>
<td class="nump">4,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(1,506)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(2,383)<span></span>
</td>
<td class="nump">4,727<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(17,802)<span></span>
</td>
<td class="num">(535)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities', window );">Less: Change in fair value and income impact of option liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(5,521)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) - diluted</a></td>
<td class="num">$ (17,802)<span></span>
</td>
<td class="num">$ (6,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings/(net loss) per share</a></td>
<td class="num">$ (20.53)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings/(net loss) per share</a></td>
<td class="num">$ (20.53)<span></span>
</td>
<td class="num">$ (8.92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding</a></td>
<td class="nump">867,096<span></span>
</td>
<td class="nump">669,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares outstanding</a></td>
<td class="nump">867,096<span></span>
</td>
<td class="nump">678,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (264)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income (loss)</a></td>
<td class="num">$ (17,799)<span></span>
</td>
<td class="num">$ (799)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value and income impact of option liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Deficit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Previously Reported [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Previously Reported [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Previously Reported [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th">
<div>Previously Reported [Member] </div>
<div>AOCI Attributable to Parent [Member]</div>
</th>
<th class="th"><div>Previously Reported [Member]</div></th>
<th class="th">
<div>Revision of Prior Period, Error Correction, Adjustment [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Revision of Prior Period, Error Correction, Adjustment [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Revision of Prior Period, Error Correction, Adjustment [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th">
<div>Revision of Prior Period, Error Correction, Adjustment [Member] </div>
<div>AOCI Attributable to Parent [Member]</div>
</th>
<th class="th"><div>Revision of Prior Period, Error Correction, Adjustment [Member]</div></th>
<th class="th" colspan="2">
<div>Revision of Prior Period, Reclassification, Adjustment [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th" colspan="2">
<div>Revision of Prior Period, Reclassification, Adjustment [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th" colspan="2">
<div>Revision of Prior Period, Reclassification, Adjustment [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th" colspan="2">
<div>Revision of Prior Period, Reclassification, Adjustment [Member] </div>
<div>AOCI Attributable to Parent [Member]</div>
</th>
<th class="th" colspan="2"><div>Revision of Prior Period, Reclassification, Adjustment [Member]</div></th>
<th class="th" colspan="2"><div>Common Stock [Member]</div></th>
<th class="th" colspan="2"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th" colspan="2"><div>Retained Earnings [Member]</div></th>
<th class="th" colspan="2"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th" colspan="2"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date (Note 2)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,685<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,685<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge', window );">Issuance of common stock upon conversion of MURF Class A &amp; Class B common stock in connection with merger (Note 2)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(15,219)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(15,218)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing', window );">Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing (Note 2)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,779<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,779<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodValuePurchaseOfRevenue', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">151<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">151<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodValuePurchasesOfRevenue', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to Vela Technologies PLC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">544<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">544<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodValueIssuedForServicesOne', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger (Note 2)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger', window );">Reduction of excise tax liability associated with the Merger (Note2)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty', window );">Capital contribution - related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">150<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">150<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">199<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">199<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(264)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(264)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(535)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(535)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (10,764)<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
<td class="num">$ (10,089)<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">$ (6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (10,770)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 675<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (10,089)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">646,264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,735<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge', window );">Issuance of common stock upon conversion of MURF Class A &amp; Class B common stock in connection with merger, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">41,183<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing', window );">Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodSharesPurchaseOfRevenue', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,955<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodSharesPurchasesOfRevenue', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to Vela Technologies PLC, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodSharesIssuedForServicesOne', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(535)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption', window );">Issuance of Common Stock upon Exercise of Conversion Option</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,424<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11,299)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">411<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(457)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">738,295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(17,802)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(17,802)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense', window );">Correction of immaterial error related to franchise tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">144<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">144<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of Common Stock for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">242<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">242<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of Common Stock for services, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of Common Stock upon vesting of restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of Common Stock upon vesting of restricted stock units, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">745<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable', window );">Issuance of Common Stock for note payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">995<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">997<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable', window );">Issuance of Common Stock for note payable, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">95,045<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock for licensing right</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,567<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,568<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">125,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStock', window );">Issuance of Common Stock under the ATM Program</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,218<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,221<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStock', window );">Issuance of Common Stock under the ATM Program, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">323,273<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification', window );">Issuance of Common Stock in Exchange for Debt Modification</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">488<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">489<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification', window );">Issuance of Common Stock in Exchange for Debt Modification, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">39,193<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption', window );">Issuance of Common Stock upon Exercise of Conversion Option</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption', window );">Issuance of Common Stock upon Exercise of Conversion Option, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">23,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,890<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,890<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants', window );">Issuance of Common Stock Upon Exercise of Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">188<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">188<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants', window );">Issuance of Common Stock Upon Exercise of Warrants, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,632<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,632<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock Upon Exercise of Warrants, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 21,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (29,101)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 414<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (6,793)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,384,801<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="31"></td></tr>
<tr><td colspan="31"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassification
    is made as the impact of the retroactive application of the Merger can be shown as a reduction to additional paid-in capital during
    the period as presenting the reduction does not result in additional paid-in capital being presented as a negative for its ending
    balance.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Reclassification
    is made as additional paid-in capital cannot be presented as a negative for either its beginning or ending balance.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Shares
    of legacy common stock have been retroactively restated to give effect to the Merger.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital contribution - related party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital correction of immaterial error related to franchise tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital reduction of excise tax liability associated with merger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>StockIssuedDuringPeriodSharesIssuanceOfCommonStock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for note payable, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance of common stock in exchange for debt modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance of common stock upon conversion of common stock in connection with merge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance of common stock upon exercise of conversion option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance of common stock upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodSharesIssuedForServicesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issed during period shares issued for services one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodSharesIssuedForServicesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issed during period share issues in connection with pipe financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodSharesPurchaseOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares purchase of revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodSharesPurchaseOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodSharesPurchasesOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares purchases of revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodSharesPurchasesOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for note payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of common stock in exchange for debt modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of common stock upon conversion of common stock in connection with merge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stocki ssued during period value issuance of common stock upon exercise of conversion option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of common stock upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodValueIssuedForServicesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issed during period value issued for services one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodValueIssuedForServicesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issed during period value issues in connection with pipe financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodValuePurchaseOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value purchase of revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodValuePurchaseOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodValuePurchasesOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value purchases of revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodValuePurchasesOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,802)<span></span>
</td>
<td class="num">$ (535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_GainLossOnChangeInFairValueOfCizzleOption', window );">Gain on change in fair value of Cizzle option</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_GainOnChangeInFairValueOfVelaOption', window );">Gain on change in fair value of Vela option</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_LossOnIssuanceOfVelaOption', window );">Loss on issuance of Vela option</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ChangesInForeignCurrencyTransactionUnrealized', window );">Change in reserve for related party uncollectible loan</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment, net</a></td>
<td class="nump">707<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_LossOnRelatedPartyLoanForgiveness', window );">Loss on related party loan forgiveness</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_RealizedGainOnShorttermInvestments', window );">Realized gain on short-term investments</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax', window );">Unrealized foreign exchange gain</a></td>
<td class="nump">13<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_LossOnChangeInFairValueOfConvertibleNotesPayable', window );">Loss (gain) on change in fair value of convertible notes payable</a></td>
<td class="num">(2,018)<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain on change in FV of the warrants</a></td>
<td class="num">(221)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability', window );">Non-cash reduction of deferred income upon exercise of option liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_LossOnIssuanceOfWarrants', window );">Loss on issuance of warrants</a></td>
<td class="nump">2,710<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">89<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,632<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_IssuanceOfCommonStockForLicensingRight', window );">Issuance of Common Stock for licensing right</a></td>
<td class="nump">1,568<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_NoncashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">10<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization of financed Directors and Officers insurance</a></td>
<td class="nump">1,666<span></span>
</td>
<td class="nump">479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_AmortizationExpense', window );">Amortization Expense</a></td>
<td class="nump">447<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="nump">929<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock for services</a></td>
<td class="nump">202<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,273)<span></span>
</td>
<td class="num">(990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,030<span></span>
</td>
<td class="num">(1,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="num">(124)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent', window );">Intangible assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows from operating activities</a></td>
<td class="num">(9,682)<span></span>
</td>
<td class="num">(7,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Issuance of loan - related party</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(490)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from the sale of short-term investments</a></td>
<td class="nump">498<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ProceedsFromIssuanceOfOption', window );">Proceeds from issuance of option</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ProceedsFromLoanRepaymentRelatedParty', window );">Proceeds from loan repayment - related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">585<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows from investing activities</a></td>
<td class="num">(43)<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts', window );">Proceeds from Merger and related PIPE Financing, net of transaction costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from the issuance of notes payable &#8211; related parties</a></td>
<td class="nump">2,626<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from the issuance of notes payable &#8211; related parties</a></td>
<td class="nump">600<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty', window );">Capital contribution - related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares related to ATM program</a></td>
<td class="nump">3,328<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ProceedsFromExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">176<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="num">(776)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="nump">113<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible promissory note payable, carried at cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,286<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows from financing activities</a></td>
<td class="nump">6,067<span></span>
</td>
<td class="nump">10,929<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and cash equivalents before effect of exchange rate changes</a></td>
<td class="num">(3,658)<span></span>
</td>
<td class="nump">3,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash</a></td>
<td class="num">(3,674)<span></span>
</td>
<td class="nump">4,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">4,228<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">4,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of Use Asset obtained in exchange for Operating Lease Liabilities</a></td>
<td class="nump">352<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense', window );">Correction of immaterial error related to franchise tax expense</a></td>
<td class="nump">144<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption', window );">Issuance of Common Stock upon exercise of conversion option</a></td>
<td class="nump">92<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_IssuanceOfCommonStockInExchangeForDebtExtension', window );">Issuance of Common Stock in exchange for debt extension</a></td>
<td class="nump">489<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote', window );">Conversion of deferred commission payable to convertible promissory note</a></td>
<td class="nump">5,378<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC upon exercise of option</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to Vela Technologies PLC upon exercise of option</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReduction', window );">Exchange of Conduit Pharmaceuticals Limited convertible notes for shares of Conduit Pharmaceuticals Inc. common stock in connection with the Merger</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DeferredUnderwritingCosts', window );">Deferred Underwriting Costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger', window );">Prepaid expense of directors and officers insurance paid out of PIPE financings proceeds in connection with the Merger</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination', window );">Accumulated deficit assumed to APIC as a result of the business combination</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing', window );">Initial value of warrant liabilities issued in connection with PIPE Financing</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_NoncashAssetsAssumedInMergerFinancing', window );">Non-Cash Assets Assumed in the Merger Financing</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_NoncashLiabilitiesAssumedInMergerFinancing', window );">Non-Cash Liabilities Assumed in the Merger Financing</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated deficit assumed to Apic as result of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_AmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_AmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_AmortizationOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_AmortizationOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ChangesInForeignCurrencyTransactionUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in foreign currency transaction unrealized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ChangesInForeignCurrencyTransactionUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of deferred commission payable to convertible promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Correction of immaterial error related to franchise tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DeferredUnderwritingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriting costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DeferredUnderwritingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_GainLossOnChangeInFairValueOfCizzleOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on change in fair value of Cizzle option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_GainLossOnChangeInFairValueOfCizzleOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_GainOnChangeInFairValueOfVelaOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on change in fair value of Vela option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_GainOnChangeInFairValueOfVelaOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial value of warrant liabilities issued in connection with pipe financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_IssuanceOfCommonStockForLicensingRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for licensing right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_IssuanceOfCommonStockForLicensingRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_IssuanceOfCommonStockInExchangeForDebtExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in exchange for debt extension.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_IssuanceOfCommonStockInExchangeForDebtExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_LossOnChangeInFairValueOfConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on change in fair value of convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_LossOnChangeInFairValueOfConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_LossOnIssuanceOfVelaOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on issuance of Vela option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_LossOnIssuanceOfVelaOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_LossOnIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_LossOnIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_LossOnRelatedPartyLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on related party loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_LossOnRelatedPartyLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_NoncashAssetsAssumedInMergerFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash assets assumed in merger financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_NoncashAssetsAssumedInMergerFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_NoncashLiabilitiesAssumedInMergerFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash liabilities assumed in merger financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_NoncashLiabilitiesAssumedInMergerFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash reduction of deferred income upon exercise of option liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expense of directors and officers insurance paid included in Apic in connection with merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital contribution related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ProceedsFromIssuanceOfOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ProceedsFromIssuanceOfOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ProceedsFromLoanRepaymentRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from loan repayment - related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ProceedsFromLoanRepaymentRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Merger and related PIPE Financing, net of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_RealizedGainOnShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Realized gain on shortterm investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_RealizedGainOnShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stocki ssued during period value issuance of common stock upon exercise of conversion option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-38<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in intangible assets (for example patents and licenses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (17,802)<span></span>
</td>
<td class="num">$ (535)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in the biotechnology sector, which is subject to various cybersecurity risks that could adversely affect our business,
financial condition, and results of operations, including intellectual property theft; fraud; extortion; harm to employees or
customers; violation of privacy laws and other litigation and legal risk; and reputational risk. We have implemented a risk-based
approach to identify and assess the cybersecurity threats that could affect our business and information systems. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zPoYDOIWgNB8">We
have implemented a risk-based approach to identify and assess cybersecurity threats that could impact our business and information
systems. As part of this strategy, the Company has engaged a third-party service provider to implement comprehensive IT and
cybersecurity policies, including Guardz, Cyber Essentials, and others. These initiatives are supported by detailed policies, staff
training programs, and the use of advanced tools such as firewalls and VPNs to prevent cybersecurity incidents. Additionally,
consultation with third-party experts has further strengthened the Company&#8217;s IT framework and improved overall compliance. We
require third-party service providers with access to personal, confidential or proprietary information</span> to implement and
maintain comprehensive cybersecurity practices consistent with applicable legal standards and industry best practices.</span>&#160;<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has engaged a third-party service provider
to implement comprehensive IT and cybersecurity policies, including Guardz, Cyber Essentials, and others. These initiatives are supported
by detailed policies and staff training programs, which have strengthened the Company&#8217;s IT framework and improved compliance.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
light of the pervasive and increasing threat from cyberattacks, the Company&#8217;s <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zCmPOEA4fMO7">Board
of Directors and the Audit Committee, with input from management, assess the Company&#8217;s cybersecurity threats </span>and the
measures implemented by the Company to mitigate and prevent cyberattacks. The <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_dbT_c20240101__20241231_zhFBMgui0wy3">Audit
Committee consults with management regarding ongoing cybersecurity initiatives, and requests management to report </span>to the
Audit Committee or the full Board regularly on their assessment of the Company&#8217;s cybersecurity program and risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, the Company is not aware of any risks from cybersecurity threats that have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240101__20241231_zxFc8G9jBSJc">materially affected or
are reasonably likely to materially affect the Company, including its business strategy, results of operations, or financial condition.</span></span></p>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Audit
Committee consults with management regarding ongoing cybersecurity initiatives, and requests management to report <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zdVkDUL0Skpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82B_z21UO3OlmiQb">Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit
Pharmaceuticals Inc., a Delaware corporation (&#8220;Conduit&#8221; or the &#8220;Company&#8221;), is a clinical-stage specialty
biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets. The Company has
developed a unique business model that allows it to act as a conduit to bring clinical assets from pharmaceutical companies and
develop new treatments for patients. Our novel approach addresses unmet medical needs and lengthens the intellectual property for
our existing assets through cutting-edge solid-form technology with the expectation of commercializing these products with life
science companies. </span>Our initial development plan is to conduct a Phase II clinical trial on AZD1656 in Lupus (including Lupus
Nephritis) and ANCA Vasculitis (AAV). We anticipate developing our Initial Pipeline (which has already undergone pre-clinical and
clinical trials) through the Phase II stage and then monetizing such clinical assets through a license, royalty, or other
transaction at this stage. At this time, we do not expect that we will commercialize any clinical assets or seek marketing approval
from the FDA (or similar organizations) as we intend to enter into agreements with third parties following Phase II clinical trials
for each such clinical asset that would provide that such third party would pursue the further development, commercialization, and
marketing of such assets.</p>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Merger
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2023 (the &#8220;Closing Date&#8221;), a merger transaction between Conduit Pharmaceuticals Limited (&#8220;Old Conduit&#8221;),
Murphy Canyon Acquisition Corp (&#8220;MURF&#8221;) and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly owned
subsidiary of MURF (&#8220;Merger Sub&#8221;), was completed (the &#8220;Merger&#8221;, see Note 2) pursuant to the initial merger agreement
dated November 8, 2022 and subsequent amendments to the merger agreement dated January 27, 2023 and May 11, 2023 (together, the &#8220;Merger
Agreement&#8221;). Pursuant to the terms of the Merger Agreement, on the Closing Date, (i) Merger Sub merged with and into Old Conduit,
with Old Conduit surviving the merger as a wholly-owned subsidiary of MURF, and (ii) MURF changed its name from Murphy Canyon Acquisition
Corp. to Conduit Pharmaceuticals Inc. The common stock of the Company (the &#8220;Common Stock&#8221;) commenced trading on The Nasdaq
Global Market under the symbol &#8220;CDT&#8221; on September 25, 2023, and the Company&#8217;s warrants commenced trading on The Nasdaq
Capital Market under the symbol &#8220;CDTTW&#8221; on September 25, 2023. On March 7, 2025, the Company filed an application to list our Common Stock on The Nasdaq Capital Market as part
of our plan to regain compliance with all NASDAQ rules. See Note 20 for additional details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Merger was accounted for as a reverse recapitalization in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;). Under the reverse recapitalization method, MURF was treated as the acquired company for financial
reporting purposes, and the accounting acquirer was assumed to have issued shares of stock for the net assets of MURF, with no goodwill
or other intangible assets recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared by the Company in accordance with U.S. GAAP as set forth by the Financial
Accounting Standards Board (&#8220;FASB&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange
Commission (&#8220;SEC&#8221;). References to U.S. GAAP issued by the FASB in these notes to the accompanying consolidated financial
statements are to the FASB Accounting Standards Codifications (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASUs&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Principles
of Consolidation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the accounts of Conduit Pharmaceuticals, Inc. and its wholly owned subsidiaries
Conduit UK Management Ltd. (United Kingdom) and Conduit Pharmaceuticals, Ltd. (Cayman Islands). As used herein, references to the &#8220;Company&#8221;
include references to Conduit Pharmaceuticals, Inc, and its subsidiaries. All intercompany balances and transactions have been eliminated
in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
and Going Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate,
that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial
statements are issued. Since its inception, the Company has generated significant losses and as of December 31, 2024, the Company had
an accumulated deficit of $<span id="xdx_901_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zj4o87HU4pTh" title="Accumulated deficit">29.1</span> million. As of December 31, 2024 and December 31, 2023, the Company had cash and cash equivalents and
short-term investments of $<span id="xdx_903_eus-gaap--Cash_iI_pn5n6_c20241231_zn0jMmbhI3x7" title="Cash and cash equivalents"><span id="xdx_903_eus-gaap--Cash_iI_pn5n6_c20231231_zw7Y2hvtVDs3" title="Cash and cash equivalents">0.6</span></span> million and $<span id="xdx_90D_eus-gaap--ShortTermInvestments_iI_pn5n6_c20241231_zRUEM8rneAkg" title="Short term investments"><span id="xdx_90E_eus-gaap--ShortTermInvestments_iI_pn5n6_c20231231_zvDMqDwwSH11" title="Short term investments">4.2</span></span> million, respectively. For the year ended December 31, 2024 and 2023, the Company had
net operating losses of $<span id="xdx_901_eus-gaap--OperatingIncomeLoss_iN_pn5n6_di_c20240101__20241231_zHLAYgQY1vva" title="Net loss">15.4</span> million and $<span id="xdx_907_eus-gaap--OperatingIncomeLoss_iN_pn5n6_di_c20230101__20231231_zioLWMcGsLy9" title="Net loss">5.3</span> million, respectively, and cash used in operating activities of $<span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zcXo0VEgDcmf" title="Operating activities">9.7</span> million and $<span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20231231_z5au0uVxXQ9f" title="Operating activities">7.7</span>
million, respectively. Management has determined that it does not have sufficient cash and other sources of liquidity to fund its current
business plan. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern for at least
the next 12 months from the financial statement filing date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s expectation is to generate operating losses and negative operating cash flows in the future and will need additional
funding to support its current business plan in addition to the remaining at the market offering program (the &#8220;Sales
Agreement&#8221;) of $<span id="xdx_90A_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20241231_zifFDEbaRNuc" title="Offering costs">12.0</span> million (See Note 20), as of the financial statement release date. Management&#8217;s plans to alleviate the
conditions that raise substantial doubt through the pursuit of additional cash resources through public or private equity or debt
financings. However, there is no assurance that such funding will be available when needed or on acceptable terms. If additional
funding is not available when required, the Company would need to delay or curtail its operations and its research and development
activities until such funding is received, all of which could have a material adverse effect on the Company and its financial
condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements have been prepared assuming the Company will continue as a going concern and do not include adjustments to reflect
the possible effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result
from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2025, the Company amended its Second Amended and Restated Certificate of Incorporation with the Secretary of State of the
State of Delaware in order to effect a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20250124__20250124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9DL8phwKiq" title="Reverse stock split">1-for-100</span> reverse stock split of its outstanding shares of common stock (the &#8220;Reverse Stock
Split&#8221;). As a result of the reverse stock split, every 100 shares of the Company&#8217;s common stock issued or outstanding were
automatically reclassified into one new share of common stock, subject to the treatment of fractional shares as described below, without
any action on the part of the holders. All historical share and per-share amounts reflected throughout the accompanying consolidated
financial statements and other financial information in this Annual Report on Form 10-K have been retroactively adjusted to reflect the
2025 Reverse Stock Split as if the split occurred as of the earliest period presented. The Reverse Stock Split did not affect the number
of authorized shares of common stock or the par value of the common stock. No fractional shares were issued in connection with the Reverse
Stock Split. Stockholders who would otherwise have been entitled to receive fractional shares as a result of the Reverse Stock Split
were entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled
multiplied by the closing price per share of the common stock (as adjusted to give effect to the Reverse Stock Split) on The Nasdaq Global
Market on January 24, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Risks and Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to companies in the development stage and pharmaceutical industry including, but not limited to, uncertainties
related to pre-clinical and clinical outcomes competitor products, regulatory approvals, dependence on key products, dependence on key
suppliers and protection of intellectual property rights (see note 15 for details on a claim against our AZD 1656 co-crystal patent).
Clinical assets currently under development will require significant additional research and development efforts, including extensive
preclinical and clinical testing and regulatory approval prior to commercialization. These efforts will require significant amounts of
additional capital, adequate personnel, infrastructure, and extensive compliance and reporting capabilities. Even if the Company&#8217;s
efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from royalties or product sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company licenses clinical assets from AstraZeneca. See Note 10. If there is a breach or other termination of such agreements, there could
be a material adverse effect on the Company&#8217;s business, financial condition, operating results, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is also subject
to risks associated with the Nasdaq Stock Market Correspondence and Subsequent Nasdaq Capital Market Listing. See note 20 for further
details.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Significant Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9N5EBnEnmaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zIe5vxmUeFeg">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents are primarily maintained with major financial institutions in the United States, United Kingdom, and Switzerland.
The Company considers cash equivalents to be short-term, highly liquid investments that (a) are readily convertible into known amounts
of cash, (b) are traded and held for cash management purposes, and (c) have original maturities of three months or less at the time of
purchase. The Switzerland bank accounts holding cash balances are uninsured, and the UK bank account, with a year-end balance of approximately
&#163;<span id="xdx_905_eus-gaap--CashUninsuredAmount_iI_uGBP_c20241231_zQI4bUKQnUY6" title="Cash, uninsured amount">100,000</span> (or approximately $<span id="xdx_904_eus-gaap--CashUninsuredAmount_iI_c20241231_zaGRR62Uw4Z9">125,000</span>) exceeds the country&#8217;s deposit limit of &#163;<span id="xdx_90F_eus-gaap--DepositAssets_iI_uGBP_c20241231_z3ShePxF9WH1" title="Deposit assets">85,000</span> (approximately $<span id="xdx_90C_eus-gaap--DepositAssets_iI_c20241231_z0WdGHQohBQ4" title="Deposit assets">107,000</span>). The Company&#8217;s
US depository bank participates in the Demand Deposit Marketplace program, insuring deposits up to $<span id="xdx_900_eus-gaap--DemandDepositAccounts_iI_pn5n6_c20241231_zfZWgquLidRl" title="Demand deposit accounts">10</span> million by sweeping amounts in
excess of the $<span id="xdx_903_ecustom--DepositInsuranceLimit_iI_c20241231_ziy0DytOkTc4" title="Deposit insurance limit">250,000</span> deposit insurance limit among participating banks. The Company has not experienced any losses on any accounts
through the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_z2fXvuCTKKHd">0.6</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
and $<span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_z8CmV6dzZ03l">4.2</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
in cash and cash equivalents on hand as of December 31, 2024 and December 31, 2023, respectively. As of December 31, 2024, $<span id="xdx_908_ecustom--CashAndCashEquivalentsNetBankOverdrafts_iI_pn5n6_c20241231_zOWaCmXXcOL1" title="Cash and cash equivalents net bank overdrafts">0.2
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of the Company&#8217;s $<span id="xdx_904_ecustom--CashAndCashEquivalentsNetBankOverdrafts_iI_pn5n6_c20231231_zbpgW4zK93r1" title="Cash and cash equivalents net bank overdrafts">0.6
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million cash and cash equivalents balance was
invested in money market funds. The money market funds do not have significant liquidity restrictions that would require the exclusion
from cash and cash equivalents.</span></p>

<p id="xdx_84D_eus-gaap--MarketableSecuritiesPolicy_z11uILEwtqR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zr2oaR3Pft5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zGvFhdFehme6">Property,
Plant and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment are initially recorded at cost. Depreciation and amortization are computed using the straight-line method over the
estimated useful lives of the assets or, for leasehold improvements, the life of the lease, if shorter. When assets are retired or otherwise
disposed of, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected
in other income or expense for the period. As of December 31, 2024, property, plant and equipment primarily consisted of leasehold improvements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zFWyZzHoR1O1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zYTsYzI9vQQ1">Leases</span>
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 842, Leases (ASC 842), the Company records a right-of-use (ROU) asset and a lease liability on the balance sheet
for all leases with terms longer than 12 months and classifies them as either operating or finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and
circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset,
whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has
the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets,
lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases
with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components,
the Company has elected not to allocate the contract consideration, and to account for the lease and non-lease components as a single
lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term.
The implicit rate within our operating leases is generally not determinable and, therefore, the Company uses the incremental borrowing
rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#8217;s incremental
borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing
rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The
operating lease ROU asset also includes any lease prepayments, offset by lease incentives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain
we will exercise that option. An option to terminate is considered unless it is reasonably certain we will not exercise the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--UseOfEstimates_zY7dhmJYGLo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zuZg498GV7R2">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial
statements as well as the reported amounts of revenues and expenses during the reporting period. Estimates are based on several factors
including the facts and circumstances available at the time the estimates are made, historical experience, risk of loss, general economic
conditions and trends, and the assessment of the probable future outcome. Actual results could differ materially from such estimates.
Estimates and assumptions are reviewed periodically by management and changes in estimates are made as management becomes aware of changes
in circumstances surrounding the estimates. The effects of changes are reflected in the financial statements in the period that they
are determined.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z0hboc6fhfs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zw3w6L0i2dUl">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 820, <i>Fair Value Measurements and Disclosures</i>, defines fair value, establishes a framework for measuring fair value, and
expands disclosures about fair value measurements. Fair value is to be determined based on the exchange price that would be received
for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants. In determining fair value, the Company used various valuation approaches. A fair
value hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes
the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that
market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
inputs reflect the Company&#8217;s assumption about the inputs that market participants would use in pricing the asset or liability developed
based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the
inputs, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1&#8212;Valuations based on quoted prices for identical instruments in active markets. Since valuations are based on quoted prices
    that are readily and regularly available in an active market, valuation of these instruments does not entail a significant degree
    of judgment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2&#8212; Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for either similar
    instruments in active markets, identical or similar instruments in markets that are not active, or model-derived valuations whose
    inputs or significant value drivers are observable or can be corroborated by observable market data.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3&#8212;Valuations based on inputs that are unobservable. These valuations require significant judgment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Level 1 assets consist of cash and cash equivalents, including money market funds, in the accompanying balance sheets
and the value of accrued expenses and other current liabilities approximate fair value due to the short-term nature of these assets and
liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company has two financial liabilities, warrant liabilities for which the fair value is determined based on
Level 2 and Level 3 inputs, and convertible debt carried at fair value for which the fair value is
determined based on Level 3 input. The Level 2 inputs are valued based on observable inputs other than quoted
prices included in Level 1, such as quoted prices for similar instruments in active markets. The level 3 inputs as such inputs are based
on unobservable inputs and require significant judgement. As of December 31 2023, the Company has one financial liability, a warrant liability for which the fair value is determined
based on Level 2 inputs as such inputs are valued based on observable inputs other than quoted prices included in Level 1, such as
quoted prices for similar instruments in active markets.  See Note 3 for further information on the Company&#8217;s
financial liabilities carried at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--FairValueTransferPolicyPolicyTextBlock_zmMVpIcF9dy7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zJ210n5wYSd8">Fair
Value Option</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected the fair value measurement option for convertible debt with embedded derivatives that would otherwise require bifurcation
and has recorded the entire hybrid financial instrument at fair value under the guidance in ASC 825, Financial Instruments. As a result,
the August 2024 Nirland Note was recorded at fair value subsequent to the Second Amendment and the A.G.P. Convertible Note was recorded
at fair value upon issuance. The notes will subsequently be remeasured at fair value each reporting date until settled or converted.
The Company reports interest expense, including accrued interest, related to the convertible debt under the fair value option, separately
from within the change in fair value of the convertible debt in the accompanying consolidated statement of operations and comprehensive
income (loss). Any changes in fair value caused by instrument-specific credit risk are presented separately in other comprehensive income.
During the year ended December 31, 2024, the Company did not record any changes in fair value related to instrument-specific credit risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zmqny0wbGnq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zWcwKdDcWrMc">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred in connection with the research and development of our clinical assets
and programs, see Note 10 for further discussion of research and development expense. Conduit holds all licenses to conduct clinical
research through a third-party pharmaceutical company. The Company expenses research and development costs and intangible assets
acquired that have no alternative future use as incurred. These expenses include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred under agreements with organizations that support the Company&#8217;s drug discovery and development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred in connection with the preclinical and clinical development of the Company&#8217;s clinical assets and programs, including
    under agreements with contract research organizations, or CROs&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to contract manufacturing organizations, or CMOs, that are primarily engaged to provide drug substance and product for our
    clinical trials, research and development programs, as well as investigative sites and consultants that conduct the Company&#8217;s
    clinical trials, nonclinical studies and other scientific development services&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing registration and validation
    batches&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related
    expenses, including salaries, related benefits and equity-based compensation expense, for employees engaged in research and development
    functions&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">acquisition costs related to the purchase of licensed intellectual property;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to compliance with quality and regulatory requirements&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments
    made under third-party licensing agreements&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">direct
    and allocated costs related to facilities, information technology, personnel and other overhead.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance
payments that we make for goods or services to be received in the future for use in research and development activities are recorded
as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or consumed or the related services are performed,
or until it is no longer expected that the goods will be delivered, or the services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_znRfGS37jvN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zZOsh9rAdqGa">General
and Administrative Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries and related costs for personnel in executive management, finance, corporate
and business development, and administrative functions. General and administrative expenses also include legal fees relating to patent
and corporate matters&#894; professional fees for accounting, auditing, tax, and administrative consulting services&#894; insurance costs&#894;
administrative travel expenses and other operating costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zpAczA2q79t5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z0NlpMWvYCrg">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 740, <i>Income Taxes</i>, sets forth standards for financial presentation and disclosure of income tax liabilities and expense.
Interest and penalties recognized have been classified in the consolidated statements of operations and comprehensive income (loss) as
income taxes. Deferred tax assets and liabilities are recognized for future tax consequences attributable to temporary differences between
the financial statement carrying amount of existing assets and liabilities and their respective tax bases and operating losses carried
forward. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change
in tax rates is recognized in the consolidated statements of operations and comprehensive income (loss) in the period that includes the
enactment date. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits of which
future realization is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zJkBnbjryKMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zWQwRNE8GDh2">Earnings/(Net
Loss) per Share</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates basic and diluted earnings/(net loss) per share under ASC Topic 260, <i>Earnings Per Share</i>. Basic earnings/(net
loss) per share is computed by dividing the net income/(loss) by the number of weighted-average common shares outstanding for the period.
Diluted earnings/(net loss) is computed by adjusting net income/(loss) based on the impact of any dilutive instruments. Diluted earnings/(net
loss) per share is computed by dividing the diluted net income/(loss) by the number of weighted-average common shares outstanding for
the period including the effect, if dilutive, of any instruments that can be settled in common shares. When computing diluted net income/(loss)
per share, the numerator is adjusted to eliminate the effects that have been recorded in net income/(loss) (net of tax, if any) attributable
to any liability-classified dilutive instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--WarrantInstrumentsPolicyTextBlock_zb3ifZGf9Nf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_86C_zZCtQMd1f6Ne" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the accounting classification of Warrants as either liability or equity by first assessing whether the Warrants meet
liability classification in accordance with ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;). Under ASC 480, a
financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies
a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares must be classified as
a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly
on any one of the following: (a) a fixed monetary amount known at inception; (b) variations in something other than the fair value of
the issuer&#8217;s equity shares; or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
financial instruments, such as the Warrants, are not required to be classified as liabilities under ASC 480, the Company assesses whether
such instruments are indexed to the Company&#8217;s own stock under ASC 815-40. In order for an instrument to be considered indexed to
an entity&#8217;s own stock, its settlement amount must always equal the difference between the following: (a) the fair value of a fixed
number of the Company&#8217;s equity shares, and (b) a fixed monetary amount or a fixed amount of a debt instrument issued by the Company.
The Company determined that the settlement amount of the Equity Classified Warrants would equal the difference between the fair value
of a fixed number of shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified as equity, while
the settlement amount of the Liability Classified Warrants would not equal the difference between the fair value of a fixed number of
shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified as a liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Equity Classified Warrants are recorded in stockholders&#8217; deficit and the Liability Classified Warrants are recorded as liabilities
in the Consolidated Balance Sheet. The Liability Classified Warrants are remeasured each period with changes in fair value recorded in
the Consolidated Statements of Operations and Comprehensive Income (Loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zfXSfxa44aaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zTvJEe4YQyb5">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company translated the assets and liabilities of foreign subsidiaries from their respective functional currency, the British pound, to
United States dollars at the appropriate spot rates as of the balance sheet date. Income and expenses of operations are translated to
United States dollars using weighted average exchange rates during the year. The foreign subsidiaries use the local currency as their
functional currency. The effects of foreign currency translation adjustments are included as a component of accumulated other comprehensive
income in the accompanying consolidated statements of changes in stockholders&#8217; deficit. Non-monetary items in the subsidiaries&#8217;
functional currency are re-measured into the reporting currency at the historical exchange rate (i.e., the rate of exchange at the date
of the transaction).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zviwSQVWkuNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zT0gOeUHmSN7">Emerging
Growth Company Status</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under
the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of
the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period
for complying with new or revised accounting standards that have different effective dates for public and private companies until the
earlier of the date that: (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended
transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with
the new or revised accounting pronouncements as of public company effective dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Merger, the Company will remain an emerging growth company, as defined by the Jumpstart Our Business Startups act of 2012, until
the earliest of <span id="xdx_906_ecustom--DescriptionForEmergingGrowthCompany_c20240101__20241231_zjcsk4iASiNa" title="Emerging growth description">(i) the last day of the combined entity&#8217;s first fiscal year following the fifth anniversary of the completion of
MURF&#8217;s initial public offering (the &#8220;MURF IPO&#8221;), (ii) the last day of the fiscal year in which the combined entity
has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the combined entity is deemed
to be a large accelerated filer, which means the market value of the combined entity&#8217;s common stock that is held by non-affiliates
exceeds $700.0 million as of the prior December 31st or (iv) the date on which the combined entity has issued more than $1.0 billion
in non-convertible debt securities during the prior three year period.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1ZDVaMonHk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zZTzVojdLiYe">Recently
Adopted Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) (&#8220;ASU 2023-07&#8221;), which enhances the segment disclosure
requirements for public entities on an annual and interim basis. Under this proposal, public entities are required to disclose significant
segment expenses that are regularly provided to the chief operating decision maker (the &#8220;CODM&#8221;) and included within each
reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#8217;s profit or loss
and assets will be required on an interim basis. Entities are also required to disclose information about the CODM&#8217;s title and
position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment
of segment performance and deciding whether how to allocate resources. Finally, ASU 2023-07 requires all segment disclosures for public
entities, even those with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023,
and interim periods within fiscal years beginning after December 15, 2024, and should be applied on a retrospective basis to all periods
presented. As of December 31, 2024, the Company only has one reportable segment. The Company adopted this accounting standard as of January
1, 2024. See Note 19 for the Company&#8217;s segments disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_845_ecustom--NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_zn0GSboqcEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zzGJPSdxsV7b">Recently
Issued Accounting Standards Not Yet Adopted</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;).
ASU 2023-09 modifies the reporting requirements for income tax disclosures related to effective tax rates and cash income taxes paid.
Pursuant to ASU 2023-09, public business entities are required to disclose certain categories in the income tax rate reconciliation,
as well as additional information for reconciling items that meet a specific quantitative threshold. Additionally, ASU 2023-09 requires
annual disclosures of income taxes paid for all entities, including the amount of income taxes paid, net of refunds received, disaggregated
by federal, state, and foreign jurisdictions. The standard is effective for fiscal years beginning after December 15, 2024, with early
adoption permitted. The Company is currently evaluating the impact of ASU 2023-09 on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, which is intended to provide more detailed information about specified categories
of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented
on the consolidated statements of operations and comprehensive income (loss). The guidance in this ASU is effective for fiscal years
beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted.
The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU
or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the
impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</span></p>

<p id="xdx_850_zuQfE7pbO0X1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger and Financing<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Merger and Financing</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--BusinessCombinationDisclosureTextBlock_zOt19ohlSSL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_82C_zrSPVGUYkYpe">Merger and Financing</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 1 &#8211; <i>Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies</i>, on September
22, 2023, the Company and MURF completed the Merger. Upon the closing of the Merger, the following occurred:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    share of Old Conduit common stock issued and outstanding immediately prior to the closing of the Merger, which totaled <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--OldConduitPharmaceuticalsLimitedMember_zRQc7HVorekl" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--OldConduitPharmaceuticalsLimitedMember_zecslu5V7UJk" title="Common stock, shares outstanding">2,000</span></span> shares,
    was exchanged for the right to receive <span id="xdx_905_eus-gaap--NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRjBoli97ZZf" title="Business acquisition right to receive number of shares">323</span> shares of the Company&#8217;s Common Stock (&#8220;Common Stock&#8221;) resulting
    in the issuance of <span id="xdx_90E_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrp2eqWJhe59" title="Number of shares issued">646,264</span> shares of Conduit Pharmaceuticals, Inc. Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition to the shares issued to legacy Conduit shareholders noted above, an additional <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__custom--ConduitConvertibleNoteHoldersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk5FXvbXgJOi" title="Shares issued after merger">3,735</span> shares of Common Stock was issued
    to Conduit convertible note holders, resulting in a total of <span id="xdx_901_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__custom--ConduitShareHoldersandConvertibleNoteHoldersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znGJEvbid2U1" title="Number of shares issued">650,000</span> shares of Common Stock being issued to Conduit shareholders
    and holders of Conduit convertible notes payable.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    connection with the Merger, <span id="xdx_90E_ecustom--BusinessAcquisitionNumberOfSharesTransferred_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zLdIrzuOdHYa" title="Number of shares transferred">450</span> shares of MURF Class A common stock held by the MURF Sponsor was transferred to MURF Directors. Each
    share was exchanged on a <span id="xdx_906_eus-gaap--CommonStockConversionBasis_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zXUotxubHbF5" title="Common stock conversion basis">one-for-one basis</span> for shares of Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    share of MURF Class A common stock held by the MURF Sponsor prior to the closing of the Merger, which totaled <span id="xdx_901_ecustom--BusinessAcquisitionNumberOfSharesTransferred_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2ZrROw2Xi8k" title="Number of shares transferred">7,090</span> shares, was exchanged
    for, on a one-for-one basis for shares of Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    share of MURF common stock subject to possible redemption that was not redeemed prior to the closing of the Merger, which totaled
    <span id="xdx_90C_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxZoPEBM1ppk" title="Number of shares held prior to business combination">580</span> shares, was exchanged for, on a one-for-one basis for shares of Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    connection with the Merger, <span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zfqLcnhQ43gb" title="Number of shares converted">33,062</span> shares of MURF Class B common stock held by the Sponsor was automatically converted into shares
    of MURF Class A common stock and then subsequently converted into shares of Common Stock on a one-for-one basis.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    connection with the Merger, A.G.P./Alliance Global Partners (&#8220;A.G.P.&#8221;), whom acted as a financial advisor to both MURF
    and Conduit, was due to receive (i) a cash fee of $<span id="xdx_90C_eus-gaap--ProfessionalFees_pn5n6_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zBVaLTSO4OWe" title="Cash fee">6.5</span> million, <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zlPFvmw6ogT7" title="Shares issued for services">13,000</span> shares of Common Stock and warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pp0p0_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zD9AOimPgLB6" title="Warrants to purchase common stock">540</span> shares
    of Common Stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zFuk1ZCZna11" title="Exercise price of warrants">1,100</span> per share pursuant to its engagement agreement with Conduit entered into on August
    2, 2022 and (ii) $<span id="xdx_90D_ecustom--DeferredUnderwritingFee_pn5n6_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zwnSjHyICE71" title="Deferred underwriting fee">4.6</span> million of deferred underwriting fees as a result of its engagement for MURF&#8217;s initial public offering.
    Upon closing of the Merger, A.G.P. received a cash payment of $<span id="xdx_909_ecustom--PaymentForAdvisoryServices_pn5n6_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zoIjICMLxc6l" title="Financial advisory fee">5.6</span> million, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zE0SCy0Cjo39" title="Shares issued for services">13,000</span> shares of Common Stock, and <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zXoL0YwQYmwj">540 </span>warrants to purchase
    <span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesStockWarrantsExercised_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zRFVq2FtqWSi" title="Warrants to purchase common stock">540</span> shares of Common Stock. The remaining $<span id="xdx_905_ecustom--DeferredCashPaymentsAmount_iI_pn5n6_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zKI5msY6RDX7" title="Cash payments due">5.7</span> million of cash payments due to A.G.P upon closing of the Merger was deferred and
    to be paid on or before March 21, 2025, with annual interest of <span id="xdx_907_ecustom--AnnualInterestRate_iI_pid_dp_uPure_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zrmPDhU5WAkh" title="Interest rate">5.5</span>%. The remaining cash payments due, which were directly attributable
    to the Merger, were accounted for as a liability with an offset to additional paid-in capital in accordance with SAB Topic 5.A on
    the Company&#8217;s consolidated balance sheet. See Note 7 for discussion of amendment of the note that took place during the year ended December 31, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    connection with the Merger, MURF entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with certain accredited
    investors (the &#8220;PIPE Investors&#8221;) for an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zPU344Rnltmd" title="Shares issued during the period">20,000</span> units, with each unit consisting of one share of Company
    common stock (the &#8220;PIPE Shares&#8221;), together with one warrant exercisable into one share of Company common stock (the &#8220;PIPE
    Warrants&#8221;), at a purchase price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zaaaJ8VZeLuh" title="Shares issued, purchase price">1,000</span> per unit, for an aggregate purchase price of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z1M3Ea2YVfw4" title="Shares issued during the period, value">20,000,000</span> (the &#8220;PIPE Financing&#8221;).
    Upon the closing of the PIPE Financing (which closed in connection with the closing of the Merger), the Company received $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zgPeYyITNGce" title="Proceeds from issuance of common stock">20.0</span> million
    in cash from the PIPE Financing, which was used to settle related party promissory notes issued by MURF to the MURF Sponsor and an
    affiliate of the MURF Sponsor as well as transaction costs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    proceeds received by the Company from the Merger and PIPE Financing, net of transaction costs, and other payments for existing liabilities
    and prepayments, totaled $8.5 million.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, MURF was treated
    as the acquired company for financial reporting purposes (see Note 1 for further details). Accordingly, for accounting purposes,
    the Merger was treated as the equivalent of the Company issuing shares for the net assets of MURF, accompanied by a recapitalization.
    The net assets of MURF were stated at historical cost with no goodwill or other intangible assets recorded.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zMHzmmRuPXxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the total Common Stock outstanding immediately after the closing of the Merger:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zmRwfzhSC5Zh" style="display: none">Schedule
of Common Stock Outstanding</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Exchange of MURF common stock subject to possible redemption for Conduit Pharmaceuticals Inc. common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pip0_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis__us-gaap--CommonStockSubjectToMandatoryRedemptionMember_z1RCLOhnbOLe" title="Exchange of MURF common stock subject to possible redemption for Conduit Pharmaceuticals Inc. common stock, shares">580</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exchange of MURF Class A common stock held by MURF Directors for Conduit Pharmaceuticals Inc. common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxC6b0h09OHk" title="Exchange of MURF Class A common stock held by MURF Directors for Conduit Pharmaceuticals Inc. common stock, shares">450</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Exchange of MURF Class A common stock held by MURF Sponsor for Conduit Pharmaceuticals Inc. common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxfpbvUTjoS8" title="Exchange of MURF Class A common stock held by MURF Sponsor for Conduit Pharmaceuticals Inc. common stock, shares">40,152</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Subtotal - Merger, net of redemptions</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zozAQ9XrK4gi" title="Business Combination, net of redemptions, shares">41,182</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3CppKDwcUa5" title="Issuance of Conduit Pharmaceuticals, Inc. common stock in connection with PIPE Financing, shares">20,000</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Exchange of Conduit Pharmaceuticals Limited ordinary shares for Conduit Pharmaceuticals Inc. common stock on the Closing Date</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWY0VDeUjWld" title="Exchange of Conduit Pharmaceuticals Limited ordinary shares for Conduit Pharmaceuticals Inc. common stock on the Closing Date, shares">646,264</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXQi6JjWROI5" title="Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date,shares">3,735</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxuWF0bLXB76" title="Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the transaction, shares">13,000</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total - Conduit Pharmaceuticals Inc. common stock outstanding as a result of the Merger, PIPE Financing, exchange of Conduit Pharmaceuticals Limited shares for shares of Conduit Pharmaceuticals Inc., issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes, and advisors.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zAbAtWqta8i2" title="Total - Conduit Pharmaceuticals Inc. common stock outstanding as a result of Business Combination, PIPE Financing, exchange of Conduit Pharmaceuticals Limited shares for shares of Conduit Pharmaceuticals Inc., issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes, and transaction services agreements, shares">724,181</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zgh2j1YuwUUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text"><p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zhBmad4CwYhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_82F_zRCO19RmjpZd">Fair Value</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zCtFMn43Fv61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period ended December 31, 2024, there were no transfers between Level 1 and Level 2, nor into or out of Level 3. The following
table presents as of December 31, 2024 the Company&#8217;s assets and liabilities subject to measurement at fair value on a
recurring basis (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_z3goVReCnn35" style="display: none">Schedule
of  Assets Subject to Measurement at Fair Value on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Cash equivalents</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_zW0HAnUpsvPi" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents">192</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_z33wWa7lwO0j" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents"><span style="-sec-ix-hidden: xdx2ixbrl0886">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_z9IX5fTZ4kj7" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents"><span style="-sec-ix-hidden: xdx2ixbrl0888">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_zb5yiPIDU7l3" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents">192</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdQMgbeQS6v1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets">192</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2kiDDR5Tmkl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets"><span style="-sec-ix-hidden: xdx2ixbrl0894">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzUmQ2pkcK2k" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUo15aFKnWJ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets">192</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible notes payable at fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_zyb4WrTSaAhj" style="text-align: right" title="Option liability"><span style="-sec-ix-hidden: xdx2ixbrl0900">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_zUl5DKjzekr9" style="text-align: right" title="Option liability"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_zcXTKq4up5m3" style="text-align: right" title="Option liability">5,856</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoUOgP3F4u9g" style="text-align: right" title="Option liability">5,856</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Liability Classified Warrants</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zSQzp4WpuF8h" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants"><span style="-sec-ix-hidden: xdx2ixbrl0908">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zqRtJD0od3tg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants">0</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_z29P0jaeyOLi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants">138</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zU3ETZrXfeIh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants">138</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgT4eaYNsP06" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8JNrw2ygA12" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0918">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUMv3HreeBu1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities">5,994</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zknkSqE01W5k" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities">5,994</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents as of December 31, 2023 the Company&#8217;s liabilities subject to measurement at fair value on a recurring
basis (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Liability Classified Warrants</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zXOzm6huL3sf" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zENvKENrXooi" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants">142</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zl9wcldzfSQe" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants"><span style="-sec-ix-hidden: xdx2ixbrl0928">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zmNKSSwrtGql" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants">142</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6q6LJ2Ls69a" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0932">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5bDizCJVXh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities">142</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLXYPUPearZ7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0936">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFBw8ee5C1L3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities">142</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zOwa1FKpVIff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents consist of highly liquid money market funds with maturities of three months or less and are reflected in the Consolidated
Balance Sheets at carrying value, which approximates fair value due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zyye7A4TPG83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents additional information about the Convertible Notes Payable subject to measurement at fair value on a recurring
basis and warrant liabilities, for which the Company used significant unobservable inputs (Level 3) (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zqxT7pULAy3b" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_z6393p8CaGjj" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible Notes</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payable</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_z1GM2RkDB3le" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Liability Classified Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ConvertibleDebtFairValueDisclosures_iS_pn3n3_zee7e5WmrIkc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0942">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsOfDebtIssuanceCosts_pn3n3_zs2UpKq7Jqof" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Fair value at Issuance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">7,899</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">229</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_iN_pn3n3_di_zR8QJkt8jZr1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of convertible note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(92</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0949">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ChangeInFairValueOfConvertibleNotesPayable_pn3n3_z4jevABFubjj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,951</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(91</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--ConvertibleDebtFairValueDisclosures_iE_pn3n3_zDGdPFy27977" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,856</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">138</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zq8srlYULYDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Notes Payable</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 7, during on October 31, 2024, the Company and Nirland agreed to amend the August 2024 Nirland Note, whereby the
August 2024 Nirland Note was amended to provide for the conversion of the August 2024 Nirland Note into shares of common stock, at
Nirland&#8217;s discretion, in a multiple of any unpaid amounts, if not otherwise previously paid, pursuant to the conversion rate
contained therein. The August 2024 Nirland Note was then amended for a second time on November
22, 2024.Additionally, as discussed in Note 7, during November 2024, the Company issued to A.G.P. a convertible promissory
note (the &#8220;A.G.P. Convertible Note&#8221;) in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241130_zbl3vtjqhtnk" title="Principal amount">5.7</span>
million to evidence the A.G.P.&#8217;s currently owed deferred commission payable. The Company elected to account for the August
2024 Nirland Note and A.G.P. Convertible Note (collectively the &#8220;Convertible Notes Payable&#8221;) at fair value. The fair
value of the Convertible Notes Payable is estimated each period using a binomial lattice model. Significant estimates in the
binomial lattice model include the Company&#8217;s stock price, volatility, risk-free rate, corporate bond yield, credit
spread, probability of default, and recovery upon default.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the August 2024 Nirland Note and A.G.P. Convertible Note as of December 31, 2024 were estimated using a binomial
lattice model. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following
table outlines the range of significant unobservable inputs used in calculating the fair value of the August 2024 Nirland Note as of
the dates noted below:</p>

<p id="xdx_895_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_zbfLS4JMsCAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zz0NnNr931ll" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Fair Value  of Assumptions</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>October 31,</b></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>2024</b></p>

</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>November 22,</b></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>2024</b></p>

</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">2024</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Stock Price</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 14%"><span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zXP1MgYtPeec" title="Measurement input">9.10</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 14%"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zqD7KjVRhKm1" title="Measurement input">10.40</span></td>
    <td style="width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zJwzZ7tNojW9" title="Measurement input">6.90</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term (years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20241031__20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z8hbVV8uD26e" title="Measurement input">0.8</span></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20241122__20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zNmDiM14K2X4" title="Measurement input">0.7</span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zaP1nUSbEZOe" title="Measurement input">0.6</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Corporate bond yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember_zZuiHbbsiz9h">9.1</span></td>
    <td>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember_zbRAZVJcZYje">8.7</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember_zu7d2zNDqHU3">11.4</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit Spread</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zAIYKzu1Az6i">15.9</span></td>
    <td>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zZ859OayB6ne">15.9</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zpRIg4xqVtc1">15.9</span></td><td style="text-align: left">%</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Probability of default</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember_zfTGPxLaGWI1">40</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember_z5C3X9drZTHd">40</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember_zuGVIZAp9sHk">40</span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Recovery upon default</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember_zeZSEtaKzvrb">20</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember_zFAalIqNOa5d">20</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember_znbq2A2VwvZa">20</span></td><td style="text-align: left">%</td></tr>

  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zsQCAwt4dx23">103.2</span></td>
    <td>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zOLVsGF4n2gk">96.5</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zYRcTsjYsIkl">123.7</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A3_zfP14TqACEL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_hus-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zaf84Dforup9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table outlines the range of significant unobservable inputs used in calculating the fair value of the A.G.P. Convertible
Note as of the dates noted below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zkqDuKLIvqSc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Fair Value  of Assumptions</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>November 25,</b></p>
                                               <p style="margin-top: 0; margin-bottom: 0"><b>2024</b></p></td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2024</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Stock Price</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 16%"><span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zBul29jM6eL2" title="Measurement input">9.10</span></td>
    <td style="width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zu6TcECljG2f" title="Measurement input">6.90</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term (years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentTerm_dtY_c20241125__20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zUa4mcOSVE1l" title="Measurement input">1</span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zdsyCXtNdts9" title="Measurement input">0.9</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Corporate bond yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_z9MXSGtaez2h">8.8</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zoNZAFPL0UM3">9.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit Spread</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zRg8nu2t6hgg">26.2</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zUwDQlb64STf">26.2</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Probability of Default</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zeMJhHg9bEjl">40</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zI8Mtigw1iX4">40</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Recovery upon default</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zPIXvbm8OyOc" title="Measurement input">0</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zfYuVgGDKdq6" title="Measurement input">0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zz2qzFr4YgDj" title="Measurement input">108.7</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zD7lCIloP8Fd" title="Measurement input">101.6</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A3_zZTljc42Ld47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liability
Classified Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PIPE Warrants, A.G.P. Warrants, and A.G.P. 2024 Warrants, as defined in Note 18, are accounted for as liabilities in accordance with ASC 815-40 and are presented
within Warrant liabilities in the consolidated balance sheets. Warrant liabilities are measured at fair value at inception and on a recurring
basis, with changes in fair value presented within other income (expense), net in the consolidated statements of operations and comprehensive
income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
measurement of the PIPE Warrants and the measurement of the A.G.P warrants are classified as Level 2 fair value measurements due to the
use of an observable market quote for the Company&#8217;s publicly traded warrants, which are considered to be a similar asset in an
active market. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PIPE Warrant and A.G.P. Warrant liabilities are calculated by multiplying the quoted market price of the Company&#8217;s publicly traded
warrants by the number of liability classified warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 11, 2024, the Company amended the exercise price of the PIPE Warrants to be $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241211_zKEFHmScQN98" title="Exercise price">8.83</span>,
at which time all PIPE Warrants were exercised. As the exercise price was amended on the same date that the PIPE Warrants were
exercised, the Company remeasured the warrant liability immediately before exercise based on the difference between the closing
stock price of the Company&#8217;s common stock on December 11, 2024, and the amendment exercise price of the PIPE Warrants,
resulting in a gain on the change in fair value of warrant liability of approximately $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20241211__20241211__us-gaap--StatementEquityComponentsAxis__custom--PIPEWarrantsMember_zJh8PVgG1982" title="Change in fair value of warrant liability">12</span>
thousand. Refer to Note 18 for additional information. Upon exercise of the PIPE Warrants, less than $<span id="xdx_904_ecustom--WarrantsExcercise_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PIPEWarrantsMember_z1zplZmyXaae" title="Warrants excercise">1</span>
thousand of Level 2 liability classified warrants remain on the consolidated balance sheet as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zrlqaJL1wSv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
measurement of the A.G.P. 2024 Warrants is classified as Level 3 due to the use of an option-pricing model that utilizes unobservable inputs and requires significant judgement. The Company estimated
the fair value of the warrants issued as the issuance date, October 29, 2024, and as of December 31, 2024, using a Black-Scholes
option-pricing model utilizing the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_z29Sb08l0Ne8" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Fair Value  of Assumptions</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>October 29, 2024</b></td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Closing stock price</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 16%"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zL0MGY7X4re1" title="Measurement input">10.48</span></td>
    <td style="width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIu51AZP2dIe" title="Measurement input">6.90</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Contractual exercise price</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCikayCpEta7" title="Measurement input">10</span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYgt4d7PslL" title="Measurement input">10.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zK4NQDMEYmGc" title="Measurement input">4.11</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zER6wFIDSePb" title="Measurement input">4.38</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Estimated volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaNjNJ2d2Opk" title="Measurement input">98.4</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7GMCDnDHHd9" title="Measurement input">98.6</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Time period to expiration (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentTerm_dtY_c20241029__20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFkT9SINyWc" title="Measurement input">5.2</span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjfcPSu19W48" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Measurement input">5.0</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zTjVzXNlD7Tb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details &#8211; Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details &#8211; Current Assets</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_zYsJbxvyAxR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82C_zEKMPzE0lnz6">Balance Sheet Details &#8211; Current Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_z8g51x79iSz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
assets consisted of the following as of December 31, 2024 and December 31, 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_z49AnDy71Qgh" style="display: none">Schedule
of Balance Sheet Details</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zzu6ecM4gGE" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_z6Ucz8rrw931" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzWXV_zvJ2rACh1pFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid directors&#8217; and officers&#8217; insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,187</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,365</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maPEAOAzWXV_zVKTyQP1yqFj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maPEAOAzWXV_zHxa6sYCZ0l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1051">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherReceivablesNetCurrent_iI_pn3n3_maPEAOAzWXV_zmYxqf7s0nb6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">489</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzWXV_ziXxF2umDgdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,505</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zh2SMobu80wc" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_zbjJT32UVxM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_829_zyVSz3lelv5l">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, we entered into an operating lease for laboratory space. The remaining lease terms for our operating
lease is approximately two years and does not provide a renewal option. We apply the short-term lease policy election, which allows us
to exclude from recognition leases with an original term of 12 months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
commencement of the laboratory lease on March 7, 2024, the Company recorded a right-of-use asset of $<span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn5n6_c20240307_z7y5MuTyDiD9" title="Right of use asset">0.4</span> million, short-term lease liability
of $<span id="xdx_900_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn5n6_c20240307_zZfG7804jXD1" title="Short term lease liability">0.2</span> million, and long-term lease liability of $<span id="xdx_90C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn5n6_c20240307_zjsPBCgW0Rbk" title="Short term lease liability">0.2</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
costs associated the Company&#8217;s operating and short-term leases are recorded within general and administrative expense in the consolidated
statement of operations and comprehensive income (loss). The following table sets forth information about our lease costs for the year
ended December 31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_ztFEfP5fALic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8B0_zH483udmyJXh" style="display: none">Schedule
of Lease Cost</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Lease Cost</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zLwTLQhOvST4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/>
2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_pn3n3_maLCzbUU_zbnjE8urBSP3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">116</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzbUU_zjRy0JmvT1mf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short-term lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--VariableLeaseCost_pn3n3_maLCzbUU_zcVbGeQ6OUOh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Variable lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LeaseCost_iT_pn3n3_mtLCzbUU_z9QQSkoMn9wc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">259</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_z1oDpuusiI63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_898_ecustom--LesseeOperatingLeaseLiabilityTableTextBlock_zrEGc5eOYk62" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information about our operating lease for the year ended December 31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8BE_zMSqtLCKem1g" style="display: none">Schedule
of Operating Lease Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Supplemental cash flow and other information</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231_z9kLoVIN0577" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/>
2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeasePayments_pn3n3_zXsxgxfBRaC" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; text-align: left">Operating cash flows from operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">143</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zcppdSH0PxU" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">ROU assets obtained in the exchange for lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">352</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average remaining lease term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zv6l9UDkzsb2" title="Weighted-average remaining lease term (in years)">2.0</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zs39Vo5dcmu2" title="Weighted-average discount rate">11.2</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A1_zy45fqanh866" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zZKj1736oPGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s future minimum lease payments for our operating lease as of the year ended December 31, 2024, are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8BC_zfNkFLRq0Y0i" style="display: none">Schedule
of Future Minimum Lease Payments For Operating Lease</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_zLfU9sYmzFl6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/>
2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold">Year ending December 31,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz2P5_zUZJ8YG7x6ck" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">140</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz2P5_zjA7uzVRRFwb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">113</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz2P5_zaEqk5RbT9gj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">253</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z70CJ5JAsMSf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(27</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zgV8WrDqUxJ5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">226</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zDfohRnlO9ek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract', window );"><strong>Liability Related To Sale Of Future Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_LiabilityRelatedToTheSaleOfFutureRevenueTextBlock', window );">Liability Related to the Sale of Future Revenue</a></td>
<td class="text"><p id="xdx_80B_ecustom--LiabilityRelatedToTheSaleOfFutureRevenueTextBlock_zSo4gYSMpXzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_82B_zvBa60A7Tgic">Liability Related to the Sale of Future Revenue</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Vela
Technologies PLC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an Agreement with SGSC to approve an Indirect Investment from Vela Technologies PLC (&#8220;Vela&#8221;) on October
20, 2020, whereby Vela agreed to provide funding to the Company for an indirect investment in AZD 1656 for use in the field in exchange
for <span id="xdx_90E_ecustom--PercentageOfFutureRevenueEarned_dp_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_z4Mg115RLVF8" title="Percentage of future revenue earned">8</span>% of future revenue earned if AZD 1656 is commercialized (the &#8220;Vela Agreement&#8221;). Total consideration under the Vela
Agreement was $<span id="xdx_906_eus-gaap--AssetAcquisitionConsiderationTransferred_pn5n6_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zPIu4nuj8hR4">2.9</span> million (&#163;<span id="xdx_903_eus-gaap--AssetAcquisitionConsiderationTransferred_pn4n6_uGBP_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zkMX9NWBC1Ik">2.35</span> million), consisting of $<span id="xdx_903_eus-gaap--PaymentsToAcquireProductiveAssets_pn5n6_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_ztV5k1WsjBuf">1.6</span> million (&#163;<span id="xdx_906_eus-gaap--PaymentsToAcquireProductiveAssets_pn4n6_uGBP_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zte4CvUUmz41">1.25</span> million) cash and the issuance of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn8n9_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zjdu2zS7lsqd" title="Number of shares, issuance">1.1</span> billion
common shares in Vela, which based on the Vela&#8217;s fair value per share and was $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_ztSPx52mHzl4" title="Number of shares issuance, value">1.3</span> million. During the year ended December 31,
2021, the Company sold all <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn8n9_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zkny5zvtDFHb" title="Number of shares, issuance">1.1</span> billion of its Vela shares for $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zCLuHH80Xsa4" title="Number of shares issuance, value">1.2</span> million and recorded a loss of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zX5dF9mWOy2c" title="Loss">0.1</span> million on the sale. The Company
received the $<span id="xdx_902_eus-gaap--PaymentsToAcquireProductiveAssets_pn5n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember__us-gaap--AssetAcquisitionAxis__custom--VelaTechnologiesPLCMember_zpDydQmJy4fi">1.6</span> million (&#163;<span id="xdx_90A_eus-gaap--PaymentsToAcquireProductiveAssets_pn4n6_uGBP_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember__us-gaap--AssetAcquisitionAxis__custom--VelaTechnologiesPLCMember_zTvkeF5odv23">1.25</span>) million cash consideration during the year ended December 31, 2020. This consideration was recorded
as a liability related to the future sale of revenue on the balance sheet in accordance with ASC 470-10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, the Company entered into an agreement with Vela which granted Vela the right, but not the obligation, to sell its <span id="xdx_901_ecustom--RoyaltyPercentage_dp_c20230401__20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember_zboLKPS4VNth" title="Royalty percentage">8</span>% royalty
interest in AZD 1656 back to Conduit. Vela paid a one-time, non-refundable option fee to Conduit of $<span id="xdx_902_ecustom--NonRefundableOptionFee_pn5n6_c20230401__20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember_zNsdqpEqSgs7" title="Non refundable option fee">0.5</span> million (&#163;<span id="xdx_90D_ecustom--NonRefundableOptionFee_pn5n6_uGBP_c20230401__20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember_zoorhKrkBxZe">0.4</span> million).
Total consideration payable to Vela upon exercise of the option was &#163;<span id="xdx_908_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn5n6_uGBP_c20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWUyWOyjgOm1" title="Total consideration payable">4.0</span> million ($<span id="xdx_905_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn4n6_c20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpKKT40JdmVj" title="Total consideration payable">5.08</span> million on the exercise date) worth of
new common shares in the combined entity after the Merger between Conduit Pharmaceuticals Limited and MURF, following the consummation
of the Merger, at a price per share equal to the volume-weighted average price per share over the ten (10) business days prior to the
date of the notice of exercise. The option contained a provision stating that in no event would the price per share for the consideration
shares be lower than $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember__srt--RangeAxis__srt--MinimumMember_z0QP0MvNRqGa">5</span> or higher than $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember__srt--RangeAxis__srt--MaximumMember_z92GQi5UHpa6">15</span>. <span id="xdx_905_ecustom--OptionAgreementDescription_c20230401__20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember_zRVFHFN3ZwG8" title="Option agreement description">The option was exercisable in whole at any time from the close of the Merger (the &#8220;Effective
Time&#8221;) until the earlier of (i) the date that was six (6) months from the Effective Time, and (ii) February 7, 2024, the expiration
date of the term.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 30, 2023, Vela exercised its option to sell back its indirect investment in AZD 1656 in exchange for <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20231130__20231130__us-gaap--MeasurementInputTypeAxis__custom--VelaOptionLiabilityMember_zPvwWOkdQ0Fl">10,157</span> shares of the Common
Stock. The Company recognized the $<span id="xdx_90C_eus-gaap--DeferredRevenue_iI_pn5n6_c20231130__us-gaap--MeasurementInputTypeAxis__custom--VelaOptionLiabilityMember_zg0xzKJuwtde" title="Deferred revenue">2.8</span> million of deferred revenue and recorded $<span id="xdx_90F_eus-gaap--OtherNonoperatingIncomeExpense_pn5n6_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__custom--VelaOptionLiabilityMember_z76vsjCrZy57" title="Other income (expense), net">2.8</span> million to other income (expense), net, on the consolidated
statement of operations and comprehensive income (loss) for the year ended December 31, 2023. As of December 31, 2023, there was no liability
for the sale of future revenue related to Vela.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cizzle
Biotechnology Holdings PLC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2022, the Company entered into an agreement with Cizzle PLC (&#8220;Cizzle&#8221;) whereby Cizzle agreed to purchase a percentage
of future revenue earned in AZD 1656, should it reach the commercialization stage. Total consideration under the agreement is specified
as $<span id="xdx_90F_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20220211__20220211__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_ztTHJoNwsxZe">1.6</span> million (&#163;<span id="xdx_90B_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_uGBP_c20220211__20220211__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zZTUeZakprLi">1.2</span> million), consisting of the issuance of the fair value of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220211__20220211__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zb6PYZDCRkB3">25.0</span> million new common shares in Cizzle on the
date of the agreement and the fair value of <span id="xdx_904_eus-gaap--SharesIssued_iI_pn5n6_c20220211__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zTG1CHNu5dw1">22.0</span> million shares to be issued at the earlier of Cizzle&#8217;s shareholder approval or
one year from the date of the agreement. The <span id="xdx_90C_eus-gaap--SharesIssued_iI_pn5n6_c20221231__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zaPuj0oNCgF5">22.0</span> million shares were received by the Company in the fourth quarter of 2022 and were
subsequently sold within the fourth quarter of 2022. The Company recorded a liability related to deferred revenue of $<span id="xdx_90F_eus-gaap--DeferredRevenue_iI_pn5n6_c20221231__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zHlMqOmSzKC3">1.4</span> million for
the consideration received from Cizzle as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
payments received for the sale of future revenue were classified as a liability related to the future sale of revenue. Under ASC 470-10-25,
a seller of future revenue should evaluate whether the proceeds received should be accounted for as debt or deferred income. In assessing
the factors that created a rebuttable presumption of debt within the guidance, the Company determined that there were factors present
to overcome the debt presumption and deferred income classification to be appropriate. The main factors the Company considered were that
the transactions in form were sales, and not debt transactions. Each agreement does not guarantee a return to each purchaser, the return
is based solely on future performance of AZD 1656 should it reach commercialization, with neither purchaser having an involvement in
generating future cash flows from AZD 1656.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 15, 2022, the Company entered into an agreement with Cizzle whereby the Company granted Cizzle the option, but not the obligation,
to sell its economic interest in AZD 1656 back to the Company. The agreement contained an option period of nine months from the date
of the agreement for Cizzle to notify the Company of its intent to exercise the option to sell its economic interest in AZD 1656. Upon
closing of the agreement, Cizzle agreed to pay the Company an option fee of $<span id="xdx_90A_ecustom--OptionFee_iI_pn5n6_c20221215__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zDoaiIwdCBO" title="Option fee">0.1</span> million (&#163;<span id="xdx_90C_ecustom--OptionFee_iI_pn5n6_uGBP_c20221215__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_za2yRUuswu7c">0.1</span> million).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2023, Cizzle exercised its option to sell back its indirect investment in AZD 1656 in exchange for <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pid_c20230926__20230926__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztpradnkmBO1">3,954
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Common Stock. The Company recognized
the $<span id="xdx_903_eus-gaap--DeferredRevenue_iI_pn5n6_c20231231__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zXVkhfhbOH9f">1.5
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of deferred revenue and recorded $<span id="xdx_90F_eus-gaap--OtherOperatingIncomeExpenseNet_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zFziWPv6Re9g">1.5
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to other income (expense), net, on the
consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2023. As of December 31, 2023,
there was no liability for the sale of future revenue related to Cizzle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_LiabilityRelatedToTheSaleOfFutureRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Revenue [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_LiabilityRelatedToTheSaleOfFutureRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DisclosureConvertibleNotesPayableAbstract', window );"><strong>Convertible Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ConvertibleNotesPayableTextBlock', window );">Convertible Notes Payable</a></td>
<td class="text"><p id="xdx_809_ecustom--ConvertibleNotesPayableTextBlock_zlot8IxaK9O8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_82C_zMkPmw4V5gz8">Convertible Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Promissory Notes Payable</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
March 2023, the Company issued a convertible promissory note payable (the &#8220;Convertible Promissory Notes Payable&#8221;) with an
aggregate principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zSt33ZPaLgC6">0.8
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to a non-related third party. <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDateDescription_c20230301__20230331__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zteyJ4NdrUT2">The
Convertible Promissory Note Payable had a maturity date of 18 months from the date of issuance.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
note carries interest at a rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_z4bB1vxqxWS1">20</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
annually, which is payable every six (6) months from the date of the note until the maturity date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 9, 2024, the Company and the loan holder signed an extension to extend the maturity date from September 20, 2024 to October
20, 2024 with the option for the Company to further extend the maturity date two times, each by an additional 30-day period. The
Company exercised both options to extend the maturity date to December 19, 2024 which included interest previously payable as well as the principal. As consideration for extending the maturity date,
the Company amended the form of repayment of the remaining interest due on the loan. As payment for the interest, the Company issued
the loan holder, (i) $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241009__20241009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJLbnt57xAil" title="Issuance of shares, value">80,000</span>&#160;worth
of Common Stock to be issued at the closing market price on the date prior to issuance and (ii)&#160;<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241009__20241009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z95rpcx4AkH3" title="Iissuance of loan shares">20,000</span>&#160;shares
of Common Stock. On October 11, 2024, the Company issued the loan holder&#160;<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241011__20241011__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT3s4zQhlqb9" title="Issuance of shares">27,812</span>&#160;shares
of Common Stock in satisfaction of the obligations in (i) and (ii) in the preceding sentence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extension met the criteria for as a debt extinguishment under ASC 470-50. As of October 9, 2024, the Company recorded a gain on debt extinguishment
of $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20241009__20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember_zIbN1jvX9LD5" title="Gain on debt extinguishment">0.1</span>
million, calculated as the difference between (i) the $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmFpPpxrJ4Wc" title="Convertible promissory notes payable">0.8 </span>million
carrying value of the Convertible Promissory Note Payable immediately prior to the amendment (ii) the $<span id="xdx_909_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zofRopCmLZXi" title=" Fair value convertible promissory notes payable">0.4</span>
million fair value of the Convertible Promissory Note Payable immediately after the amendment and (iii) the $<span id="xdx_90D_eus-gaap--StockIssued1_pn5n6_c20241009__20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFn0zJY3JUHa" title="Stock issued">0.3</span>
million fair value of the shares issued to the holder as consideration for extending the maturity date. The difference between the
$<span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqxlqRj8N0F4" title="Carrying value">0.8 </span>million
carrying value immediately prior to the amendment and the $<span id="xdx_908_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7D6uvshsWY9" title="Stock issued">0.4</span>
million fair value immediately after the amendment was recorded as a debt discount and amortized over the amended maturity date of
the Convertible Promissory Note using the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the extension of the loan, the Company entered into a consulting agreement with an unrelated third party to negotiate
the extension of the of the convertible note with the loan holder on behalf of the Company. The Company issued the third-party&#160;<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241011__20241011__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zHOOv6aVMCIc" title="Issuance of shares">8,500</span>&#160;shares
on October 11, 2024, in exchange for services provided. The fair value of the shares were $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20241010__20241010__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zZfyFIvPavT6" title="Fair value of shares">0.1</span> million, as determined
by multiplying the closing share price on October 10, 2024 (day prior to issuance) of $<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20241010__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_znTcvRKg1Io1" title="Issuance of shares">10.24</span> by the total number of shares issued, <span id="xdx_900_eus-gaap--SharesIssued_iI_pid_c20241010__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z9uR7IPV2N22" title="Shares issued">8,500</span>.
This amount was capitalized as a debt issuance cost and accreted over the amended term of the Convertible Promissory Notes Payable
using the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, and December 31, 2023, the Company incurred interest expense on the Convertible Promissory Note
Payable of $<span id="xdx_902_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zywh8nK8E95" title="Interest expense">0.5</span>
million and $<span id="xdx_909_eus-gaap--InterestExpenseDebt_pn5n6_c20230101__20231231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zTNr3EzMtwA9" title="Interest expense">0.1</span>
million, respectively. The promissory note payable remained outstanding as of December 31, 2024, therefore the Company was
considered to be in default. On March 6, 2025, the Company reached an agreement with the loan holder to pay $<span id="xdx_906_eus-gaap--RepaymentsOfConvertibleDebt_pn5n6_c20250306__20250306__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztEPp1HVmk71" title="Settlement of debt">0.7</span>
million in order to settle the March 2023 Convertible Note in full. The Company repaid the loan holder the settlement amount $<span id="xdx_908_eus-gaap--RepaymentsOfConvertibleDebt_pn5n6_c20250313__20250313__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXIbN89pBUW6" title="Settlement of debt">0.7</span>
million on March 13, 2025. See Note 20 for additional details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>August
2024 Nirland Note</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 6, 2024, the Company entered into a Senior Secured Promissory Note (the &#8220;August 2024 Nirland Note&#8221;) with Nirland,
a related party of the Company, pursuant to which the Company issued and sold to Nirland the August 2024 Note in the original principal
amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_z4aywVAoRh0c" title="Original principal amount">2.7</span> million, inclusive of a $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zn5ojNRRbKbg" title="Original issue discount">0.5</span> million&#160;original issuance discount. See Note 16 for further reference to the relationship
between the Company and Nirland. Of the total amount of the August 2024 Nirland Note, $<span id="xdx_90F_ecustom--DebtIssuedUponExecution_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zcfdqWwJPU1c" title="Debt issued upon execution">1.7</span> million&#160;was issued upon execution of
the August 2024 Nirland Note. In connection with the August 2024 Nirland Note, the Company issued to Nirland&#160;<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240806__20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_ze2WEpY7UvU6" title="Issuance of shares">125,000</span>&#160;shares
of the Company&#8217;s Common Stock on August 6, 2024. The balance of $<span id="xdx_906_ecustom--PaymentOfCommonStock_pn5n6_c20240806__20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zRTY4impwJIc" title="Payment to common stock">0.5</span> million&#160;became payable to the Company when the shares
were registered for resale in September 2024. In the event the Company completes any public or private equity or debt financing, the
Company shall be required to mandatorily prepay (&#8220;Mandatory Prepayment Right&#8221;), any amounts that may be then outstanding
under the August 2024 Nirland Note, within two business days following the closing of such financing, in an amount of no less than&#160;<span id="xdx_901_ecustom--NetProceedsReceivedPercentage_iI_pid_dp_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zYZi96ueMzx9" title="Net proceeds received, percentage">75</span>%
of the net proceeds received. Per the terms of the August 2024 Nirland Note, the Company is prohibited from entering into a variable
rate transaction without prior written consent from Nirland. The August 2024 Nirland Note bears interest at a rate of&#160;<span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zYMZ9grX2c6l" title="Debt interest rate">12</span>% per annum,
accruing daily on a 365-day basis, payable monthly in arrears as cash, or accrued at Nirland&#8217;s discretion.&#160;<span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateDescription_c20240806__20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zVloMYCgi4b8" title="Debt instrument maturity description">The August 2024
Nirland Note matures 12 months from August 6, 2024.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the Company issued to Nirland&#160;<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240806__20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_zpWUbnDVvPdc">125,000</span>&#160;shares
of the Company&#8217;s Common Stock on August 6, 2024. The Company determined that loan agreement and share issuance should were part
of a basket transaction and allocated the net proceeds on a relative fair value basis. Of the total $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_zchcntSfVCla" title="Net proceeds">2.2</span>&#160;net proceeds, $<span id="xdx_90E_eus-gaap--DebtInstrumentFeeAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_z2mTZbn4AQpj" title="Debt instrument allocated">1.2</span>&#160;million
was allocated to the August 2024 Nirland Note including $<span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_z5UguVrOwkY1" title="Gross proceeds">1.5</span>&#160;million gross proceeds, less $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_zwNy0swKsBs9" title="Original issue discount">0.3</span>&#160;million Original Issue Discount
(&#8220;OID&#8221;). The remaining $<span id="xdx_90F_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLVaNSqTG902" title="Remaining allocated to common stock">1.0</span>&#160;million was allocated to the common stock, including $<span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFtYXaezSCsg" title="Gross proceeds">1.2</span>&#160;million gross proceeds less
$<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5XBaVbuWEp1" title="Debt instrument, orginal issue discount">0.2</span>&#160;OID. The $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9Vd3RGXSuRl">1.2</span>&#160;million allocated to the common stock was considered to be a discount on the August 2024 Nirland Note making
the balance of the note to be $<span id="xdx_90E_eus-gaap--NotesPayable_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_zkjH9shq4TCb" title="Notes payable">2.7</span>&#160;million note payable, less a total debt discount of $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806_zB96tVDytGSf" title="Total debt discount">1.5</span>&#160;million. The debt discount will
be amortized to interest expense using the effective interest method over the life of the note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 31, 2024, the Company and Nirland amended the August 2024 Nirland Note (the &#8220;First Amendment&#8221;), whereby the August
2024 Nirland Note was amended to (i) provides for the conversion of the August 2024 Nirland Note into shares of Common Stock, at Nirland&#8217;s
discretion, in a multiple of any unpaid amounts, if not otherwise previously paid, pursuant to the conversion rate contained therein,
(ii) removes Nirland&#8217;s Mandatory Prepayment Right, and (iii) removes Nirland&#8217;s right of first refusal to participate in any
future equity or debt offerings of the Company. The number of shares of Common Stock issuable upon conversion of any Conversion Amount
pursuant to&#160;shall be determined by dividing (x) such conversion amount by (y) the conversion price. Conversion amount means two
and one quarter times the sum of (x) portion of the principal to be converted, redeemed or otherwise with respect to which this determination
is being made and (y) all accrued and unpaid interest with respect to such portion of the principal amount, if any. Conversion price
means, as of any conversion date or other date of determination, $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241031__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentNirlandNoteMember_zDeCD5m9M4U6" title="Conversion price per share">10.00</span>, subject to adjustment as provided within the amended agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluated the conversion feature of this note offering for embedded derivatives in accordance with&#160;ASC 815,&#160;<i>Derivatives
and Hedging</i>, and the&#160;substantial premium model&#160;in accordance with&#160;ASC 470,&#160;<i>Debt</i>. Based on our assessment,
separate accounting for the conversion feature of this note offering is not required and will be accounted for under the substantial
premium model. Under the substantial premium model, the excess above the fair value of the August 2024 Nirland Note will be recorded
in additional paid-in-capital. The August 2024 Nirland Note will be carried at amortized cost using the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the fair value of the August 2024 Nirland Note to be $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn5n6_c20241031__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zrZWpx4kR3Qe" title="Convertible notes payable">3.6</span> million as of October 31, 2024 through the use of a binomial
lattice model. See Note 3 for additional information regarding the fair value measurement of the August 2024 Nirland Note. The Company
accounted for the First Amendment as a debt extinguishment, as the First Amendment added a substantive conversion option. As of October
31, 2024, a loss on debt extinguishment of $<span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20241031__20241031__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zeHigcpOxwx3" title="Gain on debt extinguishment">2.2</span> million was recorded consisting of (i) the derecognition of the $<span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241031__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zBu6SkXPjVui" title="Carrying value">1.3</span> million carrying
value immediately prior to the First Amendment (ii) recognition of the $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleLiquidationPreferenceValue_iI_pn5n6_c20241031__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zmigBlPDP8xg" title="Par value">2.7</span> million par value and (iii) recognition of the $<span id="xdx_905_eus-gaap--ConvertibleDebt_iI_pn5n6_c20241031__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zyi6IJegKsL1" title="Convertible debt">0.8</span> million
substantial premium.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 22, 2024, the Company and Nirland entered into a Second Amendment to the August 2024 Nirland Note (the &#8220;Second
Amendment&#8221;). Pursuant to the Second Amendment, the Nirland Note may not be converted (other than partial conversions that may
be permitted pursuant to the rules and regulations of NASDAQ (or any successor entity)) prior to receipt of stockholder approval to
provide for such conversion of the Nirland Note, and subsequent issuance of the Company&#8217;s Common Stock, pursuant to the
stockholder approval rules under the rules and regulations of The Nasdaq Stock Market. If the Company has not held a special meeting
of the stockholders to approve the full conversion of the August 2024 Nirland Note on or before January 9, 2025, then the Company
shall be obligated to pay Nirland a penalty of $<span id="xdx_90C_ecustom--PenaltyPayment_pn5n6_c20241122__20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_zdhMSGQdaJdb" title="Penalty payment">0.1</span>
million per day until the special meeting is held. In addition, the existing conversion rate was amended to be two and one half
times the sum of (x) the portion of the principal to be converted, redeemed or otherwise with respect to which this determination is
being made and (y) all accrued and unpaid interest (including default interest) with respect to such portion of the principal
amount, if any divided by $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_zgB7uEnKa4J4" title="Conversion price per share">0.10</span>, prior to the Reverse Stock Split, (or following any reverse splits that may occur in a ratio greater than 10 to 1, the lower of
such reverse split price and the market price per share at the time of the Conversion Date, but in no event less than $1.00),
subject to adjustment as provided therein and to take into account any future share splits or reverse splits to maintain the
economic equivalence of the conversion rights as at the amendment effective date. The Company notes that the reverse split provision
in the preceding sentence was tripped, effective January 25, 2025, following the <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20241122__20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_ziFQJkwQFaxd" title="Reverse stock split">1-for-100</span>
reverse stock split that occurred on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the Second Amendment, the Company elected to account for the August 2024 Nirland Note at fair value under ASC 825. The Company determined that the amendment to the conversion features present in the Second Amendment fall under the
guidance within ASC 825 that notes that if a significant modification of debt occurs an entity is able to make an accounting election
on that date to account for that debt under the fair value option. At the end of each
reporting period, the Company calculates the fair value of the August 2024 Nirland Note, and any changes in fair value are reported in
the current period&#8217;s consolidated statements of operations and comprehensive income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company remeasured the fair value of the August 2024 Nirland Note as of the Second Amendment date and calculated a fair value of $<span id="xdx_904_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pn5n6_c20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_zhjAG02gNknd" title="Fair value">4.5</span>
million using a binomial lattice model. See Note 3 for additional information regarding the fair value measurement of the August 2024
Nirland Note. The Company accounted for the Second Amendment as a debt extinguishment, as the terms of the August 2024 Nirland Note were
deemed to be substantially different after the Second Amendment. As of November 22, 2024, a loss on debt extinguishment of $<span id="xdx_906_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20241122__20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_zNCj0bxYUXA8" title="Loss on debt extinguishment">0.9</span> million
was recorded consisting of (i) the derecognition of the <span id="xdx_907_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241122__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentNirlandNoteMember_zbCuY3YFpPYg" title="Carrying value">2.7</span> million carrying value immediately prior to the First Amendment (ii) derecognition
of $<span id="xdx_903_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20241122__20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_zWAnbk72OOYi" title="Accrued interest">0.1</span> million in accrued interest (iii) derecognition of the $<span id="xdx_90A_eus-gaap--ConvertibleDebt_iI_pn5n6_c20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentMember_zpNls8sqTQsd" title="Convertible debt">0.8</span> million substantial premium and (iv) recognition of the $<span id="xdx_907_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241122__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zt5Bc81OACHf" title="Debt instrument fair value">4.4</span> million
fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 9, 2024, and prior to obtaining shareholder approval, Nirland exercised their conversion option and converted $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20241209__20241209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6Ae9LQD4f87" title="Conversion option">0.1</span> million of
principal for<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20241209__20241209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaS6x1SGLbr5" title="Conversion shares"> 23,000</span> shares of common stock pursuant to the rules and regulations of the NASDAQ. As of December 31, 2024, $<span id="xdx_90A_eus-gaap--InterestPayableCurrent_iI_pn5n6_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFyyYlEIxbej" title="Accrued interest">2.6</span> million
of principal and accrued interest remains outstanding. As of December 31, 2024, the August 2024 Nirland Note had a fair value of approximately $<span id="xdx_903_eus-gaap--NotesPayableFairValueDisclosure_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zcGh1zoWf7V8" title="Payable at fair value">2.8</span> million and is included
within <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible promissory notes payable at fair value &#8211;
related parties on the consolidated balance sheets. </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, the Company recorded a $<span id="xdx_905_eus-gaap--DebtSecuritiesTradingGainLoss_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zWdchzUgyU72" title="Fair value of convertible promissory notes">1.5</span>&#160;million
gain from the change in fair value of convertible promissory note and interest expense of approximately $<span id="xdx_901_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zygE3Z8TCqve" title="Interest expense">0.4</span>
million. The interest expense of $<span id="xdx_901_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zO3CSBKmcCkd" title="Interest expense">0.4</span> million is comprised of (i) accrued interest of $<span id="xdx_902_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zH3SjwvshHuc" title="Accured interest">0.2</span> million and (ii) $<span id="xdx_90D_eus-gaap--AdjustmentForAmortization_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zlheVdlpiZal" title="Amortization expenses">0.2</span> million in
amortization expense related to the initial debt discount of $<span id="xdx_902_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zzS38OQIM9J3" title="Amortization of debt discount">1.5</span> million. The $<span id="xdx_90E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--TypeOfArrangementAxis__custom--FirstAmendmentMember_zXAvcfi2szHe" title="Loss on debt extinguishment">2.2</span>
million loss on debt extinguishment from the Frist Amendment, $<span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentMember_zMynDIssUDC" title="Loss on debt extinguishment">0.9</span>
million loss on debt extinguishment from the Second Amendment, and the $<span id="xdx_90A_ecustom--GainOnChangeInFairValue_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zSKb0HdeoUhg" title="Gain on change in fair value">1.5</span>
million gain on the change in fair value are presented within other income (expense), net, while the $<span id="xdx_90D_eus-gaap--InterestIncomeExpenseNonoperatingNet_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zoJD0F3dyi17" title="Interest expense net">0.4</span>
million of interest expense is presented within Interest expense, net, in the consolidated statement of operations and comprehensive
income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A.G.P.
Convertible Note</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 25, 2024, the Company issued to A.G.P. a convertible promissory note (the &#8220;A.G.P. Convertible Note&#8221;) in the principal
amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zSuHMwrKtMC9" title="Debt instrument face amount">5.7</span> million to evidence the A.G.P.&#8217;s currently owed deferred commission payable. Refer to the Note 9 for additional
information. Unless earlier converted as specified in the Convertible Note, the principal amount, plus all accrued but unpaid interest,
is due on November 25, 2025 (the &#8220;Maturity Date&#8221;). The convertible promissory note accrues interest at <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_z5JFikkkOLD3" title="Convertible notes interest per annum">5.5</span>% per annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any time prior to the full payment of the convertible promissory note, provided that the A.G.P. has given at least three business
days written notice to the Company, A.G.P., in its sole discretion, may elect to have all or any portion of the outstanding
principal amount and all interest accrued converted into shares of the Company&#8217;s common stock, at a fixed price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_ziG7WomMJ154" title="Fixed price">10.00</span>
(or following any reverse splits that may occur in a ratio greater than 10 to 1, the lower of such reverse split price and the
market price per share at the time of the conversion date, but in no event less than $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zDy9G8AqD5j7" title="Conversion price">1.00</span>),
subject to adjustment as provided therein and to take into account any future share splits or reverse splits. <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_pid_c20250125__20250125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zO6Iz6UrLM12" title="Reverse stock split, description">The
Company notes that the reverse split provision in the preceding sentence was tripped, effective January 25, 2025, following the 1-for-100 reverse stock split
that occurred on that date</span>. However, the conversion of the convertible promissory note may not occur prior to the
Company having sufficiently authorized shares of common stock to permit the entire conversion of the convertible promissory note. In
addition, the conversion of the convertible promissory note may also not occur prior to receipt of stockholder approval to provide
for such conversion of the convertible promissory note, and subsequent issuance of the Company&#8217;s common stock, pursuant to the
stockholder approval rules under the rules and regulations of The Nasdaq Stock Market. Further, following the A.G.P.&#8217;s ability
to convert the convertible promissory note, if at all, A.G.P. will not be entitled to receive the Company&#8217;s common stock upon
conversion, if such conversion would result in A.G.P. owning greater than <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zmTWFk59Tfbl" title="Conversion percentage">9.99</span>%
of the Company&#8217;s then currently outstanding common stock. A.G.P. is also entitled to resale registration rights as identified
in the convertible promissory note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may prepay the convertible promissory note in whole or in part. In the event of certain Events of Default (as defined in the
convertible promissory note), all outstanding principal and accrued interest under the Convertible Note will become, or may become at
A.G.P.&#8217;s election, immediately due and payable to the A.G.P.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company elected to account for the A.G.P. Convertible Note at fair value under ASC 825. The Company determined that the substantive
conversion option within the A.G.P. Convertible Note falls under the guidance within ASC 825 that notes that if a significant
modification of debt occurs an entity is able to make an accounting election on that date to account for that debt under the fair
value option. At the end of each reporting period, the Company calculates the fair value of the A.G.P. Convertible Note, and any
changes in fair value are reported in the current period&#8217;s consolidated statements of operations and comprehensive income
(loss). The change in fair value attributable to instrument-specific credit risk, if any, will be recognize within other
comprehensive income each reporting period. As an accounting policy, the Company elected to present interest expense separately from
other changes in the A.G.P. Convertible Note&#8217;s fair value. Interest expense will be presented within Interest expense, net,
while the other changes in the fair value with be presented within other income (expense), net in the consolidated statements of
operations and comprehensive income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the fair value of the A.G.P. Convertible Note to be $<span id="xdx_909_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pn5n6_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zjYQeviNrtcl" title="Fair value of convertible note">3.4</span> million as of November 25, 2024 through the use of a binomial
lattice model. See Note 3 for additional information regarding the fair value measurement of the A.G.P Convertible Promissory Note. The
Company accounted for the issuance on the A.G.P. Convertible Promissory Note as a debt extinguishment, as it was issued to evidence the
A.G.P.&#8217;s currently owed deferred commission payable discussed in Note 9. A gain on debt extinguishment of $<span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20241125__20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zA3dsNlKqew3" title="Gain on debt extinguishment">2.4</span> million was recorded
as of November 25, 2024, consisting of (i) the derecognition of the $<span id="xdx_90C_ecustom--DeferredCommissionPayable_iI_pn5n6_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zoIY0oGukjih" title="Deferred commission payable">5.7</span> million deferred commission payable and (ii) recognition of
the $<span id="xdx_907_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zKomL3d4W2Tj" title="Fair value of convertible note">3.4</span> million fair value of the A.G.P. Convertible Note. For the year ended December 31, 2024, the Company recorded a $<span id="xdx_90E_ecustom--GainOnChangeInFairValue_pn5n6_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zfqidlawkTsd" title="Gain on change in fair value">0.5</span>&#160;million
gain in the change in fair value of the A.G.P. Convertible Note and interest expense of approximately $<span id="xdx_900_eus-gaap--InterestExpenseDebt_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zBS52vGGfOvj" title="Interest expense debt">32</span> thousand. The $<span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zHlRnK0oina7" title="Gain on debt extinguishment">2.4</span> million
gain on extinguishment and $<span id="xdx_90F_ecustom--GainOnChangeInFairValueOfConvertibleNote_pn5n6_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_z5asJdUCpdaj" title="Gain on change in fair value of convertible note">0.5</span> million gain on the change in fair value are presented within other income (expense), net, while the
$<span id="xdx_90D_eus-gaap--InterestIncomeExpenseNonoperatingNet_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zHi93s1To5Rh" title="Interest expense">32 </span>thousand of interest expense is presented within Interest expense, net, in the consolidated statement of operations and comprehensive
income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ConvertibleNotesPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes Payable [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ConvertibleNotesPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DisclosureConvertibleNotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DisclosureConvertibleNotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loans Payable</a></td>
<td class="text"><p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_zqaxLvbOUin1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_820_zGCsXPJkl3c7">Loans Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loans</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2022, the Company entered into Loan Agreements (the &#8220;Loans&#8221;) with two lenders, totaling $<span id="xdx_906_eus-gaap--LoansPayable_iI_pn5n6_c20220501__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_zZYgh4PKbNoj">0.2</span> million. <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateDescription_c20220501__20220501__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_z9QoObv7fxcl">The Loans
mature two years from the date of the agreement and bear no interest.</span> Each loan was made available to the Company by the lenders in
three tranches of (i) $<span id="xdx_90F_eus-gaap--LoansPayable_iI_pn3n3_c20220501__us-gaap--AwardTypeAxis__custom--TrancheOneMember_zz1Alc6UY8J7">33</span> thousand (&#163;<span id="xdx_904_eus-gaap--LoansPayable_iI_pn3n3_uGBP_c20220501__us-gaap--AwardTypeAxis__custom--TrancheOneMember_zLhFVV7tbOYd">30</span> thousand); (ii) $<span id="xdx_908_eus-gaap--LoansPayable_iI_pn3n3_c20220501__us-gaap--AwardTypeAxis__custom--TrancheTwoMember_zxUgMOgIz6Lj">33</span> thousand (&#163;<span id="xdx_906_eus-gaap--LoansPayable_iI_pn3n3_uGBP_c20220501__us-gaap--AwardTypeAxis__custom--TrancheTwoMember_zrRZvIUlzBC9">30</span> thousand) and (iii) $<span id="xdx_902_eus-gaap--LoansPayable_iI_pn3n3_c20220501__us-gaap--AwardTypeAxis__custom--TrancheThreeMember_zuacbFWSNf4">28</span> thousand (&#163;<span id="xdx_907_eus-gaap--LoansPayable_iI_pn3n3_uGBP_c20220501__us-gaap--AwardTypeAxis__custom--TrancheThreeMember_zdlk1x920wa8">25</span>
thousand), totaling $<span id="xdx_903_eus-gaap--LoansPayable_iI_pn5n6_c20220501_z3Pf4rrrpxr4">0.2</span> million. The Loans provided for events of default, including, among others, failure to make payment,
bankruptcy and non-compliance with the terms of the Loans. As of December 31, 2024, the Company utilized all three tranches of the
first loan and two out of three tranches of the second loan, with loans payable totaling $<span id="xdx_906_eus-gaap--LoansPayable_iI_pn5n6_c20241231_zsmPi7mTDGOi"><span id="xdx_907_eus-gaap--LoansPayable_iI_pn5n6_c20231231_zF5y5rjDoy97">0.2</span></span> million at December 31, 2023 and
December 31, 2024 respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 9, 2024, the Company and the Loans holders amended the loan agreements (the &#8220;Loans Amendment&#8221;) to extend the maturity
date for the Loans to&#160;<span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20241009__20241009_zpDK1htzGvt5" title="Maturity date">December 19, 2024</span>. The Loans Amendment also modified the payment terms for the Loans from a cash payment of
&#163;<span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_uGBP_c20241009__20241009_z97DrB6edE26" title="Payment terms for loan payment">85,000</span>&#160;per loan to (1) a cash payment of &#163;<span id="xdx_903_eus-gaap--RepaymentsOfNotesPayable_uGBP_c20241009__20241009_zJplNaQtoFv2" title="Cash payment">60,000</span>, (2) &#163;<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_uGBP_c20241009__20241009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ6untE11eI4" title="Common stock converted">25,000</span>&#160;worth of shares of Common Stock converted
into USD at the prevailing exchange rate, to be issued at the closing market price on the date prior to issuance, and in consideration
for the extension, and (3)&#160;<span id="xdx_90D_ecustom--StockIssuedDuringPeriodAdditionalSharesIssued_c20241009__20241009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1t3h5UI57Ua" title="Additional shares issued">2,500</span>&#160;additional shares of Common stock. On October 11, 2024, the Company issued each of the Loan
holders&#160;<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241011__20241011__us-gaap--InvestmentTypeAxis__custom--LoanHoldersMember_zGx3lEWyZn46" title="Shares issued during period">5,690</span>&#160;shares (<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241011__20241011_zuo4h6s4ZTTc" title="Shares issued during period">11,380</span>&#160;in total). The Loans remain outstanding as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extension was accounted for as a debt extinguishment. On October 9, 2024, the Company recorded a loss on debt extinguishment of approximately
$<span id="xdx_900_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_c20241009__20241009_zUe9pjTbVFBc" title="Loss on debt extinguishment">42</span> thousand calculated as the difference between (i) the $<span id="xdx_905_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241009_zDyB6BLrTHZd" title="Debt instrument carrying value">0.2</span> million carrying value of the Loans immediately prior to the Loans Amendment
(ii) the $<span id="xdx_908_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241009_zPdAe5Nw9nwi" title="Debt instrument fair value">0.1</span> million fair value of the Loans immediately after the Loans Amendment and (iii) the $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20241009__20241009_ztnQnbqnspdl" title="Shares issued">0.1</span> million fair value of the shares
issued to the holder as consideration for extending the maturity date. The difference between the $<span id="xdx_905_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241009_zpZYIVIRLHD8" title="Debt instrument carrying value">0.2</span> million carrying value immediately
prior to the Loans Amendment and the $<span id="xdx_908_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241009_zUbmXtLUymHl" title="Debt instrument fair value">0.1</span> million fair value immediately after the Loans Amendment was recorded as a debt discount and
amortized over the term date of the Loans using the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company incurred interest expense on the Loans of approximately $<span id="xdx_905_eus-gaap--InterestExpenseDebt_pn3n3_c20240101__20241231_zFFAkuIzHpfi">40
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand related to the amortization of the debt
discount recorded as a result of the Loans Amendment. <span id="xdx_907_eus-gaap--InterestExpenseDebt_pn3n3_do_c20230101__20231231_zq7DGNEPhnle">No
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interest expense was recorded for the year ended
December 31, 2023. The Loans remained outstanding as of December 31, 2024, therefore the Company was considered to be in default. The
Company repaid the lenders the outstanding principal balance of $<span id="xdx_909_eus-gaap--RepaymentsOfDebt_pn5n6_c20250201__20250228__us-gaap--TypeOfArrangementAxis__custom--LoansAmendmentMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAk9o8ZGLPE4">0.1
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in February 2025. See Note 20 for additional
details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>October
2024 Nirland Note</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 28, 2024, the Company issued a promissory note (the &#8220;October 2024 Nirland Note&#8221;) to Nirland, a related party, in
the original principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241028__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_z2VPzvuBUCe" title="Principal amount">0.6</span>
million in exchange for funds in such amount. See Note 16 for further reference to the relationship between the Company and Nirland.
The Nirland Note bears interest at a rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241028__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember__srt--RangeAxis__srt--MinimumMember_zSmrvO0flhCg" title="Interest rate">12</span>%
per annum, is due and payable semi-annually in arrears, and matures on October 31, 2025. If an event of default under and as defined
in the Nirland Note occurs, the interest rate will be increased to <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241028__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember__srt--RangeAxis__srt--MaximumMember_zFAYLqcitnyb" title="Interest rate">18</span>%
per annum or to the maximum rate permitted by law. In connection with the Nirland Note, the Company has agreed to pay Nirland a <span id="xdx_903_ecustom--ArrangementFeePercentage_pid_dp_c20241028__20241028__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zlCIe1omRMua" title="Arrangement fee percentage">1</span>%
arrangement fee, which will be included with the principal and interest owed under the Nirland Note. The <span id="xdx_903_ecustom--ArrangementFeePercentage_pid_dp_c20241028__20241028__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zoPS1WcAXMQ" title="Arrangement fee percentage">1</span>%
arrangement fee is accounted for as a debt discount and will be amortized to interest expense, net in the consolidated statement of
operations and comprehensive income (loss) using the effective interest method over the life of the October 2024 Nirland
Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company recorded approximately $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zU05k46ODRQ9" title="Interest expense">14,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of interest expense. The interest expense of $<span id="xdx_905_eus-gaap--InterestExpense_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zNe4PWTonRw" title="Interest expense">14,000</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">is comprised of (i) accrued interest of $<span id="xdx_905_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zbGWkAjldhsc" title="Accrued interest">13,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">based on the coupon rate of the debt and (ii) amortization of the debt discount of $<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zzZxlEXxlp9j" title="Amortization of debt discount">1 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand,
with both components recorded within interest expense, net in the consolidated statement of operations and comprehensive income
(loss). Accrued interest of $<span id="xdx_90D_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zgg8SnxuywMh" title="Accrued interest">13,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was recorded as a liability on the Company&#8217;s consolidated balance sheet within accrued expenses and other current liabilities.
The $<span id="xdx_901_eus-gaap--AmortizationOfDebtDiscountPremium_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zuLhTAkhP266" title="Amortization of debt discount">1,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amortization of the debt discount decreased the debt discount contra-liability included within the Loans payable, current portion on
the consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A.G.P.
Bridge Note</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 29, 2024, the Company entered into a Bridge Loan Agreement (the &#8220;Bridge Agreement&#8221;), with A.G.P., pursuant to which
AGP. made an advance (the &#8220;Advance&#8221;) to the Company in an amount not to exceed $<span id="xdx_901_ecustom--CommitmentFees_pn5n6_c20241029__20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_z6y0OuIQip53">0.6</span> million (the &#8220;Commitment&#8221;).
As partial consideration for the Advance, the Company entered into a Common Stock Purchase Warrant Agreement (the &#8220;Warrant Agreement&#8221;)
and issued AGP warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zrcVNxYnLyH" title="Shares issued">28,625</span> shares of the Company&#8217;s common stock, $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zsDornk4mrii" title="Common stock, par value">0.0001</span> par value per share, which is equal
to <span id="xdx_904_ecustom--CommonStockClosingPricePercentage_iI_pid_dp_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_z0RECplG9Ln9">50</span>% of the sum of the Commitment divided by the closing price of the Company&#8217;s Common Stock on October 29, 2024, at an exercise
price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zi0sXjQo6jYg">10.48</span> per share. Refer to Note 18 for additional information on the warrants issued to A.G.P.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Advance, the Company issued a promissory note (the &#8220;A.G.P. Bridge Note&#8221;) to A.G.P. in the original principal
amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zOKbYeEJkwRc">0.6</span> million. The Bridge Note bears interest at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zutQZLuQwIpc">4.21</span>% per annum and is due and payable on December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted above, the Company issued to A.G.P. warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zv26Nn7i2C56">28,625</span>
shares of the Company&#8217;s common stock. The Company determined that the Bridge Note and Warrant Agreement issuance were part of
a basket transaction and allocated the net proceeds using the residual value method. The warrants issued under the Warrant Agreement
were initially recorded at their fair value of $<span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20241029__20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zoUZQKyS0hUf" title="Fair value adjustment of warrants">0.2</span>
million. The warrants were classified as derivative liabilities because they do not meet the criteria in ASC 815-40 to be considered
indexed to the entity&#8217;s own stock. Refer to Note 18 for additional information and discussion of liability classification. The $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20240806__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zQp4o5bPAUe8" title="Warrants">0.2</span>&#160;million
recorded for the warrants was considered to be a discount on the A.G.P. Bridge Note making the balance of the note to be $<span id="xdx_900_eus-gaap--NotesPayable_iI_pn5n6_c20240806__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zFDWwXGpjXfh" title="Notes payable">0.6</span>&#160;million
note payable, less a total debt discount of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zMTZ3SlZazye" title="Total debt discount">0.2</span>&#160;million.
The debt discount will be amortized to interest expense using the effective interest method over the life of the note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company recorded and paid approximately $<span id="xdx_90A_eus-gaap--InterestExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zqaBCFM3xzhk" title="Interest expense">1</span> thousand of interest expense related to the A.G.P. Additionally,
the entire debt discount of $<span id="xdx_900_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zdaPLz5wotdb" title="Amortization of debt discount">0.2</span> million was amortized and recorded as interest expense during the year. The interest expense of $<span id="xdx_90C_eus-gaap--InterestExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zCTzKZMBDQyf" title="Interest expense">1</span> thousand
and amortization of the debt discount of $<span id="xdx_900_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_z0fqAjA52Haa" title="Amortization of debt discount">0.2</span> million were recorded within Interest expense, net in the consolidated statement of operations
and comprehensive income (loss). As of December 31, 2024, the A.G.P. Bridge note was fully repaid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Commission Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DisclosureDeferredCommissionPayableAbstract', window );"><strong>Deferred Commission Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DeferredCommissionPayableTextBlock', window );">Deferred Commission Payable</a></td>
<td class="text"><p id="xdx_80B_ecustom--DeferredCommissionPayableTextBlock_ze7F4iIFqe5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_828_zJpDUtE6Q0L2">Deferred Commission Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 2, A.G.P was a financial advisor to both MURF and Old Conduit in connection with the Merger transaction. Upon the completion
of the Merger, A.G.P.: (i) received a cash fee of $<span id="xdx_900_eus-gaap--ProceedsFromFeesReceived_pn5n6_c20230921__20230922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zyLbAGLrJa71" title="Cash fee received">6.5</span> million, <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230921__20230922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgUEGmx3ucl8" title="Number of shares issued">13,000</span> shares of Common Stock, and warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zALiIPeBOtr5" title="Warrants to purchase share">540</span> shares of
Common Stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_z6csMjfMg0F6" title="Exercise price">1,100</span> per share pursuant to its engagement agreement with Old Conduit entered into on August 2,
2022, and (ii) agreed to defer payment, to be paid in the future under certain circumstances by a date no later than March 21, 2025,
of $<span id="xdx_90E_eus-gaap--PaymentsForFees_pn5n6_c20230921__20230922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zHOGL4kqbFxf" title="Deferred payment fees">5.7</span> million of fees plus annual interest of <span id="xdx_90E_ecustom--DeferredCommissionPayableAnnualInterestRate_iI_pid_dp_c20230922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zCjs9VMyFa57" title="Annual interest rate">5.5</span>% as a result of its engagement for MURF&#8217;s IPO. The $<span id="xdx_90A_ecustom--DeferredCommissionPayableNonCurrent_iI_pn5n6_c20231231__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zU3sT1cp4Dph" title="Deferred commissions payable, non-current liability">5.7</span> million deferred commissions
payable was recorded as a non-current liability on the Company&#8217;s consolidated balance sheet as of December 31, 2023. Accrued interest
was recorded as a liability on the Company&#8217;s consolidated balance sheet under accrued expenses and other current liabilities and
totaled $<span id="xdx_90F_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20241231_zHs1if2qFWY8" title="Accrued expenses and other current liabilities">0.4</span> million and $<span id="xdx_901_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20231231_zm7js835ONB1" title="Accrued expenses and other current liabilities">0.1</span> million as of December 31, 2024, and December 31, 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 25, 2024, the Company issued the A.G.P. Convertible Note in the principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241125__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_z21NUAKr6Ixl" title="Convertible principal amount">5.7</span> million to evidence the currently owed
deferred commission payable, at which time the deferred commission payable balance was removed. Refer to the Note 7 for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DeferredCommissionPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Commission Payable [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DeferredCommissionPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DisclosureDeferredCommissionPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DisclosureDeferredCommissionPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DisclosureResearchAndDevelopmentExpenseAbstract', window );"><strong>Research And Development Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock', window );">Research and Development Expense</a></td>
<td class="text"><p id="xdx_809_ecustom--DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock_zubJDKQDiaY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_829_zjS5XWJP8Onj">Research and Development Expense</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>August
2024 License Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 7, 2024, the Company and AstraZeneca AB (PUBL) (&#8220;AstraZeneca&#8221;) entered into a License Agreement, dated August 7,
2024 (the &#8220;August 2024 License Agreement&#8221;). Pursuant to the August 2024 License Agreement, AstraZeneca agreed to grant a
license to the Company under certain intellectual property rights controlled by AstraZeneca related to HK-4 Glucokinase activators AZD1656
and AZD5658 in all indications and myeloperoxidase inhibitor AZD5904 for the treatment, prevention, and prophylaxis of idiopathic male
infertility. The Company will be responsible for the development and commercialization of the Licensed Products under the August
2024 License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for the grant of the license, the Company (i) granted AstraZeneca Common Stock pursuant to a stock issuance agreement
(the &#8220;Issuance Agreement&#8221;), (ii) paid AstraZeneca an up-front payment of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--AstraZenecaMember_z3zwzbohA6gb">1.5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million,
and (iii) is obligated to pay AstraZeneca a percentage (on a tiered basis) of any amounts it may receive in connection with a grant
of a sublicense (subject to various customary exceptions). The Issuance Agreement called for the Company to issue AstraZeneca <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__dei--LegalEntityAxis__custom--AstraZenecaMember_z0A67zeqVOD6">95,044</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
shares of the Company&#8217;s Common Stock. The Issuance Agreement provides AstraZeneca with resale registration rights for such
shares. As of December 31, 2024, the Company recorded $<span id="xdx_901_eus-gaap--GeneralAndAdministrativeExpense_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--AstraZenecaMember_zxoqncFMLZu4">1.6</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--AstraZenecaMember_zCOxGRIShsJl">1.5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;million
in research and development expenses related to the share issuance and upfront payment to AstraZeneca, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AstraZeneca
has been granted a right of first negotiation to develop, manufacture, and commercialize a Licensed Product if the Company receives an
offer for, or solicits, a transaction where a third party would obtain the right to develop, manufacture, or commercialize a Licensed
Product. If AstraZeneca exercises such right, the parties will negotiate in good faith for an agreed period of time on an exclusive basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
party may terminate the August 2024 License Agreement for material breach (subject to a cure period) or insolvency of the other party.
The Company may terminate the August 2024 License Agreement for convenience (in its entirety or on a Licensed Product-by-Licensed Product
basis). In addition, AstraZeneca may terminate the August 2024 License Agreement in certain circumstances, including (but not limited
to) the Company ceasing development of all Licensed Products (subject to certain exceptions for normal pauses or gaps between clinical
studies).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the above, the Company will no longer fund the development of AZD1656 or AZD5904 under the terms of the Exclusive Funding
Agreement, dated March 26, 2021 with St George Street Capital (the &#8220;Funding Agreement&#8221;). In this regard, the Company previously
entered into a deed of amendment amending such Funding Agreement. The parties agreed that the project funding provisions of such Funding
Agreement whereby the Company had the right to fund a project or refer other parties to St George Street Capital, were amended to provide
that St George Street Capital must still include the Company in any project funding opportunities and requests but may now seek other
third-parties to fund projects in addition to the Company. In November and December 2024, the Company received a letter from St George Street Capital and formal complaints
filed with the Intellectual Property Office claiming the Company was not the sole owner of the AZD 1656 co-crystal patent. See note 15
for additional details on the claim.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>SARBORG
Service Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2024, the Company entered into a Services Agreement (the &#8220;Sarborg Service Agreement&#8221;) with SARBORG Limited
(&#8220;Sarborg&#8221;), a Cayman Islands company and related party of the Company. See Note 16 for further reference to the
relationship between the Company and Sarborg. Under the terms of the Sarborg Service Agreement, Sarborg will provide algorithmic and
cybernetic technology services to Conduit, including the development of decision-support tools and advanced cybernetic systems
tailored to enhance Conduit&#8217;s decision-making processes and maximize the value of its pharmaceutical asset
portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarborg
will perform the services to Conduit comprised of three phases: the Initial Phase (0-24 weeks) focuses on establishing a foundation for
collaboration and aligning Sarborg&#8217;s services with Conduit&#8217;s strategic goals; the Development Phase (24-36 weeks) involves
building technological infrastructure, including dashboards and predictive models; and the Ongoing Services Phase (36-52 weeks) ensures
the sustained functionality and relevance of Sarborg&#8217;s deliverables while supporting Conduit&#8217;s growth through iterative improvements
and updates. Sarborg will create specific deliverables, including reports, computer programs, software applications, APIs, mobile applications,
source code, written technical specifications and designs, operating and maintenance manuals, and other recorded data and information
arising from or relating to the services. Sarborg will provide all necessary resources to perform the services and deliver the deliverables
in accordance with the Sarborg Service Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarborg Service Agreement has an initial term of 12 months, which commenced on the effective date, and may be renewed or extended
upon mutual written agreement of the parties. Either party may terminate the Sarborg Service Agreement for any reason upon 90
days&#8217; written notice or immediately upon written notice if the other party breaches any material term of the Sarborg Service
Agreement and fails to cure such breach within thirty days or becomes insolvent, files for bankruptcy, or is placed under the
control of a receiver, trustee, or similar authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarborg Service Agreement includes provisions for the ownership and use of intellectual property. Sarborg will own its pre-existing
intellectual property rights, including proprietary tools and methodologies used in the performance of the services. Conduit will
own all deliverables resulting from the services performed by Sarborg under the Sarborg Service Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sarborg Service Agreement provides Sarborg with registration rights
for any Common Stock of Conduit that Sarborg receives as consideration under the Sarborg Service Agreement. In such event, Conduit will
use commercially reasonable efforts to (i) file a registration statement covering the resale of the Common Stock within 60 days after
the issuance; and (ii) ensure that such registration statement becomes effective within 90 days after filing. This Agreement also includes
confidentiality obligations, representations and warranties, indemnification, limitation of liability, and insurance requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the services, Conduit agreed to pay Sarborg an initial cash payment of $<span id="xdx_901_ecustom--PaymentToResearchAndDevolpmentAmount_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zGSBEwjlUzy8" title="Cash payment">0.2</span>
million and $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zaGPaxjLMJth" title="Shares, value">0.2</span>
million payable&#160;through the issuance of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zitFwoh9tVkd" title="Shares issued">22,727</span>
shares of&#160;common stock, determined by the closing price on the day preceding the execution of the Sarborg Service Agreement.
Further milestone payments payable in conjunction with the achievement of certain milestones over the term of the Sarborg Service
Agreement, totaling up to $<span id="xdx_904_ecustom--CashPayment_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_z3X3vxg9KAKl" title="Payable in cash">1.8</span>
million, are payable in cash or shares, at the discretion of Conduit. Sarborg will be reimbursed for pre-approved, necessary, and
reasonable out-of-pocket expenses directly incurred in connection with the performance of the services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
determined that the cost incurred under the Sarborg Service Agreement should be recorded to research and development expense in the
statement of operations and comprehensive income (loss), as the Sarborg Service Agreement is designed to provide the
Company with software/dashboard to aid in research and development activities. The initial cash payment of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zdTjjtUF9ay8" title="Shares, value">0.2</span>
million and issuance of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zhb8ih1P5wu7" title="Shares issued">22,727</span>
shares of Common Stock were recorded to prepaid expense and will be amortized over the initial term of the Sarborg Service Agreement to research and
development expense. As of December 31, 2024, the <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zJqrM2d0msJ8" title="Shares issued">22,727</span>
shares of common stock were yet to be issued and are recorded within accrued expense and other current liabilities in the
consolidated balance sheets. As of December 31, 2024, the Company has recognized $<span id="xdx_901_eus-gaap--AdjustmentForAmortization_pn5n6_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zirSUlvBMhF4" title="Amortization">0.2</span>
million of amortization within research and development expense in the consolidated statement of operations and comprehensive income
(loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Research And Development License Agreement [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DisclosureResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DisclosureResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share Based Compensation</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zHY0JLIDfVDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_825_z1goBzzbw7ok">Share Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2023, in connection with the Merger, the Company adopted the Conduit Pharmaceuticals Inc. 2023 Stock Incentive Plan
(the &#8220;2023 Plan&#8221;). The 2023 Plan became effective upon the closing of the Merger. The 2023 Plan initially provided for
the issuance of up to&#160;<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20230922__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeStockIncentivePlanMember_zeoQ0ABJNyhf" title="Issuance of common stock">114,976</span>&#160;shares
of Common Stock. Pursuant to the 2023 Plan&#8217;s &#8220;evergreen&#8221; provision, on February 6, 2025, the Company increased the
number of shares of Common Stock available for issuance under the 2023 Plan by <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20250206__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeStockIncentivePlanMember_zpg7tFAi2QH9" title="Issuance of common stock">69,240</span>
shares. Total shares available for issuance is <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20250101__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeStockIncentivePlanMember_zFtXfXWHh6R" title="Issuance of common stock">154,125</span> effective January
1, 2025. The number of authorized shares will automatically increase on January 1, 2026 and
continuing annually on each anniversary thereof through (and including) January 1, 2033, equal to the lesser of (i)&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_c20230921__20230922__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeStockIncentivePlanMember_zZSEblBFdode" title="Shares issued percentage">5</span>%
of the shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of
shares of common stock as determined by the Board or the applicable committee of the Board. The 2023 Plan allows for awards to be
issued to employees and non-employee directors in the form of options, stock appreciation rights, restricted stock, restricted stock
units (&#8220;RSUs&#8221;), performance stock units, dividend equivalents, other stock-based, or other cash-based awards. As of
December 31, 2024, there were&#160;<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20241231__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeStockIncentivePlanMember_zjlc6qhr0Psc" title="Shares available for issuance">84,885</span>&#160;shares
of Common Stock available for issuance under the 2023 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2024, the Company issued a total of
<span id="xdx_903_eus-gaap--SharesIssued_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxPOfTBCt3T8" title="Stock options to employees shares">56,700</span> stock options to employees and non-employee directors with an aggregate grant date fair value of $<span id="xdx_90E_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUDZ8cmoLMec" title="Stock options to employees shares granted">0.4</span> million. For
the year ended December 31, 2024 and December 31, 2023, there was a total of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zaPfzGjpnvy9" title="Share based compensation">1.6</span>&#160;million and $<span id="xdx_906_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zXlDHavOxlt5" title="Share based compensation">0.2</span> million, respectively in stock-based
compensation expense recognized within General and Administrative expenses on the consolidated statements of operations and Comprehensive
Loss, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2024, in connection with a services agreement with an unrelated third party to provide marketing services, the Company
issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240624__20240624__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAr2UgbhSLS1" title="Shares new issued">961</span> shares of its Common Stock (the &#8220;Service Shares&#8221;). The Company valued the Service Shares at $<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20240624__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxpG1u3uTKA3" title="Shares issued for services, per share">156</span>&#160;per
share, the closing price of the Company&#8217;s Common Stock on June 21, 2024, adjusted for the Reverse Stock Split. The total
compensation for these shares is $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pn5n6_c20240624__20240624__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWSkChCcPySk" title="Share based compensation">0.2</span>&#160;million
which will be recognized within general and administrative expense over the service period of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2024, certain non-employee directors elected to receive a portion of their unpaid cash retainers due under the Director
Compensation Program in the form of shares. In total, $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20241118__20241118__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorsMember_z2Kj9i6M5lze">0.1 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
of unpaid retainers was settled through the issuance <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241118__20241118__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorsMember_zeqCSzXEyFn8">10,027 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Common Stock (the &#8220;Retainer Shares&#8221;). The Company valued the Retainer Shares at $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20241118__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorsMember_zGp5kyicjAk">9.0</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share, the closing price of the Company&#8217;s Common Stock on November 18, 2024, adjusted for the Reverse Stock Split. The Company
previously accrued in the unpaid retainers in Accrued expenses and other current liabilities in the Company&#8217;s consolidated
balance sheets. Upon issuance of the shares of Common Stock, the accrual was reduced based on the value of the shares
issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2024, the Board of Directors approved a one-time equity retainer in the form of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20241118__20241118__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBmLefyjKCZ5">750 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fully
vested shares of Common Stock (the &#8220;Board Shares&#8221;) to a member of the Board of Directors for prior services. The Company
valued the Board Shares at $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241118__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zEpLlroMDCz3" title="Share price per share">9.20</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share, the closing price of the Company&#8217;s Common Stock on November 18, 2024, adjusted for the Reverse Stock Split. The total
compensation for these shares is $<span id="xdx_902_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20241118__20241118__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zaL7tRiVxE93" title="Total compensation">75</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand
which was immediately recognized within General and administrative expense in the consolidated statement of operations and
comprehensive income (loss). The shares of common stock were issued under the 2023 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
18, 2024, Mr. Heilbron elected to have the $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn5n6_c20241118__20241118__srt--TitleOfIndividualAxis__custom--MrHeilbronMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zIbELbZxenJa" title="Stock issued during period value issued for services, value">0.1</span> million owed to him under the Consulting Agreement paid in share of the Company&#8217;s
Common Stock. In total <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20241118__20241118__srt--TitleOfIndividualAxis__custom--MrHeilbronMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zlSBJelfm9i" title="Stock issued during period value issued for services, shares">8,161</span> shares are to be issued to Mr. Heilbron based on the closing price of the Company&#8217;s Common Stock on
November 18, 2024, $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20241118__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--MrHeilbronMember_z6fHwIaUs8Mh" title="Shares issued for services, per share">9.20</span> per share, adjusted for the Reverse Stock Split. As of December 31, 2024, the shares had not been issued to Mr.
Heilbron. The value of the shares are recorded as an accrued expense and other current liability on the consolidated balance sheets as
of December 31, 2024.</span></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>



<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Merger, as discussed in Notes 1 and 2, and by Unanimous Written Consent of the Board of Directors, the then
Chief Financial Officer of the Company was granted&#160;<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20231201__20231201__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zZOOk3nwlFSe" title="Shares granted">745</span>&#160;RSUs
on December 1, 2023 at a weighted average grant date fair value of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20231201__20231201_zJuFPpPskTs8" title="Weighted average grant date fair value">551</span> per unit.
The RSUs were to vest in equal annual instalments on the first three anniversaries of the closing of the Merger. Upon the then Chief
Financial Officer&#8217;s resignation, effective May 15, 2024, all such RSUs were forfeited. On June 7, 2024, by Unanimous Written
Consent of the Board of Directors, the Interim Chief Financial Officer of the Company and a Board member were each
granted&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240607__20240607__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zRrDa2KFs7Hj" title="Shares granted">372</span>&#160;shares
of immediately vested restricted stock at a weighted average grant date fair value of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240607__20240607__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zYQEGP8lBcve" title="Weighted average grant date fair value">284</span>.
The shares of restricted stock were fully vested as of the grant date.&#160;<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_do_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zv8wBqFaW3hi" title="Shares granted">No</span>&#160;additional
RSU&#8217;s or shares of restricted common stock were granted during the year ended December 31, 2024. There were&#160;<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znwVjeILgbZj" title="Shares vested">745</span>&#160;shares
of restricted common stock vested as of December 31, 2024 and&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zujcwuSwv8E2" title="Shares vested">no</span>&#160;RSUs
vested as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"></p>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zrKDiWEdwHB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes restricted stock activity for the 2023 Plan:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span id="xdx_8BE_z3DO0Eys0G8j" style="display: none">Schedule
of Restricted Stock Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards</b></span></p></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value Per Unit</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231_zvAzJuP4BzY4" style="width: 16%; text-align: right" title="Number of Awards, Outstanding">745</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231_z7dcBqJqSAoc" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding">551</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231_zy4r9o6O4czh" style="text-align: right" title="Number of Awards, Granted">745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zY3ZhFI8v3G8" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">284</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231_zkG3qLdNmqL4" style="text-align: right" title="Number of Awards, Cancelled/Forfeited">(745</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_iN_pid_di_c20240101__20241231_zCtdIEGtRuhj" style="text-align: right" title="Weighted Average Grant Date Fair Value, Cancelled/Forfeited">(551</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231_zMeNMKBTdbV7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Awards, Vested">(745</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_iN_pid_di_c20240101__20241231_zB9bUhufF7Y2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Vested">(284</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231_zjQYtVpsvdH5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Awards, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1518">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231_zTLLMpuwAGJj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1520">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zYSMwp7EYgte" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of each option award on the date of grant using the Black-Scholes option-pricing model. The Company
then recognizes the grant date fair value of each option as compensation expense ratably using the straight-line attribution method over
the service period (generally the vesting period). The Black-Scholes model incorporates the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility &#8211; the Company estimates the volatility of the share price of their peer companies at the date of grant using a &#8220;look-back&#8221;
    period which coincides with the expected term, defined below. The Company believes using a &#8220;look-back&#8221; period which coincides
    with the expected term is the most appropriate measure for determining expected volatility.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term &#8211; the Company estimates the expected term using the &#8220;simplified&#8221; method outlined in SEC Staff Accounting Bulletin
    No. 107, &#8220;Share-Based Payment.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate &#8211; the Company estimates the risk- free interest rate using the U.S. Treasury Yield curve for periods equal to
    the expected term of the options in effect at the time of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
    &#8211; the Company uses an expected dividend yield of zero because the Company has not declared nor paid a cash dividend, nor are
    there any plans to declare a dividend.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zBaIaJl265s5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimated the fair value of stock options granted in the periods presented using a Black-Scholes option-pricing model utilizing
the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B2_zGRBcoYo0Cq7" style="display: none">Schedule of Fair Value
of Stock Option Granted</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zTe9FxoLtNFh" title="Expected Volatility">83.2</span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zcl1d02WjwT" title="Expected Volatility">85.4</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z9UGhjz6BM4l" title="Expected Volatility">79.0</span>% - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zjt4AnyIiAg2" title="Expected Volatility">80.0</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z3JgiqKT57df" title="Expected term (years)">5.5</span> - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zxXQXcvmcwEh" title="Expected term (years)">5.6</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zyBX57jSy0a4" title="Expected term (years)">3.5</span> - <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_ztaWcF6568Ki" title="Expected term (years)">6.5</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zZMa1v43seSj" title="Risk-free interest rate">4.28</span>% - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z9WtdAI2SJK8" title="Risk-free interest rate">4.40</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zjbMLbwsQhuh" title="Risk-free interest rate">4.16</span>% - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zrjfVl4qTcCl" title="Risk-free interest rate">4.35</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Expected dividend yield (%)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20241231_zeDDkprb70g9" title="Expected dividend yield">0</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230101__20231231_zuz1k08Guxf8" title="Expected dividend yield">0</span></td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A0_zOGwosEQdR16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for forfeitures as they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures
arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zlD4LccAaC7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes stock option activity for the 2023 Plan:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BE_zEM2SYKmrjH9" style="display: none">Schedule
of Stock Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Intrinsic Value (in thousands)</p></td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_z89lSJcEixcg" style="width: 12%; text-align: right" title="Number of Options, Outstanding">10,717</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zaXw5uDHyNC6" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding">551</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zqmlZa8fWW5k" title="Weighted Average Remaining Contractual Term Years">8.85</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zSNWNOOx17Nf" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1560">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zaPG7aLhLJcg" style="text-align: right" title="Number of Options, Granted">56,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zmQ4YTeY53k" style="text-align: right" title="Weighted Average Exercise Price, Granted">8.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zfdVIuu2lu45" style="text-align: right" title="Number of Options, Cancelled/forfeited">1,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zb2MSpYym9Kl" style="text-align: right" title="Weighted Average Exercise Price, Cancelled/Forfeited">551</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zYYZSYL4Qqdg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1570">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zP19SrsdlKD2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1572">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_z1jc3SEVYEi7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding">65,509</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zk9sxTdDKnf9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding">81.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zn3Gqjnt0d2i" title="Weighted Average Remaining Contractual Term Years">9.72</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zu9y0C3WCqk7" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1580">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zfPXv2RcdScj" style="text-align: right" title="Number of Options, Exercisable">23,154</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zfYT7HapQtik" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">84.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zTeBGUka45G1" title="Weighted Average Remaining Contractual Term Years">9.66</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zsoDPz366TDk" style="text-align: right" title="Aggregate Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1588">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_ziJRyvS6oSo9" style="text-align: right" title="Number of Options, Unvested">42,355</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zHZP7SGlZN15" style="text-align: right" title="Weighted Average Exercise Price, Unvested">80.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zXZUWGtMgEJ3" title="Weighted Average Remaining Contractual Term Years">9.76</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zjP7aVdxXTB2" style="text-align: right" title="Aggregate Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1596">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zW7FXtZw68J" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair
value of the Company&#8217;s common stock for those options that had exercise prices lower than the fair value of the Company&#8217;s
common stock. As of December 31, 2024, the total compensation cost related to non-vested option awards not yet recognized was $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20241231_zOlHt25vwM4h" title="Cost related to non-vested option">2.4</span> million
with a weighted average remaining vesting period of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zboIsSjBkl64" title="Weighted average remaining vesting">2.07</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zMffBXayQx58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span id="xdx_822_zjXscbwacXga">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zUcA0awPmLg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Loss from operations before income
taxes for the years ended December 31, 2024 and 2023 is summarized below (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zMVxAIiHVcYl" style="display: none">Schedule of Income before Income Tax, Domestic and Foreign</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231_zj8aoHNv8tki" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_z1IT1RIWy1fb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_iB_zbAoRlECz5Wd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations before income taxes:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i01_maILFCOzobr_zQsoEnZ56P78" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; padding-left: 0.5in">US</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(12,855</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(1,990</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i01_maILFCOzobr_zRwjiNfo36Yj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.5in">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,947</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,454</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_mtILFCOzobr_zikm4NYzBAs1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,802</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(536</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A1_zBoGoEzeKrd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z0DMoB3vjxg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provision (benefit) for income taxes for the years ended December 31, 2024 and December 31, 2023 is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B2_zxhmnoyBXHKj" style="display: none">Schedule of Provision for Income Tax</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_zkf2jmA5U8yg" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zfVRTsnxp1yk" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For The Years Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2024</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_zcD79FYKzuv1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1620">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1621">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_zTlVy8Beh0dh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1623">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1624">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_zlanbZ1RLPkk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Foreign</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1626">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1627">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_zf2uGegnBRG2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Current income tax</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1629">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1630">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_z3MeELTHQa1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%">Federal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(2,429</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(843</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_zPYSZliV9Hie" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">355</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(355</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_pn3n3_znCwMjmrOSYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Foreign</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(931</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(251</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3n3_zzva8tygFM3h" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income tax</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,005</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,449</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_ztZLWMAGlhI5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in Valuation Allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,005</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,449</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zzMTb2QetDP9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Income Tax Expense</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1647">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1648">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zYm6iPW3AKyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zeq9Kfy0ZFJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax provision differed from the amount computed by applying the U.S. federal income tax rate of <span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_zY0243RDodYl">21</span>% to income (loss) before taxes, as
follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zlaiIzT87Rj4" style="display: none">Schedule
of Federal Income Tax Rate</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zREUvd2H3s3c" style="border-bottom: Black 1pt solid; text-align: center">US</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zioxz5mvuNth" style="border-bottom: Black 1pt solid; text-align: center">Foreign</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zEIGnpM0vrU8" style="border-bottom: Black 1pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>For The Year Ended</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>US</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Foreign</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Consolidated</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzbix_zsMbfVAp9cNg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Taxes at federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(2,705</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(1,039</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(3,744</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maITEBzbix_zuUmSswPUKU5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign Rate Differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1657">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91 </td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maITEBzbix_zIvbgV5iFirc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Meals &amp; Entertainment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1662">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_pn3n3_maITEBzbix_zaqsfP2LujIh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Eq Comp Perm</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1666">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IncomeTaxReconciliationConvertibleDebtAdjustment_pn3n3_maITEBzbix_zT2Npgc5Wbh9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible Debt Adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1670">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--IncomeTaxReconciliationStateReRate_pn3n3_maITEBzbix_zokB8Ld15Oxc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State Re-Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">355</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1674">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">355</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maITEBzbix_zuEidSykYiu5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(59</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzbix_zy1n58puvGEg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change In Valuation Allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,074</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">931</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,005</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzbix_zlhSe7jytOLk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total provision (benefit) for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1685">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1686">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1687">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmASuhfEOQo6" style="border-bottom: Black 1pt solid; text-align: center">US</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zXpfATiNFTCh" style="border-bottom: Black 1pt solid; text-align: center">Foreign</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zBFlZWCWregl" style="border-bottom: Black 1pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>For The Year Ended</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>US</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Foreign</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Consolidated</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzbix_zHfGaUT0Pye8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Taxes at federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(417</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">305</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(112</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzbix_zmZ9OVyOM44a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State Taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(175</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1694">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(175</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maITEBzbix_z8DbuhbmDJic" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign Rate Differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1697">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">490</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">490</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maITEBzbix_zJbdDWvcgoH" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Meals &amp; Entertainment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_pn3n3_maITEBzbix_zv0Pr4kfU13j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Eq Comp Perm</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1706">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncomeTaxReconciliationConvertibleDebtAdjustment_pn3n3_maITEBzbix_z6tILXxHK4j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Debt Adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1709">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,048</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,048</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--IncomeTaxReconciliationPurchaseAccountingAdjustments_pn3n3_maITEBzbix_zxmD3op3Czzh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Purchase Accounting Adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(609</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1714">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(609</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzbix_zKInzUrrpnhd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change In Valuation Allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">251</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,449</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzbix_zi9aJ1MvZug6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total provision (benefit) for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1721">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1722">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1723">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A1_z2QPcpWsJELg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zSMZBNIYmoDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effects of temporary differences which give rise to significant portions of deferred tax assets are as follows as of December 31
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zXEONsTeVo4" style="display: none">Schedule
of Deferred Tax Assets and Liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zbiDH8OVEin7" style="border-bottom: Black 1pt solid; text-align: center">US</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zfu5jwUxRBfl" style="border-bottom: Black 1pt solid; text-align: center">Foreign</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20241231_zkzR5g3PH9S9" style="border-bottom: Black 1pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>For The Year Ended</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>US</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Foreign</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Consolidated</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Deferred Tax Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DeferredTaxAssetsStockOptions_iI_pn3n3_maDTAGzJ4A_zpGtcoAV3Fmh" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">280</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1728">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">280</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsHedgingTransactions_iI_pn3n3_maDTAGzJ4A_zP3jcOXwpTyk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Transaction Costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1732">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">393</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzJ4A_z47NOXKKQNrj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research &amp; Development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">671</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1736">-</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">671</p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_pn3n3_maDTAGzJ4A_zZ4ACcBvPOH8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1740">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzJ4A_z0lrxbxmVF0h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net operating loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,788</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,182</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,970</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzJ4A_maNDTAzpU6_zzOChQgdkKJ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,455</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzjwi_zTg0HciqIuB7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,273</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,182</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,455</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTALNzjwi_zIniBtnKe5Ve" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets (liability)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1755">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1756">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1757">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_znmEnIClDEKe" style="border-bottom: Black 1pt solid; text-align: center">US</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zt7U4vfjY3hh" style="border-bottom: Black 1pt solid; text-align: center">Foreign</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zNNh3iKZH5ri" style="border-bottom: Black 1pt solid; text-align: center">Consolidated</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>For The Year Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>US</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Foreign</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Consolidated</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Deferred Tax Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxAssetsStockOptions_iI_pn3n3_maDTAGzJ4A_zCUi9CCfy8Sg" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">37</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1760">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">37</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsHedgingTransactions_iI_pn3n3_maDTAGzJ4A_zvxOLF2rEw11" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Transaction Costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">599</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">599</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzJ4A_zJt5jqeQdw03" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net operating loss</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">562</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">251</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">813</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzJ4A_maNDTAzpU6_zrbfj4BlPjxa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">251</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,449</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzjwi_zNC0hv4gSJ0f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Valuation allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,198</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(251</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,449</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTALNzjwi_z1HzbCuagGjk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net deferred tax assets (liability)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1779">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1780">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1781">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zYvYVgkdfzIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and December 31, 2023, the Company had net operating loss (&#8220;NOL&#8221;) carryforwards for U.S.
federal&#8221; purposes of approximately $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zONcUIuFwhQl" title="Net operating loss">8.5</span>
million and $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zrQZtTEafhz3" title="Net operating loss">1.9</span>
million, respectively, which carryforward indefinitely and can offset <span id="xdx_90A_ecustom--EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate_pid_dp_uPure_c20230101__20231231_zxP8Q80J9Ikc" title="Effective income tax rate reconciliation future income years tax rate">80</span>%
of taxable income in future years. As of December 31, 2024 and December 31, 2023, the Company had state NOL carryforwards of <span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_dxL_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z54Ipa0mrWZa" title="Net operating loss::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1789">nil</span></span> and $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zsBp23lxSEL6" title="Net operating loss">1.9</span>
million, respectively. As of December 31, 2024 and December 31, 2023, the Company had net
operating loss (&#8220;NOL&#8221;) carryforwards for foreign purposes of approximately $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z6sBzjl8N1Vd" title="Net operating loss">4.7</span>
million and $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z2mqYdV4CR6a" title="Net operating loss">1.0</span>
million, respectively, which carryforward indefinitely. Net operating loss (NOL) carryforwards are subject to limitations in
the event of a change in control under Section 382 of the Internal Revenue Code. This section limits the amount of taxable income
that can be offset by NOLs after an ownership change. The limitation is calculated as the value of the old loss corporation
multiplied by the long-term tax-exempt rate. If the new loss corporation does not continue the business enterprise of the old loss
corporation for a specified period, the NOL carryforwards may be disallowed. The Company has not yet conducted a Section 382 study
to determine whether any ownership changes have occurred that would impose annual limitations on its ability to utilize its NOL
carryforwards. Until such a study is completed, there is substantial uncertainty regarding the amount of NOL carryforwards that
could be utilized annually to offset future taxable income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company establishes a valuation allowance when it is more likely than not that the Company&#8217;s recorded net deferred tax asset
will not be realized. In determining whether a valuation allowance is required, the Company must take into account all positive and
negative evidence with regard to the utilization of a deferred tax asset. As of December 31, 2024 and December 31, 2023, the
valuation allowance for deferred tax assets totaled approximately $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20241231_z0hvDipLYfYk" title="Deferred tax assets valuation allowance">4.5</span>
million and $<span id="xdx_901_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20231231_zFAUjGhdS6mj" title="Deferred tax assets valuation allowance">1.4</span>
million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock and Preferred Stock</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zs1qrt9ByTA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_82C_zrrD6CPabe2j">Common Stock and Preferred Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, and December 31, 2023, the Company has authorized the issuance of up to <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zFNloFgi4DNa">250,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of common stock, respectively, at a par value $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zbCsuUxa08vj">0.0001 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, and December 31, 2023 there were <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_znJXFoBn2Xsk" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_z7ll3rjrklYj" title="Common stock, shares outstanding">1,384,801</span></span> and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zun38lDOR0R5" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zD0jJX6loLli" title="Common stock, shares outstanding">738,295</span></span> shares of Common Stock issued and outstanding, respectively.
<span id="xdx_905_eus-gaap--DividendsCash_do_c20240101__20241231_zJ9MCI6mzbG1">No</span> cash dividends have been declared or paid as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of the Common Stock are entitled to one vote per share, and to receive dividends, on and if declared by the board of directors and, upon
liquidation or dissolution, are entitled to receive all assets available for distribution, subordinate to the rights, preferences, and
privileges of any outstanding preferred shares (if any) with respect to dividends and in connection with liquidation, winding up and
dissolution of the Company. The holders have no preemptive or other subscription rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company has authorized the issuance of up to <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zFo4yNFaO5W5">1,000,000</span> shares of Conduit Pharmaceuticals, Inc. preferred stock
(the &#8220;Preferred Stock&#8221;). As of December 31, 2024, and December 31, 2023, <span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_dxL_c20241231_zJ2bW9FgKsrj" title="Preferred stock, shares issued::XDX::-"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_dxL_c20241231_z9eeZtHsLyji" title="Preferred stock, shares outstanding::XDX::-"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pid_dxL_c20231231_zSdI97jxcfb3" title="Preferred stock, shares issued::XDX::-"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dxL_c20231231_zmPztFppNXG3" title="Preferred stock, shares outstanding::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1815"><span style="-sec-ix-hidden: xdx2ixbrl1817"><span style="-sec-ix-hidden: xdx2ixbrl1819"><span style="-sec-ix-hidden: xdx2ixbrl1821">no</span></span></span></span></span></span></span></span> preferred shares were issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>At-the-Market
Offering</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 23, 2024, the Company entered into the Sales Agreement with A.G.P. relating to shares of the Company&#8217;s Common Stock. In
accordance with the terms of the Sales Agreement, the Company may offer and sell shares of our Common Stock having an aggregate offering
price of up to $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20241023__20241023_zTMVvXX7FPg1">3.6
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million&#160;from time to time through A.G.P.,
acting as our sales agent or principal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation to A.G.P. for sales of common stock sold pursuant to the Sales Agreement will be equal to <span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zuldWhtwn2Sd" title="Sale of stock, percentage">3.0</span>% of the gross proceeds of
any shares of common stock sold under the sales agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company sold <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z3m1KsPNxmoj">323,273
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock under the Sales Agreement
and generated $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zV5EmLbdFHw6">3.3
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million&#160;in net proceeds after paying fees
to A.G.P. and other issuance costs of $<span id="xdx_908_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zo9K1JKZTQVi">0.2
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. See Note 20 for information on the issuances
and increases to the aggregate offering price subsequent to December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings/(Net Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings/(Net Loss) Per Share</a></td>
<td class="text"><p id="xdx_800_eus-gaap--EarningsPerShareTextBlock_zvYudql1tvnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
<span id="xdx_823_zjtxFW3Iawnc">Earnings/(Net Loss) Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zIgahDeMW377" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the calculation of basic and diluted earnings/(net loss) per share (in thousands, except share amounts and per
share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zplVRWoff8he" style="display: none">Schedule
of Basic and Diluted Net Loss Per Share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zfn0S5lN5Lqe" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zOHpaNx3a6r2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
                                            the years ended</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span><b>December 31,</b></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_maNILATzJEp_z8UQOiBwl1ae" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net income (loss) - basic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(17,802</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(535</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--ChangeInFairValueAndIncomeImpactOfOptionLiabilities_iN_pn3n3_di_msNILATzJEp_z1Ky9hZe9hdj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Less: Change in fair value and income impact of option liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1836">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,521</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_iT_pn3n3_mtNILATzJEp_z7YWM3wqGVS3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Net income (loss) - diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,802</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,056</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zZtAdU2VVZ7g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Weighted average common stock outstanding, basic</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="text-align: right">867,096</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">669,739</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--OptionLiabilityConversionShares_pid_zhR4WG7c9cLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Add: Option liability conversion shares</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1845">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,200</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_zcgCt1xPrTUc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Weighted average shares used in computing net loss per share - diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">867,096</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">678,939</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EarningsPerShareBasic_pid_zrRj4i04auhc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income (loss) per share, basic</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(20.53</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.79</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_pid_zHYVozj43l1b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net income (loss) per share, diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(20.53</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8.92</td><td style="text-align: left">)</td></tr>
  </table>

<p id="xdx_8AF_zedPTUQnSKR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company notes that the adjustment to the numerator in 2023 for the change in fair value and income impact of Vela and Cizzle
accounts for changes in fair value of each option, gains (losses) at the time of issuance of each option and the statement of
operations impact of the derecognition of deferred revenue that originated upon the initial sale of royalties to both Vela and
Cizzle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ziQtr3IBQtLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities (upon conversion) that were not included in the diluted per share calculations because they would have been anti-dilutive
were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zm7r1qoMmG5i" style="display: none">Schedule
of Potentially Dilutive Securities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20241231_z8lF6z0IaIk2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zF2M9MghyTs7" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PublicWarrantsMember_zl5JWAfU4uH3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Public warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">139,790</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">139,790</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PIPEMember_zmQQ5phS9h55" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">PIPE Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1862">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AGPWarrantsMember_z0CMGaPf10k6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">A.G.P. Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">540</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">540</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePromissoryNotesPayableMember_zGpdAfvxPI6j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Promissory Notes Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">805</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zC9p8TYuoeCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,509</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,717</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zct5Ft3E26O2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1874">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,470</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zpWC5guhU2B2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>August 2024 Nirland Note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">672,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1878">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AGPConvertibleNoteMember_zXTJrNfL7Lje" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">A.G.P. Convertible Note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">576,949</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1881">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--MarchTwentyTwentyFourWarrantsMember_zuf4MDpqNsm7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>March 2024 Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1884">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AprilTwentyTwentyFourWarrantsMember_zn1dkvEjbyyi" style="vertical-align: bottom; background-color: White">
    <td>April 2024 Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,477</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1887">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AGPTwentyTwentyFourWarrantsMember_zD0sqjeOpkNk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">A.G.P. 2024 Warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">28,626</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1890">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zifmr5T3zFlb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Antidilutive Securities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,501,298</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">173,322</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zkv2dY1HCjqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zfCF6Ud2Tnt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.
<span id="xdx_828_zXUxlwsY9dm5">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to certain claims and contingent liabilities that arise in the normal course of business. While we do not expect that
the ultimate resolution of any of these pending actions will have a material effect on our consolidated results of operations, financial
position or cash flows, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action,
does not become material in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2023, prior to the Business Combination, our now wholly-owned subsidiary, Conduit Pharmaceuticals Limited, received a letter
from Strand Hanson Limited (&#8220;Strand&#8221;) claiming it was owed advisory fees pursuant to a previously executed letter.
Conduit rejected the claim from Strand and disputed the substance of the letter in full. Following such rejection, on September 7,
2023, Strand filed a claim in the Business and Property Courts of England and Wales claiming it is entitled to be paid the sum of
$<span id="xdx_901_eus-gaap--LitigationSettlementExpense_pn6n6_c20230831__20230831_zyYXKWKhT8Wd" title="Settelment expense">2</span>
million and, as a result of the completion of the Business Combination, to be issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20230831__20230831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwg6AAIH1l6d" title="Shares issued in business combination">65</span>
thousand shares of common stock. As of December 31, 2024, the potential contingency is considered probable and reasonably estimable
and as such, the Company accrued an estimated liability of $<span id="xdx_904_eus-gaap--LossContingencyAccrualProvision_pn5n6_c20240101__20241231_zs0e9gnc3TCa" title="Accrued estimated liability">0.4</span>&#160;million
in the accompanying financial statements. The trial in this matter remains scheduled for October 20, 2025. We intend to vigorously
defend against these claims. Regardless of its outcome, the litigation may impact our business due to, among other things, legal
costs and the diversion of the attention of our management.<b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In November and
December 2024, the Company received a letter from St George Street Capital and formal complaints filed with the Intellectual
Property Office claiming the Company was assigned the US Application, and was not the sole owner, of the AZD 1656 co-crystal patent.
In January 2025, Conduit issued a counter statement to the Intellectual Property Office disputing the claim filed by St George
Street Capital. As of December 31, 2024, the damages sought by St George Street Capital are unknown and the potential contingency is
not considered probable. As such, the Company has not accrued a loss contingency in the accompanying
financial statements. We intend to vigorously defend against these claims. Regardless of its outcome, the litigation may impact our
business due to, among other things, legal costs and the diversion of the attention of our management.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zPbsDD63tZc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.
<span id="xdx_829_z0s2GRX0ebrk">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Corvus
Capital Limited</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corvus
Capital Limited (&#8220;Corvus&#8221;) is a significant investor in the Company through subscribing to <span id="xdx_90F_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_pid_c20230922__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CorvusCapitalLimitedMember_zXt6Agvtmmfb">1,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common
shares prior to the closing of the Merger on September 22, 2023. As discussed in Note 2, the shares held by Corvus on the closing
date of the Merger were exchanged for shares of Conduit Pharmaceuticals Inc. common stock. The Chief Executive Officer and principal
owner of Corvus is a member of Conduit&#8217;s board of directors. Occasionally, Corvus provides advisory services to the Company
and is paid a fee for the services. As of December 31, 2024, and December 31, 2023, no advisory fees were due to Corvus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024 and 2023, the Company incurred director travel expenses payable to the board of directors member
of approximately $<span id="xdx_906_eus-gaap--TravelAndEntertainmentExpense_pn5n6_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zNOJyYXzbef1">0.4 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
and $<span id="xdx_901_eus-gaap--TravelAndEntertainmentExpense_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zoeFBQS99jO9">1.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million,
respectively. As of December 31, 2024, and December 31, 2023, the Company did not owe the CEO of Corvus any director&#8217;s fees as
the CEO of Corvus and the Company agreed to cease director&#8217;s fees to the CEO of Corvus effective at the closing of the Merger.
Amounts owed to this director are included in accrued expenses and other current liabilities in the
balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, Corvus provided a $<span id="xdx_909_eus-gaap--ProceedsFromContributedCapital_pn5n6_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CorvusCapitalLimitedMember_zK1iCl3gbjle">0.2</span> million cash contribution to the Company to maintain liquidity through the closing
of the Merger. There was no intention of repayment by both Corvus and the Company, and as such, the Company recorded the contribution
to the consolidated statement of changes in stockholders&#8217; deficit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
January and February 2023, the Company issued convertible notes payable with an aggregate principal amount of $<span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20230228__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleLoanNoteInstrumentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z1egGwZvyZXh">0.4
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million (&#163;<span id="xdx_902_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_uGBP_c20230228__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleLoanNoteInstrumentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zPENOSvRqrlf">0.3
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million) to this related party. The convertible
notes payable mature three years after issuance and bear <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230201__20230228__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleLoanNoteInstrumentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zQkHrPCvjwI2">5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
interest, only to be paid in the event of a material breach by the Company. In the event of a Change of Control, the convertible notes
payable automatically convert into common shares of the Company at a conversion price equal to a <span id="xdx_901_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_c20230201__20230228__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleLoanNoteInstrumentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zAl1IT2x6OEj">20</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
discount to the price per share paid for the most senior class of shares in respect of such Change of Control. All of the convertible
notes payable converted into Common Stock upon the closing of the Merger at a <span id="xdx_908_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_c20230201__20230228__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleLoanNoteInstrumentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zuk8ESXKDXT2">20</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
discount as specified. Refer to Note 2 above for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">At the time of the execution of the PIPE Subscription Agreement, Corvus
and its affiliates entered into a participation and inducement agreement with Nirland whereby Corvus agreed to provide certain payments
and economic benefits to Nirland. In certain circumstances, Nirland may have a right to cause Corvus to transfer <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CorvusCapitalLimitedMember_zNNFGcqS1kLg" title="New stock issued">300,484</span> shares held to Nirland.</p>

<p style="margin: 0pt 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Related
Party Loan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loans made to a related party were stated at a total principal amount of $<span id="xdx_90F_eus-gaap--LoansAndLeasesReceivableRelatedParties_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zGfUyUKNGUr9">0.8</span> million, with <span id="xdx_909_eus-gaap--OtherReceivables_iI_do_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z322FP3izxS6"><span id="xdx_901_eus-gaap--OtherReceivables_iI_do_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zDDkj9EVDRYh">no</span></span> balance outstanding at December 31, 2024
and December 31, 2023, respectively. The loan carried no interest, and as such, no interest receivable was recorded. The Company recorded
a full reserve against the loan as the related party did not have the ability to repay the loans as of December 31, 2022. On September
22, 2023, the related party paid back a significant portion of its outstanding loan and the Company forgave the remaining portion of
the loan and the Company recorded the $<span id="xdx_903_eus-gaap--LoansPayable_iI_pn5n6_c20230922__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSt0lBbusar">0.3</span> million payoff as a gain within general and administrative expense on the consolidated statement
of operations and comprehensive income (loss), as it had previously been fully reserved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nirland</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 6, 2024, the Company entered into the August 2024 Nirland Note with Nirland, a related party of the Company. The Company
determined that Nirland was a related party due to Nirland&#8217;s ownership interest in the Company concurrently with the execution
of the August 2024 Nirland Note. Additionally, on October 28, 2024, the Company issued the October 2024 Nirland Note to Nirland, and
on October 31, 2024, the Company and Nirland amended the August 2024 Nirland Note, and on November 22, 2024, the Company and Nirland
amended the August 2024 Nirland Note for a second time. Refer to Note 7, Note 8 and Note 20 above for additional
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>SARBORG</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2024, the Company entered into the Sarborg Service Agreement with Sarborg. Dr. Andrew Regan, a member of
Conduit&#8217;s board of directors, also sits on the board of directors of Sarborg but does not have an equity interest in Sarborg.
During the year ended December 31, 2024, the Company recorded $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SARBORGLtdMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServicesAgreementMember_zMYTNcXSubQh" title="Research and development expense">0.1</span>
million as research and development expense related to the Sarborg Service Agreement. Refer to Note 10 above for additional
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Officers and
Directors</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">On April 22, 2024,
the Company issued in a private placement common stock purchase warrants (the &#8220;April Warrants&#8221;) to third parties which also
included certain directors, to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240422__20240422__us-gaap--RelatedPartyTransactionAxis__custom--OfficersAndDirectorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy39m5Mfj2Te">9,077
</span>shares of the Company&#8217;s common stock, in exchange for entering into a lock-up with respect to the shares of common stock
held by such holder and for such directors, $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240422__us-gaap--RelatedPartyTransactionAxis__custom--OfficersAndDirectorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZgzjVw0jI53">12.50
</span>per warrant. The April Warrants are not exercisable until one year after their date of issuance. Each April Warrant is exercisable
into one share of the Company&#8217;s common stock at a price per share of $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pid_c20240422__20240422__us-gaap--RelatedPartyTransactionAxis__custom--OfficersAndDirectorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8JLgtznRP9h">312
</span>(as adjusted from time to time in accordance with the terms thereof) for a two-year period after the date of exercisability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (expense), net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">Other Income (expense), net</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--OtherNonoperatingIncomeAndExpenseTextBlock_zYfWDs9LQpEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span id="xdx_82B_zKFbqUt3TWxb">Other Income (expense), net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_zRaz7PHeDELc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents other income (expense), net, for the years ended December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zLEROoD1vXac" style="display: none">Schedule
of Other Expense, Net</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zCHJTZcrMjA8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zA6X4xw5wDef" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the years ended<br/> December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--RecognitionOfDeferredRevenueUponOptionExercise_pn3n3_maONIzvdl_zdwIaMrG2xX2" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Recognition of Cizzle deferred revenue upon option exercise</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1929">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,480</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--RecognitionOfDeferredRevenueUponOptionExerciseOne_pn3n3_maONIzvdl_zhHvM7NbHSm3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Recognition of Vela deferred revenue upon option exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1932">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,774</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfOption_pn3n3_maONIzvdl_zJAEl2Djxle1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of Cizzle option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1935">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,280</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfOptions_pn3n3_maONIzvdl_zB06sDcImqhh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of Vela option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1938">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">970</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfWarrantLiability_pn3n3_maONIzvdl_zUuqeccjAtm" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">221</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ChangeInFairValueOfConvertibleNotePayment_pn3n3_maONIzvdl_zuGyz8pDIRIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of convertible note payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,018</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1945">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--GainOnDebtExtinguishment_pn3n3_maONIzvdl_ze3kMRRDTqkd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gain on debt extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,473</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1948">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InterestIncomeOther_pn3n3_maONIzvdl_z1ZODWLtxLkh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxRefund_pn3n3_maONIzvdl_zPHoTmqFWzz2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income Tax Refund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1954">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ForeignCurrencyTransactionGainLossUnrealized_pn3n3_maONIzvdl_zX3cx1jkESmk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unrealized foreign currency transaction gain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherIncome_pn3n3_maONIzvdl_zNTeZ8sHMXb3" style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">115</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherNonoperatingIncome_iT_pn3n3_mtONIzvdl_maNIEzWCX_zCofSRuvuno" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total other income:</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,048</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,754</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other expense:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--LossOnIssuanceOfOptionOne_maONEzInN_zC40JIPLbHN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Loss on issuance of Vela option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1965">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">987</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--OtherIncomeUnrealizedForeignCurrencyTransactionLoss_pn3n3_maONEzInN_zUTM7r7N79U1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Change in fair value of convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1968">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">426</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpenseOther_pn3n3_maONEzInN_zf9T4tlX67cf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">577</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">211</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_pn3n3_maONEzInN_zIZKBsRBHjT3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Amortization of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">929</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1975">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LossOnIssuanceOfWarrants_pn3n3_maONEzInN_zVp9UX2yQaPc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Loss on issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,710</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1978">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LossOnDebtExtinguishment_pn3n3_maONEzInN_zdOWng6ia3o" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Loss on Debt Extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1981">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OtherExpenseChangeInFairValueOfConvertibleNotesPayable_pn3n3_maONEzInN_zeToQGOj2d85" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Realized foreign currency transaction loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">403</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--OtherExpense_pn3n3_maONEzInN_zlIUEjUUOWtd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Other expense</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1987">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNonoperatingExpense_iT_pn3n3_msNIEzWCX_mtONEzInN_zI8XW3D9aGRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total other expense</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,431</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,027</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NonoperatingIncomeExpense_iT_pn3n3_mtNIEzWCX_zcQ5VcY0Bxv9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total other (expense) income, net</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,383</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,727</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zmtiTluQTbXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_WarrantLiabilityDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_806_ecustom--WarrantLiabilityDisclosureTextBlock_zWqswt08YScb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.
<span id="xdx_822_z0z1vQFCL2he">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of the Merger, the Company assumed (i) the warrants initially included in the MURF units issued in MURF&#8217;s initial public
offering (the &#8220;Publicly Traded Warrants&#8221;), and (ii) the warrants that were included in the private placement units issued
to the Sponsor simultaneously with the closing of MURF&#8217;s initial public offering (the &#8220;Private Placement Warrants&#8221;).
In connection with the Merger, the Company also issued warrants to the PIPE Investors (the &#8220;PIPE Warrants&#8221;) pursuant to the
Subscription Agreements and to an advisor (the &#8220;A.G.P. Warrants,&#8221; and together with the PIPE Warrants, the &#8220;Liability
Classified Warrants&#8221;) pursuant to the Company&#8217;s engagement agreement with the advisor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that the settlement amount of the Publicly Traded Warrants and the Private Placement Warrants would equal the difference
between the fair value of a fixed number of shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified
as equity, while the settlement amount of the Liability Classified Warrants would not equal the difference between the fair value of
a fixed number of shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified as a liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 20, 2024, the Company issued in a private placement equity classified common stock purchase warrants (the &#8220;March 2024
Warrants&#8221;) to an investor to purchase up to an aggregate <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240320__us-gaap--TypeOfArrangementAxis__custom--MarchLockUpAgreementMember_z5drcXnXkUb5" title="Common stock purchase of waarants">2,600</span>
shares of the Company&#8217;s Common Stock, in exchange for entering into a lock-up with respect to the shares of common stock held
by such holder (the &#8220;March Lock-Up Agreement&#8221;). The Company recognized at $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--MarchLockUpAgreementMember_z2P8hk5KQ8f" title="Issuance of warrants">0.5</span>
million loss on the issuance of the warrants during the year ended December 31, 2024. The Company determined that the March 2024 Warrants
should be classified within equity and estimated the fair value of the warrants issued as of March 20, 2024, using a Black-Scholes
option-pricing model utilizing the following assumptions:</span></p>

<p id="xdx_89C_ecustom--ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock_gL3SOSBPASPWV-MQTQ_zhfw2PgPJCyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zO1HuPsadJOc" style="display: none">Schedule
of Black-Scholes Option Pricing Model</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 20, 2024</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Closing stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20240320_zDYyrtH6M8fk" style="width: 16%; text-align: right" title="Closing stock price">347</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Contractual exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20240320_z4TqI1iGO2C5" style="text-align: right" title="Contractual exercise price">318</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240320__20240320_zRP4KJdUxw1b" title="Risk-free rate">4.41</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Estimated volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240320__20240320_zASslSdPQ4sj" title="Estimated volatility">78.5</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Time period to expiration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240320__20240320_z4w1CDTsOCG" title="Time period to expiration">3</span> Years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zGx42WK9gYXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 20, 2024, the Company issued in a private placement equity classified common stock purchase warrants (the &#8220;April 2024 Warrants&#8221;)
to shareholders&#8217; of the Company to purchase up to an aggregate <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240420__us-gaap--TypeOfArrangementAxis__custom--AprilLockUpAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AprilTwentyTwentyFourWarrantsMember_zqV3OarfyFZj" title="Class of warrant or right outstanding">14,477</span> shares of the Company&#8217;s Common Stock, in exchange for
(1) $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240420__us-gaap--TypeOfArrangementAxis__custom--AprilLockUpAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AprilTwentyTwentyFourWarrantsMember_zwlt4ZsNVnB7" title="Common stock purchase of warants price per share">12.50</span> per warrant and (2) entering into a lock-up with respect to the shares of common stock held by such holders (the &#8220;April
Lock-Up Agreement&#8221;). <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240420__20240420__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z7koa7c4FtDj" title="Issuance of stock, shares">9,077</span> of the total April 2024 Warrants issued were issued to directors, related parties and management of
the Company. The Company received cash of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240401__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zlHKlDrNCFcj" title="Proceeds from warrants">0.2</span> million and recognized a $<span id="xdx_903_eus-gaap--GainLossOnInvestments_pn5n6_c20240401__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember_zyloiAWgsLcd" title="Loss from issuance of warrants">2.2</span> million loss on the issuance of the warrants during the year ended December 31, 2024. The Company determined that the April 2024 Warrants should be classified within equity and estimated the
fair value of the warrants issued as of April 20, 2024, using a Black-Scholes option-pricing model utilizing the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_C07_gL3SOSBPASPWV-MQTQ_z88lnxcVcsJi"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<div id="xdx_C0C_gL3SOSBPASPWV-MQTQ_zEWk4k4PUQGk"><div><table cellpadding="0" cellspacing="0" id="xdx_305_134_zZIyFq14jANh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Schedule of Black-Scholes Option Pricing Model (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 20, 2024</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Closing stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20240420_z5bNvZoBeXf1" style="width: 16%; text-align: right" title="Closing stock price">308</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Contractual exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20240420_zyZrkxWLBv9a" style="text-align: right" title="Contractual exercise price">312</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240420__20240420_zFJ5eTblTUG" title="Risk-free rate">4.81</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Estimated volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240420__20240420_zWZLvLeZaVM5" title="Estimated volatility">78.3</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Time period to expiration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240420__20240420_zCpkfb2n14Ti" title="Time period to expiration">3</span> Years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</div></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
partial consideration for the Advance issued to the Company by A.G.P. on October 29, 2024, the Company issued A.G.P. Warrants (the &#8220;A.G.P.
2024 Warrants&#8221;) to purchase up to&#160;<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241029__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AGPTwentyTwentyFourWarrantsMember_zo38UquRmUP3" title="Exercise price of warrants per share">28,625</span>&#160;shares of the Company&#8217;s Common Stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241029__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AGPTwentyTwentyFourWarrantsMember_z46gnHTDbvub" title="Exercise price of warrants per share">0.1048</span>&#160;per
share. The Company determined that the A.G.P. 2024 Warrants should be classified as a liability and estimated the fair value of the warrants
as of October 29, 2024, and December 31, 2024, using a Black-Scholes option-pricing model. Refer to Note 3 above for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Classified Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to MURF&#8217;s initial public offering, the Company sold <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230922__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zE22S92K5r5c" title="Warrants issued">132,250</span> units at a price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230922__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zk8ZmclFULT7" title="Warrants price per share">10.00</span> per unit. Each unit consisted of one share
of MURF Class A common stock and one redeemable Publicly Traded Warrant. Each whole Publicly Traded Warrant entitled the holder to purchase
one share of Class A common stock at a price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_z3MvsRpB5Qae" title="Warrants exercise price">11.50</span> per share, subject to adjustment. The warrants are publicly traded on The Nasdaq
Capital Market under the trading symbol CDTTW.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously
with the closing of its initial public offering, MURF consummated the private sale to the Sponsor of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230922__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantMember_zd5SlDkbHi2h" title="Warrants issued">7,540</span> private placement units at
a price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230922__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantMember_zCu0bw6tzfIj" title="Warrants price per share">10.00</span> per private placement unit. Each private placement unit was comprised of one share of MURF Class A common stock and
one Private Placement Warrant. Each Private Placement Warrant was exercisable to purchase one share of MURF Class A common stock at a
price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230922__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantMember_zeiq3nGePO4h" title="Warrants exercise price">11.50</span> per share, subject to adjustment. The private placement units (including the Class A common stock issuable upon exercise
of the warrants included in the private placement units) were not transferable, assignable, or saleable until 30 days after the completion
of a Merger, subject to certain exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the closing of the Merger on September 22, 2023, the Equity Classified Warrants were amended to entitle each holder to
purchase one share of the Company&#8217;s Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Equity Classified Warrants became exercisable 30 days after the Closing Date of the Merger. The Equity Classified Warrants will expire
five years after the Closing Date of the Merger or earlier upon redemption or liquidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will not be obligated to deliver any shares of Common Stock pursuant to the exercise of an Equity Classified Warrant and will
have no obligation to settle such exercise unless a registration statement under the Securities Act with respect to the shares of Common
Stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations
described below with respect to registration. No Equity Classified Warrant will be exercisable and we will not be obligated to issue
shares of Common Stock upon exercise unless the Common Stock issuable upon such exercise has been registered, qualified or deemed to
be exempt under the securities laws of the state of residence of the registered holder of the Equity Classified Warrant. In the event
that the conditions in the two immediately preceding sentences are not satisfied with respect to an Equity Classified Warrant, the holder
of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will
we be required to net cash settle any Equity Classified Warrant. In the event that a registration statement is not effective for the
exercised Equity Classified Warrant, the purchaser of a unit containing such Equity Classified Warrant will have paid the full purchase
price for the unit solely for the share of Common Stock underlying such unit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit
may call the Publicly Traded Warrants in whole and not in part, at a price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231_zfNABH78lE72" title="Warrant exercise price">1.00</span> per warrant,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    not less than 30 days&#8217; prior written notice of redemption to each Publicly Traded Warrant holder; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
and only if, the reported last sale price of the Common Stock equals or exceeds $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr2umUGNi4x2" title="Share price per shares">1,800.00</span> per share (as adjusted for stock splits, stock
dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing once the
Publicly Traded Warrants become exercisable and ending three business days before we send the notice of redemption to the warrant holders.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
and when the Publicly Traded Warrants become redeemable by Conduit, Conduit may not exercise its redemption right if the issuance of
shares of Common Stock upon exercise of the Publicly Traded Warrants is not exempt from registration or qualification under applicable
state blue sky laws or Conduit are unable to effect such registration or qualification. Conduit will use its best efforts to register
or qualify such shares of Common Stock under the blue sky laws of the state of residence in those states in which the Publicly Traded
Warrants were offered by Conduit in the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Conduit calls the Publicly Traded Warrants for redemption as described above, Conduit&#8217;s management will have the option to require
any holder that wishes to exercise its Publicly Traded Warrant to do so on a &#8220;cashless basis.&#8221; In determining whether to
require all holders to exercise their Publicly Traded Warrants on a &#8220;cashless basis,&#8221; Conduit&#8217;s management will consider,
among other factors, Conduit&#8217;s cash position, the number of Publicly Traded Warrants that are outstanding and the dilutive effect
on Conduit stockholders of issuing the maximum number of shares of Common Stock issuable upon the exercise of our Publicly Traded Warrants.
If Conduit&#8217;s management takes advantage of this option, all holders of Publicly Traded Warrants would pay the exercise price by
surrendering their Publicly Traded Warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x)
the product of the number of shares of Common Stock underlying the Publicly Traded Warrants, multiplied by the difference between the
exercise price of the Publicly Traded Warrants and the &#8220;fair market value&#8221; (defined below) by (y) the fair market value.
The &#8220;fair market value&#8221; for this purpose shall mean the average reported last sale price of the Common Stock for the 10 trading
days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of Publicly Traded Warrants.
If Conduit&#8217;s management takes advantage of this option, the notice of redemption will contain the information necessary to calculate
the number of shares of Common Stock to be received upon exercise of the Publicly Traded Warrants, including the &#8220;fair market value&#8221;
in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive
effect of a Publicly Traded Warrant redemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Private Placement Warrants are identical to the Publicly Traded Warrants, except that such warrants will be exercisable for cash or on
a cashless basis, at the holder&#8217;s option, and will not be redeemable by Conduit, in each case so long as they are still held by
the Sponsor or its permitted transferees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
summarized above, the Company has the option to redeem all of the Publicly Traded Warrants at a cash price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z94CLhTSFEBk" title="Warrant exercise price">0.01</span> per warrant during
the exercisability period if the Company&#8217;s common stock has closed at a trading price above $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPAYK1sEjI97" title="Share price per shares">18.00</span> for 20 days during a 30-day
trading window. Management notes that this option is within the Company&#8217;s control, therefore it does not represent an &#8220;obligation&#8221;
and does not create a liability under ASC 480. Management considered the guidance within ASC 815-40-15-7A, noting that an exercise contingency
would not preclude permanent equity classification if all of the other equity criteria are met. As all other criteria to be classified
as permanent equity are met, the Publicly Traded Warrants are classified as permanent equity on the Consolidated Balance Sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assessed the Private Placement Warrants and determined that the warrants are considered to be indexed to the entity&#8217;s own stock
and met all the criteria for permanent equity classification. As such, the Publicly Traded Warrants are classified as permanent equity
on the Consolidated Balance Sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The March 2024 Warrants are not exercisable until one year after their date of issuance. Each March
2024 Warrant is exercisable into one share of the Company&#8217;s Common Stock at a price per share of $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20240331_z2FaSSK2pOo4" title="Share price">3.18</span> (as adjusted from time to
time in accordance with the terms thereof) for a two-year period after the date of exercisability. <span id="xdx_90A_eus-gaap--SubsequentEventDescription_c20240301__20240331__us-gaap--TypeOfArrangementAxis__custom--MarchLockUpAgreementMember_zmooEv2PWghh" title="Subsequent event, description">There is no established public trading
market for the March 2024 Warrants. Notwithstanding the foregoing, the March 2024 Warrants shall vest, and not be subject to forfeiture,
with respect to 25% of such March 2024 Warrants commencing on the 90th day after the date of the March Lock-Up Agreement and 25% on each
subsequent 90-day anniversary, in each case vesting only if the holder agrees to continue to have its shares of common stock remain locked
up pursuant to the March Lock-Up Agreement on such date.</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
April 2024 Warrants are not exercisable until one year after their date of issuance. Each April 2024 Warrant is exercisable into one
share of the Company&#8217;s Common Stock at a price per share of $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20240430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--AprilLockUpAgreementMember_z5ihtOA0EO2a" title="Share price">312</span> (as adjusted from time to time in accordance with the terms thereof)
for a two-year period after the date of exercisability. <span id="xdx_900_eus-gaap--SubsequentEventDescription_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--AprilLockUpAgreementMember_zk90ILUsewu1" title="Subsequent event, description">There is no established public trading market for the April 2024 Warrants. Notwithstanding
the foregoing, the April 2024 Warrants shall vest, and not be subject to forfeiture, with respect to 25% of such March 2024 Warrants
commencing on the 90th day after the date of the April Lock-Up Agreement and 25% on each subsequent 90-day anniversary, in each case
vesting only if the holder agrees to continue to have its shares of common stock remain locked up pursuant to the April Lock-Up Agreement
on such date.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liability
Classified Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 2, <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z6huybZNwY3d" title="Shares issued during the period">20,000</span> PIPE Warrants were issued to the PIPE Investors as of the closing of the Merger pursuant to subscription
agreements. The warrants provide the PIPE Investors the right to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zO64Ex1Mltbg" title="Warrants to purchase common stock">20,000</span> shares of Common Stock at an exercise price of
$<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zrBmXn4aL4Xl" title="Warrants exercise price">1,150</span>. Additionally, on the Closing Date of the Merger, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zH4J9NVIsBV3" title="Shares issued during the period">540</span> A.G.P. Warrants to an advisor for services provided directly
related to the Merger. The warrants provide the advisor the right to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pip0_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zoD2uTnQmg45" title="Warrants to purchase common stock">540</span> shares of Common Stock at an exercise price of
$<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zSRXlfaBGYka" title="Warrants exercise price">1,100</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants issued to the PIPE Investors and the advisor contain materially the same terms and are exercisable for a period of five years,
beginning on October 22, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PIPE Warrants are exercisable for cash or on a cashless basis, at the holder&#8217;s option. The PIPE Warrants are not redeemable by
the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
A.G.P. Warrants are exercisable for cash or on a cashless basis, at the holder&#8217;s option. The Company may call the A.G.P. Warrants
for redemption, in whole and not in part, at any time after the A.G.P. Warrants become exercisable and prior to their expiration, at
a price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230922_zLItLLVxv1Wc" title="Warrants exercise price">1.00</span> per A.G.P. Warrant,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    not less than 30 days&#8217; prior written notice of redemption to each warrant holder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, the reported last sale price of the Common Stock equals or exceeds $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230922_zEe1CqE7pCG2" title="Common stock per share">1,800</span> per share (as adjusted for stock splits, stock
    dividends, recapitalizations and other similar events) for any 20 trading days within a 30-trading day period commencing once the
    A.G.P. Warrants become exercisable and ending three business days before we send the notice of redemption to the warrant holders;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
    there is a current registration statement in effect with respect to the shares of Common Stock underlying the A.G.P. Warrants for
    each day in the 30-trading day period and continuing each thereafter until the redemption date.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company calls the A.G.P. Warrants for redemption as described above, our management will have the option to require any holder that
wishes to exercise its A.G.P. Warrant to do so on a &#8220;cashless basis.&#8221; If our management takes advantage of this option, holders
of A.G.P. Warrants would pay the exercise price by surrendering their A.G.P. Warrants for that number of shares of Common Stock as calculated
pursuant to the A.G.P. Warrant. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby
lessen the dilutive effect of an A.G.P. Warrant redemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise of the A.G.P. 2024 Warrants and the issuance of the shares of Common Stock underlying the Warrants is subject to stockholder
approval under applicable rules and regulations of Nasdaq. The warrants are exercisable for a period of five years, beginning on the
stockholder approval date. The A.G.P 2024 Warrants are exercisable for cash, or on a cashless basis if at the time of exercise there
is no effective registration statement registering the resale of the warrant shares. The A.G.P. 2024 Warrants are not redeemable by the
Company. On October 29, 2024, the Company recorded a warrant liability of $<span id="xdx_907_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20241029__20241029__us-gaap--ClassOfWarrantOrRightAxis__custom--AGPTwentyTwentyFourWarrantsMember_zQ5AwxhQmKld" title="Warrant liability">0.2</span> million. As part of the special meeting of stockholders
taking place on January 9, 2025, the stockholders approved the issuance of up to an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20241029__20241029__us-gaap--ClassOfWarrantOrRightAxis__custom--AGPTwentyTwentyFourWarrantsMember_z2yaXQ7m2PBf" title="Common stock upon exercise, shares">28,625</span> shares of the Company&#8217;s
common stock upon exercise of the A.G.P. 2024 Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PIPE Warrants, A.G.P. Warrants, and the A.G.P 2024 Warrants (collectively the &#8220;Liability Classified Warrants&#8221;) are classified
as derivative liabilities because they do not meet the criteria in ASC 815-40 to be considered indexed to the entity&#8217;s own stock
as the warrants could be settled for an amount that is not equal to the difference between the fair value of a fixed number of the entity&#8217;s
shares and a fixed monetary amount. The Liability Classified Warrants are initially measured at fair value and are remeasured at fair
value at subsequent financial reporting period end dates and upon exercise (see Note 7 for additional information regarding fair value).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 11, 2024, the Company reduced the exercise price of the PIPE Warrants to be $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241211__us-gaap--ClassOfWarrantOrRightAxis__custom--PIPEWarrantsMember_zki1xQWESpWk">8.83</span>, at which time all PIPE Warrants were exercised.
The Company received approximately $<span id="xdx_907_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20241211__20241211_zEN3F8LmrRba" title="Proceeds from the exercise warrants">0.2</span> million of proceeds from the exercise of the Warrants, all of which was used to pay down the
October 2024 Nirland Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024, and December 31, 2023, the Company remeasured the fair value of the Liability Classified Warrants
and recorded a gain on the change in the fair value of $<span id="xdx_900_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_pn5n6_c20240101__20241231_zsQPe7Qc4rBl">0.2
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_905_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_pn5n6_c20230101__20231231_zU5ijkra8ir3">0.1
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respective. The gains were recorded
to other income (expense), net, on the consolidated statements of operations and comprehensive income (loss). As of December 31, 2024
and December 31, 2024, the balance sheets contained warrant liabilities of $<span id="xdx_907_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn5n6_c20241231_zU1kz0Spsjrc">0.1
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_903_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn4n6_c20231231_zLavmWgmrIj6">0.01
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_WarrantLiabilityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_WarrantLiabilityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_zd8CxAnBPR76" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.
<span id="xdx_826_z6ds53LXNvu9">Segments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has one operating segment focused on the research and development of clinical assets. The accounting policies of the single operating
segment are identical to those described in Note 1. The CODM, which the Company has identified as David Tapolczay, Chief Executive
Officer, manages the Company&#8217;s operations on a consolidated basis, assesses performance for the operating segment and decides how
to allocate resources based on consolidated net loss, which is reported on the consolidated statements of operations and comprehensive
income (loss). Depreciation expense, amortization expense, stock-based compensation expense, and non-cash lease expense are significant
noncash items included in consolidated net loss reviewed by the CODM and are reported on the consolidated statements of cash flows. The
measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. Expenditures for additions to
long-lived assets, which include purchases of property and equipment, are included in total consolidated assets reviewed by the chief
operating decision maker and are reported on the consolidated statements of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CODM uses consolidated net loss and budget-to-actual variances to assess the performance of the operating segment and determine if the
Company is progressing towards its goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zeq29aukxZVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents certain financial data for the Company&#8217;s reportable segment (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zwnjdjWmq04k">Schedule
of Financial Data for the Company&#8217;s Reportable Segment</span><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; font-weight: bold; text-align: center">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zQuzlzBZCsi" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zSHo6cOoit5b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NewLicensesMember_zwzjhtJnjcZk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Research &amp; development expense &#8211; new licenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,114</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2099">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalAssetDevelopmentMember_zQjXPw4bUVJ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Research &amp; development expense &#8211; clinical asset development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--LegalAndProfessionalFeesMember_zrUmRuEc6tai" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">General and administrative expenses &#8211; legal &amp; professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,258</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--AccountingAndAuditFeesMember_z50BW13V11fa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">General and administrative expenses &#8211; accounting &amp; audit fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,625</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,064</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--SalariesPayrollAndStockBasedCompensationMember_z540kLE8Dve4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">General and administrative expenses &#8211; salaries, payroll and stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,098</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">721</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_zNfIlJ5g4HA5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">General and administrative expenses &#8211; other</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,073</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_pn3n3_maNILzclF_zgW3TKhaO0Be" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from segment operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">15,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">5,262</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zcaBlpAaiUn1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
segment items consist of the items within Note 17 to the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zcHl3ZWg25T3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20.
<span id="xdx_82E_zTYsuP6cGUT6">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2025, the Company effected the Reverse Stock Split, pursuant to which every <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20240124__20240124_zvoh26VIF3v5" title="Number shares reverse stock split during the period">100</span> shares of the Company&#8217;s common stock
issued or outstanding were automatically reclassified into one new share of common stock, subject to the treatment of fractional shares
as previously described, without any action on the part of the holders. For a description of the Reverse Stock Split, refer to Note 1
above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Nirland Notes
Repayment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">On February 7, 2025,
the Company fully repaid its outstanding October 2024 Nirland Note to Nirland Limited in the principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20250207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--OctoberTwentyTwentyFourNirlandNoteMember_zqfUOxVMdj6e">600,000</span>.
This payment settled all obligations under the October 2024 Nirland Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the August 2024 Nirland Note, the Lender converted approximately $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20250207__20250207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_z6G0PLoH5LMi" title="Debt conversion amount">1.7 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
of the original principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20250207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zBarsZKCOfcd" title="Principal amount">2,650,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
into shares of common stock of the Company. Of the $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20250207__20250207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zgwpgBkRpGZb" title="Debt conversion amount">1.7</span> million of original principal that was converted into shares of common stock
of the Company, $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20241212__20241212__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zq9aYdW75lJa" title="Debt conversion amount">0.1</span> million was converted on December 12, 2024, while the remaining $<span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20250113__20250113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_z0AcZVIpZSof" title="Debt conversion amount"><span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20250210__20250210__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zXrqZQsRh4Ud" title="Debt conversion amount">1.6</span></span> million was converted between January 13,
2025 and February 10, 2025. On February 13, 2025,&#160;the&#160;Company paid the remaining outstanding portion of the August 2024
Nirland Note, approximately $<span id="xdx_906_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20250213__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zwhr68DAEyA2" title="Remaining outstanding">0.9</span>
million, and, accordingly, satisfied all of its obligations in all respects to Nirland. As a result of satisfying its obligations under the
August 2024 Nirland Note, all of the Company&#8217;s assets are once again free and clear of any liens, security interests or
encumbrances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>March 2023 Convertible Note
Repayment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">On March 13, 2025,
the Company fully repaid its outstanding March 2023 Convertible Note. The Company notes that the note holder agreed on March 6, 2025
to reduce the principal from $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeConvertibleNoteMember_zvmOgLfGnGJh">0.8</span>
million to $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250313__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4cg8aG1SYM5">0.7</span>
million. This payment settled all obligations under the March 2023 Convertible Note. The March 2023 Convertible Note Repayment was considered
to be in default until payment on March 13, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Nasdaq Stock
Market Correspondence and Subsequent Nasdaq Capital Market Listing</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2025, the Company presented its plan of compliance to The Nasdaq Stock Market LLC Hearing Panel (the &#8220;Panel&#8221;)
and requested an extension of time to achieve compliance with Nasdaq Listing Rules, the Minimum Bid Price (&#8220;Bid Price&#8221;),
Market Value of Publicly Held Shares (&#8220;MVPHS&#8221;) and Market Value of Listed Securities (&#8220;MVLS&#8221;) rules, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 5, 2025, the Company received a written notification from the Panel confirming it has granted the Company such an extension for
the Company to regain compliance with the MVPHS and MVLS rules, provided that the Company, (i) on or before March 12, 2025, files an
application to transfer to the Nasdaq Capital Market, which application was submitted on March 7, 2025, and (ii) on or before March 31,
2025, demonstrates compliance with all Nasdaq listing rules, which it intends to do. Additionally, the Company was also notified in the
Notice that as of February 26, 2025, it had regained compliance with the Bid Price rule. The Company notes that there is no assurance
that the Company can maintain ongoing compliance with the Bid Price Rule. The Company expects to submit its compliance document with
respect to the MVPHS and MVLS rules which will be subject to review by the Panel. The Panel, may, in its discretion, request additional
information before determining that the Company has complied with the terms of the exception. There can be no assurances that the Panel&#8217;s
decision will agree with the Company&#8217;s compliance document. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><b><i>Common Stock
Issuances in Relation to the Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The Company
increased the aggregate offering price under the Sales Agreement to up to $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250115__20250115__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zotNnjf67GW2" title="Issuance of common stock">4,835,433</span>,
$<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250206__20250206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zh6sOaEMpl4e" title="Issuance of common stock">8,183,156</span>,
$<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250210__20250210__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zPHHFLhnpl9h" title="Issuance of common stock">13,450,017</span>,
$<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250219__20250219__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zor3mp1JLC75" title="Issuance of common stock">17,816,270</span>,
and $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250310__20250310__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zUzluFCmZkcb" title="Issuance of common stock">23,922,782</span> on January 15, 2025, February 6, 2025, February 10, 2025, February 19, 2025, and March 10, respectively. From
January 22, 2025 through the issuance of the Company&#8217;s consolidated financial statements, the Company sold <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250122__20250122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMOwQp4j8m8e" title="Commons tock shares sold">4,345,913</span>
shares of the Company&#8217;s Common Stock through the Sales Agreement. The Company received proceeds of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20250122__20250122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znTxp22uLSp8" title="Commons tock shares sold, value">8.1</span>
million, net of commissions payable to A.G.P. of $<span id="xdx_903_ecustom--CommissionsPayable_iI_pn5n6_c20250122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zm8Jlj4rgSnb" title="Commissions payable">0.2</span>
million. As of the financial statement filing date, the Company has $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250328__20250328__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zGyvmDnDsHIe" title="Available common stock issuances">12.0</span> million
available under the Sales Agreement.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9N5EBnEnmaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zIe5vxmUeFeg">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents are primarily maintained with major financial institutions in the United States, United Kingdom, and Switzerland.
The Company considers cash equivalents to be short-term, highly liquid investments that (a) are readily convertible into known amounts
of cash, (b) are traded and held for cash management purposes, and (c) have original maturities of three months or less at the time of
purchase. The Switzerland bank accounts holding cash balances are uninsured, and the UK bank account, with a year-end balance of approximately
&#163;<span id="xdx_905_eus-gaap--CashUninsuredAmount_iI_uGBP_c20241231_zQI4bUKQnUY6" title="Cash, uninsured amount">100,000</span> (or approximately $<span id="xdx_904_eus-gaap--CashUninsuredAmount_iI_c20241231_zaGRR62Uw4Z9">125,000</span>) exceeds the country&#8217;s deposit limit of &#163;<span id="xdx_90F_eus-gaap--DepositAssets_iI_uGBP_c20241231_z3ShePxF9WH1" title="Deposit assets">85,000</span> (approximately $<span id="xdx_90C_eus-gaap--DepositAssets_iI_c20241231_z0WdGHQohBQ4" title="Deposit assets">107,000</span>). The Company&#8217;s
US depository bank participates in the Demand Deposit Marketplace program, insuring deposits up to $<span id="xdx_900_eus-gaap--DemandDepositAccounts_iI_pn5n6_c20241231_zfZWgquLidRl" title="Demand deposit accounts">10</span> million by sweeping amounts in
excess of the $<span id="xdx_903_ecustom--DepositInsuranceLimit_iI_c20241231_ziy0DytOkTc4" title="Deposit insurance limit">250,000</span> deposit insurance limit among participating banks. The Company has not experienced any losses on any accounts
through the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_z2fXvuCTKKHd">0.6</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
and $<span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_z8CmV6dzZ03l">4.2</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
in cash and cash equivalents on hand as of December 31, 2024 and December 31, 2023, respectively. As of December 31, 2024, $<span id="xdx_908_ecustom--CashAndCashEquivalentsNetBankOverdrafts_iI_pn5n6_c20241231_zOWaCmXXcOL1" title="Cash and cash equivalents net bank overdrafts">0.2
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of the Company&#8217;s $<span id="xdx_904_ecustom--CashAndCashEquivalentsNetBankOverdrafts_iI_pn5n6_c20231231_zbpgW4zK93r1" title="Cash and cash equivalents net bank overdrafts">0.6
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million cash and cash equivalents balance was
invested in money market funds. The money market funds do not have significant liquidity restrictions that would require the exclusion
from cash and cash equivalents.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities, Policy [Policy Text Block]</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--MarketableSecuritiesPolicy_z11uILEwtqR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zr2oaR3Pft5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zGvFhdFehme6">Property,
Plant and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment are initially recorded at cost. Depreciation and amortization are computed using the straight-line method over the
estimated useful lives of the assets or, for leasehold improvements, the life of the lease, if shorter. When assets are retired or otherwise
disposed of, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected
in other income or expense for the period. As of December 31, 2024, property, plant and equipment primarily consisted of leasehold improvements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zFWyZzHoR1O1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zYTsYzI9vQQ1">Leases</span>
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 842, Leases (ASC 842), the Company records a right-of-use (ROU) asset and a lease liability on the balance sheet
for all leases with terms longer than 12 months and classifies them as either operating or finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and
circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset,
whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has
the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets,
lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases
with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components,
the Company has elected not to allocate the contract consideration, and to account for the lease and non-lease components as a single
lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term.
The implicit rate within our operating leases is generally not determinable and, therefore, the Company uses the incremental borrowing
rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#8217;s incremental
borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing
rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The
operating lease ROU asset also includes any lease prepayments, offset by lease incentives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain
we will exercise that option. An option to terminate is considered unless it is reasonably certain we will not exercise the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_843_eus-gaap--UseOfEstimates_zY7dhmJYGLo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zuZg498GV7R2">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial
statements as well as the reported amounts of revenues and expenses during the reporting period. Estimates are based on several factors
including the facts and circumstances available at the time the estimates are made, historical experience, risk of loss, general economic
conditions and trends, and the assessment of the probable future outcome. Actual results could differ materially from such estimates.
Estimates and assumptions are reviewed periodically by management and changes in estimates are made as management becomes aware of changes
in circumstances surrounding the estimates. The effects of changes are reflected in the financial statements in the period that they
are determined.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z0hboc6fhfs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zw3w6L0i2dUl">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 820, <i>Fair Value Measurements and Disclosures</i>, defines fair value, establishes a framework for measuring fair value, and
expands disclosures about fair value measurements. Fair value is to be determined based on the exchange price that would be received
for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants. In determining fair value, the Company used various valuation approaches. A fair
value hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes
the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that
market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
inputs reflect the Company&#8217;s assumption about the inputs that market participants would use in pricing the asset or liability developed
based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the
inputs, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1&#8212;Valuations based on quoted prices for identical instruments in active markets. Since valuations are based on quoted prices
    that are readily and regularly available in an active market, valuation of these instruments does not entail a significant degree
    of judgment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2&#8212; Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for either similar
    instruments in active markets, identical or similar instruments in markets that are not active, or model-derived valuations whose
    inputs or significant value drivers are observable or can be corroborated by observable market data.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3&#8212;Valuations based on inputs that are unobservable. These valuations require significant judgment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Level 1 assets consist of cash and cash equivalents, including money market funds, in the accompanying balance sheets
and the value of accrued expenses and other current liabilities approximate fair value due to the short-term nature of these assets and
liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company has two financial liabilities, warrant liabilities for which the fair value is determined based on
Level 2 and Level 3 inputs, and convertible debt carried at fair value for which the fair value is
determined based on Level 3 input. The Level 2 inputs are valued based on observable inputs other than quoted
prices included in Level 1, such as quoted prices for similar instruments in active markets. The level 3 inputs as such inputs are based
on unobservable inputs and require significant judgement. As of December 31 2023, the Company has one financial liability, a warrant liability for which the fair value is determined
based on Level 2 inputs as such inputs are valued based on observable inputs other than quoted prices included in Level 1, such as
quoted prices for similar instruments in active markets.  See Note 3 for further information on the Company&#8217;s
financial liabilities carried at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueTransferPolicyPolicyTextBlock', window );">Fair Value Option</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--FairValueTransferPolicyPolicyTextBlock_zmMVpIcF9dy7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zJ210n5wYSd8">Fair
Value Option</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected the fair value measurement option for convertible debt with embedded derivatives that would otherwise require bifurcation
and has recorded the entire hybrid financial instrument at fair value under the guidance in ASC 825, Financial Instruments. As a result,
the August 2024 Nirland Note was recorded at fair value subsequent to the Second Amendment and the A.G.P. Convertible Note was recorded
at fair value upon issuance. The notes will subsequently be remeasured at fair value each reporting date until settled or converted.
The Company reports interest expense, including accrued interest, related to the convertible debt under the fair value option, separately
from within the change in fair value of the convertible debt in the accompanying consolidated statement of operations and comprehensive
income (loss). Any changes in fair value caused by instrument-specific credit risk are presented separately in other comprehensive income.
During the year ended December 31, 2024, the Company did not record any changes in fair value related to instrument-specific credit risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zmqny0wbGnq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zWcwKdDcWrMc">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred in connection with the research and development of our clinical assets
and programs, see Note 10 for further discussion of research and development expense. Conduit holds all licenses to conduct clinical
research through a third-party pharmaceutical company. The Company expenses research and development costs and intangible assets
acquired that have no alternative future use as incurred. These expenses include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred under agreements with organizations that support the Company&#8217;s drug discovery and development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred in connection with the preclinical and clinical development of the Company&#8217;s clinical assets and programs, including
    under agreements with contract research organizations, or CROs&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to contract manufacturing organizations, or CMOs, that are primarily engaged to provide drug substance and product for our
    clinical trials, research and development programs, as well as investigative sites and consultants that conduct the Company&#8217;s
    clinical trials, nonclinical studies and other scientific development services&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing registration and validation
    batches&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related
    expenses, including salaries, related benefits and equity-based compensation expense, for employees engaged in research and development
    functions&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">acquisition costs related to the purchase of licensed intellectual property;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to compliance with quality and regulatory requirements&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments
    made under third-party licensing agreements&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">direct
    and allocated costs related to facilities, information technology, personnel and other overhead.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance
payments that we make for goods or services to be received in the future for use in research and development activities are recorded
as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or consumed or the related services are performed,
or until it is no longer expected that the goods will be delivered, or the services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_znRfGS37jvN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zZOsh9rAdqGa">General
and Administrative Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries and related costs for personnel in executive management, finance, corporate
and business development, and administrative functions. General and administrative expenses also include legal fees relating to patent
and corporate matters&#894; professional fees for accounting, auditing, tax, and administrative consulting services&#894; insurance costs&#894;
administrative travel expenses and other operating costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zpAczA2q79t5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z0NlpMWvYCrg">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 740, <i>Income Taxes</i>, sets forth standards for financial presentation and disclosure of income tax liabilities and expense.
Interest and penalties recognized have been classified in the consolidated statements of operations and comprehensive income (loss) as
income taxes. Deferred tax assets and liabilities are recognized for future tax consequences attributable to temporary differences between
the financial statement carrying amount of existing assets and liabilities and their respective tax bases and operating losses carried
forward. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change
in tax rates is recognized in the consolidated statements of operations and comprehensive income (loss) in the period that includes the
enactment date. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits of which
future realization is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings/(Net Loss) per Share</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zJkBnbjryKMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zWQwRNE8GDh2">Earnings/(Net
Loss) per Share</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates basic and diluted earnings/(net loss) per share under ASC Topic 260, <i>Earnings Per Share</i>. Basic earnings/(net
loss) per share is computed by dividing the net income/(loss) by the number of weighted-average common shares outstanding for the period.
Diluted earnings/(net loss) is computed by adjusting net income/(loss) based on the impact of any dilutive instruments. Diluted earnings/(net
loss) per share is computed by dividing the diluted net income/(loss) by the number of weighted-average common shares outstanding for
the period including the effect, if dilutive, of any instruments that can be settled in common shares. When computing diluted net income/(loss)
per share, the numerator is adjusted to eliminate the effects that have been recorded in net income/(loss) (net of tax, if any) attributable
to any liability-classified dilutive instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_WarrantInstrumentsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_84B_ecustom--WarrantInstrumentsPolicyTextBlock_zb3ifZGf9Nf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_86C_zZCtQMd1f6Ne" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the accounting classification of Warrants as either liability or equity by first assessing whether the Warrants meet
liability classification in accordance with ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;). Under ASC 480, a
financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies
a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares must be classified as
a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly
on any one of the following: (a) a fixed monetary amount known at inception; (b) variations in something other than the fair value of
the issuer&#8217;s equity shares; or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
financial instruments, such as the Warrants, are not required to be classified as liabilities under ASC 480, the Company assesses whether
such instruments are indexed to the Company&#8217;s own stock under ASC 815-40. In order for an instrument to be considered indexed to
an entity&#8217;s own stock, its settlement amount must always equal the difference between the following: (a) the fair value of a fixed
number of the Company&#8217;s equity shares, and (b) a fixed monetary amount or a fixed amount of a debt instrument issued by the Company.
The Company determined that the settlement amount of the Equity Classified Warrants would equal the difference between the fair value
of a fixed number of shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified as equity, while
the settlement amount of the Liability Classified Warrants would not equal the difference between the fair value of a fixed number of
shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified as a liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Equity Classified Warrants are recorded in stockholders&#8217; deficit and the Liability Classified Warrants are recorded as liabilities
in the Consolidated Balance Sheet. The Liability Classified Warrants are remeasured each period with changes in fair value recorded in
the Consolidated Statements of Operations and Comprehensive Income (Loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zfXSfxa44aaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zTvJEe4YQyb5">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company translated the assets and liabilities of foreign subsidiaries from their respective functional currency, the British pound, to
United States dollars at the appropriate spot rates as of the balance sheet date. Income and expenses of operations are translated to
United States dollars using weighted average exchange rates during the year. The foreign subsidiaries use the local currency as their
functional currency. The effects of foreign currency translation adjustments are included as a component of accumulated other comprehensive
income in the accompanying consolidated statements of changes in stockholders&#8217; deficit. Non-monetary items in the subsidiaries&#8217;
functional currency are re-measured into the reporting currency at the historical exchange rate (i.e., the rate of exchange at the date
of the transaction).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p id="xdx_84E_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zviwSQVWkuNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zT0gOeUHmSN7">Emerging
Growth Company Status</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under
the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of
the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period
for complying with new or revised accounting standards that have different effective dates for public and private companies until the
earlier of the date that: (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended
transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with
the new or revised accounting pronouncements as of public company effective dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Merger, the Company will remain an emerging growth company, as defined by the Jumpstart Our Business Startups act of 2012, until
the earliest of <span id="xdx_906_ecustom--DescriptionForEmergingGrowthCompany_c20240101__20241231_zjcsk4iASiNa" title="Emerging growth description">(i) the last day of the combined entity&#8217;s first fiscal year following the fifth anniversary of the completion of
MURF&#8217;s initial public offering (the &#8220;MURF IPO&#8221;), (ii) the last day of the fiscal year in which the combined entity
has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the combined entity is deemed
to be a large accelerated filer, which means the market value of the combined entity&#8217;s common stock that is held by non-affiliates
exceeds $700.0 million as of the prior December 31st or (iv) the date on which the combined entity has issued more than $1.0 billion
in non-convertible debt securities during the prior three year period.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1ZDVaMonHk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zZTzVojdLiYe">Recently
Adopted Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) (&#8220;ASU 2023-07&#8221;), which enhances the segment disclosure
requirements for public entities on an annual and interim basis. Under this proposal, public entities are required to disclose significant
segment expenses that are regularly provided to the chief operating decision maker (the &#8220;CODM&#8221;) and included within each
reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#8217;s profit or loss
and assets will be required on an interim basis. Entities are also required to disclose information about the CODM&#8217;s title and
position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment
of segment performance and deciding whether how to allocate resources. Finally, ASU 2023-07 requires all segment disclosures for public
entities, even those with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023,
and interim periods within fiscal years beginning after December 15, 2024, and should be applied on a retrospective basis to all periods
presented. As of December 31, 2024, the Company only has one reportable segment. The Company adopted this accounting standard as of January
1, 2024. See Note 19 for the Company&#8217;s segments disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards Not Yet Adopted</a></td>
<td class="text"><p id="xdx_845_ecustom--NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_zn0GSboqcEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zzGJPSdxsV7b">Recently
Issued Accounting Standards Not Yet Adopted</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;).
ASU 2023-09 modifies the reporting requirements for income tax disclosures related to effective tax rates and cash income taxes paid.
Pursuant to ASU 2023-09, public business entities are required to disclose certain categories in the income tax rate reconciliation,
as well as additional information for reconciling items that meet a specific quantitative threshold. Additionally, ASU 2023-09 requires
annual disclosures of income taxes paid for all entities, including the amount of income taxes paid, net of refunds received, disaggregated
by federal, state, and foreign jurisdictions. The standard is effective for fiscal years beginning after December 15, 2024, with early
adoption permitted. The Company is currently evaluating the impact of ASU 2023-09 on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, which is intended to provide more detailed information about specified categories
of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented
on the consolidated statements of operations and comprehensive income (loss). The guidance in this ASU is effective for fiscal years
beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted.
The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU
or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the
impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging Growth Company Status [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>New Accounting Pronouncements Not Yet Adopted [Policy Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_WarrantInstrumentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Instruments [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_WarrantInstrumentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueTransferPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining when transfers between levels are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueTransferPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger and Financing (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Schedule of Common Stock Outstanding</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zMHzmmRuPXxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the total Common Stock outstanding immediately after the closing of the Merger:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zmRwfzhSC5Zh" style="display: none">Schedule
of Common Stock Outstanding</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Exchange of MURF common stock subject to possible redemption for Conduit Pharmaceuticals Inc. common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pip0_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis__us-gaap--CommonStockSubjectToMandatoryRedemptionMember_z1RCLOhnbOLe" title="Exchange of MURF common stock subject to possible redemption for Conduit Pharmaceuticals Inc. common stock, shares">580</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exchange of MURF Class A common stock held by MURF Directors for Conduit Pharmaceuticals Inc. common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxC6b0h09OHk" title="Exchange of MURF Class A common stock held by MURF Directors for Conduit Pharmaceuticals Inc. common stock, shares">450</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Exchange of MURF Class A common stock held by MURF Sponsor for Conduit Pharmaceuticals Inc. common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxfpbvUTjoS8" title="Exchange of MURF Class A common stock held by MURF Sponsor for Conduit Pharmaceuticals Inc. common stock, shares">40,152</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Subtotal - Merger, net of redemptions</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zozAQ9XrK4gi" title="Business Combination, net of redemptions, shares">41,182</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3CppKDwcUa5" title="Issuance of Conduit Pharmaceuticals, Inc. common stock in connection with PIPE Financing, shares">20,000</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Exchange of Conduit Pharmaceuticals Limited ordinary shares for Conduit Pharmaceuticals Inc. common stock on the Closing Date</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWY0VDeUjWld" title="Exchange of Conduit Pharmaceuticals Limited ordinary shares for Conduit Pharmaceuticals Inc. common stock on the Closing Date, shares">646,264</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXQi6JjWROI5" title="Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date,shares">3,735</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxuWF0bLXB76" title="Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the transaction, shares">13,000</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total - Conduit Pharmaceuticals Inc. common stock outstanding as a result of the Merger, PIPE Financing, exchange of Conduit Pharmaceuticals Limited shares for shares of Conduit Pharmaceuticals Inc., issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes, and advisors.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zAbAtWqta8i2" title="Total - Conduit Pharmaceuticals Inc. common stock outstanding as a result of Business Combination, PIPE Financing, exchange of Conduit Pharmaceuticals Limited shares for shares of Conduit Pharmaceuticals Inc., issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes, and transaction services agreements, shares">724,181</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets Subject to Measurement at Fair Value on Recurring Basis</a></td>
<td class="text"><p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zCtFMn43Fv61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period ended December 31, 2024, there were no transfers between Level 1 and Level 2, nor into or out of Level 3. The following
table presents as of December 31, 2024 the Company&#8217;s assets and liabilities subject to measurement at fair value on a
recurring basis (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_z3goVReCnn35" style="display: none">Schedule
of  Assets Subject to Measurement at Fair Value on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Cash equivalents</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_zW0HAnUpsvPi" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents">192</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_z33wWa7lwO0j" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents"><span style="-sec-ix-hidden: xdx2ixbrl0886">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_z9IX5fTZ4kj7" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents"><span style="-sec-ix-hidden: xdx2ixbrl0888">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_zb5yiPIDU7l3" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents">192</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdQMgbeQS6v1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets">192</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2kiDDR5Tmkl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets"><span style="-sec-ix-hidden: xdx2ixbrl0894">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzUmQ2pkcK2k" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUo15aFKnWJ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets">192</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible notes payable at fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_zyb4WrTSaAhj" style="text-align: right" title="Option liability"><span style="-sec-ix-hidden: xdx2ixbrl0900">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_zUl5DKjzekr9" style="text-align: right" title="Option liability"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_zcXTKq4up5m3" style="text-align: right" title="Option liability">5,856</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoUOgP3F4u9g" style="text-align: right" title="Option liability">5,856</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Liability Classified Warrants</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zSQzp4WpuF8h" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants"><span style="-sec-ix-hidden: xdx2ixbrl0908">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zqRtJD0od3tg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants">0</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_z29P0jaeyOLi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants">138</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zU3ETZrXfeIh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants">138</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgT4eaYNsP06" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8JNrw2ygA12" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0918">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUMv3HreeBu1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities">5,994</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zknkSqE01W5k" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities">5,994</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents as of December 31, 2023 the Company&#8217;s liabilities subject to measurement at fair value on a recurring
basis (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Liability Classified Warrants</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zXOzm6huL3sf" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zENvKENrXooi" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants">142</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zl9wcldzfSQe" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants"><span style="-sec-ix-hidden: xdx2ixbrl0928">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zmNKSSwrtGql" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants">142</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6q6LJ2Ls69a" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0932">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5bDizCJVXh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities">142</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLXYPUPearZ7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0936">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFBw8ee5C1L3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities">142</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value</a></td>
<td class="text"><p id="xdx_892_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zyye7A4TPG83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents additional information about the Convertible Notes Payable subject to measurement at fair value on a recurring
basis and warrant liabilities, for which the Company used significant unobservable inputs (Level 3) (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zqxT7pULAy3b" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_z6393p8CaGjj" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible Notes</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payable</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_z1GM2RkDB3le" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Liability Classified Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ConvertibleDebtFairValueDisclosures_iS_pn3n3_zee7e5WmrIkc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0942">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsOfDebtIssuanceCosts_pn3n3_zs2UpKq7Jqof" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Fair value at Issuance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">7,899</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">229</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_iN_pn3n3_di_zR8QJkt8jZr1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of convertible note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(92</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0949">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ChangeInFairValueOfConvertibleNotesPayable_pn3n3_z4jevABFubjj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,951</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(91</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--ConvertibleDebtFairValueDisclosures_iE_pn3n3_zDGdPFy27977" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,856</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">138</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock', window );">Schedule of Fair Value of Assumptions</a></td>
<td class="text"><p id="xdx_895_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_zbfLS4JMsCAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zz0NnNr931ll" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Fair Value  of Assumptions</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>October 31,</b></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>2024</b></p>

</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>November 22,</b></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>2024</b></p>

</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">2024</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Stock Price</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 14%"><span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zXP1MgYtPeec" title="Measurement input">9.10</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 14%"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zqD7KjVRhKm1" title="Measurement input">10.40</span></td>
    <td style="width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zJwzZ7tNojW9" title="Measurement input">6.90</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term (years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20241031__20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z8hbVV8uD26e" title="Measurement input">0.8</span></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20241122__20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zNmDiM14K2X4" title="Measurement input">0.7</span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zaP1nUSbEZOe" title="Measurement input">0.6</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Corporate bond yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember_zZuiHbbsiz9h">9.1</span></td>
    <td>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember_zbRAZVJcZYje">8.7</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember_zu7d2zNDqHU3">11.4</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit Spread</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zAIYKzu1Az6i">15.9</span></td>
    <td>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zZ859OayB6ne">15.9</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zpRIg4xqVtc1">15.9</span></td><td style="text-align: left">%</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Probability of default</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember_zfTGPxLaGWI1">40</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember_z5C3X9drZTHd">40</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember_zuGVIZAp9sHk">40</span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Recovery upon default</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember_zeZSEtaKzvrb">20</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember_zFAalIqNOa5d">20</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember_znbq2A2VwvZa">20</span></td><td style="text-align: left">%</td></tr>

  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zsQCAwt4dx23">103.2</span></td>
    <td>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zOLVsGF4n2gk">96.5</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zYRcTsjYsIkl">123.7</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock', window );">Schedule of Fair Value of Assumptions</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zrlqaJL1wSv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
measurement of the A.G.P. 2024 Warrants is classified as Level 3 due to the use of an option-pricing model that utilizes unobservable inputs and requires significant judgement. The Company estimated
the fair value of the warrants issued as the issuance date, October 29, 2024, and as of December 31, 2024, using a Black-Scholes
option-pricing model utilizing the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_z29Sb08l0Ne8" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Fair Value  of Assumptions</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>October 29, 2024</b></td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Closing stock price</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 16%"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zL0MGY7X4re1" title="Measurement input">10.48</span></td>
    <td style="width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIu51AZP2dIe" title="Measurement input">6.90</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Contractual exercise price</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCikayCpEta7" title="Measurement input">10</span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYgt4d7PslL" title="Measurement input">10.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zK4NQDMEYmGc" title="Measurement input">4.11</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zER6wFIDSePb" title="Measurement input">4.38</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Estimated volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaNjNJ2d2Opk" title="Measurement input">98.4</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7GMCDnDHHd9" title="Measurement input">98.6</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Time period to expiration (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentTerm_dtY_c20241029__20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFkT9SINyWc" title="Measurement input">5.2</span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjfcPSu19W48" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Measurement input">5.0</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_AGPConvertibleNoteMember', window );">AGP Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock', window );">Schedule of Fair Value of Assumptions</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_hus-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zaf84Dforup9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table outlines the range of significant unobservable inputs used in calculating the fair value of the A.G.P. Convertible
Note as of the dates noted below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zkqDuKLIvqSc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Fair Value  of Assumptions</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>November 25,</b></p>
                                               <p style="margin-top: 0; margin-bottom: 0"><b>2024</b></p></td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2024</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Stock Price</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 16%"><span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zBul29jM6eL2" title="Measurement input">9.10</span></td>
    <td style="width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zu6TcECljG2f" title="Measurement input">6.90</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term (years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentTerm_dtY_c20241125__20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zUa4mcOSVE1l" title="Measurement input">1</span></td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zdsyCXtNdts9" title="Measurement input">0.9</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Corporate bond yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_z9MXSGtaez2h">8.8</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zoNZAFPL0UM3">9.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Credit Spread</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zRg8nu2t6hgg">26.2</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zUwDQlb64STf">26.2</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Probability of Default</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zeMJhHg9bEjl">40</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zI8Mtigw1iX4">40</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Recovery upon default</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zPIXvbm8OyOc" title="Measurement input">0</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zfYuVgGDKdq6" title="Measurement input">0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zz2qzFr4YgDj" title="Measurement input">108.7</span></td>
    <td>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zD7lCIloP8Fd" title="Measurement input">101.6</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CDT_AGPConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CDT_AGPConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details &#8211; Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of Balance Sheet Details</a></td>
<td class="text"><p id="xdx_894_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_z8g51x79iSz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
assets consisted of the following as of December 31, 2024 and December 31, 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_z49AnDy71Qgh" style="display: none">Schedule
of Balance Sheet Details</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zzu6ecM4gGE" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_z6Ucz8rrw931" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzWXV_zvJ2rACh1pFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid directors&#8217; and officers&#8217; insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,187</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,365</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maPEAOAzWXV_zVKTyQP1yqFj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maPEAOAzWXV_zHxa6sYCZ0l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1051">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherReceivablesNetCurrent_iI_pn3n3_maPEAOAzWXV_zmYxqf7s0nb6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">489</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzWXV_ziXxF2umDgdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,505</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Cost</a></td>
<td class="text"><p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_ztFEfP5fALic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8B0_zH483udmyJXh" style="display: none">Schedule
of Lease Cost</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Lease Cost</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zLwTLQhOvST4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/>
2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_pn3n3_maLCzbUU_zbnjE8urBSP3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">116</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzbUU_zjRy0JmvT1mf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short-term lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--VariableLeaseCost_pn3n3_maLCzbUU_zcVbGeQ6OUOh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Variable lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LeaseCost_iT_pn3n3_mtLCzbUU_z9QQSkoMn9wc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">259</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_LesseeOperatingLeaseLiabilityTableTextBlock', window );">Schedule of Operating Lease Liabilities</a></td>
<td class="text"><p id="xdx_898_ecustom--LesseeOperatingLeaseLiabilityTableTextBlock_zrEGc5eOYk62" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information about our operating lease for the year ended December 31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8BE_zMSqtLCKem1g" style="display: none">Schedule
of Operating Lease Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Supplemental cash flow and other information</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231_z9kLoVIN0577" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/>
2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeasePayments_pn3n3_zXsxgxfBRaC" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; text-align: left">Operating cash flows from operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">143</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zcppdSH0PxU" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">ROU assets obtained in the exchange for lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">352</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average remaining lease term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zv6l9UDkzsb2" title="Weighted-average remaining lease term (in years)">2.0</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zs39Vo5dcmu2" title="Weighted-average discount rate">11.2</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments For Operating Lease</a></td>
<td class="text"><p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zZKj1736oPGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s future minimum lease payments for our operating lease as of the year ended December 31, 2024, are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8BC_zfNkFLRq0Y0i" style="display: none">Schedule
of Future Minimum Lease Payments For Operating Lease</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_zLfU9sYmzFl6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/>
2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold">Year ending December 31,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz2P5_zUZJ8YG7x6ck" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">140</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz2P5_zjA7uzVRRFwb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">113</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz2P5_zaEqk5RbT9gj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">253</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z70CJ5JAsMSf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(27</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zgV8WrDqUxJ5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">226</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_LesseeOperatingLeaseLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_LesseeOperatingLeaseLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zrKDiWEdwHB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes restricted stock activity for the 2023 Plan:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span id="xdx_8BE_z3DO0Eys0G8j" style="display: none">Schedule
of Restricted Stock Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards</b></span></p></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value Per Unit</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231_zvAzJuP4BzY4" style="width: 16%; text-align: right" title="Number of Awards, Outstanding">745</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231_z7dcBqJqSAoc" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding">551</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231_zy4r9o6O4czh" style="text-align: right" title="Number of Awards, Granted">745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zY3ZhFI8v3G8" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">284</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231_zkG3qLdNmqL4" style="text-align: right" title="Number of Awards, Cancelled/Forfeited">(745</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_iN_pid_di_c20240101__20241231_zCtdIEGtRuhj" style="text-align: right" title="Weighted Average Grant Date Fair Value, Cancelled/Forfeited">(551</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231_zMeNMKBTdbV7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Awards, Vested">(745</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_iN_pid_di_c20240101__20241231_zB9bUhufF7Y2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Vested">(284</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231_zjQYtVpsvdH5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Awards, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1518">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231_zTLLMpuwAGJj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1520">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Stock Option Granted</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zBaIaJl265s5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimated the fair value of stock options granted in the periods presented using a Black-Scholes option-pricing model utilizing
the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B2_zGRBcoYo0Cq7" style="display: none">Schedule of Fair Value
of Stock Option Granted</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zTe9FxoLtNFh" title="Expected Volatility">83.2</span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zcl1d02WjwT" title="Expected Volatility">85.4</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z9UGhjz6BM4l" title="Expected Volatility">79.0</span>% - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zjt4AnyIiAg2" title="Expected Volatility">80.0</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z3JgiqKT57df" title="Expected term (years)">5.5</span> - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zxXQXcvmcwEh" title="Expected term (years)">5.6</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zyBX57jSy0a4" title="Expected term (years)">3.5</span> - <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_ztaWcF6568Ki" title="Expected term (years)">6.5</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zZMa1v43seSj" title="Risk-free interest rate">4.28</span>% - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z9WtdAI2SJK8" title="Risk-free interest rate">4.40</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zjbMLbwsQhuh" title="Risk-free interest rate">4.16</span>% - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zrjfVl4qTcCl" title="Risk-free interest rate">4.35</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Expected dividend yield (%)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20241231_zeDDkprb70g9" title="Expected dividend yield">0</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230101__20231231_zuz1k08Guxf8" title="Expected dividend yield">0</span></td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zlD4LccAaC7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes stock option activity for the 2023 Plan:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BE_zEM2SYKmrjH9" style="display: none">Schedule
of Stock Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Intrinsic Value (in thousands)</p></td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_z89lSJcEixcg" style="width: 12%; text-align: right" title="Number of Options, Outstanding">10,717</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zaXw5uDHyNC6" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding">551</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zqmlZa8fWW5k" title="Weighted Average Remaining Contractual Term Years">8.85</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zSNWNOOx17Nf" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1560">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zaPG7aLhLJcg" style="text-align: right" title="Number of Options, Granted">56,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zmQ4YTeY53k" style="text-align: right" title="Weighted Average Exercise Price, Granted">8.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cancelled/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zfdVIuu2lu45" style="text-align: right" title="Number of Options, Cancelled/forfeited">1,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zb2MSpYym9Kl" style="text-align: right" title="Weighted Average Exercise Price, Cancelled/Forfeited">551</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zYYZSYL4Qqdg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1570">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zP19SrsdlKD2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1572">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_z1jc3SEVYEi7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding">65,509</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zk9sxTdDKnf9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding">81.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zn3Gqjnt0d2i" title="Weighted Average Remaining Contractual Term Years">9.72</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zu9y0C3WCqk7" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1580">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zfPXv2RcdScj" style="text-align: right" title="Number of Options, Exercisable">23,154</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zfYT7HapQtik" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">84.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zTeBGUka45G1" title="Weighted Average Remaining Contractual Term Years">9.66</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zsoDPz366TDk" style="text-align: right" title="Aggregate Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1588">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_ziJRyvS6oSo9" style="text-align: right" title="Number of Options, Unvested">42,355</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zHZP7SGlZN15" style="text-align: right" title="Weighted Average Exercise Price, Unvested">80.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zXZUWGtMgEJ3" title="Weighted Average Remaining Contractual Term Years">9.76</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zjP7aVdxXTB2" style="text-align: right" title="Aggregate Intrinsic Value"><span style="-sec-ix-hidden: xdx2ixbrl1596">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zUcA0awPmLg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Loss from operations before income
taxes for the years ended December 31, 2024 and 2023 is summarized below (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zMVxAIiHVcYl" style="display: none">Schedule of Income before Income Tax, Domestic and Foreign</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231_zj8aoHNv8tki" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_z1IT1RIWy1fb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_iB_zbAoRlECz5Wd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations before income taxes:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i01_maILFCOzobr_zQsoEnZ56P78" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; padding-left: 0.5in">US</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(12,855</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(1,990</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i01_maILFCOzobr_zRwjiNfo36Yj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.5in">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,947</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,454</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_mtILFCOzobr_zikm4NYzBAs1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,802</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(536</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Tax</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z0DMoB3vjxg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provision (benefit) for income taxes for the years ended December 31, 2024 and December 31, 2023 is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B2_zxhmnoyBXHKj" style="display: none">Schedule of Provision for Income Tax</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_zkf2jmA5U8yg" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zfVRTsnxp1yk" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>For The Years Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2024</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_zcD79FYKzuv1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1620">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1621">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_zTlVy8Beh0dh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1623">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1624">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_zlanbZ1RLPkk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Foreign</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1626">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1627">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_zf2uGegnBRG2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Current income tax</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1629">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1630">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_z3MeELTHQa1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%">Federal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(2,429</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(843</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_zPYSZliV9Hie" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">355</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(355</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_pn3n3_znCwMjmrOSYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Foreign</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(931</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(251</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3n3_zzva8tygFM3h" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income tax</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,005</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,449</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_ztZLWMAGlhI5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in Valuation Allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,005</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,449</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zzMTb2QetDP9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Income Tax Expense</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1647">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1648">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Federal Income Tax Rate</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zeq9Kfy0ZFJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax provision differed from the amount computed by applying the U.S. federal income tax rate of <span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_zY0243RDodYl">21</span>% to income (loss) before taxes, as
follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zlaiIzT87Rj4" style="display: none">Schedule
of Federal Income Tax Rate</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zREUvd2H3s3c" style="border-bottom: Black 1pt solid; text-align: center">US</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zioxz5mvuNth" style="border-bottom: Black 1pt solid; text-align: center">Foreign</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zEIGnpM0vrU8" style="border-bottom: Black 1pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>For The Year Ended</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>US</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Foreign</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Consolidated</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzbix_zsMbfVAp9cNg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Taxes at federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(2,705</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(1,039</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(3,744</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maITEBzbix_zuUmSswPUKU5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign Rate Differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1657">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91 </td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maITEBzbix_zIvbgV5iFirc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Meals &amp; Entertainment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1662">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_pn3n3_maITEBzbix_zaqsfP2LujIh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Eq Comp Perm</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1666">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IncomeTaxReconciliationConvertibleDebtAdjustment_pn3n3_maITEBzbix_zT2Npgc5Wbh9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible Debt Adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1670">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--IncomeTaxReconciliationStateReRate_pn3n3_maITEBzbix_zokB8Ld15Oxc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State Re-Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">355</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1674">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">355</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maITEBzbix_zuEidSykYiu5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(59</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzbix_zy1n58puvGEg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change In Valuation Allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,074</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">931</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,005</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzbix_zlhSe7jytOLk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total provision (benefit) for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1685">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1686">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1687">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmASuhfEOQo6" style="border-bottom: Black 1pt solid; text-align: center">US</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zXpfATiNFTCh" style="border-bottom: Black 1pt solid; text-align: center">Foreign</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zBFlZWCWregl" style="border-bottom: Black 1pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>For The Year Ended</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>US</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Foreign</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Consolidated</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzbix_zHfGaUT0Pye8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Taxes at federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(417</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">305</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(112</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzbix_zmZ9OVyOM44a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State Taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(175</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1694">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(175</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maITEBzbix_z8DbuhbmDJic" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign Rate Differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1697">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">490</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">490</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maITEBzbix_zJbdDWvcgoH" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Meals &amp; Entertainment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_pn3n3_maITEBzbix_zv0Pr4kfU13j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Eq Comp Perm</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1706">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncomeTaxReconciliationConvertibleDebtAdjustment_pn3n3_maITEBzbix_z6tILXxHK4j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Debt Adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1709">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,048</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,048</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--IncomeTaxReconciliationPurchaseAccountingAdjustments_pn3n3_maITEBzbix_zxmD3op3Czzh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Purchase Accounting Adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(609</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1714">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(609</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzbix_zKInzUrrpnhd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change In Valuation Allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">251</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,449</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzbix_zi9aJ1MvZug6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total provision (benefit) for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1721">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1722">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1723">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zSMZBNIYmoDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effects of temporary differences which give rise to significant portions of deferred tax assets are as follows as of December 31
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zXEONsTeVo4" style="display: none">Schedule
of Deferred Tax Assets and Liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zbiDH8OVEin7" style="border-bottom: Black 1pt solid; text-align: center">US</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zfu5jwUxRBfl" style="border-bottom: Black 1pt solid; text-align: center">Foreign</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20241231_zkzR5g3PH9S9" style="border-bottom: Black 1pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>For The Year Ended</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>US</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Foreign</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Consolidated</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Deferred Tax Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DeferredTaxAssetsStockOptions_iI_pn3n3_maDTAGzJ4A_zpGtcoAV3Fmh" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">280</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1728">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">280</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsHedgingTransactions_iI_pn3n3_maDTAGzJ4A_zP3jcOXwpTyk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Transaction Costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1732">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">393</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzJ4A_z47NOXKKQNrj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research &amp; Development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">671</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1736">-</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">671</p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_pn3n3_maDTAGzJ4A_zZ4ACcBvPOH8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1740">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzJ4A_z0lrxbxmVF0h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net operating loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,788</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,182</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,970</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzJ4A_maNDTAzpU6_zzOChQgdkKJ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,455</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzjwi_zTg0HciqIuB7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,273</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,182</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,455</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTALNzjwi_zIniBtnKe5Ve" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets (liability)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1755">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1756">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1757">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_znmEnIClDEKe" style="border-bottom: Black 1pt solid; text-align: center">US</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zt7U4vfjY3hh" style="border-bottom: Black 1pt solid; text-align: center">Foreign</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zNNh3iKZH5ri" style="border-bottom: Black 1pt solid; text-align: center">Consolidated</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>For The Year Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>US</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Foreign</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Consolidated</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Deferred Tax Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxAssetsStockOptions_iI_pn3n3_maDTAGzJ4A_zCUi9CCfy8Sg" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">37</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1760">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">37</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsHedgingTransactions_iI_pn3n3_maDTAGzJ4A_zvxOLF2rEw11" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Transaction Costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">599</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">599</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzJ4A_zJt5jqeQdw03" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net operating loss</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">562</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">251</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">813</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzJ4A_maNDTAzpU6_zrbfj4BlPjxa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">251</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,449</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzjwi_zNC0hv4gSJ0f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Valuation allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,198</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(251</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,449</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTALNzjwi_z1HzbCuagGjk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net deferred tax assets (liability)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1779">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1780">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1781">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings/(Net Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zIgahDeMW377" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the calculation of basic and diluted earnings/(net loss) per share (in thousands, except share amounts and per
share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zplVRWoff8he" style="display: none">Schedule
of Basic and Diluted Net Loss Per Share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zfn0S5lN5Lqe" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zOHpaNx3a6r2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
                                            the years ended</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span><b>December 31,</b></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_maNILATzJEp_z8UQOiBwl1ae" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net income (loss) - basic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(17,802</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(535</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--ChangeInFairValueAndIncomeImpactOfOptionLiabilities_iN_pn3n3_di_msNILATzJEp_z1Ky9hZe9hdj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Less: Change in fair value and income impact of option liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1836">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,521</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_iT_pn3n3_mtNILATzJEp_z7YWM3wqGVS3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Net income (loss) - diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,802</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,056</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zZtAdU2VVZ7g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Weighted average common stock outstanding, basic</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="text-align: right">867,096</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">669,739</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--OptionLiabilityConversionShares_pid_zhR4WG7c9cLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Add: Option liability conversion shares</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1845">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,200</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_zcgCt1xPrTUc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Weighted average shares used in computing net loss per share - diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">867,096</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">678,939</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EarningsPerShareBasic_pid_zrRj4i04auhc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income (loss) per share, basic</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(20.53</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.79</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_pid_zHYVozj43l1b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net income (loss) per share, diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(20.53</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8.92</td><td style="text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ziQtr3IBQtLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities (upon conversion) that were not included in the diluted per share calculations because they would have been anti-dilutive
were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zm7r1qoMmG5i" style="display: none">Schedule
of Potentially Dilutive Securities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20241231_z8lF6z0IaIk2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zF2M9MghyTs7" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PublicWarrantsMember_zl5JWAfU4uH3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Public warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">139,790</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">139,790</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PIPEMember_zmQQ5phS9h55" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">PIPE Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1862">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AGPWarrantsMember_z0CMGaPf10k6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">A.G.P. Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">540</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">540</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePromissoryNotesPayableMember_zGpdAfvxPI6j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Promissory Notes Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">805</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zC9p8TYuoeCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,509</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,717</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zct5Ft3E26O2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1874">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,470</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zpWC5guhU2B2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>August 2024 Nirland Note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">672,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1878">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AGPConvertibleNoteMember_zXTJrNfL7Lje" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">A.G.P. Convertible Note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">576,949</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1881">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--MarchTwentyTwentyFourWarrantsMember_zuf4MDpqNsm7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>March 2024 Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1884">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AprilTwentyTwentyFourWarrantsMember_zn1dkvEjbyyi" style="vertical-align: bottom; background-color: White">
    <td>April 2024 Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,477</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1887">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AGPTwentyTwentyFourWarrantsMember_zD0sqjeOpkNk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">A.G.P. 2024 Warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">28,626</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1890">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zifmr5T3zFlb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Antidilutive Securities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,501,298</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">173,322</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (expense), net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Expense, Net</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_zRaz7PHeDELc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents other income (expense), net, for the years ended December 31, 2024 and 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zLEROoD1vXac" style="display: none">Schedule
of Other Expense, Net</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zCHJTZcrMjA8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zA6X4xw5wDef" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the years ended<br/> December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--RecognitionOfDeferredRevenueUponOptionExercise_pn3n3_maONIzvdl_zdwIaMrG2xX2" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Recognition of Cizzle deferred revenue upon option exercise</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1929">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,480</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--RecognitionOfDeferredRevenueUponOptionExerciseOne_pn3n3_maONIzvdl_zhHvM7NbHSm3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Recognition of Vela deferred revenue upon option exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1932">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,774</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfOption_pn3n3_maONIzvdl_zJAEl2Djxle1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of Cizzle option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1935">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,280</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfOptions_pn3n3_maONIzvdl_zB06sDcImqhh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of Vela option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1938">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">970</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfWarrantLiability_pn3n3_maONIzvdl_zUuqeccjAtm" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">221</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ChangeInFairValueOfConvertibleNotePayment_pn3n3_maONIzvdl_zuGyz8pDIRIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of convertible note payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,018</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1945">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--GainOnDebtExtinguishment_pn3n3_maONIzvdl_ze3kMRRDTqkd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gain on debt extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,473</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1948">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InterestIncomeOther_pn3n3_maONIzvdl_z1ZODWLtxLkh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxRefund_pn3n3_maONIzvdl_zPHoTmqFWzz2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income Tax Refund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1954">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ForeignCurrencyTransactionGainLossUnrealized_pn3n3_maONIzvdl_zX3cx1jkESmk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unrealized foreign currency transaction gain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherIncome_pn3n3_maONIzvdl_zNTeZ8sHMXb3" style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">115</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherNonoperatingIncome_iT_pn3n3_mtONIzvdl_maNIEzWCX_zCofSRuvuno" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total other income:</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,048</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,754</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other expense:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--LossOnIssuanceOfOptionOne_maONEzInN_zC40JIPLbHN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Loss on issuance of Vela option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1965">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">987</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--OtherIncomeUnrealizedForeignCurrencyTransactionLoss_pn3n3_maONEzInN_zUTM7r7N79U1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Change in fair value of convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1968">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">426</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpenseOther_pn3n3_maONEzInN_zf9T4tlX67cf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">577</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">211</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_pn3n3_maONEzInN_zIZKBsRBHjT3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Amortization of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">929</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1975">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LossOnIssuanceOfWarrants_pn3n3_maONEzInN_zVp9UX2yQaPc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Loss on issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,710</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1978">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LossOnDebtExtinguishment_pn3n3_maONEzInN_zdOWng6ia3o" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Loss on Debt Extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1981">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OtherExpenseChangeInFairValueOfConvertibleNotesPayable_pn3n3_maONEzInN_zeToQGOj2d85" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Realized foreign currency transaction loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">403</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--OtherExpense_pn3n3_maONEzInN_zlIUEjUUOWtd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Other expense</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1987">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNonoperatingExpense_iT_pn3n3_msNIEzWCX_mtONEzInN_zI8XW3D9aGRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total other expense</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,431</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,027</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NonoperatingIncomeExpense_iT_pn3n3_mtNIEzWCX_zcQ5VcY0Bxv9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total other (expense) income, net</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,383</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,727</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock', window );">Schedule of Black-Scholes Option Pricing Model</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock_gL3SOSBPASPWV-MQTQ_zhfw2PgPJCyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zO1HuPsadJOc" style="display: none">Schedule
of Black-Scholes Option Pricing Model</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 20, 2024</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Closing stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20240320_zDYyrtH6M8fk" style="width: 16%; text-align: right" title="Closing stock price">347</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Contractual exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20240320_z4TqI1iGO2C5" style="text-align: right" title="Contractual exercise price">318</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240320__20240320_zRP4KJdUxw1b" title="Risk-free rate">4.41</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Estimated volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240320__20240320_zASslSdPQ4sj" title="Estimated volatility">78.5</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Time period to expiration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240320__20240320_z4w1CDTsOCG" title="Time period to expiration">3</span> Years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><div><table cellpadding="0" cellspacing="0" id="xdx_305_134_zZIyFq14jANh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Schedule of Black-Scholes Option Pricing Model (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 20, 2024</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Closing stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20240420_z5bNvZoBeXf1" style="width: 16%; text-align: right" title="Closing stock price">308</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Contractual exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20240420_zyZrkxWLBv9a" style="text-align: right" title="Contractual exercise price">312</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240420__20240420_zFJ5eTblTUG" title="Risk-free rate">4.81</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Estimated volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240420__20240420_zWZLvLeZaVM5" title="Estimated volatility">78.3</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Time period to expiration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240420__20240420_zCpkfb2n14Ti" title="Time period to expiration">3</span> Years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share Based Payment Award Stock Purchase Warrants Valuation Assumptions [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Financial Data for the Company&#8217;s Reportable Segment</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zeq29aukxZVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents certain financial data for the Company&#8217;s reportable segment (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zwnjdjWmq04k">Schedule
of Financial Data for the Company&#8217;s Reportable Segment</span><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; font-weight: bold; text-align: center">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zQuzlzBZCsi" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zSHo6cOoit5b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NewLicensesMember_zwzjhtJnjcZk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Research &amp; development expense &#8211; new licenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,114</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2099">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalAssetDevelopmentMember_zQjXPw4bUVJ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Research &amp; development expense &#8211; clinical asset development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--LegalAndProfessionalFeesMember_zrUmRuEc6tai" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">General and administrative expenses &#8211; legal &amp; professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,258</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--AccountingAndAuditFeesMember_z50BW13V11fa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">General and administrative expenses &#8211; accounting &amp; audit fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,625</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,064</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--SalariesPayrollAndStockBasedCompensationMember_z540kLE8Dve4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">General and administrative expenses &#8211; salaries, payroll and stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,098</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">721</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_zNfIlJ5g4HA5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">General and administrative expenses &#8211; other</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,073</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_pn3n3_maNILzclF_zgW3TKhaO0Be" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from segment operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">15,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">5,262</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 24, 2025</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,101,000<span></span>
</td>
<td class="nump">$ 11,299,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,419,000<span></span>
</td>
<td class="nump">5,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,682,000<span></span>
</td>
<td class="nump">7,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, uninsured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposit assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 85,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DemandDepositAccounts', window );">Demand deposit accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DepositInsuranceLimit', window );">Deposit insurance limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash Equivalents, at Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_CashAndCashEquivalentsNetBankOverdrafts', window );">Cash and cash equivalents net bank overdrafts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DescriptionForEmergingGrowthCompany', window );">Emerging growth description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) the last day of the combined entity&#8217;s first fiscal year following the fifth anniversary of the completion of
MURF&#8217;s initial public offering (the &#8220;MURF IPO&#8221;), (ii) the last day of the fiscal year in which the combined entity
has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the combined entity is deemed
to be a large accelerated filer, which means the market value of the combined entity&#8217;s common stock that is held by non-affiliates
exceeds $700.0 million as of the prior December 31st or (iv) the date on which the combined entity has issued more than $1.0 billion
in non-convertible debt securities during the prior three year period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_CashAndCashEquivalentsNetBankOverdrafts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents net bank overdrafts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_CashAndCashEquivalentsNetBankOverdrafts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DepositInsuranceLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposit insurance limit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DepositInsuranceLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DescriptionForEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description for emerging growth company</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DescriptionForEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DemandDepositAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of money in accounts that may bear interest and that the depositor is entitled to withdraw at any time without prior notice.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DemandDepositAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Common Stock Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 11, 2024</div></th>
<th class="th"><div>Oct. 09, 2024</div></th>
<th class="th"><div>Jun. 24, 2024</div></th>
<th class="th"><div>Sep. 22, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date,shares</a></td>
<td class="nump">11,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total - Conduit Pharmaceuticals Inc. common stock outstanding as a result of Business Combination, PIPE Financing, exchange of Conduit Pharmaceuticals Limited shares for shares of Conduit Pharmaceuticals Inc., issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes, and transaction services agreements, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,384,801<span></span>
</td>
<td class="nump">738,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date,shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the transaction, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date,shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total - Conduit Pharmaceuticals Inc. common stock outstanding as a result of Business Combination, PIPE Financing, exchange of Conduit Pharmaceuticals Limited shares for shares of Conduit Pharmaceuticals Inc., issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes, and transaction services agreements, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">724,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Subscription Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date,shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Business Combination, net of redemptions, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date,shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Exchange of Conduit Pharmaceuticals Limited ordinary shares for Conduit Pharmaceuticals Inc. common stock on the Closing Date, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the transaction, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Common Stock [Member] | Subscription Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date,shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Common Stock [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Business Combination, net of redemptions, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Common Stock [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Business Combination, net of redemptions, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Common Stock [Member] | Common Stock Subject to Mandatory Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Business Combination, net of redemptions, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_SubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_SubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CDT_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CDT_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger and Financing (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 11, 2024</div></th>
<th class="th"><div>Oct. 09, 2024</div></th>
<th class="th"><div>Jun. 24, 2024</div></th>
<th class="th"><div>Sep. 22, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 11, 2024</div></th>
<th class="th"><div>Sep. 22, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,384,801<span></span>
</td>
<td class="nump">738,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,384,801<span></span>
</td>
<td class="nump">738,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="nump">11,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued during the period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,568,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,328,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued during the period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=CDT_AllianceGlobalPartnersMember', window );">Alliance Global Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=CDT_AllianceGlobalPartnersMember', window );">Alliance Global Partners [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">724,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Subscription Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued during the period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_BusinessAcquisitionNumberOfSharesTransferred', window );">Number of shares transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Director [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_BusinessAcquisitionNumberOfSharesTransferred', window );">Number of shares transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Common stock conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-one basis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Sponsor [Member] | Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1', window );">Business acquisition right to receive number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Number of shares held prior to business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Common Stock [Member] | Subscription Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Common Stock [Member] | Conduit Convertible Note Holders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Common Stock [Member] | Conduit Share Holders and Convertible Note Holders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Old Conduit Pharmaceuticals Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member] | Alliance Global Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DeferredUnderwritingFee', window );">Deferred underwriting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_PaymentForAdvisoryServices', window );">Financial advisory fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DeferredCashPaymentsAmount', window );">Cash payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_AnnualInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_AnnualInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_AnnualInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_BusinessAcquisitionNumberOfSharesTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition number of shares transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_BusinessAcquisitionNumberOfSharesTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DeferredCashPaymentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred cash payments amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DeferredCashPaymentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DeferredUnderwritingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriting fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DeferredUnderwritingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_PaymentForAdvisoryServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_PaymentForAdvisoryServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issed during period shares stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of basis for conversion of convertible common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CDT_AllianceGlobalPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CDT_AllianceGlobalPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_SubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_SubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CDT_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CDT_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CDT_ConduitConvertibleNoteHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CDT_ConduitConvertibleNoteHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CDT_ConduitShareHoldersandConvertibleNoteHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CDT_ConduitShareHoldersandConvertibleNoteHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CDT_OldConduitPharmaceuticalsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CDT_OldConduitPharmaceuticalsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Assets Subject to Measurement at Fair Value on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">$ 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">5,994<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">5,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">5,994<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">5,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value (Details) - Fair Value, Inputs, Level 3 [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Balance as of December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Fair value at Issuance</a></td>
<td class="nump">7,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Conversion of convertible note</a></td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ChangeInFairValueOfConvertibleNotesPayable', window );">Change in fair value</a></td>
<td class="num">(1,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Balance as of December 31, 2024</a></td>
<td class="nump">5,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Balance as of December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Fair value at Issuance</a></td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Conversion of convertible note</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ChangeInFairValueOfConvertibleNotesPayable', window );">Change in fair value</a></td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Balance as of December 31, 2024</a></td>
<td class="nump">$ 138<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ChangeInFairValueOfConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ChangeInFairValueOfConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Fair Value of Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Nov. 22, 2024</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Oct. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.40<span></span>
</td>
<td class="nump">9.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.48<span></span>
</td>
<td class="nump">6.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | AGP Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">9.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | AGP Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Measurement input</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=CDT_CorporateBondYieldEstimatedTimingOfConversionMember', window );">Corporate Bond Yield Estimated Timing Of Conversion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=CDT_CorporateBondYieldEstimatedTimingOfConversionMember', window );">Corporate Bond Yield Estimated Timing Of Conversion [Member] | AGP Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCreditSpreadMember', window );">Measurement Input, Credit Spread [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCreditSpreadMember', window );">Measurement Input, Credit Spread [Member] | AGP Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=CDT_MeasurementInputProbabilityOfDefaultMember', window );">Measurement Input Probability Of Default [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=CDT_MeasurementInputProbabilityOfDefaultMember', window );">Measurement Input Probability Of Default [Member] | AGP Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=CDT_MeasurementInputRecoveryUponDefaultMember', window );">Measurement Input Recovery Upon Default [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=CDT_MeasurementInputRecoveryUponDefaultMember', window );">Measurement Input Recovery Upon Default [Member] | AGP Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.5<span></span>
</td>
<td class="nump">103.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">108.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.4<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Measurement Input, Exercise Price [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.11<span></span>
</td>
<td class="nump">4.38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CDT_AGPConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CDT_AGPConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=CDT_CorporateBondYieldEstimatedTimingOfConversionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=CDT_CorporateBondYieldEstimatedTimingOfConversionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCreditSpreadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCreditSpreadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=CDT_MeasurementInputProbabilityOfDefaultMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=CDT_MeasurementInputProbabilityOfDefaultMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=CDT_MeasurementInputRecoveryUponDefaultMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=CDT_MeasurementInputRecoveryUponDefaultMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 11, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Sep. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 8.83<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (221)<span></span>
</td>
<td class="num">$ (81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CDT_PIPEWarrantsMember', window );">PIPE Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_WarrantsExcercise', window );">Warrants excercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_WarrantsExcercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants excercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_WarrantsExcercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CDT_PIPEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CDT_PIPEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Balance Sheet Details (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid directors&#8217; and officers&#8217; insurance</a></td>
<td class="nump">$ 1,187<span></span>
</td>
<td class="nump">$ 1,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">489<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses &#8211; related parties</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses &#8211; related parties</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Lease Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in the exchange for lease liabilities</a></td>
<td class="nump">$ 352<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">11.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Minimum Lease Payments For Operating Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 226<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 07, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">$ 263<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short term lease liability</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Short term lease liability</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Revenue (Details Narrative)<br> $ / shares in Units, &#163; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 11, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 09, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 24, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 11, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 11, 2022 </div>
<div>GBP (&#163;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 20, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 20, 2020 </div>
<div>GBP (&#163;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 15, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 15, 2022 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares | shares</a></td>
<td class="nump">11,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issuance, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,568,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,328,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (890,000)<span></span>
</td>
<td class="nump">4,923,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=CDT_VelaOptionLiabilityMember', window );">Vela Option Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issuance, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_VelaAgreementMember', window );">Vela Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_PercentageOfFutureRevenueEarned', window );">Percentage of future revenue earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset Acquisition, Consideration Transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">&#163; 2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to Acquire Productive Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">&#163; 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issuance, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_VelaAgreementMember', window );">Vela Agreement [Member] | Vela Technologies PLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to Acquire Productive Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">&#163; 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_VelaOptionAgreementMember', window );">Vela Option Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_NonRefundableOptionFee', window );">Non refundable option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">&#163; 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_OptionAgreementDescription', window );">Option agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The option was exercisable in whole at any time from the close of the Merger (the &#8220;Effective
Time&#8221;) until the earlier of (i) the date that was six (6) months from the Effective Time, and (ii) February 7, 2024, the expiration
date of the term.<span></span>
</td>
<td class="text">The option was exercisable in whole at any time from the close of the Merger (the &#8220;Effective
Time&#8221;) until the earlier of (i) the date that was six (6) months from the Effective Time, and (ii) February 7, 2024, the expiration
date of the term.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_VelaOptionAgreementMember', window );">Vela Option Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_VelaOptionAgreementMember', window );">Vela Option Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_VelaOptionAgreementMember', window );">Vela Option Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Total consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,080,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_CizzlePlcAgreementMember', window );">Cizzle Plc Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">&#163; 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000,000.0<span></span>
</td>
<td class="nump">22,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_OptionFee', window );">Option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">&#163; 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other Operating Income (Expense), Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_CizzlePlcAgreementMember', window );">Cizzle Plc Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock Issued During Period, Shares, Purchase of Assets | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_NonRefundableOptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non refundable option fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_NonRefundableOptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_OptionAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option agreement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_OptionAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_OptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_OptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_PercentageOfFutureRevenueEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future revenue earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_PercentageOfFutureRevenueEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=CDT_VelaOptionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=CDT_VelaOptionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_VelaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_VelaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=CDT_VelaTechnologiesPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=CDT_VelaTechnologiesPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_VelaOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_VelaOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_CizzlePlcAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_CizzlePlcAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 13, 2025</div></th>
<th class="th"><div>Mar. 06, 2025</div></th>
<th class="th"><div>Jan. 25, 2025</div></th>
<th class="th"><div>Jan. 24, 2025</div></th>
<th class="th"><div>Dec. 09, 2024</div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Nov. 22, 2024</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Oct. 11, 2024</div></th>
<th class="th"><div>Oct. 10, 2024</div></th>
<th class="th"><div>Oct. 09, 2024</div></th>
<th class="th"><div>Aug. 06, 2024</div></th>
<th class="th"><div>Jun. 24, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Apr. 20, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 20, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock for licensing right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,568,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(707,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible promissory notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="nump">$ 347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,000<span></span>
</td>
<td class="nump">479,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,506,000)<span></span>
</td>
<td class="num">(211,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_ConvertiblePromissoryNotePayableMember', window );">Convertible Promissory Note Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_TwentyTwentyThreeConvertibleNoteMember', window );">2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_TwentyTwentyThreeConvertibleNoteMember', window );">2023 Convertible Note [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Settlement of debt</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_FirstAmendmentNirlandNoteMember', window );">First Amendment Nirland Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_FirstAmendmentMember', window );">First Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_FirstAmendmentMember', window );">First Amendment [Member] | Nirland Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleLiquidationPreferenceValue', window );">Par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_SecondAmendmentNirlandNoteMember', window );">Second Amendment Nirland Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_PenaltyPayment', window );">Penalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accured interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_SecondAmendmentMember', window );">Second Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Payable at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_AllianceGobalPartnersConvertibleNoteMember', window );">Alliance Gobal Partners Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Conversion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_GainOnChangeInFairValue', window );">Gain on change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Convertible notes interest per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Fixed price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DeferredCommissionPayable', window );">Deferred commission payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_GainOnChangeInFairValueOfConvertibleNote', window );">Gain on change in fair value of convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_AllianceGobalPartnersConvertibleNoteMember', window );">Alliance Gobal Partners Convertible Note [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Company notes that the reverse split provision in the preceding sentence was tripped, effective January 25, 2025, following the 1-for-100 reverse stock split
that occurred on that date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock for licensing right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Convertible Promissory Note [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock for licensing right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Convertible Promissory Note Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible promissory notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CDT_ConvertiblePromissoryNotesPayableMember', window );">Convertible Promissory Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument maturity description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Convertible Promissory Note Payable had a maturity date of 18 months from the date of issuance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Conversion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_GainOnChangeInFairValue', window );">Gain on change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CDT_ConvertiblePromissoryNotesPayableMember', window );">Convertible Promissory Notes Payable [Member] | Nirland Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accured interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingGainLoss', window );">Fair value of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CDT_ConvertiblePromissoryNotesPayableMember', window );">Convertible Promissory Notes Payable [Member] | First Amendment [Member] | Nirland Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CDT_ConvertiblePromissoryNotesPayableMember', window );">Convertible Promissory Notes Payable [Member] | Second Amendment [Member] | Nirland Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CDT_SeniorSecuredPromissoryNoteMember', window );">Senior Secured Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt instrument allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CDT_SeniorSecuredPromissoryNoteMember', window );">Senior Secured Promissory Note [Member] | Nirland Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument maturity description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The August 2024
Nirland Note matures 12 months from August 6, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Conversion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DebtIssuedUponExecution', window );">Debt issued upon execution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_PaymentOfCommonStock', window );">Payment to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_NetProceedsReceivedPercentage', window );">Net proceeds received, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CDT_SeniorSecuredPromissoryNoteMember', window );">Senior Secured Promissory Note [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDefaultLongtermDebtAmount', window );">Remaining allocated to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DebtIssuedUponExecution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt issuance upon execution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DebtIssuedUponExecution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DeferredCommissionPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred commission payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DeferredCommissionPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_GainOnChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on change in fair value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_GainOnChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_GainOnChangeInFairValueOfConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on change in fair value of convertible note</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_GainOnChangeInFairValueOfConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_NetProceedsReceivedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds received percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_NetProceedsReceivedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_PaymentOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_PaymentOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_PenaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Penalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_PenaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDefaultLongtermDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDefaultLongtermDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of preference in liquidation over convertible debt instrument's if-converted par or stated value of share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CDT_ConvertiblePromissoryNotePayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CDT_ConvertiblePromissoryNotePayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CDT_TwentyTwentyThreeConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CDT_TwentyTwentyThreeConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CDT_FirstAmendmentNirlandNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CDT_FirstAmendmentNirlandNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CDT_FirstAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CDT_FirstAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CDT_NirlandLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CDT_NirlandLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CDT_SecondAmendmentNirlandNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CDT_SecondAmendmentNirlandNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CDT_SecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CDT_SecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CDT_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CDT_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CDT_AllianceGobalPartnersConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CDT_AllianceGobalPartnersConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CDT_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CDT_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=CDT_ConvertiblePromissoryNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=CDT_ConvertiblePromissoryNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_FirstAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_FirstAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_SecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_SecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=CDT_SeniorSecuredPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=CDT_SeniorSecuredPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 29, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 28, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 11, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 09, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 09, 2024 </div>
<div>GBP (&#163;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 24, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 11, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 06, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 22, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 01, 2022 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 19,  2024<span></span>
</td>
<td class="text">Dec. 19,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Payment terms for loan payment | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">776,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(707,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instrument fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock for licensing right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,568,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (221,000)<span></span>
</td>
<td class="num">$ (81,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_OctoberTwoThousandTwentyFourNirlandNoteMember', window );">October Two Thousand Twenty Four Nirland Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ArrangementFeePercentage', window );">Arrangement fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_OctoberTwoThousandTwentyFourNirlandNoteMember', window );">October Two Thousand Twenty Four Nirland Note [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_OctoberTwoThousandTwentyFourNirlandNoteMember', window );">October Two Thousand Twenty Four Nirland Note [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=CDT_LoanHoldersMember', window );">Loan Holders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Common stock converted | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_StockIssuedDuringPeriodAdditionalSharesIssued', window );">Additional shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock for licensing right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CDT_TrancheOneMember', window );">Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CDT_TrancheTwoMember', window );">Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CDT_TrancheThreeMember', window );">Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_LoanAgreementsMember', window );">Loan Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt Instrument, Maturity Date, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Loans
mature two years from the date of the agreement and bear no interest.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_LoansAmendmentMember', window );">Loans Amendment [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_BridgeLoanAgreementMember', window );">Bridge Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">4.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_CommitmentFees', window );">Commitment fees</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares issued | shares</a></td>
<td class="nump">28,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_CommonStockClosingPricePercentage', window );">Common stock closing price percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 10.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ArrangementFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Arrangement fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ArrangementFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_CommitmentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_CommitmentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_CommonStockClosingPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock closing price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_CommonStockClosingPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_StockIssuedDuringPeriodAdditionalSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period additional shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_StockIssuedDuringPeriodAdditionalSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CDT_OctoberTwoThousandTwentyFourNirlandNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CDT_OctoberTwoThousandTwentyFourNirlandNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=CDT_LoanHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=CDT_LoanHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CDT_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CDT_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CDT_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CDT_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CDT_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CDT_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_LoanAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_LoanAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_LoansAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_LoansAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_BridgeLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_BridgeLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Commission Payable (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 11, 2024</div></th>
<th class="th"><div>Oct. 09, 2024</div></th>
<th class="th"><div>Jun. 24, 2024</div></th>
<th class="th"><div>Sep. 22, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 11, 2024</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Sep. 22, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="nump">11,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 8.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=CDT_AllianceGlobalPartnersMember', window );">Alliance Global Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Cash fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Deferred payment fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DeferredCommissionPayableAnnualInterestRate', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DeferredCommissionPayableNonCurrent', window );">Deferred commissions payable, non-current liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=CDT_AllianceGlobalPartnersMember', window );">Alliance Global Partners [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DeferredCommissionPayableAnnualInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred commission payable annual interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DeferredCommissionPayableAnnualInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DeferredCommissionPayableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred commission payable non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DeferredCommissionPayableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for fees during the current period. This element excludes cash proceeds from license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CDT_AllianceGlobalPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CDT_AllianceGlobalPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expense (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 11, 2024</div></th>
<th class="th"><div>Oct. 09, 2024</div></th>
<th class="th"><div>Jun. 24, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares related to ATM program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,328,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="nump">11,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,041,000<span></span>
</td>
<td class="nump">5,172,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,378,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock for licensing right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,568,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,666,000<span></span>
</td>
<td class="nump">$ 479,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock for licensing right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_SARBORGServiceAgreementMember', window );">SARBORG Service Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_PaymentToResearchAndDevolpmentAmount', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_CashPayment', window );">Payable in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_SARBORGServiceAgreementMember', window );">SARBORG Service Agreement [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_SARBORGServiceAgreementMember', window );">SARBORG Service Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock for licensing right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=CDT_AstraZenecaMember', window );">Astra Zeneca [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares related to ATM program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_CashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_CashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_PaymentToResearchAndDevolpmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to research and devolpment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_PaymentToResearchAndDevolpmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_SARBORGServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_SARBORGServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CDT_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CDT_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Restricted Stock Activity (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Awards, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Awards, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="nump">$ 551<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Awards, Cancelled/Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Cancelled/Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Awards, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Awards, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Fair Value of Stock Option Granted (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 20, 2024</div></th>
<th class="th"><div>Mar. 20, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">78.30%<span></span>
</td>
<td class="nump">78.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.81%<span></span>
</td>
<td class="nump">4.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.20%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.28%<span></span>
</td>
<td class="nump">4.16%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.40%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.35%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term Years</a></td>
<td class="text">2 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CDT_TwoThousandTwentyThreePlanMember', window );">2023 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding</a></td>
<td class="nump">10,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding</a></td>
<td class="nump">$ 551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term Years</a></td>
<td class="text">9 years 8 months 19 days<span></span>
</td>
<td class="text">8 years 10 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">56,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 8.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Cancelled/forfeited</a></td>
<td class="nump">1,908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled/Forfeited</a></td>
<td class="nump">$ 551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding</a></td>
<td class="nump">65,509<span></span>
</td>
<td class="nump">10,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding</a></td>
<td class="nump">$ 81.52<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">23,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 84.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term Years</a></td>
<td class="text">9 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber', window );">Number of Options, Unvested</a></td>
<td class="nump">42,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Unvested</a></td>
<td class="nump">$ 80.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1', window );">Weighted Average Remaining Contractual Term Years</a></td>
<td class="text">9 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options unvested outstanding number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by dhare based payment award options vested and expected to unvested outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment unvested award vesting period 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment Award options unvested intrinsic value 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CDT_TwoThousandTwentyThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CDT_TwoThousandTwentyThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 18, 2024</div></th>
<th class="th"><div>Oct. 11, 2024</div></th>
<th class="th"><div>Oct. 09, 2024</div></th>
<th class="th"><div>Jun. 24, 2024</div></th>
<th class="th"><div>Jun. 07, 2024</div></th>
<th class="th"><div>Dec. 01, 2023</div></th>
<th class="th"><div>Sep. 22, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 06, 2025</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Apr. 20, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 20, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,632,000<span></span>
</td>
<td class="nump">$ 199,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares issued for services, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="nump">$ 347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock for licensing right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,568,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,041,000<span></span>
</td>
<td class="nump">5,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued during period value issued for services, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 242,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Cost related to non-vested option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=CDT_NonEmployeeDirectorsMember', window );">Non-employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="nump">10,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares issued for services, per share</a></td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock for licensing right</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=CDT_MrHeilbronMember', window );">Mr. Heilbron [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares issued for services, per share</a></td>
<td class="nump">$ 9.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of Common Stock for services, shares</a></td>
<td class="nump">8,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued during period value issued for services, value</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares issued for services, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock for licensing right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of Common Stock for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued during period value issued for services, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares issued for services, per share</a></td>
<td class="nump">$ 9.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of Common Stock for services, shares</a></td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total compensation</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Stock options to employees shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Stock options to employees shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CDT_TwentyTwentyThreeStockIncentivePlanMember', window );">2023 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,240<span></span>
</td>
<td class="nump">154,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Shares issued percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CDT_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CDT_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CDT_MrHeilbronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CDT_MrHeilbronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CDT_TwentyTwentyThreeStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CDT_TwentyTwentyThreeStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Income before Income Tax, Domestic and Foreign (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract', window );"><strong>Loss from operations before income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">US</a></td>
<td class="num">$ (12,855)<span></span>
</td>
<td class="num">$ (1,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(4,947)<span></span>
</td>
<td class="nump">1,454<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before income taxes</a></td>
<td class="num">$ (17,802)<span></span>
</td>
<td class="num">$ (536)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Provision for Income Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(2,429)<span></span>
</td>
<td class="num">(843)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">355<span></span>
</td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(931)<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax</a></td>
<td class="num">(3,005)<span></span>
</td>
<td class="num">(1,449)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Change in Valuation Allowance</a></td>
<td class="nump">3,005<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Net Income Tax Expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Federal Income Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Taxes at federal statutory rate</a></td>
<td class="num">$ (3,744)<span></span>
</td>
<td class="num">$ (112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign Rate Differential</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals &amp; Entertainment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges', window );">Eq Comp Perm</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_IncomeTaxReconciliationConvertibleDebtAdjustment', window );">Convertible Debt Adjustment</a></td>
<td class="nump">268<span></span>
</td>
<td class="num">(1,048)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_IncomeTaxReconciliationStateReRate', window );">State Re-Rate</a></td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change In Valuation Allowance</a></td>
<td class="nump">3,005<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision (benefit) for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments', window );">Purchase Accounting Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(609)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Taxes at federal statutory rate</a></td>
<td class="num">(2,705)<span></span>
</td>
<td class="num">(417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign Rate Differential</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals &amp; Entertainment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges', window );">Eq Comp Perm</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_IncomeTaxReconciliationConvertibleDebtAdjustment', window );">Convertible Debt Adjustment</a></td>
<td class="nump">268<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_IncomeTaxReconciliationStateReRate', window );">State Re-Rate</a></td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change In Valuation Allowance</a></td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision (benefit) for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments', window );">Purchase Accounting Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(609)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Taxes at federal statutory rate</a></td>
<td class="num">(1,039)<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign Rate Differential</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals &amp; Entertainment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges', window );">Eq Comp Perm</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_IncomeTaxReconciliationConvertibleDebtAdjustment', window );">Convertible Debt Adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,048)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_IncomeTaxReconciliationStateReRate', window );">State Re-Rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change In Valuation Allowance</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision (benefit) for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments', window );">Purchase Accounting Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_IncomeTaxReconciliationConvertibleDebtAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation convertible debt adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_IncomeTaxReconciliationConvertibleDebtAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation purchase accounting adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_IncomeTaxReconciliationStateReRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation state re rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_IncomeTaxReconciliationStateReRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DeferredTaxAssetsStockOptions', window );">Stock options</a></td>
<td class="nump">$ 280<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsHedgingTransactions', window );">Transaction Costs</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research &amp; Development</a></td>
<td class="nump">671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">2,970<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax asset</a></td>
<td class="nump">4,455<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(4,455)<span></span>
</td>
<td class="num">(1,449)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets (liability)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DeferredTaxAssetsStockOptions', window );">Stock options</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsHedgingTransactions', window );">Transaction Costs</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research &amp; Development</a></td>
<td class="nump">671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax asset</a></td>
<td class="nump">3,273<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(3,273)<span></span>
</td>
<td class="num">(1,198)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets (liability)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_DeferredTaxAssetsStockOptions', window );">Stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsHedgingTransactions', window );">Transaction Costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research &amp; Development</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax asset</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(1,182)<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets (liability)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_DeferredTaxAssetsStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_DeferredTaxAssetsStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsHedgingTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from hedging transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsHedgingTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate', window );">Effective income tax rate reconciliation future income years tax rate</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets valuation allowance</a></td>
<td class="nump">$ 1,449<span></span>
</td>
<td class="nump">$ 4,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets valuation allowance</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="nump">3,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets valuation allowance</a></td>
<td class="nump">$ 251<span></span>
</td>
<td class="nump">$ 1,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation future income years tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Preferred Stock (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 23, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,384,801<span></span>
</td>
<td class="nump">738,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,384,801<span></span>
</td>
<td class="nump">738,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Dividends, Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction', window );">Sale of stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) - basic</a></td>
<td class="num">$ (17,802)<span></span>
</td>
<td class="num">$ (535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities', window );">Less: Change in fair value and income impact of option liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(5,521)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) - diluted</a></td>
<td class="num">$ (17,802)<span></span>
</td>
<td class="num">$ (6,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock outstanding, basic</a></td>
<td class="nump">867,096<span></span>
</td>
<td class="nump">669,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_OptionLiabilityConversionShares', window );">Add: Option liability conversion shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing net loss per share - diluted</a></td>
<td class="nump">867,096<span></span>
</td>
<td class="nump">678,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic</a></td>
<td class="num">$ (20.53)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted</a></td>
<td class="num">$ (20.53)<span></span>
</td>
<td class="num">$ (8.92)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value and income impact of option liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_OptionLiabilityConversionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option liability conversion shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_OptionLiabilityConversionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Potentially Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">1,501,298<span></span>
</td>
<td class="nump">173,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">139,790<span></span>
</td>
<td class="nump">139,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_PIPEMember', window );">PIPE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_AGPWarrantsMember', window );">AGP Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_ConvertiblePromissoryNotesPayableMember', window );">Convertible Promissory Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">65,509<span></span>
</td>
<td class="nump">10,717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_AugustTwentyTwentyFourNirlandNoteMember', window );">August 2024 Nirland Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">672,007<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_AGPConvertibleNoteMember', window );">AGP Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">576,949<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_MarchTwentyTwentyFourWarrantsMember', window );">March 2024 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_AprilTwentyTwentyFourWarrantsMember', window );">April 2024 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">14,477<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_AGPTwentyTwentyFourWarrantsMember', window );">AGP 2024 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">28,626<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_PIPEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_PIPEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_AGPWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_AGPWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_ConvertiblePromissoryNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_ConvertiblePromissoryNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_AugustTwentyTwentyFourNirlandNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_AugustTwentyTwentyFourNirlandNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_AGPConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_AGPConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_MarchTwentyTwentyFourWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_MarchTwentyTwentyFourWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_AprilTwentyTwentyFourWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_AprilTwentyTwentyFourWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_AGPTwentyTwentyFourWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CDT_AGPTwentyTwentyFourWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 11, 2024</div></th>
<th class="th"><div>Oct. 09, 2024</div></th>
<th class="th"><div>Jun. 24, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Settelment expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="nump">11,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Accrued estimated liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative)<br> $ / shares in Units, &#163; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 11, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 09, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 24, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 22, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 22, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>May 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares | shares</a></td>
<td class="nump">11,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,378,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=CDT_OfficersAndDirectorsMember', window );">Officers and Directors [Member] | Private Placement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of Stock, Consideration Received Per Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=CDT_BoardOfDirectorsMember', window );">Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Travel and Entertainment Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | 2022 Convertible Loan Note Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument, Interest Rate During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CDT_CorvusCapitalLimitedMember', window );">Corvus Capital Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common Stock, Shares Subscribed but Unissued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from Contributed Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock for licensing right, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,484,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableRelatedParties', window );">Loans and Leases Receivable, Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CDT_SARBORGLtdMember', window );">SARBORG Ltd [Member] | SARBORG Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAndLeasesReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansAndLeasesReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TravelAndEntertainmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred for travel and entertainment during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TravelAndEntertainmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=CDT_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=CDT_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CDT_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CDT_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CDT_CorvusCapitalLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CDT_CorvusCapitalLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CDT_SARBORGLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CDT_SARBORGLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_SARBORGServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_SARBORGServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Other Expense, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_RecognitionOfDeferredRevenueUponOptionExercise', window );">Recognition of Cizzle deferred revenue upon option exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_RecognitionOfDeferredRevenueUponOptionExerciseOne', window );">Recognition of Vela deferred revenue upon option exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ChangeInFairValueOfOption', window );">Change in fair value of Cizzle option</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ChangeInFairValueOfOptions', window );">Change in fair value of Vela option</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_ChangeInFairValueOfConvertibleNotePayment', window );">Change in fair value of convertible note payment</a></td>
<td class="nump">2,018<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_GainOnDebtExtinguishment', window );">Gain on debt extinguishment</a></td>
<td class="nump">2,473<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest Income</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_IncomeTaxRefund', window );">Income Tax Refund</a></td>
<td class="nump">314<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency transaction gain</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Total other income:</a></td>
<td class="nump">5,048<span></span>
</td>
<td class="nump">6,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_LossOnIssuanceOfOptionOne', window );">Loss on issuance of Vela option</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_OtherIncomeUnrealizedForeignCurrencyTransactionLoss', window );">Change in fair value of convertible notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense</a></td>
<td class="nump">577<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">929<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_LossOnIssuanceOfWarrants', window );">Loss on issuance of warrants</a></td>
<td class="nump">2,710<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_LossOnDebtExtinguishment', window );">Loss on Debt Extinguishment</a></td>
<td class="nump">3,179<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_OtherExpenseChangeInFairValueOfConvertibleNotesPayable', window );">Realized foreign currency transaction loss</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_OtherExpense', window );">Other expense</a></td>
<td class="nump">20<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Total other expense</a></td>
<td class="nump">7,431<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">$ (2,383)<span></span>
</td>
<td class="nump">$ 4,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ChangeInFairValueOfConvertibleNotePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible note payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ChangeInFairValueOfConvertibleNotePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ChangeInFairValueOfOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ChangeInFairValueOfOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ChangeInFairValueOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ChangeInFairValueOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_GainOnDebtExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on debt extinguishment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_GainOnDebtExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_IncomeTaxRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax refund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_IncomeTaxRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_LossOnDebtExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on debt extinguishment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_LossOnDebtExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_LossOnIssuanceOfOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on issuance of option one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_LossOnIssuanceOfOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_LossOnIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_LossOnIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_OtherExpenseChangeInFairValueOfConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other expense change in fair value of convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_OtherExpenseChangeInFairValueOfConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_OtherIncomeUnrealizedForeignCurrencyTransactionLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other income unrealized foreign currency transaction loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_OtherIncomeUnrealizedForeignCurrencyTransactionLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_RecognitionOfDeferredRevenueUponOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition of deferred revenue upon option exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_RecognitionOfDeferredRevenueUponOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_RecognitionOfDeferredRevenueUponOptionExerciseOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition of deferred revenue upon option exercise one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_RecognitionOfDeferredRevenueUponOptionExerciseOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Black-Scholes Option Pricing Model (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Apr. 20, 2024</div></th>
<th class="th"><div>Mar. 20, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock price</a></td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">$ 347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Contractual exercise price</a></td>
<td class="nump">$ 312<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.81%<span></span>
</td>
<td class="nump">4.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Estimated volatility</a></td>
<td class="nump">78.30%<span></span>
</td>
<td class="nump">78.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Time period to expiration</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Share price per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Share price per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 11, 2024</div></th>
<th class="th"><div>Oct. 29, 2024</div></th>
<th class="th"><div>Oct. 11, 2024</div></th>
<th class="th"><div>Oct. 09, 2024</div></th>
<th class="th"><div>Jun. 24, 2024</div></th>
<th class="th"><div>Apr. 20, 2024</div></th>
<th class="th"><div>Sep. 22, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 20, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 8.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise warrants</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Fair Value, Option, Changes in Fair Value, Gain (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember', window );">Murphy Canyon Acquisition Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800.00<span></span>
</td>
<td class="nump">1,800.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CDT_PublicWarrantMember', window );">Public Warrant [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="nump">11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Warrants price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CDT_PrivatePlacementWarrantMember', window );">Private Placement Warrant [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Warrants price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Murphy Canyon Acquisition Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CDT_AGPTwentyTwentyFourWarrantsMember', window );">AGP 2024 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock upon exercise, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CDT_AGPTwentyTwentyFourWarrantsMember', window );">AGP 2024 Warrants [Member] | Alliance Global Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CDT_PIPEWarrantsMember', window );">PIPE Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 8.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_MarchLockUpAgreementMember', window );">March Lock Up Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent event, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">There is no established public trading
market for the March 2024 Warrants. Notwithstanding the foregoing, the March 2024 Warrants shall vest, and not be subject to forfeiture,
with respect to 25% of such March 2024 Warrants commencing on the 90th day after the date of the March Lock-Up Agreement and 25% on each
subsequent 90-day anniversary, in each case vesting only if the holder agrees to continue to have its shares of common stock remain locked
up pursuant to the March Lock-Up Agreement on such date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_AprilLockUpAgreementMember', window );">April Lock Up Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent event, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">There is no established public trading market for the April 2024 Warrants. Notwithstanding
the foregoing, the April 2024 Warrants shall vest, and not be subject to forfeiture, with respect to 25% of such March 2024 Warrants
commencing on the 90th day after the date of the April Lock-Up Agreement and 25% on each subsequent 90-day anniversary, in each case
vesting only if the holder agrees to continue to have its shares of common stock remain locked up pursuant to the April Lock-Up Agreement
on such date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_AprilLockUpAgreementMember', window );">April Lock Up Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_AprilLockUpAgreementMember', window );">April Lock Up Agreement [Member] | April 2024 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_SubscriptionAgreementsMember', window );">Subscription Agreements [Member] | Murphy Canyon Acquisition Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_SubscriptionAgreementsMember', window );">Subscription Agreements [Member] | Common Stock [Member] | Murphy Canyon Acquisition Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=CDT_MurphyCanyonAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CDT_PublicWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CDT_PublicWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CDT_PrivatePlacementWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CDT_PrivatePlacementWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CDT_AGPTwentyTwentyFourWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CDT_AGPTwentyTwentyFourWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CDT_AllianceGlobalPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CDT_AllianceGlobalPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CDT_PIPEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CDT_PIPEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_MarchLockUpAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_MarchLockUpAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_AprilLockUpAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_AprilLockUpAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CDT_AprilTwentyTwentyFourWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CDT_AprilTwentyTwentyFourWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_SubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_SubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Financial Data for the Company&#8217;s Reportable Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 3,378<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">12,041<span></span>
</td>
<td class="nump">5,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from segment operations</a></td>
<td class="num">(15,419)<span></span>
</td>
<td class="num">(5,262)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative expenses &#8211; other</a></td>
<td class="nump">4,060<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from segment operations</a></td>
<td class="nump">15,419<span></span>
</td>
<td class="nump">5,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | New Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">3,114<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Clinical Asset Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Legal And Professional Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,258<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Accounting And Audit Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,625<span></span>
</td>
<td class="nump">3,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Salaries Payroll And Stock Based Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 4,098<span></span>
</td>
<td class="nump">$ 721<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=CDT_NewLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=CDT_NewLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=CDT_ClinicalAssetDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=CDT_ClinicalAssetDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=CDT_LegalAndProfessionalFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=CDT_LegalAndProfessionalFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=CDT_AccountingAndAuditFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=CDT_AccountingAndAuditFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=CDT_SalariesPayrollAndStockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=CDT_SalariesPayrollAndStockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 28, 2025</div></th>
<th class="th"><div>Mar. 10, 2025</div></th>
<th class="th"><div>Feb. 19, 2025</div></th>
<th class="th"><div>Feb. 10, 2025</div></th>
<th class="th"><div>Feb. 07, 2025</div></th>
<th class="th"><div>Feb. 06, 2025</div></th>
<th class="th"><div>Jan. 22, 2025</div></th>
<th class="th"><div>Jan. 15, 2025</div></th>
<th class="th"><div>Jan. 13, 2025</div></th>
<th class="th"><div>Dec. 12, 2024</div></th>
<th class="th"><div>Oct. 09, 2024</div></th>
<th class="th"><div>Jan. 24, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 13, 2025</div></th>
<th class="th"><div>Feb. 13, 2025</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Number shares reverse stock split during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Remaining outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares related to ATM program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,328,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Commons tock shares sold, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock for licensing right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,568,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CDT_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock for licensing right</a></td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_AugustTwentyTwentyFourNirlandNoteMember', window );">August 2024 Nirland Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CDT_TwentyTwentyThreeConvertibleNoteMember', window );">2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Commons tock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,345,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Commons tock shares sold, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CDT_CommissionsPayable', window );">Commissions payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares related to ATM program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,922,782<span></span>
</td>
<td class="nump">$ 17,816,270<span></span>
</td>
<td class="nump">$ 13,450,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,183,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,835,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | October 2024 Nirland Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | August 2024 Nirland Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Remaining outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CDT_CommissionsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commissions payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CDT_CommissionsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CDT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CDT_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CDT_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CDT_AugustTwentyTwentyFourNirlandNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CDT_AugustTwentyTwentyFourNirlandNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CDT_TwentyTwentyThreeConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CDT_TwentyTwentyThreeConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CDT_OctoberTwentyTwentyFourNirlandNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CDT_OctoberTwentyTwentyFourNirlandNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>91
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,Z&?%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( ,Z&?%J"H2E(\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( ,Z&?%KX!N]X30H  ,<_   8
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MM_UG1_@C9I QH(>'L9*445]L2JVZ0;WTQ:[>LZY)B>4+T9A5M'9(/$+N!-D
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M2RA]69^\U ]:;*K#BV>AM2BKVXS1E$EC /^OA-"'!_.!]OQK\0]02P,$%
M  @ SH9\6J<-3V8J%@  &40! !@   !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6R]W6MSFUB>Q_'G^RHH[]3L3%4G-B#?,DFJB,T=6E8(37NZY@&6L,VT)+P(
MYS*O?D&6+',1$N3K[:J9V);XG"..?'XZDO^']]^2],_%?11EPO?9=+[X<'"?
M90_O#@\7X_MH%B[>)@_1/+_E-DEG899_F]X=+A[2*)PL#YI-#Z6CHY/#61C/
M#SZ^7_[L*OWX/GG,IO$\NDJ%Q>-L%J8_/D73Y-N' _%@_8//\=U]5OS@\./[
MA_ N\J+,?[A*\^\.GY5)/(OFBSB9"VET^^% $=\IVO'RB.5=?HNC;XL77PO%
M8[E)DC^+;\S)AX.CHDO1-!IGA1'F_WR-+J+IM*#RCOSO2CUX;K0X\.77:UU;
M/OK\T=R$B^@BF0;Q)+O_<'!V($RBV_!QFGU.OAG1ZA$=%]XXF2Z6_R]\6]WW
MZ$ 8/RZR9+8Z.._!+)X__1M^7YV)%P>(\I8#I-4!4N6 _,PT'R"O#I K!YP<
M;SE@L#I@4&WA9,L!QZL#CJLM;#O@9'7 2>4 Z7S+ :>K TXK!VP]K6>K \[V
M/>!\=<#YO@>(1^N1.]K[D.?!KH[VR6#;(>OA%JOCO;V5]8"+U1'?^IP2UT,N
M5L=\>ROK01>KH[Z]E?6PB]5QW][*>N#%ZLAO;V4]].+>8R^N!U^LCO[VW\+U
MZ$O5T=\ZE-)Z]*7]?]>??]FKHU_<TGS(>O2EO4=?6H^^5!U]>=LOL+0>?6GO
MT9?6HR_5?NM/MQVR'GUI[]&7UJ,O54=?WMK*>O2EO4=?7H^^7!W][8>L1U_>
M>_3E]>C+R]$_? J592)=AEGX\7V:?!/2XOZY5WRQC+7E\7D0Q?,B@KTLS6^-
M\^.RCQ?)?)%,XTF811/!R_)_\GS-%D)R*US<A_.[:"'$\_R&9/SG?3*=1.GB
M?X3+Z#8>QYGP1O"]2^%O?_F[\)?B3E_ND\=%.)\LWA]F><\*_W"\ZL7%4R^D
M+;VX2J.O<7[T](?P.7I(TJ(S?[C1["9*_R5<)+-9LNK#\T\;VKC\B3:4R20N
M7A&$4^$JC"=O\H=S$3[$6?Y]2XOJ3[3X.<KR%TCY3]0PG<?SNT5;0]K//+3A
MA2DH69;&-X]9>#.-A"S)'V2:#W-;DWK_)ALTHUW[G&/+%W7YT^XJC9-4N(KR
M?R:_"&J:YM]=)&GZ])+MEWRH_IW_8LQ>=G_OIXCYNMWH]RRR7K=3G9YH]BN?
MH'[/1>=5>]70H-NWP<_1>!HN%G$^088__W0=OFXW^CU=1Z_;J4Y/5^^53U"_
MIZO_JKUJ:#!H;W#?I]MU.]/OZ:(HN\Y&A_%6=KR.Z#E@RHX@_Y+D#[)\W&'^
M.NOYQ9;T_&)+6CKR%N=3. WGXT@(L_PUU/BM((N_"-*1)#9TZ5.[](?8]#@N
M6@\JWLUYMW@(Q]&'@X<T6D3IU^C@XU__6SPY^D?3RRD24TE,(S&=Q P2,TG,
M(C&;Q!P2<WM@0E/R/CF#I5.\C?GUXYN3]X=?7^9@_2Z5>WA09WS("<@S?4UB
M2OO$V55#YT&%FKM*D2$_1X;<.M&;B\7C,C.*!7DRGSSFZ^ZK^S"=Y0T^9OGK
MA.E",.=YEHR?0GZQ#/D\]5:K];;CG'@6%^NV<3+_&J597.3E/,GR)7\.9?>1
M<#%-%GDD"Y=A%@E_^S6_29#^WI0[K8^A:^Z0F$IB&HGI)&:0F$EB%HG9).:0
MF-L#:\R=)^?X1:C()V?'E>2!&O,@Q]^GTP%YNJ])3&F?@CN'#ZI1$U@I? ;/
MX3/8.WQ*^?+XD'_Y%!OKE:SK?];RP,B7KX(B_#6</?QC]=VG\J'Q\L#YZ@/8
M;W%V+\RB]"Y*6P.FM9]= X;$5!+32$PG,8/$3!*S2,PF,8?$W$%MCA7+$^RP
M?H\WXK$DGE?"HT>O&L,#<OPMW3ZKQ =Y,J])3&F?1#O'!ZI1TU,I/HZ?X^/X
M%=8N#0%Q95ZI@A;/<ZQ8CK0%16N/N@8%B:DDII&83F(&B9DD9I&836(.B;D]
ML,:5R'$]<,Y/3ZMI K7F08Z_5Z\#\H1?DYC2/J5V#A-4HZ:P4IB</(?)R>N\
M$781_^<_TTCX%.>A,;Z?)]/D[H=@)--)$257SD53BK1VI6N*D)A*8AJ)Z21F
MD)A)8A:)V23FD)C; VM,D9/Z?'Q<6;B,H+8\R/'WZ'- GNQK$E/:Y]'."8)J
MU/152I#3YP0Y?9T$^2V:AL*7=7C$T6);;+2VWS4V2$PE,8W$=!(S2,PD,8O$
M;!)S2,SM@37&QFEM"CX>#"JQ ;7E08Z_1Y\#\F1?DYC2/GEVC@U4HZ:O4FR<
M/<?&V>O$1C@7PLG7>)&DPFW^OZ)?\3@/CTE<_#7J](>0YKE2?/Z>W[?XM-W=
M_3%(:T^[!@R)J22FD9A.8@:)F21FD9A-8@Z)N3VPQH"!G!'D>)#C0TY #MHU
MB2GMTW7GH$(U:AHL!=7Y<U"=MP;5YVCR^/2A29Y4T?=QO(B$+/PN3./P)I[&
MV0\A7"R2<;S,G.7G*M74:0Z=UE:[A@Z)J22FD9A.8@:)F21FD9A-8@Z)N3VP
MQM YK[^Q) ZJ[X:1/?=(S-^G^P'9XC6)*>W39^?@0#5J*BL%AWCTG!S%Q@0M
MT;&NXQDG\Z?:F2)%WCPO4!["-/O1% WM;-=L0#45U314TU'-0#43U2Q4LU'-
M036WC]:8$BNH_/G#424EJ-8\"O+WZ7: GO)K5%-V3)*= X+EL/FL'!$O]HD0
M6R-B63WZIMCLJ"@8F3U$\\6R1K4Q%EJISK% :BJJ::BFHYJ!:B:J6:AFHYJ#
M:FX?K3D6Q(8_;:K^.1;5FD=!_C[=#M!3?HUJRHZ)L7LLH!PVGY5C0=K$0GLA
MNI:D47PW%\:/:1K-QS^$+ WGBVGXM+W>\^X%C2F!5JNCFHIJ&JKIJ&:@FHEJ
M%JK9J.:@FMM':TX)"!JAC\];::4J#^FD\NFXO]>] K1GUZBF[)@NNX<%6\E.
M<>6PV-2R%]O6M83%KU$F3)-%\P9QK8=V3@-24U%-0S4=U0Q4,U'-0C4;U1Q4
M<_MHS6D 0:,55)J9C^5*B;='->?OU5R GO1K5%-V3(7=@P#EL!FM' 2;NG*Q
MO;!\RT984F,P0(6FEQ2DKJ#2YD#BT6GUA8K6<+^3T\J36&_&CLXJ2V2C"2O?
MQ6RB*O>QJ)-@4Y!#02X%_;KCR?N'U+Q7X\X!NNH%C_88UL^]9(\Z8U]Z->]3
MS?_6J_E@]X#]O@N6F[=1A![7/WLUKRA;YJ?3RH<QRJ=^_L4^\YJR8[K=AF^9
M7&OSH:)U]<M1M:EA%]N+V%=1]8NPN _ST=HOLNI5J%+EY%^V-]MYA8)6EZ.:
MCFI&P[D]&9Q(U;^T-]%6+52S4<U!-1?5AJ@V0C4/U7Q4"[8\RZLO,7_?,7EM
M"RBV9)WE+E@.FQK+^;$I6Q=?J6Z=WL!QG6"-@846O*.:BFH:JNFH9J":B6H6
MJMFHYJ":BVI#5!NAFH=J/JH%8KT(7SZMO@-XC;:I[)C*NP<96SM/<>4@VU3/
MB_N7S[_Z9I"M8866V:.:BFH:JNFH9J":B6H6JMFHYJ":BVI#5!NAFH=J/JH%
M8KWT?R"*9W(UK=B"?99CIU4%FPG+:;4IVA=?HVI_Y]Z3K;F$5N>CFHIJ&JKI
MJ&:@FHEJ%JK9J.:@FHMJ0U0;H9J':CZJ!2NM_#E$_E\UE]CZ?)9CIU4%FPG+
MN;2IT1?;B_1?;1O+UF1"2_A1344U#=5T5#-0S40U"]5L5'-0S46U(:J-4,U#
M-1_5 K&^EX!\?EQ[>X^M_V<Y=E95L(FP?&7*S18 4OL6 .SNF&UIU-Z1KFF$
M:BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ#5%MA&H>JOFH%D@-6Q<<B<>52]!<HXTJ
M.R;DSG'$<MA,6(ZCS78#4OMV __/NVZVYA6ZFP&JJ:BFH9J.:@:JF:AFH9J-
M:@ZJN:@V1+41JGFHYJ-:(#7LJ2#7W]=#&U5VS-C=\XK=!X'BRGDE;?*J?1^$
MMM+6]D,[!PBZT0&J::BFHYJ!:B:J6:AFHYJ#:BZJ#5%MA&H>JOFH%J#:-:HI
M.V;:[CG#;J$@->Q1\;(TN9P?FZT1\B_W7^\LES3>YJ_KU.]1NMS/^6DUM/Y+
MN^'#MAW8VEOK'#FDIJ*:AFHZJAFH9J*:A6HVJCFHYJ+:$-5&J.:AFH]J :I=
MHYJR8W+N'CDHUVO"K-03EU-ILT^#U&N?!KDQ<L@+5U^BFHIJ&JKIJ&:@FHEJ
M%JK9J.:@FHMJ0U0;H9J':CZJ!5)]*X'3ZEMD@X9/?@92I<Q641KN]T84I>I&
MILI%PQT'8N4:"8K:Q V.3[<L(C9[%4@_M5=!\[1-5MM>HIJ*:AJJZ:AFH)J)
M:A:JV:CFH)J+:D-4&Z&:AVH^J@52?>^#4_E,.J_^=1C:JK)C;NV^!F!W,:"X
M<K)L=C&0VG<Q^(EMGMOES@&#[BV :AJJZ:AFH)J):A:JV:CFH)J+:D-4&Z&:
MAVH^J@5]M*;]V:XI2-DQ_7:0UM-MZ2^K:\N/MON4$V*S/8#4OCU ZP?@:,4^
MJJFHIJ&:CFH&JIFH9J&:C6H.JKFH-D2U$:IYJ.:C6M!':XX "%+6\VOY+:;3
MLR.I]A83U:2ZN\ER&&RJ[Z7VZON+)$VCYVL1Q[-9F$5I'$Z%*$V3].6?X-[F
MZXCQ_?I2Q='WXKIB46.&H-7UJ*:BFH9J.JH9J&:BFH5J-JHYJ.:BVA#51JCF
MH9J/:D$?K3E#ZF7Z8G4_6V7'E-O]_2FVK'['8RCGR*9:7NI2+?_BKZ)>EG8T
MI@5:\8YJ*JIIJ*:CFH%J)JI9J&:CFH-J+JH-46V$:AZJ^:@6]-&:TZ)>.B\-
MJHN$'1-KIS>4*$G=T?-21LB;PG6Y2^'ZEHQHJ^]K][MF!:JIJ*:AFHYJ!JJ9
MJ&:AFHUJ#JJYJ#9$M1&J>:CFHUH@-]2CGQ_7ZOO01I4=\VSG!0;+83-A.64V
M]>AREWKT:GW&UVB1%?MPY3?FC6=I/"[>WEIMCSR/L^;<0>O*44U%-0W5=%0S
M4,U$-0O5;%1S4,U%M2&JC5#-0S4?U8(^6N,:A8*4'=-REW4,)O6:'-OJ,61I
MDT+M5>8_F4*MJR"T2!W55%334$U'-0/53%2S4,U&-0?57%0;HMH(U3Q4\U$M
MD.N5UJ>#ZA\!HTTJ.^;?[FL@MO:<XLKILZE1S[_L_4Y;<=TQX2'\$=Y,&S^_
M;[<[YPNIJ:BFH9J.:@:JF:AFH9J-:@ZJN:@V1+41JGFHYJ-:L-)>E@=*U721
M:Q%T7JU#479,FYW6*)2D-O9\2X&AO*D'E]OKP?=.@-:5!EHHCFHJJFFHIJ.:
M@6HFJEFH9J.:@VHNJ@U1;81J'JKYJ!;(]7+L\^.C^EJ#;%39,==V7VN@'#83
MEI-F4\HNMY>RMR;--!Y'\^6%C=/X[KZQZK"=[QPR:%D[JFFHIJ.:@6HFJEFH
M9J.:@VHNJ@U1;81J'JKYJ!:LM)?+#;$:,/7*=_'XY+2VWNC1KRWK#4I2F[M^
MMF7!L:D[E]OKSKO$0.N: RU"1S45U314TU'-0#43U2Q4LU'-0347U8:H-D(U
M#]5\5 OD>@VV*!W7-W%'6U5VS+?=%QWL)>XIKIPVFQIV>?]+W)<_7I]/HG1Y
MN1#EBRM<I<E=&LX:<P:M=$<U%=4T5--1S4 U$]4L5+-1S4$U%]6&J#9"-0_5
M?%0+5MK+94?UNO1RO0Q<EL2SVK*#JCOO-4MN678T=5T2MRP[-O7K<I>KQ^\*
M@M:%!UJVCFHJJFFHIJ.:@6HFJEFH9J.:@VHNJ@U1;81J'JKYJ!;(]4IM69*E
MTUHJL%>%9SEV7E6PJ;"<-YLZ=[EGG7M<7/MC?!_.[Z+E6UZ7T4TFN,DDOHW'
MX;:+?[0WUCEST.)W5--034<U ]5,5+-0S48U!]5<5!NBV@C5/%3S42U8::V?
M?=2+PP=G]34(5M:.26ICS\^;ER"#35G[H&=9^\Y(:%N.M#?:-1I0344U#=5T
M5#-0S40U"]5L5'-0S46U(:J-4,U#-1_5@D&]UET^%\^KJQ&T467'Y-MY-<)R
MV$Q8CIY-K?O@9VK=.U^+L+VUSIF#UKFCFH9J.JH9J&:BFH5J-JHYJ.:BVA#5
M1JCFH9J/:D$?K;'.?5"_$/MY;2LNJC6EUTS:O&9I[W@Y-Z1-;OQ,=7IK;K2N
M6=#*=%1344U#-1W5#%0S4<U"-1O5'%1S46V(:B-4\U#-1[5@4*],E^3ZGVZA
MC2H[9M_N:Q:V-IWBRMFSJ4W/O]PW>X(P3<-Y\Z9;[4SG,"$U%=4T5--1S4 U
M$]4L5+-1S4$U%]6&J#9"-0_5?%0+^FC-BQ&YGDIGYT>UY0C4GM)K+MVR'-G1
M]7(H;,K5!SW+U?WJ@J0U,M!Z=51344U#-1W5#%0S4<U"-1O5'%1S46V(:B-4
M\U#-1[6@C]8<&0V7/Z]_Z$XUI_2:2K<D1GO/RX&QJ3H?]*PZWQH8K6]<H37H
MJ*:BFH9J.JH9J&:BFH5J-JHYJ.:BVA#51JCFH9J/:L&@7J4M'36\<<5>69WE
MV&E5P6;"<N1L*MP'[17NRWQY<Q,NHHDP3F;%]0^W_F%O.]4Y4- J=E334$U'
M-0/53%2S4,U&-0?57%0;HMH(U3Q4\U$MZ*,UKT0:RN%/Y/IGZ=AUTC%)W=7U
M<C!LBM$'/8O1^ZU%T,)T5%-134,U'=4,5#-1S4(U&]4<5'-1;8AJ(U3S4,U'
MM6!0+]T^/:ZM1,@FE1U3;O>5",IA\V Y<#9%[X/VHO=/X729-V$F7$;CMX(L
M_B)(1]*@,4[0LG944U%-0S4=U0Q4,U'-0C4;U1Q4<U%MB&HC5/-0S4>U8*65
M2@P'U32IWT<2S\[J'Y'7[_=&.A>/*C6+RD7#'0?55A6UB3LY?5'B4IZP-U7C
M@_:J\=6$O7[9O]_$C=:&HYJ*:AJJZ:AFH)J):A:JV:CFH)J+:D-4&Z&:AVH^
MJ@6#>OFT*)\-SJJS[37:K+)C<NV^%D Y;"XL1<MQ47U>_LFF*/"XO2CP#_%?
MGZ/Q-%PLG@O-_TO(_XL7PBR<Y*N&Q7);K'B6]RHKWI4JODNC+$WR[^.O^1T>
M'J:K ]<WNU%Z%Z7".)P+-U&>8LFW>>&$^7&3Q_'RGEDBA)-)7'P=3H6',)Z\
MB>?Y$0]QEG\_>4SC^=VR'X7W$*5Q,BF(Y4F9+Z^&^-2/M3=)\J"<)UEQA<3'
M:594T[?X-U$AK+!H\M2Y>707+A]147T?9PLAFD_6O;AYBN2W?T@[SU9+L_D)
M*;J8GY.VIJ,X?VA//;B)[N+Y?'GMQW35G4U7Y']YR]<'RP[D9WZ:(^,?Q8=-
MQ7N*3Y>'O ]S]":*YB^';/IC>1W)L&@^'X>[HN'H]C;*QS?_=C. ;YN><H>+
M^RC*+L,L_/A^5MSM(II.%WFKC_/\^246?]C]_..\F=OB&7CT3E'SY^AA[::1
M^.ZSV/!S3WSWI>GG^9.YH)IN"L1WOS?]W!??_=9(*3GUJ>F6H?CNJNGGU^*[
M?S9*%[ETV7B+FM^B-=XBOFMLVQ7?_;K\^>'FW'Y\_Q#>16Z8YL^%13[*M_EY
M/GI[FD^LR^VQU]]DR4-^_@^$FR3+DMGRR_LH?TZFQ1WRVV^3)%M_4S3P+4G_
M7([EQ_\#4$L#!!0    ( ,Z&?%K(C9'W+@P  '=!   8    >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&ULM5QK<]NV$OTK'+?3:6?B2 1?4NIXQI&3UC-)ZLGK
M?J8IR,(-2:@@:<?Y]7<!4@1)@*N'=;_$E@P">W87NV<78"X>N?A>K"DMG1]9
MFA>OS]9EN7DUF13)FF9Q\9)O: Y_67&1Q25\%/>38B-HO%0/9>F$3*?A)(M9
M?G9YH;Z[%9<7O"I3EM-;X115EL7BZ0U-^>/K,_=L^\4G=K\NY1>3RXM-?$\_
MT_+KYE; ITD[RY)E-"\8SQU!5Z_/KMQ7B\B3#Z@1WQA]+#J_.Q+*'>??Y8>;
MY>NSJ92(IC0IY10Q_'B@"YJF<B:0X]]FTK-V3?E@]_?M[.\4> !S%Q=TP=/_
ML&6Y?GTV.W.6=!57:?F)/_Y-&T"!G"_A::'^=1Z;L=,S)ZF*DF?-PR!!QO+Z
M9_RC443G 4)&'B#- V3?![SF :6Y22V9@G4=E_'EA>"/CI"C83;YB]*->AK0
ML%R:\7,IX*\,GBLO%SPO>,J6<4F7SN<2?H"-RL+A*V<1%VOG'=BY<'YU6.Y\
M6?.JB/-E<3$I867Y_"1I5GE3KT)&5G&)\X'GY;IPWN9+NNQ/, &16[G)5NXW
M!)WQFB8O'<]]X9 I\9VOGZ^=WW_]PR+88O]I//LT/?&\5JV>FC<:4ZO4W4KI
M;B5XYL"V$W')\OO:;UG):/'*IL=Z6L\^K=S3KXI-G-#79[!I"RH>Z-GE;[^X
MX?1/&_833=;3@-]JP,=FO_P((2CEA=59ZB=]]:2,,P^7YVXTFY*+R4-7?,NP
MP O:03VQ@E:L #7,U?*_L*EJ'R\Y!**$YPE+J9,W\LIOY>^)M&!5P*X U]_;
M?,$IS7>BR7IZ"EL]A:CY_HHE[-Q)UG%^3Z4.5C$3SD.<5E0%!_;S)VB-;V0P
MMFD"G=XNO&-30CU/T/,5,IO:O2!JT47/0O>-IC&"#9W\ &R1B6T>C4";M=!F
M*+3WTH<!&BN**LZ3?>"@$QX 9V; F<\B.YIYBV:.HEFT!FJ6=H"YP.^IRE>;
M6)1/3I5#$E2TX X\,N6Q%22ZS@$@YZ;-B#]B,W>JL_!T+ZLMZ5WIT!\RU%2L
M6,LX]4*&(VO*G1JB1--H$$/Q=??"W8?4(1;N7I#ZQI+FD3:\!_*64WMZP"<^
MP%;-1%T-N63$5$3C(BBN3S1.V4\ =-\$D6+-17E>4I&!GS[0)KM8@1'3>69#
M@Z&K'V$P35E<E ]<?LW%%AH8"/AO#I[81$B)U8K(,S7L#1&98\Z]^8@9-+UP
M<7ZAW.MW*=<?6"2']/Y 11T:<E[2 OSP*89/5C2^97-/7<-$YC"?A". -#%Q
MT7QNR4GOODD$Y9HZC[$0\9A3!1:AB3N4V3)JYH[(K$F"B[.$CSP_5T1)T&55
MUV4@,5115 C%G!*>4:?:<.E*5"2L4$:I4Y&3LOB.I:Q\LL(Z%8%P+0S")X$_
M@EU3"!?G$+9$B]K)S/8D<J=#.SV?6_3Q:-[@XL2AM65*H2P&>VV@6+=O$S/1
MS^9#',\G%7T<FC&X.&7X7/+D^[DL[9>P^S.)(E;NAB$RL[H;>L-ZQ#9J/A+(
MB$[]!$_]-QW_6? L TD5!,5T4I;(E@D4'D+V(VRR$Y,&N$$XC%FX$(?;@V@>
M0' >T/H5RR%'0GK$#$',C!UXX1"+.6B,9Q*=U@F>UJ\I $_83E<A9@XW-C&^
MU!'*UCF<X#G\*@,NPG[&VU"\8KGTK:5SS0!=R47AQ/G2^6>U L>"#RPO*B%'
M6*%:DGL8&M8P1_G1V*[0Z9W@Z;T'Y"UB#DLN]H<D&%_K"'OHI$[PI#ZTA^+W
M2U8DO,KMN]G,TW,R#*[XHD?@T0F?X F_&ZR2.E@5;;"2*X%;6;,?,;,P,1H^
M^.)'X-+)G$1XOTZ1KF+0ZRD*6M8;9DM5QOH^Y(BT/=[X.=5L?65H)D!P)G K
MZ"9FRVT4K#7 @8<*)ZF V.5EHQJK)DQR '0T&A8%MF'S^4@=373R)WCROTK4
MSD)9/K&D<4*"H8#F*.*.-!\]G>P]/-F#?**BJ&H[KF9M$%O2_=0;9B#+J',W
M\D>*%$\G<V]'4:^X(4K</3,[G[O$'PKX_!J_#T$G>@]/]#=Y"7M=%83C7HS/
M<4#UX9ET8<R).F<+>)+_N&U/[SA@L *S%./S<#:,Q+9A443&1-=IW</3>C=_
MJ%;0>;\_9!7Y^=F[ 64I[[U@A#EZ.L=[>(Z_K034['(S ZB-D)8HG]3&IO]6
M;".[0598EHH\&);M^-)';!.=Z3T\T_=0[=_B\FS5]MP(3R=.])Y.]!Y>M=\*
MGE"Z;':-[*T4<4H/Q&A6\OY\6'#A<AP!4:=O;U?Z[D+LMB?&CP#P*0_98V9>
M]^=C6TRG=0]/ZWU(*G!(CO(D3;17"#E5]]\S64$P&XF*OF8%/LX*; &]]L'=
M =VW9'I_R+8L@T:#N:_)@.\>=,A=%YM[G)+Z1R3_<;9\JMGZ6M!\PL?Y1-\W
M/U!Q#V1.1O^M5][>W+YUWFUUHXYS5%\7ZNXBKINF"2_LH09?^P#']4T>,O/G
MWH@+:"KBXU3$#*?=>--KN#N__3(CKOMG;[>..;5)/TA(AIT'7+;#0ZS?N=N
MTYC_%VR3H(338>[$13L"M28Z/DYT%O&&E7$JSU1*P>XJY;I[1%]\VD.<V*1,
M;C!2,_J:Z?@[F,YHOMQV.-8QR-7B++ES]>6#9'KW(LZL@$T2Y'EDR!!PL8XP
MI"9!/DZ"WG;.8K C"]\D.FYD[,(3$QU?$QT?)SJ?6@HPW'16,):.0V2B.?&Y
MA:\YCG\(Q]GW5,FW-#.,$UA\Y<-!!9K9!#BSP?:6/IB%K93!W[AX4F;<6O$%
MD"(A&&RYN%0ITGKCZOD'&[62 I,C$3(;Z9@$FB0%.XX_+-S.1I2LV,Q62C@-
MA]UMRRAWVFT:]R77Q"; B8V2O#V,5A@DK5&_R,KV 0HGV6J[H_*Z@$-7*YJH
MK=C>&A 0+YLI[/@L]R&\,!@&2LLP;QR?YBX!SEW>X@*KL_@QT%8TEIZ).XPO
MED%D[ PQT'PDV'W9LF\JJX"V_D<8#5MSEF$^Z62OOHR=BY>[V,.8 \'NOJ/W
M+,_ECI ]%"H87UH1F 2@)UH#X,1-DT!3B0"G$BA&*EN]*#J3-@2!81US$&(=
M30D"_ "D<TK;UIT@[]Z1ZJ3G'Z>:K:\+S2N"';Q"'K5+4WT%BG0E>\0.ORMC
M&*4N [?10IYY_=/V7>O6^'N\>Q^8),0+ALU77+PC_%=SD&#'=4LN!&WO\; L
M@W@H&%!^*D3GWB4PX)4\-5Y+#EG&/[#S\L!"4'S#J4],4$)-4,(C;U\8EY9J
MPJ)>7T%N/9LD8CXT+R[1$6 U%PEQ+C(*=NC5VVNH]>LZ5J FZ?"-2T"X.$<@
MU=PEQ+G+HF.LSH4T6= !T91?;\MS\&6$BEJA6XYTO&B8A' !C\"N>4V(\YJ^
ME?-EQ4KG%DK8#%:#FCV)T\*YR9.7_0-\T$-SI_\- ^#).N<IOW]R_N;I4H:W
MV_>+L8M\5B4]OS?3Z-%R"248N;@8:L(4[G\.=9".U%7Z+UOU0)0_6#&G.LT*
M39H6^".W&D/-TD*<I;W=A@%$,>]9QDJUFX9W:]4MD+I;<I!B)6GE>=ZDGD=6
MKE53K6ZF6K5XJI92:#)*+QSKZ(>=MV=P(GB]C3A?\R45CX(IBK 8:_/BLQT"
MQT(A(V^$'8::'8:[3LUZ-T)43.U=*./&A3)'/< K1:14"[SEDH6,LG5;X'##
MG^K=F]!R'9<$(PWQ4'/'$.>.5TE2955-DR#ML(2IRS)5UC0.;V\6\-F)Y?LL
M55IN+WC?5063KT/(;7$'>AJ-'J<ZIPM-(AIV;VGTX6L"&>($\B8'3P>^V-Z_
M;WI7W5LMJ@U44^FA[?M')58%G.HD+[3<[R$CYH\TG8QVG.1!&:6*P*OZ[MA5
M8WK JOT:1XBO<,C;918N.I(X(TTAH]VW>17 3J%S%,I3O>,3V=[Q&?'C2//'
MB*#E\.=JLTG5J]#@S KO-2N2E$-PLQ=VT1%T;[P /M5L??2:048X@U2 5?R6
M"7U[;]L*NYZH^X[N;'A@91EC6FC2>84]D_XCW^R7X;#*R_JM\/;;^G\/>..^
M6JB7[ ??7[FOKM2[]!,]3?U?$GR(Q3VD)R>E*YAR^C("GQ'U6_[UAY)OU(OR
M=[PL>:9^7=,8\K<< ']?<2 YS0>Y0/M_+5S^#U!+ P04    " #.AGQ:$C<\
MTU0"  "J!0  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;*U476_:,!3]
M*U963:VTXGP!%0N1"FQJI75"I=T>ICV8Y$*L.G9F.]#^^]E.R&@%:)KV0GRO
M[SGW ]^3;(5\4@6 1L\EXVKL%5I7(XQ55D!)5$]4P,W-2LB2:&/*-5:5!)([
M4,EPZ/L#7!+*O31QOKE,$U%K1CG,)5)U61+Y,@$FMF,O\':.>[HNM'7@-*G(
M&A:@'ZNY-!;N6'): E=4<"1A-?:N@]$TMO$NX!N%K=H[(]O)4H@G:]SF8\^W
M!0&#3%L&8CX;F )CELB4\:OE]+J4%KA_WK%_=KV;7I9$P52P[S37Q=B[\E .
M*U(S?2^V-]#VT[=\F6#*_:)M$]OO>RBKE19E"S85E)0W7_+<SF$/$ R. ,(6
M$+X%Q$< 40N(7*--9:ZM&=$D3:38(FFC#9L]N-DXM.F&<OLO+K0TM]3@=#HG
M+VBCT!RD>Q$\ S2C*F-"U1+0)7I<S-#YV04Z0Y2CAT+4BO!<)5B;W)8!9VV>
M29,G/)(G"-&=X+I0Z!//(7]-@$W17>7AKO))>))Q!ED/1<$'%/IA?*"@Z=_#
MHQ/E1-T@(\<W_*=!_G@@2P8_#\VMH8T.T]HE'JF*9##VS)8JD!OPTO?O@H'_
M\5#/_XGLU03B;@+Q*?;TJ]&<6YZ)$M#Y%Z'4Q:%N&XK845B%V:27P?#*#Q.\
MV>_C0%@_ZG=!37UX[]F7(-=.#13*1,UU\XXZ;R,X$R,X;C'?^(T07;O]PW]H
M&A6[(W)-N4(,5H;2[PW-WLM&&1I#B\HMUU)HLZKN6!@Q!6D#S/U*"+TS;().
MGM/?4$L#!!0    ( ,Z&?%I#7(.U0P(  ) &   8    >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&ULG95=;YLP%(;_BN5)NUK+1[ZF#)"2=M,BK5.4=MO%M L'
M#F#5V,PVI?WWLPUAV910*3?@C_.^?LY!/D2MD(^J!-#HN6)<Q;C4NEYZGDI+
MJ(BZ%C5PLY,+61%MIK+P5"V!9$Y4,2_T_;E7$<IQ$KFUK4PBT6A&.6PE4DU5
M$?FR!B;:& ?XL+"C1:GM@I=$-2G@'O2W>BO-S!M<,EH!5U1P)"&/\2I8KA<V
MW@5\I]"JHS&RF>R%>+23319CWP(!@U1;!V)>3W #C%DC@_&[]\3#D59X/#ZX
M?W*YFUSV1,&-8#]HILL8O\<H@YPT3.]$^QGZ?&;6+Q5,N2=JN]AIB%':*"VJ
M7FP(*LJ[-WGNZW D,#ZG!6$O"!UW=Y"CO"6:))$4+9(VVKC9@4O5J0T<Y?:C
MW&MI=JG1Z61CRIN!1 ^29)07:"4EX068LFL5>=J<8..\M'=;=V[A&;<)NA-<
MEPI]Y!ED_^H]0S;@A0>\=3AJ> OI-9H$[U#HA],1O\F0[L3Y+2Y(%_W\8J+1
M1D.E?IW*O;.>G+:VMV>I:I)"C,WU4""? "=OWP1S_\,(^'0 GXZY)[N& 0K\
M_>PJ.(9&JTS4^O]2=[CCACEA"D; 9@/8;-3GJ^!7%\"-F[X&-Q_@YA=5[0&D
MN4OD#-NXYVMLBX%M<7'AQOG&?<_R>4==H@)9N%ZH4"H:KKN&,:P.[7;5=9F_
MX5VOOB.RH%PA!KF1^M<+\SEEU_^ZB1:UZSE[H4T'<\/2_#) V@"SGPNA#Q-[
MP/ 32OX 4$L#!!0    ( ,Z&?%H6]M-C[@4  $<1   8    >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&ULQ5A=;]LV%'W7KR!<H$]>G#AM$M2) 2=INP#K$*19
M^U#L@9:N+"X4J9*4'>_7[UQ*D>W6M;<6VUX2B1_WGG/N!RF?+ZQ[\ 51$(^E
M-OZB5X10O1H,?%I0*?V!K<A@)K>NE &O;C;PE2.9Q4VE'@P/#T\&I52F-SZ/
M8[=N?&[KH)6A6R=\79;2+2])V\5%[ZCW-'"G9D7@@<'XO)(S>D_AM^K6X6W0
M6<E42<8K:X2C_*(W.7IU><;KXX(/BA9^[5DPDZFU#_QRDUWT#AD0:4H#6Y#X
M-Z<KTIH- <;GUF:O<\D;UY^?K+^)W,%E*CU=6?U19:&XZ)WU1$:YK'6XLXN?
MJ>7SDNVE5OOX5RS:M8<]D=8^V++=# 2E,LU_^=CJ\'<V#-L-PXB[<1117LL@
MQ^?.+H3CU;#&#Y%JW UPRG!0W@>'685]87RUG)+SE-9.A:6X4_Y!O),&X8#P
M04B3":R6@69+<:U\JJVO'9T/ ERS@4':NKELW R_X>9H*-Y9$PHO7IN,LDT#
M V#N@ ^?@%\.=UJ\IO1 '!_UQ?!P^&*'O>-.B.-H[_1[A.AW*O2C)F_MG)R1
M)B7Q:3+UF$O#[]M4:7P>;_?)!??*5S*EBQXJRI.;4V_\_-G1R>%H!Z,7':,7
MNZSO">VMLREY3UZ@LL6$G[PRL[ZXR3"M\F5\8;)Q$][$?8&R#UY\NJ?'("ZU
M31^VDMX-ZR,E:"FLIE!&A(+$5-E :6&LMD@S( [6]<6B4&DAE$>_F/Z!,1&L
MF$NG;.U%ND'-@9J')1E$:FN="9G->5HOA<QSWFIKU&X-?B#93W+%H5-28[G)
M%'>'ABEB@&+VPN:B@8@9WP?,5-<9*Z!,0/^ Q1J;*\>+X!\<\C 2N9-U-A+0
MQCK>.1*%="7#IK+2=DG0VKJD*6K@&XFYLCHZ88^54W.9+H66"Q_16-AU0@/?
MK%G$@YIF<,V,1RWDJ@YQNAT^$!\)CN=0%UYCK F*Q+F?N']EB:P 74)<0%-M
MM*,Q&;,@QF13X=!&?EWCKY6--I1I3@H&[)<^4.D94K(3DM@':2\<6)9[X"0=
MG(D7E72!50\%9UA7W$S]RL*664)$+\C,4# ,%@M=]A-OXQ1U<X7:!^8YT+J(
M^HD: )6HYH(/+E"^N6<<R2:!RFJ5*MK(K;>U=-F??1'+5KP&;Z@@M>^OD@'0
M[POT">Q"5D@^S\#2$4JDJI!T #I=XDP*4FD\K[SX@' E8(F-< 7<,R?+UC1S
MKF$4:J!PN*EAS.)<@5E$!"KDRM%":MU(^N'V5\^,07(>^6Y0 Z$80)8Y:XH+
M.Y?]!+7&U=5DQD*%8D-2>N1:\E'TO'8Q]1$6Z(]'0]EZ9)X_.QL>G8X\:XNB
M*XD/_B;:)8<$J[D_PVV,A5;,*2:AH\\UN.P,IF_ R32-M0">&&,2?6X7>9.=
M*#9T3>X 3D%NM]S(^_OORJ)D;Q:)_RB+DFU9% W$1!);$JGIUK'(?R!LZ^&Z
M,8GF*U53I<1AF,LH1E/7*7H GUAM-X!)6S8"R1!D^N#[6YU?6@B4P.8U$H%/
M&M\5P002!MY0JA"(^DTB*(,.VU@OURX$:[WR2Q?;FU6TGG3615L/;;JM3*.E
MSP"1F5DSL_S_RPKKPO9T;'VNR</2FA'D$HX&1!/-+FD5S/C,?>IY$V/X$+N+
MBS8;'V:-Q>5OP4G!7<$\G;$KC;?WXAA_% $YQ47?'A)<CRYA8QPRE-(44UH]
M\ $-G%^M7P>S<?K"3=?<5SW[&Z<VZG/+07^PXV+ULKM8O?R!B]4]E[BXC27^
MNBW\3V^TG&V]*^WV%%Q-.P"?=(!/_CG@3O3)*DA(ARY OW0!^FHMELT4!P!T
MOTUM-Z8]U$X[:J<_<LFU/D:=+UZKPO; [RN,JJFF'01V>]Y#X*PC</9O$]AS
M'=_I?_LWR/_5J[;I.5C[N,6U>18_X3U?^TQHOG.[T>Y7@DGS<;Q:WOS$\$XZ
M?,AX7*)S;#T\.$7UN>:SO7D)MHJ?RE,;<$>/CP5)G,V\ /.YQ9=*^\(.NM].
MQG\!4$L#!!0    ( ,Z&?%I:(KV4!R0  *5L   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;+T]67/;1IKO_2NZ/*DIN0JB)?J.DU3)LI/UC*^U[$GM
M;NU#DVB2B$& 00.2F5^_W]47",J>[.X\))9(H/N[[V[]<--VG]W&VEY_V=:-
M^_'.IN]WW]^[YY8;NS5NUNYL ]^LVFYK>OBU6]]SN\Z:DE[:UO?F9V>/[FU-
MU=SYZ0?Z['WWTP_MT-=58]]WV@W;K>GVSVW=WOQXY_R._^!#M=[T^,&]GW[8
MF;6]LOVGW?L.?KL75BFKK6U<U3:ZLZL?[UR<?__\ 3Y/#_RCLC<N^5DC)HNV
M_8R_O"I_O'.& -G:+GM<P< _U_;2UC4N!&#\+FO>"5OBB^G/?O6?"7? 96&<
MO6SK7ZNRW_QXY\D=7=J5&>K^0WOS;U;P>8CK+=O:T?_UC3Q[=D<O!]>W6WD9
M(-A6#?]KO@@=ON6%N;PP)[AY(X+RA>G-3S]T[8WN\&E8#7\@5.EM *YJD"E7
M?0??5O!>_]-;TP^=U>U*]QNKGP\.OG>NT,^-JQQ^_+ZSSC:]81HVI;YB]N%W
M5]6ZJ5;5TC2]OE@NVZ'IJV:MW[=UM:RL^^%>#Q#B/O>6 LUSAF9^!)KSN7[3
M-OW&Z9=-:<M\@7N 6L!O[O%[/K]UQ1=V.=/WSPL]/YL_N&6]^X%>]VF]QT?6
MFT!3_]?%PO4=R-=_3V',Z]V?7@]U[GNW,TO[XYT=4KJ[MG=^^NM?SA^=/;L%
MV@<!V@>WK?XOY^ZMT$SC>CY3_Y]0ZLNV*8>J5^\W!I1X:8<>GJV=?M4L9X4V
M^H6MS8V![9=MMVL[WN/DKW]Y,I^?/9.7Z;?S9[KM",+PY79GFKU\>;?0 *S1
M2\ :=SAU/1@U[79V69FZWZM%U>XR&&!'6@#6-+V^,4ZCC;6E[EN],LNJK@!C
M2SN6]AK,YPZ,84_XPYM;V^'"U1\,,5#"[ZR-<Q8LM?X(;PJ0>F.<DE5@!Z.'
MIOI]L'HAQ-;;MK0U0V)JL-1.5ST" E(-ZR%>3 K\;-$AA4?;Z577;O4DAL@&
M@-KOKQNPU3UXD![Q(:SU#K# 7V;ZW=#IIH4'M=GMNM8L-]J4)0B @U6&9@M^
M"FA$JS?6EK2RKFVS!CHUCJA5-3U8>3#[ SP$:^QLU^]Q&]7"XO9+Y4A$!.Y^
MT[7#>@/&ML>/3VV); /Q*4^1'[JWRTW3UNUZ#Z:YW] .]@NPM8^43]B!*\,C
MSN+.Y;"$'>BUNEI9Y4 DFZ6-=)GI-[9;VTY=K#MKB;_O&G5E=[W=+FRGYW.R
M7/?U22IX=>MP&S#X-DJ? ;K@4D!:TSC#3F]A^QMK&Z\%>JP%KZMMU8- >(%_
M5Y<Z%_J[A7HS=+O-7E^"',&2%\O?A\I5M/PEZ$QX]\VG#S_[EX@K?E-&$91V
M402UNS3[K6GT*U?#DPX(:K<[!,3K!+YO],VFK6M0\YO&ELH-"U>5E>@][A:W
M#CM$>J!"X6JU)003^O'3\F2AG;7Z;0N:-K^K=T/G!C0E(.8L2H H2)&0UG@N
MJ=+@JF]!4(E/3XA-<P(;X;2@7*BK\&S)4BX+CA?2O-#?3#,@8O/'PF]<Z(W9
MZ_/S( #MVL(*7:$/4(G2X]&?Z?<C3'K;;9VWL4*O\%JA@9GX12I:A3ZI[B;,
M8]A+%F>$#_2LU8G$%(J^2CX!6G37U;7H1$#>!=:>$FOU(6L+VN&D0@B0T\N-
M:7#S"DC9 %G9W!R53(62.4/<CTD^"B)92%1>>!DBK>5G3Q]O-4]R<X_/7>%S
M0<Q)\T&C2]2Z$O&$1W#5M\:5YG?U2]TN0'S>F.XS&*X!@AIV(6Z_74"LYY=^
M\3&X&-@A:O]#9CX3(P$,GSY__ Q,B^E VWOW54 NS0[<R;= \O'76V$!"]W@
M*F"7658?%AG)5E6-#J9!\PTNF&TD\*$&JZO1_J9TS('4(R!!3G:FZQ4P!5_<
M@:G E3J[AF2#=;LR:$Y9(NM:O[VX>G'Q[[H;:C2M5T&QS\C)@!\AX8 =2MN;
MJF8?J43$T6 8CB   WH!!;4#K]6!.>_LDL'S+K=JZ/&N3&"( <@.G.2R NOC
M]-HVMC-HR.![2V:N8G7[U)#UO4)'[Q#/"U 1(%HP;)]F5S/]R\7%^ZC8GP+K
MCD(&3G+3E@5K#J)%WA;9P@[2H*)TB;5%9%=5 XB L5.=A4"(D0#]:L'Q1@%,
M,)15A' .TCJ.73;F&@PG_(Z*#5IGR>RP?JTDA&J(O>1_@\(3!9M6K]NVO*GJ
M6L&S+5H\-#2@_=6BMOXE0!D(;\L9!XEJ'"0B6Q%40H^BE;8AGTYD"*@"5/ !
M&V@">X'.$H)3D#MX;K'/1'N"X8$_2%J #!&$C^7%GP-)D\@4F-V4I@.G][R%
M?P*K?[ZX>IZYS[$O(JFF;T #AIH0#18]DR20_.70@:S+\R^_L/E4J'O F33$
MO7IY&67K@UW9#LT(^:N(G'#3HP60B@2#]#5M;X-[^P::JX3F&'?+F[3H))DN
MVY("?,;7PWUQ=9E1:_+53SO</'GGDTL\9-!0%)_+ .R?E!]8K!Y*FVH)<>>(
M ^)0B/THQHA)I!/=(3!0^?<__1WL8@,Y!84-KWN0_1/A^M\!PK+=YE'7P7[\
M2AYX 1DN(*QVL @HFJV: BLMB0P<S7>4QS=__C9LBX!MBB!  )8;8_;.FR-P
MF886)*L3P]E426T-H6N#[%#D#!+NS2"L!=,$QGZO<(5?6N0@0+:T'6#>J+$6
M@RR!CWAX^N"LR!_.71OD4-I>FWH@(;C94#B&3X 4<P;9L(-AP,$Z@P@4!%L%
M-CN:?;->HQ.#$$M1QM69"A0)B0*22_%FV0X+L)"+=N@G_;Y98'JX1XK#\B#U
M@V5OM6Y%6@E7Q [V;!NK]]: 0UOUXCM*GUH>U4O6>?"B%=*I8@D'[P7X'9*%
M71R2Q27Y. 233KAH2!=>V"5'$[XB,UZI5(:,[+!% P?+E1;6 GF"E[_3\Z>S
M<WTV>Z0?S.;Z_.'L@7XXNZ^?SA[KQ_ ?ZNR83FFB5I& >D@UIH6&[$4"9H-L
MJ:[3;Y?&;?2*4V)FWVJ@>@4^CWZ*\M DN% KB*XHY&V!ISOTI40^,,D=JF[(
MN2F@0:<BKP9#;[&:2BZ6N;_E>*A=@:9Q;-&N.[/-PM,K@X;L(!%@PIW/9V=(
M'V?5M_H^<N@^</<,(G1O$SBD2=FB3PCVT)2_#:X/21"8"TS-%2X+L84CKVX!
M,\R4)0M![PZAC1=RJGC4 %!P XB5#Q]8GLV6#>[TLQ GTEKH$$GCMI!:0;PP
MU+VB1 *7 %T# R1UJ J+#8 2A(E-OT?/2+&6XK#U"B)/RM1#WO9@*A:F]$^2
M%G#)+;HI^0CA_&")!6"R81^&EW8'4YG4HD+1 5;H(&R5LE<O#\,W*OP2BEFH
M]!W%B:T0%UAUC@6-T_.S,_T.C9;Z4+G/3+%/ 56D4*)(J#1@EW[#!9!Y](9D
M3&1[?'U'5",M5'$!C"*9O"I4@8MP?;<7$0'Y*4 I>I*:6@H2?5LD#$ _V%FV
M"+ M".EI+#\1Q^47X2%G_K:O>JPM21VF\'%3"UM3<>F:/%-I=\@3M'* U6>[
M3]XX^$ZA1M<5R )CUD'TL_1B-EUXZK Q ($+UADP6 ++17&PY""X,)8-3;4%
MQP#82IYT\9\O]/FCAX\ E=-EMW>8&.V  DU_=Z8N1\4WL2T007!FE_*!E+:S
M%*QGYCG)AS!VIIR.%#AY&80'[!=0(O *;&J/39EKJX /TVR B)!3A!BLID3'
MY*CM1(#R0N:,S93?]Q;@MS["4@D>D@A!I%'".Z@5P /7-HVM$8559T#P@+5@
MOSD:"<BD^22#[9,@6#-8CYE^"5Y=5ZLIKZP\T*B!;H!<S[G5@!OW.K4G&#J
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MLEI 8J9>'A4C=EC7E;T!2C*5$458:+%/!9*H1X, ),V'!$)&)\\O+-?2N:6
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M+'?^J6J'H 2<=6@S92!(TVFF7L34G8K)/*[V%0]=5ESJ93FC*M4T_ GCOH(
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MCS&U)=8,2@ >)K>,D=C_M-VC;<_->(?9FCJ9>=IVV(&?LUW;89^X61P.QDF
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MM[%GT4DXHW?=4W"CU;PIZ+"JWODR*/%R<PA @&&11B:72)-F4$SOVT/P55$
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M0I\X[47ZG"[^>W+J&&A_9]?MVB6A;U1?;7C)?L,CA-I6)F/-$.X/:5GX^_"
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M*H=$AVY47YJ2/=0!C$V6%66K4%\J:JSP/C<(LUPJ8KUN+U(6%0,9'NUW>V"
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M.';Z+I[5M[1P)TPJE:DUA[\62V,U)L/?Q[SUNL;'=5&!O#$52_GU "O </W
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M(),B7HBT6ALT (45J;(>&9-T0D)"AFID(6J+7&O]1EA*)4ZD@)$U>)V)Q6;
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MTC4EQI6TV5!':G*H)!6;9*<3S0A]Y!40RT*#0I^(!\/Z&<-025J(MRUC+GV
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M.V<FK7V28!]E"6L!%<^U9_];[4+&]CF,3/0AQ-L(0R"!$$C/Q-'T!+4=_GS
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MLA_TFCVS"!O^-TO+TZ/TE.!.RM.T^.48?C/PWJ@:;< <XMMCD)10>^D5AVC
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M>&GO;NKP\O>XR\0<KEJ/-?Q]-M-&49'\L\OO%C7=C6H/SDBO6($3GTZ&1O6
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MZ+)UPY)>-ZBL .TO)*6VFU@#_7MI^A-02P,$%     @ SH9\6@1[Z_ZL$
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MRKNE'U88#B;/,*1+AC3H'04%+2^EEV<GUBR$96J@\2*8&KBAG-(<E&MO<:O
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MS+(D&^W!&W9!#CW>Y'>#9'^?S:TS6!+_[(HWH UWHU&;?+05S^&DAWU@P3Q
M[_3=FW2<'.WA.NJXCO:A_UY"]D-D23]Z'?(=/("Q$,V<SN_9K)+"L1L5_<%5
MC=W(LI&7^R!F;@7L0I<55T\,%@ML'RC\RP:!;2#$K*J-K3FZ<9JM5R)?,5KU
MQ-(D8=^$D5P5[)MV8*,[J/A328QN%/L"<^/]3AJWT:;;12WE$_9\Q47!!)+'
M<6(=0@FU9#>YTW,POCBV7!"%]OE*E()X"^6I5T:H7%1<,E[J&BGH!7O+QDD2
M)\CSAW"K"%-98:P$0A9G]1*[[[63H,\58*D;EFN%P9(?7E5&/PH<$X#,W[*T
M/\%VE1(G3X2^R$8;L10**>PFD\7C@T"G)NQ(*&1B5QQYT8)<ER5.,>NU;Q ;
MN?KL)CP'MTD_Q<\Q?AZR:VXP(QC$$!=[KF(NP0>RG8^P,!W^[VSL\=!G?VZ@
M*"H"I,F=YTJ/;*4ER<B7!E!#W=(8!Q81"F"@J'-XD<.%T24&F_2G^#=AW[@M
M^,]0EA$BW.->=J$-)52CE KM*7L;+=%87/!*.,1K;*Z$=;[ 5-259YKN:@O?
M]\K7%\I187$T*<*>X.0/F5/LF\PZ+U<7[!*X(4^W7(%D[PGZW9MIEB5'_HW_
MGAY]B(BV(<[6UYAB\.B:#9%* '='\L3SE<"FV_2_QHINO;=AW=42;(CC6BA1
MUB4[QX3>&H$&[QO_W9N60]PJ^IW+&LCM;3V7(L>*N 2)JH8*;>VOO]]>SEI;
M+_M+<Z*#P<P@KXUP8LOVZMG4!+9-5^+.+:G.510JY&!75@SD@ M1*+9&:%2*
MJDPL1,[]"<"7#1D$V;%Y%\*4) V.PA6W;&FX:H=="VIK=+>E/)Z$MMK#5^D2
MSS^O$N"E)D&"$!A>&Q8.BP=1>%=-/S1H,7LO/E G:#QM +J"MC6S-N2%0 A$
MC'#FR#8VFEK(WBZPG9H)MK/(XV9(;]JN,71;STN2;*,+V\GLR;\7NVGA+AV%
M507@?*)-E=K\I1)<RI:/;,JQ42+0P03@O,.A:HE]H?OLK"@$L4/+I^TT$UTN
MK6Z2VPWY"&>.\+,")>5^:'9MG(W;8'RJBR9C:+LK9\]M023WC3'405A\A_YL
M;0@E>IE1EF/UT/'848EHM=04_7ZW=Z_<PB.U@5<GI,I/G@V40N>U'^;K'9O9
MKB)LE%_C)H4I)=1_&PL##W2<GC\]-TL@X[_&& QF!&,A!H6PN0%*5-Q.*L:[
MU.$F%NX-5&9-W13@@+J.5'BE%75A" I3TPE#!K;=]. QAXH /2<$)'WGL)6$
MC7VF&ZCIY,A&!>3"-[$/V^\[SVX:$NWB7>KV:1'MPV&S^6KI[$/^4(X[D,^]
MB' S3BJ?D0^?F(UTHBZH&EXFPJSARR75HZ/YB U,RE2^#OQ)8"<8^J@K^O^6
MC>+I\" >#8=L&J?389P>C&DC']%I(IVP=!)/TW&<31*6#>/#+(LGTPR-AJ.#
M^#!%(SPN)/T,!TP_V75^'6Q<+DHP2W^%(G'PY!+N&=W;[I9V%BXGS\O#%0]'
M!IZ +).P0%/<N@]ZS(1K4WAPNO)7E;EV>/'Q7U=XTP1#"_#WA<;N:Q[(07=W
M/?T/4$L#!!0    ( ,Z&?%K&BI-^5QT  -U<   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;+T\:V_;QI;?YU<,W.+"!F1%4IQ7TP9PTK0WO4T3Q,DM
M%A?[@2)'$AN*5#FD%?77[WG-@Q1%N]G%?FAC29PS9\[[-?Q^7]6?[<:81G_9
M%J7]X6S3-+OO'CRPZ<9L$SNM=J:$7U95O4T:^%BO']A=;9*,%FV+!XO9[/&#
M;9*79R^^I^_>UR^^K]JFR$OSOM:VW6Z3^O#2%-7^A[/YF?OB0[[>-/C%@Q??
M[Y*UN3'-I]W[&CX]\%"R?&M*FU>EKLWJA[/K^7<OY\]P 3WQ[]SL;?2WQJ,L
MJ^HS?GB3_7 V0XQ,8=(&023PSZUY98H"(0$>?PK0,[\G+HS_=M!_HL/#89:)
M-:^JXO<\:S8_G#T]TYE9)6W1?*CV_S1RH$<(+ZT*2__7>WEV=J;3UC;55A8#
M!MN\Y'^3+T*(^RQ8R((%X<T;$98_)DWRXONZVNL:GP9H^ <=E58#<GF)7+EI
M:O@UAW7-B]^2IJV-KE:ZV1C]LK7PN[43_3*QN<6OW]?&FK))F(9EIF^8?_C;
M3;XN\U6>)F6CK].T:LLF+]?Z?57D:6ZL/G=_77S_H %D<<L'J2#VDA%;G$!L
MOM!OJ[+96/VZS$S6!?  3NF/NG!'?;D8A?BC2:?ZX7RB%[/%U0B\AYYT#PG>
MDQ/PAD[\G^NE;6H0M?\>.C'#>S@,#_7O.[M+4O/#V0Z)7M^:LQ?_^&;^>/9\
M!-LKC^W5&/07KQ*[(?[1'Z__;//;I #&VB%$[P:EAD!I_TN*OYCHEP2$;%?G
M(#EY<=!H+AKXSV0@[LT&/O]1U7J5ETF9YDFA\](V>=.BS%GX0++YJ<P;>/X&
M1-& @,K'?P'YLVH[8=$$8'^9NH"_I^HCK'E5;7=)>= IP,DS4]MCQ)I*+XVV
MFZIN+AM3 Z0-*#+@6.3P5 :[WQK;;/G93=+H\^2"3H,V$,\"L&]-W>3+PL##
M .YS6>U!5;8H'%:!FN">$WV^Y'4@'B#/A._&%)D&R\I8;9,2["#NI'=MO:LL
M'A,?.T\O]":Y!2VM\S70J(!'06OS!B6.-+<V1F]96P!: 1JL 5.D6@,F%)Y1
M #'=@/6::J1+1"BP:>5G,(XDRU9OJB)#B2:,E@D\D1KF7EL"5\!69(P4L>1?
MG=439F:B#R:I+PW!)@"(9++;U=47$(#&% >%8OWPN9[/9I/9;*;GBT?T[U/^
M9SY[(O_JQ2-^ K!6CIN;)-/?ZMGT,1C$H@ 9(9'[5E]-%_X;$)K42?P1S\&2
M;?"'A,@'=L%LEZ;VMH$6];]]. &.VYTA+U(<IOIZ>/&$4%LH0<195L']']\\
M7<R?/+>,OW_H-*J.@OO$*A9%@S*)W#:H1_5G\-RKMLPL<_;X>YU5NJP:EB ;
M66P6\+PYX,&:.D]9W4C(]U4+HEDC)BBR -A\28L6?;%:U=7V-,;3$5OUR-NJ
M1Z,&YBVAGZ!&W9A4)'W"5O:@_R/_?C1?&OVRJ-+/@\9V=(MA8ZM'<'_L<7\\
MBOO[&B*FNCD N@52&6F$)G*'BCV$YRBX83S]'FI@#QU^W?E?C?\553D'VPEF
MMD#.IU5-YJ@!0V:;*0@T[ -&V/M[,&1@W?Z2+V!U"J+<HAABL+ FX4"?A^'/
M):*OMZ;95)FNP"SBKPJDB_0>5YA56X#DW3K+94 )K4&=K"=D"@L#5@JMD,ZW
M8#%NR2 "\_'1(E_Y4(6>F^A\Q;;;U%/]^\:4#AQ;Z :D-T.36,&2>I];H[+<
MHFF%;U<,%(]-!ZU-04B"-6NW+?^==:A!,+> $UAM5 )"WUE.HE5)R@01(5)F
M#1Z.['$%]ABB*8@W,1@U&5HGP@@X =1$PP[Z!8&V-40#A LLS*MLQ,SLO* -
ML3GX6O)]9#8 SC!UIV."_\0+_I-1P?\500]&$Z/KAB6<@>DW8-I3E%"V@>A=
MKF]>Z:=7BXF61\[EBXM);&=%L($KNB;!K%:7('SZ_,.[3Q<L(\PPI@A(5K+,
M"[2%%4<;SNY29*V0*: O_+!E1#!8L,#;<DUBGI3@Q9P3)L-8P#9@:PV:5+-%
M9V-R8CKR+2$)\4&/R#-PXKI1N#\(AMDUXD 2E+TZ*3DZZ!XT,X@(1NUZOS$$
MG\0R/(^BAS%&12&7]6?&9"9SYP7O_F<+T@>A*Z&OTKP&-; -!P [S@*\YW>'
M2Y,F<G(,%U O6@HB8H1P>PR,,:"JBENF"AH$.J &M02*X,\9[(-DRYA-$Q5#
M<:>NEGP6_(X8C'&<;9>(KY@VY!<Y+MBYVN8IA'FE6>5-4%W9W!LA#FR&MH/(
M276VRL"PI,T@E*F33 F&D#UZ#=%BX^0$7#2%2&)0T@I\\E^!%1W10[$!F16S
M-E%=<47A IS)#$* !6X1G>:$I)*B67WT/(<)T<&T8:-$00(<S2,TC _+J8I4
M  [O3^2B3P@\X+0[9#C@5)!URW(2QE+ODCI9U\G.*_/E8G:Y>'2YF.J?1%!K
MDD/:A$^ G"FK\I(_H0N"/=$QJ&;\." &%4BIZ0JA2PA(?"6@K9PM]S9X?&MD
M3:+1!Q9&]7X4(5 ]1B'4'$]88RQ9E:0E@;U>(,@E=_33*2!$6:WQEAQ(>>#4
MQ#E;HC2=GQ] %G$N! 8?D]1&UT@-)"UZH38V1V+>P%ZL05=J4B,DH[,Q%)&1
MO*&&&""3Z1JCUHI>@RK79'R ]TLX;;4'^(IVEL3$$PR>2ME.9<2F*IBT^YR<
MY=ECV(S$W!%2RB/%Y)!(U^H_VFR])09^'#:R)T_'@%!T3)(ZL>40":D<@J N
M/4#XLC]:\L^X]A:<=M5:,L15;2-C6AC(._!H:55@< +LD:ALPC:&G$X+DE5"
M<$R2#\&^^*J-"<KJJ4]G5#WV!W$$ +82!$A\#X[TM7'4GP# %3Z[/ 3KCP;\
MEGQ9"=")(X .1.M&O(<\:;T:<DX#GTHIUA'6CNHNRHPP*[,CQ[W'Z"]O.-!*
M;(72"M$/A$C@*=0>1;Y 0V3J-$?%P#2'L4-$=4#425(?P[8DTW9J"^VV0(V)
MMC%^EY$@ZZD/LIZ.!EF?V-F\%F$:#+=&(0R'6P!6Q6!),(C-M=>H4)VQ6()A
ML\-<P^(PL0"Y]FEZ,]4_7U^_#TH553: OMODL_'J('&SM>UV%^6?R6HE_E4!
M%AC?9ZZB0O&"F$L4@YZ%=5$\!!0I!-YMS9D&6GZ0(XIA3BQFNT1&2+3$'UE%
M1P:KOS? YD2BCP'T:E#5LA6$)+"'/!P269%D7H2?7)@?2(\^P)M^"Y! T9TY
M4,$<$'XN6M/=:"VY3?*"C754!2+OT-EFFV0&ZUT68'LW7>=HD"<0Z]C/9&XK
MK >+0_#1E$K1>S''R+&!V<EL* TAD:TEE@LQ(=U8$DZKEDO.;8.Y#RA?VK0
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M@)]*J%@1MSU]L\C+^C('?G"MFRPR8N+K=!3;E]AJTIO#LLZSWB #,[UG<[A
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ML0@OW *<CU\#_*FJ#8Y?OW(#V1_AI+9(3G9+O^(:H.RAAO;H1(*-?&_";.;
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MVGNHH1^MG6CL[=.D,;_\S@UF37#;9+T&=T\3?MC)-O@"&(@H*$=D8^5*;W]
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MF%[-AG-=IA<.0IXO+KK12W'PD0LEGPY@N"J3#S!S6"GOJ?Q*E-_W?CW5@CE
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M13+1]@Z;BM8;0%1H(]-J,DJ0BJQ\LB^5(9XS(:@F6$.,RH6LE*^882='2FY
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M??27Q%VRTZEQJ:PM^NU]!VT>:E?>KXY/(V0M9 <>GB?2BJ8M+N85+A(@SFM
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M1E<LU"Z YM=*V?V#6Z"YM,U_ E!+ P04    " #.AGQ:_^,GQH($   G"P
M&0   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6R=5M]SXC80?O=?L4.;#ID!
M8PPV3@K,0"YI[^$:)K_NH=,'82^@B6U1289P?WU7LG'('"&9/F!;TNZWN]IO
MEQUNA7Q6*T0-+UF:JU%CI?7ZLM-1\0HSIERQQIQ.%D)F3--2+CMJ+9$E5BE+
M.[[GA9V,\;PQ'MJ]F1P/1:%3GN-,@BJRC,G=%%.Q'36ZC?W&'5^NM-GHC(=K
MML1[U(_KF:15IT9)>(:YXB('B8M18]*]G(9&W@H\<=RJ@V\PD<R%>#:+K\FH
MX1F',,58&P1&KPU>89H:('+CWPJS49LTBH??>_0;&SO%,F<*KT3ZG2=Z-6I$
M#4APP8I4WXGMGUC%$QB\6*3*/F%;RO8'#8@+I456*9,'&<_+-WNI[N% (?+>
M4? K!=_Z71JR7GYAFHV'4FQ!&FE",Q\V5*M-SO'<).5>2SKEI*?']RLF$:84
M5P)7(J-<*V:OJ_G YBFJ\V%'DQDCW(DKR&D)Z;\#V?7AF\CU2L%UGF#R%J!#
M_M5.^GLGI_Y)Q"\8N]#KML#W_/X)O%X==,_B#4X%W2Z#GK$=<4S#1$J6+]%^
M_SV9*RV),/\<B[[$[AW'-D5TJ=8LQE&#JD2AW&!C_-LOW=#[_83G_=KS_BGT
M\3T595*D"&(!=TA.\EA3$/=:Q,\P,0SG>G?,Z9.PQYU^6*&S$"F5+<^7H T=
MJMKE/U!11=;FE37/*O- K0+T"DVV>C!+67X)>[^=4WX[?Q79'*6);;)E,E'P
MW185"4XV**E'P!^4) W$=(0;QB4\L;1 F)'28\ZU<UMHI5F>&(<9R6&,%K'B
M3@\&_0!^A2#H.A:)D,L=/^H[5RR/J3M@TJ$ %LC-:=,<GY- DW3@W'DBW]]L
MDR)M?V"W#VV2;<,) @0U 8)/$^#@!FA5WN7MVE9O%=TQ)IS&-TDW?8#E.Z!8
M.?4]BM=D<V&L;?;6RI0+:TW!LKI,GEO1-4HN*'V62_:@4/9J8)JR^+E-00CJ
M+95Z>TUL,,>92#"%0O.4_Z"U8ZW6!&2*R%?:>^73VVMPWKD&YZ9BY Z9!#1=
MZ4V.')LC0Q#G^F6-EIH;D3+C"?&Y>78.4<_U(0K</IS!X,+U(/+H<?8JKU%F
MT#0&U#D$;D"_$'KT#MW N>/JN;V0B'1#)$@7"])PV"#W73^B1Y_0Z-4-Z=$+
M#I$3*HZ$G(8=QS2Q.D:6?B?X%-9\"C_-IS=7=ZJ9G(3\7\WDD$Z?;B1'_3UH
M(K<5.W_J(M<O*&.NJ'$0\_#G\SLTXXQQ](K^R,P?0<%2>#C,\&2YE+@T.?Q*
M$IR&E+@JQ:8M E$HZ@?JP];0@Z[7&G0'95>"R(U,.VK7[2D(6P//HZW(#:*R
MC1QM5-W6A1=5(*74/LBD:C[E[H>=*@Q:@7=A#';=P(<+=^ ?PMG$^;U6-^@;
M&2)L1#)A:&4>\TW9'_M^JQ>80$R5# Q(^&X#[!P,+QG*I1W1%,2BR'4YQ]2[
M]10X*8>?5_%RA/S&Y))2 2DN2-5S!]3K9#F6E0LMUG84F@M-@Y7]7-$DB]((
MT/E""+U?& /U;#S^#U!+ P04    " #.AGQ:NL^*H/<%  !K$0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S-BYX;6RU6&UOVS80_JY?<?""P@:<6&^VI#0Q
MX"0M&J#=@B3M, S[0$NTS54259**D_WZ'2E943I9=;L-L&6*/-[K<\>CS[9<
M?)8;2A4\9FDNSP<;I8K3R43&&YH1><(+FN/*BHN,*'P5ZXDL!"6)V92E$]>V
M9Y.,L'PP/S-S-V)^QDN5LIS>")!EEA'Q=$%3OCT?.(/=Q"U;;Y2>F,S/"K*F
M=U1]+&X$ODT:+@G+:"X9ST'0U?E@X9Q>!)K>$'QB="M;8]"6+#G_K%^ND_.!
MK16B*8V5YD#PYX%>TC35C%"-+S7/02-2;VR/=]S?&MO1EB61])*GO[)$;<X'
MX0 2NB)EJF[Y]AVM[9EJ?C%/I7G"MJ*=1@.(2ZEX5F]&#3*65[_DL?9#:T-H
M[]G@UAM<HW<ER&AY1129GPF^!:&ID9L>&%/-;E2.Y3HH=TK@*L-]:GZ=QSRC
M<$\>J83A/5FF5([.)@I9:X))7+.YJ-BX>]@X+GS@N=I(>),G-'G)8((Z-8JY
M.\4NW%Z.5S0^ <\9@VN[?@\_KS'4,_R";QH*5TS&*9>EH/#[8BF50&C\T65S
MQ='KYJC3Y506)*;G \P'2<4#'<Q?_>3,[-<]^OJ-OGX?]_D=IE]2IA3X"FK=
MEQ23D,*S)6.XPI%4+ :2)X P11#F79;TRWK/I825X!E@L@NBTT7NI#$CS5(&
M(#@#:D/AB1(A@>I0 P:*9DLJFF 977#@ 9-ULK._D'"I*P ,68XL>"F12HY.
MX<?MM(PP+<AZV]*K0ZT6Y;=-!6/JJ?7Q#H:..PZG4QCA:!Q%-HRL6C8,_7'D
M![CBC/VI?S!;9!2,0]O5+*?>#$8]2)DV2)D>C)0;P1^8*9@Z5,\>[,)$+]=N
M=-]OJ%4T(H9+FM,54R,C[(69AP/EZUF#&J(YI @7V8N7?=9^A0S4&GXSBICB
MU%J]+(6@N;+>T@2CEL(Q'%MWBBAJ1KM8ZW%-V;+23%_1%<6%I.$P=,>^&^GP
MAKZ'>*FX>0BBH7ZT !1YCB9SI_C3\&GS'WICVZ[!Y_O(T[K<D'RM 06?2%H:
ME,%"NXGD,0HQY(;6^AF/\U;%>_.(A[@T5D$/XF8-XF8'(VYG>$O:+9K<!;A>
MIMV NVZJ#SSC+F$K]!8ZRR2<AAG)>(G!0=JB5+K4/ $IBO2)Y6NS_O'D[@16
MM:8M%PL='#3"=1I<6?MMTB5A%[Y+3'">L@2GDQ<@:V%L+WUUVA+5J"01):7B
MXJG2Z$C#*#"Q/]+1M[VH&GKCP/=;(-):X7%FW)$K9A <.?BQ/E"22GA%LN(U
M:J2H4-B@91K!-M+8UILOJ%)6P T5&80^SH6^A4H^("7#)@#S<JE@D?R)+8C9
MYLY"),)G#>E;>GR[@_:Q?EJ_H*<%#(.9KHH!UK<69*^[(>N.[< 'G0D&O-8]
M5VC#017F"*76W^^,B_=OXN([@0F%A]'1L<'&9Y?D][L"K^-V7 ]Z0^7CD8+?
MWF"YX+X,EJ?=W1NJ8X,9/ZQ*AQE8-Z6(-]B]PB*.=:[HS&AM&<[LJ-+:#+X1
M-F?L1"'HRE55FQ\+6U\E"II*%!Q<B9H:JO-U(255TIPP[QE9LI0I1F575>H5
ML/\8U.6#8C1CE(+"%<T*+O!:LZM.Z"<)VPV+-[#&>P<(ALY7'"2"@:U83-#K
MN*/J%)!!LM->,R:U]M@]M(Y"(BLSFP/3VG<X6H>YXS\K:!VR,"EX_!G;H<K"
M(W!#NXX\CJQ[07))JIO9)9>HFQ<99$>>=8M^)@C7.B.NZ -VCH7!Z2QPD B?
M%N)8E#IM'%]/X=,<>G7[A>A.=4OFC(,PU'@-,8_&46#76/VGM[$"N8%7D_K8
MU$VM9^B3!OK#BLQDEJ8<Z4[0-R>[%M\5Q6%:>_QI]+]4K4.<[P6U6"_H</TT
MBO2WRX'3F6L2/72\_:[[NAYT.JXBVG4\STW-=[JMLVI,6A?@C(JUN>9+,)6N
MN@LWL\T_"8OJ OU,7OT-\8&(-4.?I72%6^V3 -MD45WMJQ?%"W.=7G*%EW,S
MW%""YX4FP/45YVKWH@4T_Z_,_P902P,$%     @ SH9\6N*R%+2[!   ^PH
M !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULC5;;;N,V$'W75PS<HD@
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MK[6C;A^&%3VO:+P![9=:N_W$!^@?[-4/4$L#!!0    ( ,Z&?%J:R/(M?P8
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M'_-GG]47-"YY89[PZG_R7)<U!B1<<Y&G=;!L01IGF[_!Y_J#V HP1P<"K#K
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M+,*I1YM5H]JA-WO]2S#HO&]AW*L8]QSZ\ 3C>@'G6J/10$5ZU!1E)\1 #?2
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M9:*&7N#:0-U?,R:?-]I!-4;/_@!02P,$%     @ SH9\6C,R/_X] P  1@P
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M,==?#2C,!#V><JYV#1.@^0Z)_@!02P,$%     @ SH9\6F*^'<Y? @  [ 4
M !D   !X;"]W;W)K<VAE971S+W-H965T-3$N>&ULA51M;YLP$/XK%JNF5MH*
M(2%,&4%:&U6;U&I1TVZ?';@$JP8S^TC:?[^SH2A52?H%_/:\<?B2O=)/I@!
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MY.?KTS"T@@BJ]5!-1S4#U?JH-D U$]4L5!NBFHUJ(U1S4,U%-0_5QJCFHUJ
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MT\7%\>X>6@.!:C:J.:CFHIJ':CZJ!:@F4"U$M0C58E1+4"U%M8S2.D%UU=1
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MEV'<41+>M)+P^>1M[EPSM/Z#Y526TUA.9SF#Y4R6LUC.9CF'Y5R6\UC.9[F
MY03+A2P7L5S,<@G+I2R785PWW4:MXI"1O#CD].,ZY-#@6$,YE>4TEM-9SF Y
MD^4LEK-9SF$YE^4\EO-9+F YP7+A@7M_8Q*=-V:YA.52ELLP[BBP6M4?(^GI
MU[=?I]-U6=PILWUP]6<56_>!<BK+:2RGLYS!<B;+62QGLYS#<B[+>2SGLUS
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M@&HAJD6H%E.:G(9MVZ6O;KM\6&1Y.?M/LK[X>G9[_$Q(M7=R-*+U%5334<U
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MZN]OLVI+M?FA'N QR_]8/YWW_P502P,$%     @ SH9\6JIRHZ_0!@  1D0
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MG3%>%I#?W^>Y>%TI S2O#IG^"U!+ P04    " #.AGQ:&N.T8 8&  !A,P
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M"\0'GAC([]>,B?--TD!^_C3^#U!+ P04    " #.AGQ:$9=X5OT$  !]&P
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MK:E)4.5%"7^VE%,]7![>53%Y+=^-D\,-+3% -1/5+%2S4<U!-1?5/%3S42U
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M_-$+M;5[2DVK?%=.#CBT%@+53%2S4,U&-0?57%3S4,U'M0#50E2+4"VFM';
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M?J@!)N)K!AO1:"-MY8&QG[KS*9DXGE8$!&*I*;#Z6\,4"-%,2L>OBM2IY]3
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MDAW.@4Z ZP#U_Y0Q^7*BWU<4[Z>&_P-02P,$%     @ SH9\6GYL[S^W P
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M2FSO?ONH,]&%@D+^V^5C52;H+F,6]JE<DP3FCEZY$L0&G/CWW_#(^[/+@X'
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MR5@[)JJC;76C^-J>#F^YTF=->[D"DH(P ?K[C'-U?V,*-/]@B/\'4$L#!!0
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M@D;II0]$+AVJ@7R_IE0<;E2"XCAQ]@-02P,$%     @ SH9\6F!UUN.@ P
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M2!. [W="Z,>!^4#;3"_^ 5!+ P04    " #.AGQ:%KQC<U,%   R)@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6S-6EUOXC@4_2L6*ZUFI-TFL8%
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MU7PWN;5*V!K>=$0<@1F5]JM*^V<AX;Y+PAR!&80%OC8%OBL1VY'J,P5U%9=
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M%<>W&Y2V)Y*MBST^,R8E2XK#%<%SPO,&ZOZ"J4^+\B3OH-HF-OH?4$L#!!0
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MQKDL+POE1(MU<;B="VV.RL5P9>Y7**V!>;\00C]-K(/ZQC;Z U!+ P04
M" #.AGQ:UVWPI+\*  "UA   &0   'AL+W=O<FMS:&5E=',O<VAE970W,2YX
M;6R]W6MOVDH>!O"O,F*/5ETI"M@.E_0D2 F^VVU1TNZ^.-H7#@Q@U=CL>$A:
M:3_\CHW!##@#2$_VO#CEXOG-&'CBL?W'W+UE[&>^H)237\LDS>];"\Y7G]OM
M?+*@RRB_SE8T%<_,,K:,N+C+YNU\Q6@T+1LMD[;>Z?3:RRA.6\.[\K$Q&]YE
M:Y[$*1TSDJ^7RXC]?J1)]G;?TEK;!Y[B^8(7#[2'=ZMH3I\I_[$:,W&OO5.F
M\9*F>9REA-'9?>M!^QP:O:)!N<0_8_J6[]TFQ:J\9-G/XHXWO6]UBA'1A$YX
M043BGU<ZHDE22&(<_ZG0UJ[/HN'^[:UNERLO5N8ERNDH2_X53_GBOC5HD2F=
M1>N$/V5O+JU6J%MXDRS)R_^3MVK93HM,UCG/EE5C,8)EG&[^C7Y5+\1> UU[
MIX%>-=#/;6!4#8QS&]Q4#6X.&MR\MP[=JD'WW!YZ58/>80/]G0;]JD'_L,'M
M.PT&58/!N3W<5@UNS^U!ZVS?N<ZY?6B[-_OL=UO;OMU:^7ZW-Q^L\E-I1CP:
MWK'LC;!B>>$5-\J/=ME>?!CCM$CA,V?BV5BTX\,GFD2<3LDX8OPW^<ZB-(_*
M?.3DDTEY%"<Y^1HQ%A5A^0?Y@[1)OH@8S4F<DA]IS/,K\O>_:3WCS^*!+W&2
M%&WOVER,K>BA/:G&X6S&H;\S#HU\R5*^R(F53NFTH;U[HKVN -KB1=F],OKV
ME7G4E>*W";\FFG9%](Y^4ZUTP[A&9RB=VU.*J5;\=7I-])M3BJ56'E9,*'JE
M_'@VR:<_I+?T7=@^ :_GU\38O%3&^XJC5FSZ(H8WJ)1J>$V?!#5CTLEN,/5:
MOCLH[WQ--2A?S3S3U>ZE-TX/*KCDE7(>Q^33)H--(PO5UI?H-^ELUD]O7C\I
M/<;N[XI1LOU+_ZZ0OT*Q*/$X7>;_;ACNX\8UFMUB4O(Y7T43>M\2LXZ<LE?:
M&A8KW_FS*9Q(S$1B%A*SD9B#Q%PDYB$Q'XD%2"P$85)N;W:YO5'IPU&6OE+&
MXY>$DJ\9%QN%<?0[$O>:HJJD+HTJ$C.1F(7$;"3F(#%W@]V46+'S]CH<=(K_
M[MJO^R$\;S$?.;0 B84@3(I7=Q>OKC)>7IZOHW1"238CHVRY%-O#9YY-?A*Q
M/TV2>%+LWJ9SPHI]QZOMM.R_[T\4'C?==??>#4TS!@=OQD@YJ$NSA<0L)&8C
M,0>)N4C,0V(^$@N06 C"I)SV=CGM*7,:9F+"JMKT*9M?NNE#8B82LY"8C<0<
M).;VCOZ*ZDV;OO,6\Y%#"Y!8V#O:=A^L@!26_BXL?658GD3'$9LL2)1.R92^
MTB1;+6G*"?VU$ANTQOPHQ4OS@\1,)&8A,1N).4C,[1]]K@RC/S@.4/\H0+<-
M^4$.+4!B(0B34C;8I6QP8L]L;[KXUQ>Z?*&L\0"*DKDT6DC,1&(6$K.1F(/$
M7"3F(3$?B05(+ 1A4DQO=S&]_: #G[?(W"(Q$XE92,Q&8@X2<Y&8A\1\)!8@
ML1"$2;G5.O69T,[_]]B,NK]+$UUI1WL?\N3);%CLMJ?)"UG0D=D-7?:ZG88]
M(P?:K]O0KZ9WCV>=T%Y]J!9 M1"ER0G:JR70E GZ-IN)F+"\W!$T8T8G/!/W
MMI-5$98QBU_%YI&,$S&*<A]Q[\FS9[CJ85P<+*1F0C4+JME0S8%J+E3SH)H/
MU0*H%J(T.?)Z'7G]@Z:[%8P*,5(SH9H%U6RHYD U%ZIY4,V':@%4"U&:'.*Z
M5D=3EA0,GZ.DG/666]XK\G5=;'G+!S:3W&)F+#(>IU+ E5-?:!4/5#.AFE5I
M\C'-?E^>@MK0/AVHYD(U#ZKY4"V :B%*DT-;%^IHZDJ=@]"*F;78=1V+W):A
M%>FL"SL;$PHMWH%J)E2S*FT@[29>=P\3"BW,@6HN5/.@F@_5 J@6HC0YH76M
MCZ8N]CE(Z"A+\WA*BU)ZL?5\HA,:OQ8S9Q'9O<UJ8U:1=14CJ&9"-:O2I#.)
MFGX856B=#U1SH9H'U7RH%D"U$*7)4:W+?31UO<]C%K%ID=7CHU:-@826_T U
M$ZI94,V&:@Y4<Z&:!]5\J!9 M1"ER<FM:X^T_D<=@(+6($$U$ZI94,V&:@Y4
M<Z&:!]5\J!9 M1"ER2&N2YLT=6V3B.TK3<K31E;**>-1G)9GAZSW*PC5Y,7Q
MA18Z034+JME0S8%J;J7M3_]OF@IQJ^6D,[]-)YQ]Z/ "J!:B-#ES=9V2IBRG
M&(X6,9V)@-')NOAN-ZE.WNZ?D"V_$[K_C;"B++[\6ACQTIRSM70&MS&DT*(F
MJ&9"-0NJV5#-@6HN5/.@F@_5 J@6HC3Y:@9U>9/>^:")L@ZM8X)J)E2SH)H-
MU1RHYD(U#ZKY4"V :B%*DT-<5UCIZ@JKB[Z>K;8NSBVT3 JJ65#-AFI.I9V:
MT[K07CVHYD.UH-*T_>E[Y]J07X\0U:><M+JP25?67 Q-^L+W9KE7XK;8,:4Y
M)T]% :.Y9D4Q\)BR.&NZ7-&CFK\X?-#R)JAF034;JCF5IAG21ZW3/<P>M&X)
MJOE0+8!J(4J3,UK7+>GJNJ6CC.YM'J_(]X7H<Y$EY2G6B7@^FM>G8ZMZB>\L
MGL\I:PPPM(0)JIE0S8)J-E1S*NT@P/IA?J$E3%#-AVH!5 M1FIS?NH1)/W6Q
M(?:ZSLDH6L4\2D@8+^-B#U5U0$DM7IQ*:-D25+.@F@W5'*CF0C4/JOE0+8!J
M(4J3TUN7-^G=CSJ@!*UG@FHF5+.@F@W5'*CF0C4/JOE0+8!J(4J30UP7/NGJ
MPJ?][]Q=;>O]G]<O^83%+R+<+VM>7.9W\P4 5<6_NI^+,PTMB8)J%E2SH9H#
MU5RHYD$U7S^^&)-V=% M@/89HC0YJW6IDZZ^SM*891-*ISF9L6Q9[.MRD=%U
ML0FN9M"-N816.4$U$ZI94,V&:@Y4<Z&:IQ]?E:GQLF;07@.H%J(T.9EU_9*N
MKE^"7SI"W=_%J846-T$U"ZK94,V!:JY^7+1D=#HW@YNFRB4/VK</U0*H%J(T
M.;MU'92NKH.2=V.5QYZ@Q4Q0S81J%E2SH9H#U5RHYD$U'ZH%4"U$:?*/2]3%
M3,9'%3,9T&(FJ&9"-0NJV5#-@6HN5/.@F@_5 J@6HC0YQ'4QDZ$N9MI<9+LH
M^@]IE(L9\>8[L5%Y]G8_X7'S)%G-7QQE:'T35+.@F@W5'*CF&L?54HV_0@'M
MU8=J 50+49H<TKH.RE#707WC"\KVDMF<1&BQ$U0SH9H%U6RHYD UM]*D(KW#
M$.I'83T\: 0=4P#50I0F)VOO%]+4U4LG?V-"W?[B5$$KD*":!=5LJ.9 -1>J
M>5#-KS3IXAL-V]X VFN(TN04UC5(QHG+*#T\/7Y[<DC(I_M??=L^_"PZC"=B
M;OHP9Y2>_+Z;NK.+(PLM3X)J%E2SH9H#U5RHYD$U'ZH%4"U$:7*PZ_(DXZ/*
MDPQH>1)4,Z&:!=5LJ.9 -1>J>5#-AVH!5 M1FASBNCS)4)<G/='+?UI*35X<
M7V@E$E2SH)H-U1RHYAK'OURF-1X6@M880;4 JH4H;1/,=KZ@E)L1CX9W2\KF
M=$23)">3;)WRXK?#]QXEC,Z*JP!\]K16^^CQ!^WS@UX\WJZ9X=TJFM,O$9O'
M8H<WH3-!=J[[XB]+61"QO<.SU7U+:Y&7C/-L6=Y<T&A*6;& >'Z697Q[I^C@
M+6,_RV$/_P=02P,$%     @ SH9\6BH[ZQP4!0  V!4  !D   !X;"]W;W)K
M<VAE971S+W-H965T-S(N>&ULK9AM;]LV$,>_"N$50PNTE4C)EITY!A*GVP*L
M6Y&TW8MA+VCI;!.52(^D["2??M1#)$>BV,3H&UL/Y/%^QR/_)\X/0GY36P"-
M[K*4J_/15NO=F>>I> L95>_%#KAYLQ8RH]K<RHVG=A)H4G;*4H_X_L3+*..C
MQ;Q\]DDNYB+7*>/P22*59QF5]Y>0BL/Y"(\>']RPS587#[S%?$<W< OZR^Z3
M-'=>8R5A&7#%!$<2UN>C"WRV)..B0]GB*X.#.KI&!<I*B&_%S75R/O(+CR"%
M6!<FJ/G;PQ+2M+!D_/BO-CIJQBPZ'E\_6O^UA#<P*ZI@*=*_6:*WYZ/I""6P
MIGFJ;\3A=ZB!2@=CD:KR%QVJMI/)",6YTB*K.QL/,L:K?WI7!^*H Q[J0.H.
MI-LA'.@0U!V"$K3RK,2ZHIHNYE(<D"Q:&VO%11F;LK>A8;R8QELMS5MF^NG%
MK<F+)$\!B37Z2V]!H@]W)D44O$5_FB1Z?06:LE2]0>_0E]LK]/K5&_0*,8X^
M;T6N*$_4W-/&C<*8%]=#7E9#DH$A,4$?!==;A3[P!)*G!CSC?P-!'B$NB=/B
M%<3O48#?(N*3T.+0\OG= X<[01/3H+07#=BKXGC-8Y$!,C%Z#*E"_URLE)8F
M=?^UA:VR&MBM%NOY3.UH#.<CLV 5R#V,%C__A"?^+S;D'V3L20#")@"AR_KB
M!F*QX:Q<IR:OENSAP62865P@)21F]>^!YX#R7?%^5S:#.Y Q4V"+BW,P.PJR
MA:2R$Y9VBNUMO\#AU)][>POJN$$=OP3U*Z3T=%#G4"\ K>R,CT!)%(5VT$D#
M.G&"+K>4;Z!8^FO*)-K3-(>CR:WH;%!.LR^ FO2@,!F:O:B!BDZ"*J=Q&,EI
M] 5(40]I%@T031NBZ4E$!RHEY1JEC*Y8RO2]C6O:SQN"&W\JG_MMIMCN\JQQ
M>7:2R['@>Y":K4QZ<:$![>B]*2"TS?-9WW,?3SNN.]UXUK0]X<-^J[&^D_ W
M4TXAL_836&FS 6C&-SE3VR&8VMH3FC *.C3N,4_ .2H9L!/GFFLP)G4M<58$
MW%^M/0!+F[$]E3!I?2/?\:U4W<_T#MW .N>)U3O2&SG 8=<]YT GQ+<M'[!3
MG!=?N"G(4_9@%,34Z:80Y:82-(+"XWMDJ@>N:%4";TQ:6?&"?OYTX?I-@ME
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M?.:JY;:4C.10",(*Q&$]=S[[]XGO:4$5\1>!HS@Y1GHHKXSM=..W;.YXND=
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MK^Q,>O6G-<U&U_?A,O MANAKQ#CL_[9!_&#_3QC-:J5S-3-Y4ZG:MW&TJ@R
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ SH9\6H*A*4CR    *P(  !$
M             ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MSH9\6IE<G",0!@  G"<  !,              ( !Y $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " #.AGQ:^ ;O>$T*  #'/P  &
M    @($E"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MSH9\6JW,$S5W!@  12   !@              ("!J!(  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,Z&?%J&:42CX@(  '4*   8
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M965T.2YX;6Q02P$"% ,4    " #.AGQ:6B*]E <D  "E;   &0
M    @(%W3P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M ,Z&?%K;13&BM@8   $2   9              " @;5S  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ SH9\6C$9G*PT"0  QQD  !D
M             ("!HGH  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " #.AGQ: 9<GN? "  #;!@  &0              @($-A   >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,Z&?%KBRF7RP 0
M &X+   9              " @32'  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ SH9\6MMJO=SZ!@  *Q$  !D              ("!
M*XP  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #.AGQ:
MSGM #F4,  "B)   &0              @(%<DP  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( ,Z&?%IJINU/" 8  '4/   9
M      " @?B?  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ SH9\6AF[]@K! @  *08  !D              ("!-Z8  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #.AGQ:>FG%;N0,  "$(0
M&0              @($OJ0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( ,Z&?%J;QIAZ;0H  'H:   9              " @4JV  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ SH9\6I#W$<#
M!@  WA$  !D              ("![L   'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " #.AGQ::(0*^/ $  "J"P  &0
M@('EQP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,Z&
M?%KU*X'42 4  .@+   9              " @0S-  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ SH9\6EHY@F:=!0  2@P  !D
M         ("!B](  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " #.AGQ:#I_XP;P'  !S$P  &0              @(%?V   >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,Z&?%KVB9'MY0,  #L)
M   9              " @5+@  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ SH9\6@1[Z_ZL$   *C@  !D              ("!;N0
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #.AGQ:FRM(
M6%H%   Q#0  &0              @(%1]0  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( ,Z&?%H^&0F/0@8  ,<.   9
M  " @>+Z  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MSH9\6L:*DWY7'0  W5P  !D              ("!6P$! 'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " #.AGQ:N2O'-\<#  !3"@  &0
M            @('I'@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( ,Z&?%JY9D3IT08  " 7   9              " @><B 0!X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ SH9\6@_UI??V @
MJ08  !D              ("![RD! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " #.AGQ:>*"> KL#  # "0  &0              @($<
M+0$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,Z&?%K_
MXR?&@@0  "<+   9              " @0XQ 0!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ SH9\6KK/BJ#W!0  :Q$  !D
M     ("!QS4! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,Z&?%J:R/(M?P8  (X?   9              "
M@41+ 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ SH9\
M6BV5X0L="   SUL  !D              ("!^E$! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " #.AGQ:FE%,K%T/  "=Y0  &0
M        @(%.6@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( ,Z&?%HGR*!@ 08  - W   9              " @>)I 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ SH9\6M^\,5.> P  NPP
M !D              ("!&G ! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " #.AGQ:D5+(4%$)   \<   &0              @('O<P$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,Z&?%IJ>&O*
M7 ,  %(/   9              " @7=] 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ SH9\6C,R/_X] P  1@P  !D
M ("!"H$! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #.
MAGQ:\8H9?U\"  #^!0  &0              @(%^A $ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ,Z&?%HJ(2+OXP(  ),(   9
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M970U-"YX;6Q02P$"% ,4    " #.AGQ:Q(DNHC$6  !C>P$ &0
M    @(%ZS@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M ,Z&?%JJ<J.OT 8  $9$   9              " @>+D 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ SH9\6AKCM& &!@  83,  !D
M             ("!Z>L! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    " #.AGQ:KVUSA5<#  #;#0  &0              @($F\@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ,Z&?%KZ3$7E: 0
M (L:   9              " @;3U 0!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ SH9\6A&7>%;]!   ?1L  !D              ("!
M4_H! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #.AGQ:
M<SO\>)D0  ">$ $ &0              @(&'_P$ >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    ( ,Z&?%IFL+56I@(  !,'   9
M      " @5<0 @!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ SH9\6@G69TE1 P  APP  !D              ("!-!," 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #.AGQ:"GX6$QL&  #?(P
M&0              @(&\%@( >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+
M 0(4 Q0    ( ,Z&?%I"0_@\GP0  *L:   9              " @0X= @!X
M;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ SH9\6GYL[S^W
M P  ;!   !D              ("!Y"$" 'AL+W=O<FMS:&5E=',O<VAE970V
M-BYX;6Q02P$"% ,4    " #.AGQ:Y-^P -($  !:'   &0
M@('2)0( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( ,Z&
M?%I@==;CH ,  %@+   9              " @=LJ @!X;"]W;W)K<VAE971S
M+W-H965T-C@N>&UL4$L! A0#%     @ SH9\6A:\8W-3!0  ,B8  !D
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M=#<S+GAM;%!+ 0(4 Q0    ( ,Z&?%ID,91Q]A$  %<7 0 9
M  " @05, @!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @
MSH9\6N_F\YK.!   .AD  !D              ("!,EX" 'AL+W=O<FMS:&5E
M=',O<VAE970W-2YX;6Q02P$"% ,4    " #.AGQ:G!N>$)P,  #7U   &0
M            @($W8P( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4
M Q0    ( ,Z&?%K-9F[A<0,  ,@6   -              "  0IP @!X;"]S
M='EL97,N>&UL4$L! A0#%     @ SH9\6I>*NQS     $P(   L
M     ( !IG," %]R96QS+RYR96QS4$L! A0#%     @ SH9\6I8>JH<D!@
M\3$   \              ( !CW0" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( ,Z&?%IS?'@L40(  /LL   :              "  >!Z @!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,Z&?%K.%<Q?#P(  .HK
M   3              "  6E] @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0  !4 %0  Q<  *E_ @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>374</ContextCount>
  <ElementCount>488</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>126</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Merger and Financing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/MergerAndFinancing</Role>
      <ShortName>Merger and Financing</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Balance Sheet Details ??? Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssets</Role>
      <ShortName>Balance Sheet Details ??? Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Liability Related to the Sale of Future Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenue</Role>
      <ShortName>Liability Related to the Sale of Future Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://conduitpharma.com/role/ConvertibleNotesPayable</Role>
      <ShortName>Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Loans Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/LoansPayable</Role>
      <ShortName>Loans Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Deferred Commission Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/DeferredCommissionPayable</Role>
      <ShortName>Deferred Commission Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Research and Development Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ResearchAndDevelopmentExpense</Role>
      <ShortName>Research and Development Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Share Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ShareBasedCompensation</Role>
      <ShortName>Share Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Common Stock and Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/CommonStockAndPreferredStock</Role>
      <ShortName>Common Stock and Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Earnings/(Net Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/EarningsnetLossPerShare</Role>
      <ShortName>Earnings/(Net Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Other Income (expense), net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/OtherIncomeExpenseNet</Role>
      <ShortName>Other Income (expense), net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Merger and Financing (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/MergerAndFinancingTables</Role>
      <ShortName>Merger and Financing (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/MergerAndFinancing</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/FairValue</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Balance Sheet Details ??? Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssetsTables</Role>
      <ShortName>Balance Sheet Details ??? Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/Leases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Share Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/ShareBasedCompensation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Earnings/(Net Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/EarningsnetLossPerShareTables</Role>
      <ShortName>Earnings/(Net Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/EarningsnetLossPerShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Other Income (expense), net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/OtherIncomeExpenseNetTables</Role>
      <ShortName>Other Income (expense), net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/OtherIncomeExpenseNet</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/Warrants</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/Segments</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Schedule of Common Stock Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails</Role>
      <ShortName>Schedule of Common Stock Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Merger and Financing (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative</Role>
      <ShortName>Merger and Financing (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/MergerAndFinancingTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Schedule of Assets Subject to Measurement at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Assets Subject to Measurement at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails</Role>
      <ShortName>Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Schedule of Fair Value of Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails</Role>
      <ShortName>Schedule of Fair Value of Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Fair Value (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/FairValueDetailsNarrative</Role>
      <ShortName>Fair Value (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/FairValueTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Schedule of Balance Sheet Details (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails</Role>
      <ShortName>Schedule of Balance Sheet Details (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999053 - Disclosure - Schedule of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfLeaseCostDetails</Role>
      <ShortName>Schedule of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999054 - Disclosure - Schedule of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Schedule of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999055 - Disclosure - Schedule of Future Minimum Lease Payments For Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails</Role>
      <ShortName>Schedule of Future Minimum Lease Payments For Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999056 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/LeasesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999057 - Disclosure - Liability Related to the Sale of Future Revenue (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative</Role>
      <ShortName>Liability Related to the Sale of Future Revenue (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenue</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999058 - Disclosure - Convertible Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative</Role>
      <ShortName>Convertible Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/ConvertibleNotesPayable</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999059 - Disclosure - Loans Payable (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/LoansPayableDetailsNarrative</Role>
      <ShortName>Loans Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/LoansPayable</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999060 - Disclosure - Deferred Commission Payable (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative</Role>
      <ShortName>Deferred Commission Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/DeferredCommissionPayable</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999061 - Disclosure - Research and Development Expense (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative</Role>
      <ShortName>Research and Development Expense (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/ResearchAndDevelopmentExpense</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999062 - Disclosure - Schedule of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails</Role>
      <ShortName>Schedule of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999063 - Disclosure - Schedule of Fair Value of Stock Option Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails</Role>
      <ShortName>Schedule of Fair Value of Stock Option Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999064 - Disclosure - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999065 - Disclosure - Share Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative</Role>
      <ShortName>Share Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999066 - Disclosure - Schedule of Income before Income Tax, Domestic and Foreign (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails</Role>
      <ShortName>Schedule of Income before Income Tax, Domestic and Foreign (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999067 - Disclosure - Schedule of Provision for Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails</Role>
      <ShortName>Schedule of Provision for Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999068 - Disclosure - Schedule of Federal Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails</Role>
      <ShortName>Schedule of Federal Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999069 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999070 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999071 - Disclosure - Common Stock and Preferred Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative</Role>
      <ShortName>Common Stock and Preferred Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/CommonStockAndPreferredStock</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>999072 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Schedule of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>999073 - Disclosure - Schedule of Potentially Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>Schedule of Potentially Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>999074 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>999075 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>999076 - Disclosure - Schedule of Other Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails</Role>
      <ShortName>Schedule of Other Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>999077 - Disclosure - Schedule of Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails</Role>
      <ShortName>Schedule of Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>999078 - Disclosure - Warrants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/WarrantsDetailsNarrative</Role>
      <ShortName>Warrants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/WarrantsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>999079 - Disclosure - Schedule of Financial Data for the Company???s Reportable Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails</Role>
      <ShortName>Schedule of Financial Data for the Company???s Reportable Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>999080 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://conduitpharma.com/role/SubsequentEvents</ParentRole>
      <Position>76</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cdt-20241231.xsd</File>
    <File>cdt-20241231_cal.xml</File>
    <File>cdt-20241231_def.xml</File>
    <File>cdt-20241231_lab.xml</File>
    <File>cdt-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="1021">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="44">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>97
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "CDT",
   "nsuri": "http://conduitpharma.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "cdt-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cdt-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cdt-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cdt-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cdt-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    }
   },
   "keyStandard": 369,
   "keyCustom": 119,
   "axisStandard": 29,
   "axisCustom": 0,
   "memberStandard": 44,
   "memberCustom": 70,
   "hidden": {
    "total": 238,
    "http://conduitpharma.com/20241231": 83,
    "http://fasb.org/us-gaap/2024": 152,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 374,
   "entityCount": 1,
   "segmentCount": 126,
   "elementCount": 844,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1021,
    "http://xbrl.sec.gov/dei/2024": 44,
    "http://xbrl.sec.gov/cyd/2024": 5,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://conduitpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://conduitpharma.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://conduitpharma.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit",
     "shortName": "Consolidated Statements of Changes in Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://conduitpharma.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "CDT:GainLossOnChangeInFairValueOfCizzleOption",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "999014 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://conduitpharma.com/role/MergerAndFinancing",
     "longName": "999015 - Disclosure - Merger and Financing",
     "shortName": "Merger and Financing",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://conduitpharma.com/role/FairValue",
     "longName": "999016 - Disclosure - Fair Value",
     "shortName": "Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssets",
     "longName": "999017 - Disclosure - Balance Sheet Details \u2013 Current Assets",
     "shortName": "Balance Sheet Details \u2013 Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://conduitpharma.com/role/Leases",
     "longName": "999018 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenue",
     "longName": "999019 - Disclosure - Liability Related to the Sale of Future Revenue",
     "shortName": "Liability Related to the Sale of Future Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CDT:LiabilityRelatedToTheSaleOfFutureRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CDT:LiabilityRelatedToTheSaleOfFutureRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://conduitpharma.com/role/ConvertibleNotesPayable",
     "longName": "999020 - Disclosure - Convertible Notes Payable",
     "shortName": "Convertible Notes Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CDT:ConvertibleNotesPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CDT:ConvertibleNotesPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://conduitpharma.com/role/LoansPayable",
     "longName": "999021 - Disclosure - Loans Payable",
     "shortName": "Loans Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://conduitpharma.com/role/DeferredCommissionPayable",
     "longName": "999022 - Disclosure - Deferred Commission Payable",
     "shortName": "Deferred Commission Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CDT:DeferredCommissionPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CDT:DeferredCommissionPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://conduitpharma.com/role/ResearchAndDevelopmentExpense",
     "longName": "999023 - Disclosure - Research and Development Expense",
     "shortName": "Research and Development Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CDT:DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CDT:DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://conduitpharma.com/role/ShareBasedCompensation",
     "longName": "999024 - Disclosure - Share Based Compensation",
     "shortName": "Share Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://conduitpharma.com/role/IncomeTaxes",
     "longName": "999025 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://conduitpharma.com/role/CommonStockAndPreferredStock",
     "longName": "999026 - Disclosure - Common Stock and Preferred Stock",
     "shortName": "Common Stock and Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://conduitpharma.com/role/EarningsnetLossPerShare",
     "longName": "999027 - Disclosure - Earnings/(Net Loss) Per Share",
     "shortName": "Earnings/(Net Loss) Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://conduitpharma.com/role/CommitmentsAndContingencies",
     "longName": "999028 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://conduitpharma.com/role/RelatedPartyTransactions",
     "longName": "999029 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://conduitpharma.com/role/OtherIncomeExpenseNet",
     "longName": "999030 - Disclosure - Other Income (expense), net",
     "shortName": "Other Income (expense), net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://conduitpharma.com/role/Warrants",
     "longName": "999031 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CDT:WarrantLiabilityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CDT:WarrantLiabilityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://conduitpharma.com/role/Segments",
     "longName": "999032 - Disclosure - Segments",
     "shortName": "Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://conduitpharma.com/role/SubsequentEvents",
     "longName": "999033 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999034 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://conduitpharma.com/role/MergerAndFinancingTables",
     "longName": "999035 - Disclosure - Merger and Financing (Tables)",
     "shortName": "Merger and Financing (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://conduitpharma.com/role/FairValueTables",
     "longName": "999036 - Disclosure - Fair Value (Tables)",
     "shortName": "Fair Value (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssetsTables",
     "longName": "999037 - Disclosure - Balance Sheet Details \u2013 Current Assets (Tables)",
     "shortName": "Balance Sheet Details \u2013 Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://conduitpharma.com/role/LeasesTables",
     "longName": "999038 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://conduitpharma.com/role/ShareBasedCompensationTables",
     "longName": "999039 - Disclosure - Share Based Compensation (Tables)",
     "shortName": "Share Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://conduitpharma.com/role/IncomeTaxesTables",
     "longName": "999040 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://conduitpharma.com/role/EarningsnetLossPerShareTables",
     "longName": "999041 - Disclosure - Earnings/(Net Loss) Per Share (Tables)",
     "shortName": "Earnings/(Net Loss) Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://conduitpharma.com/role/OtherIncomeExpenseNetTables",
     "longName": "999042 - Disclosure - Other Income (expense), net (Tables)",
     "shortName": "Other Income (expense), net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://conduitpharma.com/role/WarrantsTables",
     "longName": "999043 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CDT:ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "CDT:WarrantLiabilityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CDT:ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "CDT:WarrantLiabilityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://conduitpharma.com/role/SegmentsTables",
     "longName": "999044 - Disclosure - Segments (Tables)",
     "shortName": "Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999045 - Disclosure - Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
     "longName": "999046 - Disclosure - Schedule of Common Stock Outstanding (Details)",
     "shortName": "Schedule of Common Stock Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-10-112024-10-11",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
     "longName": "999047 - Disclosure - Merger and Financing (Details Narrative)",
     "shortName": "Merger and Financing (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails",
     "longName": "999048 - Disclosure - Schedule of Assets Subject to Measurement at Fair Value on Recurring Basis (Details)",
     "shortName": "Schedule of Assets Subject to Measurement at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails",
     "longName": "999049 - Disclosure - Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value (Details)",
     "shortName": "Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember",
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember",
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails",
     "longName": "999050 - Disclosure - Schedule of Fair Value of Assumptions (Details)",
     "shortName": "Schedule of Fair Value of Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-11-22_us-gaap_MeasurementInputSharePriceMember",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-22_us-gaap_MeasurementInputSharePriceMember",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://conduitpharma.com/role/FairValueDetailsNarrative",
     "longName": "999051 - Disclosure - Fair Value (Details Narrative)",
     "shortName": "Fair Value (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2024-11-30",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-12-112024-12-11_custom_PIPEWarrantsMember",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails",
     "longName": "999052 - Disclosure - Schedule of Balance Sheet Details (Details)",
     "shortName": "Schedule of Balance Sheet Details (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://conduitpharma.com/role/ScheduleOfLeaseCostDetails",
     "longName": "999053 - Disclosure - Schedule of Lease Cost (Details)",
     "shortName": "Schedule of Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://conduitpharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails",
     "longName": "999054 - Disclosure - Schedule of Operating Lease Liabilities (Details)",
     "shortName": "Schedule of Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CDT:LesseeOperatingLeaseLiabilityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CDT:LesseeOperatingLeaseLiabilityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails",
     "longName": "999055 - Disclosure - Schedule of Future Minimum Lease Payments For Operating Lease (Details)",
     "shortName": "Schedule of Future Minimum Lease Payments For Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://conduitpharma.com/role/LeasesDetailsNarrative",
     "longName": "999056 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-07",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
     "longName": "999057 - Disclosure - Liability Related to the Sale of Future Revenue (Details Narrative)",
     "shortName": "Liability Related to the Sale of Future Revenue (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2024-10-112024-10-11",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-11-302023-11-30_custom_VelaOptionLiabilityMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "CDT:LiabilityRelatedToTheSaleOfFutureRevenueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
     "longName": "999058 - Disclosure - Convertible Notes Payable (Details Narrative)",
     "shortName": "Convertible Notes Payable (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2024-11-30",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-092024-10-09_custom_ConvertiblePromissoryNotePayableMember",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "CDT:ConvertibleNotesPayableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
     "longName": "999059 - Disclosure - Loans Payable (Details Narrative)",
     "shortName": "Loans Payable (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2022-05-01",
      "name": "us-gaap:LoansPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-092024-10-09",
      "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal",
      "unitRef": "GBP",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative",
     "longName": "999060 - Disclosure - Deferred Commission Payable (Details Narrative)",
     "shortName": "Deferred Commission Payable (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2024-10-112024-10-11",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccruedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "CDT:DeferredCommissionPayableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
     "longName": "999061 - Disclosure - Research and Development Expense (Details Narrative)",
     "shortName": "Research and Development Expense (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_SARBORGServiceAgreementMember",
      "name": "CDT:PaymentToResearchAndDevolpmentAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "CDT:DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails",
     "longName": "999062 - Disclosure - Schedule of Restricted Stock Activity (Details)",
     "shortName": "Schedule of Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails",
     "longName": "999063 - Disclosure - Schedule of Fair Value of Stock Option Granted (Details)",
     "shortName": "Schedule of Fair Value of Stock Option Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2024-04-202024-04-20",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "CDT:WarrantLiabilityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "999064 - Disclosure - Schedule of Stock Option Activity (Details)",
     "shortName": "Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
     "longName": "999065 - Disclosure - Share Based Compensation (Details Narrative)",
     "shortName": "Share Based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails",
     "longName": "999066 - Disclosure - Schedule of Income before Income Tax, Domestic and Foreign (Details)",
     "shortName": "Schedule of Income before Income Tax, Domestic and Foreign (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails",
     "longName": "999067 - Disclosure - Schedule of Provision for Income Tax (Details)",
     "shortName": "Schedule of Provision for Income Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails",
     "longName": "999068 - Disclosure - Schedule of Federal Income Tax Rate (Details)",
     "shortName": "Schedule of Federal Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "999069 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CDT:DeferredTaxAssetsStockOptions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CDT:DeferredTaxAssetsStockOptions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://conduitpharma.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999070 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "CDT:EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "CDT:EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative",
     "longName": "999071 - Disclosure - Common Stock and Preferred Stock (Details Narrative)",
     "shortName": "Common Stock and Preferred Stock (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DividendsCash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "999072 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails",
     "longName": "999073 - Disclosure - Schedule of Potentially Dilutive Securities (Details)",
     "shortName": "Schedule of Potentially Dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999074 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "From2023-08-312023-08-31",
      "name": "us-gaap:LitigationSettlementExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-08-312023-08-31",
      "name": "us-gaap:LitigationSettlementExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999075 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ConvertibleNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-222024-04-22_custom_OfficersAndDirectorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails",
     "longName": "999076 - Disclosure - Schedule of Other Expense, Net (Details)",
     "shortName": "Schedule of Other Expense, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "CDT:RecognitionOfDeferredRevenueUponOptionExercise",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "CDT:RecognitionOfDeferredRevenueUponOptionExercise",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails",
     "longName": "999077 - Disclosure - Schedule of Black-Scholes Option Pricing Model (Details)",
     "shortName": "Schedule of Black-Scholes Option Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "AsOf2024-04-20",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "CDT:WarrantLiabilityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-04-20",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "CDT:WarrantLiabilityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://conduitpharma.com/role/WarrantsDetailsNarrative",
     "longName": "999078 - Disclosure - Warrants (Details Narrative)",
     "shortName": "Warrants (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ProceedsFromIssuanceOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-12-112024-12-11",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "CDT:WarrantLiabilityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails",
     "longName": "999079 - Disclosure - Schedule of Financial Data for the Company\u2019s Reportable Segment (Details)",
     "shortName": "Schedule of Financial Data for the Company\u2019s Reportable Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember",
      "name": "us-gaap:OtherGeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999080 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "From2024-01-242024-01-24",
      "name": "us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-242024-01-24",
      "name": "us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "CDT_AGPConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AGPConvertibleNoteMember",
     "presentation": [
      "http://conduitpharma.com/role/FairValueTables",
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails",
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AGP Convertible Note [Member]",
        "documentation": "AGP Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_AGPTwentyTwentyFourWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AGPTwentyTwentyFourWarrantsMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AGP 2024 Warrants [Member]",
        "documentation": "AGP 2024 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_AGPWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AGPWarrantsMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AGP Warrants [Member]",
        "documentation": "AGP Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_AccountingAndAuditFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AccountingAndAuditFeesMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting And Audit Fees [Member]",
        "documentation": "Accounting And Audit Fees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r794"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "CDT_AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit assumed to APIC as a result of the business combination",
        "documentation": "Accumulated deficit assumed to Apic as result of business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r90",
      "r185",
      "r580",
      "r614",
      "r618"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r17",
      "r24",
      "r486",
      "r489",
      "r550",
      "r609",
      "r610",
      "r940",
      "r941",
      "r942",
      "r956",
      "r957",
      "r958",
      "r960"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r794",
      "r1104"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r956",
      "r957",
      "r958",
      "r960",
      "r1027",
      "r1110"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of financed Directors and Officers insurance",
        "verboseLabel": "Amortization expenses",
        "terseLabel": "Amortization",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "CDT_AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital contribution - related party",
        "documentation": "Capital contribution - related party"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Correction of immaterial error related to franchise tax expense",
        "documentation": "Adjustments to additional paid in capital correction of immaterial error related to franchise tax expense."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduction of excise tax liability associated with the Merger (Note2)",
        "documentation": "Adjustments to additional paid in capital reduction of excise tax liability associated with merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r401"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r44",
      "r114"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r846",
      "r860",
      "r886"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r849",
      "r863",
      "r889"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r839",
      "r850",
      "r864",
      "r881",
      "r890",
      "r894",
      "r902"
     ]
    },
    "CDT_AllianceGlobalPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AllianceGlobalPartnersMember",
     "presentation": [
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alliance Global Partners [Member]",
        "documentation": "Alliance Global Partners [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_AllianceGobalPartnersConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AllianceGobalPartnersConvertibleNoteMember",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alliance Gobal Partners Convertible Note [Member]",
        "documentation": "Alliance Gobal Partners Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_AmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Expense",
        "documentation": "Amortization Expense."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_AmortizationOfDebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AmortizationOfDebtDiscount",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount",
        "documentation": "Amortization of debt discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization of debt discount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r98",
      "r367",
      "r1050"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt issuance costs",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r773",
      "r774",
      "r948",
      "r1050"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "CDT_AnnualInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AnnualInterestRate",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "Annual interest rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "CDT_AprilLockUpAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AprilLockUpAgreementMember",
     "presentation": [
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April Lock Up Agreement [Member]",
        "documentation": "April Lock Up Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_AprilTwentyTwentyFourWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AprilTwentyTwentyFourWarrantsMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 2024 Warrants [Member]",
        "documentation": "April 2024 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ArrangementFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ArrangementFeePercentage",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement fee percentage",
        "documentation": "Arrangement fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative",
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r1023"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r1024",
      "r1025",
      "r1026"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r1023"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r140",
      "r179",
      "r211",
      "r254",
      "r262",
      "r281",
      "r285",
      "r292",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r481",
      "r483",
      "r518",
      "r574",
      "r676",
      "r762",
      "r763",
      "r794",
      "r807",
      "r983",
      "r984",
      "r1059"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r187",
      "r211",
      "r292",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r481",
      "r483",
      "r518",
      "r794",
      "r983",
      "r984",
      "r1059"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498",
      "r786"
     ]
    },
    "CDT_AstraZenecaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AstraZenecaMember",
     "presentation": [
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Astra Zeneca [Member]",
        "documentation": "Astra Zeneca [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r821",
      "r842"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r821",
      "r842"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r821",
      "r842"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "CDT_AugustTwentyTwentyFourNirlandNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "AugustTwentyTwentyFourNirlandNoteMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 2024 Nirland Note [Member]",
        "documentation": "August 2024 Nirland Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "documentation": "Leader of board of directors."
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "CDT_BoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "BoardOfDirectorsMember",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors [Member]",
        "documentation": "Board of Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_BridgeLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "BridgeLoanAgreementMember",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bridge Loan Agreement [Member]",
        "documentation": "Bridge Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r475",
      "r779",
      "r780"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r475",
      "r779",
      "r780"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange of Conduit Pharmaceuticals Limited ordinary shares for Conduit Pharmaceuticals Inc. common stock on the Closing Date, shares",
        "verboseLabel": "Number of shares issued",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "CDT_BusinessAcquisitionNumberOfSharesTransferred": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "BusinessAcquisitionNumberOfSharesTransferred",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares transferred",
        "documentation": "Business acquisition number of shares transferred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r16"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total consideration payable",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r120",
      "r477",
      "r500",
      "r501",
      "r502"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger and Financing",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r476"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r577",
      "r644",
      "r670",
      "r794",
      "r807",
      "r934"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r178",
      "r751"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_CashAndCashEquivalentsNetBankOverdrafts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "CashAndCashEquivalentsNetBankOverdrafts",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents net bank overdrafts",
        "documentation": "Cash and cash equivalents net bank overdrafts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r104",
      "r208"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents before effect of exchange rate changes",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r104"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r104"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r934",
      "r1070"
     ]
    },
    "CDT_CashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "CashPayment",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payable in cash",
        "documentation": "Cash payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, uninsured amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ChangeInFairValueAndIncomeImpactOfOptionLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ChangeInFairValueAndIncomeImpactOfOptionLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0,
       "order": 2.0
      },
      "http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Change in fair value and income impact of option liabilities",
        "documentation": "Change in fair value and income impact of option liabilities.",
        "label": "ChangeInFairValueAndIncomeImpactOfOptionLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ChangeInFairValueOfConvertibleNotePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ChangeInFairValueOfConvertibleNotePayment",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncome",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of convertible note payment",
        "documentation": "Change in fair value of convertible note payment."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ChangeInFairValueOfConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ChangeInFairValueOfConvertibleNotesPayable",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value",
        "documentation": "Change in fair value of convertible notes payable."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ChangeInFairValueOfOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ChangeInFairValueOfOption",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of Cizzle option",
        "documentation": "Change in fair value of option"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ChangeInFairValueOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ChangeInFairValueOfOptions",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncome",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of Vela option",
        "documentation": "Change in fair value of options"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ChangeInFairValueOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ChangeInFairValueOfWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncome",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liability",
        "documentation": "Change in fair value of warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "CDT_ChangesInForeignCurrencyTransactionUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ChangesInForeignCurrencyTransactionUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in reserve for related party uncollectible loan",
        "documentation": "Changes in foreign currency transaction unrealized",
        "label": "ChangesInForeignCurrencyTransactionUnrealized"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "documentation": "Person with designation of chief executive officer."
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]",
        "documentation": "Person with designation of chief financial officer."
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_CizzlePlcAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "CizzlePlcAgreementMember",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cizzle Plc Agreement [Member]",
        "documentation": "Cizzle Plc Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://conduitpharma.com/role/Cover",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r181",
      "r182",
      "r183",
      "r211",
      "r238",
      "r239",
      "r246",
      "r248",
      "r256",
      "r257",
      "r292",
      "r334",
      "r337",
      "r338",
      "r339",
      "r343",
      "r344",
      "r375",
      "r376",
      "r378",
      "r381",
      "r387",
      "r518",
      "r623",
      "r624",
      "r625",
      "r626",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r645",
      "r662",
      "r686",
      "r709",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r921",
      "r949",
      "r961"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative",
      "http://conduitpharma.com/role/FairValueDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants",
        "verboseLabel": "Exercise price",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase common stock",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase share",
        "verboseLabel": "Warrants to purchase common stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued",
        "verboseLabel": "Class of warrant or right outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ClinicalAssetDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ClinicalAssetDevelopmentMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Asset Development [Member]",
        "documentation": "Clinical Asset Development [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "CDT_CommissionsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "CommissionsPayable",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commissions payable",
        "documentation": "Commissions payable"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_CommitmentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "CommitmentFees",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment fees",
        "documentation": "Commitment fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (see note 15)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r130",
      "r576",
      "r661"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r326",
      "r327",
      "r747",
      "r976",
      "r981"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "CDT_CommonStockClosingPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "CommonStockClosingPricePercentage",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock closing price percentage",
        "documentation": "Common stock closing price percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockConversionBasis",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock conversion basis",
        "documentation": "Description of basis for conversion of convertible common stock."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative",
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative",
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r798",
      "r799",
      "r801",
      "r802",
      "r803",
      "r804",
      "r956",
      "r957",
      "r960",
      "r1027",
      "r1102",
      "r1110"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheetsParenthetical",
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Share price per shares",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "CDT_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share",
        "documentation": "Common Stock, par value $0.0001 per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheetsParenthetical",
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r662"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheetsParenthetical",
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheetsParenthetical",
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Total - Conduit Pharmaceuticals Inc. common stock outstanding as a result of Business Combination, PIPE Financing, exchange of Conduit Pharmaceuticals Limited shares for shares of Conduit Pharmaceuticals Inc., issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes, and transaction services agreements, shares",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r84",
      "r662",
      "r682",
      "r1110",
      "r1111"
     ]
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesSubscribedButUnissued",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Subscribed but Unissued",
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_CommonStockSubjectToMandatoryRedemptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSubjectToMandatoryRedemptionMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Subject to Mandatory Redemption [Member]",
        "documentation": "Shares that embody an unconditional obligation requiring the issuer to redeem the securities by transferring the assets at a specified or determinable date (or dates) or upon an event that is certain to occur, that represent equity ownership in a corporation, provide voting rights, entitle the holder to a share of the company's success through dividends and/or capital appreciation and, in the event of liquidation, provide rights to a company's assets only after bondholders, other debt holders, and preferred stockholders have been satisfied."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r18"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value $0.0001; 250,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively, 1,384,801 shares and 738,295 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r579",
      "r794"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income (loss)",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r190",
      "r192",
      "r197",
      "r570",
      "r589",
      "r590"
     ]
    },
    "CDT_ConduitConvertibleNoteHoldersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ConduitConvertibleNoteHoldersMember",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conduit Convertible Note Holders [Member]",
        "documentation": "Conduit Convertible Note Holders [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ConduitShareHoldersandConvertibleNoteHoldersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ConduitShareHoldersandConvertibleNoteHoldersMember",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conduit Share Holders and Convertible Note Holders [Member]",
        "documentation": "Conduit Share Holders and Convertible Note Holders [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r153",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r216",
      "r254",
      "r264",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r762",
      "r763",
      "r930",
      "r931",
      "r983",
      "r984"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r153",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r216",
      "r254",
      "r264",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r762",
      "r763",
      "r930",
      "r931",
      "r983",
      "r984"
     ]
    },
    "CDT_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreement [Member]",
        "documentation": "Consulting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of deferred commission payable to convertible promissory note",
        "documentation": "Conversion of deferred commission payable to convertible promissory note."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible debt",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r129",
      "r1068"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance as of December 31, 2023",
        "periodEndLabel": "Balance as of December 31, 2024",
        "verboseLabel": "Fair value of convertible note",
        "label": "Convertible Debt, Fair Value Disclosures",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1040"
     ]
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets",
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible promissory note payable",
        "verboseLabel": "Convertible promissory notes payable",
        "terseLabel": "Convertible Notes Payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r129",
      "r1068"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails",
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r127"
     ]
    },
    "CDT_ConvertibleNotesPayableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ConvertibleNotesPayableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible Notes Payable",
        "documentation": "Convertible Notes Payable [Text Block]",
        "label": "Convertible Notes Payable [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ConvertiblePromissoryNoteMember",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note [Member]",
        "documentation": "Convertible Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ConvertiblePromissoryNotePayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ConvertiblePromissoryNotePayableMember",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note Payable [Member]",
        "documentation": "Convertible Promissory Note Payable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ConvertiblePromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ConvertiblePromissoryNotesMember",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes [Member]",
        "documentation": "Convertible Promissory Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ConvertiblePromissoryNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ConvertiblePromissoryNotesPayableMember",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes Payable [Member]",
        "documentation": "Convertible Promissory Notes Payable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_CorporateBondYieldEstimatedTimingOfConversionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "CorporateBondYieldEstimatedTimingOfConversionMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Bond Yield Estimated Timing Of Conversion [Member]",
        "documentation": "Corporate Bond Yield Estimated Timing Of Conversion [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Correction of immaterial error related to franchise tax expense",
        "documentation": "Correction of immaterial error related to franchise tax expense.",
        "label": "CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_CorvusCapitalLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "CorvusCapitalLimitedMember",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corvus Capital Limited [Member]",
        "documentation": "Corvus Capital Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r952",
      "r1022"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r952"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current income tax",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r952"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r952",
      "r1022"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r912"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r912"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r914"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r914"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r824",
      "r907"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r908"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r908"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r906"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r826",
      "r909"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r911"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r911"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r912"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r913"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r910"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion option",
        "verboseLabel": "Debt conversion amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r34"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion shares",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r34"
     ]
    },
    "us-gaap_DebtDefaultLongtermDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDefaultLongtermDebtAmount",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining allocated to common stock",
        "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r209",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r332",
      "r333",
      "r345",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r361",
      "r368",
      "r369",
      "r370",
      "r528"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/FairValueTables",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r72",
      "r73",
      "r127",
      "r129",
      "r216",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r792",
      "r950",
      "r977",
      "r978",
      "r979",
      "r1049",
      "r1051"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying value",
        "verboseLabel": "Debt instrument carrying value",
        "terseLabel": "Remaining outstanding",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r129",
      "r371"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Conversion of convertible note",
        "label": "Debt Instrument, Convertible, Beneficial Conversion Feature",
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r348"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleLiquidationPreferenceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleLiquidationPreferenceValue",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Par value",
        "documentation": "Amount of excess of preference in liquidation over convertible debt instrument's if-converted par or stated value of share."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative",
      "http://conduitpharma.com/role/FairValueDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount",
        "verboseLabel": "Debt instrument face amount",
        "terseLabel": "Convertible principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r528",
      "r529",
      "r771",
      "r772",
      "r792"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of convertible note",
        "verboseLabel": "Debt instrument fair value",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r517",
      "r771",
      "r772",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1040"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument allocated",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accured interest",
        "verboseLabel": "Accrued interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r364",
      "r1049"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes interest per annum",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r372",
      "r528",
      "r529",
      "r792"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion percentage",
        "verboseLabel": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r347"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r770",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDateDescription",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument maturity description",
        "verboseLabel": "Debt Instrument, Maturity Date, Description",
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMeasurementInput",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement input",
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/FairValueTables",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r216",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r792",
      "r950",
      "r977",
      "r978",
      "r979",
      "r1049",
      "r1051"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment terms for loan payment",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Measurement input",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total debt discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r986",
      "r1048",
      "r1049",
      "r1051"
     ]
    },
    "CDT_DebtIssuedUponExecution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DebtIssuedUponExecution",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt issued upon execution",
        "documentation": "Debt issuance upon execution."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesTradingGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesTradingGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of convertible promissory notes",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "CDT_DeferredCashPaymentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DeferredCashPaymentsAmount",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash payments due",
        "documentation": "Deferred cash payments amount."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_DeferredCommissionPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DeferredCommissionPayable",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred commission payable",
        "documentation": "Deferred commission payable",
        "label": "DeferredCommissionPayable"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_DeferredCommissionPayableAnnualInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DeferredCommissionPayableAnnualInterestRate",
     "presentation": [
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual interest rate",
        "documentation": "Deferred commission payable annual interest rate."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_DeferredCommissionPayableNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DeferredCommissionPayableNonCurrent",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred commissions payable, non-current liability",
        "documentation": "Deferred commission payable non current."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_DeferredCommissionPayableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DeferredCommissionPayableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/DeferredCommissionPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred Commission Payable",
        "documentation": "Deferred Commission Payable [Text Block]",
        "label": "Deferred Commission Payable [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationLiabilityClassifiedNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred commission payable",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r1021"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income tax",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r150",
      "r952"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax asset",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_DeferredTaxAssetsHedgingTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsHedgingTransactions",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from hedging transactions."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research &amp; Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets (liability)",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "CDT_DeferredTaxAssetsStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DeferredTaxAssetsStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options",
        "documentation": "Deferred tax assets stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred tax assets valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "CDT_DeferredUnderwritingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DeferredUnderwritingCosts",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Underwriting Costs",
        "documentation": "Deferred underwriting costs."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_DeferredUnderwritingFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DeferredUnderwritingFee",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred underwriting fee",
        "documentation": "Deferred underwriting fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets",
      "http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DemandDepositAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DemandDepositAccounts",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Demand deposit accounts",
        "documentation": "The amount of money in accounts that may bear interest and that the depositor is entitled to withdraw at any time without prior notice."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_DepositAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositAssets",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposit assets",
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "CDT_DepositInsuranceLimit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DepositInsuranceLimit",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposit insurance limit",
        "documentation": "Deposit insurance limit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r43"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails",
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r653",
      "r667",
      "r668",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679",
      "r680",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r704",
      "r705",
      "r706",
      "r726",
      "r727",
      "r728",
      "r729",
      "r797",
      "r799",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails",
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r123",
      "r650",
      "r653",
      "r667",
      "r668",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679",
      "r680",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r704",
      "r705",
      "r706",
      "r726",
      "r727",
      "r728",
      "r729",
      "r754",
      "r797",
      "r799",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative warrant liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "CDT_DescriptionForEmergingGrowthCompany": {
     "xbrltype": "stringItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DescriptionForEmergingGrowthCompany",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging growth description",
        "documentation": "Description for emerging growth company"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r969",
      "r1103"
     ]
    },
    "CDT_DisclosureConvertibleNotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DisclosureConvertibleNotesPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_DisclosureDeferredCommissionPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DisclosureDeferredCommissionPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Commission Payable"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Lease Cost",
        "terseLabel": "Schedule Of Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_DisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DisclosureLiabilityRelatedToSaleOfFutureRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Related To Sale Of Future Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r403",
      "r430",
      "r431",
      "r432",
      "r782"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "documentation": "Disclosure Of Research And Development License Agreement [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_DisclosureResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DisclosureResearchAndDevelopmentExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_DisclosureWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "DisclosureWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsCash",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Cash",
        "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r114"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r819",
      "r821",
      "r842"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r819",
      "r821",
      "r842",
      "r882"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://conduitpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic earnings/(net loss) per share",
        "verboseLabel": "Net income (loss) per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r229",
      "r235",
      "r238",
      "r246",
      "r247",
      "r248",
      "r253",
      "r473",
      "r479",
      "r494",
      "r495",
      "r571",
      "r591",
      "r755"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted earnings/(net loss) per share",
        "verboseLabel": "Net income (loss) per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r229",
      "r238",
      "r246",
      "r247",
      "r248",
      "r253",
      "r473",
      "r479",
      "r494",
      "r495",
      "r571",
      "r591",
      "r755"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings/(Net Loss) per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r250"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/EarningsnetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings/(Net Loss) Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r249",
      "r251",
      "r252"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r441",
      "r464",
      "r784"
     ]
    },
    "CDT_EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate",
     "presentation": [
      "http://conduitpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective income tax rate reconciliation future income years tax rate",
        "documentation": "Effective income tax rate reconciliation future income years tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://conduitpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442",
      "r784"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://conduitpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442",
      "r784"
     ]
    },
    "CDT_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company Status",
        "documentation": "Emerging Growth Company Status [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost related to non-vested option",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative",
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative",
      "http://conduitpharma.com/role/FairValueDetailsNarrative",
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r171",
      "r194",
      "r195",
      "r196",
      "r217",
      "r218",
      "r219",
      "r221",
      "r227",
      "r230",
      "r232",
      "r255",
      "r293",
      "r296",
      "r314",
      "r389",
      "r462",
      "r463",
      "r470",
      "r471",
      "r472",
      "r474",
      "r478",
      "r479",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r531",
      "r534",
      "r550",
      "r588",
      "r609",
      "r610",
      "r611",
      "r633",
      "r709"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r846",
      "r860",
      "r886"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r843",
      "r857",
      "r883"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/FairValueDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on change in FV of the warrants",
        "verboseLabel": "Change in fair value of warrant liability",
        "terseLabel": "Fair value adjustment of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r11"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://conduitpharma.com/role/FairValueTables",
      "http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails",
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498",
      "r510",
      "r786"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://conduitpharma.com/role/FairValueTables",
      "http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails",
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498",
      "r510",
      "r786"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501",
      "r502",
      "r788"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501",
      "r502",
      "r788"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of Assumptions",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assets Subject to Measurement at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1029",
      "r1030"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://conduitpharma.com/role/FairValueTables",
      "http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails",
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails",
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r496",
      "r498",
      "r500",
      "r501",
      "r502",
      "r509",
      "r510",
      "r512",
      "r562",
      "r563",
      "r564",
      "r771",
      "r772",
      "r776",
      "r777",
      "r778",
      "r786",
      "r788"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498",
      "r500",
      "r502",
      "r786",
      "r1032",
      "r1043"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r506",
      "r507",
      "r509",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r569",
      "r786",
      "r789"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r391",
      "r396",
      "r498",
      "r510",
      "r562",
      "r776",
      "r777",
      "r778",
      "r786"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r391",
      "r396",
      "r498",
      "r500",
      "r510",
      "r563",
      "r771",
      "r772",
      "r776",
      "r777",
      "r778",
      "r786"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://conduitpharma.com/role/FairValueTables",
      "http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails",
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails",
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r498",
      "r500",
      "r501",
      "r502",
      "r510",
      "r564",
      "r771",
      "r772",
      "r776",
      "r777",
      "r778",
      "r786",
      "r788"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value",
        "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498",
      "r500",
      "r502",
      "r786",
      "r1032",
      "r1043"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://conduitpharma.com/role/FairValueTables",
      "http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails",
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails",
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r496",
      "r498",
      "r500",
      "r501",
      "r502",
      "r509",
      "r510",
      "r512",
      "r562",
      "r563",
      "r564",
      "r771",
      "r772",
      "r776",
      "r777",
      "r778",
      "r786",
      "r788"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1043"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_FairValueTransferPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueTransferPolicyPolicyTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Option",
        "documentation": "Disclosure of accounting policy for determining when transfers between levels are recognized."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "CDT_FirstAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "FirstAmendmentMember",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Amendment [Member]",
        "documentation": "First Amendment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_FirstAmendmentNirlandNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "FirstAmendmentNirlandNoteMember",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Amendment Nirland Note [Member]",
        "documentation": "First Amendment Nirland Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://conduitpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncome",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized foreign currency transaction gain",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r684",
      "r805",
      "r1045",
      "r1046",
      "r1108"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossUnrealizedAfterTax",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized foreign exchange gain",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, after Tax",
        "documentation": "Amount, after tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r746",
      "r806",
      "r1106",
      "r1109"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r864",
      "r890"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r864",
      "r890"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r864",
      "r890"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r864",
      "r890"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r864",
      "r890"
     ]
    },
    "CDT_GainLossOnChangeInFairValueOfCizzleOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "GainLossOnChangeInFairValueOfCizzleOption",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on change in fair value of Cizzle option",
        "documentation": "Gain loss on change in fair value of Cizzle option.",
        "label": "GainLossOnChangeInFairValueOfCizzleOption"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss from issuance of warrants",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r99",
      "r920"
     ]
    },
    "CDT_GainOnChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "GainOnChangeInFairValue",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on change in fair value",
        "documentation": "Gain on change in fair value"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_GainOnChangeInFairValueOfConvertibleNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "GainOnChangeInFairValueOfConvertibleNote",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on change in fair value of convertible note",
        "documentation": "Gain on change in fair value of convertible note"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_GainOnChangeInFairValueOfVelaOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "GainOnChangeInFairValueOfVelaOption",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on change in fair value of Vela option",
        "documentation": "Gain on change in fair value of Vela option.",
        "label": "GainOnChangeInFairValueOfVelaOption"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_GainOnDebtExtinguishment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "GainOnDebtExtinguishment",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncome",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gain on debt extinguishment",
        "documentation": "Gain on debt extinguishment.",
        "label": "GainOnDebtExtinguishment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on debt extinguishment, net",
        "label": "Gain on debt extinguishment",
        "verboseLabel": "Loss on debt extinguishment",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r45",
      "r46"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "verboseLabel": "General and Administrative Expense",
        "terseLabel": "Total compensation",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r689"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r821",
      "r842"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r440"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r135",
      "r139",
      "r572",
      "r586",
      "r757",
      "r762",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss from operations before income taxes:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r440"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r322",
      "r323",
      "r503",
      "r505",
      "r511",
      "r606",
      "r608",
      "r694",
      "r750",
      "r787",
      "r1073"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r503",
      "r505",
      "r511",
      "r606",
      "r608",
      "r694",
      "r750",
      "r787",
      "r1073"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://conduitpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r441",
      "r442",
      "r450",
      "r457",
      "r784",
      "r1018"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://conduitpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r441",
      "r442",
      "r450",
      "r457",
      "r784",
      "r1018"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r436",
      "r441",
      "r447",
      "r448",
      "r449",
      "r451",
      "r456",
      "r465",
      "r467",
      "r468",
      "r469",
      "r628",
      "r784"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails",
      "http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Tax Expense",
        "totalLabel": "Total provision (benefit) for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r151",
      "r231",
      "r232",
      "r254",
      "r270",
      "r285",
      "r439",
      "r441",
      "r466",
      "r593",
      "r784"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Valuation Allowance",
        "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r437",
      "r438",
      "r451",
      "r452",
      "r455",
      "r459",
      "r622"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Valuation Allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r784",
      "r1015"
     ]
    },
    "CDT_IncomeTaxReconciliationConvertibleDebtAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "IncomeTaxReconciliationConvertibleDebtAdjustment",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt Adjustment",
        "documentation": "Income tax reconciliation convertible debt adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Rate Differential",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r445",
      "r784",
      "r1015"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes at federal statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r784"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Meals &amp; Entertainment",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense."
       }
      }
     },
     "auth_ref": [
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eq Comp Perm",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r1015",
      "r1016"
     ]
    },
    "CDT_IncomeTaxReconciliationPurchaseAccountingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "IncomeTaxReconciliationPurchaseAccountingAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Accounting Adjustment",
        "documentation": "Income tax reconciliation purchase accounting adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State Taxes",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r784",
      "r1015"
     ]
    },
    "CDT_IncomeTaxReconciliationStateReRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "IncomeTaxReconciliationStateReRate",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State Re-Rate",
        "documentation": "Income tax reconciliation state re rate."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_IncomeTaxRefund": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "IncomeTaxRefund",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncome",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Refund",
        "documentation": "Income tax refund."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "CDT_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued expenses and other current liabilities",
        "documentation": "Increase decrease in accrued expenses and other current liabilities.",
        "label": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInIntangibleAssetsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets",
        "label": "Increase (Decrease) in Intangible Assets, Current",
        "documentation": "The increase (decrease) during the reporting period in intangible assets (for example patents and licenses)."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r923",
      "r947"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r864",
      "r881",
      "r890",
      "r894",
      "r902"
     ]
    },
    "CDT_InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial value of warrant liabilities issued in connection with PIPE Financing",
        "documentation": "Initial value of warrant liabilities issued in connection with pipe financing."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r905"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r905"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r905"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r262",
      "r266",
      "r272",
      "r285",
      "r527",
      "r762",
      "r763"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense debt",
        "verboseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r365",
      "r373",
      "r773",
      "r774"
     ]
    },
    "us-gaap_InterestExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest expense",
        "label": "Interest Expense, Other",
        "documentation": "Amount of interest expense classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense, net",
        "verboseLabel": "Interest expense",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r943",
      "r964"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncome",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r205",
      "r206"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r98"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r647",
      "r648",
      "r649",
      "r651",
      "r717",
      "r719",
      "r721",
      "r724",
      "r725",
      "r730",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r799"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r647",
      "r648",
      "r649",
      "r651",
      "r717",
      "r719",
      "r721",
      "r724",
      "r725",
      "r730",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r799"
     ]
    },
    "CDT_IssuanceOfCommonStockForLicensingRight": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "IssuanceOfCommonStockForLicensingRight",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Common Stock for licensing right",
        "documentation": "Issuance of common stock for licensing right.",
        "label": "IssuanceOfCommonStockForLicensingRight"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_IssuanceOfCommonStockInExchangeForDebtExtension": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "IssuanceOfCommonStockInExchangeForDebtExtension",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock in exchange for debt extension",
        "documentation": "Issuance of common stock in exchange for debt extension."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC upon exercise of option",
        "documentation": "Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for services",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r793"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "CDT_LegalAndProfessionalFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "LegalAndProfessionalFeesMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal And Professional Fees [Member]",
        "documentation": "Legal And Professional Fees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Lease Payments For Operating Lease",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "CDT_LesseeOperatingLeaseLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "LesseeOperatingLeaseLiabilityTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Lease Liabilities",
        "documentation": "Lessee Operating Lease Liability [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r72",
      "r73",
      "r74",
      "r78",
      "r79",
      "r80",
      "r81",
      "r211",
      "r292",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r482",
      "r483",
      "r484",
      "r518",
      "r660",
      "r756",
      "r807",
      "r983",
      "r1059",
      "r1060"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r131",
      "r582",
      "r794",
      "r951",
      "r971",
      "r1044"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r177",
      "r211",
      "r292",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r482",
      "r483",
      "r484",
      "r518",
      "r794",
      "r983",
      "r1059",
      "r1060"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Liabilities",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r1029"
     ]
    },
    "CDT_LiabilityRelatedToTheSaleOfFutureRevenueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "LiabilityRelatedToTheSaleOfFutureRevenueTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Related to the Sale of Future Revenue",
        "documentation": "Liability Related To The Sale Of Future Revenue [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settelment expense",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "CDT_LoanAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "LoanAgreementsMember",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreements [Member]",
        "documentation": "Loan Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_LoanHoldersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "LoanHoldersMember",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Holders [Member]",
        "documentation": "Loan Holders [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_LoansAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "LoansAmendmentMember",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Amendment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansAndLeasesReceivableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansAndLeasesReceivableRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans and Leases Receivable, Related Parties",
        "documentation": "For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r134"
     ]
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loans Payable",
        "label": "Loans Payable [Default Label]",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r129",
      "r1068"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualProvision",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued estimated liability",
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges."
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "CDT_LossOnChangeInFairValueOfConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "LossOnChangeInFairValueOfConvertibleNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss (gain) on change in fair value of convertible notes payable",
        "documentation": "Loss on change in fair value of convertible notes payable."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_LossOnDebtExtinguishment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "LossOnDebtExtinguishment",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on Debt Extinguishment",
        "documentation": "Loss on debt extinguishment."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_LossOnIssuanceOfOptionOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "LossOnIssuanceOfOptionOne",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss on issuance of Vela option",
        "documentation": "Loss on issuance of option one.",
        "label": "LossOnIssuanceOfOptionOne"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_LossOnIssuanceOfVelaOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "LossOnIssuanceOfVelaOption",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on issuance of Vela option",
        "documentation": "Loss on issuance of Vela option."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_LossOnIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "LossOnIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingExpense",
       "weight": 1.0,
       "order": 5.0
      },
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails",
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on issuance of warrants",
        "documentation": "Loss on issuance of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_LossOnRelatedPartyLoanForgiveness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "LossOnRelatedPartyLoanForgiveness",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on related party loan forgiveness",
        "documentation": "Loss on related party loan forgiveness."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_MarchLockUpAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "MarchLockUpAgreementMember",
     "presentation": [
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March Lock Up Agreement [Member]",
        "documentation": "March Lock Up Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_MarchTwentyTwentyFourWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "MarchTwentyTwentyFourWarrantsMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 2024 Warrants [Member]",
        "documentation": "March 2024 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r855"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r856"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r856"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r856"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r856"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r169",
      "r170",
      "r328",
      "r329",
      "r330",
      "r331",
      "r398",
      "r433",
      "r502",
      "r567",
      "r605",
      "r607",
      "r619",
      "r652",
      "r653",
      "r718",
      "r720",
      "r722",
      "r723",
      "r731",
      "r748",
      "r749",
      "r767",
      "r775",
      "r781",
      "r788",
      "r789",
      "r790",
      "r791",
      "r795",
      "r985",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_MeasurementInputCreditSpreadMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputCreditSpreadMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Credit Spread [Member]",
        "documentation": "Measurement input using amount above (below) yield between two debt instruments similar in maturity, but different in credit quality."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "CDT_MeasurementInputProbabilityOfDefaultMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "MeasurementInputProbabilityOfDefaultMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Probability Of Default [Member]",
        "documentation": "Measurement Input Probability Of Default [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_MeasurementInputRecoveryUponDefaultMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "MeasurementInputRecoveryUponDefaultMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Recovery Upon Default [Member]",
        "documentation": "Measurement Input Recovery Upon Default [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501",
      "r502",
      "r788"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfFairValueOfAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501",
      "r502",
      "r788"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r169",
      "r170",
      "r328",
      "r329",
      "r330",
      "r331",
      "r398",
      "r433",
      "r502",
      "r567",
      "r605",
      "r607",
      "r619",
      "r652",
      "r653",
      "r718",
      "r720",
      "r722",
      "r723",
      "r731",
      "r748",
      "r749",
      "r767",
      "r775",
      "r781",
      "r788",
      "r789",
      "r790",
      "r795",
      "r985",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "CDT_MrHeilbronMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "MrHeilbronMember",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr. Heilbron [Member]",
        "documentation": "Mr Heilbron [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "CDT_MurphyCanyonAcquisitionCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "MurphyCanyonAcquisitionCorpMember",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Murphy Canyon Acquisition Corp [Member]",
        "documentation": "Murphy Canyon Acquisition Corp [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows from operating activities",
        "negatedLabel": "Operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r107"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows",
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r107",
      "r136",
      "r175",
      "r189",
      "r191",
      "r196",
      "r211",
      "r220",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r231",
      "r232",
      "r244",
      "r292",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r473",
      "r479",
      "r495",
      "r518",
      "r587",
      "r685",
      "r707",
      "r708",
      "r805",
      "r983"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income (loss) - basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r222",
      "r223",
      "r225",
      "r226",
      "r235",
      "r236",
      "r245",
      "r248",
      "r479"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) - diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r248"
     ]
    },
    "CDT_NetProceedsReceivedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "NetProceedsReceivedPercentage",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds received, percentage",
        "documentation": "Net proceeds received percentage."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Standards Not Yet Adopted",
        "documentation": "New Accounting Pronouncements Not Yet Adopted [Policy Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_NewLicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "NewLicensesMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Licenses [Member]",
        "documentation": "New Licenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_NirlandLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "NirlandLimitedMember",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nirland Limited [Member]",
        "documentation": "Nirland Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_NonEmployeeDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "NonEmployeeDirectorsMember",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-employee Directors [Member]",
        "documentation": "Non Employee Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "CDT_NonRefundableOptionFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "NonRefundableOptionFee",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non refundable option fee",
        "documentation": "Non refundable option fee."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "CDT_NoncashAssetsAssumedInMergerFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "NoncashAssetsAssumedInMergerFinancing",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Assets Assumed in the Merger Financing",
        "documentation": "Noncash assets assumed in merger financing."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_NoncashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "NoncashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash interest expense",
        "documentation": "Non-cash interest expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_NoncashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "NoncashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense",
        "documentation": "Noncash lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_NoncashLiabilitiesAssumedInMergerFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "NoncashLiabilitiesAssumedInMergerFinancing",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Liabilities Assumed in the Merger Financing",
        "documentation": "Noncash liabilities assumed in merger financing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business acquisition right to receive number of shares",
        "documentation": "The number of shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "CDT_NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-cash reduction of deferred income upon exercise of option liability",
        "documentation": "Non-cash reduction of deferred income upon exercise of option liability.",
        "label": "NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails",
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other (expense) income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expenses):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets",
      "http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r954"
     ]
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes payable",
        "label": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r129",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payable at fair value",
        "documentation": "Fair value portion of notes payable."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r72",
      "r73",
      "r1030",
      "r1040"
     ]
    },
    "us-gaap_NotesReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesReduction",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange of Conduit Pharmaceuticals Limited convertible notes for shares of Conduit Pharmaceuticals Inc. common stock in connection with the Merger",
        "documentation": "The value of notes retired (or transferred to another entity) in noncash investing or financing transactions."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "CDT_OctoberTwentyTwentyFourNirlandNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "OctoberTwentyTwentyFourNirlandNoteMember",
     "presentation": [
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 2024 Nirland Note [Member]",
        "documentation": "October 2024 Nirland Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_OctoberTwoThousandTwentyFourNirlandNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "OctoberTwoThousandTwentyFourNirlandNoteMember",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October Two Thousand Twenty Four Nirland Note [Member]",
        "documentation": "October Two Thousand Twenty Four Nirland Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_OfficersAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "OfficersAndDirectorsMember",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officers and Directors [Member]",
        "documentation": "Officers and Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_OldConduitPharmaceuticalsLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "OldConduitPharmaceuticalsLimitedMember",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Old Conduit Pharmaceuticals Limited [Member]",
        "documentation": "Old Conduit Pharmaceuticals Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating costs and expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails",
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "negatedLabel": "Net loss",
        "label": "Loss from segment operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r757",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r793"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets",
      "http://conduitpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, current portion",
        "verboseLabel": "Short term lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets",
      "http://conduitpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, non-current portion",
        "verboseLabel": "Short term lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r543"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets",
      "http://conduitpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets. net",
        "verboseLabel": "Right of use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r793"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average remaining lease term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r793"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating loss",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r286",
      "r762",
      "r763"
     ]
    },
    "CDT_OptionAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "OptionAgreementDescription",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option agreement description",
        "documentation": "Option agreement description."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_OptionFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "OptionFee",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option fee",
        "documentation": "Option fee."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_OptionLiabilityConversionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "OptionLiabilityConversionShares",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Add: Option liability conversion shares",
        "documentation": "Option liability conversion shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r17",
      "r122"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r588"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_OtherExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "OtherExpense",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expense",
        "documentation": "Other expense."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_OtherExpenseChangeInFairValueOfConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "OtherExpenseChangeInFairValueOfConvertibleNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Realized foreign currency transaction loss",
        "documentation": "Other expense change in fair value of convertible notes payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses \u2013 other",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r1107"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncome",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r687",
      "r732",
      "r733",
      "r734"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_OtherIncomeUnrealizedForeignCurrencyTransactionLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "OtherIncomeUnrealizedForeignCurrencyTransactionLoss",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of convertible notes payable",
        "documentation": "Other income unrealized foreign currency transaction loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income:",
        "label": "Other Nonoperating Income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/OtherIncomeExpenseNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (expense), net",
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_OtherNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible promissory notes payable at fair value",
        "documentation": "Amount of long-term notes payable classified as other."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r129",
      "r1068"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r671",
      "r763",
      "r1071"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r848",
      "r862",
      "r888"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r851",
      "r865",
      "r891"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r851",
      "r865",
      "r891"
     ]
    },
    "CDT_PIPEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "PIPEMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PIPE [Member]",
        "documentation": "PIPE [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_PIPEWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "PIPEWarrantsMember",
     "presentation": [
      "http://conduitpharma.com/role/FairValueDetailsNarrative",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PIPE Warrants [Member]",
        "documentation": "PIPE Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r869"
     ]
    },
    "CDT_PaymentForAdvisoryServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "PaymentForAdvisoryServices",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial advisory fee",
        "documentation": "Payment for advisory services."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_PaymentOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "PaymentOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment to common stock",
        "documentation": "Payment of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_PaymentToResearchAndDevolpmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "PaymentToResearchAndDevolpmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash payment",
        "documentation": "Payment to research and devolpment amount.",
        "label": "PaymentToResearchAndDevolpmentAmount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred payment fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value at Issuance",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Productive Assets",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r1024",
      "r1025",
      "r1026"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of short-term investments",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToFundLongtermLoansToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance of loan - related party",
        "label": "Payments to Fund Long-Term Loans to Related Parties",
        "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates."
       }
      }
     },
     "auth_ref": [
      "r944",
      "r1056"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "CDT_PenaltyPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "PenaltyPayment",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Penalty payment",
        "documentation": "Penalty payment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "CDT_PercentageOfFutureRevenueEarned": {
     "xbrltype": "percentItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "PercentageOfFutureRevenueEarned",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of future revenue earned",
        "documentation": "Percentage of future revenue earned."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r375"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheetsParenthetical",
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r662"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheetsParenthetical",
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r375"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheetsParenthetical",
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r662",
      "r682",
      "r1110",
      "r1111"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value $0.0001; 1,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively; nil shares issued and outstanding at December 31, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r578",
      "r794"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets",
      "http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other long-term assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r936"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses \u2013 related parties",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r297",
      "r298",
      "r752"
     ]
    },
    "CDT_PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expense of directors and officers insurance paid out of PIPE financings proceeds in connection with the Merger",
        "documentation": "Prepaid expense of directors and officers insurance paid included in Apic in connection with merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid directors\u2019 and officers\u2019 insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r768",
      "r974"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_PrivatePlacementWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "PrivatePlacementWarrantMember",
     "presentation": [
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrant [Member]",
        "documentation": "Private Placement Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromContributedCapital",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Contributed Capital",
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of convertible promissory note payable, carried at cost",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "CDT_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants",
        "documentation": "Proceeds from exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash fee received",
        "documentation": "Cash received for fees during the current period. This element excludes cash proceeds from license fees."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "CDT_ProceedsFromIssuanceOfCapitalContributionRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ProceedsFromIssuanceOfCapitalContributionRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Capital contribution - related party",
        "documentation": "Proceeds from issuance of capital contribution related party.",
        "label": "ProceedsFromIssuanceOfCapitalContributionRelatedParty"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfCashFlows",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common shares related to ATM program",
        "verboseLabel": "Proceeds from issuance of common stock",
        "terseLabel": "Loss",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "CDT_ProceedsFromIssuanceOfOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ProceedsFromIssuanceOfOption",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of option",
        "documentation": "Proceeds from issuance of option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of warrants",
        "verboseLabel": "Proceeds from warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "CDT_ProceedsFromLoanRepaymentRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ProceedsFromLoanRepaymentRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from loan repayment - related party",
        "documentation": "Proceeds from loan repayment - related party."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Merger and related PIPE Financing, net of transaction costs",
        "documentation": "Proceeds from Merger and related PIPE Financing, net of transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the issuance of notes payable \u2013 related parties",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from the issuance of notes payable \u2013 related parties",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of short-term investments",
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the exercise warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash fee",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r805",
      "r1105",
      "r1107"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r548",
      "r573",
      "r585",
      "r794"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r146",
      "r149",
      "r584"
     ]
    },
    "CDT_PublicWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "PublicWarrantMember",
     "presentation": [
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrant [Member]",
        "documentation": "Public Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants [Member]",
        "documentation": "Public Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r169",
      "r170",
      "r328",
      "r329",
      "r330",
      "r331",
      "r390",
      "r398",
      "r426",
      "r427",
      "r428",
      "r433",
      "r502",
      "r565",
      "r566",
      "r567",
      "r605",
      "r607",
      "r619",
      "r652",
      "r653",
      "r718",
      "r720",
      "r722",
      "r723",
      "r731",
      "r748",
      "r749",
      "r767",
      "r775",
      "r781",
      "r788",
      "r789",
      "r790",
      "r791",
      "r795",
      "r799",
      "r980",
      "r985",
      "r1032",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r169",
      "r170",
      "r328",
      "r329",
      "r330",
      "r331",
      "r390",
      "r398",
      "r426",
      "r427",
      "r428",
      "r433",
      "r502",
      "r565",
      "r566",
      "r567",
      "r605",
      "r607",
      "r619",
      "r652",
      "r653",
      "r718",
      "r720",
      "r722",
      "r723",
      "r731",
      "r748",
      "r749",
      "r767",
      "r775",
      "r781",
      "r788",
      "r789",
      "r790",
      "r791",
      "r795",
      "r799",
      "r980",
      "r985",
      "r1032",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066"
     ]
    },
    "CDT_RealizedGainOnShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "RealizedGainOnShorttermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Realized gain on short-term investments",
        "documentation": "Realized gain on shortterm investments.",
        "label": "RealizedGainOnShorttermInvestments"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_RecognitionOfDeferredRevenueUponOptionExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "RecognitionOfDeferredRevenueUponOptionExercise",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognition of Cizzle deferred revenue upon option exercise",
        "documentation": "Recognition of deferred revenue upon option exercise."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_RecognitionOfDeferredRevenueUponOptionExerciseOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "RecognitionOfDeferredRevenueUponOptionExerciseOne",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOtherExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognition of Vela deferred revenue upon option exercise",
        "documentation": "Recognition of deferred revenue upon option exercise one."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r832",
      "r843",
      "r857",
      "r883"
     ]
    },
    "CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50",
        "documentation": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets",
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r397",
      "r554",
      "r555",
      "r575",
      "r583",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r681",
      "r683",
      "r716"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets",
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r554",
      "r555",
      "r556",
      "r557",
      "r575",
      "r583",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r681",
      "r683",
      "r716"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r555",
      "r1058"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r690",
      "r691",
      "r694"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets",
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r397",
      "r554",
      "r555",
      "r575",
      "r583",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r681",
      "r683",
      "r716",
      "r1058"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r552",
      "r553",
      "r555",
      "r558",
      "r629",
      "r630",
      "r631",
      "r692",
      "r693",
      "r694",
      "r713",
      "r715"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of notes payable",
        "label": "Cash payment",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails",
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "verboseLabel": "Research and Development Expense",
        "terseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r750",
      "r762",
      "r1067"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAxis",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r172",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r253",
      "r294",
      "r295",
      "r471",
      "r472",
      "r473",
      "r474",
      "r478",
      "r479",
      "r492",
      "r493",
      "r494",
      "r495",
      "r530",
      "r532",
      "r549",
      "r550",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r620",
      "r968"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r844",
      "r858",
      "r884"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r845",
      "r859",
      "r885"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r852",
      "r866",
      "r892"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementDomain",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r172",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r253",
      "r294",
      "r295",
      "r471",
      "r472",
      "r473",
      "r474",
      "r478",
      "r479",
      "r492",
      "r493",
      "r494",
      "r495",
      "r530",
      "r532",
      "r549",
      "r550",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r620",
      "r968"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets",
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r114",
      "r581",
      "r613",
      "r618",
      "r627",
      "r663",
      "r794"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r217",
      "r218",
      "r219",
      "r221",
      "r227",
      "r230",
      "r232",
      "r293",
      "r296",
      "r314",
      "r462",
      "r463",
      "r470",
      "r471",
      "r472",
      "r474",
      "r478",
      "r479",
      "r485",
      "r487",
      "r488",
      "r490",
      "r493",
      "r531",
      "r534",
      "r609",
      "r611",
      "r633",
      "r1110"
     ]
    },
    "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Error Correction, Adjustment [Member]",
        "documentation": "Cumulative increase (decrease) to previously issued financial statements for correction of error."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r229",
      "r230",
      "r231",
      "r232"
     ]
    },
    "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Reclassification, Adjustment [Member]",
        "documentation": "Cumulative increase (decrease) to previously issued financial statements for reclassification. Excludes adjustment for reclassification from amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r968"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails",
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of Use Asset obtained in exchange for Operating Lease Liabilities",
        "verboseLabel": "ROU assets obtained in the exchange for lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r793"
     ]
    },
    "CDT_RoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "RoyaltyPercentage",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty percentage",
        "documentation": "Royalty percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "CDT_SARBORGLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "SARBORGLtdMember",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SARBORG Ltd [Member]",
        "documentation": "SARBORG Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_SARBORGServiceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "SARBORGServiceAgreementMember",
     "presentation": [
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SARBORG Service Agreement [Member]",
        "documentation": "Sarborg Service Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_SARBORGServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "SARBORGServicesAgreementMember",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SARBORG Services Agreement [Member]",
        "documentation": "SARBORG Services Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_SalariesPayrollAndStockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "SalariesPayrollAndStockBasedCompensationMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries Payroll And Stock Based Compensation [Member]",
        "documentation": "Salaries Payroll And Stock Based Compensation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative",
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction",
     "presentation": [
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, percentage",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Warrants price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Agreement [Member]",
        "documentation": "Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r232",
      "r253",
      "r471",
      "r473",
      "r474",
      "r478",
      "r479",
      "r492",
      "r493",
      "r494",
      "r530",
      "r532",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r620",
      "r922",
      "r924",
      "r925",
      "r926",
      "r959",
      "r968",
      "r972",
      "r973",
      "r1028",
      "r1054",
      "r1055"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/EarningsnetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Potentially Dilutive Securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r475"
     ]
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Common Stock Outstanding",
        "documentation": "Tabular disclosure of the change in common stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Provision for Income Tax",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Balance Sheet Details",
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r955"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets",
      "http://conduitpharma.com/role/ScheduleOfBalanceSheetDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r50",
      "r51",
      "r52",
      "r53"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/EarningsnetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Basic and Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Federal Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r784",
      "r1015"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/OtherIncomeExpenseNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Expense, Net",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r68",
      "r690",
      "r691",
      "r694"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/SegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Data for the Company\u2019s Reportable Segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails",
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restricted Stock Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r116"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of Stock Option Granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "CDT_ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Black-Scholes Option Pricing Model",
        "documentation": "Schedule Of Share Based Payment Award Stock Purchase Warrants Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Axis]",
        "documentation": "Information by financial instrument subject to mandatory redemption."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r18",
      "r47"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "CDT_SecondAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "SecondAmendmentMember",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Amendment [Member]",
        "documentation": "Second Amendment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_SecondAmendmentNirlandNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "SecondAmendmentNirlandNoteMember",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Amendment Nirland Note [Member]",
        "documentation": "Second Amendment Nirland Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r254",
      "r259",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r290",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r313",
      "r324",
      "r325",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r759",
      "r762",
      "r763",
      "r769",
      "r796",
      "r1072",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/Segments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r254",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r275",
      "r277",
      "r278",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r758",
      "r760",
      "r761",
      "r762",
      "r764",
      "r765",
      "r766"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "CDT_SeniorSecuredPromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "SeniorSecuredPromissoryNoteMember",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Secured Promissory Note [Member]",
        "documentation": "Senior Secured Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "verboseLabel": "Share based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Awards, Cancelled/Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted Average Grant Date Fair Value, Cancelled/Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Awards, Granted",
        "verboseLabel": "Shares granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Granted",
        "verboseLabel": "Weighted average grant date fair value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Awards, Outstanding",
        "periodEndLabel": "Number of Awards, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Outstanding",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Awards, Vested",
        "label": "Shares vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted Average Grant Date Fair Value, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails",
      "http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Volatility",
        "verboseLabel": "Estimated volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails",
      "http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "verboseLabel": "Risk-free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails",
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Cancelled/forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options, Outstanding",
        "periodEndLabel": "Number of Options, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408"
     ]
    },
    "CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options, Unvested",
        "documentation": "Share based compensation arrangement by share based payment award options unvested outstanding number.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Unvested",
        "documentation": "Share based compensation arrangement by dhare based payment award options vested and expected to unvested outstanding weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued percentage",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Term Years",
        "documentation": "Share based compensation arrangement by share based payment unvested award vesting period 1.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Cancelled/Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares",
        "verboseLabel": "Shares issued for services, per share",
        "terseLabel": "Closing stock price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails",
      "http://conduitpharma.com/role/ScheduleOfFairValueOfStockOptionGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (years)",
        "verboseLabel": "Time period to expiration",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Term Years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term Years",
        "verboseLabel": "Weighted average remaining vesting",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "CDT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value",
        "documentation": "Sharebased compensation arrangement by sharebased payment Award options unvested intrinsic value 1.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Issued",
        "verboseLabel": "Shares issued",
        "terseLabel": "Stock options to employees shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued, purchase price",
        "verboseLabel": "Fixed price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifying description of each financial instrument that embodies an unconditional obligation requiring the issuer to redeem the securities by transferring the assets at a specified or determinable date (or dates) or upon an event that is certain to occur. Examples are preferred stock or trust preferred securities, each of which has redemption rights beyond the control of the issuer on a specified date or upon an event that is certain to occur."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r18"
     ]
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r977",
      "r978",
      "r979"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r977",
      "r978",
      "r979"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r938"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r793"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "CDT_SponsorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "SponsorMember",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor [Member]",
        "documentation": "Sponsor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://conduitpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfFinancialDataForCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r174",
      "r254",
      "r259",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r290",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r313",
      "r316",
      "r324",
      "r325",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r759",
      "r762",
      "r763",
      "r769",
      "r796",
      "r1072",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://conduitpharma.com/role/Cover",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r181",
      "r182",
      "r183",
      "r211",
      "r238",
      "r239",
      "r246",
      "r248",
      "r256",
      "r257",
      "r292",
      "r334",
      "r337",
      "r338",
      "r339",
      "r343",
      "r344",
      "r375",
      "r376",
      "r378",
      "r381",
      "r387",
      "r518",
      "r623",
      "r624",
      "r625",
      "r626",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r645",
      "r662",
      "r686",
      "r709",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r921",
      "r949",
      "r961"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative",
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative",
      "http://conduitpharma.com/role/FairValueDetailsNarrative",
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r84",
      "r87",
      "r88",
      "r171",
      "r194",
      "r195",
      "r196",
      "r217",
      "r218",
      "r219",
      "r221",
      "r227",
      "r230",
      "r232",
      "r255",
      "r293",
      "r296",
      "r314",
      "r389",
      "r462",
      "r463",
      "r470",
      "r471",
      "r472",
      "r474",
      "r478",
      "r479",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r531",
      "r534",
      "r550",
      "r588",
      "r609",
      "r610",
      "r611",
      "r633",
      "r709"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://conduitpharma.com/role/Cover",
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative",
      "http://conduitpharma.com/role/FairValueDetailsNarrative",
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails",
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r255",
      "r534",
      "r568",
      "r621",
      "r645",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r662",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r683",
      "r688",
      "r689",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r709",
      "r800"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://conduitpharma.com/role/Cover",
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative",
      "http://conduitpharma.com/role/FairValueDetailsNarrative",
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails",
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r255",
      "r291",
      "r534",
      "r568",
      "r621",
      "r645",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r662",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r683",
      "r688",
      "r689",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r709",
      "r800"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r847",
      "r861",
      "r887"
     ]
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensationGross",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options to employees shares granted",
        "documentation": "Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Conduit Pharmaceuticals Inc. common stock to Vela Technologies PLC upon exercise of option",
        "verboseLabel": "Stock issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "CDT_StockIssuedDuringPeriodAdditionalSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodAdditionalSharesIssued",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional shares issued",
        "documentation": "Stock issued during period additional shares issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, net of redemptions, shares",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r114"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r48",
      "r84",
      "r87",
      "r114",
      "r362"
     ]
    },
    "CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStock",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock under the ATM Program, shares",
        "documentation": "StockIssuedDuringPeriodSharesIssuanceOfCommonStock"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock for note payable, shares",
        "documentation": "Issuance of common stock for note payable, shares."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock in Exchange for Debt Modification, shares",
        "documentation": "Stock issued during period shares issuance of common stock in exchange for debt modification."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon conversion of MURF Class A &amp; Class B common stock in connection with merger, shares",
        "documentation": "Stock issued during period shares issuance of common stock upon conversion of common stock in connection with merge."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock upon Exercise of Conversion Option, shares",
        "documentation": "Stock issued during period shares issuance of common stock upon exercise of conversion option."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock Upon Exercise of Warrants, shares",
        "documentation": "Stock issued during period shares issuance of common stock upon exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock for services, shares",
        "verboseLabel": "Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the transaction, shares",
        "terseLabel": "Shares issued for services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodSharesIssuedForServicesOne": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServicesOne",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger, shares",
        "documentation": "Stock issed during period shares issued for services one."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://conduitpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/DeferredCommissionPayableDetailsNarrative",
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock for licensing right, shares",
        "verboseLabel": "Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date,shares",
        "terseLabel": "Shares issued during the period",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r83",
      "r84",
      "r114",
      "r623",
      "r709",
      "r741"
     ]
    },
    "CDT_StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing, shares",
        "documentation": "Stock issed during period share issues in connection with pipe financing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock upon vesting of restricted stock units, shares",
        "verboseLabel": "Commons tock shares sold",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodSharesPurchaseOfRevenue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfRevenue",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC, shares",
        "documentation": "Stock issued during period shares purchase of revenue."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodSharesPurchasesOfRevenue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesPurchasesOfRevenue",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Conduit Pharmaceuticals Inc. common stock to Vela Technologies PLC, shares",
        "documentation": "Stock issued during period shares purchases of revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number shares reverse stock split during the period",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Common Stock Upon Exercise of Warrants, shares",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r83",
      "r84",
      "r114"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Number of Options, Exercised",
        "terseLabel": "Common stock upon exercise, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r83",
      "r84",
      "r114",
      "r412"
     ]
    },
    "CDT_StockIssuedDuringPeriodSharesStockWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants to purchase common stock",
        "documentation": "Stock issed during period shares stock warrants exercised.",
        "label": "StockIssuedDuringPeriodSharesStockWarrantsExercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date (Note 2)",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r84",
      "r87",
      "r88",
      "r114"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock converted",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r84",
      "r87",
      "r88",
      "r114"
     ]
    },
    "CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock under the ATM Program",
        "documentation": "Stock issued during period value issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock for note payable",
        "documentation": "Issuance of common stock for note payable."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock in Exchange for Debt Modification",
        "documentation": "Stock issued during period value issuance of common stock in exchange for debt modification."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance of common stock upon conversion of MURF Class A &amp; Class B common stock in connection with merger (Note 2)",
        "documentation": "Stock issued during period value issuance of common stock upon conversion of common stock in connection with merge.",
        "label": "StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows",
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock upon Exercise of Conversion Option",
        "verboseLabel": "Issuance of Common Stock upon exercise of conversion option",
        "documentation": "Stocki ssued during period value issuance of common stock upon exercise of conversion option"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock Upon Exercise of Warrants",
        "documentation": "Stock issued during period value issuance of common stock upon exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock for services",
        "verboseLabel": "Stock issued during period value issued for services, value",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodValueIssuedForServicesOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueIssuedForServicesOne",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger (Note 2)",
        "documentation": "Stock issed during period value issued for services one."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock for licensing right",
        "verboseLabel": "Shares issued during the period, value",
        "terseLabel": "Number of shares issuance, value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r83",
      "r84",
      "r114",
      "r633",
      "r709",
      "r741",
      "r806"
     ]
    },
    "CDT_StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing (Note 2)",
        "documentation": "Stock issed during period value issues in connection with pipe financing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock upon vesting of restricted stock units",
        "verboseLabel": "Commons tock shares sold, value",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodValuePurchaseOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValuePurchaseOfRevenue",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC",
        "documentation": "Stock issued during period value purchase of revenue."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_StockIssuedDuringPeriodValuePurchasesOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValuePurchasesOfRevenue",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Conduit Pharmaceuticals Inc. common stock to Vela Technologies PLC",
        "documentation": "Stock issued during period value purchases of revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r83",
      "r84",
      "r114"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://conduitpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets",
      "http://conduitpharma.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r87",
      "r88",
      "r109",
      "r664",
      "r682",
      "r710",
      "r711",
      "r794",
      "r807",
      "r951",
      "r971",
      "r1044",
      "r1110"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/CommonStockAndPreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock and Preferred Stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r210",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r491",
      "r712",
      "r714",
      "r745"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "verboseLabel": "Reverse stock split, description",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "CDT_SubscriptionAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "SubscriptionAgreementsMember",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreements [Member]",
        "documentation": "Subscription Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventDescription",
     "presentation": [
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent event, description",
        "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r560"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r560"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r560"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r560"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r560"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r561"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/BalanceSheetDetailsCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Details \u2013 Current Assets",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://conduitpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares held prior to business combination",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r1057"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "CDT_TrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "TrancheOneMember",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche One [Member]",
        "documentation": "Tranche One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_TrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "TrancheThreeMember",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Three [Member]",
        "documentation": "Tranche Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Two [Member]",
        "documentation": "Tranche Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TravelAndEntertainmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TravelAndEntertainmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Travel and Entertainment Expense",
        "documentation": "Expenses incurred for travel and entertainment during the period."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "CDT_TwentyTwentyThreeConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "TwentyTwentyThreeConvertibleNoteMember",
     "presentation": [
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Convertible Note [Member]",
        "documentation": "2023 Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_TwentyTwentyThreeStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "TwentyTwentyThreeStockIncentivePlanMember",
     "presentation": [
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Stock Incentive Plan [Member]",
        "documentation": "2023 Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "TwentyTwentyTwoConvertibleLoanNoteInstrumentMember",
     "presentation": [
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Convertible Loan Note Instrument [Member]",
        "documentation": "2022 Convertible Loan Note Instrument [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_TwoThousandTwentyThreePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "TwoThousandTwentyThreePlanMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Plan [Member]",
        "documentation": "Two Thousand Twenty Three Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://conduitpharma.com/role/CommonStockAndPreferredStockDetailsNarrative",
      "http://conduitpharma.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative",
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative",
      "http://conduitpharma.com/role/MergerAndFinancingDetailsNarrative",
      "http://conduitpharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://conduitpharma.com/role/ResearchAndDevelopmentExpenseDetailsNarrative",
      "http://conduitpharma.com/role/ScheduleOfCommonStockOutstandingDetails",
      "http://conduitpharma.com/role/ShareBasedCompensationDetailsNarrative",
      "http://conduitpharma.com/role/SubsequentEventsDetailsNarrative",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r144",
      "r145",
      "r147",
      "r148"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://conduitpharma.com/role/ScheduleOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r793"
     ]
    },
    "CDT_VelaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "VelaAgreementMember",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vela Agreement [Member]",
        "documentation": "Vela Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_VelaOptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "VelaOptionAgreementMember",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vela Option Agreement [Member]",
        "documentation": "Vela Option Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_VelaOptionLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "VelaOptionLiabilityMember",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vela Option Liability [Member]",
        "documentation": "Vela Option Liability [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_VelaTechnologiesPLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "VelaTechnologiesPLCMember",
     "presentation": [
      "http://conduitpharma.com/role/LiabilityRelatedToSaleOfFutureRevenueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vela Technologies PLC [Member]",
        "documentation": "Vela Technologies PLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_WarrantInstrumentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "WarrantInstrumentsPolicyTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/NatureOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants",
        "documentation": "Warrant Instruments [Policy Text Block]",
        "label": "Warrant Instruments [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CDT_WarrantLiabilityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "WarrantLiabilityDisclosureTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants",
        "documentation": "Warrant Liability Disclosure [Text Block]",
        "label": "Warrant Liability Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfAdditionalInformationAboutFinancialLiabilitiesSubjectToMeasurementAtFairValueDetails",
      "http://conduitpharma.com/role/ScheduleOfAssetsSubjectToMeasurementAtFairValueOnRecurringBasisDetails",
      "http://conduitpharma.com/role/ScheduleOfBlack-scholesOptionPricingModelDetails",
      "http://conduitpharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r798",
      "r801",
      "r802",
      "r803",
      "r804"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/LoansPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "CDT_WarrantsExcercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://conduitpharma.com/20241231",
     "localname": "WarrantsExcercise",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/FairValueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants excercise",
        "documentation": "Warrants excercise."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted weighted-average common shares outstanding",
        "verboseLabel": "Weighted average shares used in computing net loss per share - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r248"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://conduitpharma.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://conduitpharma.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic weighted-average common shares outstanding",
        "verboseLabel": "Weighted average common stock outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r248"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481679/480-10-45-2A"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "855",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(C)",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2C"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-38"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(ii)",
   "Publisher": "SEC"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)",
   "Publisher": "SEC"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "6",
   "Subsection": "04",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "SEC"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-14"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0001641172-25-001246-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-001246-xbrl.zip
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M,'&3PSPUIG(Y$ FI-::A,,"FXB%(&":^<C&393R3M!XO#5Z7B 8D6+  1_P
M:8RIF' 2J)HR#5"J> E27H??W>+($8=5#C!,YK<>HI8A12)QP"#.'(5G& >Y
MYUM'8 !5Q8&@\)/GC0K''BJM%2<V\F-$H\V4P@8%N>+8-C7@&G(-0*IX#U*?
M@>#FJ.QZA#0(C:(EILEJ+HU<F(X2>.JSVK$YK3@)!*?L8!XGS/[RO0/S: ^.
M!IQ/B$(_3IW5V5\&$%3< VGAOKUU6QB\$+.\W+2D?QFT=V7?GQ;NVUO7WO&,
MX2\QW[7?*^U>3C5H_\I6/F?B)%QZ(+[2[8/GNX70X3;"Z5>]C>!\E_[J+YQU
MNY@PY8Y0UG0]0>8:P&UT2<'Y+F'8@V1T6T'%IIQH (GFYD(/Q%-<85#Q,:0U
M@&VGZPP]L.;W&E3X"BD&(#7<<>B;?_N#"A4.+84!/!7G1-.A10]8Q],+%:5J
M<CLT/U1\$^I)1@_'#BYR%1H]B0%,%?^%UEW>X[:UJT]%34=@@%G%!Z)Q^_6(
M=?'_J2"5T@QPJ?A&4A8]"%V<@@4#H9AF $+U'H-DT8/PM1U4<@MSRT=!1.[Q
MTSNJ*C48=)"*!^-Y'5;I/BZ3L>]_VDG 76(OYO><E>L:HSCB\2MXE!/9G')V
M,"0VZ!45)TK*6SRM4R]Z*/PS='M,NWDCZV<& SH#)"M^E7H/93\NMQR7B0/J
M+I[]"[O1-+S!B+<S7V('4>:]' 43[,:40E.+:;1AV.[$RZ O5-PWZJB6GC19
M.W\#H=3OH$CUH\+HSX20"T,_]COV&\\3M2.?1V<"(K'2S\(XDJ,2^>G#%%@X
M6_I$4W]ZCCH,^EG5#Z7VLTPH1Y'*$6()DR.3S5&$R_KE5-<O^T[8K1/FDPJ?
M>^+56EQ<:NA->N+V;O&FX@-3NX4ZNXC)**V@![7;\5F],=&<;0!<Q2M6,^1Z
MRZ'KX*LY.VL8>1I* _2J=X2485=_RM8/N6Y0BF.P\Y!%#0!6\@U@JUXM4F 3
M#!W.L<>J(U8RB%.P$&VHF!@-V+72&V!9]<(I6&852%15JZ<'MZ-!(YYJWX ,
MJW@EFG.,-L+?>172(I)-5DYW#@8=H.)E*Y@^R?MR6:?L!6FM#E1;Z2)]MS"_
M[U!O#S7D&4!9<8VE=R!Z0^CI8S\T@+=540-L*\ZRCK$A^D[0^4U5;4B(>MA-
MB0V KGEKU1!/HH>TZ[A6(DHT#%\=A0%XU0@N:@R*'K".@#4&GJA'SYR\'<H?
M*RXA3=R*'MC.KR U@2KJP>U6Q #@BNNH+=9%C_+6FQ]HVH@2-Y*/^ <N-!Z8
M+@T;G19J VRUCJ6<O3PH3BOH-R_;.^F3$WWA%__ KU)AK]U7WUS& &*M$ZKH
MLI?7 41%CJRIQ[HCU@I8+<-70VF J]8A54"R'[9/<,F_?K$UI#6 L^I>:KSX
MWZ^N6P[-Y#[Q&9Z'%&=/ "[@'Q81E]_2@72R"!J&:\?2!IAKKVC)R\\S49_R
MUN![)ZTSN0"4U-J/[8Y]84S#>\+W)M" .9KUR&MI#7"N^*14G#/F#@"MX-PC
MVM7(PAZF_)Z,!&B"HL83 @VI 9[:2UB2MXHD9]_#V1'.U(T #9C<:X,IMOVH
MS["4 <C:&U"9CX/#*Z_=\=FX/_C;X85>O8FE(VB'\:>65WN]+?5D,0F;//X=
M2AC@6?%&M<4L[#'>X7H3$Y;M!?'C"'NWQ2>9C3>=3 H9(-URZ8E) UC6XZ2/
M.]6WG?T,W,TF#B/0FB#?WXA6A:%RQ^^(ZQ9<HS(&:&O=5$HE3EJ+DU?3 [UK
M],OFN=NT@ '$%8^5-CIF/V]W/BNJCXG9=$QD2&T ;,5WU1Q1LT=U^UN/_$U\
M_KJ^Z:YC/94!BEIO5/(@7_+]7BRV_:3;T9KRD?MYG[E+2&:):WY,"7^[=Q-Z
MV&\RI\Q*&>"K]4(EU=PEU:0'![(B1]34X]TI\$+]K-N8:X!?Q>N4!V/HY]1M
M?8;I0[4+%*&KD/*#%A1LV 2O0QKQ*RLRV$*3([%K>0.<M8ZG_&4=KU&XC/E=
M1EFO"*WVTR_,R>M/HT7TPW>KN+(-QWYM5.TP_UQ]2E>.._O_?ESS_\T0PQ,\
M=QY%2@1D[_<86:WY-Y>2M"7%\_=[KA?MGQR=_'!\<GK\3]#ZX''EIQ2\@@SX
MAX>'@\<9]0]"NC@\.3HZ38 O-Y2L-V6!J%OA\G J>!P#G(>""IB$:WX%%;/#
M5/:4040B7KP0>8/7 U/*X=,I[J-95\6A"/:?4>-KSO\95(7>V5754H=^)H7/
M\UJ>06T865W5+@[&9]+Z(JNDJO2OAVB])L$\E"GP=Q"$R2!(DT!O6+&< *TP
M6R-7IQ0)>+@2%R0 LQBOT'7H"E::(ORO_;3</D_:/S[9/ST^>&1>+FD7(?)F
MZ"9$6FX+(00WAMV#17@/H))#WBGJZV=-Y/R'Z$RFE<X1FPD58K:_0&AM4FEM
MF4/L1RQ-V5H$/DK8[C((-IV$*,#I1?20L^!,3_8!Q]/C9G':2HJ_V5:= +M>
METZ0DO,?G90O<!$AH>BF2\5JD?2/[;H HU$G]%/Z!'GX:P>]-YT:.R7G/^HJ
MQ7X2_D(X6B^F_U0.RL8HN?EY='!T='2<'IW<X-4,TSTA9N%<K86<^#[?"+S?
MBRC_$B\7DKR#V9R$WE2L.5Y,A2)[3K(&01]-!L@[+UPA$@PCO.*4H#B8J##?
MQ\E-U#!>O]]+V!$@T>@VP1Z&%@,ITCWK)7*7G[BS029</F+J$L9)^"/-  L=
M"F&P!BD1YGX)R#L^/GAS5&R5KU&1!>UY$]/U<G,..SY^=?1+3)A8><]#NBZV
MAPFA!?J,?'ZZP/=C8[$?<S&P &N-79,5%/6*2AE36Z"9%+3T[NVWT/<P9>41
M;4)JCTYBX$CQD#@>,E6Q6TD+-+Y;AP$+:5&9<J(%<@Y\GW +]X,?SI#/3U^"
M"@8M-!9HP1TA+B7)Q?@%Q2*WI$4+C05:##Z,2QV[A$-SO@72CX?CRW0)+<I=
MFV.!Q'Q-"Z$2? :3S!\$^]XE\%F)Q^6P+@0+OL;S]N9W;<O3TC9%+=!9":,V
M#-9Q-*8PII/7[N(J)(K]J&00="EAH883[(8 Q.;CFC^S,%!05\ "_7['/LKF
MKZ(F]5F6R#S%[C((_7#!/ZYU?5Z5O(G $OE'Q96C*G\3@57R9[$MFN2O$E@@
M_SGY\T\?CWVWH?DU^39(GR_:,'GR!^XAW:C!+"HFKR&YS;H9ZO0J=.D&DYTH
M,5C&P"YI&D : @ODGS[ 7QOY_R4(J+63C:DMT.P.!R2DXF(J]G0CR(30 GUN
M"?41?T!3XX5IR+- ZBM"632 )(\G2SFK&+236:>+3@&;I(:.#3NI=@@,Z.S3
M1JN"37(WFQZF)HI-VF1^*]5MI?>P="EA@88\!E:3OZLASP*I^>UN=XE'07G=
MKJ;;(^WT(:R55DVW2%IN]M3+6\BQ0&+>3VM=_W49ELC+&J;VACP+I!ZY40C"
M0&^=+L.8GZ$D]O%5&-/&Q;9K(0OT/*/$6^#"W%?424=@@?P#%E'T#QQ@%Y66
MIIH,"^2]&TS.1I,/=YC>$Q<WM'D;D05Z5/:,XEQ_"+9 P&_1CJ&OMVPR-04L
MT.\V#"Y7:S_<8'Q!*(:!79YNM106:'!#?\/$G]'R44Q-N@725N9,T4?JNE$K
MG07:\,#'K&EPU^=9(/4XGOG$;3B3K,^S0>KA^+)Z?FJ3A(,/X_I&K<NP0=YX
M$;-(G;"U5H\YN06ZW?"PJF59Z]$Q([5 I\&:$M],)S-2&W3Z,#;4R(#0 GW.
M0WH?LW.T)A'_GER-MU=+88$&9R&BWFC>8 TUYEH@><'T? @5_Q3?UO 9:AC
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MYV1F6<+/"=89M2^[D30Z>0#Q N+S^#9+PJ\/230C\]8IG*,091::F+ 92P.
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M,>0O#"$]DOVIM/WLK[P(/O7XCO4]UP/?OFN,:WGO\O+6SZ*VDMBOS)/8)?,
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MG44L[_1J9@&Q!^?TG$2=D'1$6A!7ZD0O+%'HI:P(+'GQ&E%V?GAM(DVYA/D
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MOAN885-I.B14Y,2#>%BS311)U.YNDL9#P@0B'T3%FC6BCJ8P;.V@KD9@S;P
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MR1J;,-"30M@S,$XJBFV#YV@JJX*G6I<XJ=*T;Z71:&V CGB]QFAM=P.\GSI
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M1/"=/2CA0L&QT/75A9K4W8:D"AM)P*%$P24R=5H)T-Q2L28C66,3!MS3-ML
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MMG%<R "]H$/7WM/VR*-,L_]5I.Y+)N0NG"^229K0Q(MY&2AX'>AZ.HY0+2Y
MW*S9 0I/]J<>F9!,810V#'UY"H/. T'/E!$0P*9V W ;R\DYCS#EIJ6\>H92
MA=9V<QP,<Q9 &*R9#:3K__*5T1U2)'C8_)'F?Z6*:JF-AG,<WOU9 V&W9HW8
MF.NW1?6VU,/P*KL- T8#%D"XK#WI7M,WCH-L8AEI**I>PP!+SP&(E34SA5DX
MV?!"R,S#QDX=L4Y\B[WLDH>"]=W.U#(AZ3H,E S9 *$K6"1ZK]L$U@$S*.+T
M\T_E(D[KT4;;X1PLZ;3.'%?!59%9\L9Z*:<U);KB3:5V[I1K L4.I<"T5YR)
M(O_'.7YY&Z PPX;]8PL)^V%V@^9>=!FSU; "GINR5I5&]AZ=RF6*85)!J?<C
MWXP4\'$\:[+;HN>'I@J)88#";NUP;4O4R;>FM:7>8QZ!<12%7NRC+Q%^]**I
M1Y)8DSQ-U:/OPD+0;,7&U':Z7QQS26MV<#/BP2UHR$F*C]FC'07&R2.D;? <
M396V5_9H2[6]]LL>K<+!7J3FE& ?H8!>,6:Y2_8.^8C=?&6OL?(N4 ];.;V-
MKVU*PB%D7 M-;_N5E>N@U6##.05/ZARZ3;E@)D_WR.</VT-$S[TH0L'9JNPG
MJNE0,Q_8>=#;X,\Y5=()I^H@D3?B"E1QK)VL^0N!*TR ^*WUN;3;T'F,9/1"
MTF_JRY9:,$!7P#B.4R\JAHK+#1HU!G 7A09\0.BT&B$/$G6+X_.4_47J:%-Q
ML^TX3#1*]$,H6'-*YV')-Z'W&$;9B9J1FQ4N]D'0UM&R1OW=Q:X^&Q"$COBV
M]WK@Y3I,2L(A8&QZKN\018R6!9M&%^@%1?A9V'/6KS?UWNN3LO=Z/>+(BX-1
M8<Q1/NC1A7UT81]=V&XZ0(XN[*,+^^C"WN^*,6:GO_?_4(Q\3^FW+C=ST%DM
M(]$Y ^8#&WOR5'@2K/9, \T=W9#51#MG/BS6W,XN)M[V-[Q^-O5\+E,XHF-]
MW:D[D!WOM1H7O!]+W9X30X+7R3.H^RG0XZ%U/[X[F]Q]N4?D)61WUCE!@B;5
M :;L8LO[W721X1IL@2?@,4C+_2 M:YZ68Y#6,4CK&*3E6I"6;-HY'Z1UZF1>
M@^O8QTNT->[QCW 9*H\@92>W#R #?AW*2P]0J]OM--WL'$<FDC?"RMU#J0NX
M7#ZD6H;4T:-*Z6S3'5X&G6?O[1QG9LNKG)W4C!UP)[5VT!5#='ED)W_/,WDJ
M'-.**"I=UYFME]I-XI-A#B#0#CU0V77T:K#AG)W_"XH1\2*V7XR#)9,H=T[P
MX %M4DU-1^=!,Z'?.4^ <GMO>,@YCY2>^K;-4E)C;A[[^H!WZ<&1( >,O6)=
M37JZBT(=!IR[H/52Y<%9Z&IS >'7:K3PN4<7^8R2KY=" W=E*Z$3DIZ]*-]-
M2K,K3(H);A4^1*B+NT@840YA4PC?[3U*]-Y?H""-F*;/]M6$A'Z" K%6QS[3
M1'@,21;2N:&^$"!Z6@X070\VPD^C[7 C,=YH/> F2O3/!;:[96V37V_R)&B9
MB**[7_@S'K8=P0R^4S'(!QV)4?E/&8_9P*-\Y *G=@X>KOR?>52\#>":2F9Y
MV;I-SU;;)ODF,O[ND: RS26G4@MC6SJ.-]-"RP.%F- %Z+;W"7=B>UN;3&7-
MH&T\>@TCWLQ 2I+"[&,_;6<>^V%VQWD /";L[X4_V_.-M X$EO'7C_G!! [0
M+KLFV%((FE1>6$Y:3PZ.%L7II+/"7.1].B T4O_*1+9,ERJY[S3I.PX9F*L8
MILZ)O>&K]ZH5:[%)[Q%Q>KE6R ,%:R^RK:D^L4V636FZ% HWY88X?M7X!4=L
MF(C=,H!7V/LJ,^8?GWVTE9FW*SVM)YFYYV'B7#WJ&7^LPSC/G:Q(K]'=-P]S
M7G8G*N>\9:VNP[N0_G9%$-(DK^AB"Y!]^C G9^<2<\Y'V,E9<1&^A &* PM'
M>_'3QSG:2&(&_E&+QN^"6=C \/U>91?>L01+C-[#6I!'4_#1%'PT!7?G'14D
MLP^H@^E+S0[/1"SG<WBZ-\CUEK,XF$9>?.LMD2[FNYNOV8GLER-;4Q'90[HN
M/0$8_BQRTH9O>:;U^*;[X3M^6."4>G'P\)U1MGI@C1$G1_6L6]>K;_= 'ZL>
MU^)^>.<-))KL^E$L39CE+^Y BX<^-?O@Z'SJ_9ZLE)";YNYVV/P5\0S)*!B_
M(.+-T4XBY5YFHHJ X_S<0VYN[I1-O !:YN\01Y7]_IPI(L3SD]2+N'O@M /O
M37-B#G,V6Y#AX=C2JX*X9OR&3,OVA=6VEQUX]Y.'.4L[DY2!S7Q8<U$$1M/K
M.'O\\85@VH5=&?[8<?X9R@B:>?8>436^)4HY[4@S;8^(/]Y,;5EVT QN^HS,
M^MYYA<D3"I.4H(T0NML[)1_[X\W(AC*"9IZU)WA[+ST)IY8VT)J4_/'F;!<"
MA":TM;(CRF07A5 .NN9%M5/6'NOP)E4S$4#3XM-@][DU?[9WN5IT'-YT[%]\
MT%3^[.Q4-A.!* /6L>.G\JD_WH1L)"'0A#Y8ZTZ!3SN>'T,"CA-T#[F!T]:N
M:6@/3P',/>0IZ.+A3G-B#G,Z6Y A.+7MVHS:D<2N>Z&?&5SZYG&BUA,5.!^;
M6I+D!4+V/#R^Q2^(LB5F$FO$JW!T];G#F5V=2PF<6$TM.IU,K%\$!^,XV#S*
MQ!*V:FJ:+<AV?[J.4[5]<8)SNJDYJK4YO>9&,,VYW5C89*=P0XDJ/O*'GVTZ
MV8!3IZGY!YXZ>R@+:R[TBMQ:3.U_[/"F4D<R J/("O+K_[FK5(HFI< _5!Z\
M\J%&8JQ1<3"'2H"W-F6.+UZ/+UX[NT'^X5Z\KA_JJ!^\[K8ZV/>N,F$X%%1O
M^L30C2>F4F'*Y>WNV]!F(G?Y/69M6'I]2(GX2\#M>\ L%"+VV2^8ZJ)_46G8
MW=+32H-'D348<&Y[.B9/:)(\P=V'+,X_>S\F3[!_0 Y_%KE\6!]6\H3]*T@O
MGR.\RH_%S.RC*^8(=G'6=M9"?@4CWB%X/UA3($HE3[XQ).C=_3>#>IUPM]G)
MIX/'V4  L#OF6,;:?56R405L:W&+QPK8QPK8#NM4?XP*V)I:IKHSU:B[K=2[
M3:I@FS,$8?G17C*5-:>7OZ=ALN(G"X[Y6:(^*S7=#O:T-!*70V_I2V3J-EZ@
MN9WST4S6V(0!]T[&-H!Q^21L#3Q'ST!&Y1+'XDZD.^\J36>?[9QMZL6!#8B&
M</C<:]6F!QZN,GFZC@.>>3YE)R]8; ]H>GCG$\PK:(NQ"MFO8;*X0Y%@FB["
MYP=\&2<\%3^T$<H8U W2?S$_-08*K,SDT?D)YB",3IYRW4'=HTO\%L=K,^Y%
M2)#/>E&5#QQN/SN1S<.."^,U74/8F"'0LGG:ZWEWAGDDZM.&Q/.%%Y*E(EZ!
M=5+WF9V\'QQ>ADR!F+UOBIET[7PE_T!A]$@47B+6K-QJ=M)W6?M6UHF<#5#2
M/_>Z.LX7(7JZ"F,O]D,OFCP]A3XBJJ6AZ-"_1Z>5=:'E"';16 L1X4ZHR5-!
MWU4;G(#FAZ?(J_F%@+26<*S(YS@.V(GJ;7_SP/Y%/5_,8]TMN?9 =HQ2:ESP
M?BRY9Z:R!:^32G_W4Z!'Y?^<?91)(8SGXSE!@AZ5)@,V[U^EV7-U85.>8/W&
MW;A*Z*C)7H3GAQ4=I\D"D_!?RF1Y;7]J=FIIHKB7BT<M(FC>N1N'"?$Y9>H4
M^[<W9_MEX8%W9E7."M=W, $-OGJ<B_6E!6Z'@YN6I>7WXH41U\2O,!&)I[O?
M$\M?/$['>I("]62K4Y%F>54UTR=O=:"0[W '*K)6DPF+>;2;_E:\YI?G"- 5
MKF@XX@'"OY<DH*GB6!&*ND?# <*LX+,?3W/=]0YEN[Y%W\6?=*M;V_\ 0:[!
MMW,624&E2?;9+*'4X8%7X@T"R+64_N*@:+XH=[L?(*SF;$.(V\O6K]I/LM\S
M!?\>D1<V:YONQY5Q_C!S0,D_-!FLY;O71,O#Z&LZ'A[<1@R#9AE[YD+%3K7_
M8I</<WC@-V ?G K#,]%EH<K7,9ORJ?#P3)(%(@\++Y:6B.O 9%>3@@.<@+U*
M#IR[P_.UU>2_E.Y6_/'"2]"5%Y*NBO>V3>)Q]G<L6G!Y#*^"C%9 O^2I5NUM
M[;L4'"?W?I(#YZZ]5Y'KY"69^B07QRTNYI*F#SCQHN+?SS%-;G'R7RBY0SZ>
MQ]R!7ZR@!T_<7CY_>+.V1[&!4W:PY6'@_/I0H9Q3S<[;+S&'-YVM"1&.:[.9
ML'P33YUE8#A#3YB@[-\/WNL%^P]-0G\<\VLO8W>=RWS#3B&%^<^5%.;YX"/\
M-,J&'#V*\=<_L2_\QVC]C1$3ZBC_RB;)^9\+LNF6_RG!+R$/5&4D;/F'N?VH
MXG8SV(BQ6^#6 E]7*.#6K U+=TS+5;#U2<56/E:1(3Y<@2L[>L73$_*YA6Z'
M27[0Q'X8A5XN55W.^9K#6-*A#(C4I(^O,80SZ>$;05Q69.J*SOE,[QM&\EC6
M9&62:JW:WMISGOJ0R-(X00)P*&BR2JA9,BY9#YMITT!1ZW!Q-R5,>]"X_'JF
M%?@<30JSUB#/<<H4[Y7N392T>0?8U4A\IE@IV)!V][Q0N2YOB(JL]:SO] ;-
M0 %)!S<[:YB8'+CC)-?S>3*IE-&PVFF\GV*I&=Q6_L&^]$L3]J%98_^$W.5E
M\^L\,.(,Q0RHI/'T:?4S0YY([0O"77UXE\5\)]TU5H1,I(3I-J$7U9X\N@$/
M<)H8L0R>3(Y-B%O,+5\I$Q6[!&X2NWH1?WI\R31@DC!A%Q5?XYEA//(!3I%Z
MO(,*_P#FBLBCSWXE0KG.%QZ9JV+?]ASX#S)30-:AB=+4X2Q-H  0>LX=D$20
M>8$>DW'PSY0FP,; AJD[RB"A;<HGA&-3+VP='$4"VSL$:(HP1X5^!X95F3,(
M'6LO?VIL'2)NI97]5XPT2*3WX17"WMJC(FA_67!O^G5\@9C:25# 32F4HH3R
MV+KL(AQ%^+L7JUZ+[3_V <Z/NMQ#,\;:HR3@%FLP#78[' 2V$I8@P*P]'%(=
M2^R^<,,^NHTN:*!=0P,=!, U6%7YG#M7NZ8I\1<>16/?YU9LGIMKHQ/*((75
M%>5(@\1T'UY-O#(6@[XJIPB?G*'WR!A,0D05<4*?57%"ZV%%A% VL(CN*@Q]
MC!ERB]=CS%!CG\XQ9FAOF(\Q0\>8H6/,4.OH'&.&NHT9&D1T"DBZ<QM>"P%#
MPXCB DDWN2[L?P>L:/V:]W.LC[++4&]U>J8@/.QM6V62_X&".;MW%A-O*W8Q
M@]Z#!+,N?\YM?17*K^,IP3ZB] Y1Q$A<L)OY!7I!$7Y6ASO4'>F@\#;A%=0F
MG<%>/#S+?K=UN2/R@KAY9NS[)/6B.JO<:+R#F@?F'(.:J3.S8<*NQAZW+=Y@
M2L\]0E9/F(A7UC6F #S(0>&N81,"VUI&A H#FKS'\O8'!>&6(P@M:\D ]O)F
M'[B[>E]_M+7HE0KAMZB.=L5:'Q1L:WX@G#Y:]%L5/*:Y\^B6UQ[B(I"XJ#[^
M5'91;9^M%_Q/H\T81T^4$[P>/5%'3Y2A"?WHB1J:N^/HB7(6FJ,GZNB).GJB
M,DQV O7^=TI"&H3"?*Q#1]-Q)IMF[@%EP@6XD(;L/OPP"'A TD&+B35,FA@O
M%4:\DY^&>]76L=6VKU'J^C5AY"I-TG4.P/]"'J$/X,M]-N0^(PX3SU:8=N[(
MZ]RX.4BLZ_)GX%SLW6QVCI=+_O8 ^[^Q,WU*<E[$+TSL:"=E.UHVX$@,(.*Z
M-V/FOW/&MC;V_7291@SO0#RB8Y0_$[3@MY+U?."[L8%YK?Y(=I:Q(9T:(UN]
M49RQLS6%N[3:F\C0>6N;T.FY]+)D\IPG'/-W*FJCFZ:;-=M;(XPDMQR=1!PZ
MH4MDZNP\0',[]C<S66,3!MRSP;4!C,O6M]; <]0"5U"0=%:#2M/9>TM:K7)Q
M8 .B(1S>6]O@'MC8DZ="*G[UT00T'_*1I)2 0R&+!0IY1-TMCKWM;XK1MKKU
M5'L@.\>7&A>\'TON'6BVX'7Y$.QP"G1S+$KM?_=>A.AX3I @!82/-96UM'78
M-5U26,\-> I:VUL+IW5683AW"OP+*8JR*3K-+%7P:>DRKN.L;;-YF_A-/3(A
M0GO."LA.$1$\&.$(=3X</)4<.G?]KDS$K!QPC369=3@<_"I<.:>G5H@M5.^J
M 5RAUZ&A5V8-5$.L^:7"ES! <4#//;I0>*"*S08.4I474$NQA<JN%\E<3U'W
M&SAN!LQ!0%I[TR*C67>PP7T.$$"#X\W:VQ49O48GG*;C <)H>LY9RZ3*;ZB3
M)T'Q.;O)AH&(%L+Q'?(1XSZ8Q(6+KL)?5V>8@>-<GU<(=6O94 LLL-N/C^+$
MF[-?3+['B-!%^)S58ZV+O-E0AX-^#7ZA&6 MO6J!C=N4RXW]4#AXKFLO>^TH
MAX.[&:N@)<&:B2@O*TUS-CCA/(2,%TE7^+M4O0:.J98U$$,W\JB>>504R;X(
MHY2)XA8EG.NU/0M.H_KQ5)5&58PJ NSR<4=LX!$?><2&'HFQ;53*QDE622A:
M";H8TO?(3XDF9>S'=\J*V=M!1^M11]MA;:>+'3/:@@JSEZ]^E#(Y7K%EP6=^
MF@C]8_)TZ1%>"'XS RKS7^(J:^T+ELZQS?S8DQ--:&+;WW$G>+'E*58^-CO!
MQ_FPQSV9/5O)!U!'IG3Z46OQ+1W-(-R?Z)SS*<F)O?662!=$J.]I)U*F#_Q,
M9DQ5ADX%V'2&N\LA-.[-C1XC;Z;I8Q3ZOXK E00.G&)-92TM/? V7EM82WW;
M>Z]<R-?32Z5H-W^W55J\B41WB09WLU8E.?XR-9FKE6;60L3JRU5..^AJ;56\
MA0*,4\9*2"DFJUMV!Z93;\75(Y70#3M;LPG5AZ(.1Z 7SF*VB$W::'U^B%+3
MV:=A@*2D'W2K6(-$U*@-_23W 7YCTJ1W]]]T\"B[67O!W! K V;@2WR[ATDZ
M3VGR\)TIAZOL_Z]P2FY#$GD\FC=1[G:&G6<GPSG1:[$$8M3Z@5_8A;6@ *UG
M)X,Z_Q4\@&)O5Q'XRL9>E&>"B>9ET'%V,AP-P)@=$)?&Y[]\.3R3,&J"BT''
MV<E #OTZ[("X-%8"H&VJ$2JZ;NQJ-1Q,S)B!S5Z.V3N-+4#C)4]YU9G=/1M^
M=FHI"UC'#J 6A0/-K(+<K&2Y"9/U$S%VL/-46RCV0[-DT>]E26[R\80+?F=$
M=S+<;-[F5^!7Y/*XL>XL7E.B<_:6VCGCK(7%#B49&9;;],"RQ0 H'//!'//!
M. J,RWZ\8SX816H52Q4H]\L'TTGMR;UQN&$BFPMU]!XE238[\W)>,"**3K9\
M4\;*@HYV [W;@N<CB[N^8!>*>,YN"R$.LGCL6_1=_$FI+YCT=QZW&FPXIT6(
M;,2;N\TJ+XXW)?@E+*I4DH6F[N@\:";T@[J%Q8ON'1+A]E./)*MB[A.36^Z'
M\BTW'VPD1AL5AW/GB@LP;'#AU?>T'2L-@7FVVOF+:4ATK>&<N4R; @Q&-#>0
MHO,W<#.>U-?Q.F,X$%;<!,:RR[NNT!PZB8LDZNZ,LK9V;O(-1 YCYNZ=?C]P
M7+[-=P!@CV&UYYB\I/3<>PX3+[H)ER&C1!T[![6W%&*KF/[8D&JG=S)]R%6Y
MK:UZJGHDU"1#,'QLU0%^/[X[F]Q]N4F4T[S<REKLFM'TEE,+*VKM3FQ*DL*D
M9C]M)S3[8?; [T^3I^LXX&F9V!41T+E86Z#IL%4KF"^#V[$%>'X-DX5@BO.W
M")\?\"6[Y"M.;1F#ND%ZUK6T&"BP,I-'Y[J6@S ZJ95U!W6/6MD9]D@P>;H(
M"?)9#V5HEKQM[WZ4/98.-N&E)_>*9IF=+T+T=/F*?!$&-'EZ"GU$0'18#T6'
MWBV\^T-DP!"$D[V$T ,OB]"F?:=F?01K24N/]1&.]1$Z@-=)A:7[*="CXE*,
MJW[XC@OO0VZP%_,W(M<Q34BJJYY0?YSAUE9HR"MXT'9A+KE'Y(4=](:E+Y1]
M[#T#W+\*A@%CL-7%F@($Z V-?%\'I P9B,6AC.$ M75\*9)N3OF\#'TD(/<N
MJ3A=P.6R^M(RI#VJ+/D5EHKTDP;V%KC][,12\*K9ZL#&+,"V%GLY(M)'&@:A
M1U:%_+6:QQ1PEX,XO[0B<:A,0C'IL+=D_ZRQ)YKTM?0*0XL G'I9+067CK)N
ML7/Y4&L?7T=?;$Q)^,+VG&GD^>K;7=Y!WM[:^5=C794K7<!\P(>@M8O<H;TJ
M;/,P;/;XT%KIF>/C0T=/N^/C0T/P'#W*]GM\.,S7A^KCRIH7KU(LD>M3/@D?
M47"6)M_BL&X!4&E_:RFS&CZ[J,,5!*JUU<7X?$'1. XNV:Y#$B8EHT>ERFY#
M ]" &7 QVE/PL8]00+,T-7'"IALOB))'1*L4?56_H2%GP@VHD=C;17=R[*TS
MNJJV36F'H8&E9 /4.VRA=($>DZV;]IKO#(@F=XSQXHMF&#2S_D/#L Y7SGG<
M=HDO3,<']@&ZP%%0K)N7%=(CH8\>2#B?J_3./0<>]B1HR*Y[%NU^4C<,#.LZ
M7#EGD^'A-MPG=H,\BFA6!94?.059A"I(S?H/#=(Z7$&06JL*+(HJ;FE6@%=N
M.328Y/1#@%@KV"MFDU:%+;8:&A!5VB$0K-7,O4,4,4(6W/^/V%T6/QO=XI7=
MA@:3 3/@+=X)5VQ/Q8X'!FM]WF##J0,H"T5XG4+8"-&='@-&3\('B)0]A^R6
M7G:OH2$C1[RDRLYAQ"\V=5>DP3@#1M68.Q#K@H7'8L%JH6WEA\4M2A15FW]6
M56T6PXSR<?Y#E*?NOQ[U6>3YO[VA/KN)(YK5)N*+CUW>ON( 10K>/BJK;XMA
M[[-A1]FXHWS@D1C9=E'J8^[O8^[O8Y3.,??W,?SF&'YS#+]I![^\D(XN]&:G
MF:VGFW6B;JH$@_XJ>_=&?E42]R;%*;-I8ZN\J?GQOTLJ)&][QAA15-MC^@:?
M0FQ_\#*Y;=Z4GJVV3:;>2CSJ_NZ1X,H+R2]>E*(QI>E2*,;T\I4=R"$U@J^3
M;PYC.G3'NG,J2JO\WH7TMRN"4-$%W],LDWWZCS790 F ZM=!S#ENUN#5<W_!
M/+U0Q([:'F>=_.-_K'FGD &H.%J=>8]ZQA_K,/Z R/)$,^$Z^>8PYEEWK(.Z
ML0.AZ%./3(@05" 8T7M7##H[#[@I#Q!R'RR:W=?%64TJ='PJFZ37G=VIQW$T
M.Q_-SL<TAXW,S#7S%]JKTWS,7WC,7WC,7SB\_(5?>4C8#5.2OCT;I;J#VULJ
MA[%_DCLU2VUOM5(4QL\DC&J@ +>?R3:)0<"@X0G<%-O-_I@]3177O T5RNQ8
MJAZS$TN525K(_*AE"UP8'^V]'(P\2B=/^0UH0N["^4*C%2JZN*T9:GEUR,HJ
MI57GZ59VLJ/UZ65N@)&[H0AMP^2R]M8BE#UJ:^*,+*9/OL(I61M\M J#NJ,M
MS<%DD>#:C("KJ^DF*,?CR[01&KINMJRK-;$P8@-"XN=6D9A>3R]-1%]M-SN5
MK5'GA T1#D[T=_8<^<=X4--X4&ONQV,\J*-*V#$>U!"\0XH'M70"-8\'59T\
MC0\>^<&>/D:AKY,J/R"K#6T5AC62JX)D2+*-+2MRR99RP9K(6-5E]MEQ:6N)
MA^3^V6(NK&-RQQWC8K_5#X=<RE>IM=:OT=MN)).#Q5U[UV:/-7J/-7KWAKI/
M+5B#]KJRBJHZ[&Z;WO7>5@K"2G@  ;"F.)@EF&]4$4TZAJ/G7 -.("RM)=XK
MDEBGG):3)<]4(H<Q<]=<LQ\X3AY6W0'8IZ<LBD(O]M&7"#]Z$:<A1NHR9ZH>
MMOPQBC6 S0D'/3#'XF9]> ;J5RVSEA#T6+7,E!/W3J)CU;*#KUIV/9WHK(";
M)K9LWXU+D^U2#IK K9U99RD-8T3IV/\]#6DF1.6)!79P^[S2\.E0KF,9I?R?
M!"'=AF?0U<Y9I9.^'BNI!%PZJ+J$S>5CJF5H^WPDDI+GQ>K<BU<Y$1D]YY@\
M*]^*Z+I9BX\W7S>X+C>@Y\K>R24--)ND"4V\. CCN<*GJ.DY.[7D\S5_!F[$
M 02:Q?JTV\)-/)$SO]]ON%#H'.I^[L-E0C^XPIQ:7SL)E[8LY'^EBBP=C89S
M']H]V )UF .OA>,\IG7X %456R!^89*XP6Q.QM?Q"Z*)>.$&8R9M[CY$"K(A
M1.PEK9%M$9NJ!LAG4XR7WCGWH@@%9ZOR;E%S2S4?V'V46V'0.<]GBW4AG$=0
M3;E[GH)ZJ5?=%W^)5N>,7=S(C7Y/>>#\"P^J1)OGV6J?F;S/  #1T X!9*W0
M5^<9UYR'S)@)"#MK]<&*U\[\;%S?3 POV^5>[J.EIQZ\:-OS<:KN&^*/D]UT
MQXH"Q/7'<A_3ICR!2%NSJ6S2;F8$GR]X]A)Z'6]^O[[7* PIYF.XCVQ=7D!$
MK=E,+I!X?Q.^H)O0>^39>?F%)"6DX#.1E8Z&>[F/FIYZ$"<WRGY=A;$7^Z$7
M77B)=X4)?]3CQ2MZAYXQ2;@7^3[S>BF*9GU6%<W:?&#$OS!ZPF24+- H_\Z_
M_]NGTY./?Z6C[?=&^0>MU]+*R,@(8SOM=<QH7WHY!MHTIT:]+1VR&_055)ZM
M\C_JLJ,V&<R=%*HU0"X?Q<VE:"?SJN9U!R]DB*,P$'0+QN&W<%!;>X$O>X"!
MM6SUXY"JC8_J417<NO]'<!JQJN3OUG.W=B!P,H2E#9@<#:J</(OJK/$\7_W:
M'+9 A[[SGYHL"&Q*N',^]8V*O0[56=-LF$-(WFW(!Y 9A^ZYRO/[@2X"?;>9
MY<1"2MEB%>$]G40= ^#D&=062#T&3MZB[S>ASVM=*Y^>59I9RJ4MG\M836?;
M.XY4D.>L0>A[T9A27GS\!47X69<D6]W'5KI+G8P-J 8EWJK(;]"<41$'4X*?
MV"IC,O&B*Z2>R.H^MLJ>ZD1N0#4D\O?MIA/U?9S&7"M@U(S3($QT E?UL%:B
M22-N+<V0L-O-&'KO11X)$9UZ*\8<QU\X2"JUZ)3)WVN-,?OD)B -N( @^F0Q
MX05%C)(%H[ZP:_)*;>RX@M4>9;?9B:7$?'O8'0T8@L"SIJ)^03&[F?*)-PZ6
M3+8TR>J5:='3=!PB?D8L.7==GR0+1!K#:-)[B%B:\^7<M7UC*[J.?;Q$W+-L
M8!';-AXD7! ;X&71IH]V-S[.I%;DIY\JGMC-(*-L%(>*1N[R5\%.&^UX8]V/
MNDN/SE$J;>V.)U0#ASIZTP'WYA[ L4_I<]-(.]BS-ZODKX:JQ*U#2H:$4JU5
M$^YB+Q>-2MI:;!PV-+<(C],&Z'8@=-0=6J)7YPR5-N\ /3/=3[M<E-@8%-^T
M%Q![@1Z3ZYA='E(^.=7GD:SM$(XBF$>';D:[1/(<1[I=#NYAYPQ2B%F%1Y55
METZ?]F!Q^>S9&[H>G9\3/\%L/RV7"+L-2>3QFJ0)4IG637O;.FNT:P,W8P4\
M>=KU-*7SE"8-H3'L;,O#6@.9.ISTXW4MTO+ VJ%S'+\@DH3LU-3A8M;7EA>J
M!BPU& $=4=84-:YU@G7AJZ<0T'P(ZIJ24X<2?32LAEW%JO9 =O0[-2YX/Y;<
MT_QLP>NRGMCA%.A1@^0Y,>BF^KPF$*/2DA%JYZ1KNJ:P 3NP"=W-9%AWB!W<
M%(DV]\]1J,K24W.@V8FMYY\U?2%-V()P=N1^?>7Y:+SD85RF]^MMCZ'@IJ;?
M.>\()S?3DZE(2RHT9A04K 6">L5[>=,1A@2@.3^.&QK/V1FRXC&3M5;=;J\A
M :?FP;D[ACQQ:2$C#HR8MNM08#-D!,+.6MI!Y0$M8K@:ZBRB[U#0,^4$@L]>
MED YX5FVE$;H;;L.'+PR(Q!V3=,(RM_JL 4?BF<4/*(<B'KB+UTJ[9R7MH)J
M2+3V$@8JID3S%,6[W9T'K#XSH$&YCUA/(16*_!_G^.4M\H,LU'/Z\GSYBOR4
M1V.>>PF:8_Y:8Q)'JP)-W7QW'/PSS7,&=_^];4W6;C\V_NZ10%C(^%?LI4^M
M/+ I&H[.5MLV;*,1UQ5.]X9X_F M\F(33W<W7VO1Z<4(\1<,#K5[J]+*QL;3
M(7!%#Q@@D?8,0BH@'KYC R *K0X>B(I$6LR*J42">S]-L"BV.WPTJE)IT2$%
M^.7QPP*GU(N#@E^:$ZSVR.MZ'3!6AA)3.Y'ZUK78#.-E@8K2V.HB.3'\_QZ9
M;-AO_C]02P,$%     @ SH9\6A(X_DMNOP  >.X* !0   !C9'0M,C R-#$R
M,S%?;&%B+GAM;.R]>Y/C-I(O^O^-N-\!QW-BPHZHMEW=.V=G/+OGA.KEJ;/5
M)=VJ:L_=X]APL$A(A3%%RB!57?*GOP#X$$D\24E ]L3=B%EWMS*3OR1_2+P2
MB7_[7V_K%+UB6I \^_>OSK_]_BN$LSA/2+;Z]Z\^/;Z;/5[>WGZ%BC+*DBC-
M,_SO7V7Y5__K?_[?_Q=B__=O_^W=.W1#<)K\@*[R^-UMMLS_BNZC-?X!_8@S
M3*,RIW]%/T7IEO]+?D-23-%EOMZDN,3LA^K!/Z _??O^3\_HW3L'NS_A+,GI
MIX?;UNY+66Z*'[[[[O/GS]]F^6OT.:>_%M_&^=K-X&,9E=NBM?;]V_?U_U7J
M_Y:2[-<?^/][C@J,V/O*BA_>"O+O7_'GUH_]_.';G*Z^>__]]^??_;\?[Q[C
M%[R.WI&,O[<8?]5H<2LJO?.__.4OWXE?&U%)\NV9ILTS/GS7P&DMLU^)0;Z#
MI" _% +>71Y'I?CLUL<@K03_V[M&[!W_IW?G[]]]./_VK4B^:EZ^>(,T3_$#
M7B+AY@_E;L.H5!#.A*_J?WNA>*D&DU+Z'=?_+L.KJ,0)?]!?^(/._P=_T!_J
M?[Z+GG'Z%>*2C!]:O_[2LU4K?><;[ )3DB?7V3340^U \%G;H>4!#G3UO;OP
ME)=1.@E\5],[['L\[8WO]?R_:1;G\;0WW=$\">Q2ACSZ]:K?:\K_\8[]J0<1
MOY6L \-) Y*;,$1@\031,=2V6^MYW+.;\FB>4]EWWC,*F\NH>!:&M\6[511M
MV />_\MW."V+YE_>\7\1+Z'^AU]XWXC7."LOTZ@HYLO',H]_G;V1HGF.</+?
MOW*0_V[H -><T<:+B,:65U%+?!?GK"/;E._2ZJ57ZDN:KYU@U.\L=Q#^)7UN
M[5<OF4'0.-(3H[C(MS3&H[YQUQO7MUHC7*=,@P_8</;NT^-7_U.(H7R)A"#Z
MF8O^U[]]MS<]A4MQ4@I^G+^O>O<_7%X]_<*&<NL\$X]91%2,H+[_E@V=SEEX
M?WR)*/Z(U\^8#OP:I>F#-Q-<X0P:H1:<2^.Q2JP2VA6GSM FHNB56T#_O;*!
M-FQH7W K)V': TXP&[0^I_CO$:515A;74?SR]Y>\_8?K-TQC4G"1FYS.,RQ<
MFB\[7L\:(;R@)&:_G9]_^Z?OM1SU\$Q?[/;V^IIV<?('@FA1OKP<ML7]<U'S
MX#.$V:/19_YL]+GZ1X3W3T?+G"(V@:_:*.\=N@T:126*LD8>HPU'PH7^NP!S
M:),^>"#R@%,Q:V#3A=T3<ZV(8CYW+2YVW5\,(Y,Q!GP.5<8[UAV[N&L';RZ3
M(<O<%V*,K@FZSS-:_Y6K$5P<:;1S,&'WR(0_RC[&(NN3AD:X7<8I!<&0RX1N
MR*,!=W;HYTH\/'<>7(FC$@P5O/24D:7 \$4+31=T?#"EH&6')>QO>X:POS#,
M13,?5/1W2@D?G#! XV10_!R<!7I,\N=_)7RG@H^(V""-C:2J]<N3]C86'CS&
M.(L8B 5EX/)MD;(.=)-3QE)ES'!3\<445_ -=6SR(+CD"')(KKTX:N3A]$7M
MVM/U;UM2[OC>'9M$L/F&RRJ@6B?(2J )OG(U4*40G&5C4 YI5HFBO2R4H7)G
M*FP<[2CD?%))"[-+'TD(#&5TR$S+?'#"T"Q)")\F1NDB(LEM=AEM2!FE1KY8
M='QRQPE^ET=&!3"<<D$YY-=>!W&E=R1#M1H<MCW@,B(93JXCFI%L55@F86IA
MOQ,Q$^#^9$PE"8911GCRJ+P21HTT' ;-XGB[WHHYX[Q\P93WNA2_X*P@K_@V
MB_.U>FML@K[7.#;6K5Y,<U4&P\:QB*58-[^\1;.RI.1Y6XI%^#+G2PAL]!5Z
M#:&:S\Z78C9;9Q-1FC,7*<5B17:6_&-;E'R0J9U/3C/C;S5BNI/[)8OQ-H+3
M]T#@KHL?9TC80WN#9VAO$B#!'W#,,R/(DE29CU,9;K<3E.*N;AHY;C,"E^2.
MR-U9/C3HD>5C%FJVSP7^;<O7!%[9_WMBCS(MT>BDO2[.F"'WEF74HL%9Z(9O
MR+6]-!+BB,M#68X9N&(<IFID Y)(/_Q4"D(ED#%42?0!$X0NM@6;D!7%+/YM
MRZ*I"+_Z(*25]LD?"^0N@S2B8#ADQC=D42.-.N*GS!7]N*6;E]UEE.T8K/TC
MV>AQH\W <]#QE4'G#+_)@+,J!.?-&)1#]E1ZJ%+L48BKGB8B%3C^=I6_?I=@
M4@4C]H=]#&)_^>4.KZ+T.BN),A=,*>&#/P9HG"V*GX-S0X]IR 0AA2JQ4\:/
M>9I<YEFR)>7B):+K*,;;DHW(T^*.K(ENUWN,HJ](,LZ1)IRX:07GS6BH0SHQ
M951KHX$ZJO7#+BT\D3+%\^5MEI!7DFRC5).%HY'SM31@A-E,_95"P3ED0S:D
MC) 5^:"+_/3CF)J<[#^OF);D.<7W>8G_EJ<)INJ=(F<M?V==G%W8GW.QJ@3G
MS3B<\L9W%70ZJHCKHEKY:%''Q"IQ.J!^("/T-)*-,N*9<Q,<'%!PA 5(C!P/
M6T=08:EE)0][)Z?LI([RBO!M@9QJ%]>' KZZ1C6PID_L_QJ<0EI(0WHT0G!6
M@ZI4(G$:=>:0V=47])_:I0(JYW9UI8*3PPI-D]U5G1">G;9+>]SD6:%I_HK?
M?75$2EA-']/[,?CGU2&2%H0K&9 M_\*UY5\$;OD73BW_ @@UK-",+?_BM"U_
MEJ:$EQOZ,<V?>6X@+3/3L-4L[BLNN(!NPH1)-C@U' %*R4JU"JIT4*,$)ZKP
M7=+Y<L:/-J]TYY\LLCYCBQ%N-[PH!8/3R 6='&12IIW3J"2O&'5TQ#2E^W>1
M3X?*EXAO&'253KARP_=-8THV8F-L1;% H@]+9G%OPQ4'T.WHQ2 ;G$^. %6;
MW8T*VNO B4J\V%^RY8N58F)>,,#_8!.QI_PCKYG(GK?CU1K6PH&+W2,NRU2X
M\(3IVGB*ZG"[7O,PCO4:>CD;AQH-SOIC>R(UC]HN3UN[(1GKP GKNV^SHJ3;
MJJ'43^*IQ^VST/YAZ'F']H]#XGE04I$Z9Y9,[\OUU)B+C4 GRMS=TYPVLQL
MTQ2FH#:>4K,Q'$Q7<86?RWW3-,1^E:!/9NJ!=NDG2X'AF!::M&K*!#OA\I3#
MS]F/B\&JOWY&K!7U-ANV@&UGPAJYX$QP "?-@']<R%LI8(+'342JFGT7N_:/
M?R.8LO?ZLKO#KUB5B#!6V6>0&>=0-_"X:0:GX"2X0U)RC:HV.6IUJMI7LY^@
MC--:KVZSS;8LA$L?C*,RHT80$NJA*YDGB\.CFQ:CGF-GJ%(Z0T(-?0 8_SIN
MG8\FV3D4DIV/(]GY%T"R\XDD.P=(LHO=1QP56RIFQ3=4'+>(304FG30#=:\V
M5S1]JTX-'@FM6*7T];TX:N7!=:<=E,4#CK>4DFSE%O*,JD%HZ.",DH<&/7A$
MM(,UA<56 TY O,*4O(J=F?TD^8$4IDL S"I^ES'LX/L+&GIY,%QS "DO<C0J
MQU_J.'R1-RI>9EG"_\-+E+U&J797SDW%ZQ*N _C>BJU!'@S#'$!*Z[%,MDI%
MY7_H:,&)9*H1Z_O1\X?W4.8/[\?-']X#XY@=H_O\X3T<D@V6&XM%M.-U?RP[
M5$8=OSM2#O#[.U &!3!D<T&IR+;O+007J-:"0[;ZZ@<CN08R/LFDA-<E3T\
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MV_9^!<$$)21IU+I:4;SB\:+M=@"<S&I@L\'TKB"%\0R#5M3SN$0+=C VD>1
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M@%VB96,#U4;04XZX&31GXSQA"-663L)=V8>G%ZQP0Q?_)MKPQ=?)[C5,'6T
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MC0C:C4P5+XS ^&Z1W*PJ^TT/J$FJ".^L]+D2Z?1-0/5=27?I86>2WXVW:OM
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M7!P@A.ZI.]^,#7$^F<!G#R\A':<1*XW@MG@DXV-C;'!(AW3J<Z^R/5MJ;7K
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MY3UT%7/T8'/AX)N;WARK!\6HJOKI&D5)2D#N-V4,I+I^=;PNED'*J._L:\7
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MT#\;AFL*@57SZR8+-LBN\\9&LQA-9GELK0!(..0%$30NB*0"(>;]GWG>^ ]
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M76=2I;@,FX#I'W]D5'\0]T9$I<:I7"M5X*'?4 85QR'71U=$!\K*<3H!S\/
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MD1^;."X..;]C;ME44A_GT#@'I?L(X*_X?1-,$[7D>KH/6G^72;ZI*EI7/!K
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M:#;D##;/&?EMP[7W"V0FBN:>GCH03A]'/84\<=O 1)VIFXL3"6ABBM9'/)V
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M)&;_R*>,Z=F^B%UF*L=E-XQI8;4DV.WJ J#:+%YD1R]^G:_V-/>S;"F7-K[
M[I[@VD6F&P #"<:O'Z:J)<Q="ON_Z N*V8SQ=B"VH1J](EE]2J:*9+*V?L!F
M+ZP:S 8J4=8;FOLD3FO34M:\*MLKFH-?01\!&GFM*OW\'9CU?=>)"0E96W!\
M!#8,:D+1,1AG&;/4S79QLQV0]ZY8;V4B-="0D^P)$N7='!205G-POGM'P"B8
M*T- 02HZ$)=!MAS',_Z?Z]\V]"6(^!70.+\,TG1+XX7PIZJ! 78'IVYT"I0*
M@Z0+29[@-TW).J"SZ]<UB3/"YBTB<@[H5:,'ZHR]_]M@9\$-=.2 &'5#PYGC
MSP8-$]_9W.>$_7%V5U"MG*&87I[D021:8B$V61.>6C=>W)$@(P]TL<PG\\],
MSCB=:@0-W; -.] F!B(=?4E-TX3-,]]R$REGJY_K[S7WH]WK\-'W E^#8L(#
M(=P#=-3*F9W=PCZ[5;T_$#%GT39 Q&R8@8Y=,3'3+@7FO;.X&@N+_ UL2'<T
M>*81S2G)F 2)Z+IE$C$.9UP!Y%OSP0H^ A!99^$Y?0[!MGQ"7VZU"8//R+H^
MX(.R*_2L$5 "Z.M!NGR0DDV#+7?MF^UZ17LH5,Z<&@!>)R!*/ &FV%C#,-TP
MO=ZB36.V&_I!@7+FU+ &"L8)?, .SAK51+=FP S]H( Y\V38 P;B!#I@ETG\
MPDX?E"W^^R0GE2+0> U5': 0.7-O6$-DH!T=&['F8:A(FD+Q<.:<Z*;CO$2B
M/BFC+I,VAJ+AS!=AC8:&9G0\;&R!/ON_,S^#-1J@/?_4SL"*/1+B4 )TA8+L
MS*'1\^ $Y@[Z<KPB*7T)>-:<&LD0%(T=H1@Z<UWTQ!#(&0\0+!0'?X].XJP,
MU*YLUBC(,CJG9 ;#U'HH\!6SMRAWY!XZ[C7"03LH'*MC^#AZNJ/>P [*WV;3
M7#S]Y7$/B<BJ0N)0BZ>V$Q3?8[A&NN +X CZJNOB[1_ O^^NPF%/S$[ JU]+
M@F *JVJUA,+C\,57AT4DHQ8=AFFEGR%(2!M#P7"8'<42# W-Z'B,9S/QLBF(
MI@&=W<:7P9KFTHI&U86#J@,4%X<942QQ,=".CLT#R0-^[7H=I#%/JS,.P\UJ
M(P*\^85L2#6[#:0O%#&'J5$L$8-S!!V\VM2$6Y0?+5*RY-7B7@C/\K(B=TF6
MW9-\,G\*7K5WE78#06%UF%_%=B%VXQ4ZQFU";<P_.%(.TZ[T-O3>P!G,9/QV
MC^"Q".#VU+*'\F90^/$S$DP%:Y<DIV'-(#A(3_ !GIY@]*>#\?[CG*[ V=F.
M,7J2BKG.3%F8VD<E=6?D1V@]<A)8\ 9]/VTE*AQO\F62TM_W*UF+7[L3]B.U
M88!3,<,_P$35%QNPJ@[8C]2&!.J0"?Z!I$^ JJ*J2_I3]PFF!H#+=3;4_FXR
M^TT-VA_[15L/'.U8Y!FB\.W-U _[!=M@"'J[R<FF:=KG='VP'[4-C)AGNYUL
MBJ -S]@1^VG;P+C!MCV4H_B^EN-D7@91L<.UN V6.@;E!_3O=0?T_2=&R7RT
M_\B(<61T\)E1\9W1G_B7D([NQ11V<S:?UI4=D.,$RR>7@#0PFB[(AW$#&*H@
M0!7IZ!KS@7&/?9[GW;@B+R1*Q./E<KJZ&R9M-^R3MYGOS:LE !?0L?I(8D96
MQ"8YGJUH3#E)/#C1B):Q(_8!W!8O("?0$6O19:'R\,_9MJ@HJ3WAZZ$=36V#
M0X-AO3'V*;OCCB4QL$X7Q?LD3@X)J](_&$T10%?L4[@=PF!>X&O/XD698KJ:
M96CHAWT&AR,@?6%GX <Z;+?Q"\E$#&\Q/VT*(&EC[,-V5X TE'N 2DX8&_,#
M>NJ$&F""],;.0=,=-SAOT('LH!#[ZT)G04A=(;-1@R=GK9 <8FTVFJ%GFK$T
M0V1$XH$6SG(!Q+OW']X),"ZOGGZY7 ;Q@MS&-P$MRENQ V<QZ=O5FI'&'93U
MUV+R=SMLI$X#H>>C 0+:E;ZND/]80!Z3!7?F^K-2QR\!C?A[^Z>D=LU<!LQ=
MT6B3ZRZ-.@R%G@>GQXJW8=8)J_(J5KVZD;X(,AJJA4#1'#U_CAW06J+1[:?F
M[(PK4]D!/6=./UC4JPP'F)\)3VY+9N,79M<M2%'&?C)O75@:UI#E,.B)=NQ
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M+7LD(6NIK][0<UAO=E#0TN[+/C\T<9N*0NJ'EP+PN-[LPQW%P)*!?>5 ^AA
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M&#0GY_,A0%/S QVJEH5J#9EN!#!T3@[U0T!GYL^1(90H .[1+OT1!O3 G<'
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MCY^XQHK_NO9 ")SX]JP@,!.-HO_%/+3/A&7M@%QWXLCKH&QD1"(JG*=T%>=
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M>GT+2WGW O=0.SCDCL-MH)]8W<:,/9Q'JJT;R)3F.&@;@WL0[:1%SF"O)6$
M#2(=#.T>PU^9\%A%/"TILY&"--]>QPOVNVX*0C$*VO6*)Z*@92ZV#.PG-V%;
M9D872VYBEFPHGWSO.067B@[CHMT!H<I)9P"P)><3TVDIY56_QO.YJ%DT21](
MD"5Q\!QM[^BO)-H^)<U6#V1!N446YU8J9HA/H=UV(>NAX6 Z=9&S-W8&^Q[:
MI=])"Y]W)M-%$J2SR?R*IFR>29KM=+:M:$$&0KNH1)49.(N]$(;+9+6B>4[(
M)'W</(?53P\D6R=Q1I\CPMC43TPZ?P+MNA5?@'K"@BU:)8O8'&]Y9E">5N@(
MTC;X5]&NGE$%T!%XV#+YP-@^F=?.M9;2I>F/=W6.*BA&CF)#7N-$DHDR<-DD
MW8EQ5I?<3AYET*!0X7B[_F4+WI^.Q/3P/,-'ALK.V_5#VZ+@R15X=28\(.TV
M#BGGD>GFNY6>L1JM<05>C7?DZVXM;?J[;6#78RQ][53N@]Q0,=5$3&L$Q$MG
M*\!JZ[(+BXZLP+53? R3=2\0FP-@WA0[ 5'.(9\P+'+2]@&Q-0+FW:X3%!4\
M\@G&ZH^WJS4CL.U%/?Q['[@[?PGSGM>)6/3DN4_B4S@B!!0\_/$EH!'/NC-)
M/S.[#%+9RL0KVP]@7O8Z$99N'#ZZM1TF\6Q#\_4R8)/])DQ6A;E=&".3^<6&
M'438:>0BR&@VF4_KJ,2SQ\UJ%?!JGH]T$8O;:<:O,.3E;FI1N0V;_,<??_SN
MW?=-B[SX("_SG2_)J/KL?X[$A_FOZY\N8E.+C_._U3X_VG]_%^K?WX;OE(2X
MQ0B-*5]E?=7TP<GHJP!>A[=.;93#]AL5R_('@'2H(P:AUB_%\(FD"Y*RZ=]0
M'D_+IBQ;WJU4*D4WL6[W'7$$NE0ME\GJN7S+QZCA/A<&PV\;6KA'S$O5=ARD
MY=N>Y1X7R$(%]D=>DMU ;2Y3*U[YLB#;J;!JZ_#/S77(6X^*YBCRN)OM?E:
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MC<H.R <K/0P-D]% M2^;RU6YC$5T8);QUZ;JM=%**5/U'NV[N]Q@E).%;C&
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M*,^WTR@014FY6*V+A+/ I08? 2W?8%?\;)F#CF;QO+5XU0H&4-L)+1E@5\P
M+!CX.'Y<B#]GS&*ZSG*Z"G(BJSM>-FRV0TO4UQ5(.:'H2VR7-Z66=>$V9I1L
M5ON]6 T+L#M:C;.N:%FQQ1\0Q2T0TP#%_, J$]H?K5I8;QA!C$''4?LNPK04
M09W1:G=U1="")>CP/9*(#;?X2&*2!A'/_#9;T5C4C,OI2W71";=DNHZ'5E^K
M*\C]&(>.^RYP&HRLN@=:::JNV)F(/VGKM!F)" ;8V!&OM%17H(&\Z+L:=5>T
M+0L,=D&KZX97Q<D:!QA!;V#5W20IH8NX2&$8'D9$Q3/Q8R0 @F^E/8;$J]74
MV>KMRS\G:_AZ15)>..ICFGS)E_RY7A!O>8*_#6PQV_2'8N:!G\>2,D],GGOR
MI49BFL3LGR&I:23PRK0?"0JN/[Z?KMQRL@XUD[E/\G^1?#Q+UCRL%(@C&[/G
MD%! /7 /]2?6KSOK=A[])WZ_([UW!F73'_VI& #IMOB/E5;_,5R2V28J7K]7
M[V$GFSS+&28,C(<DBI@Q\"5(9T^F!#_54;S[D&\A^7YOCOJRL/>>3^5ZUF3E
M1U[%;S ]?Y&'G0ED%6#+-IE/)."3G$WB!WZ?GA8%5N^3.*U^%!$\3_6T9QJR
M^W_"M();(NYD(??)_M^?!W7'R^G*#-,AY#8G*\V-ZL"?\4QVAEIO#@2MQK1=
MB B:L/%TD'MWTOB5:B1&UO:/ ;N,\EIXE@_0W0<K<I6L AI# :SW\ -&M3!J
M\:@3LC<RASLQCS].&YF(/Y'5,TDEC&;-U:VQ \9, E,[Y)I(1G= [5;\Q7;W
MSW]2DO*[XNT=ORG6ZS)H?S\6QM&V-0,W:A**#'M)M'"[M*=L4H26PW@F!""1
M5R$,H[BG&AT.Y]MXS4[?@KH/2JW;I%'6"3ORLY/DJD!4<\4?Q5RH*HER*K21
M150:>"1?RM8->7#3'T# [/5'+CKN7#8"T_\3V&\SCBI*0R'BCXPU%T>+ -Y*
M@/E$PF5,?]O85<WL.3[V00!5477"PA>WNJERI]K;WJM^)[(__@]7R#-+\QI?
MV$][GK ?#N[=F 3%&9G5!<.X7[$Q+(? 3I/CHG2G/1?\T@5EM47EBE=4[^RW
MEM]D&4\V"YZK'6KG*3MXD6L'6+A32[.3P!]9L=!=NA\C[WG%0IL!T"QH"S!L
M:?+$S-7.^1-/!@$!=">)'09#,V"'*9$+9)8O&XV\5HQZXVFE+%55C$$V*\^E
M8^3!7'*\'PB;'PWSLLK!YYBR.?- I'&8TQ>+%3_XA]YB:1E':*#O'3*Z2I:(
MZ1<!;VOQ.F!W,&>'T,VJ^%T?(>OS'6R'W-&$K#\87LI8G6=ULH967I"QL=UO
M* H+SG1?S)Y:.2REK?-]*S]TO2@6LGWS5JIC[46KF-P%F2<IV4^4_2?+:<A?
M$10OS^P7<\>!3Z[&UD"L]$C%<QV3Q%Q!530Q.LH7^Q<D)G,*]NOT&A3;0.@C
M"YUYZ)$<7,_GA&\K>V%^8)O9 V'*/61G[?V1U4H0NHR*O;WWD83N7/1(%*I:
MVFSVL@M&>RFP'! [U*>/ '3BG2\6FZ**G-IZ:]4<T-:20S;G3K^H7$W/-&;&
M+^*YU7%%HTU..KP6M!SPM K2]>2;1ZIY'.=TQN?*MIA]$M?KUS#:L+5^P_C$
M;9%-=9O;H0JABV]AVW:=Q65H=ONBZ*7EF]1JOE500U/$"3O4Y4U5<]I+HJ)F
M456PR%K?VXV'';[2I<I3/][YLE*KRC_JQ=FJVE%U<1JHXE,!*) ;?KI)PR7[
M2S613I<C[&O./N9%\ N@T)1C;ONR\*J:4>J%UZKC475!W@+?0+VIO8@U9G8;
MSQ,&$T?Y8EO^T>[6R6Y [%([EG6I^O'-EZ4W9"&>,B[[GNLA;L7+%G(K,9+;
M@CQ5J/AN3N?*/,.5UC(D6Y&W]N-]J'W:92DQ^ E0&O.Z,^<R4??P QJ=D.E!
MN?,I64B3#/8I_2M[98=3AV5/"7H:$,G,3,_?-5W\!*8A:&9L?'G'WIB:Z06[
MHCEV^12CB.D!\>R%^@.WGV(RJ[RM;-_<K#8B].J*,,.+:NP72%]LF]^P>[8*
M;$"Y89]3_,?"'H_)@@^'FE.<UQA4PUK\%?N:P1*Y.DDGG>_]<<D.F4\D7=W&
M+R3+#^IR2W2DM#5VT(<E=CJ2T17DY-#/S6_A-1<?LL;8$1B6:&@(/FFE=T]R
MKB2F:?)"9V1VL?V<D=EMO".WC .FNL)[-F-@%^6SA-V>/2<M#55HT63._LO(
M$W'F:N 5S3VS14T8:XE&U[3BKF.91(QE&:_&FF\?"-N1,R+^\+B.=+8HJ#-V
MR3[;?1'.$'3PN.[XS&QFD==DO.*^-[V%V6J,78VO@\&I(!@=C"NR3C):9F'1
M*;6#9MB5\JR5F81(#UB_"GAUQF)NA1-:"X&T.7;A.VLH-$0[2=]0?NN6+S^>
M(>6.KJ2[ [^/ES=%KSD'Y;&:!$]$GFM"OCV]!!$_N8V9'9FF6V9>B(Q7^EU
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M-Q%.;R+P+GW/-Q&G<Q.!Z=WVZB[B[-UV%I3V9IS;-2&Y(L^Y[!@/6C/JSG\
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M8+,5\74S;5XG*<7Z,=#S'G:'$L(<=#R]2J+GSD*V0;%K(CVO ,3*8NDN^\
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MDDZ#=)(6=JMPN9BS&(,ZHZ<KLJP(!^:'DSO5VO<OHR3C3K RJ[+6+@=T@^*
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MD^Z33>)?3/;&HXN/= "7J,]';"L'Z-&S@4JOHB%DWVSR357ZXU\D2+,G9:8
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M#+*EYOKAL!GV9?Q "$F)1X?D\ (!;@^9^J';L,. !F//2>^",A)-&Z&N#W:
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M)4',0[5OXRQ/-Z:29UW&07^QUKL@6G?NN3P>/9+TA>ER8*TZ0Q_TH], 9>M
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M%1VP4^YU5HQ:!G0O6T-2Y+3Y5^0YW]\.W'+=0;+\@3&I_BQ&C32T/W9UDX[
MV[$'?:$>3K<FM4_L QFON50O95K4-DUI2)Y2NECH+-+> V/?L@V"?V>&H@N&
M9^__G)5#Z0CSR;T&9)0Q4^^.!!G)BEK4?#^J42\O4%@. .V/G46T(YIV[$%'
M4U2WW<]2@UN[I4\AVA8(J4A&QT*(CM&\/6R%G<JUSRH9RI#UH0+4 V,[F_J2
MWSP2=A9.UB!W@*$;V!W@&;P@;ISPP<7G(O>^^89.LJA];=+"I*Y2UH' ;/1
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M9?IAFT^M._US?G;)V=-?7>Z#@O)^XA%G]5_4/R]1*>1O_@=02P,$%     @
MSX9\6H,3.HMZ.0  *L<!  H   !E>#$Y+3$N:'1M[7UK<]O&LNUW5O$_X&;?
MNTNJHF3+>=L^KI(?.5%=Q]&UE9/*QR$P)!&# (,'9>Y??WMUSPP&)&01#ITH
M]IRJ?6*1!#"8Z7>O[G[\X]5/+Y^,1X]_?''^G/X;X?\>7UU<O7SQY/$]^2]]
M>\]\_?CIS\]_B]Y<_?;RQ7]],2OR^F%T=G]51U?I4E?1*WT=O2Z6*I_(!Y/H
MC2[3V1=T(5UZ.?2Z1]%2E?,T?QCAI^Y_7SQY_,//KZ[\NYW,U#+--@]ONQ__
MMDK_H^7Q7SSY=SZM5H\>W\,-Z7TOMU9:ZW?UB<K2.:VA3.>+6FYQ1Q;_^.F3
M%^\6Z32MQZ.S[T_/'M][^N3&5[E#Z[YETV6ETR)+/GRYCR+_Z&*=U[H\Y"L\
M*_*DP;Y?+E2Y5+%NZC16615=Y/'I7_%F=:GR:E:4RX=1LUKI,E:5_M@O??'J
MS<7S%Z_'HZO7Y\\O7OUW=/[J>?3FQ;-?7E]<7;QX$[T\_S5Z]O-/ER\OSE\]
M>Q%=_OSRXMEO'XL@NR_[>U/5Z6QS8.XZ.XV>JOCMO"R://F8W'7#RUA&^:=M
MW=5"CT=/"U4F43&+GJ>ECNNBK/"'89RHCV^BHWJAHW]GR1]-\8BV__$%\=ER
MI?+-XWL73[#__R[YN^-HH:I()<6JUDE4+U)<7Z6)+J.K4B5I/H]4GM#RXJ9,
MZU17X]%+=1WA9EFJ\EA'ET66QINHU)FJ\?.ZB)BC5%RG15Y%:1Z91T>5NTM$
M#[W668;_8J7>-_1FJV9*]\PV8,V$EA7S]?CR.JT7T?6B6(Y'N,S>6.=S-=?\
MK,ZSBU)>+YHV59KKJC++I.\6Z>HTHMVE RR7L@BS7>:F$[-#]N-KO?U)4]E/
MQB-LDOFX:$K[PZ56^?O/"=?A#?B_M!_T]FE=154SI4-(54DO?9L0#*PBK/*#
M)JI5F9Q%5:NZ0U:9NJZB55FPDN?C7C5E3-2A0265RC3V7AE:V_R[K'""E7^+
MZ28B]5"!L(@$(U7J2%WC_].%2WI<F:J,2!"JA&F,5C(M&CQ,U?:^\@=Q65[4
MT5SG6'&VB=[FQ76.A:BU2C,UI=6 CWB5X 4F55HJOP413]&^RHU+JIIXX=8U
M'N5%+O?REQC-RF(9)6D59T7%W L)X/^ EE'0.DIYP%)M(F;*4\-[S,LY)(=.
M2WK)O"Z++,.=[+IX35@QT?3O)+V(<XN(9,<TS=)Z$Z4S7+N)9O3>_,[JK28N
M570M;T-5ZU6%+U:E7I,>IL6)>*J->*)3L7LKC\QU%EAF3S.$3@/GO5P59:UR
M0ZJ;HHE(2]-FUN9HHRF=2$*B%RQ"LG4M#&$(.Z=UU0VQ6YIE>LX\T#TB>Y=2
M5TW&2@(7Z3\:30J$EG>]2./%>!23L)R":=>ZU*!X6MI*M O]2ZU(X\26-2 K
MM]4,"5Z/7<G@(,+EY_YR^N;44V&\GA?OB/GS.>N095I5H'4HS?&HHS7))MO1
MF/9U7JDJ47_0D]>:=F .@<-BG B>WH"TTFRFL5GT<1TENL8?].Y;NR-:B)[#
M%_-2SVO2\;G>D+(E(54U>F='UVEA]!C]<UZ0555E&^))$F<5J3QZY%3K'"*
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MT6\XPI)/>47/3E'+A?J2I7J+Y\$E=+A>+GW:KL]D6+3 B+V7H'?@@[8O@H)
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M5B;#>(KU@H4!J#I)$]Y<_$#L._L)0$"\'Q8<-RN+I<5C6G#/>&3N_(E3^!Y
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M$[R:O\:K^7FE!U;IV"0M1_X$72SMQZ"%5T 724[6V%SXV(8VT/>LWTB81.G
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MVTCG9MH.0.L,Z!73>K72 C>FNRRC+5(R&6N=]!#55N'9%>Y4NF!3IWH$10X
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M,+9GE*6]6 5X1VM*EPZ\=:VYN8$GE"RWIGJFP+6GL/Q89D]O7P%02P,$%
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M2S?&RBWLI6W2U[V$[W^AKXGY'U!+ P04    " #/AGQ:44&<VR4&  !O*0
M"@   &5X,S(M,2YH=&WM&FMO&CGP.Q+_P8=T$9%X!$CZ@"T2 7+ECB8HV9[4
MCV;7R_JZ:V]M;PG]]3>V%U@H[;57DH->(C4IMN?]\'@&Y[7[9MPM%IS7P]X
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MX#Y%R[W!;MX\,6^<Y*^@F#=5_@902P,$%     @ SX9\6HU&R<MU(0  2M(
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M,:HJ-G?MITP&.QH.9#">X*M)^LU OPDTHJ=&K8H:^RN-3EOMRAR-8BIP$$0
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MRA9R<K_"0U\=<K(-U=Z_1=^&:N_ELMQ[V$E13G7N02>;<"A(3V8_F9O"GH3
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M3M3!XL!^31)_-<\E:J?::6KRA >*FH(4<2UN C,U7/*ZD\'5<"L+ZC5>>\8
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M#B-+ M-AQT*?*$Q &YF680VGOU@&"JZ>H:TMC NJQ\ZYI+7NL$[SKR#.M(#
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M#%=&18JIY)TU+.5.T2JYZ*'TS;'=;T\:,55X4L\F+]3R' /@-[%L0-E,0<;
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M]^S7#+7)H3FCM$GCBLW2[14O%=]Q0<QY R!JJ#8R'I@4#F,SF+&/DFE2H$0
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MKL"TCJ&]<WKFH+:B @X@[BLC?1!DFZ9,M-N&[0J"IP>?6TPDD+\,.HOVCQ1
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MNCL^Z0MRM61-$MO#$#J9^+H"D^TA<)]:G+(( OT8AO13<B[)TKZHL@2$?--
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MXQ+$7(P,E$Z^KN-.E)0"\.=*G,*"(*4Z*;Q,XUWJ(0M(A$ _B4E)D^"^*QF
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MM]DI+8MLUFHO1(=K6:  RF8'?(H5KP3[R*%+CIF9Y31C?;U-6Q^I"J_+="*
M2H>-&;3JGDWEI4NM1<JC%Q!M]0H 3<V '8!Q33/P5O[U>/SP$:*S7(N$ZP[,
MFABE;"3^)OVUN&*RN,)/$N<:T-<XDR, BXBOBO.9SG]XXZWX>?QX?/SH&TD"
M\1N8YN;T=/RWJEG__9BVA/Y'VKS*,.GMFJ&=;&Q"=X& L3!F>M)[!75X2LPH
MH96;65).;J^:!T6(0E%$'MZ&1I.L#.*LHQ84A!T>V\RBC0XK3;J:-'15!:++
ME2RFS?1C37A]91322@UMY/=S*FKI"'E%X U-A<%KSCEH[<8L^0 N[+ .*:<8
M^(Z N^M*6HE,9DQ21B>X,7I#@HY=>D/EC;9\0H4X)[;PBUP/?F:Y=TDS5;7C
M^T2)%?V0W2;M:+B"7K8@ +!-<B:C02['1BJ81WA+.+0:FO %BER2",^8F!K1
MC2F4JH,Y+/")SL3WF4/&I"'3@#SVVFB'934!=#F&\__1L,\OZP*\;MMX@P^P
MWU.!JQTI#1'3E0;QE=%N/FUM[I";.9=FL:[FPD9.)OL^DO )1%S0MP":*5:I
ML9E8R"U\?Y7.9AEH2A-.=L:D,4M^D/O!.'[)%5_M][-O4)/ZM?(*92[L!<S,
M2GE'M[C4V?!!C9IP#<G0W1@C,2EDA/P2\YY>.9,L>UHZ$09O@<F#>02=UZM=
MDALS&Q3XODWE-:.4 #>8S_4@V20]Z^4E*5;&#[054:C2+;>MJ/9Q_"MZL@&J
M4,6@VK5,C;:4EX.D=<M>I;?E'$<6=M"LN#KD#@#,M@G4$A[&:)"@9KD4 A'P
MYHL&1Z<Z\C>GYG"25.K],=P*F 6<:WU<Q:7/&_51B[)27@Z.E=*[6?5&<L"M
M=\A,5;,4[W71=*[$K+1'C2R/QUD#J6$!9QBZZ\L"5Y5?[VURO5\FR;@SO>UW
MU&KZ%O'6"&&;O7W:LC<PK!WW6EED^D V/)3=S08?4F!E\'WM8(-_6?YQUSE"
M"4+:>W GSOP=NKX"N8D<Y,9>SY0WTTR3JO8>:*YN)R-N3L<GW^ C\F-/O1M;
M6/PX@_K"Y *I)7F"[?S(%?MB5G.M@0V>!=K&20U'O\].ZXDXK7=B ^[062+#
M%2S172KF[[;ZCCJ^I<='9X,5^T><DIOU0'XUT=6R "H2GK#HI[Z<I"T_TA)H
M[D?6ZH(H&5G?/N*IA3W;+M[,OG5@_^$^5@1(M%;F9B6;UZ"TV@-AT0XX4"S3
MBO)1DL9-&7,<D_S)4LL1>G)T=G+/M]?P[>)JA']K&Q!W@?FDJ8MTM6IRXUO_
M#!6'>S:5%E?!5=B<11A'F:I B6""TVI/Z58'K&MXX9AA?(L=3H49"J4\J5O<
M)77K:[3$5E*'ONY+GJ]/SB[^)8K!FQIL9;:J)2P8D>:>MC],S\X'E ^>NFD'
M52$"S!_ 4QC]69["Z\[C!_,41I^"IW#K2/\AGL(M)D"7(N@G!/QT'(3;A%K1
MP$%X&ZRK9XV)M$@P[ 82;W<#:2GU##%_('_Y!+8;<-AFZ72 EBF2#V$[J+ 3
M1\"LS859MKN5-+61AA0@SM9+"FQ@T!>+KUG\HEDWJBI>/3V/_YU4TX;N#S)]
MZB^/G#G5]WPQE_C^0@CAF='%RXNQ>RLR%[Y-AF^) :A7@4(S>L+)D2,D[[:_
M8H\+VG%G7_==A/!1A0  /?M([/KCQWB5-; X=F!_J$QROXS?A@&-L.HY3B:@
M=I2&(]T1I&'G2$TR\K->J648O4@G92+-Q%YJTT9?U6$F55KS#Z^NKL;VX=HR
M>E%<Q@=+FR,2D]>/"@)<RN4AIK3S]16W2^.Z'!9TFA"-.$ABW\8]J.MVB:CF
M;J5H_=[8;>S.+0PWYH/W913A*7XKDFK'3OS*5?Q)"]T@-):MQCQ!Y_&P-8N0
M'+;ZD)-<6-IS&076T4@:[-AEX$=A6/[7A2ANJPEX>%(NBN+SE/-Q"#9C22>R
M^&N=.;[__-DY,ZG5KH5Z+1G!Z3*R+=/QTY[?C:YK$H]7LE83M6/C=T).* 6P
M88LL#NV'?6Y"$EP1.-UV1W="1O>IFZ $XTV3F4-;AA$6@VA!RLD#U*-L5^GP
MG+9*=,*WAR]']8?^W[#\H_7R+]0WYP^_DY[]2>,T ?!#=^N (=?1/T%20?+S
M$4FEOZ5_;^,/!4T:OV6*G@+(<5SSDN$HO[Q]%I^.'YS%/]M (%TMH$R0J!S'
M]*"WZV1JQF1ZC>-E7:^K[^[?AQB>I$5E/[F/-%!U"/X1$,#<;^7)#R7:SQ.A
M/3B\PNL/$W[]85/-#D\/'YP=VC@DN!;E]?NW\NWH943K?/&/B[>TG"1,;'[7
MEFB_>/CMR=GA#R]<38RDA>/6SHQH:[#:)\>2%J8IWU81,A1<?LQ,ODAMY>.A
MMO(&:RL??'VUE7WK^)D/_QURE(%"E\O#_/BQ;6>EE$UAXTOF[-YJ@YS4%HYB
M\K9S ;9M\;IF9 :[=K)A/*N6\B[;<IIIO*?H2]FQ>,GIR3(U\ZO?'U7'C^P$
MT;2%IN>4XT.D>8,B#/ $I8'=P %YD>HO?=PRH64F$]D(>H5GOSW<HHSZEB[D
M@_S3I^\/WJ,G\80D]$(,*1*<1?D=_)O:W/0%\R(^%.E=D?_1R]"2^#LUPU\@
MQ@+Q_^'/[U$4?U&9Z'7#[RG!/_XZ>60PS6]NVIXYQX5U6T=*J#O9#Y^,;JQ;
MEV,<O]^9X<F-3[!S.'MF^-FV\_3AC<^6%$29K!G Q],\)W-AV-W/LKLG9S<^
MV[=H4,,3)/42T# -.WQ7=OA%(>D^N\D_LT42SIZ=A!M5;W_&*/FDJDF"S)_B
M<'_> _DE1@7'D\=Q$C]+DXFI3;5O0]S/A7M=&D!U\Z3<C'@\-A6#^+[-E^W;
MH/=S*7_)4># (_D7*9(91*?\37A)!CFV3[NUGV?HC4&J%P/Y&3W,P"%;QZ\U
MBRY^/40=<MB#G!ODW)[(N4&P[='V[.>A>8J2W\/CQ_LVKOU<K5W2:M_&N9^K
M-P@H)Z"D"F6_MF<_#\V%[U>.T;P$%OC"8X'W;;C[N8B#W/HSH_J^ ;8^D>@7
M";$B'QQ(%6,/'SS:M]W:SS,T!,(&T?5E3:YK1)5B>VXM_N2.06GF198)K8K
M%3IP&DM=(2TI0YK#"HDX1W\<EKL&B'A7'!56<>4%@T: WOE,N/ ! /(Q$N'S
M)Q=O-[ZC#Y?4/].[EA2^4T".O=M&$-/37_^_OYQV@<"W=DOY*E8\PZ1&U6L*
M$GYP8]4Q(SN@1]Z89 92H(JK"0Z.[W784+Z"K;\CV_V*GF[M0=G;L'&:M+AZ
M&L)(%> Z;/6MV^IS3WO$4_O^?6JO-&S EP4Z54H=O%SKTYYK_2?B&7\F=-%;
M&J%6UJ-O]M-QNW[4)[=RU,>/;^6P;\]B=\!\W]XXEH_C)SS^3Q)#V:\9?9XI
M/?JL4[JA.=W.Z](:]8,]@/E^S1MP?/,787LJ^Y-@V<\M&T8UC&H8U3"JSY\0
M'M9OT'4#0/,3CXI)W'@@S.K>I7+;M^'NYR+>M SXW_]Y_.W9PR<WP(QRYQ9P
M/T=UVT(47^<J/K? "!X@MUHVEM:BKU;D;JK/NWX7AU$-HQI&=;<E^;!^@ZOX
M@:[B4"KSH:,:2F7V:E37NXIW;[[[.:K!L[L-JWB;/3N[RG]JTX>'?*CXW(_1
M?053_-W1[=,E',H:O\BHGDOO/:D%<%WKXF>V:]V^C7<_5_$VV)Q#1&"_+:C!
M#OW:[=!]W*]A5,.HOIY1#3IR6+^O:_WNIOX; &H?,2K+("CL+"^*?!'SG_9M
MG/NY>K?!]=O/^>[GJ&Z\?/O^N=3JGGS"$OQA*7>7/=\P-]*=X+OII_+Y7)V0
MKN$2^N-'3R=X-#YYD.:?<I-N@D#CACFI+H0HR@@,G=N0@3]*^*=2;O&,#LJE
M06-B]&<6ABGZA$,FX_@Y&*G>)PBFC.)T'M.XW(^SM +1!/>@=B&6D?Q\99*\
MZKZ0OL+CL,V@-4AC'%UXV%X\Q<]I9.A+&([3=1SG9XQOTJ2]@>-Y&^3US=.\
M?7U[]>DU_XWOV:\2DYX5W 0])1V._N1%O"[A(YBP?_F<%IU)[USC<D=?!X'B
M_ SMA$Y7>UVF.0A.LFP3%U>Y;:Z>EC/I FFJ<?QC<44/*\4[N:(7DB @4R*M
M,\,#26(T/0YZ(Y;HXM[0)-.MINYV./3JN22^[$CEU4GP\HV5/RNA69$6[L9E
MR^HEG;+%DGY3)1"+F7:+3&RWR!%Z0!;X_E5*0O0K/O:#B+H]>[6;2&AO]^R-
MF6=F6EOKQL1"HTGW703-E:/<S'"I+:>2B 3Z\"K-LK@RYAW$B;WM<=703]EB
MJ8*[KK=\%)?%)LGJC;_D9+60L9-,79LU;BK3DB@0($5\5339#./,W4O)L*E3
MDEG2[#6@\R*1QN-H-\(E8ZM.LSBED:V+&L*0/B$S:F7**?U3*:'$R)K7@5EV
ML:M)KEI@8]#'T1]2$(KB70W-:=I9J0DM+7R278M%<K3=2Y?'\8$KU[-JX_@B
M=VIF).9@_PB3?&.50'O!*OMVX='"BZVV:2K=_V8Z-54U;Z"+[()X,[.X;A'Q
MO$F=D+XIS:+)DKHHZ:"MH2+I8YXHCR]8)3TALIQ.PW#7X& ?:4<^N4\[=,[^
MR]]_OV']\='0L5Y^<2,=ZQ]^?1WK/_JTWGCZYS;3;*LE'UTE%8G5R6^D_Z&0
M^IJ/;8EK#B/0B$@_D;8X.:4!-;-4'(8')P_M\^CM9V</\172VBO1E+."=(BV
M@9<1C*.?1(<M:6:>F1MN$GW3S.<8&3TC(S>&5>(B:Z8%]* H,GXLJ;)92E\M
M^1:06T4J?9XRH7=]98SX,?K"PYH./J(E-,>(6\A/"O<W.W121*2&U!E+9G3K
M*W6$R*,Z)ZUCU20M406WA@9!([2#(RE -HA:!\%P^+]I>^@BJ*MF(C*EI(D>
MUKPT)/XN84C\(\%*%3STRG3W8(0I5\G<D)M5T1E)>EY&NC0IV:&\3&OZ);Y'
M/]1?90F)0]:TT27D-&MA SNP+*;X7;$HDU4\2^ID'+^"1YK42_K2E$W!&?8:
MYH+=>M[2I2'#9+F)+XN,+"Q#BX:'V@F.G?N(0T<C+H*3%WW@::NO"O].7O;P
MH8OT$IM=N'<&G0E]WXGX)>F'M&Z84Y[^?U/"@J#91?2?69$O3,DV4UW0LK7.
MV;</SF*REV;%BJT-^Y91_."X<]#-^S4?=1J+'>#!*7V)K%+>Z).C(S)DZ;_N
M69M1#W)DYT]F5+J":XY.B_YT.[?<G4J^(H@%%/.4E&'/D8_Y>+-!#+]IS2,(
M/]=K()]&^FEXN63SZ<TFY=NJQ]]MFFX)SP4CH@E,-RW^_8H##=;8]@/"%LSL
MQMB#$<'(J[!^LX8O?>ME6W<AS:=9PR== PP2M[##8!E7TUY5M2XLKD**3_-Z
M'#_U"TZWWEQBO2$;=OZ$O@9V8.X;0$ORX^3\>"I+56'AQ64(CM63>*DQ&!5N
M*:\![2X9N!SJP&.LZ( O4Q99-#/P 7!'(0<N,2D2Z6[KIB0O%\:_7R7.ULOM
M'M:=); GJA;)BT?J*< FIA6]?TJ;5&%5_8:Z8?":8K8T -);R^VC<"?4Y-W2
M^(#U=S5^$@@T4@ZTW9DYG-"5H/^RVE&/9!9\0XRKD3,8L.L;?A[?7 DCL*:A
M0U]D!G8L:C#IH<ND7"73XET*IVU:C2+[E]DFI[E-*W?&O?:?)Z(!Y'C+&.A5
M- J^]G1+,K8M*I4YF"F.YD[)[Y62E[Y1E;[GISCU#>5ATL6R]@H%,A"]1:;%
MDF0SUN,]R8.I22\Q$/MJG@&I*O])<+GZ)E;H%>PL3A1,QVM-OF$SL9;H)<&0
MQ_'W&)R.-K9F#4]D96KZQ8J];(P*)A =Q/?IJEDYU2HKR^M9-=6:?'Y$0F1I
M#\C-QD 3-G7XK7YX]ZT.P=3=%Y>T>#N_*2FON4%7@5S"$]6]$:G.J5F+8G"K
MSM%L#CL!FNP"TV2X)&'H>FM=)6*T8[[+TI@=,Y;#I(F[UHIR>(S.>B1*AQ^Z
M+LTA?5B2Y9-6:1T?_)O_YY@F@T5EHQ;O$L5U.&'3SJM _E%E?W4RBD]'O(IG
M]_A_DECZX1R2XFX]_\&]<?0C; +1*VRN0&&VED0NYKP[#SY,B+#0<M 1(86
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M:\%B]<Y<T5A^YCR[K_31@&S+!K7,"3,<[5;\T>27:5GDPL02/)R^QS5R0=+
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M6VLS-N@DD_(KRC'+W-'@<P<?W[VIL%\&%^R(J<"8.X*ULR-++3F[T:+(T,Y
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MA6AVPST:GY!!MJ]8KQL<Y..'WSZ^ 43:#4@0398'D-TU:2NKX[*$SIIX:HC
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MRA!I$H3SM*0#RP$+!++*9&T:,K]:$@+G2P[3@(GY3)B81P,FYB8Q,6<#)F;
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M\R+:!4D2J16G1:4$6:V?^@IQV]KZ&;:2UL77@DY'G50OEWYF"0D7)I\3D*$
M0X-4H+L K<E@?9FF.BA#!B$4;/9L$XF])"!=DE_#Y=FSJ6RYI38UTF$JD-K>
MCL*CLZ*LM;$DY18;#^_]_N5;7Q4U[XEF AI,7VK5 D4][2Z4$,W5)89@   E
MKLC0UO@T^ XM09KZR+76CDDE7)L&C0\RCT'NF,*K(S&W>5Z+!CJ./,CEIF*5
MR=*AR1V@ _7\(RW)$I:(+/&5XN22B0?N!V0'X]'"=+7IUK-_%_(4TS#(RIY)
MU6.JEY$_EXR4J&W>%T"?5Q;%6Q=%%FC.UJJW>XM(8@T+T,KRB$23*&[$R\.Z
MGN7,2'O()94YG&P.&>?"=YP=V<#*YY6L6GL,@/,6H4\OA%?S!HFOXN2GA$*[
M-X+>A07!1Y$1#(+GED-QGUE;#/GW 8V[OU.Q&L7"8[>18!^'CMT"Q0:@U[2Z
M!B(;D9 ]J.Z-? 4 &3)H!-*N-K'@UYGCAE&;91Y6\I+J _ANJF@"/,#"F?J^
M99%-:14!OI>W.D$"M@0YJ[^WO['I-M>42/-Q/.<.<VF+,K['MVN%??@K<)K4
MKPN:9R%,YOT^&T"5("N^G/+ H)0[C*=!7Z10+2MKZ&RTM99LRT;LA4'5SI,4
MY/K:@03J()UD-M@D922.*,4.VS? PJM8 3#EFQ\2SL2Z*84PK> RX]*H]R]1
M;?P@\EOA74V,$2:"5E!/, ?G(?*$2DMLYDC# G[5T@.YW1\Y85W,+>KO3MSN
M.RBHA$E('3?F$N("(\':HH#.@9EKCQSRC5*NBNNOZHX+V6(XB+9N5-)F<?KE
MNAK[97&%!$ ;S=WA1D*E?+[(C.-.!!; /FZ9(*Y,RX3XN#"([ZC6XF:H24_9
M'\1B6HDQAMYC5P+RJ1S_(=VBHO2,K@+S3(&#??Q(AI/!NLU"G#1R-U':5WA)
M,U+I25;G_]%Y_]_ UAUY%*IK*\V2;FKT]SXS@(S;!VUAU-I"(4,I\GF*U9'>
MY2K)#QP$S[&_P=3F%M$LTEH/NJ?,)*Y-2(O\HG4T1LZ_UV;6 D3G9[JV@&X8
MBE57,JM>;>8!\K1[JV+FH>J:I4"KJR!=P$K9M5 /J-:DG#77X]:[I/'OW@H]
MEWUKVF(GD30/AT 0_ %:'JA5(:[R+]&^@ZV*WVL6E\L+R<XT3'1]<G3\.,Q"
M5 W\LY(VD9U"SHS-I7\P-%0FJC,*DS)R\TKCBSN#5_=M!V;0V6]&W.<DQ-:U
M'=?)J=@^/**D.R8&"DF!AKJ>-"),IO/%-I4:/*D-L(0(?/).FY2GYKX^ 'D^
M"Y"'1-H Y+E!(,_# <@S 'G^?+6IC81J0#WT<-E\0C<'\)^UR0-")<8_VTXY
M=+)2G#Q/<EMZY7/;2@L-(,].4&M/VTYMAM&*H@E1@\K[A(N.N+COC:7X?,'\
MF"ZT^_3-B__'WKOVR&UDV:+?^2L2C<&!C,NJEOSJ=OO< <J2U=:T90N6/0V<
M+Q?,3&851YED#LFL4LZOO['6WCL>)+,LMRV?+(N  9>J,LD(,F+'?JR]EL_L
MLN[OM2V429.8H1-YN0AN@4Q?$(])H[LDLB_JB.'3"[^'O+#F@"G.YIT3S0;'
MBO#BY>@L].L7^)AY05$:E[IV 4W!&-,77I;-FNQC_MP.)+4# K9LBL1!H\?O
MB*ZBVYS<E[GX^.:2']D8@,JOH;]),A7.?Q5$1QC=;H],!EAX2Y^>/2GPP^R!
MZ" -7D(WI5,P,%L1%4E"CFTX\8'TJR<=EEMD7Z(+4 ()3)//X4;Y1EU I4QY
M Z5A_]RX_MQS===JM@H^=M9U>W'7M-OU1,[>GIT+M?L+O7A7DK+KRR0[)'GQ
MHG:64W6T&ZL(QL4&^400.N*BH2,X!,#WZ8L*ZUB+:7U9[!22#M%:2C-A<[DW
MX&9[*+911LQJ[NO&Q7'46:5<HK-0NCBU&](=Q6_<\');GU(07,)$^'0^D6YI
M ^9EW._*<;&-A/M\7*_/M?.M*VL7JS"X:.@MH^FU>,-O6"5\3J.?V52N,F>-
M?; ?Y<CT[:^.JZ A-& VL2[N?%@LUD6O!988J>%V'XVL FI@HM!)YL80H?6<
M"=CZ>I/O7A8Z2;%8*1?CH.SHHZ(H!V'Z NRP#NF("A@O!, :B&8:B&*!:V@\
MF)9L#3RS^*[1G>(.-MVDK,5''WD'UFXC<U9H301MY:-V[Q3Y!>%L3:&ZYC4@
M=A\"%:<868E$C,Y_!91R53BSPB Q(<JI^RAUBCC]"$8D/C0<]Q[[F[ZXJ<9S
M-D=JWQ>HMWSUSZUMP#N'SYZP01>$WBDJ4-820 RBQIHKD" =;%$G'7G5VPMV
MXMMI+)D*'7L:TYI3I8D[[ =$Z,KUH[B)*J(R%Q.L@;7L*W.+D.9#!CC0$PC"
MBHM25G7O H\!A9)5E-W OH8D@:]$A!$($IM::%,9MXGLWF'KGK9;(UMA$X-I
MCHC&?HZJJXPA'>"F<H:E8")G!CB=Z52N1@ZV+Z^(?;D1WGGMT9?.LUW9Z@EN
M,.6)OJW@]UC9@]2G R4YCP6(R8S=3B.;A[<M,C[C93,52S4FXSK+H_]=_7MY
M"8JLZM_S2;&_<+>/P$PO11GWVTPWPH4_E:SB<KEX+@FY?+P[$P^/N@H$''M'
M-X6!V\'0*QZ1E3$_^7QQ5[0U!14$*K4J#AZ#;EO>>ZKZO ,/=7)Q.K*!6UHM
M?0@3Y9#Y='P8Q#(.\&0M%RDNZ@05M$4BS$('GF8_&N.Y1AOFH;TMW9MD0E&I
MAT5"190WDXG)!<.24QQ*)LP 36>K-*R!>'XQXD6 H"0H$42,$0G$4)?@TN]*
M]%)7G1N:]D4(V$1A<P7*%31OSBG)"BD0)OEKX_%6.*N+!HMEM:U&^HTIXLV@
M<92I TS%GGRRU?SS#X4(."@1QWH4PC ?()A%EADGGKYSLP8OCOT-.'1$LHIM
MY7%;;=)5'M!&DN[+TA;N;L#![B\WJ 7YVN9J6U2[SG.J&V&U/0I;3*,NI"A@
MH@#'?.;\893\J(KD0GR\XJ_?[LLU#P"AT#/!OAFU<Z93L6(X'%'S(U3=&=$+
M240]S8>RMFPHE&0O.E;*\CT2VOISU';TH&00<5T=ZEW9^Q8GMA/IT=FW9=&;
M,F!0=Z/AW907H.@"(9(>(Q2&:Z)SQBCO_0%F]+D;%NY;%$YL>O0XF-C7EB(E
M?#^FGY"30CC&;(K1!^2@( +%9ZZ2 72Q=&_0M8,Q%NZD*%VY<''9MB*[6V&Z
M!!Z*$-E1HKC7X#6:K>B93>7')@/%G*DS"-X6J^]B8O5-Y\7SQ'_P;+JR(01&
MFQO$(T++):HAV";9+]\_0B8=*)>Z@?=TSS9F*GE =Q&X- ;#Y5\WS)Q.74;1
MX_R4YZ=:V/84:8<:B0PR9'4)1;+_F#:.$F'F9^#<PNX E)M -#S#EGTIZ&M$
M],OJ1FLVWH4<D\8D:H\*WE.J2$B\8E KS6(ANXA3/"1Q+5=64-!+%A.0#N)H
M&37+=\1?.]-2TXA$/,66[QM1'/N^[SRSIF 3: M-7F""6Q]T%0^R>.HNQ]S9
M6N (RYIDE *$EQ[;B4_KBC,03^:3&O[FGM8558BQO,H>?3Y@*/)T) =HME#T
MY+!'G\)HT"+RT:4\,=\I0[H7F,RFSPQ;4B&SI>DQCW#'2=BMJB'%I#[G^%*B
MF0TM)2)ZHDYF(GN<$PW[=9T-)2JEI**]/#-,XW>":3R981KO$Z;QEQFF,<,T
M?B6%65 ']D<K*44MHC!;_#J4Z%]XW:A$X\M]ZO6+2.2K!J#NXSP 65?TI-8*
MVXTR[.KZ&U+22TBM0.Y+4;L08='6JQZ=@12BB"34W*T<S!.M\#XA>QCTC*&
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M==/BK!QL^XA\/(88#OLKM>*M9LF@M,Y.#Z8_.*[D2>*)2/SMS492=S5K 0A
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M-7V>H_J]/:1YH?S.HWHXUHZX[/; "$NLW2;.F$:>8(KRZVX._1J^Z7U:",&
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M.B.LZ%D$B,$:F=M&SGTJA)YFDH[ >Q1XV)455$S%F>&E,T3\B,!'HU=-;U(
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M3%IB*UKH2G46N%YI8[+LP($>5UL&C@1WB%RCDPL )[^T78#<K5KHE1T7G*5
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M]$LP5UB?:>/+$IX>PZ*Z['ZBM1KSQ]BK7F.\^JBG+0,JPU%(7E]I_8=E(FZ
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M40?D2!9U=!2:]%>^P#I0)!4<\+?R_RK0('2Q4F]V6JEW<N_<E7JJIB\\,.D
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MQLE#G_B.B<O,H1MR6(Y)%_LQ"&?%[,8]O" 5FXQ]]!@56,8_:G#:A:'^3:&
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M3''[8I3N?\-0G_[B+W]AK.UMIY[9SUEK<>;EIEI6#%0VJBO0@#< DMI'\O5
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M>HF6!=C:[U! WU;N=G9B,^F0@E4&SRS=*M*!FJ!2_$/ESM>W>[GXIKDK*<*
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MH[ODUIT00O?-P?HVM+6*-F_<Q>IK4'73(F;QWTY)%N>+[[?KA2DC*X>Z.X_
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M\&0)M>!95ZA_P)]S#XL 1.=0L^ 8*T%&:U1S8NQZ6<*W$30^<2@)#-_P:M+
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M]@4U9"VXZ(IC;=2?3JK1J99K4L=%8-)4.C3>EXM&OOA#L5S>A[%/Z>5MO)K
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M9AP8:#MI]2?9 W=_<R_-+:;BR$1FLF_/NK 2-@[,$NBET^XYE5\(=F">B<D
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M^]?^]E&BG]QFH'M XL:+D"#8:2938Y'S=,YJ1'[S[%NJ/A$,,B&4EUWE&]%
MH%X8!DYDNL_&0X+/0E8*C4#XID.76MT-US;;UFI,7<BQJ5$_"'18A0_19&T\
M.\Z4Z",QW));+6_ 16U8%)+<IJKMF:E-TIUG_#3:T7.BM/<=TI?V64]F"L8:
ME.Y'R@03GE&P@#E>@-8,SD:M&LT^KSUL.K@L_8Z2S2#ER1<'Q=GTO)3HVTZX
MK<DGP9$@M-,$G5.+AZ,72GY<ID^->6_851I$Z4C7D?Y$E#+8\T-D'(+ER:6
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M/0>>1=I^52+;^ !J&H+7*\?;-O&($Z]?H@04G2IN K\%C^#EF]<F=^?,_%@
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M*,2/5>Z83F$8&+RL>!<;=U+I!R=I^]A*T]2&&"[+0I!6>W@84[/E89BFV7C
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M3WLSN5B4"H?@.-?$=F"N(%/D@* X% +!H'Y0Z-E5PY.( BV!N8O;DH=S8]/
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M4(*G2OVA0!B3)FCHW:%.!?/1J6*<6?VK["6WK5Y5;<KI-,GV(:L.',>.WW-
MA45QR;;S:?J!9B+6"F:9E!M6#"D!_5(XFY-)@5WGQ+&S2\T\1[%NO/0UIMR.
M3G@&P@8PBBAQUK%ZO/,M=;'C)B;4#+3&WH_P5E\(-)LF>)0L*.A*X8]3Y/,8
M,IXZ8>:W%:/0E=VXA:_ 2N*0UYBCA4_"2"/M 2=LJV0^A$6G.G)Z0V@XIZ^2
MS 5E_FSF  4SVBLX.(%F.XE[<'L7$U&21\EA.^-LP\&IN=J)V\KA*=+(C RB
MX)V5^G9[ H7*P6^)&_N8 *[D?GH*XB!KVCE__MRV/]&2]KMA2"\6&-+'A"']
MYP)#>L &U25,Y77CIL7OFHE.%?_4>#%!)IO6Y[(;%+.EY$GBGY7E;F)EI20A
MSLI8:R&M8MLZJZX#DI>5PZS:2%DA237&X6!*G+GGGHGO6LK<G87#H@DH=D_R
M<"TZZJ6%^,G;+6!:EM:TI*+L#K>:&IL!HRV[6:O%W?5H3L4VQS-8(7S4<#S@
MNM>"A4%FG1[9'OG%W*+;-V X-<,.?K'!J,:&8?6LDHF+1PP]>7=/.%^$)J#/
MA=$#ILB$P8*6QYJL787N&GN 2(5# 7,OY=#K"8R;=I-V,A(]IM7-&VJZS:OA
MDM6X+10_(0:=\$LP6P#W93_-9X1QP1%MN2'<M<1KY>PX>W;F-BHD2B;(-&6P
MUZP;8]($]1&Q^).K&"9Z8O53W*YH(D,6CESMIH(/RLP,*6D3P/=F<:0'"-GT
MY-C':5)A9,Z)E%SW:%TPE6;RQ0DCLT8'37"PC8;MX'-[K'.&:C&23(EB(OM%
M2A<1]V<3Y[-D1RYL*K%X//;4%L<#3!$XF_ )^M2YWG@3RSGQ*^'\&$_T?F4+
MI)Z8U6O>O9O25DUJ2L2;X\MG1R,41;>^W7IM<6)7CNLU B!1:G81S!C(NB3_
M'-SXU'D)+!WDV0G)<X\RGW*V-B#&C&$FP#9A;;#5D"<188LII=![P)%R/Q@P
M[CC ULC5IX6%I_1MT_@Z#^3$W)\SB5 8"4QL?(DN))<<Q5B =M)R8(9\SWT$
M?(^6+NNTHE<P*H7,29$FWB'2N8/TE4QKZ==<7A2[OL=X#C53,J##0$5E@R+\
M'*Z3GD"+396.L3W,Y&8YB*;C=3)>C.O8UQP*?I85^HI:Q4,A5X31R5(5;[X[
MG<PB+R]L*B][9]LORJV?H9W20O[BNJU* V/5OPI<=[UK6^8T7P7(6LG=8?V[
M" $60*D-5ZJ0TJ_8]!S"JCD2WZ3H9VS?=6 ''?4TCQ+/<UT+\U!$ D_H 8J8
M&S2)0G<C@%WB6Y(\I#>703-0#.3J)/=9\3]@YW81W:VH? J]BDT301I-V_CW
MQ'MW[>>*T)U$HJP1NQ4D)'<M2PHISW,VV3Q>>#N\ SN6#<HB91#*B*45@!GK
M2!=%S%7VCR 1Q3R+"VF9S;@L#U,V4I,7$I\T?BUMD(,2&2C6Q!5 [@Z7"TRK
M!4RZ$KN?Y=,&HN(+I!K_MF,MIR.2(YPF7!FQ-SEJGYX?>Q%HMX<<Z,HR19^?
MVWNC[ T="M'J&X2$:C-&!T9#)Z%PUUH;8X YZU5@4[RNN@[0NV?8A<$V!)8G
M@=7TC(L4+ D?V _@,K&7I-)$=#P!,271%(&0X9=5X]1C-Z45G=\6W=UE703(
M$.1%2*-(JT:3Y9$BI46U7]A4R#!U9.C9VBUN>S^QVL&:;6OK[,Q7S\U5_MTG
MB>9,$LT4J?VD72R;-KE99(SS\3R]M!AR0,0R7%50[TJ&:4NR,$J1V;XA_$L7
MZ[#$(ZAH!K>Y4Z%'"L*X34J)8B;VMO_IMSDRJV+];DO%/9AB:+L_H>$P^(]]
M V(*Q*8\IBF1#YYRDA$YFSGY'4;Y37KD_L^?2:3\3E(&,7?RP<-]?O7BJZKY
M=9?\CW_X^H]QS8?R%XSR(TN5A)X;!WF7I)!K2P:NJIY:X&=@%%9#Z,IS*Z_I
M$$1$)/KE0 &-0CK2%CRPX'9.ZU#)GNYBMY-DS2FA=1%G[2/>YTL^6Z=#?:Q;
M\G#NNS$=:(PV^)-2]DIM@9^$WH_H@FL\C"-A?8@Z6C_06A!<G1U5-7G7$F3J
M:1SGHF:VAU+%>!!^]:9"#%=X<6):W!2]]O0PX/>5YU 8>Z84">L\*D)9@R#^
M;+$-%D%;\=-VC3^&X"U&#9[$ 5]DSL5MR<.1.06-C*]M($(C(!JK<44LAEIS
M XM4:3*&#XU<&1NR/":R(X9YI@X!C6.&OBPBXB*LS@8[RW;^1 E89J&AFHSZ
M;JC7[Q>HU\>$>OUQ@7I]@ONTN-6+6ZUN]8:MR9!?PKA=2'LQ,_.$FN;4T+9A
MOB0O-1[@"=C23))6'&)>=VW?/ZL-+<^=NL\T&V5FJC8EQ?P&[>&G8$PM]NW%
M;<G#N>Q@)7KB7&JV(7AE;Y0P5, S^Y;YYB=8%MM!4EO;:Z)+L&\*^K,R8=\V
MC#FB2%M9#=0U$"&&Y%'#H*\^A=EZIOCK$\6Z'VBVYRT6*(;F\2GNU50X]_!F
M99]@%C]A'*S]^YDD)Y4Y!?I=(D<L&FGYF'9$(#UD#EM]=%O*OW>1)W^"1$(\
M\=@([)I456S<;1C'B#1/,Z[2"*903%B1-N+2<LQN;\NHD9^@*ZAQN+P<+L-F
MI")MVZO@URMJSF)1\Z,X78_HHOQ9BL5NB,3F2)"B@/R/.<-(,\#U8EPQ+J5J
M%=&'QY9$()[[-H62Y\11V(1N%_%Y;1<>A]G9N<+F8C:T>7NJ\E<HP)?K@PS;
MS!T?T$6PL TQ> J>ZL9K278)2F8]U&F+8%R3#7DT]G(BW)!SJEPOC2P&I50@
M^GT#^^SNOQ,AXROY)4)EVVPQ;G(HPS@'N,VUA:TPY!([KA,5:H! *"J?86,V
MVIU(OT 0"4(KI7N<C#2A/[)0?++9V\BP%02R%"!8;/(DS\W8^12NK$V#B$9.
M\+-2+),L#5)"W&MU<$_#EN!KD=J#BR)[?W9-!.^+G(WI=(N^'V&R1BT<L->T
M%%-/$PHATX JQX7&"/R0DB2#-G%=%7T5:&5CN&\1O1<V%62#;M<,(5I[5=]R
M^#%NM&V%AO;?;//7SD#*EU-P85.9=/DCO!WCC[AB+?(FFVXZW0R%]9V=)"8@
M_ZDFQO/BI"<:*Y%005?Z%!QHT+EW !46<H\+G8IM%\V%?]K"['S_UEA-,SEU
MMQTKHI902++MLV<S1%@TY^;@;;&T(UI *7L\MNR5ILK_XXE"1+FFN?3FMM,Y
MH;J'&^6*C/L$''4BN&@33TW+Y,PP(LHT#]E]PN286I=(Y4A/[C55QF0.J._[
MM/VP"\&+S<CTW*',Q1:@D',XF^ +P &Q##A^H!0<D917%EO"*DQG02(G/(HK
MA 0L@,0N:-;%/M213!S7Y9_@QK*+*D+#K!97+>-K>M!+_:;R)5:$!HX@K3 \
MX]*Z" XVN%ZAJT?&_(9#/FT77(W[$.CGL_3Y7#ZQQ\;0I9:@\1(<7;)6LXPJ
MD6R$?CH[P63H'\33S^>%_I-8<9047CJQ2SU*?;0DY]S1F^SW,Z.6JA9M(R1E
MWW3 (DN.058O4.=+G,IK"[5W%FH_>WN",S5$#+T*Z>2*I\WB8P7PM..:+0EF
MI]!-</-GZK:E!'HN1! JK-2/O,K^%OU!^ 8/>VY>W(0>)N2(8C%IV=V^2ZL<
MIT6O)V53L5LZ\C'OL?7JFN#_4E=0SPS*_%E<V98)JNUH6=#?U5X$:15#Q[04
MY9DTWY 8)RBC6D1B8$,-Z^IFUS6W F!?];!'Y \'@3S?;66B2I-.&]QX;="V
M>;%!"%FSSE9D80']2*5L">/"H[B6CTC"/**I?,>T$&@QY$YC^.*$SQ>**+'&
M,9JP=-R;1AH;T%4[1R]LQ<-,P=00RU1B/;)&Q3B;T6S I.1!66+0X(^A 0L:
MNY*0%@ZW;ON1"/6%"7Z^6'UN1%<N,7T-ESP:N;I4\+QW2#UR\KS3N9FJ2*(X
MP5X +>8]]I'ZQH<">/CGSE-,K<_=OI5"Q\31[:I](DCACT)#N%?_1-\4ZD2)
M#H]:82M1^2,ZT8^(@C)A3()+]G+<8J#SQ?,7O\_9 -&JW\!T"X[M*I82CAC\
MO0$-U()2><;D*GBKJ[*B+@JOVJ8<JR%[D_8T ]N"K&FLT%A[<!Y+< QK/Q!+
M#UK#R)X+Y_V_"M"DC7X[-)S@OVK'"7:OR.-@;'5[XRF@5V$S*4:A'. NC04W
M\2Q(_2*7(/6ZQ0:[\'U^^Y73$7?^GTS#+(;!853" 9%:ZR#&9.#8!FC$2O#O
M8#':FT!JPT_B]6I@*PZ#I\*NKW-9:)FL,MO0=)23**P[?N.-BKE7Z #3[?VV
MV=;,(5MF/Q<UTC*8U:B0"'"HACHP6'&G#YK%'G__'R^06KN6A.>TOIG8(D++
MT]E#0/%]:>)0YLJ3Q20_?_@*3<ZQIWI1. %>\[_[%L]ONWY'1A7U+J$!7E?;
MMN.-X6: :CLZ20*0(WV5_9C4]: K+:2Y6ET?4\H8>]D?BDE$5WJ?Y*AVT-DC
M:8>]&U".TJN1'(!:":)YJ+A[EW1D/Z$,F1B,CTA0?'KQ?3=H]\L%M/L10;M?
M/5] NY\N?Z$S?43!?NF_-G8.K$5NX-,VDQRS. "]LA"A#N&T*_:B8K;!R$-G
M.9 5HB;4V1J037X7^-D3-YPS\F+5*W>?]0KP@=.DO <%V!X]X]MFV'J)"5GB
MA/4Q^/_&=T!]8@?G!-?#"2EU&T)4P'@F2P[H0J?RLW>8"JG*R=ZEA["=^)SO
MP*!^M@.CFAC1&XYH@3$5/A<32]OA:*0J\/UKG$KQ1O0Z=^?K;/XS 3;D&047
M.=S-L:8;#T.H*W\MJ9?3YH.,D-"@.34M7:),%S:5GUJG.YZ$+))V*!*[M9*J
MR]*@Y>IH,:"Y=)ZMJS4V'>1P  -SJ,&L2DILQ-R@GT$$\(XL(["7"GX&XMTZ
MSH-)DPSVY_H)9](M@IG\&:P&#@WPL/9?>F:@R]4C[LPVHI(!43=0\W$(AVAF
M9BK]J>FG.,LKY&-L!!'BBPY9YH,ZD3;;LU(\8T8RVQ)).6X=\V49EB_Q/DXZ
M1X_,AJ;:Z]:(UC3AG(BEJ^R_P(VF])J0\#@.L^_]V3W,[KV'*)[&AOP^QL?6
M1XZA4U%T?3P_ 6</IW1S"@?O#DUM N/7F#6F;G22NZ->SX&?5])SFS3W'>^
M(S=V?EFYK5$C8$,V65*)'SDLS@8;4U/&1"HI2YK8"8)I03G>!%KJ9%4Z;WM.
M4O9@W78'W">*K4J(QR2VT9>EW&2N/-C!'N)J5X[)AB[Q+C12B,M]E?VUPMQ.
M3(:;@P_&6:5Z8E7TG"&F@YQK_YI$#T[LO<+,, !60]Q8@>DG>I87?8IG,!<&
MQ1MC_S!F4'7)8B+&(8Q;24'.MC5T2;@!OVYBKK8)UK<$2& <KB%)34"YPB*(
MJUY35$+(3A'1P,"$VTP*%Y:RZB->(^?>E)->1&!P=!Z9MK7CA8\M,$+V\8X[
M=HT[3&$\R]N-L/BD?><CTJ2/:"I3$OTS*BE0.G(4+)Z-6W3\_?7# )8)4[HC
M95>1 "ZFK7:FHJ'&D..6<[&3@XDO1'!Q;$/(YJDA@P^];/X"1B_\D:XQ7.JV
MFT $3]\\5PNC,FGN^[Z2J"/ET3,,CG!+FLG(*<$_;2[6<)LH<B)C-B:/V9B0
M3[9J977,#/0J(2VS6W.5O?PW!.S]!>=4:&J =M*X[!'=JD<TE0F@%M,A_Q3H
MB8(*5>.?DP.$O8\'V,@!/AHW7=MLV1 <Q>2(]@<3VTJI@9LH/C)#JJFAVBF*
M,OZEC>22:U@CL*"ZI5/>I68?7E+IDN2-[DD":3JIY4'@3_435Q;QD<!D(']>
MQL[JR5L(T).^A,&L54+.>*(($AR0^8/%,-Z@G;4MN+,:G.?NNEIKNBS<'"EK
MJ?K!5:$#G1'_!C[$U;WD$$T;?^U%!=SLP$*C!;#Y4%V"8E DE_0+"5\A)DQV
M"YS<(0IIHE/%!17J1<=Y4%N$TQ7-?NT5=3\'_/,9N<0F31JOM4N,;J@4:*5.
M4U*[.2.6$J?,0CWFO/U?*JFREVKFZ&";ECRFVI=;K75QTJ*7)L^8W"*V,V(N
MU&J3V6_1<<!3!G8Z_'622#T%+-H<+9D6YF&,[7-SV#X\N_QCKN::_7T>/SBI
MN272[Y:T!OJ.QJDI;D?QN<$7^YQQX95'H( V7CWBK4=<93]H35U("UO32SV_
MU"958.%\+]>EI]Z9G.U72\[V8^9LOUARMDO.]F.TR0[>'Y8M]"9$UQ3X1*U!
M25*>Y#A+T]I&"Y4,F)JBYV-5E_001(:UVT:BA(V(<:R1D.IK+)X&0TA[V(=0
MFU)03 HZ?;F8]Q<Z%<0 C$WGMZ"XF?\TGJRV2PZ6;.YZAX8,-F+,8T]&,/.K
M;CWNN15(SD!5:65 -/!<21"J+"9-'3'K@X89Z7QZ^1SB?QH#BBR-;%B>OQ2&
MLE:3 _.GW3$FS1JX)C;#]J#8@;=<## 1!XKPDO.=1J6*LH638=>U3:ZSY+E<
M[)K'%74",5X1I,X'R]PT*.<9K0C/R!'B09PS)@PZ@N8KM-L=CYJBR6-/F9.9
MUE%D[SFB'-+UB -/QCW+WV^*5(@LMP^YC>SV \?_(I?!I$L<=J'6@AIVMNYW
M<J^R'ZX]5W+6N+MX!G-3]Q(;PD0KF0Q+?C27"X:'NQ.!BZVJM678J?RD%$LF
M_>1O.Z*WB&8^1 D_3_XATI=Z9)I(:JBP[I(+-=-K7M'D>!S#V/-).-65+;8B
MU8FLV\,Q<)7<7K<=JI7"S$PCN;M+A@P@-% /N9E.=!:&.D,G0-V=9C-$CTC2
M/Z*I1/C:.1=?SE4-9R67L,*>:!.)[P;.[4CE?1SW]TOT\5*G\KHA&'R+/8QP
MCV-A3LH10DSN)%ZX0=* 1=(]QB5(IF BR\:TSI  A'#=0#@5_I7M*1U$;0+E
MX*:4X0>D<N4C%#TE-S8NI#>5#4,E9<K\4@F=B5J)07RQ-O 5CIU4B9/PYXT?
M;EJRFWZB&.9:&C:A.J,$,_6*]BCZ?*ZZI^GW51\1]54R+RHN@%O"8VMM%T^4
MC$Z2=$PDH!=J[PM,Y$M&+L&+I %CM!>*?NC&-;66DOMZ/=;8,DBT7C$,Q?H=
M%:[NX#\D0"=WML0R K22=(TRWW780GA?U!L8!4\TJ)^RZKOQ(&E_#>#E.J\0
MO<M-3&^@T!9L?;.F4A2)AP48DT[:2?8PQ/7"5^4/TH0UE*XE&Q;:"MC%HO-;
M3HO*N,8+S6M.,QJL3IF[(.O@QV"?FU[4_+O< "W,PL '_315.56_4HPA]%N3
MRK>Z4AMT;$K?.:J#961B +A11?5UL:;8=[@NR24BELP-'#9L1>NW8XT6]Q%[
MI3.Y;:Y;.#F(N;!'L4?@#^/ #V0S@"H>BS!)!4^L<;DIE24VE#&CT2I 9OGT
M7DZH868IB^+;V3P!T^GHDBL^DR^8<BL\(N']B*82$J]TGCIJ5,^X,50DU9:.
ME!%Q53-14(3BW3!^@X0Y0REBF%S2-1%\P/#&MT4'WB<U8G;!\Q;H(RNN^L@A
M]M-&[L>3BQQ/*(P=<S_1/T4U26R:U".4+GRXV4P>^.$T7;= KQ:#ZQY3N2W_
M^Y'2O3\TH-C77"3YQ0NJDOQ2,J3L90?(HI[,E[,']BK[!VH# 3=V^P";/?E9
M'CZBDA !B+JBWB(%QVY/9=0@RH\P)%":\$]SP$V24^M=K9TWDZ-%UB(T>9[U
MXP%1_/#+MNX5 E60KH_O<OVQ'SSF+XNJ;H71R3<[*IF1%T:,CCYZ7[P3M+&0
M.W/>ZGVUAY6F01$H7^LG)UE84@09CFW3UE7[$?)7G^!</2)=(,?5\7'U'1HQ
M*7(@'D:V^HBN@,X_G'G<;C@3?Z*?O";.XQIKM$&Q?/;\V8LOX;+Y=_WG\-[U
M* V)0W2)D:H;9+IBY8&T7C%$J2*7YH[?E:&&$QI&2%=U>GXQ=3OX+=RP;0L6
MSS<TPK^8ZR.C?/'EL]__08<I?'Z]H_ C7;K *\I0$&OHV\M9%OUNU19=*22J
MC'U%/;1OP7;B#@,TAA\:IHM\J\.7@?S^#\^^>J$# 6<//0_'!=:]8'8WPM<E
M8%G21[6_UA+RZ0+!>S&HA!X(-3*L\5DD)_#]TP7;=NW-L LH0O"&<!.N"50'
M8HPQA&2(C@=T#<#U2&3=FOA1@VV0O-VN%*AMC-RQLAX'AC9LNP+S]'V[&6ZH
MZ;DA',JSEV]>(]RD7>$4DC\YCI/!LTIT=T#&#E[<,]JP8*D(11=9LFB=]Y96
MF"5:<"G1!!G)2HZY>PR"=D@O1C!2<?K4X'>(<@CTWQ1_B]!2>YFN9M4#@BD,
M'B($_RA%,'<EQ2"O-!!LEQKK_<%'@L'25.ANS*JJI8KJPJ;R4^O8Y59QBRV#
MDR!^H$>8$;>B?E/Y:8V8?"IY08YA F$B@/$6;.5>O'S]K.RH]J)OZY&O$)E,
MD_ )\SB2*A!)SSD"#A8=\5'O//H1<-^Y&0N3/!NC".O ,+R MCD)/P89P5J3
ML%[YX0;18F=U %Z).U0 $5PB^B8$B#B)$&TVF(!+%EPN%BTX:CN<!6PN(GL:
MO,W?51W&*:B3@+C:*"(\&ECX(XR8/,.0OZ?(U!E5%4%%^(L]QH$0R(0().\/
M5&@"UB?F##A3QKYV2Z$U&!Z*TN!,B<S2O8'C@8&93=W>]+GI4X"P*:'4@7'N
M/1,&PBC@*""!3]6 9%8P/2.@#G6!6_W6XT1ESN@FU53^@E\,+(UXN#PM<QK2
MINU'(Y*3'YN 4#/V,*O+W 4;U3J;QA@)JQ=L2QK#C_^KV!^^^4MVJ ZP=XW'
M/6K83Y5=TBM$7)?/2G\8=II A'VHC\S)[6S6=-V!X8S_A3M NB\GP[:/'?RD
M!05\H5\7!Y^ZHHI9#\4Q\CZF+/V)XF6]="KB!A(5DKVF8V(HQ(WHG3D-WHIE
M$<_]Q(B_RGX6==!/SW(\ZKEF$N%ECE2SSI-U60-24.XZ>2#!HEH4RH5-16U[
MU"-X<A#WS/%?5AFO7_^)#M^)5:SA06.U1X/8%OC-&,4IL%.UB7<O7[/J.#FT
M1HU,Y',BF&_3A!L4P_$PY]E?U!K/7J%5JJ[$CQX$%OOI3LX[N;82P^7:S&C(
M:]R7;+3IN/'Z\ \;7[-<AU?5SZ@6+A*8A:0#V8TF 9V8Q^XD/DLF7C=N8ZV,
MUO56HO;C0)D\<JLEQ$JWMBG0E&W7[YZ-!XD)Q!_Q][9C178S&J.H2KTK>F&U
MMT8!.!Z=6,&Z@(0YOR:;M^W 9&>-@$IB('OUI-<(=B4^#!0T*!FS(1$$CQ2;
MF)=@CX8]']>#(JPY.27V"*&W9@Y0T&^?3O[(AQ55H?PI>_'U$FXX7X!!IY1*
M!T1WI&XV_AIDQ0&+WA%&3]U7.&@6(\:F-8F$;]'VU5.:U+$11$GZ-M&IY_@O
M9:,VK7 )1,H+>'6P2P,(95,7-PS37U4(@+D" 3,4Q,,\]@%/4C6&TA ?I.&V
M@ O!C#V==<QM49;*8[6_^]=8<&2:ZVVIPH3?E-:#OPQMH,2>89Y6#@10EDFH
MJK$[5:/26G@R84#V/GJ*=%QEKS?Z)==VR6WCW\@D<J6/;\>!S#@"PI$P6TEF
M+GR3L/\GZ+@&S! 2VQ5FQ3[S5]NKD]Q!TLC1]D/@XDU)NS$<Y_.<C?B4C]>$
M^6/(X20#@$4GMR< ;/*-4&@?FA/(7A-K7NAO1T<61&>WY2!(W"Z< /,RX &K
M06!/MHWS+RZI 8\.65).@F0NO0\Q"ZZLI:_1^PFS)]/MM,*27Q8J;SLKD2?8
M!.P\$5PN5 P@%D!@,/$ZII=;#@U6C*A#@;A!?>6QT=(/I[4W,W41&3<Y"$"Y
M3 T']A2D(LDE=_R.=#S>\G^-U?H=%]_0OQ-K@KK#31MFF/K3)*%Z EYS$F[_
M-?-)CT#4_Y]54%R/)#,&,_H1M9'[,9IQ;QDW@0?W>\'.XKZ^IO(?;EO5T,E_
MBRR5CV8I/KU)(@4$Z*Q*BP>*X,+_0DT!"EKVHH.Q6%>]-%DB(B'AY?E[T9?%
MO[C.WN-7+ X(MY:]<GFDH%_]>S!(P!HQV=]?M@PTW>SYW=57O^U*O[9LOE^R
MV?&*6Z\X)=W%&CQ5&4QB*VO&*\MCASV28*!YA "CF6^7>\5F:B5H^/IOLFD_
MCJ!'O_KRJ^>?%9]_]L7GV6?X'&'R_7-5NC<=8@[P6\KHF\_\=O7Y9R\^_^Q5
M^O/O__\W__4V^2E=XW._?CG]]=^2'^=N:+?<U"[$WV& 61Q@R ;%%_/*RA/Q
M@UZ'PB$B7;!=@>0J0U5GW_E5-Z*C_<5SRFU_Q3:N?NR^^$(_)NHLBBE.UQ;?
M22\#_=QD,5O^M6;+Y6X($6\@5Y9@4+*+!>FQTV=@C;$U![4]C?S8!'/#A<-)
M(HL-,UVM*LRH59SE^H_G5U\\1SU.[B'%$#VQNN//*=RF%[4LCI.N1DYF@X]/
M#52Y]W/#LC3#HK1+[_<$[ //MZ-J7SKMN$WRAK_6[0JT/>L$HB(*Z_+BZ]SA
MNJ3;BJAP*JL;:N:K!_TA<=5PRPKE6$].G[SQO_A/X?R&5K3IW_OL38$1"WR"
MDR?0)_.G#8:UQZ0:OES3:Q@)#OUW^2RA982V%@I&.M]!( B?F P"UN&_,;D&
MA_;%"SF=;#\-8D6>CC@D#'1,\)!X].6,T_']GEC2O@JGWOS&K*%.@^21\IO8
MY?@[_&'M3Q>2%XY@=YT28V-DBCHJR=#CNE$R@ZWC7N,HR94Y=R==E NX,B1<
MNI&RJ!*,.KU#>?99]7G&X'\NL93%^$)7F5C!>R)+B0E4\5R9P$ZN-"^^>U4<
MJL&<8#:-[6]O*"BGQZ/5Y?_:RJ+/JOEA_3Z(IM+#Y>*(=7\BG3 Q*H<A:&Y:
M"2=$K8-P?O?<SI9?*HR2/:D5"FT5V,'J..= ZV[@9*CW)Y\*IB6CY:##8 5<
MD*\O_J"3H(-0RG[Z<E;*I@K@:K'_+F0J@62?[MW\;<BFMV%63PBY E]=I02.
M(8]P$O@+&HPI]6@[RO!A;!8.F7:;)=?T/[ZX>F[9]9.3>W+:3:F5N5R2'3X]
ME]^")3P<W5OS<O)5=FU=^LC9Q%^;C.O%U5=A7$F7A]-;7I0U-:020 3=2,DL
MMAO1RX9TJVE%A(+=T=& I4W@%O/1FC2;..9(*XO34JLS*'!=:6OV,[J<)]V[
M*;A4814L=&*#^F )I,$")J**</H3%K^SU5JAP,N%KO014#=0^Q9C?M">KBFQ
M^329('Z]8ARN/4]65TE+5KKWB+F:N'[G;+QP+_6[P6"=?PU<V_8F^X^OKIX_
M=YCC%TIR.7EX84\VO^K#L/+P&@%GIR^(K:Q3_IIAYR=W8*.41HX4*UH8^['>
M4GAC#*#7;\77S5ZN!\U#\?>5D;<(FM528*ZP*JU]Y[MG( !JJ3.>-F B8PA+
M,'O!WQ%MKDR% HAHMJ$5+_;9P3=H8>'?Q4CCL!_'/K&PMAW!-"EX/BADUM-I
M-]-QW>Q X'C"0(:']XX!6#V%625461@$(VKZ4$'-4(DU O^8#54(8'()E7./
M1SC'PQA0,T2*&%<N&6-@_0/YM_5N,EXZEA*$9-K.IB_6"M&QKA1;+AWU/.E[
MMFU@->T\4UG6(ULO1C(C6;!@$>A(D[E>5S#24I@:.?H?WZ@WP9 Y'D;0!T7O
MF7:9%GKZ*Q&Z/>%+T+3GER*%H!DK7P(Z$RZN*YZ.YD@I!@W+9')_/>NM4-1%
MR[&CXV1G123CE+,EQ8;7,@O7,D\XH(0"#%[D#X\H7ON(3+I0X"*102RV7E>(
MT<D.Q9$1GWBYT)="WT&.'OHGO:>.OMEFQ-S!IZ_L^"9;%>MWW \8J83:[D]X
M60>_;/T\B'(7N.2HXG$M-6R5",(;ST9RYYG'#ZTRVNK,%Y0R)0&U&46$V7H+
M%&L"DIZDQ2:ML]?L+#@$-6*[ ^%()RJU/+0L#&VL3M4W^:S1!N_%DL6D'_R0
M$<_H(\ ,XG,UOC![BG^+G7T2!_5N)K(_+$QD'Y.)[,7"1+8PD7T4^@U&-F<O
MI8\\ P;!U$<K\I7O)%A,DO=UP"=H[%A]D]N^&"+*$L;M$[M2.,1=M"MS&^8=
M&1?YBJKUNF.H0!SD37_Q=4&E,QH#(B732JH)'EJ/R&N)ZF'<D[)00]9H&L./
MZ?8%Y?%2WT!P*F,WJY],.(;[#& .!WF?&MBYDHN,X_NE%V9L?=(RVJ($%TBX
MW+G]-OR7,^01;?KR3V^C/2X-]ZNRL=UZ;T)3-HE,(!@'+ASG3 9TOR2WL#HB
MT$VN ^QY=5TPNY(XO,K-)08=,C?EX8_:^'/F6*6T)'0H(WG^IBK'-3:?S<I1
MJNTFS7O6$;\%]\T,8O[&\A_<Z8U%HH]J$T"-'=81(%6("@>^B4G/"TQT\&@V
MOD0G6**9@Y<G]-4P2E>6>3EQY9!2@Z,;!/IBBC5QU"G898%EQ1KW2ETGY8:C
M4$-JR$J@G"W9'B&;'$[#MCBXT<I'PCZW4]9D+D31@T R@J1DKQ$-?/AMIVG"
M^7;7UVD__WPD_*16:0=IJVM*!,#8FF(=VN3BG__14(2'EK2/<\0_S<E9#KHI
M8$\HE3E>C8@5JB3ADLR".3ZP*X*$QF,(S@"-7JYCM#&-S/T]M((X'8I9SD9=
M!9FGB<+0@GPF"%F)\4WQI82=I9%]KH?_IJ#D*K:%L,)Y"5+_8L8HSJ2\>/[B
M>2XES"(UWHX'#!6*H GX#"WYP3L#ALW;HOZ?U=AM,XQ0UU?9]57V%J0:^&KC
M>KVK4'?&:@_V>C%<V$R/CPO'QQ"TDQ7!1#IG#RJ'TXUPU$.WEG%GFT): E+]
MF#PI3!/^S_1V=H;OC]"_85@Y>..#08.]XW;BC,*1^ULI*Z<5I=*]DZA*-"M6
M1?X#EHW\QFJI<;JTJ6#EJ0,;4T*X$U%GL-6)7 JI0<LXVMG6662[3HQ6+;'=
MM0Q+.C%B'1NQIC/.G"TK9S#:'1.#5N]CF@ @R3Q6VBFPHU::@_!\!MI]!*HC
M47XRVYC7Z@*OCLR39<KMZY<F1>USJP9#;9R%XC9SI3!:5HV;IGE.7YYQ5=<N
M':NX+V(<EG'<-%+='!X*:?8N%2F@P]JUF#YNWO1!SC3?-860CU((3>21+M6F
M$@5[?FVD4H-MK+OL#:<4P;&))#7 :T)3-"+4(WR.6'A"\TB+;+-$PAG:]^V:
MN@R' \&I,Z5)"WS7IQ)/X3.:N^[V=+ C7#U2(PA G8$U,_GK12!>V%1B/ ,,
MPP[]!BWT9D/.*E8Y -I$NLB&XAVUD6$KP JE+#0@CCTI##<MIIKALHYK?YHO
MG EQ+S[[A4[E3I_=N$U:J68<"U.71X2!S*^HITL\%88 #%U;JT,E4";-B,<'
M.G.\]G V$>-$Y3MEA=H4U=)FHCVIMHVX4X/N96<)?Z[-4K6V2%SXTQ=+\9C_
MTV^QJQ_[+,9<@<T-3',''SRS)'5P-L7P.PR'FSS"_9\_DW'XG<368Y+A@X?[
M_.K%5U7SZR[Y'__P]1_CF@_E+QCE1[[?VK 6(38X1LIBM@+[BQ<&2S'1H<3+
MN_$=T7!(:A),C>MVL/&AT$JZDZ]C0B:5!=&*-3H&HUK[P\#CZ$1@L(SHC9!(
M%I;2.Q=QH#[BI;WD W0ZU,>Z)0_G4H/:VE6K:M!+#>8>Q>JNO5Y5[49>>T7<
MQLO^)#9SN5\7MR4/ZGYQP)-&2'KMNE@77-NDO89/E:B21V"G=:R/X<: "#O\
M9]L)+M*H7&R80IU%,4R49YY;WA,8/@(3B^Q?(X8AGL0)62[MQ6W)@[JTB5*T
M,48)CL%MU%I 24$^B3U<KM7%;<G#N5:43(FJT(?Z""R@0(V'/(W,V5C42BQ)
MF7,;I*&"C:>PL<M=N[@M>3AWC5-@>MF$T#\M6T_O%?QM7S5%Y+I&"JVV1^[;
MV9T5F.R#C5;_2H'WVSH(_%9Q6PI .Q. 1EFZZ48IWK5Q].:HH3/J)C4%8S*Q
MP*$NN"5BY_?M-;/<:5V$X1M>89G5.^$R2"/K;BZRK@_>$Y5%0'V=>C^:Q*YZ
M2E5C\H@*$C ]?CBT53-H2G?RJ#@XB<J[B+S[,$28S540]]\)L.0T/&EZ@T["
ME'WN3(*+:\9BD_=]1;U!&7TK9+F'XA@JB[C$A%8TP.5F>$5LHGU:G<9?=_SU
ME2=>N_9&:Q*Q^%M;:V&0MAT'X?F-B_:;Y&HO\'Y_U'*/KY=RCX]9[O'[I=QC
M*??X&(WG#>:5F2I1U1Z%;ATTJ\ (J3EAOR-F5@0XZ0>"C?&$SB0U2UU-LF*%
MDA>Y)%,"2*EMV"L?5,>(;W\TG<@D/\Y$E]AP!.FZRR+0?.I8&K_EZ+Z^%'EG
MNM!%VY!USK!6D+E 7 .L6;1S,YJ9UVT][GU(X"O/Q"/:_D^O47[52M>4Y9#L
MB_EJTM(?//=7%30Z'URV.O@0,>3GCENA1S YYN[,,;_*7K'%B1B[B,QEKI0F
M/#4C?G-*#E-K!&X8K@5$T^\D%A6!_BFSA::Q@W><^5D>"G^3$00<"AIZ0MG%
M,R5BY+;Q@3!6H"IA)3#>04_'RJ6RO6FVU$4<*SR2Y4?!8>\U\EVKYT;81[('
M\U@3'"V^$P*0&ZG!>N>I-PG?S_F!DMTL0V7!%58P!=T0?K*H:N$C&^L"FS#J
M/NOA:!O[&VE13(,AR@VP+P5(J]NC2$%I8S$I(XM4-\F4(VVG2*++I<!91-)M
MO O4PJO1FLC >BW5\^M(G*7<+3?$[X1W$RFSI#"1-:3@"DO+*Y,0I1A$+750
M3E[F^&65%Y@_H<@F[*Z47@,WCZABKCT3D8MGMZB_"YW*?4]9'HY9((Y1(?7?
M/_SY+==-?3O[6SP;R#K&R"1N) #?:6",9/%=8RM$A\W61@YG!#HQ(6CE#K85
M-@1!_8JB,GX%CRT5'A"M_>#C2YE.HID>Y3"CV*!G"#!Y-Z% (UTUELBT3A&,
M7G@PINQ/;P41\N7S+VU3TP+4^;,?WM?^B L4&XG/W,46- 67#/<N&J+^O;*Q
M$F-ZTQ<!CPZ7CZGBJW4TFSE8^?[(H'[A91;)@'.%Y^WA8 8NSND\,$;%]1M-
MVZPJZI2%IG758^/MZW8@;JTSHR)"?9L?Q&YDUT6MM7I;_+A!AOIBO1N918;?
M3"X"GH1V[)&'B'Z(#2)^5H'FI!4D2K,8+R)91#4&(7QW(H96GM6DU $0)1/K
MX32J@P9 W^YM.&KFR<X\N;!L)53-IV"%0D:Q3HAT)^:EA+"*Y!VLPN4Q9(B
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M0HI^KC'6XVF:)=DIGUG$N$(43M[AUAUB:S7!W:9;OSF!DXG:%L7%O$(B,P=
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M>W8ES9R:=),I3U$M+(GO^,5]=$[ GU)]SII%=*$W;#UPD'8UL>O:E;U"F96
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M<FDOD1V8P7E"U>/!DON"PIV]P%@-80:DR'7*ST(A7RLD"'>""I,R:$3<&SF
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M4P/DE V5&Q7L-WLBV%VVTIS;",AX4(42FWOLY<6C:W?3,4+'@L-#TPMT,M+
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MI4U)CJ?@#NL4LT<"Y6_$ 0K*U)*;A&L_'J/8.1I[L/D57H.#:85P2)WG<,/
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MATYLJK8]A?HOQ'(W6$,5QME3.-+T9_"R\ K1,W'IC0D<N[9.$5I*-QH*_YD
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MW\"2@3<*-R<D[[)G^$)XF/?Z;_K'_>!5G=&_6(5GL(FJG@@-B:&WLCTR/D1
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MG82+'H\%K8JZ"B!\JB*\TRIJM0F2[!<D'(Y@MFD,H\(+B[R:$,4L-<I:FW6
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M7#MNEL9?4A?E0+$N"AE%9ZY@-D_SD,]IAM(UG"04>\$I6'*3Z"OUME+_-+;
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MJ)82GN+SO$*(&+[*[9+T6$?-" B)(.M8&':!KTD+\(V=6W?WS@LP ,\W.PS
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MX=NSH?^;Z>QS.GY77QM<!JJ&KI:&M+6TA-,^F19ITI1DQ&",DHU*&Y[94[@
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M:=C8:]0\'10'4N1PTGCM>+PV=LKCZ&(,&YI1*V(=-NR&CQP*@7W$P!7F:%6
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M"JJ%IZ^D#4LT<2.3[IMN8#S;P@77N(R+*N\$?QD@;^'%1[4AN.;Y32]#5F6
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M-:G8I)QA&!A$) <1C&6]H%'A3.B;:#+%HG]$U8<-1T2/D"B!Z8QT5$@[N=C
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MW;C$8O*@90;,L)8FWFP66LW86^]M52:8 1_G@WG(R4EGG&M::]"D?9RG;4F
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M-XBB,)VFD0%AZ'!OD>],E;"$BDX?O&&@+7B#A0*AL$=> AD<$*%1R/-GA\$
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MSS_C0+Z37^6.:T:T64%RT#$#U$TORVK9HK>-2C.J!FPGGL>DI+9;WT>4 9W
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MV?RSOW*PZN?15Q^.9C%V!0GB:L7:@%-AV36G[,95F<S0+7\D&?!VE9)WJ;[
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M/;<*WX]#9XN.4\%T@"[0SN01K#96Q6IZ9>94->.FXV[7#T#D0L?W*%=DMCO
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MR<ZAHSJ"T:/5Z&E]SQV/B<</LT(QY*+E ,[P;W8)Q#5F;EB%8B[3J=6F^-S
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M@-D3F(]:G>@_KCGZBSU3?-W_NV0+DN([VIC8COPWT\2%):AH!+';9>FA5W(
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MG$)2%Q_?#3\=8\WIAGDHOU$5 KJ2@,LO/EN0^?@_N1RT D 6WV/'_ /\-K3
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M,M#32"*-)%[W%J21A'4F@9#!/)/PH$,JEHFQ9^D&O"2'XM7NWIF3GVK_*]V
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MLQ^J ,2Y9I81\"B6,5--FJ0_Z(%*9PN(G\KZ*V3&5LBL%R_624"P8MIV*]A
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M4:W<ELB!OY_.KR\MP &SEH".X-$:-G0^LM<6T0V+*N^[/">2O$;8JQV0HDQ
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MF7N&X>YG"J=P]TNU?//T1:L:OUJHZ^)\"E>UP!^$6&Q;<"I'U;Q&WOF#CKP
MJT<:_ !F]4J^CC(3=E#45%U_>[$[DZ,9K8NU2[J1&L:ZH69 \. 3>49.<T R
MT1;]>\&ZG,]7Z'L44M$,W()[MWKGS_!;JZ>HL\D-6#?6@?Y!2%1L"QYZ2:24
M0>A5Y,,QA4.LX!RF6&4[\\;SM]I Y!_IP@&8PI%@BM/Z=&O6XSAB5B3-I-^
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M1HNKW L^<SGO=<W H]GL_ K.IYB_[4/2>$U2NQIXE-2Y+B]Z8*9JT&6T<BC
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MJ@'XS-I<TX B+ 8:#YEM3AM31/R3O,:%&V!T1@/^N:MJ^ ^&Z03Q0QD,5.@
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M=)K'GQ?L']&3<ZU& #LWU@6*-[)=O+6>\U>/I=;:L?3X7)',Q&0W-,FH.#<
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M$VE J &C9QK2(A^(ZJ &CS"*]"G1-@6N.H.P\V.N[+<D[+>::=XI=*AQ@E&
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M(X_*H[:-H^NY#(?1]!)N+D_7]*A"3:\4SF3B%<XH=]V1[\7?X0^'UQ=[7^!
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M'?VFU*9Z_:XS(&2/RQ.<J%"Q5#KTC"Z5%<0+7?,<D].3D.#^8(\EDX#G@ [
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MT3VJ+?ETAZT6>$QTA\["?;8\3')XLIS ZPYT>#*C]P,7O&D^S_)19^\:/M%
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MR2>'OHBQU@Q5.+V'O19D* +#R-"S<?L._$@-.+JE XMT*9^A?(M><,VC#,@
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M(\DP&V<"$4PGE3435'XA@LKE\\LFJ,?CRM<_WV\Z7WNY=1-4;H\N9TZ"*BQ
M4+GL?G$9%+7<O->1P&U(1A.@$$+*RBY$6?GELZHOS\/?%?_2^?.CNF[*RB_
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MZZDW(\OAWR/\[3PAD;?-D=&FM8%?9>?*R/C7MPLX2D/RL/"LPRB V':%&N\
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M=RQJ'>]JYZ3WO7X!#5"Y=R<NU=H,A*\E9^LEI#,M@6T)6[,S:#_X< -EJKM
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MN9?T<"%=!E=:"R+C]5;PT_)"YE?<) X]+(*=U3C51/*>8N1Y<NGD>3ZOFYQ
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M@2]+F>K1\M"@NX_F<X6P*T'L4!'<+]Q4@V%),"RX6T*& $T'^+=5Z&)ACZ;
M<C[#(,C_<8>\C/AF*%T?'!?('P+C8H@XB:OG<,/7H2\A-.;/GA) %8+V*?1I
M178?PN^H5S6J+D-"",<H "08_+Y YYM<;& +@G(&5/80[;OP; (RX %T;1":
M7 $44.B)Z\^1:?5VE6IT9>AB;B$ ^_P=4/10.YNN!84^)+^;WPG!3<S>TA'?
M A,@ X0$D2[&#XDM:?F*!^Z'(12*@A& I L4_4M-76(= Y3)= 6+E7&2Z=2.
M5K6)Z9NT%9H6]@L>?"J'"K-1R?1044#N1;>I$?]Q6LONMBJ<EXA&#@Y#4 D$
M"&]^F 1[$'DFL\H :D%U*"-%NK'"&$'+0-^658"70(K.PMCLR,>(T8^O]PYG
M]\;M8KX;9J!DT\BB@"DRA>5 CIF##0,>&QNF0N?=U)*Y-H[RH>X8_PR0[D6V
M<G5*R;+$03GN*<_W9^>G;D <1('H%1HP7Q%?'UZ,@D*12C6YBKALN/61+RZL
MQI_J1QZ*$>^N)(:P^O*5$WZOT#<L3;I[-+/&'??[@QJ1ILVSFVY8G-;L8%JO
M[-13&2F"$@PJ16++THK8II3A38!E@+HAZ*)3'X/8-.#,$,?6;Z;U3"X?\89+
M-P>E(Y:(G(#;[!*QX?>!3QG&RI+N64 S"%,1MUS7GOQ(!<>H^4]R@MY=A2(
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MBB0M#I07&2J&C*&&K%A.7>3AJN,-46=ZR%"<<2/!P*Z<QIR+Z$84^#SBYY&
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M[4/F"ME_*B^!5 .4'EQ&A@ZV'V$IFPTZXQ869!XR(BQEP ,TGH*4)>+^":.
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M0X5,D#DW*@>C8D:J2)#)K-F"9'XZ':/&/XM *<?XML/3P]ZA]?0\?3S]UD3
M5J&U*<=*R-[H<RQ]FFM)B 7%L>C# NXU>V;Y"/*$(Y,M&<XYD10^3=>_ [,/
M/U15&*"ZR>[N^=QXNIF@ZQ(]X1GD[$U=%J0^""?"!P)ED7E1#(F'*;%(G/%
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MOH>],K)C=&?A/VEV9O=A^VL=*7=X9QO?/B"EB@R5M81MK<_1XS%97E-U)#+
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M5"'$;LF.!>E#FD"3@# :6L<=S=&=70XD 2$S4=H,(H]R.8@R0Y24#T8&WZ8
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MC@)U36!''',@GDD!I^%YC_ +WH3C9]8[2VIG(M1E*SQU,88H5XU]^PF=BF^
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MBR&0)"!^XYY_JH7J&N#(D@G/4?:#)$M4Z"(X&<!EP'$XU<PI8*,R.BHQ.@K
M*K-S1Z+LAJ4Z0:+58$")GZ?CI=:9I66CX8\M%%&.V*3>FY":.M=^_=@;J>?[
M_7B'3@#W-9<5+VWIR:Z7(E^&J^=F"E=R9;64(=$IILI5ZB8N9IJ,VRHJ&SRA
M2%)$+JQAYUP=)4Y,?X$P&A.H/&>&FP]N>59,PV:'&Q-?0\@X$EI B 0$ EJ(
M!^@CWB%=;<I$^1R,%1"MP!N#F#T!I#P!1.<A V7&!'*" $-=-%.@'A,[9_>X
M.U+61M94-,<6S4#\8.OQV.8,:9PU\T9PYKX.@_)LANC81+\2ULZ>74]/(ID
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M;!;,PNTPVH-( $\*/A#,CZ-BK:EWX0DN@Y@]WPTGI^9=]^;^CW2:H\*/+L_
MMJ9F#P2@9?\EVX/.%S5?S*F%2DXME;Y&Z9)+Q3)$0\+!C;]E+IMWX"^A0(B9
MR_^CC<9_!QQRPI6"FH'R-[709K+!)Q3> /YB];_CJ2%XE1(SNC_^^7\)SU3*
MH<L1JW916#-U1],R3V(ZP"?Q>YYO&-GGD$&4.7VMX(9&"^'0:"&G*,68!+;X
M%8M=W_CC_!X;YU>&=QS2W=&?=H9ZCZK,?\GT;*KZ4\<VZ,)584R4]M0@^L +
MYAO+ .KK9@!U[LZN@1?,]UA7";O[=3XK=JY^GJHOX ;70WU"HBQ@Y<<^Z)3W
M7RJV(XURLM+A)A_P]'T,G':J3Z[@M*OEQ6=]T<)^D$V)Y)"M95,R9Z>D;$HU
M#@9HF3V)94)^%*<C8M(I&W3Q:KT1G1VKS7TDKV1#33+ AY[;5A^\G%!C<D@\
MI<2^&EU,&]WR1-/7HI1DXTA\\LSY'YB^X$B.RY(,F!%G76/?K.0^\523=SD
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MK-X<_C^<C(Q__C]02P$"% ,4    " #.AGQ:X5A5>>T;   A4 $ $
M        @ $     8V1T+3(P,C0Q,C,Q+GAS9%!+ 0(4 Q0    ( ,Z&?%JY
MMH;A;1P  -!J 0 4              "  1L<  !C9'0M,C R-#$R,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( ,Z&?%H,F>LA(V(  /NL!@ 4              "
M ;HX  !C9'0M,C R-#$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( ,Z&?%H2./Y+
M;K\  'CN"@ 4              "  0^;  !C9'0M,C R-#$R,S%?;&%B+GAM
M;%!+ 0(4 Q0    ( ,Z&?%I25^$5KH(  $S/"  4              "  :]:
M 0!C9'0M,C R-#$R,S%?<')E+GAM;%!+ 0(4 Q0    ( ,^&?%J#$SJ+>CD
M "K' 0 *              "  8_= 0!E>#$Y+3$N:'1M4$L! A0#%     @
MSX9\6M77(AL+ P  Q T   H              ( !,1<" &5X,C,M,2YH=&U0
M2P$"% ,4    " #/AGQ:.(6\+OT'  #$10  "@              @ %D&@(
M97@S,2TQ+FAT;5!+ 0(4 Q0    ( ,^&?%JU@,AH^0<  "U&   *
M      "  8DB @!E>#,Q+3(N:'1M4$L! A0#%     @ SX9\6E%!G-LE!@
M;RD   H              ( !JBH" &5X,S(M,2YH=&U02P$"% ,4    " #/
MAGQ:EC3$$"8%  "P(@  "@              @ 'W, ( 97@S,BTR+FAT;5!+
M 0(4 Q0    ( ,^&?%J-1LG+=2$  $K2   )              "  44V @!E
M>#0M,2YH=&U02P$"% ,4    " #/AGQ:92 NUX:3! #FI2< #
K    @ 'A5P( 9F]R;3$P+6LN:'1M4$L%!@     -  T !P,  )'K!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:CDT="http://conduitpharma.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cdt-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CDT:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CDT:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <instant>2025-03-28</instant>
        </period>
    </context>
    <context id="AsOf2024-06-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="From2024-10-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-242025-01-24_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-24</startDate>
            <endDate>2025-01-24</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_OldConduitPharmaceuticalsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:OldConduitPharmaceuticalsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-22</instant>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_ConduitConvertibleNoteHoldersMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:ConduitConvertibleNoteHoldersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_ConduitShareHoldersandConvertibleNoteHoldersMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:ConduitShareHoldersandConvertibleNoteHoldersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_srt_DirectorMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-22</instant>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SponsorMember_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-22</instant>
        </period>
    </context>
    <context id="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-22</instant>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-22</instant>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember_us-gaap_CommonStockSubjectToMandatoryRedemptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_srt_DirectorMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SponsorMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CDT:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AGPConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ConvertibleNotesPayableMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <instant>2024-12-11</instant>
        </period>
    </context>
    <context id="From2024-12-112024-12-11_custom_PIPEWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CDT:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-11</startDate>
            <endDate>2024-12-11</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PIPEWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CDT:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-22_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-10-312024-10-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-31</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-11-222024-11-22_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-22</startDate>
            <endDate>2024-11-22</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_CorporateBondYieldEstimatedTimingOfConversionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:CorporateBondYieldEstimatedTimingOfConversionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-22_custom_CorporateBondYieldEstimatedTimingOfConversionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:CorporateBondYieldEstimatedTimingOfConversionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CorporateBondYieldEstimatedTimingOfConversionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:CorporateBondYieldEstimatedTimingOfConversionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_us-gaap_MeasurementInputCreditSpreadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-22_us-gaap_MeasurementInputCreditSpreadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputCreditSpreadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_MeasurementInputProbabilityOfDefaultMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputProbabilityOfDefaultMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-22_custom_MeasurementInputProbabilityOfDefaultMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputProbabilityOfDefaultMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MeasurementInputProbabilityOfDefaultMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputProbabilityOfDefaultMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_MeasurementInputRecoveryUponDefaultMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputRecoveryUponDefaultMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-22_custom_MeasurementInputRecoveryUponDefaultMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputRecoveryUponDefaultMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MeasurementInputRecoveryUponDefaultMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputRecoveryUponDefaultMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-22_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_us-gaap_MeasurementInputSharePriceMember_custom_AGPConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_AGPConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-11-252024-11-25_us-gaap_MeasurementInputExpectedTermMember_custom_AGPConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_AGPConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_CorporateBondYieldEstimatedTimingOfConversionMember_custom_AGPConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:CorporateBondYieldEstimatedTimingOfConversionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CorporateBondYieldEstimatedTimingOfConversionMember_custom_AGPConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:CorporateBondYieldEstimatedTimingOfConversionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_us-gaap_MeasurementInputCreditSpreadMember_custom_AGPConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputCreditSpreadMember_custom_AGPConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_MeasurementInputProbabilityOfDefaultMember_custom_AGPConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputProbabilityOfDefaultMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MeasurementInputProbabilityOfDefaultMember_custom_AGPConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputProbabilityOfDefaultMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_MeasurementInputRecoveryUponDefaultMember_custom_AGPConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputRecoveryUponDefaultMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MeasurementInputRecoveryUponDefaultMember_custom_AGPConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:MeasurementInputRecoveryUponDefaultMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-29_us-gaap_MeasurementInputSharePriceMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-29</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-29_us-gaap_MeasurementInputExercisePriceMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-29</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExercisePriceMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-29_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-29</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-29_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-29</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-10-292024-10-29_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-29</startDate>
            <endDate>2024-10-29</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="From2020-10-202020-10-20_custom_VelaAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:VelaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-20</startDate>
            <endDate>2020-10-20</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_VelaAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:VelaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_VelaAgreementMember_custom_VelaTechnologiesPLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">CDT:VelaTechnologiesPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:VelaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-04-30_custom_VelaOptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:VelaOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-30_custom_VelaOptionAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:VelaOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30_custom_VelaOptionAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:VelaOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30_custom_VelaOptionAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:VelaOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="From2023-11-302023-11-30_custom_VelaOptionLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:VelaOptionLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-30</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-30_custom_VelaOptionLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:VelaOptionLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_VelaOptionLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">CDT:VelaOptionLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-02-112022-02-11_custom_CizzlePlcAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:CizzlePlcAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-11</startDate>
            <endDate>2022-02-11</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-11_custom_CizzlePlcAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:CizzlePlcAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CizzlePlcAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:CizzlePlcAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-15_custom_CizzlePlcAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:CizzlePlcAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-15</instant>
        </period>
    </context>
    <context id="From2023-09-262023-09-26_custom_CizzlePlcAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:CizzlePlcAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CizzlePlcAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:CizzlePlcAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CizzlePlcAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:CizzlePlcAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ConvertiblePromissoryNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-03-012023-03-31_custom_ConvertiblePromissoryNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-092024-10-09_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-09</startDate>
            <endDate>2024-10-09</endDate>
        </period>
    </context>
    <context id="From2024-10-112024-10-11_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-11</startDate>
            <endDate>2024-10-11</endDate>
        </period>
    </context>
    <context id="From2024-10-092024-10-09_custom_ConvertiblePromissoryNotePayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNotePayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-09</startDate>
            <endDate>2024-10-09</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-09_custom_ConvertiblePromissoryNotePayableMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNotePayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-09</instant>
        </period>
    </context>
    <context id="From2024-10-092024-10-09_custom_ConvertiblePromissoryNotePayableMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNotePayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-09</startDate>
            <endDate>2024-10-09</endDate>
        </period>
    </context>
    <context id="From2024-10-112024-10-11_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-11</startDate>
            <endDate>2024-10-11</endDate>
        </period>
    </context>
    <context id="From2024-10-102024-10-10_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-10</startDate>
            <endDate>2024-10-10</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-10_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-10</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ConvertiblePromissoryNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-062025-03-06_custom_TwentyTwentyThreeConvertibleNoteMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:TwentyTwentyThreeConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-06</startDate>
            <endDate>2025-03-06</endDate>
        </period>
    </context>
    <context id="From2025-03-132025-03-13_custom_TwentyTwentyThreeConvertibleNoteMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:TwentyTwentyThreeConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-13</startDate>
            <endDate>2025-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:SeniorSecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:NirlandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="From2024-08-062024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:SeniorSecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:NirlandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-06</startDate>
            <endDate>2024-08-06</endDate>
        </period>
    </context>
    <context id="From2024-08-062024-08-06_custom_SeniorSecuredPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:SeniorSecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-06</startDate>
            <endDate>2024-08-06</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:SeniorSecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:SeniorSecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="AsOf2024-08-06_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="AsOf2024-08-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_FirstAmendmentNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:FirstAmendmentNirlandNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_NirlandLimitedMember_custom_FirstAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:FirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:NirlandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="From2024-10-312024-10-31_custom_NirlandLimitedMember_custom_FirstAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:FirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:NirlandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-31</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-11-222024-11-22_custom_SecondAmendmentNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:SecondAmendmentNirlandNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-22</startDate>
            <endDate>2024-11-22</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-22_custom_SecondAmendmentNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:SecondAmendmentNirlandNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="AsOf2024-11-22_custom_FirstAmendmentNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:FirstAmendmentNirlandNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="AsOf2024-11-22_custom_SecondAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:SecondAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="AsOf2024-11-22_custom_FirstAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:FirstAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="From2024-12-092024-12-09_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-09</startDate>
            <endDate>2024-12-09</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:NirlandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember_custom_FirstAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:FirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:NirlandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember_custom_SecondAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:NirlandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AllianceGobalPartnersConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="From2025-01-252025-01-25_custom_AllianceGobalPartnersConvertibleNoteMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AllianceGobalPartnersConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-25</startDate>
            <endDate>2025-01-25</endDate>
        </period>
    </context>
    <context id="From2024-11-252024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AllianceGobalPartnersConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AllianceGobalPartnersConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AllianceGobalPartnersConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-01_custom_LoanAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:LoanAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-01</instant>
        </period>
    </context>
    <context id="From2022-05-012022-05-01_custom_LoanAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:LoanAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-01_custom_TrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CDT:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-01</instant>
        </period>
    </context>
    <context id="AsOf2022-05-01_custom_TrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CDT:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-01</instant>
        </period>
    </context>
    <context id="AsOf2022-05-01_custom_TrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CDT:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-01</instant>
        </period>
    </context>
    <context id="AsOf2022-05-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <instant>2022-05-01</instant>
        </period>
    </context>
    <context id="From2024-10-092024-10-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <startDate>2024-10-09</startDate>
            <endDate>2024-10-09</endDate>
        </period>
    </context>
    <context id="From2024-10-112024-10-11_custom_LoanHoldersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">CDT:LoanHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-11</startDate>
            <endDate>2024-10-11</endDate>
        </period>
    </context>
    <context id="From2024-10-112024-10-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <startDate>2024-10-11</startDate>
            <endDate>2024-10-11</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <instant>2024-10-09</instant>
        </period>
    </context>
    <context id="From2025-02-012025-02-28_custom_LoansAmendmentMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:LoansAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:OctoberTwoThousandTwentyFourNirlandNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-28</instant>
        </period>
    </context>
    <context id="AsOf2024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:OctoberTwoThousandTwentyFourNirlandNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-28</instant>
        </period>
    </context>
    <context id="AsOf2024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:OctoberTwoThousandTwentyFourNirlandNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-28</instant>
        </period>
    </context>
    <context id="From2024-10-282024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:OctoberTwoThousandTwentyFourNirlandNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-28</startDate>
            <endDate>2024-10-28</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OctoberTwoThousandTwentyFourNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:OctoberTwoThousandTwentyFourNirlandNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-292024-10-29_custom_BridgeLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:BridgeLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-29</startDate>
            <endDate>2024-10-29</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-29_custom_BridgeLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:BridgeLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-29</instant>
        </period>
    </context>
    <context id="AsOf2024-08-06_custom_BridgeLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:BridgeLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BridgeLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:BridgeLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_AllianceGlobalPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_AllianceGlobalPartnersMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-22_custom_AllianceGlobalPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-22</instant>
        </period>
    </context>
    <context id="AsOf2023-09-22_custom_AllianceGlobalPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-22</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AllianceGlobalPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_AllianceGlobalPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CDT:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SARBORGServiceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SARBORGServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SARBORGServiceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SARBORGServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SARBORGServiceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SARBORGServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_SARBORGServiceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SARBORGServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-22_custom_TwentyTwentyThreeStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CDT:TwentyTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-22</instant>
        </period>
    </context>
    <context id="AsOf2025-02-06_custom_TwentyTwentyThreeStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CDT:TwentyTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-06</instant>
        </period>
    </context>
    <context id="AsOf2025-01-01_custom_TwentyTwentyThreeStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CDT:TwentyTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_TwentyTwentyThreeStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CDT:TwentyTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwentyTwentyThreeStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CDT:TwentyTwentyThreeStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-06-242024-06-24_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-24</startDate>
            <endDate>2024-06-24</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-24_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-24</instant>
        </period>
    </context>
    <context id="From2024-06-242024-06-24_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-24</startDate>
            <endDate>2024-06-24</endDate>
        </period>
    </context>
    <context id="From2024-11-182024-11-18_custom_NonEmployeeDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:NonEmployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-18</startDate>
            <endDate>2024-11-18</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-18_custom_NonEmployeeDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:NonEmployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-18</instant>
        </period>
    </context>
    <context id="From2024-11-182024-11-18_srt_BoardOfDirectorsChairmanMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-18</startDate>
            <endDate>2024-11-18</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-18_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-18</instant>
        </period>
    </context>
    <context id="From2024-11-182024-11-18_custom_MrHeilbronMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:MrHeilbronMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-18</startDate>
            <endDate>2024-11-18</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-18_custom_ConsultingAgreementMember_custom_MrHeilbronMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:MrHeilbronMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-18</instant>
        </period>
    </context>
    <context id="From2023-12-012023-12-01_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-01</endDate>
        </period>
    </context>
    <context id="From2023-12-012023-12-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-01</endDate>
        </period>
    </context>
    <context id="From2024-06-072024-06-07_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-07</startDate>
            <endDate>2024-06-07</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyThreePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CDT:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwoThousandTwentyThreePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CDT:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CDT:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CDT:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-10-232024-10-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <startDate>2024-10-23</startDate>
            <endDate>2024-10-23</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PIPEMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:PIPEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PIPEMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:PIPEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AGPWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AGPWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AGPWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AGPWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember20778937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ConvertiblePromissoryNotesPayableMember20778953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:ConvertiblePromissoryNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember20778968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember20778968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AugustTwentyTwentyFourNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AugustTwentyTwentyFourNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AGPConvertibleNoteMember20778984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AGPConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AGPConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MarchTwentyTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:MarchTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MarchTwentyTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:MarchTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AprilTwentyTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AprilTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AprilTwentyTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AprilTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AGPTwentyTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AGPTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AGPTwentyTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CDT:AGPTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-08-312023-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <startDate>2023-08-31</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="From2023-08-312023-08-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-31</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-22_custom_CorvusCapitalLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CDT:CorvusCapitalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-22</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CDT:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CorvusCapitalLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CDT:CorvusCapitalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-28_custom_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:TwentyTwentyTwoConvertibleLoanNoteInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="From2023-02-012023-02-28_custom_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:TwentyTwentyTwoConvertibleLoanNoteInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CorvusCapitalLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CDT:CorvusCapitalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-22_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-22</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SARBORGLtdMember_custom_SARBORGServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CDT:SARBORGLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SARBORGServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-04-222024-04-22_custom_OfficersAndDirectorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CDT:OfficersAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-22</startDate>
            <endDate>2024-04-22</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-22_custom_OfficersAndDirectorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CDT:OfficersAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-22</instant>
        </period>
    </context>
    <context id="AsOf2024-03-20_custom_MarchLockUpAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:MarchLockUpAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MarchLockUpAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:MarchLockUpAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-20_custom_AprilLockUpAgreementMember_custom_AprilTwentyTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CDT:AprilTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:AprilLockUpAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-20</instant>
        </period>
    </context>
    <context id="From2024-04-202024-04-20_us-gaap_WarrantMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-20</startDate>
            <endDate>2024-04-20</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-12-31_us-gaap_WarrantMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-12-31_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-29_custom_AllianceGlobalPartnersMember_custom_AGPTwentyTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CDT:AGPTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CDT:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-29</instant>
        </period>
    </context>
    <context id="AsOf2023-09-22_us-gaap_IPOMember_custom_PublicWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CDT:PublicWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-22</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_IPOMember_custom_PublicWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CDT:PublicWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-22_us-gaap_IPOMember_custom_PrivatePlacementWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CDT:PrivatePlacementWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-22</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-03-012024-03-31_custom_MarchLockUpAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:MarchLockUpAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-30_us-gaap_WarrantMember_custom_AprilLockUpAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:AprilLockUpAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="From2024-04-012024-04-30_custom_AprilLockUpAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:AprilLockUpAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CDT:MurphyCanyonAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-22</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <instant>2023-09-22</instant>
        </period>
    </context>
    <context id="From2024-10-292024-10-29_custom_AGPTwentyTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CDT:AGPTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-29</startDate>
            <endDate>2024-10-29</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-11_custom_PIPEWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CDT:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-11</instant>
        </period>
    </context>
    <context id="From2024-12-112024-12-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <startDate>2024-12-11</startDate>
            <endDate>2024-12-11</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="From2024-03-202024-03-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <instant>2024-04-20</instant>
        </period>
    </context>
    <context id="From2024-04-202024-04-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <startDate>2024-04-20</startDate>
            <endDate>2024-04-20</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_NewLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:NewLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_NewLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:NewLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_ClinicalAssetDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:ClinicalAssetDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_ClinicalAssetDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:ClinicalAssetDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_LegalAndProfessionalFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:LegalAndProfessionalFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_LegalAndProfessionalFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:LegalAndProfessionalFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_AccountingAndAuditFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:AccountingAndAuditFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_AccountingAndAuditFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:AccountingAndAuditFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_SalariesPayrollAndStockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:SalariesPayrollAndStockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_SalariesPayrollAndStockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CDT:SalariesPayrollAndStockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-242024-01-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <startDate>2024-01-24</startDate>
            <endDate>2024-01-24</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-07_us-gaap_SubsequentEventMember_custom_OctoberTwentyTwentyFourNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:OctoberTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-07</instant>
        </period>
    </context>
    <context id="From2025-02-072025-02-07_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-07</startDate>
            <endDate>2025-02-07</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-07_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-07</instant>
        </period>
    </context>
    <context id="From2024-12-122024-12-12_custom_AugustTwentyTwentyFourNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-12</startDate>
            <endDate>2024-12-12</endDate>
        </period>
    </context>
    <context id="From2025-01-132025-01-13_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="From2025-02-102025-02-10_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-10</startDate>
            <endDate>2025-02-10</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-13_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:AugustTwentyTwentyFourNirlandNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-13</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_TwentyTwentyThreeConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:TwentyTwentyThreeConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-13_custom_TwentyTwentyThreeConvertibleNoteMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CDT:TwentyTwentyThreeConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-13</instant>
        </period>
    </context>
    <context id="From2025-01-152025-01-15_us-gaap_SubsequentEventMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-15</startDate>
            <endDate>2025-01-15</endDate>
        </period>
    </context>
    <context id="From2025-02-062025-02-06_us-gaap_SubsequentEventMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-06</startDate>
            <endDate>2025-02-06</endDate>
        </period>
    </context>
    <context id="From2025-02-102025-02-10_us-gaap_SubsequentEventMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-10</startDate>
            <endDate>2025-02-10</endDate>
        </period>
    </context>
    <context id="From2025-02-192025-02-19_us-gaap_SubsequentEventMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-19</startDate>
            <endDate>2025-02-19</endDate>
        </period>
    </context>
    <context id="From2025-03-102025-03-10_us-gaap_SubsequentEventMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-10</startDate>
            <endDate>2025-03-10</endDate>
        </period>
    </context>
    <context id="From2025-01-222025-01-22_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-22</startDate>
            <endDate>2025-01-22</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-22_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-22</instant>
        </period>
    </context>
    <context id="From2025-03-282025-03-28_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CDT:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-28</startDate>
            <endDate>2025-03-28</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="GBPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000004">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000005">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000006">0001896212</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0085"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0088"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0109"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl0115"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0121"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0127"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0130"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0136"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0141"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0147"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0148"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0172"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0173"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0183"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0185"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0187"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0189"
      unitRef="Shares"
      xsi:nil="true"/>
    <CDT:ChangeInFairValueAndIncomeImpactOfOptionLiabilities
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValuePurchaseOfRevenue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValuePurchaseOfRevenue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValuePurchaseOfRevenue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValuePurchasesOfRevenue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValuePurchasesOfRevenue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValuePurchasesOfRevenue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuedForServicesOne
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuedForServicesOne
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuedForServicesOne
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuedForServicesOne
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuedForServicesOne
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:GainLossOnChangeInFairValueOfCizzleOption
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0528"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:GainOnChangeInFairValueOfVelaOption
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:LossOnIssuanceOfVelaOption
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:ChangesInForeignCurrencyTransactionUnrealized
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:LossOnRelatedPartyLoanForgiveness
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0543"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:RealizedGainOnShorttermInvestments
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:LossOnIssuanceOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:NoncashLeaseExpense
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:IssuanceOfCommonStockForLicensingRight
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0577"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:AmortizationExpense
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0583"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:AmortizationOfDebtDiscount
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0586"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0589"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0604"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0606"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0612"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0616"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0619"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0622"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:ProceedsFromIssuanceOfOption
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0624"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:ProceedsFromLoanRepaymentRelatedParty
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0627"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0636"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0640"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0643"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:ProceedsFromIssuanceOfCapitalContributionRelatedParty
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0645"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0649"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:ProceedsFromExerciseOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0652"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0655"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0658"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0660"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0676"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0685"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0688"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0691"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:IssuanceOfCommonStockInExchangeForDebtExtension
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0694"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0697"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0699"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0702"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesReduction
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0705"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:DeferredUnderwritingCosts
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0708"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0711"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0714"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0717"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:NoncashAssetsAssumedInMergerFinancing
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0720"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:NoncashLiabilitiesAssumedInMergerFinancing
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0723"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember"
      id="xdx2ixbrl0886"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember"
      id="xdx2ixbrl0888"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0894"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0896"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ConvertibleNotesPayableMember"
      id="xdx2ixbrl0900"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ConvertibleNotesPayableMember"
      id="xdx2ixbrl0902"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      id="xdx2ixbrl0908"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0916"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0918"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      id="xdx2ixbrl0924"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      id="xdx2ixbrl0928"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0932"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0936"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember"
      id="xdx2ixbrl0942"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0943"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0949"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1051"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1054"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1518"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1520"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreePlanMember"
      id="xdx2ixbrl1560"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember"
      id="xdx2ixbrl1570"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember"
      id="xdx2ixbrl1572"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember"
      id="xdx2ixbrl1580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember"
      id="xdx2ixbrl1588"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember"
      id="xdx2ixbrl1596"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1620"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1621"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1623"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1624"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1627"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1629"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1630"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1647"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1648"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember"
      id="xdx2ixbrl1657"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1662"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1666"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:IncomeTaxReconciliationConvertibleDebtAdjustment
      contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1670"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:IncomeTaxReconciliationStateReRate
      contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1674"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember"
      id="xdx2ixbrl1685"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1686"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1687"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1694"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember"
      id="xdx2ixbrl1697"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1706"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:IncomeTaxReconciliationConvertibleDebtAdjustment
      contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember"
      id="xdx2ixbrl1709"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:IncomeTaxReconciliationPurchaseAccountingAdjustments
      contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1714"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember"
      id="xdx2ixbrl1721"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1722"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1723"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:DeferredTaxAssetsStockOptions
      contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1728"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsHedgingTransactions
      contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1732"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1736"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1740"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember"
      id="xdx2ixbrl1755"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1756"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1757"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:DeferredTaxAssetsStockOptions
      contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1760"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      id="xdx2ixbrl1779"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember"
      id="xdx2ixbrl1780"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1781"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember"
      id="xdx2ixbrl1789"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1815"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1817"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1819"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1821"
      unitRef="Shares"
      xsi:nil="true"/>
    <CDT:ChangeInFairValueAndIncomeImpactOfOptionLiabilities
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1836"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:OptionLiabilityConversionShares
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1845"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_PIPEMember"
      id="xdx2ixbrl1862"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember20778968"
      id="xdx2ixbrl1874"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_AugustTwentyTwentyFourNirlandNoteMember"
      id="xdx2ixbrl1878"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_AGPConvertibleNoteMember"
      id="xdx2ixbrl1881"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_MarchTwentyTwentyFourWarrantsMember"
      id="xdx2ixbrl1884"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_AprilTwentyTwentyFourWarrantsMember"
      id="xdx2ixbrl1887"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_AGPTwentyTwentyFourWarrantsMember"
      id="xdx2ixbrl1890"
      unitRef="Shares"
      xsi:nil="true"/>
    <CDT:RecognitionOfDeferredRevenueUponOptionExercise
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1929"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:RecognitionOfDeferredRevenueUponOptionExerciseOne
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1932"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:ChangeInFairValueOfOption
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1935"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:ChangeInFairValueOfOptions
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1938"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:ChangeInFairValueOfConvertibleNotePayment
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1945"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:GainOnDebtExtinguishment
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1948"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:IncomeTaxRefund
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1954"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:LossOnIssuanceOfOptionOne
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1965"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:OtherIncomeUnrealizedForeignCurrencyTransactionLoss
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1968"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1975"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:LossOnIssuanceOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1978"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:LossOnDebtExtinguishment
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1981"
      unitRef="USD"
      xsi:nil="true"/>
    <CDT:OtherExpense
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1987"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_NewLicensesMember"
      id="xdx2ixbrl2099"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000015">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000016">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000017">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000018">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000019">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000020">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000021">001-41245</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000022">CONDUIT PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000024">87-3272543</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000025">4581                                             Tamiami Trail North</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-12-31" id="Fact000026">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000027">Naples</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000028">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000029">34103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000030">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000031">491-9132</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000032">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000033">CDT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000034">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2024-01-012024-12-31_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member"
      id="Fact000035">Redeemable     Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $1,150</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-01-012024-12-31_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member"
      id="Fact000036">CDTTW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-01-012024-12-31_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member"
      id="Fact000037">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000038">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000039">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000040">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000041">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000042">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000043">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000044">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2024-01-01to2024-12-31" id="Fact000045">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000046">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000047">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000048">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-03-28"
      decimals="INF"
      id="Fact000049"
      unitRef="Shares">6662755</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityListingParValuePerShare
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000050"
      unitRef="USDPShares">0.0001</dei:EntityListingParValuePerShare>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-28"
      decimals="0"
      id="Fact000051"
      unitRef="USD">41401162</dei:EntityPublicFloat>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000055">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
operate in the biotechnology sector, which is subject to various cybersecurity risks that could adversely affect our business,
financial condition, and results of operations, including intellectual property theft; fraud; extortion; harm to employees or
customers; violation of privacy laws and other litigation and legal risk; and reputational risk. We have implemented a risk-based
approach to identify and assess the cybersecurity threats that could affect our business and information systems. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zPoYDOIWgNB8"&gt;We
have implemented a risk-based approach to identify and assess cybersecurity threats that could impact our business and information
systems. As part of this strategy, the Company has engaged a third-party service provider to implement comprehensive IT and
cybersecurity policies, including Guardz, Cyber Essentials, and others. These initiatives are supported by detailed policies, staff
training programs, and the use of advanced tools such as firewalls and VPNs to prevent cybersecurity incidents. Additionally,
consultation with third-party experts has further strengthened the Company&#x2019;s IT framework and improved overall compliance. We
require third-party service providers with access to personal, confidential or proprietary information&lt;/span&gt; to implement and
maintain comprehensive cybersecurity practices consistent with applicable legal standards and industry best practices.&lt;/span&gt;&#160;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has engaged a third-party service provider
to implement comprehensive IT and cybersecurity policies, including Guardz, Cyber Essentials, and others. These initiatives are supported
by detailed policies and staff training programs, which have strengthened the Company&#x2019;s IT framework and improved compliance.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
light of the pervasive and increasing threat from cyberattacks, the Company&#x2019;s &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zCmPOEA4fMO7"&gt;Board
of Directors and the Audit Committee, with input from management, assess the Company&#x2019;s cybersecurity threats &lt;/span&gt;and the
measures implemented by the Company to mitigate and prevent cyberattacks. The &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_dbT_c20240101__20241231_zhFBMgui0wy3"&gt;Audit
Committee consults with management regarding ongoing cybersecurity initiatives, and requests management to report &lt;/span&gt;to the
Audit Committee or the full Board regularly on their assessment of the Company&#x2019;s cybersecurity program and risks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of the date of this Annual Report, the Company is not aware of any risks from cybersecurity threats that have &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240101__20241231_zxFc8G9jBSJc"&gt;materially affected or
are reasonably likely to materially affect the Company, including its business strategy, results of operations, or financial condition.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&#160;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000056">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="From2024-01-01to2024-12-31" id="Fact000057">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000058">Audit
Committee consults with management regarding ongoing cybersecurity initiatives, and requests management to report </cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-01-01to2024-12-31" id="Fact000059">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact000060">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact000061">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact000062">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact000063">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000064">688</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000065">We
have audited the accompanying consolidated balance sheets of Conduit Pharmaceuticals Inc. (the &#x201c;Company&#x201d;) as of December
31, 2024 and 2023, the related consolidated statements of operations and comprehensive income (loss), stockholders&#x2019; deficit and
cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#x201c;financial
statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the
Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period
ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000066">Marcum LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000067">Morristown, NJ</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000075"
      unitRef="USD">554000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000076"
      unitRef="USD">4228000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000078"
      unitRef="USD">2161000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000079"
      unitRef="USD">1505000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000081"
      unitRef="USD">2715000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000082"
      unitRef="USD">5733000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000084"
      unitRef="USD">263000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000087"
      unitRef="USD">40000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000090"
      unitRef="USD">1175000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000091"
      unitRef="USD">1491000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000093"
      unitRef="USD">4193000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000094"
      unitRef="USD">7224000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000102"
      unitRef="USD">1428000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000103"
      unitRef="USD">215000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000105"
      unitRef="USD">1963000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000106"
      unitRef="USD">601000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000108"
      unitRef="USD">119000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000111"
      unitRef="USD">800000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000112"
      unitRef="USD">800000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact000114"
      unitRef="USD">2985000</us-gaap:OtherNotesPayable>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000117"
      unitRef="USD">2871000</us-gaap:OtherNotesPayable>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000120"
      unitRef="USD">2871000</us-gaap:OtherNotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact000123"
      unitRef="USD">150000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact000124"
      unitRef="USD">185000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000126"
      unitRef="USD">425000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000129"
      unitRef="USD">425000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000132"
      unitRef="USD">10741000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000133"
      unitRef="USD">1801000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000135"
      unitRef="USD">107000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000138"
      unitRef="USD">138000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000139"
      unitRef="USD">142000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000142"
      unitRef="USD">5738000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000144"
      unitRef="USD">10986000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000145"
      unitRef="USD">7681000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000156"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000158"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000160"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000162"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000164"
      unitRef="Shares">1384801</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">1384801</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">738295</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">738295</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000153"
      unitRef="USD">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000154"
      unitRef="USD">7000</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000175"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000177"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000179"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000181"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000191"
      unitRef="USD">21880000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000192"
      unitRef="USD">10424000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000194"
      unitRef="USD">-29101000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000195"
      unitRef="USD">-11299000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000197"
      unitRef="USD">414000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000198"
      unitRef="USD">411000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000200"
      unitRef="USD">-6793000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000201"
      unitRef="USD">-457000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000203"
      unitRef="USD">4193000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000204"
      unitRef="USD">7224000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000209"
      unitRef="USD">3378000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000210"
      unitRef="USD">90000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000212"
      unitRef="USD">12041000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000213"
      unitRef="USD">5172000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000215"
      unitRef="USD">15419000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000216"
      unitRef="USD">5262000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000218"
      unitRef="USD">-15419000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000219"
      unitRef="USD">-5262000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000224"
      unitRef="USD">-890000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000225"
      unitRef="USD">4923000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000227"
      unitRef="USD">13000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000228"
      unitRef="USD">15000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000230"
      unitRef="USD">-1506000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000231"
      unitRef="USD">-211000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000233"
      unitRef="USD">-2383000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000234"
      unitRef="USD">4727000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000236"
      unitRef="USD">-17802000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000237"
      unitRef="USD">-535000</us-gaap:NetIncomeLoss>
    <CDT:ChangeInFairValueAndIncomeImpactOfOptionLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">5521000</CDT:ChangeInFairValueAndIncomeImpactOfOptionLiabilities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000242"
      unitRef="USD">-17802000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000243"
      unitRef="USD">-6056000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000245"
      unitRef="USDPShares">-20.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000246"
      unitRef="USDPShares">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000248"
      unitRef="USDPShares">-20.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000249"
      unitRef="USDPShares">-8.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000251"
      unitRef="Shares">867096</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000252"
      unitRef="Shares">669739</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000254"
      unitRef="Shares">867096</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000255"
      unitRef="Shares">678939</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000260"
      unitRef="USD">3000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000261"
      unitRef="USD">-264000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000263"
      unitRef="USD">-17799000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000264"
      unitRef="USD">-799000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000272"
      unitRef="Shares">20</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000268"
      unitRef="USD">-10764000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000269"
      unitRef="USD">675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="Fact000270"
      unitRef="USD">-10089000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000280"
      unitRef="Shares">646244</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000274"
      unitRef="USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000275"
      unitRef="USD">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000283"
      unitRef="USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000284"
      unitRef="USD">-6000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000294"
      unitRef="Shares">646264</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000288"
      unitRef="USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000290"
      unitRef="USD">-10770000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000291"
      unitRef="USD">675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000292"
      unitRef="USD">-10089000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000297"
      unitRef="USD">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000298"
      unitRef="USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000308"
      unitRef="Shares">3735</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000303"
      unitRef="USD">3685000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="-3"
      id="Fact000306"
      unitRef="USD">3685000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000316"
      unitRef="Shares">41183</CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000310"
      unitRef="USD">-1000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000311"
      unitRef="USD">15219000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="-3"
      id="Fact000314"
      unitRef="USD">15218000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponConversionOfCommonStockInConnectionWithMerge>
    <CDT:StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000324"
      unitRef="Shares">20000</CDT:StockIssuedDuringPeriodSharesNewIssuesInConnectionWithPipeFinancing>
    <CDT:StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000319"
      unitRef="USD">19779000</CDT:StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing>
    <CDT:StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="-3"
      id="Fact000322"
      unitRef="USD">19779000</CDT:StockIssuedDuringPeriodValueNewIssuesInConnectionWithPipeFinancing>
    <CDT:StockIssuedDuringPeriodSharesPurchaseOfRevenue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000332"
      unitRef="Shares">3955</CDT:StockIssuedDuringPeriodSharesPurchaseOfRevenue>
    <CDT:StockIssuedDuringPeriodValuePurchaseOfRevenue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000327"
      unitRef="USD">151000</CDT:StockIssuedDuringPeriodValuePurchaseOfRevenue>
    <CDT:StockIssuedDuringPeriodValuePurchaseOfRevenue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="-3"
      id="Fact000330"
      unitRef="USD">151000</CDT:StockIssuedDuringPeriodValuePurchaseOfRevenue>
    <CDT:StockIssuedDuringPeriodSharesPurchasesOfRevenue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000340"
      unitRef="Shares">10158</CDT:StockIssuedDuringPeriodSharesPurchasesOfRevenue>
    <CDT:StockIssuedDuringPeriodValuePurchasesOfRevenue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000335"
      unitRef="USD">544000</CDT:StockIssuedDuringPeriodValuePurchasesOfRevenue>
    <CDT:StockIssuedDuringPeriodValuePurchasesOfRevenue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="-3"
      id="Fact000338"
      unitRef="USD">544000</CDT:StockIssuedDuringPeriodValuePurchasesOfRevenue>
    <CDT:StockIssuedDuringPeriodSharesIssuedForServicesOne
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000348"
      unitRef="Shares">13000</CDT:StockIssuedDuringPeriodSharesIssuedForServicesOne>
    <CDT:AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000351"
      unitRef="USD">1141000</CDT:AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger>
    <CDT:AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="-3"
      id="Fact000354"
      unitRef="USD">1141000</CDT:AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger>
    <CDT:AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000357"
      unitRef="USD">150000</CDT:AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty>
    <CDT:AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="-3"
      id="Fact000360"
      unitRef="USD">150000</CDT:AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000363"
      unitRef="USD">199000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="-3"
      id="Fact000366"
      unitRef="USD">199000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000371"
      unitRef="USD">-264000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="-3"
      id="Fact000372"
      unitRef="USD">-264000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000376"
      unitRef="USD">-535000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="-3"
      id="Fact000378"
      unitRef="USD">-535000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000386"
      unitRef="Shares">738295</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000380"
      unitRef="USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000381"
      unitRef="USD">10424000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000382"
      unitRef="USD">-11299000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000383"
      unitRef="USD">411000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000384"
      unitRef="USD">-457000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000397"
      unitRef="Shares">738295</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000391"
      unitRef="USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000392"
      unitRef="USD">10424000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000393"
      unitRef="USD">-11299000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000394"
      unitRef="USD">411000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000395"
      unitRef="USD">-457000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000405"
      unitRef="Shares">738295</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000399"
      unitRef="USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000400"
      unitRef="USD">10424000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000401"
      unitRef="USD">-11299000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000402"
      unitRef="USD">411000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000403"
      unitRef="USD">-457000</us-gaap:StockholdersEquity>
    <CDT:AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000408"
      unitRef="USD">144000</CDT:AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense>
    <CDT:AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000411"
      unitRef="USD">144000</CDT:AdjustmentsToAdditionalPaidInCapitalCorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000419"
      unitRef="Shares">19500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000414"
      unitRef="USD">242000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000417"
      unitRef="USD">242000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000427"
      unitRef="Shares">745</us-gaap:StockIssuedDuringPeriodSharesOther>
    <CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000435"
      unitRef="Shares">95045</CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForNotePayable>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000429"
      unitRef="USD">2000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000430"
      unitRef="USD">995000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000433"
      unitRef="USD">997000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockForNotePayable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000443"
      unitRef="Shares">125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000437"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000438"
      unitRef="USD">1567000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000441"
      unitRef="USD">1568000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000451"
      unitRef="Shares">323273</CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStock>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">3000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStock>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000446"
      unitRef="USD">3218000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStock>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000449"
      unitRef="USD">3221000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStock>
    <CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000459"
      unitRef="Shares">39193</CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInExchangeForDebtModification>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000453"
      unitRef="USD">1000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000454"
      unitRef="USD">488000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000457"
      unitRef="USD">489000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockInExchangeForDebtModification>
    <CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000467"
      unitRef="Shares">23000</CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfConversionOption>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000462"
      unitRef="USD">92000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000465"
      unitRef="USD">92000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000470"
      unitRef="USD">2890000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000473"
      unitRef="USD">2890000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000481"
      unitRef="Shares">20000</CDT:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfWarrants>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000476"
      unitRef="USD">188000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000479"
      unitRef="USD">188000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000489"
      unitRef="Shares">750</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000484"
      unitRef="USD">1632000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000487"
      unitRef="USD">1632000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000494"
      unitRef="USD">3000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000495"
      unitRef="USD">3000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000499"
      unitRef="USD">-17802000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000501"
      unitRef="USD">-17802000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000509"
      unitRef="Shares">1384801</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000503"
      unitRef="USD">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000504"
      unitRef="USD">21880000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000505"
      unitRef="USD">-29101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000506"
      unitRef="USD">414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000507"
      unitRef="USD">-6793000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000517"
      unitRef="Shares">1384801</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000511"
      unitRef="USD">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000512"
      unitRef="USD">21880000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">-29101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000514"
      unitRef="USD">414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000515"
      unitRef="USD">-6793000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000522"
      unitRef="USD">-17802000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000523"
      unitRef="USD">-535000</us-gaap:NetIncomeLoss>
    <CDT:GainLossOnChangeInFairValueOfCizzleOption
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000529"
      unitRef="USD">1280000</CDT:GainLossOnChangeInFairValueOfCizzleOption>
    <CDT:GainOnChangeInFairValueOfVelaOption
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000532"
      unitRef="USD">970000</CDT:GainOnChangeInFairValueOfVelaOption>
    <CDT:LossOnIssuanceOfVelaOption
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000535"
      unitRef="USD">987000</CDT:LossOnIssuanceOfVelaOption>
    <CDT:ChangesInForeignCurrencyTransactionUnrealized
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000538"
      unitRef="USD">240000</CDT:ChangesInForeignCurrencyTransactionUnrealized>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000540"
      unitRef="USD">-707000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <CDT:LossOnRelatedPartyLoanForgiveness
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000544"
      unitRef="USD">12000</CDT:LossOnRelatedPartyLoanForgiveness>
    <CDT:RealizedGainOnShorttermInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000546"
      unitRef="USD">8000</CDT:RealizedGainOnShorttermInvestments>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000549"
      unitRef="USD">-13000</us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000550"
      unitRef="USD">39000</us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax>
    <CDT:LossOnChangeInFairValueOfConvertibleNotesPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000552"
      unitRef="USD">-2018000</CDT:LossOnChangeInFairValueOfConvertibleNotesPayable>
    <CDT:LossOnChangeInFairValueOfConvertibleNotesPayable
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000553"
      unitRef="USD">426000</CDT:LossOnChangeInFairValueOfConvertibleNotesPayable>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000555"
      unitRef="USD">-221000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000556"
      unitRef="USD">-81000</us-gaap:FairValueAdjustmentOfWarrants>
    <CDT:NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000559"
      unitRef="USD">4254000</CDT:NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability>
    <CDT:LossOnIssuanceOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000561"
      unitRef="USD">2710000</CDT:LossOnIssuanceOfWarrants>
    <CDT:NoncashLeaseExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000564"
      unitRef="USD">89000</CDT:NoncashLeaseExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000567"
      unitRef="USD">1632000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000568"
      unitRef="USD">199000</us-gaap:ShareBasedCompensation>
    <CDT:IssuanceOfCommonStockForLicensingRight
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000570"
      unitRef="USD">1568000</CDT:IssuanceOfCommonStockForLicensingRight>
    <CDT:NoncashInterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000573"
      unitRef="USD">536000</CDT:NoncashInterestExpense>
    <CDT:NoncashInterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000574"
      unitRef="USD">87000</CDT:NoncashInterestExpense>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000576"
      unitRef="USD">10000</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000579"
      unitRef="USD">1666000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000580"
      unitRef="USD">479000</us-gaap:AdjustmentForAmortization>
    <CDT:AmortizationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000582"
      unitRef="USD">447000</CDT:AmortizationExpense>
    <CDT:AmortizationOfDebtDiscount
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000585"
      unitRef="USD">929000</CDT:AmortizationOfDebtDiscount>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000588"
      unitRef="USD">202000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000594"
      unitRef="USD">2273000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000595"
      unitRef="USD">990000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000597"
      unitRef="USD">1225000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000598"
      unitRef="USD">215000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <CDT:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000600"
      unitRef="USD">-1030000</CDT:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <CDT:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000601"
      unitRef="USD">1746000</CDT:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000603"
      unitRef="USD">-124000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000607"
      unitRef="USD">-5000</us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000609"
      unitRef="USD">-9682000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000610"
      unitRef="USD">-7725000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000613"
      unitRef="USD">357000</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000615"
      unitRef="USD">51000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000618"
      unitRef="USD">490000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000621"
      unitRef="USD">498000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <CDT:ProceedsFromIssuanceOfOption
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000625"
      unitRef="USD">497000</CDT:ProceedsFromIssuanceOfOption>
    <CDT:ProceedsFromLoanRepaymentRelatedParty
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000628"
      unitRef="USD">585000</CDT:ProceedsFromLoanRepaymentRelatedParty>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000630"
      unitRef="USD">-43000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000631"
      unitRef="USD">725000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <CDT:ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000637"
      unitRef="USD">8493000</CDT:ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000639"
      unitRef="USD">2626000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000642"
      unitRef="USD">600000</us-gaap:ProceedsFromRelatedPartyDebt>
    <CDT:ProceedsFromIssuanceOfCapitalContributionRelatedParty
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000646"
      unitRef="USD">150000</CDT:ProceedsFromIssuanceOfCapitalContributionRelatedParty>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000648"
      unitRef="USD">3328000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <CDT:ProceedsFromExerciseOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000651"
      unitRef="USD">176000</CDT:ProceedsFromExerciseOfWarrants>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000654"
      unitRef="USD">776000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000657"
      unitRef="USD">113000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000661"
      unitRef="USD">2286000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000663"
      unitRef="USD">6067000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000664"
      unitRef="USD">10929000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000666"
      unitRef="USD">-3658000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000667"
      unitRef="USD">3929000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000669"
      unitRef="USD">-16000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000670"
      unitRef="USD">299000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000672"
      unitRef="USD">-3674000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000673"
      unitRef="USD">4228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000675"
      unitRef="USD">4228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000678"
      unitRef="USD">554000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000679"
      unitRef="USD">4228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000684"
      unitRef="USD">352000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <CDT:CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000687"
      unitRef="USD">144000</CDT:CorrectionOfImmaterialErrorRelatedToFranchiseTaxExpense>
    <CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000690"
      unitRef="USD">92000</CDT:StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfConversionOption>
    <CDT:IssuanceOfCommonStockInExchangeForDebtExtension
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000693"
      unitRef="USD">489000</CDT:IssuanceOfCommonStockInExchangeForDebtExtension>
    <CDT:ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000696"
      unitRef="USD">5378000</CDT:ConversionOfDeferredCommissionPayableToConvertiblePromissoryNote>
    <CDT:IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000700"
      unitRef="USD">151000</CDT:IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc>
    <us-gaap:StockIssued1
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000703"
      unitRef="USD">544000</us-gaap:StockIssued1>
    <us-gaap:NotesReduction
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000706"
      unitRef="USD">3685000</us-gaap:NotesReduction>
    <CDT:DeferredUnderwritingCosts
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000709"
      unitRef="USD">5738000</CDT:DeferredUnderwritingCosts>
    <CDT:PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000712"
      unitRef="USD">2253000</CDT:PrepaidExpenseOfDirectorsAndOfficersInsurancePaidIncludedInApicInConnectionWithMerger>
    <CDT:AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000715"
      unitRef="USD">6124000</CDT:AccumulatedDeficitAssumedToApicAsResultOfBusinessCombination>
    <CDT:InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000718"
      unitRef="USD">223000</CDT:InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancing>
    <CDT:NoncashAssetsAssumedInMergerFinancing
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000721"
      unitRef="USD">91000</CDT:NoncashAssetsAssumedInMergerFinancing>
    <CDT:NoncashLiabilitiesAssumedInMergerFinancing
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000724"
      unitRef="USD">124000</CDT:NoncashLiabilitiesAssumedInMergerFinancing>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000729"
      unitRef="USD">80000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000730"
      unitRef="USD">124000</us-gaap:InterestPaidNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000732">&lt;p id="xdx_80F_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zdVkDUL0Skpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
&lt;span id="xdx_82B_z21UO3OlmiQb"&gt;Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Conduit
Pharmaceuticals Inc., a Delaware corporation (&#x201c;Conduit&#x201d; or the &#x201c;Company&#x201d;), is a clinical-stage specialty
biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets. The Company has
developed a unique business model that allows it to act as a conduit to bring clinical assets from pharmaceutical companies and
develop new treatments for patients. Our novel approach addresses unmet medical needs and lengthens the intellectual property for
our existing assets through cutting-edge solid-form technology with the expectation of commercializing these products with life
science companies. &lt;/span&gt;Our initial development plan is to conduct a Phase II clinical trial on AZD1656 in Lupus (including Lupus
Nephritis) and ANCA Vasculitis (AAV). We anticipate developing our Initial Pipeline (which has already undergone pre-clinical and
clinical trials) through the Phase II stage and then monetizing such clinical assets through a license, royalty, or other
transaction at this stage. At this time, we do not expect that we will commercialize any clinical assets or seek marketing approval
from the FDA (or similar organizations) as we intend to enter into agreements with third parties following Phase II clinical trials
for each such clinical asset that would provide that such third party would pursue the further development, commercialization, and
marketing of such assets.&lt;/p&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Merger
Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 22, 2023 (the &#x201c;Closing Date&#x201d;), a merger transaction between Conduit Pharmaceuticals Limited (&#x201c;Old Conduit&#x201d;),
Murphy Canyon Acquisition Corp (&#x201c;MURF&#x201d;) and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly owned
subsidiary of MURF (&#x201c;Merger Sub&#x201d;), was completed (the &#x201c;Merger&#x201d;, see Note 2) pursuant to the initial merger agreement
dated November 8, 2022 and subsequent amendments to the merger agreement dated January 27, 2023 and May 11, 2023 (together, the &#x201c;Merger
Agreement&#x201d;). Pursuant to the terms of the Merger Agreement, on the Closing Date, (i) Merger Sub merged with and into Old Conduit,
with Old Conduit surviving the merger as a wholly-owned subsidiary of MURF, and (ii) MURF changed its name from Murphy Canyon Acquisition
Corp. to Conduit Pharmaceuticals Inc. The common stock of the Company (the &#x201c;Common Stock&#x201d;) commenced trading on The Nasdaq
Global Market under the symbol &#x201c;CDT&#x201d; on September 25, 2023, and the Company&#x2019;s warrants commenced trading on The Nasdaq
Capital Market under the symbol &#x201c;CDTTW&#x201d; on September 25, 2023. On March 7, 2025, the Company filed an application to list our Common Stock on The Nasdaq Capital Market as part
of our plan to regain compliance with all NASDAQ rules. See Note 20 for additional details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Merger was accounted for as a reverse recapitalization in accordance with accounting principles generally accepted in the United States
of America (&#x201c;U.S. GAAP&#x201d;). Under the reverse recapitalization method, MURF was treated as the acquired company for financial
reporting purposes, and the accounting acquirer was assumed to have issued shares of stock for the net assets of MURF, with no goodwill
or other intangible assets recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared by the Company in accordance with U.S. GAAP as set forth by the Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) and pursuant to the rules and regulations of the United States Securities and Exchange
Commission (&#x201c;SEC&#x201d;). References to U.S. GAAP issued by the FASB in these notes to the accompanying consolidated financial
statements are to the FASB Accounting Standards Codifications (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASUs&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Principles
of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements include the accounts of Conduit Pharmaceuticals, Inc. and its wholly owned subsidiaries
Conduit UK Management Ltd. (United Kingdom) and Conduit Pharmaceuticals, Ltd. (Cayman Islands). As used herein, references to the &#x201c;Company&#x201d;
include references to Conduit Pharmaceuticals, Inc, and its subsidiaries. All intercompany balances and transactions have been eliminated
in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Liquidity
and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate,
that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date the financial
statements are issued. Since its inception, the Company has generated significant losses and as of December 31, 2024, the Company had
an accumulated deficit of $&lt;span id="xdx_901_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zj4o87HU4pTh" title="Accumulated deficit"&gt;29.1&lt;/span&gt; million. As of December 31, 2024 and December 31, 2023, the Company had cash and cash equivalents and
short-term investments of $&lt;span id="xdx_903_eus-gaap--Cash_iI_pn5n6_c20241231_zn0jMmbhI3x7" title="Cash and cash equivalents"&gt;&lt;span id="xdx_903_eus-gaap--Cash_iI_pn5n6_c20231231_zw7Y2hvtVDs3" title="Cash and cash equivalents"&gt;0.6&lt;/span&gt;&lt;/span&gt; million and $&lt;span id="xdx_90D_eus-gaap--ShortTermInvestments_iI_pn5n6_c20241231_zRUEM8rneAkg" title="Short term investments"&gt;&lt;span id="xdx_90E_eus-gaap--ShortTermInvestments_iI_pn5n6_c20231231_zvDMqDwwSH11" title="Short term investments"&gt;4.2&lt;/span&gt;&lt;/span&gt; million, respectively. For the year ended December 31, 2024 and 2023, the Company had
net operating losses of $&lt;span id="xdx_901_eus-gaap--OperatingIncomeLoss_iN_pn5n6_di_c20240101__20241231_zHLAYgQY1vva" title="Net loss"&gt;15.4&lt;/span&gt; million and $&lt;span id="xdx_907_eus-gaap--OperatingIncomeLoss_iN_pn5n6_di_c20230101__20231231_zioLWMcGsLy9" title="Net loss"&gt;5.3&lt;/span&gt; million, respectively, and cash used in operating activities of $&lt;span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zcXo0VEgDcmf" title="Operating activities"&gt;9.7&lt;/span&gt; million and $&lt;span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20231231_z5au0uVxXQ9f" title="Operating activities"&gt;7.7&lt;/span&gt;
million, respectively. Management has determined that it does not have sufficient cash and other sources of liquidity to fund its current
business plan. These factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern for at least
the next 12 months from the financial statement filing date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s expectation is to generate operating losses and negative operating cash flows in the future and will need additional
funding to support its current business plan in addition to the remaining at the market offering program (the &#x201c;Sales
Agreement&#x201d;) of $&lt;span id="xdx_90A_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20241231_zifFDEbaRNuc" title="Offering costs"&gt;12.0&lt;/span&gt; million (See Note 20), as of the financial statement release date. Management&#x2019;s plans to alleviate the
conditions that raise substantial doubt through the pursuit of additional cash resources through public or private equity or debt
financings. However, there is no assurance that such funding will be available when needed or on acceptable terms. If additional
funding is not available when required, the Company would need to delay or curtail its operations and its research and development
activities until such funding is received, all of which could have a material adverse effect on the Company and its financial
condition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
financial statements have been prepared assuming the Company will continue as a going concern and do not include adjustments to reflect
the possible effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result
from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 24, 2025, the Company amended its Second Amended and Restated Certificate of Incorporation with the Secretary of State of the
State of Delaware in order to effect a &lt;span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20250124__20250124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9DL8phwKiq" title="Reverse stock split"&gt;1-for-100&lt;/span&gt; reverse stock split of its outstanding shares of common stock (the &#x201c;Reverse Stock
Split&#x201d;). As a result of the reverse stock split, every 100 shares of the Company&#x2019;s common stock issued or outstanding were
automatically reclassified into one new share of common stock, subject to the treatment of fractional shares as described below, without
any action on the part of the holders. All historical share and per-share amounts reflected throughout the accompanying consolidated
financial statements and other financial information in this Annual Report on Form 10-K have been retroactively adjusted to reflect the
2025 Reverse Stock Split as if the split occurred as of the earliest period presented. The Reverse Stock Split did not affect the number
of authorized shares of common stock or the par value of the common stock. No fractional shares were issued in connection with the Reverse
Stock Split. Stockholders who would otherwise have been entitled to receive fractional shares as a result of the Reverse Stock Split
were entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled
multiplied by the closing price per share of the common stock (as adjusted to give effect to the Reverse Stock Split) on The Nasdaq Global
Market on January 24, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Other
Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to risks common to companies in the development stage and pharmaceutical industry including, but not limited to, uncertainties
related to pre-clinical and clinical outcomes competitor products, regulatory approvals, dependence on key products, dependence on key
suppliers and protection of intellectual property rights (see note 15 for details on a claim against our AZD 1656 co-crystal patent).
Clinical assets currently under development will require significant additional research and development efforts, including extensive
preclinical and clinical testing and regulatory approval prior to commercialization. These efforts will require significant amounts of
additional capital, adequate personnel, infrastructure, and extensive compliance and reporting capabilities. Even if the Company&#x2019;s
efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from royalties or product sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company licenses clinical assets from AstraZeneca. See Note 10. If there is a breach or other termination of such agreements, there could
be a material adverse effect on the Company&#x2019;s business, financial condition, operating results, and prospects.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company is also subject
to risks associated with the Nasdaq Stock Market Correspondence and Subsequent Nasdaq Capital Market Listing. See note 20 for further
details.&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
of Significant Accounting Policies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9N5EBnEnmaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zIe5vxmUeFeg"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents are primarily maintained with major financial institutions in the United States, United Kingdom, and Switzerland.
The Company considers cash equivalents to be short-term, highly liquid investments that (a) are readily convertible into known amounts
of cash, (b) are traded and held for cash management purposes, and (c) have original maturities of three months or less at the time of
purchase. The Switzerland bank accounts holding cash balances are uninsured, and the UK bank account, with a year-end balance of approximately
&#xa3;&lt;span id="xdx_905_eus-gaap--CashUninsuredAmount_iI_uGBP_c20241231_zQI4bUKQnUY6" title="Cash, uninsured amount"&gt;100,000&lt;/span&gt; (or approximately $&lt;span id="xdx_904_eus-gaap--CashUninsuredAmount_iI_c20241231_zaGRR62Uw4Z9"&gt;125,000&lt;/span&gt;) exceeds the country&#x2019;s deposit limit of &#xa3;&lt;span id="xdx_90F_eus-gaap--DepositAssets_iI_uGBP_c20241231_z3ShePxF9WH1" title="Deposit assets"&gt;85,000&lt;/span&gt; (approximately $&lt;span id="xdx_90C_eus-gaap--DepositAssets_iI_c20241231_z0WdGHQohBQ4" title="Deposit assets"&gt;107,000&lt;/span&gt;). The Company&#x2019;s
US depository bank participates in the Demand Deposit Marketplace program, insuring deposits up to $&lt;span id="xdx_900_eus-gaap--DemandDepositAccounts_iI_pn5n6_c20241231_zfZWgquLidRl" title="Demand deposit accounts"&gt;10&lt;/span&gt; million by sweeping amounts in
excess of the $&lt;span id="xdx_903_ecustom--DepositInsuranceLimit_iI_c20241231_ziy0DytOkTc4" title="Deposit insurance limit"&gt;250,000&lt;/span&gt; deposit insurance limit among participating banks. The Company has not experienced any losses on any accounts
through the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had $&lt;span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_z2fXvuCTKKHd"&gt;0.6&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
and $&lt;span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_z8CmV6dzZ03l"&gt;4.2&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
in cash and cash equivalents on hand as of December 31, 2024 and December 31, 2023, respectively. As of December 31, 2024, $&lt;span id="xdx_908_ecustom--CashAndCashEquivalentsNetBankOverdrafts_iI_pn5n6_c20241231_zOWaCmXXcOL1" title="Cash and cash equivalents net bank overdrafts"&gt;0.2
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million of the Company&#x2019;s $&lt;span id="xdx_904_ecustom--CashAndCashEquivalentsNetBankOverdrafts_iI_pn5n6_c20231231_zbpgW4zK93r1" title="Cash and cash equivalents net bank overdrafts"&gt;0.6
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million cash and cash equivalents balance was
invested in money market funds. The money market funds do not have significant liquidity restrictions that would require the exclusion
from cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--MarketableSecuritiesPolicy_z11uILEwtqR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zr2oaR3Pft5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zGvFhdFehme6"&gt;Property,
Plant and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property,
plant and equipment are initially recorded at cost. Depreciation and amortization are computed using the straight-line method over the
estimated useful lives of the assets or, for leasehold improvements, the life of the lease, if shorter. When assets are retired or otherwise
disposed of, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected
in other income or expense for the period. As of December 31, 2024, property, plant and equipment primarily consisted of leasehold improvements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zFWyZzHoR1O1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zYTsYzI9vQQ1"&gt;Leases&lt;/span&gt;
&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 842, Leases (ASC 842), the Company records a right-of-use (ROU) asset and a lease liability on the balance sheet
for all leases with terms longer than 12 months and classifies them as either operating or finance leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and
circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset,
whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has
the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets,
lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases
with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components,
the Company has elected not to allocate the contract consideration, and to account for the lease and non-lease components as a single
lease component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term.
The implicit rate within our operating leases is generally not determinable and, therefore, the Company uses the incremental borrowing
rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#x2019;s incremental
borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing
rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The
operating lease ROU asset also includes any lease prepayments, offset by lease incentives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain
we will exercise that option. An option to terminate is considered unless it is reasonably certain we will not exercise the option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--UseOfEstimates_zY7dhmJYGLo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zuZg498GV7R2"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial
statements as well as the reported amounts of revenues and expenses during the reporting period. Estimates are based on several factors
including the facts and circumstances available at the time the estimates are made, historical experience, risk of loss, general economic
conditions and trends, and the assessment of the probable future outcome. Actual results could differ materially from such estimates.
Estimates and assumptions are reviewed periodically by management and changes in estimates are made as management becomes aware of changes
in circumstances surrounding the estimates. The effects of changes are reflected in the financial statements in the period that they
are determined.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z0hboc6fhfs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zw3w6L0i2dUl"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, defines fair value, establishes a framework for measuring fair value, and
expands disclosures about fair value measurements. Fair value is to be determined based on the exchange price that would be received
for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants. In determining fair value, the Company used various valuation approaches. A fair
value hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes
the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that
market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
inputs reflect the Company&#x2019;s assumption about the inputs that market participants would use in pricing the asset or liability developed
based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the
inputs, as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&#x2014;Valuations based on quoted prices for identical instruments in active markets. Since valuations are based on quoted prices
    that are readily and regularly available in an active market, valuation of these instruments does not entail a significant degree
    of judgment.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&#x2014; Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for either similar
    instruments in active markets, identical or similar instruments in markets that are not active, or model-derived valuations whose
    inputs or significant value drivers are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&#x2014;Valuations based on inputs that are unobservable. These valuations require significant judgment.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Level 1 assets consist of cash and cash equivalents, including money market funds, in the accompanying balance sheets
and the value of accrued expenses and other current liabilities approximate fair value due to the short-term nature of these assets and
liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company has two financial liabilities, warrant liabilities for which the fair value is determined based on
Level 2 and Level 3 inputs, and convertible debt carried at fair value for which the fair value is
determined based on Level 3 input. The Level 2 inputs are valued based on observable inputs other than quoted
prices included in Level 1, such as quoted prices for similar instruments in active markets. The level 3 inputs as such inputs are based
on unobservable inputs and require significant judgement. As of December 31 2023, the Company has one financial liability, a warrant liability for which the fair value is determined
based on Level 2 inputs as such inputs are valued based on observable inputs other than quoted prices included in Level 1, such as
quoted prices for similar instruments in active markets.  See Note 3 for further information on the Company&#x2019;s
financial liabilities carried at fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--FairValueTransferPolicyPolicyTextBlock_zmMVpIcF9dy7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zJ210n5wYSd8"&gt;Fair
Value Option&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has elected the fair value measurement option for convertible debt with embedded derivatives that would otherwise require bifurcation
and has recorded the entire hybrid financial instrument at fair value under the guidance in ASC 825, Financial Instruments. As a result,
the August 2024 Nirland Note was recorded at fair value subsequent to the Second Amendment and the A.G.P. Convertible Note was recorded
at fair value upon issuance. The notes will subsequently be remeasured at fair value each reporting date until settled or converted.
The Company reports interest expense, including accrued interest, related to the convertible debt under the fair value option, separately
from within the change in fair value of the convertible debt in the accompanying consolidated statement of operations and comprehensive
income (loss). Any changes in fair value caused by instrument-specific credit risk are presented separately in other comprehensive income.
During the year ended December 31, 2024, the Company did not record any changes in fair value related to instrument-specific credit risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zmqny0wbGnq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zWcwKdDcWrMc"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses consist primarily of costs incurred in connection with the research and development of our clinical assets
and programs, see Note 10 for further discussion of research and development expense. Conduit holds all licenses to conduct clinical
research through a third-party pharmaceutical company. The Company expenses research and development costs and intangible assets
acquired that have no alternative future use as incurred. These expenses include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;expenses
    incurred under agreements with organizations that support the Company&#x2019;s drug discovery and development activities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;expenses
    incurred in connection with the preclinical and clinical development of the Company&#x2019;s clinical assets and programs, including
    under agreements with contract research organizations, or CROs&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;costs
    related to contract manufacturing organizations, or CMOs, that are primarily engaged to provide drug substance and product for our
    clinical trials, research and development programs, as well as investigative sites and consultants that conduct the Company&#x2019;s
    clinical trials, nonclinical studies and other scientific development services&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    costs of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing registration and validation
    batches&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;employee-related
    expenses, including salaries, related benefits and equity-based compensation expense, for employees engaged in research and development
    functions&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;acquisition costs related to the purchase of licensed intellectual property;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;costs
    related to compliance with quality and regulatory requirements&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;payments
    made under third-party licensing agreements&#x37e; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;direct
    and allocated costs related to facilities, information technology, personnel and other overhead.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Advance
payments that we make for goods or services to be received in the future for use in research and development activities are recorded
as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or consumed or the related services are performed,
or until it is no longer expected that the goods will be delivered, or the services rendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_znRfGS37jvN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zZOsh9rAdqGa"&gt;General
and Administrative Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist primarily of salaries and related costs for personnel in executive management, finance, corporate
and business development, and administrative functions. General and administrative expenses also include legal fees relating to patent
and corporate matters&#x37e; professional fees for accounting, auditing, tax, and administrative consulting services&#x37e; insurance costs&#x37e;
administrative travel expenses and other operating costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zpAczA2q79t5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_z0NlpMWvYCrg"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;, sets forth standards for financial presentation and disclosure of income tax liabilities and expense.
Interest and penalties recognized have been classified in the consolidated statements of operations and comprehensive income (loss) as
income taxes. Deferred tax assets and liabilities are recognized for future tax consequences attributable to temporary differences between
the financial statement carrying amount of existing assets and liabilities and their respective tax bases and operating losses carried
forward. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change
in tax rates is recognized in the consolidated statements of operations and comprehensive income (loss) in the period that includes the
enactment date. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits of which
future realization is uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zJkBnbjryKMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zWQwRNE8GDh2"&gt;Earnings/(Net
Loss) per Share&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company calculates basic and diluted earnings/(net loss) per share under ASC Topic 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;. Basic earnings/(net
loss) per share is computed by dividing the net income/(loss) by the number of weighted-average common shares outstanding for the period.
Diluted earnings/(net loss) is computed by adjusting net income/(loss) based on the impact of any dilutive instruments. Diluted earnings/(net
loss) per share is computed by dividing the diluted net income/(loss) by the number of weighted-average common shares outstanding for
the period including the effect, if dilutive, of any instruments that can be settled in common shares. When computing diluted net income/(loss)
per share, the numerator is adjusted to eliminate the effects that have been recorded in net income/(loss) (net of tax, if any) attributable
to any liability-classified dilutive instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--WarrantInstrumentsPolicyTextBlock_zb3ifZGf9Nf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_86C_zZCtQMd1f6Ne" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the accounting classification of Warrants as either liability or equity by first assessing whether the Warrants meet
liability classification in accordance with ASC 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;). Under ASC 480, a
financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies
a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares must be classified as
a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly
on any one of the following: (a) a fixed monetary amount known at inception; (b) variations in something other than the fair value of
the issuer&#x2019;s equity shares; or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
financial instruments, such as the Warrants, are not required to be classified as liabilities under ASC 480, the Company assesses whether
such instruments are indexed to the Company&#x2019;s own stock under ASC 815-40. In order for an instrument to be considered indexed to
an entity&#x2019;s own stock, its settlement amount must always equal the difference between the following: (a) the fair value of a fixed
number of the Company&#x2019;s equity shares, and (b) a fixed monetary amount or a fixed amount of a debt instrument issued by the Company.
The Company determined that the settlement amount of the Equity Classified Warrants would equal the difference between the fair value
of a fixed number of shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified as equity, while
the settlement amount of the Liability Classified Warrants would not equal the difference between the fair value of a fixed number of
shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified as a liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Equity Classified Warrants are recorded in stockholders&#x2019; deficit and the Liability Classified Warrants are recorded as liabilities
in the Consolidated Balance Sheet. The Liability Classified Warrants are remeasured each period with changes in fair value recorded in
the Consolidated Statements of Operations and Comprehensive Income (Loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zfXSfxa44aaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zTvJEe4YQyb5"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company translated the assets and liabilities of foreign subsidiaries from their respective functional currency, the British pound, to
United States dollars at the appropriate spot rates as of the balance sheet date. Income and expenses of operations are translated to
United States dollars using weighted average exchange rates during the year. The foreign subsidiaries use the local currency as their
functional currency. The effects of foreign currency translation adjustments are included as a component of accumulated other comprehensive
income in the accompanying consolidated statements of changes in stockholders&#x2019; deficit. Non-monetary items in the subsidiaries&#x2019;
functional currency are re-measured into the reporting currency at the historical exchange rate (i.e., the rate of exchange at the date
of the transaction).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zviwSQVWkuNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zT0gOeUHmSN7"&gt;Emerging
Growth Company Status&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under
the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of
the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period
for complying with new or revised accounting standards that have different effective dates for public and private companies until the
earlier of the date that: (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended
transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with
the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the Merger, the Company will remain an emerging growth company, as defined by the Jumpstart Our Business Startups act of 2012, until
the earliest of &lt;span id="xdx_906_ecustom--DescriptionForEmergingGrowthCompany_c20240101__20241231_zjcsk4iASiNa" title="Emerging growth description"&gt;(i) the last day of the combined entity&#x2019;s first fiscal year following the fifth anniversary of the completion of
MURF&#x2019;s initial public offering (the &#x201c;MURF IPO&#x201d;), (ii) the last day of the fiscal year in which the combined entity
has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the combined entity is deemed
to be a large accelerated filer, which means the market value of the combined entity&#x2019;s common stock that is held by non-affiliates
exceeds $700.0 million as of the prior December 31st or (iv) the date on which the combined entity has issued more than $1.0 billion
in non-convertible debt securities during the prior three year period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1ZDVaMonHk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zZTzVojdLiYe"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) (&#x201c;ASU 2023-07&#x201d;), which enhances the segment disclosure
requirements for public entities on an annual and interim basis. Under this proposal, public entities are required to disclose significant
segment expenses that are regularly provided to the chief operating decision maker (the &#x201c;CODM&#x201d;) and included within each
reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#x2019;s profit or loss
and assets will be required on an interim basis. Entities are also required to disclose information about the CODM&#x2019;s title and
position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment
of segment performance and deciding whether how to allocate resources. Finally, ASU 2023-07 requires all segment disclosures for public
entities, even those with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023,
and interim periods within fiscal years beginning after December 15, 2024, and should be applied on a retrospective basis to all periods
presented. As of December 31, 2024, the Company only has one reportable segment. The Company adopted this accounting standard as of January
1, 2024. See Note 19 for the Company&#x2019;s segments disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_zn0GSboqcEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zzGJPSdxsV7b"&gt;Recently
Issued Accounting Standards Not Yet Adopted&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;).
ASU 2023-09 modifies the reporting requirements for income tax disclosures related to effective tax rates and cash income taxes paid.
Pursuant to ASU 2023-09, public business entities are required to disclose certain categories in the income tax rate reconciliation,
as well as additional information for reconciling items that meet a specific quantitative threshold. Additionally, ASU 2023-09 requires
annual disclosures of income taxes paid for all entities, including the amount of income taxes paid, net of refunds received, disaggregated
by federal, state, and foreign jurisdictions. The standard is effective for fiscal years beginning after December 15, 2024, with early
adoption permitted. The Company is currently evaluating the impact of ASU 2023-09 on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, which is intended to provide more detailed information about specified categories
of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented
on the consolidated statements of operations and comprehensive income (loss). The guidance in this ASU is effective for fiscal years
beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted.
The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU
or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the
impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_850_zuQfE7pbO0X1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000734"
      unitRef="USD">-29100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000736"
      unitRef="USD">600000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000738"
      unitRef="USD">600000</us-gaap:Cash>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000740"
      unitRef="USD">4200000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000742"
      unitRef="USD">4200000</us-gaap:ShortTermInvestments>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000744"
      unitRef="USD">-15400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact000746"
      unitRef="USD">-5300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000748"
      unitRef="USD">-9700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact000750"
      unitRef="USD">-7700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000752"
      unitRef="USD">12000000.0</us-gaap:DeferredOfferingCosts>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2025-01-242025-01-24_us-gaap_SubsequentEventMember"
      id="Fact000754">1-for-100</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000756">&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9N5EBnEnmaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zIe5vxmUeFeg"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents are primarily maintained with major financial institutions in the United States, United Kingdom, and Switzerland.
The Company considers cash equivalents to be short-term, highly liquid investments that (a) are readily convertible into known amounts
of cash, (b) are traded and held for cash management purposes, and (c) have original maturities of three months or less at the time of
purchase. The Switzerland bank accounts holding cash balances are uninsured, and the UK bank account, with a year-end balance of approximately
&#xa3;&lt;span id="xdx_905_eus-gaap--CashUninsuredAmount_iI_uGBP_c20241231_zQI4bUKQnUY6" title="Cash, uninsured amount"&gt;100,000&lt;/span&gt; (or approximately $&lt;span id="xdx_904_eus-gaap--CashUninsuredAmount_iI_c20241231_zaGRR62Uw4Z9"&gt;125,000&lt;/span&gt;) exceeds the country&#x2019;s deposit limit of &#xa3;&lt;span id="xdx_90F_eus-gaap--DepositAssets_iI_uGBP_c20241231_z3ShePxF9WH1" title="Deposit assets"&gt;85,000&lt;/span&gt; (approximately $&lt;span id="xdx_90C_eus-gaap--DepositAssets_iI_c20241231_z0WdGHQohBQ4" title="Deposit assets"&gt;107,000&lt;/span&gt;). The Company&#x2019;s
US depository bank participates in the Demand Deposit Marketplace program, insuring deposits up to $&lt;span id="xdx_900_eus-gaap--DemandDepositAccounts_iI_pn5n6_c20241231_zfZWgquLidRl" title="Demand deposit accounts"&gt;10&lt;/span&gt; million by sweeping amounts in
excess of the $&lt;span id="xdx_903_ecustom--DepositInsuranceLimit_iI_c20241231_ziy0DytOkTc4" title="Deposit insurance limit"&gt;250,000&lt;/span&gt; deposit insurance limit among participating banks. The Company has not experienced any losses on any accounts
through the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had $&lt;span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_z2fXvuCTKKHd"&gt;0.6&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
and $&lt;span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_z8CmV6dzZ03l"&gt;4.2&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
in cash and cash equivalents on hand as of December 31, 2024 and December 31, 2023, respectively. As of December 31, 2024, $&lt;span id="xdx_908_ecustom--CashAndCashEquivalentsNetBankOverdrafts_iI_pn5n6_c20241231_zOWaCmXXcOL1" title="Cash and cash equivalents net bank overdrafts"&gt;0.2
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million of the Company&#x2019;s $&lt;span id="xdx_904_ecustom--CashAndCashEquivalentsNetBankOverdrafts_iI_pn5n6_c20231231_zbpgW4zK93r1" title="Cash and cash equivalents net bank overdrafts"&gt;0.6
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million cash and cash equivalents balance was
invested in money market funds. The money market funds do not have significant liquidity restrictions that would require the exclusion
from cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000758"
      unitRef="GBP">100000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000759"
      unitRef="USD">125000</us-gaap:CashUninsuredAmount>
    <us-gaap:DepositAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000761"
      unitRef="GBP">85000</us-gaap:DepositAssets>
    <us-gaap:DepositAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000763"
      unitRef="USD">107000</us-gaap:DepositAssets>
    <us-gaap:DemandDepositAccounts
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000765"
      unitRef="USD">10000000</us-gaap:DemandDepositAccounts>
    <CDT:DepositInsuranceLimit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000767"
      unitRef="USD">250000</CDT:DepositInsuranceLimit>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000768"
      unitRef="USD">600000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000769"
      unitRef="USD">4200000</us-gaap:CashEquivalentsAtCarryingValue>
    <CDT:CashAndCashEquivalentsNetBankOverdrafts
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000771"
      unitRef="USD">200000</CDT:CashAndCashEquivalentsNetBankOverdrafts>
    <CDT:CashAndCashEquivalentsNetBankOverdrafts
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000773"
      unitRef="USD">600000</CDT:CashAndCashEquivalentsNetBankOverdrafts>
    <us-gaap:MarketableSecuritiesPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000775">&lt;p id="xdx_84D_eus-gaap--MarketableSecuritiesPolicy_z11uILEwtqR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000777">&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zr2oaR3Pft5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zGvFhdFehme6"&gt;Property,
Plant and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property,
plant and equipment are initially recorded at cost. Depreciation and amortization are computed using the straight-line method over the
estimated useful lives of the assets or, for leasehold improvements, the life of the lease, if shorter. When assets are retired or otherwise
disposed of, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected
in other income or expense for the period. As of December 31, 2024, property, plant and equipment primarily consisted of leasehold improvements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000779">&lt;p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zFWyZzHoR1O1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zYTsYzI9vQQ1"&gt;Leases&lt;/span&gt;
&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 842, Leases (ASC 842), the Company records a right-of-use (ROU) asset and a lease liability on the balance sheet
for all leases with terms longer than 12 months and classifies them as either operating or finance leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and
circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset,
whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has
the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets,
lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases
with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components,
the Company has elected not to allocate the contract consideration, and to account for the lease and non-lease components as a single
lease component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term.
The implicit rate within our operating leases is generally not determinable and, therefore, the Company uses the incremental borrowing
rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#x2019;s incremental
borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing
rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The
operating lease ROU asset also includes any lease prepayments, offset by lease incentives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain
we will exercise that option. An option to terminate is considered unless it is reasonably certain we will not exercise the option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000781">&lt;p id="xdx_843_eus-gaap--UseOfEstimates_zY7dhmJYGLo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zuZg498GV7R2"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial
statements as well as the reported amounts of revenues and expenses during the reporting period. Estimates are based on several factors
including the facts and circumstances available at the time the estimates are made, historical experience, risk of loss, general economic
conditions and trends, and the assessment of the probable future outcome. Actual results could differ materially from such estimates.
Estimates and assumptions are reviewed periodically by management and changes in estimates are made as management becomes aware of changes
in circumstances surrounding the estimates. The effects of changes are reflected in the financial statements in the period that they
are determined.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000783">&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z0hboc6fhfs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zw3w6L0i2dUl"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, defines fair value, establishes a framework for measuring fair value, and
expands disclosures about fair value measurements. Fair value is to be determined based on the exchange price that would be received
for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants. In determining fair value, the Company used various valuation approaches. A fair
value hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes
the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that
market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
inputs reflect the Company&#x2019;s assumption about the inputs that market participants would use in pricing the asset or liability developed
based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the
inputs, as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&#x2014;Valuations based on quoted prices for identical instruments in active markets. Since valuations are based on quoted prices
    that are readily and regularly available in an active market, valuation of these instruments does not entail a significant degree
    of judgment.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&#x2014; Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for either similar
    instruments in active markets, identical or similar instruments in markets that are not active, or model-derived valuations whose
    inputs or significant value drivers are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&#x2014;Valuations based on inputs that are unobservable. These valuations require significant judgment.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Level 1 assets consist of cash and cash equivalents, including money market funds, in the accompanying balance sheets
and the value of accrued expenses and other current liabilities approximate fair value due to the short-term nature of these assets and
liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company has two financial liabilities, warrant liabilities for which the fair value is determined based on
Level 2 and Level 3 inputs, and convertible debt carried at fair value for which the fair value is
determined based on Level 3 input. The Level 2 inputs are valued based on observable inputs other than quoted
prices included in Level 1, such as quoted prices for similar instruments in active markets. The level 3 inputs as such inputs are based
on unobservable inputs and require significant judgement. As of December 31 2023, the Company has one financial liability, a warrant liability for which the fair value is determined
based on Level 2 inputs as such inputs are valued based on observable inputs other than quoted prices included in Level 1, such as
quoted prices for similar instruments in active markets.  See Note 3 for further information on the Company&#x2019;s
financial liabilities carried at fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueTransferPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000785">&lt;p id="xdx_84D_eus-gaap--FairValueTransferPolicyPolicyTextBlock_zmMVpIcF9dy7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zJ210n5wYSd8"&gt;Fair
Value Option&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has elected the fair value measurement option for convertible debt with embedded derivatives that would otherwise require bifurcation
and has recorded the entire hybrid financial instrument at fair value under the guidance in ASC 825, Financial Instruments. As a result,
the August 2024 Nirland Note was recorded at fair value subsequent to the Second Amendment and the A.G.P. Convertible Note was recorded
at fair value upon issuance. The notes will subsequently be remeasured at fair value each reporting date until settled or converted.
The Company reports interest expense, including accrued interest, related to the convertible debt under the fair value option, separately
from within the change in fair value of the convertible debt in the accompanying consolidated statement of operations and comprehensive
income (loss). Any changes in fair value caused by instrument-specific credit risk are presented separately in other comprehensive income.
During the year ended December 31, 2024, the Company did not record any changes in fair value related to instrument-specific credit risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueTransferPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000787">&lt;p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zmqny0wbGnq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zWcwKdDcWrMc"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses consist primarily of costs incurred in connection with the research and development of our clinical assets
and programs, see Note 10 for further discussion of research and development expense. Conduit holds all licenses to conduct clinical
research through a third-party pharmaceutical company. The Company expenses research and development costs and intangible assets
acquired that have no alternative future use as incurred. These expenses include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;expenses
    incurred under agreements with organizations that support the Company&#x2019;s drug discovery and development activities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;expenses
    incurred in connection with the preclinical and clinical development of the Company&#x2019;s clinical assets and programs, including
    under agreements with contract research organizations, or CROs&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;costs
    related to contract manufacturing organizations, or CMOs, that are primarily engaged to provide drug substance and product for our
    clinical trials, research and development programs, as well as investigative sites and consultants that conduct the Company&#x2019;s
    clinical trials, nonclinical studies and other scientific development services&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    costs of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing registration and validation
    batches&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;employee-related
    expenses, including salaries, related benefits and equity-based compensation expense, for employees engaged in research and development
    functions&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;acquisition costs related to the purchase of licensed intellectual property;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;costs
    related to compliance with quality and regulatory requirements&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;payments
    made under third-party licensing agreements&#x37e; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;direct
    and allocated costs related to facilities, information technology, personnel and other overhead.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Advance
payments that we make for goods or services to be received in the future for use in research and development activities are recorded
as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or consumed or the related services are performed,
or until it is no longer expected that the goods will be delivered, or the services rendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000789">&lt;p id="xdx_84B_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_znRfGS37jvN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zZOsh9rAdqGa"&gt;General
and Administrative Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist primarily of salaries and related costs for personnel in executive management, finance, corporate
and business development, and administrative functions. General and administrative expenses also include legal fees relating to patent
and corporate matters&#x37e; professional fees for accounting, auditing, tax, and administrative consulting services&#x37e; insurance costs&#x37e;
administrative travel expenses and other operating costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000791">&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zpAczA2q79t5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_z0NlpMWvYCrg"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;, sets forth standards for financial presentation and disclosure of income tax liabilities and expense.
Interest and penalties recognized have been classified in the consolidated statements of operations and comprehensive income (loss) as
income taxes. Deferred tax assets and liabilities are recognized for future tax consequences attributable to temporary differences between
the financial statement carrying amount of existing assets and liabilities and their respective tax bases and operating losses carried
forward. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change
in tax rates is recognized in the consolidated statements of operations and comprehensive income (loss) in the period that includes the
enactment date. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits of which
future realization is uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000793">&lt;p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zJkBnbjryKMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zWQwRNE8GDh2"&gt;Earnings/(Net
Loss) per Share&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company calculates basic and diluted earnings/(net loss) per share under ASC Topic 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;. Basic earnings/(net
loss) per share is computed by dividing the net income/(loss) by the number of weighted-average common shares outstanding for the period.
Diluted earnings/(net loss) is computed by adjusting net income/(loss) based on the impact of any dilutive instruments. Diluted earnings/(net
loss) per share is computed by dividing the diluted net income/(loss) by the number of weighted-average common shares outstanding for
the period including the effect, if dilutive, of any instruments that can be settled in common shares. When computing diluted net income/(loss)
per share, the numerator is adjusted to eliminate the effects that have been recorded in net income/(loss) (net of tax, if any) attributable
to any liability-classified dilutive instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <CDT:WarrantInstrumentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000795">&lt;p id="xdx_84B_ecustom--WarrantInstrumentsPolicyTextBlock_zb3ifZGf9Nf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_86C_zZCtQMd1f6Ne" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the accounting classification of Warrants as either liability or equity by first assessing whether the Warrants meet
liability classification in accordance with ASC 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;). Under ASC 480, a
financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies
a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares must be classified as
a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly
on any one of the following: (a) a fixed monetary amount known at inception; (b) variations in something other than the fair value of
the issuer&#x2019;s equity shares; or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
financial instruments, such as the Warrants, are not required to be classified as liabilities under ASC 480, the Company assesses whether
such instruments are indexed to the Company&#x2019;s own stock under ASC 815-40. In order for an instrument to be considered indexed to
an entity&#x2019;s own stock, its settlement amount must always equal the difference between the following: (a) the fair value of a fixed
number of the Company&#x2019;s equity shares, and (b) a fixed monetary amount or a fixed amount of a debt instrument issued by the Company.
The Company determined that the settlement amount of the Equity Classified Warrants would equal the difference between the fair value
of a fixed number of shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified as equity, while
the settlement amount of the Liability Classified Warrants would not equal the difference between the fair value of a fixed number of
shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified as a liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Equity Classified Warrants are recorded in stockholders&#x2019; deficit and the Liability Classified Warrants are recorded as liabilities
in the Consolidated Balance Sheet. The Liability Classified Warrants are remeasured each period with changes in fair value recorded in
the Consolidated Statements of Operations and Comprehensive Income (Loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CDT:WarrantInstrumentsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000797">&lt;p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zfXSfxa44aaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zTvJEe4YQyb5"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company translated the assets and liabilities of foreign subsidiaries from their respective functional currency, the British pound, to
United States dollars at the appropriate spot rates as of the balance sheet date. Income and expenses of operations are translated to
United States dollars using weighted average exchange rates during the year. The foreign subsidiaries use the local currency as their
functional currency. The effects of foreign currency translation adjustments are included as a component of accumulated other comprehensive
income in the accompanying consolidated statements of changes in stockholders&#x2019; deficit. Non-monetary items in the subsidiaries&#x2019;
functional currency are re-measured into the reporting currency at the historical exchange rate (i.e., the rate of exchange at the date
of the transaction).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <CDT:EmergingGrowthCompanyStatusPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000799">&lt;p id="xdx_84E_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zviwSQVWkuNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zT0gOeUHmSN7"&gt;Emerging
Growth Company Status&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under
the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of
the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period
for complying with new or revised accounting standards that have different effective dates for public and private companies until the
earlier of the date that: (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended
transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with
the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the Merger, the Company will remain an emerging growth company, as defined by the Jumpstart Our Business Startups act of 2012, until
the earliest of &lt;span id="xdx_906_ecustom--DescriptionForEmergingGrowthCompany_c20240101__20241231_zjcsk4iASiNa" title="Emerging growth description"&gt;(i) the last day of the combined entity&#x2019;s first fiscal year following the fifth anniversary of the completion of
MURF&#x2019;s initial public offering (the &#x201c;MURF IPO&#x201d;), (ii) the last day of the fiscal year in which the combined entity
has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the combined entity is deemed
to be a large accelerated filer, which means the market value of the combined entity&#x2019;s common stock that is held by non-affiliates
exceeds $700.0 million as of the prior December 31st or (iv) the date on which the combined entity has issued more than $1.0 billion
in non-convertible debt securities during the prior three year period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CDT:EmergingGrowthCompanyStatusPolicyTextBlock>
    <CDT:DescriptionForEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000801">(i) the last day of the combined entity&#x2019;s first fiscal year following the fifth anniversary of the completion of
MURF&#x2019;s initial public offering (the &#x201c;MURF IPO&#x201d;), (ii) the last day of the fiscal year in which the combined entity
has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the combined entity is deemed
to be a large accelerated filer, which means the market value of the combined entity&#x2019;s common stock that is held by non-affiliates
exceeds $700.0 million as of the prior December 31st or (iv) the date on which the combined entity has issued more than $1.0 billion
in non-convertible debt securities during the prior three year period.</CDT:DescriptionForEmergingGrowthCompany>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000803">&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1ZDVaMonHk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zZTzVojdLiYe"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) (&#x201c;ASU 2023-07&#x201d;), which enhances the segment disclosure
requirements for public entities on an annual and interim basis. Under this proposal, public entities are required to disclose significant
segment expenses that are regularly provided to the chief operating decision maker (the &#x201c;CODM&#x201d;) and included within each
reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#x2019;s profit or loss
and assets will be required on an interim basis. Entities are also required to disclose information about the CODM&#x2019;s title and
position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment
of segment performance and deciding whether how to allocate resources. Finally, ASU 2023-07 requires all segment disclosures for public
entities, even those with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023,
and interim periods within fiscal years beginning after December 15, 2024, and should be applied on a retrospective basis to all periods
presented. As of December 31, 2024, the Company only has one reportable segment. The Company adopted this accounting standard as of January
1, 2024. See Note 19 for the Company&#x2019;s segments disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <CDT:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000805">&lt;p id="xdx_845_ecustom--NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_zn0GSboqcEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zzGJPSdxsV7b"&gt;Recently
Issued Accounting Standards Not Yet Adopted&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;).
ASU 2023-09 modifies the reporting requirements for income tax disclosures related to effective tax rates and cash income taxes paid.
Pursuant to ASU 2023-09, public business entities are required to disclose certain categories in the income tax rate reconciliation,
as well as additional information for reconciling items that meet a specific quantitative threshold. Additionally, ASU 2023-09 requires
annual disclosures of income taxes paid for all entities, including the amount of income taxes paid, net of refunds received, disaggregated
by federal, state, and foreign jurisdictions. The standard is effective for fiscal years beginning after December 15, 2024, with early
adoption permitted. The Company is currently evaluating the impact of ASU 2023-09 on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, which is intended to provide more detailed information about specified categories
of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented
on the consolidated statements of operations and comprehensive income (loss). The guidance in this ASU is effective for fiscal years
beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted.
The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU
or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the
impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;

</CDT:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000807">&lt;p id="xdx_80F_eus-gaap--BusinessCombinationDisclosureTextBlock_zOt19ohlSSL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_82C_zrSPVGUYkYpe"&gt;Merger and Financing&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
discussed in Note 1 &#x2013; &lt;i&gt;Nature of the Business, Basis of Presentation and Summary of Significant Accounting Policies&lt;/i&gt;, on September
22, 2023, the Company and MURF completed the Merger. Upon the closing of the Merger, the following occurred:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
    share of Old Conduit common stock issued and outstanding immediately prior to the closing of the Merger, which totaled &lt;span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--OldConduitPharmaceuticalsLimitedMember_zRQc7HVorekl" title="Common stock, shares issued"&gt;&lt;span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--OldConduitPharmaceuticalsLimitedMember_zecslu5V7UJk" title="Common stock, shares outstanding"&gt;2,000&lt;/span&gt;&lt;/span&gt; shares,
    was exchanged for the right to receive &lt;span id="xdx_905_eus-gaap--NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRjBoli97ZZf" title="Business acquisition right to receive number of shares"&gt;323&lt;/span&gt; shares of the Company&#x2019;s Common Stock (&#x201c;Common Stock&#x201d;) resulting
    in the issuance of &lt;span id="xdx_90E_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrp2eqWJhe59" title="Number of shares issued"&gt;646,264&lt;/span&gt; shares of Conduit Pharmaceuticals, Inc. Common Stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    addition to the shares issued to legacy Conduit shareholders noted above, an additional &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__custom--ConduitConvertibleNoteHoldersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk5FXvbXgJOi" title="Shares issued after merger"&gt;3,735&lt;/span&gt; shares of Common Stock was issued
    to Conduit convertible note holders, resulting in a total of &lt;span id="xdx_901_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__custom--ConduitShareHoldersandConvertibleNoteHoldersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znGJEvbid2U1" title="Number of shares issued"&gt;650,000&lt;/span&gt; shares of Common Stock being issued to Conduit shareholders
    and holders of Conduit convertible notes payable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    connection with the Merger, &lt;span id="xdx_90E_ecustom--BusinessAcquisitionNumberOfSharesTransferred_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zLdIrzuOdHYa" title="Number of shares transferred"&gt;450&lt;/span&gt; shares of MURF Class A common stock held by the MURF Sponsor was transferred to MURF Directors. Each
    share was exchanged on a &lt;span id="xdx_906_eus-gaap--CommonStockConversionBasis_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zXUotxubHbF5" title="Common stock conversion basis"&gt;one-for-one basis&lt;/span&gt; for shares of Common Stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
    share of MURF Class A common stock held by the MURF Sponsor prior to the closing of the Merger, which totaled &lt;span id="xdx_901_ecustom--BusinessAcquisitionNumberOfSharesTransferred_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z2ZrROw2Xi8k" title="Number of shares transferred"&gt;7,090&lt;/span&gt; shares, was exchanged
    for, on a one-for-one basis for shares of Common Stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
    share of MURF common stock subject to possible redemption that was not redeemed prior to the closing of the Merger, which totaled
    &lt;span id="xdx_90C_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxZoPEBM1ppk" title="Number of shares held prior to business combination"&gt;580&lt;/span&gt; shares, was exchanged for, on a one-for-one basis for shares of Common Stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    connection with the Merger, &lt;span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zfqLcnhQ43gb" title="Number of shares converted"&gt;33,062&lt;/span&gt; shares of MURF Class B common stock held by the Sponsor was automatically converted into shares
    of MURF Class A common stock and then subsequently converted into shares of Common Stock on a one-for-one basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    connection with the Merger, A.G.P./Alliance Global Partners (&#x201c;A.G.P.&#x201d;), whom acted as a financial advisor to both MURF
    and Conduit, was due to receive (i) a cash fee of $&lt;span id="xdx_90C_eus-gaap--ProfessionalFees_pn5n6_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zBVaLTSO4OWe" title="Cash fee"&gt;6.5&lt;/span&gt; million, &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zlPFvmw6ogT7" title="Shares issued for services"&gt;13,000&lt;/span&gt; shares of Common Stock and warrants to purchase &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pp0p0_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zD9AOimPgLB6" title="Warrants to purchase common stock"&gt;540&lt;/span&gt; shares
    of Common Stock at an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zFuk1ZCZna11" title="Exercise price of warrants"&gt;1,100&lt;/span&gt; per share pursuant to its engagement agreement with Conduit entered into on August
    2, 2022 and (ii) $&lt;span id="xdx_90D_ecustom--DeferredUnderwritingFee_pn5n6_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zwnSjHyICE71" title="Deferred underwriting fee"&gt;4.6&lt;/span&gt; million of deferred underwriting fees as a result of its engagement for MURF&#x2019;s initial public offering.
    Upon closing of the Merger, A.G.P. received a cash payment of $&lt;span id="xdx_909_ecustom--PaymentForAdvisoryServices_pn5n6_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zoIjICMLxc6l" title="Financial advisory fee"&gt;5.6&lt;/span&gt; million, &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zE0SCy0Cjo39" title="Shares issued for services"&gt;13,000&lt;/span&gt; shares of Common Stock, and &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zXoL0YwQYmwj"&gt;540 &lt;/span&gt;warrants to purchase
    &lt;span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesStockWarrantsExercised_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zRFVq2FtqWSi" title="Warrants to purchase common stock"&gt;540&lt;/span&gt; shares of Common Stock. The remaining $&lt;span id="xdx_905_ecustom--DeferredCashPaymentsAmount_iI_pn5n6_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zKI5msY6RDX7" title="Cash payments due"&gt;5.7&lt;/span&gt; million of cash payments due to A.G.P upon closing of the Merger was deferred and
    to be paid on or before March 21, 2025, with annual interest of &lt;span id="xdx_907_ecustom--AnnualInterestRate_iI_pid_dp_uPure_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zrmPDhU5WAkh" title="Interest rate"&gt;5.5&lt;/span&gt;%. The remaining cash payments due, which were directly attributable
    to the Merger, were accounted for as a liability with an offset to additional paid-in capital in accordance with SAB Topic 5.A on
    the Company&#x2019;s consolidated balance sheet. See Note 7 for discussion of amendment of the note that took place during the year ended December 31, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    connection with the Merger, MURF entered into subscription agreements (the &#x201c;Subscription Agreements&#x201d;) with certain accredited
    investors (the &#x201c;PIPE Investors&#x201d;) for an aggregate of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zPU344Rnltmd" title="Shares issued during the period"&gt;20,000&lt;/span&gt; units, with each unit consisting of one share of Company
    common stock (the &#x201c;PIPE Shares&#x201d;), together with one warrant exercisable into one share of Company common stock (the &#x201c;PIPE
    Warrants&#x201d;), at a purchase price of $&lt;span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zaaaJ8VZeLuh" title="Shares issued, purchase price"&gt;1,000&lt;/span&gt; per unit, for an aggregate purchase price of $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z1M3Ea2YVfw4" title="Shares issued during the period, value"&gt;20,000,000&lt;/span&gt; (the &#x201c;PIPE Financing&#x201d;).
    Upon the closing of the PIPE Financing (which closed in connection with the closing of the Merger), the Company received $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zgPeYyITNGce" title="Proceeds from issuance of common stock"&gt;20.0&lt;/span&gt; million
    in cash from the PIPE Financing, which was used to settle related party promissory notes issued by MURF to the MURF Sponsor and an
    affiliate of the MURF Sponsor as well as transaction costs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    proceeds received by the Company from the Merger and PIPE Financing, net of transaction costs, and other payments for existing liabilities
    and prepayments, totaled $8.5 million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, MURF was treated
    as the acquired company for financial reporting purposes (see Note 1 for further details). Accordingly, for accounting purposes,
    the Merger was treated as the equivalent of the Company issuing shares for the net assets of MURF, accompanied by a recapitalization.
    The net assets of MURF were stated at historical cost with no goodwill or other intangible assets recorded.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zMHzmmRuPXxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the total Common Stock outstanding immediately after the closing of the Merger:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zmRwfzhSC5Zh" style="display: none"&gt;Schedule
of Common Stock Outstanding&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Exchange of MURF common stock subject to possible redemption for Conduit Pharmaceuticals Inc. common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pip0_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis__us-gaap--CommonStockSubjectToMandatoryRedemptionMember_z1RCLOhnbOLe" title="Exchange of MURF common stock subject to possible redemption for Conduit Pharmaceuticals Inc. common stock, shares"&gt;580&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Exchange of MURF Class A common stock held by MURF Directors for Conduit Pharmaceuticals Inc. common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxC6b0h09OHk" title="Exchange of MURF Class A common stock held by MURF Directors for Conduit Pharmaceuticals Inc. common stock, shares"&gt;450&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Exchange of MURF Class A common stock held by MURF Sponsor for Conduit Pharmaceuticals Inc. common stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxfpbvUTjoS8" title="Exchange of MURF Class A common stock held by MURF Sponsor for Conduit Pharmaceuticals Inc. common stock, shares"&gt;40,152&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Subtotal - Merger, net of redemptions&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zozAQ9XrK4gi" title="Business Combination, net of redemptions, shares"&gt;41,182&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3CppKDwcUa5" title="Issuance of Conduit Pharmaceuticals, Inc. common stock in connection with PIPE Financing, shares"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Exchange of Conduit Pharmaceuticals Limited ordinary shares for Conduit Pharmaceuticals Inc. common stock on the Closing Date&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWY0VDeUjWld" title="Exchange of Conduit Pharmaceuticals Limited ordinary shares for Conduit Pharmaceuticals Inc. common stock on the Closing Date, shares"&gt;646,264&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXQi6JjWROI5" title="Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date,shares"&gt;3,735&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxuWF0bLXB76" title="Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the transaction, shares"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total - Conduit Pharmaceuticals Inc. common stock outstanding as a result of the Merger, PIPE Financing, exchange of Conduit Pharmaceuticals Limited shares for shares of Conduit Pharmaceuticals Inc., issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes, and advisors.&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zAbAtWqta8i2" title="Total - Conduit Pharmaceuticals Inc. common stock outstanding as a result of Business Combination, PIPE Financing, exchange of Conduit Pharmaceuticals Limited shares for shares of Conduit Pharmaceuticals Inc., issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes, and transaction services agreements, shares"&gt;724,181&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zgh2j1YuwUUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_OldConduitPharmaceuticalsLimitedMember"
      decimals="INF"
      id="Fact000809"
      unitRef="Shares">2000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_OldConduitPharmaceuticalsLimitedMember"
      decimals="INF"
      id="Fact000811"
      unitRef="Shares">2000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000813"
      unitRef="Shares">323</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000815"
      unitRef="Shares">646264</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_ConduitConvertibleNoteHoldersMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000817"
      unitRef="Shares">3735</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_ConduitShareHoldersandConvertibleNoteHoldersMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000819"
      unitRef="Shares">650000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <CDT:BusinessAcquisitionNumberOfSharesTransferred
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_srt_DirectorMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000821"
      unitRef="Shares">450</CDT:BusinessAcquisitionNumberOfSharesTransferred>
    <us-gaap:CommonStockConversionBasis
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_srt_DirectorMember_us-gaap_CommonClassAMember"
      id="Fact000823">one-for-one basis</us-gaap:CommonStockConversionBasis>
    <CDT:BusinessAcquisitionNumberOfSharesTransferred
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000825"
      unitRef="Shares">7090</CDT:BusinessAcquisitionNumberOfSharesTransferred>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000827"
      unitRef="Shares">580</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SponsorMember_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000829"
      unitRef="Shares">33062</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProfessionalFees
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      id="Fact000831"
      unitRef="USD">6500000</us-gaap:ProfessionalFees>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember"
      decimals="INF"
      id="Fact000833"
      unitRef="Shares">13000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember"
      decimals="0"
      id="Fact000835"
      unitRef="Shares">540</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember"
      decimals="INF"
      id="Fact000837"
      unitRef="USDPShares">1100</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CDT:DeferredUnderwritingFee
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      id="Fact000839"
      unitRef="USD">4600000</CDT:DeferredUnderwritingFee>
    <CDT:PaymentForAdvisoryServices
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      id="Fact000841"
      unitRef="USD">5600000</CDT:PaymentForAdvisoryServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember"
      decimals="INF"
      id="Fact000843"
      unitRef="Shares">13000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember"
      decimals="-3"
      id="Fact000844"
      unitRef="Shares">540000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <CDT:StockIssuedDuringPeriodSharesStockWarrantsExercised
      contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember"
      decimals="INF"
      id="Fact000846"
      unitRef="Shares">540</CDT:StockIssuedDuringPeriodSharesStockWarrantsExercised>
    <CDT:DeferredCashPaymentsAmount
      contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      id="Fact000848"
      unitRef="USD">5700000</CDT:DeferredCashPaymentsAmount>
    <CDT:AnnualInterestRate
      contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_AllianceGlobalPartnersMember"
      decimals="INF"
      id="Fact000850"
      unitRef="Pure">0.055</CDT:AnnualInterestRate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember"
      decimals="INF"
      id="Fact000852"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember"
      decimals="INF"
      id="Fact000854"
      unitRef="USDPShares">1000</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember"
      decimals="0"
      id="Fact000856"
      unitRef="USD">20000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember"
      decimals="-5"
      id="Fact000858"
      unitRef="USD">20000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000860">&lt;p id="xdx_894_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zMHzmmRuPXxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the total Common Stock outstanding immediately after the closing of the Merger:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zmRwfzhSC5Zh" style="display: none"&gt;Schedule
of Common Stock Outstanding&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Exchange of MURF common stock subject to possible redemption for Conduit Pharmaceuticals Inc. common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pip0_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis__us-gaap--CommonStockSubjectToMandatoryRedemptionMember_z1RCLOhnbOLe" title="Exchange of MURF common stock subject to possible redemption for Conduit Pharmaceuticals Inc. common stock, shares"&gt;580&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Exchange of MURF Class A common stock held by MURF Directors for Conduit Pharmaceuticals Inc. common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxC6b0h09OHk" title="Exchange of MURF Class A common stock held by MURF Directors for Conduit Pharmaceuticals Inc. common stock, shares"&gt;450&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Exchange of MURF Class A common stock held by MURF Sponsor for Conduit Pharmaceuticals Inc. common stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxfpbvUTjoS8" title="Exchange of MURF Class A common stock held by MURF Sponsor for Conduit Pharmaceuticals Inc. common stock, shares"&gt;40,152&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Subtotal - Merger, net of redemptions&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zozAQ9XrK4gi" title="Business Combination, net of redemptions, shares"&gt;41,182&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3CppKDwcUa5" title="Issuance of Conduit Pharmaceuticals, Inc. common stock in connection with PIPE Financing, shares"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Exchange of Conduit Pharmaceuticals Limited ordinary shares for Conduit Pharmaceuticals Inc. common stock on the Closing Date&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWY0VDeUjWld" title="Exchange of Conduit Pharmaceuticals Limited ordinary shares for Conduit Pharmaceuticals Inc. common stock on the Closing Date, shares"&gt;646,264&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXQi6JjWROI5" title="Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date,shares"&gt;3,735&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxuWF0bLXB76" title="Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the transaction, shares"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total - Conduit Pharmaceuticals Inc. common stock outstanding as a result of the Merger, PIPE Financing, exchange of Conduit Pharmaceuticals Limited shares for shares of Conduit Pharmaceuticals Inc., issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes, and advisors.&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zAbAtWqta8i2" title="Total - Conduit Pharmaceuticals Inc. common stock outstanding as a result of Business Combination, PIPE Financing, exchange of Conduit Pharmaceuticals Limited shares for shares of Conduit Pharmaceuticals Inc., issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes, and transaction services agreements, shares"&gt;724,181&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember_us-gaap_CommonStockSubjectToMandatoryRedemptionMember"
      decimals="INF"
      id="Fact000862"
      unitRef="Shares">580</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_srt_DirectorMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000864"
      unitRef="Shares">450</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SponsorMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000866"
      unitRef="Shares">40152</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000868"
      unitRef="Shares">41182</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000870"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000872"
      unitRef="Shares">646264</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000874"
      unitRef="Shares">3735</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000876"
      unitRef="Shares">13000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember"
      decimals="INF"
      id="Fact000878"
      unitRef="Shares">724181</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000880">&lt;p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zhBmad4CwYhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span id="xdx_82F_zRCO19RmjpZd"&gt;Fair Value&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zCtFMn43Fv61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the period ended December 31, 2024, there were no transfers between Level 1 and Level 2, nor into or out of Level 3. The following
table presents as of December 31, 2024 the Company&#x2019;s assets and liabilities subject to measurement at fair value on a
recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_z3goVReCnn35" style="display: none"&gt;Schedule
of  Assets Subject to Measurement at Fair Value on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: left; padding-bottom: 2.5pt"&gt;Cash equivalents&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_zW0HAnUpsvPi" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents"&gt;192&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_z33wWa7lwO0j" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0886"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_z9IX5fTZ4kj7" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0888"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_zb5yiPIDU7l3" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents"&gt;192&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdQMgbeQS6v1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets"&gt;192&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2kiDDR5Tmkl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0894"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzUmQ2pkcK2k" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0896"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUo15aFKnWJ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets"&gt;192&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible notes payable at fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_zyb4WrTSaAhj" style="text-align: right" title="Option liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0900"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_zUl5DKjzekr9" style="text-align: right" title="Option liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0902"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_zcXTKq4up5m3" style="text-align: right" title="Option liability"&gt;5,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoUOgP3F4u9g" style="text-align: right" title="Option liability"&gt;5,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Liability Classified Warrants&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zSQzp4WpuF8h" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0908"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zqRtJD0od3tg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_z29P0jaeyOLi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;138&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zU3ETZrXfeIh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;138&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgT4eaYNsP06" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8JNrw2ygA12" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0918"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUMv3HreeBu1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;5,994&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zknkSqE01W5k" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;5,994&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents as of December 31, 2023 the Company&#x2019;s liabilities subject to measurement at fair value on a recurring
basis (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: left; padding-bottom: 2.5pt"&gt;Liability Classified Warrants&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zXOzm6huL3sf" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0924"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zENvKENrXooi" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;142&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zl9wcldzfSQe" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0928"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zmNKSSwrtGql" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;142&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6q6LJ2Ls69a" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0932"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5bDizCJVXh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;142&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLXYPUPearZ7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0936"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFBw8ee5C1L3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;142&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zOwa1FKpVIff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
equivalents consist of highly liquid money market funds with maturities of three months or less and are reflected in the Consolidated
Balance Sheets at carrying value, which approximates fair value due to their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zyye7A4TPG83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents additional information about the Convertible Notes Payable subject to measurement at fair value on a recurring
basis and warrant liabilities, for which the Company used significant unobservable inputs (Level 3) (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zqxT7pULAy3b" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_z6393p8CaGjj" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Convertible Notes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Payable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_z1GM2RkDB3le" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Liability Classified Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ConvertibleDebtFairValueDisclosures_iS_pn3n3_zee7e5WmrIkc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0942"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PaymentsOfDebtIssuanceCosts_pn3n3_zs2UpKq7Jqof" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Fair value at Issuance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;7,899&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;229&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_iN_pn3n3_di_zR8QJkt8jZr1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Conversion of convertible note&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(92&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0949"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ChangeInFairValueOfConvertibleNotesPayable_pn3n3_z4jevABFubjj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,951&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(91&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ConvertibleDebtFairValueDisclosures_iE_pn3n3_zDGdPFy27977" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,856&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;138&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zq8srlYULYDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Convertible
Notes Payable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
discussed in Note 7, during on October 31, 2024, the Company and Nirland agreed to amend the August 2024 Nirland Note, whereby the
August 2024 Nirland Note was amended to provide for the conversion of the August 2024 Nirland Note into shares of common stock, at
Nirland&#x2019;s discretion, in a multiple of any unpaid amounts, if not otherwise previously paid, pursuant to the conversion rate
contained therein. The August 2024 Nirland Note was then amended for a second time on November
22, 2024.Additionally, as discussed in Note 7, during November 2024, the Company issued to A.G.P. a convertible promissory
note (the &#x201c;A.G.P. Convertible Note&#x201d;) in the principal amount of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241130_zbl3vtjqhtnk" title="Principal amount"&gt;5.7&lt;/span&gt;
million to evidence the A.G.P.&#x2019;s currently owed deferred commission payable. The Company elected to account for the August
2024 Nirland Note and A.G.P. Convertible Note (collectively the &#x201c;Convertible Notes Payable&#x201d;) at fair value. The fair
value of the Convertible Notes Payable is estimated each period using a binomial lattice model. Significant estimates in the
binomial lattice model include the Company&#x2019;s stock price, volatility, risk-free rate, corporate bond yield, credit
spread, probability of default, and recovery upon default.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the August 2024 Nirland Note and A.G.P. Convertible Note as of December 31, 2024 were estimated using a binomial
lattice model. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following
table outlines the range of significant unobservable inputs used in calculating the fair value of the August 2024 Nirland Note as of
the dates noted below:&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_zbfLS4JMsCAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zz0NnNr931ll" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Fair Value  of Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;October 31,&lt;/b&gt;&lt;/p&gt;

&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;

&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;November 22,&lt;/b&gt;&lt;/p&gt;

&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;

&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Stock Price&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 14%"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zXP1MgYtPeec" title="Measurement input"&gt;9.10&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 14%"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zqD7KjVRhKm1" title="Measurement input"&gt;10.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zJwzZ7tNojW9" title="Measurement input"&gt;6.90&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20241031__20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z8hbVV8uD26e" title="Measurement input"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20241122__20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zNmDiM14K2X4" title="Measurement input"&gt;0.7&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zaP1nUSbEZOe" title="Measurement input"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Corporate bond yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember_zZuiHbbsiz9h"&gt;9.1&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember_zbRAZVJcZYje"&gt;8.7&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember_zu7d2zNDqHU3"&gt;11.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Credit Spread&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zAIYKzu1Az6i"&gt;15.9&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zZ859OayB6ne"&gt;15.9&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zpRIg4xqVtc1"&gt;15.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Probability of default&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember_zfTGPxLaGWI1"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember_z5C3X9drZTHd"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember_zuGVIZAp9sHk"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Recovery upon default&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember_zeZSEtaKzvrb"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember_zFAalIqNOa5d"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember_znbq2A2VwvZa"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;

  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zsQCAwt4dx23"&gt;103.2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zOLVsGF4n2gk"&gt;96.5&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zYRcTsjYsIkl"&gt;123.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zfP14TqACEL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_hus-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zaf84Dforup9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table outlines the range of significant unobservable inputs used in calculating the fair value of the A.G.P. Convertible
Note as of the dates noted below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zkqDuKLIvqSc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Fair Value  of Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;November 25,&lt;/b&gt;&lt;/p&gt;
                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Stock Price&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 16%"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zBul29jM6eL2" title="Measurement input"&gt;9.10&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zu6TcECljG2f" title="Measurement input"&gt;6.90&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentTerm_dtY_c20241125__20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zUa4mcOSVE1l" title="Measurement input"&gt;1&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zdsyCXtNdts9" title="Measurement input"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Corporate bond yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_z9MXSGtaez2h"&gt;8.8&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zoNZAFPL0UM3"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Credit Spread&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zRg8nu2t6hgg"&gt;26.2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zUwDQlb64STf"&gt;26.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Probability of Default&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zeMJhHg9bEjl"&gt;40&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zI8Mtigw1iX4"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Recovery upon default&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zPIXvbm8OyOc" title="Measurement input"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zfYuVgGDKdq6" title="Measurement input"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zz2qzFr4YgDj" title="Measurement input"&gt;108.7&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zD7lCIloP8Fd" title="Measurement input"&gt;101.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zZTljc42Ld47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Liability
Classified Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
PIPE Warrants, A.G.P. Warrants, and A.G.P. 2024 Warrants, as defined in Note 18, are accounted for as liabilities in accordance with ASC 815-40 and are presented
within Warrant liabilities in the consolidated balance sheets. Warrant liabilities are measured at fair value at inception and on a recurring
basis, with changes in fair value presented within other income (expense), net in the consolidated statements of operations and comprehensive
income (loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
measurement of the PIPE Warrants and the measurement of the A.G.P warrants are classified as Level 2 fair value measurements due to the
use of an observable market quote for the Company&#x2019;s publicly traded warrants, which are considered to be a similar asset in an
active market. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
PIPE Warrant and A.G.P. Warrant liabilities are calculated by multiplying the quoted market price of the Company&#x2019;s publicly traded
warrants by the number of liability classified warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 11, 2024, the Company amended the exercise price of the PIPE Warrants to be $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241211_zKEFHmScQN98" title="Exercise price"&gt;8.83&lt;/span&gt;,
at which time all PIPE Warrants were exercised. As the exercise price was amended on the same date that the PIPE Warrants were
exercised, the Company remeasured the warrant liability immediately before exercise based on the difference between the closing
stock price of the Company&#x2019;s common stock on December 11, 2024, and the amendment exercise price of the PIPE Warrants,
resulting in a gain on the change in fair value of warrant liability of approximately $&lt;span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20241211__20241211__us-gaap--StatementEquityComponentsAxis__custom--PIPEWarrantsMember_zJh8PVgG1982" title="Change in fair value of warrant liability"&gt;12&lt;/span&gt;
thousand. Refer to Note 18 for additional information. Upon exercise of the PIPE Warrants, less than $&lt;span id="xdx_904_ecustom--WarrantsExcercise_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PIPEWarrantsMember_z1zplZmyXaae" title="Warrants excercise"&gt;1&lt;/span&gt;
thousand of Level 2 liability classified warrants remain on the consolidated balance sheet as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zrlqaJL1wSv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
measurement of the A.G.P. 2024 Warrants is classified as Level 3 due to the use of an option-pricing model that utilizes unobservable inputs and requires significant judgement. The Company estimated
the fair value of the warrants issued as the issuance date, October 29, 2024, and as of December 31, 2024, using a Black-Scholes
option-pricing model utilizing the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_z29Sb08l0Ne8" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Fair Value  of Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;October 29, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Closing stock price&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 16%"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zL0MGY7X4re1" title="Measurement input"&gt;10.48&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIu51AZP2dIe" title="Measurement input"&gt;6.90&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Contractual exercise price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCikayCpEta7" title="Measurement input"&gt;10&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYgt4d7PslL" title="Measurement input"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zK4NQDMEYmGc" title="Measurement input"&gt;4.11&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zER6wFIDSePb" title="Measurement input"&gt;4.38&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Estimated volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaNjNJ2d2Opk" title="Measurement input"&gt;98.4&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7GMCDnDHHd9" title="Measurement input"&gt;98.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Time period to expiration (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentTerm_dtY_c20241029__20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFkT9SINyWc" title="Measurement input"&gt;5.2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjfcPSu19W48" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Measurement input"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zTjVzXNlD7Tb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000882">&lt;p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zCtFMn43Fv61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the period ended December 31, 2024, there were no transfers between Level 1 and Level 2, nor into or out of Level 3. The following
table presents as of December 31, 2024 the Company&#x2019;s assets and liabilities subject to measurement at fair value on a
recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_z3goVReCnn35" style="display: none"&gt;Schedule
of  Assets Subject to Measurement at Fair Value on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: left; padding-bottom: 2.5pt"&gt;Cash equivalents&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_zW0HAnUpsvPi" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents"&gt;192&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_z33wWa7lwO0j" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0886"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_z9IX5fTZ4kj7" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0888"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--CashAndCashEquivalentsMember_zb5yiPIDU7l3" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Cash equivalents"&gt;192&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdQMgbeQS6v1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets"&gt;192&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2kiDDR5Tmkl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0894"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzUmQ2pkcK2k" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0896"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUo15aFKnWJ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Assets"&gt;192&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible notes payable at fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_zyb4WrTSaAhj" style="text-align: right" title="Option liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0900"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_zUl5DKjzekr9" style="text-align: right" title="Option liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0902"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_zcXTKq4up5m3" style="text-align: right" title="Option liability"&gt;5,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zoUOgP3F4u9g" style="text-align: right" title="Option liability"&gt;5,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Liability Classified Warrants&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zSQzp4WpuF8h" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0908"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zqRtJD0od3tg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_z29P0jaeyOLi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;138&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zU3ETZrXfeIh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;138&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgT4eaYNsP06" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8JNrw2ygA12" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0918"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUMv3HreeBu1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;5,994&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zknkSqE01W5k" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;5,994&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents as of December 31, 2023 the Company&#x2019;s liabilities subject to measurement at fair value on a recurring
basis (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: left; padding-bottom: 2.5pt"&gt;Liability Classified Warrants&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zXOzm6huL3sf" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0924"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zENvKENrXooi" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;142&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zl9wcldzfSQe" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0928"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zmNKSSwrtGql" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Warrant Liability - PIPE Warrants"&gt;142&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6q6LJ2Ls69a" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0932"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5bDizCJVXh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;142&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLXYPUPearZ7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0936"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFBw8ee5C1L3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Liabilities"&gt;142&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="Fact000884"
      unitRef="USD">192000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CashAndCashEquivalentsMember"
      decimals="-3"
      id="Fact000890"
      unitRef="USD">192000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000892"
      unitRef="USD">192000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000898"
      unitRef="USD">192000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ConvertibleNotesPayableMember"
      decimals="-3"
      id="Fact000904"
      unitRef="USD">5856000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_ConvertibleNotesPayableMember_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000906"
      unitRef="USD">5856000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000910"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000912"
      unitRef="USD">138000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000914"
      unitRef="USD">138000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000920"
      unitRef="USD">5994000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000922"
      unitRef="USD">5994000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000926"
      unitRef="USD">142000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000930"
      unitRef="USD">142000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000934"
      unitRef="USD">142000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000938"
      unitRef="USD">142000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000940">&lt;p id="xdx_892_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zyye7A4TPG83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents additional information about the Convertible Notes Payable subject to measurement at fair value on a recurring
basis and warrant liabilities, for which the Company used significant unobservable inputs (Level 3) (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zqxT7pULAy3b" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--ConvertibleNotesPayableMember_z6393p8CaGjj" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Convertible Notes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Payable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_z1GM2RkDB3le" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Liability Classified Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ConvertibleDebtFairValueDisclosures_iS_pn3n3_zee7e5WmrIkc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0942"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PaymentsOfDebtIssuanceCosts_pn3n3_zs2UpKq7Jqof" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Fair value at Issuance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;7,899&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;229&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_iN_pn3n3_di_zR8QJkt8jZr1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Conversion of convertible note&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(92&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0949"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ChangeInFairValueOfConvertibleNotesPayable_pn3n3_z4jevABFubjj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,951&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(91&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ConvertibleDebtFairValueDisclosures_iE_pn3n3_zDGdPFy27977" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,856&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;138&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember"
      decimals="-3"
      id="Fact000945"
      unitRef="USD">7899000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000946"
      unitRef="USD">229000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember"
      decimals="-3"
      id="Fact000948"
      unitRef="USD">92000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <CDT:ChangeInFairValueOfConvertibleNotesPayable
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember"
      decimals="-3"
      id="Fact000951"
      unitRef="USD">-1951000</CDT:ChangeInFairValueOfConvertibleNotesPayable>
    <CDT:ChangeInFairValueOfConvertibleNotesPayable
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000952"
      unitRef="USD">-91000</CDT:ChangeInFairValueOfConvertibleNotesPayable>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_ConvertibleNotesPayableMember"
      decimals="-3"
      id="Fact000954"
      unitRef="USD">5856000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000955"
      unitRef="USD">138000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-11-30"
      decimals="-5"
      id="Fact000957"
      unitRef="USD">5700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000959">&lt;p id="xdx_895_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_zbfLS4JMsCAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zz0NnNr931ll" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Fair Value  of Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;October 31,&lt;/b&gt;&lt;/p&gt;

&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;

&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;November 22,&lt;/b&gt;&lt;/p&gt;

&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;

&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Stock Price&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 14%"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zXP1MgYtPeec" title="Measurement input"&gt;9.10&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 14%"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zqD7KjVRhKm1" title="Measurement input"&gt;10.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zJwzZ7tNojW9" title="Measurement input"&gt;6.90&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20241031__20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z8hbVV8uD26e" title="Measurement input"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20241122__20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zNmDiM14K2X4" title="Measurement input"&gt;0.7&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zaP1nUSbEZOe" title="Measurement input"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Corporate bond yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember_zZuiHbbsiz9h"&gt;9.1&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember_zbRAZVJcZYje"&gt;8.7&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember_zu7d2zNDqHU3"&gt;11.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Credit Spread&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zAIYKzu1Az6i"&gt;15.9&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zZ859OayB6ne"&gt;15.9&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zpRIg4xqVtc1"&gt;15.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Probability of default&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember_zfTGPxLaGWI1"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember_z5C3X9drZTHd"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember_zuGVIZAp9sHk"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Recovery upon default&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember_zeZSEtaKzvrb"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember_zFAalIqNOa5d"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember_znbq2A2VwvZa"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;

  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zsQCAwt4dx23"&gt;103.2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241122__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zOLVsGF4n2gk"&gt;96.5&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zYRcTsjYsIkl"&gt;123.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-10-31_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact000961"
      unitRef="Pure">9.10</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-22_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact000963"
      unitRef="Pure">10.40</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact000965"
      unitRef="Pure">6.90</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-10-312024-10-31_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact000967">P0Y9M18D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-11-222024-11-22_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact000969">P0Y8M12D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact000971">P0Y7M6D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-10-31_custom_CorporateBondYieldEstimatedTimingOfConversionMember"
      decimals="INF"
      id="Fact000972"
      unitRef="Pure">9.1</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-22_custom_CorporateBondYieldEstimatedTimingOfConversionMember"
      decimals="INF"
      id="Fact000973"
      unitRef="Pure">8.7</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_custom_CorporateBondYieldEstimatedTimingOfConversionMember"
      decimals="INF"
      id="Fact000974"
      unitRef="Pure">11.4</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-10-31_us-gaap_MeasurementInputCreditSpreadMember"
      decimals="INF"
      id="Fact000975"
      unitRef="Pure">15.9</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-22_us-gaap_MeasurementInputCreditSpreadMember"
      decimals="INF"
      id="Fact000976"
      unitRef="Pure">15.9</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputCreditSpreadMember"
      decimals="INF"
      id="Fact000977"
      unitRef="Pure">15.9</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-10-31_custom_MeasurementInputProbabilityOfDefaultMember"
      decimals="INF"
      id="Fact000978"
      unitRef="Pure">40</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-22_custom_MeasurementInputProbabilityOfDefaultMember"
      decimals="INF"
      id="Fact000979"
      unitRef="Pure">40</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_custom_MeasurementInputProbabilityOfDefaultMember"
      decimals="INF"
      id="Fact000980"
      unitRef="Pure">40</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-10-31_custom_MeasurementInputRecoveryUponDefaultMember"
      decimals="INF"
      id="Fact000981"
      unitRef="Pure">20</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-22_custom_MeasurementInputRecoveryUponDefaultMember"
      decimals="INF"
      id="Fact000982"
      unitRef="Pure">20</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_custom_MeasurementInputRecoveryUponDefaultMember"
      decimals="INF"
      id="Fact000983"
      unitRef="Pure">20</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-10-31_us-gaap_MeasurementInputDiscountRateMember"
      decimals="INF"
      id="Fact000984"
      unitRef="Pure">103.2</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-22_us-gaap_MeasurementInputDiscountRateMember"
      decimals="INF"
      id="Fact000985"
      unitRef="Pure">96.5</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember"
      decimals="INF"
      id="Fact000986"
      unitRef="Pure">123.7</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock
      contextRef="From2024-01-012024-12-31_custom_AGPConvertibleNoteMember"
      id="Fact000988">&lt;p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_hus-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zaf84Dforup9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table outlines the range of significant unobservable inputs used in calculating the fair value of the A.G.P. Convertible
Note as of the dates noted below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zkqDuKLIvqSc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Fair Value  of Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;November 25,&lt;/b&gt;&lt;/p&gt;
                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Stock Price&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 16%"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zBul29jM6eL2" title="Measurement input"&gt;9.10&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zu6TcECljG2f" title="Measurement input"&gt;6.90&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentTerm_dtY_c20241125__20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zUa4mcOSVE1l" title="Measurement input"&gt;1&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zdsyCXtNdts9" title="Measurement input"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Corporate bond yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_z9MXSGtaez2h"&gt;8.8&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--CorporateBondYieldEstimatedTimingOfConversionMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zoNZAFPL0UM3"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Credit Spread&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zRg8nu2t6hgg"&gt;26.2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zUwDQlb64STf"&gt;26.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Probability of Default&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zeMJhHg9bEjl"&gt;40&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zI8Mtigw1iX4"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Recovery upon default&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zPIXvbm8OyOc" title="Measurement input"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRecoveryUponDefaultMember__us-gaap--DebtInstrumentAxis__custom--AGPConvertibleNoteMember_zfYuVgGDKdq6" title="Measurement input"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zz2qzFr4YgDj" title="Measurement input"&gt;108.7&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zD7lCIloP8Fd" title="Measurement input"&gt;101.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-25_us-gaap_MeasurementInputSharePriceMember_custom_AGPConvertibleNoteMember"
      decimals="INF"
      id="Fact000990"
      unitRef="Pure">9.10</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_AGPConvertibleNoteMember"
      decimals="INF"
      id="Fact000992"
      unitRef="Pure">6.90</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-11-252024-11-25_us-gaap_MeasurementInputExpectedTermMember_custom_AGPConvertibleNoteMember"
      id="Fact000994">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_AGPConvertibleNoteMember"
      id="Fact000996">P0Y10M24D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-25_custom_CorporateBondYieldEstimatedTimingOfConversionMember_custom_AGPConvertibleNoteMember"
      decimals="INF"
      id="Fact000997"
      unitRef="Pure">8.8</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_custom_CorporateBondYieldEstimatedTimingOfConversionMember_custom_AGPConvertibleNoteMember"
      decimals="INF"
      id="Fact000998"
      unitRef="Pure">9.0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-25_us-gaap_MeasurementInputCreditSpreadMember_custom_AGPConvertibleNoteMember"
      decimals="INF"
      id="Fact000999"
      unitRef="Pure">26.2</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputCreditSpreadMember_custom_AGPConvertibleNoteMember"
      decimals="INF"
      id="Fact001000"
      unitRef="Pure">26.2</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-25_custom_MeasurementInputProbabilityOfDefaultMember_custom_AGPConvertibleNoteMember"
      decimals="INF"
      id="Fact001001"
      unitRef="Pure">40</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_custom_MeasurementInputProbabilityOfDefaultMember_custom_AGPConvertibleNoteMember"
      decimals="INF"
      id="Fact001002"
      unitRef="Pure">40</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-25_custom_MeasurementInputRecoveryUponDefaultMember_custom_AGPConvertibleNoteMember"
      decimals="INF"
      id="Fact001004"
      unitRef="Pure">0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_custom_MeasurementInputRecoveryUponDefaultMember_custom_AGPConvertibleNoteMember"
      decimals="INF"
      id="Fact001006"
      unitRef="Pure">0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-25_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001008"
      unitRef="Pure">108.7</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001010"
      unitRef="Pure">101.6</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-11"
      decimals="INF"
      id="Fact001012"
      unitRef="USDPShares">8.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-12-112024-12-11_custom_PIPEWarrantsMember"
      decimals="-3"
      id="Fact001014"
      unitRef="USD">12000</us-gaap:FairValueAdjustmentOfWarrants>
    <CDT:WarrantsExcercise
      contextRef="AsOf2024-12-31_custom_PIPEWarrantsMember"
      decimals="-3"
      id="Fact001016"
      unitRef="USD">1000</CDT:WarrantsExcercise>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member"
      id="Fact001018">&lt;p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zrlqaJL1wSv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
measurement of the A.G.P. 2024 Warrants is classified as Level 3 due to the use of an option-pricing model that utilizes unobservable inputs and requires significant judgement. The Company estimated
the fair value of the warrants issued as the issuance date, October 29, 2024, and as of December 31, 2024, using a Black-Scholes
option-pricing model utilizing the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_z29Sb08l0Ne8" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Fair Value  of Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;October 29, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Closing stock price&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 16%"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zL0MGY7X4re1" title="Measurement input"&gt;10.48&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIu51AZP2dIe" title="Measurement input"&gt;6.90&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Contractual exercise price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCikayCpEta7" title="Measurement input"&gt;10&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYgt4d7PslL" title="Measurement input"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zK4NQDMEYmGc" title="Measurement input"&gt;4.11&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zER6wFIDSePb" title="Measurement input"&gt;4.38&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Estimated volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaNjNJ2d2Opk" title="Measurement input"&gt;98.4&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7GMCDnDHHd9" title="Measurement input"&gt;98.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Time period to expiration (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentTerm_dtY_c20241029__20241029__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFkT9SINyWc" title="Measurement input"&gt;5.2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjfcPSu19W48" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Measurement input"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-10-29_us-gaap_MeasurementInputSharePriceMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact001020"
      unitRef="Pure">10.48</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact001022"
      unitRef="Pure">6.90</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-10-29_us-gaap_MeasurementInputExercisePriceMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact001024"
      unitRef="Pure">10</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExercisePriceMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact001026"
      unitRef="Pure">10.00</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-10-29_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact001028"
      unitRef="Pure">4.11</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact001030"
      unitRef="Pure">4.38</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-10-29_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact001032"
      unitRef="Pure">98.4</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact001034"
      unitRef="Pure">98.6</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-10-292024-10-29_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member"
      id="Fact001036">P5Y2M12D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member"
      id="Fact001038">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001040">&lt;p id="xdx_80D_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_zYsJbxvyAxR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;span id="xdx_82C_zEKMPzE0lnz6"&gt;Balance Sheet Details &#x2013; Current Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_z8g51x79iSz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
assets consisted of the following as of December 31, 2024 and December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_z49AnDy71Qgh" style="display: none"&gt;Schedule
of Balance Sheet Details&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zzu6ecM4gGE" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_z6Ucz8rrw931" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzWXV_zvJ2rACh1pFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid directors&#x2019; and officers&#x2019; insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,187&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,365&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maPEAOAzWXV_zVKTyQP1yqFj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maPEAOAzWXV_zHxa6sYCZ0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses &#x2013; related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1051"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherReceivablesNetCurrent_iI_pn3n3_maPEAOAzWXV_zmYxqf7s0nb6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;489&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1054"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzWXV_ziXxF2umDgdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,505&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zh2SMobu80wc" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001042">&lt;p id="xdx_894_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_z8g51x79iSz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
assets consisted of the following as of December 31, 2024 and December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_z49AnDy71Qgh" style="display: none"&gt;Schedule
of Balance Sheet Details&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zzu6ecM4gGE" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_z6Ucz8rrw931" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzWXV_zvJ2rACh1pFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid directors&#x2019; and officers&#x2019; insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,187&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,365&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maPEAOAzWXV_zVKTyQP1yqFj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maPEAOAzWXV_zHxa6sYCZ0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses &#x2013; related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1051"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherReceivablesNetCurrent_iI_pn3n3_maPEAOAzWXV_zmYxqf7s0nb6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;489&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1054"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzWXV_ziXxF2umDgdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,505&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001044"
      unitRef="USD">1187000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001045"
      unitRef="USD">1365000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact001047"
      unitRef="USD">85000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact001048"
      unitRef="USD">140000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001050"
      unitRef="USD">400000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001053"
      unitRef="USD">489000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001056"
      unitRef="USD">2161000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001057"
      unitRef="USD">1505000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001059">&lt;p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_zbjJT32UVxM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
&lt;span id="xdx_829_zyVSz3lelv5l"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, we entered into an operating lease for laboratory space. The remaining lease terms for our operating
lease is approximately two years and does not provide a renewal option. We apply the short-term lease policy election, which allows us
to exclude from recognition leases with an original term of 12 months or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
commencement of the laboratory lease on March 7, 2024, the Company recorded a right-of-use asset of $&lt;span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn5n6_c20240307_z7y5MuTyDiD9" title="Right of use asset"&gt;0.4&lt;/span&gt; million, short-term lease liability
of $&lt;span id="xdx_900_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn5n6_c20240307_zZfG7804jXD1" title="Short term lease liability"&gt;0.2&lt;/span&gt; million, and long-term lease liability of $&lt;span id="xdx_90C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn5n6_c20240307_zjsPBCgW0Rbk" title="Short term lease liability"&gt;0.2&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
costs associated the Company&#x2019;s operating and short-term leases are recorded within general and administrative expense in the consolidated
statement of operations and comprehensive income (loss). The following table sets forth information about our lease costs for the year
ended December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_ztFEfP5fALic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;span id="xdx_8B0_zH483udmyJXh" style="display: none"&gt;Schedule
of Lease Cost&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Lease Cost&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zLwTLQhOvST4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseCost_pn3n3_maLCzbUU_zbnjE8urBSP3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzbUU_zjRy0JmvT1mf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Short-term lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--VariableLeaseCost_pn3n3_maLCzbUU_zcVbGeQ6OUOh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Variable lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LeaseCost_iT_pn3n3_mtLCzbUU_z9QQSkoMn9wc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;259&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_z1oDpuusiI63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--LesseeOperatingLeaseLiabilityTableTextBlock_zrEGc5eOYk62" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth information about our operating lease for the year ended December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;span id="xdx_8BE_zMSqtLCKem1g" style="display: none"&gt;Schedule
of Operating Lease Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Supplemental cash flow and other information&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231_z9kLoVIN0577" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeasePayments_pn3n3_zXsxgxfBRaC" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;143&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zcppdSH0PxU" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;ROU assets obtained in the exchange for lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;352&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zv6l9UDkzsb2" title="Weighted-average remaining lease term (in years)"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zs39Vo5dcmu2" title="Weighted-average discount rate"&gt;11.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zy45fqanh866" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zZKj1736oPGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s future minimum lease payments for our operating lease as of the year ended December 31, 2024, are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;span id="xdx_8BC_zfNkFLRq0Y0i" style="display: none"&gt;Schedule
of Future Minimum Lease Payments For Operating Lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231_zLfU9sYmzFl6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;Year ending December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz2P5_zUZJ8YG7x6ck" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz2P5_zjA7uzVRRFwb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;113&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz2P5_zaEqk5RbT9gj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;253&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z70CJ5JAsMSf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(27&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zgV8WrDqUxJ5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;226&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zDfohRnlO9ek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-03-07"
      decimals="-5"
      id="Fact001061"
      unitRef="USD">400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-03-07"
      decimals="-5"
      id="Fact001063"
      unitRef="USD">200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-03-07"
      decimals="-5"
      id="Fact001065"
      unitRef="USD">200000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001067">&lt;p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_ztFEfP5fALic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;span id="xdx_8B0_zH483udmyJXh" style="display: none"&gt;Schedule
of Lease Cost&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Lease Cost&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zLwTLQhOvST4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseCost_pn3n3_maLCzbUU_zbnjE8urBSP3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzbUU_zjRy0JmvT1mf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Short-term lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--VariableLeaseCost_pn3n3_maLCzbUU_zcVbGeQ6OUOh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Variable lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LeaseCost_iT_pn3n3_mtLCzbUU_z9QQSkoMn9wc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;259&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001069"
      unitRef="USD">116000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001071"
      unitRef="USD">128000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001073"
      unitRef="USD">15000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001075"
      unitRef="USD">259000</us-gaap:LeaseCost>
    <CDT:LesseeOperatingLeaseLiabilityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001077">&lt;p id="xdx_898_ecustom--LesseeOperatingLeaseLiabilityTableTextBlock_zrEGc5eOYk62" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth information about our operating lease for the year ended December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;span id="xdx_8BE_zMSqtLCKem1g" style="display: none"&gt;Schedule
of Operating Lease Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Supplemental cash flow and other information&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231_z9kLoVIN0577" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeasePayments_pn3n3_zXsxgxfBRaC" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;143&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zcppdSH0PxU" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;ROU assets obtained in the exchange for lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;352&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zv6l9UDkzsb2" title="Weighted-average remaining lease term (in years)"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zs39Vo5dcmu2" title="Weighted-average discount rate"&gt;11.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CDT:LesseeOperatingLeaseLiabilityTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001079"
      unitRef="USD">143000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001081"
      unitRef="USD">352000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact001083">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001085"
      unitRef="Pure">0.112</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001087">&lt;p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zZKj1736oPGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s future minimum lease payments for our operating lease as of the year ended December 31, 2024, are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;span id="xdx_8BC_zfNkFLRq0Y0i" style="display: none"&gt;Schedule
of Future Minimum Lease Payments For Operating Lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231_zLfU9sYmzFl6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;Year ending December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz2P5_zUZJ8YG7x6ck" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz2P5_zjA7uzVRRFwb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;113&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz2P5_zaEqk5RbT9gj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;253&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z70CJ5JAsMSf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(27&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zgV8WrDqUxJ5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;226&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001089"
      unitRef="USD">140000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001091"
      unitRef="USD">113000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001093"
      unitRef="USD">253000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001095"
      unitRef="USD">27000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001097"
      unitRef="USD">226000</us-gaap:OperatingLeaseLiability>
    <CDT:LiabilityRelatedToTheSaleOfFutureRevenueTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001099">&lt;p id="xdx_80B_ecustom--LiabilityRelatedToTheSaleOfFutureRevenueTextBlock_zSo4gYSMpXzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
&lt;span id="xdx_82B_zvBa60A7Tgic"&gt;Liability Related to the Sale of Future Revenue&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Vela
Technologies PLC&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an Agreement with SGSC to approve an Indirect Investment from Vela Technologies PLC (&#x201c;Vela&#x201d;) on October
20, 2020, whereby Vela agreed to provide funding to the Company for an indirect investment in AZD 1656 for use in the field in exchange
for &lt;span id="xdx_90E_ecustom--PercentageOfFutureRevenueEarned_dp_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_z4Mg115RLVF8" title="Percentage of future revenue earned"&gt;8&lt;/span&gt;% of future revenue earned if AZD 1656 is commercialized (the &#x201c;Vela Agreement&#x201d;). Total consideration under the Vela
Agreement was $&lt;span id="xdx_906_eus-gaap--AssetAcquisitionConsiderationTransferred_pn5n6_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zPIu4nuj8hR4"&gt;2.9&lt;/span&gt; million (&#xa3;&lt;span id="xdx_903_eus-gaap--AssetAcquisitionConsiderationTransferred_pn4n6_uGBP_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zkMX9NWBC1Ik"&gt;2.35&lt;/span&gt; million), consisting of $&lt;span id="xdx_903_eus-gaap--PaymentsToAcquireProductiveAssets_pn5n6_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_ztV5k1WsjBuf"&gt;1.6&lt;/span&gt; million (&#xa3;&lt;span id="xdx_906_eus-gaap--PaymentsToAcquireProductiveAssets_pn4n6_uGBP_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zte4CvUUmz41"&gt;1.25&lt;/span&gt; million) cash and the issuance of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn8n9_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zjdu2zS7lsqd" title="Number of shares, issuance"&gt;1.1&lt;/span&gt; billion
common shares in Vela, which based on the Vela&#x2019;s fair value per share and was $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20201020__20201020__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_ztSPx52mHzl4" title="Number of shares issuance, value"&gt;1.3&lt;/span&gt; million. During the year ended December 31,
2021, the Company sold all &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn8n9_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zkny5zvtDFHb" title="Number of shares, issuance"&gt;1.1&lt;/span&gt; billion of its Vela shares for $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zCLuHH80Xsa4" title="Number of shares issuance, value"&gt;1.2&lt;/span&gt; million and recorded a loss of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember_zX5dF9mWOy2c" title="Loss"&gt;0.1&lt;/span&gt; million on the sale. The Company
received the $&lt;span id="xdx_902_eus-gaap--PaymentsToAcquireProductiveAssets_pn5n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember__us-gaap--AssetAcquisitionAxis__custom--VelaTechnologiesPLCMember_zpDydQmJy4fi"&gt;1.6&lt;/span&gt; million (&#xa3;&lt;span id="xdx_90A_eus-gaap--PaymentsToAcquireProductiveAssets_pn4n6_uGBP_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--VelaAgreementMember__us-gaap--AssetAcquisitionAxis__custom--VelaTechnologiesPLCMember_zTvkeF5odv23"&gt;1.25&lt;/span&gt;) million cash consideration during the year ended December 31, 2020. This consideration was recorded
as a liability related to the future sale of revenue on the balance sheet in accordance with ASC 470-10.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2023, the Company entered into an agreement with Vela which granted Vela the right, but not the obligation, to sell its &lt;span id="xdx_901_ecustom--RoyaltyPercentage_dp_c20230401__20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember_zboLKPS4VNth" title="Royalty percentage"&gt;8&lt;/span&gt;% royalty
interest in AZD 1656 back to Conduit. Vela paid a one-time, non-refundable option fee to Conduit of $&lt;span id="xdx_902_ecustom--NonRefundableOptionFee_pn5n6_c20230401__20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember_zNsdqpEqSgs7" title="Non refundable option fee"&gt;0.5&lt;/span&gt; million (&#xa3;&lt;span id="xdx_90D_ecustom--NonRefundableOptionFee_pn5n6_uGBP_c20230401__20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember_zoorhKrkBxZe"&gt;0.4&lt;/span&gt; million).
Total consideration payable to Vela upon exercise of the option was &#xa3;&lt;span id="xdx_908_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn5n6_uGBP_c20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWUyWOyjgOm1" title="Total consideration payable"&gt;4.0&lt;/span&gt; million ($&lt;span id="xdx_905_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn4n6_c20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpKKT40JdmVj" title="Total consideration payable"&gt;5.08&lt;/span&gt; million on the exercise date) worth of
new common shares in the combined entity after the Merger between Conduit Pharmaceuticals Limited and MURF, following the consummation
of the Merger, at a price per share equal to the volume-weighted average price per share over the ten (10) business days prior to the
date of the notice of exercise. The option contained a provision stating that in no event would the price per share for the consideration
shares be lower than $&lt;span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember__srt--RangeAxis__srt--MinimumMember_z0QP0MvNRqGa"&gt;5&lt;/span&gt; or higher than $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember__srt--RangeAxis__srt--MaximumMember_z92GQi5UHpa6"&gt;15&lt;/span&gt;. &lt;span id="xdx_905_ecustom--OptionAgreementDescription_c20230401__20230430__us-gaap--TypeOfArrangementAxis__custom--VelaOptionAgreementMember_zRVFHFN3ZwG8" title="Option agreement description"&gt;The option was exercisable in whole at any time from the close of the Merger (the &#x201c;Effective
Time&#x201d;) until the earlier of (i) the date that was six (6) months from the Effective Time, and (ii) February 7, 2024, the expiration
date of the term.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 30, 2023, Vela exercised its option to sell back its indirect investment in AZD 1656 in exchange for &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20231130__20231130__us-gaap--MeasurementInputTypeAxis__custom--VelaOptionLiabilityMember_zPvwWOkdQ0Fl"&gt;10,157&lt;/span&gt; shares of the Common
Stock. The Company recognized the $&lt;span id="xdx_90C_eus-gaap--DeferredRevenue_iI_pn5n6_c20231130__us-gaap--MeasurementInputTypeAxis__custom--VelaOptionLiabilityMember_zg0xzKJuwtde" title="Deferred revenue"&gt;2.8&lt;/span&gt; million of deferred revenue and recorded $&lt;span id="xdx_90F_eus-gaap--OtherNonoperatingIncomeExpense_pn5n6_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__custom--VelaOptionLiabilityMember_z76vsjCrZy57" title="Other income (expense), net"&gt;2.8&lt;/span&gt; million to other income (expense), net, on the consolidated
statement of operations and comprehensive income (loss) for the year ended December 31, 2023. As of December 31, 2023, there was no liability
for the sale of future revenue related to Vela.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cizzle
Biotechnology Holdings PLC&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 11, 2022, the Company entered into an agreement with Cizzle PLC (&#x201c;Cizzle&#x201d;) whereby Cizzle agreed to purchase a percentage
of future revenue earned in AZD 1656, should it reach the commercialization stage. Total consideration under the agreement is specified
as $&lt;span id="xdx_90F_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20220211__20220211__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_ztTHJoNwsxZe"&gt;1.6&lt;/span&gt; million (&#xa3;&lt;span id="xdx_90B_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_uGBP_c20220211__20220211__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zZTUeZakprLi"&gt;1.2&lt;/span&gt; million), consisting of the issuance of the fair value of &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220211__20220211__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zb6PYZDCRkB3"&gt;25.0&lt;/span&gt; million new common shares in Cizzle on the
date of the agreement and the fair value of &lt;span id="xdx_904_eus-gaap--SharesIssued_iI_pn5n6_c20220211__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zTG1CHNu5dw1"&gt;22.0&lt;/span&gt; million shares to be issued at the earlier of Cizzle&#x2019;s shareholder approval or
one year from the date of the agreement. The &lt;span id="xdx_90C_eus-gaap--SharesIssued_iI_pn5n6_c20221231__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zaPuj0oNCgF5"&gt;22.0&lt;/span&gt; million shares were received by the Company in the fourth quarter of 2022 and were
subsequently sold within the fourth quarter of 2022. The Company recorded a liability related to deferred revenue of $&lt;span id="xdx_90F_eus-gaap--DeferredRevenue_iI_pn5n6_c20221231__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zHlMqOmSzKC3"&gt;1.4&lt;/span&gt; million for
the consideration received from Cizzle as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
payments received for the sale of future revenue were classified as a liability related to the future sale of revenue. Under ASC 470-10-25,
a seller of future revenue should evaluate whether the proceeds received should be accounted for as debt or deferred income. In assessing
the factors that created a rebuttable presumption of debt within the guidance, the Company determined that there were factors present
to overcome the debt presumption and deferred income classification to be appropriate. The main factors the Company considered were that
the transactions in form were sales, and not debt transactions. Each agreement does not guarantee a return to each purchaser, the return
is based solely on future performance of AZD 1656 should it reach commercialization, with neither purchaser having an involvement in
generating future cash flows from AZD 1656.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 15, 2022, the Company entered into an agreement with Cizzle whereby the Company granted Cizzle the option, but not the obligation,
to sell its economic interest in AZD 1656 back to the Company. The agreement contained an option period of nine months from the date
of the agreement for Cizzle to notify the Company of its intent to exercise the option to sell its economic interest in AZD 1656. Upon
closing of the agreement, Cizzle agreed to pay the Company an option fee of $&lt;span id="xdx_90A_ecustom--OptionFee_iI_pn5n6_c20221215__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zDoaiIwdCBO" title="Option fee"&gt;0.1&lt;/span&gt; million (&#xa3;&lt;span id="xdx_90C_ecustom--OptionFee_iI_pn5n6_uGBP_c20221215__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_za2yRUuswu7c"&gt;0.1&lt;/span&gt; million).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 26, 2023, Cizzle exercised its option to sell back its indirect investment in AZD 1656 in exchange for &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pid_c20230926__20230926__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztpradnkmBO1"&gt;3,954
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Common Stock. The Company recognized
the $&lt;span id="xdx_903_eus-gaap--DeferredRevenue_iI_pn5n6_c20231231__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zXVkhfhbOH9f"&gt;1.5
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million of deferred revenue and recorded $&lt;span id="xdx_90F_eus-gaap--OtherOperatingIncomeExpenseNet_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--CizzlePlcAgreementMember_zFziWPv6Re9g"&gt;1.5
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million to other income (expense), net, on the
consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2023. As of December 31, 2023,
there was no liability for the sale of future revenue related to Cizzle.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CDT:LiabilityRelatedToTheSaleOfFutureRevenueTextBlock>
    <CDT:PercentageOfFutureRevenueEarned
      contextRef="From2020-10-202020-10-20_custom_VelaAgreementMember"
      decimals="INF"
      id="Fact001101"
      unitRef="Pure">0.08</CDT:PercentageOfFutureRevenueEarned>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="From2020-10-202020-10-20_custom_VelaAgreementMember"
      decimals="-5"
      id="Fact001102"
      unitRef="USD">2900000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="From2020-10-202020-10-20_custom_VelaAgreementMember"
      decimals="-4"
      id="Fact001103"
      unitRef="GBP">2350000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2020-10-202020-10-20_custom_VelaAgreementMember"
      decimals="-5"
      id="Fact001104"
      unitRef="USD">1600000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2020-10-202020-10-20_custom_VelaAgreementMember"
      decimals="-4"
      id="Fact001105"
      unitRef="GBP">1250000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-10-202020-10-20_custom_VelaAgreementMember"
      decimals="-8"
      id="Fact001107"
      unitRef="Shares">1100000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-202020-10-20_custom_VelaAgreementMember"
      decimals="-5"
      id="Fact001109"
      unitRef="USD">1300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_VelaAgreementMember"
      decimals="-8"
      id="Fact001111"
      unitRef="Shares">1100000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_custom_VelaAgreementMember"
      decimals="-5"
      id="Fact001113"
      unitRef="USD">1200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-012021-12-31_custom_VelaAgreementMember"
      decimals="-5"
      id="Fact001115"
      unitRef="USD">100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2020-01-012020-12-31_custom_VelaAgreementMember_custom_VelaTechnologiesPLCMember"
      decimals="-5"
      id="Fact001116"
      unitRef="USD">1600000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2020-01-012020-12-31_custom_VelaAgreementMember_custom_VelaTechnologiesPLCMember"
      decimals="-4"
      id="Fact001117"
      unitRef="GBP">1250000</us-gaap:PaymentsToAcquireProductiveAssets>
    <CDT:RoyaltyPercentage
      contextRef="From2023-04-012023-04-30_custom_VelaOptionAgreementMember"
      decimals="INF"
      id="Fact001119"
      unitRef="Pure">0.08</CDT:RoyaltyPercentage>
    <CDT:NonRefundableOptionFee
      contextRef="From2023-04-012023-04-30_custom_VelaOptionAgreementMember"
      decimals="-5"
      id="Fact001121"
      unitRef="USD">500000</CDT:NonRefundableOptionFee>
    <CDT:NonRefundableOptionFee
      contextRef="From2023-04-012023-04-30_custom_VelaOptionAgreementMember"
      decimals="-5"
      id="Fact001122"
      unitRef="GBP">400000</CDT:NonRefundableOptionFee>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-04-30_custom_VelaOptionAgreementMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001124"
      unitRef="GBP">4000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-04-30_custom_VelaOptionAgreementMember_us-gaap_CommonStockMember"
      decimals="-4"
      id="Fact001126"
      unitRef="USD">5080000.00</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-04-30_custom_VelaOptionAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001127"
      unitRef="USDPShares">5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-04-30_custom_VelaOptionAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001128"
      unitRef="USDPShares">15</us-gaap:SaleOfStockPricePerShare>
    <CDT:OptionAgreementDescription
      contextRef="From2023-04-012023-04-30_custom_VelaOptionAgreementMember"
      id="Fact001130">The option was exercisable in whole at any time from the close of the Merger (the &#x201c;Effective
Time&#x201d;) until the earlier of (i) the date that was six (6) months from the Effective Time, and (ii) February 7, 2024, the expiration
date of the term.</CDT:OptionAgreementDescription>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-11-302023-11-30_custom_VelaOptionLiabilityMember"
      decimals="INF"
      id="Fact001131"
      unitRef="Shares">10157</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2023-11-30_custom_VelaOptionLiabilityMember"
      decimals="-5"
      id="Fact001133"
      unitRef="USD">2800000</us-gaap:DeferredRevenue>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31_custom_VelaOptionLiabilityMember"
      decimals="-5"
      id="Fact001135"
      unitRef="USD">2800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2022-02-112022-02-11_custom_CizzlePlcAgreementMember"
      decimals="-5"
      id="Fact001136"
      unitRef="USD">1600000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2022-02-112022-02-11_custom_CizzlePlcAgreementMember"
      decimals="-5"
      id="Fact001137"
      unitRef="GBP">1200000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-02-112022-02-11_custom_CizzlePlcAgreementMember"
      decimals="INF"
      id="Fact001138"
      unitRef="Shares">25.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-02-11_custom_CizzlePlcAgreementMember"
      decimals="-5"
      id="Fact001139"
      unitRef="Shares">22000000.0</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-12-31_custom_CizzlePlcAgreementMember"
      decimals="-5"
      id="Fact001140"
      unitRef="Shares">22000000.0</us-gaap:SharesIssued>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2022-12-31_custom_CizzlePlcAgreementMember"
      decimals="-5"
      id="Fact001141"
      unitRef="USD">1400000</us-gaap:DeferredRevenue>
    <CDT:OptionFee
      contextRef="AsOf2022-12-15_custom_CizzlePlcAgreementMember"
      decimals="-5"
      id="Fact001143"
      unitRef="USD">100000</CDT:OptionFee>
    <CDT:OptionFee
      contextRef="AsOf2022-12-15_custom_CizzlePlcAgreementMember"
      decimals="-5"
      id="Fact001144"
      unitRef="GBP">100000</CDT:OptionFee>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2023-09-262023-09-26_custom_CizzlePlcAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001145"
      unitRef="Shares">3954</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2023-12-31_custom_CizzlePlcAgreementMember"
      decimals="-5"
      id="Fact001146"
      unitRef="USD">1500000</us-gaap:DeferredRevenue>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2023-01-012023-12-31_custom_CizzlePlcAgreementMember"
      decimals="-5"
      id="Fact001147"
      unitRef="USD">1500000</us-gaap:OtherOperatingIncomeExpenseNet>
    <CDT:ConvertibleNotesPayableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001149">&lt;p id="xdx_809_ecustom--ConvertibleNotesPayableTextBlock_zlot8IxaK9O8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
&lt;span id="xdx_82C_zMkPmw4V5gz8"&gt;Convertible Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Convertible
Promissory Notes Payable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
March 2023, the Company issued a convertible promissory note payable (the &#x201c;Convertible Promissory Notes Payable&#x201d;) with an
aggregate principal amount of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zSt33ZPaLgC6"&gt;0.8
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million to a non-related third party. &lt;span id="xdx_900_eus-gaap--DebtInstrumentMaturityDateDescription_c20230301__20230331__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zteyJ4NdrUT2"&gt;The
Convertible Promissory Note Payable had a maturity date of 18 months from the date of issuance.&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
note carries interest at a rate of &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_z4bB1vxqxWS1"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
annually, which is payable every six (6) months from the date of the note until the maturity date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 9, 2024, the Company and the loan holder signed an extension to extend the maturity date from September 20, 2024 to October
20, 2024 with the option for the Company to further extend the maturity date two times, each by an additional 30-day period. The
Company exercised both options to extend the maturity date to December 19, 2024 which included interest previously payable as well as the principal. As consideration for extending the maturity date,
the Company amended the form of repayment of the remaining interest due on the loan. As payment for the interest, the Company issued
the loan holder, (i) $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241009__20241009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJLbnt57xAil" title="Issuance of shares, value"&gt;80,000&lt;/span&gt;&#160;worth
of Common Stock to be issued at the closing market price on the date prior to issuance and (ii)&#160;&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241009__20241009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z95rpcx4AkH3" title="Iissuance of loan shares"&gt;20,000&lt;/span&gt;&#160;shares
of Common Stock. On October 11, 2024, the Company issued the loan holder&#160;&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241011__20241011__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT3s4zQhlqb9" title="Issuance of shares"&gt;27,812&lt;/span&gt;&#160;shares
of Common Stock in satisfaction of the obligations in (i) and (ii) in the preceding sentence.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
extension met the criteria for as a debt extinguishment under ASC 470-50. As of October 9, 2024, the Company recorded a gain on debt extinguishment
of $&lt;span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20241009__20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember_zIbN1jvX9LD5" title="Gain on debt extinguishment"&gt;0.1&lt;/span&gt;
million, calculated as the difference between (i) the $&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmFpPpxrJ4Wc" title="Convertible promissory notes payable"&gt;0.8 &lt;/span&gt;million
carrying value of the Convertible Promissory Note Payable immediately prior to the amendment (ii) the $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zofRopCmLZXi" title=" Fair value convertible promissory notes payable"&gt;0.4&lt;/span&gt;
million fair value of the Convertible Promissory Note Payable immediately after the amendment and (iii) the $&lt;span id="xdx_90D_eus-gaap--StockIssued1_pn5n6_c20241009__20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFn0zJY3JUHa" title="Stock issued"&gt;0.3&lt;/span&gt;
million fair value of the shares issued to the holder as consideration for extending the maturity date. The difference between the
$&lt;span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqxlqRj8N0F4" title="Carrying value"&gt;0.8 &lt;/span&gt;million
carrying value immediately prior to the amendment and the $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241009__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotePayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7D6uvshsWY9" title="Stock issued"&gt;0.4&lt;/span&gt;
million fair value immediately after the amendment was recorded as a debt discount and amortized over the amended maturity date of
the Convertible Promissory Note using the effective interest method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the extension of the loan, the Company entered into a consulting agreement with an unrelated third party to negotiate
the extension of the of the convertible note with the loan holder on behalf of the Company. The Company issued the third-party&#160;&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241011__20241011__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zHOOv6aVMCIc" title="Issuance of shares"&gt;8,500&lt;/span&gt;&#160;shares
on October 11, 2024, in exchange for services provided. The fair value of the shares were $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20241010__20241010__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zZfyFIvPavT6" title="Fair value of shares"&gt;0.1&lt;/span&gt; million, as determined
by multiplying the closing share price on October 10, 2024 (day prior to issuance) of $&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20241010__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_znTcvRKg1Io1" title="Issuance of shares"&gt;10.24&lt;/span&gt; by the total number of shares issued, &lt;span id="xdx_900_eus-gaap--SharesIssued_iI_pid_c20241010__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z9uR7IPV2N22" title="Shares issued"&gt;8,500&lt;/span&gt;.
This amount was capitalized as a debt issuance cost and accreted over the amended term of the Convertible Promissory Notes Payable
using the effective interest method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2024, and December 31, 2023, the Company incurred interest expense on the Convertible Promissory Note
Payable of $&lt;span id="xdx_902_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zywh8nK8E95" title="Interest expense"&gt;0.5&lt;/span&gt;
million and $&lt;span id="xdx_909_eus-gaap--InterestExpenseDebt_pn5n6_c20230101__20231231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zTNr3EzMtwA9" title="Interest expense"&gt;0.1&lt;/span&gt;
million, respectively. The promissory note payable remained outstanding as of December 31, 2024, therefore the Company was
considered to be in default. On March 6, 2025, the Company reached an agreement with the loan holder to pay $&lt;span id="xdx_906_eus-gaap--RepaymentsOfConvertibleDebt_pn5n6_c20250306__20250306__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztEPp1HVmk71" title="Settlement of debt"&gt;0.7&lt;/span&gt;
million in order to settle the March 2023 Convertible Note in full. The Company repaid the loan holder the settlement amount $&lt;span id="xdx_908_eus-gaap--RepaymentsOfConvertibleDebt_pn5n6_c20250313__20250313__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXIbN89pBUW6" title="Settlement of debt"&gt;0.7&lt;/span&gt;
million on March 13, 2025. See Note 20 for additional details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;August
2024 Nirland Note&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 6, 2024, the Company entered into a Senior Secured Promissory Note (the &#x201c;August 2024 Nirland Note&#x201d;) with Nirland,
a related party of the Company, pursuant to which the Company issued and sold to Nirland the August 2024 Note in the original principal
amount of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_z4aywVAoRh0c" title="Original principal amount"&gt;2.7&lt;/span&gt; million, inclusive of a $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zn5ojNRRbKbg" title="Original issue discount"&gt;0.5&lt;/span&gt; million&#160;original issuance discount. See Note 16 for further reference to the relationship
between the Company and Nirland. Of the total amount of the August 2024 Nirland Note, $&lt;span id="xdx_90F_ecustom--DebtIssuedUponExecution_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zcfdqWwJPU1c" title="Debt issued upon execution"&gt;1.7&lt;/span&gt; million&#160;was issued upon execution of
the August 2024 Nirland Note. In connection with the August 2024 Nirland Note, the Company issued to Nirland&#160;&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240806__20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_ze2WEpY7UvU6" title="Issuance of shares"&gt;125,000&lt;/span&gt;&#160;shares
of the Company&#x2019;s Common Stock on August 6, 2024. The balance of $&lt;span id="xdx_906_ecustom--PaymentOfCommonStock_pn5n6_c20240806__20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zRTY4impwJIc" title="Payment to common stock"&gt;0.5&lt;/span&gt; million&#160;became payable to the Company when the shares
were registered for resale in September 2024. In the event the Company completes any public or private equity or debt financing, the
Company shall be required to mandatorily prepay (&#x201c;Mandatory Prepayment Right&#x201d;), any amounts that may be then outstanding
under the August 2024 Nirland Note, within two business days following the closing of such financing, in an amount of no less than&#160;&lt;span id="xdx_901_ecustom--NetProceedsReceivedPercentage_iI_pid_dp_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zYZi96ueMzx9" title="Net proceeds received, percentage"&gt;75&lt;/span&gt;%
of the net proceeds received. Per the terms of the August 2024 Nirland Note, the Company is prohibited from entering into a variable
rate transaction without prior written consent from Nirland. The August 2024 Nirland Note bears interest at a rate of&#160;&lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zYMZ9grX2c6l" title="Debt interest rate"&gt;12&lt;/span&gt;% per annum,
accruing daily on a 365-day basis, payable monthly in arrears as cash, or accrued at Nirland&#x2019;s discretion.&#160;&lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateDescription_c20240806__20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zVloMYCgi4b8" title="Debt instrument maturity description"&gt;The August 2024
Nirland Note matures 12 months from August 6, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As noted above, the Company issued to Nirland&#160;&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240806__20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_zpWUbnDVvPdc"&gt;125,000&lt;/span&gt;&#160;shares
of the Company&#x2019;s Common Stock on August 6, 2024. The Company determined that loan agreement and share issuance should were part
of a basket transaction and allocated the net proceeds on a relative fair value basis. Of the total $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_zchcntSfVCla" title="Net proceeds"&gt;2.2&lt;/span&gt;&#160;net proceeds, $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFeeAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_z2mTZbn4AQpj" title="Debt instrument allocated"&gt;1.2&lt;/span&gt;&#160;million
was allocated to the August 2024 Nirland Note including $&lt;span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_z5UguVrOwkY1" title="Gross proceeds"&gt;1.5&lt;/span&gt;&#160;million gross proceeds, less $&lt;span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_zwNy0swKsBs9" title="Original issue discount"&gt;0.3&lt;/span&gt;&#160;million Original Issue Discount
(&#x201c;OID&#x201d;). The remaining $&lt;span id="xdx_90F_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLVaNSqTG902" title="Remaining allocated to common stock"&gt;1.0&lt;/span&gt;&#160;million was allocated to the common stock, including $&lt;span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFtYXaezSCsg" title="Gross proceeds"&gt;1.2&lt;/span&gt;&#160;million gross proceeds less
$&lt;span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5XBaVbuWEp1" title="Debt instrument, orginal issue discount"&gt;0.2&lt;/span&gt;&#160;OID. The $&lt;span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9Vd3RGXSuRl"&gt;1.2&lt;/span&gt;&#160;million allocated to the common stock was considered to be a discount on the August 2024 Nirland Note making
the balance of the note to be $&lt;span id="xdx_90E_eus-gaap--NotesPayable_iI_pn5n6_c20240806__us-gaap--ShortTermDebtTypeAxis__custom--SeniorSecuredPromissoryNoteMember_zkjH9shq4TCb" title="Notes payable"&gt;2.7&lt;/span&gt;&#160;million note payable, less a total debt discount of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806_zB96tVDytGSf" title="Total debt discount"&gt;1.5&lt;/span&gt;&#160;million. The debt discount will
be amortized to interest expense using the effective interest method over the life of the note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 31, 2024, the Company and Nirland amended the August 2024 Nirland Note (the &#x201c;First Amendment&#x201d;), whereby the August
2024 Nirland Note was amended to (i) provides for the conversion of the August 2024 Nirland Note into shares of Common Stock, at Nirland&#x2019;s
discretion, in a multiple of any unpaid amounts, if not otherwise previously paid, pursuant to the conversion rate contained therein,
(ii) removes Nirland&#x2019;s Mandatory Prepayment Right, and (iii) removes Nirland&#x2019;s right of first refusal to participate in any
future equity or debt offerings of the Company. The number of shares of Common Stock issuable upon conversion of any Conversion Amount
pursuant to&#160;shall be determined by dividing (x) such conversion amount by (y) the conversion price. Conversion amount means two
and one quarter times the sum of (x) portion of the principal to be converted, redeemed or otherwise with respect to which this determination
is being made and (y) all accrued and unpaid interest with respect to such portion of the principal amount, if any. Conversion price
means, as of any conversion date or other date of determination, $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241031__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentNirlandNoteMember_zDeCD5m9M4U6" title="Conversion price per share"&gt;10.00&lt;/span&gt;, subject to adjustment as provided within the amended agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
evaluated the conversion feature of this note offering for embedded derivatives in accordance with&#160;ASC 815,&#160;&lt;i&gt;Derivatives
and Hedging&lt;/i&gt;, and the&#160;substantial premium model&#160;in accordance with&#160;ASC 470,&#160;&lt;i&gt;Debt&lt;/i&gt;. Based on our assessment,
separate accounting for the conversion feature of this note offering is not required and will be accounted for under the substantial
premium model. Under the substantial premium model, the excess above the fair value of the August 2024 Nirland Note will be recorded
in additional paid-in-capital. The August 2024 Nirland Note will be carried at amortized cost using the effective interest method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined the fair value of the August 2024 Nirland Note to be $&lt;span id="xdx_90A_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn5n6_c20241031__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zrZWpx4kR3Qe" title="Convertible notes payable"&gt;3.6&lt;/span&gt; million as of October 31, 2024 through the use of a binomial
lattice model. See Note 3 for additional information regarding the fair value measurement of the August 2024 Nirland Note. The Company
accounted for the First Amendment as a debt extinguishment, as the First Amendment added a substantive conversion option. As of October
31, 2024, a loss on debt extinguishment of $&lt;span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20241031__20241031__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zeHigcpOxwx3" title="Gain on debt extinguishment"&gt;2.2&lt;/span&gt; million was recorded consisting of (i) the derecognition of the $&lt;span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241031__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zBu6SkXPjVui" title="Carrying value"&gt;1.3&lt;/span&gt; million carrying
value immediately prior to the First Amendment (ii) recognition of the $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleLiquidationPreferenceValue_iI_pn5n6_c20241031__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zmigBlPDP8xg" title="Par value"&gt;2.7&lt;/span&gt; million par value and (iii) recognition of the $&lt;span id="xdx_905_eus-gaap--ConvertibleDebt_iI_pn5n6_c20241031__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zyi6IJegKsL1" title="Convertible debt"&gt;0.8&lt;/span&gt; million
substantial premium.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 22, 2024, the Company and Nirland entered into a Second Amendment to the August 2024 Nirland Note (the &#x201c;Second
Amendment&#x201d;). Pursuant to the Second Amendment, the Nirland Note may not be converted (other than partial conversions that may
be permitted pursuant to the rules and regulations of NASDAQ (or any successor entity)) prior to receipt of stockholder approval to
provide for such conversion of the Nirland Note, and subsequent issuance of the Company&#x2019;s Common Stock, pursuant to the
stockholder approval rules under the rules and regulations of The Nasdaq Stock Market. If the Company has not held a special meeting
of the stockholders to approve the full conversion of the August 2024 Nirland Note on or before January 9, 2025, then the Company
shall be obligated to pay Nirland a penalty of $&lt;span id="xdx_90C_ecustom--PenaltyPayment_pn5n6_c20241122__20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_zdhMSGQdaJdb" title="Penalty payment"&gt;0.1&lt;/span&gt;
million per day until the special meeting is held. In addition, the existing conversion rate was amended to be two and one half
times the sum of (x) the portion of the principal to be converted, redeemed or otherwise with respect to which this determination is
being made and (y) all accrued and unpaid interest (including default interest) with respect to such portion of the principal
amount, if any divided by $&lt;span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_zgB7uEnKa4J4" title="Conversion price per share"&gt;0.10&lt;/span&gt;, prior to the Reverse Stock Split, (or following any reverse splits that may occur in a ratio greater than 10 to 1, the lower of
such reverse split price and the market price per share at the time of the Conversion Date, but in no event less than $1.00),
subject to adjustment as provided therein and to take into account any future share splits or reverse splits to maintain the
economic equivalence of the conversion rights as at the amendment effective date. The Company notes that the reverse split provision
in the preceding sentence was tripped, effective January 25, 2025, following the &lt;span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20241122__20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_ziFQJkwQFaxd" title="Reverse stock split"&gt;1-for-100&lt;/span&gt;
reverse stock split that occurred on that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of the Second Amendment, the Company elected to account for the August 2024 Nirland Note at fair value under ASC 825. The Company determined that the amendment to the conversion features present in the Second Amendment fall under the
guidance within ASC 825 that notes that if a significant modification of debt occurs an entity is able to make an accounting election
on that date to account for that debt under the fair value option. At the end of each
reporting period, the Company calculates the fair value of the August 2024 Nirland Note, and any changes in fair value are reported in
the current period&#x2019;s consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company remeasured the fair value of the August 2024 Nirland Note as of the Second Amendment date and calculated a fair value of $&lt;span id="xdx_904_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pn5n6_c20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_zhjAG02gNknd" title="Fair value"&gt;4.5&lt;/span&gt;
million using a binomial lattice model. See Note 3 for additional information regarding the fair value measurement of the August 2024
Nirland Note. The Company accounted for the Second Amendment as a debt extinguishment, as the terms of the August 2024 Nirland Note were
deemed to be substantially different after the Second Amendment. As of November 22, 2024, a loss on debt extinguishment of $&lt;span id="xdx_906_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20241122__20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_zNCj0bxYUXA8" title="Loss on debt extinguishment"&gt;0.9&lt;/span&gt; million
was recorded consisting of (i) the derecognition of the &lt;span id="xdx_907_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241122__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentNirlandNoteMember_zbCuY3YFpPYg" title="Carrying value"&gt;2.7&lt;/span&gt; million carrying value immediately prior to the First Amendment (ii) derecognition
of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20241122__20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentNirlandNoteMember_zWAnbk72OOYi" title="Accrued interest"&gt;0.1&lt;/span&gt; million in accrued interest (iii) derecognition of the $&lt;span id="xdx_90A_eus-gaap--ConvertibleDebt_iI_pn5n6_c20241122__us-gaap--DebtInstrumentAxis__custom--SecondAmendmentMember_zpNls8sqTQsd" title="Convertible debt"&gt;0.8&lt;/span&gt; million substantial premium and (iv) recognition of the $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241122__us-gaap--DebtInstrumentAxis__custom--FirstAmendmentMember_zt5Bc81OACHf" title="Debt instrument fair value"&gt;4.4&lt;/span&gt; million
fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 9, 2024, and prior to obtaining shareholder approval, Nirland exercised their conversion option and converted $&lt;span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20241209__20241209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6Ae9LQD4f87" title="Conversion option"&gt;0.1&lt;/span&gt; million of
principal for&lt;span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20241209__20241209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaS6x1SGLbr5" title="Conversion shares"&gt; 23,000&lt;/span&gt; shares of common stock pursuant to the rules and regulations of the NASDAQ. As of December 31, 2024, $&lt;span id="xdx_90A_eus-gaap--InterestPayableCurrent_iI_pn5n6_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFyyYlEIxbej" title="Accrued interest"&gt;2.6&lt;/span&gt; million
of principal and accrued interest remains outstanding. As of December 31, 2024, the August 2024 Nirland Note had a fair value of approximately $&lt;span id="xdx_903_eus-gaap--NotesPayableFairValueDisclosure_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zcGh1zoWf7V8" title="Payable at fair value"&gt;2.8&lt;/span&gt; million and is included
within &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Convertible promissory notes payable at fair value &#x2013;
related parties on the consolidated balance sheets. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2024, the Company recorded a $&lt;span id="xdx_905_eus-gaap--DebtSecuritiesTradingGainLoss_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zWdchzUgyU72" title="Fair value of convertible promissory notes"&gt;1.5&lt;/span&gt;&#160;million
gain from the change in fair value of convertible promissory note and interest expense of approximately $&lt;span id="xdx_901_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zygE3Z8TCqve" title="Interest expense"&gt;0.4&lt;/span&gt;
million. The interest expense of $&lt;span id="xdx_901_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zO3CSBKmcCkd" title="Interest expense"&gt;0.4&lt;/span&gt; million is comprised of (i) accrued interest of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zH3SjwvshHuc" title="Accured interest"&gt;0.2&lt;/span&gt; million and (ii) $&lt;span id="xdx_90D_eus-gaap--AdjustmentForAmortization_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zlheVdlpiZal" title="Amortization expenses"&gt;0.2&lt;/span&gt; million in
amortization expense related to the initial debt discount of $&lt;span id="xdx_902_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember_zzS38OQIM9J3" title="Amortization of debt discount"&gt;1.5&lt;/span&gt; million. The $&lt;span id="xdx_90E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--TypeOfArrangementAxis__custom--FirstAmendmentMember_zXAvcfi2szHe" title="Loss on debt extinguishment"&gt;2.2&lt;/span&gt;
million loss on debt extinguishment from the Frist Amendment, $&lt;span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember__dei--LegalEntityAxis__custom--NirlandLimitedMember__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentMember_zMynDIssUDC" title="Loss on debt extinguishment"&gt;0.9&lt;/span&gt;
million loss on debt extinguishment from the Second Amendment, and the $&lt;span id="xdx_90A_ecustom--GainOnChangeInFairValue_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zSKb0HdeoUhg" title="Gain on change in fair value"&gt;1.5&lt;/span&gt;
million gain on the change in fair value are presented within other income (expense), net, while the $&lt;span id="xdx_90D_eus-gaap--InterestIncomeExpenseNonoperatingNet_pn5n6_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesPayableMember_zoJD0F3dyi17" title="Interest expense net"&gt;0.4&lt;/span&gt;
million of interest expense is presented within Interest expense, net, in the consolidated statement of operations and comprehensive
income (loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;A.G.P.
Convertible Note&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 25, 2024, the Company issued to A.G.P. a convertible promissory note (the &#x201c;A.G.P. Convertible Note&#x201d;) in the principal
amount of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zSuHMwrKtMC9" title="Debt instrument face amount"&gt;5.7&lt;/span&gt; million to evidence the A.G.P.&#x2019;s currently owed deferred commission payable. Refer to the Note 9 for additional
information. Unless earlier converted as specified in the Convertible Note, the principal amount, plus all accrued but unpaid interest,
is due on November 25, 2025 (the &#x201c;Maturity Date&#x201d;). The convertible promissory note accrues interest at &lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_z5JFikkkOLD3" title="Convertible notes interest per annum"&gt;5.5&lt;/span&gt;% per annum.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
any time prior to the full payment of the convertible promissory note, provided that the A.G.P. has given at least three business
days written notice to the Company, A.G.P., in its sole discretion, may elect to have all or any portion of the outstanding
principal amount and all interest accrued converted into shares of the Company&#x2019;s common stock, at a fixed price of $&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_ziG7WomMJ154" title="Fixed price"&gt;10.00&lt;/span&gt;
(or following any reverse splits that may occur in a ratio greater than 10 to 1, the lower of such reverse split price and the
market price per share at the time of the conversion date, but in no event less than $&lt;span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zDy9G8AqD5j7" title="Conversion price"&gt;1.00&lt;/span&gt;),
subject to adjustment as provided therein and to take into account any future share splits or reverse splits. &lt;span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_pid_c20250125__20250125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zO6Iz6UrLM12" title="Reverse stock split, description"&gt;The
Company notes that the reverse split provision in the preceding sentence was tripped, effective January 25, 2025, following the 1-for-100 reverse stock split
that occurred on that date&lt;/span&gt;. However, the conversion of the convertible promissory note may not occur prior to the
Company having sufficiently authorized shares of common stock to permit the entire conversion of the convertible promissory note. In
addition, the conversion of the convertible promissory note may also not occur prior to receipt of stockholder approval to provide
for such conversion of the convertible promissory note, and subsequent issuance of the Company&#x2019;s common stock, pursuant to the
stockholder approval rules under the rules and regulations of The Nasdaq Stock Market. Further, following the A.G.P.&#x2019;s ability
to convert the convertible promissory note, if at all, A.G.P. will not be entitled to receive the Company&#x2019;s common stock upon
conversion, if such conversion would result in A.G.P. owning greater than &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zmTWFk59Tfbl" title="Conversion percentage"&gt;9.99&lt;/span&gt;%
of the Company&#x2019;s then currently outstanding common stock. A.G.P. is also entitled to resale registration rights as identified
in the convertible promissory note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may prepay the convertible promissory note in whole or in part. In the event of certain Events of Default (as defined in the
convertible promissory note), all outstanding principal and accrued interest under the Convertible Note will become, or may become at
A.G.P.&#x2019;s election, immediately due and payable to the A.G.P.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company elected to account for the A.G.P. Convertible Note at fair value under ASC 825. The Company determined that the substantive
conversion option within the A.G.P. Convertible Note falls under the guidance within ASC 825 that notes that if a significant
modification of debt occurs an entity is able to make an accounting election on that date to account for that debt under the fair
value option. At the end of each reporting period, the Company calculates the fair value of the A.G.P. Convertible Note, and any
changes in fair value are reported in the current period&#x2019;s consolidated statements of operations and comprehensive income
(loss). The change in fair value attributable to instrument-specific credit risk, if any, will be recognize within other
comprehensive income each reporting period. As an accounting policy, the Company elected to present interest expense separately from
other changes in the A.G.P. Convertible Note&#x2019;s fair value. Interest expense will be presented within Interest expense, net,
while the other changes in the fair value with be presented within other income (expense), net in the consolidated statements of
operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined the fair value of the A.G.P. Convertible Note to be $&lt;span id="xdx_909_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pn5n6_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zjYQeviNrtcl" title="Fair value of convertible note"&gt;3.4&lt;/span&gt; million as of November 25, 2024 through the use of a binomial
lattice model. See Note 3 for additional information regarding the fair value measurement of the A.G.P Convertible Promissory Note. The
Company accounted for the issuance on the A.G.P. Convertible Promissory Note as a debt extinguishment, as it was issued to evidence the
A.G.P.&#x2019;s currently owed deferred commission payable discussed in Note 9. A gain on debt extinguishment of $&lt;span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20241125__20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zA3dsNlKqew3" title="Gain on debt extinguishment"&gt;2.4&lt;/span&gt; million was recorded
as of November 25, 2024, consisting of (i) the derecognition of the $&lt;span id="xdx_90C_ecustom--DeferredCommissionPayable_iI_pn5n6_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zoIY0oGukjih" title="Deferred commission payable"&gt;5.7&lt;/span&gt; million deferred commission payable and (ii) recognition of
the $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241125__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zKomL3d4W2Tj" title="Fair value of convertible note"&gt;3.4&lt;/span&gt; million fair value of the A.G.P. Convertible Note. For the year ended December 31, 2024, the Company recorded a $&lt;span id="xdx_90E_ecustom--GainOnChangeInFairValue_pn5n6_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zfqidlawkTsd" title="Gain on change in fair value"&gt;0.5&lt;/span&gt;&#160;million
gain in the change in fair value of the A.G.P. Convertible Note and interest expense of approximately $&lt;span id="xdx_900_eus-gaap--InterestExpenseDebt_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zBS52vGGfOvj" title="Interest expense debt"&gt;32&lt;/span&gt; thousand. The $&lt;span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zHlRnK0oina7" title="Gain on debt extinguishment"&gt;2.4&lt;/span&gt; million
gain on extinguishment and $&lt;span id="xdx_90F_ecustom--GainOnChangeInFairValueOfConvertibleNote_pn5n6_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_z5asJdUCpdaj" title="Gain on change in fair value of convertible note"&gt;0.5&lt;/span&gt; million gain on the change in fair value are presented within other income (expense), net, while the
$&lt;span id="xdx_90D_eus-gaap--InterestIncomeExpenseNonoperatingNet_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--AllianceGobalPartnersConvertibleNoteMember_zHi93s1To5Rh" title="Interest expense"&gt;32 &lt;/span&gt;thousand of interest expense is presented within Interest expense, net, in the consolidated statement of operations and comprehensive
income (loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

</CDT:ConvertibleNotesPayableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-03-31_custom_ConvertiblePromissoryNotesPayableMember"
      decimals="-5"
      id="Fact001150"
      unitRef="USD">800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2023-03-012023-03-31_custom_ConvertiblePromissoryNotesPayableMember"
      id="Fact001151">The
Convertible Promissory Note Payable had a maturity date of 18 months from the date of issuance.</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-03-31_custom_ConvertiblePromissoryNotesPayableMember"
      decimals="INF"
      id="Fact001152"
      unitRef="Pure">0.20</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-092024-10-09_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001154"
      unitRef="USD">80000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-092024-10-09_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001156"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-112024-10-11_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001158"
      unitRef="Shares">27812</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-10-092024-10-09_custom_ConvertiblePromissoryNotePayableMember"
      decimals="-5"
      id="Fact001160"
      unitRef="USD">100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2024-10-09_custom_ConvertiblePromissoryNotePayableMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001162"
      unitRef="USD">800000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2024-10-09_custom_ConvertiblePromissoryNotePayableMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001164"
      unitRef="USD">400000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:StockIssued1
      contextRef="From2024-10-092024-10-09_custom_ConvertiblePromissoryNotePayableMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001166"
      unitRef="USD">300000</us-gaap:StockIssued1>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-10-09_custom_ConvertiblePromissoryNotePayableMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001168"
      unitRef="USD">800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2024-10-09_custom_ConvertiblePromissoryNotePayableMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001170"
      unitRef="USD">400000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-112024-10-11_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember_custom_ConsultingAgreementMember"
      decimals="INF"
      id="Fact001172"
      unitRef="Shares">8500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-102024-10-10_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember_custom_ConsultingAgreementMember"
      decimals="-5"
      id="Fact001174"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-10-10_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember_custom_ConsultingAgreementMember"
      decimals="INF"
      id="Fact001176"
      unitRef="USDPShares">10.24</us-gaap:SharePrice>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-10-10_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember_custom_ConsultingAgreementMember"
      decimals="INF"
      id="Fact001178"
      unitRef="Shares">8500</us-gaap:SharesIssued>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember"
      decimals="-5"
      id="Fact001180"
      unitRef="USD">500000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-01-012023-12-31_custom_ConvertiblePromissoryNotesPayableMember"
      decimals="-5"
      id="Fact001182"
      unitRef="USD">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2025-03-062025-03-06_custom_TwentyTwentyThreeConvertibleNoteMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001184"
      unitRef="USD">700000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2025-03-132025-03-13_custom_TwentyTwentyThreeConvertibleNoteMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001186"
      unitRef="USD">700000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember"
      decimals="-5"
      id="Fact001188"
      unitRef="USD">2700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember"
      decimals="-5"
      id="Fact001190"
      unitRef="USD">500000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <CDT:DebtIssuedUponExecution
      contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember"
      decimals="-5"
      id="Fact001192"
      unitRef="USD">1700000</CDT:DebtIssuedUponExecution>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-08-062024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember"
      decimals="INF"
      id="Fact001194"
      unitRef="Shares">125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <CDT:PaymentOfCommonStock
      contextRef="From2024-08-062024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember"
      decimals="-5"
      id="Fact001196"
      unitRef="USD">500000</CDT:PaymentOfCommonStock>
    <CDT:NetProceedsReceivedPercentage
      contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember"
      decimals="INF"
      id="Fact001198"
      unitRef="Pure">0.75</CDT:NetProceedsReceivedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember"
      decimals="INF"
      id="Fact001200"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2024-08-062024-08-06_custom_SeniorSecuredPromissoryNoteMember_custom_NirlandLimitedMember"
      id="Fact001202">The August 2024
Nirland Note matures 12 months from August 6, 2024.</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-08-062024-08-06_custom_SeniorSecuredPromissoryNoteMember"
      decimals="INF"
      id="Fact001203"
      unitRef="Shares">125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember"
      decimals="-5"
      id="Fact001205"
      unitRef="USD">2200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember"
      decimals="-5"
      id="Fact001207"
      unitRef="USD">1200000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember"
      decimals="-5"
      id="Fact001209"
      unitRef="USD">1500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember"
      decimals="-5"
      id="Fact001211"
      unitRef="USD">300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtDefaultLongtermDebtAmount
      contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001213"
      unitRef="USD">1000000.0</us-gaap:DebtDefaultLongtermDebtAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001215"
      unitRef="USD">1200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001217"
      unitRef="USD">200000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2024-08-06_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001218"
      unitRef="USD">1200000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-08-06_custom_SeniorSecuredPromissoryNoteMember"
      decimals="-5"
      id="Fact001220"
      unitRef="USD">2700000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2024-08-06"
      decimals="-5"
      id="Fact001222"
      unitRef="USD">1500000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-10-31_custom_FirstAmendmentNirlandNoteMember"
      decimals="INF"
      id="Fact001224"
      unitRef="USDPShares">10.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2024-10-31_custom_NirlandLimitedMember_custom_FirstAmendmentMember"
      decimals="-5"
      id="Fact001226"
      unitRef="USD">3600000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-10-312024-10-31_custom_NirlandLimitedMember_custom_FirstAmendmentMember"
      decimals="-5"
      id="Fact001228"
      unitRef="USD">2200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-10-31_custom_NirlandLimitedMember_custom_FirstAmendmentMember"
      decimals="-5"
      id="Fact001230"
      unitRef="USD">1300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentConvertibleLiquidationPreferenceValue
      contextRef="AsOf2024-10-31_custom_NirlandLimitedMember_custom_FirstAmendmentMember"
      decimals="-5"
      id="Fact001232"
      unitRef="USD">2700000</us-gaap:DebtInstrumentConvertibleLiquidationPreferenceValue>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-10-31_custom_NirlandLimitedMember_custom_FirstAmendmentMember"
      decimals="-5"
      id="Fact001234"
      unitRef="USD">800000</us-gaap:ConvertibleDebt>
    <CDT:PenaltyPayment
      contextRef="From2024-11-222024-11-22_custom_SecondAmendmentNirlandNoteMember"
      decimals="-5"
      id="Fact001236"
      unitRef="USD">100000</CDT:PenaltyPayment>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-11-22_custom_SecondAmendmentNirlandNoteMember"
      decimals="INF"
      id="Fact001238"
      unitRef="USDPShares">0.10</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2024-11-222024-11-22_custom_SecondAmendmentNirlandNoteMember"
      id="Fact001240">1-for-100</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2024-11-22_custom_SecondAmendmentNirlandNoteMember"
      decimals="-5"
      id="Fact001242"
      unitRef="USD">4500000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-11-222024-11-22_custom_SecondAmendmentNirlandNoteMember"
      decimals="-5"
      id="Fact001244"
      unitRef="USD">900000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-11-22_custom_FirstAmendmentNirlandNoteMember"
      decimals="-5"
      id="Fact001246"
      unitRef="USD">2700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2024-11-222024-11-22_custom_SecondAmendmentNirlandNoteMember"
      decimals="-5"
      id="Fact001248"
      unitRef="USD">100000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-11-22_custom_SecondAmendmentMember"
      decimals="-5"
      id="Fact001250"
      unitRef="USD">800000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2024-11-22_custom_FirstAmendmentMember"
      decimals="-5"
      id="Fact001252"
      unitRef="USD">4400000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2024-12-092024-12-09_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001254"
      unitRef="USD">100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2024-12-092024-12-09_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001256"
      unitRef="Shares">23000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001258"
      unitRef="USD">2600000</us-gaap:InterestPayableCurrent>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember"
      decimals="-5"
      id="Fact001260"
      unitRef="USD">2800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:DebtSecuritiesTradingGainLoss
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember"
      decimals="-5"
      id="Fact001262"
      unitRef="USD">1500000</us-gaap:DebtSecuritiesTradingGainLoss>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember"
      decimals="-5"
      id="Fact001264"
      unitRef="USD">400000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember"
      decimals="-5"
      id="Fact001266"
      unitRef="USD">400000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember"
      decimals="-5"
      id="Fact001268"
      unitRef="USD">200000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember"
      decimals="-5"
      id="Fact001270"
      unitRef="USD">200000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember"
      decimals="-5"
      id="Fact001272"
      unitRef="USD">1500000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember_custom_FirstAmendmentMember"
      decimals="-5"
      id="Fact001274"
      unitRef="USD">2200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember_custom_NirlandLimitedMember_custom_SecondAmendmentMember"
      decimals="-5"
      id="Fact001276"
      unitRef="USD">900000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <CDT:GainOnChangeInFairValue
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember"
      decimals="-5"
      id="Fact001278"
      unitRef="USD">1500000</CDT:GainOnChangeInFairValue>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember"
      decimals="-5"
      id="Fact001280"
      unitRef="USD">400000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember"
      decimals="-5"
      id="Fact001282"
      unitRef="USD">5700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember"
      decimals="INF"
      id="Fact001284"
      unitRef="Pure">0.055</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember"
      decimals="INF"
      id="Fact001286"
      unitRef="USDPShares">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember"
      decimals="INF"
      id="Fact001288"
      unitRef="USDPShares">1.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2025-01-252025-01-25_custom_AllianceGobalPartnersConvertibleNoteMember_us-gaap_SubsequentEventMember"
      id="Fact001290">The
Company notes that the reverse split provision in the preceding sentence was tripped, effective January 25, 2025, following the 1-for-100 reverse stock split
that occurred on that date</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember"
      decimals="INF"
      id="Fact001292"
      unitRef="Pure">0.0999</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember"
      decimals="-5"
      id="Fact001294"
      unitRef="USD">3400000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-11-252024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember"
      decimals="-5"
      id="Fact001296"
      unitRef="USD">2400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <CDT:DeferredCommissionPayable
      contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember"
      decimals="-5"
      id="Fact001298"
      unitRef="USD">5700000</CDT:DeferredCommissionPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2024-11-25_custom_AllianceGobalPartnersConvertibleNoteMember"
      decimals="-5"
      id="Fact001300"
      unitRef="USD">3400000</us-gaap:DebtInstrumentFairValue>
    <CDT:GainOnChangeInFairValue
      contextRef="From2024-01-012024-12-31_custom_AllianceGobalPartnersConvertibleNoteMember"
      decimals="-5"
      id="Fact001302"
      unitRef="USD">500000</CDT:GainOnChangeInFairValue>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-01-012024-12-31_custom_AllianceGobalPartnersConvertibleNoteMember"
      decimals="-3"
      id="Fact001304"
      unitRef="USD">32000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-12-31_custom_AllianceGobalPartnersConvertibleNoteMember"
      decimals="-5"
      id="Fact001306"
      unitRef="USD">2400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <CDT:GainOnChangeInFairValueOfConvertibleNote
      contextRef="From2024-01-012024-12-31_custom_AllianceGobalPartnersConvertibleNoteMember"
      decimals="-5"
      id="Fact001308"
      unitRef="USD">500000</CDT:GainOnChangeInFairValueOfConvertibleNote>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2024-01-012024-12-31_custom_AllianceGobalPartnersConvertibleNoteMember"
      decimals="-3"
      id="Fact001310"
      unitRef="USD">32000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001312">&lt;p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_zqaxLvbOUin1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_820_zGCsXPJkl3c7"&gt;Loans Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Loans&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 1, 2022, the Company entered into Loan Agreements (the &#x201c;Loans&#x201d;) with two lenders, totaling $&lt;span id="xdx_906_eus-gaap--LoansPayable_iI_pn5n6_c20220501__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_zZYgh4PKbNoj"&gt;0.2&lt;/span&gt; million. &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateDescription_c20220501__20220501__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_z9QoObv7fxcl"&gt;The Loans
mature two years from the date of the agreement and bear no interest.&lt;/span&gt; Each loan was made available to the Company by the lenders in
three tranches of (i) $&lt;span id="xdx_90F_eus-gaap--LoansPayable_iI_pn3n3_c20220501__us-gaap--AwardTypeAxis__custom--TrancheOneMember_zz1Alc6UY8J7"&gt;33&lt;/span&gt; thousand (&#xa3;&lt;span id="xdx_904_eus-gaap--LoansPayable_iI_pn3n3_uGBP_c20220501__us-gaap--AwardTypeAxis__custom--TrancheOneMember_zLhFVV7tbOYd"&gt;30&lt;/span&gt; thousand); (ii) $&lt;span id="xdx_908_eus-gaap--LoansPayable_iI_pn3n3_c20220501__us-gaap--AwardTypeAxis__custom--TrancheTwoMember_zxUgMOgIz6Lj"&gt;33&lt;/span&gt; thousand (&#xa3;&lt;span id="xdx_906_eus-gaap--LoansPayable_iI_pn3n3_uGBP_c20220501__us-gaap--AwardTypeAxis__custom--TrancheTwoMember_zrRZvIUlzBC9"&gt;30&lt;/span&gt; thousand) and (iii) $&lt;span id="xdx_902_eus-gaap--LoansPayable_iI_pn3n3_c20220501__us-gaap--AwardTypeAxis__custom--TrancheThreeMember_zuacbFWSNf4"&gt;28&lt;/span&gt; thousand (&#xa3;&lt;span id="xdx_907_eus-gaap--LoansPayable_iI_pn3n3_uGBP_c20220501__us-gaap--AwardTypeAxis__custom--TrancheThreeMember_zdlk1x920wa8"&gt;25&lt;/span&gt;
thousand), totaling $&lt;span id="xdx_903_eus-gaap--LoansPayable_iI_pn5n6_c20220501_z3Pf4rrrpxr4"&gt;0.2&lt;/span&gt; million. The Loans provided for events of default, including, among others, failure to make payment,
bankruptcy and non-compliance with the terms of the Loans. As of December 31, 2024, the Company utilized all three tranches of the
first loan and two out of three tranches of the second loan, with loans payable totaling $&lt;span id="xdx_906_eus-gaap--LoansPayable_iI_pn5n6_c20241231_zsmPi7mTDGOi"&gt;&lt;span id="xdx_907_eus-gaap--LoansPayable_iI_pn5n6_c20231231_zF5y5rjDoy97"&gt;0.2&lt;/span&gt;&lt;/span&gt; million at December 31, 2023 and
December 31, 2024 respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 9, 2024, the Company and the Loans holders amended the loan agreements (the &#x201c;Loans Amendment&#x201d;) to extend the maturity
date for the Loans to&#160;&lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20241009__20241009_zpDK1htzGvt5" title="Maturity date"&gt;December 19, 2024&lt;/span&gt;. The Loans Amendment also modified the payment terms for the Loans from a cash payment of
&#xa3;&lt;span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_uGBP_c20241009__20241009_z97DrB6edE26" title="Payment terms for loan payment"&gt;85,000&lt;/span&gt;&#160;per loan to (1) a cash payment of &#xa3;&lt;span id="xdx_903_eus-gaap--RepaymentsOfNotesPayable_uGBP_c20241009__20241009_zJplNaQtoFv2" title="Cash payment"&gt;60,000&lt;/span&gt;, (2) &#xa3;&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_uGBP_c20241009__20241009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ6untE11eI4" title="Common stock converted"&gt;25,000&lt;/span&gt;&#160;worth of shares of Common Stock converted
into USD at the prevailing exchange rate, to be issued at the closing market price on the date prior to issuance, and in consideration
for the extension, and (3)&#160;&lt;span id="xdx_90D_ecustom--StockIssuedDuringPeriodAdditionalSharesIssued_c20241009__20241009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1t3h5UI57Ua" title="Additional shares issued"&gt;2,500&lt;/span&gt;&#160;additional shares of Common stock. On October 11, 2024, the Company issued each of the Loan
holders&#160;&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241011__20241011__us-gaap--InvestmentTypeAxis__custom--LoanHoldersMember_zGx3lEWyZn46" title="Shares issued during period"&gt;5,690&lt;/span&gt;&#160;shares (&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241011__20241011_zuo4h6s4ZTTc" title="Shares issued during period"&gt;11,380&lt;/span&gt;&#160;in total). The Loans remain outstanding as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
extension was accounted for as a debt extinguishment. On October 9, 2024, the Company recorded a loss on debt extinguishment of approximately
$&lt;span id="xdx_900_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_c20241009__20241009_zUe9pjTbVFBc" title="Loss on debt extinguishment"&gt;42&lt;/span&gt; thousand calculated as the difference between (i) the $&lt;span id="xdx_905_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241009_zDyB6BLrTHZd" title="Debt instrument carrying value"&gt;0.2&lt;/span&gt; million carrying value of the Loans immediately prior to the Loans Amendment
(ii) the $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241009_zPdAe5Nw9nwi" title="Debt instrument fair value"&gt;0.1&lt;/span&gt; million fair value of the Loans immediately after the Loans Amendment and (iii) the $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20241009__20241009_ztnQnbqnspdl" title="Shares issued"&gt;0.1&lt;/span&gt; million fair value of the shares
issued to the holder as consideration for extending the maturity date. The difference between the $&lt;span id="xdx_905_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20241009_zpZYIVIRLHD8" title="Debt instrument carrying value"&gt;0.2&lt;/span&gt; million carrying value immediately
prior to the Loans Amendment and the $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20241009_zUbmXtLUymHl" title="Debt instrument fair value"&gt;0.1&lt;/span&gt; million fair value immediately after the Loans Amendment was recorded as a debt discount and
amortized over the term date of the Loans using the effective interest method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, the Company incurred interest expense on the Loans of approximately $&lt;span id="xdx_905_eus-gaap--InterestExpenseDebt_pn3n3_c20240101__20241231_zFFAkuIzHpfi"&gt;40
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand related to the amortization of the debt
discount recorded as a result of the Loans Amendment. &lt;span id="xdx_907_eus-gaap--InterestExpenseDebt_pn3n3_do_c20230101__20231231_zq7DGNEPhnle"&gt;No
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;interest expense was recorded for the year ended
December 31, 2023. The Loans remained outstanding as of December 31, 2024, therefore the Company was considered to be in default. The
Company repaid the lenders the outstanding principal balance of $&lt;span id="xdx_909_eus-gaap--RepaymentsOfDebt_pn5n6_c20250201__20250228__us-gaap--TypeOfArrangementAxis__custom--LoansAmendmentMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAk9o8ZGLPE4"&gt;0.1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million in February 2025. See Note 20 for additional
details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;October
2024 Nirland Note&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 28, 2024, the Company issued a promissory note (the &#x201c;October 2024 Nirland Note&#x201d;) to Nirland, a related party, in
the original principal amount of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241028__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_z2VPzvuBUCe" title="Principal amount"&gt;0.6&lt;/span&gt;
million in exchange for funds in such amount. See Note 16 for further reference to the relationship between the Company and Nirland.
The Nirland Note bears interest at a rate of &lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241028__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember__srt--RangeAxis__srt--MinimumMember_zSmrvO0flhCg" title="Interest rate"&gt;12&lt;/span&gt;%
per annum, is due and payable semi-annually in arrears, and matures on October 31, 2025. If an event of default under and as defined
in the Nirland Note occurs, the interest rate will be increased to &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241028__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember__srt--RangeAxis__srt--MaximumMember_zFAYLqcitnyb" title="Interest rate"&gt;18&lt;/span&gt;%
per annum or to the maximum rate permitted by law. In connection with the Nirland Note, the Company has agreed to pay Nirland a &lt;span id="xdx_903_ecustom--ArrangementFeePercentage_pid_dp_c20241028__20241028__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zlCIe1omRMua" title="Arrangement fee percentage"&gt;1&lt;/span&gt;%
arrangement fee, which will be included with the principal and interest owed under the Nirland Note. The &lt;span id="xdx_903_ecustom--ArrangementFeePercentage_pid_dp_c20241028__20241028__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zoPS1WcAXMQ" title="Arrangement fee percentage"&gt;1&lt;/span&gt;%
arrangement fee is accounted for as a debt discount and will be amortized to interest expense, net in the consolidated statement of
operations and comprehensive income (loss) using the effective interest method over the life of the October 2024 Nirland
Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, the Company recorded approximately $&lt;span id="xdx_90E_eus-gaap--InterestExpenseDebt_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zU05k46ODRQ9" title="Interest expense"&gt;14,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of interest expense. The interest expense of $&lt;span id="xdx_905_eus-gaap--InterestExpense_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zNe4PWTonRw" title="Interest expense"&gt;14,000&lt;/span&gt; &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;is comprised of (i) accrued interest of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zbGWkAjldhsc" title="Accrued interest"&gt;13,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;based on the coupon rate of the debt and (ii) amortization of the debt discount of $&lt;span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zzZxlEXxlp9j" title="Amortization of debt discount"&gt;1 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand,
with both components recorded within interest expense, net in the consolidated statement of operations and comprehensive income
(loss). Accrued interest of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zgg8SnxuywMh" title="Accrued interest"&gt;13,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;was recorded as a liability on the Company&#x2019;s consolidated balance sheet within accrued expenses and other current liabilities.
The $&lt;span id="xdx_901_eus-gaap--AmortizationOfDebtDiscountPremium_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OctoberTwoThousandTwentyFourNirlandNoteMember_zuLhTAkhP266" title="Amortization of debt discount"&gt;1,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;amortization of the debt discount decreased the debt discount contra-liability included within the Loans payable, current portion on
the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;A.G.P.
Bridge Note&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 29, 2024, the Company entered into a Bridge Loan Agreement (the &#x201c;Bridge Agreement&#x201d;), with A.G.P., pursuant to which
AGP. made an advance (the &#x201c;Advance&#x201d;) to the Company in an amount not to exceed $&lt;span id="xdx_901_ecustom--CommitmentFees_pn5n6_c20241029__20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_z6y0OuIQip53"&gt;0.6&lt;/span&gt; million (the &#x201c;Commitment&#x201d;).
As partial consideration for the Advance, the Company entered into a Common Stock Purchase Warrant Agreement (the &#x201c;Warrant Agreement&#x201d;)
and issued AGP warrants to purchase up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zrcVNxYnLyH" title="Shares issued"&gt;28,625&lt;/span&gt; shares of the Company&#x2019;s common stock, $&lt;span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zsDornk4mrii" title="Common stock, par value"&gt;0.0001&lt;/span&gt; par value per share, which is equal
to &lt;span id="xdx_904_ecustom--CommonStockClosingPricePercentage_iI_pid_dp_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_z0RECplG9Ln9"&gt;50&lt;/span&gt;% of the sum of the Commitment divided by the closing price of the Company&#x2019;s Common Stock on October 29, 2024, at an exercise
price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zi0sXjQo6jYg"&gt;10.48&lt;/span&gt; per share. Refer to Note 18 for additional information on the warrants issued to A.G.P.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Advance, the Company issued a promissory note (the &#x201c;A.G.P. Bridge Note&#x201d;) to A.G.P. in the original principal
amount of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zOKbYeEJkwRc"&gt;0.6&lt;/span&gt; million. The Bridge Note bears interest at a rate of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zutQZLuQwIpc"&gt;4.21&lt;/span&gt;% per annum and is due and payable on December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
noted above, the Company issued to A.G.P. warrants to purchase up to &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zv26Nn7i2C56"&gt;28,625&lt;/span&gt;
shares of the Company&#x2019;s common stock. The Company determined that the Bridge Note and Warrant Agreement issuance were part of
a basket transaction and allocated the net proceeds using the residual value method. The warrants issued under the Warrant Agreement
were initially recorded at their fair value of $&lt;span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20241029__20241029__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zoUZQKyS0hUf" title="Fair value adjustment of warrants"&gt;0.2&lt;/span&gt;
million. The warrants were classified as derivative liabilities because they do not meet the criteria in ASC 815-40 to be considered
indexed to the entity&#x2019;s own stock. Refer to Note 18 for additional information and discussion of liability classification. The $&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20240806__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zQp4o5bPAUe8" title="Warrants"&gt;0.2&lt;/span&gt;&#160;million
recorded for the warrants was considered to be a discount on the A.G.P. Bridge Note making the balance of the note to be $&lt;span id="xdx_900_eus-gaap--NotesPayable_iI_pn5n6_c20240806__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zFDWwXGpjXfh" title="Notes payable"&gt;0.6&lt;/span&gt;&#160;million
note payable, less a total debt discount of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20240806__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zMTZ3SlZazye" title="Total debt discount"&gt;0.2&lt;/span&gt;&#160;million.
The debt discount will be amortized to interest expense using the effective interest method over the life of the note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, the Company recorded and paid approximately $&lt;span id="xdx_90A_eus-gaap--InterestExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zqaBCFM3xzhk" title="Interest expense"&gt;1&lt;/span&gt; thousand of interest expense related to the A.G.P. Additionally,
the entire debt discount of $&lt;span id="xdx_900_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zdaPLz5wotdb" title="Amortization of debt discount"&gt;0.2&lt;/span&gt; million was amortized and recorded as interest expense during the year. The interest expense of $&lt;span id="xdx_90C_eus-gaap--InterestExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zCTzKZMBDQyf" title="Interest expense"&gt;1&lt;/span&gt; thousand
and amortization of the debt discount of $&lt;span id="xdx_900_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_z0fqAjA52Haa" title="Amortization of debt discount"&gt;0.2&lt;/span&gt; million were recorded within Interest expense, net in the consolidated statement of operations
and comprehensive income (loss). As of December 31, 2024, the A.G.P. Bridge note was fully repaid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LoansPayable
      contextRef="AsOf2022-05-01_custom_LoanAgreementsMember"
      decimals="-5"
      id="Fact001313"
      unitRef="USD">200000</us-gaap:LoansPayable>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2022-05-012022-05-01_custom_LoanAgreementsMember"
      id="Fact001314">The Loans
mature two years from the date of the agreement and bear no interest.</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:LoansPayable
      contextRef="AsOf2022-05-01_custom_TrancheOneMember"
      decimals="-3"
      id="Fact001315"
      unitRef="USD">33000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="AsOf2022-05-01_custom_TrancheOneMember"
      decimals="-3"
      id="Fact001316"
      unitRef="GBP">30000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="AsOf2022-05-01_custom_TrancheTwoMember"
      decimals="-3"
      id="Fact001317"
      unitRef="USD">33000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="AsOf2022-05-01_custom_TrancheTwoMember"
      decimals="-3"
      id="Fact001318"
      unitRef="GBP">30000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="AsOf2022-05-01_custom_TrancheThreeMember"
      decimals="-3"
      id="Fact001319"
      unitRef="USD">28000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="AsOf2022-05-01_custom_TrancheThreeMember"
      decimals="-3"
      id="Fact001320"
      unitRef="GBP">25000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="AsOf2022-05-01"
      decimals="-5"
      id="Fact001321"
      unitRef="USD">200000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001322"
      unitRef="USD">200000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact001323"
      unitRef="USD">200000</us-gaap:LoansPayable>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2024-10-092024-10-09" id="Fact001325">2024-12-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2024-10-092024-10-09"
      decimals="0"
      id="Fact001327"
      unitRef="GBP">85000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-10-092024-10-09"
      decimals="0"
      id="Fact001329"
      unitRef="GBP">60000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2024-10-092024-10-09_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001331"
      unitRef="GBP">25000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <CDT:StockIssuedDuringPeriodAdditionalSharesIssued
      contextRef="From2024-10-092024-10-09_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001333"
      unitRef="Shares">2500</CDT:StockIssuedDuringPeriodAdditionalSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-112024-10-11_custom_LoanHoldersMember"
      decimals="INF"
      id="Fact001335"
      unitRef="Shares">5690</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-112024-10-11"
      decimals="INF"
      id="Fact001337"
      unitRef="Shares">11380</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-10-092024-10-09"
      decimals="-3"
      id="Fact001339"
      unitRef="USD">42000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-10-09"
      decimals="-5"
      id="Fact001341"
      unitRef="USD">200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2024-10-09"
      decimals="-5"
      id="Fact001343"
      unitRef="USD">100000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-092024-10-09"
      decimals="-5"
      id="Fact001345"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-10-09"
      decimals="-5"
      id="Fact001347"
      unitRef="USD">200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2024-10-09"
      decimals="-5"
      id="Fact001349"
      unitRef="USD">100000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001350"
      unitRef="USD">40000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001351"
      unitRef="USD">0</us-gaap:InterestExpenseDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2025-02-012025-02-28_custom_LoansAmendmentMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001352"
      unitRef="USD">100000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember"
      decimals="-5"
      id="Fact001354"
      unitRef="USD">600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001356"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001358"
      unitRef="Pure">0.18</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <CDT:ArrangementFeePercentage
      contextRef="From2024-10-282024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember"
      decimals="INF"
      id="Fact001360"
      unitRef="Pure">0.01</CDT:ArrangementFeePercentage>
    <CDT:ArrangementFeePercentage
      contextRef="From2024-10-282024-10-28_custom_OctoberTwoThousandTwentyFourNirlandNoteMember"
      decimals="INF"
      id="Fact001362"
      unitRef="Pure">0.01</CDT:ArrangementFeePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-01-012024-12-31_custom_OctoberTwoThousandTwentyFourNirlandNoteMember"
      decimals="0"
      id="Fact001364"
      unitRef="USD">14000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-12-31_custom_OctoberTwoThousandTwentyFourNirlandNoteMember"
      decimals="0"
      id="Fact001366"
      unitRef="USD">14000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2024-01-012024-12-31_custom_OctoberTwoThousandTwentyFourNirlandNoteMember"
      decimals="0"
      id="Fact001368"
      unitRef="USD">13000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-012024-12-31_custom_OctoberTwoThousandTwentyFourNirlandNoteMember"
      decimals="-3"
      id="Fact001370"
      unitRef="USD">1000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2024-01-012024-12-31_custom_OctoberTwoThousandTwentyFourNirlandNoteMember"
      decimals="0"
      id="Fact001372"
      unitRef="USD">13000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-012024-12-31_custom_OctoberTwoThousandTwentyFourNirlandNoteMember"
      decimals="0"
      id="Fact001374"
      unitRef="USD">1000</us-gaap:AmortizationOfDebtDiscountPremium>
    <CDT:CommitmentFees
      contextRef="From2024-10-292024-10-29_custom_BridgeLoanAgreementMember"
      decimals="-5"
      id="Fact001375"
      unitRef="USD">600000</CDT:CommitmentFees>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-10-29_custom_BridgeLoanAgreementMember"
      decimals="INF"
      id="Fact001377"
      unitRef="Shares">28625</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-10-29_custom_BridgeLoanAgreementMember"
      decimals="INF"
      id="Fact001379"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <CDT:CommonStockClosingPricePercentage
      contextRef="AsOf2024-10-29_custom_BridgeLoanAgreementMember"
      decimals="INF"
      id="Fact001380"
      unitRef="Pure">0.50</CDT:CommonStockClosingPricePercentage>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-10-29_custom_BridgeLoanAgreementMember"
      decimals="INF"
      id="Fact001381"
      unitRef="USDPShares">10.48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-10-29_custom_BridgeLoanAgreementMember"
      decimals="-5"
      id="Fact001382"
      unitRef="USD">600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-10-29_custom_BridgeLoanAgreementMember"
      decimals="INF"
      id="Fact001383"
      unitRef="Pure">0.0421</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-10-29_custom_BridgeLoanAgreementMember"
      decimals="INF"
      id="Fact001384"
      unitRef="Shares">28625</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-10-292024-10-29_custom_BridgeLoanAgreementMember"
      decimals="-5"
      id="Fact001386"
      unitRef="USD">200000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-08-06_custom_BridgeLoanAgreementMember"
      decimals="-5"
      id="Fact001388"
      unitRef="USD">200000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-08-06_custom_BridgeLoanAgreementMember"
      decimals="-5"
      id="Fact001390"
      unitRef="USD">600000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2024-08-06_custom_BridgeLoanAgreementMember"
      decimals="-5"
      id="Fact001392"
      unitRef="USD">200000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-12-31_custom_BridgeLoanAgreementMember"
      decimals="-3"
      id="Fact001394"
      unitRef="USD">1000</us-gaap:InterestExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-012024-12-31_custom_BridgeLoanAgreementMember"
      decimals="-5"
      id="Fact001396"
      unitRef="USD">200000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-12-31_custom_BridgeLoanAgreementMember"
      decimals="-3"
      id="Fact001398"
      unitRef="USD">1000</us-gaap:InterestExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-012024-12-31_custom_BridgeLoanAgreementMember"
      decimals="-5"
      id="Fact001400"
      unitRef="USD">200000</us-gaap:AmortizationOfDebtDiscountPremium>
    <CDT:DeferredCommissionPayableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001402">&lt;p id="xdx_80B_ecustom--DeferredCommissionPayableTextBlock_ze7F4iIFqe5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
&lt;span id="xdx_828_zJpDUtE6Q0L2"&gt;Deferred Commission Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
discussed in Note 2, A.G.P was a financial advisor to both MURF and Old Conduit in connection with the Merger transaction. Upon the completion
of the Merger, A.G.P.: (i) received a cash fee of $&lt;span id="xdx_900_eus-gaap--ProceedsFromFeesReceived_pn5n6_c20230921__20230922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zyLbAGLrJa71" title="Cash fee received"&gt;6.5&lt;/span&gt; million, &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230921__20230922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgUEGmx3ucl8" title="Number of shares issued"&gt;13,000&lt;/span&gt; shares of Common Stock, and warrants to purchase &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zALiIPeBOtr5" title="Warrants to purchase share"&gt;540&lt;/span&gt; shares of
Common Stock at an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_z6csMjfMg0F6" title="Exercise price"&gt;1,100&lt;/span&gt; per share pursuant to its engagement agreement with Old Conduit entered into on August 2,
2022, and (ii) agreed to defer payment, to be paid in the future under certain circumstances by a date no later than March 21, 2025,
of $&lt;span id="xdx_90E_eus-gaap--PaymentsForFees_pn5n6_c20230921__20230922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zHOGL4kqbFxf" title="Deferred payment fees"&gt;5.7&lt;/span&gt; million of fees plus annual interest of &lt;span id="xdx_90E_ecustom--DeferredCommissionPayableAnnualInterestRate_iI_pid_dp_c20230922__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zCjs9VMyFa57" title="Annual interest rate"&gt;5.5&lt;/span&gt;% as a result of its engagement for MURF&#x2019;s IPO. The $&lt;span id="xdx_90A_ecustom--DeferredCommissionPayableNonCurrent_iI_pn5n6_c20231231__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_zU3sT1cp4Dph" title="Deferred commissions payable, non-current liability"&gt;5.7&lt;/span&gt; million deferred commissions
payable was recorded as a non-current liability on the Company&#x2019;s consolidated balance sheet as of December 31, 2023. Accrued interest
was recorded as a liability on the Company&#x2019;s consolidated balance sheet under accrued expenses and other current liabilities and
totaled $&lt;span id="xdx_90F_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20241231_zHs1if2qFWY8" title="Accrued expenses and other current liabilities"&gt;0.4&lt;/span&gt; million and $&lt;span id="xdx_901_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20231231_zm7js835ONB1" title="Accrued expenses and other current liabilities"&gt;0.1&lt;/span&gt; million as of December 31, 2024, and December 31, 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 25, 2024, the Company issued the A.G.P. Convertible Note in the principal amount of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241125__dei--LegalEntityAxis__custom--AllianceGlobalPartnersMember_z21NUAKr6Ixl" title="Convertible principal amount"&gt;5.7&lt;/span&gt; million to evidence the currently owed
deferred commission payable, at which time the deferred commission payable balance was removed. Refer to the Note 7 for additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CDT:DeferredCommissionPayableTextBlock>
    <us-gaap:ProceedsFromFeesReceived
      contextRef="From2023-09-212023-09-22_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      id="Fact001404"
      unitRef="USD">6500000</us-gaap:ProceedsFromFeesReceived>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-09-212023-09-22_custom_AllianceGlobalPartnersMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001406"
      unitRef="Shares">13000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-09-22_custom_AllianceGlobalPartnersMember"
      decimals="INF"
      id="Fact001408"
      unitRef="Shares">540</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-22_custom_AllianceGlobalPartnersMember"
      decimals="INF"
      id="Fact001410"
      unitRef="USDPShares">1100</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PaymentsForFees
      contextRef="From2023-09-212023-09-22_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      id="Fact001412"
      unitRef="USD">5700000</us-gaap:PaymentsForFees>
    <CDT:DeferredCommissionPayableAnnualInterestRate
      contextRef="AsOf2023-09-22_custom_AllianceGlobalPartnersMember"
      decimals="INF"
      id="Fact001414"
      unitRef="Pure">0.055</CDT:DeferredCommissionPayableAnnualInterestRate>
    <CDT:DeferredCommissionPayableNonCurrent
      contextRef="AsOf2023-12-31_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      id="Fact001416"
      unitRef="USD">5700000</CDT:DeferredCommissionPayableNonCurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001418"
      unitRef="USD">400000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact001420"
      unitRef="USD">100000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-11-25_custom_AllianceGlobalPartnersMember"
      decimals="-5"
      id="Fact001422"
      unitRef="USD">5700000</us-gaap:DebtInstrumentFaceAmount>
    <CDT:DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001424">&lt;p id="xdx_809_ecustom--DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock_zubJDKQDiaY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
&lt;span id="xdx_829_zjS5XWJP8Onj"&gt;Research and Development Expense&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;August
2024 License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 7, 2024, the Company and AstraZeneca AB (PUBL) (&#x201c;AstraZeneca&#x201d;) entered into a License Agreement, dated August 7,
2024 (the &#x201c;August 2024 License Agreement&#x201d;). Pursuant to the August 2024 License Agreement, AstraZeneca agreed to grant a
license to the Company under certain intellectual property rights controlled by AstraZeneca related to HK-4 Glucokinase activators AZD1656
and AZD5658 in all indications and myeloperoxidase inhibitor AZD5904 for the treatment, prevention, and prophylaxis of idiopathic male
infertility. The Company will be responsible for the development and commercialization of the Licensed Products under the August
2024 License Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
consideration for the grant of the license, the Company (i) granted AstraZeneca Common Stock pursuant to a stock issuance agreement
(the &#x201c;Issuance Agreement&#x201d;), (ii) paid AstraZeneca an up-front payment of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--AstraZenecaMember_z3zwzbohA6gb"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;million,
and (iii) is obligated to pay AstraZeneca a percentage (on a tiered basis) of any amounts it may receive in connection with a grant
of a sublicense (subject to various customary exceptions). The Issuance Agreement called for the Company to issue AstraZeneca &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__dei--LegalEntityAxis__custom--AstraZenecaMember_z0A67zeqVOD6"&gt;95,044&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
shares of the Company&#x2019;s Common Stock. The Issuance Agreement provides AstraZeneca with resale registration rights for such
shares. As of December 31, 2024, the Company recorded $&lt;span id="xdx_901_eus-gaap--GeneralAndAdministrativeExpense_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--AstraZenecaMember_zxoqncFMLZu4"&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;million
and $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--AstraZenecaMember_zCOxGRIShsJl"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;million
in research and development expenses related to the share issuance and upfront payment to AstraZeneca, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AstraZeneca
has been granted a right of first negotiation to develop, manufacture, and commercialize a Licensed Product if the Company receives an
offer for, or solicits, a transaction where a third party would obtain the right to develop, manufacture, or commercialize a Licensed
Product. If AstraZeneca exercises such right, the parties will negotiate in good faith for an agreed period of time on an exclusive basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Either
party may terminate the August 2024 License Agreement for material breach (subject to a cure period) or insolvency of the other party.
The Company may terminate the August 2024 License Agreement for convenience (in its entirety or on a Licensed Product-by-Licensed Product
basis). In addition, AstraZeneca may terminate the August 2024 License Agreement in certain circumstances, including (but not limited
to) the Company ceasing development of all Licensed Products (subject to certain exceptions for normal pauses or gaps between clinical
studies).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the above, the Company will no longer fund the development of AZD1656 or AZD5904 under the terms of the Exclusive Funding
Agreement, dated March 26, 2021 with St George Street Capital (the &#x201c;Funding Agreement&#x201d;). In this regard, the Company previously
entered into a deed of amendment amending such Funding Agreement. The parties agreed that the project funding provisions of such Funding
Agreement whereby the Company had the right to fund a project or refer other parties to St George Street Capital, were amended to provide
that St George Street Capital must still include the Company in any project funding opportunities and requests but may now seek other
third-parties to fund projects in addition to the Company. In November and December 2024, the Company received a letter from St George Street Capital and formal complaints
filed with the Intellectual Property Office claiming the Company was not the sole owner of the AZD 1656 co-crystal patent. See note 15
for additional details on the claim.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;SARBORG
Service Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 12, 2024, the Company entered into a Services Agreement (the &#x201c;Sarborg Service Agreement&#x201d;) with SARBORG Limited
(&#x201c;Sarborg&#x201d;), a Cayman Islands company and related party of the Company. See Note 16 for further reference to the
relationship between the Company and Sarborg. Under the terms of the Sarborg Service Agreement, Sarborg will provide algorithmic and
cybernetic technology services to Conduit, including the development of decision-support tools and advanced cybernetic systems
tailored to enhance Conduit&#x2019;s decision-making processes and maximize the value of its pharmaceutical asset
portfolio.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sarborg
will perform the services to Conduit comprised of three phases: the Initial Phase (0-24 weeks) focuses on establishing a foundation for
collaboration and aligning Sarborg&#x2019;s services with Conduit&#x2019;s strategic goals; the Development Phase (24-36 weeks) involves
building technological infrastructure, including dashboards and predictive models; and the Ongoing Services Phase (36-52 weeks) ensures
the sustained functionality and relevance of Sarborg&#x2019;s deliverables while supporting Conduit&#x2019;s growth through iterative improvements
and updates. Sarborg will create specific deliverables, including reports, computer programs, software applications, APIs, mobile applications,
source code, written technical specifications and designs, operating and maintenance manuals, and other recorded data and information
arising from or relating to the services. Sarborg will provide all necessary resources to perform the services and deliver the deliverables
in accordance with the Sarborg Service Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Sarborg Service Agreement has an initial term of 12 months, which commenced on the effective date, and may be renewed or extended
upon mutual written agreement of the parties. Either party may terminate the Sarborg Service Agreement for any reason upon 90
days&#x2019; written notice or immediately upon written notice if the other party breaches any material term of the Sarborg Service
Agreement and fails to cure such breach within thirty days or becomes insolvent, files for bankruptcy, or is placed under the
control of a receiver, trustee, or similar authority.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Sarborg Service Agreement includes provisions for the ownership and use of intellectual property. Sarborg will own its pre-existing
intellectual property rights, including proprietary tools and methodologies used in the performance of the services. Conduit will
own all deliverables resulting from the services performed by Sarborg under the Sarborg Service Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Sarborg Service Agreement provides Sarborg with registration rights
for any Common Stock of Conduit that Sarborg receives as consideration under the Sarborg Service Agreement. In such event, Conduit will
use commercially reasonable efforts to (i) file a registration statement covering the resale of the Common Stock within 60 days after
the issuance; and (ii) ensure that such registration statement becomes effective within 90 days after filing. This Agreement also includes
confidentiality obligations, representations and warranties, indemnification, limitation of liability, and insurance requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consideration of the services, Conduit agreed to pay Sarborg an initial cash payment of $&lt;span id="xdx_901_ecustom--PaymentToResearchAndDevolpmentAmount_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zGSBEwjlUzy8" title="Cash payment"&gt;0.2&lt;/span&gt;
million and $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zaGPaxjLMJth" title="Shares, value"&gt;0.2&lt;/span&gt;
million payable&#160;through the issuance of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zitFwoh9tVkd" title="Shares issued"&gt;22,727&lt;/span&gt;
shares of&#160;common stock, determined by the closing price on the day preceding the execution of the Sarborg Service Agreement.
Further milestone payments payable in conjunction with the achievement of certain milestones over the term of the Sarborg Service
Agreement, totaling up to $&lt;span id="xdx_904_ecustom--CashPayment_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_z3X3vxg9KAKl" title="Payable in cash"&gt;1.8&lt;/span&gt;
million, are payable in cash or shares, at the discretion of Conduit. Sarborg will be reimbursed for pre-approved, necessary, and
reasonable out-of-pocket expenses directly incurred in connection with the performance of the services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
determined that the cost incurred under the Sarborg Service Agreement should be recorded to research and development expense in the
statement of operations and comprehensive income (loss), as the Sarborg Service Agreement is designed to provide the
Company with software/dashboard to aid in research and development activities. The initial cash payment of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zdTjjtUF9ay8" title="Shares, value"&gt;0.2&lt;/span&gt;
million and issuance of &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zhb8ih1P5wu7" title="Shares issued"&gt;22,727&lt;/span&gt;
shares of Common Stock were recorded to prepaid expense and will be amortized over the initial term of the Sarborg Service Agreement to research and
development expense. As of December 31, 2024, the &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zJqrM2d0msJ8" title="Shares issued"&gt;22,727&lt;/span&gt;
shares of common stock were yet to be issued and are recorded within accrued expense and other current liabilities in the
consolidated balance sheets. As of December 31, 2024, the Company has recognized $&lt;span id="xdx_901_eus-gaap--AdjustmentForAmortization_pn5n6_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServiceAgreementMember_zirSUlvBMhF4" title="Amortization"&gt;0.2&lt;/span&gt;
million of amortization within research and development expense in the consolidated statement of operations and comprehensive income
(loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

</CDT:DisclosureOfResearchAndDevelopmentLicenseAgreementTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31_custom_AstraZenecaMember"
      decimals="-5"
      id="Fact001425"
      unitRef="USD">1500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_custom_AstraZenecaMember"
      decimals="INF"
      id="Fact001426"
      unitRef="Shares">95044</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_AstraZenecaMember"
      decimals="-5"
      id="Fact001427"
      unitRef="USD">1600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_AstraZenecaMember"
      decimals="-5"
      id="Fact001428"
      unitRef="USD">1500000</us-gaap:ResearchAndDevelopmentExpense>
    <CDT:PaymentToResearchAndDevolpmentAmount
      contextRef="From2024-01-012024-12-31_custom_SARBORGServiceAgreementMember"
      decimals="-5"
      id="Fact001430"
      unitRef="USD">200000</CDT:PaymentToResearchAndDevolpmentAmount>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SARBORGServiceAgreementMember"
      decimals="-5"
      id="Fact001432"
      unitRef="USD">200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SARBORGServiceAgreementMember"
      decimals="INF"
      id="Fact001434"
      unitRef="Shares">22727</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <CDT:CashPayment
      contextRef="AsOf2024-12-31_custom_SARBORGServiceAgreementMember"
      decimals="-5"
      id="Fact001436"
      unitRef="USD">1800000</CDT:CashPayment>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SARBORGServiceAgreementMember"
      decimals="-5"
      id="Fact001438"
      unitRef="USD">200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SARBORGServiceAgreementMember"
      decimals="INF"
      id="Fact001440"
      unitRef="Shares">22727</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SARBORGServiceAgreementMember"
      decimals="INF"
      id="Fact001442"
      unitRef="Shares">22727</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_custom_SARBORGServiceAgreementMember"
      decimals="-5"
      id="Fact001444"
      unitRef="USD">200000</us-gaap:AdjustmentForAmortization>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001446">&lt;p id="xdx_80C_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zHY0JLIDfVDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;11.
&lt;span id="xdx_825_z1goBzzbw7ok"&gt;Share Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 22, 2023, in connection with the Merger, the Company adopted the Conduit Pharmaceuticals Inc. 2023 Stock Incentive Plan
(the &#x201c;2023 Plan&#x201d;). The 2023 Plan became effective upon the closing of the Merger. The 2023 Plan initially provided for
the issuance of up to&#160;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20230922__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeStockIncentivePlanMember_zeoQ0ABJNyhf" title="Issuance of common stock"&gt;114,976&lt;/span&gt;&#160;shares
of Common Stock. Pursuant to the 2023 Plan&#x2019;s &#x201c;evergreen&#x201d; provision, on February 6, 2025, the Company increased the
number of shares of Common Stock available for issuance under the 2023 Plan by &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20250206__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeStockIncentivePlanMember_zpg7tFAi2QH9" title="Issuance of common stock"&gt;69,240&lt;/span&gt;
shares. Total shares available for issuance is &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20250101__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeStockIncentivePlanMember_zFtXfXWHh6R" title="Issuance of common stock"&gt;154,125&lt;/span&gt; effective January
1, 2025. The number of authorized shares will automatically increase on January 1, 2026 and
continuing annually on each anniversary thereof through (and including) January 1, 2033, equal to the lesser of (i)&#160;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_c20230921__20230922__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeStockIncentivePlanMember_zZSEblBFdode" title="Shares issued percentage"&gt;5&lt;/span&gt;%
of the shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of
shares of common stock as determined by the Board or the applicable committee of the Board. The 2023 Plan allows for awards to be
issued to employees and non-employee directors in the form of options, stock appreciation rights, restricted stock, restricted stock
units (&#x201c;RSUs&#x201d;), performance stock units, dividend equivalents, other stock-based, or other cash-based awards. As of
December 31, 2024, there were&#160;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20241231__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeStockIncentivePlanMember_zjlc6qhr0Psc" title="Shares available for issuance"&gt;84,885&lt;/span&gt;&#160;shares
of Common Stock available for issuance under the 2023 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year ended December 31, 2024, the Company issued a total of
&lt;span id="xdx_903_eus-gaap--SharesIssued_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxPOfTBCt3T8" title="Stock options to employees shares"&gt;56,700&lt;/span&gt; stock options to employees and non-employee directors with an aggregate grant date fair value of $&lt;span id="xdx_90E_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUDZ8cmoLMec" title="Stock options to employees shares granted"&gt;0.4&lt;/span&gt; million. For
the year ended December 31, 2024 and December 31, 2023, there was a total of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_pn5n6_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zaPfzGjpnvy9" title="Share based compensation"&gt;1.6&lt;/span&gt;&#160;million and $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zXlDHavOxlt5" title="Share based compensation"&gt;0.2&lt;/span&gt; million, respectively in stock-based
compensation expense recognized within General and Administrative expenses on the consolidated statements of operations and Comprehensive
Loss, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 24, 2024, in connection with a services agreement with an unrelated third party to provide marketing services, the Company
issued &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240624__20240624__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAr2UgbhSLS1" title="Shares new issued"&gt;961&lt;/span&gt; shares of its Common Stock (the &#x201c;Service Shares&#x201d;). The Company valued the Service Shares at $&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20240624__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxpG1u3uTKA3" title="Shares issued for services, per share"&gt;156&lt;/span&gt;&#160;per
share, the closing price of the Company&#x2019;s Common Stock on June 21, 2024, adjusted for the Reverse Stock Split. The total
compensation for these shares is $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_pn5n6_c20240624__20240624__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zWSkChCcPySk" title="Share based compensation"&gt;0.2&lt;/span&gt;&#160;million
which will be recognized within general and administrative expense over the service period of the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 18, 2024, certain non-employee directors elected to receive a portion of their unpaid cash retainers due under the Director
Compensation Program in the form of shares. In total, $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20241118__20241118__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorsMember_z2Kj9i6M5lze"&gt;0.1 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
of unpaid retainers was settled through the issuance &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241118__20241118__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorsMember_zeqCSzXEyFn8"&gt;10,027 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of Common Stock (the &#x201c;Retainer Shares&#x201d;). The Company valued the Retainer Shares at $&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20241118__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorsMember_zGp5kyicjAk"&gt;9.0&lt;/span&gt; &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share, the closing price of the Company&#x2019;s Common Stock on November 18, 2024, adjusted for the Reverse Stock Split. The Company
previously accrued in the unpaid retainers in Accrued expenses and other current liabilities in the Company&#x2019;s consolidated
balance sheets. Upon issuance of the shares of Common Stock, the accrual was reduced based on the value of the shares
issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 18, 2024, the Board of Directors approved a one-time equity retainer in the form of &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20241118__20241118__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBmLefyjKCZ5"&gt;750 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;fully
vested shares of Common Stock (the &#x201c;Board Shares&#x201d;) to a member of the Board of Directors for prior services. The Company
valued the Board Shares at $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241118__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zEpLlroMDCz3" title="Share price per share"&gt;9.20&lt;/span&gt; &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share, the closing price of the Company&#x2019;s Common Stock on November 18, 2024, adjusted for the Reverse Stock Split. The total
compensation for these shares is $&lt;span id="xdx_902_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20241118__20241118__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zaL7tRiVxE93" title="Total compensation"&gt;75&lt;/span&gt; &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand
which was immediately recognized within General and administrative expense in the consolidated statement of operations and
comprehensive income (loss). The shares of common stock were issued under the 2023 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;November
18, 2024, Mr. Heilbron elected to have the $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn5n6_c20241118__20241118__srt--TitleOfIndividualAxis__custom--MrHeilbronMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zIbELbZxenJa" title="Stock issued during period value issued for services, value"&gt;0.1&lt;/span&gt; million owed to him under the Consulting Agreement paid in share of the Company&#x2019;s
Common Stock. In total &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20241118__20241118__srt--TitleOfIndividualAxis__custom--MrHeilbronMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zlSBJelfm9i" title="Stock issued during period value issued for services, shares"&gt;8,161&lt;/span&gt; shares are to be issued to Mr. Heilbron based on the closing price of the Company&#x2019;s Common Stock on
November 18, 2024, $&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20241118__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--MrHeilbronMember_z6fHwIaUs8Mh" title="Shares issued for services, per share"&gt;9.20&lt;/span&gt; per share, adjusted for the Reverse Stock Split. As of December 31, 2024, the shares had not been issued to Mr.
Heilbron. The value of the shares are recorded as an accrued expense and other current liability on the consolidated balance sheets as
of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;



&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Restricted
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Merger, as discussed in Notes 1 and 2, and by Unanimous Written Consent of the Board of Directors, the then
Chief Financial Officer of the Company was granted&#160;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20231201__20231201__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zZOOk3nwlFSe" title="Shares granted"&gt;745&lt;/span&gt;&#160;RSUs
on December 1, 2023 at a weighted average grant date fair value of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20231201__20231201_zJuFPpPskTs8" title="Weighted average grant date fair value"&gt;551&lt;/span&gt; per unit.
The RSUs were to vest in equal annual instalments on the first three anniversaries of the closing of the Merger. Upon the then Chief
Financial Officer&#x2019;s resignation, effective May 15, 2024, all such RSUs were forfeited. On June 7, 2024, by Unanimous Written
Consent of the Board of Directors, the Interim Chief Financial Officer of the Company and a Board member were each
granted&#160;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240607__20240607__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zRrDa2KFs7Hj" title="Shares granted"&gt;372&lt;/span&gt;&#160;shares
of immediately vested restricted stock at a weighted average grant date fair value of $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240607__20240607__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zYQEGP8lBcve" title="Weighted average grant date fair value"&gt;284&lt;/span&gt;.
The shares of restricted stock were fully vested as of the grant date.&#160;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_do_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zv8wBqFaW3hi" title="Shares granted"&gt;No&lt;/span&gt;&#160;additional
RSU&#x2019;s or shares of restricted common stock were granted during the year ended December 31, 2024. There were&#160;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znwVjeILgbZj" title="Shares vested"&gt;745&lt;/span&gt;&#160;shares
of restricted common stock vested as of December 31, 2024 and&#160;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zujcwuSwv8E2" title="Shares vested"&gt;no&lt;/span&gt;&#160;RSUs
vested as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zrKDiWEdwHB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes restricted stock activity for the 2023 Plan:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_z3DO0Eys0G8j" style="display: none"&gt;Schedule
of Restricted Stock Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Awards&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Grant Date Fair Value Per Unit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231_zvAzJuP4BzY4" style="width: 16%; text-align: right" title="Number of Awards, Outstanding"&gt;745&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231_z7dcBqJqSAoc" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding"&gt;551&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231_zy4r9o6O4czh" style="text-align: right" title="Number of Awards, Granted"&gt;745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zY3ZhFI8v3G8" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;284&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231_zkG3qLdNmqL4" style="text-align: right" title="Number of Awards, Cancelled/Forfeited"&gt;(745&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_iN_pid_di_c20240101__20241231_zCtdIEGtRuhj" style="text-align: right" title="Weighted Average Grant Date Fair Value, Cancelled/Forfeited"&gt;(551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231_zMeNMKBTdbV7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Awards, Vested"&gt;(745&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_iN_pid_di_c20240101__20241231_zB9bUhufF7Y2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Vested"&gt;(284&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231_zjQYtVpsvdH5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Awards, Outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1518"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231_zTLLMpuwAGJj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1520"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zYSMwp7EYgte" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates the fair value of each option award on the date of grant using the Black-Scholes option-pricing model. The Company
then recognizes the grant date fair value of each option as compensation expense ratably using the straight-line attribution method over
the service period (generally the vesting period). The Black-Scholes model incorporates the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility &#x2013; the Company estimates the volatility of the share price of their peer companies at the date of grant using a &#x201c;look-back&#x201d;
    period which coincides with the expected term, defined below. The Company believes using a &#x201c;look-back&#x201d; period which coincides
    with the expected term is the most appropriate measure for determining expected volatility.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term &#x2013; the Company estimates the expected term using the &#x201c;simplified&#x201d; method outlined in SEC Staff Accounting Bulletin
    No. 107, &#x201c;Share-Based Payment.&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate &#x2013; the Company estimates the risk- free interest rate using the U.S. Treasury Yield curve for periods equal to
    the expected term of the options in effect at the time of grant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividends
    &#x2013; the Company uses an expected dividend yield of zero because the Company has not declared nor paid a cash dividend, nor are
    there any plans to declare a dividend.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zBaIaJl265s5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimated the fair value of stock options granted in the periods presented using a Black-Scholes option-pricing model utilizing
the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span id="xdx_8B2_zGRBcoYo0Cq7" style="display: none"&gt;Schedule of Fair Value
of Stock Option Granted&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zTe9FxoLtNFh" title="Expected Volatility"&gt;83.2&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zcl1d02WjwT" title="Expected Volatility"&gt;85.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z9UGhjz6BM4l" title="Expected Volatility"&gt;79.0&lt;/span&gt;% - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zjt4AnyIiAg2" title="Expected Volatility"&gt;80.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z3JgiqKT57df" title="Expected term (years)"&gt;5.5&lt;/span&gt; - &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zxXQXcvmcwEh" title="Expected term (years)"&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zyBX57jSy0a4" title="Expected term (years)"&gt;3.5&lt;/span&gt; - &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_ztaWcF6568Ki" title="Expected term (years)"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zZMa1v43seSj" title="Risk-free interest rate"&gt;4.28&lt;/span&gt;% - &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z9WtdAI2SJK8" title="Risk-free interest rate"&gt;4.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zjbMLbwsQhuh" title="Risk-free interest rate"&gt;4.16&lt;/span&gt;% - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zrjfVl4qTcCl" title="Risk-free interest rate"&gt;4.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Expected dividend yield (%)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20241231_zeDDkprb70g9" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230101__20231231_zuz1k08Guxf8" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zOGwosEQdR16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for forfeitures as they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures
arise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zlD4LccAaC7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes stock option activity for the 2023 Plan:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BE_zEM2SYKmrjH9" style="display: none"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Term (years)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Aggregate&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Intrinsic Value (in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_z89lSJcEixcg" style="width: 12%; text-align: right" title="Number of Options, Outstanding"&gt;10,717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zaXw5uDHyNC6" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;551&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zqmlZa8fWW5k" title="Weighted Average Remaining Contractual Term Years"&gt;8.85&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zSNWNOOx17Nf" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1560"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zaPG7aLhLJcg" style="text-align: right" title="Number of Options, Granted"&gt;56,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zmQ4YTeY53k" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;8.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zfdVIuu2lu45" style="text-align: right" title="Number of Options, Cancelled/forfeited"&gt;1,908&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zb2MSpYym9Kl" style="text-align: right" title="Weighted Average Exercise Price, Cancelled/Forfeited"&gt;551&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zYYZSYL4Qqdg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1570"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zP19SrsdlKD2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1572"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_z1jc3SEVYEi7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding"&gt;65,509&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zk9sxTdDKnf9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;81.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zn3Gqjnt0d2i" title="Weighted Average Remaining Contractual Term Years"&gt;9.72&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zu9y0C3WCqk7" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1580"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercisable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zfPXv2RcdScj" style="text-align: right" title="Number of Options, Exercisable"&gt;23,154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zfYT7HapQtik" style="text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;84.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zTeBGUka45G1" title="Weighted Average Remaining Contractual Term Years"&gt;9.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zsoDPz366TDk" style="text-align: right" title="Aggregate Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1588"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_ziJRyvS6oSo9" style="text-align: right" title="Number of Options, Unvested"&gt;42,355&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zHZP7SGlZN15" style="text-align: right" title="Weighted Average Exercise Price, Unvested"&gt;80.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zXZUWGtMgEJ3" title="Weighted Average Remaining Contractual Term Years"&gt;9.76&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zjP7aVdxXTB2" style="text-align: right" title="Aggregate Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1596"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zW7FXtZw68J" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair
value of the Company&#x2019;s common stock for those options that had exercise prices lower than the fair value of the Company&#x2019;s
common stock. As of December 31, 2024, the total compensation cost related to non-vested option awards not yet recognized was $&lt;span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20241231_zOlHt25vwM4h" title="Cost related to non-vested option"&gt;2.4&lt;/span&gt; million
with a weighted average remaining vesting period of &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zboIsSjBkl64" title="Weighted average remaining vesting"&gt;2.07&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2023-09-22_custom_TwentyTwentyThreeStockIncentivePlanMember"
      decimals="INF"
      id="Fact001448"
      unitRef="Shares">114976</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2025-02-06_custom_TwentyTwentyThreeStockIncentivePlanMember"
      decimals="INF"
      id="Fact001450"
      unitRef="Shares">69240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2025-01-01_custom_TwentyTwentyThreeStockIncentivePlanMember"
      decimals="INF"
      id="Fact001452"
      unitRef="Shares">154125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="From2023-09-212023-09-22_custom_TwentyTwentyThreeStockIncentivePlanMember"
      decimals="INF"
      id="Fact001454"
      unitRef="Pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_custom_TwentyTwentyThreeStockIncentivePlanMember"
      decimals="INF"
      id="Fact001456"
      unitRef="Shares">84885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001458"
      unitRef="Shares">56700</us-gaap:SharesIssued>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact001460"
      unitRef="USD">400000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="Fact001462"
      unitRef="USD">1600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="Fact001464"
      unitRef="USD">200000</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-06-242024-06-24_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001466"
      unitRef="Shares">961</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-24_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001468"
      unitRef="USDPShares">156</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-06-242024-06-24_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="Fact001470"
      unitRef="USD">200000</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-11-182024-11-18_custom_NonEmployeeDirectorsMember"
      decimals="-5"
      id="Fact001471"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-11-182024-11-18_custom_NonEmployeeDirectorsMember"
      decimals="INF"
      id="Fact001472"
      unitRef="Shares">10027</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-11-18_custom_NonEmployeeDirectorsMember"
      decimals="INF"
      id="Fact001473"
      unitRef="USDPShares">9.0</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-11-182024-11-18_srt_BoardOfDirectorsChairmanMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001474"
      unitRef="Shares">750</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharePrice
      contextRef="AsOf2024-11-18_us-gaap_CommonStockMember_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact001476"
      unitRef="USDPShares">9.20</us-gaap:SharePrice>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-11-182024-11-18_srt_BoardOfDirectorsChairmanMember_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001478"
      unitRef="USD">75000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-11-182024-11-18_custom_MrHeilbronMember_custom_ConsultingAgreementMember"
      decimals="-5"
      id="Fact001480"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-11-182024-11-18_custom_MrHeilbronMember_custom_ConsultingAgreementMember"
      decimals="INF"
      id="Fact001482"
      unitRef="Shares">8161</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharePrice
      contextRef="AsOf2024-11-18_custom_ConsultingAgreementMember_custom_MrHeilbronMember"
      decimals="INF"
      id="Fact001484"
      unitRef="USDPShares">9.20</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-12-012023-12-01_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember"
      decimals="INF"
      id="Fact001486"
      unitRef="Shares">745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-12-012023-12-01"
      decimals="INF"
      id="Fact001488"
      unitRef="USDPShares">551</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-06-072024-06-07_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember"
      decimals="INF"
      id="Fact001490"
      unitRef="Shares">372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-06-072024-06-07_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefFinancialOfficerMember"
      decimals="INF"
      id="Fact001492"
      unitRef="USDPShares">284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001494"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001496"
      unitRef="Shares">745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001498"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001500">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zrKDiWEdwHB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes restricted stock activity for the 2023 Plan:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_z3DO0Eys0G8j" style="display: none"&gt;Schedule
of Restricted Stock Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Awards&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Grant Date Fair Value Per Unit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231_zvAzJuP4BzY4" style="width: 16%; text-align: right" title="Number of Awards, Outstanding"&gt;745&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231_z7dcBqJqSAoc" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding"&gt;551&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231_zy4r9o6O4czh" style="text-align: right" title="Number of Awards, Granted"&gt;745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zY3ZhFI8v3G8" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;284&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231_zkG3qLdNmqL4" style="text-align: right" title="Number of Awards, Cancelled/Forfeited"&gt;(745&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_iN_pid_di_c20240101__20241231_zCtdIEGtRuhj" style="text-align: right" title="Weighted Average Grant Date Fair Value, Cancelled/Forfeited"&gt;(551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231_zMeNMKBTdbV7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Awards, Vested"&gt;(745&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_iN_pid_di_c20240101__20241231_zB9bUhufF7Y2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Vested"&gt;(284&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231_zjQYtVpsvdH5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Awards, Outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1518"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231_zTLLMpuwAGJj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1520"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001502"
      unitRef="Shares">745000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001504"
      unitRef="USDPShares">551</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001506"
      unitRef="Shares">745000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001508"
      unitRef="USDPShares">284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001510"
      unitRef="Shares">745000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001512"
      unitRef="USDPShares">551</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001514"
      unitRef="Shares">745000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001516"
      unitRef="USDPShares">284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001522">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zBaIaJl265s5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimated the fair value of stock options granted in the periods presented using a Black-Scholes option-pricing model utilizing
the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span id="xdx_8B2_zGRBcoYo0Cq7" style="display: none"&gt;Schedule of Fair Value
of Stock Option Granted&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zTe9FxoLtNFh" title="Expected Volatility"&gt;83.2&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zcl1d02WjwT" title="Expected Volatility"&gt;85.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z9UGhjz6BM4l" title="Expected Volatility"&gt;79.0&lt;/span&gt;% - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zjt4AnyIiAg2" title="Expected Volatility"&gt;80.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z3JgiqKT57df" title="Expected term (years)"&gt;5.5&lt;/span&gt; - &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zxXQXcvmcwEh" title="Expected term (years)"&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zyBX57jSy0a4" title="Expected term (years)"&gt;3.5&lt;/span&gt; - &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_ztaWcF6568Ki" title="Expected term (years)"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zZMa1v43seSj" title="Risk-free interest rate"&gt;4.28&lt;/span&gt;% - &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z9WtdAI2SJK8" title="Risk-free interest rate"&gt;4.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zjbMLbwsQhuh" title="Risk-free interest rate"&gt;4.16&lt;/span&gt;% - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zrjfVl4qTcCl" title="Risk-free interest rate"&gt;4.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Expected dividend yield (%)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20241231_zeDDkprb70g9" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230101__20231231_zuz1k08Guxf8" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001524"
      unitRef="Pure">0.832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001526"
      unitRef="Pure">0.854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001528"
      unitRef="Pure">0.790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001530"
      unitRef="Pure">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      id="Fact001532">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      id="Fact001534">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_srt_MinimumMember"
      id="Fact001536">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_srt_MaximumMember"
      id="Fact001538">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001540"
      unitRef="Pure">0.0428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001542"
      unitRef="Pure">0.0440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001544"
      unitRef="Pure">0.0416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001546"
      unitRef="Pure">0.0435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001548"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001550"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001552">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zlD4LccAaC7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes stock option activity for the 2023 Plan:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BE_zEM2SYKmrjH9" style="display: none"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Term (years)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Aggregate&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Intrinsic Value (in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_z89lSJcEixcg" style="width: 12%; text-align: right" title="Number of Options, Outstanding"&gt;10,717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zaXw5uDHyNC6" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;551&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zqmlZa8fWW5k" title="Weighted Average Remaining Contractual Term Years"&gt;8.85&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zSNWNOOx17Nf" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1560"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zaPG7aLhLJcg" style="text-align: right" title="Number of Options, Granted"&gt;56,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zmQ4YTeY53k" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;8.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled/forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zfdVIuu2lu45" style="text-align: right" title="Number of Options, Cancelled/forfeited"&gt;1,908&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zb2MSpYym9Kl" style="text-align: right" title="Weighted Average Exercise Price, Cancelled/Forfeited"&gt;551&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zYYZSYL4Qqdg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1570"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zP19SrsdlKD2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1572"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_z1jc3SEVYEi7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding"&gt;65,509&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zk9sxTdDKnf9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding"&gt;81.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zn3Gqjnt0d2i" title="Weighted Average Remaining Contractual Term Years"&gt;9.72&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zu9y0C3WCqk7" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1580"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercisable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zfPXv2RcdScj" style="text-align: right" title="Number of Options, Exercisable"&gt;23,154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zfYT7HapQtik" style="text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;84.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zTeBGUka45G1" title="Weighted Average Remaining Contractual Term Years"&gt;9.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zsoDPz366TDk" style="text-align: right" title="Aggregate Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1588"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_ziJRyvS6oSo9" style="text-align: right" title="Number of Options, Unvested"&gt;42,355&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zHZP7SGlZN15" style="text-align: right" title="Weighted Average Exercise Price, Unvested"&gt;80.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zXZUWGtMgEJ3" title="Weighted Average Remaining Contractual Term Years"&gt;9.76&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyThreePlanMember_zjP7aVdxXTB2" style="text-align: right" title="Aggregate Intrinsic Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1596"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreePlanMember"
      decimals="INF"
      id="Fact001554"
      unitRef="Shares">10717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreePlanMember"
      decimals="INF"
      id="Fact001556"
      unitRef="USDPShares">551</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreePlanMember"
      id="Fact001558">P8Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember"
      decimals="-3"
      id="Fact001562"
      unitRef="Shares">56700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember"
      decimals="INF"
      id="Fact001564"
      unitRef="USDPShares">8.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember"
      decimals="-3"
      id="Fact001566"
      unitRef="Shares">1908000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember"
      decimals="INF"
      id="Fact001568"
      unitRef="USDPShares">551</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember"
      decimals="INF"
      id="Fact001574"
      unitRef="Shares">65509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember"
      decimals="INF"
      id="Fact001576"
      unitRef="USDPShares">81.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember"
      id="Fact001578">P9Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember"
      decimals="-3"
      id="Fact001582"
      unitRef="Shares">23154000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember"
      decimals="INF"
      id="Fact001584"
      unitRef="USDPShares">84.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember"
      id="Fact001586">P9Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <CDT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember"
      decimals="-3"
      id="Fact001590"
      unitRef="Shares">42355000</CDT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber>
    <CDT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember"
      decimals="INF"
      id="Fact001592"
      unitRef="USDPShares">80.07</CDT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice>
    <CDT:ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember"
      id="Fact001594">P9Y9M3D</CDT:ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001598"
      unitRef="USD">2400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-01-01to2024-12-31" id="Fact001600">P2Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001602">&lt;p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zMffBXayQx58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12.
&lt;span id="xdx_822_zjXscbwacXga"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zUcA0awPmLg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Loss from operations before income
taxes for the years ended December 31, 2024 and 2023 is summarized below (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zMVxAIiHVcYl" style="display: none"&gt;Schedule of Income before Income Tax, Domestic and Foreign&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231_zj8aoHNv8tki" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20231231_z1IT1RIWy1fb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_iB_zbAoRlECz5Wd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from operations before income taxes:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i01_maILFCOzobr_zQsoEnZ56P78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; padding-left: 0.5in"&gt;US&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(12,855&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(1,990&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i01_maILFCOzobr_zRwjiNfo36Yj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.5in"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,947&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,454&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_mtILFCOzobr_zikm4NYzBAs1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Loss from operations before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(17,802&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(536&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zBoGoEzeKrd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z0DMoB3vjxg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
provision (benefit) for income taxes for the years ended December 31, 2024 and December 31, 2023 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8B2_zxhmnoyBXHKj" style="display: none"&gt;Schedule of Provision for Income Tax&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_zkf2jmA5U8yg" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231_zfVRTsnxp1yk" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For The Years Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_zcD79FYKzuv1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1620"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1621"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_zTlVy8Beh0dh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1623"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1624"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_zlanbZ1RLPkk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1626"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1627"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_zf2uGegnBRG2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current income tax&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1630"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Deferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_z3MeELTHQa1e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(2,429&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(843&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_zPYSZliV9Hie" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;355&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(355&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_pn3n3_znCwMjmrOSYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(931&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(251&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3n3_zzva8tygFM3h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred income tax&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,005&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,449&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_ztZLWMAGlhI5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in Valuation Allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,449&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zzMTb2QetDP9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net Income Tax Expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1647"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1648"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zYm6iPW3AKyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zeq9Kfy0ZFJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax provision differed from the amount computed by applying the U.S. federal income tax rate of &lt;span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_zY0243RDodYl"&gt;21&lt;/span&gt;% to income (loss) before taxes, as
follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zlaiIzT87Rj4" style="display: none"&gt;Schedule
of Federal Income Tax Rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zREUvd2H3s3c" style="border-bottom: Black 1pt solid; text-align: center"&gt;US&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zioxz5mvuNth" style="border-bottom: Black 1pt solid; text-align: center"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zEIGnpM0vrU8" style="border-bottom: Black 1pt solid; text-align: center"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For The Year Ended&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;US&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzbix_zsMbfVAp9cNg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Taxes at federal statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(2,705&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(1,039&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(3,744&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maITEBzbix_zuUmSswPUKU5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign Rate Differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1657"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91 &lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maITEBzbix_zIvbgV5iFirc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Meals &amp;amp; Entertainment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1662"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_pn3n3_maITEBzbix_zaqsfP2LujIh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Eq Comp Perm&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1666"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--IncomeTaxReconciliationConvertibleDebtAdjustment_pn3n3_maITEBzbix_zT2Npgc5Wbh9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Convertible Debt Adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1670"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationStateReRate_pn3n3_maITEBzbix_zokB8Ld15Oxc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State Re-Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;355&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1674"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;355&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maITEBzbix_zuEidSykYiu5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(76&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(59&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzbix_zy1n58puvGEg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change In Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,074&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;931&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,005&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzbix_zlhSe7jytOLk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total provision (benefit) for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1685"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1686"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1687"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmASuhfEOQo6" style="border-bottom: Black 1pt solid; text-align: center"&gt;US&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zXpfATiNFTCh" style="border-bottom: Black 1pt solid; text-align: center"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zBFlZWCWregl" style="border-bottom: Black 1pt solid; text-align: center"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For The Year Ended&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;US&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzbix_zHfGaUT0Pye8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Taxes at federal statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(417&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;305&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(112&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzbix_zmZ9OVyOM44a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State Taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(175&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1694"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(175&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maITEBzbix_z8DbuhbmDJic" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign Rate Differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1697"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maITEBzbix_zJbdDWvcgoH" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Meals &amp;amp; Entertainment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_pn3n3_maITEBzbix_zv0Pr4kfU13j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Eq Comp Perm&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1706"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--IncomeTaxReconciliationConvertibleDebtAdjustment_pn3n3_maITEBzbix_z6tILXxHK4j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Debt Adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1709"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,048&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,048&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--IncomeTaxReconciliationPurchaseAccountingAdjustments_pn3n3_maITEBzbix_zxmD3op3Czzh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Purchase Accounting Adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(609&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1714"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(609&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzbix_zKInzUrrpnhd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change In Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;251&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,449&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzbix_zi9aJ1MvZug6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total provision (benefit) for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1721"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1722"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1723"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A1_z2QPcpWsJELg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zSMZBNIYmoDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tax effects of temporary differences which give rise to significant portions of deferred tax assets are as follows as of December 31
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zXEONsTeVo4" style="display: none"&gt;Schedule
of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zbiDH8OVEin7" style="border-bottom: Black 1pt solid; text-align: center"&gt;US&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zfu5jwUxRBfl" style="border-bottom: Black 1pt solid; text-align: center"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231_zkzR5g3PH9S9" style="border-bottom: Black 1pt solid; text-align: center"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For The Year Ended&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;US&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Deferred Tax Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredTaxAssetsStockOptions_iI_pn3n3_maDTAGzJ4A_zpGtcoAV3Fmh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;280&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1728"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;280&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsHedgingTransactions_iI_pn3n3_maDTAGzJ4A_zP3jcOXwpTyk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Transaction Costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1732"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzJ4A_z47NOXKKQNrj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research &amp;amp; Development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;671&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1736"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;671&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_pn3n3_maDTAGzJ4A_zZ4ACcBvPOH8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1740"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzJ4A_z0lrxbxmVF0h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net operating loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,788&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,182&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,970&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzJ4A_maNDTAzpU6_zzOChQgdkKJ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzjwi_zTg0HciqIuB7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,273&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,182&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,455&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTALNzjwi_zIniBtnKe5Ve" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets (liability)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1755"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1756"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1757"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_znmEnIClDEKe" style="border-bottom: Black 1pt solid; text-align: center"&gt;US&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zt7U4vfjY3hh" style="border-bottom: Black 1pt solid; text-align: center"&gt;Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zNNh3iKZH5ri" style="border-bottom: Black 1pt solid; text-align: center"&gt;Consolidated&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For The Year Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;US&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Deferred Tax Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxAssetsStockOptions_iI_pn3n3_maDTAGzJ4A_zCUi9CCfy8Sg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1760"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsHedgingTransactions_iI_pn3n3_maDTAGzJ4A_zvxOLF2rEw11" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Transaction Costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzJ4A_zJt5jqeQdw03" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;562&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;251&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzJ4A_maNDTAzpU6_zrbfj4BlPjxa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;251&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,449&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzjwi_zNC0hv4gSJ0f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,198&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(251&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,449&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTALNzjwi_z1HzbCuagGjk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net deferred tax assets (liability)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1779"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1780"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1781"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zYvYVgkdfzIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and December 31, 2023, the Company had net operating loss (&#x201c;NOL&#x201d;) carryforwards for U.S.
federal&#x201d; purposes of approximately $&lt;span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zONcUIuFwhQl" title="Net operating loss"&gt;8.5&lt;/span&gt;
million and $&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zrQZtTEafhz3" title="Net operating loss"&gt;1.9&lt;/span&gt;
million, respectively, which carryforward indefinitely and can offset &lt;span id="xdx_90A_ecustom--EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate_pid_dp_uPure_c20230101__20231231_zxP8Q80J9Ikc" title="Effective income tax rate reconciliation future income years tax rate"&gt;80&lt;/span&gt;%
of taxable income in future years. As of December 31, 2024 and December 31, 2023, the Company had state NOL carryforwards of &lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_dxL_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z54Ipa0mrWZa" title="Net operating loss::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1789"&gt;nil&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zsBp23lxSEL6" title="Net operating loss"&gt;1.9&lt;/span&gt;
million, respectively. As of December 31, 2024 and December 31, 2023, the Company had net
operating loss (&#x201c;NOL&#x201d;) carryforwards for foreign purposes of approximately $&lt;span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z6sBzjl8N1Vd" title="Net operating loss"&gt;4.7&lt;/span&gt;
million and $&lt;span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z2mqYdV4CR6a" title="Net operating loss"&gt;1.0&lt;/span&gt;
million, respectively, which carryforward indefinitely. Net operating loss (NOL) carryforwards are subject to limitations in
the event of a change in control under Section 382 of the Internal Revenue Code. This section limits the amount of taxable income
that can be offset by NOLs after an ownership change. The limitation is calculated as the value of the old loss corporation
multiplied by the long-term tax-exempt rate. If the new loss corporation does not continue the business enterprise of the old loss
corporation for a specified period, the NOL carryforwards may be disallowed. The Company has not yet conducted a Section 382 study
to determine whether any ownership changes have occurred that would impose annual limitations on its ability to utilize its NOL
carryforwards. Until such a study is completed, there is substantial uncertainty regarding the amount of NOL carryforwards that
could be utilized annually to offset future taxable income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company establishes a valuation allowance when it is more likely than not that the Company&#x2019;s recorded net deferred tax asset
will not be realized. In determining whether a valuation allowance is required, the Company must take into account all positive and
negative evidence with regard to the utilization of a deferred tax asset. As of December 31, 2024 and December 31, 2023, the
valuation allowance for deferred tax assets totaled approximately $&lt;span id="xdx_90F_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20241231_z0hvDipLYfYk" title="Deferred tax assets valuation allowance"&gt;4.5&lt;/span&gt;
million and $&lt;span id="xdx_901_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20231231_zFAUjGhdS6mj" title="Deferred tax assets valuation allowance"&gt;1.4&lt;/span&gt;
million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001604">&lt;p id="xdx_89A_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zUcA0awPmLg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Loss from operations before income
taxes for the years ended December 31, 2024 and 2023 is summarized below (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zMVxAIiHVcYl" style="display: none"&gt;Schedule of Income before Income Tax, Domestic and Foreign&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231_zj8aoHNv8tki" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20231231_z1IT1RIWy1fb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_iB_zbAoRlECz5Wd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from operations before income taxes:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i01_maILFCOzobr_zQsoEnZ56P78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; padding-left: 0.5in"&gt;US&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(12,855&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(1,990&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i01_maILFCOzobr_zRwjiNfo36Yj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.5in"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,947&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,454&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_mtILFCOzobr_zikm4NYzBAs1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Loss from operations before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(17,802&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(536&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001609"
      unitRef="USD">-12855000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001610"
      unitRef="USD">-1990000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001612"
      unitRef="USD">-4947000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001613"
      unitRef="USD">1454000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001615"
      unitRef="USD">-17802000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001616"
      unitRef="USD">-536000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001618">&lt;p id="xdx_89C_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z0DMoB3vjxg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
provision (benefit) for income taxes for the years ended December 31, 2024 and December 31, 2023 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8B2_zxhmnoyBXHKj" style="display: none"&gt;Schedule of Provision for Income Tax&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_zkf2jmA5U8yg" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231_zfVRTsnxp1yk" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For The Years Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_zcD79FYKzuv1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1620"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1621"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_zTlVy8Beh0dh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1623"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1624"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_zlanbZ1RLPkk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1626"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1627"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_zf2uGegnBRG2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current income tax&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1630"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Deferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_z3MeELTHQa1e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(2,429&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(843&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_zPYSZliV9Hie" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;355&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(355&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_pn3n3_znCwMjmrOSYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(931&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(251&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3n3_zzva8tygFM3h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred income tax&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,005&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,449&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_ztZLWMAGlhI5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in Valuation Allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,449&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zzMTb2QetDP9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net Income Tax Expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1647"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1648"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001632"
      unitRef="USD">-2429000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001633"
      unitRef="USD">-843000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001635"
      unitRef="USD">355000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001636"
      unitRef="USD">-355000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001638"
      unitRef="USD">-931000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001639"
      unitRef="USD">-251000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001641"
      unitRef="USD">-3005000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001642"
      unitRef="USD">-1449000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001644"
      unitRef="USD">3005000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001645"
      unitRef="USD">1449000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001650">&lt;p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zeq9Kfy0ZFJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax provision differed from the amount computed by applying the U.S. federal income tax rate of &lt;span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_zY0243RDodYl"&gt;21&lt;/span&gt;% to income (loss) before taxes, as
follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zlaiIzT87Rj4" style="display: none"&gt;Schedule
of Federal Income Tax Rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zREUvd2H3s3c" style="border-bottom: Black 1pt solid; text-align: center"&gt;US&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zioxz5mvuNth" style="border-bottom: Black 1pt solid; text-align: center"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zEIGnpM0vrU8" style="border-bottom: Black 1pt solid; text-align: center"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For The Year Ended&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;US&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzbix_zsMbfVAp9cNg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Taxes at federal statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(2,705&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(1,039&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(3,744&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maITEBzbix_zuUmSswPUKU5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign Rate Differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1657"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91 &lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maITEBzbix_zIvbgV5iFirc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Meals &amp;amp; Entertainment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1662"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_pn3n3_maITEBzbix_zaqsfP2LujIh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Eq Comp Perm&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1666"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--IncomeTaxReconciliationConvertibleDebtAdjustment_pn3n3_maITEBzbix_zT2Npgc5Wbh9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Convertible Debt Adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1670"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationStateReRate_pn3n3_maITEBzbix_zokB8Ld15Oxc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State Re-Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;355&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1674"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;355&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maITEBzbix_zuEidSykYiu5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(76&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(59&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzbix_zy1n58puvGEg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change In Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,074&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;931&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,005&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzbix_zlhSe7jytOLk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total provision (benefit) for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1685"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1686"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1687"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmASuhfEOQo6" style="border-bottom: Black 1pt solid; text-align: center"&gt;US&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zXpfATiNFTCh" style="border-bottom: Black 1pt solid; text-align: center"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zBFlZWCWregl" style="border-bottom: Black 1pt solid; text-align: center"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For The Year Ended&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;US&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzbix_zHfGaUT0Pye8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Taxes at federal statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(417&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;305&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(112&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzbix_zmZ9OVyOM44a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State Taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(175&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1694"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(175&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maITEBzbix_z8DbuhbmDJic" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign Rate Differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1697"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maITEBzbix_zJbdDWvcgoH" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Meals &amp;amp; Entertainment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_pn3n3_maITEBzbix_zv0Pr4kfU13j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Eq Comp Perm&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1706"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--IncomeTaxReconciliationConvertibleDebtAdjustment_pn3n3_maITEBzbix_z6tILXxHK4j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Debt Adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1709"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,048&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,048&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--IncomeTaxReconciliationPurchaseAccountingAdjustments_pn3n3_maITEBzbix_zxmD3op3Czzh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Purchase Accounting Adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(609&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1714"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(609&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzbix_zKInzUrrpnhd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change In Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;251&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,449&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzbix_zi9aJ1MvZug6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total provision (benefit) for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1721"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1722"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1723"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001651"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001653"
      unitRef="USD">-2705000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001654"
      unitRef="USD">-1039000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001655"
      unitRef="USD">-3744000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001658"
      unitRef="USD">91000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001659"
      unitRef="USD">91000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001661"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001663"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001665"
      unitRef="USD">84000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001667"
      unitRef="USD">84000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <CDT:IncomeTaxReconciliationConvertibleDebtAdjustment
      contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001669"
      unitRef="USD">268000</CDT:IncomeTaxReconciliationConvertibleDebtAdjustment>
    <CDT:IncomeTaxReconciliationConvertibleDebtAdjustment
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001671"
      unitRef="USD">268000</CDT:IncomeTaxReconciliationConvertibleDebtAdjustment>
    <CDT:IncomeTaxReconciliationStateReRate
      contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001673"
      unitRef="USD">355000</CDT:IncomeTaxReconciliationStateReRate>
    <CDT:IncomeTaxReconciliationStateReRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001675"
      unitRef="USD">355000</CDT:IncomeTaxReconciliationStateReRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001677"
      unitRef="USD">-76000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001678"
      unitRef="USD">17000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001679"
      unitRef="USD">-59000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-012024-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001681"
      unitRef="USD">2074000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-012024-12-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001682"
      unitRef="USD">931000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001683"
      unitRef="USD">3005000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001689"
      unitRef="USD">-417000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001690"
      unitRef="USD">305000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001691"
      unitRef="USD">-112000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001693"
      unitRef="USD">-175000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001695"
      unitRef="USD">-175000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001698"
      unitRef="USD">490000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001699"
      unitRef="USD">490000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001701"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001702"
      unitRef="USD">2000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001703"
      unitRef="USD">2000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001705"
      unitRef="USD">3000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001707"
      unitRef="USD">3000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <CDT:IncomeTaxReconciliationConvertibleDebtAdjustment
      contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001710"
      unitRef="USD">-1048000</CDT:IncomeTaxReconciliationConvertibleDebtAdjustment>
    <CDT:IncomeTaxReconciliationConvertibleDebtAdjustment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001711"
      unitRef="USD">-1048000</CDT:IncomeTaxReconciliationConvertibleDebtAdjustment>
    <CDT:IncomeTaxReconciliationPurchaseAccountingAdjustments
      contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001713"
      unitRef="USD">-609000</CDT:IncomeTaxReconciliationPurchaseAccountingAdjustments>
    <CDT:IncomeTaxReconciliationPurchaseAccountingAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001715"
      unitRef="USD">-609000</CDT:IncomeTaxReconciliationPurchaseAccountingAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001717"
      unitRef="USD">1198000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001718"
      unitRef="USD">251000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001719"
      unitRef="USD">1449000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001725">&lt;p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zSMZBNIYmoDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tax effects of temporary differences which give rise to significant portions of deferred tax assets are as follows as of December 31
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zXEONsTeVo4" style="display: none"&gt;Schedule
of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zbiDH8OVEin7" style="border-bottom: Black 1pt solid; text-align: center"&gt;US&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zfu5jwUxRBfl" style="border-bottom: Black 1pt solid; text-align: center"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231_zkzR5g3PH9S9" style="border-bottom: Black 1pt solid; text-align: center"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For The Year Ended&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;US&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Deferred Tax Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredTaxAssetsStockOptions_iI_pn3n3_maDTAGzJ4A_zpGtcoAV3Fmh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;280&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1728"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;280&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsHedgingTransactions_iI_pn3n3_maDTAGzJ4A_zP3jcOXwpTyk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Transaction Costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1732"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzJ4A_z47NOXKKQNrj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research &amp;amp; Development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;671&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1736"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;671&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_pn3n3_maDTAGzJ4A_zZ4ACcBvPOH8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1740"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzJ4A_z0lrxbxmVF0h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net operating loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,788&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,182&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,970&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzJ4A_maNDTAzpU6_zzOChQgdkKJ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzjwi_zTg0HciqIuB7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,273&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,182&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,455&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTALNzjwi_zIniBtnKe5Ve" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets (liability)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1755"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1756"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1757"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_znmEnIClDEKe" style="border-bottom: Black 1pt solid; text-align: center"&gt;US&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zt7U4vfjY3hh" style="border-bottom: Black 1pt solid; text-align: center"&gt;Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zNNh3iKZH5ri" style="border-bottom: Black 1pt solid; text-align: center"&gt;Consolidated&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;For The Year Ended&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;US&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Foreign&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Consolidated&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Deferred Tax Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxAssetsStockOptions_iI_pn3n3_maDTAGzJ4A_zCUi9CCfy8Sg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1760"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsHedgingTransactions_iI_pn3n3_maDTAGzJ4A_zvxOLF2rEw11" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Transaction Costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzJ4A_zJt5jqeQdw03" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;562&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;251&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzJ4A_maNDTAzpU6_zrbfj4BlPjxa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;251&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,449&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzjwi_zNC0hv4gSJ0f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,198&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(251&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,449&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTALNzjwi_z1HzbCuagGjk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net deferred tax assets (liability)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1779"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1780"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1781"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <CDT:DeferredTaxAssetsStockOptions
      contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001727"
      unitRef="USD">280000</CDT:DeferredTaxAssetsStockOptions>
    <CDT:DeferredTaxAssetsStockOptions
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001729"
      unitRef="USD">280000</CDT:DeferredTaxAssetsStockOptions>
    <us-gaap:DeferredTaxAssetsHedgingTransactions
      contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001731"
      unitRef="USD">393000</us-gaap:DeferredTaxAssetsHedgingTransactions>
    <us-gaap:DeferredTaxAssetsHedgingTransactions
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001733"
      unitRef="USD">393000</us-gaap:DeferredTaxAssetsHedgingTransactions>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001735"
      unitRef="USD">671000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001737"
      unitRef="USD">671000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001739"
      unitRef="USD">141000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001741"
      unitRef="USD">141000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001743"
      unitRef="USD">1788000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001744"
      unitRef="USD">1182000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001745"
      unitRef="USD">2970000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001747"
      unitRef="USD">3273000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001748"
      unitRef="USD">1182000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001749"
      unitRef="USD">4455000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001751"
      unitRef="USD">3273000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001752"
      unitRef="USD">1182000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001753"
      unitRef="USD">4455000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <CDT:DeferredTaxAssetsStockOptions
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001759"
      unitRef="USD">37000</CDT:DeferredTaxAssetsStockOptions>
    <CDT:DeferredTaxAssetsStockOptions
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001761"
      unitRef="USD">37000</CDT:DeferredTaxAssetsStockOptions>
    <us-gaap:DeferredTaxAssetsHedgingTransactions
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001763"
      unitRef="USD">599000</us-gaap:DeferredTaxAssetsHedgingTransactions>
    <us-gaap:DeferredTaxAssetsHedgingTransactions
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001765"
      unitRef="USD">599000</us-gaap:DeferredTaxAssetsHedgingTransactions>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001767"
      unitRef="USD">562000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001768"
      unitRef="USD">251000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001769"
      unitRef="USD">813000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001771"
      unitRef="USD">1198000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001772"
      unitRef="USD">251000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001773"
      unitRef="USD">1449000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001775"
      unitRef="USD">1198000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001776"
      unitRef="USD">251000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001777"
      unitRef="USD">1449000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="Fact001783"
      unitRef="USD">8500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="Fact001785"
      unitRef="USD">1900000</us-gaap:OperatingLossCarryforwards>
    <CDT:EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001787"
      unitRef="Pure">0.80</CDT:EffectiveIncomeTaxRateReconciliationFutureIncomeYearsTaxRate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact001791"
      unitRef="USD">1900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_us-gaap_ForeignCountryMember"
      decimals="-5"
      id="Fact001793"
      unitRef="USD">4700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember"
      decimals="-5"
      id="Fact001795"
      unitRef="USD">1000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001797"
      unitRef="USD">4500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact001799"
      unitRef="USD">1400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001801">&lt;p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zs1qrt9ByTA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;13.
&lt;span id="xdx_82C_zrrD6CPabe2j"&gt;Common Stock and Preferred Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, and December 31, 2023, the Company has authorized the issuance of up to &lt;span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zFNloFgi4DNa"&gt;250,000,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of common stock, respectively, at a par value $&lt;span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zbCsuUxa08vj"&gt;0.0001 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, and December 31, 2023 there were &lt;span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_znJXFoBn2Xsk" title="Common stock, shares issued"&gt;&lt;span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_z7ll3rjrklYj" title="Common stock, shares outstanding"&gt;1,384,801&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zun38lDOR0R5" title="Common stock, shares issued"&gt;&lt;span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zD0jJX6loLli" title="Common stock, shares outstanding"&gt;738,295&lt;/span&gt;&lt;/span&gt; shares of Common Stock issued and outstanding, respectively.
&lt;span id="xdx_905_eus-gaap--DividendsCash_do_c20240101__20241231_zJ9MCI6mzbG1"&gt;No&lt;/span&gt; cash dividends have been declared or paid as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Holders
of the Common Stock are entitled to one vote per share, and to receive dividends, on and if declared by the board of directors and, upon
liquidation or dissolution, are entitled to receive all assets available for distribution, subordinate to the rights, preferences, and
privileges of any outstanding preferred shares (if any) with respect to dividends and in connection with liquidation, winding up and
dissolution of the Company. The holders have no preemptive or other subscription rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company has authorized the issuance of up to &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zFo4yNFaO5W5"&gt;1,000,000&lt;/span&gt; shares of Conduit Pharmaceuticals, Inc. preferred stock
(the &#x201c;Preferred Stock&#x201d;). As of December 31, 2024, and December 31, 2023, &lt;span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_dxL_c20241231_zJ2bW9FgKsrj" title="Preferred stock, shares issued::XDX::-"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_dxL_c20241231_z9eeZtHsLyji" title="Preferred stock, shares outstanding::XDX::-"&gt;&lt;span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pid_dxL_c20231231_zSdI97jxcfb3" title="Preferred stock, shares issued::XDX::-"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dxL_c20231231_zmPztFppNXG3" title="Preferred stock, shares outstanding::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1815"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1817"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1819"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1821"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; preferred shares were issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;At-the-Market
Offering&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 23, 2024, the Company entered into the Sales Agreement with A.G.P. relating to shares of the Company&#x2019;s Common Stock. In
accordance with the terms of the Sales Agreement, the Company may offer and sell shares of our Common Stock having an aggregate offering
price of up to $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20241023__20241023_zTMVvXX7FPg1"&gt;3.6
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million&#160;from time to time through A.G.P.,
acting as our sales agent or principal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
compensation to A.G.P. for sales of common stock sold pursuant to the Sales Agreement will be equal to &lt;span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zuldWhtwn2Sd" title="Sale of stock, percentage"&gt;3.0&lt;/span&gt;% of the gross proceeds of
any shares of common stock sold under the sales agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, the Company sold &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z3m1KsPNxmoj"&gt;323,273
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Common Stock under the Sales Agreement
and generated $&lt;span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zV5EmLbdFHw6"&gt;3.3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million&#160;in net proceeds after paying fees
to A.G.P. and other issuance costs of $&lt;span id="xdx_908_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zo9K1JKZTQVi"&gt;0.2
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million. See Note 20 for information on the issuances
and increases to the aggregate offering price subsequent to December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001802"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001803"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001805"
      unitRef="Shares">1384801</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001807"
      unitRef="Shares">1384801</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001809"
      unitRef="Shares">738295</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001811"
      unitRef="Shares">738295</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DividendsCash
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001812"
      unitRef="USD">0</us-gaap:DividendsCash>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001813"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-10-232024-10-23"
      decimals="-5"
      id="Fact001822"
      unitRef="USD">3600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SalesAgreementMember"
      decimals="INF"
      id="Fact001824"
      unitRef="Pure">0.030</us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SalesAgreementMember"
      decimals="INF"
      id="Fact001825"
      unitRef="Shares">323273</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SalesAgreementMember"
      decimals="-5"
      id="Fact001826"
      unitRef="USD">3300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SalesAgreementMember"
      decimals="-5"
      id="Fact001827"
      unitRef="USD">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001829">&lt;p id="xdx_800_eus-gaap--EarningsPerShareTextBlock_zvYudql1tvnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14.
&lt;span id="xdx_823_zjtxFW3Iawnc"&gt;Earnings/(Net Loss) Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zIgahDeMW377" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the calculation of basic and diluted earnings/(net loss) per share (in thousands, except share amounts and per
share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zplVRWoff8he" style="display: none"&gt;Schedule
of Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zfn0S5lN5Lqe" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zOHpaNx3a6r2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
                                            the years ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_maNILATzJEp_z8UQOiBwl1ae" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Net income (loss) - basic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(17,802&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(535&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ChangeInFairValueAndIncomeImpactOfOptionLiabilities_iN_pn3n3_di_msNILATzJEp_z1Ky9hZe9hdj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 20pt"&gt;Less: Change in fair value and income impact of option liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1836"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,521&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_iT_pn3n3_mtNILATzJEp_z7YWM3wqGVS3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Net income (loss) - diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(17,802&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(6,056&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zZtAdU2VVZ7g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Weighted average common stock outstanding, basic&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;867,096&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;669,739&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--OptionLiabilityConversionShares_pid_zhR4WG7c9cLe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 20pt"&gt;Add: Option liability conversion shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1845"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_zcgCt1xPrTUc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Weighted average shares used in computing net loss per share - diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;867,096&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;678,939&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EarningsPerShareBasic_pid_zrRj4i04auhc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net income (loss) per share, basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(20.53&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.79&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_pid_zHYVozj43l1b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net income (loss) per share, diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(20.53&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(8.92&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zedPTUQnSKR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company notes that the adjustment to the numerator in 2023 for the change in fair value and income impact of Vela and Cizzle
accounts for changes in fair value of each option, gains (losses) at the time of issuance of each option and the statement of
operations impact of the derecognition of deferred revenue that originated upon the initial sale of royalties to both Vela and
Cizzle.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ziQtr3IBQtLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive securities (upon conversion) that were not included in the diluted per share calculations because they would have been anti-dilutive
were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zm7r1qoMmG5i" style="display: none"&gt;Schedule
of Potentially Dilutive Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20241231_z8lF6z0IaIk2" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zF2M9MghyTs7" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PublicWarrantsMember_zl5JWAfU4uH3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Public warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;139,790&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;139,790&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PIPEMember_zmQQ5phS9h55" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;PIPE Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1862"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AGPWarrantsMember_z0CMGaPf10k6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;A.G.P. Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;540&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;540&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePromissoryNotesPayableMember_zGpdAfvxPI6j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Promissory Notes Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;805&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zC9p8TYuoeCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65,509&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zct5Ft3E26O2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1874"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,470&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zpWC5guhU2B2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;August 2024 Nirland Note&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;672,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1878"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AGPConvertibleNoteMember_zXTJrNfL7Lje" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;A.G.P. Convertible Note&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;576,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1881"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--MarchTwentyTwentyFourWarrantsMember_zuf4MDpqNsm7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;March 2024 Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1884"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AprilTwentyTwentyFourWarrantsMember_zn1dkvEjbyyi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;April 2024 Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1887"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AGPTwentyTwentyFourWarrantsMember_zD0sqjeOpkNk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;A.G.P. 2024 Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;28,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1890"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zifmr5T3zFlb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Antidilutive Securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,501,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;173,322&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zkv2dY1HCjqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001831">&lt;p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zIgahDeMW377" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the calculation of basic and diluted earnings/(net loss) per share (in thousands, except share amounts and per
share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zplVRWoff8he" style="display: none"&gt;Schedule
of Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zfn0S5lN5Lqe" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zOHpaNx3a6r2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
                                            the years ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_maNILATzJEp_z8UQOiBwl1ae" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Net income (loss) - basic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(17,802&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(535&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ChangeInFairValueAndIncomeImpactOfOptionLiabilities_iN_pn3n3_di_msNILATzJEp_z1Ky9hZe9hdj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 20pt"&gt;Less: Change in fair value and income impact of option liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1836"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,521&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_iT_pn3n3_mtNILATzJEp_z7YWM3wqGVS3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Net income (loss) - diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(17,802&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(6,056&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zZtAdU2VVZ7g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Weighted average common stock outstanding, basic&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;867,096&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;669,739&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--OptionLiabilityConversionShares_pid_zhR4WG7c9cLe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 20pt"&gt;Add: Option liability conversion shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1845"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_zcgCt1xPrTUc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Weighted average shares used in computing net loss per share - diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;867,096&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;678,939&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EarningsPerShareBasic_pid_zrRj4i04auhc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net income (loss) per share, basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(20.53&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.79&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_pid_zHYVozj43l1b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net income (loss) per share, diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(20.53&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(8.92&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001833"
      unitRef="USD">-17802000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001834"
      unitRef="USD">-535000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <CDT:ChangeInFairValueAndIncomeImpactOfOptionLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001837"
      unitRef="USD">5521000</CDT:ChangeInFairValueAndIncomeImpactOfOptionLiabilities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001839"
      unitRef="USD">-17802000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001840"
      unitRef="USD">-6056000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001842"
      unitRef="Shares">867096</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001843"
      unitRef="Shares">669739</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <CDT:OptionLiabilityConversionShares
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001846"
      unitRef="Shares">9200</CDT:OptionLiabilityConversionShares>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001848"
      unitRef="Shares">867096</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001849"
      unitRef="Shares">678939</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001851"
      unitRef="USDPShares">-20.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001852"
      unitRef="USDPShares">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001854"
      unitRef="USDPShares">-20.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001855"
      unitRef="USDPShares">-8.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001857">&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ziQtr3IBQtLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive securities (upon conversion) that were not included in the diluted per share calculations because they would have been anti-dilutive
were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zm7r1qoMmG5i" style="display: none"&gt;Schedule
of Potentially Dilutive Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20241231_z8lF6z0IaIk2" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zF2M9MghyTs7" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PublicWarrantsMember_zl5JWAfU4uH3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Public warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;139,790&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;139,790&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PIPEMember_zmQQ5phS9h55" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;PIPE Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1862"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AGPWarrantsMember_z0CMGaPf10k6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;A.G.P. Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;540&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;540&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePromissoryNotesPayableMember_zGpdAfvxPI6j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Promissory Notes Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;805&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zC9p8TYuoeCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65,509&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zct5Ft3E26O2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1874"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,470&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zpWC5guhU2B2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;August 2024 Nirland Note&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;672,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1878"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AGPConvertibleNoteMember_zXTJrNfL7Lje" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;A.G.P. Convertible Note&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;576,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1881"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--MarchTwentyTwentyFourWarrantsMember_zuf4MDpqNsm7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;March 2024 Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1884"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AprilTwentyTwentyFourWarrantsMember_zn1dkvEjbyyi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;April 2024 Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1887"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--AGPTwentyTwentyFourWarrantsMember_zD0sqjeOpkNk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;A.G.P. 2024 Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;28,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1890"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zifmr5T3zFlb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Antidilutive Securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,501,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;173,322&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact001859"
      unitRef="Shares">139790</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact001860"
      unitRef="Shares">139790</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_PIPEMember"
      decimals="INF"
      id="Fact001863"
      unitRef="Shares">20000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_AGPWarrantsMember"
      decimals="INF"
      id="Fact001865"
      unitRef="Shares">540</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_AGPWarrantsMember"
      decimals="INF"
      id="Fact001866"
      unitRef="Shares">540</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesPayableMember20778937"
      decimals="INF"
      id="Fact001868"
      unitRef="Shares">800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_ConvertiblePromissoryNotesPayableMember20778953"
      decimals="INF"
      id="Fact001869"
      unitRef="Shares">805</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001871"
      unitRef="Shares">65509</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001872"
      unitRef="Shares">10717</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember20778968"
      decimals="INF"
      id="Fact001875"
      unitRef="Shares">1470</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_AugustTwentyTwentyFourNirlandNoteMember"
      decimals="INF"
      id="Fact001877"
      unitRef="Shares">672007</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_AGPConvertibleNoteMember20778984"
      decimals="INF"
      id="Fact001880"
      unitRef="Shares">576949</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_MarchTwentyTwentyFourWarrantsMember"
      decimals="INF"
      id="Fact001883"
      unitRef="Shares">2600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_AprilTwentyTwentyFourWarrantsMember"
      decimals="INF"
      id="Fact001886"
      unitRef="Shares">14477</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_AGPTwentyTwentyFourWarrantsMember"
      decimals="INF"
      id="Fact001889"
      unitRef="Shares">28626</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001892"
      unitRef="Shares">1501298</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001893"
      unitRef="Shares">173322</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001895">&lt;p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zfCF6Ud2Tnt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;15.
&lt;span id="xdx_828_zXUxlwsY9dm5"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Legal
Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to certain claims and contingent liabilities that arise in the normal course of business. While we do not expect that
the ultimate resolution of any of these pending actions will have a material effect on our consolidated results of operations, financial
position or cash flows, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action,
does not become material in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2023, prior to the Business Combination, our now wholly-owned subsidiary, Conduit Pharmaceuticals Limited, received a letter
from Strand Hanson Limited (&#x201c;Strand&#x201d;) claiming it was owed advisory fees pursuant to a previously executed letter.
Conduit rejected the claim from Strand and disputed the substance of the letter in full. Following such rejection, on September 7,
2023, Strand filed a claim in the Business and Property Courts of England and Wales claiming it is entitled to be paid the sum of
$&lt;span id="xdx_901_eus-gaap--LitigationSettlementExpense_pn6n6_c20230831__20230831_zyYXKWKhT8Wd" title="Settelment expense"&gt;2&lt;/span&gt;
million and, as a result of the completion of the Business Combination, to be issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20230831__20230831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwg6AAIH1l6d" title="Shares issued in business combination"&gt;65&lt;/span&gt;
thousand shares of common stock. As of December 31, 2024, the potential contingency is considered probable and reasonably estimable
and as such, the Company accrued an estimated liability of $&lt;span id="xdx_904_eus-gaap--LossContingencyAccrualProvision_pn5n6_c20240101__20241231_zs0e9gnc3TCa" title="Accrued estimated liability"&gt;0.4&lt;/span&gt;&#160;million
in the accompanying financial statements. The trial in this matter remains scheduled for October 20, 2025. We intend to vigorously
defend against these claims. Regardless of its outcome, the litigation may impact our business due to, among other things, legal
costs and the diversion of the attention of our management.&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In November and
December 2024, the Company received a letter from St George Street Capital and formal complaints filed with the Intellectual
Property Office claiming the Company was assigned the US Application, and was not the sole owner, of the AZD 1656 co-crystal patent.
In January 2025, Conduit issued a counter statement to the Intellectual Property Office disputing the claim filed by St George
Street Capital. As of December 31, 2024, the damages sought by St George Street Capital are unknown and the potential contingency is
not considered probable. As such, the Company has not accrued a loss contingency in the accompanying
financial statements. We intend to vigorously defend against these claims. Regardless of its outcome, the litigation may impact our
business due to, among other things, legal costs and the diversion of the attention of our management.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2023-08-312023-08-31"
      decimals="-6"
      id="Fact001897"
      unitRef="USD">2000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-08-312023-08-31_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001899"
      unitRef="Shares">65000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001901"
      unitRef="USD">400000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001903">&lt;p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zPbsDD63tZc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;16.
&lt;span id="xdx_829_z0s2GRX0ebrk"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Corvus
Capital Limited&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corvus
Capital Limited (&#x201c;Corvus&#x201d;) is a significant investor in the Company through subscribing to &lt;span id="xdx_90F_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_pid_c20230922__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CorvusCapitalLimitedMember_zXt6Agvtmmfb"&gt;1,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;common
shares prior to the closing of the Merger on September 22, 2023. As discussed in Note 2, the shares held by Corvus on the closing
date of the Merger were exchanged for shares of Conduit Pharmaceuticals Inc. common stock. The Chief Executive Officer and principal
owner of Corvus is a member of Conduit&#x2019;s board of directors. Occasionally, Corvus provides advisory services to the Company
and is paid a fee for the services. As of December 31, 2024, and December 31, 2023, no advisory fees were due to Corvus.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2024 and 2023, the Company incurred director travel expenses payable to the board of directors member
of approximately $&lt;span id="xdx_906_eus-gaap--TravelAndEntertainmentExpense_pn5n6_c20240101__20241231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zNOJyYXzbef1"&gt;0.4 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
and $&lt;span id="xdx_901_eus-gaap--TravelAndEntertainmentExpense_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zoeFBQS99jO9"&gt;1.0 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million,
respectively. As of December 31, 2024, and December 31, 2023, the Company did not owe the CEO of Corvus any director&#x2019;s fees as
the CEO of Corvus and the Company agreed to cease director&#x2019;s fees to the CEO of Corvus effective at the closing of the Merger.
Amounts owed to this director are included in accrued expenses and other current liabilities in the
balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, Corvus provided a $&lt;span id="xdx_909_eus-gaap--ProceedsFromContributedCapital_pn5n6_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CorvusCapitalLimitedMember_zK1iCl3gbjle"&gt;0.2&lt;/span&gt; million cash contribution to the Company to maintain liquidity through the closing
of the Merger. There was no intention of repayment by both Corvus and the Company, and as such, the Company recorded the contribution
to the consolidated statement of changes in stockholders&#x2019; deficit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
January and February 2023, the Company issued convertible notes payable with an aggregate principal amount of $&lt;span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20230228__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleLoanNoteInstrumentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z1egGwZvyZXh"&gt;0.4
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million (&#xa3;&lt;span id="xdx_902_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_uGBP_c20230228__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleLoanNoteInstrumentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zPENOSvRqrlf"&gt;0.3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million) to this related party. The convertible
notes payable mature three years after issuance and bear &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230201__20230228__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleLoanNoteInstrumentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zQkHrPCvjwI2"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
interest, only to be paid in the event of a material breach by the Company. In the event of a Change of Control, the convertible notes
payable automatically convert into common shares of the Company at a conversion price equal to a &lt;span id="xdx_901_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_c20230201__20230228__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleLoanNoteInstrumentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zAl1IT2x6OEj"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
discount to the price per share paid for the most senior class of shares in respect of such Change of Control. All of the convertible
notes payable converted into Common Stock upon the closing of the Merger at a &lt;span id="xdx_908_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_c20230201__20230228__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoConvertibleLoanNoteInstrumentMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zuk8ESXKDXT2"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
discount as specified. Refer to Note 2 above for additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At the time of the execution of the PIPE Subscription Agreement, Corvus
and its affiliates entered into a participation and inducement agreement with Nirland whereby Corvus agreed to provide certain payments
and economic benefits to Nirland. In certain circumstances, Nirland may have a right to cause Corvus to transfer &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CorvusCapitalLimitedMember_zNNFGcqS1kLg" title="New stock issued"&gt;300,484&lt;/span&gt; shares held to Nirland.&lt;/p&gt;

&lt;p style="margin: 0pt 0"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Related
Party Loan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
loans made to a related party were stated at a total principal amount of $&lt;span id="xdx_90F_eus-gaap--LoansAndLeasesReceivableRelatedParties_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zGfUyUKNGUr9"&gt;0.8&lt;/span&gt; million, with &lt;span id="xdx_909_eus-gaap--OtherReceivables_iI_do_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z322FP3izxS6"&gt;&lt;span id="xdx_901_eus-gaap--OtherReceivables_iI_do_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zDDkj9EVDRYh"&gt;no&lt;/span&gt;&lt;/span&gt; balance outstanding at December 31, 2024
and December 31, 2023, respectively. The loan carried no interest, and as such, no interest receivable was recorded. The Company recorded
a full reserve against the loan as the related party did not have the ability to repay the loans as of December 31, 2022. On September
22, 2023, the related party paid back a significant portion of its outstanding loan and the Company forgave the remaining portion of
the loan and the Company recorded the $&lt;span id="xdx_903_eus-gaap--LoansPayable_iI_pn5n6_c20230922__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSt0lBbusar"&gt;0.3&lt;/span&gt; million payoff as a gain within general and administrative expense on the consolidated statement
of operations and comprehensive income (loss), as it had previously been fully reserved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Nirland&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 6, 2024, the Company entered into the August 2024 Nirland Note with Nirland, a related party of the Company. The Company
determined that Nirland was a related party due to Nirland&#x2019;s ownership interest in the Company concurrently with the execution
of the August 2024 Nirland Note. Additionally, on October 28, 2024, the Company issued the October 2024 Nirland Note to Nirland, and
on October 31, 2024, the Company and Nirland amended the August 2024 Nirland Note, and on November 22, 2024, the Company and Nirland
amended the August 2024 Nirland Note for a second time. Refer to Note 7, Note 8 and Note 20 above for additional
information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;SARBORG&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 12, 2024, the Company entered into the Sarborg Service Agreement with Sarborg. Dr. Andrew Regan, a member of
Conduit&#x2019;s board of directors, also sits on the board of directors of Sarborg but does not have an equity interest in Sarborg.
During the year ended December 31, 2024, the Company recorded $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SARBORGLtdMember__us-gaap--TypeOfArrangementAxis__custom--SARBORGServicesAgreementMember_zMYTNcXSubQh" title="Research and development expense"&gt;0.1&lt;/span&gt;
million as research and development expense related to the Sarborg Service Agreement. Refer to Note 10 above for additional
information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Officers and
Directors&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 22, 2024,
the Company issued in a private placement common stock purchase warrants (the &#x201c;April Warrants&#x201d;) to third parties which also
included certain directors, to purchase up to an aggregate of &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240422__20240422__us-gaap--RelatedPartyTransactionAxis__custom--OfficersAndDirectorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy39m5Mfj2Te"&gt;9,077
&lt;/span&gt;shares of the Company&#x2019;s common stock, in exchange for entering into a lock-up with respect to the shares of common stock
held by such holder and for such directors, $&lt;span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240422__us-gaap--RelatedPartyTransactionAxis__custom--OfficersAndDirectorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZgzjVw0jI53"&gt;12.50
&lt;/span&gt;per warrant. The April Warrants are not exercisable until one year after their date of issuance. Each April Warrant is exercisable
into one share of the Company&#x2019;s common stock at a price per share of $&lt;span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pid_c20240422__20240422__us-gaap--RelatedPartyTransactionAxis__custom--OfficersAndDirectorsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8JLgtznRP9h"&gt;312
&lt;/span&gt;(as adjusted from time to time in accordance with the terms thereof) for a two-year period after the date of exercisability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="AsOf2023-09-22_custom_CorvusCapitalLimitedMember"
      decimals="INF"
      id="Fact001904"
      unitRef="Shares">1000</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="From2024-01-012024-12-31_custom_BoardOfDirectorsMember"
      decimals="-5"
      id="Fact001905"
      unitRef="USD">400000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="From2023-01-012023-12-31_custom_BoardOfDirectorsMember"
      decimals="-5"
      id="Fact001906"
      unitRef="USD">1000000.0</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="From2023-01-012023-12-31_custom_CorvusCapitalLimitedMember"
      decimals="-5"
      id="Fact001907"
      unitRef="USD">200000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2023-02-28_custom_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_srt_ChiefExecutiveOfficerMember"
      decimals="-5"
      id="Fact001908"
      unitRef="USD">400000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2023-02-28_custom_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_srt_ChiefExecutiveOfficerMember"
      decimals="-5"
      id="Fact001909"
      unitRef="GBP">300000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-02-012023-02-28_custom_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001910"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="From2023-02-012023-02-28_custom_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001911"
      unitRef="Pure">0.20</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="From2023-02-012023-02-28_custom_TwentyTwentyTwoConvertibleLoanNoteInstrumentMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001912"
      unitRef="Pure">0.20</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_custom_CorvusCapitalLimitedMember"
      decimals="-5"
      id="Fact001914"
      unitRef="Shares">300484000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:LoansAndLeasesReceivableRelatedParties
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-5"
      id="Fact001915"
      unitRef="USD">800000</us-gaap:LoansAndLeasesReceivableRelatedParties>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001916"
      unitRef="USD">0</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001917"
      unitRef="USD">0</us-gaap:OtherReceivables>
    <us-gaap:LoansPayable
      contextRef="AsOf2023-09-22_us-gaap_RelatedPartyMember"
      decimals="-5"
      id="Fact001918"
      unitRef="USD">300000</us-gaap:LoansPayable>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_SARBORGLtdMember_custom_SARBORGServicesAgreementMember"
      decimals="-5"
      id="Fact001920"
      unitRef="USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-04-222024-04-22_custom_OfficersAndDirectorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001921"
      unitRef="Shares">9077</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-04-22_custom_OfficersAndDirectorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001922"
      unitRef="USDPShares">12.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2024-04-222024-04-22_custom_OfficersAndDirectorsMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001923"
      unitRef="USD">312</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001925">&lt;p id="xdx_80C_eus-gaap--OtherNonoperatingIncomeAndExpenseTextBlock_zYfWDs9LQpEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;17.
&lt;span id="xdx_82B_zKFbqUt3TWxb"&gt;Other Income (expense), net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_zRaz7PHeDELc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents other income (expense), net, for the years ended December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zLEROoD1vXac" style="display: none"&gt;Schedule
of Other Expense, Net&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231_zCHJTZcrMjA8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231_zA6X4xw5wDef" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the years ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--RecognitionOfDeferredRevenueUponOptionExercise_pn3n3_maONIzvdl_zdwIaMrG2xX2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Recognition of Cizzle deferred revenue upon option exercise&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1929"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--RecognitionOfDeferredRevenueUponOptionExerciseOne_pn3n3_maONIzvdl_zhHvM7NbHSm3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Recognition of Vela deferred revenue upon option exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1932"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,774&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ChangeInFairValueOfOption_pn3n3_maONIzvdl_zJAEl2Djxle1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of Cizzle option&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1935"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,280&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ChangeInFairValueOfOptions_pn3n3_maONIzvdl_zB06sDcImqhh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of Vela option&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1938"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ChangeInFairValueOfWarrantLiability_pn3n3_maONIzvdl_zUuqeccjAtm" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ChangeInFairValueOfConvertibleNotePayment_pn3n3_maONIzvdl_zuGyz8pDIRIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of convertible note payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,018&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1945"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--GainOnDebtExtinguishment_pn3n3_maONIzvdl_ze3kMRRDTqkd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gain on debt extinguishment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1948"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InterestIncomeOther_pn3n3_maONIzvdl_z1ZODWLtxLkh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--IncomeTaxRefund_pn3n3_maONIzvdl_zPHoTmqFWzz2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Income Tax Refund&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1954"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ForeignCurrencyTransactionGainLossUnrealized_pn3n3_maONIzvdl_zX3cx1jkESmk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unrealized foreign currency transaction gain&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherIncome_pn3n3_maONIzvdl_zNTeZ8sHMXb3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;115&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherNonoperatingIncome_iT_pn3n3_mtONIzvdl_maNIEzWCX_zCofSRuvuno" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total other income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,048&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--LossOnIssuanceOfOptionOne_maONEzInN_zC40JIPLbHN5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Loss on issuance of Vela option&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1965"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--OtherIncomeUnrealizedForeignCurrencyTransactionLoss_pn3n3_maONEzInN_zUTM7r7N79U1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Change in fair value of convertible notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1968"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;426&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestExpenseOther_pn3n3_maONEzInN_zf9T4tlX67cf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_pn3n3_maONEzInN_zIZKBsRBHjT3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Amortization of debt issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;929&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1975"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--LossOnIssuanceOfWarrants_pn3n3_maONEzInN_zVp9UX2yQaPc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Loss on issuance of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,710&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1978"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--LossOnDebtExtinguishment_pn3n3_maONEzInN_zdOWng6ia3o" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Loss on Debt Extinguishment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1981"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--OtherExpenseChangeInFairValueOfConvertibleNotesPayable_pn3n3_maONEzInN_zeToQGOj2d85" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Realized foreign currency transaction loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;403&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--OtherExpense_pn3n3_maONEzInN_zlIUEjUUOWtd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Other expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1987"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherNonoperatingExpense_iT_pn3n3_msNIEzWCX_mtONEzInN_zI8XW3D9aGRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total other expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--NonoperatingIncomeExpense_iT_pn3n3_mtNIEzWCX_zcQ5VcY0Bxv9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total other (expense) income, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,383&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,727&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zmtiTluQTbXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001927">&lt;p id="xdx_890_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_zRaz7PHeDELc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents other income (expense), net, for the years ended December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zLEROoD1vXac" style="display: none"&gt;Schedule
of Other Expense, Net&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231_zCHJTZcrMjA8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231_zA6X4xw5wDef" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the years ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--RecognitionOfDeferredRevenueUponOptionExercise_pn3n3_maONIzvdl_zdwIaMrG2xX2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Recognition of Cizzle deferred revenue upon option exercise&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1929"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--RecognitionOfDeferredRevenueUponOptionExerciseOne_pn3n3_maONIzvdl_zhHvM7NbHSm3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Recognition of Vela deferred revenue upon option exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1932"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,774&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ChangeInFairValueOfOption_pn3n3_maONIzvdl_zJAEl2Djxle1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of Cizzle option&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1935"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,280&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ChangeInFairValueOfOptions_pn3n3_maONIzvdl_zB06sDcImqhh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of Vela option&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1938"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ChangeInFairValueOfWarrantLiability_pn3n3_maONIzvdl_zUuqeccjAtm" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ChangeInFairValueOfConvertibleNotePayment_pn3n3_maONIzvdl_zuGyz8pDIRIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of convertible note payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,018&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1945"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--GainOnDebtExtinguishment_pn3n3_maONIzvdl_ze3kMRRDTqkd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gain on debt extinguishment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1948"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InterestIncomeOther_pn3n3_maONIzvdl_z1ZODWLtxLkh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--IncomeTaxRefund_pn3n3_maONIzvdl_zPHoTmqFWzz2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Income Tax Refund&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1954"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ForeignCurrencyTransactionGainLossUnrealized_pn3n3_maONIzvdl_zX3cx1jkESmk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unrealized foreign currency transaction gain&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherIncome_pn3n3_maONIzvdl_zNTeZ8sHMXb3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;115&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherNonoperatingIncome_iT_pn3n3_mtONIzvdl_maNIEzWCX_zCofSRuvuno" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total other income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,048&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--LossOnIssuanceOfOptionOne_maONEzInN_zC40JIPLbHN5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Loss on issuance of Vela option&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1965"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--OtherIncomeUnrealizedForeignCurrencyTransactionLoss_pn3n3_maONEzInN_zUTM7r7N79U1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Change in fair value of convertible notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1968"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;426&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestExpenseOther_pn3n3_maONEzInN_zf9T4tlX67cf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_pn3n3_maONEzInN_zIZKBsRBHjT3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Amortization of debt issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;929&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1975"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--LossOnIssuanceOfWarrants_pn3n3_maONEzInN_zVp9UX2yQaPc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Loss on issuance of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,710&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1978"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--LossOnDebtExtinguishment_pn3n3_maONEzInN_zdOWng6ia3o" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Loss on Debt Extinguishment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1981"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--OtherExpenseChangeInFairValueOfConvertibleNotesPayable_pn3n3_maONEzInN_zeToQGOj2d85" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Realized foreign currency transaction loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;403&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--OtherExpense_pn3n3_maONEzInN_zlIUEjUUOWtd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Other expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1987"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherNonoperatingExpense_iT_pn3n3_msNIEzWCX_mtONEzInN_zI8XW3D9aGRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total other expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--NonoperatingIncomeExpense_iT_pn3n3_mtNIEzWCX_zcQ5VcY0Bxv9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total other (expense) income, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,383&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,727&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <CDT:RecognitionOfDeferredRevenueUponOptionExercise
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001930"
      unitRef="USD">1480000</CDT:RecognitionOfDeferredRevenueUponOptionExercise>
    <CDT:RecognitionOfDeferredRevenueUponOptionExerciseOne
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001933"
      unitRef="USD">2774000</CDT:RecognitionOfDeferredRevenueUponOptionExerciseOne>
    <CDT:ChangeInFairValueOfOption
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001936"
      unitRef="USD">1280000</CDT:ChangeInFairValueOfOption>
    <CDT:ChangeInFairValueOfOptions
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001939"
      unitRef="USD">970000</CDT:ChangeInFairValueOfOptions>
    <CDT:ChangeInFairValueOfWarrantLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001941"
      unitRef="USD">221000</CDT:ChangeInFairValueOfWarrantLiability>
    <CDT:ChangeInFairValueOfWarrantLiability
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001942"
      unitRef="USD">81000</CDT:ChangeInFairValueOfWarrantLiability>
    <CDT:ChangeInFairValueOfConvertibleNotePayment
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001944"
      unitRef="USD">2018000</CDT:ChangeInFairValueOfConvertibleNotePayment>
    <CDT:GainOnDebtExtinguishment
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001947"
      unitRef="USD">2473000</CDT:GainOnDebtExtinguishment>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001950"
      unitRef="USD">13000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001951"
      unitRef="USD">15000</us-gaap:InterestIncomeOther>
    <CDT:IncomeTaxRefund
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001953"
      unitRef="USD">314000</CDT:IncomeTaxRefund>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001956"
      unitRef="USD">2000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001957"
      unitRef="USD">39000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:OtherIncome
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001959"
      unitRef="USD">7000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001960"
      unitRef="USD">115000</us-gaap:OtherIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001962"
      unitRef="USD">5048000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001963"
      unitRef="USD">6754000</us-gaap:OtherNonoperatingIncome>
    <CDT:LossOnIssuanceOfOptionOne
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001966"
      unitRef="USD">987000</CDT:LossOnIssuanceOfOptionOne>
    <CDT:OtherIncomeUnrealizedForeignCurrencyTransactionLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001969"
      unitRef="USD">426000</CDT:OtherIncomeUnrealizedForeignCurrencyTransactionLoss>
    <us-gaap:InterestExpenseOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001971"
      unitRef="USD">577000</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001972"
      unitRef="USD">211000</us-gaap:InterestExpenseOther>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001974"
      unitRef="USD">929000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <CDT:LossOnIssuanceOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001977"
      unitRef="USD">2710000</CDT:LossOnIssuanceOfWarrants>
    <CDT:LossOnDebtExtinguishment
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001980"
      unitRef="USD">3179000</CDT:LossOnDebtExtinguishment>
    <CDT:OtherExpenseChangeInFairValueOfConvertibleNotesPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001983"
      unitRef="USD">16000</CDT:OtherExpenseChangeInFairValueOfConvertibleNotesPayable>
    <CDT:OtherExpenseChangeInFairValueOfConvertibleNotesPayable
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001984"
      unitRef="USD">403000</CDT:OtherExpenseChangeInFairValueOfConvertibleNotesPayable>
    <CDT:OtherExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001986"
      unitRef="USD">20000</CDT:OtherExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001989"
      unitRef="USD">7431000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001990"
      unitRef="USD">2027000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001992"
      unitRef="USD">-2383000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001993"
      unitRef="USD">4727000</us-gaap:NonoperatingIncomeExpense>
    <CDT:WarrantLiabilityDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001995">&lt;p id="xdx_806_ecustom--WarrantLiabilityDisclosureTextBlock_zWqswt08YScb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;18.
&lt;span id="xdx_822_z0z1vQFCL2he"&gt;Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the closing of the Merger, the Company assumed (i) the warrants initially included in the MURF units issued in MURF&#x2019;s initial public
offering (the &#x201c;Publicly Traded Warrants&#x201d;), and (ii) the warrants that were included in the private placement units issued
to the Sponsor simultaneously with the closing of MURF&#x2019;s initial public offering (the &#x201c;Private Placement Warrants&#x201d;).
In connection with the Merger, the Company also issued warrants to the PIPE Investors (the &#x201c;PIPE Warrants&#x201d;) pursuant to the
Subscription Agreements and to an advisor (the &#x201c;A.G.P. Warrants,&#x201d; and together with the PIPE Warrants, the &#x201c;Liability
Classified Warrants&#x201d;) pursuant to the Company&#x2019;s engagement agreement with the advisor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined that the settlement amount of the Publicly Traded Warrants and the Private Placement Warrants would equal the difference
between the fair value of a fixed number of shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified
as equity, while the settlement amount of the Liability Classified Warrants would not equal the difference between the fair value of
a fixed number of shares and a fixed monetary amount (or a fixed amount of a debt instrument) and must be classified as a liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 20, 2024, the Company issued in a private placement equity classified common stock purchase warrants (the &#x201c;March 2024
Warrants&#x201d;) to an investor to purchase up to an aggregate &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240320__us-gaap--TypeOfArrangementAxis__custom--MarchLockUpAgreementMember_z5drcXnXkUb5" title="Common stock purchase of waarants"&gt;2,600&lt;/span&gt;
shares of the Company&#x2019;s Common Stock, in exchange for entering into a lock-up with respect to the shares of common stock held
by such holder (the &#x201c;March Lock-Up Agreement&#x201d;). The Company recognized at $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--MarchLockUpAgreementMember_z2P8hk5KQ8f" title="Issuance of warrants"&gt;0.5&lt;/span&gt;
million loss on the issuance of the warrants during the year ended December 31, 2024. The Company determined that the March 2024 Warrants
should be classified within equity and estimated the fair value of the warrants issued as of March 20, 2024, using a Black-Scholes
option-pricing model utilizing the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock_gL3SOSBPASPWV-MQTQ_zhfw2PgPJCyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zO1HuPsadJOc" style="display: none"&gt;Schedule
of Black-Scholes Option Pricing Model&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 20, 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Closing stock price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20240320_zDYyrtH6M8fk" style="width: 16%; text-align: right" title="Closing stock price"&gt;347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Contractual exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20240320_z4TqI1iGO2C5" style="text-align: right" title="Contractual exercise price"&gt;318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240320__20240320_zRP4KJdUxw1b" title="Risk-free rate"&gt;4.41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Estimated volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240320__20240320_zASslSdPQ4sj" title="Estimated volatility"&gt;78.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Time period to expiration&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240320__20240320_z4w1CDTsOCG" title="Time period to expiration"&gt;3&lt;/span&gt; Years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zGx42WK9gYXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 20, 2024, the Company issued in a private placement equity classified common stock purchase warrants (the &#x201c;April 2024 Warrants&#x201d;)
to shareholders&#x2019; of the Company to purchase up to an aggregate &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240420__us-gaap--TypeOfArrangementAxis__custom--AprilLockUpAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AprilTwentyTwentyFourWarrantsMember_zqV3OarfyFZj" title="Class of warrant or right outstanding"&gt;14,477&lt;/span&gt; shares of the Company&#x2019;s Common Stock, in exchange for
(1) $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240420__us-gaap--TypeOfArrangementAxis__custom--AprilLockUpAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AprilTwentyTwentyFourWarrantsMember_zwlt4ZsNVnB7" title="Common stock purchase of warants price per share"&gt;12.50&lt;/span&gt; per warrant and (2) entering into a lock-up with respect to the shares of common stock held by such holders (the &#x201c;April
Lock-Up Agreement&#x201d;). &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240420__20240420__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z7koa7c4FtDj" title="Issuance of stock, shares"&gt;9,077&lt;/span&gt; of the total April 2024 Warrants issued were issued to directors, related parties and management of
the Company. The Company received cash of $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240401__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zlHKlDrNCFcj" title="Proceeds from warrants"&gt;0.2&lt;/span&gt; million and recognized a $&lt;span id="xdx_903_eus-gaap--GainLossOnInvestments_pn5n6_c20240401__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember_zyloiAWgsLcd" title="Loss from issuance of warrants"&gt;2.2&lt;/span&gt; million loss on the issuance of the warrants during the year ended December 31, 2024. The Company determined that the April 2024 Warrants should be classified within equity and estimated the
fair value of the warrants issued as of April 20, 2024, using a Black-Scholes option-pricing model utilizing the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_C07_gL3SOSBPASPWV-MQTQ_z88lnxcVcsJi"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C0C_gL3SOSBPASPWV-MQTQ_zEWk4k4PUQGk"&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_305_134_zZIyFq14jANh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Schedule of Black-Scholes Option Pricing Model (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;April 20, 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Closing stock price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20240420_z5bNvZoBeXf1" style="width: 16%; text-align: right" title="Closing stock price"&gt;308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Contractual exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20240420_zyZrkxWLBv9a" style="text-align: right" title="Contractual exercise price"&gt;312&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240420__20240420_zFJ5eTblTUG" title="Risk-free rate"&gt;4.81&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Estimated volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240420__20240420_zWZLvLeZaVM5" title="Estimated volatility"&gt;78.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Time period to expiration&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240420__20240420_zCpkfb2n14Ti" title="Time period to expiration"&gt;3&lt;/span&gt; Years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
partial consideration for the Advance issued to the Company by A.G.P. on October 29, 2024, the Company issued A.G.P. Warrants (the &#x201c;A.G.P.
2024 Warrants&#x201d;) to purchase up to&#160;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241029__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AGPTwentyTwentyFourWarrantsMember_zo38UquRmUP3" title="Exercise price of warrants per share"&gt;28,625&lt;/span&gt;&#160;shares of the Company&#x2019;s Common Stock at an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241029__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AGPTwentyTwentyFourWarrantsMember_z46gnHTDbvub" title="Exercise price of warrants per share"&gt;0.1048&lt;/span&gt;&#160;per
share. The Company determined that the A.G.P. 2024 Warrants should be classified as a liability and estimated the fair value of the warrants
as of October 29, 2024, and December 31, 2024, using a Black-Scholes option-pricing model. Refer to Note 3 above for additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Equity
Classified Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to MURF&#x2019;s initial public offering, the Company sold &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230922__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zE22S92K5r5c" title="Warrants issued"&gt;132,250&lt;/span&gt; units at a price of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230922__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zk8ZmclFULT7" title="Warrants price per share"&gt;10.00&lt;/span&gt; per unit. Each unit consisted of one share
of MURF Class A common stock and one redeemable Publicly Traded Warrant. Each whole Publicly Traded Warrant entitled the holder to purchase
one share of Class A common stock at a price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_z3MvsRpB5Qae" title="Warrants exercise price"&gt;11.50&lt;/span&gt; per share, subject to adjustment. The warrants are publicly traded on The Nasdaq
Capital Market under the trading symbol CDTTW.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Simultaneously
with the closing of its initial public offering, MURF consummated the private sale to the Sponsor of &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230922__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantMember_zd5SlDkbHi2h" title="Warrants issued"&gt;7,540&lt;/span&gt; private placement units at
a price of $&lt;span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230922__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantMember_zCu0bw6tzfIj" title="Warrants price per share"&gt;10.00&lt;/span&gt; per private placement unit. Each private placement unit was comprised of one share of MURF Class A common stock and
one Private Placement Warrant. Each Private Placement Warrant was exercisable to purchase one share of MURF Class A common stock at a
price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230922__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantMember_zeiq3nGePO4h" title="Warrants exercise price"&gt;11.50&lt;/span&gt; per share, subject to adjustment. The private placement units (including the Class A common stock issuable upon exercise
of the warrants included in the private placement units) were not transferable, assignable, or saleable until 30 days after the completion
of a Merger, subject to certain exceptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the closing of the Merger on September 22, 2023, the Equity Classified Warrants were amended to entitle each holder to
purchase one share of the Company&#x2019;s Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Equity Classified Warrants became exercisable 30 days after the Closing Date of the Merger. The Equity Classified Warrants will expire
five years after the Closing Date of the Merger or earlier upon redemption or liquidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will not be obligated to deliver any shares of Common Stock pursuant to the exercise of an Equity Classified Warrant and will
have no obligation to settle such exercise unless a registration statement under the Securities Act with respect to the shares of Common
Stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations
described below with respect to registration. No Equity Classified Warrant will be exercisable and we will not be obligated to issue
shares of Common Stock upon exercise unless the Common Stock issuable upon such exercise has been registered, qualified or deemed to
be exempt under the securities laws of the state of residence of the registered holder of the Equity Classified Warrant. In the event
that the conditions in the two immediately preceding sentences are not satisfied with respect to an Equity Classified Warrant, the holder
of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will
we be required to net cash settle any Equity Classified Warrant. In the event that a registration statement is not effective for the
exercised Equity Classified Warrant, the purchaser of a unit containing such Equity Classified Warrant will have paid the full purchase
price for the unit solely for the share of Common Stock underlying such unit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Conduit
may call the Publicly Traded Warrants in whole and not in part, at a price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231_zfNABH78lE72" title="Warrant exercise price"&gt;1.00&lt;/span&gt; per warrant,&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;upon
    not less than 30 days&#x2019; prior written notice of redemption to each Publicly Traded Warrant holder; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;if,
and only if, the reported last sale price of the Common Stock equals or exceeds $&lt;span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr2umUGNi4x2" title="Share price per shares"&gt;1,800.00&lt;/span&gt; per share (as adjusted for stock splits, stock
dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing once the
Publicly Traded Warrants become exercisable and ending three business days before we send the notice of redemption to the warrant holders.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
and when the Publicly Traded Warrants become redeemable by Conduit, Conduit may not exercise its redemption right if the issuance of
shares of Common Stock upon exercise of the Publicly Traded Warrants is not exempt from registration or qualification under applicable
state blue sky laws or Conduit are unable to effect such registration or qualification. Conduit will use its best efforts to register
or qualify such shares of Common Stock under the blue sky laws of the state of residence in those states in which the Publicly Traded
Warrants were offered by Conduit in the offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
Conduit calls the Publicly Traded Warrants for redemption as described above, Conduit&#x2019;s management will have the option to require
any holder that wishes to exercise its Publicly Traded Warrant to do so on a &#x201c;cashless basis.&#x201d; In determining whether to
require all holders to exercise their Publicly Traded Warrants on a &#x201c;cashless basis,&#x201d; Conduit&#x2019;s management will consider,
among other factors, Conduit&#x2019;s cash position, the number of Publicly Traded Warrants that are outstanding and the dilutive effect
on Conduit stockholders of issuing the maximum number of shares of Common Stock issuable upon the exercise of our Publicly Traded Warrants.
If Conduit&#x2019;s management takes advantage of this option, all holders of Publicly Traded Warrants would pay the exercise price by
surrendering their Publicly Traded Warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x)
the product of the number of shares of Common Stock underlying the Publicly Traded Warrants, multiplied by the difference between the
exercise price of the Publicly Traded Warrants and the &#x201c;fair market value&#x201d; (defined below) by (y) the fair market value.
The &#x201c;fair market value&#x201d; for this purpose shall mean the average reported last sale price of the Common Stock for the 10 trading
days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of Publicly Traded Warrants.
If Conduit&#x2019;s management takes advantage of this option, the notice of redemption will contain the information necessary to calculate
the number of shares of Common Stock to be received upon exercise of the Publicly Traded Warrants, including the &#x201c;fair market value&#x201d;
in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive
effect of a Publicly Traded Warrant redemption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Private Placement Warrants are identical to the Publicly Traded Warrants, except that such warrants will be exercisable for cash or on
a cashless basis, at the holder&#x2019;s option, and will not be redeemable by Conduit, in each case so long as they are still held by
the Sponsor or its permitted transferees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
summarized above, the Company has the option to redeem all of the Publicly Traded Warrants at a cash price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z94CLhTSFEBk" title="Warrant exercise price"&gt;0.01&lt;/span&gt; per warrant during
the exercisability period if the Company&#x2019;s common stock has closed at a trading price above $&lt;span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPAYK1sEjI97" title="Share price per shares"&gt;18.00&lt;/span&gt; for 20 days during a 30-day
trading window. Management notes that this option is within the Company&#x2019;s control, therefore it does not represent an &#x201c;obligation&#x201d;
and does not create a liability under ASC 480. Management considered the guidance within ASC 815-40-15-7A, noting that an exercise contingency
would not preclude permanent equity classification if all of the other equity criteria are met. As all other criteria to be classified
as permanent equity are met, the Publicly Traded Warrants are classified as permanent equity on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
assessed the Private Placement Warrants and determined that the warrants are considered to be indexed to the entity&#x2019;s own stock
and met all the criteria for permanent equity classification. As such, the Publicly Traded Warrants are classified as permanent equity
on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The March 2024 Warrants are not exercisable until one year after their date of issuance. Each March
2024 Warrant is exercisable into one share of the Company&#x2019;s Common Stock at a price per share of $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_c20240331_z2FaSSK2pOo4" title="Share price"&gt;3.18&lt;/span&gt; (as adjusted from time to
time in accordance with the terms thereof) for a two-year period after the date of exercisability. &lt;span id="xdx_90A_eus-gaap--SubsequentEventDescription_c20240301__20240331__us-gaap--TypeOfArrangementAxis__custom--MarchLockUpAgreementMember_zmooEv2PWghh" title="Subsequent event, description"&gt;There is no established public trading
market for the March 2024 Warrants. Notwithstanding the foregoing, the March 2024 Warrants shall vest, and not be subject to forfeiture,
with respect to 25% of such March 2024 Warrants commencing on the 90th day after the date of the March Lock-Up Agreement and 25% on each
subsequent 90-day anniversary, in each case vesting only if the holder agrees to continue to have its shares of common stock remain locked
up pursuant to the March Lock-Up Agreement on such date.&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
April 2024 Warrants are not exercisable until one year after their date of issuance. Each April 2024 Warrant is exercisable into one
share of the Company&#x2019;s Common Stock at a price per share of $&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20240430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--AprilLockUpAgreementMember_z5ihtOA0EO2a" title="Share price"&gt;312&lt;/span&gt; (as adjusted from time to time in accordance with the terms thereof)
for a two-year period after the date of exercisability. &lt;span id="xdx_900_eus-gaap--SubsequentEventDescription_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--AprilLockUpAgreementMember_zk90ILUsewu1" title="Subsequent event, description"&gt;There is no established public trading market for the April 2024 Warrants. Notwithstanding
the foregoing, the April 2024 Warrants shall vest, and not be subject to forfeiture, with respect to 25% of such March 2024 Warrants
commencing on the 90th day after the date of the April Lock-Up Agreement and 25% on each subsequent 90-day anniversary, in each case
vesting only if the holder agrees to continue to have its shares of common stock remain locked up pursuant to the April Lock-Up Agreement
on such date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Liability
Classified Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
discussed in Note 2, &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z6huybZNwY3d" title="Shares issued during the period"&gt;20,000&lt;/span&gt; PIPE Warrants were issued to the PIPE Investors as of the closing of the Merger pursuant to subscription
agreements. The warrants provide the PIPE Investors the right to purchase up to &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zO64Ex1Mltbg" title="Warrants to purchase common stock"&gt;20,000&lt;/span&gt; shares of Common Stock at an exercise price of
$&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zrBmXn4aL4Xl" title="Warrants exercise price"&gt;1,150&lt;/span&gt;. Additionally, on the Closing Date of the Merger, the Company issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20230921__20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zH4J9NVIsBV3" title="Shares issued during the period"&gt;540&lt;/span&gt; A.G.P. Warrants to an advisor for services provided directly
related to the Merger. The warrants provide the advisor the right to purchase up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pip0_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zoD2uTnQmg45" title="Warrants to purchase common stock"&gt;540&lt;/span&gt; shares of Common Stock at an exercise price of
$&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230922__us-gaap--BusinessAcquisitionAxis__custom--MurphyCanyonAcquisitionCorpMember_zSRXlfaBGYka" title="Warrants exercise price"&gt;1,100&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrants issued to the PIPE Investors and the advisor contain materially the same terms and are exercisable for a period of five years,
beginning on October 22, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
PIPE Warrants are exercisable for cash or on a cashless basis, at the holder&#x2019;s option. The PIPE Warrants are not redeemable by
the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
A.G.P. Warrants are exercisable for cash or on a cashless basis, at the holder&#x2019;s option. The Company may call the A.G.P. Warrants
for redemption, in whole and not in part, at any time after the A.G.P. Warrants become exercisable and prior to their expiration, at
a price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230922_zLItLLVxv1Wc" title="Warrants exercise price"&gt;1.00&lt;/span&gt; per A.G.P. Warrant,&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;upon
    not less than 30 days&#x2019; prior written notice of redemption to each warrant holder;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;if,
    and only if, the reported last sale price of the Common Stock equals or exceeds $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230922_zEe1CqE7pCG2" title="Common stock per share"&gt;1,800&lt;/span&gt; per share (as adjusted for stock splits, stock
    dividends, recapitalizations and other similar events) for any 20 trading days within a 30-trading day period commencing once the
    A.G.P. Warrants become exercisable and ending three business days before we send the notice of redemption to the warrant holders;
    and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;provided
    there is a current registration statement in effect with respect to the shares of Common Stock underlying the A.G.P. Warrants for
    each day in the 30-trading day period and continuing each thereafter until the redemption date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the Company calls the A.G.P. Warrants for redemption as described above, our management will have the option to require any holder that
wishes to exercise its A.G.P. Warrant to do so on a &#x201c;cashless basis.&#x201d; If our management takes advantage of this option, holders
of A.G.P. Warrants would pay the exercise price by surrendering their A.G.P. Warrants for that number of shares of Common Stock as calculated
pursuant to the A.G.P. Warrant. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby
lessen the dilutive effect of an A.G.P. Warrant redemption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise of the A.G.P. 2024 Warrants and the issuance of the shares of Common Stock underlying the Warrants is subject to stockholder
approval under applicable rules and regulations of Nasdaq. The warrants are exercisable for a period of five years, beginning on the
stockholder approval date. The A.G.P 2024 Warrants are exercisable for cash, or on a cashless basis if at the time of exercise there
is no effective registration statement registering the resale of the warrant shares. The A.G.P. 2024 Warrants are not redeemable by the
Company. On October 29, 2024, the Company recorded a warrant liability of $&lt;span id="xdx_907_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20241029__20241029__us-gaap--ClassOfWarrantOrRightAxis__custom--AGPTwentyTwentyFourWarrantsMember_zQ5AwxhQmKld" title="Warrant liability"&gt;0.2&lt;/span&gt; million. As part of the special meeting of stockholders
taking place on January 9, 2025, the stockholders approved the issuance of up to an aggregate of &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20241029__20241029__us-gaap--ClassOfWarrantOrRightAxis__custom--AGPTwentyTwentyFourWarrantsMember_z2yaXQ7m2PBf" title="Common stock upon exercise, shares"&gt;28,625&lt;/span&gt; shares of the Company&#x2019;s
common stock upon exercise of the A.G.P. 2024 Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
PIPE Warrants, A.G.P. Warrants, and the A.G.P 2024 Warrants (collectively the &#x201c;Liability Classified Warrants&#x201d;) are classified
as derivative liabilities because they do not meet the criteria in ASC 815-40 to be considered indexed to the entity&#x2019;s own stock
as the warrants could be settled for an amount that is not equal to the difference between the fair value of a fixed number of the entity&#x2019;s
shares and a fixed monetary amount. The Liability Classified Warrants are initially measured at fair value and are remeasured at fair
value at subsequent financial reporting period end dates and upon exercise (see Note 7 for additional information regarding fair value).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 11, 2024, the Company reduced the exercise price of the PIPE Warrants to be $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241211__us-gaap--ClassOfWarrantOrRightAxis__custom--PIPEWarrantsMember_zki1xQWESpWk"&gt;8.83&lt;/span&gt;, at which time all PIPE Warrants were exercised.
The Company received approximately $&lt;span id="xdx_907_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20241211__20241211_zEN3F8LmrRba" title="Proceeds from the exercise warrants"&gt;0.2&lt;/span&gt; million of proceeds from the exercise of the Warrants, all of which was used to pay down the
October 2024 Nirland Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2024, and December 31, 2023, the Company remeasured the fair value of the Liability Classified Warrants
and recorded a gain on the change in the fair value of $&lt;span id="xdx_900_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_pn5n6_c20240101__20241231_zsQPe7Qc4rBl"&gt;0.2
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and $&lt;span id="xdx_905_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_pn5n6_c20230101__20231231_zU5ijkra8ir3"&gt;0.1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, respective. The gains were recorded
to other income (expense), net, on the consolidated statements of operations and comprehensive income (loss). As of December 31, 2024
and December 31, 2024, the balance sheets contained warrant liabilities of $&lt;span id="xdx_907_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn5n6_c20241231_zU1kz0Spsjrc"&gt;0.1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and $&lt;span id="xdx_903_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn4n6_c20231231_zLavmWgmrIj6"&gt;0.01
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

</CDT:WarrantLiabilityDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-03-20_custom_MarchLockUpAgreementMember"
      decimals="INF"
      id="Fact001997"
      unitRef="Shares">2600</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-12-31_custom_MarchLockUpAgreementMember"
      decimals="-5"
      id="Fact001999"
      unitRef="USD">500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <CDT:ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002003">&lt;p id="xdx_89C_ecustom--ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock_gL3SOSBPASPWV-MQTQ_zhfw2PgPJCyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zO1HuPsadJOc" style="display: none"&gt;Schedule
of Black-Scholes Option Pricing Model&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 20, 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Closing stock price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20240320_zDYyrtH6M8fk" style="width: 16%; text-align: right" title="Closing stock price"&gt;347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Contractual exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20240320_z4TqI1iGO2C5" style="text-align: right" title="Contractual exercise price"&gt;318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240320__20240320_zRP4KJdUxw1b" title="Risk-free rate"&gt;4.41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Estimated volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240320__20240320_zASslSdPQ4sj" title="Estimated volatility"&gt;78.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Time period to expiration&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240320__20240320_z4w1CDTsOCG" title="Time period to expiration"&gt;3&lt;/span&gt; Years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_305_134_zZIyFq14jANh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Schedule of Black-Scholes Option Pricing Model (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;April 20, 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Closing stock price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20240420_z5bNvZoBeXf1" style="width: 16%; text-align: right" title="Closing stock price"&gt;308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Contractual exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20240420_zyZrkxWLBv9a" style="text-align: right" title="Contractual exercise price"&gt;312&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240420__20240420_zFJ5eTblTUG" title="Risk-free rate"&gt;4.81&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Estimated volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240420__20240420_zWZLvLeZaVM5" title="Estimated volatility"&gt;78.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Time period to expiration&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240420__20240420_zCpkfb2n14Ti" title="Time period to expiration"&gt;3&lt;/span&gt; Years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;</CDT:ScheduleOfShareBasedPaymentAwardStockPurchaseWarrantsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-20"
      decimals="INF"
      id="Fact002005"
      unitRef="USDPShares">347</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-03-20"
      decimals="INF"
      id="Fact002007"
      unitRef="USDPShares">318</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-03-202024-03-20"
      decimals="INF"
      id="Fact002009"
      unitRef="Pure">0.0441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-03-202024-03-20"
      decimals="INF"
      id="Fact002011"
      unitRef="Pure">0.785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2024-03-202024-03-20" id="Fact002013">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-04-20_custom_AprilLockUpAgreementMember_custom_AprilTwentyTwentyFourWarrantsMember"
      decimals="INF"
      id="Fact002015"
      unitRef="Shares">14477</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-04-20_custom_AprilLockUpAgreementMember_custom_AprilTwentyTwentyFourWarrantsMember"
      decimals="INF"
      id="Fact002017"
      unitRef="USDPShares">12.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-04-202024-04-20_us-gaap_WarrantMember_srt_DirectorMember"
      decimals="INF"
      id="Fact002019"
      unitRef="Shares">9077</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-04-012024-12-31_us-gaap_WarrantMember_srt_DirectorMember"
      decimals="-5"
      id="Fact002021"
      unitRef="USD">200000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:GainLossOnInvestments
      contextRef="From2024-04-012024-12-31_srt_DirectorMember"
      decimals="-5"
      id="Fact002023"
      unitRef="USD">2200000</us-gaap:GainLossOnInvestments>
    <us-gaap:SharePrice
      contextRef="AsOf2024-04-20"
      decimals="INF"
      id="Fact002025"
      unitRef="USDPShares">308</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-04-20"
      decimals="INF"
      id="Fact002027"
      unitRef="USDPShares">312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-04-202024-04-20"
      decimals="INF"
      id="Fact002029"
      unitRef="Pure">0.0481</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-04-202024-04-20"
      decimals="INF"
      id="Fact002031"
      unitRef="Pure">0.783</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2024-04-202024-04-20" id="Fact002033">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-10-29_custom_AllianceGlobalPartnersMember_custom_AGPTwentyTwentyFourWarrantsMember"
      decimals="INF"
      id="Fact002035"
      unitRef="Shares">28625</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-10-29_custom_AllianceGlobalPartnersMember_custom_AGPTwentyTwentyFourWarrantsMember"
      decimals="INF"
      id="Fact002037"
      unitRef="USDPShares">0.1048</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-09-22_us-gaap_IPOMember_custom_PublicWarrantMember"
      decimals="INF"
      id="Fact002039"
      unitRef="Shares">132250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-09-22_us-gaap_IPOMember_custom_PublicWarrantMember"
      decimals="INF"
      id="Fact002041"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_us-gaap_IPOMember_custom_PublicWarrantMember"
      decimals="INF"
      id="Fact002043"
      unitRef="USDPShares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-09-22_us-gaap_IPOMember_custom_PrivatePlacementWarrantMember"
      decimals="INF"
      id="Fact002045"
      unitRef="Shares">7540</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-09-22_us-gaap_IPOMember_custom_PrivatePlacementWarrantMember"
      decimals="INF"
      id="Fact002047"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-22_us-gaap_IPOMember_custom_PrivatePlacementWarrantMember"
      decimals="INF"
      id="Fact002049"
      unitRef="USDPShares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002051"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002053"
      unitRef="USDPShares">1800.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002055"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002057"
      unitRef="USDPShares">18.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact002059"
      unitRef="USDPShares">3.18</us-gaap:SharePrice>
    <us-gaap:SubsequentEventDescription
      contextRef="From2024-03-012024-03-31_custom_MarchLockUpAgreementMember"
      id="Fact002061">There is no established public trading
market for the March 2024 Warrants. Notwithstanding the foregoing, the March 2024 Warrants shall vest, and not be subject to forfeiture,
with respect to 25% of such March 2024 Warrants commencing on the 90th day after the date of the March Lock-Up Agreement and 25% on each
subsequent 90-day anniversary, in each case vesting only if the holder agrees to continue to have its shares of common stock remain locked
up pursuant to the March Lock-Up Agreement on such date.</us-gaap:SubsequentEventDescription>
    <us-gaap:SharePrice
      contextRef="AsOf2024-04-30_us-gaap_WarrantMember_custom_AprilLockUpAgreementMember"
      decimals="INF"
      id="Fact002063"
      unitRef="USDPShares">312</us-gaap:SharePrice>
    <us-gaap:SubsequentEventDescription
      contextRef="From2024-04-012024-04-30_custom_AprilLockUpAgreementMember"
      id="Fact002065">There is no established public trading market for the April 2024 Warrants. Notwithstanding
the foregoing, the April 2024 Warrants shall vest, and not be subject to forfeiture, with respect to 25% of such March 2024 Warrants
commencing on the 90th day after the date of the April Lock-Up Agreement and 25% on each subsequent 90-day anniversary, in each case
vesting only if the holder agrees to continue to have its shares of common stock remain locked up pursuant to the April Lock-Up Agreement
on such date.</us-gaap:SubsequentEventDescription>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember"
      decimals="INF"
      id="Fact002067"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember"
      decimals="INF"
      id="Fact002069"
      unitRef="Shares">20000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember_custom_SubscriptionAgreementsMember"
      decimals="INF"
      id="Fact002071"
      unitRef="USDPShares">1150</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-09-212023-09-22_custom_MurphyCanyonAcquisitionCorpMember"
      decimals="0"
      id="Fact002073"
      unitRef="Shares">540</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember"
      decimals="INF"
      id="Fact002075"
      unitRef="Shares">540</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-22_custom_MurphyCanyonAcquisitionCorpMember"
      decimals="INF"
      id="Fact002077"
      unitRef="USDPShares">1100</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-22"
      decimals="INF"
      id="Fact002079"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-22"
      decimals="INF"
      id="Fact002081"
      unitRef="USDPShares">1800</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-10-292024-10-29_custom_AGPTwentyTwentyFourWarrantsMember"
      decimals="-5"
      id="Fact002083"
      unitRef="USD">200000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-10-292024-10-29_custom_AGPTwentyTwentyFourWarrantsMember"
      decimals="INF"
      id="Fact002085"
      unitRef="Shares">28625</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-11_custom_PIPEWarrantsMember"
      decimals="INF"
      id="Fact002086"
      unitRef="USDPShares">8.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-12-112024-12-11"
      decimals="-5"
      id="Fact002088"
      unitRef="USD">200000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact002089"
      unitRef="USD">200000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact002090"
      unitRef="USD">100000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact002091"
      unitRef="USD">100000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-4"
      id="Fact002092"
      unitRef="USD">10000.00</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002094">&lt;p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_zd8CxAnBPR76" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;19.
&lt;span id="xdx_826_z6ds53LXNvu9"&gt;Segments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has one operating segment focused on the research and development of clinical assets. The accounting policies of the single operating
segment are identical to those described in Note 1. The CODM, which the Company has identified as David Tapolczay, Chief Executive
Officer, manages the Company&#x2019;s operations on a consolidated basis, assesses performance for the operating segment and decides how
to allocate resources based on consolidated net loss, which is reported on the consolidated statements of operations and comprehensive
income (loss). Depreciation expense, amortization expense, stock-based compensation expense, and non-cash lease expense are significant
noncash items included in consolidated net loss reviewed by the CODM and are reported on the consolidated statements of cash flows. The
measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. Expenditures for additions to
long-lived assets, which include purchases of property and equipment, are included in total consolidated assets reviewed by the chief
operating decision maker and are reported on the consolidated statements of cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
CODM uses consolidated net loss and budget-to-actual variances to assess the performance of the operating segment and determine if the
Company is progressing towards its goals.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zeq29aukxZVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents certain financial data for the Company&#x2019;s reportable segment (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zwnjdjWmq04k"&gt;Schedule
of Financial Data for the Company&#x2019;s Reportable Segment&lt;/span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zQuzlzBZCsi" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zSHo6cOoit5b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NewLicensesMember_zwzjhtJnjcZk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Research &amp;amp; development expense &#x2013; new licenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,114&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2099"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalAssetDevelopmentMember_zQjXPw4bUVJ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Research &amp;amp; development expense &#x2013; clinical asset development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--LegalAndProfessionalFeesMember_zrUmRuEc6tai" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;General and administrative expenses &#x2013; legal &amp;amp; professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,258&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--AccountingAndAuditFeesMember_z50BW13V11fa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;General and administrative expenses &#x2013; accounting &amp;amp; audit fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,625&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,064&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--SalariesPayrollAndStockBasedCompensationMember_z540kLE8Dve4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;General and administrative expenses &#x2013; salaries, payroll and stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,098&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;721&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_zNfIlJ5g4HA5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;General and administrative expenses &#x2013; other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,073&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingIncomeLoss_pn3n3_maNILzclF_zgW3TKhaO0Be" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from segment operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zcaBlpAaiUn1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
segment items consist of the items within Note 17 to the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002096">&lt;p id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zeq29aukxZVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents certain financial data for the Company&#x2019;s reportable segment (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zwnjdjWmq04k"&gt;Schedule
of Financial Data for the Company&#x2019;s Reportable Segment&lt;/span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zQuzlzBZCsi" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zSHo6cOoit5b" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NewLicensesMember_zwzjhtJnjcZk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Research &amp;amp; development expense &#x2013; new licenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,114&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2099"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalAssetDevelopmentMember_zQjXPw4bUVJ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Research &amp;amp; development expense &#x2013; clinical asset development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--LegalAndProfessionalFeesMember_zrUmRuEc6tai" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;General and administrative expenses &#x2013; legal &amp;amp; professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,258&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--AccountingAndAuditFeesMember_z50BW13V11fa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;General and administrative expenses &#x2013; accounting &amp;amp; audit fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,625&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,064&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--SalariesPayrollAndStockBasedCompensationMember_z540kLE8Dve4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;General and administrative expenses &#x2013; salaries, payroll and stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,098&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;721&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_zNfIlJ5g4HA5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;General and administrative expenses &#x2013; other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,073&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingIncomeLoss_pn3n3_maNILzclF_zgW3TKhaO0Be" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from segment operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_NewLicensesMember"
      decimals="-3"
      id="Fact002098"
      unitRef="USD">3114000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_ClinicalAssetDevelopmentMember"
      decimals="-3"
      id="Fact002101"
      unitRef="USD">264000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_ClinicalAssetDevelopmentMember"
      decimals="-3"
      id="Fact002102"
      unitRef="USD">90000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_LegalAndProfessionalFeesMember"
      decimals="-3"
      id="Fact002104"
      unitRef="USD">2258000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_LegalAndProfessionalFeesMember"
      decimals="-3"
      id="Fact002105"
      unitRef="USD">314000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_AccountingAndAuditFeesMember"
      decimals="-3"
      id="Fact002107"
      unitRef="USD">1625000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_AccountingAndAuditFeesMember"
      decimals="-3"
      id="Fact002108"
      unitRef="USD">3064000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember_custom_SalariesPayrollAndStockBasedCompensationMember"
      decimals="-3"
      id="Fact002110"
      unitRef="USD">4098000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember_custom_SalariesPayrollAndStockBasedCompensationMember"
      decimals="-3"
      id="Fact002111"
      unitRef="USD">721000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact002113"
      unitRef="USD">4060000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact002114"
      unitRef="USD">1073000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact002116"
      unitRef="USD">15419000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact002117"
      unitRef="USD">5262000</us-gaap:OperatingIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002119">&lt;p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zcHl3ZWg25T3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;20.
&lt;span id="xdx_82E_zTYsuP6cGUT6"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 24, 2025, the Company effected the Reverse Stock Split, pursuant to which every &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20240124__20240124_zvoh26VIF3v5" title="Number shares reverse stock split during the period"&gt;100&lt;/span&gt; shares of the Company&#x2019;s common stock
issued or outstanding were automatically reclassified into one new share of common stock, subject to the treatment of fractional shares
as previously described, without any action on the part of the holders. For a description of the Reverse Stock Split, refer to Note 1
above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Nirland Notes
Repayment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On February 7, 2025,
the Company fully repaid its outstanding October 2024 Nirland Note to Nirland Limited in the principal amount of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20250207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--OctoberTwentyTwentyFourNirlandNoteMember_zqfUOxVMdj6e"&gt;600,000&lt;/span&gt;.
This payment settled all obligations under the October 2024 Nirland Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
respect to the August 2024 Nirland Note, the Lender converted approximately $&lt;span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20250207__20250207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_z6G0PLoH5LMi" title="Debt conversion amount"&gt;1.7 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
of the original principal amount of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20250207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zBarsZKCOfcd" title="Principal amount"&gt;2,650,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;under
into shares of common stock of the Company. Of the $&lt;span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20250207__20250207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zgwpgBkRpGZb" title="Debt conversion amount"&gt;1.7&lt;/span&gt; million of original principal that was converted into shares of common stock
of the Company, $&lt;span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20241212__20241212__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zq9aYdW75lJa" title="Debt conversion amount"&gt;0.1&lt;/span&gt; million was converted on December 12, 2024, while the remaining $&lt;span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20250113__20250113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_z0AcZVIpZSof" title="Debt conversion amount"&gt;&lt;span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20250210__20250210__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zXrqZQsRh4Ud" title="Debt conversion amount"&gt;1.6&lt;/span&gt;&lt;/span&gt; million was converted between January 13,
2025 and February 10, 2025. On February 13, 2025,&#160;the&#160;Company paid the remaining outstanding portion of the August 2024
Nirland Note, approximately $&lt;span id="xdx_906_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20250213__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyFourNirlandNoteMember_zwhr68DAEyA2" title="Remaining outstanding"&gt;0.9&lt;/span&gt;
million, and, accordingly, satisfied all of its obligations in all respects to Nirland. As a result of satisfying its obligations under the
August 2024 Nirland Note, all of the Company&#x2019;s assets are once again free and clear of any liens, security interests or
encumbrances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;March 2023 Convertible Note
Repayment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On March 13, 2025,
the Company fully repaid its outstanding March 2023 Convertible Note. The Company notes that the note holder agreed on March 6, 2025
to reduce the principal from $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeConvertibleNoteMember_zvmOgLfGnGJh"&gt;0.8&lt;/span&gt;
million to $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250313__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4cg8aG1SYM5"&gt;0.7&lt;/span&gt;
million. This payment settled all obligations under the March 2023 Convertible Note. The March 2023 Convertible Note Repayment was considered
to be in default until payment on March 13, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Nasdaq Stock
Market Correspondence and Subsequent Nasdaq Capital Market Listing&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 11, 2025, the Company presented its plan of compliance to The Nasdaq Stock Market LLC Hearing Panel (the &#x201c;Panel&#x201d;)
and requested an extension of time to achieve compliance with Nasdaq Listing Rules, the Minimum Bid Price (&#x201c;Bid Price&#x201d;),
Market Value of Publicly Held Shares (&#x201c;MVPHS&#x201d;) and Market Value of Listed Securities (&#x201c;MVLS&#x201d;) rules, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 5, 2025, the Company received a written notification from the Panel confirming it has granted the Company such an extension for
the Company to regain compliance with the MVPHS and MVLS rules, provided that the Company, (i) on or before March 12, 2025, files an
application to transfer to the Nasdaq Capital Market, which application was submitted on March 7, 2025, and (ii) on or before March 31,
2025, demonstrates compliance with all Nasdaq listing rules, which it intends to do. Additionally, the Company was also notified in the
Notice that as of February 26, 2025, it had regained compliance with the Bid Price rule. The Company notes that there is no assurance
that the Company can maintain ongoing compliance with the Bid Price Rule. The Company expects to submit its compliance document with
respect to the MVPHS and MVLS rules which will be subject to review by the Panel. The Panel, may, in its discretion, request additional
information before determining that the Company has complied with the terms of the exception. There can be no assurances that the Panel&#x2019;s
decision will agree with the Company&#x2019;s compliance document. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;b&gt;&lt;i&gt;Common Stock
Issuances in Relation to the Sales Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company
increased the aggregate offering price under the Sales Agreement to up to $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250115__20250115__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zotNnjf67GW2" title="Issuance of common stock"&gt;4,835,433&lt;/span&gt;,
$&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250206__20250206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zh6sOaEMpl4e" title="Issuance of common stock"&gt;8,183,156&lt;/span&gt;,
$&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250210__20250210__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zPHHFLhnpl9h" title="Issuance of common stock"&gt;13,450,017&lt;/span&gt;,
$&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250219__20250219__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zor3mp1JLC75" title="Issuance of common stock"&gt;17,816,270&lt;/span&gt;,
and $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250310__20250310__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zUzluFCmZkcb" title="Issuance of common stock"&gt;23,922,782&lt;/span&gt; on January 15, 2025, February 6, 2025, February 10, 2025, February 19, 2025, and March 10, respectively. From
January 22, 2025 through the issuance of the Company&#x2019;s consolidated financial statements, the Company sold &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesOther_c20250122__20250122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMOwQp4j8m8e" title="Commons tock shares sold"&gt;4,345,913&lt;/span&gt;
shares of the Company&#x2019;s Common Stock through the Sales Agreement. The Company received proceeds of $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20250122__20250122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znTxp22uLSp8" title="Commons tock shares sold, value"&gt;8.1&lt;/span&gt;
million, net of commissions payable to A.G.P. of $&lt;span id="xdx_903_ecustom--CommissionsPayable_iI_pn5n6_c20250122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zm8Jlj4rgSnb" title="Commissions payable"&gt;0.2&lt;/span&gt;
million. As of the financial statement filing date, the Company has $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250328__20250328__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zGyvmDnDsHIe" title="Available common stock issuances"&gt;12.0&lt;/span&gt; million
available under the Sales Agreement.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2024-01-242024-01-24"
      decimals="INF"
      id="Fact002121"
      unitRef="Shares">100</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-02-07_us-gaap_SubsequentEventMember_custom_OctoberTwentyTwentyFourNirlandNoteMember"
      decimals="0"
      id="Fact002122"
      unitRef="USD">600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2025-02-072025-02-07_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember"
      decimals="-5"
      id="Fact002124"
      unitRef="USD">1700000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-02-07_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember"
      decimals="0"
      id="Fact002126"
      unitRef="USD">2650000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2025-02-072025-02-07_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember"
      decimals="-5"
      id="Fact002128"
      unitRef="USD">1700000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2024-12-122024-12-12_custom_AugustTwentyTwentyFourNirlandNoteMember"
      decimals="-5"
      id="Fact002130"
      unitRef="USD">100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2025-01-132025-01-13_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember"
      decimals="-5"
      id="Fact002132"
      unitRef="USD">1600000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2025-02-102025-02-10_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember"
      decimals="-5"
      id="Fact002134"
      unitRef="USD">1600000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2025-02-13_us-gaap_SubsequentEventMember_custom_AugustTwentyTwentyFourNirlandNoteMember"
      decimals="-5"
      id="Fact002136"
      unitRef="USD">900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-03-31_custom_TwentyTwentyThreeConvertibleNoteMember"
      decimals="-5"
      id="Fact002137"
      unitRef="USD">800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-03-13_custom_TwentyTwentyThreeConvertibleNoteMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact002138"
      unitRef="USD">700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-152025-01-15_us-gaap_SubsequentEventMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact002140"
      unitRef="USD">4835433</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-02-062025-02-06_us-gaap_SubsequentEventMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact002142"
      unitRef="USD">8183156</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-02-102025-02-10_us-gaap_SubsequentEventMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact002144"
      unitRef="USD">13450017</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-02-192025-02-19_us-gaap_SubsequentEventMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact002146"
      unitRef="USD">17816270</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-03-102025-03-10_us-gaap_SubsequentEventMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact002148"
      unitRef="USD">23922782</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-01-222025-01-22_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002150"
      unitRef="Shares">4345913</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-222025-01-22_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact002152"
      unitRef="USD">8100000</us-gaap:StockIssuedDuringPeriodValueOther>
    <CDT:CommissionsPayable
      contextRef="AsOf2025-01-22_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact002154"
      unitRef="USD">200000</CDT:CommissionsPayable>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-03-282025-03-28_custom_SalesAgreementMember"
      decimals="-5"
      id="Fact002156"
      unitRef="USD">12000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000288"
          xlink:label="Fact000288"
          xlink:type="locator"/>
        <link:footnote id="Footnote000387" xlink:label="Footnote000387" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Shares
    of legacy common stock have been retroactively restated to give effect to the Merger.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000288"
          xlink:to="Footnote000387"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0289"
          xlink:label="xdx2ixbrl0289"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0289"
          xlink:to="Footnote000387"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000290"
          xlink:label="Fact000290"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000290"
          xlink:to="Footnote000387"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000291"
          xlink:label="Fact000291"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000291"
          xlink:to="Footnote000387"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000292"
          xlink:label="Fact000292"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000292"
          xlink:to="Footnote000387"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000294"
          xlink:label="Fact000294"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000294"
          xlink:to="Footnote000387"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0282"
          xlink:label="xdx2ixbrl0282"
          xlink:type="locator"/>
        <link:footnote id="Footnote000388" xlink:label="Footnote000388" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reclassification
    is made as additional paid-in capital cannot be presented as a negative for either its beginning or ending balance.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0282"
          xlink:to="Footnote000388"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000283"
          xlink:label="Fact000283"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000283"
          xlink:to="Footnote000388"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000284"
          xlink:label="Fact000284"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000284"
          xlink:to="Footnote000388"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0285"
          xlink:label="xdx2ixbrl0285"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0285"
          xlink:to="Footnote000388"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0286"
          xlink:label="xdx2ixbrl0286"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0286"
          xlink:to="Footnote000388"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0296"
          xlink:label="xdx2ixbrl0296"
          xlink:type="locator"/>
        <link:footnote id="Footnote000389" xlink:label="Footnote000389" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reclassification
    is made as the impact of the retroactive application of the Merger can be shown as a reduction to additional paid-in capital during
    the period as presenting the reduction does not result in additional paid-in capital being presented as a negative for its ending
    balance.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0296"
          xlink:to="Footnote000389"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000297"
          xlink:label="Fact000297"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000297"
          xlink:to="Footnote000389"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000298"
          xlink:label="Fact000298"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000298"
          xlink:to="Footnote000389"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0299"
          xlink:label="xdx2ixbrl0299"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0299"
          xlink:to="Footnote000389"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0300"
          xlink:label="xdx2ixbrl0300"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0300"
          xlink:to="Footnote000389"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
